ACE_n estäjät - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Lääkehoito (https://sydan.fi/elamaa-sairauden-kanssa/laakehoito/)/ACE:n estäjät
ACE:n estäjät (https://sydan.fi/fakta/acen-
estajat/)
ACE:n estäjät ovat tavallisimpia verenpainelääkkeitä. Niitä käytetään myös
sydämen vajaatoiminnan hoidossa.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 23.6.2022
 
Lue seuraavaksi ATR:n salpaajan ja neprilysiinin estäjän yhdistelmä (https://sydan.fi/fakta/atrn-salpaajan-ja-neprilysiinin-
estajan-yhdistelma/)
ACE (engl. ) eli angiotensiinikonvertaasi on
entsyymi, jonka vaikutuksesta syntyy angiotensiini II -nimistä ainetta.
Angiotensiini II vuorostaan on voimakas verisuonten supistaja. Kun sen
syntymistä estetään lääkkeellä, verisuonten toiminta paranee (ne laajenevat),
minkä seurauksena verenpaine laskee, ja sydämen pumppaustyö helpottuu.
ACE:n estäjien käyttöaiheita ovat kohonnut verenpaine, sydämen vajaatoiminta,
sydämen vajaatoiminnan ehkäisy ja ennusteen parantaminen tietyissä
sydänsairauksissa.
Hoito aloitetaan yleensä pienellä annoksella, jota suurennetaan, kunnes
päästään toivottuun vaikutukseen. Ennusteen parantamiseen tähtäävässä
hoidossa pyritään tutkimuksissa osoitettuun tehokkaaseen annokseen tai
suurimpaan siedettyyn annokseen.
Verenpaineen hoidossa (https://sydan.fi/fakta/kohonneen-verenpaineen-
laakehoito/) ACE:n estäjään liitetään usein nesteenpoistolääke eli diureetti tai
kalsiuminestäjä. Saatavilla onkin useita ns. yhdistelmävalmisteita, joissa samaan
pilleriin on pakattu useampaa lääkeainetta. Hoito helpottuu, kun pillerimäärä on
mahdollisimman pieni.
ACE:n estäjien yleisin haittavaikutus on kuiva ärsytysyskä, jota kokee 10-20
prosenttia käyttäjistä. Jos yskä on haitallisen voimakas, lääke kannattaa vaihtaa
toiseen, useimmiten vaikutukseltaan muuten samankaltaiseen ATR:n salpaajaan
(https://sydan.fi/fakta/atrn-salpaajat/). Jos verenpaine laskee liikaa, voi ilmetä
huimausta erityisesti pystyasennossa. Turvotus, jota kutsutaan
angioneuroottiseksi ödeemiksi, on hyvin harvinainen, mutta vakava haitta, sillä
turvotus voi ahtauttaa hengitysteitä. Muuten ACE:n estäjät ovat hyvin
siedettyjä.
Harvinaisissa tilanteissa (molempien munuaisvaltimoiden ahtauma) hoito ACE:n
estäjällä saattaa heikentää munuaisten toimintaa eli nostaa veren
kreatiniiniarvoa (S-krea). Siksi tätä arvoa mitataan erityisesti hoidon alussa, ja
jatkossa esimerkiksi vuosittain. Kohtuullinen kreatiniiniarvon nousu on kuitenkin
hyväksyttävää, koska kokonaisvaikutus on munuaistenkin kannalta suotuisa.
ACE:n estäjillä on epäsuoria vaikutuksia elimistön suolatasapainoon. Veren
kaliumarvo (S-K) saattaa nousta, jos munuaisten toiminta on heikentynyt
sekä yhteiskäytössä eräiden muiden lääkkeiden kanssa. Kaliumarvo, kuten myösangiotensin converting enzyme Lue seuraavaksi ATR:n salpaajan ja neprilysiinin estäjän yhdistelmä (https://sydan.fi/fakta/atrn-salpaajan-ja-neprilysiinin-
estajan-yhdistelma/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
veren natriumarvo (S-Na) mitataan yleensä aina samalla kertaa kreatiniiniarvon
kanssa.
ACE:n estäjillä on alempi erityiskorvattavuus (65%) verenpainetaudissa ja
sydämen vajaatoiminnan hoidossa.
 
Lääkeaine Valmistenimet Huomauksia
EnalapriiliLinatil
Renitec
Linatilsan
enalaprilEnalapril-nimellä neljän eri lääketehtaan valmistamia
rinnakkaisvalmisteita
Kinapriili Accupro
LisinopriiliCardiostad
LisinoprilLisinopril-nimellä kahden eri lääketehtaan valmistamia
rinnakkaisvalmisteita
PerindopriiliCoversyl
PerindoprilPerindopril-nimellä kolmen eri lääketehtaan valmistamia
rinnakkaisvalmisteita
RamipriiliCardace
RamiprilRamipril-nimellä kolmen eri lääketehtaan valmistamia
rinnakkaisvalmisteita
 Lue seuraavaksi ATR:n salpaajan ja neprilysiinin estäjän yhdistelmä (https://sydan.fi/fakta/atrn-salpaajan-ja-neprilysiinin-
estajan-yhdistelma/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
ATR_n salpaajat - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Lääkehoito (https://sydan.fi/elamaa-sairauden-kanssa/laakehoito/)/ATR:n salpaajat
ATR:n salpaajat (https://sydan.fi/fakta/atrn-
salpaajat/)
ATR:n (angiotensiinireseptorin) salpaajia käytetään kohonneen verenpaineen
ja sydämen vajaatoiminnan hoidossa.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 23.6.2022
 
Lue seuraavaksi ACE:n estäjät (https://sydan.fi/fakta/acen-estajat/)
ATR:n salpaajien vaikutus on läheistä sukua ACE:n estäjille
(https://sydan.fi/fakta/acen-estajat/). ATR:n salpaajat estävät verisuonia
supistavan angiotensiini II:n kiinnittymisen vaikutuskohtaansa (reseptoriin),
minkä seurauksena verisuonet laajenevat, verenpaine laskee ja sydämen työ
kevenee. Täsmällisempi nimitys onkin AT II -reseptorin salpaajat.
Verenpaineen hoidossa ATR:n salpaajaan liitetään usein nesteenpoistolääke eli
diureetti tai kalsiuminestäjä. Saatavilla on useita ns. yhdistelmävalmisteita, joissa
samaan pilleriin on pakattu useampaa lääkeainetta. Hoito helpottuu, kun
pillerimäärä on mahdollisimman pieni.
Läheisen vaikutusmekanisminsa vuoksi ACE:n estäjiä ja ATR:n salpaajia ei käytetä
yhdessä. Poikkeus voidaan tehdä nefrologin tai kardiologin erityisen harkinnan
perusteella.
ATR:n salpaajilla on samoja vaikutuksia munuaisten toimintaan ja
suolatasapainoon kuin ACE:n estäjillä, joten kreatiniini-, kalium- ja natriumarvoja
seurataan hoidon aikana säännöllisesti.
ACE:n estäjillä esiintyy usein haittavaikutuksena kuivaa yskää, mutta vastaavaa
haittaa ei ilmene ATR:n salpaajan hoidon aikana kuin harvoin. Niinpä ACE:n
vaihto ATR:n salpaajaan on näissä tilanteissa luonteva vaihtoehto.
ATR:n salpaajilla on alempi erityiskorvattavuus (65%) verenpainetaudissa ja
sydämen vajaatoiminnan hoidossa.
 
Lääkeaine Valmistenimet Huomauksia
Eprosartaani Teveten Korvattavuus vain verenpainetaudissa
KandesartaaniAtacand
Candemox
Candestad
Candexetil
Candesartan
KandrozidCandesartan-nimellä useita rinnakkaisvalmisteita
LosartaaniCozaar
Losarstad
Losatrix
LosartanLosartan-nimellä useita rinnakkaisvalmisteita
OlmesartaaniOlmetec
OlmesartanKorvattavuus vain verenpainetaudissa
Olmesartan-nimellä useita rinnakkaisvalmisteitaLue seuraavaksi ACE:n estäjät (https://sydan.fi/fakta/acen-estajat/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
TelmisartaaniMicardis
Tolura
TelmisartanTelmisartan-nimellä useita rinnakkaisvalmisteita
ValsartaaniDiovan
Valsarstad
ValsartanValsartan-nimellä useita rinnakkaisvalmisteita
 Lue seuraavaksi ACE:n estäjät (https://sydan.fi/fakta/acen-estajat/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Alkoholi ja sydän - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Terveys & Hyvinvointi (https://sydan.fi/terveys-hyvinvointi/)/
Alkoholi ja sydän
Alkoholi ja sydän
Kohtuullisen alkoholin käytön epäiltiin pitkään olevan hyödyllistä
valtimoterveydelle, mutta viimeaikaiset tutkimukset ovat osoittaneet
alkoholin monet haitat sydämen toiminnalle.
Kuva: Cecilia Bergström
Anna-Mari Hekkala, ylilääkäri
Julkaistu 17.3.2025
 
Lue seuraavaksi Angels in America vaatii näyttelijöiltä kestävyyttä (https://sydan.fi/artikkeli/angels-in-america-vaatii-
nayttelijoilta-kestavyytta/)
Eräisiin vanhoihin tutkimuksiin perustuen vallalla oli pitkään väittämä, että pieni
annos alkoholia, tyypillisesti punaviiniä, jopa päivittäin nautittuna olisi sydämelle
hyödyksi.  Tämä käsitys on nyttemmin kumottu. Alkoholin vaikutukset ovat
yksilöllisiä, eikä tutkimuksissa ole voitu osoittaa sydänterveydelle hyödyllistä
alkoholin määrää.
Tähän artikkeliin on koottu tietoa alkoholin vaikutuksista sydän- ja
verenkiertoelimistöön.
Verenpaine
Alkoholi laajentaa akuutisti verisuonia, ja laskee siten verenpainetta. Joskus
tällainen reaktio saattaa johtaa, erityisesti kuumalla ilmalla tai saunomisen
yhteydessä, jopa pyörtymiseen.
Pitkäaikaisessa säännöllisessä käytössä alkoholi lisää nesteen kertymistä
elimistöön ja aktivoi sympaattista hermostoa. Lisäksi alkoholijuomien kalorit
kerryttävät painoa. Näin ollen lopputulos on verenpaineen kohoaminen.
Verenpaineen hoidossa siten alkoholin käytön vähentäminen ja lopettaminen on
hyvä elintapavalintoihin liittyvä hoitokeino.
Rytmihäiriöt
Runsas alkoholin käyttö altistaa rytmihäiriöille, erityisesti eteisvärinälle ja
eteislisälyönneille.
Eteisvärinässä (https://sydan.fi/eteisvarina) sydämen rytmi on epätasainen, ja
sydän lyö yleensä selvästi normaalia nopeammin. Eteisvärinä on tärkeä
aivoinfarktin aiheuttaja. Aivoinfarktille altistaa myös kohonnut verenpaine,
joten alkoholi on sitäkin kautta aivoinfarktin riskitekijä.
Akuutti runsas käyttö altistaa eteisvärinäkohtaukselle. Tunnetaan termit
”lomasydänrytmihäiriö ”  (holiday heart) ja ” krapulaflimmeri ”  (eteisvärinästä
käytetään myös termiä flimmeri). Myös säännöllinen, pitkäaikainen käyttö
suurentaa eteisvärinän riskiä.
Alkoholi altistaa myös sydämen lisälyönneille
(https://sydan.fi/fakta/lisalyonnit/). Lisälyöntien aiheuttamat oireet voivat olla
moninaisia, tyypillisimmillään sydämen ” muljahtelun ”  tuntemuksia, tai tunne
lyhyistä sydämen tykyttelyistä.
Jos ilmaantuu rytmihäiriön oireita, alkoholin käyttöä kannattaa vähentää tai
lopettaa käyttö kokonaan.Lue seuraavaksi Angels in America vaatii näyttelijöiltä kestävyyttä (https://sydan.fi/artikkeli/angels-in-america-vaatii-
nayttelijoilta-kestavyytta/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sydänlihassairaus (sydämen vajaatoiminta)
Alkoholin säännöllinen käyttö voi aiheuttaa laajentavan sydänlihassairauden
(https://sydan.fi/fakta/lisalyonnit/) eli dilatoivan kardiomyopatian. Sairaus
syntyy alkoholin hajoamistuotteiden suorista sydänlihasvaikutuksista.
Arviolta noin 30%:lla laajentavaa kardiomyopatiaa sairastavista alkoholi on ollut
vaikuttamassa sairauden syntyyn. Alttiuteen vaikuttavat perimä, etninen tausta
ja alkoholin elämänaikainen käyttö. Naiset ovat alttiimpia sairastumaan
kardiomyopatiaan.
Kardiomyopatiassa sydämen pumppaustoiminta heikkenee. Kehittyy sydämen
vajaatoiminta (https://sydan.fi/sydantietoa/sydansairaudet/sydamen-
vajaatoiminta/). Sydämen vajaatoiminnan tyypillisiä oireita ovat
rasitusuupuminen ja hengenahdistus.
Sepelvaltimotauti
Viinien, erityisesti punaviinien sisältämillä fenoliyhdisteillä saattaa olla
valtimokovettumataudin etenemistä hidastavia vaikutuksia. Kohtuukäyttö voi
suurentaa ” hyvän ”  HDL-kolesterolin pitoisuutta ja vähentää veren
hyytymisalttiutta. Koska alkoholilla on monia sydämelle ja esimerkiksi maksalle
haitallisia vaikutuksia, alkoholia, edes viiniä, ei suositella sydämen
valtimoterveyden edistämiseen.Lue seuraavaksi Angels in America vaatii näyttelijöiltä kestävyyttä (https://sydan.fi/artikkeli/angels-in-america-vaatii-
nayttelijoilta-kestavyytta/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Anafylaktinen reaktio (äkillinen yliherkkyysreaktio) - Terveyskirjasto.pdf
Lue artikkeli:
Terveyskirjasto.fi
Anafylaktinen reaktio (äkillinen
yliherkkyysreaktio)
Lääkärikirja Duodecim
15.8.2022
Ihotautien ja allergologian erikoislääkäri Heli Hyry
Keskeistä
Anafylaktinen reaktio tarkoittaa
äkillistä vakavaa moneen elimeen
yhtaikaa vaikuttavaa
yliherkkyyskohtausta, johon
liittyy usein laaja-alainen
nokkosihottuma ja turvotuksia.
Anafylaktisen reaktion aiheuttaa
tavallisesti allergia ruoalle,
lääkkeelle tai ampiaiselle.
Kohtaus hoidetaan aina
välittömästi
adrenaliinipistoksella. Sen
jälkeen lisähoitona voidaan
käyttää mm. kortisonia ja
antihistamiinia.
Aiheuttaja selvitetään
erikoissairaanhoidossa esitietojen
ja allergiatestien avulla.
Anafylaktisen reaktion
määritelmä ja oireet
Anafylaktinen reaktio eli anafylaksia
tarkoittaa monioireista vakavaa äkillistä
yliherkkyysreaktiota. Se alkaa tavallisesti
kämmenten, hiuspohjan ja huulien
voimakkaalla kutinalla. Kutina leviäämuutamassa minuutissa ympäri kehon.
Koko iholle nousee nokkospaukamia.
Huulissa ja silmäluomissa, usein
muuallakin, on selvää turvotusta
(angioedeemaa ). Potilaan kurkkua kuristaa,
ääni käheytyy ja henki saattaa vinkua.
Vatsaa kouristaa, ja potilas saattaa oksentaa
tai ripuloida. Pulssi on kiihtynyt ja iho on
punakka. Vaikeimmissa tapauksissa
verenpaine laskee ja sydämeen tulee
rytmihäiriöitä. Potilas on hengenvaarassa.
Anafylaktinen reaktio kehittyy huippuunsa
10–30 minuutissa. Kaikkia näitä oireita ei
kuitenkaan tule kaikille.
Pelkkää nokkosihottuman ja
angioedeeman yhdistelmää yksinään ei
nimitetä anafylaksiaksi. Lisäksi tarvitaan
jonkin muun elimen alueelta
allergistyyppistä oireilua, kuten keuhkoista
(hengenahdistus tai vinkuminen),
verenkiertoelimistöstä (verenpaineen lasku)
tai ruoansulatuskanavasta (vatsakipu,
oksentelu). Myös muunlaiset kahden elimen
alueen oireen yhdistelmät jälkimmäisistä
(ilman iho-oireitakin) luokitellaan
anafylaksiaksi varsinkin, jos niiden
ilmaantumista edeltää altistuminen
tunnetulle anafylaksian aiheuttajalle.
On arvioitu, että Suomessa hoidetaan
vuosittain noin 150–250 potilasta
anafylaktisen reaktion vuoksi. Huonossa
tasapainossa oleva astma sekä sydän- ja
verisuonisairaudet lisäävät anafylaksian
vaarallisuutta.
Anafylaksian aiheuttajia
Lähes aina anafylaksian aiheuttaja on
allergia, mutta se voi myös aiheutua
pelkästä fyysisestä rasituksesta tai monen
tekijän yhdistelmästä. Jos potilaalla on
harvinainen syöttösolujen sairaus
(systeeminen mastosytoosi), anafylaksia
laukeaa herkästi monenlaisista syistä. Aina
anafylaksiaan ei löydy mitään syytä, vaan se
ilmaantuu itsestään.
Yli puolet kaikista anafylaksioista johtuu
ruoka-allergioista. Lapsilla ruoan
aiheuttamat anafylaksiat ovat paljon
yleisempiä kuin aikuisilla. Periaatteessa
mikä hyvänsä ruoka voi aiheuttaa
anafylaksian. Lapsilla niistä yleisimpiä
Suomessa ovat maito, vehnä, muna,
pähkinät, hedelmät ja kala. Aikuisten ruoka-
anafylaksioista yleisimpiä ovat pähkinät.
Myös hedelmät (varsinkin kiivi ja persikka),
viljat (varsinkin vehnä ja tattari), äyriäiset,
siemenet (varsinkin seesam), palkokasvit
(herneet, pavut, soija, lupiini) ja kala ovat
tunnettuja anafylaksian aiheuttajia.
Fyysisen rasituksen sellaisenaan
aiheuttama anafylaksia on melko helppo
diagnosoida viimeistään siinä vaiheessa, kun
se on toistunut useamman kerran. Todellisia
salapoliisitaitoja tarvitaan silloin, kun
aiheuttajana onkin useamman syyn
yhdistelmä. Vehnä on tavallisin
ruokarasitusanafylaksian aiheuttaja.
Ruokarasitusanafylaksia tarkoittaa sitä, ettei
vehnä yksin eikä juoksulenkki yksin aiheuta
anafylaksiaa, mutta jos syö vehnää ja lähtee
muutaman tunnin sisällä lenkille, saa
anafylaktisen reaktion. Myös flunssa ja
krapula voivat pahentaa allergisia reaktioita.Hyönteisistä ampiaisen ja mehiläisen
pistot  kuuluvat melko tavallisiin
anafylaksian aiheuttajiin. Monet hyönteiset
voivat syötynäkin aiheuttaa anafylaksiaa,
mutta se on harvinaista, koska niitä syödään
niin vähän.
Lääkeaineista antibiootit ja kipulääkkeet
aiheuttavat useimmin anafylaktisia
reaktioita. Paljon harvinaisempia ovat
vaikeat reaktiot lääkkeiden apuaineille.
Rokotteidenkin aiheuttamat anafylaktiset
reaktiot ovat harvinaisia. Silti kaikkialla,
missä rokotteita annetaan, on varmuudeksi
adrenaliinia valmiina pistettäväksi
mahdollisen anafylaktisen reaktion
hoitamiseksi. Jos on vaikea välitön allergia
joillekin rokotteille tai niiden
apuaineille/jäämille (kananmuna, gelatiini,
neomysiini), asia tulisi mainita ennen
rokottamista.
Viivästynyt kosketusallergia  neomysiinille
ei voi aiheuttaa anafylaksiaa. Vaikeastikin
kananmunalle allergiset voidaan
pääsääntöisesti rokottaa kananmunaa
sisältävällä rokotteella, mutta se edellyttää
erityistoimia. Jos on saanut varman
anafylaktisen reaktion jostakin rokotteesta,
täsmälleen samaa rokotetta ei yleensä
anneta uudelleen.
Muita tunnettuja anafylaktisen reaktion
aiheuttajia ovat röntgentehosteaineet,
verituotteet ja biologiset lääkkeet (solujen
avulla tuotetut lääkeaineet). Ruoan (esim.
hieman vanhentuneen kalan) sisältämä
histamiini ja muut biogeeniset amiinit
voivat aiheuttaa anafylaktisia oireita ilman
allergiaa kyseiselle ruoka-aineille.
Anafylaktisen reaktion
erottaminen muista
reaktioista
Osa anafylaktisina pidetyistä reaktioista
osoittautuu tarkemmissa tutkimuksissa
joksikin muuksi reaktioksi. Sellaisia ovat
ennen kaikkea tavallinen pyörtyminen ,
paniikkikohtaus  tai sydämen
rytmihäiriökohtaus.
Tavallisessa pyörtymisessä potilas on
kalpea, usein kylmänhikinen, pulssi on
hidas ja heikko. Iho ei punoita, turvotuksia
tai nokkosihottumaa ei ole. Anafylaksiassa
taas useimmiten iho punoittaa ja
kuumottaa, pulssi on tiheä ja potilaalla on
usein turvotusta huulissa, kielessä, nielussa,
silmäluomissa ja käsissä. Pyörtymisessä on
kyse siitä, että aivot eivät saa riittävästi
happea veren mukana. Siksi pyörtynyt herää
nopeasti, kun hänet asettaa makuulle ja
nostaa jalat koholle niin, että verta ohjautuu
enemmän aivoihin kuin jalkoihin.
Pyörtymisen aiheuttaa tyypillisesti se, että
on seisonut pitkään paikallaan. Muita
tavallisia aiheuttajia ovat kipu, pelko tai
epämiellyttävät kokemukset, kuten rokotus,
verinäytteen otto tai veren näkeminen.
Paniikkikohtauksessa oireet voivat olla
hyvin monenlaisia: sydämentykytystä,
rintakipua, hikoilua, vapinaa,
hengenahdistusta, liian tiheää hengitystä ,
vatsaoireita, huimausta, puutumista,
vilunväreitä, kuumia aaltoja, punoitusta,
pelkoa ja levottomuutta. Kuitenkaan
nokkosihottumaa tai angioedeemaa ei ole.
Ei niitä tosin aina ole anafylaktisessa
reaktiossakaan. Paniikkikohtaukset toistuvat
herkästi jännittävissä tilanteissa. Kun
jotakin pelottavaa on tapahtunut aiemmin
elämässä, mikä tahansa tekijä, joka
muistuttaa siitä tilanteesta, voi käynnistää
paniikkikohtauksen. Tällaisia voivat olla
esimerkiksi kalan haju, tietty lääke,
valkoisen takin näkeminen tai allergiatestien
tekeminen iholle.Rytmihäiriöitä epäillään anafylaktiseksi
reaktioksi erityisen usein puudutteiden
käytön yhteydessä. Se johtuu siitä, että
monet puudutevalmisteet sisältävät
adrenaliinia, joka saa helposti sydämen
tykyttämään voimakkaasti. Adrenaliini voi
aiheuttaa myös vapinaa, heikotusta ja
levottomuutta. Jos samanaikaisesti sattuu
vielä makaamaan hammaslääkärissä niin,
että on vaikeaa hengittää, kun vettä valuu
nieluun, tulee helposti mieleen, että kyse voi
olla vaarallisesta allergisesta reaktiosta.
Täysin ilman paniikkikohtaustakin monille
tulee jännittäessä punoitusta erityisesti
kasvoille, kaulalle ja ylävartalolle.
Anafylaksia puudutteista on kuitenkin
äärimmäinen harvinaisuus.
Rytmihäiriön  taustalla voi olla myös
sydänsairaus. On muitakin perussairauksia,
jotka voivat selittää osan anafylaktiseen
reaktioon kuuluviksi luulluista oireista.
Tällaisia ovat esimerkiksi huonosti
hoitotasapainossa oleva astma,
nokkosihottuma ja angioedeema, joihin voi
liittyä kohtauksittain esiintyviä oireita. Myös
kroonisten suolistosairauksien oireita voi
erehtyä luulemaan anafylaksiaan liittyviksi
suolioireiksi. Niiden mahdollisuuden voi
sulkea pois sairauskohtaisilla tutkimuksilla.
Anafylaksian syyn
selvittäminen
Anafylaktisen reaktion syyn selvittäminen
kuuluu pääsääntöisesti
erikoissairaanhoitoon. Se tapahtuu yleensä
vasta viikkoja tai kuukausia reaktion
jälkeen. Allergiatestit eivät toimi ihan heti
vaikean reaktion jälkeen, koska
allergiavasta-aineet ovat kuluneet loppuun
reaktion aikana. Optimaalinen ajankohta
testien tekemiselle on 1–6 kuukautta
reaktiosta.
Potilaan iän ja pääasiallisten oireiden
perusteella reaktiota selvittelevät mm.
ihotautilääkärit, keuhkolääkärit tai
lastenlääkärit. Tutkimuksen ensimmäinen ja
tärkein vaihe on se, että potilas ja lääkäri
yhdessä käyvät tarkkaan läpi, mitä on
tapahtunut ennen anafylaktista reaktiota.
Jos reaktioita on ollut useampi, etsitään
mahdollista yhdistävää tekijää.
Jos reaktion epäillään johtuvan ruoka-
allergiasta tai hyönteisen pistosta, voidaan
tehdä allergiatutkimuksia verikokeina (ja
joskus ihon pistotesteinä ). Epävarmoissa
tapauksissa saatetaan joutua tekemään em.
tutkimusten lisäksi myös altistus. Se
tarkoittaa sitä, että lääkettä tai ruokaa
syödään sairaalassa pienistä annoksista
alkaen ja seurataan, mitä tapahtuu.
Mahdollinen allerginen reaktio hoidetaan.
Anafylaktisen reaktion aiheuttajaksi
epäiltyjä ruokia tai lääkkeitä ei pidä reaktion
jälkeen kokeilla kotona omin päin.
Anafylaksian ensihoito
Jos tilanne vaikuttaa uhkaavalta eikä
käytettävissä ole adrenaliinikynää, auttajan
tulee ensimmäiseksi soittaa hätänumeroon
112, sillä silloin tarvitaan nopeaa
ammattiapua.
Anafylaksian ensihoito on
adrenaliini.  Jos potilaalla on käyttövalmis
adrenaliinikynä (Jext -, Emerade  tai
EpiPen -autoinjektori), sen sisältämä
adrenaliini tulee pistää viivytyksettä reiden
(tai olkavarren) lihakseen pakkauksen
ohjeen mukaan (ks. Adrenaliinikynän
käyttö ). Ruiskun turhasta käytöstä ei ole
muuta haittaa kuin edellä kuvatut
adrenaliinin sivuvaikutukset. Ne menevät
ohi puolessa tunnissa. Adrenaliinikyniä ei
saa ilman reseptiä apteekista.Alle 30 kg painavalle lapselle käytetään
lapsille tarkoitettua kynää, jossa on
pienempi annos (150 ug) kuin aikuisten
kynissä. Tavanomainen aikuisten
adrenaliinikynän vahvuus on 300 ug.
Joissakin tapauksissa lääkäri voi määrätä
erityisvahvan 500 ug:n kynän aikuiselle.
Toinen adrenaliiniannos voidaan antaa
tarvittaessa parinkymmenen minuutin
kuluttua. Olisikin järkevää pitää mukanaan
kahta adrenaliiniruiskua.
Kuva 1. Adrenaliinikynän käyttö
Adrenaliinik ynällä pistetään kohtisuorassa
kulmassa reiden ulkosivun lihakseen,
tarvittaessa  vaatteiden läpi.
Hoitoa voi täydentää avaavalla
astmalääkkeellä, antihistamiinilla ja
kortisonitableteilla. Joka viidennellä oireet
uusivat 8–10 tunnin kuluttua alkureaktion
rauhoituttua. Kortisoni vaimentaa
myöhäisreaktiota. Anafylaktisen reaktion
saanutta on hyvä seurata 6–10 tuntia
ensiapuvalmiuden omaavassa
hoitoyksikössä. Päivystävä lääkäri kirjoittaa
ensiapulääkereseptejä mahdollisten tulevien
reaktioiden varalle.
Myöhemmin potilas lähetetään
erikoissairaanhoitoon reaktion syyn
selvittämiseksi.® ®
®
Vaikeasti ampiais- tai mehiläisallergisille
annetaan siedätyshoitoa , jotta ei tarvitsisi
pelätä jokaista pistiäistä. Siedätyksestä
huolimatta on hyvä kantaa adrenaliinikynää
ja muita ensiapulääkkeitä mukanaan. Jos on
kyseessä poikkeuksellisen voimakas ruoka-
allergia tai välttämättä tarvittava lääke,
saatetaan siedättää niille.
Jos on taipumusta saada anafylaktisia
reaktioita, kannattaa pitää
ensiapulääkkeiden lisäksi mukanaan SOS-
passia, johon on merkitty, mille aineelle on
allerginen ja mitä pitäisi tehdä ensiapuna.
Lääkäri auttaa tietojen täyttämisessä.
Milloin hoitoon?
Kaikkien vaikeiden (adrenaliinihoitoa
edellyttäneiden) anafylaktisten reaktioiden
yhteydessä suositellaan päivystyksellistä
lääkärin arviota, vaikka oireet
helpottuisivatkin omalla
ensiapulääkityksellä. Vähintäänkin
kannattaa varmistua siitä, että
adrenaliinikyniä ja muita ensiapulääkkeitä
riittää, jos oireet alkavatkin pian uudelleen.Jos kyse ei ole anafylaktisesta reaktiosta,
vaan esimerkiksi ampiaisen pistosta tulee
vain epänormaalin voimakas paikallinen
turvotus pistoskohtaan, ei tarvitse hakeutua
heti lääkäriin. Myöhemmin voi täysin
kiireettömästi käydä kyllä lääkärin
vastaanotolla kysymässä, olisiko syytä tehdä
allergiatestejä tai pitää mukanaan
allergialääkkeitä.
Jos ampiaisen piston aiheuttaman
paikallisreaktion lisäksi on muutamia
nokkospaukamia muuallakin, mutta ei ole
yhtään heikko olo ja oireet helpottavat
nopeasti ensiapulääkkeillä, ei ole
välttämätöntä lähteä heti päivystykseen.
Lääkärin vastaanotolle kannattaa kuitenkin
hakeutua viikkojen kuluessa
ensiapulääkkeiden ja siedätyshoidon tarpeen
arviota varten. Jos anafylaktisessa
reaktiossa on mahaoireita, heikko olo tai on
vaikeaa hengittää, on aiheellista oireiden
voimakkuuden mukaan hakeutua
lääkäripäivystykseen tai soittaa
hätänumeroon 112.
Kirjallisuutta
1. Kekki J. Anafylaksia. Lääkärin tietokannat / Lääkärin käsikirja [online; vaatii
käyttäjätunnuksen] . Kustannus Oy Duodecim . Päivitetty 20.8.21.
2. Mäkelä M, Kivistö J, Kukkonen AK. Laukaisevat allergeenit  ja anafylaksia. Lääketieteellinen
Aikakauskirja Duodecim  2021;137 (11):1137 -44. [https://www.duodecimlehti.fi/duo16257]
3. Kauppi P, Voutilainen H. Ruokayliherkkyyden tutkiminen.  Allergiset sairaudet ja astma -
tietokanta [online; vaatii käyttäjätunnuksen] . Kustannus Oy Duodecim . Päivitetty 9.10.20.
Aiemmat kirjoittajat: Ihotautien erikoislääkäri Matti Hannuksela ja iho- ja sukupuolitautien
erikoislääkäri Anna Hannuksela-Svahn
Artikkelin tunnus: dlk00201 (012.015)
© 2025 Kustannus Oy Duodecim
Anatomy, Thorax, Heart Coronary Arteries - StatPearls - NCBI Bookshelf.pdf
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
Anatomy, Thorax, Heart Coronary Arteries
Ifeanyichukwu Ogobuiro; Chase J. Wehrle; Faiz Tuma.
Last Update: July 24, 2023.
Introduction
The coronary arteries run along the coronary sulcus of the myocardium of the heart. Their main
function is to supply blood to the heart. This is a crucial function for myocardial function and
subsequently homeostasis of the body. The arrangement of coronary arteries varies among people
significantly.
Structure and Function
There are two primary coronary arteries, the right coronary artery (RCA) and the left main
coronary artery (LMCA). Both of these originate from the root of the aorta. The RCA emerges
from the anterior ascending aorta and supplies blood primarily to the right atrium, right
ventricle. The sinoatrial nodal artery is a branch of the RCA that supplies the SA node. The RCA
also supplies the AV node via a septal perforating branch in 90% of people.[1]  The RCA then
classically descends into smaller branches including the right posterior descending artery (PDA)
and acute marginal artery. The posterior descending artery is responsible for blood supply to the
posterior one-third of the interventricular septum. The left anterior descending artery (LAD)
supplies the anterior two-thirds of the septum.[2] The LAD is one of two major branches of the
LMCA, with the other being the left circumflex (LCx) coronary arteries. Combined, these two
supply blood to the left atrium and left ventricle. The circumflex artery is responsible for blood
supply to the left atrium and the posterior-lateral aspect of the left ventricle while the LAD
supplies blood to the anterior portion of the left ventricle. Other small branches of the coronary
arteries are the obtuse marginal artery (OMA), diagonals, and septal perforator (SP). 
Embryology
The current understanding of coronary artery embryology posits that coronary arteries stem from
the epicardial atrioventricular and interventricular grooves with its proximal section merging into
the aortic valve sinuses during fetal development. The vascular connection from the
atrioventricular valve and the interventricular valve to the aortic valve sinuses gives rise to the
right coronary artery and the LMCA. The connection only occurs after the aortopulmonary
rotation has been completed. This phenomenon explains the proximity of the vascular connection
from the atrioventricular and interventricular grooves to the aortic root since coronary arteries
have to pierce through a sinus wall late in the cardiac development and do so via the shortest
route possible.[3]
Blood Supply and Lymphatics
The RCA and LMCA extend from the aortic root to supply different regions of the heart.
The RCA gives rise to the sinoatrial nodal branch of the right coronary artery, posterior
descending artery branch of the RCA, and the marginal branch. The LMCA branches into the
circumflex and LAD. The circumflex artery gives rise to the left marginal artery and posterior
descending artery (in a left-dominant heart). The left anterior descending artery gives off the
diagonal branches.Author Information and Affiliations
The RCA supplies blood to the right side of the heart. The sinoatrial nodal branch of the RCA
provides blood to the SA node, and the atrioventricular nodal artery delivers blood to the AV
node. The marginal branch of the right coronary artery provides blood supply to the lateral
portion of the right ventricle. The posterior descending artery branch supplies blood to the
inferior aspect of the heart.
The LMCA supplies blood to the left side of the heart. The LAD provides blood to the anterior
ventricular septum and the greater portion of the anterior portion of the left ventricle. The LCx
supplies blood to the lateral wall of the left ventricle and sometimes to the posterior inferior
aspect of the heart when there is left heart dominance.
The heart has a lymphatic system (lymphatic vessels, lymph nodes, and lymphoid organs) just
like every other organ in the body. The lymphatic system penetrates through the sub-epicardium,
myocardium, and sub-endocardium. The direction of flow starts at the sub-endocardial layer
where the lymphatic capillaries absorb interstitial fluid to the collecting lymphatic vessels within
the sub-epicardial layer. There are two main collecting lymphatic vessels. The first one runs
along with the conal vein then towards the left pulmonary trunk as it approaches towards the
mediastinum to drain into the left and right ventricles. The second main collecting lymphatic
vessels travel along the left marginal vein, coronary sinus, and left atrium up to the mediastinum.
[4]
Physiologic Variants
There are numerous normal physiological coronary artery variances. Starting with the coronary
dominance, the PDA in 70% of patients arises from the right coronary artery (known as right
dominance); in about 10% of cases, a branch from the LCx supplies the inferior segment of the
heart (known as left dominance). In about 20% of cases, there is a dual supply from both the
right coronary artery and the LCx (known as codominance).[5]  Though the PDA mainly supplies
blood to the inferior wall and inferior third of the interventricular septum, there are known cases
where the PDA is a small, relatively redundant artery. In this case, the RCA, LCx, and the obtuse
marginal branches supply the inferior wall directly.[6] The atrioventricular nodal artery supplies
the AV node and comes from the RCA. The sino-atrial nodal blood supply in 60% of cases is
from the proximal RCA, but variants can be seen with blood supply from proximal LCx.[7]
In most cases, epicardial fat surrounds the coronary arteries. However, in 0.15% - 25% of cases
angiographically and 5 - 86% on autopsy, the coronary arteries are embedded directly into the
myocardium. This phenomenon is known as a myocardial bridge. The LAD is the most
commonly affected artery, and the patients are usually asymptomatic even under stress testing.[8]
Other physiologic variants include an acute take-off of the LCx in which the angle between
the LMCA and the LCx is less than or equal to 45 degrees. This variant occurs in about 2%
percent of the population.[9] Another rare variation is the high take-off of a coronary ostium
where the ostium is 5mm or more above the aortic sino-tubular junction. High take-offs may be
seen in patients with a bicuspid aortic valve, and the RCA is most commonly affected.[10] In 5%
of the population, Shepherd's crook RCA exists. In this situation, the RCA has a normal site of
origin from the aorta but immediately courses higher than usual. It is usually clinically
insignificant except during percutaneous intervention where patients with this physiological
variant are at risk for complications.[5] Finally, there is variation in blood supply to the AV node.
The septal perforating branch supplying the AV node has its' origin from the RCA in 90% of
patients and from the LCA in the remaining 10%.[1]
Clinical Significance
The limitation of blood flow through the coronary arteries that cause malfunctioning of the
myocardium is known as coronary artery disease. Atherosclerosis is the number one cause of
coronary artery disease. Other etiologies include Prinzmetal angina and congenital coronary
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.artery abnormalities. Stenosis of the branches of the LMCA or the RCA affects specific locations
of the heart. For instance, the LAD stenosis affects the anterior septum, anterior free base, and
mid-cavity level, apical segments of the septum, and anterior wall. The LCx stenosis affects the
anterolateral wall and the inferolateral wall. The posterior descending coronary artery stenosis
affects the inferior septum and inferior free wall. These pathologies can be seen via multiple
diagnostic modules such as EKG, CT angiogram, and echocardiogram, although the diagnostic
gold standard test is invasive coronary angiography.
Complete occlusion of the LAD results in an anterior wall MI, which appears as ST elevations in
the precordial leads (V1-V4). Occlusion of the LCx results in a lateral wall MI, which appears as
ST elevations in leads I, aVL, and V5-6. Occlusion of the PDA results in an inferior infarction,
which would appear in leads II, III, and aVF.
Review Questions
Access free multiple choice questions on this topic.
Comment on this article.
Figure
Coronary arteries Image courtesy S Bhimji MD
References
Pejković B, Krajnc I, Anderhuber F, Kosutić D. Anatomical aspects of the arterial blood
supply to the sinoatrial and atrioventricular nodes of the human heart. J Int Med Res. 2008
Jul-Aug;36(4):691-8. [PubMed: 18652764]
JAMES TN, BURCH GE. Blood supply of the human interventricular septum. Circulation.
1958 Mar;17(3):391-6. [PubMed: 13511658]
Chiu IS, Anderson RH. Can we better understand the known variations in coronary arterial
anatomy? Ann Thorac Surg. 2012 Nov;94(5):1751-60. [PubMed: 23036687]
Huang LH, Lavine KJ, Randolph GJ. Cardiac Lymphatic Vessels, Transport, and Healing of
the Infarcted Heart. JACC Basic Transl Sci. 2017 Aug;2(4):477-483. [PMC free article:
PMC5628514] [PubMed: 28989985]
Shriki JE, Shinbane JS, Rashid MA, Hindoyan A, Withey JG, DeFrance A, Cunningham M,
Oliveira GR, Warren BH, Wilcox A. Identifying, characterizing, and classifying congenital
anomalies of the coronary arteries. Radiographics. 2012 Mar-Apr;32(2):453-68. [PubMed:
22411942]
Apitzsch J, Kühl HP, Mühlenbruch G, Mahnken AH. Unusual malignant coronary artery
anomaly: results of coronary angiography, MR imaging, and multislice CT. Cardiovasc
Intervent Radiol. 2010 Apr;33(2):389-93. [PubMed: 19657692]
Karadag B, Ayan F, Ismailoglu Z, Goksedef D, Ataev Y, Vural VA. Extraordinary cause of
ischemic chest pain in a young man: congenital ostial atresia of the right coronary artery. J
Cardiol. 2009 Oct;54(2):335-8. [PubMed: 19782277]
Villa AD, Sammut E, Nair A, Rajani R, Bonamini R, Chiribiri A. Coronary artery anomalies
overview: The normal and the abnormal. World J Radiol. 2016 Jun 28;8(6):537-55. [PMC
free article: PMC4919754] [PubMed: 27358682]
Angelini P, Trujillo A, Sawaya F, Lee VV. "Acute takeoff" of the circumflex artery: a newly
recognized coronary anatomic variant with potential clinical consequences. Tex Heart Inst J.
2008;35(1):28-31. [PMC free article: PMC2322910] [PubMed: 18427647]
Menke DM, Waller BF, Pless JE. Hypoplastic coronary arteries and high takeoff position of
the right coronary ostium. A fatal combination of congenital coronary artery anomalies in an
amateur athlete. Chest. 1985 Aug;88(2):299-301. [PubMed: 4017686]
Disclosure: Ifeanyichukwu Ogobuiro declares no relevant financial relationships with ineligible companies.
Disclosure: Chase Wehrle declares no relevant financial relationships with ineligible companies.
Disclosure: Faiz Tuma declares no relevant financial relationships with ineligible companies.
Copyright  © 2025, StatPearls Publishing LLC.
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
(CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work,
provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article,
provided that you credit the author and journal.
Bookshelf ID: NBK534790PMID: 30521211
Angioedeema (_allerginen turvotus_) - Terveyskirjasto.pdf
Lue artikkeli:
Terveyskirjasto.fi
Angioedeema ("allerginen turvotus")
Lääkärikirja Duodecim
4.2.2022
Ihotautien ja allergologian erikoislääkäri Heli Hyry
Keskeistä
Angioedeema tarkoittaa
paikallista turvotuskohtausta tai
sairautta, jossa esiintyy tällaisia
kohtauksia.
Tavallisimmin kyse on kroonisen
nokkosihottuman
ilmenemismuodosta tai
allergiasta.
Varsinaisen lääkeallergian lisäksi
kyse voi olla särkylääkkeiden tai
tiettyjen verenpainelääkkeiden
(ACE:n estäjien)
vaikutusmekanismista.
Tavallista angioedeemaa
hoidetaan samoilla lääkkeillä
kuin nokkosihottumaa tai
allergioitakin: esim.
kortisonitableteilla,
antihistamiinitableteilla
(estohoito) ja joskus
adrenaliinilla.
Harvinaista perinnöllistä
angioedeemaa (HAE) hoidetaan
muun tyyppisillä juuri HAE-
tautiin kehitetyillä lääkkeillä.
Angioedeemaa (eli angioödeemaa) on 15–
20 %:lla väestöstä ainakin kerran
elämässään. Sillä tarkoitetaan pienen
ihoalueen tai limakalvon, esimerkiksihuulen, kielen, nielun, sormen, käsivarren,
silmäluomen tai posken, kohtauksittaista
turpoamista (kuva 1). Angioedeemat voidaan
jakaa tavallisiin, joita on yli 99 %
tapauksista, ja perinnöllisiin, hereditaarisiin
angioedeemiin (HAE), joita on selvästi alle
1 % tapauksista. HAE-potilaita on koko
Suomessa vain vähän yli 100.
Kuva 1. Angioedeema (turvotus)
kasvoissa.  Angioedeem a eli ”allerginen
turvotus” kasvoissa. Turvotus on tyypillisest i
voimakkain silmien ympäristössä, ja iho
punoittaa paikoin.
Angioedeemat voidaan jakaa myös
syntymekanisminsa mukaan: 1)
syöttösoluvälitteisiin, 2)
bradykiniinivälitteisiin ja 3) ilman tunnettua
mekanismia kehittyviin turvotuksiin.
Syöttösoluvälitteiset ovat näistä
tavallisimpia.
Angioedeem an syyt
Syöttösoluvälitteiselle angioedeemalle
on tyypillistä samanaikainen
nokkosihottuma  ja kutina sekä toisinaan
myös hengenahdistus ja verenpaineen lasku.
Tällaista yhdistelmää kutsutaan
anafylaksiaksi . Syöttösoluista vapautuu
välittäjäaineita (mm. histamiinia), jotka
laajentavat ihon verisuonia ja lisäävät
nesteen tihkumista kudokseen. Tällä
mekanismilla syntyy mm. allergiaan liittyvä
angioedeema.
Allergian aiheuttaja voi olla ruoka-aine,
kuten pähkinät, pistävä hyönteinen, kuten
ampiainen tai lääke, kuten kipulääkkeet ja
antibiootit. Turvotus kehittyy
voimakkaimmilleen minuuteissa tai
muutamassa kymmenessä minuutissa. Se
kestää 1–3 vuorokautta ja häviää merkkiä
jättämättä. Anafylaksiaan liittyvän
angioedeeman aiheuttajista voi lukea
tarkemmin artikkelista anafylaksia .
Tavallisessa
angioedeemakohtaustaipumuksessa
sellaisenaan tai krooniseen (pitkäaikaiseen)
nokkosihottumaan liittyen voi olla kyse ns.
autoimmuunisairaudesta . Siinä elimistö
erehtyy tuottamaan syöttösoluja aktivoivia
vasta-aineita. Tällöin syöttösoluista
vapautuu tarpeettomasti histamiinia ja
muita turvotusta aiheuttavia välittäjäaineita.
Angioedeemataipumuksen taustalla saattaa
olla joskus jokin sairauden alkuvaiheessa
sairastettu infektio, esimerkiksi tavallinen
flunssa, mutta tauti alkaa usein myös ilman
mitään syytä.
Bradykiniinivälitteisessä
angioedeemassa  ei ole nokkosihottumaa
eikä kutinaa. Turvotusta tulee tavallisimmin
kasvoihin, raajoihin tai suoliston alueelle,
jolloin siihen liittyy voimakasta vatsakipua
ja pahoinvointia. Harvinaisempaa on
kurkunpään hengenvaarallinen
turpoaminen. Nimensä mukaisesti tämäangioedeematyyppi johtuu siitä, että
bradykiniinin (pienen aminohapoista
koostuva välittäjäaineen) pitoisuus suurenee
ja aiheuttaa verisuonten laajenemisen ja
nesteen pääsyn kudokseen turvotusalueelle.
Turvotus kehittyy voimakkaimmilleen 8–12
tunnissa ja häviää joskus vasta viiden
vuorokauden kuluttua.
Tällä mekanismilla syntyy angioedeema,
joka liittyy ACE:n estäjiksi kutsuttuihin
verenpainelääkkeisiin (lääkkeen vaikuttavan
aineen nimessä on pääte '-priili'). Kyse ei ole
lääkeallergiasta, vaan muusta
sivuvaikutuksesta. Näiden aiheuttama
angioedeema voi tulla jo ensimmäisestä
lääkeannoksesta, useimmiten kuitenkin
vasta muutaman kuukauden tai vuoden
hoidon jälkeen. Turvotuskohtauksia tulee
satunnaisesti päivien tai kuukausienkin
välein, vaikka potilas ottaakin lääkettä joka
päivä. Tämä eroaa varsinaisesta
lääkeallergiasta, jolloin angioedeemaa tai
muita allergiaoireita ilmenisi joka kerta, kun
ottaa lääkettä. Bradykiniinin välittämät
kohtaukset voivat jatkua vielä muutaman
kuukauden ajan ACE-estäjälääkityksen
lopettamisesta. Tämäkin eroaa
lääkeallergioista, joissa oireilu ei enää toistu
lääkkeen lopettamisen jälkeen.
Bradykiniinin välityksellä syntyvät myös
HAE-taudin turvotuskohtaukset. HAE
esiintyy suvuittain. Oireilu alkaa yleensä jo
lapsuudessa. HAE-taudissa yksi
bradykiniinin tuottoa säätelevistä tekijöistä,
C1-inhibiittori, puuttuu tai toimii huonosti,
ja bradykiniinia pääsee kertymään.
Kohtauksen saattaa käynnistää henkinen
stressi, fyysinen kuormitus, pienet vammat
(kolhut, haavat), leikkaukset, infektiot ja
sopimattomat lääkkeet (ACE:n estäjät,
estrogeenivalmisteet).
Angioedeem an
toteaminen
Angioedeeman toteamisessa on tärkeintä
hyvät esitiedot. Turvotuskohtauksen aikana
voidaan ottaa tryptaasiverikoe (anafylaksian
osoittamiseksi). Jälkikäteen diagnosoitaessa
on hyötyä siitä, jos turvotus on valokuvattu
kohtauksen aikana (epäselvissä tapauksissa
myös normaalitilassa).
Jos angioedeeman epäillään johtuvan
ruoka-allergiasta tai hyönteisen pistosta,
voidaan tehdä allergiatutkimuksia
verikokeina (ja joskus ihon pistotesteinä).
Epävarmoissa tapauksissa saatetaan joutua
tekemään em. tutkimusten lisäksi myös
altistus. Se tarkoittaa sitä, että lääkettä tai
ruokaa syödään sairaalassa pienistä
annoksista alkaen ja seurataan, mitä
tapahtuu. Mahdollinen allerginen reaktio
hoidetaan.
Perinnöllistä angioedeemaa epäiltäessä
otetaan joukko verikokeita, ns. HAE-paketti.
Kaikkein harvinaisimmat muutenkin jo
harvinaisen perinnöllisen angioedeeman
muodoista eivät näy siinä. Tällöin saattaa
olla apua geenitestiverikokeista.
Tavallisenkin angioedeeman
luokittelemiseksi ja oikean hoidon
etsimiseksi joudutaan toisinaan
turvautumaan myös lääkehoitokokeiluihin.
Angioedeem an hoito
Syöttösoluvälitteisessä
angioedeemakohtauksessa ilman reseptiä
apteekista saatavat hydrokortisonitabletit
(esim. Kyypakkaus  tai Ampikyy )
helpottavat turvotusta yleensä jonkin
verran. Antihistamiini ei juurikaan auta
kohtauksen aikana, mutta mahdolliseen
samanaikaiseen nokkosihottumaan se
yleensä tehoaa.Lääkärin hoitokeinoja ovat
syöttösoluvälitteisessä
angioedeemakohtauksessa vahvempi
kortisonilääkitys (esim. prednisolonitabletit)
ja hengitystä vaikeuttavissa tilanteissa
adrenaliinipistos. Nämä hoidot saatetaan
määrätä myös kotiin ensiapulääkkeiksi
varsinkin, jos on kyse anafylaktiseen
reaktioon liittyvästä angioedeemasta. Usein
toistuvien kohtausten estohoidossa
antihistamiinitabletit tehoavat yleensä
hyvin, kun niitä käytetään riittävän suurella
annoksella päivittäin säännöllisesti.
Perinnöllisen angioedeeman lääkitys
poikkeaa täysin tavallisen angioedeeman
hoidosta. Kohtaushoitona käytetään
pistettävinä lääkkeinä mm. bradykiniinin
estäjä ikatibanttia tai C1-esteraasin estäjää.
Koska kyse on hyvin harvinaisesta
sairaudesta, niitä löytyy pääsääntöisesti vain
keskussairaalatasoisilta
päivystyspoliklinikoilta. Kurkunpään
alueelle osunut turvotus voisi hoidon
viivästyessä johtaa kuolemaan. Siksi monet
HAE-potilaat pitävät lääkkeitä mukanaan ja
pistävät ne tarvittaessa itse. HAE-potilaat
tarvitsevat lyhytaikaista estohoitoa ennen
leikkauksia. Tiheästi oireilevat tarvitsevat
pitkäaikaista estohoitoa. HAE-taudin
hoitoon on viime vuosina tullut paljon uusia
lääkkeitä ja vanhempiin lääkkeisiin uusia
annostelutapoja. Estohoito on mahdollista
toteuttaa tablettilääkitykselläkin.
Milloin hoitoon?
Hoitoon hakeudutaan välittömästi , jos
turvotus on kielessä tai nielussa ja se on
ahtauttamassa hengitysteitä tai
turvotukseen liittyy laaja-alainen
nokkosihottuma ja hengityksen
vinkumista tai verenpaineen lasku
(tuntuu huimauksena, heikotuksena ja® ®
tajunnan heikkenemisenä varsinkin
pystyasennossa) tai
turvotusten lisäksi on kovia, aaltomaisia
vatsakipuja.
Hoitoon voi hakeutua lähiviikkoina , jos
angioedeemaan liittyy nokkosihottumaa
eivätkä oireet ole kovin häiritseviä.
Perinnöllistä angioedeemaa sairastavat
noudattavat hoitavalta lääkäriltä saamiaan
ohjeita hoitoon hakeutumisesta.
Angioedeem an ehkäisyAngioedeemataipumusta sairautena ei voida
ehkäistä enempää tavallisessa kuin
perinnöllisessäkään muodossa. Tiheästi
toistuvia oireita eli turvotuskohtauksia
voidaan estää em. estolääkityksillä. Jos on
huomannut kohtaustensa liittyvän aina
infektioihin, riittää, että käyttää
estolääkitystä niiden aikana. Joitakin
infektioita voi ehkäistä rokotuksilla. Jos on
kyse allergiasta tai lääkkeen
sivuvaikutuksesta, aiheuttajaa voi välttää
sen jälkeen, kun se on saatu selville.
Kirjallisuutta
1. Harvima I, Ackermann L. Angioödeem at. Allergiset sairaudet ja astma -tietokanta [online;
vaatii käyttäjätunnuksen] . Kustannus Oy Duodecim . Päivitetty 9.10.20.
2. Salava A. Angioedeem a. Ajankohtaista Lääkärin käsikirjasta. Lääketieteellinen Aikakauskirja
Duodecim  2020;136 (8):951-3. [https://www.duodecimlehti.fi/duo15513]
3. Belbézier A, Bocquet A, Bouillet L. Idiopathic Angioedema: Current Challenges. J Asthma
Allergy. 2020;13:137 -144 [https://www.dovepress.com/getfile.php?fileID=57449]
4. Maurer M, Magerl M, Betschel S ym. The international WAO/EAACI guideline for the
management of hereditary angioedema - the 2021 revision and update Allergy 2022; Jan 10.
[https://onlinelibrary.wiley.com/doi/10.1111/all.15214]
Aiemmat kirjoittajat: Ihotautien erikoislääkäri Matti Hannuksela ja iho- ja sukupuolitautien
erikoislääkäri Anna Hannuksela-Svahn
Artikkelin tunnus: dlk00642 (012.003)
© 2025 Kustannus Oy Duodecim
Angioplasty and stent placement - heart_ MedlinePlus Medical Encyclopedia.pdf
Home → Medical Encyclopedia → Angioplasty and stent placement - heart
URL of this page: //medlineplus.gov/ency/article/007473.htm
Angioplasty and stent placement - heart
Angioplasty is a procedure to open narrowed or blocked blood vessels that supply blood to the heart.
These blood vessels are called the coronary arteries.
A coronary artery stent is a small, metal mesh tube that expands inside a coronary artery. A stent is
often placed during or immediately after angioplasty. It helps prevent the artery from closing up again. A
drug-eluting stent has medicine embedded in it that helps prevent the artery from closing in the long
term. These are the most common kind of stent.
Watch this video about:
Balloon angioplasty - short
segment
Description
Before the angioplasty procedure begins, you will receive some pain medicine. You may also be given
medicine that relaxes you, and blood-thinning medicines to prevent a blood clot from forming.
You will lie on a padded table. Your doctor (usually a heart specialist called a cardiologist) will insert a
flexible tube (catheter) into an artery. Sometimes the catheter will be placed in your arm or wrist, or in
your upper leg (groin) area. You will be awake during the procedure.
The doctor will use live x-ray pictures to carefully guide the catheter up into your heart and arteries.
Liquid contrast (sometimes called "dye," will be injected into your body to highlight blood flow through
the arteries. This helps the doctor see any blockages in the blood vessels that lead to your heart.
A guide wire is moved into and across the blockage. A balloon catheter is pushed over the guide wire
and into the blockage. The balloon on the end is blown up (inflated). This opens the blocked vessel and
restores proper blood flow to the heart.
A wire mesh tube (stent) may then be placed in this blocked area. The stent is inserted along with the
balloon catheter. It expands when the balloon is inflated. The stent is left there to help keep the artery
open.
An official website of the United States governmentHere’s how you know
National Institutes of Health /National Library of Medicine

The stent is almost always coated with a drug (called a drug-eluting stent). This type of stent may lower
the chance of the artery closing back up in the future.
Why the Procedure is Performed
Arteries can become narrowed or blocked by deposits called plaque. Plaque is made up of fat and
cholesterol that builds up on the inside of artery walls. This condition is called hardening of the arteries
(atherosclerosis).
Angioplasty may be used to treat:
Blockage in a coronary artery during or after a heart attack
Blockage or narrowing of one or more coronary arteries that may lead to poor heart function (heart
failure)
Narrowings that reduce blood flow and cause persistent chest pain (angina) that medicines do not
control
Not every blockage can or needs to be treated with angioplasty. Some people who have several
blockages or blockages in certain locations may need coronary bypass surgery. Some blockages are
treated with medical therapy rather than an interventional procedure.
Risks
Angioplasty is generally safe, but ask your doctor about the possible complications. Risks of angioplasty
and stent placement are:
Allergic reaction to the drug used in a drug-eluting stent, the stent material (very rare), or the x-ray
dye.
Bleeding or clotting in the area where the catheter was inserted.
Blood clot.
Clogging of the inside of the stent (in-stent restenosis). This can be life threatening.
Damage to a heart valve or blood vessel.
Heart attack.
Kidney failure (higher risk in people who already have kidney problems).
Irregular heartbeat (arrhythmias).
Stroke (this is rare).
Before the Procedure
Angioplasty is often performed when you go to the hospital or emergency room for chest pain, or after a
heart attack. If you are admitted to the hospital for angioplasty:
Tell your health care provider what medicines you are taking, even medicines or herbs you bought
without a prescription.
You will most often be asked not to drink or eat anything for 6 to 8 hours before the test.
Take the mediciness your provider told you to take with a small sip of water.
Tell your provider if you are allergic to seafood, you have had a bad reaction to contrast material or
iodine in the past, you are taking sildenafil (Viagra) or similar medicines, or you are or might be
pregnant.
After the Procedure
The average hospital stay is 2 days or less. Some people may not even have to stay overnight in the
hospital.
In general, people who have angioplasty are able to walk around within a few hours after the procedure,
depending on how the procedure went and where the catheter was placed. Complete recovery takes a
week or less. You will be given information how to care for yourself after angioplasty.
Outlook (Prognosis)
For most people, angioplasty greatly improves blood flow through the coronary artery and the heart. It
may help you avoid the need for coronary artery bypass surgery (CABG).
Angioplasty does not cure the cause of the blockage in your arteries. Your arteries may become narrow
again.
Follow your heart-healthy diet, exercise, stop smoking (if you smoke), and reduce stress to lower your
chances of having another blocked artery. Your provider may prescribe medicine to help lower your
cholesterol or control your blood pressure. Taking these steps can help reduce your chances of
complications from atherosclerosis.
Health Content
Provider
06/01/2025Alternative Names
PCI; Percutaneous coronary intervention; Balloon angioplasty; Coronary angioplasty; Coronary artery
angioplasty; Percutaneous transluminal coronary angioplasty; Heart artery dilatation; Angina - stent
placement; Acute coronary syndrome - stent placement; Coronary artery disease - stent placement;
CAD - stent placement; Coronary heart disease - stent placement; ACS - stent placement; Heart attack
- stent placement; Myocardial infarction - stent placement; MI - stent placement; Coronary
revascularization - stent placement
References
Kumbhani DJ, Bhatt DL. Percutaneous coronary intervention. In: Libby P, Bonow RO, Mann DL,
Tomaselli GF, Bhatt DL, Solomon SD, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular
Medicine. 12th ed. Philadelphia, PA: Elsevier; 2022:chap 41.
Lawton, J, Tamis-Holland, JE. et al. 2021 ACC/AHA/SCAI Guideline for coronary artery
revascularization: A report of the American College of Cardiology/American Heart Association Joint
Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):e21–e129. PMID: 34895950
pubmed.ncbi.nlm.nih.gov/34895950/ [https://pubmed.ncbi.nlm.nih.gov/34895950/].
Morrow DA, de Lemos J. Stable ischemic heart disease. In: Libby P, Bonow RO, Mann DL, Tomaselli
GF, Bhatt DL, Solomon SD, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.
12th ed. Philadelphia, PA: Elsevier; 2022:chap 40.
Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the
management of patients with chronic coronary disease: a report of the American Heart
Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
Circulation. 2023;148(9):e9–e119. PMID: 37471501
pubmed.ncbi.nlm.nih.gov/37471501/ [https://pubmed.ncbi.nlm.nih.gov/37471501/].
Review Date 7/14/2024
Updated by: Michael A. Chen, MD, PhD, Associate Professor of Medicine, Division of Cardiology,
Harborview Medical Center, University of Washington Medical School, Seattle, WA. Also reviewed by
David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial
team.
Learn how to cite this page
A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an
independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to
achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy,
editorial process, and privacy policy.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A
licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are
provided for information only – they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is
made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein
into any other language. © 1997-2025 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is
strictly prohibited.
National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 U.S. Department of Health and Human Services
National Institutes of Health
Angioplasty_ Procedure, Types & Recovery.pdf
Locations:
Angioplasty
Angioplasty is a procedure that creates more space inside an artery that
has plaque built up inside it. Your healthcare provider uses a tiny balloon
to force plaque against the artery walls so blood can get through your
artery. Often, they also place a stent or tube inside the newly opened
space to keep it open.
ContentsOverviewProcedure DetailsRecovery and Outlook
Additional Common Questions
Overview
What is angioplasty?
Angioplasty is a minimally invasive procedure that opens arteries (large
blood vessels) to let blood flow more easily. It most commonly
treats atherosclerosis (a collection of plaque made of fat and
cholesterol) in your arteries.
ADVERTISEMENTAbu Dhabi|Canada|Florida|London|Nevada|OhioOverview
Ad
Cleveland Clinic is a non-profit academic medical
center. Advertising on our site helps support our
mission. We do not endorse non-Cleveland Clinic
products or services.Policy
Angioplasty involves a tiny medical balloon that pushes plaque through
in spots that are too narrow or blocked.
Angioplasties are generally safe procedures. They’re less invasive than
other heart and vascular procedures, like bypass surgery.
Your cardiovascular health is very important to your overall health.
Angioplasties are often necessary to try to prevent serious complications
of atherosclerosis, like heart attack and stroke.
Types of angioplasty
Healthcare providers use certain words to explain which arteries they’re
treating. The two most common include:
Coronary artery angioplasty. The coronary arteries are major blood
vessels that supply blood to your heart. Another name for this
procedure is percutaneous coronary intervention (PCI).
Peripheral artery angioplasty. Peripheral arteries are blood vessels
that carry blood away from your heart to your extremities, like your
legs and arms.Ad
Different angioplasty techniques include:
Balloon angioplasty. Most angioplasty procedures involve a tiny
medical balloon to move the plaque out of the way and off to the side
of the artery wall.
Angioplasty with or without stenting. Your provider may or may not
place a permanent stent (a small tube) in the newly opened artery to
help keep it open. Stent placement comes after most angioplasties.
Excimer laser coronary angioplasty (ELCA). This is an alternative to
using a balloon to unblock a coronary artery. The laser destroys the
plaque. It’s not as common as balloon angioplasty.
ADVERTISEMENT
When might I need angioplasty?
You may need angioplasty if you have:
A heart attack. Angioplasty may limit damage to your heart during or
right after a heart attack. In this case, it’s an emergency treatment.
Carotid artery disease. The carotid arteries are in your neck. Left
untreated, blocked carotid arteries can lead to a stroke.Ad
Chronic kidney disease. When plaque collects in the arteries in your
kidneys, it affects how much blood and oxygen can reach them.
Sometimes, a renal (kidney) artery angioplasty can help.
Coronary artery disease (CAD). Your coronary arteries make it
possible for your heart to beat and pump blood throughout your
body. A blocked coronary artery can cause chest pain and/or a heart
attack.
Peripheral artery disease (PAD). Angioplasty can clear plaque in the
major arteries in your arms, legs and pelvis. Without treatment, PAD
can lead to pain, ulcers and gangrene.
Your healthcare provider will use an angiogram (an imaging procedure)
to help guide the angioplasty.
Procedure Details
Ad
During angioplasty, a balloon forces plaque against your artery wall to make more room for blood
to flow through.
How do I prepare for angioplasty?
Your provider will give you specific instructions for preparing for the
procedure. They’ll also go over your medications and health history. In
general, your provider will likely:Ad
Tell you to not eat or drink anything except water (fast) for eight
hours before the test
Adjust your medications (especially if you take anticoagulants)
Ask if you’ve had an allergic reaction to contrast dye or anesthesia
before
Ask if you’re pregnant
For your safety, you won’t be allowed to drive yourself home on the same
day of the procedure. You should figure out transportation from the
hospital if you’re going home the same day. You may need to stay
overnight at the hospital.
What happens during angioplasty?
In general, you can expect the following during angioplasty:
1. You change into a medical gown and lie on your back for the
procedure.
2. A healthcare provider gives you medicine that makes you feel
relaxed (a sedative) through an IV. But you’ll still be awake enough to
follow instructions.
3. Certain monitors will keep track of your vital signs, like your pulse
and oxygen levels, during the procedure.
4. A provider gives you local anesthesia to numb the area where they’ll
access an artery. This is usually in your groin or arm. You may feel
pressure in this area during the procedure, but you shouldn’t feel
pain.
5. A provider accesses a blood vessel with a needle. They slide a
sheath (or tube) over the needle and into a large artery.Ad
6. They pass wires and catheters through the tube to the artery they’re
targeting.
7. An X-ray machine rotates around you (called fluoroscopy). It allows
the provider to see where the catheter is going from all angles.
8. Once your provider gets to the targeted artery, they put a special dye
into the tube. They look at X-rays to watch the dye go through your
artery. For a few seconds, you might feel flushed or like you need to
pee.
9. The provider can find the blockage or narrowing of your artery with
the imaging. They’ll cross the problem area with a guide wire. This
allows the balloon-tipped catheter to pass over the wire.
10. Once across the blockage, they’ll briefly inflate the balloon. They may
need to do this more than once.
11. The provider will look at more X-rays to see how much blood flow
has improved.
12. They’ll usually then put in a permanent stent. Stronger than a
balloon, the stent keeps the artery open after balloon removal.
ADVERTISEMENT
Ad
After the procedure, the healthcare provider takes out the catheter. A
provider will use a bandage to cover the place where the catheter went
into your skin. They’ll put pressure on the site to stop or prevent any
bleeding. You may need to lie on your back for a few hours if the catheter
was in your groin.
How long does angioplasty take?
A typical angioplasty procedure can take 30 minutes to two hours. You’ll
then need to recover in the hospital afterward. Your healthcare provider
can give you a better idea of what to expect for your overall hospital stay.
What are the risks of angioplasty?
The risks of angioplasty include:
A repeat blockage if you don’t get a stent in your artery
Abnormal heartbeats (arrhythmia)
Allergic reaction to the contrast dye or anesthetic
Blood vessel or kidney damage
Blood clots
Heart attack
Low blood pressure
Pain, bleeding or infection where a needle or catheter went into your
skin
Stroke
It’s a good idea to get angioplasty from a healthcare provider who does
them often (at a high-volume center). Most of the time, they’re safe
procedures. Serious complications are rare.Ad
You’re more likely to have complications if you:
Are over 65 years
Have kidney disease
Have several blocked arteries
Care at Cleveland Clinic
Cardiology Care
Cardiology Care for Children
Make an Appointment
Recovery and Outlook
What is the recovery time for angioplasty?
You’ll need to stay at the hospital for several hours or even overnight to
recover from angioplasty. If you’re leaving the hospital the same day,
someone else needs to drive you home.
ADVERTISEMENT
Ad
You may feel tired after the procedure. Get rest at home and drink fluids.
Your provider may tell you to limit your activities for a couple of days
after you get home. Your wound may be sensitive or bruised for a week
or more.
You may need to take medicines like aspirin or other blood thinners after
the angioplasty. If your provider prescribed blood thinners, it’s important
to take these as directed. Don’t miss any doses. If you think you need to
stop taking them, you should discuss it with your provider before you do.
You should be able to drive and go back to work about a week after the
angioplasty. But this can vary depending on the type. Check with your
provider.
When should I call my healthcare
provider?
You’ll have a follow-up visit after you go home. But you should contact
your healthcare provider after an angioplasty if:
You have bleeding or an infection where the catheter went through
your skin
Your leg color changes
It hurts or feels warm where the catheter was
Additional Common Questions
What is the success rate of angioplasty?Ad
The success rate of angioplasty varies for several reasons, including:
The type of angioplasty and the artery that’s blocked
The severity of the blockage
Your overall health
Your age
Your healthcare provider will give you a better idea of what you can
expect. Don’t hesitate to ask questions.
ADVERTISEMENT
Is angioplasty painful?
Overall, angioplasty should involve minimal pain. You may feel some
temporary mild pain or discomfort when the provider:
Inserts an IV line with a needle to give you a sedative
Injects local anesthesia
Inflates the angioplasty balloon
Ad
Beetasalpaajat - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Lääkehoito (https://sydan.fi/elamaa-sairauden-kanssa/laakehoito/)/Beetasalpaajat
Beetasalpaajat
(https://sydan.fi/fakta/beetasalpaajat/)
Beetasalpaajia käytetään monien rytmihäiriöiden, sepelvaltimotaudin,
sydämen vajaatoiminnan ja kohonneen verenpaineen hoidossa.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 30.6.2022
Päivitetty 10.10.2023
 
Lue seuraavaksi Nesteenpoistolääkkeet (diureetit) (https://sydan.fi/fakta/nesteenpoistolaakkeet-diureetit/)
Nämä lääkkeet ovat käytetyimpiä sydänlääkkeitä. Vaihtoehtoja on paljon, kuin
myös yksilöllisiä annosmahdollisuuksia.
Vaikutuskohde beetareseptorit
Beetareseptorit ovat adrenaliinin ja sen sukuisten sydämen toimintaa
kiihdyttävien hormonien vaikutuskohtia. Niitä on kahdenlaisia. Beeta-1-
reseptoreja on eniten sydämessä, beeta-2-reseptoreja muun muassa
keuhkoputkissa. Beetasalpaaja-lääkkeiden vaikutukset perustuvat sydämen
beeta-1-reseptorien salpaukseen.
Tällaisia erityisesti beeta-1-reseptoreja selektiivisesti salpaavia lääkeaineita ovat
asebutololi, atenololi, betaksololi, bisoprololi, metoprololi ja nebivololi. Joissain
tilanteissa myös beeta-2-reseptorien salpauksesta voi olla apua, esimerkiksi
tiettyjen vapinatyyppinen hoidossa. Tällöin käytetään propranololia.
Verisuonten seinämissä on alfareseptoreja ja niiden ärsytys supistaa verisuonia.
Siten alfareseptoreja salpaavilla lääkkeillä on verisuonia laajentavaa vaikutusta.
Karvediloli ja labetaloli salpaavat sekä alfa- että beetareseptoreja. Myös
nebivololilla on verisuonia laajentavaa vaikutusta, mikä perustuu muuhun kuin
alfareseptorien salpaukseen.
Beetasalpaajien vaikutukset eri sydänsairauksissa
Beetasalpaajilla on monia rytmihäiriöitä estäviä ja lievittäviä vaikutuksia. Niillä
on eteisvärinäkohtauksia (https://sydan.fi/fakta/eteisvarina/) estävää tehoa,
mutta erityisen hyödyllisiä ne ovat sykkeen rauhoittamisessa eteisvärinän
aikana. Oireet lievittyvät, kun sydämen syke laskee. Ne voivat vähentää terveen
sydämen lisälyöntejä (https://sydan.fi/fakta/lisalyonnit/) ja niistä aiheutuvia
tuntemuksia. Beetasalpaajia käytetään myös kammiotakykardioiden
(https://sydan.fi/fakta/kammiotakykardia/) estämiseen, esimerkiksi pitkä QT-
oireyhtymässä tai sydäninfarktin jälkeen.
Beetasalpaajat hidastavat lepopulssia ja rajoittavat sykkeen nopeutumista
rasituksessa. Ne myös vähentävät lievästi sydänlihaksen supistusvireyttä ja
alentavat verenpainetta. Näiden vaikutusten summana sydämen hapen- ja
energiantarve vähenee, mikä on eduksi sepelvaltimotaudissa
(https://sydan.fi/sydantietoa/sydansairaudet/sepelvaltimotauti/), kun angina
pectoris -oireet lievittyvät.Lue seuraavaksi Nesteenpoistolääkkeet (diureetit) (https://sydan.fi/fakta/nesteenpoistolaakkeet-diureetit/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Beetasalpaajat parantavat ennustetta sydämen heikosta pumppaustoiminnasta
johtuvassa vajaatoiminnassa (systolinen vajaatoiminta). Sydämen
vajaatoiminnassa (https://sydan.fi/sydantietoa/sydansairaudet/sydamen-
vajaatoiminta/) elimistö pyrkii käskyttämään sydäntä adrenaliinipiiskauksella.
Tämä kuluttaa sairaan sydämen vähäisiä energiavaroja ja altistaa rytmihäiriöille.
Beetasalpaajat hillitsevät tätä prosessia.
Näitä lääkkeitä on käytetty vuosikymmenien ajan kohonneen verenpaineen
(https://sydan.fi/sydantietoa/terveys-hyvinvointi/verenpaine/) hoitoon.
Nykypäivänä verenpaineen hoitoon valitaan ensilinjassa muita valmisteita, kuten
ACE-estäjä (https://sydan.fi/fakta/acen-estajat/), ATR:n salpaaja
(https://sydan.fi/fakta/atrn-salpaajat/) tai kalsiuminestäjä
(https://sydan.fi/fakta/kalsiuminestajat/). Beetasalpaajia voidaan edelleen
käyttää muiden lisänä, tai tilanteissa, joissa verenpaineen kohoamisen lisäksi
ongelmana on sykkeen kohoaminen.
Erityishuomioita beetasalpaajien käytöstä
Beetasalpaajat hidastavat sykettä. Vaikutus on usein annosriippuvainen.
Urheilevat ihmiset voivat kokea beetasalpaajat kiusallisina, koska niitä
käyttäessä väsyy rasituksessa helpommin.
Beetasalpaajat voivat huonontaa ääreisverenkiertoa, mikä tuntuu käsien ja
jalkojen kylmyytenä erityisesti pakkasilmoilla. Jos tämä on kiusallista, voidaan
valita valmiste, jolla on verisuonia laajentavaa vaikutusta. Alaraajavaltimoiden
ahtautumisesta johtuva katkokävely ei yleensä ole este beetasalpaajien käytölle.
Astma voi pahentua, mutta tämä on yleensä vältettävissä valmisteen ja
annoksen oikealla valinnalla. Ihottuma, kuten psoriasis voi pahentua.
Painajaisunet ja miehillä erektiohäiriöt voivat olla mahdollisia, mutta onneksi
harvinaisia haittoja.
Jos beetasalpaajahoito lopetetaan, se on yleensä tehtävä vähitellen annosta
pienentäen 1 – 2 viikon aikana, ellei käytetty annos ole ollut pieni. Äkillinen
lopettaminen voi aiheuttaa sydämentykytystä. Eräitä beetasalpaajia, kuten
bisoprololia ja propranololia voidaan käyttää myös vain tarvittaessa, jos
rytmihäiriötuntemuksia esiintyy harvoin. Lääkäri antaa tarkat ohjeet, jos
lääkettä on lupa käyttää tällä tavoin.Lue seuraavaksi Nesteenpoistolääkkeet (diureetit) (https://sydan.fi/fakta/nesteenpoistolaakkeet-diureetit/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Beetasalpaajilla on taulukossa mainituin poikkeuksin alempi erityiskorvaus (65 %)
kroonisessa verenpainetaudissa, kroonisessa sepelvaltimotaudissa ja kroonisissa
sydämen rytmihäiriöissä.
 
Lääkeaine Valmistenimet Huomauksia
Asebutololi Diasectral Ei valmistetta tällä hetkellä
AtenololiAtenblock
Tenoprin
BisoprololiBisoproact
Emconcor
Orloc
Bisoprolol *Bisoprolol-nimellä rinnakkaisvalmisteita seitsemältä
lääkeyritykseltä
KarvediloliCardiol
Carveratio
CarvedilolAlfa- ja beetasalpaaja. Alempi erityiskorvaus
kroonisessa sydämen vajaatoiminnassa ja
kroonisessa verenpainetaudissa. Carvedilol-nimellä
rinnakkaisvalmisteita kolmelta lääkeyritykseltä.
LabetaloliAlbetol
LabetalolAlfa- ja beetasalpaaja, ei sv-korvausta. Käytetään
erityisesti raskausajan kohonneen verenpaineen
hoidossa
MetoprololiMetohexal
Metomylan
Metoprolin
Seloken
Spesicor
MetoprololMetoprolol-nimellä rinnakkaisvalmisteita kolmelta
lääkeyritykseltä
NebivololiHypoloc
Nebivolol OrionPeruskorvaus
PindololiPinloc
ViskenErityislupavalmisteita
PropranololiDociton retard
(erityislupavalmiste)
Propral
Ranoprin
Inderal
PropranololPropranolol-nimellä rinnakkaisvalmisteita kolmelta
lääkeyritykseltä
Seliprololi Celiprolol Vitabalans
SotaloliSotacor
Sotalol MylanKäytetään lähinnä rytmihäiriölääkkeenä, k.s. myös
RytmihäiriölääkkeetLue seuraavaksi Nesteenpoistolääkkeet (diureetit) (https://sydan.fi/fakta/nesteenpoistolaakkeet-diureetit/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sydänyhteisön jäsenyydellä tuet toimintaamme
LIITY MUKAAN (HTTPS://SYDAN.FI/LIITY-JASENEKSI)Lue seuraavaksi Nesteenpoistolääkkeet (diureetit) (https://sydan.fi/fakta/nesteenpoistolaakkeet-diureetit/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Coronary Arteries_ Anatomy and Function.pdf
Locations:
Coronary Arteries
The right and left coronary arteries supply blood to your heart. They’re
the first branches off the aorta, which is the main artery in your body.
These arteries and their branches supply all parts of the heart muscle
with blood.
ContentsOverviewFunctionAnatomyConditions and Disorders
CareAdditional Common Questions
Overview
What are coronary arteries?
The coronary arteries are major blood vessels in your body, supplying
blood to your heart. They make it possible for your heart to beat and
pump blood throughout your body. You have a right coronary artery
(RCA) and a left main coronary artery (LMCA). Each contains smaller
branches that go deep inside your heart muscle.
ADVERTISEMENTAbu Dhabi|Canada|Florida|London|Nevada|Ohio
Ad
Cleveland Clinic is a non-profit academic medical
center. Advertising on our site helps support our
mission. We do not endorse non-Cleveland Clinic
products or services.Policy
Care at Cleveland Clinic
Get Coronary Artery Disease Treatment
Find a Doctor and Specialists
Make an Appointment
Function
What is the purpose of the coronary
artery?
The function of the coronary arteries and their branches is to supply your
heart with blood. Your heart muscles need the oxygen and nutrients in
blood so they can pump blood through your heart and the rest of your
body.Ad
Anatomy
Where are the coronary arteries located?
Your coronary arteries are around and inside your heart muscle. They
branch off your aorta, which is the main artery in your body. They start at
the aortic root, which is the first part of your aorta that emerges from the
left ventricle of your heart. The left ventricle is where oxygenated blood
leaves your heart and starts its journey through your body. The coronary
artery branches are the first of many branches off your aorta.
Coronary artery structure
There are two coronary arteries, each containing several branches:
Right coronary artery (RCA): The RCA supplies blood to your right
atrium and right ventricle (where deoxygenated blood goes before
heading to the lungs). Its branches supply the sinoatrial (SA) and
atrioventricular (AV) nodes. These nodes send electrical signals
through your heart, so the heart muscles know when to contract.
Branches of the RCA also deliver blood to one-third of your
interventricular septum, which is the wall between your heart’s two
lower chambers.
Left main coronary artery (LMCA): The LMCA supplies blood to your
left atrium and left ventricle. This is where oxygenated blood arrives
from your lungs before your heart pumps it out to the rest of your
body. Its branches supply blood to the other two-thirds of your
interventricular septum.
ADVERTISEMENTAd
Is the structure of the coronary artery always the
same?
It’s important to note that sometimes the structure of the coronary artery
branches varies from person to person. Some examples are:
Coronary arteries are usually surrounded by a layer of fat but in some
people the arteries are within the heart muscle itself.
Blood supply to the SA and AV nodes comes from the LCMA, not the
RCA, in about 10% of people.
Sometimes a single coronary artery arises from the aorta, then
divides into right and left branches.
Most of these variations aren’t harmful and don’t produce symptoms. But
in rare cases (less than 1% of people) coronary artery abnormalities can
lead to serious problems or even death.
How big are the coronary arteries?
The main coronary arteries are usually between 3 and 4 millimeters in
diameter. That’s a little smaller than the width of a drinking straw. The
sizes of the arteries vary slightly according to your sex, body weight and
even ethnicity.Ad
What are the coronary arteries made of?
The walls of all arteries, including the coronary arteries, contain three
layers:
Tunica intima: The inner layer touches your blood and keeps it
flowing smoothly through your arteries.
Media: The middle layer is elastic, so it expands and contracts to
maintain the right blood pressure in your arteries.
Adventitia: The outer layer contains tiny vessels that deliver oxygen
and nutrients from your blood to the cells in your heart.
Conditions and Disorders
What conditions and disorders affect the
coronary arteries?
Coronary artery disease (CAD) is the most common condition that
affects your coronary arteries. CAD is often the result of atherosclerosis,
which is plaque buildup inside your arteries. Clogged arteries prevent
blood from getting to your heart, which can lead to a heart attack.
Acute coronary syndrome is a condition that results in a sudden loss of
blood flow to your heart through your coronary arteries. A heart attack is
a type of acute coronary syndrome. Like CAD, these conditions are also a
result of atherosclerosis.
Less common conditions that affect your coronary arteries include:
Aneurysms: Bulges in a blood vessel wall.
Congenital (present at birth) abnormalities in your arteries.Ad
Coronary spasms: Sudden tightening of the muscles in your arteries.
When these muscles tighten or spasm, your arteries are temporarily
blocked. This can lead to chest pain called Prinzmetal angina.
Care
How can I keep my coronary arteries
healthy?
Keep your heart and coronary arteries healthy by:
Eating a healthy, balanced diet low in sodium, cholesterol and
saturated fats.
Exercising regularly.
Managing your blood pressure.
Not smoking or using tobacco products.
Reducing alcohol consumption.
Additional Common Questions
When should I call my doctor?
Call 911 right away if you experience any of the following symptoms,
which could be signs of a heart attack:
ADVERTISEMENT
Ad
Chest pain.
Cold sweat.
Jaw, neck, back, arm or shoulder pain.
Shortness of breath.
Weakness or light-headedness.
A note from Cleveland Clinic
Your coronary arteries carry blood to your heart. They supply your heart
muscles with the oxygen and nutrients they need to pump blood through
your body. Coronary artery disease (CAD) occurs if these arteries clog
and don’t deliver enough blood to your heart. You can reduce your risk of
CAD or a heart attack by exercising, eating a healthy diet and not
smoking or using tobacco products.
ADVERTISEMENT
Ad
Coronary angioplasty and stent insertion - NHS.pdf
 (Link: www.nhs.uk/)
Overview
Coronary angioplasty and stent insertion
A coronary angioplasty is a procedure used to widen blocked or narrowed coronary arteries (the main blood vessels
supplying the heart).
The term "angioplasty" means using a balloon to stretch open a narrowed or blocked artery. However, most modern
angioplasty procedures also involve inserting a short wire mesh tube, called a stent, into the artery during the procedure.
The stent is left in place permanently to allow blood to flow more freely.
Coronary angioplasty is sometimes known as percutaneous transluminal coronary angioplasty (PTCA). The combination of
coronary angioplasty with stenting is usually referred to as percutaneous coronary intervention (PCI).
When a coronary angioplasty is used
Like all organs in the body, the heart needs a constant supply of blood. This is supplied by the coronary arteries.
In some people, these arteries can become narrowed and hardened (known as atherosclerosis (Link:
www.nhs.uk/conditions/atherosclerosis/)), which can cause coronary heart disease (Link: www.nhs.uk/conditions/coronary-
heart-disease/).
If the flow of blood to the heart becomes restricted, it can lead to chest pain known as angina (Link:
www.nhs.uk/conditions/angina/), which is usually triggered by physical activity or stress.
While angina can often be treated with medication, a coronary angioplasty may be required to restore the blood supply
to the heart in severe cases where medication is ineffective.
Coronary angioplasties are also often used as an emergency treatment after a heart attack (Link:
www.nhs.uk/conditions/heart-attack/).
What are the benefits of a coronary angioplasty?
In most cases, the blood flow through the coronary arteries improves after an angioplasty. Many people
find their symptoms get significantly better and they're able to do more than they could before the procedure.
If you've had a heart attack, an angioplasty can increase your chances of surviving more than clot-busting medication
(thrombolysis). The procedure can also reduce your chances of having another heart attack in the future.
How a coronary angioplasty is performed
A coronary angioplasty is performed using local anaesthetic (Link: www.nhs.uk/conditions/local-anaesthesia/), which
means you'll be awake while the procedure is carried out.
A thin, flexible tube called a catheter will be inserted into one of your arteries through an incision in your groin, wrist or
arm. This is guided to the affected coronary artery using an X-ray (Link: www.nhs.uk/conditions/x-ray/) video.
When the catheter is in place, a thin wire is guided down the length of the affected coronary artery, delivering a small
balloon to the affected section of artery. This is then inflated to widen the artery, squashing fatty deposits against the
artery wall so blood can flow through it more freely when the deflated balloon is removed.
If a stent is being used, this will be around the balloon before it's inserted. The stent will expand when the balloon is
inflated and remains in place when the balloon is deflated and removed.
A coronary angioplasty usually takes between 30 minutes and 2 hours. If you're being treated for angina, you'll normally
be able to go home later the same day or the day after you have the procedure. You'll need to avoid heavy lifting,
strenuous activities and driving for at least a week.
If you've been admitted to hospital following a heart attack, you may need to stay in hospital for several days after the
angioplasty procedure before going home.
Read more about: 
What happens during a coronary angioplasty (Link: www.nhs.uk/conditions/coronary-angioplasty/what-happens/)You can change your cookie settings at any time using our cookies page (Link: www.nhs.uk/our-policies/cookies-policy/).
Health A-Z (Link: www.nhs.uk/conditions/) NHS services (Link: www.nhs.uk/nhs-services/) Live Well (Link: www.nhs.uk/live-well/) M
Overview
How it's performed (Link: www.nhs.uk/conditions/coronary-angioplasty/what-happens/)
Recovery (Link: www.nhs.uk/conditions/coronary-angioplasty/recovery/)
Risks (Link: www.nhs.uk/conditions/coronary-angioplasty/risks/)
Alternatives (Link: www.nhs.uk/conditions/coronary-angioplasty/alternatives/)
Recovering from a coronary angioplasty (Link: www.nhs.uk/conditions/coronary-angioplasty/recovery/)
How safe is a coronary angioplasty?
A coronary angioplasty is 1 of the most common types of treatment for the heart.
As the procedure doesn't involve making major incisions in the body, it's usually carried out safely in most people. Doctors
refer to this as a minimally invasive form of treatment.
The risk of serious complications from a coronary angioplasty is generally small, but this depends on factors such as:
your age
your general health
whether you've had a heart attack
Serious problems that can occur as a result of the procedure include:
excessive bleeding
a heart attack
a stroke (Link: www.nhs.uk/conditions/stroke/)
Read more about the possible complications of a coronary angioplasty (Link: www.nhs.uk/conditions/coronary-
angioplasty/risks/).
Are there any alternatives?
If many coronary arteries have become blocked and narrowed, or the structure of your arteries is abnormal, a coronary
artery bypass graft (Link: www.nhs.uk/conditions/coronary-artery-bypass-graft-cabg/) may be considered.
This is a type of invasive surgery where sections of healthy blood vessel are taken from other parts of the body and
attached to the coronary arteries. Blood is diverted through these vessels, so it bypasses the narrowed or clogged parts of
the arteries.
Read more about the alternatives to a coronary angioplasty (Link: www.nhs.uk/conditions/coronary-
angioplasty/alternatives/).
Page last reviewed: 04 October 2022
Next review due: 04 October 2025
Dyslipidemioiden hoito.pdf
Dys li pi de mioi den hoito
Dyslipidemiahoidon päätavoitteena on  ehkäistä ja hoitaa
valtimokovettumatautia, joka voi aiheuttaa sydän tai- aivoinfarktin ja
katkokävelyä.
Monesti kolesteroliarvot paranevat jo pelkillä elämäntapam uutoksilla. Ruokavaliohoito ja
liikunnan lisääminen, mahdollisen tupakoinnin lopettaminen ja ylipainoisella laihduttaminen
voivat palauttaa kolesteroliarvot normaaleiksi.
Tärkeintä on muuttaa ruokavalion rasvan laatua. Kasviöljyt, erityisesti rypsiöljy,
kasvisrasvapohjaiset levitteet sekä kalat ovat hyviä pehmeän, tyydyttymättömän rasvan
lähteitä. Jos HDL-arvo on matala, ovat kestävyysliikunnan lisääminen, laihduttaminen ja
tupakoinnin lopettaminen paikallaan. Jos triglyseridiarvo on suurentunut, kannattaa vähentää
ruokavaliosta kokonaisrasvan määrää sekä vähentää alkoholinkäyttöä. Suuren riskin potilaille
tulisi elämäntapamuutoksiin tähtäävän ohjauksen ohella aloittaa mahdollisimman varhain myös
lääkehoito, useimmiten statiinilääkitys.
Aiheeseen liittyvää
Tarkistettu 13.12.2019Omahoito
ESC_Guidelines.pdf
2023 ESC Guidelines for the management 
of acute coronary syndromes
Developed by the task force on the management of acute coronary 
syndromes of the European Society of Cardiology (ESC)
Authors/Task Force Members: Robert A. Byrne  
 *†, (Chairperson) (Ireland), 
Xavier Rossello  
‡, (Task Force Co-ordinator) (Spain), J.J. Coughlan  
‡, 
(Task Force Co-ordinator) (Ireland), Emanuele Barbato  
 (Italy), Colin Berry  
(United Kingdom), Alaide Chieffo  
 (Italy), Marc J. Claeys  
 (Belgium), 
Gheorghe-Andrei Dan  
 (Romania), Marc R. Dweck  
 (United Kingdom), 
Mary Galbraith  
 (United Kingdom), Martine Gilard (France), 
Lynne Hinterbuchner  
 (Austria), Ewa A. Jankowska  
 (Poland), Peter Jüni 
(United Kingdom), Takeshi Kimura (Japan), Vijay Kunadian  
 (United Kingdom), 
Margret Leosdottir  
 (Sweden), Roberto Lorusso  
 (Netherlands), 
Roberto F.E. Pedretti  
 (Italy), Angelos G. Rigopoulos  
 (Greece), 
Maria Rubini Gimenez  
 (Germany), Holger Thiele (Germany),  
Pascal Vranckx (Belgium), Sven Wassmann (Germany), Nanette Kass Wenger 
(United States of America), Borja Ibanez  
 *†, (Chairperson) (Spain), and ESC 
Scientific Document Group
* Corresponding authors: Robert A. Byrne, Department of Cardiology and Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, Dublin, Ireland, and School of Pharmacy 
and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland. Tel: +353-1-2483190, E-mail: robertabyrne@rcsi.ie; and Borja Ibanez, Clinical Research 
Department, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, and Cardiology Department, IIS-Fundación Jiménez Díaz University Hospital, Madrid, Spain, CIBERCV, ISCIII, Madrid, Spain. Tel: +3491 4531200, E-mail: bibanez@cnic.es
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
and Heart Failure Association (HFA).
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, E-Cardiology, Myocardial and Pericardial Diseases, Thrombosis.
Patient Forum  
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC 
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the 
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; 
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from 
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case 
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices at the time of prescription.
This article is co-published with permission in European Heart Journal and European Heart Journal - Acute Cardiovascular Care. All rights reserved. © The European Society of Cardiology 
2023. The articles are identical except for stylistic differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions, please e-mail: 
journals.permissions@oup.comEuropean Heart Journal (2023) 44, 3720–3826 
https://doi.org/10.1093/eurheartj/ehad191
ESC GUIDELINESDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Document Reviewers: Sigrun Halvorsen, (Clinical Practice Guidelines Review Co-ordinator) (Norway), 
Stefan James, (Clinical Practice Guidelines Review Co-ordinator) (Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Nina Ajmone Marsan (Netherlands), Sotiris Antoniou (United Kingdom), 
Riccardo Asteggiano (Italy), Maria Bäck (Sweden), Davide Capodanno (Italy), Ruben Casado-Arroyo (Belgium), 
Salvatore Cassese (Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France), 
Gregory Ducrocq (France), Volkmar Falk (Germany), Laurent Fauchier (France), Tobias Geisler (Germany), Diana 
A. Gorog (United Kingdom), Lene Holmvang (Denmark), Tiny Jaarsma (Sweden), Hywel Wynne Jones (United 
Kingdom), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), 
Konstantin A. Krychtiuk (Austria), Ulf Landmesser (Germany), George Lazaros (Greece), Basil S. Lewis (Israel), 
Bertil Lindahl (Sweden), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Mamas A. Mamas (United 
Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United 
Kingdom), Christian Mueller (Switzerland), Lis Neubeck (United Kingdom), Josef Niebauer (Austria), Jens 
Cosedis Nielsen (Denmark), Alexander Niessner (Austria), Valeria Paradies (Netherlands), Agnes A. Pasquet 
(Belgium), Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), 
Bianca Rocca (Italy), Giuseppe M.C. Rosano (Italy), Leyla Elif Sade (United States of America / Türkiye), 
François Schiele (France), Jolanta M. Siller-Matula (Austria), Christian Sticherling (Switzerland), Robert F. Storey 
(United Kingdom), Matthias Thielmann (Germany), Christiaan Vrints (Belgium), Stephan Windecker (Switzerland), Rune Wiseth (Norway), and Adam Witkowski (Poland)
All experts involved in the development of these guidelines have submitted declarations of interest. These have 
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary documents that include background information and 
evidence tables.
Keywords Guidelines • Acute cardiac care • Acute coronary syndrome • Antithrombotic therapy • Fibrinolysis • High- 
sensitivity troponin • Invasive strategy • MINOCA • Myocardial infarction • Non-ST-elevation myocardial infarction 
• Patient-centred care • Percutaneous coronary intervention • Recommendations • Reperfusion therapy • 
Revascularization • Secondary prevention • ST-segment elevation myocardial infarction • Unstable angina
Table of contents
1. Preamble .............................................................................................................. 3727
2. Introduction ....................................................................................................... 3728
2.1. Definitions | Acute coronary syndromes and myocardial 
infarction ............................................................................................................. 3730
2.2. Epidemiology of acute coronary syndromes .............................. 3732
2.3. Number and breakdown of classes of recommendations ... 3732
2.4. What is new ............................................................................................. 3733
3. Triage and diagnosis ........................................................................................ 3735
3.1. Clinical presentation and physical examination ......................... 3735
3.1.1. Clinical presentation ...................................................................... 3735
3.1.2. History taking and physical examination .............................. 3737
3.2. Diagnostic tools | Electrocardiogram ............................................ 3737
3.2.1. Acute coronary syndrome with persistent ST-segment 
elevation (suspected ST-elevation myocardial infarction) ......... 3738
3.2.2. Acute coronary syndrome without persistent ST- 
segment elevation (non-ST elevation acute coronary 
syndrome) ...................................................................................................... 3738
3.3. Diagnostic tools | Biomarkers ........................................................... 3739
3.3.1. High-sensitivity cardiac troponins ............................................ 37393.3.2. Central laboratory vs. point of care ....................................... 3739
3.3.3. Confounders of cardiac troponin concentration ............. 3739
3.3.4. Rapid ‘rule-in’ and ‘rule-out’ algorithms ................................ 3739
3.3.4.1. European Society of Cardiology 0 h/1 h and 0 h/2 h 
algorithms .................................................................................................. 3740
3.3.4.1.1. Rule-out ............................................................................. 3740
3.3.4.1.2. Rule-in ................................................................................ 3740
3.3.4.1.3. Observe ............................................................................. 3740
3.3.4.2. Practical guidance on how to implement the 
European Society of Cardiology 0 h/1 h algorithm ................. 3742
3.3.5. Other biomarkers .......................................................................... 3742
3.4. Diagnostic tools | Non-invasive imaging ....................................... 3742
3.4.1. Echocardiography ........................................................................... 3742
3.4.2. Computed tomography ............................................................... 3742
3.4.3. Cardiac magnetic resonance imaging with or without 
stress testing ................................................................................................. 3742
3.5. Differential diagnosis for acute chest pain .................................. 3743
4. Initial measures for patients presenting with suspected acute coronary syndrome | Initial treatment ........................................................ 3743
4.1. Pre-hospital logistics of care .............................................................. 3743
4.1.1. Time to treatment ......................................................................... 3743ESC Guidelines                                                                                                                                                                                          3721Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

4.1.2. Healthcare systems and system delays .................................. 3743
4.1.3. Emergency medical services ....................................................... 3743
4.1.4. General practitioners .................................................................... 3744
4.1.5. Organization of ST-elevation myocardial infarction 
treatment in networks .............................................................................. 3744
4.2. Emergency care ....................................................................................... 3744
4.2.1. Initial diagnosis and monitoring ................................................ 3744
4.2.2. Acute pharmacotherapy .............................................................. 3744
4.2.2.1. Oxygen ....................................................................................... 3744
4.2.2.2. Nitrates ...................................................................................... 3744
4.2.2.3. Pain relief ................................................................................... 3744
4.2.2.4. Intravenous beta-blockers .................................................. 3744
5. Acute-phase management of patients with acute coronary syndrome .................................................................................................................. 3745
5.1. Selection of invasive strategy and reperfusion therapy ......... 3745
5.2. Acute coronary syndrome managed with invasive strategy 3745
5.2.1. Primary percutaneous coronary intervention strategy for 
ST-elevation myocardial infarction ...................................................... 3745
5.2.1.1. Invasive strategy in ST-elevation myocardial infarction 
late presenters ......................................................................................... 3747
5.2.2. Immediate invasive strategy for non-ST elevation acute 
coronary syndrome .................................................................................... 3747
5.2.3. Routine vs. selective invasive strategy .................................... 3747
5.2.3.1. Early vs. delayed invasive strategy for non-ST elevation acute coronary syndrome .............................................. 3747
5.2.4. Summary of invasive strategies for patients with non-ST 
elevation acute coronary syndrome ................................................... 3747
5.3. Fibrinolysis and pharmaco-invasive strategy in patients with 
ST-elevation myocardial infarction .......................................................... 3749
5.3.1. Benefit and indication of fibrinolysis ....................................... 3749
5.3.1.1. Pre-hospital fibrinolysis ........................................................ 3749
5.3.1.2. Angiography and percutaneous coronary 
intervention after fibrinolysis (pharmaco-invasive strategy) 3749
5.3.1.2.1. Comparison of fibrinolytic agents .......................... 3749
5.3.1.2.2. Hazards of fibrinolysis and contraindications .... 3749
5.4. Patients not undergoing reperfusion ............................................. 3749
5.4.1. Patients who are not candidates for invasive coronary 
angiography .................................................................................................... 3749
5.4.2. Patients with coronary artery disease not amenable to 
revascularization .......................................................................................... 3749
6. Antithrombotic therapy ................................................................................ 3750
6.1. Antiplatelet therapy in the acute phase ....................................... 3752
6.1.1. Oral antiplatelet therapy ............................................................. 3752
6.1.2. Timing of loading dose of oral antiplatelet therapy ......... 3753
6.1.2.1. Pre-treatment in patients with suspected ST- elevation myocardial infarction ........................................................ 3753
6.1.2.2. Pre-treatment in patients with non-ST-elevation acute coronary syndrome .................................................................. 3753
6.1.2.3. Summary of pre-treatment strategies ........................... 3753
6.1.3. Intravenous antiplatelet drugs ................................................... 3753
6.2. Anticoagulant treatment in the acute phase .............................. 3754
6.2.1. Anticoagulation in patients with ST-elevation myocardial 
infarction undergoing primary percutaneous coronary 
intervention ................................................................................................... 3754
6.2.2. Anticoagulation in patients with non-ST-elevation acute 
coronary syndrome undergoing angiography and percutaneous 
coronary intervention if indicated ....................................................... 3754
6.3. Maintenance antithrombotic therapy after revascularization 37556.3.1. Shortening dual antiplatelet therapy ....................................... 3756
6.3.2. De-escalation from potent P2Y
12 inhibitor to 
clopidogrel ..................................................................................................... 3756
6.3.3. Summary of alternative antiplatelet strategies to reduce 
bleeding risk in the first 12 months after acute coronary 
syndrome ........................................................................................................ 3757
6.4. Long-term treatment ............................................................................ 3759
6.4.1. Prolonging antithrombotic therapy beyond 12 months 3759
6.5. Antiplatelet therapy in patients requiring oral anticoagulation ................................................................................................. 3760
6.5.1. Acute coronary syndrome patients requiring anticoagulation ............................................................................................. 3760
6.5.2. Patients requiring vitamin K antagonists or undergoing 
coronary artery bypass surgery ............................................................ 3762
6.6. Antithrombotic therapy as an adjunct to fibrinolysis ............. 3762
6.7. Antithrombotic therapy in patients not undergoing reperfusion ......................................................................................................... 3762
7. Acute coronary syndrome with unstable presentation .................. 3762
7.1. Out-of-hospital cardiac arrest in acute coronary syndrome 3763
7.1.1. Systems of care ................................................................................ 3763
7.2. Cardiogenic shock complicating acute coronary syndrome 3763
8. Management of acute coronary syndrome during hospitalization 3764
8.1. Coronary care unit/intensive cardiac care unit ......................... 3764
8.1.1. Monitoring ......................................................................................... 3764
8.1.2. Ambulation ........................................................................................ 3764
8.1.3. Length of stay in the intensive cardiac care unit ............... 3765
8.2. In-hospital care ........................................................................................ 3765
8.2.1. Length of hospital stay ................................................................. 3765
8.2.2. Risk assessment ............................................................................... 3765
8.2.2.1. Clinical risk assessment ........................................................ 3765
8.2.2.2. Imaging risk assessment ....................................................... 3765
8.2.2.3. Biomarkers for risk assessment ....................................... 3765
8.2.2.4. Bleeding risk assessment .....................................................
3765
8.2.2.5. Integrating ischaemic and bleeding risks ....................... 3765
9. Technical aspects of invasive strategies .................................................. 3766
9.1. Percutaneous coronary intervention ............................................. 3766
9.1.1. Vascular access ................................................................................ 3766
9.1.2. Intravascular imaging/physiology of the infarct-related 
artery ................................................................................................................ 3766
9.1.2.1. Intravascular imaging ............................................................. 3766
9.1.2.2. Intravascular physiology ....................................................... 3767
9.1.3. Timing of revascularization with percutaneous coronary intervention ................................................................................................... 3767
9.1.4. Balloons and stents ........................................................................ 3768
9.1.5. Embolic protection and microvascular salvage strategies 3768
9.1.5.1. Thrombus aspiration ............................................................ 3768
9.1.5.2. Interventions to protect the microcirculation .......... 3768
9.2. Coronary artery bypass grafting ...................................................... 3768
9.2.1. Indication and timing of coronary artery bypass grafting in 
acute coronary syndrome patients ..................................................... 3768
9.2.2. Technical considerations specific to acute coronary 
syndrome patients ...................................................................................... 3768
9.3. Spontaneous coronary artery dissection ..................................... 3768
9.3.1. Intravascular imaging ..................................................................... 3769
9.3.2. Revascularization ............................................................................. 3769
10. Management of patients with multivessel disease ........................... 3769
10.1. Management of multivessel disease in acute coronary syndrome complicated by cardiogenic shock ..................................... 37693722                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

10.2. Patients with multivessel coronary artery disease 
undergoing primary percutaneous coronary intervention ............ 3770
10.3. Timing of non-infarct-related artery revascularization in 
acute coronary syndrome ........................................................................... 3771
10.3.1. Patients presenting with ST-elevation myocardial infarction and multivessel coronary artery disease ...................... 3771
10.3.2. Patients presenting with non-ST-elevation acute 
coronary syndrome and multivessel coronary artery disease . 3771
10.4. Evaluation of non-infarct-related artery stenosis severity 
(angiography vs. physiology) ....................................................................... 3771
10.5. Hybrid revascularization ................................................................... 3772
11. Myocardial infarction with non-obstructive coronary arteries . 3772
12. Special situations ............................................................................................ 3775
12.1. Type 2 myocardial infarction and acute myocardial injury 3775
12.2. Complications ....................................................................................... 3775
12.2.1. Heart failure ................................................................................... 3775
12.2.2. Mechanical complications ......................................................... 3776
12.2.3. Left ventricular thrombus ......................................................... 3776
12.2.4. Post-acute coronary syndrome pericarditis ..................... 3776
12.2.5. Arrhythmias .................................................................................... 3776
12.2.5.1. Atrial fibrillation .................................................................... 3776
12.2.5.2. Ventricular arrhythmias .................................................... 3777
12.2.6. Bleeding ............................................................................................ 3777
12.2.6.1. Management of bleeding .................................................. 3777
12.3. Comorbid conditions ......................................................................... 3778
12.3.1. Patients at high bleeding risk and with blood disorders 
(anaemia and thrombocytopaenia) ..................................................... 3778
12.3.2. Chronic kidney disease .............................................................. 3779
12.3.3. Diabetes mellitus .......................................................................... 3779
12.3.4. Older adults with frailty and multimorbidity ................... 3779
12.3.4.1. The older person ................................................................. 3779
12.3.4.2. Frailty and multimorbidity ................................................ 3779
12.3.5. Pregnancy ........................................................................................ 3780
12.3.6. Drug abuse ...................................................................................... 3780
12.3.7. Patients with cancer .................................................................... 3780
12.3.8. Coronavirus disease (COVID-19) ........................................ 3780
13. Long-term treatment ................................................................................... 3781
13.1. Cardiac rehabilitation ......................................................................... 3783
13.1.1. Comprehensive cardiac rehabilitation ................................. 3783
13.1.2. Digital health .................................................................................. 3783
13.1.3. Adherence and persistence ..................................................... 3783
13.2. Lifestyle management ......................................................................... 3783
13.2.1. Tobacco ........................................................................................... 3783
13.2.2. Nutrition and alcohol ................................................................. 3783
13.2.3. Physical activity and exercise .................................................. 3784
13.2.4. Psychological considerations ................................................... 3784
13.2.5. Resumption of activities ............................................................ 3784
13.3. Pharmacological treatment .............................................................. 3784
13.3.1. Antithrombotic therapy ............................................................ 3784
13.3.2. Lipid-lowering therapy ............................................................... 3784
13.3.3. Beta-blockers ................................................................................. 3785
13.3.4. Nitrates and calcium channel blockers ............................... 3786
13.3.5. Renin–angiotensin–aldosterone system inhibitors ......... 3786
13.3.6. Medications for diabetes ........................................................... 3786
13.3.6.1. Sodium–glucose co-transporter 2 inhibitors ........... 3786
13.3.6.2. Glucagon-like peptide-1 receptor agonists .............. 3787
13.3.7. Proton pump inhibitors ............................................................. 378713.3.8. Vaccination ...................................................................................... 3787
13.3.9. Anti-inflammatory drugs ........................................................... 3787
13.3.10. Hormone replacement therapy .......................................... 3787
14. Patient perspectives ..................................................................................... 3788
14.1. Patient-centred care ........................................................................... 3788
14.2. Shared decision-making ..................................................................... 3789
14.3. Informed consent ................................................................................ 3789
14.4. Research participation and consent in the acute setting .... 3790
14.5. Patient satisfaction and expectations .......................................... 3790
14.6. Patient-reported outcome measures and patient-reported 
experience measures ..................................................................................... 3791
14.7. Preparation for discharge ................................................................. 3791
15. Key messages .................................................................................................. 3791
16. Gaps in evidence ............................................................................................ 3793
17. Sex differences ............................................................................................... 3795
18. ‘What to do’ and ‘What not to do’ messages from the Guidelines ................................................................................................................. 3796
19. Quality indicators .......................................................................................... 3801
20. Supplementary data ...................................................................................... 3801
21. Data availability statement ......................................................................... 3801
22. Author information ...................................................................................... 3801
23. Appendix ........................................................................................................... 3801
24. References ........................................................................................................ 3802
Tables of Recommendations
Recommendation Table 1 — Recommendations for clinical and 
diagnostic tools for patients with suspected acute coronary 
syndrome .................................................................................................................. 3738
Recommendation Table 2 — Recommendations for non-invasive 
imaging in the initial assessment of patients with suspected acute 
coronary syndrome .............................................................................................. 3742
Recommendation Table 3 — Recommendations for the initial 
management of patients with acute coronary syndrome ................... 3745
Recommendation Table 4 — Recommendations for reperfusion 
therapy and timing of invasive strategy ....................................................... 3750
Recommendation Table 5 — Recommendations for antiplatelet and 
anticoagulant therapy in acute coronary syndrome .............................. 3758
Recommendation Table 6 — Recommendations for  
alternative antithrombotic therapy regimens ........................................... 3759
Recommendation Table 7 — Recommendations for fibrinolytic 
therapy ....................................................................................................................... 3762
Recommendation Table 8 — Recommendations for cardiac arrest and out-of-hospital cardiac arrest ................................................................. 3763
Recommendation Table 9 — Recommendations for cardiogenic 
shock .......................................................................................................................... 3764
Recommendation Table 10 — Recommendations for in-hospital 
management ............................................................................................................ 3766
Recommendation Table 11 — Recommendations for technical 
aspects of invasive strategies ............................................................................ 3769
Recommendation Table 12 — Recommendations for management of patients with multivessel disease .............................................................. 3772
Recommendation Table 13 — Recommendations for myocardial 
infarction with non-obstructive coronary arteries ................................. 3775
Recommendation Table 14 — Recommendations for acute 
coronary syndrome complications ................................................................ 3777
Recommendation Table 15 — Recommendations for acute 
coronary syndrome comorbid conditions ................................................. 3781ESC Guidelines                                                                                                                                                                                          3723Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Recommendation Table 16 — Recommendations for long-term 
management ............................................................................................................ 3787
Recommendation Table 17 — Recommendations for patient 
perspectives in acute coronary syndrome care ....................................... 3791
List of tables
Table 1 Classes of recommendations .......................................................... 3728
Table 2 Levels of evidence ................................................................................ 3728
Table 3 Definitions of terms related to invasive strategy and reperfusion therapy commonly used in this document ....................... 3731
Table 4 New recommendations .................................................................... 3733
Table 5 Revised recommendations ............................................................... 3734
Table 6 Dose regimen of antiplatelet and anticoagulant drugs in 
acute coronary syndrome patients ............................................................... 3751
Table 7 Suggested strategies to reduce bleeding risk related to 
percutaneous coronary intervention ............................................................ 3760
Table 8 Gaps in evidence .................................................................................. 3793
Table 9 ‘What to do’ and ‘What not to do’ ............................................. 3796
List of figures
Figure 1 Central illustration .............................................................................. 3729
Figure 2 The spectrum of clinical presentations, electrocardiographic findings, and high-sensitivity cardiac troponin levels in patients with 
acute coronary syndrome ................................................................................. 3730
Figure 3 Classification of patients presenting with suspected acute 
coronary syndrome: from a working to a final diagnosis .................... 3732
Figure 4 An overview of the initial triage, management and 
investigation of patients who present with signs and symptoms 
potentially consistent with acute coronary syndrome ......................... 3736
Figure 5 The A.C.S. assessment for the initial evaluation of patients 
with suspected acute coronary syndrome ................................................. 3737
Figure 6 The 0 h/1 h or 0 h/2 h rule-out and rule-in algorithms using 
high-sensitivity cardiac troponin assays in patients presenting to the 
emergency department with suspected NSTEMI and without an 
indication for immediate invasive angiography ......................................... 3741
Figure 7 Modes of presentation and pathways to invasive 
management and myocardial revascularization in patients presenting 
with STEMI .............................................................................................................. 3746
Figure 8 Selection of invasive strategy and reperfusion therapy in 
patients presenting with NSTE-ACS ............................................................ 3748
Figure 9 Antithrombotic treatments in acute coronary syndrome: pharmacological targets ...................................................................................... 3752
Figure 10 Recommended default antithrombotic therapy regimens 
in acute coronary syndrome patients without an indication for oral 
anticoagulation ....................................................................................................... 3755
Figure 11 Alternative antiplatelet strategies to reduce bleeding risk in 
the first 12 months after an ACS .................................................................. 3757
Figure 12 Antithrombotic regimens in patients with acute coronary syndrome and an indication for oral anticoagulation ................................ 3761
Figure 13 A practical algorithm to guide intravascular imaging in 
acute coronary syndrome patients ............................................................... 3767
Figure 14 Algorithm for the management of acute coronary 
syndrome patients with multivessel coronary artery disease ............ 3770
Figure 15 Underlying causes for patients with a working diagnosis of 
myocardial infarction with non-obstructive coronary arteries ......... 3773
Figure 16 Evaluation of patients with a working diagnosis of MINOCA .................................................................................................................. 3774Figure 17 Long-term management after acute coronary syndrome 3782
Figure 18 Lipid-lowering therapy in ACS patients .................................. 3785
Figure 19 A person-centred approach to the ACS journey .............. 3789
Figure 20 Acute coronary syndrome patient expectations ................ 3790
Abbreviations and acronyms
AβYSS Beta Blocker Interruption After 
Uncomplicated Myocardial Infarction
ACCOAST A Comparison of Prasugrel at the Time of 
Percutaneous Coronary Intervention or as 
Pretreatment at the Time of Diagnosis in 
Patients with Non-ST Elevation Myocardial 
Infarction
ACE Angiotensin-converting enzyme
ACS Acute coronary syndrome
AF Atrial fibrillation
AFIRE Atrial Fibrillation and Ischemic Events With 
Rivaroxaban in Patients With Stable Coronary Artery Disease
AMI Acute myocardial infarction
ARB Angiotensin receptor blocker
ARC-HBR Academic Research Consortium for High Bleeding Risk
ARNI Angiotensin receptor/neprilysin inhibitor
ASCVD Atherosclerotic cardiovascular disease
ASSENT 3 ASsessment of the Safety and Efficacy of a New 
Thrombolytic 3
ATLANTIC Administration of Ticagrelor in the Cath Lab or 
in the Ambulance for New ST Elevation 
Myocardial Infarction to Open the Coronary 
Artery
AUGUSTUS An Open-Label, 2 × 2 Factorial, Randomized 
Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and 
Aspirin Versus Aspirin Placebo in Patients With 
Atrial Fibrillation and Acute Coronary 
Syndrome or Percutaneous Coronary 
Intervention
AV Atrioventricular
BARC Bleeding Academic Research Consortium
b.i.d. Bis in die (twice a day)
BBB Bundle branch block
BEACON Better Evaluation of Acute Chest Pain with Coronary Computed Tomography Angiography
BETAMI BEtablocker Treatment After Acute Myocardial Infarction in Patients Without 
Reduced Left Ventricular Systolic Function
BMS Bare metal stent
BNP Brain natriuretic peptide
CABG Coronary artery bypass grafting
CAD Coronary artery disease
CAPITAL-RCT Carvedilol Post-Intervention Long-Term 
Administration in Large-scale Randomized Controlled Trial
CAPRICORN CArvedilol Post-infaRct survIval COntRolled evaluatioN
CCS Chronic coronary syndrome3724                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

CCTA Coronary computed tomography angiography
CCU Coronary care unit
CHA 2DS2-VASc Congestive heart failure, Hypertension, Age, 
Diabetes, Stroke or TIA-Vascular disease
CHAMPION PCI Cangrelor versus Standard Therapy to 
Achieve Optimal Management of Platelet 
Inhibition
CHAMPION PHOENIXA Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary 
Intervention
CHAMPION PLATFORMCangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet 
Inhibition
CKD Chronic kidney disease
CMR Cardiac magnetic resonance
CI Confidence interval
COACT Coronary Angiography after Cardiac Arrest
COLCOT Colchicine Cardiovascular Outcomes Trial
COMFORTABLE- 
AMIComparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute 
ST-Elevation Myocardial Infarction
COMPARE-ACUTE Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD
COMPASS Cardiovascular Outcomes for People Using 
Anticoagulation Strategies
COMPLETE Complete vs. Culprit-only Revascularization to 
Treat Multivessel Disease After Early PCI for STEMI
COVID-19 Coronavirus disease 2019
CR Cardiac rehabilitation
CRT Cardiac resynchronization therapy— defibrillator/pacemaker
CS Cardiogenic shock
CT Computed tomography
CV Cardiovascular
CVD Cardiovascular disease
CvLPRIT Complete versus Lesion-only Primary PCI Trial
cTn Cardiac troponin
CULPRIT-SHOCK Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock
DANAMI-3– PRIMULTIThird Danish Study of Optimal Acute Treatment of Patients with ST-Segment Elevation Myocardial Infarction—Primary PCI 
in Multivessel Disease
DANBLOCK Danish Trial of Beta Blocker Treatment After 
Myocardial Infarction Without Reduced 
Ejection Fraction
DAPT Dual antiplatelet therapy
DAT Dual antithrombotic therapy
DCB Drug-coated balloon
DES Drug-eluting stent(s)
DM Diabetes mellitus
ECG Electrocardiography/gram
ECMO Extracorporeal membrane oxygenation
eGFR Estimated glomerular filtration rate
ED Emergency department
EMS Emergency medical service(s)
EPHESUS Eplerenone Post-AMI Heart failure Efficacy and 
SUrvival StudyESC European Society of Cardiology
EXAMINATION Everolimus-Eluting Stents Versus Bare-Metal 
Stents in ST Segment Elevation Myocardial Infarction
ExTRACT-TIMI 25 Enoxaparin and Thrombolysis Reperfusion for 
Acute myocardial infarction Treatment 
Thrombolysis In Myocardial Infarction—Study 25
FAME Fractional Flow Reserve versus Angiography for Multivessel Evaluation
FAMOUS-NSTEMI Fractional flow reserve (FFR) versus 
angiography in guiding management to 
optimise outcomes in non-ST segment 
elevation myocardial infarction
FAST-MI French Registry of Acute ST-elevation and 
non-ST-elevation Myocardial Infarction
FFR Fractional flow reserve
FLOWER-MI Flow Evaluation to Guide Revascularization in 
Multivessel ST-Elevation Myocardial Infarction
FMC First medical contact
GLP-1RA Glucagon-like peptide-1 receptor agonist
GP Glycoprotein
GRACE Global Registry of Acute Coronary Events
HBR High bleeding risk
HCR Hybrid coronary revascularization
HF Heart failure
HFrEF Heart failure with reduced ejection fraction
HOST-REDUCE-P -
OLYTECH-ACSHarmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial— 
Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS 
Patients
HR Hazard ratio
HR-QoL Health-related quality of life
hs-cTn High-sensitivity cardiac troponin
IABP Intra-aortic balloon counter pulsation/pumping
IABP-SHOCK II Intraaortic Balloon Pump in Cardiogenic Shock II
ICA Invasive coronary angiography
ICCU Intensive cardiac care unit
ICD Implantable cardioverter defibrillator
ICU Intensive care unit
IMPROVE-IT Improved Reduction of Outcomes: Vytorin 
Efficacy International Trial
INR International normalized ratio
IRA Infarct-related artery
ISAR-REACT 5 Intracoronary stenting and Antithrombotic 
regimen Rapid Early Action for Coronary 
Treatment
ISIS-4 Fourth International Study of Infarct Survival
i.v. Intravenous
IVUS Intravascular ultrasound
LAD Left anterior descending
LBBB Left bundle branch block
LD Loading dose
LDL-C Low-density lipoprotein-cholesterol
LIMA Left internal mammary artery
LMWH Low-molecular-weight heparin
LoDoCo2 Low-dose Colchicine trial-2
LV Left ventricular(cle)
LVAD Left ventricular assist device
LVEF Left ventricular ejection fraction
MACE Major adverse cardiovascular eventsESC Guidelines                                                                                                                                                                                          3725Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

MASTER DAPT Management of High Bleeding Risk Patients 
Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus 
Prolonged DAPT Regimen
MATRIX Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic 
Implementation of angioX
MCS Mechanical circulatory support
MD Maintenance dose
MI Myocardial infarction
MINOCA Myocardial infarction with non-obstructive coronary arteries
MRA Mineralocorticoid receptor antagonist
MVD Multivessel disease
MVO Microvascular obstruction
NOAC Non-vitamin K antagonist oral anticoagulant
NORSTENT Norwegian Coronary Stent Trial
NPV Negative predictive value
NRT Nicotine replacement therapy
NSTE Non-ST elevation
NSTE-ACS Non-ST elevation acute coronary syndrome
NSTEMI Non-ST-elevation myocardial infarction
NT-pro BNP N-terminal pro B-type natriuretic peptide
NYHA New York Heart Association
o.d. Once a day
OAC Oral anticoagulant/ation
OASIS-5 Fifth Organization to Assess Strategies in Acute Ischemic Syndromes
OASIS-6 The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment 
Elevation Acute Myocardial Infarction
OAT Occluded Artery Trial
OCT Optical coherence tomography
ODYSSEY 
OUTCOMESEvaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During 
Treatment With Alirocumab
OHCA Out-of-hospital cardiac arrest
OR Odds ratio
PARADISE-MI Prospective ARNI vs ACE Inhibitor Trial to 
Determine Superiority in Reducing Heart 
Failure Events After MI
PCI Percutaneous coronary intervention
PCSK9 Proprotein convertase subtilisin/kexin type 9
PE Pulmonary embolism
PEGASUS-TIMI 54 PrEvention with TicaGrelor of SecondAry 
Thrombotic Events in High-RiSk Patients with 
Prior AcUte Coronary Syndrome— Thrombolysis In Myocardial Infarction
PEPCAD NSTEMI Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation 
Myocardial Infarction
PLATO PLATelet inhibition and patient Outcomes
POC Point of care
POPular Genetics Cost-effectiveness of CYP2C19 Genotype 
Guided Treatment With Antiplatelet Drugs in 
Patients With ST-segment-elevation Myocardial 
Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment
PPCI Primary percutaneous coronary interventionPPI Proton pump inhibitor
PPV Positive predictive value
PRAMI Preventive Angioplasty in Myocardial Infarction
PREM Patient-reported experience measure
PROM Patient-reported outcome measure
QI Quality indicator
RAAS Renin–angiotensin–aldosterone system
RAPID-CTCA Rapid Assessment of Potential Ischaemic heart 
Disease with CTCA
RCT Randomized controlled trial
REALITY Restrictive and Liberal Transfusion  
Strategies in Patients With Acute Myocardial Infarction
REBOOT-CNIC TREatment With Beta-blockers After myOcardial Infarction withOut Reduced 
Ejection fracTion
REDUCE-SWEDE -
HEARTEvaluation of Decreased Usage of Betablockers 
After Myocardial Infarction in the 
SWEDEHEART Registry
REMINDER Double-Blind, Randomized, 
Placebo-Controlled Trial Evaluating The Safety 
And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial 
Infarction
REVELATION REVascularization With PaclitaxEL-Coated Balloon Angioplasty Versus Drug-Eluting 
Stenting in Acute Myocardial InfarcTION
RIVAL RadIal Vs femorAL access for coronary 
intervention
ROMICAT II Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography
ROSC Return of spontaneous circulation
RR Relative risk
RV Right ventricular
SAPT Single antiplatelet therapy
SBP Systolic blood pressure
s.c. Subcutaneous
SCAD Spontaneous coronary artery dissection
SHOCK Should We Emergently Revascularize 
Occluded Coronaries for Cardiogenic Shock
SGLT2 Sodium–glucose co-transporter 2
SMART-DECISION Long-term Beta-blocker Therapy After Acute 
Myocardial Infarction
SPECT Single-photon emission computerized tomography
STE ST elevation
STEMI ST-elevation myocardial infarction
STOPDAPT-2-ACS ShorT and OPtimal Duration of Dual 
AntiPlatelet Therapy-2 Study for the Patients 
With ACS
STREAM Strategic Reperfusion Early After Myocardial Infarction
SWEDEHEART Swedish Web-System for Enhancement and 
Development of Evidence-Based Care in Heart 
Disease Evaluated According to 
Recommended Therapies
TALOS-AMI TicAgrelor Versus CLOpidogrel in Stabilized 
Patients With Acute Myocardial Infarction
TAT Triple antithrombotic therapy3726                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

TICO Ticagrelor Monotherapy After 3 Months in the 
Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome
TIMI Thrombolysis In Myocardial Infarction
TLR Target lesion revascularization
TOMAHAWK Immediate Unselected Coronary Angiography Versus Delayed Triage in Survivors of 
Out-of-hospital Cardiac Arrest Without 
ST-segment Elevation
TOPIC Timing of Platelet Inhibition After Acute Coronary Syndrome
TOTAL Trial of routine aspiration ThrOmbecTomy 
with PCI vs. PCI ALone in patients with STEMI
TRITON-TIMI 38 TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN 
with Prasugrel Thrombolysis In Myocardial 
Infarction 38
TROPICAL-ACS Testing Responsiveness to Platelet Inhibition 
on Chronic Antiplatelet Treatment For Acute 
Coronary Syndromes
TTE Transthoracic echocardiography
TWILIGHT Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
UA Unstable angina
UFH Unfractionated heparin
VA-ECMO Veno-arterial extracorporeal membrane 
oxygenation
VALIANT VALsartan In Acute myocardial iNfarcTion
VF Ventricular fibrillation
VKA Vitamin K antagonist
VT Ventricular tachycardia
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of as -
sisting health professionals in proposing the best diagnostic or therapeut -
ic approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals and the European Society of 
Cardiology (ESC) makes its Guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider -
ation of each patient’s health condition and in consultation with that pa -
tient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and reg
-
ulations applicable in each country to drugs and devices at the time of prescription, and, where appropriate, to respect the ethical rules of 
their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated. ESC Policies and Procedures for for -
mulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines).The Members of this Task Force were selected by the ESC to 
represent professionals involved with the medical care of patients 
with this pathology. The selection procedure aimed to include 
members from across the whole of the ESC region and from rele -
vant ESC Subspecialty Communities. Consideration was given to 
diversity and inclusion, notably with respect to gender and country 
of origin. The Task Force performed a critical evaluation of diag -
nostic and therapeutic approaches, including assessment of the risk-benefit ratio. The strength of every recommendation and the level of evidence supporting them were weighed and scored ac
-
cording to predefined scales as outlined below. The Task Force fol -
lowed ESC voting procedures, and all approved recommendations 
were subject to a vote and achieved at least 75% agreement among 
voting members.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules and 
can be found on the ESC website (http://www.escardio.org/ Guidelines
) and have been compiled in a report published in a supple -
mentary document with the guidelines. The Task Force received its en -
tire financial support from the ESC without any involvement from the 
healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible for the approval process. ESC Guidelines undergo extensive review 
by the CPG Committee and external experts, including members 
from across the whole of the ESC region and from relevant ESC 
Subspecialty Communities and National Cardiac Societies. After appro
-
priate revisions, the guidelines are signed off by all the experts involved 
in the Task Force. The finalized document is signed off by the CPG 
Committee for publication in the European Heart Journal
. The guidelines 
were developed after careful consideration of the scientific and medical 
knowledge and the evidence available at the time of their writing. Tables 
of evidence summarizing the findings of studies informing development 
of the guidelines are included. The ESC warns readers that the technical 
language may be misinterpreted and declines any responsibility in this 
respect.
Off-label use of medication may be presented in this guideline if a 
sufficient level of evidence shows that it can be considered medically ap -
propriate for a given condition. However, the final decisions concerning 
an individual patient must be made by the responsible health profes -
sional giving special consideration to: 
•The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
•Country-specific health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health profes
-
sionals are subject, where applicable.ESC Guidelines                                                                                                                                                                                          3727Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

2. Introduction
The major aspects of the management of patients with acute coronary 
syndromes described in this European Society of Cardiology (ESC) 
Guideline are summarized in Figure 1.Table 2 Levels of evidence
Level of
evidence A
Level of
evidence B
Level of
evidence CData derived from multiple randomized clinical trialsor meta-analyses.
Data derived from a single randomized clinical trial
or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2023
©ESC 2023Table 1 Classes of recommendations
©ESC 2023Classes of recommen dationsClass I Evidence and/or general agreement
that a given treatment or proc edure is
beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure.  Is recommen ded or is indicatedWording to use Deﬁnition
Class III Evidence or general agreement that the
given treatment or proc edure is not
useful/eﬀective, and in some casesmay be harmful. Is not recommended     Class IIb Usefulness/eﬃcacy is less wellestablished by evidence/opinion.May be considered    Class IIa Weight of evidence/opinion is infavour of usefulness/eﬃcacy. Should be consideredClass II 
©ESC 20233728                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Aim for complete 
revascularization
2
3
4
1
5
ACS encompasses a spectrum
Think secondary preventionAbnormal
ECG?Clinical
context?Stable
patient?Think ‘A.C.S.’ at initial assessment
Think antithrombotic therapyPrimary PCI Fibrinolysis
(If timely primary PCI not feasible)Immediate angiography ± PCI
AND
OR OR OREarly (<24 h) angiography
should be considered
Aspirin UFH LMWH Bivalirudin Fondaparinux P2Y12 inhibitorSTEMI
ORVery high-risk NSTE-ACS High-risk NSTE-ACS
Antiplatelet therapy
+Anticoagulant therapy
PCI
Antithrombotic 
therapyLipid lowering 
therapySmoking 
cessationCardiac 
rehabilitationRisk factor
managementPsychosocial
considerationsCABGBased on clinical status, co-morbidities,
and disease complexity
ORConsider adjunctive tests
to guide revascularizationThink invasive management
Think revascularization
Intravascular imaging Intravascular physiologyUnstable angina NSTEMI STEMIFigure 1 Central illustration. ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; ECG, electrocardiogram; LMWH, low molecular- 
weight heparin; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PPCI, primary percutaneous coronary 
intervention; STEMI, ST-elevation myocardial infarction; UFH, unfractionated heparin. Patients with acute coronary syndrome (ACS) can initially present with 
a wide variety of clinical signs and symptoms and it is important that there is a high degree of awareness of this amongst both the general public and healthcare 
providers. If ACS is suspected, think ‘A.C.S.’ for the initial triage and assessment. This involves performing an electrocardiogram (ECG) to assess for Abnormalities or evidence of ischaemia, taking a targeted clinical history to assess the clinical Context of the presentation, and carrying out a targeted clinical 
examination to assess for clinical and haemodynamic Stability. Based on the initial assessment, the healthcare provider can decide whether immediate invasive 
management is required. Patients with ST-elevation myocardial infarction (STEMI) require primary percutaneous coronary intervention (PPCI) (or fibrinoly
-
sis if PPCI within 120 min is not feasible); patients with non-ST-elevation ACS (NSTE-ACS) with very high-risk features require immediate angiography ± PCI 
if indicated; patients with NSTE-ACS and high-risk features should undergo inpatient angiography (angiography within 24 h should be considered). A com -
bination of antiplatelet and anticoagulant therapy is indicated acutely for patients with ACS. The majority of patients with ACS will eventually undergo re -
vascularization, most commonly with PCI. Once the final diagnosis of ACS has been established, it is important to implement measures to prevent recurrent events and to optimize cardiovascular risk. This consists of medical therapy, lifestyle changes and cardiac rehabilitation, as well as consideration of psycho
-
social factors.ESC Guidelines                                                                                                                                                                                          3729Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

2.1. Definitions | Acute coronary 
syndromes and myocardial infarction
Acute coronary syndromes (ACS) encompass a spectrum of condi -
tions that include patients presenting with recent changes in clinical 
symptoms or signs, with or without changes on 12-lead electrocardio -
gram (ECG) and with or without acute elevations in cardiac tropo -
nin (cTn) concentrations ( Figure 2 ). Patients presenting with 
suspected ACS may eventually receive a diagnosis of acute myocar -
dial infarction (AMI) or unstable angina (UA). The diagnosis of myocardial infarction (MI) is associated with cTn release and is 
made based on the fourth universal definition of MI.1UA is defined 
as myocardial ischaemia at rest or on minimal exertion in the ab -
sence of acute cardiomyocyte injury/necrosis. It is characterized by 
specific clinical findings of prolonged (
>20 min) angina at rest; new 
onset of severe angina; angina that is increasing in frequency, longer in duration, or lower in threshold; or angina that occurs after a re
-
cent episode of MI. ACS are associated with a broad range of clinical 
presentations, from patients who are symptom free at presentation 
to patients with ongoing chest discomfort/symptoms and patients
Increasing chest
pain/s ymptomsOligo/
asymptomatic Persistent chest
pain/s ymptomsCardi ogenic sho ck/
acute h eart fa ilure Cardi ac
arrest
Normal ST segment
depression ST segment
elevationMalignant
arrhythmiaClinical
prese ntation
ECG
findings
hs-cTnlevelsThe ACS spectrum
FinaldiagnosisWorkingdiagnosis
Non-elevated
Unstable
angina NSTE-ACS
NSTEMIRise and fall 
STEMISTEMI
Figure 2 The spectrum of clinical presentations, electrocardiographic findings, and high-sensitivity cardiac troponin levels in patients with acute coronary 
syndrome. ACS, acute coronary syndrome; ECG, electrocardiogram; hs-cTn, high-sensitivity cardiac troponin; NSTE-ACS, non-ST-elevation acute coronary 
syndrome; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.3730                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

with cardiac arrest, electrical/haemodynamic instability, or cardio -
genic shock (CS) ( Figure 2).
Patients presenting with suspected ACS are typically classified based 
on ECG at presentation for the purposes of initial management. After 
this, patients can be further classified based on the presence or absence 
of cardiac troponin elevation (once these results are available), as de -
monstrated in Figures 2 and 3. These features (ECG changes and cardiac 
troponin elevation) are important in the initial triage and diagnosis of patients with ACS, helping to risk stratify patients and guide the initial 
management strategy. However, after the acute management and sta
-
bilization phase, most aspects of the subsequent management strategy are common to all patients with ACS (regardless of the initial ECG pattern or the presence/absence of cardiac troponin elevation at 
presentation) and can therefore be considered under a common 
pathway. A glossary of the terms related to invasive strategies and 
reperfusion therapy commonly used in this document, and their 
associated definitions, is provided in 
Table 3.
While they are closely related, it is important to recognize that ACS 
is not the same as MI.1AMI is defined as cardiomyocyte necrosis in the 
clinical setting of acute myocardial ischaemia. This includes MI due to 
atherothrombotic events (Type 1 MI) and also other potential causes 
of myocardial ischaemia and myocyte necrosis (Type 2–5 MI) 
(Supplementary data online, Table S1). Myocardial injury is another 
distinct entity, used to describe troponin release due to mechanisms other than myocardial ischaemia and not meeting the criteria for MI outlined in Supplementary data online, Table S1
. Myocardial injury 
can be acute or chronic depending on whether there is evidence of dynamic change in the elevated troponins on serial testing. Some 
causes of myocardial injury include myocarditis, sepsis, takotsubo car
-
diomyopathy, heart valve disease, cardiac arrhythmias, and heart fail -
ure (HF).
The focus of this guideline is largely centred on the management of 
patients who will eventually receive a diagnosis of Type 1 MI. 
However, at every stage of the management of patients presenting 
with ACS, physicians must carefully consider other differential diag -
noses in their clinical assessment because they are common, asso -
ciated with different underlying pathological mechanisms, have different prognoses, and frequently require different treatment ap
-
proaches. More information is provided in the Supplementary 
data online. In general, detailed information regarding the results of individual trials will not be provided in the main guideline. 
However, where appropriate, this information is provided in the 
Supplementary data online evidence tables.Table 3 Definitions of terms related to invasive strat -
egy and reperfusion therapy commonly used in this 
document
Term Definition
First medical contact (FMC) The time point when the patient is initially 
assessed by a physician, paramedic, nurse, 
or other trained emergency medical 
services worker who can obtain and 
interpret the ECG and deliver initial 
interventions (e.g. defibrillation). FMC can 
be either in the pre-hospital setting or 
upon patient arrival at the hospital (e.g. 
the emergency department)
STEMI diagnosis The time at which a patient with ischaemic 
symptoms is interpreted as presenting 
with ACS and ST-segment elevation (or 
ST-segment elevation equivalent)
Primary PCIaEmergent PCI with balloon, stent, or other approved device, performed on the 
IRA without previous fibrinolytic 
treatment
Primary PCI strategy
aEmergency coronary angiography and PCI 
of the IRA if indicated
Rescue PCIaEmergency PCI performed as soon as possible in cases of failed fibrinolytic 
treatment
Routine early PCI strategy 
after fibrinolysis
aCoronary angiography, with PCI of the IRA if indicated, performed between 2 h 
and 24 h after successful fibrinolysis
Pharmaco-invasive strategy
aFibrinolysis combined with rescue PCI (in 
cases of failed fibrinolysis) or routine early 
PCI strategy (in cases of successful 
fibrinolysis)
Immediate invasive strategy Emergency coronary angiography (i.e. as soon as possible) and PCI/CABG of the IRA if indicated
Early invasive strategy Early coronary angiography (<24 h from diagnosis of ACS) and PCI/CABG of the 
IRA if indicated
Selective invasive strategy Coronary angiography ± PCI/CABG 
based on clinical assessment and/or 
non-invasive testing
©ESC 2023
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; ECG, 
electrocardiogram; IRA, infarct-related artery; PCI, percutaneous coronary intervention; 
STE-ACS, ST-segment-elevation acute coronary syndrome. 
aCABG may also be indicated instead of PCI in certain circumstances.ESC Guidelines                                                                                                                                                                                          3731Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

2.2. Epidemiology of acute coronary 
syndromes
Cardiovascular disease (CVD) is the most common cause of mortality 
and morbidity worldwide, with a substantial portion of this burden borne by low- and middle-income countries.
2,3ACS is often the first 
clinical manifestation of CVD. In 2019, there were an estimated 5.8 mil -
lion new cases of ischaemic heart disease in the 57 ESC member coun -
tries.3The median age-standardized incidence estimate per 100 000 
people was 293.3 (interquartile ratio 195.8–529.5). CVD remains the most common cause of death within ESC member countries, account
-
ing for just under 2.2 million deaths in females and just over 1.9 million deaths in males in the most recent year of available data. Ischaemic heart disease is the most common cause of CVD death, accounting for 38% of all CVD deaths in females and 44% in males.
3
2.3. Number and breakdown of classes of 
recommendations
The total number of recommendations in this guideline is 193. A sum -
mary of the recommendations according to Class of Recommendation 
and Level of Evidence (LoE) is also provided. As per Class of 
Recommendation, there were 106 Class I, 70 Class II, and 17 Class III 
recommendations. As per LoE, there were 56 LoE A, 64 LoE B, and 
73 LoE C recommendations.
STEMI
NSTE-ACSSTEMI
NSTEMI
Unstable angina 
Non-ACS diagnosis
hs-cTn levels
± Angiography
± ImagingFinal diagnosisbWorking diagnosisaFurther investigations
 Clinical presentation
If a patient has
signs/symptoms
suggestive of ACS,
perform an ECG
within 10 min of FMCECGFigure 3 Classification of patients presenting with suspected acute coronary syndrome: from a working to a final diagnosis. ACS, acute coronary syndrome; 
ECG, electrocardiogram; FMC, first medical contact; hs-cTn, high-sensitivity cardiac troponin; MI, myocardial infarction; NSTE-ACS, non-ST-elevation acute 
coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction: STEMI, ST-elevation myocardial infarction. aThe working ACS diagnosis can be clas -
sified as STEMI or NSTE-ACS on the basis of available clinical information and ECG findings. This allows for initial triage and assessment. bThe final diagnosis is 
based on symptoms, ECG and troponin for the diagnosis of MI as well as the results of other tests (i.e. imaging and/or angiography) to facilitate understanding of the mechanism and subclassification of the type of MI. Patients initially assigned a working diagnosis of STEMI or NSTE-ACS may eventually receive a final 
non-ACS diagnosis.3732                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

2.4. What is new
Table 4 New recommendations
Recommendations ClassaLevelb
Recommendations for antiplatelet and anticoagulant therapy in acute coronary syndrome
If patients presenting with ACS stop DAPT to undergo coronary artery bypass grafting, it is recommended they resume DAPT after surgery 
for at least 12 months.I C
In older ACS patients, especially if HBR, clopidogrel as the P2Y 12 receptor inhibitor may be considered. IIb B
Recommendations for alternative antithrombotic therapy regimens
In patients who are event-free after 3–6 months of DAPT and who are not high ischaemic risk, single antiplatelet therapy (preferably with a 
P2Y 12 receptor inhibitor) should be considered.IIa A
P2Y 12 inhibitor monotherapy may be considered as an alternative to aspirin monotherapy for long-term treatment. IIb A
In HBR patients, aspirin or P2Y 12 receptor inhibitor monotherapy after 1 month of DAPT may be considered. IIb B
In patients requiring OAC, withdrawing antiplatelet therapy at 6 months while continuing OAC may be considered. IIb B
De-escalation of antiplatelet therapy in the first 30 days after an ACS event is not recommended. III B
Recommendations for cardiac arrest and out-of-hospital cardiac arrest
Evaluation of neurological prognosis (no earlier than 72 h after admission) is recommended in all comatose survivors after cardiac arrest. I C
Transport of patients with out-of-hospital cardiac arrest to a cardiac arrest centre according to local protocol should be considered. IIa C
Recommendations for technical aspects of invasive strategies
In patients with spontaneous coronary artery dissection, PCI is recommended only for patients with symptoms and signs of ongoing 
myocardial ischaemia, a large area of myocardium in jeopardy, and reduced antegrade flow. I C
Intravascular imaging should be considered to guide PCI. IIa A
Intravascular imaging (preferably optical coherence tomography) may be considered in patients with ambiguous culprit lesions. IIb C
Recommendations for multivessel disease in ACS patients presenting in cardiogenic shock
Staged PCI of non-IRA should be considered. IIa C
Recommendations for multivessel disease in haemodynamically stable STEMI patients undergoing primary PCIIt is recommended that PCI of the non-IRA is based on angiographic severity. I B
Invasive epicardial functional assessment of non-culprit segments of the IRA is not recommended during the index procedure. III C
Recommendations for acute coronary syndrome complicationsImplantation of a permanent pacemaker is recommended when high-degree AV block does not resolve within a waiting period of at least 5 
days after MI.I C
Cardiac magnetic resonance imaging should be considered in patients with equivocal echocardiographic images or in cases of high clinical 
suspicion of LV thrombus.IIa C
Following an acute anterior MI, a contrast echocardiogram may be considered for the detection of LV thrombus if the apex is not well visualized on echocardiography.IIb C
In selected patients with high-degree AV block in the context of an anterior wall MI and acute heart failure, early device implantation (cardiac 
resynchronization therapy—defibrillator/pacemaker) may be considered.IIb C
In patients with recurrent life-threatening ventricular arrhythmias, sedation or general anaesthesia to reduce sympathetic drive may be 
considered.IIb C
Recommendations for acute coronary syndrome comorbid conditions
It is recommended to base the choice of long-term glucose-lowering treatment on the presence of comorbidities, including heart failure, 
chronic kidney disease, and obesity.I A
For frail older patients with comorbidities, a holistic approach is recommended to individualize interventional and pharmacological 
treatments after careful evaluation of the risks and benefits.I B
An invasive strategy is recommended in cancer patients presenting with high-risk ACS with expected survival ≥6 months. I B
A temporary interruption of cancer therapy is recommended in patients in whom the cancer therapy is suspected to be a contributing cause 
of ACS.I C
A conservative non-invasive strategy should be considered in ACS patients with poor cancer prognosis (i.e. with expected life survival <6 
months) and/or very high bleeding risk.IIa C
Aspirin is not recommended in cancer patients with a platelet count <10 000/μL. III C
ContinuedESC Guidelines                                                                                                                                                                                          3733Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Clopidogrel is not recommended in cancer patients with a platelet count <30 000/μL. III C
In ACS patients with cancer and <50 000/μL platelet count, prasugrel or ticagrelor are not recommended. III C
Recommendations for long-term management
It is recommended to intensify lipid-lowering therapy during the index ACS hospitalization for patients who were on lipid-lowering therapy 
before admission.I C
Low-dose colchicine (0.5 mg once a day) may be considered, particularly if other risk factors are insufficiently controlled or if recurrent 
cardiovascular disease events occur under optimal therapy.IIb A
Combination therapy with a high-dose statin plus ezetimibe may be considered during index hospitalization. IIb B
Recommendations for patient perspectives in acute coronary syndrome care
Patient-centred care is recommended by assessing and adhering to individual patient preferences, needs and beliefs, ensuring that patient 
values are used to inform all clinical decisions.I B
It is recommended to include ACS patients in decision-making (as much as their condition allows) and to inform them about the risk of adverse events, radiation exposure, and alternative options. Decision aids should be used to facilitate the discussion.I B
It is recommended to assess symptoms using methods that help patients to describe their experience. I C
Use of the ‘teach back’ technique for decision support during the securing of informed consent should be considered. IIa B
Patient discharge information should be provided in both written and verbal formats prior to discharge. Adequate preparation and 
education for patient discharge using the teach back technique and/or motivational interviewing, giving information in chunks, and checking for understanding, should be considered.IIa B
Assessment of mental well-being using a validated tool and onward psychological referral when appropriate should be considered. IIa B
©ESC 2023
ACS, acute coronary syndrome; AV, atrioventricular; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; IRA, infarct-related artery; LV, left ventricular(cle); MI, myocardial infarction; 
OAC, oral anticoagulant/ation; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.
Table 5 Revised recommendations
Recommendations in 2017 and 2020 versions ClassaLoEbRecommendations in 2023 version ClassaLoEb
Recommendations for imaging for patients with suspected NSTE-ACS
In patients with no recurrence of chest pain, normal ECG 
findings, and normal levels of cardiac troponin (preferably 
high sensitivity), but still with suspected ACS, a 
non-invasive stress test (preferably with imaging) for 
inducible ischaemia or CCTA is recommended before 
deciding on an invasive approach.I BIn patients with suspected ACS, non-elevated (or 
uncertain) hs-cTn, no ECG changes and no recurrence of 
pain, incorporating CCTA or a non-invasive stress 
imaging test as part of the initial workup should be 
considered.IIa A
Recommendations for timing of invasive strategy in NSTE-ACS
An early invasive strategy within 24 h is recommended in 
patients with any of the following high-risk criteria: 
•Diagnosis of NSTEMI suggested by the diagnostic 
algorithm recommended in Section 3
•Dynamic or presumably new contiguous ST/T-segment 
changes suggesting ongoing ischaemia
•Transient ST-segment elevation
•GRACE risk score >140.I AAn early invasive strategy within 24 h should be 
considered in patients with at least one of the following 
high-risk criteria: 
•Confirmed diagnosis of NSTEMI based on current 
recommended ESC hs-cTn algorithms
•Dynamic ST-segment or T wave changes
•Transient ST-segment elevation
•GRACE risk score >140.IIa A
Recommendations for antiplatelet and anticoagulant therapy in STEMI
A potent P2Y 12 inhibitor (prasugrel or ticagrelor), or 
clopidogrel if these are not available or are contraindicated, 
is recommended before (or at latest at the time of) PCI, and 
maintained over 12 months, unless there are contraindications such as excessive risk of bleeding.I APre-treatment with a P2Y
12 receptor inhibitor may be 
considered in patients undergoing a primary PCI strategy.
IIb B
Recommendations for long-term antithrombotic therapy
After stent implantation in patients undergoing a strategy 
of DAPT, stopping aspirin after 3–6 months should be 
considered, depending on the balance between the 
ischaemic and bleeding risks.IIa AIn patients who are event-free after 3–6 months of DAPT and who are not high ischaemic risk, SAPT (preferably 
with a P2Y
12 receptor inhibitor) should be considered.IIa A
Continued3734                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

New/revised concepts 
•ACS should be considered a spectrum, which encompasses both 
non-ST-elevation (NSTE)-ACS and ST-elevation MI (STEMI).
•A section on the management of ACS in patients with cancer is provided.
•A section on patient perspectives is provided.
3. Triage and diagnosis
3.1. Clinical presentation and physical 
examination
3.1.1. Clinical presentation
Acute chest discomfort—which may be described as pain, pressure, 
tightness, heaviness, or burning—is the leading presenting symptom prompting consideration of the clinical diagnosis of ACS and the initi -
ation of testing aligned with specific diagnostic algorithms ( Figure 4).
Chest pain descriptors should be classified as cardiac, possibly car -
diac, and likely non-cardiac. Further information on the suggested use 
of these terms is provided in the Supplementary data online. The use 
of the descriptor ‘atypical’ should be avoided. Chest pain-equivalent 
symptoms include dyspnoea, epigastric pain, and pain in the left or right 
arm or neck/jaw.
Misdiagnosis or delayed diagnosis is sometimes due to an incomplete 
history or difficulty in eliciting symptoms from the patient. In order to 
understand the complexity of ACS-related symptomatology, careful history taking and comprehensive interaction with the patient are 
crucial and may help to facilitate an early and accurate diagnosis. 
Further information is provided in the Supplementary data online
, in-
cluding Figure S1, which outlines some of the most common symptoms 
of ACS in women and men.Recommendations for cardiac arrest and out-of-hospital cardiac arrest
Delayed as opposed to immediate angiography should be 
considered among haemodynamically stable patients 
without ST-segment elevation successfully resuscitated after out-of-hospital cardiac arrest.IIa BRoutine immediate angiography after resuscitated cardiac 
arrest is not recommended in haemodynamically stable 
patients without persistent ST-segment elevation (or equivalents).III A
Targeted temperature management (also called therapeutic hypothermia), aiming for a constant 
temperature between 32 and 36 C for at least 24 h, is 
indicated in patients who remain unconscious after 
resuscitation from cardiac arrest (of presumed cardiac 
cause).I BTemperature control (i.e. continuous monitoring of core 
temperature and active prevention of fever [i.e. >37.7°C]) 
is recommended after either out-of-hospital or in-hospital cardiac arrest for adults who remain unresponsive after 
return of spontaneous circulation.I B
Recommendations for in-hospital management
When echocardiography is suboptimal/inconclusive, an 
alternative imaging method (CMR preferably) should be 
considered.IIa CWhen echocardiography is suboptimal/inconclusive, 
CMR imaging may be considered. IIb C
Recommendations for management of multivessel disease in haemodynamically stable STEMI patients undergoing primary PCI
Routine revascularization of non-IRA lesions should be 
considered in STEMI patients with multivessel disease 
before hospital discharge.IIa AComplete revascularization is recommended either 
during the index PCI procedure or within 45 days. I A
Recommendations for acute coronary syndrome comorbid conditions
Glucose-lowering therapy should be considered in ACS 
patients with blood glucose >10 mmol/L (>180 mg/dL), 
with the target adapted to comorbidities, while episodes 
of hypoglycaemia should be avoided.IIa BGlucose-lowering therapy should be considered in 
patients with ACS with persistent hyperglycaemia, while 
episodes of hypoglycaemia should be avoided.IIa C
©ESC 2023
ACS, acute coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic resonance; DAPT, dual antiplatelet therapy; ECG, electrocardiography/gram; 
ESC European Society of Cardiology; GRACE, Global Registry of Acute Coronary Events; hs-cTn, high-sensitivity cardiac troponin; IRA, infarct-related artery; NSTE-ACS, non-ST-elevation 
acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy; STEMI, ST-elevation myocardial 
infarction. 
aClass of recommendation. 
bLevel of evidence.ESC Guidelines                                                                                                                                                                                          3735Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

It is important that awareness of the symptoms associated with 
ACS is high among the general population, in particular red flag 
symptoms such as prolonged chest pain (>15 min) and/or recurrent 
pain within 1 h, which should prompt patients or other members of the public to seek urgent medical help. Continuous education, pro -
motion, and advocacy efforts are important to make sure that this 
information is as widely available as possible to the general 
population.
ACS
prese ntation
Initial A.C.S.
assessmentECG Physical examination Clinical history Vital signs hs-cTna levels
Non-immediate
angiographyEchoIntravascular
imaginghs-cTna
levelsNon-invasive
imagingECG
monitoring
PCI CABGLong-term
medical therapyLifestyle
measuresSmoking
cessationSTEMINSTE-ACS
with very high-risk featuresbNSTE-ACS
without very high-risk featuresb
Immediate angiography ± 
PPCI or fibrinolysis if timely
PPCI not feasible
PPCI ATT FibrinolysisImmediate angiography 
± PCIConsider angiography
within 24 h for NSTE-ACS
with high risk features
Working
diagnosis
Early invasive
angiography
according to
patient risk
Further
management
Further
investigations
PCI ATT
 PCI ATT
Figure 4 An overview of the initial triage, management and investigation of patients who present with signs and symptoms potentially consistent with acute 
coronary syndrome. ACS, acute coronary syndrome; ATT, antithrombotic therapy; CABG, coronary artery bypass grafting; ECG, electrocardiogram; hs-cTn, 
high-sensitivity cardiac troponin; NSTE-ACS, non-ST-elevation acute coronary syndrome; PPCI, primary percutaneous coronary intervention; STEMI, 
ST-elevation myocardial infarction. The ‘A.C.S.’ assessment is detailed in Figure 5 . aResults of hs-cTn measurements are not required for the initial stratifi -
cation of ACS and the initial emergency management (i.e. for patients with a working diagnosis of STEMI or very high-risk NSTE-ACS) should not be delayed 
based on this. bFor patients with NSTE-ACS with very high-risk features, immediate angiography is recommended. For patients with NSTE-ACS with high- 
risk features, early invasive angiography (i.e. <24 h) should be considered and inpatient invasive angiography is recommended. See Recommendation Table 4 
for details.3736                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

3.1.2. History taking and physical examination
Patients with suspected ACS present in a broad range of clinical scen -
arios, including in the community, at the emergency department (ED), 
or in the inpatient setting. It is crucial to take a focused medical history 
and accurately characterize the presenting symptoms in order to 
manage the patient via the appropriate care pathway as soon as 
possible.
Prompt assessment of vital signs is recommended at first medical 
contact (FMC), at the same time as acquisition of an initial ECG 
(Figure 5 ). In patients presenting with suspected ACS, physical examin -
ation is recommended and is useful both to eliminate differential diag -
noses and to identify very high-risk and high-risk ACS features. This may 
be particularly relevant for patients presenting with cardiac arrest, signs of CS, and/or haemodynamic or electrical instability.
4Focused physical 
examination should include checking for the presence of all major 
pulses, measurement of blood pressure in both arms, auscultation of 
the heart and lungs, and assessing for signs of HF or circulatory 
compromise.3.2. Diagnostic tools | Electrocardiogram
The resting 12-lead ECG is the first-line diagnostic tool in the assess -
ment of patients with suspected ACS. It is recommended that an ECG is obtained immediately upon FMC and interpreted by a qualified 
emergency medical technician or physician within 10 min.
4,5It should 
be repeated as necessary, especially if symptoms have waned at FMC. 
Based on the initial ECG, patients with suspected ACS can be differen -
tiated into two working diagnoses: 
•Patients with acute chest pain (or chest pain-equivalent signs/symptoms) and persistent ST-segment elevation 
(or ST-segment elevation equivalents) on ECG (working 
diagnosis: ST-segment elevation MI: STEMI)
. The vast major -
ity of these patients will sustain myocardial necrosis and troponin ele -
vation, fulfilling the criteria for an MI, but MI will not be the final diagnosis in all patients with a working diagnosis of STEMI.
•Patients with acute chest pain (or chest pain-equivalent 
signs/symptoms) but without persistent ST-segment 
A
 C
 S
Abnormal
ECG?Clinical
context?Stable
patient?
Perform an ECG to assess 
for evidence of ischaemia  
or other abnormalitiesConsider the clinical 
context and available 
investigationsPerform an exam to assess 
if the patient is clinically 
and vitally stable
Figure 5 The A.C.S. assessment for the initial evaluation of patients with suspected acute coronary syndrome. ECG, electrocardiogram. This figure sum -
marizes the initial ‘A.C.S. assessment’ that can be performed for a patient presenting with suspected ACS. ‘A’ stands for ‘Abnormal ECG?’: an ECG should be 
performed within 10 min of FMC and assessed for evidence of abnormalities or ischaemia. ‘C’ stands for ‘Clinical Context?’: it is important to consider the 
clinical context of the patient’s presentation and the results of any investigations that are available. This should also include a targeted history with the aim of 
determining the patient’s symptoms and elucidating any other relevant background information. ‘S’ stands for ‘Stable Patient?’: the patient should be quickly assessed to determine if they are clinically stable—this should include assessment of the clinical vital signs, including heart rate, blood pressure, and oxygen 
saturations, if possible, as well as checking for potential signs of CS.ESC Guidelines                                                                                                                                                                                          3737Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

elevation (or ST-segment elevation equivalents) on ECG 
(working diagnosis: non-ST-elevation [NSTE]-ACS). 
These patients may exhibit other ECG alterations, including transient 
ST-segment elevation, persistent or transient ST-segment depres -
sion, and T wave abnormalities, including hyperacute T waves, T wave inversion, biphasic T waves, flat T waves, and pseudo- 
normalization of T waves. Alternatively, the ECG may be normal. 
The majority of patients in this category who subsequently display 
a typical rise and fall in cardiac troponin levels (i.e. fulfilling MI criteria 
as per the fourth universal definition of MI) will receive a final diagno
-
sis of non-ST-elevation MI (NSTEMI). In other patients, the troponin level will remain below the 99th centile and they will receive a final diagnosis of UA, although with high-sensitivity troponin assays this 
diagnosis has become less common. It is also important to recognize 
that NSTEMI or UA will not be the final diagnosis in all patients with 
an initial working diagnosis of NSTE-ACS.
3.2.1. Acute coronary syndrome with persistent 
ST-segment elevation (suspected ST-elevation 
myocardial infarction)
The priority for these patients is the implementation of reperfusion ther -
apy as soon as possible (see Section 5). In the appropriate clinical context, 
ST-segment elevation (measured at the J-point) is considered suggestive 
of ongoing coronary artery acute occlusion in the following cases:
New ST elevation at the J-point in at least two contiguous leads: 
•≥
2.5 mm in men <40 years, ≥2 mm in men ≥40 years, or ≥1.5 mm 
in women regardless of age in leads V2–V3
•and/or ≥1 mm in the other leads (in the absence of left ventricular 
[LV] hypertrophy or left bundle branch block [LBBB]).
In patients with suspected inferior STEMI, it is recommended to re -
cord right precordial leads (V3R and V4R) in order to assess for ST-segment elevation.
6Posterior leads (V7–V9) can also be recorded 
to investigate for posterior STEMI, particularly in patients with ongoing 
symptoms and an inconclusive standard 12-lead ECG.
The diagnosis of ongoing acute coronary artery occlusion on ECG 
can sometimes be challenging, and some cases may warrant prompt 
management and triage for immediate reperfusion therapy despite 
the absence of ST-segment elevation. It is also important to recognize that while the most sensitive sign for ongoing acute coronary 
artery occlusion is ST-segment elevation, there are other ECG find
-
ings that can be suggestive of ongoing coronary artery occlusion (or severe ischaemia). If these findings are present, prompt triage for 
immediate reperfusion therapy is indicated (see 
Supplementary data 
online, Figure S2).
ST-segment depression in leads V1–V3 (especially when the terminal 
T wave is positive) and/or ST-segment elevation in V7–V9 are highly 
suggestive of posterior coronary artery occlusion (often the left cir -
cumflex artery).1,7ST-segment elevation in V3R and V4R is highly sug -
gestive of ongoing RV ischaemia.8ST depression ≥1 mm in ≥6 surface 
leads (inferolateral ST depression), coupled with ST-segment elevation in aVR and/or V1, suggests multivessel ischaemia or left main coronary 
artery obstruction, particularly if the patient presents with haemo -
dynamic compromise.9–11
Bundle branch block (BBB). In patients with a high clinical sus -
picion of ongoing myocardial ischaemia, the presence of LBBB, right 
bundle branch block (RBBB), or a paced rhythm precludes an accurate 
assessment of the presence or absence of ST-segment elevation. 
Therefore, patients presenting with these ECG patterns in combination 
with signs/symptoms that are highly suspicious for ongoing myocardial 
ischaemia should be managed similarly to those with clear ST-segment elevation, regardless of whether the BBB is previously known (see 
Supplementary data online).4
3.2.2. Acute coronary syndrome without persistent 
ST-segment elevation (non-ST elevation acute 
coronary syndrome)
While the ECG in the setting of NSTE-ACS may be normal in more 
than one-third of patients, characteristic ECG abnormalities are fre -
quently present and increase the diagnostic probability of ACS.12–16
These ECG abnormalities include ST depression and T wave changes (especially biphasic T waves or prominent negative T waves 
[Wellens’ sign, related to severe proximal left anterior descending ar
-
tery stenosis]), (see Supplementary data online, Figure S3).
Recommendation Table 1 — Recommendations for 
clinical and diagnostic tools for patients with suspected 
acute coronary syndrome
Recommendations ClassaLevelb
It is recommended to base the diagnosis and initial 
short-term risk stratification of ACS on a 
combination of clinical history, symptoms, vital signs, 
other physical findings, ECG, and hs-cTn.1,17,18I B
ECG
Twelve-lead ECG recording and interpretation is 
recommended as soon as possible at the point of FMC, with a target of <10 min.
5,19I B
Continuous ECG monitoring and the availability of defibrillator capacity is recommended as soon as 
possible in all patients with suspected STEMI, in 
suspected ACS with other ECG changes or ongoing 
chest pain, and once the diagnosis of MI is made.
20,21I B
The use of additional ECG leads (V3R, V4R, and V7– 
V9) is recommended in cases of inferior STEMI or if 
total vessel occlusion is suspected and standard leads 
are inconclusive.22–24I B
An additional 12-lead ECG is recommended in cases 
with recurrent symptoms or diagnostic uncertainty.I C
Continued3738                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

3.3. Diagnostic tools | Biomarkers
3.3.1. High-sensitivity cardiac troponins
After excluding clinical and ECG signs suggestive of STEMI or very high- 
risk NSTE-ACS, biomarkers play a complementary role in the diagnosis, 
risk stratification, and management of patients with suspected ACS. 
Measurement of a biomarker of cardiomyocyte injury, preferably high- 
sensitivity cardiac troponin (hs-cTn), is recommended in all patients 
with suspected ACS.15,17,25–27,53,54If the clinical presentation is com -
patible with myocardial ischaemia, then a rise and/or fall in cTn above 
the 99th percentile of healthy individuals points to a diagnosis of MI 
as per the criteria in the fourth universal definition of MI.1In patients 
with MI, levels of cTn rise rapidly (i.e. usually within 1 h if using high- 
sensitivity assays) after symptom onset and remain elevated for a vari -
able period of time (usually several days).1,15,26,53,55–58
Advances in technology have led to a refinement in cTn assays and 
have improved their accuracy in detecting and quantifying cardiomyo -
cyte injury.1,12–15,18,26,34,35,53,55–60Data from large multicentre studies 
have consistently shown that hs-cTn assays increase diagnostic accuracy for MI at the time of presentation in comparison to conventional assays, 
especially in patients presenting early after chest pain onset, enabling 
more rapid ‘rule-in’ and ‘rule-out’ of MI.
1,12–15,26,34,35,53,55–58Overall, 
hs-cTn T and hs-cTn I subunit assays appear to provide comparable diagnostic accuracy in the early diagnosis of MI.
28,32,61,62The use of 
the terms ‘normal’ and ‘abnormal’ to describe hs-cTn levels should be avoided; instead, the terms ‘non-elevated’ and ‘elevated’ should be 
used to refer to hs-cTn levels below and above the 99th percentile. Some of the clinical implications of hs-cTn assays are detailed in 
Supplementary data online, Table S2.
It is also important to consider that there are other clinical conditions 
apart from Type 1 MI in which elevations in cTn can be observed (see 
Supplementary data online, Section 3.3.1 and Table S3).
3.3.2. Central laboratory vs. point of care
The vast majority of cTn assays that run on automated platforms in the central laboratory are sensitive (i.e. allow for the detection of cTn in ∼20–50% of healthy individuals) or high-sensitivity (i.e. allow for the de
-
tection of cTn in ∼
50–95% of healthy individuals) assays. 
High-sensitivity assays are recommended over lower-sensitivity assays, 
as they provide higher diagnostic accuracy at an identical low 
cost.1,12,15,25–27,57,63
The majority of currently used point-of-care (POC) tests cannot be 
considered high-sensitivity assays.64The advantage of POC tests is a 
shorter turnaround time. However, this is counterbalanced by lower sensitivity, lower diagnostic accuracy, and lower negative predictive va
-
lue (NPV). A randomized trial in low-risk chest pain patients with sus -
pected NSTE-ACS and onset of symptoms ≥
2 h before ambulance 
presentation reported that the use of a pre-hospital rule-out strategy (with a single POC conventional troponin T test) resulted in a signifi
-
cant reduction of 30-day healthcare costs and a comparable major ad -
verse cardiovascular event (MACE) rate in comparison to an ED rule-out strategy (with evaluation as per standard local practice).
65
Overall, automated assays have been more thoroughly evaluated 
than POC tests and are currently preferred.1,12–15,26,34,35,53,55–58
However, this is a rapidly developing field and it will be important to re-evaluate this preference when more extensively validated high- 
sensitivity POC tests are clinically available.
66–68
3.3.3. Confounders of cardiac troponin concentration
In patients presenting with suspected NSTE-ACS, four clinical variables 
affect hs-cTn concentrations beyond the presence or absence of MI. These variables are: age (concentrations in healthy very young vs. 
‘healthy’ very old individuals differ by up to 300%); renal dysfunction 
(differences between otherwise healthy patients with very high vs. 
very low estimated glomerular filtration rate [eGFR] of up to 300%); 
time from chest pain onset (>300%); and, to a lesser extent, sex 
(≈40%).
28,34,35,69–76Despite the potential baseline differences in 
hs-cTn values based on these four variables, absolute changes in 
hs-cTn levels are still of diagnostic and prognostic value. Current data 
on the use of sex-specific hs-cTn values in the diagnosis of MI have 
been controversial and failed to demonstrate a clear clinical bene -
fit.74,75,77–80Therefore, until automated tools (i.e. risk assessment cal -
culators) incorporating the effect of all four clinical variables (age, eGFR, time from chest pain onset, and sex) are available, the use of uni
-
form cut-off concentrations should remain the standard of care for the early diagnosis of MI.
28,30,31,34,35,73,81,82
3.3.4. Rapid ‘rule-in’ and ‘rule-out’ algorithms
Due to their higher sensitivity and diagnostic accuracy for the detection of MI at presentation, the time interval to the second cTn assessment can be shortened with the use of hs-cTn assays. This substantially re
-
duces the delay to diagnosis, translating into shorter stays in the ED, lower costs, and less diagnostic uncertainty for patients.
15,83–88It is re -
commended to use the 0 h/1 h algorithm (best option) or the 0 h/2 h Blood sampling
It is recommended to measure cardiac troponins 
with high-sensitivity assays immediately after 
presentation and to obtain the results within 60 min of blood sampling.
15,25–27I B
It is recommended to use an ESC algorithmic approach with serial hs-cTn measurements (0 h/1 h 
or 0 h/2 h) to rule in and rule out NSTEMI.
28–44I B
Additional testing after 3 h is recommended if the first two hs-cTn measurements of the 0 h/1 h 
algorithm are inconclusive and no alternative 
diagnoses explaining the condition have been 
made.
45,46I B
The use of established risk scores (e.g. GRACE risk score) for prognosis estimation should be 
considered.
47–49IIa B
Triage for emergency reperfusion strategy
It is recommended that patients with suspected 
STEMI are immediately triaged for an emergency 
reperfusion strategy.50–52I A
©ESC 2023
ACS, acute coronary syndrome; ECG, electrocardiogram; ESC, European Society of 
Cardiology; FMC, first medical contact; GRACE, Global Registry of Acute Coronary 
Events; hs-cTn, high-sensitivity cardiac troponin; MI, myocardial infarction; NSTEMI, 
non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.ESC Guidelines                                                                                                                                                                                          3739Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

algorithm (second-best option) (Figure 6 ). These algorithms have been 
derived and validated in large multicentre diagnostic studies using cen -
tral adjudication of the final diagnosis for all currently available hs-cTn 
assays.27–39,62,70,73,82,89–93Optimal thresholds for rule-out were se -
lected to allow a sensitivity and NPV of at least 99%. Optimal thresholds 
for rule-in were selected to allow a positive predictive value (PPV) of at 
least 70%. These algorithms were developed from large derivation co -
horts and then validated in large independent validation cohorts. The previous ESC 0 h/3 h algorithm was considered as an alternative,
40,56
but three recent large diagnostic studies suggested that the ESC 0 h/ 
3 h algorithm appears to balance efficacy and safety less well than more rapid protocols using lower rule-out concentrations, including 
the ESC 0 h/1 h algorithm.
41–43The very high safety and high efficacy 
of applying the ESC 0 h/1 h algorithm was recently confirmed in three 
real-life implementation studies, including one randomized controlled 
trial (RCT).44,94,95Therefore, the ESC 0 h/3 h algorithm is an alternative 
for cases where the ESC 0 h/1 h or 0 h/2 h algorithms are not available. 
Of note, patients assigned to the ‘rule-out’ pathway using the ESC 0 h/ 
1 h or 0 h/2 h algorithms have a very low rate of clinical events through 
to 30 days.95,96
3.3.4.1. European Society of Cardiology 0 h/1 h and 0 h/2 h 
algorithms
The ESC 0 h/1 h and 0 h/2 h algorithms are based on two underlying 
concepts: firstly, hs-cTn is a continuous variable and the probability of MI increases with increasing hs-cTn values.
28,30,31,34,35,73,82
Secondly, early absolute changes in the levels within 1 h or 2 h can be used as surrogates for absolute changes over 3 h or 6 h and provide in
-
cremental diagnostic value to the single cTn assessment at presenta -
tion.27,28,30,31,34,35,73,82,97The cut-off concentrations within the 0 h/ 
1 h and 0 h/2 h algorithms are assay specific (Supplementary data online, Table S4).
27,28,30,31,34,35,73,82
3.3.4.1.1. Rule-out. The NPV for MI in patients assigned to the 
‘rule-out’ pathway has exceeded 99% in several large validation cohorts.
28–30,34,35,73Assignment to the rule-out pathway does not al -
ways equal outpatient management. However, when used in conjunc -
tion with clinical and ECG findings, the 0 h/1 h and 0 h/2 h algorithms 
will enable the identification of appropriate candidates for early dis -
charge and outpatient management. Even after the ruling out of MI, elective non-invasive or invasive imaging may be appropriate according 
to clinical and risk assessment, and an alternative diagnosis to MI should be identified.
3.3.4.1.2. Rule-in. The PPV for MI in patients meeting the ‘rule-in’ 
pathway criteria in several studies has been ∼70–75%. Most of the ‘rule-in’ pathway patients with diagnoses other than MI still have condi -
tions that require specialist cardiology input and either coronary angi -
ography or non-invasive imaging in order to establish an accurate final diagnosis.
28,30,31,34,35,73,82Therefore, the vast majority of patients 
triaged towards the ‘rule-in’ pathway by these algorithms will require hospital admission and invasive coronary angiography (ICA).
3.3.4.1.3. Observe. Patients who do not qualify for the ‘rule-out’ or 
‘rule-in’ pathways are assigned to the ‘observe’ pathway. These patients re -
present a heterogeneous group and have been shown to have a mortality 
rate that is comparable to rule-in patients.98Therefore, an individual as -
sessment based on the particular risk profile of the patient (i.e. risk scores) 
is of paramount importance for patients in this group. Additionally, a third 
measurement of cTn at 3 h (
± echocardiography) is recommended as the 
next step in order to guide further management.45,46
Most patients in the observe zone with a high degree of clinical 
suspicion of ACS (e.g. relevant increase in cTn from presentation 
to 3 h) are candidates for ICA. Conversely, most patients with a 
low to intermediate likelihood for ACS according to clinical judg -
ment are candidates for non-invasive imaging after transfer from the ED to the ward. Computed tomography (CT) angiography can 
be used to aid diagnosis and, in particular, to identify patients with non-obstructed coronary arteries who can be discharged if other 
relevant diseases have been excluded. CT angiography can also iden
-
tify patients with obstructive coronary disease in whom revascular -
ization may be considered. In the appropriate clinical context, if 
alternative conditions have been identified that explain the cTn va -
lues (i.e. rapid ventricular rate response to atrial fibrillation [AF], 
marked anaemia, or a hypertensive emergency), further diagnostic 
testing (i.e. ICA) may not be required.
The same concepts apply to the 0 h/2 h algorithm. Cut-off levels for 
both the 0 h/1 h and 0 h/2 h algorithms are also assay specific, and these 
cut-off levels are shown in Supplementary data online, Table S4.99
The ESC 0 h/1 h and 0 h/2 h algorithms should always be integrated 
with a detailed clinical assessment and a 12-lead ECG. Repeat blood 
sampling is mandatory in cases where there is ongoing or recurrent 
chest pain. Recently, artificial intelligence models that include serial 
hs-cTn measurements in conjunction with individual risk profiles have 
been proposed to be useful to facilitate a personalized diagnostic evalu -
ation of patients with suspected MI. Similarly, risk-assessment models 
combining hs-cTn values at presentation and after early or late resam -
pling have been developed to predict MI events during the first 30 days. These models may facilitate alternative hs-cTn cut-offs based on the 
balance between NPV and PPV best suited to individual clinical sites.
27
A diagnostic approach to the use of the ESC 0 h/1 h and 0 h/2 h algo -
rithms is shown in Figure 6.3740                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Patient presents with a suspected NSTEMI and 
without an indication for immediate invasive angiography
Appropriate management can be determined
based on the hs-cTn levels and clinical situationTake hs-cTn at 0 h and 1  h/2 h
Very low initial hs-cTna
Low initial hs-cTn and no
increase in 1  h/2 h hs-cTn
Patients who do not meet
the criteria for either of
the other two pathways 
Observe pathway Rule-out pathway Rule-in pathwayHigh initial hs-cTn
OR OR
Increase in 1  h/2 h hs-cTn
Figure 6 The 0 h/1 h or 0 h/2 h rule-out and rule-in algorithms using high-sensitivity cardiac troponin assays in patients presenting to the emergency de -
partment with suspected NSTEMI and without an indication for immediate invasive angiography. hs-cTn, high-sensitivity cardiac troponin; NSTEMI, 
non-ST-elevation myocardial infarction. Patients are classified into one of three pathways as per the results of their hs-cTn values at 0 h (time of initial blood 
test) and 1 h or 2 h later. Patients with a very low initial hs-cTn value or patients with a low initial value and no 1 h/2 h change in hs-cTn are assigned to the 
‘rule-out’ pathway. Patients with a high initial hs-cTn value or a 1 h/2 h change in hs-cTn are assigned to the ‘rule-in’ pathway. Patients who do not meet the criteria for the rule-out or rule-in strategies are assigned to the ‘observe’ pathway, and these patients should have hs-cTn levels checked at 3 h ± echocar
-
diography in order to decide on further management. Cut-offs are assay specific (see Supplementary material online, Table S4) and derived to meet 
pre-defined criteria for sensitivity and specificity for NSTEMI. Potential management and testing options for each of the three strategies are provided in the relevant sections of the main text.
12–15,26,27,53,55–58,100,101 aOnly applicable if the chest pain onset was >3 h prior to the 0 h hs-cTn measurement.ESC Guidelines                                                                                                                                                                                          3741Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

3.3.4.2. Practical guidance on how to implement the European 
Society of Cardiology 0 h/1 h algorithm
In order to maximize the safety and feasibility of implementing the 0 h/ 
1 h algorithm, blood samples for hs-cTn at 0 h and 1 h should be ob -
tained irrespective of other clinical details and pending results (see ca -
veats of using rapid algorithms in Supplementary data online, Section 3.3. 
2.2). This may result in unnecessary cTn measurements in the ∼
10– 
15% of patients with very low 0 h concentrations and chest pain onset 
>3 h, but substantially facilitates the process and thereby further in -
creases patient safety. Similarly, the 0 h blood sample should be ob -
tained immediately after admission to the ED.
3.3.5. Other biomarkers
The use of biomarkers other than cTn for the diagnosis of ACS is not 
recommended (unless cTn is not available). Among the multitude of additional biomarkers evaluated for the diagnosis of NSTEMI, only cre
-
atine kinase myocardial band isoenzyme, myosin-binding protein C, and copeptin may have clinical relevance when used in combination with 
(standard) cTn T/I, although in most clinical situations their incremental 
value above and beyond cTn is limited.
45,46,83,102–114
3.4. Diagnostic tools | Non-invasive imaging
3.4.1. Echocardiography
In emergency rooms and chest pain units, transthoracic echocardiog -
raphy (TTE) performed or interpreted by trained healthcare profes -
sionals should be routinely available. In cases of suspected ACS with 
diagnostic uncertainty, TTE can be useful to identify signs suggestive of 
ongoing ischaemia or prior MI. However, this should not result in rele -
vant delays in transfer to the cardiac catheterization laboratory if there is suspicion of an acute coronary artery occlusion. TTE can also be useful 
to suggest alternative aetiologies associated with chest pain (i.e. acute 
aortic disease, RV signs in pulmonary embolism [PE]). All patients pre
-
senting with CS or haemodynamic instability should undergo emergency TTE to try to identify the underlying cause—in particular, to assess LV 
and RV function and look for evidence of mechanical complications.
3.4.2. Computed tomography
Upon clinical presentation, CT is often the diagnostic tool of choice for ruling out alternative potentially life-threatening differential diagnoses of ACS, like PE or aortic dissection (this should be an ECG-gated con
-
trast CT angiogram with full coverage of the thoracic aorta and the proximal head and neck vessels). Generally, CT does not have a role 
in patients presenting with suspicion of ongoing acute coronary occlu
-
sion, for whom emergency ICA is the priority.
Coronary CT angiography (CCTA) has been investigated in many trials 
for the assessment of patients presenting to the ED with suspected 
NSTE-ACS. However, trials investigating CCTA in the era of hs-cTn as -
says may be of greater relevance for contemporary practice. The BEACON (Better Evaluation of Acute Chest Pain with Coronary 
Computed Tomography Angiography) study showed no reduction of in- 
hospital duration of stay or hospital admission in the CCTA arm com
-
pared with patients investigated with hs-cTn, with similar results to those observed in the ROMICAT II (Rule Out Myocardial Ischemia/Infarction by 
Computer Assisted Tomography) and RAPID-CTCA (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) trials.
115–117In the lat -
ter study, a default approach using early non-invasive CCTA in patients with suspected NSTE-ACS did not improve clinical outcomes at 1 year 
and was associated with a modest increase in the duration and cost of 
the hospital stay. A default approach using CCTA as the first-line imaging 
investigation in patients with suspected NSTE-ACS is therefore not recommended. However, CCTA may provide added value in certain clin
-
ical settings (i.e. for patients in the observe zone in whom cTn and ECG 
results remain inconclusive). A normal CCTA (ruling out both obstructive 
and non-obstructive plaque) has a high NPV to exclude ACS and is asso -
ciated with excellent clinical outcomes.
The systematic use of CCTA in rule-out patients after hospital dis -
charge may identify the presence of obstructive or non-obstructive pla -
que and guide preventative medical therapies.118CCTA can also be 
used to risk stratify selected low-risk NSTEMI patients. Such patients, 
who are found to have normal coronary arteries, non-obstructive cor -
onary disease, or distal obstructive disease, may then not require ICA.
119–121Of note, the utility of CCTA may be limited in patients 
with tachycardia, established coronary artery disease (CAD), previous stents, or extensive coronary calcification.
3.4.3. Cardiac magnetic resonance imaging with or 
without stress testing
Cardiac magnetic resonance (CMR) imaging delineates cardiac struc -
ture and function, and also has the ability to provide assessments of 
myocardial perfusion and the pattern of myocardial injury. CMR is 
the imaging test of choice when poor echocardiographic windows pre -
clude diagnostic echocardiographic evaluation. CMR allows direct visu -
alization of infarcted regions, providing information on scarring and 
viability that can be differentiated from other forms of myocardial injury 
(e.g. myocarditis). CMR is therefore of particular clinical value in estab -
lishing a diagnosis of AMI where there is diagnostic uncertainty. CMR can also be useful in identifying the culprit vascular territory and in con
-
firming a diagnosis of myocarditis or takotsubo cardiomyopathy, amongst other differentials. CMR is of particular value in establishing a diagnosis in patients presenting with a working diagnosis of myocardial 
infarction with non-obstructive coronary arteries (MINOCA) following 
invasive angiography and is the gold standard for the assessment of LV 
thrombus.
Recommendation Table 2 — Recommendations for 
non-invasive imaging in the initial assessment of patients 
with suspected acute coronary syndrome
Recommendations ClassaLevelb
Emergency TTE is recommended in patients with 
suspected ACS presenting with cardiogenic shock or 
suspected mechanical complications.I C
In patients with suspected ACS, non-elevated (or 
uncertain) hs-cTn levels, no ECG changes and no 
recurrence of pain, incorporating CCTA or a 
non-invasive stress imaging test as part of the initial 
workup should be considered.116,122–127IIa A
Emergency TTE should be considered at triage in cases of diagnostic uncertainty but this should not 
result in delays in transfer to the cardiac 
catheterization laboratory if there is suspicion of an 
acute coronary artery occlusion.IIa C
Routine, early CCTA in patients with suspected ACS is not recommended.
117III B
©ESC 2023
ACS, acute coronary syndrome; CCTA, coronary computed tomography angiography; 
ECG, electrocardiogram; hs-cTn, high-sensitivity cardiac troponin; TTE, transthoracic 
echocardiography. 
aClass of recommendation. 
bLevel of evidence.3742                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Cardiac magnetic resonance can also assess myocardial perfusion 
with pharmacological stress. This can be used as an alternative to 
CCTA in the assessment of patients in the observe zone following 
ECG and hs-cTn assessments, particularly in those with advanced, es -
tablished CAD, in whom assessments of myocardial perfusion and via -
bility may provide more useful information than CCTA. Some 
additional information on CMR, single-photon emission computerized 
tomography (SPECT) perfusion imaging and stress echocardiography 
is provided in the Supplementary data online.
Depending on local expertise and availability, other forms of stress 
imaging (e.g. SPECT, nuclear, stress echo) can be used to assess patients 
in the observe zone.
3.5. Differential diagnosis for acute chest 
pain
Several cardiac and non-cardiac conditions that may mimic ACS should 
be considered in the differential diagnosis of acute chest pain as part of the clinical assessment. More information about the differential diagno
-
sis of acute chest pain is provided in the sections on MINOCA and Type 2 MI and in the 
Supplementary data online, Table S5.
4. Initial measures for patients 
presenting with suspected acute 
coronary syndrome | Initial 
treatment
4.1. Pre-hospital logistics of care
Individuals experiencing acute chest pain in the community represent 
an undifferentiated population, often presenting ad hoc to first med -
ical responders in the pre-hospital setting. These patients should 
undergo immediate risk assessment and triage following local proto -
cols established within the emergency medical service (EMS) (
Figures 7 and 8).
If the first responding medical professional suspects ACS, a 12-lead 
ECG should be acquired and analysed as soon as possible. It is recom -
mended that all medical and paramedical personnel caring for ACS pa -
tients within the EMS setting have access to defibrillation equipment and are trained in basic cardiac life support. Patients with suspected 
ACS are initially categorized on the basis of the 12-lead ECG and 
triaged into two initial treatment pathways: (i) one for patients with 
an ECG consistent with STEMI (persistent ST-segment elevation or 
equivalent ECG patterns) (
Figure 7); and (ii) one for patients without 
ST-segment elevation or equivalent ECG patterns (suspected NSTE-ACS) (Figure 8
). The initial ECG-guided risk stratification should 
also trigger treatment decisions in the pre-hospital setting, including the 
choice of target hospital, and serve to determine the sequence of initial 
investigations and interventions (including pharmacological), in particu -
lar, the timing of ICA.
An initial diagnosis of suspected STEMI portends a higher risk of im -
mediate, life-threatening complications (e.g. ventricular fibrillation 
[VF]). Accordingly, there is an indication for initiating an emergency re -
perfusion strategy and direct transfer to a centre with 24/7 PCI capabil -
ities. Patients who present with an ECG without ST-segment elevation 
(or equivalent ECG patterns) but have ongoing ischaemic symptoms should undergo pre-hospital triage in accordance with protocols for pa
-
tients in the STEMI pathway, since they also face immediate risks, in -
cluding ventricular arrhythmias.4.1.1. Time to treatment
Time to treatment is vital for the care of patients triaged to the STEMI 
pathway. Components of the total ischaemic time, contributors to delays 
in initial management, and the selection of reperfusion strategy for STEMI 
patients are shown in Figure 7 . Treatment times reflect the efficiency and 
quality of care of a system taking care of patients with suspected STEMI. The multidisciplinary STEMI treatment pathway should be subject to 
continuous clinical audit in order to assess the treatment times for indi
-
vidual patients and identify opportunities for healthcare improvement 
through quality indicators (QIs). If projected QIs are not met, interven -
tions are needed to improve the performance of the system.
Recognition of ischaemic symptoms by individuals in the community 
has pivotal importance in activation of the out-of-hospital pathway, and 
this is especially relevant to first responders without healthcare training. 
The recommended action should be to contact the EMS rather than to 
self-present to an ED or primary care clinician.
The time from symptom onset to ‘first call for help’ is associated with 
socioeconomic factors and sex.128In order to avoid delays through fail -
ure to recognize and act on symptoms of a ‘heart attack’, community 
education initiatives should target less well-served groups (i.e. those 
from deprived communities, ethnic minority groups) and use targeted 
public health messaging (i.e. avoiding stereotyped messaging that under -
pins a negative bias based on sex, ethnicity, or social background, and using language and images that will resonate with those groups). System delays are representative of the quality of care and it is recom
-
mended to measure these as QIs.
4.1.2. Healthcare systems and system delays
For patients with suspected STEMI, the system delay (the time from when the patient contacts the healthcare system to reperfusion) is amenable to improvement by organizational measures, whereas patient 
delay is multifactorial. System delay is a predictor of mortality in STEMI 
patients treated with primary PCI (PPCI).
129–131When a working diag -
nosis of STEMI is made in the pre-hospital setting (EMS), immediate ac -
tivation of the catheterization laboratory team reduces treatment 
delays and mortality.132–136
When a STEMI working diagnosis is made by the EMS in the pre- 
hospital setting and the patient is triaged for emergency invasive manage -
ment, they should bypass the ED and go straight to the catheterization laboratory. Bypassing the ED is associated with a significant saving in the 
time from FMC to wire crossing and may be associated with improved 
survival.
137–139For patients presenting to a non-PCI centre with a sus -
pected STEMI, the ‘door-in to door-out time’—defined as the duration 
between arrival of the patient at the hospital to discharge of the patient 
in an ambulance ‘en route’ to the PCI centre—is also an important clinical 
performance measure, and a door-in to door-out time of ≤
30 min is re -
commended to expedite reperfusion therapy.140
4.1.3. Emergency medical services
At a national level, an EMS with an easily recalled and well-publicised un -
ique medical dispatching number (112 for most European Union coun -
tries) is important to speed-up system activation. Parallel circuits 
for the referral and transport of patients with suspected STEMI that by -
pass the EMS should be avoided. The ambulance system plays a critical 
role in the early management of patients with suspected STEMI, including 
immediately establishing the initial diagnosis, triage, and treatment.129,141
Ambulances in the EMS must be equipped with ECG recorders, de -
fibrillators, telemetry devices, and at least one person trained in ad -
vanced life support. The quality of the care provided depends on the ESC Guidelines                                                                                                                                                                                          3743Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

training of the staff involved. Ambulance personnel must be trained to 
recognize ischaemic symptoms, administer oxygen when appropriate, 
secure intravenous (i.v.) access, effectively relieve pain, administer fi -
brinolysis when indicated, and provide basic life support.142
Ambulance staff should record an ECG as soon as possible for diagnos -
tic purposes and either interpret the ECG or transmit it so that it can be reviewed by experienced staff to establish or refute a working diagnosis 
of STEMI. Regular and structured training of ambulance staff is manda
-
tory for a high-quality pre-hospital service.
4.1.4. General practitioners
In some countries, primary care clinicians (general practitioners) play an 
important role in the early care of patients with suspected ACS and may provide the FMC. Education and training of general practitioners 
in emergency, pre-hospital care is essential for the delivery of optimal 
pre-hospital care in this setting. The responsibilities of the primary 
care clinicians may include diagnosis, activation of the EMS, risk stratifi
-
cation, and initiation of pre-hospital treatment. However, in most set -
tings, consultation with a general practitioner instead of a direct call to the EMS will increase the pre-hospital delay. Therefore, the public 
should be educated to call the EMS directly rather than a primary 
care physician for symptoms suggestive of ACS.
4.1.5. Organization of ST-elevation myocardial 
infarction treatment in networks
It is recommended that a regional reperfusion strategy is established to 
maximize the efficiency of care for patients with a working diagnosis of 
STEMI.143The optimal treatment of patients with a working diagnosis 
of STEMI should be based on the implementation of networks between 
hospitals with various levels of clinical service provision (the ‘hub and 
spoke’ model), linked by a prioritized and efficient ambulance service. 
A PCI centre is a multidisciplinary acute care centre that provides emer -
gency invasive management 24/7 for patients presenting with suspected 
STEMI. This centre should also provide intensive care facilities, and 
more advanced centres should offer cardio-thoracic services, advanced 
haemodynamic support, and surgery.
The goal of STEMI networks is to provide optimal care while minimizing 
delays, thereby improving clinical outcomes. Cardiologists should actively 
collaborate with all stakeholders, particularly emergency physicians, in estab -
lishing such networks. The main features of such a network are detailed in 
Supplementary data online, Table S6. It is recommended that the EMS should 
transport patients with a working diagnosis of STEMI to hospitals with a 24/7 
service for PCI, bypassing non-PCI-capable hospitals.144Further information 
on this topic is provided in the Supplementary data online.
Geographic areas where the expected transfer time to the primary 
PCI centre makes it impossible to routinely achieve the maximal allow -
able delays indicated in the recommendations should develop protocols for rapid fibrinolysis at the place of STEMI diagnosis, with the aim of 
treatment within 10 min of FMC, followed by immediate transfer to a centre with 24/7 service for PCI. Such networks increase the propor
-
tion of patients receiving reperfusion with the shortest possible treat -
ment delay.145–147The quality of care, time delays, and patient 
outcomes should be measured and reported to the healthcare profes -
sionals contributing to the EMS.
4.2. Emergency care
4.2.1. Initial diagnosis and monitoring
Management of ACS starts from the point of FMC, when a working diagnosis of ACS is established. The working diagnosis of ACS is usually based on symptoms consistent with myocardial ischaemia and the signs 
on a 12-lead ECG (see Section 3.2
). It is recommended to initiate ECG 
monitoring as soon as possible in all patients with suspected ACS in or -
der to detect life-threatening arrhythmias and to allow prompt defibril -
lation if indicated.
4.2.2. Acute pharmacotherapy
4.2.2.1. Oxygen
Oxygen supplementation is recommended in ACS patients with hypox -
aemia (oxygen saturations <
90%). Oxygen supplementation in patients 
who are not hypoxic (oxygen saturations >90%) is not associated with 
clinical benefits and is therefore not recommended.148,149
4.2.2.2. Nitrates
Sublingual nitrate may be helpful to relieve ischaemic symptoms. 
However, a reduction in chest pain after nitroglycerine administra -
tion can be misleading and is not recommended as a diagnostic man -
oeuvre.150In patients with an ECG compatible with ongoing STEMI 
and symptom relief after nitroglycerine administration, it is recom -
mended to obtain another 12-lead ECG. Complete normalization 
of ST-segment elevation, along with relief of symptoms, after nitro -
glycerine administration is suggestive of coronary spasm, with or without associated MI. Nitrates should not be given to patients 
with hypotension, marked bradycardia or tachycardia, RV infarction, 
known severe aortic stenosis, or phosphodiesterase 5 inhibitor use 
within the previous 24–48 h.
4.2.2.3. Pain relief
Intravenous opioids (e.g. morphine 5–10 mg) should be considered for 
the relief of severe chest pain. Other forms of pain relief (e.g. nitrous 
oxide/oxygen plus i.v. acetaminophen/paracetamol) have been re -
ported to be inferior to morphine.151However, morphine may en -
hance nausea and vomiting and slow the gastrointestinal absorption of oral medicines, which may delay the onset of action of orally admi
-
nistered antiplatelet therapy.152,153Evidence from small-scale trials sug -
gests that i.v. morphine may also reduce myocardial and microvascular 
damage when given to patients with ongoing acute coronary artery oc -
clusion, though co-administration with metoclopramide appears to 
negate this effect. Conversely, morphine has also been reported to re -
duce antiplatelet activity after administration of ticagrelor, though this effect was rescued by metoclopramide administration.
154,155The posi -
tive effects of morphine on myocardial damage may potentially be re -
lated to reduced oxygen consumption as a result of decreased 
preload and negative inotropy and chronotropy.
Platelet inhibition induced by oral P2Y 12 receptor antagonists may 
be delayed in patients with ongoing MI. Morphine may also further re -
duce absorption, delay the onset of action, and decrease the antipla -
telet effect of oral P2Y 12 receptor inhibitors in MI patients, although 
this effect may vary between the different P2Y 12 inhibitors.153,156– 
158Further research is ongoing in this area, but at present it should 
be noted that currently available clinical data have not demonstrated 
any increase in the risk of adverse clinical outcomes as a result of any 
interaction between morphine and antiplatelet agents in the setting of 
ACS.159–161
4.2.2.4. Intravenous beta-blockers
Few RCTs testing early i.v. beta-blockers have been performed in the era of invasive management for patients with a working diagnosis of STEMI. Not all beta-blockers appear to exert the same 3744                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

cardio-protective effect in the context of ongoing acute coronary oc -
clusion, with metoprolol demonstrating the greatest protective effect 
in experimental studies.162Intravenous metoprolol is also the most 
widely tested beta-blocker in trials enrolling patients undergoing PPCI.
163,164While the long-term clinical benefits associated with early 
i.v. metoprolol administration are not clear, it is safe when used in pa -
tients without signs of acute HF and has been consistently associated 
with a reduction in the incidence of VF and microvascular obstruction 
(MVO).163–171Based on these data, i.v. beta-blockers (preferably meto -
prolol) should be considered at the time of presentation in patients with a working diagnosis of STEMI undergoing PPCI with no signs of 
acute HF, a systolic blood pressure (SBP) >
120 mmHg, and without 
other contraindications.163–166,169Administration of i.v. beta-blockers 
in patients with suspected NSTE-ACS has not been tested.
5. Acute-phase management of 
patients with acute coronary 
syndrome
5.1. Selection of invasive strategy and 
reperfusion therapy
The definitions of the terms related to invasive strategy and reperfusion 
therapy are presented in Table 3.
Depending on the initial assessment of the ECG, the clinical context 
and haemodynamic stability, patients with suspected ACS should be classified as either: 
(i)Patients with a working diagnosis of STEMI. These patients should be triaged for immediate reperfusion therapy (i.e. a PPCI strategy 
or fibrinolysis if PPCI is not possible within 120 min of diagnosis) 
(Figure 7).
Or
(ii)Patients with a working diagnosis of NSTE-ACS. For these patients: 
•An inpatient invasive strategy is recommended.
•An immediate invasive strategy is recommended when any very high-risk feature is present (Figure 8).
•An early (i.e. within 24 h) invasive strategy should be considered 
when any high-risk features are present (Figure 8).
5.2. Acute coronary syndrome managed 
with invasive strategy
Invasive management strategies are time sensitive. It is recommended that 
patients triaged to an immediate invasive strategy (those with high suspi -
cion of ongoing acute coronary artery occlusion [i.e. persistent 
ST-segment elevation or equivalents] or NSTE-ACS with any very high- 
risk characteristics) receive emergency angiography as soon as possible. 
High-risk NSTE-ACS patients (e.g. ruled in as NSTEMI as per the 0 h/1 h 
or 0 h/2 h ESC algorithms, with dynamic ST-segment or T wave changes, 
with transient ST-segment elevation, or with a Global Registry of Acute 
Coronary Events [GRACE] risk score >
140) should be considered for 
an early invasive strategy (i.e. undergoing angiography within 24 h).
5.2.1. Primary percutaneous coronary intervention 
strategy for ST-elevation myocardial infarction
In patients with a working diagnosis of STEMI, a PPCI strategy (i.e. im -
mediate angiography and PCI as needed) is the preferred reperfusion 
strategy, provided it can be performed in a timely manner (i.e. within Recommendation Table 3 — Recommendations for the 
initial management of patients with acute coronary 
syndrome
Recommendations ClassaLevelb
Hypoxia
Oxygen is recommended in patients with 
hypoxaemia (SaO 2 <90%).I C
Routine oxygen is not recommended in patients 
without hypoxaemia (SaO 2 >90%).148,172III A
Symptoms
Intravenous opioids should be considered to relieve 
pain.IIa C
A mild tranquilizer should be considered in very 
anxious patients.IIa C
Intravenous beta-blockers
Intravenous beta-blockers (preferably metoprolol) 
should be considered at the time of presentation in 
patients undergoing PPCI with no signs of acute heart failure, an SBP >120 mmHg, and no other 
contraindications.
163–167,169IIa A
Pre-hospital logistics of care
It is recommended that the pre-hospital 
management of patients with a working diagnosis of 
STEMI is based on regional networks designed to 
deliver reperfusion therapy expeditiously and 
effectively, with efforts made to make PPCI available 
to as many patients as possible.145I B
It is recommended that PPCI-capable centres deliver a 24/7 service and are able to perform PPCI without 
delay.
173,174I B
It is recommended that patients transferred for PPCI 
bypass the emergency department and CCU/ICU and are transferred directly to the catheterization 
laboratory.
137,175–178I B
It is recommended that EMS transfer patients with suspected STEMI to a PCI-capable centre, bypassing 
non-PCI centres.I C
ContinuedIt is recommended that ambulance teams are trained 
and equipped to identify ECG patterns suggestive of 
acute coronary occlusion and to administer initial 
therapy, including defibrillation, and fibrinolysis when 
applicable.142I C
It is recommended that all hospitals and EMS participating in the care of patients with suspected 
STEMI record and audit delay times and work 
together to achieve and maintain quality targets.I C
©ESC 2023
CCU, cardiac care unit; ECG, electrocardiogram; EMS, emergency medical services; ICU, 
intensive care unit; i.v., intravenous; PPCI, primary percutaneous coronary intervention; 
SaO 2, saturation of oxygen; SBP, systolic blood pressure; STEMI, ST-elevation myocardial 
infarction. 
aClass of recommendation. 
bLevel of evidence.ESC Guidelines                                                                                                                                                                                          3745Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

120 min of the ECG-based diagnosis, Figure 7). RCTs have shown that if 
the delay to treatment is similar, PPCI is superior to fibrinolysis in reducing 
mortality, non-fatal reinfarction, and stroke.52,179However, in some cir -
cumstances, PPCI is not an immediate option and fibrinolysis should be initiated expeditiously as part of a pharmaco-invasive strategy, provided 
the patient has presented within 12 h of symptom onset (see 
Section 5.3).
There is a lack of contemporaneous data to inform the treatment delay 
limit at which the advantage of PCI over fibrinolysis is lost. For simplicity, an 
absolute time of 120 min from STEMI diagnosis to PCI-mediated reperfu -
sion (i.e. wire crossing of the infarct-related artery [IRA]) rather than a rela -
tive PCI-related delay over fibrinolysis has been chosen. Given the recommended time interval of 10 min from STEMI diagnosis to administra
-
tion of a bolus of fibrinolytics (see below), the 120 min absolute time delay would correspond to a relative PCI-related delay in the range of 110– 
120 min. This is within the range of the times identified as the limit of delay 
below which PCI should be chosen in older studies and registries.
176,180–184
For patients who undergo fibrinolysis, rescue PCI is indicated if fibrin -
olysis fails (i.e. ST-segment resolution <
50% within 60–90 min of fi -
brinolytic administration) or in the presence of haemodynamic or electrical instability, worsening ischaemia, or persistent chest 
pain.
184,185Patients with successful fibrinolysis should undergo early invasive angiography (i.e. within 2–24 h from the time of the lytic bolus 
injection) (see Section 5.3).186
Patients with a working diagnosis of STEMI who present to a 
non-PCI centre should be immediately transferred to a PCI-capable 
centre (Figure 7) for a timely PPCI strategy. If PPCI is not feasible within 
120 min, patients should undergo immediate fibrinolysis followed by 
transfer to a PCI centre without waiting for signs of reperfusion. For 
patients presenting after 12 h from symptom onset, a PPCI strategy 
is preferred over fibrinolysis in all cases.
Emergency coronary artery bypass grafting (CABG) surgery should 
be considered for patients with a patent IRA but with unsuitable anat -
omy for PCI, and either a large myocardial area at jeopardy or with CS. 
In patients with MI-related mechanical complications who require cor -
onary revascularization, CABG is recommended at the time of surgical 
repair. In STEMI patients with failed PCI or with an acute coronary oc -
clusion not amenable to PCI, emergency CABG is infrequently per -
formed because the benefits of surgical revascularization in this 
setting are less certain.185,187,188Because there will be a delay to reper -
fusion with CABG in this situation, the probability of myocardial salvage 
to a degree sufficient to impact on prognosis is considered low. In add -
ition, the surgical risks of CABG in this setting may be elevated.
Onset of
symptoms
FMC
location
Mode of 
FMCPatient self presents
to hospital
PCI centre Non-PCI centre AmbulancePatient calls 
EMS
ororPatient with symptoms of ACS and
ECG consistent with STEMITotal 
ischaemic 
timePatient
self 
presentsPatient
calls
 EMS
PPCI
strategy
ReperfusionPPCI
strategyFibrinolysis
strategy
Immediate transfer 
to PCI centre
for primary PCIImmediate transfer 
to PCI centre
 after fibrinolysisPatient delay
System delayEMS delay
Total ischaemic time
YES
 NO
Aim: 
<60 min to
wire crossing Determine 
therapeutic 
strategy
Aim:
<90 min to
wire crossingAim:
<10 min to
lytic bolusPCI possible in <120 min?Total ischaemic time and
sources of delay to reperfusion
Figure 7 Modes of presentation and pathways to invasive management and myocardial revascularization in patients presenting with STEMI. ACS, acute 
coronary syndrome; ECG, electrocardiogram; EMS, emergency medical services; FMC, first medical contact; PCI, percutaneous coronary intervention; 
PPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.3746                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

5.2.1.1. Invasive strategy in ST-elevation myocardial infarction late 
presenters
While routine immediate angiography and PCI (if indicated) are clearly 
associated with clinical benefit in patients presenting within 12 h of symptom onset, the value of a routine PPCI strategy in STEMI patients 
presenting later than 12 h after symptom onset is less well established.
A small RCT in 347 STEMI patients presenting 12–48 h after symp -
tom onset and without persistent symptoms reported that a routine 
PPCI strategy improved myocardial salvage and long-term survival com -
pared with conservative treatment.189,190This observation is supported 
by a recent analysis of data from three nationwide observational studies 
from the FAST-MI (French Registry of Acute ST-elevation and 
non-ST-elevation Myocardial Infarction) programme, which showed a 
significant lower rate of all-cause death at 1 month (2.1% vs. 7.2%) 
and after a median follow-up of 58 months (30.4% vs. 78.7%) with an in -
vasive strategy in comparison to conservative treatment.191However, in 
stable patients with persistent occlusion of the IRA 3–28 days after MI, 
the large (n = 2166) Occluded Artery Trial (OAT) reported no clinical 
benefit from routine coronary intervention with medical management in comparison to medical management alone.
192,193A meta-analysis of 
trials testing whether late recanalization of an occluded IRA is beneficial 
also showed no benefit of reperfusion.194Therefore, routine PCI of an 
occluded IRA in STEMI patients presenting >48 h after onset of symp -
toms and without persistent symptoms is not indicated.192,193These pa -
tients should be managed in the same way as patients with chronic total 
occlusion according to the ESC Guidelines for the diagnosis and manage -
ment of chronic coronary syndromes (CCS).195
5.2.2. Immediate invasive strategy for non-ST 
elevation acute coronary syndrome
An immediate invasive strategy refers to emergency (i.e. as soon as pos -
sible) angiography and PCI if indicated. This is recommended for pa -
tients with a working diagnosis of NSTE-ACS and any of the 
following very high-risk criteria: 
•Haemodynamic instability or CS.
•Recurrent or ongoing chest pain refractory to medical treatment.
•Acute HF presumed secondary to ongoing myocardial ischaemia.
•Life-threatening arrhythmias or cardiac arrest after presentation.
•Mechanical complications.
•Recurrent dynamic ECG changes suggestive of ischaemia (particularly with intermittent ST-segment elevation).
5.2.3. Routine vs. selective invasive strategy
A routine invasive strategy with inpatient coronary angiography is re -
commended for patients with a confirmed diagnosis of NSTEMI or a 
working diagnosis of NSTE-ACS and a high index of suspicion for 
UA. In patients with a working diagnosis of NSTE-ACS, multiple 
RCTs comparing routine vs. selective invasive strategies have been 
conducted and their results have been pooled in several meta- 
analyses.196–200The available evidence indicates that a routine invasive 
strategy does not reduce all-cause mortality risk in the overall popula -
tion of NSTE-ACS patients, but reduces the risk of composite ischae -
mic endpoints, particularly in high-risk patients. A routine invasive 
strategy can increase the risk of peri-procedural complications and 
bleeding. However, most of the available evidence is based on old 
RCTs that were conducted before the implementation of several im -
portant developments in PCI, including radial access, modern 
drug-eluting stents (DES), complete functional revascularization for multivessel disease (MVD), improved co-adjuvant pharmacological 
therapies, and contemporary biomarker assays.
5.2.3.1. Early vs. delayed invasive strategy for non-ST elevation acute 
coronary syndrome
An early invasive strategy refers to routine invasive angiography (and 
PCI if needed) within 24 h of presentation. This should be considered in patients with a working diagnosis of NSTE-ACS and any of the fol
-
lowing high-risk criteria: 
•A confirmed diagnosis of NSTEMI based on current recommended 
ESC hs-cTn algorithms.
•Dynamic ST-segment or T wave changes.
•Transient ST-segment elevation.
•A GRACE risk score >
140.
Several meta-analyses have pooled data from multiple RCTs assessing 
different timing intervals of invasive angiography among NSTE-ACS pa -
tients. None of these studies observed superiority of early invasive strat -
egies compared with routine invasive strategies for death or non-fatal MI, 
although early invasive strategies were associated with a lower risk 
of recurrent/refractory ischaemia and a shorter duration of hospital 
stay.201–203A collaborative meta-analysis comparing an early vs. a delayed 
invasive strategy using a modified individual patient data approach ob -
served no difference in mortality overall but a survival benefit in high-risk 
patients, including those with a GRACE risk score >
140 and those with 
positive troponin, although tests for interaction were inconclusive.202
The largest meta-analysis to date (17 RCTs >10 000 patients) reported 
that, in all-comers with NSTE-ACS, early ICA only significantly reduced the risk of recurrent ischaemia and duration of stay, with no significant re
-
ductions in all-cause mortality, MI, admission for HF, or repeat revascular -
ization.203The main limitation of the interpretation of meta-analyses of 
these RCTs is the variability of the time to invasive angiography in the in -
dividual trials: while invasive angiography was virtually always performed 
within 24 h of randomization in the early invasive strategy groups, the 
time from randomization to angiography was heterogeneous in the de -
layed invasive groups. In many trials, delayed angiography was performed within 24 h of randomization (albeit later than in the early angiography arm of the respective trial). Additionally, the diagnosis of NSTEMI was 
not based on the current recommended ESC hs-cTn algorithms. 
Moreover, studies assessing the value of a GRACE risk score >
140 to 
guide the timing of ICA and revascularization in the era of hs-cTn for 
the diagnosis of NSTEMI are lacking. Further detail on the interaction be -
tween treatment effect according to GRACE score and its components in 
individual trials is provided in the Supplementary data online. Data from 
observational studies is concordant with trial data, without a strong signal of benefit with early versus delayed coronary angiography.
204
A selective invasive approach after appropriate ischaemia testing or 
detection of obstructive CAD by CCTA is recommended in patients 
without very high- or high-risk features and a low index of suspicion 
for NSTE-ACS. These patients should be managed as per the ESC 
Guidelines for the management of CCS.195A selective invasive ap -
proach is also appropriate for patients with NSTEMI or UA who are 
not deemed good candidates for coronary angiography.
5.2.4. Summary of invasive strategies for patients 
with non-ST elevation acute coronary syndrome
In summary, very high-risk NSTE-ACS patients are recommended to 
undergo an immediate invasive strategy with emergency angiography ESC Guidelines                                                                                                                                                                                          3747Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

and PCI if required. High-risk NSTE-ACS patients are recommended 
to undergo an inpatient invasive strategy and should be considered for an early invasive strategy (i.e. within 24 h). For patients who do 
not meet any of the very high-risk or high-risk criteria (generally patients with clinical suspicion for NSTE-ACS and non-elevated tro
-
ponins or patients with elevated troponins not meeting the criteria 
for MI), the strategy can be tailored based on the degree of clinical 
suspicion. For patients with a high index of suspicion for UA, an 
FMC
FMC
locationPCI centre Non-PCI centre Ambulance
Immediate transfer
Early/inpatient transferor
Very high
riskaVery high
risk
Risk stratify
and determine 
therapeutic 
strategy 
Inpatient transfer
In patients without very-high or
high-risk features and a low indexof suspicion for unstable angina(if required)High riskaHigh risk
Non-high
risk
Selective
invasive
strategy 
(Class I)Inpatient
invasive
 strategy
(Class I)Inpatient
invasive
 strategy
(Class I)Early (<24 h)
invasive
strategy
(Class IIa)
Immediate
invasive
strategy
(Class I)Non-high
riskPatient with symptoms of ACS and ECG consistent with NSTE-ACS
Haemodynamic instability or cardiogenic shockRecurrent or ongoing chest pain refractory to medical treatmentAcute heart failure presumed secondary to ongoing myocardial ischaemiaLife-threatening arrhythmias or cardiac arrest after presentationMechanical complicationsRecurrent dynamic ECG changes suggestive of ischaemia
Confirmed diagnosis of NSTEMI based on ESC algorithms
GRACE risk score >140Transient ST-segment elevationDynamic ST-segment or T wave changesFigure 8 Selection of invasive strategy and reperfusion therapy in patients presenting with NSTE-ACS. ACS, acute coronary syndrome; CS, cardiogenic 
shock; ECG, electrocardiogram; FMC, first medical contact; GRACE, Global Registry of Acute Coronary Events; hs-cTn, high-sensitivity cardiac troponin; 
NSTE-ACS, non-ST-elevation acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; UA, 
unstable angina. This figure summarizes the selection of invasive strategy and reperfusion therapy in patients presenting with ACS. aRisk criteria: Patients 
who meet any one of the ‘very high-risk’ NSTE-ACS criteria should undergo an immediate invasive strategy; these very high-risk criteria include haemo -
dynamic instability or CS, recurrent or refractory chest pain despite medical treatment, life-threatening arrhythmias, mechanical complications of MI, HF clearly related to ACS, and recurrent dynamic ST-segment or T wave changes, particularly with intermittent ST-segment elevation. Patients with 
NSTE-ACS who meet any of the ‘high-risk’ criteria (confirmed NSTEMI as per the hs-cTn-based ESC algorithm, NSTE-ACS with GRACE score >
140, dy -
namic ST-segment or T wave changes, or transient ST-segment elevation) should be considered for early invasive angiography (i.e. within 24 h) and should 
undergo an inpatient invasive strategy. An invasive strategy during hospital admission is recommended in NSTE-ACS patients with high-risk criteria or with a 
high index of suspicion for UA. In selected patients a selective invasive strategy can also be an option. See Recommendation Table 4 for full details.3748                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

inpatient invasive strategy is recommended. Conversely, for patients 
with a low index of suspicion, a selective invasive approach is 
recommended.
5.3. Fibrinolysis and pharmaco-invasive 
strategy in patients with ST-elevation 
myocardial infarction
5.3.1. Benefit and indication of fibrinolysis
Fibrinolytic therapy is an important reperfusion strategy for STEMI pa -
tients presenting within 12 h of symptom onset when PPCI cannot be 
performed in a timely manner; it prevents 30 early deaths per 1000 pa -
tients treated within 6 h of symptom onset.205The largest absolute treat -
ment benefit is seen among those patients at the highest risk, including the elderly. Successful reperfusion is generally associated with significant im
-
provement in ischaemic symptoms, ≥
50% ST-segment resolution, 
and haemodynamic stability. The doses of fibrinolytic agents and concomi -
tant antithrombotic therapies are given in the Fibrinolysis and Pharmaco- invasive Strategy provided in the 
Supplementary data online, Section 6.3.
5.3.1.1. Pre-hospital fibrinolysis
If trained medical or allied health staff can interpret the ECG on site, or transmit the ECG for remote interpretation, it is recommended to ini
-
tiate fibrinolytic therapy in the pre-hospital setting. A fibrin-specific 
agent (i.e. tenecteplase, alteplase, or reteplase) is the preferred agent. 
The goal is to start fibrinolytic therapy within 10 min of the STEMI diag -
nosis. Fibrinolytic therapy initiation should not be delayed by waiting for the results of cardiac biomarker testing. In a meta-analysis of six rando
-
mized trials (
n = 6434), pre-hospital fibrinolysis compared with in- 
hospital fibrinolysis reduced early mortality by 17%, particularly when administered in the first 2 h after symptom onset.
51,206These, and 
more recent, data support the pre-hospital initiation of fibrinolytic treatment when a reperfusion strategy is indicated.
145,207–209The 
STREAM (Strategic Reperfusion Early After Myocardial Infarction) trial demonstrated that pre-hospital fibrinolysis followed by an early PCI 
strategy was associated with a similar outcome to transfer for PPCI 
in STEMI patients presenting within 3 h of symptom onset who could 
not undergo PPCI within 1 h of FMC, although a slight excess of intra
-
cranial bleeding was observed with the investigational strategy.184,210
This excess in intracranial bleeding was blunted by halving the dose 
of tenecteplase in patients >75 years of age.
5.3.1.2. Angiography and percutaneous coronary intervention after 
fibrinolysis (pharmaco-invasive strategy)
It is recommended that patients should be transferred to a PCI centre 
immediately after initiation of lytic therapy (Figure 7 ). In cases of failed 
fibrinolysis or evidence of re-occlusion or re-infarction with recurrence 
of ST-segment elevation, immediate angiography and rescue PCI are in -
dicated.185,211In this setting, re-administration of fibrinolysis is not 
beneficial and is discouraged.185Even if it is likely that fibrinolysis is suc -
cessful (e.g. ST-segment resolution >
50% at 60–90 min; typical reper -
fusion arrhythmia; and disappearance of chest pain), routine early 
angiography (i.e. within 2–24 h) is recommended. Several randomized trials have shown that routine early angiography with subsequent PCI (if required) after fibrinolysis reduced the rates of re-infarction and re
-
current ischaemia in comparison to a ‘watchful waiting’ strategy (i.e. a 
strategy in which angiography and revascularization were performed 
only in patients with spontaneous or induced severe ischaemia or LV dysfunction, or in patients with a positive outpatient ischaemia 
test).
186,209,212–215A network meta-analysis including 15 357 STEMI pa -
tients treated with fibrinolytic therapy (
n = 4212), PPCI (n = 6139), or 
fibrinolysis followed by routine immediate or early PCI (n = 5006) in -
vestigated whether STEMI patients should be transferred to a 
PCI-capable facility immediately (defined as a facilitated PCI approach) 
or within a day (e.g. <
24 h, defined as a pharmaco-invasive ap -
proach).209After PPCI, the pharmaco-invasive strategy was the second 
most favourable approach, with an odds ratio (OR) for death of 0.79 
(95% confidence interval [CI], 0.59–1.08) compared with conventional 
fibrinolytic therapy. This supports the safety of transferring STEMI pa -
tients to a PCI-capable centre for angiography within 2–24 h. The bene -
fit of routine early PCI after fibrinolysis was demonstrated without an 
increased risk of adverse events (stroke or major bleeding), and across the spectrum of the investigated patient subgroups.
209,216Therefore, 
early angiography with subsequent PCI if required is the recommended standard of care after successful fibrinolysis (Figure 7). Observational 
analysis of registry data has also provided some further support for 
the use of a pharmaco-invasive strategy.
130
The optimal time delay between successful fibrinolysis and PCI has 
not been clearly defined; there has been a wide variation in this time 
delay in trials, ranging from a median of 1.3 to 17 h.184,185,206,215,217
Based on these data, a time window for PCI of 2–24 h after successful 
lysis is recommended.
5.3.1.2.1. Comparison of fibrinolytic agents. Some information on 
comparisons of fibrinolytic agents is provided in the Supplementary 
data online, Section 6.3.1.
5.3.1.2.2. Hazards of fibrinolysis and contraindications. Some infor -
mation regarding the hazards of, and contraindications to, fibrinolysis is provided in the 
Supplementary data online, Section 6.3.2.
5.4. Patients not undergoing reperfusion
The management of ACS patients not undergoing reperfusion is dis -
cussed in the Supplementary data online, Section 5.2.
5.4.1. Patients who are not candidates for invasive 
coronary angiography
Information regarding the management of NSTE-ACS patients who are 
not candidates for invasive angiography is provided in the 
Supplementary data online, Section 5.2.1.
5.4.2. Patients with coronary artery disease not 
amenable to revascularization
Information regarding the management of ACS patients with CAD that 
is not amenable to revascularization is provided in the Supplementary 
data online, Section 5.2.2.ESC Guidelines                                                                                                                                                                                          3749Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

6. Antithrombotic therapy
Antithrombotic treatment is an important component of the manage -
ment of all patients presenting with ACS. The specific choice and com -
bination of therapy, the time of its initiation, and the treatment duration 
depend on various patient and procedural factors. Treatment decisions 
must be made weighing the benefits of antithrombotic therapy against 
the risk of bleeding, including severe, life-threatening bleeding.231,232
Recommended anticoagulant and antiplatelet drugs and their dosing 
(for use during and after ACS) are summarized in Table 6 and illustrated 
in Figure 9.Recommendation Table 4 — Recommendations for re -
perfusion therapy and timing of invasive strategy
Recommendations ClassaLevelb
Recommendations for reperfusion therapy for patients with 
STEMI
Reperfusion therapy is recommended in all patients 
with a working diagnosis of STEMI (persistent 
ST-segment elevation or equivalentsc) and symptoms 
of ischaemia of ≤12 h duration.51,182I A
A PPCI strategy is recommended over fibrinolysis if 
the anticipated time from diagnosis to PCI is <120 min.
52,218,219I A
If timely PPCI (<120 min) cannot be performed in patients with a working diagnosis of STEMI, 
fibrinolytic therapy is recommended within 12 h of 
symptom onset in patients without 
contraindications.
176,183I A
Rescue PCI is recommended for failed fibrinolysis 
(i.e. ST-segment resolution <50% within 60–90 min 
of fibrinolytic administration) or in the presence of 
haemodynamic or electrical instability, worsening 
ischaemia, or persistent chest pain.184,185I A
In patients with a working diagnosis of STEMI and a time from symptom onset >12 h, a PPCI strategy is 
recommended in the presence of ongoing symptoms 
suggestive of ischaemia, haemodynamic instability, or 
life-threatening arrhythmias.
220I C
A routine PPCI strategy should be considered in 
STEMI patients presenting late (12–48 h) after 
symptom onset.189–191,221IIa B
Routine PCI of an occluded IRA is not recommended in STEMI patients presenting >48 h after symptom 
onset and without persistent symptoms.
189,192,193III A
Transfer/interventions after fibrinolysis
Transfer to a PCI-capable centre is recommended in 
all patients immediately after fibrinolysis.184– 
186,212,213,222–224I A
Emergency angiography and PCI of the IRA, if 
indicated are recommended in patients with 
new-onset or persistent heart failure/shock after 
fibrinolysis.185,225I A
Angiography and PCI of the IRA, if indicated, is recommended between 2 and 24 h after successful fibrinolysis.
186,212,213,217,224I A
ContinuedInvasive strategy in NSTE-ACS
An invasive strategy during hospital admission is 
recommended in NSTE-ACS patients with high-risk 
criteria or a high index of suspicion for unstable angina.
196–200I A
A selective invasive approach is recommended in patients without very high- or high-risk NSTE-ACS 
criteria and with a low index of suspicion for 
NSTE-ACS.
196–200I A
An immediate invasive strategy is recommended in 
patients with a working diagnosis of NSTE-ACS and with at least one of the following very high-risk 
criteria: 
•Haemodynamic instability or cardiogenic shock
•Recurrent or refractory chest pain despite medical 
treatment
•In-hospital life-threatening arrhythmias
•Mechanical complications of MI
•Acute heart failure presumed secondary to 
ongoing myocardial ischaemia
•Recurrent dynamic ST-segment or T wave changes, 
particularly intermittent ST-segment elevation.I C
An early invasive strategy within 24 h should be 
considered in patients with at least one of the 
following high-risk criteria: 
•Confirmed diagnosis of NSTEMI based on current 
recommended ESC hs-cTn algorithms
•Dynamic ST-segment or T wave changes
•Transient ST-segment elevation
•GRACE risk score >140
202,226–230IIa A
©ESC 2023
ACS, acute coronary syndrome; ECG, electrocardiogram; ESC, European Society of 
Cardiology; GRACE, Global Registry of Acute Coronary Events; hs-cTn, high-sensitivity 
cardiac troponin; IRA, infarct-related artery; MI, myocardial infarction; NSTE-ACS, 
non-ST-elevation acute coronary syndrome; NSTEMI, non-ST-elevation myocardial 
infarction; PPCI, primary percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence. 
cST-segment elevation equivalents are presented in Supplementary data online, Figure S2.3750                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Table 6 Dose regimen of antiplatelet and anticoagulant drugs in acute coronary syndrome patients
I. Antiplatelet drugs
Aspirin LD of 150–300 mg orally or 75–250 mg i.v. if oral ingestion is not possible, followed by oral MD of 75–100 mg o.d.; no specific dose adjustment in 
CKD patients.
P2Y12 receptor inhibitors (oral or i.v.)
Clopidogrel LD of 300–600 mg orally, followed by an MD of 75 mg o.d.; no specific dose adjustment in CKD patients. 
Fibrinolysis: at the time of fibrinolysis an initial dose of 300 mg (75 mg for patients older than 75 years of age).
Prasugrel LD of 60 mg orally, followed by an MD of 10 mg o.d. In patients with body weight <60 kg, an MD of 5 mg o.d. is recommended. In patients aged 
≥75 years, prasugrel should be used with caution, but a MD of 5 mg o.d. should be used if treatment is deemed necessary. No specific dose 
adjustment in CKD patients. Prior stroke is a contraindication for prasugrel.
Ticagrelor LD of 180 mg orally, followed by an MD of 90 mg b.i.d.; no specific dose adjustment in CKD patients.
Cangrelor Bolus of 30 mcg/kg i.v. followed by 4 mcg/kg/min infusion for at least 2 h or the duration of the procedure (whichever is longer). 
In the transition from cangrelor to a thienopyridine, the thienopyridine should be administered immediately after discontinuation of cangrelor 
with an LD (clopidogrel 600 mg or prasugrel 60 mg); to avoid a potential DDI, prasugrel may also be administered 30 min before the cangrelor infusion is stopped. Ticagrelor (LD 180 mg) should be administered at the time of PCI to minimize the potential gap in platelet inhibition during 
the transition phase.
GP IIb/IIIa receptor inhibitors (i.v.)
Eptifibatide Double bolus of 180 mcg/kg i.v. (given at a 10-min interval) followed by an infusion of 2.0 mcg/kg/min for up to 18 h. 
For CrCl 30–50 mL/min: first LD, 180 mcg/kg i.v. bolus (max 22.6 mg); maintenance infusion, 1 mcg/kg/min (max 7.5 mg/h). Second LD (if PCI), 
180 mcg/kg i.v. bolus (max 22.6 mg) should be administered 10 min after the first bolus. Contraindicated in patients with end-stage renal disease 
and with prior ICH, ischaemic stroke within 30 days, fibrinolysis, or platelet count <100 000/mm
3.
Tirofiban Bolus of 25 mcg/kg i.v. over 3 min, followed by an infusion of 0.15 mcg/kg/min for up to 18 h. For CrCl ≤60 mL/min: LD, 25 mcg/kg i.v. over 5 min followed by a maintenance infusion of 0.075 mcg/kg/min continued for up to 18 h. 
Contraindicated in patients with prior ICH, ischaemic stroke within 30 days, fibrinolysis, or platelet count <100 000/mm
3.
II. Anticoagulant drugs
UFH Initial treatment: i.v. bolus 70–100 U/kg followed by i.v. infusion titrated to achieve an aPTT of 60–80 s. 
During PCI: 70–100 U/kg i.v. bolus or according to ACT in case of UFH pre-treatment.
Enoxaparin Initial treatment: for treatment of ACS 1 mg/kg b.i.d. subcutaneously for a minimum of 2 days and continued until clinical stabilization. In patients 
whose CrCl is below 30 mL per minute (by Cockcroft–Gault equation), the enoxaparin dosage should be reduced to 1 mg per kg o.d. 
During PCI: for patients managed with PCI, if the last dose of enoxaparin was given less than 8 h before balloon inflation, no additional dosing is 
needed. If the last s.c. administration was given more than 8 h before balloon inflation, an i.v. bolus of 0.3 mg/kg enoxaparin sodium should be administered.
Bivalirudin During PPCI: 0.75 mg/kg i.v. bolus followed by i.v. infusion of 1.75 mg/kg/h for 4 h after the procedure. In patients whose CrCl is below 30 mL/min (by Cockcroft–Gault equation), maintenance infusion should be reduced to 1 mg/kg/h.
Fondaparinux Initial treatment: 2.5 mg/d subcutaneously. During PCI: A single bolus of UFH is recommended. 
Avoid if CrCl <20 mL/min.
©ESC 2023
ACS, acute coronary syndrome; ACT, activated clotting time; aPPT, activated partial thromboplastin time; b.i.d., bis in die (twice a day); CKD, chronic kidney disease; CrCl, creatinine 
clearance; DDI, drug–drug interactions; ICH, intracranial haemorrhage; i.v. intravenous; LD, loading dose; MD, maintenance dose; o.d., once a day; PPCI, primary percutaneous coronary 
intervention; s.c. subcutaneous; UFH, unfractionated heparin.ESC Guidelines                                                                                                                                                                                          3751Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

6.1. Antiplatelet therapy in the acute 
phase
6.1.1. Oral antiplatelet therapy
Antiplatelet drugs play a key role in the acute phase of treatment for 
ACS. Table 6 summarizes the dosing regimens of the available oral 
and i.v. antiplatelet drugs. The choice of antiplatelet regimen should 
take the bleeding risk of the patient into account. Factors associated 
with an elevated bleeding risk have been detailed by the Academic Research Consortium on High Bleeding Risk (ARC-HBR).
233The presence of one major or two minor ARC-HBR risk factors indicates 
high bleeding risk (HBR). Of note, the presence of multiple major risk factors is associated with a progressive increase in the bleeding risk.
234
Aspirin treatment is started with a loading dose (LD) as soon as pos -
sible, followed by maintenance treatment ( Table 6).235Current evi -
dence supports an aspirin maintenance dose (MD) of 75–100 mg once a day (o.d.).
236,237
Based on the results of the phase III PLATelet inhibition and patient 
Outcomes (PLATO) and TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel 
Eptifibatide
Tirofiban
Clopidogrel
AspirinTicagrelor
Prasugrel
CangrelorRivaroxaban
Apixaban
Edoxaban
UFH
Enoxaparin
Dabigatran
BivalirudinFondaparinuxGP IIb/IIIa
TxA2P2Y12 receptor
Thromboxane
receptorThrombin
receptorADP
P PPlaque rupture or
plaque erosion
Platelet
activation
TF:FVIIa Aggregation of
activated platelets
FibrinogenFibrin
FXa
Thrombin
Mature
fibrin clot
Figure 9 Antithrombotic treatments in acute coronary syndrome: pharmacological targets. ADP, adenosine diphosphate; FVIIa, Factor VIIa; FXa, Factor Xa; 
GP, glycoprotein; TF, tissue factor; TxA 2, thromboxane A 2; UFH, unfractionated heparin. Drugs with oral administration are shown in blue and drugs with 
preferred parenteral administration in red.3752                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) studies, 
dual antiplatelet therapy (DAPT) including aspirin and a potent P2Y 12 
receptor inhibitor (prasugrel or ticagrelor) is recommended as the de -
fault DAPT strategy for ACS patients.238,239Clopidogrel, which is char -
acterized by less effective and more variable platelet inhibition, should 
only be used when prasugrel or ticagrelor are contraindicated/not avail -
able, or in some patients considered otherwise at HBR (e.g. ≥
1 major 
or ≥2 minor ARC-HBR criteria).233,240–242In addition, the use of clopi -
dogrel may be considered in older patients (e.g. ≥
70 years).242,243
Prasugrel should be considered in preference to ticagrelor for ACS 
patients who proceed to PCI. The Intracoronary Stenting and Antithrombotic Regimen Rapid Early Action for Coronary Treatment 
(ISAR-REACT) 5 RCT is the largest head-to-head comparison of 1-year 
DAPT with prasugrel vs. DAPT with ticagrelor in patients with ACS 
planned for invasive evaluation, >80% of whom underwent PCI.
244A 
treatment strategy with prasugrel (LD given as soon as possible after ran -
domization for patients undergoing PPCI and after delineation of coron -
ary anatomy for patients presenting with NSTE-ACS) vs. ticagrelor (LD 
given as soon as possible after randomization in all cases) significantly re -
duced the composite endpoint of death, MI, or stroke (6.9% vs. 9.3%, P =  
0.006) without any increase in bleeding complications (4.8% vs. 5.4%, P =  
0.46). Limitations of this study include an open-label design and limited 
data on medically managed or CABG-treated patients.
6.1.2. Timing of loading dose of oral antiplatelet 
therapy
Both aspirin and oral P2Y 12 inhibitors achieve platelet inhibition more 
rapidly following an oral LD. Pre-treatment refers to a strategy in which 
an antiplatelet drug, usually a P2Y 12 receptor inhibitor, is given before 
coronary angiography and, therefore, before the coronary anatomy is known. Although a potential benefit with pre-treatment in the setting 
of ACS has been hypothesized, large-scale randomized trials supporting 
a routine pre-treatment strategy with P2Y
12 receptor inhibitors are 
lacking. Caution in relation to pre-treatment may be of particular rele -
vance in patients at HBR (e.g. those receiving an oral anticoagulant 
[OAC]).
6.1.2.1. Pre-treatment in patients with suspected ST-elevation 
myocardial infarction
The Administration of Ticagrelor in the Cath Lab or in the Ambulance 
for New ST Elevation Myocardial Infarction to Open the Coronary 
Artery (ATLANTIC) trial is the only randomized study testing the 
safety and efficacy of different timings of P2Y 12 receptor inhibitor initi -
ation in patients with a working diagnosis of STEMI undergoing PPCI.245
In this trial, patients were randomized to receive a ticagrelor LD either 
during transfer to a PPCI centre or immediately before angiography.245
The median difference between the timing of P2Y 12 receptor inhibitor 
loading with the two treatment strategies was 31 min. In this study, the pre-treatment strategy failed to meet the pre-specified primary end
-
point of improved ST-segment elevation resolution or Thrombolysis In Myocardial Infarction (TIMI) flow before intervention. Rates of major 
and minor bleeding events were identical in both treatment arms. 
These results were supported by real-world data obtained from the 
SWEDEHEART (Swedish Web-System for Enhancement and 
Development of Evidence-Based Care in Heart Disease Evaluated 
According to Recommended Therapies) registry in STEMI patients.
246
Prasugrel pre-treatment has not been directly investigated in patients with STEMI.6.1.2.2. Pre-treatment in patients with non-ST-elevation acute 
coronary syndrome
The randomized A Comparison of Prasugrel at the Time of 
Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction 
(ACCOAST) trial not only demonstrated a lack of benefit with respect 
to ischaemic outcomes with prasugrel pre-treatment, but also a sub
-
stantially higher bleeding risk.247In this study, the median time from first 
LD to the start of coronary angiography in the pre-treatment group was 4.4 h. With respect to pre-treatment data for ticagrelor, the 
ISAR-REACT 5 trial showed that a ticagrelor-based strategy with rou
-
tine pre-treatment was inferior to a prasugrel-based strategy with a de -
ferred LD in NSTE-ACS patients.244The DUBIUS (Downstream 
Versus Upstream Strategy for the Administration of P2Y12 Receptor 
Blockers) trial also attempted to address this question but was stopped 
early for futility as there was no difference between upstream vs. down -
stream oral P2Y 12 administration in patients with NSTE-ACS (both 
NSTEMI and UA) scheduled for coronary angiography within 72 h of 
hospital admission.248
6.1.2.3. Summary of pre-treatment strategies
In patients with a working diagnosis of STEMI undergoing PPCI, pre- treatment with a P2Y
12 receptor inhibitor may be considered.245In pa-
tients with a working diagnosis of NSTE-ACS, routine pre-treatment with a P2Y
12 receptor inhibitor before knowing the coronary anatomy 
in patients anticipated to undergo an early invasive strategy (i.e. <24 h) 
is not recommended.244,245,247For patients with a working diagnosis of 
NSTE-ACS, where there is an anticipated delay to invasive angiography 
(i.e. >24 h), pre-treatment with a P2Y 12 receptor inhibitor may be con -
sidered according to the bleeding risk of the patient. In all ACS patients 
proceeding to PCI who did not receive P2Y 12 receptor inhibitor pre- 
treatment, an LD is recommended at the time of PCI.
6.1.3. Intravenous antiplatelet drugs
Peri-interventional i.v. antiplatelet drugs include P2Y 12 receptor inhibi -
tors (cangrelor) and glycoprotein (GP) IIb/IIIa inhibitors (eptifibatide and tirofiban). Most of the trials evaluating GP IIb/IIIa inhibitors in 
PCI-treated ACS patients pre-date the era of routine DAPT, in particu
-
lar, early initiation of DAPT including an LD of a potent P2Y 12 receptor 
inhibitor.249,250There is no strong evidence for any additional benefit 
with the routine use of GP IIb/IIIa inhibitors in ACS patients scheduled 
for coronary angiography. Nevertheless, their use should be considered 
for bailout if there is evidence of no-reflow or a thrombotic complica -
tion during PCI. Another potential use for GP IIb/IIIa inhibitors is in the setting of high-risk PCI in patients who have not been pre-treated with 
P2Y
12 receptor inhibitors.
Cangrelor is a direct reversible, short-acting P2Y 12 receptor inhibitor 
that has been evaluated during PCI for CCS and ACS in clinical trials 
against clopidogrel, both with administration before (Cangrelor versus 
Standard Therapy to Achieve Optimal Management of Platelet 
Inhibition [CHAMPION PCI]) and after (CHAMPION PLATFORM 
and CHAMPION PHOENIX [A Clinical Trial Comparing Cangrelor 
to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention]) PCI.
251–253A meta-analysis of 
these trials showed that the benefit of cangrelor with respect to major ischaemic endpoints was counterbalanced by an increase in minor 
bleeding complications.
254It is also important to note that the benefit 
of cangrelor with respect to ischaemic endpoints was attenuated in 
CHAMPION PCI with upfront administration of clopidogrel, and ESC Guidelines                                                                                                                                                                                          3753Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

data for its use in conjunction with ticagrelor or prasugrel treatment are 
limited. Due to its proven efficacy in preventing intra-procedural and 
post-procedural stent thrombosis in P2Y 12 receptor inhibitor-naïve pa -
tients, cangrelor may be considered on a case-by-case basis in P2Y 12 re-
ceptor inhibitor-naïve ACS patients undergoing PCI, including in patients for whom it may not be feasible to give oral drugs in the setting 
of emergent PCI (e.g. CS patients and/or patients on mechanical 
ventilation).
6.2. Anticoagulant treatment in the acute 
phase
Anticoagulation is an important component of the initial treatment of 
ACS and of the peri-procedural treatment for ACS patients managed with an invasive strategy. Therefore, parenteral anticoagulation is re
-
commended for all ACS patients at the time of diagnosis.255Table 6
provides an overview of the relevant anticoagulant drugs and their dos -
ing in ACS patients.
In general, a crossover between anticoagulants should be avoided in 
patients with ACS (especially between unfractionated heparin [UFH] 
and low-molecular-weight heparin [LMWH]), with the exception of 
adding UFH to fondaparinux when a patient presenting with NSTE-ACS proceeds to PCI after a period of fondaparinux treatment 
(see below for further detail).
256,257Anticoagulants should generally be 
discontinued immediately after PCI, except in specific clinical settings 
such as the confirmed presence of LV aneurysm with thrombus forma -
tion or AF requiring anticoagulation. In addition, for bivalirudin in pa -
tients with STEMI undergoing PCI, a full dose post-PCI infusion is 
recommended.
In this section of the guideline, we summarize the recommendations 
for anticoagulant treatment in the acute phase for patients with STEMI undergoing PPCI and for patients with NSTE-ACS undergoing angiog
-
raphy (and PCI if indicated).
6.2.1. Anticoagulation in patients with ST-elevation 
myocardial infarction undergoing primary 
percutaneous coronary intervention
Unfractionated heparin has been established as the standard of care in 
patients with STEMI undergoing PPCI due to its favourable risk/benefit profile. In these patients, anticoagulation should be given during the in
-
vasive procedure. High-quality evidence with respect to the benefit of administering anticoagulation at an earlier time point in patients under
-
going a PPCI strategy is lacking.
Alternatives to UFH that should be considered in patients with 
STEMI undergoing PPCI include enoxaparin (a LMWH) and bivalirudin 
(a direct thrombin inhibitor). The ATOLL (STEMI Treated With 
Primary Angioplasty and Intravenous Lovenox or Unfractionated 
Heparin) trial reported a reduction in the primary endpoint at 30 
days (incidence of death, complication of MI, procedure failure, or ma -
jor bleeding) with enoxaparin in comparison to UFH in patients with 
STEMI undergoing PPCI.258
In the BivaliRudin with prolonged full-dose Infusion durinG primary 
PCI versus Heparin Trial 4 (BRIGHT-4), 6016 patients with STEMI 
undergoing PPCI were randomized to either bivalirudin (with a full 
dose post-PCI infusion) or UFH.259The use of GP IIb/IIIa inhibitors 
was restricted to patients who experienced thrombotic complications. 
The primary endpoint (a composite of all-cause mortality or Bleeding 
Academic Research Consortium [BARC] type 3–5 bleeding at 30 
days), the individual components of the primary endpoint, and definite 
or probable stent thrombosis were all significantly reduced in the bivalirudin group.259Based on the totality of the available data, bivalir -
udin with a full-dose post-PCI infusion should be considered as an alter -
native to UFH, although further studies to confirm these findings in non-East Asian populations are required. Bivalirudin is also the recom
-
mended alternative to UFH in patients presenting with ACS who have a history of heparin-induced thrombocytopaenia. Additional information 
about bivalirudin, including 
evidence tables summarizing the relevant 
clinical trials, is provided in the Supplementary data online.
Based on the results of the OASIS-6 (The Safety and Efficacy of 
Fondaparinux Versus Control Therapy in Patients With ST Segment 
Elevation Acute Myocardial Infarction) trial, fondaparinux is not recom -
mended in patients with STEMI undergoing PPCI.260
To summarize, parenteral anticoagulation is recommended for pa -
tients with STEMI undergoing PPCI and UFH is the default choice of 
anticoagulant at present. Enoxaparin and bivalirudin should be consid -
ered as alternatives to UFH in these patients but fondaparinux is not 
recommended.
6.2.2. Anticoagulation in patients with 
non-ST-elevation acute coronary syndrome 
undergoing angiography and percutaneous coronary 
intervention if indicated
Patients with NSTE-ACS are also recommended to receive parenteral 
anticoagulation. In patients with NSTE-ACS who are anticipated to undergo immediate or early (i.e. <24 h from the time of diagnosis) in
-
vasive angiography and PCI if indicated, parenteral anticoagulation at the time of diagnosis is recommended, and UFH has been historically 
established as the anticoagulant of choice. However, in a meta-analysis 
of trials comparing UFH with enoxaparin, mortality and major bleeding 
was not different between both agents in patients with NSTE-ACS or 
stable patients scheduled for PCI.
261Therefore, enoxaparin should be 
considered as an alternative to UFH in these patients (especially in cases 
where monitoring of clotting times is complex).
NSTE-ACS patients who do not undergo early invasive angiography 
(i.e. within 24 h of diagnosis) will have an extended initial treatment 
phase consisting of only pharmacological treatment. In these patients, 
fondaparinux therapy is recommended in preference to enoxaparin while awaiting invasive angiography, based on the favourable outcomes 
demonstrated with fondaparinux in comparison to enoxaparin in the 
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes 
(OASIS-5) trial.
262Of note, guiding catheter thrombus formation was 
of concern with fondaparinux and, therefore, a full-dose bolus of 
UFH should be given if the patient proceeds to PCI. The potential im -
pact of contemporary changes in clinical practice (including radial ac -
cess, early catheterization, and infrequent GP IIb/IIIa inhibitor 
therapy) on the treatment effect observed in OASIS-5 should also be 
considered. If fondaparinux is not available, enoxaparin should be con -
sidered for these patients.
Intravenous enoxaparin should also be considered as an anticoagu -
lant for PCI in patients with NSTE-ACS in whom subcutaneous (s.c.) 
enoxaparin was used while awaiting coronary angiography.261
In summary, parenteral anticoagulation is recommended for patients 
with NSTE-ACS. For patients with NSTE-ACS undergoing immediate 
or early angiography (± PCI if indicated), UFH is recommended but en -
oxaparin should be considered as an alternative to UFH. For patients with NSTE-ACS who are not anticipated to undergo early angiography, 
fondaparinux (with a UFH bolus at time of PCI) is recommended in 
preference to enoxaparin, although enoxaparin should be considered if fondaparinux is not available.3754                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

6.3. Maintenance antithrombotic therapy 
after revascularization
While continuation of anticoagulation after PCI is not necessary in the 
vast majority of patients (i.e. those without an indication for long-term OAC), post-interventional antiplatelet treatment is mandatory in ACS 
patients. Following PCI, a default DAPT regimen consisting of a potent 
P2Y
12 receptor inhibitor (prasugrel or ticagrelor) and aspirin is generally recommended for 12 months, irrespective of the stent 
type, unless there are contraindications.236,238,239,244,263In specific clin -
ical scenarios, the default DAPT duration can be shortened (
<12 
months), extended (>12 months), or modified (switching DAPT, 
DAPT de-escalation). The recommended default antithrombotic treat -
ment options for ACS patients without an indication for OAC are shown in 
Figure 10.
Routine 
antiplatelet
pretreatmentACS
(Class I)PPCI
(Class IIb)
ACS
+(Class I)
(Class I)Proceeding to PCI
(Class IIa)
Prasugrel Ticagrelor >NSTE-ACSb
(Class III)
Anticoagulation
Choice of 
P2Y 12 inhibitorc 
Default DAPT
strategy for the
first 12 months
after ACSc
Default strategy
beyond the first
12 months
after ACS
Invasive Coronary Angiography
If prasugrel and ticagrelor 
are unavailable, contraindicated, 
or cannot be tolerated
Angiography 
<24 h
(Class I)UFH
PPCI
(Class IIa)Enoxaparin
PPCI
(Class III)Fondaparinux
Aspirin
Aspirin
P2Y 12 inhibitor
(Class I)AspirinP2Y 12 inhibitor
Prasugrel
Ticagrelor
ClopidogrelP2Y 12 inhibitor
1
36Time
(months)
9
12
NSTE-ACS STEMI
(Class IIa)EnoxaparinAngiography
<24 h
(Class I)
FondaparinuxaAngiography
>24 h
(Class I)UFHPPCI
 PPCI
(Class IIa)Bivalirudin
Figure 10 Recommended default antithrombotic therapy regimens in acute coronary syndrome patients without an indication for oral anticoagulation. 
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, per -
cutaneous coronary intervention; PPCI, primary percutaneous coronary intervention; UFH, unfractionated heparin. Algorithm for antithrombotic therapy in 
ACS patients without an indication for oral anticoagulation undergoing invasive evaluation. aFondaparinux (plus a single bolus of UFH at the time of PCI) is 
recommended in preference to enoxaparin for NSTE-ACS patients in cases of medical treatment or logistical constraints for transferring the NSTE-ACS 
patient to PCI within 24 h of symptom onset. bRoutine pre-treatment with a P2Y 12 receptor inhibitor in NSTE-ACS patients in whom coronary anatomy 
is not known and early invasive management (<24 h) is planned is not recommended, but pre-treatment with a P2Y 12 receptor inhibitor may be considered in 
NSTE-ACS patients who are not expected to undergo an early invasive strategy (<24 h) and do not have HBR. cClopidogrel is recommended for 12 months 
DAPT if prasugrel and ticagrelor are not available, cannot be tolerated, or are contraindicated, and may be considered in older ACS patients (typically defined as older than 70–80 years of age).ESC Guidelines                                                                                                                                                                                          3755Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

6.3.1. Shortening dual antiplatelet therapy
Several RCTs and meta-analyses have compared standard 12-month 
DAPT with ≤6 months DAPT followed by aspirin monotherapy in 
ACS patients.264–267In some of these trials, the reduction in bleeding 
events associated with abbreviated DAPT regimens came at the cost 
of an increase in the rates of ischaemic complications. In a large-scale 
network meta-analysis, 3-month DAPT but not 6-month DAPT was as -
sociated with higher rates of MI or stent thrombosis in ACS patients.264
A number of large RCTs have investigated DAPT duration further 
shortened to 1–3 months followed by P2Y 12 receptor inhibitor mono -
therapy in patients with and without ACS.268–271In general, low to 
intermediate ischaemic risk patients were included, and early mono -
therapy with clopidogrel or ticagrelor was used. Some trials included a comparison with more prolonged DAPT than usual in the control 
arm. Patients with STEMI tended to be excluded or under-represented.
The TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk 
Patients After Coronary Intervention) trial examined the effect of tica -
grelor monotherapy vs. ticagrelor plus aspirin for 1 year after 3 months 
of DAPT (ticagrelor and aspirin) on clinically relevant bleeding. This 
study enrolled ‘high-risk’ patients as per the trial inclusion criteria, 
which meant that the enrolled patients had at least one clinical feature 
and one angiographic feature associated with a high risk of ischaemic or 
bleeding events. However, in order to be randomized the patients were 
also required to have not experienced a major bleeding or ischaemic 
event in the 3 months following hospital discharge.271STEMI patients 
were excluded from this study. Bleeding events (BARC type 2, 3, or 5 bleeding) were significantly reduced by omitting aspirin after 3 
months, without a signal of increased ischaemic risk. A dedicated sub
-
group analysis suggested these findings were consistent in 4614 patients with NSTEMI/UA.
272In the TICO (Ticagrelor Monotherapy After 3 
Months in the Patients Treated With New Generation Sirolimus 
Stent for Acute Coronary Syndrome) trial, ticagrelor monotherapy 
vs. ticagrelor plus aspirin for up to 1 year after 3 months of DAPT (ti -
cagrelor and aspirin) was tested in 3056 ACS patients (36% STEMI).273
Net adverse clinical events and major bleeding events were significantly 
reduced with ticagrelor monotherapy, and major adverse cardiac and 
cerebrovascular events were not significantly different. Limitations of 
this study included the selected population assessed and the lower 
than expected event rates. A study-level meta-analysis of outcomes 
in a population of patients (with both ACS and CCS) fitted with a 
DES also reported a beneficial effect of shortened DAPT for 1–3 
months on major bleeding events, as well as a neutral effect on death, 
MI, and stroke.274
The STOPDAPT-2-ACS (ShorT and OPtimal Duration of Dual 
AntiPlatelet Therapy-2 Study for the Patients With ACS) trial investi -
gated a short DAPT strategy in ACS patients.275At 1–2 months, pa -
tients were randomized to either clopidogrel monotherapy or 
continued DAPT for 12 months. Non-inferiority of the investigational 
strategy for the composite endpoint of cardiovascular (CV) or bleeding 
events was not proven, suggesting that systematic very short duration 
DAPT (i.e. <
3 months) followed by clopidogrel monotherapy is not a 
useful strategy in ACS patients.
The MASTER DAPT (Management of High Bleeding Risk Patients Post 
Bioresorbable Polymer Coated Stent Implantation With an Abbreviated 
Versus Prolonged DAPT Regimen) trial examined a strategy of abbre -
viated DAPT (1 month) followed by either aspirin or P2Y 12 inhibitor 
monotherapy vs. DAPT ≥3 months (standard therapy) in a cohort of 
4579 HBR patients (49% ACS, 12% STEMI) undergoing PCI with a bioab -
sorbable polymer-coated stent.276Net adverse clinical events and major adverse cardiac or cerebral events were comparable between the 
groups, whereas major or clinically relevant non-major bleeding events 
were significantly reduced in the abbreviated therapy group.
6.3.2. De-escalation from potent P2Y 12 inhibitor to 
clopidogrel
The need to switch between oral P2Y 12 receptor inhibitors is not 
uncommon as a consequence of bleeding complications (or concern re -
garding bleeding), non-bleeding side effects (e.g. dyspnoea on ticagrelor, 
allergic reactions), and socioeconomic factors.277,278As such, switching 
between oral P2Y 12 receptor inhibitors may be considered in selected 
cases.
P2Y 12 receptor inhibitor de-escalation (i.e. switching from prasugrel/ 
ticagrelor to clopidogrel) in ACS patients may be considered as an al -
ternative strategy to the default treatment regimen in order to reduce the risk of bleeding events. However, it is important to note that there 
is a potential risk of increased ischaemic events with de-escalation and 
this strategy is not recommended in the first 30 days after the index 
ACS event. In the TROPICAL-ACS (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute 
Coronary Syndromes) trial (44% NSTE-ACS, 56% STEMI), an approach 
of DAPT de-escalation from prasugrel to clopidogrel (at 2 weeks after 
ACS) was guided by platelet function testing and was non-inferior to 
standard treatment with prasugrel at 1 year after PCI in terms of net 
clinical benefit.
279In the Cost-effectiveness of CYP2C19 Genotype 
Guided Treatment With Antiplatelet Drugs in Patients With 
ST-segment-elevation Myocardial Infarction Undergoing Immediate 
PCI With Stent Implantation: Optimization of Treatment (POPular 
Genetics) trial, DAPT de-escalation from ticagrelor/prasugrel to clopi -
dogrel guided by CYP2C19 genotyping in ACS patients undergoing 
PPCI within the previous 48 h was non-inferior to standard treatment 
with ticagrelor or prasugrel at 12 months with respect to thrombotic 
events and resulted in a lower incidence of bleeding.280
The single-centre TOPIC (Timing of Platelet Inhibition After Acute 
Coronary Syndrome) trial used an unguided de-escalation approach in 
645 ACS patients (60% NSTE-ACS, 40% STEMI) from ticagrelor/prasu -
grel to clopidogrel after 1 month of DAPT with ticagrelor/prasugrel and aspirin. Net adverse clinical events and bleeding events were reduced, 
whereas the rate of ischaemic endpoints was unchanged.
281The 
TALOS-AMI (TicAgrelor versus CLOpidogrel in Stabilised Patients with 
Acute Myocardial Infarction) trial investigated unguided de-escalation in 
2697 ACS patients (46% NSTEMI/UA, 54% STEMI) from ticagrelor to clo -
pidogrel after 1 month of DAPT with ticagrelor and aspirin.282This uni -
form unguided de-escalation strategy led to significant 12-month 
reductions in net adverse clinical events and bleeding events. The 
HOST-REDUCE-POLYTECH-ACS (Harmonizing Optimal Strategy for 
Treatment of Coronary Artery Diseases Trial—Comparison of 
REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS 
Patients) trial tested a different method of de-escalation—a reduction 
in prasugrel dose rather than switching to clopidogrel. In this trial, 2338 
low-risk ACS patients <
75 years of age (14% STEMI, 25% NSTEMI, and 
61% UA) were randomized to low-dose prasugrel (5 mg daily) or standard-dose prasugrel (10 mg daily) after 1 month of DAPT with 
standard-dose prasugrel.
283Prasugrel dose de-escalation was associated 
with fewer net adverse clinical events and bleeding events, mainly by re -
ducing bleeding events without an increase in ischaemic events. It should 
be noted that the TALOS-AMI and HOST-REDUCE-POLYTECH-ACS 
trials only included East Asian populations.3756                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

6.3.3. Summary of alternative antiplatelet strategies 
to reduce bleeding risk in the first 12 months after 
acute coronary syndrome
Considering the totality of evidence from the scientific literature, alterna -
tives to the default strategy of 12 months DAPT in patients with ACS in -
clude shortening the DAPT duration to 1 or 3–6 months (depending on 
the balance of bleeding and ischaemic risks) and de-escalating DAPT from 
prasugrel/ticagrelor-based DAPT to clopidogrel-based DAPT. However, 
it should be noted that much of the evidence on these strategies in ACS 
patients is derived from trials powered primarily for bleeding outcomes, many of which had a non-inferiority design and were, therefore, not pow
-
ered to detect potentially relevant differences in ischaemic outcomes. The patient populations enrolled in these studies were also often relatively se
-
lected, often excluding or under-representing the highest risk ACS pa -
tients. As such, it is important to reflect that even meta-analyses of the available randomized evidence cannot overcome the potential selection 
bias at the point of entry in the relevant randomized trials.
These important limitations explain why these strategies should at 
present remain considered as alternative strategies to the default of 12 months DAPT. From a practical perspective, this means that these 
strategies should not be employed as a default strategy in the wider 
ACS population but can be considered when there is a specific motiv -
ation for their use (i.e. aiming to reduce the risk of bleeding events in 
HBR patients or if there are other specific concerns regarding a 
12-month potent P2Y 12 inhibitor-based DAPT regimen). 
De-escalation of antiplatelet therapy in the first 30 days is not recom -
mended, but de-escalation of P2Y 12 receptor inhibitor therapy may be 
considered as an alternative strategy beyond 30 days after an ACS, in 
order to reduce the risk of bleeding events. DAPT abbreviation strat -
egies (followed preferably by P2Y 12 inhibitor monotherapy within the 
first 12 months post-ACS) should be considered in patients who are event-free after 3–6 months of DAPT and who are not high ischaemic 
risk, with the duration of DAPT guided by the ischaemic and bleeding 
risks of the patient. For HBR patients, aspirin or P2Y
12 receptor inhibi -
tor monotherapy after 1 month of DAPT may be considered. Please 
see Recommendation Table 6 for full details. These alternative antipla -
telet strategies to reduce bleeding risk in the first 12 months after ACS are also summarized in 
Figure 11.
0
1
3
6
9
12
Antiplatelet strategies to reduce bleeding risk in the first 12 months after ACS
Abbreviated DAPT strategies DAPT de-escalation strategies
Time
(Months)In HBR
patients
only
1 month 
DAPT
3 month 
DAPT
6 month 
DAPT
P2Y12 inhibitor
or 
aspirin monotherapyIn HBR and 
non-HBR patientsPotent P2Y12 inhibitor-based DAPT
Aspirin + Prasugrel
Aspirin + ClopidogrelAspirin + Ticagrelor OR
De-escalation
Change from potent P2Y12
inhibitor to clopidogrel
Figure 11 Alternative antiplatelet strategies to reduce bleeding risk in the first 12 months after an ACS. ACS, acute coronary syndrome; DAPT, dual 
antiplatelet therapy; HBR, high bleeding risk; PFT, platelet function test.ESC Guidelines                                                                                                                                                                                          3757Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

To summarise, antiplatelet strategies to reduce bleeding risk in the first 
12 months after an ACS can be divided into abbreviated DAPT strategies 
and DAPT de-escalation strategies. Twelve-month DAPT (preferably 
with prasugrel or ticagrelor) remains the default strategy for patients 
with ACS (Figure 10 ) and these strategies should only be used as alterna -
tives to this strategy, in general driven by a motivation to reduce the risk of bleeding events (i.e. if the patient is HBR or if there are other specific 
concerns regarding 12-month potent P2Y
12 inhibitor-based DAPT).
The specific alternative antiplatelet strategies employed (i.e. choice 
of P2Y 12 inhibitor, duration of DAPT, choice of SAPT agent) to reduce 
bleeding risk should be chosen based on the bleeding risk of the patient 
(HBR or not) and these recommendations are summarized in 
Recommendation Table 6.
Recommendation Table 5 — Recommendations for 
antiplatelet and anticoagulant therapy in acute coronary 
syndrome
Recommendations ClassaLevelb
Antiplatelet therapy
Aspirin is recommended for all patients without 
contraindications at an initial oral LD of 150–300 mg (or 75–250 mg i.v.) and an MD of 75–100 mg o.d. for 
long-term treatment.
284,285I A
In all ACS patients, a P2Y 12 receptor inhibitor is 
recommended in addition to aspirin, given as an initial 
oral LD followed by an MD for 12 months unless 
there is HBRc.238,239,263,286I A
A proton pump inhibitor in combination with DAPT is recommended in patients at high risk of 
gastrointestinal bleeding.
287,288I A
Prasugrel is recommended in P2Y 12 receptor 
inhibitor-naïve patients proceeding to PCI (60 mg LD, 10 mg o.d. MD, 5 mg o.d. MD for patients aged 
≥75 years or with a body weight <60 kg).
239I B
Ticagrelor is recommended irrespective of the treatment strategy (invasive or conservative) 
(180 mg LD, 90 mg b.i.d. MD).
238I B
Clopidogrel (300–600 mg LD, 75 mg o.d. MD) is recommended when prasugrel or ticagrelor are not available, cannot be tolerated, or are 
contraindicated.
263,289I C
If patients presenting with ACS stop DAPT to undergo CABG, it is recommended they resume 
DAPT after surgery for at least 12 months.I C
Prasugrel should be considered in preference to ticagrelor for ACS patients who proceed to 
PCI.
244,290IIa B
GP IIb/IIIa receptor antagonists should be considered 
if there is evidence of no-reflow or a thrombotic 
complication during PCI.IIa C
In P2Y 12 receptor inhibitor-naïve patients 
undergoing PCI, cangrelor may be considered.251–254IIb A
In older ACS patients,d especially if HBR,c clopidogrel 
as the P2Y 12 receptor inhibitor may be 
considered.242,243,291IIb B
ContinuedPre-treatment with a P2Y 12 receptor inhibitor may 
be considered in patients undergoing a primary PCI 
strategy.244,245IIb B
Pre-treatment with a P2Y 12 receptor inhibitor may 
be considered in NSTE-ACS patients who are not 
expected to undergo an early invasive strategy 
(<24 h) and do not have HBRc.263IIb C
Pre-treatment with a GP IIb/IIIa receptor antagonist is not recommended.
292III A
Routine pre-treatment with a P2Y 12 receptor 
inhibitor in NSTE-ACS patients in whom coronary anatomy is not known and early invasive 
management (<24 h) is planned is not 
recommended.
244,247,248,293–295III A
Anticoagulant therapy
Parenteral anticoagulation is recommended for all 
patients with ACS at the time of diagnosis.255,296I A
Routine use of a UFH bolus (weight-adjusted i.v. bolus during PCI of 70–100 IU/kg) is recommended 
in patients undergoing PCI.I C
Intravenous enoxaparin at the time of PCI should be considered in patients pre-treated with 
subcutaneous enoxaparin.
256,261,297IIa B
Discontinuation of parenteral anticoagulation should be considered immediately after an invasive 
procedure.IIa C
Patients with STEMI
Enoxaparin should be considered as an alternative to 
UFH in patients with STEMI undergoing PPCI.
258,261,298IIa A
Bivalirudin with a full-dose post PCI infusion should be considered as an alternative to UFH in patients 
with STEMI undergoing PPCI.
259,299,300–303IIa A
Fondaparinux is not recommended in patients with STEMI undergoing PPCI.
260III B
Patients with NSTE-ACS
For patients with NSTE-ACS in whom early invasive 
angiography (i.e. within 24 h) is not anticipated, 
fondaparinux is recommended.262,304I B
For patients with NSTE-ACS in whom early invasive angiography (i.e. within 24 h) is anticipated, enoxaparin 
should be considered as an alternative to UFH.
256IIa B
Combining antiplatelets and OAC
As the default strategy for patients with atrial 
fibrillation and CHA 2DS2-VASc score ≥1 in men and 
≥2 in women, after up to 1 week of triple antithrombotic therapy following the ACS event, dual antithrombotic therapy using a NOAC at the 
recommended dose for stroke prevention and a 
single oral antiplatelet agent (preferably clopidogrel) 
for up to 12 months is recommended.
305–310I A
During PCI, a UFH bolus is recommended in any of 
the following circumstances: 
•if the patient is on a NOAC
•if the INR is <2.5 in VKA-treated patients.I C
Continued3758                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

6.4. Long-term treatment
By default, DAPT consisting of a potent P2Y 12 receptor inhibitor in add -
ition to aspirin is recommended for a minimum of 12 months after an 
ACS event; exceptions include patients for whom surgery is urgently 
needed, patients in whom OAC is indicated, and patients in whom the 
risk of bleeding is too high for other reasons.238,239,263After PCI for 
ACS, ischaemic and bleeding events both markedly decrease over time. Further information regarding long-term antithrombotic strategies (i.e. 
beyond 12 months) is provided in the Supplementary data online.
6.4.1. Prolonging antithrombotic therapy beyond 12 
months
Prolonged antithrombotic therapy options: See Supplementary data online, Figure S4; Tables S7 and S8
for additional in -
formation.314–319In patients with an indication for OAC with VKA in 
combination with aspirin and/or clopidogrel, careful 
regulation of the dose intensity of VKA with a target 
INR of 2.0–2.5 and a time in the therapeutic range 
>70% should be considered.305–308,311IIa B
When rivaroxaban is used and concerns about HBR prevail over ischaemic stroke, rivaroxaban 15 mg o.d. 
should be considered in preference to rivaroxaban 
20 mg o.d. for the duration of concomitant SAPT or 
DAPT.
307IIa B
In patients at HBR,c dabigatran 110 mg b.i.d. should 
be considered in preference to dabigatran 150 mg b.i.d. for the duration of concomitant SAPT or 
DAPT, to mitigate bleeding risk.
305IIa B
In patients requiring anticoagulation and treated medically, a single antiplatelet agent in addition to an 
OAC should be considered for up to 1 year.
308,312IIa B
In patients treated with an OAC, aspirin plus clopidogrel for longer than 1 week and up to 1 month should be considered in those with high 
ischaemic risk or with other anatomical/procedural 
characteristics that are judged to outweigh the 
bleeding risk.
eIIa C
In patients requiring OAC, withdrawing antiplatelet therapy at 6 months while continuing OAC may be 
considered.
313IIb B
The use of ticagrelor or prasugrel as part of triple 
antithrombotic therapy is not recommended.III C
©ESC 2023
ACS, acute coronary syndrome; b.i.d., bis in die (twice a day); CHA 2DS2-VASc, Congestive 
heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Stroke or transient ischaemic 
attack, Vascular disease; DAPT, dual antiplatelet therapy; GP, glycoprotein; HBR, high 
bleeding risk; INR, international normalized ratio; i.v., intravenous; LD, loading dose; MD, 
maintenance dose; NOAC, non-vitamin K antagonist oral anticoagulant; NSTE-ACS, non-ST-elevation acute coronary syndrome; OAC, oral anticoagulant; PPCI, primary 
percutaneous coronary intervention; SAPT, single antiplatelet therapy; STEMI, 
ST-elevation myocardial infarction; UFH, unfractionated heparin; VKA, vitamin K 
antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cHBR should be assessed in a structured manner, e.g. presence of a single major or two 
minor characteristics as defined by ARC-HBR (see section 8.2.2.3 in Supplementary data 
online). 
dThe definition of older patients varies across trials, ranging from 70 to 80 years of age. 
Frailty and comorbidities should also be taken in consideration. 
eSee Antiplatelet therapy in patients requiring oral anticoagulation Section 6.2 in 
Supplementary data online for more information on high-risk features of stent-driven 
recurrent events.Recommendation Table 6 — Recommendations for  
alternative antithrombotic therapy regimens
Recommendations ClassaLevelb
Shortening/de-escalation of antithrombotic therapy
In patients who are event-free after 3–6 months of 
DAPT and who are not high ischaemic risk, single 
antiplatelet therapy (preferably with a P2Y 12 
receptor inhibitor) should be considered.264,268– 
271,273,274,276,313,320IIa A
De-escalation of P2Y 12 receptor inhibitor treatment 
(e.g. with a switch from prasugrel/ticagrelor to clopidogrel) may be considered as an alternative DAPT strategy to reduce bleeding risk.
279–282,321,322IIb A
In HBR patients, aspirin or P2Y 12 receptor inhibitor 
monotherapy after 1 month of DAPT may be 
considered.276,313IIb B
De-escalation of antiplatelet therapy in the first 30 days after an ACS event is not recommended.
238,323III B
Prolonging antithrombotic therapy
Discontinuation of antiplatelet treatment in patients 
treated with an OAC is recommended after 12 
months.324,325I B
Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention should be 
considered in patients with high ischaemic risk and 
without HBR
c.314–318IIa A
Adding a second antithrombotic agent to aspirin for 
extended long-term secondary prevention may be 
considered in patients with moderate ischaemic risk 
and without HBRc.314–318IIb A
P2Y 12 inhibitor monotherapy may be considered as 
an alternative to aspirin monotherapy for long-term 
treatment.326,327IIb A
©ESC 2023
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; 
OAC, oral anticoagulant. 
aClass of recommendation. 
bLevel of evidence. 
cThe evidence supporting this approach (prolonged treatment with a second 
antithrombotic agent) is based on trials in which the duration of prolonged treatment 
was as follows: mean of 23 months (COMPASS), mean of 18 months (DAPT trial), and 
median of 33 months (PEGASUS-TIMI 54). Therefore, the benefits and risks associated 
with continuation of these respective treatments beyond these time points is at present 
unclear.ESC Guidelines                                                                                                                                                                                          3759Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

6.5. Antiplatelet therapy in patients 
requiring oral anticoagulation
6.5.1. Acute coronary syndrome patients requiring 
anticoagulation
In 6–8% of patients undergoing PCI, long-term OAC is indicated 
and should also be continued during the invasive procedure. Interruption of the long-term OAC and bridging with parenteral antic
-
oagulants may lead to an increase in thrombo-embolic episodes and bleeds.
328–330In patients undergoing PCI, it is unknown whether it is 
safer to bridge non-vitamin K antagonist (VKA) OACs (NOACs) with parenteral anticoagulants or to continue NOACs without additional 
parenteral anticoagulation. In VKA-treated patients, no parenteral antic
-
oagulation is needed if the international normalized ratio (INR) is >
2.5.311,331,332Strategies to minimize PCI-related complications in pa -
tients on OAC are listed in Table 7.
Evidence on the management of ACS patients with an indication for 
long-term OAC undergoing PCI is derived from subgroups of 
RCTs.305–309,333Patients with STEMI (who generally carry a higher 
atherothrombotic risk) were under-represented (∼10% of the study populations) in the major RCTs.
305,307–309Pivotal trials testing the 
benefit of NOACs as part of the antithrombotic regimen in patients with an indication for long-term anticoagulation undergoing PCI are dis
-
cussed in the Supplementary data online.
All of these trials were individually powered to address the safety of 
the tested strategy with regard to bleeding events, but not to reliably as -
sess differences in individual ischaemic endpoints. In a meta-analysis of all four NOAC-based RCTs comparing dual antithrombotic therapy (DAT) 
with triple antithrombotic therapy (TAT) in AF patients undergoing PCI 
(encompassing 10 234 patients), the primary safety endpoint 
(International Society on Thrombosis and Haemostasis major or clinically 
relevant non-major bleeding) was significantly lower with DAT vs. TAT (relative risk [RR] 0.66, 95% CI, 0.56–0.78; P <
0.001).310There were 
no significant differences in all-cause and CV death, stroke, or trial- defined major adverse cardiovascular events (MACE). However, DAT 
was associated with a borderline increased risk of MI (RR 1.22, 95% 
CI, 0.99–1.52; P = 0.07) and a significant increase in stent thrombosis 
(RR 1.59, 95% CI, 1.01–2.50; P = 0.04). This translates into an absolute 
reduction in major bleeding events of 2.3% compared with an absolute increase in stent thrombosis of 0.4%, without an effect on overall 
MACE. When interpreting the results of these studies, an important gen
-
eral point is that the treatment effect is confounded by the use of 
NOACs in the DAT treatment arms and VKAs in the TAT arms.
Secondary analyses from the AUGUSTUS (An Open-Label, 2 × 2 
Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety 
of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin 
Placebo in Patients With Atrial Fibrillation and Acute Coronary 
Syndrome or Percutaneous Coronary Intervention) trial indicate that 
the stent thrombosis rate was highest within the first 30 days after ran -
domization, with higher rates in the non-aspirin group.334Aspirin treat -
ment reduced ischaemic events (CV death, MI, stroke, stent 
thrombosis) but also increased major bleeding events in the first 30 
days. Aspirin treatment did not impact on ischaemic event rates after 
30 days and for up to 6 months, but did increase the bleeding risk during 
this time period.334,335In the MASTER DAPT trial, 4579 HBR patients 
were allocated to 1 month vs. 6 months of DAPT after implantation of a 
biodegradable-polymer sirolimus-eluting stent; half of the patients pre -
sented with ACS and a third were on OAC treatment.276A sub-analysis 
of this study reported that stopping DAPT after 1 month and stopping single antiplatelet therapy (SAPT) after 6 months while maintaining OAC was safe with respect to ischaemic events in patients taking clin
-
ically indicated long-term OAC therapy.313
In patients with ACS, the indication for OAC should be re-assessed 
and treatment continued only if a compelling indication exists (e.g. par -
oxysmal, persistent, or permanent AF with a CHA 2DS2-VASc 
[Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mel -
litus, Stroke or transient ischaemic attack, Vascular disease] score ≥
1 in 
men and ≥2 in women; mechanical heart valve; or recent/a history of 
recurrent or unprovoked deep vein thrombosis or PE). Although 
they have been tested in a minority of patients in the major RCTs, in 
the absence of robust safety and efficacy data, the use of prasugrel or ticagrelor as part of TAT is not recommended. The intensity of OAC 
should be carefully monitored, with a target INR of 2.0–2.5 in patients 
treated with VKA (with the exception of individuals with a mechanical 
prosthetic valve in the mitral position).
Overall, in patients with AF without mechanical prosthetic valves or 
moderate to severe mitral stenosis, the evidence supports the use of 
NOACs over VKAs as they reduce bleeding risk. DAT with a NOAC 
at the recommended dose for stroke prevention and SAPT (preferably 
clopidogrel, which was used in >
90% of patients in the major RCTs) is 
recommended as the default strategy for up to 12 months after up to 1 
week of TAT (with NOAC and DAPT consisting of aspirin and clopido -
grel) ( Figure 12)—the up to 1 week duration of TAT is based on the 
median treatment duration in the investigational arm of the 
AUGUSTUS trial.308Although none of the available RCTs were de -
signed to detect differences in ischaemic events, the numerically higher 
risk of stent thrombosis and MI is offset by the lower risk of bleeding, 
with a resultant neutral effect on total mortality.310,336–338
Table 7 Suggested strategies to reduce bleeding risk 
related to percutaneous coronary intervention
•Anticoagulant doses adjusted to body weight and renal function, 
especially in women and older patients
•Radial artery approach as default vascular access
•Proton pump inhibitors in patients on dual antiplatelet therapy at 
higher-than-average risk of gastrointestinal bleeds (i.e. history of 
gastrointestinal ulcer/haemorrhage, anticoagulant therapy, chronic 
non-steroidal anti-inflammatory drug/corticosteroid use), or two or 
more of: 
(a)Age ≥65 years
(b)Dyspepsia
(c)Gastro-oesophageal reflux disease
(d)Helicobacter pylori infection
(e)Chronic alcohol use
•In patients on OAC: 
(a)PCI performed without interruption of VKAs or NOACs
(b)In patients on VKAs, do not administer UFH if INR >2.5
(c)In patients on NOACs, regardless of the timing of the last 
administration of NOACs, add low-dose parenteral 
anticoagulation (e.g. enoxaparin 0.5 mg/kg i.v. or UFH 60 IU/kg)
•Aspirin is indicated but avoid pre-treatment with P2Y 12 receptor 
inhibitors
•GP IIb/IIIa receptor inhibitors only for bailout or peri-procedural 
complications
©ESC 2023
GP, glycoprotein; INR, international normalized ratio; i.v., intravenous; NOAC, non-vitamin 
K antagonist oral anticoagulant; OAC, oral anticoagulation/anticoagulant; PCI, 
percutaneous coronary intervention; UFH, unfractionated heparin; VKA, vitamin K 
antagonist.3760                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

At variance with the default strategy, DAT may be shortened to 6 
months by withdrawing the antiplatelet therapy in certain patients; 
for example, in patients with multiple HBR factors. In patients with 
high ischaemic risk or other anatomical/procedural characteristics 
that outweigh the bleeding risk, TAT should be prolonged for up to 
1 month, followed by DAT for up to 12 months.
There is currently limited evidence to support the use of OAC with 
ticagrelor or prasugrel as DAT after ACS and/or PCI as an alternative to 
TAT; ticagrelor was used in 5–12% and prasugrel in 1–2% of patients, 
respectively, in the four pivotal RCTs.305,307–309,339
In medically managed ACS patients, current data support DAT over 
TAT, with a single antiplatelet agent (most commonly clopidogrel) for at least 6 months.
308In the AUGUSTUS trial, ∼24% of enrolled patients pre -
sented with medically managed ACS.308In these patients, apixaban signifi -
cantly reduced bleeding events compared with a VKA, while no significant differences were observed in death or ischaemic events. The use of aspirin, in comparison to placebo, led to more bleeding events but no significant 
differences in death, hospitalization, or ischaemic events were observed.
308
Regarding the need to continue with any antiplatelet agent beyond 
12 months after ACS and/or PCI in patients with an indication for 
OAC, the AFIRE (Atrial Fibrillation and Ischemic Events With 
Rivaroxaban in Patients With Stable Coronary Artery Disease) trial 
randomized 2236 AF patients treated with PCI or CABG more than 
1 year earlier or with documented CAD to receive either rivaroxaban 
monotherapy or combination therapy with rivaroxaban plus a single antiplatelet agent.
324Rivaroxaban monotherapy was non-inferior to 
combination therapy for the primary efficacy composite endpoint of 
stroke, systemic embolism, MI, UA requiring revascularization, or over -
all death, and superior with regard to the primary safety endpoint of 
major bleeding. This trial and another prematurely terminated trial sup -
port the recommendation to stop antiplatelet therapy after 12 months and continue with OAC monotherapy in most patients.
325
0 weeks
up to 1 week
up to 1 month
6 months3 months
9 months
12 months
Beyond
12 monthsPatients with ACS and an indication for OAC
Default strategy
TAT: (N)OAC + DAPT
(Class I)
DAT: (N)OAC + SAPT
(Class I)
DAT: (N)OAC + SAPT
(Class I)TAT: (N)OAC + DAPT
(Class IIa)
(N)OAC monotherapy
(Class I)(N)OAC monotherapy
(Class I)DAT: 
(N)OAC + SAPT
(Class I)(N)OAC
monotherapy
(Class IIb)Strategy to reduce
ischaemic riska
Time from ACS
Figure 12 Antithrombotic regimens in patients with acute coronary syndrome and an indication for oral anticoagulation. ACS, acute coronary syndrome; 
ARC-HBR, Academic Research Consortium for High Bleeding Risk; DAPT, dual antiplatelet therapy; DAT, dual antithrombotic therapy; NOAC, non-vitamin 
K antagonist oral anticoagulant; OAC, oral anticoagulation/anticoagulant; SAPT, single antiplatelet therapy; TAT, triple antithrombotic therapy; VKA, vitamin K 
antagonist. OAC: preference for a NOAC over VKA for the default strategy and in all other scenarios if no contraindications. For both TAT and DAT regimens, 
the recommended doses for the NOACs are as follows: Apixaban 5 mg b.i.d., Dabigatran 110 mg or 150 mg b.i.d., Edoxaban 60 mg o.d., Rivaroxaban 15 mg or 20 mg o.d. NOAC dose reductions are recommended in patients based on certain criteria for each of the NOACs (including renal function, body weight, concomi
-
tant medications and age). SAPT: preference for a P2Y 12 receptor inhibitor (usually clopidogrel) over aspirin. See Bleeding risk assessment in Supplementary data 
online, Section 8.2.2.3 for details on the ARC-HBR criteria. In addition, patients with a PRECISE-DAPT score of ≥
25 are regarded as high bleeding risk. aSee 
Supplementary material online, Table S9 for examples of high-risk features of stent-driven recurrent events.ESC Guidelines                                                                                                                                                                                          3761Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

6.5.2. Patients requiring vitamin K antagonists or 
undergoing coronary artery bypass surgery
In patients for whom a VKA is mandated (e.g. patients with mechanical 
prosthetic valves), DAT with a VKA and SAPT (preferably clopidogrel) is indicated after an up to 1-week period of TAT (with aspirin and clo
-
pidogrel).306A network meta-analysis has reported that compared 
with TAT (consisting of VKA plus aspirin and clopidogrel), DAT (VKA plus clopidogrel) was associated with a trend towards a reduction 
in TIMI major bleeding, with no significant difference observed in 
MACE.
336
In ACS patients undergoing CABG with an established indication for 
OAC, anticoagulation in combination with SAPT should be resumed after CABG as soon as possible and TAT should be avoided.
6.6. Antithrombotic therapy as an adjunct 
to fibrinolysis
ISIS-2 (Second International Study Of Infarct Survival) demonstrated 
that the benefits of aspirin and fibrinolytics (i.e. streptokinase) were additive.
340The first dose of aspirin (162–325 mg) should be chewed 
or given i.v. and a low dose (75–100 mg) given orally daily from the next day thereafter. Clopidogrel added to aspirin reduces the risk of 
CV events and overall mortality in patients treated with fibrinolysis 
and should be added to aspirin following lytic therapy.
341,342Based 
on the available RCTs, there is insufficient evidence to support or refute 
improved outcomes with ticagrelor or prasugrel in patients with STEMI 
treated with thrombolytics.343–345There is no evidence that adminis -
tration of GP IIb/IIIa receptor inhibitors improves myocardial perfusion 
or outcomes in patients treated with fibrinolysis, and it may increase 
the risk of bleeding events.346
Parenteral anticoagulation is recommended until revascularization, if 
performed. Despite an increased risk of major bleeding, the net clinical 
benefit favoured enoxaparin over UFH in the ASsessment of the 
Safety and Efficacy of a New Thrombolytic 3 (ASSENT 3) trial (n =  
6095).347In the large Enoxaparin and Thrombolysis Reperfusion for 
Acute myocardial infarction Treatment–Thrombolysis In Myocardial 
Infarction 25 (ExTRACT–TIMI 25) trial (n = 20 506), a lower dose 
of enoxaparin was given to patients ≥75 years old and to those 
with impaired renal function (estimated creatinine clearance 
<30 mL/min). Enoxaparin was associated with a reduction in the 
risk of death and re-infarction at 30 days when compared with a weight-adjusted UFH dose, but at the cost of a significant increase 
in non-cerebral bleeding complications. The net clinical benefit (i.e. ab
-
sence of death, non-fatal infarction, and intracranial haemorrhage) fa -
voured enoxaparin.348,349In the large OASIS-6 trial, fondaparinux was 
superior to placebo or UFH in preventing death and re-infarction, es -
pecially in patients who received streptokinase.260,350In a large trial 
with streptokinase, significantly fewer re-infarctions were seen with bi -
valirudin given for 48 h compared with UFH, although at the cost of a modest non-significant increase in non-cerebral bleeding complica
-
tions.351Bivalirudin has not been studied with fibrin-specific agents, 
and there is no evidence to support direct thrombin inhibitors as an 
adjunct to fibrinolysis.260,350
Weight-adjusted i.v. tenecteplase, low-dose aspirin, clopidogrel given 
orally, and enoxaparin i.v. followed by s.c. administration until the time 
of PCI (revascularization) represents the most extensively studied 
antithrombotic regimen as part of a pharmaco-invasive strat -
egy.184,186,213,346,352Further information on fibrinolytic therapy, includ -
ing antithrombotic co-therapies and contraindications is provided in 
Supplementary data online, Tables S10 and S11.6.7. Antithrombotic therapy in patients 
not undergoing reperfusion
Patients with a final diagnosis of ACS who do not undergo reperfusion 
should receive a P2Y 12 receptor inhibitor in addition to aspirin, maintained 
over 12 months unless there is HBR. Among ACS patients who are med -
ically managed without revascularization, the combination of aspirin and ti -
cagrelor for up to 12 months has demonstrated a benefit in comparison to aspirin and clopidogrel.
238,361The combination of aspirin and prasugrel can 
also be justified in preference to aspirin and clopidogrel if coronary angiog -
raphy has been performed and CAD is confirmed.239,362As such, potent 
P2Y 12 inhibitor-based DAPT is a reasonable option for patients with a final 
diagnosis of ACS not undergoing reperfusion, unless concerns over the 
bleeding risk prevail (e.g. based on ARC-HBR criteria).238,361A DAPT regi -
men based on clopidogrel and aspirin may provide a good net clinical bene -
fit among older ACS patients.242,363Further information regarding 
antithrombotic therapy in ACS patients who do not undergo reperfusion 
is provided in the Supplementary data online.
7. Acute coronary syndrome with 
unstable presentation
In some cases, ACS patients can present with haemodynamic com -
promise (i.e. out-of-hospital cardiac arrest [OHCA] and/or CS).Recommendation Table 7 — Recommendations for 
fibrinolytic therapy
Recommendations ClassaLevelb
Fibrinolytic therapy
When fibrinolysis is the reperfusion strategy, it is 
recommended to initiate this treatment as soon as 
possible after diagnosis in the pre-hospital setting 
(aim for target of <10 min to lytic bolus).206,353–355I A
A fibrin-specific agent (i.e. tenecteplase, alteplase, or reteplase) is recommended.
356,357I B
A half-dose of tenecteplase should be considered in patients >75 years of age.
184IIa B
Antiplatelet co-therapy with fibrinolysis
Aspirin and clopidogrel are recommended.340–342I A
Anticoagulation co-therapy with fibrinolysis
Anticoagulation is recommended in patients treated 
with fibrinolysis until revascularization (if performed) 
or for the duration of hospital stay (up to 8 
days).260,347,348,350,357–360I A
Enoxaparin i.v. followed by s.c. is recommended as the preferred anticoagulant.
347,348,357–360I A
When enoxaparin is not available, UFH is recommended as a weight-adjusted i.v. bolus, 
followed by infusion.
357I B
In patients treated with streptokinase, an i.v. bolus of fondaparinux followed by an s.c. dose 24 h later should be considered.
260IIa B
©ESC 2023
i.v., intravenous; s.c, subcutaneous; UFH, unfractionated heparin. 
aClass of recommendation. 
bLevel of evidence.3762                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

7.1. Out-of-hospital cardiac arrest in acute 
coronary syndrome
While a small minority of all patients with ACS present as OHCA, ACS 
is the most common cause of OHCA.364–366In patients with OHCA, 
resuscitation efforts should follow the European Resuscitation 
Council Guidelines.367The majority of adult cardiac arrest cases are 
associated with obstructive CAD and ACS should be included in the 
differential diagnosis.365,368Therefore, ICA can be part of the post- 
resuscitation management for patients who are estimated to have a high probability of acute coronary occlusion (e.g. persistent 
ST-segment elevation or equivalents and/or haemodynamic and/or 
electrical instability).
367,369Neurological status (e.g. comatose vs. non- 
comatose) and survival probability (i.e. favourable benefit/risk ratio vs. futility) should also be included in the decision-making algorithm.
Despite the lack of dedicated trials, patients with return of spontan -
eous circulation (ROSC) and persistent ST-segment elevation should, in 
general, undergo a PPCI strategy (immediate ICA and PCI if indicated), 
based on the overall clinical situation and a reasonable benefit/risk ratio. 
Based on registry reports, emergent ICA and PCI are associated with 
good outcomes in this setting, particularly in patients who are non- 
comatose at initial assessment.368,370,371
The management of patients with ROSC without evidence of 
ST-segment elevation should be individualized according to haemo -
dynamic and neurological status. In OHCA with an initial shockable 
rhythm and without ST-segment elevation or equivalents and without 
CS, routine immediate ICA is not superior to a delayed invasive strategy 
based on data from the COACT (Coronary Angiography after Cardiac 
Arrest) and TOMAHAWK (Immediate Unselected Coronary Angiography Versus Delayed Triage in Survivors of Out-of-hospital 
Cardiac Arrest Without ST-segment Elevation) RCTs.
372,373Smaller, 
underpowered trials (EMERGE [EMERGEncy versus delayed coronary 
angiogram in survivors of out-of-hospital cardiac arrest with no obvious 
non-cardiac cause of arrest], PEARL [A Pilot Randomized Clinical Trial 
of Early Coronary Angiography Versus No Early Coronary 
Angiography for Post-Cardiac Arrest Patients Without ECG ST 
Segment Elevation], and COUPE [Coronariography in OUt of hosPital Cardiac arrEst]) have also pointed to the same conclu
-
sion.372–377Further detail on these trials is provided in the 
Supplementary data online, Evidence Tables.
Based on data from the COACT and TOMAHAWK trials, it appears 
reasonable to delay ICA in haemodynamically stable patients with re -
suscitated OHCA without ST-segment elevation or equivalents. Initial 
evaluation in the ED or intensive cardiac care unit (ICCU) should focus 
on excluding non-coronary causes (cerebrovascular events, respiratory 
failure, non-cardiogenic shock, PE, or intoxication). Echocardiography is 
also useful in the evaluation of these patients. The decision to perform 
selective coronary angiography (and PCI if indicated) should also con -
sider factors associated with poor neurological outcome and the likeli -
hood of ACS.
In patients who remain unresponsive after ROSC, monitoring of 
core temperature and actively preventing fever (defined as a tempera -
ture >
37.7°C) is recommended to improve neurological out -
come.367,378–385A recent study compared device-based temperature 
control of 36°C for 24 h followed by targeting of 37°C for either 12 or 48 h (for total intervention times of 36 and 72 h, respectively) or un
-
til the patient regained consciousness in 789 patients with OHCA of a presumed cardiac cause (
∼45% with ST segment elevation on ECG; im -
mediate coronary angiography performed in 92% and PCI in 43%). This study reported comparable outcomes with both strategies with respect to the primary endpoint (death, severe disability, or coma) at 
90 days.
384In all comatose survivors, evaluation of neurological progno -
sis no earlier than 72 h after admission is recommended.367,378–383,386
7.1.1. Systems of care
There is increasing evidence suggesting that specialized hospitals for pa -
tients following OHCA (referred to as cardiac arrest centres) may be 
associated with clinical benefits.367See Supplementary data online, 
Section 7.1.1 for expanded information on this topic.
7.2. Cardiogenic shock complicating acute 
coronary syndrome
Early revascularization with either PCI or CABG is recommended for 
patients with AMI complicated by CS, based on the results of the SHOCK (Should We Emergently Revascularize Occluded Coronaries Recommendation Table 8 — Recommendations for 
cardiac arrest and out-of-hospital cardiac arrest
Recommendations ClassaLevelb
Cardiac arrest and OHCA
A PPCI strategy is recommended in patients with 
resuscitated cardiac arrest and an ECG with persistent ST-segment elevation (or 
equivalents).
368,387,388I B
Routine immediate angiography after resuscitated cardiac arrest is not recommended in 
haemodynamically stable patients without persistent 
ST-segment elevation (or equivalents).
373–377III A
Temperature control
Temperature control (i.e. continuous monitoring of 
core temperature and active prevention of fever [i.e. 
>37.7°C]) is recommended after either 
out-of-hospital or in-hospital cardiac arrest for adults who remain unresponsive after return of 
spontaneous circulation.
378–385,389I B
Systems of care
It is recommended that healthcare systems 
implement strategies to facilitate transfer of all 
patients in whom ACS is suspected after resuscitated 
cardiac arrest directly to a hospital offering 24/7 PPCI 
via one specialized EMS.390–392I C
Transport of patients with OHCA to a cardiac arrest 
centre according to local protocols should be 
considered.391,393IIa C
Evaluation of neurological prognosis
Evaluation of neurological prognosis (no earlier than 
72 h after admission) is recommended in all 
comatose survivors after cardiac arrest.386I C
©ESC 2023
ACS, acute coronary syndrome; ECG, electrocardiogram; EMS, emergency medical 
services; OHCA, out-of-hospital cardiac arrest; PPCI, primary percutaneous coronary 
intervention. 
aClass of recommendation. 
bLevel of evidence.ESC Guidelines                                                                                                                                                                                          3763Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

for Cardiogenic Shock) trial.394–396While most patients will proceed to 
PCI at the time of diagnostic angiography if myocardial revascularization 
is indicated, surgical revascularization represents a valuable treatment 
option in patients in whom attempted PCI of the IRA has failed or if 
the coronary anatomy is not amenable to PCI.395,397,398In the presence 
of CS due to AMI-related mechanical complications, surgical or percu -
taneous treatment may also be indicated and the strategy should be 
decided based on discussion between members of the Heart Team.
In the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock 
II) trial, intra-aortic balloon pump (IABP) use was not associated with 
lower 30-day mortality.399Therefore, in the absence of mechanical com -
plications, the routine use of an IABP is not recommended for CS com -
plicating AMI. The role of mechanical circulatory devices (veno-arterial 
extracorporeal membrane oxygenation [VA-ECMO], micro-axial 
pump) in the AMI setting is not well established and large-scale rando -
mized trials are warranted.400,401The Extracorporeal Membrane 
Oxygenation in the Therapy of Cardiogenic Shock trial randomized 
122 patients (51% with STEMI) with rapidly deteriorating or severe CS 
to either immediate implementation of VA-ECMO or an initially conser -
vative strategy (which allowed for downstream use of VA-ECMO).402
The immediate implementation of VA-ECMO did not result in improved 
clinical outcomes.402However, the interpretation of this trial is challen -
ging because of the ∼
40% crossover rate to VA-ECMO in the conserva -
tive arm, the inclusion of heterogenous phenotypes of CS, and inclusion 
of crossover in the combined primary endpoint. As a result of these lim -
itations, this trial cannot adequately answer if mechanical circulatory sup -
port (MCS) is able to reduce mortality in this setting.
It is important to note that while there is still a lack of high-quality 
randomized data supporting the use of MCS in ACS patients presenting with CS, some recent observational analyses have reported that the use 
of intravascular LV assist devices may be associated with an increased 
risk of adverse events in comparison to IABP in this setting, including 
mortality and bleeding.
401,403Therefore, while MCS may be considered 
in selected patients with ACS and severe/refractory CS, caution should be exercised in this regard until further randomized data are available. 
The management of patients with CS complicating AMI and MVD is 
presented in Section 10.8. Management of acute coronary 
syndrome during hospitalization
8.1. Coronary care unit/intensive cardiac 
care unit
Following reperfusion, it is recommended to admit high-risk ACS pa -
tients (including all STEMI patients) to a coronary care unit (CCU) or 
ICCU. Conditions in patients with ACS that act as acute risk modifiers 
include ongoing myocardial ischaemia (e.g. failed reperfusion), acute HF 
and/or hypoperfusion, CS, cardiac arrest with coma, malignant (life- 
threatening) cardiac arrhythmias, high-degree atrioventricular block, 
and acute renal failure (with oliguria). All ICCUs must have appropriate diagnostic facilities to guide the delivery of pharmacological and invasive 
treatment. The staff should be thoroughly familiar with the manage
-
ment of all aspects of ACS, including: arrhythmias, HF, mechanical circulatory support, invasive and non-invasive haemodynamic monitor
-
ing (arterial and pulmonary artery pressures), respiratory monitoring, 
mechanical ventilation, and temperature control.408The CCU/ICCU 
should also be able to manage patients with renal and pulmonary dis -
ease. The desirable organization, structure, and criteria of CCU/ 
ICCUs have been detailed in an ESC–Acute CardioVascular Care 
Association position paper.408
8.1.1. Monitoring
It is recommended to initiate ECG monitoring as soon as possible in all 
patients with ACS in order to detect life-threatening arrhythmias and al -
low prompt defibrillation if indicated. ECG monitoring for arrhythmias 
and new ST-segment elevation/depression is recommended for at least 
24 h after symptom onset in all high-risk patients with ACS, including 
all STEMI patients.409Longer monitoring could be considered in patients 
at intermediate to high risk of cardiac arrhythmias (i.e. those with more 
than one of the following criteria: haemodynamically unstable, presenting 
with major arrhythmias, left ventricular ejection fraction [LVEF] <40%, 
failed reperfusion, additional critical coronary stenoses of major vessels, or complications related to PCI). Further monitoring for arrhythmias will 
be dependent on the estimated risk. When a patient leaves the ICCU or equivalent, monitoring may be continued by telemetry. It is recom
-
mended that personnel adequately equipped and trained to manage life- threatening arrhythmias and cardiac arrest accompany patients who are 
transferred between facilities during the time window in which they re
-
quire continuous rhythm monitoring.409
8.1.2. Ambulation
Early ambulation (i.e. out of bed on day 1) is recommended in the ma -
jority of patients with ACS. This is facilitated by using radial access for Recommendation Table 9 — Recommendations for 
cardiogenic shock
Recommendations ClassaLevelb
Immediate coronary angiography and PCI of the IRA 
(if indicated) is recommended in patients with CS 
complicating ACS.394,396,404I B
Emergency CABG is recommended for ACS-related CS if PCI of the IRA is not feasible/unsuccessful.
394,395I B
In cases of haemodynamic instability, emergency surgical/catheter-based repair of mechanical 
complications of ACS is recommended, based on 
Heart Team discussion.I C
Fibrinolysis should be considered in STEMI patients presenting with CS if a PPCI strategy is not available 
within 120 min from the time of STEMI diagnosis and 
mechanical complications have been ruled out.
184,354IIa C
ContinuedIn patients with ACS and severe/refractory CS, 
short-term mechanical circulatory support may be 
considered.402IIb C
The routine use of an IABP in ACS patients with CS and without mechanical complications is not 
recommended.
399,405–407III B
©ESC 2023
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CS, cardiogenic 
shock; IABP, intra-aortic balloon pump; IRA, infarct-related artery; PPCI, primary 
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.3764                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

invasive management. Patients with extensive myocardial damage, HF, 
hypotension, or arrhythmias may initially rest in bed before assessment 
of myocardial function and clinical stabilization. Prolongation of bed rest 
and limitation of physical activity may occasionally be required in pa -
tients with large infarcts or severe complications.
8.1.3. Length of stay in the intensive cardiac care unit
The optimal length of stay in the ICCU and hospital should be individua -
lized according to the patient’s clinical situation, taking into account 
their baseline cardiac risk and comorbidities, baseline mental/functional 
status, and social support.410,411Of note, the majority of adverse in- 
hospital events occur early after admission and the initiation of 
treatment.
8.2. In-hospital care
8.2.1. Length of hospital stay
The impact of both successful reperfusion and knowledge of the coron -
ary anatomy (due to increasing rates of ICA) has resulted in progressive reductions in the length of stay after ACS, alongside significant reduc
-
tions in 30-day mortality, suggesting that discharge within 72 h is not as -
sociated with late mortality.411–417Candidates for early discharge after 
PCI can be identified using simple criteria.413,414In one study, patients 
meeting the following criteria were considered to be ‘low risk’ and suit -
able for early discharge: age <
70 years, LVEF >45%, one- or two-vessel 
disease, successful PCI, and no persistent arrhythmias.413A recently 
published consensus document also presents a template and flow chart to support reasonable decision-making regarding post-procedural 
length of stay for a broad spectrum of patients undergoing PCI.
418
Early (i.e. same day) transfer to a local hospital following successful 
PPCI is routine practice. This can be done safely under adequate mon -
itoring and supervision in selected patients (i.e. patients without signs or 
symptoms consistent with ongoing myocardial ischaemia, without ar -
rhythmias, who are haemodynamically stable, who are not requiring 
vasoactive or mechanical support, and who are not scheduled for fur -
ther revascularization).419
8.2.2. Risk assessment
Early and late risk stratification soon after presentation is useful to aid 
decision-making in patients presenting with ACS.
8.2.2.1. Clinical risk assessment
All patients with ACS (in particular, patients with STEMI) should have 
an early assessment of short-term risk, including an evaluation of the ex -
tent of myocardial damage, the achievement of successful reperfusion, 
and the presence of clinical markers of high risk of further events (i.e. 
older age, tachycardia, hypotension, Killip class >I, anterior MI, previous 
MI, elevated initial serum creatinine, history of HF, peripheral arterial 
disease or anaemia). Several risk scores have been developed based on readily identifiable parameters in the acute phase before reperfu
-
sion.420,421A number of prognostic models that aim to estimate the 
longer-term risk of all-cause mortality, or the combined risk of all-cause 
mortality or MI, have also been developed. These models have been 
formulated into clinical risk scores and, among these, the GRACE risk 
score offers the best discriminative performance and is therefore re -
commended for risk assessment.48,421–425Additional information re -
garding the GRACE score is provided in the Supplementary data online.8.2.2.2. Imaging risk assessment
LV dysfunction is a key prognostic factor for patients with ACS.426It is 
recommended that the LVEF is determined before hospital discharge in all patients with ACS. Routine echocardiography after PPCI is recom
-
mended to assess resting LV, RV, and valvular function. In addition, echocardiography can be used to exclude early post-infarction mechan
-
ical complications and LV thrombus. In the limited number of cases in which echocardiography is suboptimal or inconclusive, CMR may be a valuable alternative.
427–431
In patients presenting days after an acute ACS event with a com -
pleted MI, the presence of recurrent angina or documented ischaemia and proven viability in a large myocardial territory may help to guide the 
strategy of planned revascularization of an occluded IRA.
192,432,433
In patients with a pre-discharge LVEF of ≤40%, re-evaluation of the 
LVEF 6–12 weeks after complete revascularization and optimal medical 
therapy is recommended to assess the potential need for primary pre -
vention implantable cardioverter defibrillator (ICD) implantation.434
Additional parameters that are measured by imaging in these patients 
and that have been used as endpoints in clinical trials include: (i) infarct size (CMR, SPECT, and positron emission tomography); (ii) myocar
-
dium at risk (SPECT, CMR); (iii) MVO (CMR); and (iv) intra-myocardial haemorrhage (CMR). Infarct size, MVO and intra-myocardial haemor
-
rhage are predictors of both long-term mortality and HF in STEMI sur -
vivors.435–438
8.2.2.3. Biomarkers for risk assessment
Beyond diagnostic utility, initial cTn levels add prognostic information in addition to clinical and ECG variables in terms of predicting the risk of short- and long-term mortality. While hs-cTn T and I have comparable 
diagnostic accuracy, hs-cTn T has slightly greater prognostic accuracy 
regarding mortality.
61,439–441Serial measurements are useful to identify 
peak levels of cTn for risk stratification purposes in patients with estab -
lished MI. The higher the hs-cTn levels, the greater the risk of 
death.31,55,442However, evidence is limited regarding the optimal 
time points of serial hs-cTn measurement. Serum creatinine and 
eGFR should also be determined in all patients with ACS because 
they affect prognosis and are key elements of the GRACE risk score.443
Similarly, natriuretic peptides (brain natriuretic peptide [BNP] and 
N-terminal pro-BNP [NT-pro BNP]) provide prognostic information 
in addition to cTn regarding the risk of death and acute HF, and the de -
velopment of AF.444Additional information on the use of biomarkers 
for this purpose is presented in the Supplementary data online.
8.2.2.4. Bleeding risk assessment
Major bleeding events are associated with increased mortality in pa -
tients with ACS.231Further detail on scores that may be considered 
for estimation of bleeding risk is provided in the Supplementary data 
online, including Table S12.
8.2.2.5. Integrating ischaemic and bleeding risks
Major bleeding events affect prognosis in a similar way to spontaneous 
ischaemic complications.445,446Given the trade-off between ischaemic 
and bleeding risks for any antithrombotic regimen, risk scores may be 
useful to tailor antithrombotic duration and intensity, in order to maxi -
mize ischaemic protection and minimize bleeding risk in the individual 
patient. Specific risk scores have been developed for patients on 
DAPT following PCI, in the settings of both CCS and ACS. Further de -
tail on available scores is provided in the Supplementary data online.ESC Guidelines                                                                                                                                                                                          3765Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

9. Technical aspects of invasive 
strategies
9.1. Percutaneous coronary intervention
9.1.1. Vascular access
Timely PCI with concomitant antithrombotic drugs has reduced the 
ischaemic risk in patients with ACS. However, this strategy is also associated with an increased bleeding risk, which affects prognosis 
at least as much as ischaemic complications and is associated with im -
paired survival.448,449Among patients undergoing PCI, access-related 
bleeding accounts for 30–70% of total bleeding events.450There is 
strong evidence demonstrating that reducing access-site bleeding 
events with the use of radial access translates into significant clinical 
benefits.448,449The largest randomized trials on this topic in patients 
with ACS are the RadIal Vs femorAL access for coronary intervention 
(RIVAL) trial with 7021 ACS patients and the Minimizing Adverse 
Haemorrhagic Events by TRansradial Access Site and Systemic 
Implementation of angioX (MATRIX) trial with 8404 ACS patients 
(47.6% with STEMI).451,452These trials have demonstrated signifi -
cantly lower rates of access site-related bleeding, surgical access 
site repair, and blood transfusion with radial compared with femoral 
access. In the MATRIX trial, no significant interaction was observed 
between the type of ACS and the benefit associated with the radial 
approach, suggesting that the results of this trial can be extended 
to patients across the entire spectrum of ACS.453In a cost- 
effectiveness analysis of the MATRIX trial, radial access was also as -
sociated with significant savings in terms of quality-adjusted life years 
and PCI-related costs.454Therefore, radial access is recommended as 
the preferred approach in ACS patients undergoing invasive assess -
ment with or without PCI. However, femoral access may still be se -
lectively chosen instead of radial access in certain patients (i.e. 
depending on the haemodynamic situation and other technical as -
pects during the index PCI procedure).
9.1.2. Intravascular imaging/physiology of the 
infarct-related artery
9.1.2.1. Intravascular imaging
As a diagnostic tool, intravascular imaging is useful in ACS patients 
without significant obstructive CAD on coronary angiography. Excluding an atherothrombotic cause in the main coronary arteries 
for the ACS may have important clinical implications, not only for im
-
mediate invasive management but also for potentially lifelong 
antithrombotic therapies. Intravascular imaging is also useful in cases 
where there is ambiguity regarding the culprit lesion. Culprit lesion ambiguity can be present in more than 30% of patients with sus
-
pected NSTE-ACS and over 10% of patients may have multiple cul -
prit lesions.455,456The recommendations for intravascular imaging 
in ACS are presented in Figure 13.
The role of intravascular imaging is well established as a tool to guide 
and optimize PCI. Evidence in support of intravascular ultrasound (IVUS) guidance in ACS generally derives from subgroup analyses of all- 
comers trials. Meta-analysis of available randomized trials confirms the 
superiority of IVUS guidance in the reduction of MACE, although a de
-
finitive, large-scale, multinational trial is missing.457–459Smaller RCTs 
have evaluated the role of optical coherence tomography (OCT) (see Supplementary data online).
460Recommendation Table 10 — Recommendations for 
in-hospital management
Recommendations ClassaLevelb
Logistical issues for hospital stay
It is recommended that all hospitals participating in 
the care of high-risk patients have an ICCU/CCU 
equipped to provide all required aspects of care, 
including treatment of ischaemia, severe heart failure, 
arrhythmias, and common comorbidities.I C
It is recommended that high-risk patients (including all STEMI patients and very high-risk NSTE-ACS patients) have ECG monitoring for a minimum of 24 h.I C
It is recommended that high-risk patients with successful reperfusion therapy and an uncomplicated 
clinical course (including all STEMI patients and very 
high-risk NSTE-ACS patients) are kept in the CCU/ 
ICCU for a minimum of 24 h whenever possible, after 
which they may be moved to a step-down monitored 
bed for an additional 24–48 h.I C
Discharge of selected high-risk patients within 48– 72 h should be considered if early rehabilitation and adequate follow-up are arranged.
411,413,415,447IIa A
Same-day transfer in selected stable patients after successful and uneventful PCI should be 
considered.
419IIa C
Imaging
Routine echocardiography is recommended during 
hospitalization to assess regional and global LV 
function, detect mechanical complications, and exclude LV thrombus.I C
When echocardiography is suboptimal/inconclusive, CMR imaging may be considered.IIb C
©ESC 2023
ACS, acute coronary syndrome; CCU, cardiac care unit; CMR, cardiac magnetic resonance; 
ECG, electrocardiogram; ICCU, intensive cardiac care unit; LV, left ventricular; NSTE-ACS, 
non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary 
intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.3766                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

9.1.2.2. Intravascular physiology
Intracoronary physiology is increasingly being used in patients with 
ACS to assess the haemodynamic significance of intermediate severity non-IRA stenoses (see Section 10
). However, PCI of the IRA should 
not be deferred based on invasive epicardial functional assessment in patients with ACS. The coronary microcirculation begins to re
-
cover within 24 h of PPCI and acute functional assessment of the IRA may underestimate the true haemodynamic severity of the cor
-
onary stenosis.461Beyond 1 week from the acute event, fractional 
flow reserve (FFR) measurement has been reported to reliably predict abnormal nuclear imaging results.
462Additional information about the role of intracoronary physiology in the IRA is presented in the Supplementary data online.
9.1.3. Timing of revascularization with percutaneous 
coronary intervention
In some patients with ACS undergoing ICA, an initial conservative man -
agement strategy with optimized guideline-directed medical therapy 
may be considered on a case-by-case basis. The specific circumstances include ACS patients with small calibre vessels, an occluded small side branch, or concerns regarding non-compliance with antithrombotic 
Working diagnosis: ACS
Clear culprit lesion,
suitable for PCINo clear culprit lesion
PCI of culprit lesionConsider further
investigations as requiredTreat as per
imaging findingsIntravascular imaging
to guide PCI
(Class lla)Intravascular imagingPotential ambiguous 
angiographic findings  
Multivessel disease
Hazy lesion/calcification  
Tortuosity/eccentricity
Potential further
investigations
Left ventriculography
Echocardiography
Cardiac MRIPotential intravascular
imaging findings
Coronary plaque pathology
Erosion Nodule RuptureIVUS or OCTIntravascular imaging
(preferably OCT) in
patients with ambiguous
culprit lesions
(Class llb)Coronary angiography
SCAD No lesion
Figure 13 A practical algorithm to guide intravascular imaging in acute coronary syndrome patients. ACS, acute coronary syndrome; IVUS, intravascular 
ultrasound; MRI, magnetic resonance imaging; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; SCAD, spontaneous coronary 
artery dissection.ESC Guidelines                                                                                                                                                                                          3767Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

therapy. In the context of complex CAD and anticipated complex PCI, 
an initial conservative strategy in medically stabilized patients without 
ongoing symptoms allows time for Heart Team discussion regarding 
the optimal revascularization strategy.
9.1.4. Balloons and stents
New-generation DES are associated with superior safety and improved 
efficacy compared with bare metal stents (BMS) and first-generation DES. The Norwegian Coronary Stent Trial (NORSTENT)—the largest 
clinical trial comparing outcomes of patients treated with new- 
generation DES or BMS—reported that the primary endpoint of death 
or MI was comparable in both treatment groups. Both target lesion re
-
vascularization (TLR) and stent thrombosis were reduced in the DES 
group and there was no treatment effect by ACS presentation inter -
action for the primary endpoint.463The COMFORTABLE-AMI 
(Comparison of Biolimus Eluted From an Erodible Stent Coating 
With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) 
and EXAMINATION (Everolimus-Eluting Stents Versus Bare-Metal 
Stents in ST Segment Elevation Myocardial Infarction) trials have also 
reported the clinical superiority of DES over BMS in terms of lower 
rates of re-infarction, target lesion revascularization, and stent throm -
bosis.464,465This clinical benefit was preserved at longer-term follow- 
up.466–468
A strategy of drug-coated balloon (DCB) angioplasty without 
stenting has also been proposed for patients with NSTE-ACS. In the 
small, prospective, randomized, single-centre REVELATION 
(REVascularization With PaclitaxEL-Coated Balloon Angioplasty 
Versus Drug-Eluting Stenting in Acute Myocardial InfarcTION) trial, 
DCB PCI vs. DES PCI was investigated in 120 patients undergoing 
PPCI. The primary endpoint of target vessel FFR at 9 months was not significantly different between the two groups.
469In the small 
PEPCAD NSTEMI (Bare Metal Stent Versus Drug Coated Balloon 
With Provisional Stenting in Non-ST-Elevation Myocardial Infarction) 
trial, 210 patients were randomized to compare a DCB with primary 
stent treatment (BMS or DES).470During a mean follow-up period of 
9.2 months, DCB treatment was non-inferior to treatment with a stent, with a target lesion failure (primary study endpoint) rate of 3.8% vs. 
6.6% (P = 0.53). Given the limitations of these studies (in particular, 
the relatively small sample sizes), the use of DCB in NSTE-ACS requires further investigation in order to better inform future guideline 
recommendations.
471
9.1.5. Embolic protection and microvascular salvage 
strategies
9.1.5.1. Thrombus aspiration
Large RCTs have failed to demonstrate a clinical benefit with routine 
manual thrombus aspiration in comparison to conventional PPCI.472– 
474In an individual patient data meta-analysis, thrombus aspiration 
was associated with fewer CV deaths and with more strokes or transi -
ent ischaemic attacks in the subgroup of patients with high thrombus 
burden (TIMI thrombus Grade 3).475However, in a sub-analysis from 
TOTAL (a Trial of routine aspiration ThrOmbecTomy with PCI vs. 
PCI ALone in patients with STEMI), routine thrombus aspiration did 
not improve outcomes at 1 year and was also associated with an in -
creased rate of stroke in patients with high thrombus burden.476In pa-
tients with NSTE-ACS and thrombus-containing lesions, PCI with 
adjunctive thrombus aspiration was not associated with a reduction 
in MVO 4 days after the index procedure or with fewer MACE after 
up to 1 year of follow-up.477Based on these data, routine thrombus aspiration is not recommended, but in cases of large residual thrombus 
burden after opening the vessel with a guide wire or a balloon, throm -
bus aspiration may be considered.
9.1.5.2. Interventions to protect the microcirculation
The damage inflicted on the myocardium during AMI is the result of is -
chaemia and subsequent reperfusion (ischaemia/reperfusion injury). In patient-level pooled analyses, infarct size and MVO are independent 
predictors of long-term mortality and HF in survivors of 
STEMI.
436,478Strategies to reduce ischaemia/reperfusion injury in gen -
eral (and MVO in particular) remain an unmet clinical need. Further in -
formation regarding interventions to protect the microcirculation that 
are under clinical or experimental investigation is presented in the 
Supplementary data online.
9.2. Coronary artery bypass grafting
9.2.1. Indication and timing of coronary artery bypass 
grafting in acute coronary syndrome patients
There are no dedicated RCTs comparing percutaneous vs. surgical re -
vascularization in patients with ACS. In the setting of STEMI, CABG 
should be considered only when PPCI is not feasible, particularly in 
the presence of ongoing ischaemia or large areas of jeopardized 
myocardium.479
In patients requiring immediate revascularization in the setting of 
very high-risk NSTE-ACS, PCI is usually preferred for reasons of time -
liness, unless concomitant mechanical complications dictate a prefer -
ence for surgical intervention.
In other patients with ACS, the choice of revascularization modality 
should be made according to the number of diseased vessels and  the gen -
eral principles of myocardial revascularization.250In patients with MVD, 
the choice of revascularization modality will be influenced by the overall anatomical disease complexity and the presence of comorbidities (includ
-
ing diabetes) in patients with low predicted surgical risk and mortality who are considered suitable for either modality. This is based on data from two 
large-scale individual patient meta-analyses.
480,481
9.2.2. Technical considerations specific to acute 
coronary syndrome patients
The patient profile, including the need for emergency or extremely ex -
peditious revascularization, may influence both the technique of CABG 
(including on-pump beating heart CABG) and the choice and use of 
CABG conduits. The need for prompt surgical revascularization in 
emergency circumstances does not facilitate the use of full arterial re -
vascularization due to the prolonged period required for graft harvest -
ing. Accordingly, the use of total venous graft-based CABG or the use of single left internal mammary artery plus additional venous grafts may 
be useful in this setting.
397
9.3. Spontaneous coronary artery 
dissection
Spontaneous coronary artery dissection (SCAD) is an infrequent cause 
of ACS in general but accounts for a significant proportion of ACS cases in young/middle-aged women.
482The pathophysiology underlying SCAD 
is different to that of Type 1 MI and there are some differences in its man -
agement and outcomes. For these reasons, it is of paramount importance 
that an accurate diagnosis is established. Until evidence from ongoing 
prospective trials becomes available, patients with SCAD should receive 
the same pharmacological therapy as other ACS patients.4833768                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

9.3.1. Intravascular imaging
There are no RCTs to guide management strategies in patients with 
SCAD. The use of intravascular imaging is based on observations re -
ported from clinical cohort studies and expert opinion.482,484,485In 
cases of diagnostic uncertainty after angiography, the use of intracor -
onary imaging with OCT or IVUS has to be carefully considered. 
There should be sufficient diagnostic uncertainty to justify coronary 
instrumentation, and even if this is the case, other factors like vessel 
tortuosity, vessel diameter, and a distal lesion location may prohibi -
tively increase the risk.482If the decision is made to perform intravas -
cular imaging, it is imperative to ensure the guide wire is located within 
the true lumen of the coronary artery before advancing the imaging 
catheter.482In patients with a diagnosis of SCAD on angiography 
and a plan for medical therapy, additional coronary instrumentation 
and intravascular imaging is not recommended on safety 
grounds.482,484,485
9.3.2. Revascularization
Conservative medical management, as opposed to PCI, is generally re -
commended for patients with SCAD.482In an international case series, 
coronary complications following PCI occurred in >30% of pa -
tients.486–488In a pooled analysis of three SCAD-PCI cohorts including 
215 patients (94% female) drawn from Dutch, Spanish, and UK regis -
tries, and a matched cohort of conservatively managed SCAD patients 
(
n = 221), PCI was associated with complications in ≈40% of cases (in -
cluding 13% with serious complications). PCI is recommended only for SCAD with associated symptoms and signs of ongoing myocardial is
-
chaemia, a large area of myocardium in jeopardy, and reduced ante -
grade flow. Useful strategies for these patients may include minimal plain balloon angioplasty to restore flow, followed by a conservative 
strategy, targeted stenting to seal the proximal and distal ends of the 
dissection, and/or extended stent lengths to prevent propagation of 
the haematoma. In patients with SCAD, CABG is recommended when dissection affects the left main or two proximal vessels, if PCI 
is not feasible or unsuccessful, and if there are symptoms and signs of 
ongoing myocardial ischaemia. In a small observational study, patients 
with SCAD treated with CABG had favourable early clinical outcomes, 
with an event rate up to 5 years similar to that of patients treated con
-
servatively, despite a significant (68%) rate of graft occlusion at 5 
years.486The rate of graft occlusion over time can be explained by 
the fact that CABG in these patients may be technically challenging as 
the dissected coronary artery is more prone to anastomosis failure, 
and because spontaneous healing over time may restore the flow in 
the anastomosed vessel.486,489For this reason, vein grafts should be 
considered in these patients in order to preserve arterial conduits for future use.
48510. Management of patients with 
multivessel disease
Approximately half of ACS patients have coronary MVD.500
Management of non-IRA disease varies depending on the clinical 
setting.
10.1. Management of multivessel disease in 
acute coronary syndrome complicated by 
cardiogenic shock
Cardiogenic shock may occur in up to 4–11% of ACS patients, and oc -
curs more frequently in the presence of complete coronary occlu -
sion.501,502Ischaemia-related HF, acute severe mitral regurgitation, 
and mechanical complications are the major precipitating causes of 
CS in ACS. Irrespective of the mode of presentation (i.e. with or with -
out ST-segment elevation or equivalent ECG patterns), these patients 
should be transferred as soon as possible to a tertiary care centre (e.g. a 
shock centre) where ICA can be performed, supported by specialists 
with relevant experience (the Shock Team).503,504
In the SHOCK trial, which compared emergency revascularization 
with initial medical stabilization in 302 patients with acute MI compli -
cated by CS, ∼
60% had anterior MI and 85% had MVD.394Among 
the patients assigned to emergency revascularization, 64% underwent 
PCI and 36% underwent CABG. There were no differences in mortality 
at 30 days (primary endpoint), but at 6 months mortality was lower in 
the group assigned to revascularization than in the group assigned to 
medical therapy. Based on this evidence, immediate coronary angiog -
raphy, and PCI if feasible, is recommended in patients with acute MI 
complicated by CS. In patients with coronary anatomy unsuitable for 
PCI, emergency CABG is recommended.394
Nearly 80% of ACS patients with CS have MVD. Based on the Culprit 
Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock 
(CULPRIT-SHOCK) trial including ACS patients (both with and with -
out ST-segment elevation or equivalent), PCI during the index Recommendation Table 11 — Recommendations for 
technical aspects of invasive strategies
Recommendations ClassaLevelb
Radial access is recommended as the standard 
approach, unless there are overriding procedural 
considerations.451,452I A
PCI with stent deployment in the IRA during the index procedure is recommended in patients 
undergoing PPCI.
490–494I A
ContinuedDrug-eluting stents are recommended in preference 
to bare metal stents in all cases.463,466,468I A
In patients with spontaneous coronary artery 
dissection, PCI is recommended only for patients with symptoms and signs of ongoing myocardial 
ischaemia, a large area of myocardium in jeopardy, 
and reduced antegrade flow.I C
Intravascular imaging should be considered to guide 
PCI.
495–499IIa A
Coronary artery bypass grafting should be considered in patients with an occluded IRA when PPCI is not feasible/unsuccessful and there is a large 
area of myocardium in jeopardy.IIa C
Intravascular imaging (preferably optical coherence tomography) may be considered in patients with 
ambiguous culprit lesions.IIb C
The routine use of thrombus aspiration is not recommended.
472–474III A
©ESC 2023
IRA, infarct-related artery; PCI, percutaneous coronary intervention; PPCI, primary 
percutaneous coronary intervention. 
aClass of recommendation. 
bLevel of evidence.ESC Guidelines                                                                                                                                                                                          3769Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

procedure should be restricted to the IRA only.404In the 
CULPRIT-SHOCK trial, IRA-only PCI was associated with a significant 
reduction in all-cause death or renal replacement therapy at 30-day 
follow-up (RR 0.83, 95% CI, 0.71–0.96).404At 1-year follow-up, mortal -
ity did not differ significantly between the two groups.505
For patients undergoing emergency CABG, appropriate peri- 
operative strategies (particularly in relation to prophylactic or on- 
demand mechanical circulatory support) may be considered based on 
pre-operative clinical status (e.g. age, comorbidities, electrical instability, 
the extent of jeopardized myocardium, the duration of ischaemia from 
the time of symptom onset, right ventricular involvement, and the feasi -
bility of cardiac surgery from technical/logistical perspectives). Figure 14
shows the algorithm for the management of patients with ACS and MVD.10.2. Patients with multivessel coronary 
artery disease undergoing primary 
percutaneous coronary intervention
Multivessel disease is evident in approximately half of patients undergo -
ing PPCI and is associated with an adverse prognosis.506,507
Over the past decade, a series of RCTs have provided clinical evidence 
that supports preventive revascularization of non-IRA after successful 
PPCI of the IRA. The pivotal clinical trials (in chronological order) include 
PRAMI (Preventive Angioplasty in Myocardial Infarction), CvLPRIT 
(Complete versus Lesion-only Primary PCI Trial), DANAMI-3– 
PRIMULTI (Third Danish Study of Optimal Acute Treatment of 
Patients with ST-Segment Elevation Myocardial Infarction—Primary 
PCI in Multivessel Disease), COMPARE-ACUTE (Comparison 
Cardiogenic shock STEMIPatient with ACS undergoing PCI of IRA with an angiographically significant stenosis in ≥ 1 non-IRA
Complete revascularization,
either during the index
procedure or within
45 daysa
(Class I)NSTE-ACS
Immediate PCI of IRA only
(Class I)
Staged complete
revascularization
(Class IIa)Complete revascularizationb
(Class IIa)
Functional invasive
evaluation of the non-IRA
during the index procedure
(Class IIb)
Figure 14 Algorithm for the management of acute coronary syndrome patients with multivessel coronary artery disease. CABG, coronary artery bypass 
grafting; IRA, infarct-related artery; MVD, multivessel disease; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary inter -
vention; STEMI, ST-elevation myocardial infarction; TIMI, Thrombolysis In Myocardial Infarction.aIn patients presenting with STEMI and MVD without CS, 
complete revascularization either during the index PCI procedure or within 45 days, with PCI of non-IRA based on angiographic severity, is recommended. 
bIn patients presenting with NSTE-ACS and MVD, complete revascularization, preferably during the index procedure should be considered. Functional in -
vasive evaluation of non-IRA severity during the index procedure may be considered.3770                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Between FFR Guided Revascularization Versus Conventional Strategy in 
Acute STEMI Patients With MVD), and COMPLETE (Complete vs. 
Culprit-only Revascularization to Treat Multivessel Disease After Early 
PCI for STEMI) (further details on these trials is provided in the 
Supplementary data online evidence tables).508–511
In a systematic review of 10 randomized trials that included 7030 pa -
tients with STEMI and MVD, complete revascularization was associated 
with reduced CV mortality compared with IRA-only PCI.512All-cause 
mortality was comparable in both groups. Complete revascularization 
was also associated with a reduced composite of CV death or new MI, sup -
porting complete revascularization in patients with STEMI and MVD.512
10.3. Timing of non-infarct-related artery 
revascularization in acute coronary 
syndrome
10.3.1. Patients presenting with ST-elevation 
myocardial infarction and multivessel coronary 
artery disease
The previous ESC STEMI Guidelines recommended non-IRA PCI dur -
ing the index procedure. The primary rationale for this recommenda -
tion was that all trials available until then had performed MVD PCI in 
that time frame. However, in the COMPLETE trial, non-IRA PCI in pa -
tients allocated to complete revascularization was performed either during hospitalization (67% of cases) or after discharge (33% of cases), 
at a mean time of 23 days after discharge but always within 45 days.
511
No treatment effect by timing of PCI interaction was observed. Given 
that the optimal timing of revascularization (immediate vs. staged) has still not been investigated in adequately sized randomized trials with a 
superiority design, no recommendation in favour of an immediate vs. 
a staged (i.e. either during index hospitalization or within 45 days of dis
-
charge) non-IRA PCI strategy can be formulated. No surgical studies have specifically investigated non-IRA revascularization.
10.3.2. Patients presenting with non-ST-elevation 
acute coronary syndrome and multivessel coronary 
artery disease
While there are a large number of studies providing evidence for patients 
presenting with STEMI and MVD, there are fewer data guiding the man -
agement of patients presenting with NSTE-ACS and MVD.513Currently, 
there is no dedicated trial comparing complete revascularization against 
IRA-only PCI for these patients. Observational studies and meta-analyses 
of non-randomized studies suggest that complete revascularization is as -
sociated with fewer deaths and MACE during follow-up in comparison to IRA-only PCI.
514,515However, given that these are analyses of treatment 
effects based on non-randomized studies, the results should be consid -
ered as hypothesis-generating at best and this remains a gap in evidence.
10.4. Evaluation of non-infarct-related 
artery stenosis severity (angiography vs. 
physiology)
Overestimation of the severity of non-IRA lesions during the PPCI proced -
ure when assessed by quantitative coronary angiography as compared 
with a repeated angiogram performed within 9 months has been re -
ported.516Microvascular constriction may also occur in the non-IRAs, 
leading to some variation in functional measurements between baseline 
and follow-up, although the impact on decision-making may be mo -
dest.517–520A sub-analysis of the FAME (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) trial reported that 65% of lesions 
in the angiographic severity range of 50–70% diameter stenosis, and 20% of 
lesions in the range 71–90%, have an FFR value above 0.80.521
The PRIME-FFR registry included 533 ACS patients and reported that 
systematic FFR measurement led to a change in the management strategy 
in 38% of cases (e.g. from CABG to PCI or to medical treatment), without 
an impact on MACE, death/MI, or angina symptoms at 1 year.522A sub -
group analysis of the FAME trial in 328 patients with ACS (UA or 
NSTEMI) and MVD reported that the adoption of FFR to guide PCI re -
sulted in similar risk reductions of MACE compared with patients with stable angina, with a lower number of stents implanted and less contrast 
media use.
523The FAMOUS-NSTEMI (Fractional Flow Reserve Versus 
Angiographically Guided Management to Optimise Outcomes in 
Unstable Coronary Syndromes) trial randomized 350 patients with 
NSTE-ACS and at least one coronary stenosis (with diameter stenosis 
>30%) to either angiography-guided or FFR-guided management (medical 
therapy, PCI, or CABG), and demonstrated that a higher proportion of 
patients in the FFR-guided management group were initially treated with medical therapy. The FLOWER-MI (Flow Evaluation to Guide 
Revascularization in Multivessel ST-Elevation Myocardial Infarction) study 
randomized 1171 patients undergoing PPCI with MVD to complete re
-
vascularization guided by FFR or angiography. Compared with an 
angiography-guided approach, an FFR-guided strategy did not reduce the risk of death, MI, or urgent revascularization at 1 year.
524PCI was per -
formed in 66.2% of patients in the FFR-guided group and in 97.1% of the angiography-guided group. In FLOWER-MI, complete revascularization 
during the index procedure was only performed in 4% of patients in 
both groups, and functional evaluation was mainly undertaken at the 
time of the second procedure.
524However, based on the study design, 
complete revascularization could also be performed during a separate 
staged procedure as early as possible before hospital discharge and within 
5 days of the initial procedure.
A meta-analysis of 10 RCTs (including 3031 patients undergoing PPCI) 
assessed outcomes in patients with complete revascularization vs. 
IRA-only PCI according to whether the decision to carry out non-IRA preventive PCI was based on angiography alone or on angiography plus 
FFR.
525Preventive PCI of the non-IRA was associated with a significant 
reduction in cardiac death and non-fatal MI only when the decision to 
proceed with non-IRA PCI was based solely on angiography. Similar find -
ings were reported in another meta-analysis of seven RCTs including a total of 6597 patients undergoing PPCI.
526In patients randomised to 
the complete revascularization arm, an angiography-guided strategy (≥70% diameter stenosis) for non-IRA lesions was associated with lower 
rates of recurrent MI, whereas an FFR-guided (≤0.80 for lesions with 
≤90% diameter stenosis) guided approach was not. In another 
meta-analysis, which pre-dated the FLOWER-MI trial, there was no het
-
erogeneity in the primary outcome when complete revascularization was 
performed using an FFR-guided strategy (OR 0.78, 95% CI, 0.43–1.44) or 
an angiography-guided strategy (OR 0.61, 95% CI, 0.38–0.97; P = 0.52 for 
interaction).512A pooled post-hoc patient-level analysis of three RCTs 
(FAME, DANAMI-3–PRIMULTI, and FAMOUS-NSTEMI) in ACS pa -
tients treated with a functionally complete revascularization strategy 
(i.e. PCI of the stenosis with FFR ≤
0.80, deferral to medical therapy sten -
osis with FFR >
0.80) reported that the residual SYNTAX score (a proxy 
of the residual coronary stenosis deferred to medical therapy) was not 
associated with MACE at 2 years, suggesting that it may be safe to defer the management of functionally non-significant stenoses in the 
non-IRA.
527The FRAME AMI (FFR Versus Angiography-Guided 
Strategy for Management of AMI With Multivessel Disease) trial com -
pared selective PCI guided by FFR (PCI if FFR ≤
0.80) to routine PCI ESC Guidelines                                                                                                                                                                                          3771Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

guided by angiography (PCI if diameter stenosis >50%) of the non-IRA(s) 
in patients presenting with AMI who had undergone successful PCI of the 
IRA (47% STEMI, 53% NSTEMI).528This study reported that at a median 
follow-up of 3.5 years, the primary endpoint (death, MI, or repeat revas -
cularization) occurred less frequently in patients randomized to the 
FFR-guided strategy, mainly driven by differences in patients presenting 
with NSTEMI. However, the trial was terminated early, with only 562 
out of an intended 1292 patients enrolled, and there was a relatively small 
number of primary outcome events.
10.5. Hybrid revascularization
Hybrid coronary revascularization (HCR) is defined as combined or consecutive procedures consisting of an internal mammary artery graft to the left anterior descending artery (LAD) and PCI to the other 
non-LAD vessels for the treatment of MVD.
529The preferred surgical 
technique for HCR is a minimally invasive left anterior mini- 
thoracotomy or robotic-assisted left internal mammary artery 
(LIMA)-LAD. The rationale for HCR is to combine the prognostic ben -
efits of a LIMA for grafting of the LAD with the potential benefits of contemporary PCI with DES for disease in arteries that would other
-
wise be revascularized using vein grafts (which are prone to occlu -
sion).530There is limited evidence from RCTs to support hybrid 
revascularization. Clinical decision-making in this regard should involve 
the Heart Team. Clinical criteria supporting an HCR strategy in ACS pa -
tients with an indication for CABG may include MVD with LAD suitable for CABG and non-LAD lesions suitable for PCI, atheroma in the as
-
cending aorta, an unprotected left main coronary artery that is unsuit -
able for PCI, complex LAD disease, advanced age, low LVEF (
≤30%), 
frailty, diabetes mellitus, renal failure, prior sternotomy, and the lack 
of available bypass conduits. 11. Myocardial infarction with 
non-obstructive coronary arteries
Myocardial infarction with non-obstructive coronary arteries 
(MINOCA) refers to the clinical situation when a patient presents with symptoms suggestive of ACS, demonstrates troponin elevation, 
and has non-obstructive coronary arteries at the time of coronary angi
-
ography (defined as coronary artery stenosis <
50% in any major epicar -
dial vessel). The reported prevalence of MINOCA varies widely across 
studies (from around 1% to 14% of patients with ACS undergoing angi -
ography).533MINOCA can be considered as an umbrella term that en -
compasses a heterogeneous group of underlying causes. This includes both coronary and non-coronary pathologies, with the latter including 
both cardiac and extra-cardiac disorders (
Figure 15).4,18,534–537Recommendation Table 12 — Recommendations for 
management of patients with multivessel disease
Recommendations ClassaLevelb
It is recommended to base the revascularization 
strategy (IRA PCI, multivessel PCI/CABG) on the 
patient’s clinical status and comorbidities, as well as 
their disease complexity, according to the principles of management of myocardial 
revascularization.
480,481I B
Multivessel disease in ACS patients presenting in cardiogenic 
shock
IRA-only PCI during the index procedure is 
recommended.404,505I B
Staged PCI of non-IRA should be considered.cIIa C
ContinuedMultivessel disease in haemodynamically stable STEMI patients 
undergoing PPCI
Complete revascularization is recommended either 
during the index PCI procedure or within 45 days.
508–511,531I A
It is recommended that PCI of the non-IRA is based on angiographic severity.
511,524I B
Invasive epicardial functional assessment of non-culprit segments of the IRA is not 
recommended during the index procedure.III C
Multivessel disease in haemodynamically stable NSTE-ACS 
patients undergoing PCI
In patients presenting with NSTE-ACS and MVD, 
complete revascularization should be considered, preferably during the index procedure.
513,514IIa C
Functional invasive evaluation of non-IRA severity during the index procedure may be 
considered.
518,527,528,532IIb B
©ESC 2023
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; IRA, 
infarct-related artery; MVD, multivessel disease; NSTE-ACS, non-ST-elevation acute 
coronary syndrome; PCI, percutaneous coronary intervention; PPCI, primary 
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence. 
cBased on ischaemia, symptoms, patient comorbidities, and clinical condition.3772                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

When a diagnosis is not established following coronary angiography, 
MINOCA represents a working diagnosis as opposed to a final diagno -
sis. It is vital for clinicians to perform further assessments and investiga -
tions to establish the underlying cause of the MINOCA, which will allow 
a final diagnosis to be established and patients to be managed appropri -
ately. Failure to identify the underlying cause of MINOCA may result in inadequate or inappropriate therapy.
ICA is the recommended definitive diagnostic test for ACS pa -
tients. If the underlying cause of MINOCA is not established using ICA alone, further evaluation using left ventriculography (including measurement of LV end-diastolic pressure), functional assessment with measurement of microvascular function/coronary reactivity, 
and intravascular imaging can be useful to identify the underlying 
cause.
456,538,539The term ‘functional coronary angiography’ refers 
to the combination of coronary angiography with adjunctive tests (e.g. testing for coronary microvascular dysfunction and vasoreactiv
-
ity) (Figure 16).
Non-coronary, cardiac causes
Coronary embolism
Coronary microvascular dysfunctionCoronary spasmCoronary thrombosisMyocardial bridgingPlaque rupture/erosionSpontaneous coronary artery dissectionCoronary causes
Acute respiratory distress syndromeAllergic/hypersensitivity reactionsEnd-stage renal failureIn/f_lammationPulmonary embolismSepsisStrokeNon-cardiac causes
Cardiac traumaCardiomyopathyCardiotoxinsMyocarditisStrenuous exerciseTakotsubo cardiomyopathyTransplant rejectionFigure 15 Underlying causes for patients with a working diagnosis of myocardial infarction with non-obstructive coronary arteries. This figure outlines 
some of the potential differential diagnoses in patients with a working diagnosis of MINOCA after coronary angiography, but this list is not exhaustive.ESC Guidelines                                                                                                                                                                                          3773Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Cath lab
assessment
Step 1
Clinical historyAssessments to considera
Ward
assessment
Step 2
Post discharge
care
Step 3Detailed angiographic 
assessment ± LV
angiography (incl. LVeDP)Physical exam
Intravascular
imaging
(IVUS/OCT)ECG assessment
Assess for coronary
microvascular dysfunction
± vasoreactivity (ACh testing)
Clinical historyAssessments to considera
CMRIPhysical exam
Blood testsbECG assessment
CTPA/CT braincEchocardiography
Assessments to consideraThe MINOCA diagnostic algorithm
Follow-up clinic
evaluationRepeat
echocardiographyRepeat
CMRICardiac
rehabilitationFigure 16 Evaluation of patients with a working diagnosis of MINOCA. ACh, acetylcholine; CMRI, cardiac magnetic resonance imaging; CT, computed 
tomography; CTPA, computed tomography pulmonary angiogram; ECG, electrocardiogram; IVUS, intravascular ultrasound; LV, left ventricular; LVeDP, 
left ventricular end-diastolic pressure; MINOCA, myocardial infarction with non-obstructive coronary arteries; NSTE-ACS, Non-ST elevation acute coron -
ary syndrome; NTpro BNP, N terminal pro brain natriuretic peptide; OCT, optical coherence tomography; STEMI, ST-elevation myocardial infarction; UA, unstable angina. Patients presenting with STEMI present directly to catheter lab as per the current standard of care pathway (1)
. In this context, when non- 
obstructive coronary arteries are identified then further assessment should be considered. When patients are subsequently admitted to the ward then in -
vestigations as shown in (2) should be considered. Patients presenting with NSTE-ACS or UA are often stabilized on the ward (2) prior to transfer to the 
cath lab (1)
. In this context the order in which the investigations are carried out will vary depending on the location these patients are managed during first 
contact. MINOCA patients require follow-up review (3) and may require repeat assessment using echocardiography and magnetic resonance imaging, de -
pending on the initial findings. aOptions for adjunctive tests. Patients will not require all investigations but instead the appropriate tests should be selected 
based on their presentation and clinical course. bExamples of potential blood tests include: full blood count, renal profile, troponin, C-reactive protein, 
D-dimer, NT-pro BNP. cA CT scan of the brain should be considered if a cranial pathology (i.e. intracranial bleed) is suspected that might have resulted 
in ST elevation.3774                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

If the underlying cause of MINOCA is not established using functional 
coronary angiography, then non-invasive imaging (i.e. echocardiog -
raphy, CMR, CT) is recommended, as clinically appropriate. CMR is 
one of the key diagnostic tools to determine the underlying cause of 
MINOCA.540–544CMR can identify the underlying cause in up to 87% 
of patients with a working diagnosis of MINOCA and should be per -
formed as soon as possible after presentation in these patients to maxi -
mize its diagnostic yield, ideally during the index admission.545
Diagnosis of the underlying cause of MINOCA will enable the appro -
priate treatment to be initiated based on the final diagnosis. Secondary prevention therapies should be considered for those with evidence of 
coronary atherosclerotic disease and to control risk factors. The man
-
agement of takotsubo syndrome is not informed by any prospective RCTs, and treatment is largely supportive and empiric.
546,547The treat -
ment of patients with myocarditis has been covered by previous ESC 
documents.548,549Ischemia with non-obstructive coronary arteries 
(INOCA) has also been described in the context of CCS.550,551
Additional information about MINOCA is provided in the Supplementary data online, including Table S13.
12. Special situations
12.1. Type 2 myocardial infarction and 
acute myocardial injury
Pathological processes other than atherothrombosis commonly under -
lie the presentation of patients with acute chest pain with troponin ele -
vation. These include Type 2 MI and myocardial injury as defined in the 
fourth universal definition of MI.1Type 2 MI is an ischaemic myocardial 
injury in the context of a mismatch between oxygen supply and demand 
that is not related to acute coronary atherothrombosis. This may occur 
in the context of atherosclerosis and an oxygen supply/demand imbal -
ance, with an oxygen supply/demand imbalance alone, secondary to vasospasm or coronary microvascular dysfunction, or secondary to 
non-atherosclerotic coronary dissection. These causes of Type 2 MI can be divided into those with underlying coronary (e.g. coronary em
-
bolus, dissection, spasm, microvascular dysfunction) or non-coronary mechanisms (supply demand mismatch due to hypoxia, hypotension, 
anaemia, tachycardia, bradycardia).1Type 2 MI is common and asso -
ciated with a prognosis similar to Type 1 MI.12
Myocardial injury is characterized by myocyte necrosis and tropo -
nin elevation due to mechanisms other than myocardial ischaemia and 
can be acute (e.g. sepsis, myocarditis, takotsubo) or chronic (e.g. HF, 
cardiomyopathies, severe valve heart disease). Myocardial injury is in -
creasingly appreciated in the era of hs-cTn assays, which are not spe -
cific for MI. In patients who have elevated hs-cTn values and do not 
have evidence of acute myocardial ischaemia, a diagnosis of myocar -
dial injury can be made. It is important to recognize that this diagnosis 
can change if subsequent investigations indicate that the patient meets 
the criteria for MI.
Despite some common risk factors, the pathophysiology of Type 2 
MI is different to that of Type 1 MI. Therefore, the natural history and appropriate management strategy of these two conditions also differs 
in some important respects. Type 2 and Type 1 MI require diagnostic 
distinction, which is best achieved by following an algorithmic ap
-
proach.1,553Once patients with suspected Type 2 MI and myocardial 
injury have been stabilized and any precipitating illnesses have been 
treated, targeted echocardiography and/or coronary angiography (in -
vasive or CCTA) can be used to identify contributory (and prognos -
tically important) cardiac conditions and to guide appropriate 
long-term cardiovascular treatments.12Due to the lack of robust sci -
entific evidence investigating management strategies and the wide 
range of precipitating causes, there are currently no specific recom -
mended pharmacological interventions for patients with Type 2 MI. Therefore, management should instead focus on identifying and treat
-
ing any precipitating conditions (e.g. anaemia, hypoxia) alongside strict control of CV risk factors.
12.2. Complications
12.2.1. Heart failure
Acute HF may occur as a complication of ACS. Acute HF as a result of ACS significantly increases the risk of other in-hospital complications, 
including worsening of renal function, respiratory failure, pneumonia, 
and death. De novo acute HF complicating ACS should be distinguished 
from pre-existing HF exacerbated by ACS.
554–556This can be challen -
ging and the presence of acute HF may impede the straightforward 
diagnosis of ACS. Patients with ACS and acute HF are more likely to 
present with resting dyspnoea and clinical signs/symptoms of fluid over -
load. In some clinical scenarios, increased troponin levels in patients with acute HF may reflect myocardial injury due to HF rather than myo
-
cardial necrosis due to ischaemia.
Patients with ACS complicated by acute HF require urgent and co- 
ordinated management of both conditions. The management of acute 
HF should follow current recommendations included in the ESC 
Guidelines on HF and ancillary documents.557–559The use of diuretics, 
vasodilators, inotropic agents, and vasopressors should be considered 
according to the established algorithms. Mechanical circulatory support 
may also be considered in selected cases. Invasive respiratory support 
and/or renal replacement therapy may be required in some circum -
stances.557–559
Patients presenting with acute HF (including patients with CS) com -
plicating ACS require immediate ICA.250,394,396These patients should 
also undergo emergency echocardiography/chest ultrasonography to gather information about LV and RV function, regional wall motion ab
-
normalities, valvular function, and possible mechanical complica -
tions.250,557,560In patients with ACS, CS may occur as a result of Recommendation Table 13 — Recommendations for 
myocardial infarction with non-obstructive coronary 
arteries
Recommendations ClassaLevelb
In patients with a working diagnosis of MINOCA, 
CMR imaging is recommended after invasive 
angiography if the final diagnosis is not clear.544,545I B
Management of MINOCA according to the final established underlying diagnosis is recommended, 
consistent with the appropriate disease-specific 
guidelines.
546,550,552I B
In all patients with an initial working diagnosis of MINOCA, it is recommended to follow a diagnostic algorithm to determine the underlying final diagnosis.I C
©ESC 2023
CMR, cardiac magnetic resonance; MINOCA, myocardial infarction with non-obstructive 
coronary arteries. 
aClass of recommendation. 
bLevel of evidence.ESC Guidelines                                                                                                                                                                                          3775Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

extensive ischaemia due to MVD, acute severe mitral regurgitation, and 
mechanical complications. Patients with ACS and CS should be trans -
ferred as soon as possible to a PCI centre where immediate coronary 
angiography, and PCI of the IRA if needed, can be performed.404,505In 
patients with CS complicating ACS in whom the coronary anatomy is 
not suitable for PCI, emergency CABG is recommended. 
Management of MVD in this context is detailed in Section 10.
The clinical benefit of percutaneous MCS devices and/or VA-ECMO 
in the context of ACS remains unclear.402,561Micro-axial MCS devices 
have not been associated with lower 30-day mortality in comparison to 
IABP in observational studies.400In a large retrospective registry of 48  
306 patients (>80% ACS) undergoing PCI with MCS, micro-axial MCS support was associated with higher mortality and bleeding rates in com
-
parison to IABP.562Similar results were observed in another 
propensity-matched registry analysis confined to patients with CS, where micro-axial MCS support was also associated with more compli
-
cations and higher mortality than IABP.563In the IABP-SHOCK II trial, 
the routine use of IABP in patients with ACS and CS did not reduce 30-day, 1-year, or 6-year mortality.
399,405,407Based on these data, a 
benefit of LVAD in patients with ACS has not been demonstrated, 
and given that observational data have suggested that this may be asso -
ciated with harm, caution is advised in this regard until further RCT evi -
dence is available.
12.2.2. Mechanical complications
Mechanical complications may occur in the first days following MI, 
most commonly in patients presenting with STEMI. The incidence 
of mechanical complications has fallen significantly in the era of 
PPCI.564A recent large epidemiological investigation including almost 
9 million ACS patients reported an overall prevalence of mechanical 
complications in 0.27% of STEMI cases and 0.06% of NSTEMI cases, 
with in-hospital mortality rates of 42.4% and 18%, respectively.564
Mechanical complications are life-threatening and therefore require 
prompt identification and management (Supplementary data online, 
Table S14 ). Sudden hypotension, the recurrence of chest pain, new 
cardiac murmurs suggestive of acute mitral regurgitation or a ven -
tricular septal defect, pulmonary congestion, or jugular vein distension 
should raise suspicion of a mechanical complication. Immediate echo -
cardiographic assessment is indicated when mechanical complications 
are suspected.
The use of temporary MCS for mechanical complications, either to 
improve pre-operative clinical/haemodynamic status or prophylactical -
ly, represents a new trend in management. However, this approach re -
quires more data and evidence in order to determine if it provides a clinical benefit.
565–568Surgery is currently regarded as the treatment 
of choice for patients with ACS and mechanical complications, although 
percutaneous strategies are occasionally used in selected candidates 
with a prohibitive risk profile or contraindications to a surgical ap -
proach.569–572A multidisciplinary approach to the management of 
these patients is of paramount importance, and should apply to all 
stages of care, from the initial stabilization of the patient to discussion 
and application of the therapeutic strategy, including palliative 
care.573,574Patients with ACS-related mechanical complications should 
be considered for IABP while awaiting surgery.
12.2.3. Left ventricular thrombus
While the incidence of LV thrombus following AMI has declined due to advances in reperfusion and antithrombotic therapies, it remains relatively common, particularly following anterior STEMI, where it 
can be present in >9% of patients according to a large 
meta-analysis.
575,576
Echocardiography remains the first-line imaging test for the detec -
tion of LV thrombus. In patients where the apex is not well visualized 
on regular echocardiography, contrast echocardiography may be con -
sidered for improved image quality. CMR is the gold standard imaging 
modality for the diagnosis and assessment of LV thrombi. 
Contemporary CMR data report LV thrombi in up to 6.3% of all 
STEMI patients and in 12.2% of those with anterior STEMI, suggesting that the incidence of LV thrombi may be underestimated with echocar
-
diography.577Patients with LV thrombi that were not evident on echo -
cardiography but were detected by CMR appear to have similar clinical outcomes to patients with LV thrombi that were evident on echocar
-
diography.578Therefore, CMR should be considered in patients with 
equivocal echocardiographic images or in patients considered to be at a particularly high risk of LV thrombus.
The timing of imaging for LV thrombus may also be relevant, given 
that the identification of LV thrombus has been reported to increase 
in the first 2 weeks post-MI.
579While more contemporary data are re -
quired, these data suggest that a high proportion of LV thrombi may 
develop following hospital discharge, indicating that delayed imaging 
at 2 weeks in high-risk patients may be of value.
Once an LV thrombus has been diagnosed, OAC therapy (warfarin 
or NOAC) should be considered for 3–6 months, guided by repeated 
echocardiography or CMR and with consideration of bleeding risk 
and the need for concomitant antiplatelet therapy.580,581However, 
there are a lack of prospective randomized data on the optimal antic -
oagulation regimen, anticoagulation duration, and the combination of 
oral anticoagulation with antiplatelet agents in patients with LV 
thrombus following MI.581The choice of therapy should be tailored 
to the patient’s clinical status and the results of follow-up investigations.
12.2.4. Post-acute coronary syndrome pericarditis
Pericardial complications that may develop after an AMI include early infarct-associated pericarditis (occurring from a few hours to 4 days after AMI, mostly transient), late pericarditis or post-cardiac injury 
(Dressler) syndrome (typically occurring 1–2 weeks after AMI), and 
pericardial effusion.
548,582This topic is discussed further in the 
Supplementary data online.
12.2.5. Arrhythmias
12.2.5.1. Atrial fibrillation
Atrial fibrillation is the most frequent supraventricular arrhythmia in pa -
tients with ACS.583AF may be pre-existing, first time detected, or of 
new onset during ACS management. Patients with AF have a greater 
number of comorbidities compared with patients without AF and are 
at higher risk of complications.584In most cases, AF is well tolerated 
and no specific treatment is required, apart from anticoagulation.585
Prompt treatment is required for AF causing acute haemodynamic in -
stability, with electrical cardioversion being the preferred approach. 
Adequate rate control can be achieved by administration of beta- 
blockers depending on the presence of HF and low ejection fraction. 
For patients with depressed LVEF, amiodarone or digoxin could be 
used (preferably amiodarone). In cases of hypotension, digoxin is pre -
ferred over amiodarone or beta-blockers. Patients with AF and risk fac -
tors for thrombo-embolism should be adequately treated with chronic oral anticoagulation.
585ACS patients with documented AF of any 3776                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

length have worse short- and long-term prognoses when compared 
with patients in sinus rhythm.584,586There is some evidence to suggest 
that transient, self-terminating AF during STEMI may be a predictor of 
an increased risk of stroke during long-term follow-up.584,587
12.2.5.2. Ventricular arrhythmias
With the widespread increased uptake of emergency reperfusion ther -
apies for patients with STEMI, the incidence of malignant arrhythmias (ventricular tachycardia [VT] and ventricular fibrillation [VF]) has signifi
-
cantly declined. Nevertheless, 6–8% of patients with STEMI develop haemodynamically significant VT or VF.
588The typical arrhythmia presen -
tation is unstable, frequently polymorphic, and relatively fast VT, often degenerating into VF. Urgent reperfusion is most important as ischaemia 
is often the trigger for these arrhythmias. Early administration of i.v. or 
oral beta-blockers reduces the incidence of malignant arrhyth
-
mias.163,164,169,589Beta-blockers or amiodarone are recommended if ma -
lignant arrhythmias occur and lidocaine may be considered if these are contraindicated.
163,164,169,589,590The prognostic role of early VT/VF 
within the first 48 h of STEMI is still controversial. Several studies have suggested that patients with early VT/VF have increased 30-day mortality 
but no increase in long-term arrhythmic risk.
591–593Another study has 
suggested that while malignant ventricular arrhythmias occurring at the 
time of reperfusion do not confer poor prognosis, sustained VT or VF 
occurring during ongoing ischaemia or late after reperfusion (>48 h) is 
associated with an increase in long-term mortality.594Sustained VT/VF 
late after reperfusion (>48 h) requires an evaluation for ICD implant -
ation for secondary prevention of sudden cardiac death. Ventricular pre -
mature beats are very frequent during the first 24 h after reperfusion for 
STEMI and no specific therapy is required.
Primary prevention of sudden cardiac death with ICD implantation 
within 40 days after MI is generally not indicated. Patients should be re- 
evaluated for ICD implantation post-revascularization after a period of 
6–12 weeks on evidence-based treatments, although patients with a 
pre-existing impaired LVEF may be considered for ICD implantation 
for primary prevention even within the early post-infarction period. 
Some patients may develop electrical storm and/or incessant VT des -
pite complete revascularization and treatment with anti-arrhythmic 
drugs. Overdrive stimulation may help to control this situation; how -
ever, recurrence of VT/VF upon cessation of stimulation is frequent 
and catheter ablation of such triggers appears to be the preferred treat -
ment option in centres with that expertise. Successful radiofrequency 
ablation has been shown to abolish recurrent VT/VF.595
Non-sustained monomorphic VT is the most common form of ven -
tricular arrhythmia in the early phase of ACS, and usually does not re -
quire anti-arrhythmic treatment. Accelerated idioventricular rhythm at 
reperfusion is frequent and does not require intervention given its be -
nign nature.596
12.2.6. Bleeding
Bleeding is associated with a poor prognosis in ACS patients.231,597,598
The mechanisms by which bleeding increases the risk of death are com -
plex and multifactorial.599While intracranial or massive haemorrhage 
directly threatens life through fatal brain damage or sudden cardiocir -
culatory collapse, other less severe forms of haemorrhage may increase 
the risk of death through indirect mechanisms. Blood transfusion may 
increase systemic inflammation and represents one of the possible links 
between bleeding and subsequent mortality.600Bleeding is also a major 
driver of unplanned DAPT discontinuation and the interruption of 
other medication (e.g. statins, beta-blockers).601,60212.2.6.1. Management of bleeding
See Supplementary data online, Section 12.1.3.1.
Recommendation Table 14 — Recommendations for 
acute coronary syndrome complications
Recommendations ClassaLevelb
Heart failure
IABP should be considered in patients with 
haemodynamic instability/cardiogenic shock due to ACS-related mechanical complications.IIa C
LV thrombus
CMR imaging should be considered in patients with 
equivocal echocardiographic images or in cases of 
high clinical suspicion of LV thrombus.
577,578IIa C
Oral anticoagulant therapy (VKA or NOAC) should be considered for 3–6 months in patients with 
confirmed LV thrombus.
603IIa C
Following an acute anterior MI, a contrast echocardiogram may be considered for the detection of LV thrombus if the apex is not well 
visualized on echocardiography.
604IIb C
Atrial fibrillation
Intravenous beta-blockers are recommended when 
rate control is needed in the absence of acute HF or 
hypotension.605I C
Intravenous amiodarone is recommended when rate control is needed in the presence of acute HF and no 
hypotension.
606I C
Immediate electrical cardioversion is recommended in patients with ACS and haemodynamic 
instability and when adequate rate control 
cannot be achieved promptly with pharmacological 
agents.I C
Intravenous amiodarone is recommended to facilitate electrical cardioversion and/or decrease risk 
for early recurrence of AF after electrical 
cardioversion in unstable patients with recent-onset AF.
607,608I C
In patients with documented de novo AF during the 
acute phase of ACS, long-term oral anticoagulation 
should be considered depending on the CHA 2DS2- 
VASc score, after taking the HAS-BLED score and 
the need for concomitant antiplatelet therapy into 
consideration. NOACs are the preferred 
drugs.583,584,587IIa C
Ventricular arrythmias
ICD therapy is recommended to reduce sudden 
cardiac death in patients with symptomatic HF 
(NYHA Class II–III) and LVEF ≤35% despite optimal 
medical therapy for >3 months and at least 6 weeks 
after MI who are expected to survive for at least 1 year with good functional status.
434,609,610I A
ContinuedESC Guidelines                                                                                                                                                                                          3777Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

12.3. Comorbid conditions
12.3.1. Patients at high bleeding risk and with blood 
disorders (anaemia and thrombocytopaenia)
Anaemia is more prevalent in elderly/frail ACS patients and in patients 
with multimorbidity (i.e. HF, chronic kidney disease [CKD], diabetes mellitus, cancer, and autoimmune diseases). In some cases, severe an
-
aemia may precipitate Type 2 MI. Persistent or worsening anaemia in patients with ACS is associated with an increased risk of recurrent is
-
chaemic events, death, and major bleeding.623–625According to the 
ARC-HBR, haemoglobin <11 g/dL at the time of PCI constitutes a ma -
jor criterion for HBR, whereas haemoglobin between 11 and 13 g/dL 
(12 g/dL for women) is a minor criterion.
There is no established strategy for treating anaemia in patients with 
ACS. The efficacy and safety of blood transfusion in this clinical scenario 
remains unknown. In the majority of studies investigating different transfusion protocols, a liberal blood transfusion strategy has been de
-
fined as any red blood cell transfusion at a haemoglobin level <
9–10 g/ 
dL, while a restrictive blood transfusion strategy has been defined as any 
transfusion at a haemoglobin level <7–8 g/dL. Observational data sug -
gest that a liberal blood transfusion strategy may be associated with an 
increase in all-cause mortality.626–630The open-label Restrictive and 
Liberal Transfusion Strategies in Patients With Acute Myocardial 
Infarction (REALITY) trial enrolled 668 ACS patients who were rando -
mized to management with a restrictive (triggered by haemoglobin ≤
8) 
or a liberal (triggered by haemoglobin ≤10) transfusion strategy.631The 
composite outcome (all-cause death, stroke, recurrent MI, or emer -
gency revascularization) at 30 days occurred in a comparable number 
of patients in both arms (11% vs. 14%, RR 0.79, with a one-sided 
97.5% CI of 0.00–1.19), meeting the pre-specified non-inferiority criter -
ion. All components of the composite endpoint were numerically high -
er in the liberal transfusion strategy arm. The trial was not powered to detect superiority of the restrictive strategy, and the CI included what 
may be a clinically important harm. The pre-specified 1-year follow-up 
of the REALITY trial yielded contradictory conclusions to the 30-day 
outcomes: at 1 year, the restrictive transfusion strategy (vs. a liberal Intravenous beta-blocker and/or amiodarone 
treatment is recommended for patients with 
polymorphic VT and/or VF unless 
contraindicated.611–614I B
Prompt and complete revascularization is recommended to treat myocardial ischaemia that 
may be present in patients with recurrent VT and/or 
VF.
368,388I C
Transvenous catheter pacing termination and/or 
overdrive pacing should be considered if VT cannot 
be controlled by repeated electrical cardioversion.IIa C
Radiofrequency catheter ablation at a specialized ablation centre followed by ICD implantation should 
be considered in patients with recurrent VT, VF, or 
electrical storm despite complete revascularization 
and optimal medical therapy.IIa C
Treatment of recurrent VT with haemodynamic 
relevance (despite repeated electrical cardioversion) 
with lidocaine may be considered if beta-blockers, amiodarone, and overdrive stimulation are not 
effective/applicable.
615IIb C
In patients with recurrent life-threatening ventricular arrhythmias, sedation or general 
anaesthesia to reduce sympathetic drive may be 
considered.
616IIb C
ICD implantation or the temporary use of a wearable 
cardioverter defibrillator may be considered <40 
days after MI in selected patients (incomplete 
revascularization, pre-existing LVEF dysfunction, 
occurrence of arrhythmias >48 h after STEMI onset, 
polymorphic VT or VF).IIb C
Treatment of asymptomatic and haemodynamically 
irrelevant ventricular arrhythmias with 
anti-arrhythmic drugs is not recommended.III C
Bradyarrhythmias
In cases of sinus bradycardia with haemodynamic 
intolerance or high-degree AV block without stable 
escape rhythm:
•i.v. positive chronotropic medication (adrenaline, 
vasopressin, and/or atropine) is 
recommended.617,618I C
•temporary pacing is recommended in cases of 
failure to respond to atropine.I C
•urgent angiography with a view to revascularization is recommended if the patient 
has not received previous reperfusion therapy.I C
Implantation of a permanent pacemaker is recommended when high-degree AV block does not resolve within a waiting period of at least 5 days 
after MI.I C
ContinuedIn selected patients with high-degree AV block in the 
context of an anterior wall MI and acute HF, early 
device implantation (CRT-D/CRT-P) may be 
considered.619,620IIb C
Pacing is not recommended if high-degree AV block resolves after revascularization or spontaneously.
620–622III B
©ESC 2023
ACS, acute coronary syndrome; AF, atrial fibrillation; AV, atrioventricular; CHA 2DS2-VASc, 
Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes, previous Stroke/ 
transient ischaemic attack/thrombo-embolism (doubled), Vascular disease, Age: 65–74, 
Sex (female); CMR, cardiac magnetic resonance; CRT-D/CRT-P, cardiac 
resynchronization therapy—defribillator/pacemaker; HAS-BLED, Hypertension, 
Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile 
INR, Elderly, Drug/alcohol usage; HF, heart failure; IABP, intra-aortic balloon pump; ICD, 
implantable cardioverter defibrillator; LV, left ventricular; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulant; 
NYHA, New York Heart Association; STEMI, ST-elevation myocardial infarction; VF, ventricular fibrillation; VKA, vitamin K antagonist; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.3778                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

approach) did not achieve non-inferiority in terms of MACE. In add -
ition, a post-hoc analysis of MACE between day 30 and 1 year demon -
strated an increased risk in the restrictive transfusion strategy group.632
Therefore, no formal recommendation as to the optimal transfusion 
strategy (liberal vs. restrictive) in patients with ACS can be made at present.
Although there are several classifications to grade the severity 
of thrombocytopaenia, clinically relevant thrombocytopaenia can 
be defined as a platelet count <100 000/μL or a relative drop in platelet 
count of 50% from baseline in the context of ACS. Thrombocytopaenia 
increases the risk of death, major bleeding events, and life-threatening 
thrombotic events.
633,634The ARC-HBR criteria define a platelet count 
<100 000/μL as a major criterion for HBR. Management of GP IIb/IIIa 
inhibitor- and heparin-induced thrombocytopaenia is discussed in the 
Supplementary data online.
12.3.2. Chronic kidney disease
Moderate to severe CKD (stages III–V) is present in more than 30% of 
ACS patients.635Patients with ACS and concomitant CKD receive less 
interventional and pharmacological treatment and have a worse prog -
nosis than patients with normal kidney function.636–638Likely contrib -
uting factors to this worse prognosis include a larger number of 
comorbidities and an increased risk of in-hospital complications, includ -
ing serious bleeding complications.639Although evidence from RCTs is 
lacking, data from observational and registry-based studies indicate that ACS patients with moderate to severe CKD have a better 
prognosis with early revascularization than with medical therapy 
alone.
640,641
The type and dose of antithrombotic agent (see Supplementary data 
online, Table S15 ) and the amount of contrast agent should be consid -
ered based on kidney function.635,642In relation to supplementary i.v. 
hydration during and after revascularization, the evidence around choice, timing, and duration of treatment is somewhat conflicting.
643
Taking the clinical circumstances and patient characteristics into consid -
eration, i.v. hydration should be considered as part of the management of ACS patients with a low eGFR undergoing invasive management to 
minimize the risk of contrast-induced nephropathy.
250,635,642,644,645For 
recommendations on long-term treatment in patients with ACS and 
concomitant CKD, please refer to the 2021 ESC Guidelines on cardio -
vascular disease prevention.646
12.3.3. Diabetes mellitus
ACS patients with diabetes mellitus (DM) may more commonly pre -
sent with non-specific symptoms, which can lead to delays in both diag -
nosis and access to treatment.647,648Both treatment in the acute phase 
and risk factor management post-ACS is poorer in patients with DM and these patients tend to have more advanced CAD at diagnosis. 
These factors likely contribute to the worse long-term prognosis asso
-
ciated with ACS in patients with DM, particularly in patients requiring insulin treatment.
649–651
All patients with ACS, regardless of a history of DM, should have 
their glycaemic status evaluated during hospitalization. Given that 
the ACS itself may give rise to hyperglycaemia due to catechol -
amine-induced stress, a diagnosis of DM made during hospitalization 
should be subsequently confirmed. While several studies have shown 
the benefits of managing hyperglycaemia (
>11.0 mmol/L or 200 mg/ 
dL) in hospitalized ACS patients, the risk of hypoglycaemia-related 
events when using intensive insulin therapy should not be ne -
glected.652–654Glucose lowering is important in order to prevent microvascular 
complications in patients with DM. However, recent trial evidence has shown that the reduction in the risk of new ACS events, HF, 
and renal impairment with glucose-lowering medications like so
-
dium–glucose co-transporter 2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1-RA) is independent of baseline 
glycosylated haemoglobin (HbA1c) levels.
655–657This should be taken 
into consideration when choosing glucose-lowering therapy for pa -
tients with DM and concomitant CAD. For further details, please re -
fer to the 2023 ESC Guidelines on diabetes and cardiovascular diseases and the 2021 ESC Guidelines on cardiovascular disease 
prevention.
646,658
12.3.4. Older adults with frailty and multimorbidity
12.3.4.1. The older person
Older adults represent an increasing proportion of ACS patients. One 
of the major predictors of adverse outcomes following ACS is age, but patients aged ≥75 years are often excluded from or under-represented 
in clinical trials.
659,660Older age is associated with frailty, multimorbid -
ity, and a greater risk of both ischaemic and bleeding events in patients 
with ACS.661Hs-cTn assays have an excellent diagnostic performance 
in the older person, but the specificity of the test is lower than in young -
er patients, and elevated cTn levels are more commonly associated with 
conditions other than ACS in older patients.662
There are limited data on the optimal management of older adults 
with ACS.663A small RCT enrolling older patients (≥80 years) with 
NSTE-ACS reported the superiority of an invasive vs. a conservative 
strategy in the reduction of the composite of MI, need for urgent revas -
cularization, stroke, and death. No treatment effect was shown for all- 
cause death and the benefit associated with the invasive strategy was 
diluted with increasing age.664In the absence of robust clinical trial 
evidence, decisions regarding how to manage older patients should 
be individualized based on patient characteristics (i.e. ischaemic and 
bleeding risks, estimated life expectancy, comorbidities, the need for 
non-cardiac surgery, quality of life, frailty, cognitive and functional im -
pairment, patient values and preferences, and the estimated risks and benefits of an invasive strategy).
In the context of STEMI, PPCI has drastically improved outcomes for 
all ages. However, data are limited in the ‘very old’ cohort, with lack of formal assessment of frailty or comorbidity.
665In the context of CS and 
cardiac arrest, age is an independent predictor of mortality following PCI.
666,667In the absence of robust RCT data, PPCI should be consid -
ered for all patients with STEMI. When PPCI cannot be performed in a timely manner, fibrinolysis may be a reasonable strategy in these pa
-
tients. For details regarding pharmacotherapy in older patients, please see the 
Supplementary data online.
12.3.4.2. Frailty and multimorbidity
Geriatric syndromes (i.e. frailty and multimorbidity) are associated with adverse outcomes in older patients with ACS.
668,669Frailty is a syn -
drome characterized by reduced biological reserve, leading to a failure of homeostatic mechanisms following stressor events, including ACS. 
There is a lack of consensus on which frailty assessment tool is optimal 
in older patients with CV disease.
670,671
Frail patients with NSTE-ACS less frequently receive ACS pharma -
cotherapies and invasive assessment, have more complex coronary dis -
ease, have longer durations of hospital stay, and are at higher risk of 
death.672Specifically, frail patients are reported to have a higher rate 
of a composite of all-cause mortality, MI, stroke, unplanned ESC Guidelines                                                                                                                                                                                          3779Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

revascularization, and major bleeding.673Frail older adults with 
NSTE-ACS have poor health-related quality of life (HRQoL) at baseline. 
Invasive management appears to be associated with modest improve -
ments in HRQoL through to 1 year follow-up in these patients. This im -
provement in HRQoL is most marked in frail and pre-frail patients, who 
receive a proportionally larger benefit than robust patients.674In older 
adults with NSTE-ACS referred for coronary angiography, the pres -
ence of multimorbidity is associated with an increased risk of long-term adverse CV events, driven by a higher risk of all-cause mortality.
675
Undiagnosed cognitive impairment is also common in older patients 
with NSTE-ACS undergoing ICA, and these patients are more likely to experience MACE at 1 year.
676
In the absence of robust RCT data to inform healthcare professionals 
about the management of frail patients presenting with ACS, it is re -
commended to adapt a holistic approach to individualize interventional 
and pharmacological treatments after careful evaluation of risks vs. ben -
efits. To aid in decision-making, the routine assessment of frailty (e.g. Rockwood Frailty Score) and comorbidity (e.g. Charlson index) in 
ACS patients is recommended. Following risk stratification using frailty assessment and evaluation of the comorbidity burden, it may be rea
-
sonable to offer optimal medical therapy plus an invasive strategy to frail patients at high risk of future CV events and low risk of complications, 
and to offer optimal medical therapy alone to those who are deemed to 
be at low risk of future events with a high risk of developing procedural complications. For those patients for whom any form of treatment 
might be futile, then a palliative end-of-life care approach should be 
considered.
12.3.5. Pregnancy
Acute coronary syndrome diagnostic criteria are the same for preg -
nant and non-pregnant patients.677Pregnant women with STEMI 
should not be managed differently to non-pregnant women. Given 
the high mortality associated with STEMI in pregnancy, PPCI is the 
preferred reperfusion therapy.678The management plan for pregnant 
women with ACS should be determined by a multidisciplinary team 
consisting of cardiologists, obstetricians, anaesthesiologists, and neo -
natologists, and these patients should be treated in an intensive care unit that can provide maternal monitoring and obstetric care.
678,679
ACS treatment should not be delayed for delivery. Delivery should be ideally postponed for at least 2 weeks post-ACS as there is in
-
creased risk of maternal mortality during this time.678It has been de -
monstrated that SCAD is the most common cause of AMI in pregnancy, and this tends to occur mainly in the late pregnancy or 
early post-partum periods.
680,681Further details are provided in the 
Supplementary data online.
12.3.6. Drug abuse
Acute coronary syndrome in the setting of drug abuse is covered in the 
Supplementary data online.
12.3.7. Patients with cancer
The four most common types of cancer in patients with ACS are pros -
tate, breast, colon, and lung.682Patients with a history of cancer should 
be treated like all other ACS patients, but the management of ACS pa -
tients with active cancer has some specific issues that need to be taken 
into consideration. Outcomes vary across types of cancer and the balance between the ischaemic and bleeding risks should be considered 
on an individual basis.
The percentage of ACS patients with a current diagnosis of cancer is 
rising, and currently constitutes ∼
3% of patients in large observational 
studies.683Patients with active cancer presenting with ACS pose im -
portant challenges as there are significant gaps in scientific knowledge. 
Therefore, recommendations based on solid evidence are scarce. 
Patients with active cancer presenting with ACS tend to be older, 
with a larger number of comorbidities and more extensive CAD. 
These patients often have concomitant haematologic and coagulation 
abnormalities that may present a challenge with respect to both the use of antithrombotic therapy and the performing of PCI.
684
Observational studies have reported that ACS in patients with cancer is associated with increased risk of major CV events, bleeding, and car
-
diac and non-cardiac mortality.682,683,685,686As per the ARC-HBR cri -
teria, patients with active cancer diagnosed in the past 12 months are considered as HBR.
The diagnosis of ACS in patients with cancer should be based on the 
same principles as in patients without cancer. The management of ACS 
in patients with cancer can be challenging because of frailty, increased 
bleeding risk, thrombocytopaenia, and increased thrombotic risk.687
Temporary interruption of cancer treatment and an urgent multidiscip -
linary approach is recommended.688Cancer patients with ACS have 
been reported to less frequently undergo invasive management; how -
ever, invasive management (and PCI with DES if needed) is recom -
mended in ACS patients with cancer, as long as the prognosis is >
6 
months or, irrespective of the prognosis, if the patient is unstable.689
Retrospective data have reported both a lower use of invasive manage -
ment in cancer patients with STEMI, and better outcomes in patients 
who do undergo invasive management.682,686,689Invasive management 
in patients with advanced cancer or life expectancy <6 months has 
been reported to not demonstrate a mortality benefit compared 
with a conservative approach and therefore a conservative strategy 
should be considered in these patients.690When the coronary anatomy 
is not amenable for PCI, CABG surgery can be considered after a multi -
disciplinary team discussion and where the cancer prognosis is >
12 
months. Given that they are considered to be HBR, the preferred 
P2Y 12 inhibitor for ACS patients with active cancer is clopidogrel.687
Potential drug–drug interactions with cancer therapies should be 
checked when using ticagrelor or clopidogrel, since some 
pharmacokinetic-based drug–drug interactions via CYP450 may occur.
When acute ischaemia is provoked by cancer therapy, alternative 
cancer therapies should be considered after a multidisciplinary team 
discussion. Some specific cancer treatments can have cardiotoxic vas -
cular effects that can lead to ACS ( Supplementary data online, 
Table S16 ). Following ACS, a review of the cancer medications is re -
commended, and any cancer drug associated with thrombosis and MI 
should be stopped. Cancer therapies that are not associated with MI 
can be restarted once revascularization (when indicated) has been com -
pleted and the patient is stabilized on ACS medical therapy without 
complications. Additional information can be found in the 
Supplementary data online, including Supplementary data online, 
Table S16 and in the 2022 ESC Guidelines on cardio-oncology.684
12.3.8. Coronavirus disease (COVID-19)
A section on the impact of Coronavirus disease (COVID-19) on ACS management is presented in the Supplementary data online.3780                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

13. Long-term treatment
Secondary prevention after ACS is central to increase quality of life and 
to decrease morbidity and mortality. This should start as early as pos -
sible after the index event.716–718The topic is covered in detail in the 
2019 CCS Guidelines and the 2021 Prevention Guidelines.195,646
Optimal medical therapy and treatment targets are well defined and are summarized in Figure 17
. A figure aimed at educating patients on im -
proving their ‘heart health’ after an ACS event is provided in the 
Supplementary data online, Figure S5.Recommendation Table 15 — Recommendations for 
acute coronary syndrome comorbid conditions
Recommendations ClassaLevelb
Chronic kidney disease
The use of low- or iso-osmolar contrast media (at 
the lowest possible volume) is recommended for 
invasive strategies.691–693I A
It is recommended to assess kidney function using eGFR in all patients with ACS.I C
It is recommended to apply the same diagnostic and therapeutic strategies in patients with CKD (dose 
adjustment may be necessary) as in patients with 
normal kidney function.I C
Hydration during and after angiography should be considered in patients at risk of contrast-induced nephropathy, especially in patients with acute kidney 
injury and/or CKD with eGFR <30 mL/min/ 
1.73 m
2.694–697IIa B
Diabetes
It is recommended to base the choice of long-term 
glucose-lowering treatment on the presence of comorbidities, including heart failure, CKD, and 
obesity.
698–704I A
It is recommended to assess glycaemic status at initial evaluation in all patients with ACS.
705–707I B
It is recommended to frequently monitor blood glucose levels in patients with known diabetes 
mellitus or hyperglycaemia (defined as glucose levels ≥11.1 mmol/L or ≥200 mg/dL).I C
Glucose-lowering therapy should be considered in patients with ACS with persistent hyperglycaemia, 
while episodes of hypoglycaemia should be 
avoided.
708,709IIa C
Older adults
It is recommended to apply the same diagnostic and 
treatment strategies in older patients as in younger 
patients.662,664,665,710,711I B
It is recommended to adapt the choice and dosage of antithrombotic agent, as well as of secondary 
prevention medications, to renal function, 
co-medications, comorbidities, frailty, cognitive 
function, and specific contraindications.
363,712I B
For frail older patients with comorbidities, a holistic 
approach is recommended to individualize 
interventional and pharmacological treatments after 
careful evaluation of the risks and benefits.668,673,676I B
ContinuedPatients with cancer
An invasive strategy is recommended in cancer 
patients presenting with high-risk ACS with expected 
survival ≥6 months.682,689,690I B
A temporary interruption of cancer therapy is recommended in patients in whom the cancer therapy is suspected to be a contributing cause of 
ACS
c.713,714I C
A conservative non-invasive strategy should be considered in ACS patients with poor cancer 
prognosis
d (i.e. with expected survival <6 months) 
and/or very high bleeding risk.690IIa C
Aspirin is not recommended in cancer patients with a platelet count <10 000/μL.
715III C
Clopidogrel is not recommended in cancer patients with a platelet count <30 000/μL.III C
In ACS patients with cancer and <50 000/μL platelet 
count, prasugrel or ticagrelor are not recommended.III C
©ESC 2023
ACS, acute coronary syndrome; CKD, chronic kidney disease; eGFR, estimated glomerular 
filtration rate. 
aClass of recommendation. 
bLevel of evidence. 
cAnticancer therapies associated with high risk of ACS (very common [>10%]) include: 
capecitabine, paclitaxel, cisplatin, carfilzomib, bevacizumab, ramucirumab, aflibercept, 
axitinib, sorafenib, pazopanib, cabozantinib, lenvatinib, ponatinib, and erlotinib. 
dRelated to advanced cancer stage and/or severe irreversible non-CV comorbidities.ESC Guidelines                                                                                                                                                                                          3781Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Smoking cessation
Healthy diet
Regular exercise
Healthy weight
Support healthy 
lifestyle choices
Continue optimal
pharmacological  and
cardio-protective treatment
Reach and sustain risk 
factor treatment targets
Discharge on cardio-
protective medications,
start lifestyle management
and refer to cardiac rehabArrange OPD review to  
manage comorbidities  
and discuss patient goals  
and preferences
1
 2
 3
Psychosocial
managementAntithrombotic
therapy
Lipid-lowering
therapy
Annual influenza
vaccinationLong term treatment after ACS
Treatment goals
Promote drug
adherence and
persistence
+
other treatments
as appropriatea
Systolic BP
<130 mmHg 
and diastolic 
BP <80 mmHg
(if tolerated)b
LDL-C <1.4 mmol/L 
(<55 mg/dL)
HbA1c <53 mmol/mol 
(<7%)c
Figure 17 Long-term management after acute coronary syndrome. ACS, acute coronary syndrome; HbA1c, glycosylated haemoglobin; LDL-C, low- 
density lipoprotein cholesterol; OPD, outpatient department. aSee Recommendation Table 16 for other pharmacological treatments after ACS. bFor pa -
tients ≥
70 years of age the systolic target should be <140 mmHg and down to 130 mmHg if tolerated.646cFor patients with diabetes mellitus.3782                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

13.1. Cardiac rehabilitation
13.1.1. Comprehensive cardiac rehabilitation
Secondary prevention is most effectively provided through cardiac re -
habilitation (CR).716,717All ACS patients should participate in a com -
prehensive CR programme, which should start as early as possible 
after the ACS event.716,717,719CR may be performed in inpatient or 
outpatient settings, taking age, frailty, results of prognostic risk stratifi -
cation, and comorbidities into account.716Comprehensive CR is a 
multidisciplinary intervention, supervised and performed by a team and usually co-ordinated by a cardiologist.
716The core components 
of CR include patient assessment, management and control of CV risk factors, physical activity counselling, prescription of exercise train
-
ing, dietary advice, tobacco counselling, patient education, psychosocial management, and vocational support.
716Several studies have found 
that CR programmes after atherosclerotic cardiovascular disease (ASCVD) events or revascularization reduce CV hospitalizations, MI, 
CV mortality and, in some studies, all-cause mortality.
720–725Despite 
proven benefits, the rates of referral to, participation in, and implemen -
tation of CR programmes are low.726–730Another identified issue is 
that many patients adopt healthier lifestyles during CR but relapse to 
pre-morbid habits when returning to everyday life.731Therefore, there 
is an unmet need for complementary pathways to the classical centre- based CR model. In addition to alternatives to CR, there is also a need 
for stronger endorsement of CR by physicians, cardiologists, and 
healthcare professionals.
732,733It is also important to initiate and estab -
lish a strong partnership between patients and healthcare professionals as early as possible.
732–734
13.1.2. Digital health
Telerehabilitation may be an effective strategy to maintain a healthy life -
style over time and can support or even partially replace conventional, centre-based CR.
729Telerehabilitation means rehabilitation from a dis -
tance, covering all CR core components, including telecoaching, social interaction, telemonitoring, and e-learning.
735,736Studies in patients 
with CAD have shown that telerehabilitation can be equivalent to trad -
itional CR in terms of achieving functional improvement, managing risk 
factors, and increasing patient well-being.737–741Few data are available 
about the effect of telerehabilitation on recurrent events.742
Nevertheless, in a meta-analysis no significant difference was found be -
tween mortality following telehealth interventions and centre-based 
supervised CR.743Also, most trials have only focused on one of the 
CR core components—exercise training and/or physical activity.742
Therefore, more research on the impact of telerehabilitation on out -
comes is still needed, as are investigations into health and digital literacy in CR.
13.1.3. Adherence and persistence
Promotion of both adherence (the extent to which a patient adheres to 
a prescribed treatment or lifestyle advice) and persistence (the length of 
time between initiation and discontinuation of a prescribed treatment 
or lifestyle advice) are key in preventing recurrent CV events after ACS. 
Adherence to medication has been shown to be sub-optimal, ranging 
from 50% in primary prevention to 66% in secondary prevention. It 
is estimated that 9% of ASCVD events in Europe occur as a result of 
sub-optimal medication adherence.646Contributors to sub-optimal ad -
herence and persistence are multidimensional and include: polyphar -
macy, drug regimen complexity, the doctor–patient relationship, a 
lack of patient-centred care and disease acceptance, concern regarding 
side effects, cognitive ability, mental and physical disorders, financial aspects, living alone, and depression.646,744–749Polypills, which include 
guideline-recommended treatments for secondary prevention, have been shown to increase adherence in post-ACS patients and may im
-
prove therapeutic targets.750–752The Secondary Prevention of 
Cardiovascular Disease in the Elderly (SECURE) study is the only RCT testing the impact of a strategy based on a polypill (containing as
-
pirin, ramipril, and atorvastatin) vs. usual care on hard outcomes in ACS 
patients. The polypill strategy was associated with a significant reduc -
tion in major CV events, driven by a significant 33% reduction in CV 
mortality.753The use of technology to improve medication adherence 
is also generating interest: mobile phone applications and mobile health (mHealth) tools may improve medication adherence, but clinical trials 
of sufficient size and duration are needed.
754–756Finally, it is important 
to recognize that adherence has complex underlying psychological dri -
vers, and therefore a whole-systems approach is mandatory. This should include the education of health professionals, the use of patient- 
reported outcomes and experience measures, patient education, and 
patient-centred care.
734,757,758
13.2. Lifestyle management
Lifestyle management is one of the cornerstones of comprehensive 
CR.716While most of the evidence regarding the benefits of a 
healthy lifestyle on prognosis comes from primary prevention, studies in secondary prevention settings indicate similar beneficial 
effects.
716,724,759–763
13.2.1. Tobacco
Tobacco abstinence is associated with a reduced risk of re-infarction 
(30–40%) and death (35–45%) after ACS.763–765Measures to promote 
cessation of smoking are therefore a priority after ACS. Interventions 
for smoking cessation should begin during hospitalization using a com -
bination of behavioural interventions, pharmacotherapy, and counsel -
ling.18,766Many patients continue or resume smoking after ACS, in 
particular patients with depression and environmental exposures.646
During encounters with smokers, the ‘very brief advice’ evidence-based 
intervention should be used to facilitate dialogue between the patient 
and healthcare worker.646Drug interventions, including nicotine- 
replacement therapy (NRT), bupropion and varenicline, should be con -
sidered along with behavioural support. All forms of NRT are effective, 
and the anti-depressant bupropion aids in long-term smoking cessation 
with similar efficacy to NRT.646,766Varenicline is the most effective 
medical treatment to support smoking cessation and is safe to use in ACS patients.
767–770An average weight gain of 5 kg can be expected 
when a person quits smoking, but it is important to recognize that the CV risk from continued smoking outweighs the CV risk from gain
-
ing weight.646
E-cigarettes have been used to help smokers quit, but evidence on 
their impact on successful smoking cessation is insufficient, particularly with regard to whether using e-cigarettes actually helps the person re
-
main tobacco free. While e-cigarettes do contain nicotine, they do not contain as many tobacco chemicals as cigarettes. Caution should be gi
-
ven with respect to the use of e-cigarettes, as current evidence suggests they are harmful to CV health by increasing arterial stiffness, heart rate and blood pressure, and by causing endothelial dysfunction.
771
13.2.2. Nutrition and alcohol
A healthy diet and eating habits influence CV risk. Adopting a Mediterranean-style diet can help reduce CV risk in all individuals, in
-
cluding persons at high CV risk and patients with ASCVD.761,762,772ESC Guidelines                                                                                                                                                                                          3783Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Supplementary data online, Table S17 summarizes the characteristics of 
a healthy diet that should be adhered to. For further details on nutrition, 
please refer to the 2021 ESC Guidelines on cardiovascular disease 
prevention.646
With regard to alcohol consumption, recent data suggest that alco -
hol abstainers have the lowest risk of CVD outcomes, that any amount 
of alcohol uniformly increases blood pressure and body mass index, and 
that a weekly consumption of >
100 g of alcohol is associated with de -
creased life expectancy.773–775Accordingly, it is recommended to re -
strict alcohol consumption to a maximum of 100 g per week (same 
limit for men and women).646
13.2.3. Physical activity and exercise
Based on extensive data from the general population, sedentary behav -
iour, defined as time spent sitting or lying with low energy expenditure, while awake, is an independent risk factor for all-cause mortality.
776,777
According to recommendations from the World Health Organization, adults with chronic conditions should limit their amount of sedentary time, replacing it with physical activity of any intensity (including light in
-
tensity).646,778General physical activity recommendations include a 
combination of regular aerobic physical activity and resistance exercise throughout the week, which also forms the basis of recommendations 
for patients post-ACS.
646,778However, it is important to recognize that 
daily physical activity does not replace participation in exercise-based 
CR. With support from multiple randomized trials, exercise training 
is a pivotal part of comprehensive CR and participation in exercise- 
based CR should be offered to all patients after ACS.779
Cardiorespiratory fitness is a strong predictor of future prognosis both in the general population and in post-ACS patients.
780
13.2.4. Psychological considerations
There is a two-fold risk of anxiety and mood disorders in patients with heart disease. Depression, anxiety, and psychological stress are associated with worse outcomes. Psychological and pharmaco
-
logical interventions can have a beneficial effect and should be consid -
ered for ACS patients with depression, anxiety, and stress.781It is 
recommended that all patients have their mental well-being assessed 
using validated tools before discharge, with consideration of onward 
psychological referral when appropriate.782For further details, 
please refer to the 2021 ESC Guidelines on cardiovascular disease 
prevention.646
13.2.5. Resumption of activities
Information on the resumption of activities, sexual activity, and environmental factors is presented in the Supplementary data online, 
Section 13.1.2.
13.3. Pharmacological treatment
13.3.1. Antithrombotic therapy
Recommendations for antithrombotic therapy are included in Section 6.
13.3.2. Lipid-lowering therapy
Dyslipidaemia should be managed according to the current dyslipidae -
mia guidelines, with a combination of lifestyle and pharmacological interventions.783Trials have consistently demonstrated that lower low- 
density lipoprotein-cholesterol (LDL-C) levels after ACS are associated with lower CV event rates.
784The current treatment goal for second -
ary prevention is to lower LDL-C to <
1.4 mmol/L (<55 mg/dL) and to 
achieve a ≥50% LDL-C reduction from baseline. For patients who ex -
perience a second CV event within 2 years (not necessarily of the same type as the first event), an LDL-C goal of <
1.0 mmol/L (<40 mg/dL) ap -
pears to confer additional benefit.783,785,786
After an ACS event, lipid-lowering treatment should be initiated as 
early as possible, both for prognostic benefit and to increase patient adherence after discharge. It is recommended that a high-intensity sta
-
tin (e.g. atorvastatin or rosuvastatin) is initiated as early as possible after hospital admission, preferably before planned PCI, and pre
-
scribed up to the highest tolerated dose in order to reach the LDL-C 
goals.783,787The intensity of statin therapy should be increased in pa -
tients who were receiving low- or moderate-intensity statin treatment 
before the ACS event. In IMPROVE-IT (Improved Reduction of 
Outcomes: Vytorin Efficacy International Trial), ezetimibe treatment 
early after ACS (within 10 days) was added on top of prior statin ther -
apy or initiated concomitantly in statin-naïve patients (two-thirds of 
patients) and compared with statin monotherapy.788Treatment with 
ezetimibe was shown to be safe and provided long-term benefits for 
CV outcomes. As such, if patients are on a maximally tolerated statin 
dose, or have no prior statin treatment, and have LDL-C levels which 
indicate it is unlikely that targets will be reached with statin therapy 
alone, initiating ezetimibe in addition to a statin (or statin plus ezeti -
mibe combination treatment) may be considered during the ACS 
hospitalization.783,788In the ODYSSEY OUTCOMES (Evaluation of 
Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, treatment with the proprotein con
-
vertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab was in -
itiated as early as 1 month after ACS.786Treatment with PCSK9 
inhibitors has been shown to be safe and effective in lowering LDL-C 
in patients hospitalized with ACS.789–791Recent data have also shown 
improvements in plaque phenotype and plaque regression in ACS pa -
tients treated with PCSK9 inhibitors.792,793Combined with the data 
from trials on the long-term benefits of PCSK9 inhibitors and observa -
tional data on the importance of lowering LDL-C early after ACS, 
PCSK9 inhibitor treatment should be initiated during ACS hospitaliza -
tion in patients who were not at their LDL-C goal despite being on statin and ezetimibe treatment before admission.
785,786,794–796
In all cases, lipid levels should be re-evaluated 4–6 weeks after each 
treatment or dose adjustment to determine whether treatment goals 
have been achieved and to check for any safety issues; the therapeutic 
regimen can then be adapted accordingly. If the LDL-C goals are not 
achieved with the maximum tolerated dose of a statin alone after 4– 
6 weeks following ACS, adding ezetimibe is recommended.783,788
Initiation of PCSK9 inhibitor treatment is recommended in patients 
who do not reach their LDL-C goal despite maximum tolerated statin and ezetimibe therapy.
783,785,786Finally, icosapent ethyl, at a dose of 2 g 
b.i.d., can be used in combination with a statin in patients with ACS and triglyceride levels of 1.5–5.6 mmol/L (135–499 mg/dL) despite statin 
treatment.
783,797An algorithm for lipid-lowering management in ACS 
patients is outlined in Figure 18.
For a detailed description of the different lipid-lowering drug classes 
and respective trial data, please refer to the Supplementary data online.3784                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

13.3.3. Beta-blockers
The clinical benefit of beta-blockers after ACS in patients with reduced 
LVEF is supported by evidence from contemporary trials.557,798–800
However, the evidence for prescribing beta-blockers after uncompli -
cated ACS in patients with LVEF >40% 
is less well established. With the exception of the CAPRICORN (CArvedilol Post-infaRct survIval COntRolled evaluatioN) trial, which only recruited patients with LVEF ≤40%, all large RCTs testing the benefits of post-MI beta-blocker 
maintenance were performed in the pre-reperfusion era.
801Pooled 
data demonstrated that post-MI beta-blocker therapy reduced the 
Prior treatment
LDL-C <1.4 mmol/L
or 55 mg/dLaAdd
ezetimibe
(Class I)LDL-C <1.4 mmol/L
or 55 mg/dLa
LDL-C <1.4 mmol/L
or 55 mg/dLa
On highest tolerated
statin and ezetimibe,
add PCSK9i
(Class I)LDL-C <1.4 mmol/L
or 55 mg/dLaLipid lowering therapy in ACS patients
Y
YN
N
NNo
change in
therapy
No change in therapy
Y
No change in therapyY
No
change in
therapyAdd
PCSK9i
(Class I)NLLT -naive,
irrespective of
LDL-C values
Initiate
high-potency
high-dose statin
(Class I)
Combination
therapy
with statin and
ezetimibe
(Class IIb)Change to
high-potency
high-dose statin
(Class I)On low-potency/
low-dose statin,
irrespective 
of LDL-C valuesOn highest
tolerated statinOn highest tolerated
statin and ezetimibe
Combination
therapy
with statin and
ezetimibe
(Class IIb)
On highest tolerated statin,
add ezetimibe
(Class I)
On highest tolerated statin
and ezetimibe, add PCSK9i
(Class I)During admission
Outpatient follow-up
After 4–6 weeks
After further 4–6 weeksFigure 18 Lipid-lowering therapy in ACS patients. ACS, acute coronary syndrome; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering ther-
apy; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor. aConsider LDL-C <1.0 mmol/L if recurrent event.ESC Guidelines                                                                                                                                                                                          3785Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

risk of death by >20%. These trials mostly enrolled patients with STEMI, 
making the evidence for their benefit in NSTEMI less robust. In addition, 
since these trials were performed, the clinical scenario has changed dra -
matically, with improvements in invasive strategies and associated pharmacotherapy resulting in an improved prognosis for patients 
with ACS.
718Modern observational studies and meta-analyses of these 
trials have yielded mixed results, with some studies suggesting a benefit 
of beta-blocker therapy irrespective of LVEF, and others reaching the 
opposite conclusion.557,800,802–804
There is only one small, open-label trial, CAPITAL-RCT (Carvedilol 
Post-Intervention Long-Term Administration in Large-scale 
Randomized Controlled Trial), that randomized 801 STEMI patients 
with successful PPCI and preserved LVEF to carvedilol or control.805
During a 3-year follow-up, the incidence of a composite of all-cause death, 
MI, hospitalization for HF, and hospitalization for ACS was not significantly 
different between the two groups. However, the trial was underpowered 
and therefore this scientific question remains open. There are four on -
going pragmatic prospective large-scale RCTs in Europe randomizing ACS patients without reduced LVEF to beta-blocker or control: 
REBOOT-CNIC (TREatment With Beta-blockers After myOcardial 
Infarction withOut Reduced Ejection fracTion), 8468 ACS patients with 
LVEF >
40%; REDUCE-SWEDEHEART (Evaluation of Decreased Usage 
of Betablockers After Myocardial Infarction in the SWEDEHEART Registry), 5000 ACS patients with LVEF ≥50% (NCT03278509); 
BETAMI (BEtablocker Treatment After Acute Myocardial Infarction in 
Patients Without Reduced Left Ventricular Systolic Function), 10 000 
ACS patients with LVEF >40%; and DANBLOCK (Danish Trial of Beta 
Blocker Treatment After Myocardial Infarction Without Reduced 
Ejection Fraction), 3570 ACS patients with LVEF >40%.
806–808
The duration of beta-blocker therapy after uncomplicated ACS is 
also another controversial topic. There are some observational studies 
suggesting that the clinical benefit of beta-blocker therapy is restricted 
to the first year after the index ACS event, but the non-randomized na -
ture of the studies limits their conclusions.809There are two ongoing 
large-scale RCTs testing the impact of beta-blocker withdrawal after 
6–12 months following uncomplicated ACS in patients with preserved 
LVEF: AβYSS (Beta Blocker Interruption After Uncomplicated 
Myocardial Infarction; NCT03498066) and SMART-DECISION 
(Long-term Beta-blocker Therapy After Acute Myocardial Infarction; 
NCT04769362).810
13.3.4. Nitrates and calcium channel blockers
Intravenous nitrates may be useful during the acute phase in STEMI pa -
tients with hypertension or HF, provided there is no hypotension or RV 
infarction. In the ISIS-4 (Fourth International Study of Infarct Survival) 
trial, oral nitrates had no survival benefit in MI patients.811Their use 
is therefore restricted to the control of residual angina, as recom -
mended in the 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
195Calcium channel blocker use was 
not associated with prognostic benefit in a systematic review including 
28 trials.812Calcium channel blocker use can be considered in the con -
text of residual angina and for blood pressure control as recommended in the 2021 ESC Guidelines on CVD prevention and the 2019 ESC 
Guidelines for the diagnosis and management of CCS.
195,646
13.3.5. Renin–angiotensin–aldosterone system 
inhibitors
Angiotensin-converting enzyme (ACE) inhibitors have been demon -
strated to improve outcomes in post-MI patients with additional conditions, such as clinical HF and/or LVEF ≤
40%, diabetes, CKD, 
and/or hypertension.813–817A systematic overview of (old) trials of 
ACE inhibition early in STEMI showed that their use is associated 
with a small but significant reduction in 30-day mortality, especially in 
anterior MIs.818
In the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial, 
valsartan was found to be non-inferior to captopril in patients with a 
recent MI plus HF and/or LVEF ≤40%.819
There is established evidence that patients with heart failure with re -
duced ejection fraction (HFrEF), regardless of aetiology, benefit from 
ACE inhibitors.820–823Angiotensin receptor/neprilysin inhibitors 
(ARNI) have been shown to be superior to ACE inhibitors in patients with established HF (of different aetiologies) and LVEF ≤40%.
824
However, in the more recent PARADISE-MI (Prospective ARNI vs 
ACE Inhibitor Trial to Determine Superiority in Reducing Heart 
Failure Events After MI), a dedicated study in patients with recent 
ACS (1–7 days) complicated by HF and/or LVEF ≤40%, an ARNI com -
bination (sacubitril plus valsartan) was not associated with a significantly lower incidence of death from CV causes or incident HF in comparison 
to the active comparator ramipril.
825
In general, ACE inhibitors (or sacubitril plus valsartan as a replace -
ment for them) are recommended for patients with established HFrEF regardless of the aetiology.
557These agents may be considered 
for patients with HF with mildly reduced ejection fraction.557Patients 
who tolerate neither ACE inhibitors nor ARNI are recommended to be treated with an angiotensin receptor blocker.
In the Eplerenone Post-AMI Heart failure Efficacy and SUrvival Study 
(EPHESUS), the mineralocorticoid receptor antagonist (MRA) eplere -
none was associated with reduced mortality and CV hospitalizations in patients with a recent MI and LV dysfunction with symptoms of ei
-
ther HF or diabetes.826The Double-Blind, Randomized, 
Placebo-Controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial 
Infarction (REMINDER) trial randomized 1012 patients with acute 
STEMI without HF to eplerenone or placebo within 24 h of symptom 
onset.
827The primary endpoint was the composite of CV mortality, re- 
hospitalization, or extended initial hospital stay due to diagnosis of HF, 
sustained VT or VF, ejection fraction ≤40%, or elevated BNP/NT-pro 
BNP at 1 month or more after randomization. Eplerenone was asso -
ciated with a significant reduction in the primary composite endpoint, 
although this difference was primarily driven by BNP levels.827
13.3.6. Medications for diabetes
13.3.6.1. Sodium–glucose co-transporter 2 inhibitors
Pharmacological blockade of SGLT2 induces glycosuria with lowering of 
plasma glucose levels, improving glycaemic control without hypogly -
caemia, and leading to reductions in weight and blood pressure.828In 
patients with type 2 diabetes and established ASCVD, three trials 
(with empagliflozin, canagliflozin, and dapagliflozin) have demonstrated 
significant CV benefits.656,829,830In a meta-analysis of these three trials, 
MACE were reduced by 11%, with no clear effect on stroke or MI. This 
benefit was only seen in patients with established ASCVD.698The ben -
efits of SGLT2 inhibitors may relate more to cardio-renal haemo -
dynamic effects than to atherosclerosis.646Further recommendations 
for patients with diabetes can be found in the current ESC Guidelines on diabetes, pre-diabetes,and cardiovascular diseases.
831
In patients with HF regardless of their LVEF, dapagliflozin and empa -
gliflozin have been shown to significantly reduce the risk of worsening HF or CV death, both in the presence or absence of type 2 3786                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

diabetes.702,703,832,833In the EMMY (EMpagliflozin in patients with acute 
MYocardial infarction) trial, empagliflozin led to a significant improve -
ment in NT-pro BNP reduction over 26 weeks post-MI, accompanied 
by a significant improvement in echocardiographic functional and 
structural parameters.834Ongoing outcome trials in ACS populations 
will be useful to better define the role of these agents in the absence of HF.
835
13.3.6.2. Glucagon-like peptide-1 receptor agonists
In a systematic review and meta-analysis of seven trials (56 004 patients with type 2 diabetes) testing different GLP1-RAs, their use was asso
-
ciated with reductions in the incidence of MACE, CV death, all-cause 
mortality, MI, and stroke.699
13.3.7. Proton pump inhibitors
Proton pump inhibitors (PPIs) reduce the risk of upper gastroduodenal 
bleeding in patients treated with antiplatelet agents.287,836,837Therapy 
with a PPI is indicated for patients receiving any antithrombotic regimen who are at high risk of gastrointestinal bleeding (for details see Section 
8.2.2.3, Bleeding risk assessment, in the Supplementary data online).
PPIs that inhibit CYP2C19, particularly omeprazole and esomepra -
zole, may reduce the pharmacodynamic response to clopidogrel, though there is no strong evidence that this results in an increased 
risk of ischaemic events or stent thrombosis in clinical trials and propen
-
sity score-matched studies.287,288,838–842Importantly, no interaction 
between the concomitant use of PPIs and aspirin, prasugrel or ticagre -
lor has been observed.
13.3.8. Vaccination
An annual influenza vaccination in patients with stable ASCVD appears 
to be associated with reduced incidence of MI, an improved prognosis 
in patients with HF, and decreased CV risk in adults aged 65 years and 
older.843,844In addition, influenza vaccination given early after an MI or 
in high-risk CAD has been shown to result in a lower risk of all-cause 
death and CV death at 12 months.845–847Therefore, influenza vaccin -
ation is recommended for all ACS patients and should be given prefer -
entially during index hospitalization during influenza season for those 
not protected by a seasonal influenza vaccination.
13.3.9. Anti-inflammatory drugs
Inflammation plays a central role in the pathogenesis of atherosclerosis 
and acute coronary events. Several recent trials have tested the role of the anti-inflammatory agent colchicine in acute and chronic coronary 
syndromes.
848,849In the Colchicine Cardiovascular Outcomes Trial 
(COLCOT), which enrolled 4745 patients with a recent ACS event, 
low-dose colchicine (0.5 mg daily) was associated with a significant re -
duction of the primary composite endpoint (CV death, resuscitated cardiac arrest, MI, stroke, or urgent revascularization) in comparison 
to placebo.
850Of note, pneumonia was more frequent in the colchicine 
group. The Low-dose Colchicine trial-2 (LoDoCo2) enrolled 5522 pa -
tients with CCS (84% of whom had prior ACS) who were randomized to colchicine (0.5 mg daily) or placebo.
851The primary endpoint (com -
posite of CV death, MI, stroke, or ischaemia-driven coronary revascu -
larization) rate was significantly lower in the colchicine group; however, the incidence of non-CV death was higher in the colchicine group. The 
benefits of colchicine in reducing CV events have been shown to be 
consistent irrespective of history and timing of prior ACS.
85213.3.10. Hormone replacement therapy
For further information on hormone replacement therapy in patients 
with ACS, please see the Supplementary data online.
Recommendation Table 16 — Recommendations for 
long-term management
Recommendations ClassaLevelb
Cardiac rehabilitation
It is recommended that all ACS patients participate in 
a medically supervised, structured, comprehensive, multidisciplinary exercise-based cardiac rehabilitation 
and prevention programme.
721–724,853,854I A
Lifestyle management
It is recommended that ACS patients adopt a healthy 
lifestyle, including: 
•stopping all smoking of tobacco
•healthy diet (Mediterranean style)
•alcohol restriction
•regular aerobic physical activity and resistance exercise
•reduced sedentary time
724,761,763,772,773,776,777,855– 
858I B
In smokers, offering follow-up support, nicotine 
replacement therapy, varenicline or bupropion, 
individually or in combination, should be 
considered.859–864IIa A
Pharmacological treatment
Lipid-lowering therapy
It is recommended that high-dose statin therapy is 
initiated or continued as early as possible, regardless 
of initial LDL-C values.787,865–867I A
It is recommended to aim to achieve an LDL-C level of <1.4 mmol/L (<55 mg/dL) and to reduce LDL-C 
by ≥50% from baseline.
868,869I A
If the LDL-C goal is not achieved despite maximally 
tolerated statin therapy after 4–6 weeks, the addition of ezetimibe is recommended.
788I B
If the LDL-C goal is not achieved despite maximally tolerated statin therapy and ezetimibe after 4–6 
weeks, the addition of a PCSK9 inhibitor is 
recommended.
785,786,795,796I A
It is recommended to intensify lipid-lowering therapy
c during the index ACS hospitalization for 
patients who were on lipid-lowering therapy before 
admission.I C
For patients with a recurrent atherothrombotic event (recurrence within 2 years of first ACS 
episode) while taking maximally tolerated statin-based therapy, an LDL-C goal of <1.0 mmol/L 
(<40 mg/dL) may be considered.
785,786IIb B
Combination therapy with high-dose statin plus 
ezetimibe may be considered during index 
hospitalization.788IIb B
ContinuedESC Guidelines                                                                                                                                                                                          3787Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

14. Patient perspectives
14.1. Patient-centred care
The management of patients with ACS should not only consider the 
best available evidence with regard to clinical management strategies, 
but also should be mindful of the provision of care that is respectful 
of and responsive to individual patient preferences, needs, and values, 
ensuring that these values are included in clinical decision-making.881
Patient-centred care should be guided by ethical values when consid -
ering a patient’s physical, emotional, and psychological needs. Adopting a person-centred care approach after an ACS event improves patient 
outcomes and enhances quality of life.
882Patients who are regarded 
as equal partners in their ACS medical management are more likely 
to actively engage and participate in their own healthcare.883
Educating and involving patients in their care should be seen as a con -
tinuous process. Engaging and educating the patient is a key component of ACS care and should take place throughout their patient journey, 
from admission to hospital discharge and cardiac rehabilitation 
(
Figure 19).Beta-blockers
Beta-blockers are recommended in ACS patients 
with LVEF ≤40% regardless of HF symptoms.801,870– 
872I A
Routine beta-blockers for all ACS patients regardless 
of LVEF should be considered.798,873–878IIa B
RAAS system inhibitors
Angiotensin-converting enzyme (ACE) inhibitorsd 
are recommended in ACS patients with HF 
symptoms, LVEF ≤40%, diabetes, hypertension, and/ 
or CKD.195,813–817,879I A
Mineralocorticoid receptor antagonists are 
recommended in ACS patients with an LVEF ≤40% 
and HF or diabetes.826,880I A
Routine ACE inhibitors for all ACS patients regardless of LVEF should be considered.
816,817IIa A
Adherence to medication
A polypill should be considered as an option to 
improve adherence and outcomes in secondary 
prevention after ACS.753IIa B
Imaging
In patients with pre-discharge LVEF ≤40%, repeat 
evaluation of the LVEF 6–12 weeks after an ACS (and 
after complete revascularization and the institution 
of optimal medical therapy) is recommended to 
assess the potential need for sudden cardiac death 
primary prevention ICD implantation.I C
Cardiac magnetic resonance imaging should be 
considered as an adjunctive imaging modality in order 
to assess the potential need for primary prevention 
ICD implantation.IIa C
Vaccination
Influenza vaccination is recommended for all ACS 
patients.843,845–847I A
ContinuedAnti-inflammatory drugs
Low-dose colchicine (0.5 mg once daily) may be 
considered, particularly if other risk factors are 
insufficiently controlled or if recurrent cardiovascular disease events occur under optimal therapy.
850,851IIb A
©ESC 2023
ACS, acute coronary syndrome; CKD, chronic kidney disease; HF, heart failure; ICD, 
implantable cardioverter defibrillator; LDL-C, low-density lipoprotein-cholesterol; LVEF, 
left ventricular ejection fraction; PCSK9, proprotein convertase subtilisin/kexin type 9; 
RAAS, renin–angiotensin–aldosterone system. 
aClass of recommendation. 
bLevel of evidence. 
cIncrease statin potency/dose if the patient was on low-potency/low-dose statin, add 
ezetimibe if the patient was only on statins at highest tolerated dose, or add PCSK9 
inhibitor if the patient was on statins plus ezetimibe. 
dAngiotensin receptor blockers in cases of intolerance.3788                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

14.2. Shared decision-making
Shared decision-making is a process, during which the patient and a 
healthcare professional work together to make an informed decision 
about the patient’s care.884During this process, information is pro -
vided, comprehension checked, and the patient is given an opportunity to ask questions in order to equip them with the tools needed to make 
an informed decision.
Using a shared decision-making approach during the consent process 
allows the patient’s preferences to be established.884Discovery of the 
patient’s concerns, goals, preferences, and values should be a central 
component of this process. The use of validated decision aids and 
audio-visual tools may also be helpful to facilitate informed consent 
and promote patient involvement.884–88714.3. Informed consent
Informed consent should include the components listed in 
Supplementary data online, Table S18.885,888Informed consent is an op -
portunity to educate patients about the proposed procedure, the asso -
ciated risks and benefits, and any available alternative interventions or 
treatments.886,887Assessment of the patient’s understanding of the in -
formation given to them during the informed consent process using the 
‘teach back’ technique should be considered ( Supplementary data 
online, Figure S6).885,889–891The teach back method assesses under -
standing by asking patients to state in their own words what they need to know or do about their health.
Informed consent is an ethical and legal obligation for medical practi -
tioners and is required before any invasive procedure. The information 
Premorbid
conditionConsider all
risk
factorsEstablish medical
history and
prior medicationsConsider
psychosocial
factors
Hospital
admissionIndividualize care
at triagePerform a person-centred
clinical assessmentEmploy shared
decision-making
Preparing for
dischargeExplain regarding 
long-term treatmentEducate about 
lifestyle modificationConsider mental
and emotional healthAt every stage, consider physical and psychosocial needsTaking a person-centred approach to the ACS journeyFigure 19 A person-centred approach to the ACS journey. ACS, acute coronary syndrome.ESC Guidelines                                                                                                                                                                                          3789Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

should be provided in a simple and clear format. In patients undergoing 
emergency invasive angiography, a shortened informed consent pro -
cess is appropriate. If a shortened informed consent process has 
been used, it is important that there is contact with the patient and/ 
or family member after the intervention when the patient is physically 
and psychologically stable or following the death of the patient.892
Further information can be found in the Supplementary data online.
14.4. Research participation and consent in 
the acute setting
With unstable ACS patients, it is often challenging to obtain their con -
sent for emergency procedures—and even more challenging to enrol 
in clinical trials due to a number of factors, including the necessity for 
prompt clinical care, increased pain and stress levels, and impairment 
of consciousness. Where clinical trials are conducted, patient involve -
ment in enrolment decisions is paramount, if possible.893,894A short witnessed verbal consent, followed by written consent after the acute 
phase, has been shown to be less stressful and more positively re -
ceived than written consent in the acute setting.894The research 
and consent process must follow the ethical and legal requirements 
in the relevant country. Further information can be found in the 
Supplementary data online.
14.5. Patient satisfaction and expectations
Focusing healthcare around the needs and preferences of patients has 
the potential to improve clinical outcomes, quality of care and patient satisfaction, while decreasing healthcare costs and health disparities.
881
Patient perception of care is built on interpersonal interactions, the quality of clinical communication, delivery of care, and the administra
-
tive management of care. ACS patient expectations are summarized 
in Figure 20 and further information can be found in the 
Supplementary data online, Table S19.
...their ACS symptoms
to be recognised...high quality, effective
and safe care delivered
by professionals…the right care
at the right time
…their physical, mental
and emotional wellbeing
to be considered…clear, comprehensible 
information…shared decision
making and respect 
for their preferences
…consideration of,
and support for,
their family and carers…attention to both
 their physical and 
environmental needs…a clean and safe
hospital environment
ACS patients expect…
Figure 20 Acute coronary syndrome patient expectations. ACS, acute coronary syndrome.3790                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

14.6. Patient-reported outcome measures 
and patient-reported experience 
measures
Understanding and measuring patient expectations and health out -
comes using patient-reported outcome measures (PROMs) and pa -
tient-reported experience measures (PREMs) is central to improving 
patient satisfaction and delivering patient-centred care.895The quality 
of care for ACS patients should be measured during the patient’s jour -
ney from initial presentation until discharge. Further information can be found in the 
Supplementary data online. Further information on 
PROMs and PREMs is also provided in the Supplementary data online.
14.7. Preparation for discharge
Many ACS patients may not be fully aware of what has happened to 
them and how to best manage their healthcare after discharge, leading to them both wanting and needing more information upon dis
-
charge.896Cognitive impairment can occur as a complication of ACS 
and some patients may have difficulty with instructions for care when 
transitioning towards discharge home.897Therefore, discharge infor -
mation should be provided in both verbal and written formats and 
should include a discharge letter outlining the key components of the 
evidence-based discharge plan ( Supplementary data online, 
Table S20).898–901Some important messages aimed at patients on 
how to improve their heart health after ACS are demonstrated in 
Supplementary data online, Figure S5. Moreover, following an ACS 
event, anxiety and depression are frequently encountered and confer an increased risk of non-adherence to medications and lifestyle changes, 
subsequent MACE, and death.
902–904Non-adherence also generally in -
creases over time, which has additional impact on clinical outcomes.905
Assessing and identifying these patients and intervening with onward 
psychological referral is recommended.858Further information can be 
found in the Supplementary data online . A summary of patient con -
cerns and educational needs throughout their ACS journey is also pro -
vided in Supplementary data online, Figure S7.15. Key messages
Epidemiology of ACS
Acute coronary syndromes encompass a spectrum of conditions that 
include patients with a recent change in clinical symptoms or signs, 
with or without changes on 12-lead ECG and with or without acute ele -
vations in cardiac troponin concentrations. ACS are commonly classi -
fied based on ECG at presentation and the presence or absence of 
troponin elevation into UA, NSTEMI, or STEMI. The incidence of STEMI is decreasing whereas the incidence of NSTEMI is increasing. 
While there are some sex differences in the epidemiology of ACS, wo
-
men and men receive equal benefit from invasive and non-invasive man -
agement strategies and, in general, should be managed similarly.
Diagnostic tools (ECG, troponin, and non-invasive imaging)
Chest pain/discomfort is the most common symptom initiating the ACS 
diagnostic and therapeutic pathway. High-sensitivity troponin measure -
ments and rapid ‘rule-in’ and ‘rule-out’ algorithms should be used in patients 
with suspected NSTE-ACS. MI is not the only condition resulting in cardi -
omyocyte injury and cardiac troponin elevation, and other conditions should also be considered in the differential diagnosis. Non-invasive imaging 
can be useful to increase diagnostic accuracy and optimize risk assessment.
STEMI management networks
Co-ordination between EMS and hospitals with common written proto -
cols is central to the management of STEMI. EMS should transfer patients 
immediately to 24/7 high-volume PCI centres regardless of the initial 
treatment strategy (PPCI or pre-hospital fibrinolysis). EMS should always 
alert the PCI centre immediately after selection of the reperfusion strat -
egy, and patient transfer to the PCI centre should bypass the ED.
Invasive strategy and reperfusion therapy
An invasive strategy is recommended for patients with ACS. Invasive strat -
egies are time sensitive. For STEMI and very high-risk NSTE-ACS, an im -
mediate invasive strategy is recommended. For patients with NSTE-ACS 
an inpatient invasive strategy is recommended; in NSTE-ACS patients 
with high-risk characteristics, an early invasive strategy (
<24 h) should 
be considered. If timely (within 120 min from time of diagnosis) PPCI can -
not be performed in patients with STEMI, fibrinolytic therapy is indicated 
within 12 h of symptom onset in patients without contraindications.
Antithrombotic therapy
Antithrombotic therapy is indicated in all ACS patients, regardless of the 
management strategy. This consists of both antiplatelet and anticoagulant therapy. Aspirin is recommended for all ACS patients at an initial loading 
dose and a longer-term maintenance dose. In addition to aspirin, a P2Y
12 
receptor inhibitor is recommended, and should be maintained over 12 Recommendation Table 17 — Recommendations for 
patient perspectives in acute coronary syndrome care
Recommendations ClassaLevelb
Patient-centred care is recommended by assessing 
and adhering to individual patient preferences, needs 
and beliefs, ensuring that patient values are used to inform all clinical decisions.
744,881,906,907I B
It is recommended to include ACS patients in decision-making (as much as their condition allows) 
and to inform them about the risk of adverse events, 
radiation exposure, and alternative options. Decision 
aids can be used to facilitate the discussion.
908,909I B
It is recommended to assess symptoms using methods that help patients to describe their 
experience.
910I C
Use of the ‘teach back’ technique for decision support during the securing of informed consent 
should be considered.
885,889–891IIa B
ContinuedPatient discharge information should be provided in 
both written and verbal formats prior to discharge. 
Adequate preparation and education for patient 
discharge using the teach back technique and/or 
motivational interviewing, giving information in 
chunks, and checking for understanding should be 
considered.885,896,911IIa B
Assessment of mental well-being using a validated tool and onward psychological referral when 
appropriate should be considered.
903,904,912,913IIa B
©ESC 2023
ACS, acute coronary syndrome. 
aClass of recommendation. 
bLevel of evidence.ESC Guidelines                                                                                                                                                                                          3791Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

months unless there are concerns regarding HBR. Regarding P2Y 12 recep -
tor inhibitor choice, prasugrel and ticagrelor are recommended in prefer -
ence to clopidogrel, and prasugrel should be considered in preference to 
ticagrelor for ACS patients who undergo PCI. Pre-treatment (i.e. treat -
ment with a P2Y 12 receptor inhibitor prior to coronary angiography) in pa -
tients with NSTE-ACS is not recommended routinely but may be 
considered for patients with STEMI undergoing PPCI. Parenteral anticoa -
gulation is recommended for all patients at the time of diagnosis. Discontinuation of parenteral anticoagulation should be considered imme
-
diately after the invasive procedure. Some patients with ACS will also have an indication for long-term OAC, most commonly AF. In these patients, TAT for up to 1 week, followed by DAT using a NOAC at the recom
-
mended dose for stroke prevention and a single oral antiplatelet agent (preferably clopidogrel), is recommended as the default strategy.
ACS with unstable presentation
A PPCI strategy is recommended in patients with resuscitated cardiac 
arrest and an ECG with persistent ST elevation (or ST elevation equiva -
lents), whereas routine immediate angiography is not recommended in 
patients with an ECG without persistent ST elevation (or equivalents). 
Temperature control (i.e. continuous monitoring of core temperature 
and active prevention of fever [i.e. >
37.7°C]) is recommended in pa -
tients with OHCA who remain unresponsive after ROSC. In patients with CS complicating ACS, emergency coronary angiography is recom
-
mended, whereas the routine use of IABP in ACS patients with CS and 
no mechanical complications is not.
Early care
Following reperfusion, it is recommended to admit high-risk ACS patients, 
including all STEMI patients, to a CCU/ICCU. ECG monitoring for ar -
rhythmias and ST-segment changes is recommended for at least 24 h after symptom onset in all high-risk patients with ACS. It is recommended that all hospitals participating in the care of high-risk ACS patients have an 
ICCU/CCU equipped to provide all required aspects of care including 
treatment of ischaemia, severe HF, arrhythmias, and common co- 
morbidities. It is also recommended that the LVEF is determined before 
hospital discharge in all patients with ACS. Discharge of high-risk ACS pa
-
tients within 48–72 h should be considered in selected patients if early re -
habilitation and adequate follow-up are arranged.
Technical aspects during PPCI
Routine radial access and use of DES are the standard of care during PCI for ACS. Intravascular imaging should be considered to guide PCI and 
may be considered in patients with ambiguous culprit lesions. 
Routine thrombus aspiration is not recommended. CABG should be 
considered in patients with an occluded IRA when PCI is not feasible 
or unsuccessful and there is a large area of myocardium in jeopardy. 
In patients presenting with SCAD, PCI is recommended only for pa
-
tients with symptoms and signs of ongoing myocardial ischaemia, a large 
area of myocardium in jeopardy, and reduced antegrade flow.
Management of patients with MVD
For patients with MVD, it is recommended to base the revascularization 
strategy (IRA PCI, multivessel PCI/CABG) on the patient’s clinical status 
and comorbidities, as well as their disease complexity, according to the principles of management of myocardial revascularization. For patients 
with MVD presenting with CS, IRA-only PCI during the index procedure 
is recommended. For patients with STEMI undergoing PPCI, complete re
-
vascularization is recommended either during the index PCI or within 45 
days. In patients presenting with NSTE-ACS and MVD, complete revascu -
larization should be considered, preferably during the index procedure. 
For patients with STEMI, it is recommended that decisions regarding PCI of non-IRA are based on angiographic severity, whereas for patients 
with NSTE-ACS, functional invasive evaluation of non-IRA severity during 
the index procedure may be considered.
MINOCA
The term MINOCA refers to the situation where patients present with 
symptoms suggestive of ACS and demonstrate troponin elevation and 
non-obstructive coronary arteries at the time of coronary angiography, 
i.e. coronary artery stenosis <
50% in any major epicardial vessel. 
MINOCA is best considered as a working diagnosis that encompasses a 
heterogenous group of underlying causes (both cardiac and extra-cardiac) 
and is found in 1–14% of patients with ACS. In all patients with an initial 
working diagnosis of MINOCA, it is recommended to follow a diagnostic 
algorithm to determine the underlying cause. CMR imaging is a key diag -
nostic tool in patients with a working diagnosis of MINOCA.
Special patient subsets
Chronic kidney disease: moderate to severe CKD is present in >
30% of 
ACS patients. These patients receive less interventional and pharmaco -
logical treatment and have a worse prognosis in comparison to patients with normal kidney function. It is recommended to apply the same diag
-
nostic and therapeutic strategies in patients with CKD (dose adjustment may be necessary) as for patients with normal kidney function.
Older adults: in general, older adults should undergo the same diag -
nostic and treatment strategies, including invasive angiography and re -
vascularization, as younger patients.
Patients with cancer: management of ACS in patients with cancer can 
be challenging for several reasons, including frailty, increased bleeding 
risk, thrombocytopaenia, and increased thrombotic risk. An invasive 
strategy is recommended in cancer patients presenting with high-risk 
ACS with expected survival ≥
6 months. A conservative non-invasive 
strategy should be considered in ACS patients with poor cancer prog -
nosis (with expected survival <
6 months) and/or very high bleeding risk.
Long-term treatment
Secondary prevention after ACS should be offered to every patient and should start as early as possible after the index event. This includes car
-
diac rehabilitation, lifestyle management, and pharmacological treat -
ment, and has been shown to both increase quality of life and 
decrease morbidity and mortality. 
Patient perspectives
Some of the key first steps in the timely diagnosis and treatment of ACS 
are reliant on a comprehensive assessment of symptoms. An incom -
plete history or poorly elicited symptoms can result in delay or misdiag -
nosis. Patient-centred care is recommended as a critical tenet of routine clinical management and involves consideration of a patient’s 
physical, emotional, and psychological needs.
The provision of care that is respectful of, and responsive to, individ -
ual patient preferences, needs and values, is important in the manage -
ment of patients with ACS. It is recommended, as much as possible, 
to include ACS patients in decision-making. Preparing for discharge be -
gins on admission. Educating and informing the patient using the teach 
back method and educationally appropriate material should be inte -
grated into the patient care pathway.
Quality indicators
Acute coronary syndrome QIs aim to audit practice and improve clin -
ical outcomes in real-life patients by demonstrating the gap between 
optimal guideline-based treatment and actual care of ACS patients. 
Subsequent measures to improve QI attainment can be implemented 
based on the local, regional, and global assessment of QIs.3792                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

16. Gaps in evidence
Table 8 Gaps in evidence
Section Gaps in evidence Research recommendations to address 
these gaps
3 Triage and diagnosis •Observe zone: how can we improve the guidance for and 
management of patients assigned to the observe zone of 
the 0 h/1 h and 0 h/2 h ESC algorithms to improve their 
poor outcome?
•No testing rule: what is the added value of biomarkers other than hs-cTn for rapid rule-out of NSTE-ACS compared with usual care?
•There is insufficient evidence to set sex-specific thresholds for troponin levels.
•The role of non-invasive anatomy (e.g. CCTA) or functional imaging (e.g. stress testing strategies) for low-risk NSTE-ACS patients should be further evaluated.•Observe zone: prospectively evaluate changes in the 0 h/1 h and 0 h/2 h ESC algorithms to improve the 
outcomes of patients assigned to the observe zone.
•No testing rule: randomization of patients to 
strategies with and without new biomarkers to evaluate whether their use improves clinical outcomes.
•Prospectively evaluate the impact of using sex-specific cut-offs on the diagnosis, treatment, 
and outcomes of patients presenting to the ED with 
suspected ACS.
•Adequately powered RCTs testing whether non-invasive imaging improves clinical outcomes in patients presenting with NSTE-ACS.
4 Initial measures for patients presenting with suspected STEMI | Initial treatment•The impact of early i.v. beta-blockers on clinical outcomes in patients with a working diagnosis of STEMI remains unclear.
•Infarct size and microvascular obstruction are the main determinants of long-term prognosis. Interventions 
which serve to limit infarct size are needed.•Patients randomized to i.v. beta-blockers (ideally 
metoprolol) or placebo before PPCI, with hard endpoints evaluated.
•Translate cardio-protective therapies from experimental to clinical setting by executing 
adequately powered trials.
5 Acute-phase management of patients with NSTE-ACS•The comparison of routine or selective invasive assessment in low-risk NSTE-ACS has not been 
adequately evaluated.
•The optimal timing of invasive angiography in high-risk 
NSTE-ACS patients remains uncertain.•Low-risk patients should be randomized to routine 
or selective invasive strategy.
•RCTs testing different time intervals to perform 
angiography within the 72 h window after the initial presentation.
6 Antithrombotic therapy •Whether pre-treatment with oral P2Y
12 receptor 
inhibitors prior to ICA improves clinical outcomes in NSTE-ACS patients is uncertain.
•Whether platelet function testing or genetic testing to guide de-escalation of oral P2Y
12 receptor inhibitors after 
the first month of therapy following PCI improves clinical management and outcomes remains unclear.
•The optimal long-term antithrombotic regimen in NSTE-ACS patients who have undergone PCI is 
unknown.
•After stopping DAPT, a head-to-head comparison based 
on superiority between aspirin monotherapy and clopidogrel monotherapy is required.•Randomize patients to pre-treatment with oral P2Y
12 receptor inhibitors or no pre-treatment, 
prior to ICA.
•Randomize ACS patients to prasugrel or ticagrelor, both without pre-treatment.
•A strategy based on platelet function testing or genetic testing should be prospectively tested in patients who may benefit from de-escalating antithrombotic therapy.
•RCTs evaluating the benefit-risk balance for 
ischaemic bleeding events for different periods of 
antithrombotic duration.
•A head-to-head randomized comparison testing for superiority is needed to compare aspirin vs. clopidogrel monotherapy after DAPT.
7 Acute coronary syndrome with unstable presentation•The role of percutaneous MCS devices in patients presenting with ACS and CS remains unclear.•Randomized comparisons between standard of care and percutaneous MCS devices in ACS with CS.
8 Management of acute coronary syndrome during hospitalization•Clinical improvement through the use of risk stratification based on risk prediction models.•Patients randomized to a particular intervention or to usual care based on validated risk prediction models.
9 Technical aspects of invasive strategies•Does intravascular imaging-guided revascularization strategy improve clinical outcomes in patients  with ACS?
•Does intracoronary physiology assessment of myocardial 
reperfusion after PPCI improve risk stratification and/or 
stratified medicine for limiting microvascular dysfunction and reperfusion injury/MVO post ACS?•RCTs evaluating the efficacy of an intravascular imaging-guided revascularization strategy to improve meaningful clinical outcomes in patients with ACS.
•Prospectively evaluate whether intracoronary physiology assessment of myocardial reperfusion better stratifies patient risk.
ContinuedESC Guidelines                                                                                                                                                                                          3793Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

•In ACS patients with an IRA that is unsuitable for stent 
implantation, does drug-coated balloon treatment of the IRA improve clinical outcomes?
•Microvascular obstruction associated with PPCI represents an unmet clinical need in patients with ACS. Development of therapies for the prevention and treatment of MVO is urgently needed.
•Does early implementation of MCS in the management of 
high-risk ACS patients improve clinical outcomes?
•Does intracoronary hypothermia reduce infarct size and 
improve clinical outcomes in STEMI patients undergoing PPCI?
•What is the optimal antiplatelet strategy in patients presenting with SCAD? Specific gaps in knowledge surround antithrombotic treatment in the acute and 
post-ACS periods, including the optimal combination and 
duration of treatment.•Patients with an IRA unsuitable for stent implantation randomized to drug-coated balloon treatment or usual care to evaluate clinical outcomes.
•Pre-clinical and clinical research is needed to evaluate cardio-protective therapies aimed at reducing microvascular obstruction.
•RCTs evaluating the benefit of using MCS in 
high-risk patients.
•Randomized trials are needed to demonstrate both 
whether intracoronary hypothermia reduces myocardial infarct size, and if this translates into clinical improvement.
•RCTs evaluating several antiplatelet strategies in patients with SCAD with the aim of determining 
which results in the greatest clinical benefit.
10 Management of patients with multivessel disease•Does complete revascularization of NSTE-ACS with multivessel CAD improve clinical outcomes vs. 
culprit-only PCI?
•Does management of non-infarct-related CAD with intravascular imaging guidance to identify rupture-prone atherosclerotic plaque improve clinical outcomes?
•Does FFR-guided management improve clinical outcomes vs. standard angiography-guided management in 
NSTE-ACS?
•What is the optimal timing of coronary revascularization 
(immediate vs. index hospitalization vs. staged) for non-IRA revascularization in STEMI and NSTE-ACS?
•Does intensive medical therapy improve outcomes in patients with MVD compared with standard secondary prevention?
•The clinical utility of hybrid coronary revascularization in ACS patients with multivessel CAD is uncertain.•Patients with NSTE-ACS and MVD randomized to 
complete vs. culprit-only PCI.
•RCTs testing whether the use of intravascular 
imaging to guide the management of non-infarct-related lesions improves clinical outcomes.
•Patients randomized to FFR-guided management vs. standard angiography-guided management in 
NSTE-ACS.
•Three-arm study comparing the clinical benefits of 
immediate, in-hospital and staged coronary revascularization strategies.
•Patients with MVD randomized to intensive secondary prevention vs. usual care to evaluate whether the former strategy improves clinical 
outcomes.
•RCTs assessing the clinical benefit of hybrid 
revascularization.
12 Special situations •How to better differentiate Type 2 from Type 1 MI before invasive assessment.
•The optimal management strategy in older adults with NSTE-ACS is not known.
•The optimal management strategy in older frail, comorbid adults with NSTE-ACS is not known.
•The optimal management strategy in older frail, comorbid 
adults with STEMI is not known.
•Optimal antiplatelet therapy and its duration to manage 
ACS in pregnant patients are not known.
•The optimal management strategy for pregnant women with NSTE-ACS is not known.
•There is a need to further evaluate the contribution of social determinants of health.•Prospective evaluation of diagnostic strategies aimed at better classifying patients according to their type of MI (Type 1 vs. Type 2).
•Further studies recruiting older adults should be conducted to evaluate whether the current standard of care also benefits this subset of patients.
•Older frail, comorbid patients should not be 
systematically excluded from RCTs.
•Prospective data are needed to better understand 
which antiplatelet therapy regimen is best for pregnant women.
•Observational data are needed in patients with ACS to evaluate the real impact of social determinants of health on clinical outcomes. Randomized 
interventions aimed at reducing social inequalities 
are needed to evaluate how to reduce this gap.
13 Long-term treatment •To evaluate the uptake, safety, and outcomes for 
alternative forms of cardiac rehabilitation, with a focus on 
telemedicine and eHealth.
•How to improve referral for and uptake of CR, especially for groups with low participation, including women, older persons, and ethnic minorities.•Remote cardiac rehabilitation methods need 
randomized data to evaluate their true potential.
•Further monitoring is needed to increase the 
participation of historically under-represented patients in CR.
Continued3794                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

17. Sex differences
There are currently no data supporting the differential management of 
ACS based on sex. However, several studies have reported that wo -
men presenting with ACS are treated differently than men.914–918
This includes being less likely than men to receive ICA, timely revascu -
larization, CR, and secondary prevention medications.914–918
Healthcare providers and policymakers should be conscious of this 
potential gender bias in the management of ACS and make a concerted effort to ensure that women with ACS receive evidence-based care.In order to ensure the generalizability of the findings yielded by 
RCTs, patient recruitment should be reflective of real-world popula -
tions from different socioeconomic backgrounds.919Several studies 
have reported that a disproportionately low proportion of women are recruited to CV trials.
920–922Alongside historic under- 
representation of other subsets of patients, including older patients 
and ethnic minorities, this suggests an underlying recruitment bias.923
Increased representation of female patients in future clinical trials is re -
quired to better inform the optimal management of women with 
ACS.924•The role of personalized medicine in the short- and 
long-term treatment of ACS needs to be further studied.
•How to address additional risk from non-traditional risk factors, e.g. cardio-obstetrics, cardio-oncology, and inflammatory conditions, needs further attention.
•Inflammation as a treatment target in patients with atherosclerosis still needs unravelling, as well as the use of biomarkers of inflammation (high-sensivity C-reactive 
protein, interleukins 1 and 6) to guide treatment of 
residual risk.
•The role of lipoprotein (a) in guiding treatment and as an independent treatment target needs to be studied further.
•The added cardio-protective role of beta-blockers in post-ACS patients without reduced LVEF on otherwise optimal medical therapy needs to be clarified.
•The added cardio-protective role of ACE inhibitors/ARBs in post-ACS patients without reduced LVEF on otherwise optimal medical therapy needs to be clarified.
•The future role of new treatment options, using mRNA- and siRNA-based therapies targeting lipid metabolism and inflammation, needs to be explored.
•It has to be determined whether SGLT2 inhibitors—in 
the specific group of patients with ACS without heart 
failure or diabetes—improve clinical outcomes, 
regardless of diabetes status.•Patients randomized to personalized strategies vs. usual care are needed to determine the role of precision medicine in ACS.
•Prospective cohorts are needed to evaluate non-traditional risk factors and residual risk.
•RCTs testing whether management based on the use of biomarkers of inflammation improves clinical outcomes.
•RCTs testing whether lipoprotein (a) measurement to guide medical management further improves clinical outcomes.
•Patients randomized to beta-blocker and no beta-blocker use to evaluate treatment efficacy in patients with ACS and LVEF >40%.
•RCTs evaluating the benefit of using ACE inhibitors/ 
ARBs vs. placebo on top of standard care in ACS 
patients with LVEF >40%.
•Randomized data are needed to evaluate the role of mRNA- and siRNA-based therapies in the current context of lipid management and lipid targets.
•ACS patients without HF or diabetes should be randomized to SGLT2 inhibitors vs. standard of 
care.
14 Patient perspectives •The feasibility of performing short witnessed verbal 
consent followed by written consent after the acute phase needs further evaluation.
•There is a need to assess the contribution of social determinants of health on ACS incidence and prognosis.
•The use of validated patient-reported outcome and experience measures in evidence-based medicine should 
be increased.
•Quality of life is a relevant outcome not captured in most 
trials.
•Use of validated decision aids and audio-visual tools can be helpful to make informed choices that consider patients’ values and preferences and promote patient involvement.•Studies comparing verbal vs. written consent to evaluate safety endpoints and any ethical concerns.
•The influence of social determinants of health on clinical outcomes should be evaluated, as well as those interventions aimed at reducing social inequalities.
•PROMs/PREMs should have a more prominent role 
in RCTs evaluating patients with ACS.
•Include quality of life as a prominent outcome in 
clinical trials.
•Testing the use of validated decision aids and audio-visual tools to improve decisions around informed choices.
19 Quality indicators •There is a lack of implementation studies evaluating whether prospectively monitoring and reporting ESC QIs for ACS improve clinical outcomes.•Implementation studies evaluating a quality of care programme based on the evaluation of ESC QIs for ACS.
General •Patients included in clinical trials represent a relatively small proportion of real-life patients.•Conduct clinical trials that enrol more representative patient populations (e.g. pragmatic clinical trials).
©ESC 2023
Ongoing trials addressing some of these gaps in evidence are presented in the Supplementary data online. 
ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; CR, 
cardiac rehabilitation; CS, cardiogenic shock; DAPT, dual antiplatelet therapy; ED, emergency department; ESC, European Society of Cardiology; FFR, fractional flow reserve; HF, heart failure; ICA, 
invasive coronary angiography; IRA, infarct-related artery; i.v., intravenous; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MI, myocardial infarction; MINOCA, 
myocardial infarction with non-obstructive coronary arteries; mRNA, messenger ribonucleic acid; MVD, multivessel disease; MVO, microvascular obstruction; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PPCI, primary percutaneous coronary intervention; PREM, patient-reported experience measure; PROM, 
patient-reported outcome measure; QI, quality indicator; RCT, randomized controlled trial; SCAD, spontaneous coronary artery dissection; SGLT2, sodium-glucose co-transporter 2; siRNA, 
small interfering ribodeoxynucleic acid; STEMI, ST-elevation myocardial infarction.ESC Guidelines                                                                                                                                                                                          3795Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

18. ‘What to do’ and ‘What not to 
do’ messages from the Guidelines
Table 9 ‘What to do’ and ‘What not to do’
Recommendations for clinical and 
diagnostic tools for patients with suspected 
acute coronary syndromeClassaLevelb
It is recommended that patients with suspected 
STEMI are immediately triaged for an emergency 
reperfusion strategy.I A
It is recommended to base the diagnosis and initial short-term risk stratification of ACS on a 
combination of clinical history, symptoms, vital signs, other physical findings, ECG, and hs-cTn.I B
Twelve-lead ECG recording and interpretation is recommended as soon as possible at the point of first 
medical contact, with a target of <10 min.I B
Continuous ECG monitoring and the availability of defibrillator capacity is recommended as soon as 
possible in all patients with suspected STEMI, in suspected ACS with other ECG changes or ongoing 
chest pain, and once the diagnosis of MI is made.I B
The use of additional ECG leads (V3R, V4R, and V7– 
V9) is recommended in cases of inferior STEMI or if 
total vessel occlusion is suspected and standard leads 
are inconclusive.I B
An additional 12-lead ECG is recommended in cases with recurrent symptoms or diagnostic 
uncertainty.I C
It is recommended to measure cardiac troponins with high-sensitivity assays immediately after 
presentation and to obtain the results within 60 min 
of blood sampling.I B
It is recommended to use an ESC algorithmic approach with serial hs-cTn measurements (0 h/1 h 
or 0 h/2 h) to rule in and rule out NSTEMI.I B
Additional testing after 3 h is recommended if the 
first two hs-cTn measurements of the 0 h/1 h 
algorithm are inconclusive and no alternative 
diagnoses explaining the condition have been made.I B
Recommendations for non-invasive imaging in the initial 
assessment of patients with suspected acute coronary 
syndrome
Emergency TTE is recommended in patients with 
suspected ACS presenting with cardiogenic shock or suspected mechanical complications.I C
Routine, early coronary computed tomography angiography in patients with suspected ACS is not 
recommended.III B
ContinuedRecommendations for the initial management of patients with 
acute coronary syndrome
It is recommended that the pre-hospital 
management of patients with a working diagnosis of STEMI is based on regional networks designed to 
deliver reperfusion therapy expeditiously and 
effectively, with efforts made to make PPCI available 
to as many patients as possible.I B
It is recommended that PPCI-capable centres deliver 
a 24/7 service and are able to perform PPCI without 
delay.I B
It is recommended that patients transferred for PPCI 
bypass the emergency department and CCU/ICU 
and are transferred directly to the catheterization laboratory.I B
Oxygen is recommended in patients with hypoxaemia (SaO
2 <90%).I C
It is recommended that EMS transfer patients with suspected STEMI to a PCI-capable centre, bypassing 
non-PCI centres.I C
It is recommended that ambulance teams are trained and equipped to identify ECG patterns suggestive of 
acute coronary occlusion and to administer initial 
therapy, including defibrillation, and fibrinolysis when 
applicable.I C
It is recommended that all hospitals and EMS 
participating in the care of patients with suspected 
STEMI record and audit delay times and work 
together to achieve and maintain quality targets.I C
Routine oxygen is not recommended in patients with oxygen saturation >90%.III A
Recommendations for reperfusion therapy and timing of 
invasive strategy
Recommendations for reperfusion therapy for patients with 
STEMI
Reperfusion therapy is recommended in all patients 
with a working diagnosis of STEMI (persistent 
ST-segment elevation or equivalents) and symptoms 
of ischaemia of ≤12 h duration.I A
A PPCI strategy is recommended over fibrinolysis if the anticipated time from diagnosis to PCI is 
<120 min.I A
If timely PPCI (<120 min) cannot be performed in patients with a working diagnosis of STEMI, 
fibrinolytic therapy is recommended within 12 h of 
symptom onset in patients without 
contraindications.I A
Rescue PCI is recommended for failed fibrinolysis 
(i.e. ST-segment resolution <50% within 60–90 min 
of fibrinolytic administration) or in the presence of 
haemodynamic or electrical instability, worsening 
ischaemia, or persistent chest pain.I A
Continued3796                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

In patients with a working diagnosis of STEMI and a 
time from symptom onset >12 h, a PPCI strategy is 
recommended in the presence of ongoing symptoms 
suggestive of ischaemia, haemodynamic instability, or 
life-threatening arrhythmias.I C
Routine PCI of an occluded IRA is not recommended in STEMI patients presenting >48 h after symptom 
onset and without persistent symptoms.III A
Transfer/interventions after fibrinolysis
Transfer to a PCI-capable centre is recommended in 
all patients immediately after fibrinolysis.I A
Emergency angiography and PCI of the IRA, if 
indicated is recommended in patients with 
new-onset or persistent heart failure/shock after 
fibrinolysis.I A
Angiography and PCI of the IRA, if indicated, is recommended between 2 and 24 h after successful 
fibrinolysis.I A
Invasive strategy in NSTE-ACS
An invasive strategy during hospital admission is 
recommended in NSTE-ACS patients with high-risk 
criteria or with a high index of suspicion for unstable 
angina.I A
A selective invasive approach is recommended in 
patients without very high- or high-risk features and a 
low index of suspicion for NSTE-ACS.I A
An immediate invasive strategy is recommended in 
patients with a working diagnosis of NSTE-ACS and 
with at least one of the following very high-risk 
criteria: 
•Haemodynamic instability or cardiogenic shock
•Recurrent or refractory chest pain despite medical 
treatment
•In-hospital life-threatening arrhythmias
•Mechanical complications of MI
•Acute heart failure presumed secondary to 
ongoing myocardial ischaemia
Recurrent dynamic ST-segment or T wave changes, 
particularly intermittent ST-segment elevation.I C
Recommendations for antiplatelet and anticoagulant therapy in acute coronary syndrome
Antiplatelet therapy
Aspirin is recommended for all patients without 
contraindications at an initial oral LD of 150–300 mg 
(or 75–250 mg i.v.) and an MD of 75–100 mg o.d. for 
long-term treatment.I A
In all ACS patients, a P2Y
12 receptor inhibitor is 
recommended in addition to aspirin, given as an initial 
oral LD followed by an MD for 12 months unless 
there is high bleeding risk.I A
A proton pump inhibitor in combination with dual antiplatelet therapy is recommended in patients at 
high risk of gastrointestinal bleeding.I A
ContinuedPrasugrel is recommended in P2Y 12 receptor 
inhibitor-naïve patients proceeding to PCI (60 mg LD, 10 mg o.d. MD, 5 mg o.d. MD for patients aged 
≥75 years or with a body weight <60 kg).I B
Ticagrelor is recommended irrespective of the treatment strategy (invasive or conservative) 
(180 mg LD, 90 mg twice a day MD).I B
Clopidogrel (300–600 mg LD, 75 mg o.d. MD) is recommended when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated.I C
If patients presenting with ACS stop DAPT to undergo CABG, it is recommended they resume 
DAPT after surgery for at least 12 months.I C
Pre-treatment with a glycoprotein IIb/IIIa antagonist is not recommended.III A
Routine pre-treatment with a P2Y
12 receptor 
inhibitor in NSTE-ACS patients in whom coronary 
anatomy is not known and early invasive management (<24 h) is planned is not 
recommended.III A
Anticoagulant therapy
Parenteral anticoagulation is recommended for all 
patients with ACS at the time of diagnosis.I A
Routine use of a UFH bolus (weight-adjusted i.v. bolus during PCI of 70–100 IU/kg) is recommended 
in patients undergoing PCI.I C
Patients with STEMI
Fondaparinux is not recommended in patients with 
STEMI undergoing PPCI.III B
Patients with NSTE-ACS
For patients with NSTE-ACS in whom early invasive 
angiography (i.e. within 24 h) is not anticipated, 
fondaparinux is recommended.I B
Combining antiplatelets and OAC
As the default strategy for patients with atrial 
fibrillation and CHA
2DS2-VASc score ≥1 in men and 
≥2 in women, after up to 1 week of triple antithrombotic therapy following the ACS event, dual antithrombotic therapy using a non-vitamin K 
antagonist oral anticoagulant at the recommended 
dose for stroke prevention and a single oral 
antiplatelet agent (preferably clopidogrel) for up to 
12 months is recommended.I A
During PCI, a UFH bolus is recommended in any of the following circumstances: 
•if the patient is on a NOAC
•if the INR is <2.5 in VKA-treated patients.I C
The use of ticagrelor or prasugrel as part of triple antithrombotic therapy is not recommended.III C
ContinuedESC Guidelines                                                                                                                                                                                          3797Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Recommendations for alternative antithrombotic therapy 
regimens
Discontinuation of antiplatelet treatment in patients 
treated with an oral anticoagulant is recommended after 12 months.I B
De-escalation of antiplatelet therapy in the first 30 days after ACS is not recommended.III B
Recommendations for fibrinolytic therapy
When fibrinolysis is the reperfusion strategy, it is 
recommended to initiate this treatment as soon as 
possible after diagnosis in the pre-hospital setting 
(aim for target of <10 min to lytic bolus).I A
A fibrin-specific agent (i.e. tenecteplase, alteplase, or 
reteplase) is recommended.I B
Antiplatelet co-therapy with fibrinolysis
Aspirin and clopidogrel are recommended. I A
Anticoagulation co-therapy with fibrinolysis
Anticoagulation is recommended in patients treated 
with fibrinolysis until revascularization (if performed) or for the duration of hospital stay (up to 8 days).I A
Enoxaparin i.v. followed by subcutaneous is recommended as the preferred anticoagulant.I A
When enoxaparin is not available, unfractionated heparin is recommended as a weight-adjusted i.v. 
bolus, followed by infusion.I B
Recommendations for cardiac arrest and out-of-hospital 
cardiac arrest
A PPCI strategy is recommended in patients with 
resuscitated cardiac arrest and an ECG with 
persistent ST-segment elevation (or equivalents).I B
Temperature control (i.e. continuous monitoring of 
core temperature and active prevention of fever [i.e. 
>37.7°C]) is recommended after either 
out-of-hospital or in-hospital cardiac arrest for adults who remain unresponsive after return of 
spontaneous circulation.I B
Routine immediate angiography after resuscitated 
cardiac arrest is not recommended in 
haemodynamically stable patients without persistent 
ST-segment elevation (or equivalents).III A
Systems of care
It is recommended that healthcare systems 
implement strategies to facilitate transfer of all patients in whom ACS is suspected after resuscitated 
cardiac arrest directly to a hospital offering 24/7 PPCI 
via one specialized EMS.I C
Evaluation of neurological prognosis
Evaluation of neurological prognosis (no earlier than 
72 h after admission) is recommended in all 
comatose survivors after cardiac arrest.I C
ContinuedRecommendations for cardiogenic shock
Immediate coronary angiography and PCI of the IRA 
(if indicated) is recommended in patients with CS 
complicating ACS.I B
Emergency CABG is recommended for  ACS-related CS if PCI of the IRA is not feasible/ unsuccessful.I B
In cases of haemodynamic instability, emergency surgical/catheter-based repair of mechanical 
complications of ACS is recommended, based on 
Heart Team discussion.I C
The routine use of an intra-aortic balloon pump in ACS patients with CS and without mechanical complications is not recommended.III B
Recommendations for in-hospital management
It is recommended that all hospitals participating in 
the care of high-risk patients have an ICCU/CCU 
equipped to provide all required aspects of care, 
including treatment of ischaemia, severe heart failure, arrhythmias, and common comorbidities.I C
It is recommended that high-risk patients (including all STEMI patients and very high-risk NSTE-ACS 
patients) have ECG monitoring for a minimum of 24 h.I C
It is recommended that high-risk patients with successful reperfusion therapy and an uncomplicated 
clinical course (including all STEMI patients and very 
high-risk NSTE-ACS patients) are kept in the CCU/ 
ICCU for a minimum of 24 h whenever possible, after 
which they may be moved to a step-down monitored bed for an additional 24–48 h.I C
Recommendations for technical aspects of invasive strategies
Radial access is recommended as the standard 
approach, unless there are over-riding procedural 
considerations.I A
PCI with stent deployment in the IRA during the 
index procedure is recommended for patients 
undergoing PPCI.I A
Drug-eluting stents are recommended in preference 
to bare metal stents in all cases.I A
In patients with spontaneous coronary artery dissection, PCI is recommended only for patients 
with symptoms and signs of ongoing myocardial 
ischaemia, a large area of myocardium in jeopardy, 
and reduced antegrade flow.I C
The routine use of thrombus aspiration is not 
recommended.III A
Recommendations for management of patients with 
multivessel disease
It is recommended to base the revascularization 
strategy (IRA PCI, multivessel PCI/CABG) on the 
patient’s clinical status and comorbidities, as well as 
their disease complexity, according to the principles 
of management of myocardial revascularization.I B
Continued3798                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Multivessel disease in ACS patients presenting in cardiogenic 
shock
IRA-only PCI during the index procedure is 
recommended.I B
Multivessel disease in haemodynamically stable STEMI patients 
undergoing PPCI
Complete revascularization is recommended either 
during the index PCI procedure or within 45 days.I A
It is recommended that PCI of the non-IRA is based on angiographic severity.I B
Invasive epicardial functional assessment of 
non-culprit segments of the IRA is not 
recommended during the index procedure.III C
Recommendations for myocardial infarction with non-obstructive coronary arteries
In patients with a working diagnosis of MINOCA 
CMR imaging is recommended after invasive 
angiography if the final diagnosis is not clearI B
Management of MINOCA according to the final 
established underlying diagnosis is recommended, 
consistent with the appropriate disease-specific 
guidelines.I B
In all patients with an initial working diagnosis of MINOCA, it is recommended to follow a diagnostic 
algorithm to determine the underlying final diagnosis.I C
Recommendations for acute coronary syndrome complications
Atrial fibrillation
Intravenous beta-blockers are recommended when 
rate control is needed in the absence of acute HF or 
hypotension.I C
Intravenous amiodarone is recommended when rate control is needed in the presence of acute HF and no 
hypotension.I C
Immediate electrical cardioversion is recommended in patients with ACS and haemodynamic instability and when adequate rate control cannot be achieved 
promptly with pharmacological agents.I C
Intravenous amiodarone is recommended to 
facilitate electrical cardioversion and/or decrease risk of early recurrence of AF after electrical 
cardioversion in unstable patients with recent-onset 
AF.I C
Ventricular arrythmias
Implantable cardioverter defibrillator use is 
recommended to reduce sudden cardiac death in 
patients with symptomatic HF (NYHA Class II–III) 
and LVEF ≤35% despite optimal medical therapy for 
>3 months and at least 6 weeks after MI who are 
expected to survive for at least 1 year with good functional status.I A
Intravenous beta-blocker and/or amiodarone treatment is recommended for patients with 
polymorphic VT and/or VF unless contraindicated.I B
ContinuedPrompt and complete revascularization is 
recommended to treat myocardial ischaemia that may 
be present in patients with recurrent VT and/or VF.I C
Bradyarrhythmias
In cases of sinus bradycardia with haemodynamic 
intolerance or high-degree AV block without stable 
escape rhythm:
•i.v. positive chronotropic medication (adrenaline, 
vasopressin, and/or atropine) is recommended.
•temporary pacing is recommended in cases of failure to respond to atropine.
•urgent angiography with a view to 
revascularization is recommended if the patient 
has not received previous reperfusion therapy.I C
Implantation of a permanent pacemaker is recommended when high-degree AV block does not resolve within a waiting period of at least 5 days after 
MI.I C
Pacing is not recommended if high-degree AV block 
resolves after revascularization or spontaneously.III B
Treatment of asymptomatic and haemodynamically irrelevant ventricular arrhythmias with 
anti-arrhythmic drugs is not recommended.III C
Recommendations for acute coronary syndrome comorbid 
conditions
Chronic kidney disease
The use of low- or iso-osmolar contrast media (at 
the lowest possible volume) is recommended for 
invasive strategies.I A
It is recommended to assess kidney function using 
eGFR in all patients with ACS.I C
It is recommended to apply the same diagnostic and 
therapeutic strategies in patients with CKD (dose 
adjustment may be necessary) as in patients with 
normal kidney function.I C
Diabetes
It is recommended to base the choice of long-term 
glucose-lowering treatment on the presence of 
comorbidities, including heart failure, CKD, and 
obesity.I A
It is recommended to assess glycaemic status at initial 
evaluation in all patients with ACS.I B
It is recommended to frequently monitor blood glucose levels in patients with known diabetes 
mellitus or hyperglycaemia (defined as glucose levels 
≥11.1 mmol/L or ≥200 mg/dL).I C
Older adults
It is recommended to apply the same diagnostic and 
treatment strategies in older patients as in younger patients.I B
ContinuedESC Guidelines                                                                                                                                                                                          3799Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

It is recommended to adapt the choice and dosage of 
antithrombotic agent, as well as of secondary 
prevention medications, to renal function, 
co-medications, comorbidities, frailty, cognitive 
function, and specific contraindications.I B
For frail older patients with comorbidities, a holistic approach is recommended to individualize interventional and pharmacological treatments after 
careful evaluation of the risks and benefits.I B
An invasive strategy is recommended in cancer 
patients presenting with high-risk ACS with expected 
life survival ≥6 months.I B
A temporary interruption of cancer therapy is 
recommended in patients in whom the cancer 
therapy is suspected to be a contributing cause of 
ACS.I C
Aspirin is not recommended in cancer patients with a 
platelet count <10 000/μL.III C
Clopidogrel is not recommended in cancer patients 
with a platelet count <30 000/μL.III C
In ACS patients with cancer and <50 000/μL platelet 
count, prasugrel or ticagrelor are not recommended.III C
Recommendations for long-term management
It is recommended that all ACS patients participate in 
a medically supervised, structured, comprehensive, 
multidisciplinary exercise-based cardiac rehabilitation and prevention programme.I A
It is recommended that ACS patients adopt a healthy lifestyle, including: 
•stopping all smoking of tobacco
•healthy diet (Mediterranean style)
•alcohol restriction
•regular aerobic physical activity and resistance 
exercise
•reduced sedentary timeI B
Pharmacological treatment
Lipid-lowering therapy
It is recommended that high-dose statin therapy is 
initiated or continued as early as possible, regardless 
of initial LDL-C values.I A
It is recommended to aim to achieve an LDL-C level of <1.4 mmol/L (<55 mg/dL) and to reduce LDL-C 
by ≥50% from baseline.I A
If the LDL-C goal is not achieved despite maximally tolerated statin therapy and ezetimibe after 4–6 
weeks, the addition of a PCSK9 inhibitor is 
recommendedI A
If the LDL-C goal is not achieved despite maximally tolerated statin therapy after 4–6 weeks, the addition of ezetimibe is recommended.I B
It is recommended to intensify lipid-lowering therapy during the index ACS hospitalization for patients 
who were on lipid-lowering therapy before 
admission.I C
ContinuedBeta-blockers
Beta-blockers are recommended in ACS patients 
with LVEF ≤40% regardless of HF symptoms.I A
RAAS system inhibitors
Angiotensin-converting enzyme inhibitors are 
recommended in ACS patients with HF symptoms, 
LVEF ≤40%, diabetes, hypertension, and/or CKD.I A
Mineralocorticoid receptor antagonists are recommended in ACS patients with an LVEF ≤40% 
and HF or diabetes.I A
Imaging
In patients with pre-discharge LVEF ≤40%, repeat 
evaluation of the LVEF 6–12 weeks after an ACS (and 
after complete revascularization and the institution 
of optimal medical therapy) is recommended to 
assess the potential need for sudden cardiac death 
primary prevention ICD implantation.I C
Vaccination
Influenza vaccination is recommended for all ACS 
patients.I A
Recommendations for patient perspectives in acute coronary 
syndrome care
Patient-centred care is recommended by assessing 
and adhering to individual patient preferences, needs and beliefs, ensuring that patient values are used to 
inform all clinical decisions.I B
It is recommended to include ACS patients in decision-making (as much as their condition allows) 
and to inform them about the risk of adverse events, 
radiation exposure, and alternative options. Decision 
aids should be used to facilitate the discussion.I B
It is recommended to assess symptoms using methods that help patients to describe their 
experience.I C
©ESC 2023
ACS, acute coronary syndrome; AV, atrioventricular; CABG, coronary artery bypass 
grafting; CCU, cardiac care unit; CHA 2DS2-VASc, Congestive heart failure, 
Hypertension, Age ≥75 years, Diabetes mellitus, Stroke or transient ischaemic attack, 
Vascular disease; CKD, chronic kidney disease; CMR, cardiac magnetic resonance; CS, cardiogenic shock; DAPT, dual antiplatelet therapy; ECG, electrocardiogram; ESC, 
European Society of Cardiology; HF, heart failure; hs-cTn, high-sensitivity cardiac 
troponin; ICU, intensive care unit; IRA, infarct-related artery; i.v., intravenous; LD, 
loading dose; LDL-C, low-density lipoprotein cholesterol; MD, maintenance dose; 
MINOCA, myocardial infarction with non-obstructive coronary arteries; LVEF, left 
ventricular ejection fraction; MI, myocardial infarction; NSTE-ACS, non-ST-elevation 
acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; NYHA, 
New York Heart Association; o.d., once daily; OAC, oral anticoagulant; PCI, 
percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 
9; PPCI, primary percutaneous coronary intervention; RAAS, renin–angiotensin– 
aldosterone system; STEMI, ST-elevation myocardial infarction; UFH, unfractionated 
heparin; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.3800                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

19. Quality indicators
Quality indicators are tools that can be used to evaluate care quality, 
including structures, processes, and outcomes of care.925They may 
also serve as a mechanism for enhancing adherence to guideline recom -
mendations, through associated quality improvement initiatives and the 
benchmarking of care providers.926,927As such, the role of QIs in im -
proving care and outcomes for CVD is increasingly recognized by 
healthcare authorities, professional organizations, payers, and the 
public.925
The ESC understands the need for measuring and reporting quality 
and outcomes of CV care and has established methods for the develop -
ment of the ESC QIs for the quantification of care and outcomes for 
CVDs.925To date, the ESC has developed QI suites for a number of 
CVDs in parallel with the writing of the ESC Clinical Practice 
Guidelines. Previous QIs for the management of AMI have been tested 
in numerous large registries.928–933A systematic review of these studies 
has shown that there is room for improvement in terms of levels of at -
tainment of QIs.934
The ESC aims to harmonize its QIs for various CV conditions and in -
tegrate them with ESC registries.935,936This integrative approach pro -
vides ‘real-world’ data about the patterns and outcomes of care for 
CVD across Europe.
20. Supplementary data
Supplementary data are available at European Heart Journal online.
21. Data availability statement
No new data were generated or analysed in support of this research.
22. Author information
Author/Task Force Member Affiliations: Xavier Rossello, 
Cardiology Department, Hospital Universitari Son Espases, Palma de 
Mallorca, Spain, Clinical Research Department Centro Nacional de 
Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Health 
Research Institute of the Balearic Islands (IdiSBa), Universitat de les 
Illes Balears (UIB), Palma de Mallorca, Spain; J.J. Coughlan, 
Cardiovascular Research Institute, Mater Private Network, Dublin, 
Ireland; Emanuele Barbato, Clinical and Molecular Medicine, 
Sapienza University, Rome, Italy; Colin Berry, British Heart 
Foundation, Glasgow Cardiovascular Research Centre, University of 
Glasgow, Glasgow, United Kingdom, Cardiology, NHS Golden 
Jubilee, Clydebank, United Kingdom, Cardiology, NHS Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom; Alaide 
Chieffo, IRCCS San Raffaele Scientific Institute, IRCCS San Raffaele 
Scientific Institute, Milan, Italy, University Vita-Salute San Raffaele, 
Milan, Italy; Marc J. Claeys, Cardiology, Antwerp University 
Hospital, Edegem, Belgium; Gheorghe-Andrei Dan, Colentina 
University Hospital, Cardiology Dpt., “Carol Davila” University of Medicine Bucharest, Romania; Marc R. Dweck, British Heart 
Foundation Centre for Cardiovascular Sciences, Chancellors Building, 
Little France Crescent, Little France, Edinburgh, United Kingdom; 
Mary Galbraith (United Kingdom), ESC Patient Forum, Sophia 
Antipolis, France; Martine Gilard, Cardiology, INSERM UMR 1304 
GETBO- Brest University, Brest, France; Lynne Hinterbuchner, Department of Cardiology, Clinic of Internal Medicine II, Paracelsus 
Medical University of Salzburg, Salzburg, Austria; Ewa 
A. Jankowska, Institute of Heart Diseases, Wroclaw Medical 
University, Wroclaw, Poland, Institute of Heart Diseases, University 
Hospital in Wroclaw, Wroclaw, Poland; Peter Jüni, Nuffield 
Department of Population Health, University of Oxford, Oxford, 
United Kingdom; Takeshi Kimura, Department of Cardiology, 
Hirakata Kohsai Hospital, Osaka, Japan; Vijay Kunadian, 
Translational and Clinical Research Institute, Faculty of Medical 
Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom, Cardiothoracic Centre, Freeman Hospital, Newcastle upon 
Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, 
United Kingdom; Margret Leosdottir, Department of Cardiology, 
Skane University Hospital, Malmö, Sweden, Department of Clinical 
Sciences, Malmö, Lund University, Malmö, Sweden; Roberto 
Lorusso, Cardio-Thoracic Surgery, Maastricht University Medical 
Centre, Maastricht, Netherlands, Cardiovascular Research Institute 
Maastricht, Maastricht, Netherlands; Roberto F.E. Pedretti, 
Cardiovascular Department, IRCCS MultiMedica, Milan, Italy; Angelos G. Rigopoulos, Adult Cardiology, Mitera General 
Hospital-Hygeia Group, Athens, Greece; Maria Rubini Gimenez, 
Department of Internal Medicine and Cardiology, Heart Center 
Leipzig at the University of Leipzig, Leipzig, Germany, Cardiovascular 
Research Institute Basel, University Hospital Basel, Basel, Switzerland; 
Holger Thiele, Internal Medicine/Cardiology; Heart Center Leipzig at University of Leipzig, Leipzig, Germany, Leipzig Heart Science, 
Leipzig, Germany; Pascal Vranckx, Cardiology and Critical Care 
Medicine, Jessa Ziekenhuis, Hasselt, Belgium, Faculty of Medicine and 
Life Sciences, University of Hasselt, Hasselt, Belgium; Sven 
Wassmann, Cardiology, Cardiology Pasing, Munich, Germany; 
Faculty of Medicine, University of the Saarland, Homburg/Saar, 
Germany; Nanette Kass Wenger, Department of Medicine 
(Cardiology), Emory University School of Medicine, Atlanta, GA, United 
States of America, Consultant, Emory Heart and Vascular Center 
Emory University, School of Medicine, Atlanta, GA, United States of 
America, Founding Consultant, Emory Women’s Heart Center, Emory 
University School of Medicine, Atlanta, GA, United States of America.
23. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Sigrun Halvorsen (CPG Review 
Co-ordinator) (Norway), Stefan James (CPG Review Co-ordinator) (Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Nina 
Ajmone Marsan (Netherlands), Sotiris Antoniou (United Kingdom), 
Riccardo Asteggiano (Italy), Maria Bäck (Sweden), Davide Capodanno (Italy), Ruben Casado-Arroyo (Belgium), Salvatore Cassese 
(Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), 
Jean-Philippe Collet (France), Gregory Ducrocq (France), Volkmar 
Falk (Germany), Laurent Fauchier (France), Tobias Geisler 
(Germany), Diana A. Gorog (United Kingdom), Lene Holmvang (Denmark), Tiny Jaarsma (Sweden), Hywel Wynne Jones (United 
Kingdom), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), Dipak Kotecha (United Kingdom), Konstantin 
A. Krychtiuk (Austria), Ulf Landmesser (Germany), George Lazaros 
(Greece), Basil S. Lewis (Israel), Bertil Lindahl (Sweden), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Mamas A. Mamas ESC Guidelines                                                                                                                                                                                          3801Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

(United Kingdom), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Christian 
Mueller (Switzerland), Lis Neubeck (United Kingdom), Josef Niebauer 
(Austria), Jens Cosedis Nielsen (Denmark), Alexander Niessner 
(Austria), Valeria Paradies (Netherlands), Agnes A. Pasquet (Belgium), 
Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark), 
Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Giuseppe 
M. C. Rosano (Italy), Leyla Elif Sade (United States of America/ 
Türkiye), François Schiele (France), Jolanta M. Siller-Matula (Austria), 
Christian Sticherling (Switzerland), Robert F. Storey (United 
Kingdom), Matthias Thielmann (Germany), Christiaan Vrints 
(Belgium), Stephan Windecker (Switzerland), Rune Wiseth (Norway), and Adam Witkowski (Poland).
ESC National Cardiac Societies actively involved in the review 
process of the 2023 ESC Guidelines for the management of acute cor -
onary syndromes:
Algeria: Algerian Society of Cardiology, Mohammed El Amine 
Bouzid; Armenia: Armenian Cardiologists Association, Hamlet 
Hayrapetyan; Austria: Austrian Society of Cardiology, Bernhard 
Metzler; Belgium: Belgian Society of Cardiology, Patrizio Lancellotti; 
Bosnia and Herzegovina: Association of Cardiologists of Bosnia 
and Herzegovina, Mugdim Bajrić; Bulgaria: Bulgarian Society of 
Cardiology, Kiril Karamfiloff; Cyprus: Cyprus Society of Cardiology, 
Andreas Mitsis; Czechia: Czech Society of Cardiology, Petr Ostadal; 
Denmark: Danish Society of Cardiology, Rikke Sørensen; Egypt: 
Egyptian Society of Cardiology, Tamer Elwasify; Estonia: Estonian 
Society of Cardiology, Toomas Marandi; Finland: Finnish Cardiac 
Society, Essi Ryödi; France: French Society of Cardiology, 
Jean-Philippe Collet; Georgia: Georgian Society of Cardiology, 
Archil Chukhrukidze; Germany: German Cardiac Society, Julinda 
Mehilli; Greece: Hellenic Society of Cardiology, Periklis Davlouros; 
Hungary: Hungarian Society of Cardiology, Dávid Becker; Iceland: 
Icelandic Society of Cardiology, Ingibjörg Jóna Guðmundsdóttir; 
Ireland: Irish Cardiac Society, James Crowley; Israel: Israel Heart 
Society, Yigal Abramowitz; Italy: Italian Federation of Cardiology, 
Ciro Indolfi; Kazakhstan: Association of Cardiologists of 
Kazakhstan, Orazbek Sakhov; Kosovo (Republic of): Kosovo 
Society of Cardiology, Shpend Elezi; Kyrgyzstan: Kyrgyz Society of 
Cardiology, Medet Beishenkulov; Latvia: Latvian Society of 
Cardiology, Andrejs Erglis; Lebanon: Lebanese Society of 
Cardiology, Nicolas Moussallem; Libya: Libyan Cardiac Society, 
Hisham Benlamin; Lithuania: Lithuanian Society of Cardiology, 
Olivija Dobilienė; Luxembourg: Luxembourg Society of Cardiology, 
Philippe Degrell; Malta: Maltese Cardiac Society, Matthew Mercieca 
Balbi; Moldova (Republic of): Moldavian Society of Cardiology, 
Aurel Grosu; Morocco: Moroccan Society of Cardiology, Zouhair 
Lakhal; Netherlands
: Netherlands Society of Cardiology, Jurriën 
ten Berg; North Macedonia: The National Society of Cardiology 
of North Macedonia, Hristo Pejkov; Norway: Norwegian Society of 
Cardiology, Kristin Angel; Poland: Polish Cardiac Society, Adam 
Witkowski; Portugal: Portuguese Society of Cardiology, Manuel De 
Sousa Almeida; Romania: Romanian Society of Cardiology, Ovidiu 
Chioncel; San Marino: San Marino Society of Cardiology, Luca 
Bertelli; Serbia: Cardiology Society of Serbia, Sinisa Stojkovic; 
Slovakia: Slovak Society of Cardiology, Martin Studenčan; 
Slovenia: Slovenian Society of Cardiology, Peter Radšel; Spain: 
Spanish Society of Cardiology, Jose Luis Ferreiro; Sweden: Swedish 
Society of Cardiology, Annica Ravn-Fischer; Switzerland: Swiss 
Society of Cardiology, Lorenz Räber; Syrian Arab Republic: 
Syrian Cardiovascular Association, Mohammed Yassin Bani Marjeh; Tunisia: Tunisian Society of Cardiology and Cardiovascular Surgery, 
Majed Hassine; Türkiye: Turkish Society of Cardiology, Aylin 
Yildirir; Ukraine: Ukrainian Association of Cardiology, Alexander 
Parkhomenko; United Kingdom of Great Britain and 
Northern Ireland: British Cardiovascular Society, Adrian Paul 
Banning.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands).
24. References
1.Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth univer -
sal definition of myocardial infarction (2018). Eur Heart J 2019;
40:237–269. https://doi. 
org/10.1093/eurheartj/ehy462
2.GBD 2017 Causes of Death Collaborators. Global, regional, and national 
age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. 
Lancet 2018;
392:1736–1788. https://doi.org/10.1016/s0140-6736(18)32203-7
3.Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European 
Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022;43: 
716–799. https://doi.org/10.1093/eurheartj/ehab892
4.Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC 
Guidelines for the management of acute myocardial infarction in patients presenting 
with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society 
of Cardiology (ESC). Eur Heart J 2018;39:119–177. https://doi.org/10.1093/ 
eurheartj/ehx393
5.Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV, Kirk JD, et al. Frequency 
and consequences of recording an electrocardiogram >10 minutes after arrival in an 
emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). Am J Cardiol 2006;97:437–442. https://doi.org/10.1016/j.amjcard. 
2005.09.073
6.
Lopez-Sendon J, Coma-Canella I, Alcasena S, Seoane J, Gamallo C. Electrocardiographic findings in acute right ventricular infarction: sensitivity and speci
-
ficity of electrocardiographic alterations in right precordial leads V4R, V3R, V1, V2, and V3. J Am Coll Cardiol 1985;
6:1273–1279. https://doi.org/10.1016/s0735-1097(85) 
80213-8
7.Schmitt C, Lehmann G, Schmieder S, Karch M, Neumann F-J, Scho¨mig A. Diagnosis of acute myocardial infarction in angiographically documented occluded infarct vessel: 
limitations of ST-segment elevation in standard and extended ECG leads. Chest 
2001;
120:1540–1546. https://doi.org/10.1378/chest.120.5.1540
8.Kosuge M, Kimura K, Ishikawa T, Hongo Y, Shigemasa T, Sugiyama M, et al. Implications 
of the absence of ST-segment elevation in lead V4R in patients who have inferior wall 
acute myocardial infarction with right ventricular involvement. Clin Cardiol 2001;24: 
225–230. https://doi.org/10.1002/clc.4960240310
9.Yan AT, Yan RT, Kennelly BM, Anderson FA, Budaj A, López-Sendón J, et al. 
Relationship of ST elevation in lead aVR with angiographic findings and outcome in 
non-ST elevation acute coronary syndromes. Am Heart J 2007;154:71–78. https:// 
doi.org/10.1016/j.ahj.2007.03.037
10.Hirano T, Tsuchiya K, Nishigaki K, Sou K, Kubota T, Ojio S, et al. Clinical features of 
emergency electrocardiography in patients with acute myocardial infarction caused 
by left main trunk obstruction. Circ J 2006;70:525–529. https://doi.org/10.1253/circj. 
70.525
11.Yamaji H, Iwasaki K, Kusachi S, Murakami T, Hirami R, Hamamoto H, et al. Prediction 
of acute left main coronary artery obstruction by 12-lead electrocardiography. ST seg -
ment elevation in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol 
2001;
38:1348–1354. doi: doi: 10.1016/S0735-1097(01)01563-7
12.Chapman AR, Shah ASV, Lee KK, Anand A, Francis O, Adamson P, et al. Long-term 
outcomes in patients with type 2 myocardial infarction and myocardial injury. 3802                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Circulation 2018;137:1236–1245. https://doi.org/10.1161/CIRCULATIONAHA.117. 
031806
13.Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbücher 
D, et al. Effect of definition on incidence and prognosis of type 2 myocardial infarction. J 
Am Coll Cardiol 2017;70:1558–1568. https://doi.org/10.1016/j.jacc.2017.07.774
14.Neumann JT, Sorensen NA, Rubsamen N, Ojeda F, Renné T, Qaderi V, et al. 
Discrimination of patients with type 2 myocardial infarction. Eur Heart J 2017;38: 
3514–3520. https://doi.org/10.1093/eurheartj/ehx457
15.Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Chapman AR, et al. High-sensitivity 
troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet 2018;392:919–928. 
https://doi.org/10.1016/S0140-6736(18)31923-8
16.
Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, et al. The se -
cond Euro Heart Survey on acute coronary syndromes: characteristics, treatment, 
and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. 
Eur Heart J 2006;
27:2285–2293. https://doi.org/10.1093/eurheartj/ehl196
17.Twerenbold R, Boeddinghaus J, Nestelberger T, Wildi K, Rubini Gimenez M, 
Badertscher P, et al. Clinical use of high-sensitivity cardiac troponin in patients with sus -
pected myocardial infarction. J Am Coll Cardiol 2017;
70:996–1012. https://doi.org/10. 
1016/j.jacc.2017.07.718
18.Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC 
Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;
42:1289–1367. https:// 
doi.org/10.1093/eurheartj/ehaa575
19.Rokos IC, French WJ, Koenig WJ, Stratton SJ, Nighswonger B, Strunk B, et al. 
Integration of pre-hospital electrocardiograms and ST-elevation myocardial infarction receiving center (SRC) networks: impact on door-to-balloon times across 10 inde
-
pendent regions. JACC Cardiovasc Interv 2009;
2:339–346. https://doi.org/10.1016/j. 
jcin.2008.11.013
20.O’Doherty M, Tayler DI, Quinn E, Vincent R, Chamberlain DA. Five hundred patients 
with myocardial infarction monitored within one hour of symptoms. Br Med J (Clin Res 
Ed) 1983;
286:1405–1408. https://doi.org/10.1136/bmj.286.6375.1405
21.Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, et al. Incidence of 
and outcomes associated with ventricular tachycardia or fibrillation in patients under -
going primary percutaneous coronary intervention. JAMA 2009;
301:1779–1789. 
https://doi.org/10.1001/jama.2009.600
22.Kulkarni AU, Brown R, Ayoubi M, Banka VS. Clinical use of posterior electrocardio -
graphic leads: a prospective electrocardiographic analysis during coronary occlusion. Am Heart J 1996;
131:736–741. https://doi.org/10.1016/s0002-8703(96)90280-x
23.Casas RE, Marriott HJL, Glancy DL. Value of leads V7-V9 in diagnosing posterior wall acute myocardial infarction and other causes of tall R waves in V1-V2. Am J Cardiol 
1997;
80:508–509. https://doi.org/10.1016/s0002-9149(97)00404-9
24.Zalenski RJ, Rydman RJ, Sloan EP, Hahn KH, Cooke D, Fagan J, et al. Value of posterior 
and right ventricular leads in comparison to the standard 12-lead electrocardiogram in 
evaluation of ST-segment elevation in suspected acute myocardial infarction. Am J 
Cardiol 1997;79:1579–1585. https://doi.org/10.1016/s0002-9149(97)00202-6
25.Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diag -
nosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 
361
:858–867. https://doi.org/10.1056/NEJMoa0900428
26.Reichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti S, Balmelli C, et al. Introduction 
of high-sensitivity troponin assays: impact on myocardial infarction incidence and prog -
nosis. Am J Med 2012;
125:1205–1213.e1. https://doi.org/10.1016/j.amjmed.2012.07. 
015
27.Neumann JT, Twerenbold R, Ojeda F, Sörensen NA, Chapman AR, Shah ASV, et al. 
Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J 
Med 2019;
380:2529–2540. https://doi.org/10.1056/NEJMoa1803377
28.Boeddinghaus J, Twerenbold R, Nestelberger T, Badertscher P, Wildi K, Puelacher C, 
et al. Clinical validation of a novel high-sensitivity cardiac troponin I assay for early diag -
nosis of acute myocardial infarction. Clin Chem 2018;
64:1347–1360. https://doi.org/10. 
1373/clinchem.2018.286906
29.Neumann JT, Sorensen NA, Rubsamen N, Ojeda F, Schock A, Seddighizadeh P, et al. 
Evaluation of a new ultra-sensitivity troponin I assay in patients with suspected myo -
cardial infarction. Int J Cardiol 2019;
283:35–40. https://doi.org/10.1016/j.ijcard.2018.12. 
001
30.Neumann JT, Sorensen NA, Schwemer T, Ojeda F, Bourry R, Sciacca V, et al. Diagnosis 
of myocardial infarction using a high-sensitivity troponin I 1-hour algorithm. JAMA 
Cardiol 2016;
1:397–404. https://doi.org/10.1001/jamacardio.2016.0695
31.Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, et al. 
One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity car -
diac troponin T. Arch Intern Med 2012;
172:1211–1218. https://doi.org/10.1001/ 
archinternmed.2012.3698
32.Boeddinghaus J, Twerenbold R, Nestelberger T, Koechlin L, Wussler D, Meier M, et al. 
Clinical use of a new high-sensitivity cardiac troponin I assay in patients with suspected 
myocardial infarction. Clin Chem 2019;
65:1426–1436. https://doi.org/10.1373/ 
clinchem.2019.30472533.Boeddinghaus J, Lopez-Ayala P, Nestelberger T, Koechlin L, Münch T, Miro O, et al. 
Prospective validation of the ESC 0/1h-algorithm using high-sensitivity cardiac tropo -
nin I. Am J Cardiol 2021;
158:152–153. https://doi.org/10.1016/j.amjcard.2021.08.007
34.Boeddinghaus J, Nestelberger T, Twerenbold R, Neumann JT, Lindahl B, Giannitsis E, 
et al. Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis 
of myocardial infarction. Eur Heart J 2018;
39:3780–3794. https://doi.org/10.1093/ 
eurheartj/ehy514
35.Twerenbold R, Badertscher P, Boeddinghaus J, Nestelberger T, Wildi K, Puelacher C, 
et al. 0/1-Hour triage algorithm for myocardial infarction in patients with renal dysfunc -
tion. Circulation 2018;
137:436–451. https://doi.org/10.1161/CIRCULATIONAHA. 
117.028901
36.Boeddinghaus J, Reichlin T, Cullen L, Greenslade JH, Parsonage WA, Hammett C, et al. 
Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarc -
tion by use of high-sensitivity cardiac troponin I. Clin Chem 2016;
62:494–504. https:// 
doi.org/10.1373/clinchem.2015.249508
37.Wildi K, Cullen L, Twerenbold R, Greenslade JH, Parsonage W, Boeddinghaus J, et al. 
Direct comparison of 2 rule-out strategies for acute myocardial infarction: 2-h accel -
erated diagnostic protocol vs 2-h algorithm. Clin Chem 2017;
63:1227–1236. https:// 
doi.org/10.1373/clinchem.2016.268359
38.Nestelberger T, Boeddinghaus J, Greenslade J, Parsonage WA, Than M, Wussler D, 
et al. Two-hour algorithm for rapid triage of suspected acute myocardial infarction 
using a high-sensitivity cardiac troponin I assay. Clin Chem 2019;
65:1437–1447. 
https://doi.org/10.1373/clinchem.2019.305193
39.Koechlin L, Boeddinghaus J, Nestelberger T, Lopez-Ayala P, Wussler D, Shrestha S, 
et al. Performance of the ESC 0/2h-algorithm using high-sensitivity cardiac troponin 
I in the early diagnosis of myocardial infarction. Am Heart J 2021;242:132–137. 
https://doi.org/10.1016/j.ahj.2021.08.008
40.Wildi K, Nelles B, Twerenbold R, Rubini Giménez M, Reichlin T, Singeisen H, et al. 
Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction. Am Heart J 2016;181:16–25. https://doi.org/10.1016/j.ahj.2016.07.013
41.Badertscher P, Boeddinghaus J, Twerenbold R, Nestelberger T, Wildi K, Wussler D, 
et al. Direct comparison of the 0/1h and 0/3h algorithms for early rule-out of acute 
myocardial infarction. Circulation 2018;137:2536–2538. https://doi.org/10.1161/ 
CIRCULATIONAHA.118.034260
42.Chapman AR, Anand A, Boeddinghaus J, Ferry AV, Sandeman D, Adamson PD, et al. 
Comparison of the efficacy and safety of early rule-out pathways for acute myocardial 
infarction. Circulation 2017;135:1586–1596. https://doi.org/10.1161/ 
CIRCULATIONAHA.116.025021
43.
Chapman AR, Fujisawa T, Lee KK, Andrews JP, Anand A, Sandeman D, et al. Novel 
high-sensitivity cardiac troponin I assay in patients with suspected acute coronary syn -
drome. Heart 2019;
105:616–622. https://doi.org/10.1136/heartjnl-2018-314093
44.Chew DP, Lambrakis K, Blyth A, Seshadri A, Edmonds MJR, Briffa T, et al. A rando -
mized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the rapid assessment of possible acute coronary syndrome in the emergency depart
-
ment with high-sensitivity troponin T study (RAPID-TnT). Circulation 2019;
140: 
1543–1556. https://doi.org/10.1161/CIRCULATIONAHA.119.042891
45.Nestelberger T, Wildi K, Boeddinghaus J, Twerenbold R, Reichlin T, Giménez MR, et al. 
Characterization of the observe zone of the ESC 2015 high-sensitivity cardiac troponin 0h/1h-algorithm for the early diagnosis of acute myocardial infarction. Int J Cardiol 
2016;
207:238–245. https://doi.org/10.1016/j.ijcard.2016.01.112
46.Lopez-Ayala P, Nestelberger T, Boeddinghaus J, Koechlin L, Ratmann PD, Strebel I, et al. Novel criteria for the observe-zone of the ESC 0/1h-hs-cTnT algorithm. 
Circulation 2021;144:773–787. https://doi.org/10.1161/CIRCULATIONAHA.120. 
052982
47.Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. 
Predictors of hospital mortality in the global registry of acute coronary events. Arch 
Intern Med 2003;163:2345–2353. https://doi.org/10.1001/archinte.163.19.2345
48.
Fox KA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should pa -
tients with acute coronary disease be stratified for management according to their 
risk? Derivation, external validation and outcomes using the updated GRACE risk 
score. BMJ Open 2014;
4:e004425. https://doi.org/10.1136/bmjopen-2013-004425
49.Wenzl FA, Kraler S, Ambler G, Weston C, Herzog SA, Räber L, et al. Sex-specific 
evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multination
-
al analysis with external cohort validation. Lancet 2022;
400:744–756. https://doi.org/ 
10.1016/s0140-6736(22)01483-0
50.Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. 
Lancet 1986;
1:397–402.
51.Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771–775. 
https://doi.org/10.1016/s0140-6736(96)02514-7
52.Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. 
Lancet 2003;361:13–20. https://doi.org/10.1016/s0140-6736(03)12113-7
53.Reichlin T, Twerenbold R, Maushart C, Reiter M, Moehring B, Schaub N, et al. Risk 
stratification in patients with unstable angina using absolute serial changes of 3 high- ESC Guidelines                                                                                                                                                                                          3803Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

sensitive troponin assays. Am Heart J 2013;165:371–378.e3. https://doi.org/10.1016/j. 
ahj.2012.11.010
54.Anand A, Lee KK, Chapman AR, Ferry AV, Adamson PD, Strachan FE, et al. 
High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: a 
stepped-wedge cluster randomized controlled trial. Circulation 2021;143: 
2214–2224. https://doi.org/10.1161/CIRCULATIONAHA.120.052380
55.Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J 2014;35: 
552–556. https://doi.org/10.1093/eurheartj/eht530
56.Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC 
Guidelines for the management of acute coronary syndromes in patients presenting 
without persistent ST-segment elevation: Task Force for the management of acute 
coronary syndromes in patients presenting without persistent ST-segment elevation 
of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315. https:// 
doi.org/10.1093/eurheartj/ehv320
57.Mueller C, Giannitsis E, Mockel M, Huber K, Mair J, Plebani M, et al. Rapid rule out of 
acute myocardial infarction: novel biomarker-based strategies. Eur Heart J Acute 
Cardiovasc Care 2017;6:218–222. https://doi.org/10.1177/2048872616653229
58.Mockel M, Giannitsis E, Mueller C, Huber K, Jaffe AS, Mair J, et al. Rule-in of acute myo -
cardial infarction: focus on troponin. Eur Heart J Acute Cardiovasc Care 2017;
6:212–217. 
https://doi.org/10.1177/2048872616653228
59.Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, et al. Clinical 
and therapeutic profile of patients presenting with acute coronary syndromes who do 
not have significant coronary artery disease. The Platelet Glycoprotein IIb/IIIa in 
Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial in -
vestigators. Circulation 2000;
102:1101–1106. https://doi.org/10.1161/01.cir.102.10. 
1101
60.Westermann D, Neumann JT, Sorensen NA, Blankenberg S. High-sensitivity assays for 
troponin in patients with cardiac disease. Nat Rev Cardiol 2017;
14:472–483. https://doi. 
org/10.1038/nrcardio.2017.48
61.Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, et al. Direct 
comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute 
myocardial infarction. Eur Heart J 2014;35:2303–2311. https://doi.org/10.1093/ 
eurheartj/ehu188
62.Boeddinghaus J, Nestelberger T, Twerenbold R, Koechlin L, Meier M, Troester V, et al. 
High-sensitivity cardiac troponin I assay for early diagnosis of acute myocardial infarc -
tion. Clin Chem 2019;
65:893–904. https://doi.org/10.1373/clinchem.2018.300061
63.Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et al. Sensitive troponin I assay in 
early diagnosis of acute myocardial infarction. N Engl J Med 2009;
361:868–877. https:// 
doi.org/10.1056/NEJMoa0903515
64.Collinson PO, Saenger AK, Apple FS; IFCC C-CB. High sensitivity, contemporary and 
point-of-care cardiac troponin assays: educational aids developed by the IFCC 
Committee on Clinical Application of Cardiac Bio-Markers. Clin Chem Lab Med 
2019;57:623–632. https://doi.org/10.1515/cclm-2018-1211
65.Camaro C, Aarts GWA, Adang EMM, van Hout R, Brok G, Hoare A, et al. Rule-out of 
non-ST-segment elevation acute coronary syndrome by a single, pre-hospital troponin 
measurement: a randomized trial. Eur Heart J 2023;44:1705–1714. https://doi.org/10. 
1093/eurheartj/ehad056
66.Pickering JW, Young JM, George PM, Watson AS, Aldous SJ, Troughton RW, et al. 
Validity of a novel point-of-care troponin assay for single-test rule-out of acute myo -
cardial infarction. JAMA Cardiol 2018;
3:1108–1112. https://doi.org/10.1001/jamacardio. 
2018.3368
67.Apple FS, Schulz K, Schmidt CW, van Domburg TSY, Fonville JM, de Theije FK. Determination of sex-specific 99th percentile upper reference limits for a point of 
care high sensitivity cardiac troponin I assay. Clin Chem Lab Med 2021;
59: 
1574–1578. https://doi.org/10.1515/cclm-2021-0262
68.Sorensen NA, Neumann JT, Ojeda F, Giannitsis E, Spanuth E, Blankenberg S, et al. 
Diagnostic evaluation of a high-sensitivity troponin I point-of-care assay. Clin Chem 
2019;65:1592–1601. https://doi.org/10.1373/clinchem.2019.307405
69.Azmy C, Guerard S, Bonnet X, Gabrielli F, Skalli W. EOS orthopaedic imaging system 
to study patellofemoral kinematics: assessment of uncertainty. Orthop Traumatol Surg 
Res 2010;96:28–36. https://doi.org/10.1016/j.rcot.2009.12.003
70.Chapman AR, Lee KK, McAllister DA, Cullen L, Greenslade JH, Parsonage W, et al. 
Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes 
in patients with suspected acute coronary syndrome. JAMA 2017;318:1913–1924. 
https://doi.org/10.1001/jama.2017.17488
71.Hillinger P, Twerenbold R, Wildi K, Rubini Gimenez M, Jaeger C, Boeddinghaus J, et al. 
Gender-specific uncertainties in the diagnosis of acute coronary syndrome. Clin Res 
Cardiol 2017;106:28–37. https://doi.org/10.1007/s00392-016-1020-y
72.Miller-Hodges E, Anand A, Shah ASV, Chapman AR, Gallacher P, Lee KK, et al. 
High-sensitivity cardiac troponin and the risk stratification of patients with renal im -
pairment presenting with suspected acute coronary syndrome. Circulation 2018; 
137
:425–435. https://doi.org/10.1161/CIRCULATIONAHA.117.030320
73.Twerenbold R, Neumann JT, Sorensen NA, Ojeda F, Karakas M, Boeddinghaus J, et al. 
Prospective validation of the 0/1-h algorithm for early diagnosis of myocardial infarc -
tion. J Am Coll Cardiol 2018;
72:620–632. https://doi.org/10.1016/j.jacc.2018.05.04074.Rubini Gimenez M, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, 
Hillinger P, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac 
troponin T in suspected myocardial infarction. JAMA Cardiol 2016;
1:912–920. https:// 
doi.org/10.1001/jamacardio.2016.2882
75.Mueller-Hennessen M, Lindahl B, Giannitsis E, Biener M, Vafaie M, deFilippi CR, et al. 
Diagnostic and prognostic implications using age- and gender-specific cut-offs for high- 
sensitivity cardiac troponin T-sub-analysis from the TRAPID-AMI study. Int J Cardiol 
2016;209:26–33. https://doi.org/10.1016/j.ijcard.2016.01.213
76.Sorensen NA, Neumann JT, Ojeda F, Schäfer S, Magnussen C, Keller T, et al. Relations 
of sex to diagnosis and outcomes in acute coronary syndrome. J Am Heart Assoc 2018; 
7:e007297. https://doi.org/10.1161/JAHA.117.007297
77.Rubini Gimenez M, Badertscher P, Twerenbold R, Boeddinghaus J, Nestelberger T, 
Wussler D, et al. Impact of the US Food and Drug Administration-approved sex- 
specific cutoff values for high-sensitivity cardiac troponin T to diagnose myocardial in -
farction. Circulation 2018;
137:1867–1869. https://doi.org/10.1161/circulationaha.117. 
031940
78.Lee KK, Ferry AV, Anand A, Strachan FE, Chapman AR, Kimenai DM, et al. Sex-specific 
thresholds of high-sensitivity troponin in patients with suspected acute coronary syn -
drome. J Am Coll Cardiol 2019;
74:2032–2043. https://doi.org/10.1016/j.jacc.2019.07. 
082
79.Kimenai DM, Lindahl B, Jernberg T, Bekers O, Meex SJR, Eggers KM. Sex-specific ef -
fects of implementing a high-sensitivity troponin I assay in patients with suspected acute coronary syndrome: results from SWEDEHEART registry. Sci Rep 2020;
10: 
15227. https://doi.org/10.1038/s41598-020-72204-2
80.Peacock WF, Baumann BM, Rivers EJ, Davis TE, Handy B, Jones CW, et al. Using sex- 
specific cutoffs for high-sensitivity cardiac troponin T to diagnose acute myocardial in -
farction. Acad Emerg Med 2021;
28:463–466. https://doi.org/10.1111/acem.14098
81.Zhao Y, Izadnegahdar M, Lee MK, Kavsak PA, Singer J, Scheuermeyer F, et al. 
High-sensitivity cardiac troponin-optimizing the diagnosis of acute myocardial infarc -
tion/injury in women (CODE-MI): rationale and design for a multicenter, stepped- 
wedge, cluster-randomized trial. Am Heart J 2020;
229:18–28. https://doi.org/10. 
1016/j.ahj.2020.06.013
82.Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, et al. Utility 
of absolute and relative changes in cardiac troponin concentrations in the early diag -
nosis of acute myocardial infarction. Circulation 2011;
124:136–145. https://doi.org/10. 
1161/CIRCULATIONAHA.111.023937
83.Wildi K, Boeddinghaus J, Nestelberger T, Twerenbold R, Badertscher P, Wussler D, 
et al. Comparison of fourteen rule-out strategies for acute myocardial infarction. Int 
J Cardiol 2019;
283:41–47. https://doi.org/10.1016/j.ijcard.2018.11.140
84.Ambavane A, Lindahl B, Giannitsis E, Roiz J, Mendivil J, Frankenstein L, et al. Economic 
evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarc -
tion using the high-sensitivity cardiac troponin T assay in the emergency department. 
PLoS One 2017;
12:e0187662. https://doi.org/10.1371/journal.pone.0187662
85.Boeddinghaus J, Nestelberger T, Twerenbold R, Wildi K, Badertscher P, Cupa J, et al. 
Direct comparison of 4 very early rule-out strategies for acute myocardial infarction 
using high-sensitivity cardiac troponin I. Circulation 2017;
135:1597–1611. https://doi. 
org/10.1161/CIRCULATIONAHA.116.025661
86.Ljung L, Lindahl B, Eggers KM, Frick M, Linder R, Löfmark HB, et al. A rule-out strategy 
based on high-sensitivity troponin and HEART score reduces hospital admissions. Ann 
Emerg Med 2019;73:491–499. https://doi.org/10.1016/j.annemergmed.2018.11.039
87.Odqvist M, Andersson PO, Tygesen H, Eggers KM, Holzmann MJ. High-sensitivity tro -
ponins and outcomes after myocardial infarction. J Am Coll Cardiol 2018;
71: 
2616–2624. https://doi.org/10.1016/j.jacc.2018.03.515
88.Twerenbold R, Jaeger C, Rubini Gimenez M, Wildi K, Reichlin T, Nestelberger T, et al. 
Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction. Eur 
Heart J 2016;
37:3324–3332. https://doi.org/10.1093/eurheartj/ehw232
89.Greenslade J, Cho E, Van Hise C, Hawkins T, Parsonage W, Ungerer J, et al. Evaluating 
rapid rule-out of acute myocardial infarction using a high-sensitivity cardiac troponin I 
assay at presentation. Clin Chem 2018;64:820–829. https://doi.org/10.1373/clinchem. 
2017.283887
90.Pickering JW, Than MP, Cullen L, Aldous S, ter Avest E, Body R, et al. Rapid rule-out of 
acute myocardial infarction with a single high-sensitivity cardiac troponin T measure -
ment below the limit of detection: a collaborative meta-analysis. Ann Intern Med 2017; 
166
:715–724. https://doi.org/10.7326/M16-2562
91.Shah AS, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, et al. High-sensitivity 
cardiac troponin I at presentation in patients with suspected acute coronary syn -
drome: a cohort study. Lancet 2015;
386:2481–2488. https://doi.org/10.1016/S0140- 
6736(15)00391-8
92.Boeddinghaus J, Nestelberger T, Lopez-Ayala P, Koechlin L, Buechi M, Miro O, et al. 
Diagnostic performance of the European Society of Cardiology 0/1-h algorithms in late presenters. J Am Coll Cardiol 2021;
77:1264–1267. https://doi.org/10.1016/j.jacc. 
2021.01.004
93.Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, deFilippi C, McCord J, et al. 
Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial 3804                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

infarction with high-sensitivity cardiac troponin T. Ann Emerg Med 2016;68:76–87.e4. 
https://doi.org/10.1016/j.annemergmed.2015.11.013
94.Stoyanov KM, Hund H, Biener M, Gandowitz J, Riedle C, Löhr J, et al. RAPID-CPU: a 
prospective study on implementation of the ESC 0/1-hour algorithm and safety of dis -
charge after rule-out of myocardial infarction. Eur Heart J Acute Cardiovasc Care 2019;
9: 
39–51. https://doi.org/10.1177/2048872619861911
95.Twerenbold R, Costabel JP, Nestelberger T, Campos R, Wussler D, Arbucci R, et al. 
Outcome of applying the ESC 0/1-hour algorithm in patients with suspected myocar -
dial infarction. J Am Coll Cardiol 2019;
74:483–494. https://doi.org/10.1016/j.jacc.2019. 
05.046
96.Nestelberger T, Boeddinghaus J, Wussler D, Twerenbold R, Badertscher P, Wildi K, 
et al. Predicting major adverse events in patients with acute myocardial infarction. J 
Am Coll Cardiol 2019;
74:842–854. https://doi.org/10.1016/j.jacc.2019.06.025
97.Rubini Gimenez M, Wildi K, Wussler D, Koechlin L, Boeddinghaus J, Nestelberger T, et al. Early kinetics of cardiac troponin in suspected acute myocardial infarction. Rev 
Esp Cardiol (Engl Ed) 2021;74:502–509. https://doi.org/10.1016/j.rec.2020.04.008
98.Chiang CH, Chiang CH, Lee GH, Gi W-T, Wu Y-K, Huang S-S, et al. Safety and efficacy 
of the European Society of Cardiology 0/1-hour algorithm for diagnosis of myocardial 
infarction: systematic review and meta-analysis. Heart 2020;106:985–991. https://doi. 
org/10.1136/heartjnl-2019-316343
99.Vigen R, Kutscher P, Fernandez F, Yu A, Bertulfo B, Hashim IA, et al. Evaluation of a 
novel rule-out myocardial infarction protocol incorporating high-sensitivity troponin 
T in a US hospital. Circulation 2018;138:2061–2063. https://doi.org/10.1161/ 
circulationaha.118.033861
100.
Katus H, Ziegler A, Ekinci O, Giannitsis E, Stough WG, Achenbach S, et al. Early diag -
nosis of acute coronary syndrome. Eur Heart J 2017;
38:3049–3055. https://doi.org/10. 
1093/eurheartj/ehx492
101. Koechlin L, Boeddinghaus J, Lopez-Ayala P, Nestelberger T, Wussler D, Mais F, et al. 
Diagnostic discrimination of a novel high-sensitivity cardiac troponin I assay and deriv -
ation/validation of an assay-specific 0/1h-algorithm. Am Heart J 2023;
255:58–70. 
https://doi.org/10.1016/j.ahj.2022.10.007
102. Kaier TE, Twerenbold R, Puelacher C, Marjot J, Imambaccus N, Boeddinghaus J, et al. 
Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the 
early diagnosis of acute myocardial infarction. Circulation 2017;
136:1495–1508. https:// 
doi.org/10.1161/CIRCULATIONAHA.117.028084
103. Boeddinghaus J, Reichlin T, Nestelberger T, Twerenbold R, Meili Y, Wildi K, et al. Early 
diagnosis of acute myocardial infarction in patients with mild elevations of cardiac 
troponin. Clin Res Cardiol 2017;106:457–467. https://doi.org/10.1007/s00392-016- 
1075-9
104. Hillinger P, Twerenbold R, Jaeger C, Wildi K, Reichlin T, Gimenez MR, et al. Optimizing 
early rule-out strategies for acute myocardial infarction: utility of 1-hour copeptin. Clin 
Chem 2015;61:1466–1474. https://doi.org/10.1373/clinchem.2015.242743
105. Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, et al. Copeptin improves early 
diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010;55:2096–2106. https:// 
doi.org/10.1016/j.jacc.2010.01.029
106. Möckel M, Searle J, Hamm C, Slagman A, Blankenberg S, Huber K, et al. Early discharge 
using single cardiac troponin and copeptin testing in patients with suspected acute cor -
onary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 
2015;
36:369–376. https://doi.org/10.1093/eurheartj/ehu178
107. Mueller C, Mockel M, Giannitsis E, Huber K, Mair J, Plebani M, et al. Use of copeptin for 
rapid rule-out of acute myocardial infarction. Eur Heart J Acute Cardiovasc Care 2018;
7: 
570–576. https://doi.org/10.1177/2048872617710791
108. Mueller-Hennessen M, Lindahl B, Giannitsis E, Vafaie M, Biener M, Haushofer AC, et al. 
Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction. Int J 
Cardiol 2019;276:261–267. https://doi.org/10.1016/j.ijcard.2018.10.084
109. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, et al. 
Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am 
Coll Cardiol 2009;54:60–68. https://doi.org/10.1016/j.jacc.2009.01.076
110.
Stallone F, Schoenenberger AW, Puelacher C, Rubini Gimenez M, Walz B, 
Naduvilekoot Devasia A, et al. Incremental value of copeptin in suspected acute myo -
cardial infarction very early after symptom onset. Eur Heart J Acute Cardiovasc Care 
2016;
5:407–415. https://doi.org/10.1177/2048872616641289
111. Vargas KG, Kassem M, Mueller C, Wojta J, Huber K. Copeptin for the early rule-out of 
non-ST-elevation myocardial infarction. Int J Cardiol 2016;
223:797–804. https://doi. 
org/10.1016/j.ijcard.2016.08.304
112. Wildi K, Zellweger C, Twerenbold R, Jaeger C, Reichlin T, Haaf P, et al. Incremental 
value of copeptin to highly sensitive cardiac troponin I for rapid rule-out of myocardial 
infarction. Int J Cardiol 2015;190:170–176. https://doi.org/10.1016/j.ijcard.2015.04.133
113. Zellweger C, Wildi K, Twerenbold R, Reichlin T, Naduvilekoot A, Neuhaus JD, et al. 
Use of copeptin and high-sensitive cardiac troponin T for diagnosis and prognosis in 
patients with diabetes mellitus and suspected acute myocardial infarction. Int J 
Cardiol 2015;190:190–197. https://doi.org/10.1016/j.ijcard.2015.04.134
114. Restan IZ, Sanchez AY, Steiro OT, Lopez-Ayala P, Tjora HL, Langørgen J, et al. Adding 
stress biomarkers to high-sensitivity cardiac troponin for rapid non-ST-elevation myocardial infarction rule-out protocols. Eur Heart J Acute Cardiovasc Care 2022;11: 
201–212. https://doi.org/10.1093/ehjacc/zuab124
115. Dedic A, Lubbers MM, Schaap J, Lammers J, Lamfers EJ, Rensing BJ, et al. Coronary CT 
angiography for suspected ACS in the era of high-sensitivity troponins: randomized 
multicenter study. J Am Coll Cardiol 2016;67:16–26. https://doi.org/10.1016/j.jacc. 
2015.10.045
116. Hoffmann U, Truong QA, Schoenfeld DA, Chou ET, Woodard PK, Nagurney JT, et al. 
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med 
2012;367:299–308. https://doi.org/10.1056/NEJMoa1201161
117. Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O’Brien R, et al. Early com -
puted tomography coronary angiography in patients with suspected acute coronary 
syndrome: randomised controlled trial. BMJ 2021;
374:n2106. https://doi.org/10. 
1136/bmj.n2106
118. Lee KK, Bularga A, O’Brien R, Ferry AV, Doudesis D, Fujisawa T, et al. Troponin-guided 
coronary computed tomographic angiography after exclusion of myocardial infarction. 
J Am Coll Cardiol 2021;
78:1407–1417. https://doi.org/10.1016/j.jacc.2021.07.055
119. Kofoed KF, Engstrom T, Sigvardsen PE, Linde JJ, Torp-Pedersen C, de Knegt M, et al. 
Prognostic value of coronary CT angiography in patients with non-ST-segment eleva -
tion acute coronary syndromes. J Am Coll Cardiol 2021;
77:1044–1052. https://doi.org/ 
10.1016/j.jacc.2020.12.037
120. Linde JJ, Hove JD, Sorgaard M, Kelbæk H, Jensen GB, Kühl JT, et al. Long-term clinical 
impact of coronary CT angiography in patients with recent acute-onset chest pain: the randomized controlled CATCH trial. JACC Cardiovasc Imaging 2015;
8:1404–1413. 
https://doi.org/10.1016/j.jcmg.2015.07.015
121. Linde JJ, Kelbæk H, Hansen TF, Sigvardsen PE, Torp-Pedersen C, Bech J, et al. Coronary 
CT angiography in patients with non-ST-segment elevation acute coronary syndrome. 
J Am Coll Cardiol 2020;75:453–463. https://doi.org/10.1016/j.jacc.2019.12.012
122. Samad Z, Hakeem A, Mahmood SS, Pieper K, Patel MR, Simel DL, et al. A meta-analysis 
and systematic review of computed tomography angiography as a diagnostic triage 
tool for patients with chest pain presenting to the emergency department. J Nucl 
Cardiol 2012;19:364–376. https://doi.org/10.1007/s12350-012-9520-2
123. Litt HI, Gatsonis C, Snyder B, Singh H, Miller CD, Entrikin DW, et al. CT angiography 
for safe discharge of patients with possible acute coronary syndromes. N Engl J Med 
2012;366:1393–1403. https://doi.org/10.1056/NEJMoa1201163
124. Hulten E, Pickett C, Bittencourt MS, Villines TC, Petrillo S, Di Carli MF, et al. Outcomes 
after coronary computed tomography angiography in the emergency department: a 
systematic review and meta-analysis of randomized, controlled trials. J Am Coll 
Cardiol 2013;61:880–892. https://doi.org/10.1016/j.jacc.2012.11.061
125. Gaibazzi N, Reverberi C, Badano L. Usefulness of contrast stress-echocardiography or 
exercise-electrocardiography to predict long-term acute coronary syndromes in pa -
tients presenting with chest pain without electrocardiographic abnormalities or 
12-hour troponin elevation. Am J Cardiol 2011;
107:161–167. https://doi.org/10.1016/ 
j.amjcard.2010.08.066
126. Lim SH, Anantharaman V, Sundram F, Chan ES-Y, Ang ES, Yo SL, et al. Stress myocar -
dial perfusion imaging for the evaluation and triage of chest pain in the emergency de -
partment: a randomized controlled trial. J Nucl Cardiol 2013;
20:1002–1012. https://doi. 
org/10.1007/s12350-013-9736-9
127. Nabi F, Kassi M, Muhyieddeen K, Chang SM, Xu J, Peterson LE, et al. Optimizing evalu -
ation of patients with low-to-intermediate-risk acute chest pain: a randomized study comparing stress myocardial perfusion tomography incorporating stress-only imaging 
versus cardiac CT. J Nucl Med 2016;
57:378–384. https://doi.org/10.2967/jnumed.115. 
166595
128. Jackson AM, Zhang R, Findlay I, Robertson K, Lindsay M, Morris T, et al. Healthcare 
disparities for women hospitalized with myocardial infarction and angina. Eur Heart J 
Qual Care Clin Outcomes 2020;
6:156–165. https://doi.org/10.1093/ehjqcco/qcz040
129. Terkelsen CJ, Sørensen JT, Maeng M, Jensen LO, Tilsted HH, Trautner S, et al. System 
delay and mortality among patients with STEMI treated with primary percutaneous 
coronary intervention. JAMA 2010;304:763–771. https://doi.org/10.1001/jama.2010. 
1139
130. Jortveit J, Pripp AH, Halvorsen S. Outcomes after delayed primary percutaneous cor -
onary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway. Eur Heart J Cardiovasc Pharmacother 2022;
8:442–451. https://doi. 
org/10.1093/ehjcvp/pvab041
131. Larsen AI, Løland KH, Hovland S, Bleie Ø, Eek C, Fossum E, et al. 
Guideline-recommended time less than 90 minutes from ECG to primary percutan -
eous coronary intervention for ST-segment-elevation myocardial infarction is asso -
ciated with major survival benefits, especially in octogenarians: a contemporary 
report in 11 226 patients from NORIC. J Am Heart Assoc 2022;
11:e024849. https:// 
doi.org/10.1161/jaha.122.024849
132. Fordyce CB, Al-Khalidi HR, Jollis JG, Roettig ML, Gu J, Bagai A, et al. Association of rapid 
care process implementation on reperfusion times across multiple 
ST-segment-elevation myocardial infarction networks. Circ Cardiovasc Interv 2017; 
10:
e004061. https://doi.org/10.1161/circinterventions.116.004061
133. Stowens JC, Sonnad SS, Rosenbaum RA. Using EMS dispatch to trigger STEMI alerts 
decreases door-to-balloon times. West J Emerg Med 2015;16:472–480. https://doi. 
org/10.5811/westjem.2015.4.24248ESC Guidelines                                                                                                                                                                                          3805Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

134. Squire BT, Tamayo-Sarver JH, Rashi P, Koenig W, Niemann JT. Effect of prehospital 
cardiac catheterization lab activation on door-to-balloon time, mortality, and false- 
positive activation. Prehosp Emerg Care 2014;18:1–8. https://doi.org/10.3109/ 
10903127.2013.836263
135. Shavadia JS, Roe MT, Chen AY, Lucas J, Fanaroff AC, Kochar A, et al. Association be -
tween cardiac catheterization laboratory pre-activation and reperfusion timing metrics 
and outcomes in patients with ST-segment elevation myocardial infarction undergoing 
primary percutaneous coronary intervention: a report from the ACTION registry. 
JACC Cardiovasc Interv 2018;
11:1837–1847. https://doi.org/10.1016/j.jcin.2018.07.020
136. Kontos MC, Gunderson MR, Zegre-Hemsey JK, Lange DC, French WJ, Henry TD, 
et al. Prehospital activation of hospital resources (PreAct) ST-segment-elevation myo -
cardial infarction (STEMI): a standardized approach to prehospital activation and direct 
to the catheterization laboratory for STEMI recommendations from the American 
Heart Association’s mission: lifeline program. J Am Heart Assoc 2020;
9:e011963. 
https://doi.org/10.1161/jaha.119.011963
137. Bagai A, Jollis JG, Dauerman HL, Peng SA, Rokos IC, Bates ER, et al. Emergency depart -
ment bypass for ST-segment-elevation myocardial infarction patients identified with a 
prehospital electrocardiogram: a report from the American Heart Association 
Mission: Lifeline program. Circulation 2013;
128:352–359. https://doi.org/10.1161/ 
circulationaha.113.002339
138. Scholz KH, Friede T, Meyer T, Jacobshagen C, Lengenfelder B, Jung J, et al. Prognostic 
significance of emergency department bypass in stable and unstable patients with 
ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2020; 
9
:34–44. https://doi.org/10.1177/2048872618813907
139. Meisel SR, Kleiner-Shochat M, Abu-Fanne R, Frimerman A, Danon A, Minha S, et al. 
Direct admission of patients with ST-segment-elevation myocardial infarction to the 
catheterization laboratory shortens pain-to-balloon and door-to-balloon time inter -
vals but only the pain-to-balloon interval impacts short- and long-term mortality. J 
Am Heart Assoc 2021;
10:e018343. https://doi.org/10.1161/jaha.120.018343
140. Wang TY, Nallamothu BK, Krumholz HM, Li S, Roe MT, Jollis JG, et al. Association of 
door-in to door-out time with reperfusion delays and outcomes among patients trans -
ferred for primary percutaneous coronary intervention. JAMA 2011;
305:2540–2547. 
https://doi.org/10.1001/jama.2011.862
141. Huber K, De Caterina R, Kristensen SD, Verheugt FWA, Montalescot G, Maestro LB, et al. Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in 
patients with ST-elevation myocardial infarction. Eur Heart J 2005;
26:2063–2074. 
https://doi.org/10.1093/eurheartj/ehi413
142. Welsh RC, Chang W, Goldstein P, Adgey J, Granger CB, Verheugt FW, et al. Time to 
treatment and the impact of a physician on prehospital management of acute ST ele -
vation myocardial infarction: insights from the ASSENT-3 PLUS trial. Heart 2005;
91: 
1400–1406. https://doi.org/10.1136/hrt.2004.054510
143. Jollis JG, Al-Khalidi HR, Roettig ML, Berger PB, Corbett CC, Doerfler SM, et al. Impact 
of regionalization of ST-segment-elevation myocardial infarction care on treatment 
times and outcomes for emergency medical services-transported patients presenting 
to hospitals with percutaneous coronary intervention: mission: lifeline accelerator-2. 
Circulation 2018;
137:376–387. https://doi.org/10.1161/circulationaha.117.032446
144. Fosbol EL, Granger CB, Jollis JG, Monk L, Lin L, Lytle BL, et al. The impact of a statewide 
pre-hospital STEMI strategy to bypass hospitals without percutaneous coronary inter -
vention capability on treatment times. Circulation 2013;
127:604–612. https://doi.org/ 
10.1161/circulationaha.112.118463
145. Kalla K, Christ G, Karnik R, Malzer R, Norman G, Prachar H, et al. Implementation of 
guidelines improves the standard of care: the Viennese registry on reperfusion strat -
egies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006; 
113
:2398–2405. https://doi.org/10.1161/circulationaha.105.586198
146. Henry TD, Sharkey SW, Burke MN, Chavez IJ, Graham KJ, Henry CR, et al. A regional 
system to provide timely access to percutaneous coronary intervention for 
ST-elevation myocardial infarction. Circulation 2007;
116:721–728. https://doi.org/10. 
1161/circulationaha.107.694141
147. Le May MR, So DY, Dionne R, Glover CA, Froeschl MPV, Wells GA, et al. A citywide 
protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 
2008;358:231–240. https://doi.org/10.1056/NEJMoa073102
148. Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. Oxygen therapy in 
suspected acute myocardial infarction. N Engl J Med 2017;377:1240–1249. https://doi. 
org/10.1056/NEJMoa1706222
149. Stewart RAH, Jones P, Dicker B, Jiang Y, Smith T, Swain A, et al. High flow oxygen and 
risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, 
cluster randomised, crossover trial. BMJ 2021;372:n355. https://doi.org/10.1136/bmj. 
n355
150. Henrikson CA, Howell EE, Bush DE, Miles JS, Meininger GR, Friedlander T, et al. Chest 
pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern 
Med 2003;139:979–986. https://doi.org/10.7326/0003-4819-139-12-200312160- 
00007
151. Charpentier S, Galinski M, Bounes V, Ricard-Hibon A, El-Khoury C, Elbaz M, et al. 
Nitrous oxide/oxygen plus acetaminophen versus morphine in ST elevation myocar -
dial infarction: open-label, cluster-randomized, non-inferiority study. Scand J Trauma 
Resusc Emerg Med 2020;
28:36. https://doi.org/10.1186/s13049-020-00731-y152. Silvain J, Storey RF, Cayla G, Esteve J-B, Dillinger J-G, Rousseau H, et al. P2Y12 receptor 
inhibition and effect of morphine in patients undergoing primary PCI for ST-segment 
elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 
2016;
116:369–378. https://doi.org/10.1160/th15-12-0944
153. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, et al. 
Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous cor
-
onary intervention. Circ Cardiovasc Interv 2015;
8:e001593. https://doi.org/10.1161/ 
circinterventions.114.001593
154. Saad M, Meyer-Saraei R, de Waha-Thiele S, Stiermaier T, Graf T, Fuernau G, et al. 
Impact of morphine treatment with and without metoclopramide coadministration on ticagrelor-induced platelet inhibition in acute myocardial infarction: the randomized MonAMI trial. Circulation 2020;
141:1354–1356. https://doi.org/10.1161/circulationaha. 
119.042816
155. Stiermaier T, Schaefer P, Meyer-Saraei R, Saad M, de Waha-Thiele S, Pöss J, et al. 
Impact of morphine treatment with and without metoclopramide coadministration on myocardial and microvascular injury in acute myocardial infarction: insights from the randomized MonAMI trial. J Am Heart Assoc 2021;10:e018881. https://doi.org/ 
10.1161/jaha.120.018881
156.
Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, et al. Morphine de -
lays and attenuates ticagrelor exposure and action in patients with myocardial infarc -
tion: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 
2016;
37:245–252. https://doi.org/10.1093/eurheartj/ehv547
157. Zhang Y, Wang N, Gu Q. Effects of morphine on P2Y(12) platelet inhibitors in patients with acute myocardial infarction: a meta-analysis. Am J Emerg Med 2021;
41:219–228. 
https://doi.org/10.1016/j.ajem.2020.11.003
158. Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, et al. Morphine and car -
diovascular outcomes among patients with non-ST-segment elevation acute coronary 
syndromes undergoing coronary angiography. J Am Coll Cardiol 2020;
75:289–300. 
https://doi.org/10.1016/j.jacc.2019.11.035
159. Kubica A, Kosobucka A, Niezgoda P, Adamski P, Buszko K, Lesiak M, et al. ANalgesic 
Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myo -
cardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicen -
tre, open-label, phase II, randomised clinical trial. BMJ Open 2021;
11:e043330. https:// 
doi.org/10.1136/bmjopen-2020-043330
160. Batchelor R, Liu DH, Bloom J, Noaman S, Chan W. Association of periprocedural 
intravenous morphine use on clinical outcomes in ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention: systematic review 
and meta-analysis. Catheter Cardiovasc Interv 2020;
96:76–88. https://doi.org/10.1002/ 
ccd.28561
161. Bonin M, Mewton N, Roubille F, Morel O, Cayla G, Angoulvant D, et al. Effect and 
safety of morphine use in acute anterior ST-segment elevation myocardial infarction. 
J Am Heart Assoc 2018;7:e006833. https://doi.org/10.1161/jaha.117.006833
162. Clemente-Moragón A, Gómez M, Villena-Gutiérrez R, Lalama DV, García-Prieto J, 
Martínez F, et al. Metoprolol exerts a non-class effect against ischaemia-reperfusion 
injury by abrogating exacerbated inflammation. Eur Heart J 2020;41:4425–4440. 
https://doi.org/10.1093/eurheartj/ehaa733
163. Ibanez B, Macaya C, Sánchez-Brunete V, Pizarro G, Fernández-Friera L, Mateos A, et al. 
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of meto
-
prolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation 2013;
128:1495–1503. https://doi.org/10.1161/circulationaha.113. 
003653
164. Roolvink V, Ibáñez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, et al. Early 
intravenous beta-blockers in patients with ST-segment elevation myocardial infarction 
before primary percutaneous coronary intervention. J Am Coll Cardiol 2016;
67: 
2705–2715. https://doi.org/10.1016/j.jacc.2016.03.522
165. Pizarro G, Fernández-Friera L, Fuster V, Fernández-Jiménez R, García-Ruiz JM, 
García-Álvarez A, et al. Long-term benefit of early pre-reperfusion metoprolol admin -
istration in patients with acute myocardial infarction: results from the 
METOCARD-CNIC trial (effect of metoprolol in cardioprotection during an acute 
myocardial infarction). J Am Coll Cardiol 2014;
63:2356–2362. https://doi.org/10.1016/ 
j.jacc.2014.03.014
166. García-Ruiz JM, Fernández-Jiménez R, García-Alvarez A, Pizarro G, Galán-Arriola C, Fernández-Friera L, et al. Impact of the timing of metoprolol administration during 
STEMI on infarct size and ventricular function. J Am Coll Cardiol 2016;
67:2093–2104. 
https://doi.org/10.1016/j.jacc.2016.02.050
167. Hoedemaker NP, Roolvink V, de Winter RJ, van Royen N, Fuster V, García-Ruiz JM, et al. Early intravenous beta-blockers in patients undergoing primary percutaneous 
coronary intervention for ST-segment elevation myocardial infarction: a patient- 
pooled meta-analysis of randomized clinical trials. Eur Heart J Acute Cardiovasc Care 
2020;9:469–477. https://doi.org/10.1177/2048872619830609
168. Sterling LH, Filion KB, Atallah R, Reynier P, Eisenberg MJ. Intravenous beta-blockers in 
ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Int J 
Cardiol 2017;228:295–302. https://doi.org/10.1016/j.ijcard.2016.11.1333806                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

169. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, et al. Early 
intravenous beta-blockers in patients with acute coronary syndrome–a meta-analysis 
of randomized trials. Int J Cardiol 2013;168:915–921. https://doi.org/10.1016/j.ijcard. 
2012.10.050
170. Elgendy IY, Elgendy AY, Mahmoud AN, Mansoor H, Mojadidi MK, Bavry AA, et al. 
Intravenous β
-blockers for patients undergoing primary percutaneous coronary inter -
vention: a meta-analysis of randomized trials. Int J Cardiol 2016;
223:891–897. https:// 
doi.org/10.1016/j.ijcard.2016.08.293
171. García-Prieto J, Villena-Gutiérrez R, Gómez M, Bernardo E, Pun-García A, García-Lunar I, et al. Neutrophil stunning by metoprolol reduces infarct size. Nat 
Commun 2017;
8:14780. https://doi.org/10.1038/ncomms14780
172. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. Air versus oxygen 
in ST-segment-elevation myocardial infarction. Circulation 2015;131:2143–2150. 
https://doi.org/10.1161/circulationaha.114.014494
173. Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, et al. Reperfusion 
therapy for ST elevation acute myocardial infarction in Europe: description of the cur -
rent situation in 30 countries. Eur Heart J 2010;
31:943–957. https://doi.org/10.1093/ 
eurheartj/ehp492
174. Hall M, Laut K, Dondo TB, Alabas OA, Brogan RA, Gutacker N, et al. Patient and hos -
pital determinants of primary percutaneous coronary intervention in England, 2003– 
2013. Heart 2016;
102:313–319. https://doi.org/10.1136/heartjnl-2015-308616
175. Widimsky P, Fajadet J, Danchin N, Wijns W. “Stent 4 Life” targeting PCI at all who will 
benefit the most. A joint project between EAPCI, Euro-PCR, EUCOMED and the ESC 
Working Group on Acute Cardiac Care. EuroIntervention 2009;
4:555–557. doi: doi:10. 
4244/EIJV4I5A94
176. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, et al. Hospital 
delays in reperfusion for ST-elevation myocardial infarction: implications when select -
ing a reperfusion strategy. Circulation 2006;
114:2019–2025. https://doi.org/10.1161/ 
circulationaha.106.638353
177. Steg PG, Cambou JP, Goldstein P, Durand E, Sauval P, Kadri Z, et al. Bypassing the 
emergency room reduces delays and mortality in ST elevation myocardial infarction: 
the USIC 2000 registry. Heart 2006;
92:1378–1383. https://doi.org/10.1136/hrt.2006. 
101972
178. Baran KW, Kamrowski KA, Westwater JJ, Tschida VH, Alexander CF, Beahrs MM, et al. 
Very rapid treatment of ST-segment-elevation myocardial infarction: utilizing prehos -
pital electrocardiograms to bypass the emergency department. Circ Cardiovasc Qual 
Outcomes 2010;
3:431–437. https://doi.org/10.1161/circoutcomes.110.942631
179. Huynh T, Perron S, O’Loughlin J, Joseph L, Labrecque M, Tu JV, et al. Comparison of 
primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-elevation myocardial infarction: Bayesian hierarchical meta-analyses of 
randomized controlled trials and observational studies. Circulation 2009;
119: 
3101–3109. https://doi.org/10.1161/circulationaha.108.793745
180. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic ther -
apy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003;
92: 
824–826. https://doi.org/10.1016/s0002-9149(03)00891-9
181. Betriu A, Masotti M. Comparison of mortality rates in acute myocardial infarction trea -
ted by percutaneous coronary intervention versus fibrinolysis. Am J Cardiol 2005;
95: 
100–101. https://doi.org/10.1016/j.amjcard.2004.08.069
182. Boersma E. Does time matter? A pooled analysis of randomized clinical trials compar -
ing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;
27:779–788. https://doi.org/10.1093/ 
eurheartj/ehi810
183. Pinto DS, Frederick PD, Chakrabarti AK, Kirtane AJ, Ullman E, Dejam A, et al. Benefit 
of transferring ST-segment-elevation myocardial infarction patients for percutaneous 
coronary intervention compared with administration of onsite fibrinolytic declines as 
delays increase. Circulation 2011;
124:2512–2521. https://doi.org/10.1161/ 
circulationaha.111.018549
184. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. 
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J 
Med 2013;368:1379–1387. https://doi.org/10.1056/NEJMoa1301092
185. Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. 
Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005;353:2758–2768. https://doi.org/10.1056/NEJMoa050849
186. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al. Routine 
early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 
360:2705–2718. https://doi.org/10.1056/NEJMoa0808276
187.
Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, Foody JoAnne M, Krumholz HM, Phillips CO, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic ther
-
apy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am 
Coll Cardiol 2007;
49:422–430. https://doi.org/10.1016/j.jacc.2006.09.033
188. Sutton AG, Campbell PG, Graham R, Price DJA, Gray JC, Grech ED, et al. A rando -
mized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early 
Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004;
44: 
287–296. https://doi.org/10.1016/j.jacc.2003.12.059189. Schömig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, et al. 
Mechanical reperfusion in patients with acute myocardial infarction presenting more 
than 12 hours from symptom onset: a randomized controlled trial. JAMA 2005;
293: 
2865–2872. https://doi.org/10.1001/jama.293.23.2865
190. Ndrepepa G, Kastrati A, Mehilli J, Antoniucci D, Schömig A. Mechanical reperfusion 
and long-term mortality in patients with acute myocardial infarction presenting 12 
to 48 hours from onset of symptoms. JAMA 2009;301:487–488. https://doi.org/10. 
1001/jama.2009.32
191. Bouisset F, Gerbaud E, Bataille V, Coste P, Puymirat E, Belle L, et al. Percutaneous myo -
cardial revascularization in late-presenting patients with STEMI. J Am Coll Cardiol 2021; 
78
:1291–1305. https://doi.org/10.1016/j.jacc.2021.07.039
192. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. 
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J 
Med 2006;
355:2395–2407. https://doi.org/10.1056/NEJMoa066139
193. Menon V, Pearte CA, Buller CE, Steg PhG, Forman SA, White HD, et al. Lack of benefit 
from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded 
Artery Trial. Eur Heart J 2009;30:183–191. https://doi.org/10.1093/eurheartj/ehn486
194. Ioannidis JPA, Katritsis DG. Percutaneous coronary intervention for late reperfusion 
after myocardial infarction in stable patients. Am Heart J 2007;154:1065–1071. 
https://doi.org/10.1016/j.ahj.2007.07.049
195. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 
ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur 
Heart J 2020;41:407–477. https://doi.org/10.1093/eurheartj/ehz425
196. O’Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, et al. 
Early invasive vs conservative treatment strategies in women and men with unstable 
angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA 
2008;300:71–80. https://doi.org/10.1001/jama.300.1.71
197. Mehta SR, Cannon CP, Fox KAA, Wallentin L, Boden WE, Spacek R, et al. Routine vs 
selective invasive strategies in patients with acute coronary syndromes: a collaborative 
meta-analysis of randomized trials. JAMA 2005;293:2908–2917. https://doi.org/10. 
1001/jama.293.23.2908
198.
Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JGP, et al. Long-term 
outcome of a routine versus selective invasive strategy in patients with 
non-ST-segment elevation acute coronary syndrome a meta-analysis of individual pa -
tient data. J Am Coll Cardiol 2010;
55:2435–2445. https://doi.org/10.1016/j.jacc.2010.03. 
007
199. Fanning JP, Nyong J, Scott IA, Aroney CN, Walters DL. Routine invasive strategies ver -
sus selective invasive strategies for unstable angina and non-ST elevation myocardial 
infarction in the stent era. Cochrane Database Syst Rev 2016;
2016:CD004815. 
https://doi.org/10.1002/14651858.CD004815.pub4
200. Elgendy IY, Mahmoud AN, Wen X, Bavry AA. Meta-analysis of randomized trials of long-term all-cause mortality in patients with non-ST-elevation acute coronary syn
-
drome managed with routine invasive versus selective invasive strategies. Am J 
Cardiol 2017;
119:560–564. https://doi.org/10.1016/j.amjcard.2016.11.005
201. Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong Y-H, Kozinski M, et al. Optimal 
timing of coronary invasive strategy in non-ST-segment elevation acute coronary syn -
dromes: a systematic review and meta-analysis. Ann Intern Med 2013;
158:261–270. 
https://doi.org/10.7326/0003-4819-158-4-201302190-00006
202. Jobs A, Mehta SR, Montalescot G, Vicaut E, van’t Hof AWJ, Badings EA, et al. Optimal 
timing of an invasive strategy in patients with non-ST-elevation acute coronary syn -
drome: a meta-analysis of randomised trials. Lancet 2017;
390:737–746. https://doi. 
org/10.1016/s0140-6736(17)31490-3
203. Kite TA, Kurmani SA, Bountziouka V, Cooper NJ, Lock ST, Gale CP, et al. Timing of 
invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of ran -
domized controlled trials. Eur Heart J 2022;
43:3148–3161. https://doi.org/10.1093/ 
eurheartj/ehac213
204. Eggers KM, James SK, Jernberg T, Lindahl B. Timing of coronary angiography in patients with non-ST-elevation acute coronary syndrome: long-term clinical outcomes from 
the nationwide SWEDEHEART registry. EuroIntervention 2022;
18:582–589. https:// 
doi.org/10.4244/eij-d-21-00982
205. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collabora -
tive overview of early mortality and major morbidity results from all randomised trials 
of more than 1000 patients. Lancet 1994;
343:311–322. https://doi.org/10.1016/ 
S0140-6736(94)91161-4
206. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and pre -
hospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000; 
283
:2686–2692. https://doi.org/10.1001/jama.283.20.2686
207. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien P-Y, Cristofini P, et al. Impact of 
time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: 
data from the CAPTIM randomized clinical trial. Circulation 2003;
108:2851–2856. 
https://doi.org/10.1161/01.Cir.0000103122.10021.F2
208. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous 
coronary intervention in patients with ST-segment elevation acute myocardial infarc -
tion (ASSENT-4 PCI): randomised trial. Lancet 2006;
367:569–578. https://doi.org/10. 
1016/s0140-6736(06)68147-6ESC Guidelines                                                                                                                                                                                          3807Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

209. Fazel R, Joseph TI, Sankardas MA, Pinto DS, Yeh RW, Kumbhani DJ, et al. Comparison 
of reperfusion strategies for ST-segment-elevation myocardial infarction: a multivari -
ate network meta-analysis. J Am Heart Assoc 2020;
9:e015186. https://doi.org/10. 
1161/jaha.119.015186
210. Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, et al. 
ST-segment-elevation myocardial infarction patients randomized to a 
pharmaco-invasive strategy or primary percutaneous coronary intervention: strategic 
Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. 
Circulation 2014;
130:1139–1145. https://doi.org/10.1161/circulationaha.114.009570
211. Arbel Y, Ko DT, Yan AT, Cantor WJ, Bagai A, Koh M, et al. Long-term follow-up of the 
trial of routine angioplasty and stenting after fibrinolysis to enhance reperfusion in acute myocardial infarction (TRANSFER-AMI). Can J Cardiol 2018;34:736–743. 
https://doi.org/10.1016/j.cjca.2018.02.005
212. Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, et al. Immediate 
angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the 
Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction 
(CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008; 
371:559–568. https://doi.org/10.1016/s0140-6736(08)60268-8
213. Bøhmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in 
acute myocardial infarction in areas with very long transfer distances results of the 
NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial 
infarction). J Am Coll Cardiol 2010;55:102–110. https://doi.org/10.1016/j.jacc.2009.08. 
007
214. Scheller B, Hennen B, Hammer B, Walle J, Hofer C, Hilpert V, et al. Beneficial effects of 
immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 
2003;42:634–641. https://doi.org/10.1016/s0735-1097(03)00763-0
215.
Le May MR, Wells GA, Labinaz M, Davies RF, Turek M, Leddy D, et al. Combined angio -
plasty and pharmacological intervention versus thrombolysis alone in acute myocardial 
infarction (CAPITAL AMI study). J Am Coll Cardiol 2005;
46:417–424. https://doi.org/10. 
1016/j.jacc.2005.04.042
216. Abdel-Qadir H, Yan AT, Tan M, Borgia F, Piscione F, Di Mario C, et al. Consistency of 
benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. 
Heart 2015;
101:1554–1561. https://doi.org/10.1136/heartjnl-2015-307815
217. Madan M, Halvorsen S, Di Mario C, Tan M, Westerhout CM, Cantor WJ, et al. 
Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myo
-
cardial infarction: a patient-level analysis of the randomized early routine invasive clin -
ical trials. JACC Cardiovasc Interv 2015;
8:166–174. https://doi.org/10.1016/j.jcin.2014.09. 
005
218. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A 
comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial in -
farction. N Engl J Med 2003;
349:733–742. https://doi.org/10.1056/NEJMoa025142
219. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. 
Circulation 2003;
108:1809–1814. https://doi.org/10.1161/01.Cir.0000091088.63921. 
8c
220. Gierlotka M, Gasior M, Wilczek K, Hawranek M, Szkodzinski J, Paczek P, et al. 
Reperfusion by primary percutaneous coronary intervention in patients with 
ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of 
symptoms (from a prospective national observational study [PL-ACS]). Am J Cardiol 
2011;107:501–508. https://doi.org/10.1016/j.amjcard.2010.10.008
221. Busk M, Kaltoft A, Nielsen SS, Bottcher M, Rehling M, Thuesen L, et al. Infarct size and 
myocardial salvage after primary angioplasty in patients presenting with symptoms 
for<12 h vs. 12–72 h. Eur Heart J 2009;30:1322–1330. https://doi.org/10.1093/ 
eurheartj/ehp113
222. Borgia F, Goodman SG, Halvorsen S, Cantor WJ, Piscione F, Le May MR, et al. Early 
routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in 
ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J 2010;31: 
2156–2169. https://doi.org/10.1093/eurheartj/ehq204
223. D’Souza SP, Mamas MA, Fraser DG, Fath-Ordoubadi F. Routine early coronary angio -
plasty versus ischaemia-guided angioplasty after thrombolysis in acute ST-elevation 
myocardial infarction: a meta-analysis. Eur Heart J 2011;
32:972–982. https://doi.org/ 
10.1093/eurheartj/ehq398
224. Fernandez-Avilés F, Alonso JJ, Castro-Beiras A, Vázquez N, Blanco J, Alonso-Briales J, 
et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia- 
guided conservative approach for acute myocardial infarction with ST-segment eleva -
tion (GRACIA-1): a randomised controlled trial. Lancet 2004;
364:1045–1053. https:// 
doi.org/10.1016/s0140-6736(04)17059-1
225. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, et al. One-year 
survival following early revascularization for cardiogenic shock. JAMA 2001;
285: 
190–192. https://doi.org/10.1001/jama.285.2.190
226. Lemkes JS, Janssens GN, van der Hoeven NW, van de Ven PM, Marques KMJ, Nap A, et al. Timing of revascularization in patients with transient ST-segment elevation myo
-
cardial infarction: a randomized clinical trial. Eur Heart J 2019;
40:283–291. https://doi. 
org/10.1093/eurheartj/ehy651227. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand J-P, Faxon DP, et al. Early versus 
delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009;
360: 
2165–2175. https://doi.org/10.1056/NEJMoa0807986
228. Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, Kløvgaard L, et al. 
Early versus standard care invasive examination and treatment of patients with 
non-ST-segment elevation acute coronary syndrome. Circulation 2018;138: 
2741–2750. https://doi.org/10.1161/circulationaha.118.037152
229. Butt JH, Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, et al. 
Importance of risk assessment in timing of invasive coronary evaluation and treatment 
of patients with non-ST-segment-elevation acute coronary syndrome: insights from 
the VERDICT trial. J Am Heart Assoc 2021;10:e022333. https://doi.org/10.1161/jaha. 
121.022333
230. Barbarawi M, Kheiri B, Zayed Y, Barbarawi O, Chahine A, Haykal T, et al. Meta-analysis 
of optimal timing of coronary intervention in non-ST-elevation acute coronary syn -
drome. Catheter Cardiovasc Interv 2020;
95:185–193. https://doi.org/10.1002/ccd. 
28280
231. Vranckx P, White HD, Huang Z, Mahaffey KW, Armstrong PW, Van de Werf F, et al. 
Validation of BARC bleeding criteria in patients with acute coronary syndromes: the 
TRACER trial. J Am Coll Cardiol 2016;
67:2135–2144. https://doi.org/10.1016/j.jacc. 
2016.02.056
232. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann F-J, Schömig A, et al. 
Periprocedural bleeding and 1-year outcome after percutaneous coronary interven -
tions: appropriateness of including bleeding as a component of a quadruple end point. 
J Am Coll Cardiol 2008;
51:690–697. https://doi.org/10.1016/j.jacc.2007.10.040
233. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining 
high bleeding risk in patients undergoing percutaneous coronary intervention: a con -
sensus document from the Academic Research Consortium for High Bleeding Risk. Eur 
Heart J 2019;
40:2632–2653. https://doi.org/10.1093/eurheartj/ehz372
234. Doomun D, Doomun I, Schukraft S, Arroyo D, Cook S, Huwyler T, et al. Ischemic and 
bleeding outcomes according to the academic research consortium high bleeding risk criteria in all comers treated by percutaneous coronary interventions. Front Cardiovasc 
Med 2021;
8:620354. https://doi.org/10.3389/fcvm.2021.620354
235. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of 
antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by pro -
longed antiplatelet therapy in various categories of patients. BMJ 1994;
308:81–106. 
https://doi.org/10.1136/bmj.308.6921.81
236. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC fo -
cused update on dual antiplatelet therapy in coronary artery disease developed in col -
laboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery 
disease of the European Society of Cardiology (ESC) and of the European Association 
for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;
39:213–260. https://doi.org/ 
10.1093/eurheartj/ehx419
237. Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, et al. Comparative 
effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med 2021;
384: 
1981–1990. https://doi.org/10.1056/NEJMoa2102137
238. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor 
versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 
1045–1057. https://doi.org/10.1056/NEJMoa0904327
239. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. 
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J 
Med 2007;357:2001–2015. https://doi.org/10.1056/NEJMoa0706482
240. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, et al. Bleeding and stent 
thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015;36: 
1762–1771. https://doi.org/10.1093/eurheartj/ehv104
241. Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG, et al. Expert position paper 
on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014;35:209–215. https://doi.org/10.1093/eurheartj/eht375
242. Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, et al. 
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with 
non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open- 
label, non-inferiority trial. Lancet 2020;395:1374–1381. https://doi.org/10.1016/ 
s0140-6736(20)30325-1
243. Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, et al. Ticagrelor versus 
clopidogrel in elderly patients with acute coronary syndromes: a substudy from the 
prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. 
Circ Cardiovasc Qual Outcomes 2012;5:680–688. https://doi.org/10.1161/ 
circoutcomes.111.964395
244. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. 
Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 
2019;381:1524–1534. https://doi.org/10.1056/NEJMoa1908973
245. Montalescot G, van’t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. 
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 
2014;371:1016–1027. https://doi.org/10.1056/NEJMoa1407024
246. Koul S, Smith JG, Götberg M, Omerovic E, Alfredsson J, Venetsanos D, et al. No benefit 
of ticagrelor pretreatment compared with treatment during percutaneous coronary 3808                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

intervention in patients with ST-segment-elevation myocardial infarction undergoing 
primary percutaneous coronary intervention. Circ Cardiovasc Interv 2018;11: 
e005528. https://doi.org/10.1161/circinterventions.117.005528
247. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay J-F, et al. 
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. 
N Engl J Med 2013;369:999–1010. https://doi.org/10.1056/NEJMoa1308075
248. Tarantini G, Mojoli M, Varbella F, Caporale R, Rigattieri S, Andò G, et al. Timing of oral 
P2Y(12) inhibitor administration in patients with non-ST-segment elevation acute cor -
onary syndrome. J Am Coll Cardiol 2020;
76:2450–2459. https://doi.org/10.1016/j.jacc. 
2020.08.053
249. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, et al. 
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;
359:189–198. https://doi.org/10.1016/ 
s0140-6736(02)07442-1
250. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 
ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165. 
https://doi.org/10.1093/eurheartj/ehy394
251. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. 
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 
361:2318–2329. https://doi.org/10.1056/NEJMoa0908628
252. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of 
platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 
368:1303–1313. https://doi.org/10.1056/NEJMoa1300815
253. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, et al. 
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361: 
2330–2341. https://doi.org/10.1056/NEJMoa0908629
254. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, et al. Effect of 
cangrelor on periprocedural outcomes in percutaneous coronary interventions: a 
pooled analysis of patient-level data. Lancet 2013;382:1981–1992. https://doi.org/10. 
1016/s0140-6736(13)61615-3
255. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST 
elevation: a meta-analysis. Lancet 2000;355:1936–1942. https://doi.org/10.1016/ 
s0140-6736(00)02324-2
256. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin 
vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute 
coronary syndromes managed with an intended early invasive strategy: primary results 
of the SYNERGY randomized trial. JAMA 2004;292:45–54. https://doi.org/10.1001/ 
jama.292.1.45
257.
Cohen M, Mahaffey KW, Pieper K, Pollack CV, Antman EM, Hoekstra J, et al. A sub -
group analysis of the impact of prerandomization antithrombin therapy on outcomes 
in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment 
elevation acute coronary syndromes. J Am Coll Cardiol 2006;
48:1346–1354. https:// 
doi.org/10.1016/j.jacc.2006.05.058
258. Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, et al. 
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary 
intervention for ST-elevation myocardial infarction: the international randomised 
open-label ATOLL trial. Lancet 2011;
378:693–703. https://doi.org/10.1016/s0140- 
6736(11)60876-3
259. Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, et al. Bivalirudin plus a high-dose in -
fusion versus heparin monotherapy in patients with ST-segment elevation myocardial 
infarction undergoing primary percutaneous coronary intervention: a randomised trial. 
Lancet 2022;
400:1847–1857. https://doi.org/10.1016/s0140-6736(22)01999-7
260. Yusuf S, Mehta SR, Chrolavicius S, Cohen M, Grines CL, Goodman S, et al. Effects of 
fondaparinux on mortality and reinfarction in patients with acute ST-segment eleva -
tion myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;
295: 
1519–1530. https://doi.org/10.1001/jama.295.13.joc60038
261. Silvain J, Beygui F, Barthélémy O, Pollack C, Cohen M, Zeymer U, et al. Efficacy and 
safety of enoxaparin versus unfractionated heparin during percutaneous coronary 
intervention: systematic review and meta-analysis. BMJ 2012;
344:e553. https://doi. 
org/10.1136/bmj.e553
262. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes 
Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syn -
dromes. N Engl J Med 2006;
354:1464–1476. https://doi.org/10.1056/NEJMoa055443
263. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of 
pretreatment with clopidogrel and aspirin followed by long-term therapy in patients 
undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 
358
:527–533. https://doi.org/10.1016/s0140-6736(01)05701-4
264. Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, et al. 
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in pa -
tients with or without acute coronary syndromes: an individual patient data pairwise 
and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 
2017;
38:1034–1043. https://doi.org/10.1093/eurheartj/ehw627
265. Hahn J-Y, Song YB, Oh J-H, Cho D-K, Lee JB, Doh J-H, et al. 6-month versus 12-month 
or longer dual antiplatelet therapy after percutaneous coronary intervention in pa -
tients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non- inferiority trial. Lancet 2018; 391:1274–1284. https://doi.org/10.1016/s0140-6736(18) 
30493-8
266. Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, et al. Six 
months versus 12 months dual antiplatelet therapy after drug-eluting stent implant -
ation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, 
non-inferiority trial. BMJ 2018;
363:k3793. https://doi.org/10.1136/bmj.k3793
267. De Luca G, Damen SA, Camaro C, Benit E, Verdoia M, Rasoul S, et al. Final results of 
the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). 
EuroIntervention 2019;
15:e990–e998. https://doi.org/10.4244/eij-d-19-00539
268. Hahn J-Y, Song YB, Oh J-H, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor 
monotherapy vs dual antiplatelet therapy on cardiovascular events in patients under -
going percutaneous coronary intervention: the SMART-CHOICE randomized clinical 
trial. JAMA 2019;
321:2428–2437. https://doi.org/10.1001/jama.2019.8146
269. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin 
for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopi -
dogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months 
after implantation of a drug-eluting stent: a multicentre, open-label, randomised 
superiority trial. Lancet 2018;
392:940–949. https://doi.org/10.1016/s0140-6736(18) 
31858-0
270. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 
1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplate -
let therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019;
321:2414–2427. https://doi.org/ 
10.1001/jama.2019.8145
271. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor 
with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;
381: 
2032–2042. https://doi.org/10.1056/NEJMoa1908419
272. Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, et al. Ticagrelor 
alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in pa -
tients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. 
Eur Heart J 2020;
41:3533–3545. https://doi.org/10.1093/eurheartj/ehaa670
273. Kim BK, Hong SJ, Cho YH, Yun KHo, Kim YH, Suh Y, et al. Effect of ticagrelor mono -
therapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in pa -
tients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 
2020;
323:2407–2416. https://doi.org/10.1001/jama.2020.7580
274. Giacoppo D, Matsuda Y, Fovino LN, D’Amico G, Gargiulo G, Byrne RA, et al. Short 
dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged 
dual antiplatelet therapy after percutaneous coronary intervention with second- 
generation drug-eluting stents: a systematic review and meta-analysis of randomized 
clinical trials. Eur Heart J 2021;
42:308–319. https://doi.org/10.1093/eurheartj/ehaa739
275. Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al. 
Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet ther -
apy with 12 months of dual antiplatelet therapy in patients with acute coronary syn -
drome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol 2022;
7: 
407–417. https://doi.org/10.1001/jamacardio.2021.5244
276. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, et al. Dual antiplatelet therapy 
after PCI in patients at high bleeding risk. N Engl J Med 2021;
385:1643–1655. https:// 
doi.org/10.1056/NEJMoa2108749
277. Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, et al. 
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among 
myocardial infarction patients: insights from the treatment with adenosine diphos -
phate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) observational study. Am Heart J 
2017;
183:62–68. https://doi.org/10.1016/j.ahj.2016.10.006
278. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International 
expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. 
Circulation 2017;
136:1955–1975. https://doi.org/10.1161/circulationaha.117.031164
279. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de- 
escalation of antiplatelet treatment in patients with acute coronary syndrome under -
going percutaneous coronary intervention (TROPICAL-ACS): a randomised, open- 
label, multicentre trial. Lancet 2017;
390:1747–1757. https://doi.org/10.1016/s0140- 
6736(17)32155-4
280. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van’t Hof AWJ, van der Harst P, et al. A genotype-guided strategy for oral P2Y(12) inhibitors in primary 
PCI. N Engl J Med 2019;
381:1621–1631. https://doi.org/10.1056/NEJMoa1907096
281. Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, et al. Benefit of 
switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 
2017;38:3070–3078. https://doi.org/10.1093/eurheartj/ehx175
282. Kim CJ, Park MW, Kim MC, Choo EH, Hwang B-H, Lee KY, et al. Unguided de- 
escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial 
infarction undergoing percutaneous coronary intervention (TALOS-AMI): an 
investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet 2021;398:1305–1316. https://doi.org/10.1016/s0140-6736(21)01445-8ESC Guidelines                                                                                                                                                                                          3809Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

283. Kim HS, Kang J, Hwang D, Han J-K, Yang H-M, Kang H-J, et al. Prasugrel-based de- 
escalation of dual antiplatelet therapy after percutaneous coronary intervention in pa -
tients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open- 
label, multicentre, non-inferiority randomised trial. Lancet 2020;
396:1079–1089. 
https://doi.org/10.1016/s0140-6736(20)31791-8
284. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised 
trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke 
in high risk patients. BMJ 2002;
324:71–86. https://doi.org/10.1136/bmj.324.7329.71
285. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary 
prevention of vascular disease: collaborative meta-analysis of individual participant 
data from randomised trials. Lancet 2009;373:1849–1860. https://doi.org/10.1016/ 
s0140-6736(09)60503-1
286. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopi -
dogrel in addition to aspirin in patients with acute coronary syndromes without 
ST-segment elevation. N Engl J Med 2001;
345:494–502. https://doi.org/10.1056/ 
NEJMoa010746
287. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel 
with or without omeprazole in coronary artery disease. N Engl J Med 2010;
363: 
1909–1917. https://doi.org/10.1056/NEJMoa1007964
288. Gargiulo G, Costa F, Ariotti S, Biscaglia S, Campo G, Esposito G, et al. Impact of proton 
pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: insights from the PROlonging Dual-antiplatelet 
treatment after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J 
2016;174:95–102. https://doi.org/10.1016/j.ahj.2016.01.015
289.
Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. 
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syn
-
dromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;
376: 
1233–1243. https://doi.org/10.1016/s0140-6736(10)61088-4
290. Coughlan JJ, Aytekin A, Lahu S, Ndrepepa G, Menichelli M, Mayer K, et al. Ticagrelor or 
prasugrel for patients with acute coronary syndrome treated with percutaneous cor -
onary intervention: a prespecified subgroup analysis of a randomized clinical trial. JAMA 
Cardiol 2021;
6:1121–1129. https://doi.org/10.1001/jamacardio.2021.2228
291. Szummer K, Montez-Rath ME, Alfredsson J, Erlinge D, Lindahl B, Hofmann R, et al. 
Comparison between ticagrelor and clopidogrel in elderly patients with an acute cor -
onary syndrome: insights from the SWEDEHEART registry. Circulation 2020;
142: 
1700–1708. https://doi.org/10.1161/circulationaha.120.050645
292. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, et al. Early 
versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 
2009;
360:2176–2190. https://doi.org/10.1056/NEJMoa0901316
293. Dworeck C, Redfors B, Angerås O, Haraldsson I, Odenstedt J, Ioanes D, et al. 
Association of pretreatment with P2Y12 receptor antagonists preceding percutan -
eous coronary intervention in non-ST-segment elevation acute coronary syndromes with outcomes. JAMA Netw Open 2020;
3:e2018735. https://doi.org/10.1001/ 
jamanetworkopen.2020.18735
294. Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, et al. Early and 
sustained dual oral antiplatelet therapy following percutaneous coronary intervention: 
a randomized controlled trial. JAMA 2002;
288:2411–2420. https://doi.org/10.1001/ 
jama.288.19.2411
295. Dawson LP, Chen D, Dagan M, Bloom J, Taylor A, Duffy SJ, et al. Assessment of pre -
treatment with oral P2Y12 inhibitors and cardiovascular and bleeding outcomes in pa -
tients with non-ST elevation acute coronary syndromes: a systematic review and 
meta-analysis. JAMA Netw Open 2021;
4:e2134322. https://doi.org/10.1001/ 
jamanetworkopen.2021.34322
296. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. 
JAMA 1996;
276:811–815. doi: doi:10.1001/jama.1996.03540100055028
297. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, et al. Assessment 
of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial in -
farction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;
100:1602–1608. https:// 
doi.org/10.1161/01.cir.100.15.1602
298. Collet JP, Huber K, Cohen M, Zeymer U, Goldstein P, Pollack C, et al. A direct com -
parison of intravenous enoxaparin with unfractionated heparin in primary percutan -
eous coronary intervention (from the ATOLL trial). Am J Cardiol 2013;
112: 
1367–1372. https://doi.org/10.1016/j.amjcard.2013.07.003
299. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. 
Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;
355: 
2203–2216. https://doi.org/10.1056/NEJMoa062437
300. Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, et al. 
Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 
2015;373:997–1009. https://doi.org/10.1056/NEJMoa1507854
301. Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al. Abciximab and 
heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 
2011;365:1980–1989. https://doi.org/10.1056/NEJMoa1109596302. Erlinge D, Omerovic E, Fröbert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin 
versus heparin monotherapy in myocardial infarction. N Engl J Med 2017;377: 
1132–1142. https://doi.org/10.1056/NEJMoa1706443
303. Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs heparin with or with -
out tirofiban during primary percutaneous coronary intervention in acute myocardial 
infarction: the BRIGHT randomized clinical trial. JAMA 2015;
313:1336–1346. https:// 
doi.org/10.1001/jama.2015.2323
304. Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht H-J, et al. Low-dose vs 
standard-dose unfractionated heparin for percutaneous coronary intervention in 
acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 rando -
mized trial. JAMA 2010;
304:1339–1349. https://doi.org/10.1001/jama.2010.1320
305. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrom -
botic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;
377: 
1513–1524. https://doi.org/10.1056/NEJMoa1708454
306. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJGL, Herrman J-P, et al. 
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy 
and undergoing percutaneous coronary intervention: an open-label, randomised, con -
trolled trial. Lancet 2013;
381:1107–1115. https://doi.org/10.1016/s0140-6736(12) 
62177-1
307. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. 
Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J 
Med 2016;
375:2423–2434. https://doi.org/10.1056/NEJMoa1611594
308. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic 
therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 
380:1509–1524. https://doi.org/10.1056/NEJMoa1817083
309. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. 
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after suc -
cessful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a ran -
domised, open-label, phase 3b trial. Lancet 2019;
394:1335–1343. https://doi.org/10. 
1016/s0140-6736(19)31872-0
310. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and ef -
ficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fib -
rillation following percutaneous coronary intervention: a systematic review and 
meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical 
trials. Eur Heart J 2019;
40:3757–3767. https://doi.org/10.1093/eurheartj/ehz732
311. Dewilde WJ, Janssen PW, Kelder JC, Verheugt FWA, De Smet BJGL, Adriaenssens T, 
et al. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral 
anticoagulation during percutaneous coronary intervention: subgroup analysis from 
the WOEST trial. EuroIntervention 2015;
11:381–390. https://doi.org/10.4244/ 
eijy14m06_07
312. Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, et al. 
Antithrombotic therapy in patients with atrial fibrillation and acute coronary syn -
drome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS trial. 
Circulation 2019;
140:1921–1932. https://doi.org/10.1161/circulationaha.119.043308
313. Smits PC, Frigoli E, Tijssen J, Jüni P, Vranckx P, Ozaki Y, et al. Abbreviated antiplatelet 
therapy in patients at high bleeding risk with or without oral anticoagulant therapy 
after coronary stenting: an open-label, randomized, controlled trial. Circulation 2021; 
144
:1196–1211. https://doi.org/10.1161/circulationaha.121.056680
314. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. 
Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 
2017;377:1319–1330. https://doi.org/10.1056/NEJMoa1709118
315. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al. Rivaroxaban 
with or without aspirin in patients with stable coronary artery disease: an international, 
randomised, double-blind, placebo-controlled trial. Lancet 2018;391:205–218. https:// 
doi.org/10.1016/s0140-6736(17)32458-3
316. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve 
or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 
371:2155–2166. https://doi.org/10.1056/NEJMoa1409312
317. Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, et al. Ischaemic risk and 
efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 2016; 
37:1133–1142. https://doi.org/10.1093/eurheartj/ehv531
318. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of 
ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372: 
1791–1800. https://doi.org/10.1056/NEJMoa1500857
319.
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in pa -
tients with stable coronary disease and diabetes. N Engl J Med 2019;
381:1309–1320. 
https://doi.org/10.1056/NEJMoa1908077
320. Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, et al. P2Y12 inhibitor 
monotherapy or dual antiplatelet therapy after coronary revascularisation: individual 
patient level meta-analysis of randomised controlled trials. BMJ 2021;
373:n1332. 
https://doi.org/10.1136/bmj.n1332
321. Shoji S, Kuno T, Fujisaki T, Takagi H, Briasoulis A, Deharo P, et al. De-escalation of dual 
antiplatelet therapy in patients with acute coronary syndromes. J Am Coll Cardiol 2021; 
78:763–777. https://doi.org/10.1016/j.jacc.2021.06.0123810                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

322. Laudani C, Greco A, Occhipinti G, Ingala S, Calderone D, Scalia L, et al. Short duration 
of DAPT versus de-escalation after percutaneous coronary intervention for acute cor -
onary syndromes. JACC Cardiovasc Interv 2022;
15:268–277. https://doi.org/10.1016/j. 
jcin.2021.11.028
323. Giustino G, Mehran R, Dangas GD, Kirtane AJ, Redfors B, Généreux P, et al. 
Characterization of the average daily ischemic and bleeding risk after primary PCI 
for STEMI. J Am Coll Cardiol 2017;
70:1846–1857. https://doi.org/10.1016/j.jacc.2017. 
08.018
324. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic ther -
apy for atrial fibrillation with stable coronary disease. N Engl J Med 2019;
381: 
1103–1113. https://doi.org/10.1056/NEJMoa1904143
325. Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, et al. 
Open-label randomized trial comparing oral anticoagulation with and without single 
antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease 
beyond 1 year after coronary stent implantation. Circulation 2019;
139:604–616. 
https://doi.org/10.1161/circulationaha.118.036768
326. Chiarito M, Sanz-Sánchez J, Cannata F, Cao D, Sturla M, Panico C, et al. Monotherapy 
with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with estab -
lished atherosclerosis: a systematic review and meta-analysis. Lancet 2020;
395: 
1487–1495. https://doi.org/10.1016/s0140-6736(20)30315-9
327. Koo BK, Kang J, Park KW, Rhee T-M, Yang H-M, Won KB, et al. Aspirin versus clopi -
dogrel for chronic maintenance monotherapy after percutaneous coronary interven -
tion (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, 
multicentre trial. Lancet 2021;
397:2487–2496. https://doi.org/10.1016/s0140- 
6736(21)01063-1
328. Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, Belle L, et al. Antiplatelet 
therapy in patients with anticoagulants undergoing percutaneous coronary stenting 
(from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol 2009;
104: 
338–342. https://doi.org/10.1016/j.amjcard.2009.03.053
329. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, et al. Management of 
antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on 
Thrombosis, European Heart Rhythm Association (EHRA), European Association of 
Percutaneous Cardiovascular Interventions (EAPCI) and European Association of 
Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and 
Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35:3155–3179. 
https://doi.org/10.1093/eurheartj/ehu298
330.
Ruiz-Nodar JM, Marín F, Hurtado JA, Valencia J, Pinar E, Pineda J, et al. Anticoagulant 
and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutan -
eous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;
51:818–825. https://doi.org/10.1016/j.jacc.2007.11. 
035
331. Beyer-Westendorf J, Gelbricht V, Förster K, Ebertz F, Kohler C, Werth S, et al. 
Peri-interventional management of novel oral anticoagulants in daily care: results 
from the prospective Dresden NOAC registry. Eur Heart J 2014;
35:1888–1896. 
https://doi.org/10.1093/eurheartj/eht557
332. Kiviniemi T, Karjalainen P, Pietilä M, Ylitalo A, Niemelä M, Vikman S, et al. Comparison 
of additional versus no additional heparin during therapeutic oral anticoagulation in pa -
tients undergoing percutaneous coronary intervention. Am J Cardiol 2012;
110:30–35. 
https://doi.org/10.1016/j.amjcard.2012.02.045
333. Fiedler KA, Maeng M, Mehilli J, Schulz-Schüpke S, Byrne RA, Sibbing D, et al. Duration 
of triple therapy in patients requiring oral anticoagulation after drug-eluting stent im -
plantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015;
65:1619–1629. https://doi.org/ 
10.1016/j.jacc.2015.02.050
334. Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, et al. Stent 
thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation 2020;
141:781–783. https://doi.org/10.1161/ 
circulationaha.119.044584
335. Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk/ 
benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and 
late after an acute coronary syndrome or percutaneous coronary intervention: insights 
from AUGUSTUS. Circulation 2020;141:1618–1627. https://doi.org/10.1161/ 
circulationaha.120.046534
336. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Safety and 
efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing per -
cutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol 2019;
4:747–755. https://doi.org/10.1001/jamacardio.2019.1880
337. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Optimal an -
tithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis. JAMA Cardiol 2020;
5: 
582–589. https://doi.org/10.1001/jamacardio.2019.6175
338. Capodanno D, Di Maio M, Greco A, Bhatt DL, Gibson CM, Goette A, et al. Safety and 
efficacy of double antithrombotic therapy with non-vitamin K antagonist oral anticoa -
gulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Am Heart Assoc 2020; 9: 
e017212. https://doi.org/10.1161/jaha.120.017212
339. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, et al. 2018 Joint 
European consensus document on the management of antithrombotic therapy in atrial 
fibrillation patients presenting with acute coronary syndrome and/or undergoing per -
cutaneous cardiovascular interventions: a joint consensus document of the European 
Heart Rhythm Association (EHRA), European Society of Cardiology Working Group 
on Thrombosis, European Association of Percutaneous Cardiovascular Interventions 
(EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the 
Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin 
America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of 
Southern Africa (CASSA). Europace 2019;
21:192–193. https://doi.org/10.1093/ 
europace/euy174
340. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral as -
pirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: 
ISIS-2. Lancet 1988;
2:349–360.
341. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to 
aspirin in 45,852 patients with acute myocardial infarction: randomised placebo- 
controlled trial. Lancet 2005;
366:1607–1621. https://doi.org/10.1016/s0140- 
6736(05)67660-x
342. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, 
et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarc -
tion with ST-segment elevation. N Eng J Med 2005;
352:1179–1189. https://doi.org/10. 
1056/NEJMoa050522
343. Osman M, Kheiri B, Shigle AJ, Saleem M, Osman K, Sengupta PP, et al. Ticagrelor after 
pharmacological thrombolysis in patients with ST-segment elevation myocardial in -
farctions: insight from a trial sequential analysis. J Thromb Thrombolysis 2019;
48: 
661–667. https://doi.org/10.1007/s11239-019-01953-3
344. Berwanger O, Lopes RD, Moia DDF, Fonseca FA, Jiang L, Goodman SG, et al. 
Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis: 
TREAT trial. J Am Coll Cardiol 2019;
73:2819–2828. https://doi.org/10.1016/j.jacc. 
2019.03.011
345. Kheiri B, Osman M, Abdalla A, Haykal T, Barbarawi M, Zayed Y, et al. Ticagrelor versus 
clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarc -
tion: a systematic review and meta-analysis of randomized clinical trials. J Thromb 
Thrombolysis 2018;
46:299–303. https://doi.org/10.1007/s11239-018-1706-2
346. Sánchez PL, Gimeno F, Ancillo P, Sanz JJ, Alonso-Briales JH, Bosa F, et al. Role of the 
paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction 
undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial. Circ 
Cardiovasc Interv 2010;
3:297–307. https://doi.org/10.1161/circinterventions.109. 
920868
347. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enox -
aparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute 
myocardial infarction. Lancet 2001;
358:605–613. https://doi.org/10.1016/s0140- 
6736(01)05775-0
348. Giraldez RR, Nicolau JC, Corbalan R, Gurfinkel EP, Juarez U, Lopez-Sendon J, et al. 
Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocar -
dial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. Eur Heart J 2007;
28:1566–1573. https://doi.org/10.1093/ 
eurheartj/ehm179
349. White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky L, et al. 
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial in -
farction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J 
2007;
28:1066–1071. https://doi.org/10.1093/eurheartj/ehm081
350. Peters RJ, Joyner C, Bassand JP, Afzal R, Chrolavicius S, Mehta SR, et al. The role of 
fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J 2008;
29:324–331. https://doi.org/ 
10.1093/eurheartj/ehm616
351. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised 
trial. Lancet 2001;358:1855–1863. https://doi.org/10.1016/s0140-6736(01)06887-8
352. Fernández-Avilés F, Alonso JJ, Peña G, Blanco J, Alonso-Briales J, Lopez-Mesa J, et al. 
Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, 
controlled trial. Eur Heart J 2007;28:949–960. https://doi.org/10.1093/eurheartj/ 
ehl461
353.
Björklund E, Stenestrand U, Lindbäck J, Svensson L, Wallentin L, Lindahl B. Pre-hospital 
thrombolysis delivered by paramedics is associated with reduced time delay and mor -
tality in ambulance-transported real-life patients with ST-elevation myocardial infarc -
tion. Eur Heart J 2006;
27:1146–1152. https://doi.org/10.1093/eurheartj/ehi886
354. Bonnefoy E, Steg PG, Boutitie F, Dubien P-Y, Lapostolle F, Roncalli J, et al. Comparison 
of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J 2009;
30:1598–1606. https://doi.org/ 
10.1093/eurheartj/ehp156
355. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, et al. 
Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a ESC Guidelines                                                                                                                                                                                          3811Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

randomised study. Lancet 2002;360:825–829. https://doi.org/10.1016/s0140-6736(02) 
09963-4
356. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) 
Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute 
myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354: 
716–722. https://doi.org/10.1016/s0140-6736(99)07403-6
357. GUSTO investigators. An international randomized trial comparing four thrombolytic 
strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682. https://doi. 
org/10.1056/nejm199309023291001
358. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AAJ, Arntz HR, et al. 
Efficacy and safety of tenecteplase in combination with the low-molecular-weight hep -
arin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of 
the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS rando -
mized trial in acute myocardial infarction. Circulation 2003;
108:135–142. https://doi. 
org/10.1161/01.Cir.0000081659.72985.A8
359. Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L, et al. 
Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfrac -
tionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis 
and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). 
Circulation 2001;
104:648–652. https://doi.org/10.1161/hc3101.093866
360. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JCL, Hamer B, Bassand J-P, et al. 
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. 
Circulation 2002;
105:1642–1649. https://doi.org/10.1161/01.cir.0000013402.34759. 
46
361. James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, et al. Ticagrelor versus 
clopidogrel in patients with acute coronary syndromes intended for non-invasive man -
agement: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;
342:d3527. https://doi.org/10.1136/bmj.d3527
362. Wiviott SD, White HD, Ohman EM, Fox KAA, Armstrong PW, Prabhakaran D, et al. 
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment ele -
vation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 2013;
382:605–613. https://doi.org/10. 
1016/s0140-6736(13)61451-8
363. Savonitto S, Ferri LA, Piatti L, Grosseto D, Piovaccari G, Morici N, et al. Comparison of 
reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute 
coronary syndromes undergoing early percutaneous revascularization. Circulation 
2018;
137:2435–2445. https://doi.org/10.1161/circulationaha.117.032180
364. Patterson T, Perkins GD, Hassan Y, Moschonas K, Gray H, Curzen N, et al. Temporal 
trends in identification, management, and clinical outcomes after out-of-hospital car -
diac arrest: insights from the myocardial ischaemia national audit project database. 
Circ Cardiovasc Interv 2018;
11:e005346. https://doi.org/10.1161/circinterventions.117. 
005346
365. Byrne R, Constant O, Smyth Y, Callagy G, Nash P, Daly K, et al. Multiple source sur -
veillance incidence and aetiology of out-of-hospital sudden cardiac death in a rural population in the West of Ireland. Eur Heart J 2008;
29:1418–1423. https://doi.org/ 
10.1093/eurheartj/ehn155
366. Kroupa J, Knot J, Ulman J, Bednar F, Dohnalova A, Motovska Z. Characteristics and sur -
vival determinants in patients after out-of-hospital cardiac arrest in the era of 24/7 cor -
onary intervention facilities. Heart Lung Circ 2017;
26:799–807. https://doi.org/10.1016/ 
j.hlc.2016.11.012
367. Perkins GD, Graesner JT, Semeraro F, Olasveengen T, Soar J, Lott C, et al. European 
Resuscitation Council Guidelines 2021: executive summary. Resuscitation 2021;
161: 
1–60. https://doi.org/10.1016/j.resuscitation.2021.02.003
368. Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J, et al. 
Immediate percutaneous coronary intervention is associated with better survival after 
out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hos -
pital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010;
3:200–207. https://doi.org/10. 
1161/circinterventions.109.913665
369. Nolan JP, Sandroni C, Böttiger BW, Cariou A, Cronberg T, Friberg H, et al. European 
Resuscitation Council and European Society of Intensive Care Medicine guidelines 
2021: post-resuscitation care. Intensive Care Med 2021;
47:369–421. https://doi.org/ 
10.1007/s00134-021-06368-4
370. Rab T, Kern KB, Tamis-Holland JE, Henry TD, McDaniel M, Dickert NW, et al. Cardiac 
arrest: a treatment algorithm for emergent invasive cardiac procedures in the resusci -
tated comatose patient. J Am Coll Cardiol 2015;
66:62–73. https://doi.org/10.1016/j.jacc. 
2015.05.009
371. Gorjup V, Radsel P, Kocjancic ST, Erzen D, Noc M. Acute ST-elevation myocardial in -
farction after successful cardiopulmonary resuscitation. Resuscitation 2007;
72: 
379–385. https://doi.org/10.1016/j.resuscitation.2006.07.013
372. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen 
MM, et al. Coronary angiography after cardiac arrest without ST segment elevation: 
one-year outcomes of the COACT randomized clinical trial. JAMA Cardiol 2020;
5: 
1358–1365. https://doi.org/10.1001/jamacardio.2020.3670373. Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, et al. Angiography after 
out-of-hospital cardiac arrest without ST-segment elevation. N Engl J Med 2021;385: 
2544–2553. https://doi.org/10.1056/NEJMoa2101909
374. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, 
et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J 
Med 2019;380:1397–1407. https://doi.org/10.1056/NEJMoa1816897
375. Kern KB, Radsel P, Jentzer JC, Seder DB, Lee KS, Lotun K, et al. Randomized pilot clin -
ical trial of early coronary angiography versus no early coronary angiography after car -
diac arrest without ST-segment elevation: the PEARL study. Circulation 2020;
142: 
2002–2012. https://doi.org/10.1161/circulationaha.120.049569
376. Hauw-Berlemont C, Lamhaut L, Diehl JL, Andreotti C, Varenne O, Leroux P, et al. 
Emergency vs delayed coronary angiogram in survivors of out-of-hospital cardiac ar -
rest: results of the randomized, multicentric EMERGE trial. JAMA Cardiol 2022;
7: 
700–707. https://doi.org/10.1001/jamacardio.2022.1416
377. Viana-Tejedor A, Andrea-Riba R, Scardino C, Ariza-Solé A, Bañeras J, García-García C, 
et al. Coronary angiography in patients without ST-segment elevation following 
out-of-hospital cardiac arrest. Rev Esp Cardiol (Engl Ed) 2022;
76:94–102. https://doi. 
org/10.1016/j.rec.2022.05.013
378. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to 
improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549–556. 
https://doi.org/10.1056/NEJMoa012689
379. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. 
Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypo -
thermia. N Engl J Med 2002;
346:557–563. https://doi.org/10.1056/NEJMoa003289
380. Belliard G, Catez E, Charron C, Caille V, Aegerter P, Dubourg O, et al. Efficacy of 
therapeutic hypothermia after out-of-hospital cardiac arrest due to ventricular fibril -
lation. Resuscitation 2007;
75:252–259. https://doi.org/10.1016/j.resuscitation.2007.04. 
014
381. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted 
temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med 2013; 
369
:2197–2206. https://doi.org/10.1056/NEJMoa1310519
382. Vaahersalo J, Hiltunen P, Tiainen M, Oksanen T, Kaukonen K-M, Kurola J, et al. 
Therapeutic hypothermia after out-of-hospital cardiac arrest in Finnish intensive 
care units: the FINNRESUSCI study. Intensive Care Med 2013;39:826–837. https:// 
doi.org/10.1007/s00134-013-2868-1
383. Nolan JP, Sandroni C, Andersen LW, Böttiger BW, Cariou A, Cronberg T, et al. 
ERC-ESICM guidelines on temperature control after cardiac arrest in adults. 
Resuscitation 2022;172:229–236. https://doi.org/10.1016/j.resuscitation.2022.01.009
384. Hassager C, Schmidt H, Møller JE, Grand J, Mølstrøm S, Beske RP, et al. Duration of 
device-based fever prevention after cardiac arrest. N Engl J Med 2023;388:888–897. 
https://doi.org/10.1056/NEJMoa2212528
385. Wolfrum S, Roedl K, Hanebutte A, Pfeifer R, Kurowski V, Riessen R, et al. Temperature 
control after in-hospital cardiac arrest: a randomized clinical trial. Circulation 2022;146: 
1357–1366. https://doi.org/10.1161/circulationaha.122.060106
386. Sandroni C, Geocadin RG. Neurological prognostication after cardiac arrest. Curr Opin 
Crit Care 2015;21:209–214. https://doi.org/10.1097/mcc.0000000000000202
387. Garot P, Lefevre T, Eltchaninoff H, Morice M-C, Tamion F, Abry B, et al. Six-month 
outcome of emergency percutaneous coronary intervention in resuscitated patients 
after cardiac arrest complicating ST-elevation myocardial infarction. Circulation 2007; 
115:1354–1362. https://doi.org/10.1161/circulationaha.106.657619
388. Spaulding CM, Joly LM, Rosenberg A, Monchi M, Weber SN, Dhainaut J-FA, et al. 
Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N 
Engl J Med 1997;336:1629–1633. https://doi.org/10.1056/nejm199706053362302
389. Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullén S, et al. Hypothermia 
versus normothermia after out-of-hospital cardiac arrest. N Engl J Med 2021;384: 
2283–2294. https://doi.org/10.1056/NEJMoa2100591
390. Callaway CW, Schmicker R, Kampmeyer M, Powell J, Rea TD, Daya MR, et al. 
Receiving hospital characteristics associated with survival after out-of-hospital cardiac 
arrest. Resuscitation 2010;81:524–529. https://doi.org/10.1016/j.resuscitation.2009.12. 
006
391. Wnent J, Seewald S, Heringlake M, Lemke H, Brauer K, Lefering R, et al. Choice of hos -
pital after out-of-hospital cardiac arrest – a decision with far-reaching consequences: a 
study in a large German city. Crit Care 2012;
16:R164. https://doi.org/10.1186/cc11516
392. Kragholm K, Malta Hansen C, Dupre ME, Xian Y, Strauss B, Tyson C, et al. Direct trans -
port to a percutaneous cardiac intervention center and outcomes in patients with 
out-of-hospital cardiac arrest. Circ Cardiovasc Qual Outcomes 2017;
10:e003414. 
https://doi.org/10.1161/circoutcomes.116.003414
393. Yeo JW, Ng ZHC, Goh AXC, Gao JF, Liu N, Lam SWS, et al. Impact of cardiac arrest 
centers on the survival of patients with nontraumatic out-of-hospital cardiac arrest: a 
systematic review and meta-analysis. J Am Heart Assoc 2022;
11:e023806. https://doi. 
org/10.1161/jaha.121.023806
394. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early re -
vascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl 
J Med 1999;
341:625–634. https://doi.org/10.1056/nejm199908263410901
395. White HD, Assmann SF, Sanborn TA, Jacobs AK, Webb JG, Sleeper LA, et al. 
Comparison of percutaneous coronary intervention and coronary artery bypass 3812                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

grafting after acute myocardial infarction complicated by cardiogenic shock: results 
from the Should We Emergently Revascularize Occluded Coronaries for 
Cardiogenic Shock (SHOCK) trial. Circulation 2005;112:1992–2001. https://doi.org/ 
10.1161/circulationaha.105.540948
396. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, et al. Early revas -
cularization and long-term survival in cardiogenic shock complicating acute myocardial 
infarction. JAMA 2006;
295:2511–2515. https://doi.org/10.1001/jama.295.21.2511
397. Liakopoulos OJ, Schlachtenberger G, Wendt D, Choi Y-H, Slottosch I, Welp H, et al. 
Early clinical outcomes of surgical myocardial revascularization for acute coronary syn -
dromes complicated by cardiogenic shock: a report from the north-Rhine-Westphalia 
surgical myocardial infarction registry. J Am Heart Assoc 2019;
8:e012049. https://doi. 
org/10.1161/jaha.119.012049
398. Thielmann M, Wendt D, Slottosch I, Welp H, Schiller W, Tsagakis K, et al. Coronary 
artery bypass graft surgery in patients with acute coronary syndromes after primary 
percutaneous coronary intervention: a current report from the north-Rhine Westphalia surgical myocardial infarction registry. J Am Heart Assoc 2021;
10: 
e021182. https://doi.org/10.1161/jaha.121.021182
399. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich H-G, Hausleiter J, et al. Intraaortic 
balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 
367:1287–1296. https://doi.org/10.1056/NEJMoa1208410
400. Schrage B, Ibrahim K, Loehn T, Werner N, Sinning J-M, Pappalardo F, et al. Impella sup -
port for acute myocardial infarction complicated by cardiogenic shock. Circulation 
2019;
139:1249–1258. https://doi.org/10.1161/circulationaha.118.036614
401. Miller PE, Bromfield SG, Ma Q, Crawford G, Whitney J, DeVries A, et al. Clinical out -
comes and cost associated with an intravascular microaxial left ventricular assist device 
vs intra-aortic balloon pump in patients presenting with acute myocardial infarction 
complicated by cardiogenic shock. JAMA Intern Med 2022;
182:926–933. https://doi. 
org/10.1001/jamainternmed.2022.2735
402. Ostadal P, Rokyta R, Karasek J, Kruger A, Vondrakova D, Janotka M, et al. 
Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: results 
of the ECMO-CS randomized clinical trial. Circulation 2022;
147:454–464. https://doi. 
org/10.1161/circulationaha.122.062949
403. Kim Y, Shapero K, Ahn SS, Goldsweig AM, Desai N, Altin SE. Outcomes of mechanical 
circulatory support for acute myocardial infarction complicated by cardiogenic shock. 
Catheter Cardiovasc Interv 2022;99:658–663. https://doi.org/10.1002/ccd.29834
404. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI strategies 
in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017; 
377:2419–2432. https://doi.org/10.1056/NEJMoa1710261
405. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich H-G, Hausleiter J, et al. 
Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by 
cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open- 
label trial. Lancet 2013;382:1638–1645. https://doi.org/10.1016/s0140-6736(13) 
61783-3
406. Unverzagt S, Buerke M, de Waha A, Haerting J, Pietzner D, Seyfarth M, et al. 
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction compli -
cated by cardiogenic shock. Cochrane Database Syst Rev 2015;
2015:Cd007398. 
https://doi.org/10.1002/14651858.CD007398.pub3
407. Thiele H, Zeymer U, Thelemann N, Neumann F-J, Hausleiter J, Abdel-Wahab M, et al. 
Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarc -
tion: long-term 6-year outcome of the randomized IABP-SHOCK II trial. Circulation 
2018;
139:395–403. https://doi.org/10.1161/circulationaha.118.038201
408. Bonnefoy-Cudraz E, Bueno H, Casella G, De Maria E, Fitzsimons D, Halvorsen S, et al. 
Editor’s Choice – acute cardiovascular care association position paper on intensive cardiovascular care units: an update on their definition, structure, organisation and function. Eur Heart J Acute Cardiovasc Care 2018;
7:80–95. https://doi.org/10.1177/ 
2048872617724269
409. Winkler C, Funk M, Schindler DM, Hemsey JZ, Lampert R, Drew BJ. Arrhythmias in patients with acute coronary syndrome in the first 24 hours of hospitalization. 
Heart Lung 2013;42:422–427. https://doi.org/10.1016/j.hrtlng.2013.07.010
410.
Wasfy JH, Kennedy KF, Masoudi FA, Ferris TG, Arnold SV, Kini V, et al. Predicting 
length of stay and the need for postacute care after acute myocardial infarction to im -
prove healthcare efficiency. Circ Cardiovasc Qual Outcomes 2018;
11:e004635. https:// 
doi.org/10.1161/circoutcomes.118.004635
411. Melberg T, Jørgensen M, Ørn S, Solli T, Edland U, Dickstein K. Safety and health status 
following early discharge in patients with acute myocardial infarction treated with pri -
mary PCI: a randomized trial. Eur J Prev Cardiol 2015;
22:1427–1434. https://doi.org/10. 
1177/2047487314559276
412. Berger AK, Duval S, Jacobs DR Jr, Barber C, Vazquez G, Lee S, et al. Relation of length 
of hospital stay in acute myocardial infarction to postdischarge mortality. Am J Cardiol 
2008;
101:428–434. https://doi.org/10.1016/j.amjcard.2007.09.090
413. Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR, et al. Safety 
and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1998;31:967–972. https://doi.org/10. 
1016/s0735-1097(98)00031-x
414. De Luca G, Suryapranata H, van’t Hof AW, de Boer M-J, Hoorntje JCA, Dambrink J-HE, et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation 2004;109: 
2737–2743. https://doi.org/10.1161/01.Cir.0000131765.73959.87
415.
Novobilsky K, Stipal R, Cerny P, Horak I, Kaucak V, Mrozek J, et al. Safety of early dis -
charge in low risk patients after acute ST-segment elevation myocardial infarction, treated with primary percutaneous coronary intervention. Open label, randomized 
trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2019;
163:61–66. 
https://doi.org/10.5507/bp.2018.041
416. Albanese M, Alpaslan K, Ouarrak T, Merguet P, Schneider S, Schöls W. In-hospital 
major arrhythmias, arrhythmic death and resuscitation after successful primary percu -
taneous intervention for acute transmural infarction: a retrospective single-centre 
cohort study. BMC Cardiovasc Disord 2018;
18:116. https://doi.org/10.1186/s12872- 
018-0851-z
417. Yndigegn T, Gilje P, Dankiewicz J, Mokhtari A, Isma N, Holmqvist J, et al. Safety of early 
hospital discharge following admission with ST-elevation myocardial infarction treated with percutaneous coronary intervention: a nationwide cohort study. EuroIntervention 
2022;
17:1091–1099. https://doi.org/10.4244/eij-d-21-00501
418. Seto AH, Shroff A, Abu-Fadel M, Blankenship JC, Boudoulas KD, Cigarroa JE, et al. 
Length of stay following percutaneous coronary intervention: an expert consensus document update from the society for cardiovascular angiography and interventions. 
Catheter Cardiovasc Interv 2018;92:717–731. https://doi.org/10.1002/ccd.27637
419.
Estévez-Loureiro R, Calviño-Santos R, Vázquez JM, Barge-Caballero E, Salgado-Fernández J, Piñeiro M, et al. Safety and feasibility of returning patients early 
to their originating centers after transfer for primary percutaneous coronary interven
-
tion. Rev Esp Cardiol 2009;
62:1356–1364. https://doi.org/10.1016/s1885-5857(09) 
73529-7
420. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. 
TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical 
score for risk assessment at presentation: an intravenous nPA for treatment of infarct -
ing myocardium early II trial substudy. Circulation 2000;
102:2031–2037. https://doi. 
org/10.1161/01.cir.102.17.2031
421. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. 
Prediction of risk of death and myocardial infarction in the six months after presenta -
tion with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;
333:1091. https://doi.org/10.1136/bmj.38985.646481.55
422. Aragam KG, Tamhane UU, Kline-Rogers E, Li J, Fox KAA, Goodman SG, et al. Does 
simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of 
the TIMI and GRACE risk scores. PLoS One 2009;
4:e7947. https://doi.org/10.1371/ 
journal.pone.0007947
423. D’Ascenzo F, Biondi-Zoccai G, Moretti C, Bollati M, Omedè P, Sciuto F, et al. TIMI, 
GRACE and alternative risk scores in Acute Coronary Syndromes: a meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 pa
-
tients. Contemp Clin Trials 2012;
33:507–514. https://doi.org/10.1016/j.cct.2012.01.001
424. Gale CP, Manda SO, Weston CF, Birkhead JS, Batin PD, Hall AS. Evaluation of risk 
scores for risk stratification of acute coronary syndromes in the Myocardial 
Infarction National Audit Project (MINAP) database. Heart 2009;
95:221–227. 
https://doi.org/10.1136/hrt.2008.144022
425. D’Ascenzo F, De Filippo O, Gallone G, Mittone G, Deriu MA, Iannaccone M, et al. 
Machine learning-based prediction of adverse events following an acute coronary syn -
drome (PRAISE): a modelling study of pooled datasets. Lancet 2021;
397:199–207. 
https://doi.org/10.1016/s0140-6736(20)32519-8
426. Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, et al. The prog -
nostic importance of left ventricular function in patients with ST-segment elevation 
myocardial infarction: the HORIZONS-AMI trial. Eur Heart J Acute Cardiovasc Care 
2014;
3:67–77. https://doi.org/10.1177/2048872613507149
427. de Waha S, Eitel I, Desch S, Fuernau G, Lurz P, Stiermaier T, et al. Prognosis after 
ST-elevation myocardial infarction: a study on cardiac magnetic resonance imaging ver -
sus clinical routine. Trials 2014;
15:249. https://doi.org/10.1186/1745-6215-15-249
428. Larose E, Côté J, Rodés-Cabau J, Noël B, Barbeau G, Bordeleau E, et al. 
Contrast-enhanced cardiovascular magnetic resonance in the hyperacute phase of 
ST-elevation myocardial infarction. Int J Cardiovasc Imaging 2009;
25:519–527. https:// 
doi.org/10.1007/s10554-009-9451-4
429. Stiermaier T, Jobs A, de Waha S, Fuernau G, Pöss J, Desch S, et al. Optimized prognosis 
assessment in ST-segment-elevation myocardial infarction using a cardiac magnetic 
resonance imaging risk score. Circ Cardiovasc Imaging 2017;10:e006774. https://doi. 
org/10.1161/circimaging.117.006774
430. de Waha S, Desch S, Eitel I, Fuernau G, Zachrau J, Leuschner A, et al. Impact of early vs. 
late microvascular obstruction assessed by magnetic resonance imaging on long-term 
outcome after ST-elevation myocardial infarction: a comparison with traditional prog -
nostic markers. Eur Heart J 2010;
31:2660–2668. https://doi.org/10.1093/eurheartj/ 
ehq247
431. van Kranenburg M, Magro M, Thiele H, de Waha S, Eitel I, Cochet A, et al. Prognostic 
value of microvascular obstruction and infarct size, as measured by CMR in STEMI pa -
tients. JACC Cardiovasc Imaging 2014;
7:930–939. https://doi.org/10.1016/j.jcmg.2014. 
05.010
432. van Loon RB, Veen G, Baur LHB, Kamp O, Bronzwaer JGF, Twisk JWR, et al. Improved 
clinical outcome after invasive management of patients with recent myocardial ESC Guidelines                                                                                                                                                                                          3813Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

infarction and proven myocardial viability: primary results of a randomized controlled 
trial (VIAMI-trial). Trials 2012;13:1. https://doi.org/10.1186/1745-6215-13-1
433. van Loon RB, Veen G, Baur LH, Twisk JW, van Rossum AC. Long-term follow-up of the viability guided angioplasty after acute myocardial infarction (VIAMI) trial. Int J 
Cardiol 2015;186:111–116. https://doi.org/10.1016/j.ijcard.2015.03.152
434.
Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and 
the prevention of sudden cardiac death: the Task Force for the management of pa -
tients with ventricular arrhythmias and the prevention of sudden cardiac death of 
the European Society of Cardiology (ESC). Endorsed by: Association for European 
Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;
36:2793–2867. 
https://doi.org/10.1093/eurheartj/ehv316
435. Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, et al. Cardiac MRI endpoints 
in myocardial infarction experimental and clinical trials: JACC Scientific Expert Panel. J 
Am Coll Cardiol 2019;
74:238–256. https://doi.org/10.1016/j.jacc.2019.05.024
436. Stone GW, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM, et al. Relationship 
between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. J Am Coll Cardiol 2016;67:1674–1683. https://doi.org/10.1016/j. 
jacc.2016.01.069
437.
Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ische -
mia/reperfusion injury. J Am Coll Cardiol 2015;
65:1454–1471. https://doi.org/10.1016/j. 
jacc.2015.02.032
438. Eitel I, de Waha S, Wöhrle J, Fuernau G, Lurz P, Pauschinger M, et al. Comprehensive 
prognosis assessment by CMR imaging after ST-segment elevation myocardial infarc -
tion. J Am Coll Cardiol 2014;
64:1217–1226. https://doi.org/10.1016/j.jacc.2014.06.1194
439. Haaf P, Reichlin T, Twerenbold R, Hoeller R, Rubini Gimenez M, Zellweger C, et al. Risk 
stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. Eur Heart J 2014;
35:365–375. https://doi.org/10.1093/eurheartj/ 
eht218
440. Tveit SH, Myhre PL, Hoff NJS, Le TM, Seljeflot I, Røysland R, et al. Superiority of high 
sensitivity cardiac troponin T vs. I for long-term prognostic value in patients with chest 
pain; data from the Akershus Cardiac Examination (ACE) 3 study. Clin Biochem 2020; 
78:10–17. https://doi.org/10.1016/j.clinbiochem.2019.12.016
441. Welsh P, Preiss D, Hayward C, Shah ASV, McAllister D, Briggs A, et al. Cardiac tropo -
nin T and troponin I in the general population. Circulation 2019;
139:2754–2764. 
https://doi.org/10.1161/circulationaha.118.038529
442. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use 
high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;
33: 
2252–2257. https://doi.org/10.1093/eurheartj/ehs154
443. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau J-L, et al. 
Relation between renal dysfunction and cardiovascular outcomes after myocardial in -
farction. N Engl J Med 2004;
351:1285–1295. https://doi.org/10.1056/NEJMoa041365
444. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations 
for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute 
Cardiac Care. Eur Heart J 2012;
33:2001–2006. https://doi.org/10.1093/eurheartj/ 
ehq509
445. Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, et al. Balancing the 
risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. 
Am Heart J 2017;186:91–99. https://doi.org/10.1016/j.ahj.2017.01.010
446. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. 
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary 
syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event 
Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 
2017;38:804–810. https://doi.org/10.1093/eurheartj/ehw525
447. Newby LK, Hasselblad V, Armstrong PW, Van de Werf F, Mark DB, White HD, et al. 
Time-based risk assessment after myocardial infarction. Implications for timing of dis -
charge and applications to medical decision-making. Eur Heart J 2003;
24:182–189. 
https://doi.org/10.1016/s0195-668x(02)00301-9
448. Kwok CS, Khan MA, Rao SV, Kinnaird T, Sperrin M, Buchan I, et al. Access and non- 
access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and 
meta-analysis. Circ Cardiovasc Interv 2015;
8:e001645. https://doi.org/10.1161/ 
circinterventions.114.001645
449. Ndrepepa G, Neumann FJ, Richardt G, Schulz S, Tölg R, Stoyanov KM, et al. Prognostic 
value of access and non-access sites bleeding after percutaneous coronary interven -
tion. Circ Cardiovasc Interv 2013;
6:354–361. https://doi.org/10.1161/circinterventions. 
113.000433
450. Rao SV, Cohen MG, Kandzari DE, Bertrand OF, Gilchrist IC. The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and 
future directions. J Am Coll Cardiol 2010;
55:2187–2195. https://doi.org/10.1016/j.jacc. 
2010.01.039
451. Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, et al. Radial versus femoral 
access for coronary angiography and intervention in patients with acute coronary syn -
dromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011;
377: 
1409–1420. https://doi.org/10.1016/s0140-6736(11)60404-2452. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, et al. Radial versus fem -
oral access in patients with acute coronary syndromes undergoing invasive manage -
ment: a randomised multicentre trial. Lancet 2015;
385:2465–2476. https://doi.org/ 
10.1016/s0140-6736(15)60292-6
453. Vranckx P, Frigoli E, Rothenbühler M, Tomassini F, Garducci S, Andò G, et al. Radial 
versus femoral access in patients with acute coronary syndromes with or without 
ST-segment elevation. Eur Heart J 2017;
38:1069–1080. https://doi.org/10.1093/ 
eurheartj/ehx048
454. Lee P, Liew D, Brennan A, Stub D, Lefkovits J, Reid CM, et al. Cost-effectiveness of 
radial access percutaneous coronary intervention in acute coronary syndrome. Am J 
Cardiol 2021;156:44–51. https://doi.org/10.1016/j.amjcard.2021.06.034
455. Kerensky RA, Wade M, Deedwania P, Boden WE, Pepine CJ. Revisiting the culprit le -
sion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angio -
graphic core laboratory. J Am Coll Cardiol 2002;
39:1456–1463. https://doi.org/10.1016/ 
s0735-1097(02)01770-9
456. Johnson TW, Räber L, di Mario C, Bourantas C, Jia H, Mattesini A, et al. Clinical use of 
intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiog -
raphy findings, and guiding interventional decision-making: an expert consensus docu -
ment of the European Association of Percutaneous Cardiovascular Interventions. Eur 
Heart J 2019;
40:2566–2584. https://doi.org/10.1093/eurheartj/ehz332
457. di Mario C, Koskinas KC, Räber L. Clinical benefit of IVUS guidance for coronary stent -
ing: the ULTIMATE step toward definitive evidence? J Am Coll Cardiol 2018;
72: 
3138–3141. https://doi.org/10.1016/j.jacc.2018.10.029
458. Gao XF, Wang ZM, Wang F, Gu Y, Ge Z, Kong X-Q, et al. Intravascular ultrasound 
guidance reduces cardiac death and coronary revascularization in patients undergoing 
drug-eluting stent implantation: results from a meta-analysis of 9 randomized trials and 
4724 patients. Int J Cardiovasc Imaging 2019;
35:239–247. https://doi.org/10.1007/ 
s10554-019-01555-3
459. Darmoch F, Alraies MC, Al-Khadra Y, Moussa Pacha H, Pinto DS, Osborn EA. Intravascular ultrasound imaging-guided versus coronary angiography-guided percu
-
taneous coronary intervention: a systematic review and meta-analysis. J Am Heart 
Assoc 2020;
9:e013678. https://doi.org/10.1161/jaha.119.013678
460. Jia H, Dai J, He L, Xu Y, Shi Y, Zhao L, et al. EROSION III: a multicenter RCT of 
OCT-guided reperfusion in STEMI with early infarct artery patency. JACC Cardiovasc 
Interv 2022;
15:846–856. https://doi.org/10.1016/j.jcin.2022.01.298
461. Cuculi F, De Maria GL, Meier P, Dall’Armellina E, de Caterina AR, Channon KM, et al. 
Impact of microvascular obstruction on the assessment of coronary flow reserve, in -
dex of microcirculatory resistance, and fractional flow reserve after ST-segment ele -
vation myocardial infarction. J Am Coll Cardiol 2014;
64:1894–1904. https://doi.org/10. 
1016/j.jacc.2014.07.987
462. De Bruyne B, Pijls NH, Bartunek J, Kulecki K, Bech J-W, De Winter H, et al. Fractional 
flow reserve in patients with prior myocardial infarction. Circulation 2001;
104: 
157–162. https://doi.org/10.1161/01.cir.104.2.157
463. Bønaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygård O, et al. Drug-eluting 
or bare-metal stents for coronary artery disease. N Engl J Med 2016;375:1242–1252. 
https://doi.org/10.1056/NEJMoa1607991
464. Räber L, Kelbæk H, Ostojic M, Baumbach A, Heg D, Tüller D, et al. Effect of 
biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovas -
cular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012;
308:777–787. https://doi.org/10.1001/jama.2012. 
10065
465. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. 
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 
2012;
380:1482–1490. https://doi.org/10.1016/s0140-6736(12)61223-9
466. Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, et al. 
Clinical outcomes in patients with ST-segment elevation myocardial infarction treated 
with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year re -
sults of a randomised trial. Lancet 2016;
387:357–366. https://doi.org/10.1016/s0140- 
6736(15)00548-6
467. Brugaletta S, Gomez-Lara J, Ortega-Paz L, Jimenez-Diaz V, Jimenez M, 
Jiménez-Quevedo P, et al. 10-Year follow-up of patients with everolimus-eluting ver -
sus bare-metal stents after ST-segment elevation myocardial infarction. J Am Coll 
Cardiol 2021;
77:1165–1178. https://doi.org/10.1016/j.jacc.2020.12.059
468. Räber L, Yamaji K, Kelbæk H, Engstrøm T, Baumbach A, Roffi M, et al. Five-year clinical 
outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: ran -
domized comparison of biodegradable polymer-based biolimus-eluting stents with 
bare-metal stents in patients with acute ST-segment elevation myocardial infarction. 
Eur Heart J 2019;
40:1909–1919. https://doi.org/10.1093/eurheartj/ehz074
469. Vos NS, Fagel ND, Amoroso G, Herrman J-PR, Patterson MS, Piers LH, et al. 
Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial in -
farction: the REVELATION randomized trial. JACC Cardiovasc Interv 2019;
12: 
1691–1699. https://doi.org/10.1016/j.jcin.2019.04.016
470. Scheller B, Ohlow MA, Ewen S, Kische S, Rudolph TK, Clever YP, et al. Bare metal or 
drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial 3814                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention 2020;15: 
1527–1533. https://doi.org/10.4244/eij-d-19-00723
471. Belkacemi A, Agostoni P, Nathoe HM, Voskuil M, Shao CL, Van Belle E, et al. First re -
sults of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial 
infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus 
bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percu -
taneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. J Am Coll Cardiol 2012;
59:2327–2337. https://doi.org/10.1016/ 
j.jacc.2012.02.027
472. Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. 
Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J 
Med 2013;
369:1587–1597. https://doi.org/10.1056/NEJMoa1308789
473. Lagerqvist B, Fröbert O, Olivecrona GK, Gudnason T, Maeng M, Alström P, et al. 
Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med 
2014;371:1111–1120. https://doi.org/10.1056/NEJMoa1405707
474. Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. Randomized trial of pri -
mary PCI with or without routine manual thrombectomy. N Engl J Med 2015;
372: 
1389–1398. https://doi.org/10.1056/NEJMoa1415098
475. Jolly SS, James S, Džavík V, Cairns JA, Mahmoud KD, Zijlstra F, et al. Thrombus aspir -
ation in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation 2017;
135:143–152. 
https://doi.org/10.1161/circulationaha.116.025371
476. Jolly SS, Cairns JA, Lavi S, Cantor WJ, Bernat I, Cheema AN, et al. Thrombus aspiration 
in patients with high thrombus burden in the TOTAL trial. J Am Coll Cardiol 2018;
72: 
1589–1596. https://doi.org/10.1016/j.jacc.2018.07.047
477. Thiele H, de Waha S, Zeymer U, Desch S, Scheller B, Lauer B, et al. Effect of aspiration 
thrombectomy on microvascular obstruction in NSTEMI patients: the TATORT-NSTEMI trial. J Am Coll Cardiol 2014;64:1117–1124. https://doi.org/10. 
1016/j.jacc.2014.05.064
478.
de Waha S, Patel MR, Granger CB, Ohman EM, Maehara A, Eitel I, et al. Relationship 
between microvascular obstruction and adverse events following primary percutan -
eous coronary intervention for ST-segment elevation myocardial infarction: an individ -
ual patient data pooled analysis from seven randomized trials. Eur Heart J 2017;
38: 
3502–3510. https://doi.org/10.1093/eurheartj/ehx414
479. Corrigendum to: 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur 
Heart J 2019;
40:3096. https://doi.org/10.1093/eurheartj/ehz507
480. Sabatine MS, Bergmark BA, Murphy SA, O’Gara PT, Smith PK, Serruys PW, et al. 
Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data 
meta-analysis. Lancet 2021;398:2247–2257. https://doi.org/10.1016/s0140-6736(21) 
02334-5
481. Head SJ, Milojevic M, Daemen J, Ahn J-M, Boersma E, Christiansen EH, et al. Mortality 
after coronary artery bypass grafting versus percutaneous coronary intervention with 
stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 
2018;391:939–948. https://doi.org/10.1016/s0140-6736(18)30423-9
482.
Adlam D, Alfonso F, Maas A, Vrints C. European Society of Cardiology, Acute Cardiovascular Care Association, SCAD study group: a position paper on spontan
-
eous coronary artery dissection. Eur Heart J 2018;
39:3353–3368. https://doi.org/10. 
1093/eurheartj/ehy080
483. Alfonso F, de la Torre Hernández JM, Ibáñez B, Sabaté M, Pan M, Gulati R, et al. 
Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in pa -
tients with Spontaneous Coronary Artery Dissection) randomized clinical trial. Rev 
Esp Cardiol (Engl Ed) 2022;
75:515–522. https://doi.org/10.1016/j.rec.2021.08.003
484. Jackson R, Al-Hussaini A, Joseph S, van Soest G, Wood A, Macaya F, et al. Spontaneous 
coronary artery dissection: pathophysiological insights from optical coherence tomog -
raphy. JACC Cardiovasc Imaging 2019;
12:2475–2488. https://doi.org/10.1016/j.jcmg. 
2019.01.015
485. Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, et al. 
Spontaneous coronary artery dissection: current state of the science: a scientific state -
ment from the American Heart Association. Circulation 2018;
137:e523–e557. https:// 
doi.org/10.1161/cir.0000000000000564
486. Tweet MS, Eleid MF, Best PJM, Lennon RJ, Lerman A, Rihal CS, et al. Spontaneous cor -
onary artery dissection: revascularization versus conservative therapy. Circ Cardiovasc 
Interv 2014;
7:777–786. https://doi.org/10.1161/circinterventions.114.001659
487. Saw J, Aymong E, Sedlak T, Buller CE, Starovoytov A, Ricci D, et al. Spontaneous cor -
onary artery dissection: association with predisposing arteriopathies and precipitating 
stressors and cardiovascular outcomes. Circ Cardiovasc Interv 2014;
7:645–655. https:// 
doi.org/10.1161/circinterventions.114.001760
488. Lettieri C, Zavalloni D, Rossini R, Morici N, Ettori F, Leonzi O, et al. Management and 
long-term prognosis of spontaneous coronary artery dissection. Am J Cardiol 2015; 
116
:66–73. https://doi.org/10.1016/j.amjcard.2015.03.039
489. Hayes SN, Tweet MS, Adlam D, Kim ESH, Gulati R, Price JE, et al. Spontaneous cor -
onary artery dissection: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;
76: 
961–984. https://doi.org/10.1016/j.jacc.2020.05.084
490. Nordmann AJ, Hengstler P, Harr T, Young J, Bucher HC. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. Am J Med 2004;
 116:253–262. https:// 
doi.org/10.1016/j.amjmed.2003.08.035
491. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of 
angioplasty with stenting, with or without abciximab, in acute myocardial infarction. 
N Engl J Med 2002;346:957–966. https://doi.org/10.1056/NEJMoa013404
492. Belle L, Motreff P, Mangin L, Rangé G, Marcaggi X, Marie A, et al. Comparison of im -
mediate with delayed stenting using the minimalist immediate mechanical intervention approach in acute ST-segment-elevation myocardial infarction: the MIMI study. Circ 
Cardiovasc Interv 2016;
9:e003388. https://doi.org/10.1161/circinterventions.115. 
003388
493. Kelbæk H, Høfsten DE, Køber L, Helqvist S, Kløvgaard L, Holmvang L, et al. Deferred 
versus conventional stent implantation in patients with ST-segment elevation myocar -
dial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. Lancet 
2016;
387:2199–2206. https://doi.org/10.1016/s0140-6736(16)30072-1
494. Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, Eteiba H, et al. A rando -
mized trial of deferred stenting versus immediate stenting to prevent no- or slow- reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am 
Coll Cardiol 2014;
63:2088–2098. https://doi.org/10.1016/j.jacc.2014.02.530
495. Hong SJ, Kim BK, Shin DH, Nam CM, Kim JS, Ko Y-G, et al. Effect of intravascular 
ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the 
IVUS-XPL randomized clinical trial. JAMA 2015;
314:2155–2163. https://doi.org/10. 
1001/jama.2015.15454
496. Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, et al. Intravascular ultrasound versus 
angiography-guided drug-eluting stent implantation: the ULTIMATE trial. J Am Coll 
Cardiol 2018;72:3126–3137. https://doi.org/10.1016/j.jacc.2018.09.013
497. Gao XF, Ge Z, Kong XQ, Kan J, Han L, Lu S, et al. 3-Year outcomes of the ULTIMATE 
trial comparing intravascular ultrasound versus angiography-guided drug-eluting stent 
implantation. JACC Cardiovasc Interv 2021;14:247–257. https://doi.org/10.1016/j.jcin. 
2020.10.001
498. Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P, et al. 
Optical coherence tomography to optimize results of percutaneous coronary inter -
vention in patients with non-ST-elevation acute coronary syndrome: results of the 
multicenter, randomized DOCTORS study (Does Optical Coherence Tomography 
Optimize Results of Stenting). Circulation 2016;
134:906–917. https://doi.org/10. 
1161/circulationaha.116.024393
499. Kala P, Cervinka P, Jakl M, Kanovsky J, Kupec A, Spacek R, et al. OCT guidance during 
stent implantation in primary PCI: a randomized multicenter study with nine months of 
optical coherence tomography follow-up. Int J Cardiol 2018;
250:98–103. https://doi. 
org/10.1016/j.ijcard.2017.10.059
500. Secemsky EA, Butala N, Raja A, Khera R, Wang Y, Curtis JP, et al. Temporal changes 
and institutional variation in use of percutaneous coronary intervention for ST-elevation myocardial infarction with multivessel coronary artery disease in the 
United States: an NCDR research to practice project. JAMA Cardiol 2021;6: 
574–580. https://doi.org/10.1001/jamacardio.2020.5354
501. Holmes DR Jr, Berger PB, Hochman JS, Granger CB, Thompson TD, Califf RM, et al. 
Cardiogenic shock in patients with acute ischemic syndromes with and without 
ST-segment elevation. Circulation 1999;100:2067–2073. https://doi.org/10.1161/01. 
cir.100.20.2067
502.
Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardio -
genic shock complicating myocardial infarction: an update 2019. Eur Heart J 2019;
40: 
2671–2683. https://doi.org/10.1093/eurheartj/ehz363
503. Papolos AI, Kenigsberg BB, Berg DD, Alviar CL, Bohula E, Burke JA, et al. Management 
and outcomes of cardiogenic shock in cardiac ICUs with versus without shock teams. J 
Am Coll Cardiol 2021;
78:1309–1317. https://doi.org/10.1016/j.jacc.2021.07.044
504. Rab T, Ratanapo S, Kern KB, Basir MB, McDaniel M, Meraj P, et al. Cardiac shock care 
centers: JACC review topic of the week. J Am Coll Cardiol 2018;72:1972–1980. https:// 
doi.org/10.1016/j.jacc.2018.07.074
505. Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, et al. 
One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med 2018; 
379:1699–1710. https://doi.org/10.1056/NEJMoa1808788
506. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, et al. Impact 
of multivessel disease on reperfusion success and clinical outcomes in patients under -
going primary percutaneous coronary intervention for acute myocardial infarction. Eur 
Heart J 2007;
28:1709–1716. https://doi.org/10.1093/eurheartj/ehm184
507. Dziewierz A, Siudak Z, Rakowski T, Zasada W, Dubiel JS, Dudek D. Impact of multi -
vessel coronary artery disease and noninfarct-related artery revascularization on out -
come of patients with ST-elevation myocardial infarction transferred for primary 
percutaneous coronary intervention (from the EUROTRANSFER Registry). Am J 
Cardiol 2010;
106:342–347. https://doi.org/10.1016/j.amjcard.2010.03.029
508. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. Randomized 
trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013;
369: 
1115–1123. https://doi.org/10.1056/NEJMoa1305520
509. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, et al. 
Complete revascularisation versus treatment of the culprit lesion only in patients 
with ST-segment elevation myocardial infarction and multivessel disease ESC Guidelines                                                                                                                                                                                          3815Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

(DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015; 
386:665–671. https://doi.org/10.1016/s0140-6736(15)60648-1
510. Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh 
CE, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarc -
tion. N Engl J Med 2017;
376:1234–1244. https://doi.org/10.1056/NEJMoa1701067
511. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al. Complete 
revascularization with multivessel PCI for myocardial infarction. N Engl J Med 2019; 
381
:1411–1421. https://doi.org/10.1056/NEJMoa1907775
512. Bainey KR, Engstrøm T, Smits PC, Gershlick AH, James SK, Storey RF, et al. Complete 
vs culprit-lesion-only revascularization for ST-segment elevation myocardial infarction: 
a systematic review and meta-analysis. JAMA Cardiol 2020;5:881–888. https://doi.org/ 
10.1001/jamacardio.2020.1251
513. Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, et al. Single-staged 
compared with multi-staged PCI in multivessel NSTEMI patients: the SMILE trial. J 
Am Coll Cardiol 2016;67:264–272. https://doi.org/10.1016/j.jacc.2015.10.082
514. Siebert VR, Borgaonkar S, Jia X, Nguyen HL, Birnbaum Y, Lakkis NM, et al. 
Meta-analysis comparing multivessel versus culprit coronary arterial revascularization for patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 
2019;124:1501–1511. https://doi.org/10.1016/j.amjcard.2019.07.071
515. Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, et al. Complete versus 
culprit-only lesion intervention in patients with acute coronary syndromes. J Am Coll 
Cardiol 2018;72:1989–1999. https://doi.org/10.1016/j.jacc.2018.07.089
516.
Hanratty CG, Koyama Y, Rasmussen HH, Nelson GIC, Hansen PS, Ward MR. 
Exaggeration of nonculprit stenosis severity during acute myocardial infarction: impli -
cations for immediate multivessel revascularization. J Am Coll Cardiol 2002;
40:911–916. 
https://doi.org/10.1016/s0735-1097(02)02049-1
517. Gibson CM, Ryan KA, Murphy SA, Mesley R, Marble SJ, Giugliano RP, et al. Impaired 
coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. 
J Am Coll Cardiol 1999;
34:974–982. https://doi.org/10.1016/s0735-1097(99)00335-6
518. Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, et al. Fractional flow 
reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv 2010;3:1274–1281. https://doi. 
org/10.1016/j.jcin.2010.08.025
519.
Musto C, De Felice F, Rigattieri S, Chin D, Marra A, Nazzaro MS, et al. Instantaneous 
wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarc
-
tion: the WAVE study. Am Heart J 2017;
193:63–69. https://doi.org/10.1016/j.ahj. 
2017.07.017
520. Erbay A, Penzel L, Abdelwahed YS, Klotsche J, Schatz A-S, Steiner J, et al. Feasibility and 
diagnostic reliability of quantitative flow ratio in the assessment of non-culprit lesions in acute coronary syndrome. Int J Cardiovasc Imaging 2021;
37:1815–1823. https://doi. 
org/10.1007/s10554-021-02195-2
521. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. 
Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 
2010;55:2816–2821. https://doi.org/10.1016/j.jacc.2009.11.096
522. Van Belle E, Baptista SB, Raposo L, Henderson J, Rioufol G, Santos L, et al. Impact of 
routine fractional flow reserve on management decision and 1-year clinical outcome of patients with acute coronary syndromes: PRIME-FFR (Insights From the POST-IT 
[Portuguese Study on the Evaluation of FFR-Guided Treatment of Coronary 
Disease] and R3F [French FFR Registry] Integrated Multicenter Registries – 
Implementation of FFR [Fractional Flow Reserve] in Routine Practice). Circ 
Cardiovasc Interv 2017;10:e004296. https://doi.org/10.1161/circinterventions.116. 
004296
523. Sels JW, Tonino PA, Siebert U, Fearon WF, Van’t Veer M, De Bruyne B, et al. Fractional 
flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study. JACC Cardiovasc Interv 2011;4:1183–1189. https://doi. 
org/10.1016/j.jcin.2011.08.008
524. Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, et al. 
Multivessel PCI guided by FFR or angiography for myocardial infarction. N Engl J 
Med 2021;385:297–308. https://doi.org/10.1056/NEJMoa2104650
525. Wald DS, Hadyanto S, Bestwick JP. Should fractional flow reserve follow angiographic 
visual inspection to guide preventive percutaneous coronary intervention in 
ST-elevation myocardial infarction? Eur Heart J Qual Care Clin Outcomes 2020;6: 
186–192. https://doi.org/10.1093/ehjqcco/qcaa012
526.
Gallone G, Angelini F, Fortuni F, Gnecchi M, De Filippo O, Baldetti L, et al. 
Angiography- vs. physiology-guided complete revascularization in patients with 
ST-elevation myocardial infarction and multivessel disease: who is the better gatekeep -
er in this setting? A meta-analysis of randomized controlled trials. Eur Heart J Qual Care 
Clin Outcomes 2020;
6:199–200. https://doi.org/10.1093/ehjqcco/qcaa007
527. Kobayashi Y, Lønborg J, Jong A, Nishi T, De Bruyne B, Høfsten DE, et al. Prognostic 
value of the residual SYNTAX score after functionally complete revascularization in 
ACS. J Am Coll Cardiol 2018;
72:1321–1329. https://doi.org/10.1016/j.jacc.2018.06.069
528. Lee JM, Kim HK, Park KH, Choo EH, Kim CJ, Lee SH, et al. Fractional flow reserve ver -
sus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial. Eur Heart J 2023; 44:473–484. https://doi.org/10.1093/ 
eurheartj/ehac763
529. Harskamp RE, Bonatti JO, Zhao DX, Puskas JD, de Winter RJ, Alexander JH, et al. 
Standardizing definitions for hybrid coronary revascularization. J Thorac Cardiovasc 
Surg 2014;
147:556–560. https://doi.org/10.1016/j.jtcvs.2013.10.019
530. Doenst T, Haverich A, Serruys P, Bonow RO, Kappetein P, Falk V, et al. PCI and CABG 
for treating stable coronary artery disease: JACC review topic of the week. J Am Coll 
Cardiol 2019;73:964–976. https://doi.org/10.1016/j.jacc.2018.11.053
531. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al. 
Randomized trial of complete versus lesion-only revascularization in patients undergo -
ing primary percutaneous coronary intervention for STEMI and multivessel disease: 
the CvLPRIT trial. J Am Coll Cardiol 2015;
65:963–972. https://doi.org/10.1016/j.jacc. 
2014.12.038
532. Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, et al. Fractional flow 
reserve vs. angiography in guiding management to optimize outcomes in 
non-ST-segment elevation myocardial infarction: the British Heart Foundation 
FAMOUS-NSTEMI randomized trial. Eur Heart J 2015;
36:100–111. https://doi.org/ 
10.1093/eurheartj/ehu338
533. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. 
Circulation 2015;131:861–870. https://doi.org/10.1161/circulationaha.114.011201
534. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio ALP, et al. ESC 
working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J 2017;38:143–153. https://doi.org/10.1093/eurheartj/ehw149
535. Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, et al. 
Contemporary diagnosis and management of patients with myocardial infarction in 
the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation 2019;139:e891–e908. https://doi.org/10. 
1161/cir.0000000000000670
536.
Matta A, Nader V, Canitrot R, Delmas C, Bouisset F, Lhermusier T, et al. Myocardial 
bridging is significantly associated to myocardial infarction with non-obstructive coron -
ary arteries. Eur Heart J Acute Cardiovasc Care 2022;
11:501–507. https://doi.org/10. 
1093/ehjacc/zuac047
537. Pargaonkar VS, Kimura T, Kameda R, Tanaka S, Yamada R, Schwartz JG, et al. Invasive 
assessment of myocardial bridging in patients with angina and no obstructive coronary 
artery disease. EuroIntervention 2021;
16:1070–1078. https://doi.org/10.4244/eij-d-20- 
00779
538. Ford TJ, Ong P, Sechtem U, Beltrame J, Camici PG, Crea F, et al. Assessment of vascular 
dysfunction in patients without obstructive coronary artery disease: why, how, and 
when. JACC Cardiovasc Interv 2020;13:1847–1864. https://doi.org/10.1016/j.jcin.2020. 
05.052
539. Occhipinti G, Bucciarelli-Ducci C, Capodanno D. Diagnostic pathways in myocardial infarction with non-obstructive coronary artery disease (MINOCA). Eur Heart J 
Acute Cardiovasc Care 2021;10:813–822. https://doi.org/10.1093/ehjacc/zuab049
540. Eitel I, Behrendt F, Schindler K, Kivelitz D, Gutberlet M, Schuler G, et al. Differential 
diagnosis of suspected apical ballooning syndrome using contrast-enhanced magnetic 
resonance imaging. Eur Heart J 2008;29:2651–2659. https://doi.org/10.1093/eurheartj/ 
ehn433
541.
Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, et al. Clinical characteristics and cardiovascular magnetic resonance find
-
ings in stress (takotsubo) cardiomyopathy. JAMA 2011;
306:277–286. https://doi.org/ 
10.1001/jama.2011.992
542. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. 
Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert 
recommendations. J Am Coll Cardiol 2018;
72:3158–3176. https://doi.org/10.1016/j. 
jacc.2018.09.072
543. Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, et al. Comprehensive car -
diac magnetic resonance imaging in patients with suspected myocarditis: the 
MyoRacer-trial. J Am Coll Cardiol 2016;
67:1800–1811. https://doi.org/10.1016/j.jacc. 
2016.02.013
544. Reynolds HR, Maehara A, Kwong RY, Sedlak T, Saw J, Smilowitz NR, et al. Coronary 
optical coherence tomography and cardiac magnetic resonance imaging to determine 
underlying causes of myocardial infarction with nonobstructive coronary arteries in 
women. Circulation 2021;
143:624–640. https://doi.org/10.1161/circulationaha.120. 
052008
545. Pathik B, Raman B, Mohd Amin NH, Mahadavan D, Rajendran S, McGavigan AD, et al. 
Troponin-positive chest pain with unobstructed coronary arteries: incremental diag -
nostic value of cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc 
Imaging 2016;
17:1146–1152. https://doi.org/10.1093/ehjci/jev289
546. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al. Current 
state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of 
Cardiology. Eur J Heart Fail 2016;
18:8–27. https://doi.org/10.1002/ejhf.424
547. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International ex -
pert consensus document on Takotsubo syndrome (Part II): diagnostic workup, 3816                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

outcome, and management. Eur Heart J 2018;39:2047–2062. https://doi.org/10.1093/ 
eurheartj/ehy077
548. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC 
Guidelines for the diagnosis and management of pericardial diseases: the Task Force 
for the diagnosis and management of pericardial diseases of the European Society of 
Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic 
Surgery (EACTS). Eur Heart J 2015;36:2921–2964. https://doi.org/10.1093/eurheartj/ 
ehv318
549. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current 
state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a 
position statement of the European Society of Cardiology Working Group on 
Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636–2648,2648a-2648d. 
https://doi.org/10.1093/eurheartj/eht210
550. Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, et al. Stratified 
medical therapy using invasive coronary function testing in angina: the CorMicA trial. 
J Am Coll Cardiol 2018;72:2841–2855. https://doi.org/10.1016/j.jacc.2018.09.006
551. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, et al. An EAPCI 
expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary 
Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders 
International Study Group. Eur Heart J 2020;41:3504–3520. https://doi.org/10.1093/ 
eurheartj/ehaa503
552.
Cerrato E, Giacobbe F, Quadri G, Macaya F, Bianco M, Mori R, et al. Antiplatelet ther -
apy in patients with conservatively managed spontaneous coronary artery dissection 
from the multicentre DISCO registry. Eur Heart J 2021;
42:3161–3171. https://doi. 
org/10.1093/eurheartj/ehab372
553. McCarthy CP, Raber I, Chapman AR, Sandoval Y, Apple FS, Mills NL, et al. Myocardial 
injury in the era of high-sensitivity cardiac troponin assays: a practical approach for clin -
icians. JAMA Cardiol 2019;
4:1034–1042. https://doi.org/10.1001/jamacardio.2019.2724
554. Bahit MC, Lopes RD, Clare RM, Newby LK, Pieper KS, Van de Werf F, et al. Heart fail -
ure complicating non-ST-segment elevation acute coronary syndrome: timing, predic -
tors, and clinical outcomes. JACC Heart Fail 2013;
1:223–229. https://doi.org/10.1016/j. 
jchf.2013.02.007
555. Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. 
Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the 
ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;
19:1242–1254. https:// 
doi.org/10.1002/ejhf.890
556. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, Lo ́pez-Sendón J, et al. 
Determinants and prognostic impact of heart failure complicating acute coronary syn -
dromes: observations from the Global Registry of Acute Coronary Events (GRACE). 
Circulation 2004;
109:494–499. https://doi.org/10.1161/01.Cir.0000109691.16944.Da
557. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 
Eur Heart J 2021;
42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368
558. Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, 
pathophysiology and contemporary management of cardiogenic shock—a position 
statement from the Heart Failure Association of the European Society of 
Cardiology. Eur J Heart Fail 2020;22:1315–1341. https://doi.org/10.1002/ejhf.1922
559. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. 
The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 
2019;21:137–155. https://doi.org/10.1002/ejhf.1369
560. Lancellotti P, Price S, Edvardsen T, Cosyns B, Neskovic AN, Dulgheru R, et al. The use 
of echocardiography in acute cardiovascular care: recommendations of the European 
Association of Cardiovascular Imaging and the Acute Cardiovascular Care Association. 
Eur Heart J Cardiovasc Imaging 2015;16:119–146. https://doi.org/10.1093/ehjci/jeu210
561. Thiele H, Jobs A, Ouweneel DM, Henriques JPS, Seyfarth M, Desch S, et al. 
Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 
2017;38:3523–3531. https://doi.org/10.1093/eurheartj/ehx363
562.
Amin AP, Spertus JA, Curtis JP, Desai N, Masoudi FA, Bach RG, et al. The evolving land -
scape of impella use in the United States among patients undergoing percutaneous 
coronary intervention with mechanical circulatory support. Circulation 2020;
141: 
273–284. https://doi.org/10.1161/circulationaha.119.044007
563. Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, et al. 
Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among pa
-
tients with acute myocardial infarction complicated by cardiogenic shock. JAMA 
2020;
323:734–745. https://doi.org/10.1001/jama.2020.0254
564. Elbadawi A, Elgendy IY, Mahmoud K, Barakat AF, Mentias A, Mohamed AH, et al. 
Temporal trends and outcomes of mechanical complications in patients with acute 
myocardial infarction. JACC Cardiovasc Interv 2019;
12:1825–1836. https://doi.org/10. 
1016/j.jcin.2019.04.039
565. Schrage B, Becher PM, Goßling A, Savarese G, Dabboura S, Yan I, et al. Temporal 
trends in incidence, causes, use of mechanical circulatory support and mortality in car -
diogenic shock. ESC Heart Fail 2021;
8:1295–1303. https://doi.org/10.1002/ehf2.13202566. Watkins AC, Maassel NL, Ghoreishi M, Dawood MY, Pham SM, Kon ZN, et al. 
Preoperative venoarterial extracorporeal membrane oxygenation slashes risk score 
in advanced structural heart disease. Ann Thorac Surg 2018;
106:1709–1715. https:// 
doi.org/10.1016/j.athoracsur.2018.07.038
567. Ronco D, Matteucci M, Ravaux JM, Marra S, Torchio F, Corazzari C, et al. Mechanical 
circulatory support as a bridge to definitive treatment in post-infarction ventricular 
septal rupture. JACC Cardiovasc Interv 2021;14:1053–1066. https://doi.org/10.1016/j. 
jcin.2021.02.046
568. Matteucci M, Fina D, Jiritano F, Meani P, Raffa GM, Kowalewski M, et al. The use of 
extracorporeal membrane oxygenation in the setting of postinfarction mechanical 
complications: outcome analysis of the Extracorporeal Life Support Organization 
Registry. Interact Cardiovasc Thorac Surg 2020;31:369–374. https://doi.org/10.1093/ 
icvts/ivaa108
569. Assenza GE, McElhinney DB, Valente AM, Pearson DD, Volpe M, Martucci G, et al. 
Transcatheter closure of post-myocardial infarction ventricular septal rupture. Circ 
Cardiovasc Interv 2013;6:59–67. https://doi.org/10.1161/circinterventions.112.972711
570. Kilic A, Sultan I, Chu D, Wang Y, Gleason TG. Mitral valve surgery for papillary muscle 
rupture: outcomes in 1342 patients from the society of thoracic surgeons database. 
Ann Thorac Surg 2020;110:1975–1981. https://doi.org/10.1016/j.athoracsur.2020.03. 
097
571. Valle JA, Miyasaka RL, Carroll JD. Acute mitral regurgitation secondary to papillary 
muscle tear: is transcatheter edge-to-edge mitral valve repair a new paradigm? Circ 
Cardiovasc Interv 2017;10:e005050. https://doi.org/10.1161/circinterventions.117. 
005050
572. Terashima M, Fujiwara S, Yaginuma GY, Takizawa K, Kaneko U, Meguro T. Outcome 
of percutaneous intrapericardial fibrin-glue injection therapy for left ventricular free 
wall rupture secondary to acute myocardial infarction. Am J Cardiol 2008;101: 
419–421. https://doi.org/10.1016/j.amjcard.2007.09.086
573. Damluji AA, van Diepen S, Katz JN, Menon V, Tamis-Holland JE, Bakitas M, et al. 
Mechanical complications of acute myocardial infarction: a scientific statement from 
the American Heart Association. Circulation 2021;144:e16–e35. https://doi.org/10. 
1161/cir.0000000000000985
574. Gong FF, Vaitenas I, Malaisrie SC, Maganti K. Mechanical complications of acute myo -
cardial infarction: a review. JAMA Cardiol 2021;
6:341–349. https://doi.org/10.1001/ 
jamacardio.2020.3690
575. Robinson AA, Jain A, Gentry M, McNamara RL. Left ventricular thrombi after STEMI in 
the primary PCI era: a systematic review and meta-analysis. Int J Cardiol 2016;
221: 
554–559. https://doi.org/10.1016/j.ijcard.2016.07.069
576. Levine GN, McEvoy JW, Fang JC, Ibeh C, McCarthy CP, Misra A, et al. Management of 
patients at risk for and with left ventricular thrombus: a scientific statement from the 
American Heart Association. Circulation 2022;146:e205–e223. https://doi.org/10. 
1161/cir.0000000000001092
577. Bulluck H, Chan MHH, Paradies V, Yellon RL, Ho HH, Chan MY, et al. Incidence and 
predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute 
ST-segment elevation myocardial infarction treated by primary percutaneous coron -
ary intervention: a meta-analysis. J Cardiovasc Magn Reson 2018;
20:72. https://doi.org/ 
10.1186/s12968-018-0494-3
578. Velangi PS, Choo C, Chen KA, Kazmirczak F, Nijjar PS, Farzaneh-Far A, et al. Long-term 
embolic outcomes after detection of left ventricular thrombus by late gadolinium en -
hancement cardiovascular magnetic resonance imaging: a matched cohort study. Circ 
Cardiovasc Imaging 2019;
12:e009723. https://doi.org/10.1161/circimaging.119.009723
579. Funke Küpper AJ, Verheugt FW, Peels CH, Galema TW, Roos JP. Left ventricular 
thrombus incidence and behavior studied by serial two-dimensional echocardiography 
in acute anterior myocardial infarction: left ventricular wall motion, systemic embolism and oral anticoagulation. J Am Coll Cardiol 1989;
13:1514–1520. https://doi.org/10.1016/ 
0735-1097(89)90341-0
580. Zhang Z, Si D, Zhang Q, Jin L, Zheng H, Qu M, et al. Prophylactic rivaroxaban therapy 
for left ventricular thrombus after anterior ST-segment elevation myocardial infarc -
tion. JACC Cardiovasc Interv 2022;
15:861–872. https://doi.org/10.1016/j.jcin.2022.01. 
285
581. Dalia T, Lahan S, Ranka S, Goyal A, Zoubek S, Gupta K, et al. Warfarin versus direct 
oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis. Thromb J 2021;
19:7. https://doi.org/10.1186/s12959-021-00259-w
582. Verma BR, Montane B, Chetrit M, Khayata M, Furqan MM, Ayoub C, et al. Pericarditis 
and post-cardiac injury syndrome as a sequelae of acute myocardial infarction. Curr 
Cardiol Rep 2020;22:127. https://doi.org/10.1007/s11886-020-01371-5
583. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial in -
farction: a systematic review of the incidence, clinical features and prognostic implica -
tions. Eur Heart J 2009;
30:1038–1045. https://doi.org/10.1093/eurheartj/ehn579
584. Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L, et al. All types of 
atrial fibrillation in the setting of myocardial infarction are associated with impaired 
outcome. Heart 2016;
102:926–933. https://doi.org/10.1136/heartjnl-2015-308678
585. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 
ESC Guidelines for the diagnosis and management of atrial fibrillation developed in col -
laboration with the European Association for Cardio-Thoracic Surgery (EACTS). The 
Task Force for the diagnosis and management of atrial fibrillation of the European ESC Guidelines                                                                                                                                                                                          3817Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Society of Cardiology (ESC). Developed with the special contribution of the European 
Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498. https:// 
doi.org/10.1093/eurheartj/ehaa612
586. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA, et al. Atrial fibrillation 
and death after myocardial infarction: a community study. Circulation 2011;123: 
2094–2100. https://doi.org/10.1161/circulationaha.110.990192
587. Siu CW, Jim MH, Ho HH, Miu R, Lee SWL, Lau CP, et al. Transient atrial fibrillation 
complicating acute inferior myocardial infarction: implications for future risk of ische -
mic stroke. Chest 2007;
132:44–49. https://doi.org/10.1378/chest.06-2733
588. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, et al. 
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute 
myocardial infarction. Crit Care Med 2011;
39:78–83. https://doi.org/10.1097/CCM. 
0b013e3181fd6ad7
589. Piccini JP, Hranitzky PM, Kilaru R, Rouleau JL, White HD, Aylward PE, et al. Relation of 
mortality to failure to prescribe beta blockers acutely in patients with sustained ven -
tricular tachycardia and ventricular fibrillation following acute myocardial infarction 
(from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am 
J Cardiol 2008;
102:1427–1432. https://doi.org/10.1016/j.amjcard.2008.07.033
590. Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymorphous ventricu -
lar tachycardia associated with acute myocardial infarction. Circulation 1991;
84: 
1543–1551. https://doi.org/10.1161/01.cir.84.4.1543
591. Liang JJ, Fender EA, Cha YM, Lennon RJ, Prasad A, Barsness GW, et al. Long-term out -
comes in survivors of early ventricular arrhythmias after acute ST-elevation and 
non-ST-elevation myocardial infarction treated with percutaneous coronary interven -
tion. Am J Cardiol 2016;
117:709–713. https://doi.org/10.1016/j.amjcard.2015.12.002
592. Mehta RH, Yu J, Piccini JP, Tcheng JE, Farkouh ME, Reiffel J, et al. Prognostic significance 
of postprocedural sustained ventricular tachycardia or fibrillation in patients undergo -
ing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). Am J Cardiol 2012;
109:805–812. https://doi.org/10.1016/j.amjcard.2011.10.043
593. Masuda M, Nakatani D, Hikoso S, Suna S, Usami M, Matsumoto S, et al. Clinical impact 
of ventricular tachycardia and/or fibrillation during the acute phase of acute myocardial 
infarction on in-hospital and 5-year mortality rates in the percutaneous coronary inter -
vention era. Circ J 2016;
80:1539–1547. https://doi.org/10.1253/circj.CJ-16-0183
594. Podolecki T, Lenarczyk R, Kowalczyk J, Jedrzejczyk-Patej E, Chodor P, Mazurek M, et al. 
Prognostic significance of complex ventricular arrhythmias complicating ST-segment 
elevation myocardial infarction. Am J Cardiol 2018;
121:805–809. https://doi.org/10. 
1016/j.amjcard.2017.12.036
595. Komatsu Y, Hocini M, Nogami A, Maury P, Peichl P, Iwasaki YK, et al. Catheter ablation 
of refractory ventricular fibrillation storm after myocardial infarction. Circulation 2019; 
139:2315–2325. https://doi.org/10.1161/circulationaha.118.037997
596. Terkelsen CJ, Sørensen JT, Kaltoft AK, Nielsen SS, Thuesen L, Bøtker HE, et al. 
Prevalence and significance of accelerated idioventricular rhythm in patients with 
ST-elevation myocardial infarction treated with primary percutaneous coronary inter -
vention. Am J Cardiol 2009;
104:1641–1646. https://doi.org/10.1016/j.amjcard.2009.07. 
037
597. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, et al. A risk score 
to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 
55
:2556–2566. https://doi.org/10.1016/j.jacc.2009.09.076
598. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, et al. Associations of 
major bleeding and myocardial infarction with the incidence and timing of mortality in 
patients presenting with non-ST-elevation acute coronary syndromes: a risk model 
from the ACUITY trial. Eur Heart J 2009;30:1457–1466. https://doi.org/10.1093/ 
eurheartj/ehp110
599. Rao SV. The conundrum of reducing ischemic and bleeding events after PCI. J Am Coll 
Cardiol 2015;65:1421–1423. https://doi.org/10.1016/j.jacc.2015.02.012
600. Kwok CS, Sherwood MW, Watson SM, Nasir SB, Sperrin M, Nolan J, et al. Blood trans -
fusion after percutaneous coronary intervention and risk of subsequent adverse out -
comes: a systematic review and meta-analysis. JACC Cardiovasc Interv 2015;
8:436–446. 
https://doi.org/10.1016/j.jcin.2014.09.026
601. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual 
antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;
382: 
1714–1722. https://doi.org/10.1016/s0140-6736(13)61720-1
602. Reidenberg MM. Drug discontinuation effects are part of the pharmacology of a drug. J 
Pharmacol Exp Ther 2011;339:324–328. https://doi.org/10.1124/jpet.111.183285
603. Abdelnabi M, Saleh Y, Fareed A, Nossikof A, Wang L, Morsi M, et al. Comparative study 
of oral anticoagulation in left ventricular thrombi (no-LVT trial). J Am Coll Cardiol 2021; 
77:1590–1592. https://doi.org/10.1016/j.jacc.2021.01.049
604. Weinsaft JW, Kim J, Medicherla CB, Ma CL, Codella NCF, Kukar N, et al. 
Echocardiographic algorithm for post-myocardial infarction LV thrombus: a gatekeep -
er for thrombus evaluation by delayed enhancement CMR. JACC Cardiovasc Imaging 
2016;
9:505–515. https://doi.org/10.1016/j.jcmg.2015.06.017
605. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, et al. The evidence 
regarding the drugs used for ventricular rate control. J Fam Pract 2000;
49:47–59
606. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, et al. Acute treatment of 
recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxin-controlled study. Eur Heart J 1995;16:521–528. 
https://doi.org/10.1093/oxfordjournals.eurheartj.a060945
607. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous 
conversion and maintenance of sinus rhythm by amiodarone in patients with heart fail -
ure and atrial fibrillation: observations from the veterans affairs Congestive Heart fail -
ure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998;
98: 
2574–2579. https://doi.org/10.1161/01.cir.98.23.2574
608. Hofmann R, Steinwender C, Kammler J, Kypta A, Wimmer G, Leisch F, et al. 
Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with ad -
vanced congestive heart failure or cardiogenic shock. Wien Klin Wochenschr 2004; 
116
:744–749. https://doi.org/10.1007/s00508-004-0264-0
609. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic im -
plantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;
346:877–883. https://doi.org/10.1056/NEJMoa013474
610. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an 
implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 
352
:225–237. https://doi.org/10.1056/NEJMoa043399
611. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 
2000;102:742–747. https://doi.org/10.1161/01.cir.102.7.742
612.
Miwa Y, Ikeda T, Mera H, Miyakoshi M, Hoshida K, Yanagisawa R, et al. Effects of land -
iolol, an ultra-short-acting beta1-selective blocker, on electrical storm refractory to 
class III antiarrhythmic drugs. Circ J 2010;
74:856–863. https://doi.org/10.1253/circj.cj- 
09-0772
613. Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, 
et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricu -
lar fibrillation. N Engl J Med 1999;
341:871–878. https://doi.org/10.1056/ 
nejm199909163411203
614. Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA, et al. 
Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyar -
rhythmias. J Am Coll Cardiol 1996;
27:67–75. https://doi.org/10.1016/0735-1097(95) 
00427-0
615. Gorenek B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, 
Huber K, et al. Cardiac arrhythmias in acute coronary syndromes: position paper 
from the joint EHRA, ACCA, and EAPCI task force. Europace 2014;
16:1655–1673. 
https://doi.org/10.1093/europace/euu208
616. Kalarus Z, Svendsen JH, Capodanno D, Dan GA, De Maria E, Gorenek B, et al. Cardiac 
arrhythmias in the emergency settings of acute coronary syndrome and revasculariza -
tion: an European Heart Rhythm Association (EHRA) consensus document, endorsed 
by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), 
and European Acute Cardiovascular Care Association (ACCA). Europace 2019;
21: 
1603–1604. https://doi.org/10.1093/europace/euz163
617. Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior myocardial infarction. J Am Coll Cardiol 1984;
4:35–38. https://doi.org/10.1016/s0735- 
1097(84)80315-0
618. Brady WJ, Swart G, DeBehnke DJ, Ma OJ, Aufderheide TP. The efficacy of atropine in 
the treatment of hemodynamically unstable bradycardia and atrioventricular block: 
prehospital and emergency department considerations. Resuscitation 1999;41: 
47–55. https://doi.org/10.1016/s0300-9572(99)00032-5
619. Kusumoto FM, Calkins H, Boehmer J, Buxton AE, Chung MK, Gold MR, et al. HRS/ 
ACC/AHA expert consensus statement on the use of implantable cardioverter- 
defibrillator therapy in patients who are not included or not well represented in clinical 
trials. Circulation 2014;130:94–125. https://doi.org/10.1161/cir.0000000000000056
620. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 
2021;42:3427–3520. https://doi.org/10.1093/eurheartj/ehab364
621. Jim MH, Chan AO, Tse HF, Barold SS, Lau CP. Clinical and angiographic findings of complete atrioventricular block in acute inferior myocardial infarction. Ann Acad 
Med Singap 2010;39:185–190. https://doi.org/10.47102/annals-acadmedsg. 
V39N3p185
622. Gang UJ, Hvelplund A, Pedersen S, Iversen A, Jons C, Abildstrom SZ, et al. High-degree 
atrioventricular block complicating ST-segment elevation myocardial infarction in the era of primary percutaneous coronary intervention. Europace 2012;14:1639–1645. 
https://doi.org/10.1093/europace/eus161
623.
Vicente-Ibarra N, Marín F, Pernías-Escrig V, Sandín-Rollán M, Núñez-Martínez L, Lozano T, et al. Impact of anemia as risk factor for major bleeding and mortality in pa
-
tients with acute coronary syndrome. Eur J Intern Med 2019;
61:48–53. https://doi.org/ 
10.1016/j.ejim.2018.12.004
624. Younge JO, Nauta ST, Akkerhuis KM, Deckers JW, van Domburg RT. Effect of anemia 
on short- and long-term outcome in patients hospitalized for acute coronary syn -
dromes. Am J Cardiol 2012;
109:506–510. https://doi.org/10.1016/j.amjcard.2011.09. 
046
625. Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, et al. Relationship be -
tween baseline haemoglobin and major bleeding complications in acute coronary syn -
dromes. Eur Heart J 2010;
31:50–58. https://doi.org/10.1093/eurheartj/ehp4013818                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

626. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical prac -
tice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 
2016;
316:2025–2035. https://doi.org/10.1001/jama.2016.9185
627. Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood 
transfusion with increased mortality in myocardial infarction: a meta-analysis and 
diversity-adjusted study sequential analysis. JAMA Intern Med 2013;
173:132–139. 
https://doi.org/10.1001/2013.jamainternmed.1001
628. Carson JL, Stanworth SJ, Dennis JA, Trivella M, Roubinian N, Fergusson DA, et al. 
Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database 
Syst Rev 2021;12:CD002042. https://doi.org/10.1002/14651858.CD002042.pub5
629. Cooper HA, Rao SV, Greenberg MD, Rumsey MP, McKenzie M, Alcorn KW, et al. 
Conservative versus liberal red cell transfusion in acute myocardial infarction (the 
CRIT Randomized Pilot Study). Am J Cardiol 2011;108:1108–1111. https://doi.org/ 
10.1016/j.amjcard.2011.06.014
630. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NMA, et al. 
Transfusion practice and outcomes in non-ST-segment elevation acute coronary syn -
dromes. Am Heart J 2008;
155:1047–1053. https://doi.org/10.1016/j.ahj.2008.01.009
631. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, Cachanado M, 
Durand-Zaleski I, et al. Effect of a restrictive vs liberal blood transfusion strategy on 
major cardiovascular events among patients with acute myocardial infarction and an -
emia: the REALITY randomized clinical trial. JAMA 2021;
325:552–560. https://doi.org/ 
10.1001/jama.2021.0135
632. Gonzalez-Juanatey JR, Lemesle G, Puymirat E, Ducrocq G, Cachanado M, Arnaiz JA, et al. One-year major cardiovascular events after restrictive versus liberal blood trans
-
fusion strategy in patients with acute myocardial infarction and anemia: the REALITY 
randomized trial. Circulation 2022;
145:486–488. https://doi.org/10.1161/ 
circulationaha.121.057909
633. Gore JM, Spencer FA, Gurfinkel EP, López-Sendón J, Steg PG, Granger CB, et al. 
Thrombocytopenia in patients with an acute coronary syndrome (from the Global 
Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2009;
103:175–180. 
https://doi.org/10.1016/j.amjcard.2008.08.055
634. Vora AN, Chenier M, Schulte PJ, Goodman S, Peterson ED, Pieper K, et al. Long-term 
outcomes associated with hospital acquired thrombocytopenia among patients with 
non-ST-segment elevation acute coronary syndrome. Am Heart J 2014;
168:189– -
196.e1. https://doi.org/10.1016/j.ahj.2014.04.010
635. Szummer K, Lundman P, Jacobson SH, Schön S, Lindbäck J, Stenestrand U, et al. 
Relation between renal function, presentation, use of therapies and in-hospital com -
plications in acute coronary syndrome: data from the SWEDEHEART register. J 
Intern Med 2010;
268:40–49. https://doi.org/10.1111/j.1365-2796.2009.02204.x
636. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myo
-
cardial infarction. J Am Coll Cardiol 2003;
42:201–208. https://doi.org/10.1016/s0735- 
1097(03)00572-2
637. Panchal HB, Zheng S, Devani K, White CJ, Leinaar EF, Mukherjee D, et al. Impact of 
chronic kidney disease on revascularization and outcomes in patients with ST-elevation myocardial infarction. Am J Cardiol 2021;
150:15–23. https://doi.org/10. 
1016/j.amjcard.2021.03.057
638. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. 
Association of estimated glomerular filtration rate and albuminuria with all-cause and 
cardiovascular mortality in general population cohorts: a collaborative meta-analysis. 
Lancet 2010;375:2073–2081. https://doi.org/10.1016/s0140-6736(10)60674-5
639. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Piñero G, Avezum A, et al. Creatinine 
clearance and adverse hospital outcomes in patients with acute coronary syndromes: 
findings from the global registry of acute coronary events (GRACE). Heart 2003;89: 
1003–1008. https://doi.org/10.1136/heart.89.9.1003
640. Szummer K, Lundman P, Jacobson SH, Scho ̈n S, Lindbäck J, Stenestrand U, et al. 
Influence of renal function on the effects of early revascularization in 
non-ST-elevation myocardial infarction: data from the Swedish Web-System for 
Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated 
According to Recommended Therapies (SWEDEHEART). Circulation 2009;120: 
851–858. https://doi.org/10.1161/circulationaha.108.838169
641. Huang HD, Alam M, Hamzeh I, Virani S, Deswal A, Aguilar D, et al. Patients with severe 
chronic kidney disease benefit from early revascularization after acute coronary syn -
drome. Int J Cardiol 2013;
168:3741–3746. https://doi.org/10.1016/j.ijcard.2013.06.013
642. Kume K, Yasuoka Y, Adachi H, Noda Y, Hattori S, Araki R, et al. Impact of 
contrast-induced acute kidney injury on outcomes in patients with ST-segment eleva -
tion myocardial infarction undergoing primary percutaneous coronary intervention. 
Cardiovasc Revasc Med 2013;
14:253–257. https://doi.org/10.1016/j.carrev.2013.07.009
643. Bangalore S, Briguori C. Preventive strategies for contrast-induced acute kidney injury: 
and the winner is…. Circ Cardiovasc Interv 2017;
10:e005262. https://doi.org/10.1161/ 
circinterventions.117.005262
644. Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, et al. Use of intra -
venous iodinated contrast media in patients with kidney disease: consensus statements 
from the American College of Radiology and the National Kidney Foundation. Kidney 
Med 2020;
2:85–93. https://doi.org/10.1016/j.xkme.2020.01.001645. Schweiger MJ, Chambers CE, Davidson CJ, Zhang S, Blankenship J, Bhalla NP, et al. 
Prevention of contrast induced nephropathy: recommendations for the high risk pa -
tient undergoing cardiovascular procedures. Catheter Cardiovasc Interv 2007;
69: 
135–140. https://doi.org/10.1002/ccd.20964
646. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC 
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 
42
:3227–3337. https://doi.org/10.1093/eurheartj/ehab484
647. Ängerud KH, Brulin C, Näslund U, Eliasson M. Longer pre-hospital delay in first myo -
cardial infarction among patients with diabetes: an analysis of 4266 patients in the nor -
thern Sweden MONICA Study. BMC Cardiovasc Disord 2013;
13:6. https://doi.org/10. 
1186/1471-2261-13-6
648. Fu R, Li S-D, Song C-X, Yang J-A, Xu H-Y, Gao X-J, et al. Clinical significance of diabetes 
on symptom and patient delay among patients with acute myocardial infarction–an 
analysis from China Acute Myocardial Infarction (CAMI) registry. J Geriatr Cardiol 
2019;
16:395–400. https://doi.org/10.11909/j.issn.1671-5411.2019.05.002
649. Rossello X, Ferreira JP, McMurray JJ, Aguilar D, Pfeffer MA, Pitt B, et al. Editor’s choice– 
impact of insulin-treated diabetes on cardiovascular outcomes following high-risk 
myocardial infarction. Eur Heart J Acute Cardiovasc Care 2019;8:231–241. https://doi. 
org/10.1177/2048872618803701
650. Wallert J, Mitchell A, Held C, Hagström E, Leosdottir M, Olsson EMG. Cardiac rehabili -
tation goal attainment after myocardial infarction with versus without diabetes: a na -
tionwide registry study. Int J Cardiol 2019;
292:19–24. https://doi.org/10.1016/j.ijcard. 
2019.04.049
651. Ritsinger V, Jensen J, Ohm D, Omerovic E, Koul S, Fröbert O, et al. Elevated admission 
glucose is common and associated with high short-term complication burden after acute myocardial infarction: insights from the VALIDATE-SWEDEHEART study. 
Diab Vasc Dis Res 2019;
16:582–584. https://doi.org/10.1177/1479164119871540
652. Weston C, Walker L, Birkhead J. Early impact of insulin treatment on mortality for 
hyperglycaemic patients without known diabetes who present with an acute coronary 
syndrome. Heart 2007;93:1542–1546. https://doi.org/10.1136/hrt.2006.108696
653. Ritsinger V, Malmberg K, Mårtensson A, Rydén L, Wedel H, Norhammar A. Intensified 
insulin-based glycaemic control after myocardial infarction: mortality during 20 year 
follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute 
Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol 2014;2:627–633. 
https://doi.org/10.1016/s2213-8587(14)70088-9
654. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus con -
ventional glucose control in critically ill patients. N Engl J Med 2009;
360:1283–1297. 
https://doi.org/10.1056/NEJMoa0810625
655. Rossello X, Yellon DM. A new era in the management of type 2 diabetes: is cardiopro -
tection at long last a reality? Int J Cardiol 2017;
228:198–200. https://doi.org/10.1016/j. 
ijcard.2016.11.246
656. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, 
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;
373: 
2117–2128. https://doi.org/10.1056/NEJMoa1504720
657. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. 
Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375: 
311–322. https://doi.org/10.1056/NEJMoa1603827
658. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC 
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collab -
oration with the EASD. Eur Heart J 2020;
41:255–323. https://doi.org/10.1093/ 
eurheartj/ehz486
659. Sinclair H, Batty JA, Qiu W, Kunadian V. Engaging older patients in cardiovascular re -
search: observational analysis of the ICON-1 study. Open Heart 2016;
3:e000436. 
https://doi.org/10.1136/openhrt-2016-000436
660. Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S, Battler A, et al. Age, clinical 
presentation, and outcome of acute coronary syndromes in the Euroheart acute cor -
onary syndrome survey. Eur Heart J 2006;
27:789–795. https://doi.org/10.1093/ 
eurheartj/ehi774
661. Lopes RD, White JA, Tricoci P, White HD, Armstrong PW, Braunwald E, et al. Age, 
treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syn -
drome patients: insights from the EARLY ACS trial. Int J Cardiol 2013;
167:2580–2587. 
https://doi.org/10.1016/j.ijcard.2012.06.053
662. Reiter M, Twerenbold R, Reichlin T, Haaf P, Peter F, Meissner J, et al. Early diagnosis of 
acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. 
Eur Heart J 2011;
32:1379–1389. https://doi.org/10.1093/eurheartj/ehr033
663. Mills GB, Ratcovich H, Adams-Hall J, Beska B, Kirkup E, Raharjo DE, et al. Is the con -
temporary care of the older persons with acute coronary syndrome evidence-based? European Heart Journal Open 2021;
2:oeab044. https://doi.org/10.1093/ehjopen/ 
oeab044
664. Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, et al. Invasive versus 
conservative strategy in patients aged 80 years or older with non-ST-elevation myo -
cardial infarction or unstable angina pectoris (After Eighty study): an open-label rando -
mised controlled trial. Lancet 2016;
387:1057–1065. https://doi.org/10.1016/s0140- 
6736(15)01166-6
665. Bueno H, Betriu A, Heras M, Alonso JJ, Cequier A, Garcia EJ, et al. Primary angioplasty 
vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA ESC Guidelines                                                                                                                                                                                          3819Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

(TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and 
pooled analysis with previous studies. Eur Heart J 2011;32:51–60. https://doi.org/10. 
1093/eurheartj/ehq375
666. Kunadian V, Qiu W, Ludman P, Redwood S, Curzen N, Stables R, et al. Outcomes in 
patients with cardiogenic shock following percutaneous coronary intervention in the 
contemporary era: an analysis from the BCIS database (British Cardiovascular 
Intervention Society). JACC Cardiovasc Interv 2014;7:1374–1385. https://doi.org/10. 
1016/j.jcin.2014.06.017
667. Kunadian V, Bawamia B, Maznyczka A, Zaman A, Qiu W. Outcomes following primary 
percutaneous coronary intervention in the setting of cardiac arrest: a registry database 
study. Eur Heart J Acute Cardiovasc Care 2015;4:6–15. https://doi.org/10.1177/ 
2048872614534079
668. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardi -
ology: definition, assessment and clinical implications for general cardiology. A consen -
sus document of the Council for Cardiology Practice (CCP), Association for Acute 
Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied 
Professions (ACNAP), European Association of Preventive Cardiology (EAPC), 
European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), 
Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, 
WG Thrombosis, of the European Society of Cardiology, European Primary Care 
Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;
29:216–227. https://doi.org/10. 
1093/eurjpc/zwaa167
669. Walker DM, Gale CP, Lip G, Martin-Sanchez FJ, McIntyre HF, Mueller C, et al. Editor’s 
choice–frailty and the management of patients with acute cardiovascular disease: a 
position paper from the Acute Cardiovascular Care Association. Eur Heart J Acute 
Cardiovasc Care 2018;
7:176–193. https://doi.org/10.1177/2048872618758931
670. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 
2013;381:752–762. https://doi.org/10.1016/s0140-6736(12)62167-9
671. Chung KJNC, Wilkinson C, Veerasamy M, Kunadian V. Frailty scores and their utility in 
older patients with cardiovascular disease. Interv Cardiol 2021;16:e05. https://doi.org/ 
10.15420/icr.2020.18
672. Gu SZ, Qiu W, Batty JA, Sinclair H, Veerasamy M, Brugaletta S, et al. Coronary artery 
lesion phenotype in frail older patients with non-ST-elevation acute coronary syn -
drome undergoing invasive care. EuroIntervention 2019;
15:e261–e268. https://doi. 
org/10.4244/eij-d-18-00848
673. Batty J, Qiu W, Gu S, Sinclair H, Veerasamy M, Beska B, et al. One-year clinical out -
comes in older patients with non-ST elevation acute coronary syndrome undergoing coronary angiography: an analysis of the ICON1 study. Int J Cardiol 2019;
274:45–51. 
https://doi.org/10.1016/j.ijcard.2018.09.086
674. Beska B, Coakley D, MacGowan G, Adams-Hall J, Wilkinson C, Kunadian V, et al. Frailty 
and quality of life after invasive management for non-ST elevation acute coronary syn -
drome. Heart 2022;
108:203–211. https://doi.org/10.1136/heartjnl-2021-319064
675. Beska B, Mills GB, Ratcovich H, Wilkinson C, Damluji AA, Kunadian V, et al. Impact of 
multimorbidity on long-term outcomes in older adults with non-ST elevation acute 
coronary syndrome in the North East of England: a multi-centre cohort study of pa -
tients undergoing invasive care. BMJ Open 2022;
12:e061830. https://doi.org/10.1136/ 
bmjopen-2022-061830
676. Gu SZ, Beska B, Chan D, Neely D, Batty JA, Adams-Hall J, et al. Cognitive decline in 
older patients with non-ST elevation acute coronary syndrome. J Am Heart Assoc 
2019;
8:e011218. https://doi.org/10.1161/jaha.118.011218
677. Ismail S, Wong C, Rajan P, Vidovich MI. ST-elevation acute myocardial infarction in pregnancy: 2016 update. Clin Cardiol 2017;40:399–406. https://doi.org/10.1002/clc. 
22655
678.
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular dis
-
eases during pregnancy. Eur Heart J 2018;
39:3165–3241. https://doi.org/10.1093/ 
eurheartj/ehy340
679. Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll 
Cardiol 2008;
52:171–180. https://doi.org/10.1016/j.jacc.2008.03.049
680. Elkayam U, Jalnapurkar S, Barakkat MN, Khatri N, Kealey AJ, Mehra A, et al. 
Pregnancy-associated acute myocardial infarction: a review of contemporary experi -
ence in 150 cases between 2006 and 2011. Circulation 2014;
129:1695–1702. https:// 
doi.org/10.1161/circulationaha.113.002054
681. Elkayam U, Goland S, Pieper PG, Silverside CK. High-risk cardiac disease in pregnancy: 
Part I. J Am Coll Cardiol 2016;
68:396–410. https://doi.org/10.1016/j.jacc.2016.05.048
682. Bharadwaj A, Potts J, Mohamed MO, Parwani P, Swamy P, Lopez-Mattei JC, et al. Acute 
myocardial infarction treatments and outcomes in 6.5 million patients with a current 
or historical diagnosis of cancer in the USA. Eur Heart J 2020;41:2183–2193. https:// 
doi.org/10.1093/eurheartj/ehz851
683. Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans AACM, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated 
with primary percutaneous coronary intervention. Am J Cardiol 2013;112:1867–1872. 
https://doi.org/10.1016/j.amjcard.2013.08.019
684. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic 
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 
(IC-OS): developed by the Task Force on cardio-oncology of the European Society 
of Cardiology (ESC). Eur Heart J 2022;43:4229–4361. https://doi.org/10.1093/ 
eurheartj/ehac244
685. Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, et al. 
Percutaneous coronary intervention in cancer patients: a report of the prevalence 
and outcomes in the United States. Eur Heart J 2019;40:1790–1800. https://doi.org/ 
10.1093/eurheartj/ehy769
686. Pothineni NV, Shah NN, Rochlani Y, Saad M, Kovelamudi S, Marmagkiolis K, et al. 
Temporal trends and outcomes of acute myocardial infarction in patients with cancer. Ann Transl Med 2017;5:482. https://doi.org/10.21037/atm.2017.11.29
687.
Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al. 
Evaluation and management of cancer patients presenting with acute cardiovascular 
disease: a Consensus Document of the Acute CardioVascular Care (ACVC) associ -
ation and the ESC Council of Cardio-Oncology-Part 1: acute coronary syndromes 
and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;
10:947–959. 
https://doi.org/10.1093/ehjacc/zuab056
688. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur 
Heart J 2019;
40:1756–1763. https://doi.org/10.1093/eurheartj/ehy453
689. Mohamed MO, Van Spall HGC, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY, et al. 
Effect of primary percutaneous coronary intervention on in-hospital outcomes among 
active cancer patients presenting with ST-elevation myocardial infarction: a propensity 
score matching analysis. Eur Heart J Acute Cardiovasc Care 2021;10:829–839. https://doi. 
org/10.1093/ehjacc/zuaa032
690. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary inter -
vention in metastatic cancer patients with acute coronary syndrome over a 10-year 
period. J Cancer Res Clin Oncol 2016;
142:471–479. https://doi.org/10.1007/s00432- 
015-2056-5
691. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic ef -
fects in high-risk patients undergoing angiography. N Engl J Med 2003;
348:491–499. 
https://doi.org/10.1056/NEJMoa021833
692. Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, et al. Renal toxicity evaluation and 
comparison between visipaque (Iodixanol) and hexabrix (Ioxaglate) in patients with re -
nal insufficiency undergoing coronary angiography: the RECOVER study: a randomized 
controlled trial. J Am Coll Cardiol 2006;
48:924–930. https://doi.org/10.1016/j.jacc.2006. 
06.047
693. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, et al. 
Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double- 
blind trial of contrast-induced nephropathy in patients with chronic kidney disease. 
Circulation 2007;
115:3189–3196. https://doi.org/10.1161/circulationaha.106.671644
694. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium 
bicarbonate vs sodium chloride for the prevention of contrast medium-induced ne -
phropathy in patients undergoing coronary angiography: a randomized trial. JAMA 
2008;
300:1038–1046. https://doi.org/10.1001/jama.300.9.1038
695. Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AYJ, Jorgensen M, et al. 
Haemodynamic-guided fluid administration for the prevention of contrast-induced 
acute kidney injury: the POSEIDON randomised controlled trial. Lancet 2014;
383: 
1814–1823. https://doi.org/10.1016/s0140-6736(14)60689-9
696. Giacoppo D, Gargiulo G, Buccheri S, Aruta P, Byrne RA, Cassese S, et al. Preventive 
strategies for contrast-induced acute kidney injury in patients undergoing percutan -
eous coronary procedures: evidence from a hierarchical Bayesian network 
meta-analysis of 124 trials and 28240 patients. Circ Cardiovasc Interv 2017;
10: 
e004383. https://doi.org/10.1161/circinterventions.116.004383
697. Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, et al. 
Prophylactic hydration to protect renal function from intravascular iodinated contrast 
material in patients at high risk of contrast-induced nephropathy (AMACING): a pro -
spective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 
2017;
389:1312–1322. https://doi.org/10.1016/s0140-6736(17)30057-0
698. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors 
for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. 
Lancet 2019;
393:31–39. https://doi.org/10.1016/s0140-6736(18)32590-x
699. Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. 
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in pa -
tients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular 
outcome trials. Lancet Diabetes Endocrinol 2019;
7:776–785. https://doi.org/10.1016/ 
s2213-8587(19)30249-9
700. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. 
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 
2019;
380:2295–2306. https://doi.org/10.1056/NEJMoa1811744
701. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, 
et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383: 
1436–1446. https://doi.org/10.1056/NEJMoa20248163820                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

702. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. 
Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 
2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
703. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular 
and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383: 
1413–1424. https://doi.org/10.1056/NEJMoa2022190
704. Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empa -
gliflozin on worsening heart failure events in patients with heart failure and a preserved 
ejection fraction: the EMPEROR-preserved trial. Circulation 2021;
144:1284–1294. 
https://doi.org/10.1161/circulationaha.121.056824
705. Ferrannini G, De Bacquer D, De Backer G, Kotseva K, Mellbin L, Wood D, et al. 
Screening for glucose perturbations and risk factor management in dysglycemic pa -
tients with coronary artery disease–a persistent challenge in need of substantial im -
provement: a report from ESC EORP EUROASPIRE V. Diabetes Care 2020;
43: 
726–733. https://doi.org/10.2337/dc19-2165
706. Shahim B, De Bacquer D, De Backer G, Gyberg V, Kotseva K, Mellbin L, et al. The prog -
nostic value of fasting plasma glucose, two-hour postload glucose, and HbA(1c) in pa -
tients with coronary artery disease: a report from EUROASPIRE IV: a survey from the 
European Society of Cardiology. Diabetes Care 2017;
40:1233–1240. https://doi.org/10. 
2337/dc17-0245
707. Ritsinger V, Tanoglidi E, Malmberg K, Näsman P, Rydén L, Tenerz Å, et al. Sustained 
prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with 
Acute Myocardial Infarction cohort. Diab Vasc Dis Res 2015;
12:23–32. https://doi.org/ 
10.1177/1479164114551746
708. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- 
and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute 
coronary events. Eur Heart J 2005;26:1255–1261. https://doi.org/10.1093/eurheartj/ 
ehi230
709. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, et al. 
U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2005;46:178–180. 
https://doi.org/10.1016/j.jacc.2005.03.052
710.
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in 
older people: a meta-analysis of individual participant data from 28 randomised con -
trolled trials. Lancet 2019;
393:407–415. https://doi.org/10.1016/s0140-6736(18) 
31942-1
711. Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, et al. Effect of 
simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clin
-
ical trial. JAMA Cardiol 2019;
4:846–854. https://doi.org/10.1001/jamacardio.2019.2306
712. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. 
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. 
N Engl J Med 2012;
367:1297–1309. https://doi.org/10.1056/NEJMoa1205512
713. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complica -
tions of cancer therapy: best practices in diagnosis, prevention, and management: Part 
2. J Am Coll Cardiol 2017;
70:2552–2565. https://doi.org/10.1016/j.jacc.2017.09.1095
714. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020;
17: 
503–522. https://doi.org/10.1038/s41569-020-0347-2
715. Long M, Ye Z, Zheng J, Chen W, Li L. Dual anti-platelet therapy following percutan -
eous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis. BMC Pharmacol Toxicol 2020;
21:31. https://doi.org/10.1186/ 
s40360-020-00409-2
716. Ambrosetti M, Abreu A, Corrà U, Davos CH, Hansen D, Frederix I, et al. Secondary 
prevention through comprehensive cardiovascular rehabilitation: from knowledge to 
implementation. 2020 update. A position paper from the Secondary Prevention and 
Rehabilitation Section of the European Association of Preventive Cardiology. Eur J 
Prev Cardiol 2020;
28:460–495. https://doi.org/10.1177/2047487320913379
717. Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, et al. Standardization 
and quality improvement of secondary prevention through cardiovascular rehabilita -
tion programmes in Europe: the avenue towards EAPC accreditation programme: a position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2020;
28: 
496–509. https://doi.org/10.1177/2047487320924912
718. Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs: challenges for 
research and for patient care. J Am Coll Cardiol 2015;
66:1273–1285. https://doi.org/10. 
1016/j.jacc.2015.07.018
719. Frederix I, Dendale P, Schmid JP. Who needs secondary prevention? Eur J Prev Cardiol 
2017;24:8–13. https://doi.org/10.1177/2047487317706112
720. Rea F, Ronco R, Pedretti RFE, Merlino L, Corrao G. Better adherence with 
out-of-hospital healthcare improved long-term prognosis of acute coronary syn -
dromes: evidence from an Italian real-world investigation. Int J Cardiol 2020;
318: 
14–20. https://doi.org/10.1016/j.ijcard.2020.06.017
721. Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf MI, Hackbusch M, et al. 
Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease pa -
tients treated according to contemporary evidence based medicine: update of the Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol 2020; 27: 
1756–1774. https://doi.org/10.1177/2047487320905719
722. Santiago de Araújo Pio C, Marzolini S, Pakosh M, Grace SL. Effect of cardiac rehabili -
tation dose on mortality and morbidity: a systematic review and meta-regression ana -
lysis. Mayo Clin Proc 2017;
92:1644–1659. https://doi.org/10.1016/j.mayocp.2017.07. 
019
723. van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D. Lessons 
from contemporary trials of cardiovascular prevention and rehabilitation: a systematic 
review and meta-analysis. Int J Cardiol 2017;
232:294–303. https://doi.org/10.1016/j. 
ijcard.2016.12.125
724. Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. 
Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database 
Syst Rev 2021;11:Cd001800. https://doi.org/10.1002/14651858.CD001800.pub4
725. Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, et al. 
Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database 
Syst Rev 2016;2016:CD001800. https://doi.org/10.1002/14651858.CD001800.pub3
726. Benzer W, Rauch B, Schmid JP, Zwisler AD, Dendale P, Davos CH, et al. 
Exercise-based cardiac rehabilitation in twelve European countries: results of the European cardiac rehabilitation registry. Int J Cardiol 2017;228:58–67. https://doi.org/ 
10.1016/j.ijcard.2016.11.059
727.
Clark RA, Conway A, Poulsen V, Keech W, Tirimacco R, Tideman P. Alternative mod -
els of cardiac rehabilitation: a systematic review. Eur J Prev Cardiol 2015;
22:35–74. 
https://doi.org/10.1177/2047487313501093
728. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Lifestyle 
and impact on cardiovascular risk factor control in coronary patients across 27 coun -
tries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V 
registry. Eur J Prev Cardiol 2019;
26:824–835. https://doi.org/10.1177/ 
2047487318825350
729. Frederix I, Vanhees L, Dendale P, Goetschalckx K. A review of telerehabilitation for 
cardiac patients. J Telemed Telecare 2015;
21:45–53. https://doi.org/10.1177/ 
1357633x14562732
730. Conraads VM, Deaton C, Piotrowicz E, Santaularia N, Tierney S, Piepoli MF, et al. 
Adherence of heart failure patients to exercise: barriers and possible solutions: a pos -
ition statement of the Study Group on Exercise Training in Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2012;
14: 
451–458. https://doi.org/10.1093/eurjhf/hfs048
731. De Bacquer D, Astin F, Kotseva K, Pogosova N, De Smedt D, De Backer G, et al. Poor 
adherence to lifestyle recommendations in patients with coronary heart disease: re -
sults from the EUROASPIRE surveys. Eur J Prev Cardiol 2021;
29:383–395. https://doi. 
org/10.1093/eurjpc/zwab115
732. Dalal HM, Taylor RS. Telehealth technologies could improve suboptimal rates of par -
ticipation in cardiac rehabilitation. Heart 2016;
102:1155–1156. https://doi.org/10. 
1136/heartjnl-2016-309429
733. Lavie CJ, Arena R, Franklin BA. Cardiac rehabilitation and healthy life-style interven -
tions: rectifying program deficiencies to improve patient outcomes. J Am Coll Cardiol 
2016;
67:13–15. https://doi.org/10.1016/j.jacc.2015.09.103
734. Fors A, Taft C, Ulin K, Ekman I. Person-centred care improves self-efficacy to control 
symptoms after acute coronary syndrome: a randomized controlled trial. Eur J 
Cardiovasc Nurs 2016;
15:186–194. https://doi.org/10.1177/1474515115623437
735. Frederix I, Caiani EG, Dendale P, Anker S, Bax J, Böhm A, et al. ESC e-Cardiology 
Working Group Position Paper: overcoming challenges in digital health implementa -
tion in cardiovascular medicine. Eur J Prev Cardiol 2019;
26:1166–1177. https://doi. 
org/10.1177/2047487319832394
736. Rosselló X, Stanbury M, Beeri R, Kirchhof P, Casadei B, Kotecha D. Digital learning and the future cardiologist. Eur Heart J 2019;
40:499–501. https://doi.org/10.1093/ 
eurheartj/ehy884
737. Frederix I, Solmi F, Piepoli MF, Dendale P. Cardiac telerehabilitation: a novel cost- 
efficient care delivery strategy that can induce long-term health benefits. Eur J Prev 
Cardiol 2017;24:1708–1717. https://doi.org/10.1177/2047487317732274
738. Avila A, Claes J, Buys R, Azzawi M, Vanhees L, Cornelissen V. Home-based exercise with telemonitoring guidance in patients with coronary artery disease: does it improve 
long-term physical fitness? Eur J Prev Cardiol 2020;27:367–377. https://doi.org/10.1177/ 
2047487319892201
739. Claes J, Cornelissen V, McDermott C, Moyna N, Pattyn N, Cornelis N, et al. Feasibility, 
acceptability, and clinical effectiveness of a technology-enabled cardiac rehabilitation 
platform (physical activity toward health-I): randomized controlled trial. J Med 
Internet Res 2020;22:e14221. https://doi.org/10.2196/14221
740. Kraal JJ, Peek N, Van den Akker-Van Marle ME, Kemps HM. Effects of home-based 
training with telemonitoring guidance in low to moderate risk patients entering cardiac 
rehabilitation: short-term results of the FIT@Home study. Eur J Prev Cardiol 2014;21: 
26–31. https://doi.org/10.1177/2047487314552606
741. Maddison R, Rawstorn JC, Stewart RAH, Benatar J, Whittaker R, Rolleston A, et al. 
Effects and costs of real-time cardiac telerehabilitation: randomised controlled non- inferiority trial. Heart 2019;105:122–129. https://doi.org/10.1136/heartjnl-2018- 
313189ESC Guidelines                                                                                                                                                                                          3821Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

742. Scherrenberg M, Wilhelm M, Hansen D, Völler H, Cornelissen V, Frederix I, et al. The 
future is now: a call for action for cardiac telerehabilitation in the COVID-19 pandemic 
from the secondary prevention and rehabilitation section of the European Association 
of Preventive Cardiology. Eur J Prev Cardiol 2020;28:524–540. https://doi.org/10.1177/ 
2047487320939671
743. Huang K, Liu W, He D, Huang B, Xiao D, Peng Y, et al. Telehealth interventions versus 
center-based cardiac rehabilitation of coronary artery disease: a systematic review and 
meta-analysis. Eur J Prev Cardiol 2015;22:959–971. https://doi.org/10.1177/ 
2047487314561168
744. Wolf A, Vella R, Fors A. The impact of person-centred care on patients’ care experi -
ences in relation to educational level after acute coronary syndrome: secondary out -
come analysis of a randomised controlled trial. Eur J Cardiovasc Nurs 2019;
18:299–308. 
https://doi.org/10.1177/1474515118821242
745. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and consequences. Am J Med Sci 2016;
351:387–399. https://doi.org/10.1016/j. 
amjms.2016.01.010
746. Arlt AD, Nestoriuc Y, Rief W. Why current drug adherence programs fail: addressing psychological risk factors of nonadherence. Curr Opin Psychiatry 2017;30:326–333. 
https://doi.org/10.1097/yco.0000000000000345
747.
Easthall C, Taylor N, Bhattacharya D. Barriers to medication adherence in patients 
prescribed medicines for the prevention of cardiovascular disease: a conceptual frame -
work. Int J Pharm Pract 2019;
27:223–231. https://doi.org/10.1111/ijpp.12491
748. Seabury SA, Dougherty JS, Sullivan J. Medication adherence as a measure of the quality 
of care provided by physicians. Am J Manag Care 2019;
25:78–83.
749. Pedretti RFE, Hansen D, Ambrosetti M, Back M, Berger T, Ferreira MC, et al. How to 
optimize the adherence to a guideline-directed medical therapy in the secondary pre -
vention of cardiovascular diseases: a clinical consensus statement from the European 
Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2022;
30:149–166. 
https://doi.org/10.1093/eurjpc/zwac204
750. Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, et al. A poly -
pill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 
2014;
64:2071–2082. https://doi.org/10.1016/j.jacc.2014.08.021
751. Selak V, Webster R, Stepien S, Bullen C, Patel A, Thom S, et al. Reaching cardiovascular 
prevention guideline targets with a polypill-based approach: a meta-analysis of rando -
mised clinical trials. Heart 2019;
105:42–48. https://doi.org/10.1136/heartjnl-2018- 
313108
752. Castellano JM, Fuster V, Jennings C, Prescott E, Bueno H. Role of the polypill for sec -
ondary prevention in ischaemic heart disease. Eur J Prev Cardiol 2017;
24:44–51. https:// 
doi.org/10.1177/2047487317707324
753. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. 
Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;
387: 
967–977. https://doi.org/10.1056/NEJMoa2208275
754. Palmer MJ, Barnard S, Perel P, Free C. Mobile phone-based interventions for improving 
adherence to medication prescribed for the primary prevention of cardiovascular dis -
ease in adults. Cochrane Database Syst Rev 2018;
6:CD012675. https://doi.org/10.1002/ 
14651858.CD012675.pub2
755. Guerriero C, Cairns J, Roberts I, Rodgers A, Whittaker R, Free C. The cost- 
effectiveness of smoking cessation support delivered by mobile phone text messaging: 
Txt2stop. Eur J Health Econ 2013;
14:789–797. https://doi.org/10.1007/s10198-012- 
0424-5
756. Gandapur Y, Kianoush S, Kelli HM, Misra S, Urrea B, Blaha MJ, et al. The role of 
mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review. Eur Heart J Qual Care Clin Outcomes 2016;2:237–244. https://doi. 
org/10.1093/ehjqcco/qcw018
757. Fortuna RJ, Nagel AK, Rocco TA, Legette-Sobers S, Quigley DD. Patient experience with care and its association with adherence to hypertension medications. Am J 
Hypertens 2018;31:340–345. https://doi.org/10.1093/ajh/hpx200
758. Keenan J. Improving adherence to medication for secondary cardiovascular disease 
prevention. Eur J Prev Cardiol 2017;24:29–35. https://doi.org/10.1177/ 
2047487317708145
759.
Geidl W, Schlesinger S, Mino E, Miranda L, Pfeifer K. Dose-response relationship be -
tween physical activity and mortality in adults with noncommunicable diseases: a sys -
tematic review and meta-analysis of prospective observational studies. Int J Behav Nutr 
Phys Act 2020;
17:109. https://doi.org/10.1186/s12966-020-01007-5
760. Ekblom O, Ek A, Cider Å, Hambraeus K, Börjesson M. Increased physical activity post- 
myocardial infarction is related to reduced mortality: results from the SWEDEHEART 
registry. J Am Heart Assoc 2018;
7:e010108. https://doi.org/10.1161/jaha.118.010108
761. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, Quintana-Navarro GM, Fuentes F, Garcia-Rios A, et al. Long-term secondary prevention of cardiovascular disease with 
a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled 
trial. Lancet 2022;399:1876–1885. https://doi.org/10.1016/s0140-6736(22)00122-2
762. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial 
infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779–785. 
https://doi.org/10.1161/01.cir.99.6.779763. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in 
patients with coronary heart disease: a systematic review. JAMA 2003;290:86–97. 
https://doi.org/10.1001/jama.290.1.86
764. Chow CK, Jolly S, Rao-Melacini P, Fox KAA, Anand SS, Yusuf S. Association of diet, 
exercise, and smoking modification with risk of early cardiovascular events after acute 
coronary syndromes. Circulation 2010;121:750–758. https://doi.org/10.1161/ 
circulationaha.109.891523
765. United States Public Health Service Office of the Surgeon General. Smoking Cessation: A Report of the Surgeon General. In: US Department of Health and Human Services; 
2020.
766. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA 
Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American 
Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/ 
AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/ 
AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the 
Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for 
the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, 
and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and 
Management of Patients Undergoing Noncardiac Surgery. Circulation 2016;134: 
e123–e155. https://doi.org/10.1161/cir.0000000000000404
767. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; 
2013:CD009329. https://doi.org/10.1002/14651858.CD009329.pub2
768. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for 
smoking cessation in hospitalized patients with acute coronary syndrome. Circulation 
2016;133:21–30. https://doi.org/10.1161/circulationaha.115.019634
769.
Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ. Varenicline and adverse car -
diovascular events: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2016;
5:e002849. https://doi.org/10.1161/jaha.115.002849
770. Windle SB, Dehghani P, Roy N, Old W, Grondin FR, Bata I, et al. Smoking abstinence 1 
year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital. CMAJ 2018;
190:E347–E354. https://doi. 
org/10.1503/cmaj.170377
771. Kavousi M, Pisinger C, Barthelemy JC, De Smedt D, Koskinas K, Marques-Vidal P, et al. 
Electronic cigarettes and health with special focus on cardiovascular effects: position 
paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev 
Cardiol 2020;28:1552–1566. https://doi.org/10.1177/2047487320941993
772. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention 
of cardiovascular disease with a mediterranean diet supplemented with extra-virgin ol -
ive oil or nuts. N Engl J Med 2018;
378:e34. https://doi.org/10.1056/NEJMoa1800389
773. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk 
thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;
391: 
1513–1523. https://doi.org/10.1016/s0140-6736(18)30134-x
774. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association be -
tween alcohol and cardiovascular disease: Mendelian randomisation analysis based 
on individual participant data. BMJ 2014;
349:g4164. https://doi.org/10.1136/bmj.g4164
775. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, et al. Conventional and gen -
etic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 
men and women in China. Lancet 2019;
393:1831–1842. https://doi.org/10.1016/ 
s0140-6736(18)31772-0
776. Ekelund U, Tarp J, Steene-Johannessen J, Hansen BH, Jefferis B, Fagerland MW, et al. 
Dose-response associations between accelerometry measured physical activity and 
sedentary time and all cause mortality: systematic review and harmonised 
meta-analysis. BMJ 2019;
366:l4570. https://doi.org/10.1136/bmj.l4570
777. Patterson R, McNamara E, Tainio M, de Sá TH, Smith AD, Sharp SJ, et al. Sedentary 
behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. Eur J 
Epidemiol 2018;33:811–829. https://doi.org/10.1007/s10654-018-0380-1
778. WHO Guidelines Review Committee. WHO Guidelines on Physical Activity and 
Sedentary Behaviour. World Health Organization, 2020.
779. Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise 
intensity assessment and prescription in cardiovascular rehabilitation and beyond: why 
and how: a position statement from the Secondary Prevention and Rehabilitation 
Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 
2022;29:230–245. https://doi.org/10.1093/eurjpc/zwab007
780. De Schutter A, Kachur S, Lavie CJ, Menezes A, Shum KK, Bangalore S, et al. Cardiac 
rehabilitation fitness changes and subsequent survival. Eur Heart J Qual Care Clin 
Outcomes 2018;4:173–179. https://doi.org/10.1093/ehjqcco/qcy018
781. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for 
depression in patients with coronary artery disease. Cochrane Database Syst Rev 2011; 
2011:Cd008012. https://doi.org/10.1002/14651858.CD008012.pub33822                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

782. Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P, et al. 
Psychological interventions for coronary heart disease: cochrane systematic review 
and meta-analysis. Eur J Prev Cardiol 2018;25:247–259. https://doi.org/10.1177/ 
2047487317739978
783. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ 
EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce car -
diovascular risk. Eur Heart J 2020;
41:111–188. https://doi.org/10.1093/eurheartj/ 
ehz455
784. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. 
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the 
European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;
38: 
2459–2472. https://doi.org/10.1093/eurheartj/ehx144
785. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. 
Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J 
Med 2017;376:1713–1722. https://doi.org/10.1056/NEJMoa1615664
786. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and 
cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379: 
2097–2107. https://doi.org/10.1056/NEJMoa1801174
787. Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, 
et al. Meta-analysis of time-related benefits of statin therapy in patients with acute cor -
onary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2014; 
113
:1753–1764. https://doi.org/10.1016/j.amjcard.2014.02.034
788. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. 
Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 
2015;
372:2387–2397. https://doi.org/10.1056/NEJMoa1410489
789. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. 
Evolocumab for early reduction of LDL cholesterol levels in patients with acute cor -
onary syndromes (EVOPACS). J Am Coll Cardiol 2019;
74:2452–2462. https://doi.org/ 
10.1016/j.jacc.2019.08.010
790. Trankle CR, Wohlford G, Buckley LF, Kadariya D, Ravindra K, Markley R, et al. 
Alirocumab in acute myocardial infarction: results from the Virginia Commonwealth 
University Alirocumab Response Trial (VCU-AlirocRT). J Cardiovasc Pharmacol 2019; 
74
:266–269. https://doi.org/10.1097/fjc.0000000000000706
791. Iannuzzo G, Gentile M, Bresciani A, Mallardo V, Di Lorenzo A, Merone P, et al. 
Inhibitors of protein convertase subtilisin/kexin 9 (PCSK9) and acute coronary syn -
drome (ACS): the state-of-the-art. J Clin Med 2021;
10:1510. https://doi.org/10.3390/ 
jcm10071510
792. Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, et al. Effect of alirocumab 
added to high-intensity statin therapy on coronary atherosclerosis in patients with 
acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA 2022; 
327
:1771–1781. https://doi.org/10.1001/jama.2022.5218
793. Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of evolo -
cumab on coronary plaque phenotype and burden in statin-treated patients following 
myocardial infarction. JACC Cardiovasc Imaging 2022;
15:1308–1321. https://doi.org/10. 
1016/j.jcmg.2022.03.002
794. Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al. Low-density 
lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J 2021;
42: 
243–252. https://doi.org/10.1093/eurheartj/ehaa1011
795. Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, et al. Efficacy of 
evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: 
a prespecified secondary analysis from the FOURIER trial. JAMA Cardiol 2020;5: 
952–957. https://doi.org/10.1001/jamacardio.2020.0882
796. O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. 
Long-term evolocumab in patients with established atherosclerotic cardiovascular dis -
ease. Circulation 2022;
146:1109–1119. https://doi.org/10.1161/circulationaha.122. 
061620
797. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. 
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J 
Med 2019;
380:11–22. https://doi.org/10.1056/NEJMoa1812792
798. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β blockade after myocardial in -
farction: systematic review and meta regression analysis. BMJ 1999;
318:1730–1737. 
https://doi.org/10.1136/bmj.318.7200.1730
799. Martínez-Milla J, Raposeiras-Roubín S, Pascual-Figal DA, Ibáñez B. Role of beta- 
blockers in cardiovascular disease in 2019. Rev Esp Cardiol (Engl Ed) 2019;
72: 
844–852. https://doi.org/10.1016/j.rec.2019.04.014
800. Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, et al. Effect of 
oral β
-blocker treatment on mortality in contemporary post-myocardial infarction pa -
tients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2019; 
5
:12–20. https://doi.org/10.1093/ehjcvp/pvy034
801. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with 
left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;
357: 
1385–1390. https://doi.org/10.1016/s0140-6736(00)04560-8
802. Kim J, Kang D, Park H, Kang M, Park TK, Lee JM, et al. Long-term β-blocker therapy and 
clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J 2020;41:3521–3529. https://doi.org/10.1093/ 
eurheartj/ehaa376
803. Raposeiras-Roubín S, Abu-Assi E, Redondo-Diéguez A, González-Ferreiro R, 
López-López A, Bouzas-Cruz N, et al. Prognostic benefit of beta-blockers after acute 
coronary syndrome with preserved systolic function. Still relevant today? Rev Esp 
Cardiol (Engl Ed) 2015;68:585–591. https://doi.org/10.1016/j.rec.2014.07.028
804. Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, et al. β
-blockers and 
mortality after acute myocardial infarction in patients without heart failure or ventricu -
lar dysfunction. J Am Coll Cardiol 2017;
69:2710–2720. https://doi.org/10.1016/j.jacc. 
2017.03.578
805. Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, et al. Long-term 
use of carvedilol in patients with ST-segment elevation myocardial infarction treated 
with primary percutaneous coronary intervention. PLoS One 2018;
13:e0199347. 
https://doi.org/10.1371/journal.pone.0199347
806. Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabés JA, 
Sánchez PL, et al. Rationale and design of the pragmatic clinical trial tREatment with 
Beta-blockers after myOcardial infarction withOut reduced ejection fracTion 
(REBOOT). Eur Heart J Cardiovasc Pharmacother 2021;8:291–301. https://doi.org/10. 
1093/ehjcvp/pvab060
807. Munkhaugen J, Ruddox V, Halvorsen S, Dammen T, Fagerland MW, Hernæs KH, et al. 
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): rationale and design of a prospective, randomized, open, blinded end point study. Am Heart J 2019;208: 
37–46. https://doi.org/10.1016/j.ahj.2018.10.005
808.
Kristensen AMD, Bovin A, Zwisler AD, Cerquira C, Torp-Pedersen C, Bøtker HE, et al. 
Design and rationale of the Danish trial of beta-blocker treatment after myocardial in -
farction without reduced ejection fraction: study protocol for a randomized con -
trolled trial. Trials 2020;
21:415. https://doi.org/10.1186/s13063-020-4214-6
809. Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, et al. β blockers and mor -
tality after myocardial infarction in patients without heart failure: multicentre pro -
spective cohort study. BMJ 2016;
354:i4801. https://doi.org/10.1136/bmj.i4801
810. Zeitouni M, Kerneis M, Lattuca B, Guedeney P, Cayla G, Collet JP, et al. Do patients 
need lifelong β
-blockers after an uncomplicated myocardial infarction? Am J 
Cardiovasc Drugs 2019;19:431–438. https://doi.org/10.1007/s40256-019-00338-4
811. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral cap -
topril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;
345:669–685. https://doi.org/10. 
1016/S0140-6736(95)90865-X
812. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989;
299:1187–1192. https://doi.org/10.1136/ 
bmj.299.6709.1187
813. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical 
trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left 
ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333: 
1670–1676. https://doi.org/10.1056/nejm199512213332503
814. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of cap -
topril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction–results of the survival and ventricular enlargement trial. N Engl 
J Med 1992;
327:669–677. https://doi.org/10.1056/nejm199209033271001
815. The AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;
342: 
821–828. https://doi.org/10.1016/0140-6736(93)92693-N
816. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients 
with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782–788. https://doi.org/10. 
1016/s0140-6736(03)14286-9
817. The Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, 
Pogue Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, 
ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 
145–153. https://doi.org/10.1056/nejm200001203420301
818.
ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibi -
tors in the early treatment of acute myocardial infarction: systematic overview of in -
dividual data from 100,000 patients in randomized trials. Circulation 1998;
97: 
2202–2212. https://doi.org/10.1161/01.cir.97.22.2202
819. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. 
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, 
left ventricular dysfunction, or both. N Engl J Med 2003;
349:1893–1906. https://doi. 
org/10.1056/NEJMoa032292
820. Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the 
CONSENSUS trial). Am J Cardiol 1990;66:D40–D45. https://doi.org/10.1016/0002- 
9149(90)90475-g
821.
Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme in -
hibitors on mortality and morbidity in patients with heart failure. JAMA 1995;
273: 
1450–1456. https://doi.org/10.1001/jama.1995.03520420066040ESC Guidelines                                                                                                                                                                                          3823Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

822. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, 
et al. Comparative effects of low and high doses of the angiotensin-converting enzyme 
inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 
100:2312–2318. https://doi.org/10.1161/01.cir.100.23.2312
823. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J 
Med 1991;325:293–302. https://doi.org/10.1056/nejm199108013250501
824. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. 
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 
371:993–1004. https://doi.org/10.1056/NEJMoa1409077
825. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin 
receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med 2021;385: 
1845–1855. https://doi.org/10.1056/NEJMoa2104508
826.
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a se -
lective aldosterone blocker, in patients with left ventricular dysfunction after myocar -
dial infarction. N Engl J Med 2003;
348:1309–1321. https://doi.org/10.1056/ 
NEJMoa030207
827. Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, et al. Early 
eplerenone treatment in patients with acute ST-elevation myocardial infarction with -
out heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J 2014;
35: 
2295–2302. https://doi.org/10.1093/eurheartj/ehu164
828. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond 
glycaemic control. Nat Rev Cardiol 2020;
17:761–772. https://doi.org/10.1038/s41569- 
020-0406-8
829. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. 
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 
2017;377:644–657. https://doi.org/10.1056/NEJMoa1611925
830. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and 
cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357. https:// 
doi.org/10.1056/NEJMoa1812389
831. Nikolaus M, Massimo F, Katharina S, Dirk M-W, Ramzi AA, Manuel JA, et al. 2023 ESC 
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur 
Heart J 2023; https://doi.org/10.1093/eurheartj/ehad192
832. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in 
heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461. 
https://doi.org/10.1056/NEJMoa2107038
833. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. 
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl 
J Med 2022;387:1089–1098. https://doi.org/10.1056/NEJMoa2206286
834. von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. 
Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J 2022;43: 
4421–4432. https://doi.org/10.1093/eurheartj/ehac494
835. Harrington J, Udell JA, Jones WS, Anker SD, Bhatt DL, Petrie MC, et al. Empagliflozin in 
patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am 
Heart J 2022;253:86–98. https://doi.org/10.1016/j.ahj.2022.05.010
836. Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC, et al. Lansoprazole for the 
prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033–2038. https://doi.org/10.1056/NEJMoa012877
837.
Casado Arroyo R, Polo-Tomas M, Roncalés MP, Scheiman J, Lanas A. Lower GI bleed -
ing is more common than upper among patients on dual antiplatelet therapy: long- 
term follow-up of a cohort of patients commonly using PPI co-therapy. Heart 2012; 
98
:718–723. https://doi.org/10.1136/heartjnl-2012-301632
838. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the 
proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics 
of prasugrel and clopidogrel. J Clin Pharmacol 2008;
48:475–484. https://doi.org/10. 
1177/0091270008315310
839. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, et al. Impact of pro -
ton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 
101
:714–719. https://doi.org/10.1160/TH08-12-0808
840. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of ome -
prazole on the antiplatelet action of clopidogrel associated with aspirin: the rando -
mized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll 
Cardiol 2008;
51:256–260. https://doi.org/10.1016/j.jacc.2007.06.064
841. O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. 
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or with -
out a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;
374: 
989–997. https://doi.org/10.1016/s0140-6736(09)61525-7
842. Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association 
of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and tica -
grelor: insights from the platelet inhibition and patient outcomes trial. Circulation 
2012;
125:978–986. https://doi.org/10.1161/circulationaha.111.032912
843. Yedlapati SH, Khan SU, Talluri S, Lone AN, Khan MZ, Khan MS, et al. Effects of influ -
enza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular 
disease: a systematic review and meta-analysis. J Am Heart Assoc 2021;
10:e019636. 
https://doi.org/10.1161/jaha.120.019636844. Liprandi ÁS, Liprandi MIS, Zaidel EJ, Aisenberg GM, Baranchuk A, Barbosa ECD, et al. 
Influenza vaccination for the prevention of cardiovascular disease in the Americas: con -
sensus document of the Inter-American Society of Cardiology and the World Heart 
Federation. Glob Heart 2021;
16:55. https://doi.org/10.5334/gh.1069
845. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute cor -
onary syndromes and planned percutaneous coronary interventions (FLUVACS) 
study. Eur Heart J 2004;
25:25–31. https://doi.org/10.1016/j.ehj.2003.10.018
846. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A, et al. Influenza vaccination reduces cardiovascular events in patients 
with acute coronary syndrome. Eur Heart J 2011;
32:1730–1735. https://doi.org/10. 
1093/eurheartj/ehr004
847. Fröbert O, Götberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al. 
Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo- controlled, multicenter trial. Circulation 2021;144:1476–1484. https://doi.org/10.1161/ 
circulationaha.121.057042
848.
Chen Y, Zhang H, Chen Y, Li M, Luo W, Liu Y, et al. Colchicine may become a new 
cornerstone therapy for coronary artery disease: a meta-analysis of randomized con -
trolled trials. Clin Rheumatol 2022;
41:1873–1887. https://doi.org/10.1007/s10067-022- 
06050-0
849. Razavi E, Ramezani A, Kazemi A, Attar A. Effect of treatment with colchicine after 
acute coronary syndrome on major cardiovascular events: a systematic review and 
meta-analysis of clinical trials. Cardiovasc Ther 2022;
2022:8317011. https://doi.org/ 
10.1155/2022/8317011
850. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and 
safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381: 
2497–2505. https://doi.org/10.1056/NEJMoa1912388
851. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine 
in patients with chronic coronary disease. N Engl J Med 2020;383:1838–1847. https:// 
doi.org/10.1056/NEJMoa2021372
852. Opstal TSJ, Fiolet ATL, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, et al. 
Colchicine in patients with chronic coronary disease in relation to prior acute coron -
ary syndrome. J Am Coll Cardiol 2021;
78:859–866. https://doi.org/10.1016/j.jacc.2021. 
06.037
853. Ji H, Fang L, Yuan L, Zhang Q. Effects of exercise-based cardiac rehabilitation in pa -
tients with acute coronary syndrome: a meta-analysis. Med Sci Monit 2019;
25: 
5015–5027. https://doi.org/10.12659/msm.917362
854. Candelaria D, Randall S, Ladak L, Gallagher R. Health-related quality of life and exercise-based cardiac rehabilitation in contemporary acute coronary syndrome pa
-
tients: a systematic review and meta-analysis. Qual Life Res 2020;
29:579–592. https:// 
doi.org/10.1007/s11136-019-02338-y
855. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. The 
effects of a smoking cessation intervention on 14.5-year mortality: a randomized clin -
ical trial. Ann Intern Med 2005;
142:233–239. https://doi.org/10.7326/0003-4819-142- 
4-200502150-00005
856. Becerra-Tomás N, Blanco Mejía S, Viguiliouk E, Khan T, Kendall CWC, Kahleova H, 
et al. Mediterranean diet, cardiovascular disease and mortality in diabetes: a systematic 
review and meta-analysis of prospective cohort studies and randomized clinical trials. 
Crit Rev Food Sci Nutr 2020;
60:1207–1227. https://doi.org/10.1080/10408398.2019. 
1565281
857. Liu Y, Lee DC, Li Y, Zhu W, Zhang R, Sui X, et al. Associations of resistance exercise 
with cardiovascular disease morbidity and mortality. Med Sci Sports Exerc 2019;51: 
499–508. https://doi.org/10.1249/mss.0000000000001822
858. Saeidifard F, Medina-Inojosa JR, West CP, Olson TP, Somers VK, Bonikowske AR, et al. 
The association of resistance training with mortality: a systematic review and 
meta-analysis. Eur J Prev Cardiol 2019;26:1647–1665. https://doi.org/10.1177/ 
2047487319850718
859. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement 
therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018;5: 
CD000146. https://doi.org/10.1002/14651858.CD000146.pub5
860. Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N. Antidepressants 
for smoking cessation. Cochrane Database Syst Rev 2020;4:CD000031. https://doi.org/ 
10.1002/14651858.CD000031.pub5
861. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine recep -
tor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016;
2016: 
CD006103. https://doi.org/10.1002/14651858.CD006103.pub7
862. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different 
doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2019;
4:CD013308. https://doi.org/10.1002/ 
14651858.Cd013308
863. Woolf KJ, Zabad MN, Post JM, McNitt S, Williams GC, Bisognano JD. Effect of nicotine 
replacement therapy on cardiovascular outcomes after acute coronary syndromes. 
Am J Cardiol 2012;110:968–970. https://doi.org/10.1016/j.amjcard.2012.05.028
864. Suissa K, Larivière J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety 
of smoking cessation interventions in patients with cardiovascular disease: a network 
meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10: 
e002458. https://doi.org/10.1161/circoutcomes.115.0024583824                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

865. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, et al. Early in -
tensive vs a delayed conservative simvastatin strategy in patients with acute coronary 
syndromes: phase Z of the A to Z trial. JAMA 2004;
292:1307–1316. https://doi.org/10. 
1001/jama.292.11.1307
866. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late 
benefits of high-dose atorvastatin in patients with acute coronary syndromes: results 
from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;
46:1405–1410. https://doi.org/ 
10.1016/j.jacc.2005.03.077
867. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects 
of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the 
MIRACL study: a randomized controlled trial. JAMA 2001;285:1711–1718. https:// 
doi.org/10.1001/jama.285.13.1711
868. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and 
safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 
170,000 participants in 26 randomised trials. Lancet 2010;376:1670–1681. https:// 
doi.org/10.1016/s0140-6736(10)61350-5
869. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B. Efficacy and 
safety of LDL-lowering therapy among men and women: meta-analysis of individual 
data from 174,000 participants in 27 randomised trials. Lancet 2015;385: 
1397–1405. https://doi.org/10.1016/s0140-6736(14)61368-4
870. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a rando -
mised trial. Lancet 1999;
353:9–13. https://doi.org/10.1016/S0140-6736(98)11181-9
871. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol 
on survival in severe chronic heart failure. N Engl J Med 2001;
344:1651–1658. https:// 
doi.org/10.1056/nejm200105313442201
872. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: 
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure 
(MERIT-HF). Lancet 1999;353:2001–2007. https://doi.org/10.1016/S0140-6736(99) 
04440-2
873. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then 
oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622–1632. https://doi.org/10.1016/s0140- 
6736(05)67661-1
874. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, et al. Clinical outcomes 
with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J 
Med 2014;127:939–953. https://doi.org/10.1016/j.amjmed.2014.05.032
875.
Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, et al. Meta-analysis of relation 
between oral β
-blocker therapy and outcomes in patients with acute myocardial in -
farction who underwent percutaneous coronary intervention. Am J Cardiol 2015; 
115
:1529–1538. https://doi.org/10.1016/j.amjcard.2015.02.057
876. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of beta- 
blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol 2015;
66: 
1431–1441. https://doi.org/10.1016/j.jacc.2015.07.047
877. Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, et al. β
-blocker ther -
apy and cardiac events among patients with newly diagnosed coronary heart disease. J 
Am Coll Cardiol 2014;
64:247–252. https://doi.org/10.1016/j.jacc.2014.04.042
878. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β
-blocker use 
and clinical outcomes in stable outpatients with and without coronary artery disease. 
JAMA 2012;308:1340–1349. https://doi.org/10.1001/jama.2012.12559
879. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on car -
diovascular and microvascular outcomes in people with diabetes mellitus: results of the 
HOPE study and MICRO-HOPE substudy. Lancet 2000;
355:253–259. https://doi.org/ 
10.1016/S0140-6736(99)12323-7
880. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spir -
onolactone on morbidity and mortality in patients with severe heart failure. N Engl J 
Med 1999;
341:709–717. https://doi.org/10.1056/nejm199909023411001
881. Hirpa M, Woreta T, Addis H, Kebede S. What matters to patients? A timely question for value-based care. PLoS One 2020;
15:e0227845. https://doi.org/10.1371/journal. 
pone.0227845
882. Ebrahimi Z, Patel H, Wijk H, Ekman I, Olaya-Contreras P. A systematic review on im -
plementation of person-centered care interventions for older people in 
out-of-hospital settings. Geriatr Nurs 2021;
42:213–224. https://doi.org/10.1016/j. 
gerinurse.2020.08.004
883. Gluyas H. Patient-centred care: improving healthcare outcomes. Nurs Stand 2015;
30: 
50–57, quiz 59. https://doi.org/10.7748/ns.30.4.50.e10186
884. Kok MM, von Birgelen C. Involving the patient’s perspective and preferences concern -
ing coronary angiography and percutaneous coronary intervention. EuroIntervention 
2020;
15:1228–1231. https://doi.org/10.4244/eijv15i14a221
885. Astin F, Stephenson J, Probyn J, Holt J, Marshall K, Conway D. Cardiologists’ and pa -
tients’ views about the informed consent process and their understanding of the an -
ticipated treatment benefits of coronary angioplasty: a survey study. Eur J Cardiovasc 
Nurs 2020;
19:260–268. https://doi.org/10.1177/1474515119879050
886. Flynn D, Knoedler MA, Hess EP, Murad MH, Erwin PJ, Montori VM, et al. Engaging pa -
tients in health care decisions in the emergency department through shared decision- making: a systematic review. Acad Emerg Med 2012;
19:959–967. https://doi.org/10. 
1111/j.1553-2712.2012.01414.x887. Grant EV, Summapund J, Matlock DD, Vaughan Dickson V, Iqbal S, Patel S, et al. Patient 
and cardiologist perspectives on shared decision making in the treatment of older 
adults hospitalized for acute myocardial infarction. Med Decis Making 2020;
40: 
279–288. https://doi.org/10.1177/0272989x20912293
888. Shah P, Thornton I, Turrin D, Hipskind JE. Informed consent. In: StatPearls. Treasure 
Island (FL): StatPearls Publishing, Copyright © 2022, StatPearls Publishing LLC, 2022.
889. Prochnow JA, Meiers SJ, Scheckel MM. Improving patient and caregiver new medica -
tion education using an innovative teach-back toolkit. J Nurs Care Qual 2019;
34: 
101–106. https://doi.org/10.1097/ncq.0000000000000342
890. Klingbeil C, Gibson C. The Teach Back Project: a system-wide evidence based practice implementation. J Pediatr Nurs 2018;
42:81–85. https://doi.org/10.1016/j.pedn.2018.06. 
002
891. Ha Dinh TT, Bonner A, Clark R, Ramsbotham J, Hines S. The effectiveness of the teach- 
back method on adherence and self-management in health education for people with 
chronic disease: a systematic review. JBI Database System Rev Implement Rep 2016;14: 
210–247. https://doi.org/10.11124/jbisrir-2016-2296
892. Dickert NW, Scicluna VM, Adeoye O, Angiolillo DJ, Blankenship JC, Devireddy CM, 
et al. Emergency consent: patients’ and surrogates’ perspectives on consent for clinical 
trials in acute stroke and myocardial infarction. J Am Heart Assoc 2019;8:e010905. 
https://doi.org/10.1161/jaha.118.010905
893. Dickert NW, Miller FG. Involving patients in enrolment decisions for acute myocardial 
infarction trials. BMJ 2015;351:h3791. https://doi.org/10.1136/bmj.h3791
894. Olsson A, Ring C, Josefsson J, Eriksson A, Rylance R, Fröbert O, et al. Patient experi -
ence of the informed consent process during acute myocardial infarction: a sub-study 
of the VALIDATE-SWEDEHEART trial. Trials 2020;
21:246. https://doi.org/10.1186/ 
s13063-020-4147-0
895. El-Haddad C, Hegazi I, Hu W. Understanding patient expectations of health care: a 
qualitative study. J Patient Exp 2020;
7:1724–1731. https://doi.org/10.1177/ 
2374373520921692
896. Scott JT, Thompson DR. Assessing the information needs of post-myocardial infarc -
tion patients: a systematic review. Patient Educ Couns 2003;
50:167–177. https://doi. 
org/10.1016/s0738-3991(02)00126-x
897. Saczynski JS, McManus DD, Waring ME, Lessard D, Anatchkova MD, Gurwitz JH, et al. 
Change in cognitive function in the month after hospitalization for acute coronary syn -
dromes: findings from TRACE-CORE (Transition, Risks, and Actions in Coronary Events-Center for Outcomes Research and Education). Circ Cardiovasc Qual 
Outcomes 2017;
10:e001669. https://doi.org/10.1161/circoutcomes.115.001669
898. Goldman JD, Harte FM. Transition of care to prevent recurrence after acute coronary 
syndrome: the critical role of the primary care provider and pharmacist. Postgrad Med 
2020;
132:426–432. https://doi.org/10.1080/00325481.2020.1740512
899. Huriani E. Myocardial infarction patients’ learning needs: perceptions of patients, family 
members and nurses. Int J Nurs Sci 2019;6:294–299. https://doi.org/10.1016/j.ijnss. 
2019.05.001
900. Messerli AW, Deutsch C. Implementation of institutional discharge protocols and 
transition of care following acute coronary syndrome. Cardiovasc Revasc Med 2020; 
21:1180–1188. https://doi.org/10.1016/j.carrev.2020.02.013
901. Schiele F, Lemesle G, Angoulvant D, Krempf M, Kownator S, Cheggour S, et al. 
Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. Eur Heart J Acute Cardiovasc Care 2020;9:788–801. https://doi.org/10. 
1177/2048872619844444
902.
Murphy B, Le Grande M, Alvarenga M, Worcester M, Jackson A. Anxiety and depres -
sion after a cardiac event: prevalence and predictors. Front Psychol 2019;
10:3010. 
https://doi.org/10.3389/fpsyg.2019.03010
903. Ceccarini M, Manzoni GM, Castelnuovo G. Assessing depression in cardiac patients: what measures should be considered? Depress Res Treat 2014;
2014:148256. https:// 
doi.org/10.1155/2014/148256
904. Moser DK. “The rust of life”: impact of anxiety on cardiac patients. Am J Crit Care 2007; 
16:361–369. https://doi.org/10.4037/ajcc2007.16.4.361
905. Turgeon RD, Koshman SL, Dong Y, Graham MM. P2Y12 inhibitor adherence trajec -
tories in patients with acute coronary syndrome undergoing percutaneous coronary 
intervention: prognostic implications. Eur Heart J 2022;
43:2303–2313. https://doi. 
org/10.1093/eurheartj/ehac116
906. Poitras ME, Maltais ME, Bestard-Denommé L, Stewart M, Fortin M. What are the ef -
fective elements in patient-centered and multimorbidity care? A scoping review. BMC 
Health Serv Res 2018;
18:446. https://doi.org/10.1186/s12913-018-3213-8
907. Hochhalter AK, Song J, Rush J, Sklar L, Stevens A. Making the Most of Your Healthcare 
intervention for older adults with multiple chronic illnesses. Patient Educ Couns 2010; 
81
:207–213. https://doi.org/10.1016/j.pec.2010.01.018
908. Hess EP, Knoedler MA, Shah ND, Kline JA, Breslin M, Branda ME, et al. The chest pain 
choice decision aid: a randomized trial. Circ Cardiovasc Qual Outcomes 2012;5:251–259. 
https://doi.org/10.1161/circoutcomes.111.964791
909. Hess EP, Hollander JE, Schaffer JT, Kline JA, Torres CA, Diercks DB, et al. Shared de -
cision making in patients with low risk chest pain: prospective randomized pragmatic 
trial. BMJ 2016;
355:i6165. https://doi.org/10.1136/bmj.i6165
910. van Oosterhout REM, de Boer AR, Maas A, Rutten FH, Bots ML, Peters SAE. Sex dif -
ferences in symptom presentation in acute coronary syndromes: a systematic review ESC Guidelines                                                                                                                                                                                          3825Downloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

and meta-analysis. J Am Heart Assoc 2020;9:e014733. https://doi.org/10.1161/jaha.119. 
014733
911. Hedegaard U, Kjeldsen LJ, Pottegård A, Henriksen JE, Lambrechtsen J, Hangaard J, et al. 
Improving medication adherence in patients with hypertension: a randomized trial. Am 
J Med 2015;128:1351–1361. https://doi.org/10.1016/j.amjmed.2015.08.011
912. Bauer LK, Caro MA, Beach SR, Mastromauro CA, Lenihan E, Januzzi JL, et al. Effects of 
depression and anxiety improvement on adherence to medication and health beha -
viors in recently hospitalized cardiac patients. Am J Cardiol 2012;
109:1266–1271. 
https://doi.org/10.1016/j.amjcard.2011.12.017
913. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. 
Depression and the risk for cardiovascular diseases: systematic review and meta ana -
lysis. Int J Geriatr Psychiatry 2007;
22:613–626. https://doi.org/10.1002/gps.1723
914. Redfors B, Angerås O, Råmunddal T, Petursson P, Haraldsson I, Dworeck C, et al. 
Trends in gender differences in cardiac care and outcome after acute myocardial in -
farction in Western Sweden: a report from the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to 
Recommended Therapies (SWEDEHEART). J Am Heart Assoc 2015;
4:e001995. 
https://doi.org/10.1161/jaha.115.001995
915. Anand SS, Xie CC, Mehta S, Franzosi MG, Joyner C, Chrolavicius S, et al. Differences in 
the management and prognosis of women and men who suffer from acute coronary 
syndromes. J Am Coll Cardiol 2005;
46:1845–1851. https://doi.org/10.1016/j.jacc.2005. 
05.091
916. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al. 
Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute 
coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk 
Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early 
Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005;45: 
832–837. https://doi.org/10.1016/j.jacc.2004.11.055
917.
Bugiardini R, Yan AT, Yan RT, Fitchett D, Langer A, Manfrini O, et al. Factors influen -
cing underutilization of evidence-based therapies in women. Eur Heart J 2011;
32: 
1337–1344. https://doi.org/10.1093/eurheartj/ehr027
918. Samayoa L, Grace SL, Gravely S, Scott LB, Marzolini S, Colella TJF. Sex differences in 
cardiac rehabilitation enrollment: a meta-analysis. Can J Cardiol 2014;
30:793–800. 
https://doi.org/10.1016/j.cjca.2013.11.007
919. Rossello X, Mas-Lladó C, Pocock S, Vicent L, van de Werf F, Chin CT, et al. Sex differ -
ences in mortality after an acute coronary syndrome increase with lower country 
wealth and higher income inequality. Rev Esp Cardiol (Engl Ed) 2022;
75:392–400. 
https://doi.org/10.1016/j.rec.2021.05.006
920. Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, 
elderly patients, and racial minorities in the randomized trials used for cardiovascular 
guidelines. JAMA Internal Medicine 2014;
174:1868–1870. https://doi.org/10.1001/ 
jamainternmed.2014.4758
921. Cho L, Vest AR, O’Donoghue ML, Ogunniyi MO, Sarma AA, Denby KJ, et al. Increasing 
participation of women in cardiovascular trials. J Am College Cardiol 2021;78:737–751. 
https://doi.org/10.1016/j.jacc.2021.06.022
922. Gong IY, Tan NS, Ali SH, Lebovic G, Mamdani M, Goodman SG, et al. Temporal trends 
of women enrollment in major cardiovascular randomized clinical trials. Can J Cardiol 
2019;35:653–660. https://doi.org/10.1016/j.cjca.2019.01.010
923. Rossello X, Ferreira JP, Caimari F, Lamiral Z, Sharma A, Mehta C, et al. Influence of sex, 
age and race on coronary and heart failure events in patients with diabetes and post- acute coronary syndrome. Clin Res Cardiol 2021;110:1612–1624. https://doi.org/10. 
1007/s00392-021-01859-2924.
Mas-Llado C, González-Del-Hoyo M, Siquier-Padilla J, Blaya-Peña L, Coughlan JJ, García 
de la Villa B, et al. Representativeness in randomised clinical trials supporting acute cor -
onary syndrome guidelines. Eur Heart J Qual Care Clin Outcomes 2023. https://doi.org/ 
10.1093/ehjqcco/qcad007
925. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European Society of 
Cardiology methodology for the development of quality indicators for the quantifica -
tion of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes 2022;
8: 
4–13. https://doi.org/10.1093/ehjqcco/qcaa069
926. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the United 
Kingdom after removal of financial incentives. N Engl J Med 2018;
379:948–957. https:// 
doi.org/10.1056/NEJMsa1801495
927. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality 8 years into global payment. N Engl J Med 2019;381:252–263. https://doi.org/10.1056/ 
NEJMsa1813621
928. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indicators 
for the care and outcomes of adults with atrial fibrillation. Europace 2021;23:494–495. 
https://doi.org/10.1093/europace/euaa253
929. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, et al. 2020 Update of the 
quality indicators for acute myocardial infarction: a position paper of the Association 
for Acute Cardiovascular Care: the study group for quality indicators from the ACVC 
and the NSTE-ACS guideline group. Eur Heart J Acute Cardiovasc Care 2021;10: 
224–233. https://doi.org/10.1093/ehjacc/zuaa037
930.
Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomström-Lundqvist C, et al. 
European Society of Cardiology Quality Indicators for the care and outcomes of car -
diac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society 
of Cardiology. Europace 2022;
24:165–172. https://doi.org/10.1093/europace/euab193
931. Aktaa S, Gencer B, Arbelo E, Davos CH, Désormais I, Hollander M, et al. European 
Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: devel -
oped by the Working Group for Cardiovascular Disease Prevention Quality Indicators 
in collaboration with the European Association for Preventive Cardiology of the 
European Society of Cardiology. Eur J Prev Cardiol 2022;
29:1060–1071. https://doi. 
org/10.1093/eurjpc/zwab160
932. Schiele F, Gale CP, Simon T, Fox KAA, Bueno H, Lettino M, et al. The 2020 ESC-ACVC 
quality indicators for the management of acute myocardial infarction applied to the 
FAST-MI registries. Eur Heart J Acute Cardiovasc Care 2021;
10:207–215. https://doi. 
org/10.1093/ehjacc/zuab010
933. Rossello X, Medina J, Pocock S, Van de Werf F, Chin CT, Danchin N, et al. Assessment 
of quality indicators for acute myocardial infarction management in 28 countries and 
use of composite quality indicators for benchmarking. Eur Heart J Acute Cardiovasc Care 
2020;9:911–922. https://doi.org/10.1177/2048872620911853
934. Rossello X, Massó-van Roessel A, Perelló-Bordoy A, Mas-Lladó C, Ramis-Barceló MF, 
Vives-Borrás M, et al. Assessment of the ESC quality indicators in patients with acute 
myocardial infarction: a systematic review. Eur Heart J Acute Cardiovasc Care 2021;10: 
878–889. https://doi.org/10.1093/ehjacc/zuab042
935. Batra G, Aktaa S, Wallentin L, Maggioni AP, Wilkinson C, Casadei B, et al. Methodology 
for the development of international clinical data standards for common cardiovascu -
lar conditions: European Unified Registries for Heart Care Evaluation and Randomised 
Trials (EuroHeart). Eur Heart J Qual Care Clin Outcomes 2021;
9:161–168. https://doi. 
org/10.1093/ehjqcco/qcab052
936. Rossello X, Massó-van Roessel A, Chioncel O, Tavazzi L, Ferrari R, Vahanian A, et al. 
EURObservational Research Programme: a bibliometric assessment of its scientific 
output. Eur Heart J Qual Care Clin Outcomes 2022;
8:804–811. https://doi.org/10. 
1093/ehjqcco/qcac0413826                                                                                                                                                                                          ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 04 February 2025

Elämäntapaohjaus - Hoito- ja palveluketjut - pirha.fi.pdf
Elämänt apaohjaus
Sydänystävällinen ra vitsemus
Sydänystävällinen ruoka valio edist ää kunt outumist a, parant aa lääk ehoidon v astetta sekä hidast aa ja saatt aa jop a
ehkäist ä taudin et enemist ä. Se m yös v aikutt aa positiivisesti sepel valtimot audin t aust alla ole viin v eren rasv a-
aineen vaihdunnan häir iöön, k ohonneeseen v erenpaineeseen ja sok eriaineen vaihdunnan poikk eavuuksiin.
Sydänystävällinen ruoka valio on oleellinen osa sepel valtimot audin omahoit oa myös p allolaajennuksen t ai
ohitusleikkauksen jälk een.
Sydänystävällinen ruoka valio k oostuu kaikille suosit eltavasta ja monipuolisest a ruo asta.  Ruokak olmion (Sydänliitt o,
pdf) a vulla v oi hahmott aa, mist ä sy dänystävällinen ja monipuolinen ruoka valio k oostuu. H yvä pohja
sydänystävälliseen ruoka valioon muodostuu kasviksist a, hedelmist ä ja mar joist a sekä k okojyv ävilja-v almist eista.
Kolmion huipulla ole via ruokia tulisi sy ödä har voin ja har kiten, ne sisäl tävät runsaasti sy dänt erveyden kannal ta
epäedullisia k ovia rasv oja, suolaa ja sok eria.
R a v i nno n m e r k i t y s e nn e n  l e i k k a u st a  j a  l e i k k a u k se st a  t o i p u e ssa
Vajaara vitsemustila lisää leikkausk omplikaatioiden r iskiä ja hidast aa toipumist a. Mikäli ra vitsemustilasi on heik entynyt
ja/ tai sinulla on haast eita riittävän ra vitsemuksen t oteuttamisessa ennen leikkaust a, asiast a tulee k eskust ella
hoitohenkilökunnan kanssa.  R avinnont arve kasv aa suur en leikkauksen jälk een. Leikkauksest a toipuv a tarvitsee
riittävästi ener giaa ja muit a ravintoaineit a, jott a leikkaushaa vat ja muut kudokset p arane vat. 
Leikkauksen jälk een sairaala ymp äristö, vuodelepo, mahdollinen huono vointisuus ja kipu v oivat aiheutt aa
ruokahalutt omuutt a ja ummetust a. Osast ohoidossa on useit a eri mahdollisuuksia t ehost aa ra vinnonsaantia ja hoit aa
ummetust a. Ot a rohkeasti asia esiin hoit ohenkilökunnan kanssa. 
Ennen leikkaust a ja k otiutumisen jälk een on t ärkeää huolehtia, ett ä ruoka valio tuk ee h yvää ra vitsemustilaa ennen
leikkaust a ja kunt outumist a sen jälk een. Riitt ävän ra vinnonsaannin kannal ta on suosit eltavaa: 
Syödä säännöllisesti ja usein (2–3 tunnin v älein), 4–6 k ertaa p äivässä 
Pitää il tapalan ja aamup alan v äli enint ään 10–11 tunnin mitt aisena 
Syödä jokaisella at erialla ja v älipalalla jot akin pr oteiinia sisäl tävää. K iinnit ä erityisesti huomiot a aamu - ja il tapalan
sekä v älipalojen pr oteiininläht eisiin 
Hyviä pr oteiinin läht eitä ovat mait otuott eet (mait o, piimä, jogur tti, viili, rahka, mait opohjaiset jälkiruo at, pir telöt,
jäätelö, er ilaiset juust ot), soijatuott eet ( juoma, soijapohjaiset v aihtoehdot jogur tille, rahkalle ja v anukkaille, t ofu),
kananmuna, liha, kala, br oiler i, kasvipr oteiiniv almist eet, p ähkinät. 
Mikäli ruokahalusi on heik entynyt ja ruokamäärät jää vät vähäisiksi, ener giansaantia v oi tehost aa rasv ankä yttöä
lisäämällä, sillä rasv a lisää t ehokkaasti ruokien ener giatihe yttä: 
Leipien p äälle r eilu k erros kasvirasv alevitettä, jossa on rasv aa v ähint ään 60 %  
Öljyä kasvist en joukk oon, öljypohjaist a salaatinkastik etta salaattiin, juokse vaa mar gariinia k eittoihin ja puur oihin 
Kasvirasv avalmist eita (kasvirasv apohjaiset k ermat) ruo anvalmistuksessa 
Siement en, p ähkinöiden, mant elijauheen, maap ähkinä voin, a vokadon ja majoneesin h yödyntäminen. 
Apteekist a ost ettavien t äydenn ysra vintovalmist eiden kä yttö on suosit eltavaa, jos ruokahalu on huono ja/t ai paino
laskee tahatt omasti. 
Painonhallinnan tuki
Sydänt erveyteen on mahdollist a vaikutt aa tekemällä h yviä v alint oja ja sy ömällä sopivia määr iä kulutukseen nähden.
Jo mal tillinenkin p ainonpudotus autt aa y lipainoist a vaikutt amaan useisiin r iskit ekijöihin ja t ekee liikkumist a4.3.2025 klo 17.17 Elämäntapaohjaus - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/elamantapaohjaus 2/5
helpommaksi.    
Ylipaino on y ksi sepel valtimot audin r iskit ekijä. 
Tavoitteena on BMI alle 25k g/m2. Ylip ainoisilla, sekä liha villa p ainon pudott aminen p ysyv ästi 5-10%. 
Ylipainon hoit ona t ärkeässä osassa on sy dänt erveellinen ruoka valio ja liikunt a. 
Tavoitteiden saa vuttamisen apuna v oivat olla ra vitsemusasiantuntijat, sekä liikkumisen ammattilaiset.
Suunt erveys
Hamp aiden kiinnit yskudost en tulehdus, p arodontiitti on r iskit ekijä sepel valtimoit a aht auttavan at eroomaplakin
muodostumiselle, v erisuont en tukk eutumiselle ja läpp ätulehduksille.
Suun ja hamp aiden säännöllinen hoit o ehkäisee suun tulehduksia. Suun ja hamp aiden t arkastuksessa on h yvä kä ydä
säännöllisesti v ähint ään k erran vuodessa. Huolehdi h yvästä suuh ygieniast a: har jaa hamp aat 2x/vr k, puhdist a
hammasv älit p äivitt äin ja har jaa kieli t arvittaessa. 
Huomioi, ett ä osa sepel valtimot autilääkit yksist ä voi aiheutt aa m yös suuv aikutuksia.
Päiht eettömyyden tuki 
T u p a k o i nt i
Tupakointi on y ksi t ärkeimmist ä sepel valtimot audin hoidett avista riskit ekijöist ä ja sen vuoksi tup akoinnin lopett aminen
on er ittäin t ärkeää sy dänpotilaalle.
Sepel valtimot audin r iski puolittuu vuodessa ja p arinkymmenen vuoden tup akoimatt omuus pienent ää riskin lähes
samalle t asolle kuin niillä, jotka eiv ät ole k oskaan tup akoineet.
Jokaisen sepel valtimot autia sairast avan tup akoijan tulee saada r iittävä vier oitushoit o. Vier oitus tulee kä ynnist ää
sairaalahoidon aikana ja vier oituksen tuen tulee jatkua sairaalast a kotiutumisen jälk een.
Nikotiinivier oitukseen kä ytetyt tuott eet o vat tur vallisia sepel valtimot autia sairast avilla.
Pirkanmaan tup akast a ja nik otiinist a vier oituksen t oimint amalli
Tupakast a vier oituksen neuv ontakortti
A l k o h o l i
Alkoholin kä yttöön sy dänsairauksien y hteydessä liitt yy riskejä, jotka saatt avat pahent aa sy dänoir eita. Jos alk oholia
käyttää, määrän tulee p ysyä kohtuurajoissa.
Alkoholin v aikutukset sepel valtimot autipotilaalla:
Nost aa v erenpainett a ja v ähent ää v erenpainelääkit yksen v aikutust a
Vähent ää sy dämen supistumisv oimaa ja v oi aiheutt aa sy dämen v ajaat oimint aa
Lisää sy dämen r ytmihäir iöitä
Hämär tää muistia, jolloin lääkk eiden ott aminen v oi jäädä v äliin t ai niit ä voidaan ott aa liian usein
Voi voimist aa tai heik entää lääkk eiden ime ytymist ä
Altistaa tapaturmille ja jos on kä ytössä v eren h yytymiseen v aikutt avia lääkk eitä, kehon sisäist en v erenvuor ojen r iski
lisäänt yy
Krapulassa r ytmihäir iön käänt äminen t akaisin nor maaliin sinusr ytmiin on hankalamp aa
Alkoholissa on lisäksi runsaasti kalor eita, lähes y htä paljon kuin rasv assa. Runsas kä yttö lihott aa ja v aikutt aa v eren
sokeritasap ainoon
Seksuaalineuv onta
Seksuaalisuus on osa ihmisyy ttä ja sillä on er ilaisia mer kityksiä ja ilmenemismuot oja er i elämäntilant eissa.
Sairastumisen k ohdat essa elimist ö saatt aa v aatia aikaa t oipuakseen. Seksielämä aktiv oituu y leensä luonnost aan, kun
vointi helpottuu ja t oipuminen et enee sekä y leinen fyysinen suor itusky ky p aranee. F yysisenä rasituksena y hdyntää v oi4.3.2025 klo 17.17 Elämäntapaohjaus - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/elamantapaohjaus 3/5
turvallisesti k okeilla, kun kahden por rasv älin kulk eminen onnistuu. 
Mahdollinen seksuaalinen halutt omuus on sairastumisen y hteydessä mahdollist a. Kunnon k ohentuessa tilanne y leensä
normalisoituu, mutt a jos seksuaalisuut een liitt yy haast eita, niin hae apua esim. seksuaalit erapeutin v astaanot olta
(seksuaalineuv onta@sy dansairaala.fi). Er ektiolääkk eiden kä ytöstä ohjaa potilas k eskust elemaan lääkär in kanssa.
Mikäli on t ehty ohitusleikkaus: Rint akehän kuor mitust a tulee v älttää kahden kuukauden ajan leikkauksest a, jolloin jotkin
yhdyntäasennot saatt avat olla liian kuor mittavia. Leikkauksen jälk een elimist ö vaatii aikaa t oipuakseen, mutt a intiimi
läheisyys ja k osketus on sallittua.
 
Edellinen
Sairaanhoit ajan ohjausSeur aa v a
Sepel valtimot autipotilaan sosiaalitur va
H y ö d y l l i si ä  l i nk k e j ä
R a v i t se m u s
R a vit semust er apia
Sy dänmer kki 
K olest er oli ja ruoka  (Sydänliitt o)
Suolankä y t t ö (Sydänliitt o)
Sy dän ja ruoka -suositus  (Sydänliitt o)
Sepel v al timot auti ja ruoka  (Sydänliitt o)
Sy dänsair aus ja ruoka v alio (Terveysky lä)
Ruoka & R a vit semus (Sydänliitt o)
P a i no nh a l l i nna n t u k i  j a  l i i k u n t a
Liha vuuden Kä yp ä hoit o -suositus 
P ainonhallint at alo (Terveysky lä)
P ainonhallint apolku (Terveysky lä)
Liikunt a sepel v al timot audin hoidossa  (Terveysky lä)
Liikunt a vinkit (Sydänliitt o)
Sair astuneen liikunt a (Sydänliitt o)
T est aa liikunt at ot tumuksesi  (Sydänliitt o)
S u u n t e r v e y s
Suun hoit o sy dän- ja v er isuonisair auksissa  (Terveyskir jasto)
Lääkk eiden v aikutukset suun t er v e y t een (Terveyskir jasto)
P ar odontiitin y ht e ys sy dän- ja v er isuonisair auksiin  (Terveyskir jasto)
P ä i h t e e t t ö m y y de n t u k i
T up akka- ja nik otiinir iippuvuuden ehkäisy ja hoit o (Käypä hoit o -suositus)
T up ak oinnin lopet t aminen  (Terveyskir jasto)
T up ak oinnin t är k eimmät tunnetut t er v e yshait at (Terveyskir jasto)
T up akka (THL)
Sy dänsair aus ja tup akka (Terveysky lä)
Sa vut on ja nik otiinit on elämä  (Hengit ysliitt o)
 
T up ak ointi ja alk oholi (Sydänsairaala)
Alk oholi ja t er v e ys (Terveyskir jasto)
Sy dänsair aus ja alk oholi (Terveysky lä)
Alk oholi (THL)4.3.2025 klo 17.17 Elämäntapaohjaus - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/elamantapaohjaus 4/5
Hyvä ja mielekäs arki - Sydänsairaala.pdf
Etusivu (https://www.sydansairaala.fi)➝Tietoa (https://www.sydansairaala.fi/tietoa/)➝Hyvä ja mielekäs arki
Hyvä ja mielekäs arki
Sepelvaltimotaudista huolimatta voit tehdä samoja asioita kuin ennenkin,
sydämesi huomioon ottaen. Muista nauttia elämästä: sairaudesta ei
tarvitse tulla arkea tai harrastuksia rajoittava tekijä.
Uni ja lepo
Säännöllinen unirytmi ja riittävä unen määrä ovat tärkeitä terveyden ja
hyvinvoinnin kannalta. Hyvä uni palauttaa elimistöä päivän rasituksista,
edistää oppimista ja muistamista. Kiinnitä huomiota siis riittävään lepoon ja
palautumiseen.
Sydän.fi: Riittavästi unta ja lepoa (https://sydan.fi/fakta/riittavasti-unta-ja-
lepoa/)
Seksu aa li suus ja seksi
Seksuaalisuus kuuluu niin yksin eläjille kuin parisuhteessa oleville.
Parhaimmillaan seksuaalisuus on meille voimavara.
Seksuaalisuus on osa ihmisen persoonallisuuta ja se ei katoa
sairastumisen tai ikääntymisen myötä, mutta voi muuttaa merkitystään.
Seksuaaliseen aktiivisuuteen liittyvä rasitus on turvallista, jos pystyt
nousemaan kaksi kerrosta portaita ilman hengenahdistusta tai rintakipua ja
itsestä tuntuu, että olet valmis seksiin.
Sepelvaltimotauti itsessään tai siihen käytetty lääkehoito voivat aiheuttaa
seksuaalitoiminnan häiriötä sekä miehille että naisille. Nämä voivat esiintyä
muun muassa seksuaalisena haluttomuutena, erektiohäiriönä tai
limakalvojen kuivuutena. Näistä seksuaalisuuteen liittyvistä asioista on lupa
kysyä ja puhua. Sydänsairaalan henkilökunta vastaa mielellään mieltä
askarruttaviin kysymyksiin ja järjestää sinulle halutetessasi ajan
seksuaalineuvojan vastaanotolle. Seksuaalineuvojan kanssa on
mahdollisuus keskustella yksin tai voit ottaa kumppanin mukaan.Aihee seen liit tyvää
Sydänsairaus ja sujuva arki (linkki
Terveyskylän sivulle) ➝
(https://www.terveyskyla.fi/sydansairaudet/itsehoit
ja-sujuva-arki)
Unettomuuden omahoito (linkki Terveyskylän
sivulle) ➝
(https://www.mielenterveystalo.fi/aikuiset/itsehoito
ja-
oppaat/itsehoito/unettomuuden_omahoito/Pages/d
Sydänsairaus ja seksi (linkki Terveyskylän
sivulle) ➝
(https://www.terveyskyla.fi/sydansairaudet/itsehoit
ja-seksi)
Sydän ja seksi (linkki Sydänliiton sivulle) ➝
(https://sydan.fi/fakta/sydan-ja-seksi/)
Suu kuntoon (linkki Sydänliiton sivulle) ➝
(https://sydan.fi/suu-kuntoon/)
Sydänsairaus ja mieliala (linkki Terveyskylän
sivulle) ➝
(https://www.terveyskyla.fi/sydansairaudet/itsehoit
ja-mieliala)
Sydänsairaudet ja matkustaminen (linkki
Sydänliiton sivulle) ➝
(https://sydan.fi/fakta/sydansairaudet-ja-
matkustaminen/)
Sepelvaltimotaudin omahoito ➝
(https://www.sydansairaala.fi/tietoa/omahoito/)
Sydän ja suun terveys -tietotesti (linkki
Sydänliiton sivulle) 
(https://sydan.fi/fakta/sydan-ja-suun-
terveys-tietotesti/)
Työkaluja mielen hyvinvointiin (linkki
Terveyskylän sivulle) 
(https://www.mielenterveystalo.fi/aikuiset/itseh
ja-
oppaat/itsehoito/tyokaluja_itsehoito/Pages/defau
Jaa sivu:➝
➝(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Seksuaalineuvoja on kouluttautunut seksologian erikoiskoulutuksessa.
Koulutuksen myötä hän osaa kohdata erilaisia seksuaalisuuteen liittyviä
kysymyksiä ja antaa tietoa sydänsairauden ja siihen liittyvien hoitojen
vaikutuksista seksuaalisuuteen.
Voit ottaa yhteyttä myös puhelimitse p. 03 311 69239 ja 03 311 66165 tai
lähettää sähköpostia osoitteeseen seksuaalineuvonta@sydansairaala.fi.
Sauno minen
Saunomista pidetään rentouttavana ja terveellisenä. Kohtuullinen
saunominen sopii hyvin sydänpotilaalle, se parantaa verenkiertoa, alentaa
verenpainetta ja laajentaa verisuonia.
Ota löylyt maltillisest, saunan sopiva lämpötila on 60-80 astetta. Älä ota
saunaan mennessäsi nitroa, poista kaikki lääkelaastarit saunomisen ajaksi
ja ota verenpainelääkkeesi vasta saunomisen jälkeen. Kuuntele kehoasi ja
sauno vointisi mukaan.
Suun terveys
Suun terveydestä huolehtiminen kuuluu tärkeänä osana sepelvaltimotaudin
omahoitoon. Hoitamattomissa hampaissa ja ikenissä saattaa piillä
tulehdus, joka lisää sydäninfarktin ja läppätulehduksen vaaraa.
Sydän.fi: Hyvä suun terveys on osa sydänterveyden edistämistä
(https://sydan.fi/fakta/hyva-suun-terveys-on-osa-sydanterveyden-
edistamista/)
Hammaslääkärissä on suositeltavaa käydä vuoden välein. Tämä koskee
myös tilanteita, mikäli sinulla on hammasproteesi tai -implantti. Hampaiden
harjaaminen aamuin illoin sekä hammasvälien puhdistaminen ovat osa
päivittäistä suun hoitoa.
Mieliala
Sairastuminen on usein yllättävä ja vaikea asia. Se voi herättää monenlaisia
tunteita kuten vihaa, surua, turvattomuutta ja pelkoja. Nämä tunteet ovat
luonnollisia ja normaaleja mielen reaktioita muuttuneen tilanteen takia. Älä
kuitenkaan epäröi hakea ammattiapua tai vertaisryhmän tukea, jos koet
tilanteen ylivoimaisena eivätkä omat voimavarasi enää riitä tilanteen
hallitsemiseen. Ammattiapua voi hakea esimerkiksi oman
terveyskeskuksen kautta.
Sydän.fi: Vertaistuki (https://sydan.fi/fakta/vertaistuki/)
Autolla ajaminen ja lento mat kus ta minen
Vakaassa vaiheessa oleva sepelvaltimotauti ei ole este matkustamiselle.
Suunnittele matkakohteesi ja matkustustapasi huolellisesti etukäteen ja
keskustele tarvitaessa lääkärisi kanssa asiasta.
Sepelvaltimotaudilla tai sairastetulla sydäninfarktilla voi olla vaikutusta
autolla ajamiseen, yleensä määräaikaisesti. Lääkäri kertoo aina
mahdollisesta ajokiellosta ennen sairaalasta kotiutumista.
Ammattiautoilijan kohdalla paluu työelämään arvioidaan rasituskokeen ja
lääkärintarkastuksen perusteella.
Lentomatkustaminen on sallittua sepelvaltimotautia sairastaville. Et
kuitenkaan voi lentää, mikäli et pysty kävelemään 50 metriä tai et pysty
nousemaan portaita yhtä kerrosväliä ilman rintakipua tai hengenahdistusta.(http://www.facebook.com/sharer/sharer.php?
u=https://www.sydansairaala.fi/tietoa/hyva-
arki/) (http://twitter.com/share?
url=https://www.sydansairaala.fi/tietoa/hyva-
arki/&text=Hyvä ja mielekäs arki)
(http://www.linkedin.com/shareArticle?
url=https://www.sydansairaala.fi/tietoa/hyva-
arki/&title=Hyvä ja mielekäs
arki&summary=&source=https://www.sydansairaala
arki/) (mailto:?subject=Hyvä ja
mielekäs
arki&body=https://www.sydansairaala.fi/tietoa/hyva
arki/)
Myös tuore sydänsairaus tai juuri tehdyt hoitomuutokset ovat este
lentomatkustamiselle. Varmista lääkäriltäsi ja lentoyhtiöltä onko
lentomatkustaminen sallittua.
Sydän.fi: Sydänsairaudet ja lentomatkustaminen
(https://sydan.fi/fakta/sydansairaudet-ja-lentomatkustaminen/)
Ota matkavakuutus ja tarkista korvausten sisältö tilanteessa, mikäli joudut
matkalla hakeutumaan lääkärin hoitoon pitkäaikaissairauden takia.
(https://www.sydansairaala.fi/)
Usein kysyttyä
(http://www.sydansairaala.fi/tietoa/usein-
kysyttya/)
Anna
palautetta
(https://www.sydansairaala.fi/anna-
palautetta/)Palve lu neu vonta
Tampere 03 311 64145
Arkisin klo 7.30–15
info@sydansairaala.fi
Jos haluat perua ajan tai sinulla
on kysyttävää hoitoosi liittyen, ota
yhteyttä puhelimitse sinua
hoitavaan yksikköön.Yksityisvastaanottojen
ajanvaraus ja tiedustelut
Tampere p. 050 573 6875
ma–to klo 11–18, pe klo 11–15
Jyväskylä p. 041 731 3712
ma–pe klo 10–14
Huom. Matkapuhelinnumeroihin
ei voi lähettää tekstiviestejä.
Varaa aika
(https://sydansairaala.mbooking.fi/ajanvaraus)Sydänsairaala sosiaalisessa
mediassa
Facebook
(https://www.facebook.com/sydansairaala)
Instagram
(https://www.instagram.com/sydansairLinkedIn
(https://fi.linkedin.com/comYouTube
(https://www.yo
(https://www.sydansairaala.fi/ajanko
on-yksi-maailman-parhaista-
sydansairaaloista-myos-2024/)
(https://www.sydansairaala.fi/amma
Yhteys tiedot
Hämeenlinna
Hämeenlinnan
Sydänsairaala
Parantolankatu 6
13530 Hämeenlinna
P. (Vaihde) 03 6291Jyväskylä
Sydänsairaala Nova
Hoitajantie 3
40620 Jyväskylä
P. (Vaihde) 014 269
1811Riihimäki
Riihimäen
Sydänsairaala
Kontiontie 77
11120 Riihimäki
P. (Vaihde) 03 6291Tampere
Tampereen
Sydänsairaala
Elämänaukio 1
33520 Tampere
P. (Vaihde) 03 311
716Valkeakoski
Valkeakosken
Sydänsairaala
Ulvajankatu 20
37600 Valkeakoski
P. (Vaihde) 03 311
611
© 2017 Sydänsairaala - Saavutettavuus (https://www.sydansairaala.fi/saavutettavuus/) - Tietosuojaseloste (https://www.sydansairaala.fi/rekisteriseloste/) - Anna palautetta
(https://www.sydansairaala.fi/anna-palautetta/)

Intravenous Radiocontrast Media_ A Review of Allergic Reactions.pdf
PUBLISHED MAY 22, 2012
Intravenous Radiocontrast Media: A Review of Allergic
Reactions
Manouchehr Saljoughian, PharmD, PhD
Department of Pharmacy
Alta Bates Summit Medical Center
Berkeley, California
US Pharm. 2012;37(5):HS-14-HS-16.
Intravenous radiocontrast, or IV dye, is used for many different diagnostic
procedures to enhance the images in various radiologic studies. Examples of
studies include computed tomography (CT) scans, angiograms, and
pyelograms. These diagnostic procedures are done on a daily basis in
hospital interventional radiology and cardiology departments around the
world. In general, they are used to enhance the visibility of blood vessels.
There are two basic types of contrast media that are used for most radiologic
studies: ionic high-osmolality contrast media and nonionic low-osmolality
contrast media. The latter has become the preferred form of IV dye in recent
years, given its better safety record, especially for women who are
breastfeeding. However, it is far more expensive than high-osmolality
contrast media. Allergy reactions to IV dye are common, can range from mild
to moderate, and can sometimes be life-threatening.
It is believed that people who have an allergy to seafood (shellfish) may show
an allergy to contrast media as well, due to the presence of iodine in both. We
will briefly review the types, applications, and allergy profile of these products
in this article.1
ADVERTISEMENT
1
Types of Radiocontrast Media
Both high-osmolar contrast media (ionic) and low-osmolar contrast media
(nonionic or organic) agents contain iodine and are administered
intravenously. Most intravascular contrast media are derivatives of tri-
iodobenzoic acid. The iodine molecule is an effective x-ray absorber in the
energy range where most clinical systems operate. Iodinated contrast media
are the most efficient products to enhance the visibility of vascular structures
and organs during radiographic procedures. The ionic type creates more
charged particles and causes a high osmolality in blood, which may cause a
potentially life-threatening contrast media reaction in some individuals with
medical conditions. The nonionic agents generate less dissociation and
particles and decrease this risk, but are much more expensive. The nonionic
contrast media are much more widely used today. The iodine concentration
of contrast media is determined by the number of iodine molecules in
milligrams present in a milliliter of a solution (mg/mL).
Concentration of any contrast media agent determines how radiopaque the
agent will be. The higher the iodine concentration, the better the chance that
more x-ray photons will be absorbed. Therefore, that particular contrast agent
may be more radiopaque than a comparable low-iodine concentrated agent.
The osmolality of a solution is the measurement of the number of molecules
and particles in a solution per kilogram of water. In other words, osmolality
can be described as a measurement of the number of molecules that can
crowd out or displace water molecules in a kilogram of water. The
radiographic significance of the osmolality value of contrast media is that it
is higher than the osmolality value of blood plasma. Any solution that has an
osmolality value greater than blood plasma is said to be a hyperosmolar
solution. Therefore, ionic and nonionic contrast media are hyperosmolar
solutions when compared to blood plasma.
Since certain radiographic procedures, such as myelography, cannot use
ionic contrast media, the discovery of nonionic contrast media in 1974 (e.g.,
metrizamide) revolutionized these procedures.
Contrast Media Applications
Examples of currently used ionic and nonionic contrast media are perflutren-
protein type-A microspheres injection (Optison), iohexol injection
(Omnipaque), and nonionic iodixanol injection (Visipaque).2
2
Optison is used in patients with suboptimal echocardiograms to opacify the
left ventricle and to improve the delineation of the left ventricular endocardial
borders.
Omnipaque is used for angiocardiography; aortography including studies of
the aortic root, aortic arch, ascending aorta, and abdominal aorta and its
branches; contrast enhancement for CT scan of head and body imaging; IV
digital subtraction angiography (DSA) of the head, neck, abdominal, renal, and
peripheral vessels; peripheral arteriography; and excretory urography.
Nonionic or organically bound iodine contrast media such as Visipaque (270
mgI/mL) are used for DSA. Visipaque Injection (320 mgI/mL) is used for
angiocardiography, peripheral arteriography, visceral arteriography, and
cerebral arteriography. Visipaque Injection (270 mgI/mL and 320 mgI/mL) is
indicated for CT of the head and body (excretory urography). Visipaque
Injection (270 mgI/mL) is also indicated for peripheral venography. Another
example of the nonionics is Isovue-300 (iopamidol), which is used to help
diagnosecertain disorders of the heart, brain, blood vessels, and nervous
system.
Dosing and Administration
It is reported that the calculation of contrast media dose and injection rate on
the basis of lean body weight leads to increased patient-to-patient uniformity
of hepatic parenchymal and vascular enhancement. This is likely related to
the greater perfusion of contrast media to solid organs, muscles, and vessels
compared with the highly variable but poorly perfused adipose tissue. As an
example, the volume and injection rate of contrast material administration
based proportionately on a 70-kg man with 25% body fat or a 70-kg woman
with 30% body fat is about 45 g iodine IV at 0.9 g/sec.
The rate or speed of contrast media injections may increase the risk of an
adverse reaction. Also, the viscosity or thickness of the contrast media can
cause resistance to its flow. The viscosity is related to the concentration, the
size of the molecules in a specific contrast agent, and the temperature of the
contrast agent. Contrast media with higher viscosity values should be
injected at a slower rate. Heating the contrast media, usually to body
temperature, reduces viscosity. Iodine concentration, viscosity, temperature
of the contrast media, catheter inner diameter, catheter length, and the
number of catheter holes are all factors that influence contrast media flow.1,3
4
1
Allergies
In most cases, shortly after infusion, iodinated contrast media cause a
warming sensation throughout the body. In certain areas of the body this
feeling is more pronounced. Patients receiving contrast media via IV typically
experience a hot feeling around the throat, and this hot sensation gradually
moves down to the pelvic area.
Reactions to IV dye are observed in 5% to 8% of patients who receive them.
Mild reactions include a feeling of warmth, nausea, and vomiting. Generally,
these symptoms occur only for a short period of time and do not require
treatment. Moderate reactions, including severe vomiting, hives, and swelling,
occur in 1% of patients receiving contrast media and frequently require
treatment. Severe, life-threatening reactions, including anaphylaxis, occur in
0.1% of people receiving contrast media, with an expected death rate of one
person in every 75,000. The most severe reactions, including death, have
been reported to occur at similar rates with both types of contrast media.
Reactions to contrast media are not a true allergy, but rather a pseudoallergy
in nature, meaning that there is no allergic antibody present that causes the
reaction. Rather, contrast media act to directly release histamine and other
chemicals from mast cells. The iodine concentration has an effect on the
severity of an adverse reaction. The higher the iodine concentration, the
greater the risk of an adverse reaction.
Iodinated contrast media are toxic to the kidneys and kidney functions. The
serum creatinine of the patient receiving a dose should be monitored before
the procedure. In addition, the estimated glomerular filtration rate (eGFR)
should be no lower than 30 mL/min in patients receiving iodinated contrast,
and discretion should be used in patients with eGFR less than 45 mL/min.
Following injections with extra fluids is highly recommended.
Numerous studies have shown that although iodine is common in contrast
media, iodine is not the cause of allergic reactions. Certain proteins in
seafood, rather, are the cause of allergy in patients with seafood allergies. It
is noted that true allergic effects are by definition immunoglobulin E–related,
and studies have shown that contrast media cause no such reaction in vivo.
Therefore, contrast media or the iodine is not likely to act as an allergen.
Radiocontrast Media Allergy Diagnosis5
9
1
5
Skin testing and RAST (radioallergosorbent test) have not been helpful in the
diagnosis of contrast media allergy. Small “test” doses are also not helpful,
with reports of severe, life-threatening reactions occurring even at such
amounts. Severe reactions to larger doses of contrast media have been
observed after a person tolerated a small dose of IV dye. Therefore, the
diagnosis of contrast media allergy is made only after symptoms have
occurred. Otherwise, it is only possible to determine that a person is at
increased risk of a reaction to contrast media based on the risk factors
outlined below.
Allergy Prevention and Treatment
As mentioned above, the purpose of using these contrast agents is for
diagnosis, but like any medical procedure in any radiological study, the right
dose or volume of contrast media needs to be determined prior to a
procedure. The total volume or dose is dependent upon several factors:
iodine concentration of the contrast media; type of injectable contrast media
(ionic or nonionic); patient’s body weight, anatomical structures or regions;
speed of the injection; and age or disease process that could increase the
risk of an adverse reaction. The treatment of an acute reaction to contrast
media is no different from any other anaphylactic reaction. Treatment may
include injectable epinephrine and antihistamines, as well as the use of IV
fluids for low blood pressure and shock.
Contrast media reactions can be prevented by a test dose for the intended
contrast or the use of an alternative; the use of nonionic versus ionic media if
applicable; and the use of certain medicines prior to the administration of
contrast media such as prednisone 50 mg orally taken at 13, 7, and 1 hour
prior to procedure, or diphenhydramine (Benadryl) 50 mg orally, IV or
intramuscularly, 1 hour prior to receiving radiocontrast media.
Risk Factors
As mentioned above, people who have seafood allergy are not at risk if they
need to use contrast media. In addition, people with an allergy to topical
iodine cleaners or iodides are also not at increased risk for reactions to
contrast media. Patients who are at higher risk include those with past
reactions to contrast media (up to 44%); those with asthma; those who have
a history of heart and kidney and thyroid (both hypo- and hyperthyroidism)
diseases; those taking beta-blockers or metformin; and females and the
elderly (appear to be at higher risk for severe reactions).6
7
7
8,11
Note: Timely follow-up of serum creatinine levels in patients with diabetes
who are receiving metformin therapy is highly important, and monitoring is
required by pharmacists. Nearly 4% of patients with diabetes mellitus and
normal renal function may develop contrast material–associated neuropathy
with nonionic contrast media. Roughly 8% of patients with diabetes receiving
metformin, whose baseline serum creatinine levels are below 1.5 mg/dL,
develop an increased risk of lactic acidosis requiring metformin therapy to be
withheld for at least 48 hours after administration of IV contrast material. The
FDA currently recommends metformin monitoring in patients who are
undergoing radiologic procedures involving administration of IV contrast
media.
REFERENCES
1. American College of Radiology (ACR) Manual on Contrast Media. 2010. Version 7.
2. Meth MJ, Maibach HI. Current understanding of contrast media reactions and implications for
clinical management. Drug Saf. 2006;29:133-141.
3. Thomson K, Varma D. Safe use of radiographic contrast media. Australian Prescriber. 2010;33:19-22.
www.australianprescriber.com/magazine/33/1/19/22/.
4. Ho LM, Rendon C. Nelson RC, DeLong DM.Determining contrast medium dose and rate on basis of
lean body weight: does this strategy improve patient-to-patient uniformity of hepatic enhancement
during multi–detector row CT?
Radiology. 2007;243,431-437.
5. Boehm I. Seafood allergy and radiocontrast media: are physicians propagating a myth? Am J Med.
2008;121(8):e19.
6. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med.
2006;354:379-385.
7. Tramer MR, von Elm E, Loubeyre P, Hauser C. Pharmacological prevention of serious anaphylactic
reactions due to iodinated contrast media: systematic review. BMJ. 2006;333:675.
8. Canter LM. Anaphylactoid reactions to radiocontrast media. Allergy Asthma Proc. 2005;26:199-203.
9. Brockow K. Contrast media hypersensitivity: scope of the problem. Toxicology. 2005;209:189-192.
10. www.medscape.com/viewarticle/489319_5.
11. Keller DM,
Iodinated contrast media raises risk for thyroid dysfunction.Arch Intern Med. 2012;172:153-159.
To comment on this article, contact rdavidson@uspharamcist.com.
We recommend
Contrast-Induced Nephropathy
Mary Ann E. Zagaria , US Pharmacist , 2008
Risk of Contrast Media in Reduced Kidney Function
Patients Overstated
   By staf f, US Pharmacist , 2020
Industry NewsSingle photon emission computed tomography dual
isotope myocardial perfusion imaging in women with
systemic lupus erythematosus. II. Predictive factors for
perf...
Ian N Bruce , J Rheumatol , 2003
Reducing the Emission of X-Ray Contrast Agents to the
Environment: Decentralized Collection of Urine Bags11
US Pharmacist , 2024
A Review of Infused Allergy Treatments
Debika Kundu , US Pharmacist , 2023
New Drug for Bone Scans Approved
By staf f, US Pharmacist , 2011and Its Acceptance
Jutta Niederste-Hollenberg , GAIA  - Ecological
Perspectives for Science and Society , 2018
Is Structural Damage Evaluation by Traditional
Radiographs Still Relevant in Rheumatoid Arthritis
Clinical Trials?
J Rheumatol , 2014
Dr. Malaviya, et al reply
J Rheumatol , 2010
Topical natural-origin polynucleotides in radiation-
induced skin and mucosal toxicity
Stefania Giudici , Folia Medica , 2022
Powered by
Copyright © 2000 - 2025 Jobson Medical Information LLC unless otherwise noted. All
rights reserved. Reproduction in whole or in part without permission is prohibited.
Jatkohoito osastolla tai sydänvalvonnassa - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p al v eluk et jut  / Sepel v al timot autipotilaan hoit ok et ju  / Sepel v al timot autik oht aus  /
Jat k ohoit o osast olla t ai sy dän v al v onnassa
 Sepel v al timot autipotilaan hoit ok et ju
Sepel v al timot audin diagnostiikka
Sepel v al timot audin hoit o
Sepel v al timot autik oht aus
Sepel v al timot autik oht aus
Sepel v al timok oht auksen r iskinar vio
Sepel v al timok oht auksen ensihoit o (NS TEMI/U AP)
Sepel v al timok oht auksen ensihoit o (S TEMI)
V ar jo ainekuv aus ja r eper fuusiohoit o
Jat k ohoit o osast olla t ai sy dän v al v onnassa
Sepel v al timot audin lääk ehoit o
Sy dän v almennus
Sepel v al timot audin jatk ohoit o ja seurant a



Jatk ohoit o osast olla t ai sy dän v al v onnassa
Vuodelepo p yr it ään minimoimaan
Jatkuv a r y tminseurant a kliinisen tilant een mukaan, S TEMI potilailla aina v ähint ään 2 4hKuuntele4.3.2025 klo 17.24 Jatkohoito osastolla tai sydänvalvonnassa - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotautikohtaus/jatkohoito-osastolla-tai-sydanvalvonnassa 1/3
P otilaan r iskit ekijät kar t oit et aan ja t ehdään sy dämen ul traäänitutkimus
Aloit et aan hoit osuosituksen mukainen lääkit ys sepel v al timot autiin ja t ar vitt aessa sy dämen v ajaat oimint aan
Sepel v al timot autik oht auksen Kä yp ä hoit o -suositukseen 
Sy dämen v ajaat oiminnan Kä yp ä hoit o -suositukseen 
Sepel v al timot autik oht aus - Hoit o ja ohjant a vuodeosast olla
Sepel v al timot audin r iskit ekijöiden hoit o sekä potilaan ohjaaminen, sit outt aminen ja osallist aminen omahoit oon
aloit et aan moniammatillisena y ht eist y önä sairaalajakson alussa ja sit ä jatk et aan k ok o sairaalahoit ojakson ajan ja sen
jälk een.
S a i r a a nh o i t a j a  a nt a a  p o t i l a i l l e  y k si l ö l l i st ä  h o i t o a  j a  o h j a u st a
S e pe l v a l t i m o t a u t i k o h t a u sp o t i l a a n  h o i t o  v u o d e o sa st o l l a
NEWS-pist eit ä seurat aan säännöllisesti 2x/vuor okaudessa t ai use ammin potilaan v oinnin mukaan.
Ry tminseurant aa t ot eut et aan t ar vitt aessa lääkär in ohjeiden mukaan (r y tmihäir iöiden mahdollisuuksien vuoksi)
V er ensok er ia seurat aan niil t ä, joilla on
Tiedossa ole v a diabet es (hoit ot asap aino a ar vioiden y ksilöllisesti)
Uusi sepel v al timot auti, er illisen ohjeen mukaan: Diabet eksen seulont a sepel v al timot autik oht auksen y ht e y dessä
  (T er v e yspor tti, pdf)
Punktiok ohtien seuraaminen, mahdollist en punktiok ohtien k omplikaatioiden vuoksi 
P er if eer isen suoniy ht e y den t ar peellisuuden ar vioiminen / suoniy ht e y den y lläpit äminen.
V oinnin seuraaminen ja t ar vitt aessa v oinnin muut oksien hoit aminen, mm. kivun huomioiminen ja t ar vitt aessa lääkär in
k onsul t oiminen v oinnin muut oksist a
Mobilisointi kun lääkär i on määr itt än y t t älle tur v allisen aloitusajank ohdan, fysiot erapeutti t ap aa potilaan.
Sy däninf ar ktipotilaan fysiot er apia sair aalassa
Lääk ehoidost a huolehtiminen
Ohjaus
Jatk ok ontr ollien ohjaaminen / huolehtiminen
Sy däninf ar ktipotilaan jat k ohoit o vuodeosast olla  (T er v e yspor tti)
S e pe l v a l t i m o t a u t i po t i l a a n o h j a u s sa i r a a l a ssa
Sepel v al timot autipotilaan ohjaus
 
Edellinen
V ar jo ainekuv aus ja r eper fuusiohoit oSeur aa v a
Sepel v al timot audin lääk ehoit o
Päivit ett y 28 . 11.202 44.3.2025 klo 17.24 Jatkohoito osastolla tai sydänvalvonnassa - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotautikohtaus/jatkohoito-osastolla-tai-sydanvalvonnassa 2/3
KSSHP-ei kiireellistä arviota vaativat oireet ja anamneesi.pdf
4.3.2025 klo 17.30 KSSHP
https://www.terveysportti.fi/xmedia/shp/shp01323/Ei_kiireellista_arviota_vaativat_oireet.html 1/1
KSSHP-ennaltaehkäisy ja riskit.pdf
4.3.2025 klo 17.28 KSSHP
https://www.terveysportti.fi/xmedia/shp/shp01323/Ennaltaehkaisy_ja_riskitekijoiden_tunnistaminen.html 1/1
KSSHP.sepelvaltimotautikohtauksen oireet ja tunnistaminen.pdf
Kalsiuminestäjät - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Lääkehoito (https://sydan.fi/elamaa-sairauden-kanssa/laakehoito/)/Kalsiuminestäjät
Kalsiuminestäjät
(https://sydan.fi/fakta/kalsiuminestajat/)
Kalsiuminestäjiä käytetään kohonneen verenpaineen, sepelvaltimotaudin ja
eräiden rytmihäiriöiden hoitoon.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 27.6.2022
 
Lue seuraavaksi Nesteenpoistolääkkeet (diureetit) (https://sydan.fi/fakta/nesteenpoistolaakkeet-diureetit/)
Kalsiuminestäjät eli kalsiumkanavan salpaajat vaikuttavat solujen pintakerroksen
kalsiumkanaviin. Nämä kanavat ovat eräänlaisia portteja, joiden kautta kalsium
kulkee solun sisälle, ja verisuonten seinämien sileän lihaksen supistuminen
käynnistyy. Tapahtuman estäminen lääkkeellä johtaa verisuonen seinämän
rentoutumiseen, ja verisuonet laajenevat. Sydämen työ helpottuu.
Sydämen rytmiin vaikuttavissa soluissa on myös kalsiumkanavia, joiden
salpaaminen hidastaa pulssia ja estää rytmihäiriöitä.
Kalsiuminestäjiä on kaksi pääluokkaa, koska vaikutukset voivat kohdistua
pääasiassa vain verisuoniin, ja lisäksi sydämen sähköiseen toimintaan.
sydämeen ja verisuoniin vaikuttavat (verapamiili ja diltiatseemi)
pelkästään verisuoniin vaikuttavat eli verisuoniselektiiviset
(dihydropyridiinit).
Sydämeen ja verisuoniin vaikuttavat
kalsiuminestäjät
Näitä kalsiuminestäjiä kutsutaan myös sydänvaikutteisiksi. Saatavilla on kaksi
vaihtoehtoa, verapamiili ja diltiatseemi. Niitä käytetään nykyisin pääasiassa
rytmihäiriöiden hoitoon. Tavallisin tilanne on pysyvän eteisvärinän
(https://sydan.fi/fakta/pysyvan-eteisvarinan-hoito/) sykkeen rauhoittaminen,
kun beetasalpaajat (https://sydan.fi/fakta/beetasalpaajat/) eivät sovi tai eivät
ole riittävän tehokkaita. Lääke saattaa olla riittävä myös eteisvärinän estossa,
mutta erityisen hyvin ne toimivat tiettyjen eteistakykardioiden
(https://sydan.fi/fakta/supraventrikulaariset-takykardiat/) estolääkkeinä.
Sydänvaikutteisia kalsiminestäjiä käytetään beetasalpaajien vaihtoehtona myös
oireisen sepelvaltimotaudin hoidossa.
Näitä lääkkeitä ei voi käyttää, jos sydämen pumppausvoima (ejektiofraktio) on
alentunut.
Tavallisin haittavaikutus on ummetus.
Verisuoniselektiiviset kalsiuminestäjät
Verisuoniselektiivisten kalsiuminestäjien tärkein käyttöaihe on kohonnut
verenpaine. Niitä voidaan joskus käyttää myös sepelvaltimotaudin oireiden
hoitoon, yleensä yhdessä beetasalpaajalääkkeen kanssa.Lue seuraavaksi Nesteenpoistolääkkeet (diureetit) (https://sydan.fi/fakta/nesteenpoistolaakkeet-diureetit/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Nämä lääkkeet ovat erittäin suosittuja verenpaineen hoidossa, koska ne ovat
varsin tehokkaita, eikä haittavaikutuksiakaan juuri ole.
Mahdolliset haitat johtuvat niiden verisuonia laajentavasta vaikutuksesta.
Varasinkin hoidon alkuvaiheessa voi esiintyä ihon punoitusta ja kuumotusta, sekä
päänsärkyä. Nämä ongelmat menevät yleensä ohi lääkityksen jatkuessa.
Yksi haittavaikutus voi olla nilkkojen turvotus. Se ei ole vaarallista, eikä ole
merkki sydämen vajaatoiminnasta. Turvotus voi kuitenkin olla niin kiusallista,
että lääke on syytä vaihtaa toiseen vaihtoehtoon. Lääkkeen ottaminen illalla
saattaa myös lievittää ongelmaa.
Kalsiuminestäjillä on alempi erityiskorvattavuus (65 %) kohonneen
verenpaineen. Eräät valmisteet (taulukko) ovat erityiskorvattavia myös
sepelvaltimotaudissa ja tietyissä rytmihäiriöissä.
Lääkeaine Valmistenimet Huomauksia
Sydänvaikutteiset (sykettä hidastavat)
DiltiatseemiCardizem
Dilmin
DilzemAlempi erityiskorvaus kroonisessa verenpainetaudissa,
kroonisessa sepelvaltimotaudissa ja kroonisissa sydämen
rytmihäiriöissä
VerapamiiliIsoptin
VerpamilAlempi erityiskorvaus kroonisessa verenpainetaudissa,
kroonisessa sepelvaltimotaudissa ja kroonisissa sydämen
rytmihäiriöissä
Verisuonivaikutteiset (dihydropyridiinit)
AmlodipiiniAmloratio
Norvasc
AmlodipinAlempi erityiskorvaus kroonisessa verenpainetaudissa ja
kroonisessa sepelvaltimotaudissa
Amlodipin-nimellä rinnakkaisvalmiste kuudelta eri
lääkeyritykseltä
FelodipiiniPlendil
FelodipinAlempi erityiskorvaus kroonisessa verenpainetaudissa
Felodipin-nimellä rinnakkaisvalmiste kolmelta eri
lääkeyritykseltä
IsradipiiniLomir
IsradipineAlempi erityiskorvaus kroonisessa verenpainetaudissa
NifedipiiniNifedipin
CoractenAlempi erityiskorvaus kroonisessa verenpainetaudissa ja
kroonisessa sepelvaltimotaudissa
Nifedipin-nimellä rinnakkaisvalmiste neljältä eri
lääkeyritykseltä
Nisoldipiini SyscorAlempi erityiskorvaus kroonisessa verenpainetaudissa ja
kroonisessa sepelvaltimotaudissa
Nilvadipiini Escor Alempi erityiskorvaus kroonisessa verenpainetaudissaLue seuraavaksi Nesteenpoistolääkkeet (diureetit) (https://sydan.fi/fakta/nesteenpoistolaakkeet-diureetit/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
LerkanidipiiniOridip
Zanidip
LercanidipinAlempi erityiskorvaus kroonisessa verenpainetaudissa
 Lue seuraavaksi Nesteenpoistolääkkeet (diureetit) (https://sydan.fi/fakta/nesteenpoistolaakkeet-diureetit/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Kestävyys, voima ja liikehallinta ovat kunnon kolme aluetta – tärkeitä myös sydänsairaalle - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Sairastuneen liikunta (https://sydan.fi/elamaa-sairauden-kanssa/sairastuneen-liikunta/)/
Kestävyys, voima ja liikehallinta ovat kunnon kolme aluetta –  tärkeitä myös sydänsairaalle
Kestävyys, voima ja liikehallinta ovat kunnon
kolme aluetta –  tärkeitä myös sydänsairaalle
Kestävyys auttaa jaksamaan fyysistä rasitusta, lihaskunto helpottaa
ponnistelua vaativissa tehtävissä ja liikehallinta pitää yllä tasapainoa ja
motoriikkaa.
Kuva: Jarno Hämäläinen
Annukka Alapappila ja Paula Mannonen
Lue seuraavaksi Täytyykö rasitusta varoa sydäntapahtuman jälkeen? (https://sydan.fi/fakta/taytyyko-rasitusta-varoa/)
Julkaistu 31.8.2018
Päivitetty 5.8.2019
 
Sydäninfarktista (https://sydan.fi/fact/sydaninfarkti/) tai sydämeen
kohdistuvasta toimenpiteestä kuten ohitusleikkaus
(https://sydan.fi/fact/ohitusleikkaus-kiertaa-sepelvaltimon-ahtauman/) tai
pallolaajennus (https://sydan.fi/fact/pallolaajennus-avaa-suonen-tukoksen/),
toipumisen alkuvaiheessa on hyvä aloittaa liikunta maltillisesti. Liikkumisessa
tulee noudattaa sairaalassa saatuja ohjeita ja  kuunnella omia tuntemuksia
liikunnan aikana ja sen jälkeen.  Jos olo tuntuu epävarmalta, voi hakeutua
sydänpotilaille tarkoitettuun liikuntaryhmään tai terveydenhuollon
ammattilaisen luo keskustelemaan liikunnasta ja siten rohkaistua liikkumaan.
Kunto koostuu kolmesta osa-alueesta. Kestävyys auttaa jaksamaan fyysistä
rasitusta, lihaskunto helpottaa ponnistelua vaativissa tehtävissä ja liikehallinta
pitää yllä tasapainoa ja motoriikkaa. Jotkut liikunnan muodot harjoittavat vain
yhtä kunnon osa-aluetta, toiset useampaa.  Kaikki kolme ovat tärkeitä
toimintakyvylle.
Kestävyyskuntoa kohennetaan pidempikestoisella, hieman hengästyttävällä
liikunnalla, joka parantaa erityisesti keuhkojen, sydämen ja verenkiertoelimistön
toimintaa. Tämä kunnon osa-alue on sydänpotilaalle tärkeä, mutta kannattaa
kuitenkin harjoittaa myös lihaksia ja liikehallintaa. Etenkin ikääntyvillä ihmisillä
näiden kahden heikkeneminen voi rajoittaa elämää paljon.
Parhaimman hyödyn antaa kokonaisuus, joka sisältää viikossa vähintään
3–4 kertaa, mielellään päivittäin, 30 – 60 minuuttia kerrallaan, hyöty- ja
arkiliikuntaa
3–5 kertaa, mielellään päivittäin, 20 – 60 minuuttia kerrallaan,
kohtuukuormitteista kestävyysliikuntaa. Kohtuullisuus tarkoittaa, että
liikunta nostaa jonkin verran sykettä ja saa hengästymään lievästi.
2–3 lihaskuntoa ja liikehallintaa kehittävää kohtuukuormitteista
harjoituskertaa, 8 – 10 liikettä, toistoja 8 – 12 kutakin liikettä ja 1 – 3 sarjaa.
Aikasuositus voi tuntua suurelta, mutta seitsemälle päivälle ja erilaisiin
liikkumisen tapoihin jaettuna se ei ole ollenkaan mahdoton.  Jos et ole
aikaisemmin liikkunut juuri lainkaan, tai olet vielä huonossa kunnossa,Lue seuraavaksi Täytyykö rasitusta varoa sydäntapahtuman jälkeen? (https://sydan.fi/fakta/taytyyko-rasitusta-varoa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
aikasuosituksia ei edes tarvitse seurata tiukasti. Siinä tilanteessa kaikki
liikkumisen lisääminen tekee hyvää. Pikku hiljaa liikunta lisääntyy ja siihen
kannattaa olla tyytyväinen.
Fyysisen aktivisuuden lisääminen
Fyysinen aktiivisuus on tärkeää varsinaisen liikunnan rinnalla.  Se voi olla hyöty-
ja arkiliikuntaa kuten esimerkiksi puutarhatöitä, kotitöitä tai vaikkapa kirjastoon
kävelyä. Jokainen askel siis kannattaa ottaa ja on hyväksi myös sydänsairautta
sairastavalle. Olennaista on, että itse havahtuu huomaamaan niitä hetkiä
elämässä, jolloin voi lisätä fyysistä aktiivisuutta.
Kestävyyskunnon parantaminen
Kun aloittelija lähtee lenkille, jo lyhyt lenkki saa hänet haukkomaan henkeään.
Säännöllisen harjoittelun jatkuessa matka ennen läkähtymistä pitenee pikku
hiljaa ja jossain vaiheessa onnistuu jo koko lenkin kiertäminen pysähtymättä.
Kestävyyskunto on siis parantunut.
Pohjimmiltaan hyvä kestävyyskunto tarkoittaa, että lihakset saavat rasituksessa
riittävästi happea ja ravinteita. Harjoittelun seurauksena
sydän pystyy aikaisempaa paremmin kasvattamaan elimistöön virtaavan
veren määrää nostamalla sykettä ja pumppaamalla joka lyönnillä enemmän
verta.
lihaksiin on kasvanut lisää hiussuonia ja solujen kyky ottaa verestä happea
on parantunut. Harjoittelu on auttanut elimistöä myös käyttämään
enemmän rasvoja energianlähteenä.
keuhkojen ja verisuoniston toiminta ovat tehostuneet ja aineenvaihdunta
vilkastunut.
Liikkuminen lisää kestävyyttä silloin, kun se jatkuu pidemmän aikaa kerralla ja
saa sykkeen kohoamaan hieman. Hidas kävely kaupassa, pulahdus järveen tai
kukkien kastelu kotona eivät siis vielä paranna jaksamista, vaikka niistä on muuta
hyötyä ja iloa.
Hyviä lajeja kestävyyden harjoitteluun on paljon: kävely, uinti, pyöräily, hiihto,
luistelu, aerobic ja vastaavat jumpat, kuntopyöräily, soutaminen, porraskävely,
luistelu, jalkapallo ja monet muut pallopelit, retkeily luonnossa ja hölkkä. NäitäLue seuraavaksi Täytyykö rasitusta varoa sydäntapahtuman jälkeen? (https://sydan.fi/fakta/taytyyko-rasitusta-varoa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
kaikkia voi tehdä eri vauhdilla, jolloin rasitustasokin vaihtelee. Oikeastaan kaikki
suuria lihasryhmiä kuormittavat lajit ja työt käyvät kestävyysharjoittelusta.
Kestävyyden harjoittaminen olisi hyvä saada osaksi arkista toimintaa. Kunto ei
näin käänny laskuun, vaikka erillinen liikunnan harrastaminen jäisikin jossain
tilanteessa vähemmälle.  Lihasten käyttöä voi lisätä moniin tehtäviin ja
rutiineihin, kun istuu alas ja miettii asiaa.
Lihaskunnon kehittäminen
Lihakset ovat yleensä parhaassa kunnossa noin 30-vuotiaana, jonka jälkeen
niiden voima alkaa vähentyä. Iän myötä lihasten kunnosta huolehtiminen tulee
entistä tärkeämmäksi, sillä muuten monista jokapäiväisistä toimista –  kuten
tuolista nouseminen tai portaiden kiipeäminen –  ei enää tahdo selvitä.
Säännöllinen lihasvoimaharjoittelu vahvistaa lihaksia muutamassa kuukaudessa,
myös iäkkäillä kuntoilijoilla.  Lisäksi tämän tyyppinen liikunta vahvistaa luustoa.
Lihasvoimaharjoittelu on aina syytä aloittaa ohjaajan kanssa. Sydänpotilaille
oikean tehon ja tekniikan oppiminen on vielä muita tärkeämpää. Hae neuvoja
ohjatusta kuntoutusryhmästä tai fysioterapeutilta.
Lihaskuntoa voi harjoittaa kuntosalilla, joiden laitteet antavat monia
mahdollisuuksia eri lihasryhmien treenaamiseen. Ulkona voi kokeilla
sydänoireisille laadittua helppoa kunto-ohjelmaa
(https://sydan.fi/sydanoireisen-helppo-kunto-ohjelma/) . Kotona tehtävä
liikesarja voi puolestaan olla vaikkapa tällainen:
alkuverryttely lihasten lämmittämiseksi (ehkäisee vammojen syntyä ja
valmistaa elimistön liikkeelle)
nousu varpailleen 8 – 15 kertaa (pohjelihakset)
punnerrus seinää vasten 10 kertaa (kädet ja rintalihakset)
asetu konttausasentoon ja nosta vastakkainen käsi ja jalka suoraksi ilmaan
puolta vaihdellen 8 – 15 kertaa (selkälihakset)
nojaa sohvalla taaksepäin selkä pyöristyneenä ja vedä napaa sisään. Nosta
jalat ilmaan ja tee pyöräilyliikkeitä 8 – 15 kertaa (vatsalihakset)
seiso hartioiden levyisessä haara-asennossa, nosta kädet eteen ja kyykisty
niin, että reiden ja polven kulma on suora eli 90 astetta. Toista 8 – 15 kertaa
(reisilihakset)Lue seuraavaksi Täytyykö rasitusta varoa sydäntapahtuman jälkeen? (https://sydan.fi/fakta/taytyyko-rasitusta-varoa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Tee liikesarja 1 – 3 kertaa. Toistojen välissä pidetään pieni tauko ja lopuksi lihaksia
venytellään, mikä ehkäisee niiden kipeytymistä.
Lihaskunnon paraneminen edellyttää, että harjoitettava lihas väsyy. Tee liikkeet
rauhallisesti ja muista hengittää liikkeen aikana, jotta sydän ei rasitu
tarpeettomasti. Uloshengitys ajoitetaan ponnistusvaiheeseen.
Lihasvoiman paraneminen vaatii 1 – 3 harjoituskertaa viikossa. Mitä
tehokkaampaa harjoitus on, sitä enemmän se vahvistaa lihaksia ja luustoa. 
Tehoa lisätään vähitellen lihasten voimistuessa.
Liikehallintaa kannattaa harjoitella
Liikehallinta eli motorinen kunto tarkoittaa hyvää yhteistoimintaa kehon
tietoista liikuttamista säätelevien aivojen sekä aistien, hermoston ja lihasten
välillä. Harjoittelun avulla voidaan parantaa niin ympäristöstä tulevien
havaintojen käsittelyä ja tasapainon hallintaa kuin liikkeiden tehokkuutta,
tarkkuutta ja sopivuutta tilanteeseen.
Liikehallinnan osa-alueita ovat
tasapaino eri asennoissa
nopea reagointi sekä liikkeelle lähtiessä että tarvittaessa; esimerkiksi silloin,
kun näkee pallon muuttavan pelissä yllättäen suuntaa
rytmi- ja koordinaatiokyky, joka näkyy liikkeen oikeana ajoituksena ja
raajojen hyvänä yhteistoimintana muun muassa tanssijoilla
liikkeiden sujuvuus, notkeus ja ketteryys
Lisäksi liikehallintaan kuuluu kyky tulkita aistien välittämää tietoa sekä määrittää
ja muuttaa tarpeen mukaan omaa asentoaan tai liikkeen suuntaa, nopeutta tai
voimaa.
Osa kestävyys- tai lihaskuntoa kehittävästä liikunnasta lisää samalla
liikehallintaa. Tarkoitukseen sopivat kaikki lajit, pelit, työt ja leikit, jotka vaativat
koordinaatiota, ketteryyttä, käännöksiä tai nopeita spurtteja.
Hyviä motorista kuntoa kehittäviä liikuntatapoja ovat luistelu ja rullaluistelu,
laskettelu, rullalautailu, maila- ja pallopelit, tanssit, voimistelu ja monet
itämaiset lajit tai-chistä joogaan.  Lähes automaattisesti sujuva kävely tai hölkkä
ei sen sijaan kehitä tätä kunnon osa-aluetta, joten ainakin kerran viikossaLue seuraavaksi Täytyykö rasitusta varoa sydäntapahtuman jälkeen? (https://sydan.fi/fakta/taytyyko-rasitusta-varoa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
kannattaa vaikkapa tanssia ympäri asuntoa tai peuhata lasten kanssa. 
Tasapainoa voi harjoittaa esimerkiksi tasapainolaudalla tai -tyynyllä tai
pelkästään tekemällä välillä kotitöitä yhdellä jalalla seisten.
Ikääntyminen ja eri sairaudet heikentävät usein motorisia taitoja, mutta
harjoittelemalla niitä voi pitää yllä ja kehittää. Kun harjoittaa lihasten ja
verenkiertoelimistön lisäksi myös aivoja ja koko hermojärjestelmää, vähentää
samalla virhearvioinnista, huonosta tasapainosta tai kömpelyydestä johtuvien
tapaturmien vaaraa.
Lue myös
Ajatuksia arkiliikunnasta (https://sydan.fi/fact/ajatuksia-arkiliikunnasta/)ja
Tasapainoharjoittelusta varmuutta liikkumiseen
(https://sydan.fi/tasapainoharjoittelusta-varmuutta-liikkumiseen/)Lue seuraavaksi Täytyykö rasitusta varoa sydäntapahtuman jälkeen? (https://sydan.fi/fakta/taytyyko-rasitusta-varoa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Kohonneen verenpaineen hoito.pdf
Ko hon neen ve ren pai neen hoito
Kohonnutta verenpainetta hoidetaan ensisijaisesti terveellisillä elintavoilla.
Kohonnutta verenpainetta voi ehkäistä ja hoitaa terveellisillä elintavoilla. Elintapoihin on hyvä
kiinnittää huomioita, kun verenpaine ylittää ihanteellisen tason 120/80 mmHg.
Jos verenpaine ei laske riittävästi terveellisillä elämäntavoilla, tarvitaan rinnalle lääkehoitoa.
Verenpainetasosta, kohde-elinvaurioista ja liitännäissai rauksista riippuen lääkehoito aloitetaan
heti tai kuuden kuukauden elintapahoidon jälkeen.
Verenpaineen hoito elintavoilla
Näin hoidat verenpainettasi elintavoilla:
Lääkehoito
Verenpainelääkkeitä on useita, ja se valitaan aina yksilöllisesti. Valintaa vaikuttavat
potilaan ikä, muut sairaudet ja elintavat. Verenpainelääkkeinä käytetään ACE:n estäjiä,
ATR-salpaajia, beetasalpaajia, diureetteja (nesteenpoistolääkkeitä) ja kalsiumkanavan
salpaajia.Vähennä suolan käyttöä. Suositus on enintään 5g (teelusikallinen) päivässä.  Tällä
hetkellä suolan saantimme on tuplasti suurempi.
Lisää liikuntaa. Esimerkiksi reipasta kävelyä 30minuuttia viisi kertaa viikossa.
Lisää kasvisten ja täysviljavalmisteiden käyttöä, kiinnitä huomiota hyvien rasvojen
käyttöön. Näistä saat kaliumia, magnesiumia ja kalsiumia, jotka alentavat
verenpainetta.
Vähennä ylipainoa. Jo 5-10 % painon pudottamisella on vaikutusta.
Vähennä alkoholinkäyttöä. Naisilla hyväksyttävä määrä on korkeintaan yksi
ravintola-annos ja miehillä kaksi ravintola-annosta päivässä.
Vältä stressiä.
Vältä salmiakkia ja lakritsia.
Lopeta tupakointi.
Tuoreimpien suositusten mukaan verenpaineen lääkehoito aloitetaan
yhdistelmävalmisteella. Tämä tarkoittaa, että yksi tabletti sisältää kahta eri tavalla
vaikuttavaa lääkeainetta. Pieni annos yhdistelmävalmistetta on usein tehokkaampi
kuin maksimaalinen annos yhtä vaikuttavaa ainetta sisältävää lääkettä.
Yhdistelmävalmisteet ovat hyvin siedettyjä.
Seuranta
Verenpainetta seurataan kotimittauksilla. Seurantakäyntejä sairaanhoitaja,
terveydenhoitajan tai lääkärin vastaanotolla suositellaan 1-2 kuukauden välein kun
verenpainelääkitys on aloitettu tai sitä on muutettu. Kun yksilöllinen hoitotavoite on
saavutettu, suositellaan seurantakäyntejä 6-12 kuukauden välein.
Seurantakäynnin aikana tarkistetaan vointi, syke ja verenpainetaso
kotimittausseurannasta. Samalla varmistetaan lääkehoidon sopivuus ja arvioidaan
ovatko elintavat toteutuneet sovitulla tavalla.
Aiheeseen liittyvää
Tarkistettu 13.7.2020Verenpaineen hoito elintavoilla (sydan .fi)
Kohonnut verenpaine.pdf
Kohonnut ver enpaine
Käypä hoito -suositus | Julkaistu: 10.09.2020 | Tila:
Aihepiiri(t): Kardiologia , Kliininen farmakologia , Sisätaudit , Työterveyshuolto , Yleislääketiede
Suomalaisen Lääkäriseuran Duodecimin ja Suomen Verenpaineyhdistys ry:n asettama työryhmä
 
Miten viitata Käypä hoito -suositukseen?  «K1»
Keskeinen sanoma
Kohonnut verenpa ine on maailmanlaajuisest i merkittävin terveitä elinvuosia vähentävä riskitekijä ja aiheuttaa vuosittain noin 10,4
miljoonaa ennena ikaista kuolemaa. Kohonneen verenpa ineen ehkäisyn ja hoidon tavoitteena  on estää siihen liittyviä kohde-
elinvaurioita, vähentää ennena ikaisia sydän- ja verisuonitautitapahtumia ja -kuolemia ja lisätä terveiden elinvuosien määrää.
Aikuisikäisistä suomalaisista noin kahdella miljoonalla on kohonnut verenpa ine. Vain joka viidennen verenpa ine on ihanteellisella
tasolla.
Kohonneen verenpa ineen ja sen haittojen tehokas ehkäisy edellyttää vaikuttavia toimenpit eitä erityisest i koko väestön natriuminsa annin
vähentämiseksi.
Noin miljoona suomalaista käyttää verenpainetta alentavia lääkkeitä, mutta heistä vain noin 40 %:lla verenpa ine on hoitotavoitteessa .
Hoitotavoitteiden saavuttamiseksi ACE:n estäjiin tai ATR:n salpaajiin ja kalsiumkanavan salpaajiin ja diureetteihin perustuvaa
yhdistelmähoitoa tulee lisätä.
Beetasalpaajien käyttöä suositellaan, jos se on muiden sairauksien johdosta aiheellista.
Lääkehoitoa suositellaan, jos vastaanotolla mitattu systolinen painetaso on elintapahoidoista huolimatta ≥ 140 mmHg tai diastolinen ≥
90 mmHg ja
kotona itse mitattu systolinen painetaso on ≥ 135 mmHg tai diastolinen painetaso ≥ 85 mmHg tai
verenpa ineen pitkäaikaisrekisteröinnissä  systolisen paineen päivätaso on ≥ 135 mmHg tai diastolinen päivätaso ≥ 85 mmHg.
Hoidon tavoitteena  on alentaa verenpa ine
< 140/90 mmHg:iin (kotitaso < 135/85 mmHg)
< 130/80 mmHg:iin (kotitaso < 125/80 mmHg), jos tautiriski on suuri ja tavoite voidaan haitoitta saavuttaa
< 150/90 mmHg:iin (kotitaso < 140/85 mmHg), jos potilas on > 80-vuotias. Yksilöllisest i matalampikin tavoite mahdollinen.
< 140/80 mmHg:iin (kotitaso < 135/80 mmHg), jos potilaalla on diabetes. Tiukempaan hoitotavoitteeseen < 130/80 mmHg (kotitaso
< 125/80 mmHg) pyritään, jos se voidaan haitoitta saavuttaa.
< 130/80 mmHg:iin (kotitaso < 125/80 mmHg) kroonista munuaistautia sairastavalla (eGFR < 60 ml/min/1, 73 m) tai jos
diabeettiseen tai ei-diabeettiseen nefropatiaan liittyy albuminuria (U-Alb > 300 mg/vrk tai U-Alb/Krea > 30 mg/mmol) ja tavoite
voidaan haitoitta saavuttaa.
Tiivistelmä ja potilasversio
Suosituksen tiivistelmä «Kohonnut verenpa ine»  ja lyhyt abstrakti englannik si «Hypertensio n»
Suosituksen yleiskielinen potilasversio suomeksi «Ver enpa ine koholla?» ja ruotsiksi «Högt blodtryck?»
Tavoitteet
Suosituksen tavoitteena  on tehostaa ja yhdenm ukaistaa kohonneen verenpa ineen  ehkäisyä, diagnostiikkaa ja hoitoa ja siten vähentää
sydän- ja verisuonisa irauksia ja niihin liittyviä kuolemia.
Kohderyhmät
Suositus on tarkoitettu perusterveydenhuollossa, työterveyshuollossa ja erikoissairaanhoidossa verenpa inepo tilaita hoitaville,
apteekkihenkilökunnalle sekä kohonneen  verenpa ineen ehkäisyn ohjelmia suunnit televille ja toteuttaville.
Epidemiologia
Kohonnut verenpa ine on maailmanlaajuisest i tärkein terveitä elinvuosia vähentävä riskitekijä ja aiheuttaa vuosittain 10,4 miljoona
ennena ikaista kuolemaa [1].
Verenpa ineen haitallista iänmukaista kohoamista säätelevät perinnö llinen alttius ja elintavat.
Kohonneen verenpa ineen tärkeimpiä muutettavissa olevia riskitekijöitä ovat liiallinen suolan (natriumin) saanti, runsas alkoholin
käyttö, vähäinen fyysinen aktiivisuus ja ylipaino.
Kulttuureissa , joissa suolaa käytetään vähän tai ei lainkaan, väestön verenpa inetaso on iästä riippu matta 100–110/60–70 mmHg [2].24.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 1/29
Esiintyvyys ja ilmaantuvuus
Valtaosalla ihmisistä verenpa ine nousee iän myötä.
Diastolisen verenpa ineen keskiarvo suurenee noin 55 vuoden ikään ja systolisen noin 80 vuoden ikään asti «Ver enpa inetasot
suomalaisessa  väestössä vuonna 2017».
Suomalaisten verenpa inetaso on laskenut merkittävästi 1970-luvun alusta. Myönteinen kehitys on kuitenkin 2000-luvulla hidastunut
[3], [4], [5], [6], [7].
Aikuisikäisten suomalaisten verenpa ine aleni vuodesta 1980 vuoteen 2000 kaikissa ikäkohorteissa , miehillä keskimäärin
10/6 mmHg ja naisilla keskimäärin 16/8 mmHg. Verenpa ineen alenem inen pysähtyi nuoremmissa ikäkohorteissa  (30–44-
vuotiaat) mutta jatkui iäkkäämmissä ikäkohorteissa  vuodesta 2000 vuoteen 2011. Alenem a oli kaikilla miehillä keskimäärin 4/2
mmHg ja kaikilla naisilla keskimäärin 5/3 mmHg [4].
Jos kohonneen verenpa ineen kriteerinä pidetään raja-arvoja 140 ja 90 mmHg tai kohonneen verenpa ineen lääkehoitoa, noin puolella 30
vuotta täyttäneist ä suomalaisista on FinTerveys 2017 -tutkimuksen mukaan kohonnut verenpa ine [7], «Ver enpa inetaudin yleisyys».
Kuva 1.
Verenpa inetasot suomalaisessa  väestössä vuonna 2017
Lähde: Päivikki Koponen,  Katja Borodulin, Annamari Lundqvist, Katri Sääksjärvi ja Seppo  Koskinen,  toim. Terveys, toimintakyky ja
hyvinvointi Suomessa  – FinTerveys 2017 -tutkimus. Terveyden ja hyvinvoinnin laitos (THL), Raportti 4/2018, 236 sivua. Helsink i 20124.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 2/29
Kuva 2.
Verenpa inetaudin yleisyys
Lähde: Päivikki Koponen,  Katja Borodulin, Annamari Lundqvist, Katri Sääksjärvi ja Seppo  Koskinen,  toim. Terveys, toimintakyky ja
hyvinvointi Suomessa  – FinTerveys 2017 -tutkimus. Terveyden ja hyvinvoinnin laitos (THL), Raportti 4/2018, 236 sivua. Helsink i 2012
Hoitotilanne
Vuonna 2017 noin 28 % yli 30-vuotiaista suomalaisista ilmoitti käyttävänsä verenpa inelääkkeitä [7].
Vuonna 2017 noin 46 % henkilöistä, joilla oli kohonnut verenpa ine, ei ollut lääkehoidon piirissä [7].
Vaikka hoitotavoitteessa  olevien osuus on kasvanut Suomessa  viime vuosikymmenien aikana, kohonneen verenpa ineen lääkehoidossa
olevista vain 42 %:lla verenpa inea rvot alittavat 140/90 mmHg [5], [7].
Sairastuvuus ja kuolleisuus sydän- ja verisuonitauteihin
Sairastuvuus ja kuolleisuus sydän- ja verisuonitauteihin lisääntyvät verenpa ineen nousun myötä ilman selvää systolisen tai diastolisen
verenpa ineen kynnysarvoa [8].
Sepel valtimotauti- ja aivohalvauskuolleisuus 2–3-kertaistuvat verenpa ineen kohotessa  20/10 mmHg [8].
Kohonnut verenpa ine kasvattaa eteisvärinän riskin lähes kaksink ertaiseksi ja on oleellinen taustatekijä joka kuudennel la
eteisvärinäpotilaalla [9].
Sydämen vajaatoiminna n ilmaantuvuus on kohonneen verenpa ineen hoitotutkimuksissa  keskimäärin 8,5 tapausta tuhatta
potilasvuotta kohden, mikä on vain hieman pienem pi kuin sepel valtimotaudin (11,7) ja aivoverenkierron häiriöiden (9,1)
ilmaantuvuus [10].
Sydämen vajaatoiminna n riskiä hypertensio potilaalla suurentavat entisest ään > 65 vuoden ikä, diabetes ja suuri valtimosairauksien
riski [10].
Kohonnut verenpa ine lyhentää odotettavissa olevaa elinaikaa [11]. Lyhenem än on raportoitu olevan 25–59-vuotiailla suomalaismiehillä
keskimäärin 2,7 vuotta ja naisilla 2,0 vuotta, jos diastolinen paine on > 104 mmHg ja vertailukohtana pidetään < 95 mmHg:n painetta
[12]. Framinghamin tutkimuksen mukaan 50-vuotiaiden miesten tai naisten, joiden verenpa ine oli < 120/80 mmHg, sydän- ja
verisuonitaudeista vapaiden elinvuosien odote oli 7,2/7,1 vuotta pitempi kuin miehillä tai naisilla, joiden verenpa ine oli ≥ 140/90 mmHg.
Elinajan odote oli vastaavasti 5,0 (miehet) ja 5,2 (naiset) vuotta pitempi [11].
Muut sydän- ja verisuonitautien vaaratekijät monink ertaistavat kohonneen verenpa ineen haitat [13].
Koska myös useiden muiden vaaratekijöiden tasot ovat suomalaisilla korkeat [7] (ks. taulukko 1), jo lievästi kohonnut verenpa ine saattaa
lisätä väestön sydän- ja verisuonitautivaaraa merkittävästi.
Suomalaisten 35–64-vuotiaiden miesten ja naisten ikävakioitu sepel valtimo- ja aivohalvauskuolleisuus ovat 40 vuodessa  pienent yneet
sydän- ja verisuonitautien vaaratekijätasojen alenem isen ansio sta noin 80 % [14].
Taulukko 1. Sydän- ja verisuonitautien vaaratekijöiden ja kohonneen verenpaineen liitännäissairauksien esiintyvyys (%) verenpainelääkettä
käyttämättömillä 25–64-vuotiailla, joiden verenpaine oli FinTerveys 2017 -tutkimuksen mukaan tyydyttävä tai kohonnut.
Miehet Naiset
Riskitekijäprofiili Tyydyttävä
(SVP 130–139Lievästi
kohonnutKohtalaisesti tai
huomattavastiTyydyttävä
(SVP 130–139Lievästi
kohonnutKohtalaisesti tai
huomattavasti4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 3/29
Miehet Naiset
tai DVP 85–89)
(n=333)(SVP 140–
159 tai DVP
90–99)
(n=315)kohonnut (SVP ≥
160 tai DVP ≥ 100)
(n=85)tai DVP 85–89)
(n=243)(SVP 140–
159 tai DVP
90–99)
(n=195)kohonnut (SVP ≥
160 tai DVP ≥ 100)
(n=60)
Ei muita vaaratekijöitä 5 6 3 17 7 7
1 tai 2 vaaratekijää 27 24 20 34 32 29
3 tai useampia muita
vaaratekijöitätai diabetes
tai liitännäissairaus68 70 77 49 61 64
SVP, systolinen verenpaine; DVP, diastolinen verenpaine
 Tupakointi, dyslipidemia (LDL-kolesterolipitoisuus > 3,0 mmol/l, triglyseridipitoisuus > 1,7 mmol/l tai HDL-kolesterolipitoisuus pieni (miehet < 1,0
mmol/l, naiset < 1,2 mmol/l)), lähisuvussa varhain esiintyneet sydän- ja verisuonitaudit (sydäninfarkti < 60- (miehet) tai 65-vuotiaana (naiset) tai
aivohalvaus < 75-vuotiaana, vyötärölihavuus (vyötärön ympärys miehillä > 100 cm ja naisilla > 90 cm).
 Ohitusleikkaus tai sepelvaltimoiden pallolaajennus, lääkärin toteama sydäninfarkti, aivoinfarkti, sepelvaltimotauti tai sydämen vajaatoiminta
Verenpaineen mittaus
Kohonneen verenpa ineen diagnoosi perustuu vastaanotolla (mahdollisuuksien mukaan ensisij aisest i hoitajan vastaanotolla) ja kotona tai
pitkäaikaisrekisteröinnin avulla määritettyyn painetasoon. Ks. kohta Verenpa inetason luokittelu «A1». Kotimittaus on suositeltavin ja
useim miten riittävä tapa seurata verenpa inetta.
Mittausvälineistö
Mittaukset tehdään puolueettomassa teknisessä  ja kliinisessä  testauksessa  hyväksytyllä verenpa inem ittarilla (lisätietoa: dabl
Educational Trust http://d ableducational.org/ ja STRIDE BP https://www. stridebp.org/ind ex.php) [15]. Rannem ittarin käyttöä
suositellaan vain, jos oikean kokoisen manset in käyttö ei olkavarren mallin (lyhyt, paksu) vuoksi ole mahdollista. Useim mat
mittarivalmistajat suosittelevat tarkistamaan laitteiden toiminna n ja mittaustarkkuuden joka toinen vuosi.
Esivalmistelut ja mittauksen suorittaminen
Terveydenhuollossa ja kotona itse tehtyjä mittauksia edeltävän puolen tunnin aikana vältetään
raskasta fyysistä ponnist elua
tupakointia
kofeiinipit oisten juomien (kahvi, tee, kolajuomat ja ns. ener giajuomat) nauttimista.
Mittaus tehdään taulukossa 2 esitettävällä tavalla [16].
Verenpa ine voidaan mitata oikeasta tai vasemmasta olkavarresta, vaikka oikeasta olkavarresta mitattu verenpa ine on keskimäärin 0–
2/0–1 mmHg korkeampi kuin vasemmasta mitattu [17], [18], [19]. Kotimittaukset ja verenpa ineen pitkäaikaisrekisteröinti tehdään ei-
dominoivasta kädestä, ellei käsivarsien välillä ole merkittävää paine-eroa (ks. alla).
Uudelta verenpa inepo tilaalta verenpa ine mitataan toistetusti molemmista olkavarsista mahdollisen puolieron toteamiseksi.
Jos oikealta ja vasemmalta mitatut paineet eroavat toisistaan merkittävästi (> 10 mmHg) [20], seurantamittauksissa  käytetään sitä kättä,
josta mitattu verenpa ine on korkeampi.
Painem anset ti asetetaan paljastettuun olkavarteen siten, että kumipussin keskiosa on olkavarsivaltimon päällä.
Mittaus aloitetaan, kun tutkittava on istunut mittauspaikalla 5 minuuttia manset ti olkavarteen kiinnit ettynä [21].
Mittaus toistetaan 1–2 minuutin kuluttua.
Mittaustulokset kirjataan seurantalomakkeelle.
Verenpa ineen mittaustulos kirjataan automaattimittarilla tehtävissä mittauksissa  1 mmHg:n ja kuuntelumenet elmällä tehtävissä 2
mmHg:n tarkkuudella.
Terveydenhuollon mittauksissa  sykkeen säännöllisyys tarkistetaan, jos mittaus tehdään automaattimittarilla.
Mittaus tehdään kuuntelumenet elmällä, jos automaattimittaus ei onnist u. Kuuntelumenet elmää käytettäessä  stetoskoopin kalvo- tai
suppilo-osa asetetaan tiiviisti mutta kevyesti kyynärtaipeeseen olkavarsivaltimon päälle [22].
Pulssiaallon vaihtelu vaikeuttaa verenpa ineen mittaamista eteisvärinässä. Oskillometriset mittarit mittaavat systolisen paineen
tyydyttävällä tarkkuudella, mutta diastolisen paineen osalta esiint yy enem män mittausepä tarkkuutta [23].
Elohopeamittareiden myynti Euroopan unionin alueella on nykyään kielletty, joten kuuntelumenet elmään perustuvat mittaukset
joudutaan useim miten tekemään aneroidimittarilla tai digitaalisella mittarilla, joka näyttää manset tipaineen reaaliaikaisest i [24].
Taulukko 2. Tiivistelmä verenpaineen kertamittauksen suorituksesta
Tärkeimmät huomioitavat seikat Huomioitava myös
Mittari Käytetään kliinisissä testeissä hyväksyttyä mallia. Mittaustarkkuus tarkistetaan joka toinen vuosi.
Mansetin kumipussi Leveys/olkavarren ympärysmitta
12 cm, jos ympärysmitta 26–32 cm
15 cm, jos ympärysmitta 33–41 cm
18 cm, jos ympärysmitta > 41 cmMansetin koko valittava olkavarren mukaan.1
1
1 
2
1
2
®4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 4/29
Tärkeimmät huomioitavat seikat Huomioitava myös
Mittauspaikka Mittaus tehdään olkavarresta. Mittauksen aikana tutkittava istuu kyynärvarsi
tuettuna mansetin alareuna sydämen alareunan
tasolla.
Mittausolot Tutkittava lepää 5 minuuttia istuallaan ennen mittausta, mansetti paikalleen
asetettuna.Ympäristön tulee olla rauhallinen. Tutkittavaa
ei saa kuormittaa fyysisesti eikä henkisesti.
Keskustelua on vältettävä.
Mittaustapa Kuuntelumenetelmällä mitattaessa painetta nostetaan värttinävaltimon sykettä
tunnustellen aluksi 30 mmHg yli systolisen paineen ja sitten lasketaan 2–3
mmHg/s.Systolinen paine = Korotkoffin äänien vaihe I,
diastolinen paine = vaihe V (tai vaihe IV, jos
vaihe V ei ole todettavissa)
Mittaustulos Painelukemat kirjataan 1 mmHg:n tarkkuudella tai kuuntelumenetelmää
käytettäessä 2 mmHg:n tarkkuudella.Paine mitataan kahdesti 1–2 minuutin välein ja
molemmat tulokset kirjataan.
Terveydenhuollossa tehtävät mittaukset
Lääkäreiden mittaama verenpa inetaso on keskimäärin korkeampi kuin hoitajien mittaama [25].
Terveydenhuollon itsemittauspist eiden mittaustulokset näyttävät asettuvan lääkärin ja hoitajan mittaamien arvojen väliin [25].
Ortostaattisen hypotensio n toteamiseksi verenpa ine mitataan iäkkäiltä ja diabeetikoilta myös makuulla sekä 1 ja 3 minuutin kuluttua
makuulta seiso maan nousemisen jälkeen [26], [27], [28].
Ortostaattisessa  hypotensio ssa systolinen  verenpa ine alenee vähintään 20 mmHg tai diastolinen vähintään 10 mmHg ja potilaalla
esiint yy selviä ortostatismin oireita.
Vaikka hoitajan huolellisest i tekemiin verenpa inem ittauksiin perustuva neljän kaksoismittauksen keskiarvo korreloi kohde-
elinvaurioihin (sydämen vasemman kammion massaan ja virtsan albumiininer ityksen suuruuteen)  kotimittausten ja
pitkäaikaisrekisteröinnin verenpa inek eskiarvojen veroisest i [21], se näyttää ennu stavan valtimotautitapahtumia huonommin kuin
kotimittaukset ja pitkäaikaisrekisteröinti [29].
Verenpaineen kotimittaus
Kotona itse tehdyt verenpa inem ittaukset kuvaavat luotettavammin tavanomaista painetasoa ja kohde-elinvaurioiden vaaraa kuin
vastaanotto-oloissa tehdyt kertamittaukset [30]. Lisäksi ne ennu stavat paremmin ja lähes pitkäaikaisrekisteröinnin veroisest i [29]
valtimotautitapahtumia ja -kuolemia [31], [32].
Verenpa ine ja syke mitataan ennen lääkkeen ottoa aamulla kello 6–9 ja illalla kello 18–21 kahdesti 1–2 minuutin välein 4–7 päivän ajan.
Aamumittausten, iltamittausten ja aamu- ja iltamittausten keskiarvot lasketaan ja kirjataan. Iltamittausten tasoa korkeampi
aamumittausten taso voi viitata uniapnea an tai runsaaseen alkoholin käyttöön [33].
Neljän päivän mittauskeskiarvot riittävät hoidon arviointiin [21], [34].
Lääkärin ja hoitajan tulee varmistaa, että mittaukset on tehty edellä mainittujen vaatimusten mukaisest i.
Ks. esim erkki verenpa inem ittausten seurantalomakkeista ja omaseurannasta https://www. svpy.fi/@Bin/17 1658/Ver enpa inek ortti.pdf
tai https://sy dan.fi/fact/verenpa ineen- omaseuranta/.
Verenpaineen pitkäaikaisrekisteröinti
Pitkäaikaisrekisteröinnin verenpa ineen keskiarvolla on vahvempi yhteys sydämen vasemman kammion hypertrofiaan ja
mikroalbuminuriaan kuin vastaanoton kertamittauksen tuloksella [35], ja se myös ennu staa paremmin valtimotautitapahtumia ja -
kuolemia [36], [37].
Pitkäaikaisrekisteröinti on toistaiseksi yleisin tapa selvittää yöllistä verenpa inetta, jolla on vahva ennu stearvo [26], [38], [39] sekä päivä-
yövaihtelua.
Yöllinen kohonnut verenpa ine ja puuttuva päivä-yövaihtelu ("non-dipping ") ovat tavallisia diabetesta, uniapnea a ja munuaisten
vajaatoimintaa sairastavilla.
Rekisteröinnist ä on lisäksi apua, kun
potilas ei halua tai osaa toteuttaa kotimittauksia suositellulla tavalla
kotimittaukset ovat vasta-aiheisia  (mittausneu roosi)
epäillään "valkotakkihypertensio ta" (kotimittaus voi olla riittävä)
epäillään piilevää hypertensio ta (kotimittaus voi olla riittävä)
epäillään kohtauksellista verenpa ineen nousua ja laskua
koti- ja vastaanottomittausten tulosten välillä on huomattava ristiriita
arvioidaan huonoa hoitovastetta (vähintään 3 lääkettä)
selvitetään lääkehoidon yhteydessä  esiin tyviä hypotensio -oireita.
Mittauksen yhteydessä  tutkittavan on pidettävä tapahtumapäiväkirjaa.
Verenpainetason luokittelu
Vastaanottomittauksia käytetään ensisij aisest i seulonnassa (taulukko 3 ja kuva «Kohonneen verenpa ineen seulonta ja diagnosointi»).
Kohonneen verenpa ineen luokittelu perustuu ensisij aisest i vastaanoton ulkopuolella tehtyihin mittauksiin (4–7 päivän aikana aamulla ja
illalla kotona tehtyjen kaksoismittausten keskiarvo tai verenpa ineen pitkäaikaisrekisteröinti) (taulukko 3, taulukko 4 ja kuva
«Kohonneen verenpa ineen seulonta ja diagnosointi»).4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 5/29
Jos vastaanoton ulkopuoliset mittaukset eivät onnist u, luokittelu perustuu vastaanottomittauksiin (neljän eri päivänä tehdyn
kaksoismittauksen keskiarvo).
Valtimotautiriskin osalta toisiaan vastaavat vastaanotto-, kotimittaus- ja pitkäaikaisrekisteröinti-verenpa inetasot esitetään taulukossa 4
ja . Ks. myös [36], [40].
Verenpa inetaso ja verenpa ineen luokittelu varmistetaan elintapahoidon aikana kotimittauksella tai pitkäaikaisrekisteröinnil lä, jos
vastaanotolla mitattu systolinen painetaso on 140–199 mmHg tai diastolinen painetaso 90–129 mmHg. Piilevän hypertensio n
mahdollisuus selvitetään kotimittauksella tai pitkäaikaisrekisteröinnil lä, jos vastaanotolla mitattu painetaso on 130–139 tai 85–89
mmHg ja potilaalla on muita valtimotaudin vaaratekijöitä. Ks. myös kohta Piilevä hypertensio  «A2».
"Valkotakkihypertensiolla" eli isoloituneella v astaanottohypertensiolla tarkoitetaan tilannet ta, jossa verenpa ine on
vastaanotolla lääkärin tai hoitajan mittaamana kohonnut (≥ 140/90 mmHg) mutta kotona itse mitattu verenpa ine tai
pitkäaikaisrekisteröinnin päivätaso on normaali (< 135/85 mmHg).
45–74-vuotiaista suomalaisista 16 %:lla ja hoitamattomista hypertensiiv isistä 45–74-vuotiaista suomalaisista 38 %:lla on niin sanottu
valkotakkihypertensio  [41].
Valkotakkihypertensiiv isten elintavat ovat keskimäärin paremmat kuin niiden, joilla on piilevä tai vakiintunut hypertensio  [41].
Metabolisia riskitekijöitä esiint yy valkotakkihypertensiiv isillä enem män kuin normotensiiv isillä mutta vähemmän kuin potilailla,
joilla on piilevä tai vakiintunut hypertensio  [41].
Valkotakkihypertensio  enna koi vakiintuneen hypertensio n ilmaantumista [42], [43].
Valkotakkihypertensio on liittyvä kardiovaskulaaritapahtumien vaara on pienem pi kuin piilevään ja vakiintuneeseen hypertensio on
liittyvä [44], mutta suurempi kuin normotensio on liittyvä [45], [46].
Hoitopäätös tehdään kotimittauksen tai pitkäaikaisrekisteröinnin perusteella.
Elintapahoito aloitetaan kaikille.
Verenpa inetta seurataan säännöllisin välein lääkehoidon tarpeid en arvioimiseksi. Ks. kohta Seuranta «A13».
Piilevässä h ypertensiossa kotona itse mitattu verenpa ine tai pitkäaikaisrekisteröinnin päivätaso on kohonnut (≥ 135/85 mmHg)
mutta vastaanotolla mitattu verenpa ine on normaali (< 140/90 mmHg). Vastaanottomittauksella normotensiiv isiksi todetuista 45–74-
vuotiaista suomalaisista 14 %:lla on piilevä hypertensio  [47].
Potilailla on usein muita sydän- ja verisuonitautien vaaratekijöitä [44], [48], [49], [50] [51], [52], [53] ja heidän elintapansa ovat
epäterveellisem mät kuin normotensiiv isten ja valkotakkihypertensiiv isten [41], [53].
Kohde-elinvaurioiden esiint yvyys on suurentunut [51], [54], [55], [56].
Sydän- ja verisuonitautiriski on suurentunut [44], [45], [48], [49], [51], [57], [58].
Hoitopäätös (tehostettu elintapahoito ja tarvittaessa  lääkehoito) tehdään kotimittauksen tai pitkäaikaisrekisteröinnin tulosten ja
muun riskitekijäprofiilin perusteella.
Pseudohypertensiossa mi tattu verenpa ine on korkea ja reagoi huonosti lääkitykseen [59].
Vaikeahoitoiseen kohonneeseen verenpa ineeseen tavallisest i liittyvät kohde-elinvauriot puuttuvat.
Potilaat ovat usein iäkkäitä.
Pseudohypertensio n syynä on yleensä  olkavarsivaltimon kalkkiutuminen,  jolloin manset timenet elmällä tehty mittaus antaa liian
suuria arvoja todelliseen painetasoon nähden.
Taulukko 3. Uuden potilaan vastaanottomittauksiin perustuva verenpainetason luokitus
Luokka SVP (mmHg) DVP (mmHg)
Optimaalinen < 120 ja < 80
Normaali 120–129 ja/tai 80–84
Korkea normaali 130–139 ja/tai 85–89
Kohonnut verenpaine
Lievästi kohonnut 140–159 ja/tai 90–99
Kohtalaisesti kohonnut 160–179 ja/tai 100–109
Huomattavasti kohonnut ≥ 180 ja/tai ≥ 110
Hypertensiivinen kriisi ≥ 200 ja/tai ≥ 130
Isoloitunut systolinen hypertensio ≥ 140 ja < 90
 Vaikeusaste luokitellaan systolisen verenpaineen mukaan.
Taulukko 4. Vastaanottopainetta vastaavat paineet kotimittauksille ja pitkäaikaisrekisteröinnille.
Vastaanottopaine, mmHg Kotipaine, mmHgPitkäaikaisrekisteröinti,
24 t, mmHgPitkäaikaisrekisteröinti,
päivä, mmHgPitkäaikaisrekisteröinti,
yö, mmHg
120/80 120/80 115/75 120/80 100/65
130/80 125/80 125/75 130/80 110/65
140/90 135/85 130/80 135/85 120/701
14.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 6/29
Vastaanottopaine, mmHg Kotipaine, mmHgPitkäaikaisrekisteröinti,
24 t, mmHgPitkäaikaisrekisteröinti,
päivä, mmHgPitkäaikaisrekisteröinti,
yö, mmHg
150/90 140/85
160/100 145/90
Kuva 3.
Kohonneen verenpa ineen seulonta ja diagnosointi. Jos verenpa ine on koholla vastaanottomittauksissa , kohonneen verenpa ineen diagnoosi
tulee varmistaa ensisij aisest i vastaanoton ulkopuolisilla mittauksilla. Elleivät vastaanoton ulkopuoliset mittaukset ole toteutettavissa,
diagnoosin tulee perustua toistettuihin vastaanotolla tehtäviin mittauksiin.
Lähde: 2018 ESC/ESH Guidelines for the management of arterial hypertensio n. Eur Heart J 2018;39:3021-104
Perustutkimukset ja sydän- ja verisuonitautien vaaratekijöiden selvitys
Kun verenpa ine on todettu kohonneek si, tehdään perustutkimukset ja valtimosairauksien vaaratekijöiden selvitys. Valtimotaudin
kokonaisriski voidaan arvioida primaarisessa  ehkäisyssä "terveillä" FINRISKI-laskurin avulla https://www. terveyskirjasto.fi/pg t00013.
Anamn eesi:
sukuanamneesi (vanhemmat, sisarukset):
hypertensio , tyypin 2 diabetes, dyslipidemia
sepel valtimo- tai aivoverenkiertotapahtumat (etenkin < 55-vuotiailla miehillä ja < 65-vuotiailla naisilla)
muut sydän- ja verisuonitaudit:
sepel valtimotauti, sairastettu sydäninfarkti
aivoverenkierron sairaudet (aivohalvaus: aivoinfarkti, aivojen sisäinen verenvuoto, lukinkalvon alainen verenvuoto; TIA)
perifeerisen valtimoverenkierron sairaudet
sydämen vasemman kammion toimintahäiriö (infarktin jälkitila, kardiomyopatiat)
sydämen vajaatoiminta
sydänläppien sairaudet
aortan sairaudet (dilataatio, dissek oituma)
rytmihäiriöt
muut hoitoon vaikuttavat sairaudet:
diabetes
munuaissairaus tai -vaurio
astma
kihti
hypertensio n kulku (alku, etenem inen,  vaikeusaste)
lääkkeiden käyttö (ks. kohta Eksogeenisen ja sekundaarisen hypertensio n epäily «A3»)
elintavat:
ravinto, erityisest i suolan käyttö, rasvojen laatu, kasvisten, marjojen ja hedelmien käyttö
painoindeksi ja vyötärön ympärysmitta
liikunta ja fyysinen aktiivisuus
alkoholin käyttö (Audit-tutkimus https://www. terveysportti.fi/xmedia/hoi/hoi50028b.pdf)
lakritsiuutetta sisältävien tuotteiden käyttö (ks. kohta Eksogeenisen ja sekundaarisen hypertensio n epäily «A3»)
tupakointi
huumeiden käyttö
kuormittavat psyykkiset ja sosiaaliset tekijät
Kliininen tutkimus:
inspek tio:
yleishabitus
kaulalaskimot4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 7/29
alaraajojen turvotus
palpaatio:
valtimot (a. radialikset (symmetrisyys), a. femoralis, a. dorsalis pedis, a. tibialis posterior)
vasemman kammion kärkisysäys
vatsa
auskultaatio:
sydän
valtimosuhinat (a. carotis, vatsa-aortta, a. renalis, a. femoralis)
keuhkot
silmänpohjat (jos diastolinen paine ≥ 120 mmHg) (ks. kohta Silmät «A6»)
paino, pituus, painoindeksi (BMI), vyötärön ympärysmitta [60], (ks. Käypä hoito -suositus Lihavuus (lapset , nuoret ja aikuiset)
«Lihavuus (lapset , nuoret ja aikuiset)»).
Laboratorio- ja kuvantami stutkimukset:
perusverenkuva
virtsan kemiallinen seulontatutkimus ja U-Alb/Krea (taulukko 5)
plasman kreatiniinipit oisuus ja glomerulusten laskenna llinen suodatusnopeus (eGFR, ks. CKD-EPI GFR-laskuri
http://www. vshp.fi/medserv/klkemi/fi/ok/GFR.htm?lang=fi )
plasman kalium- ja natriumpitoisuus
plasman kolesterolipitoisuus, HDL-kolesterolipitoisuus, LDL-kolesterolipitoisuus ja triglyseridipitoisuus
plasman paastoglukoosipit oisuus
EKG
thoraxröntgenkuvaus sydämen vajaatoimintaa epäiltäessä
sydämen kaikututkimus tarvittaessa  (ks. kohta Vasemman kammion hypertrofia «A7»)
munuaisten kaikututkimus tarvittaessa  (ks. kohta Munuaisvaurio «A8»)
Taulukko 5. Albuminurian ja proteinurian (makroalbuminurian) raja-arvot
Kertanäyte U-Alb/Krea-suhde
(mg/mmol)Vuorokausikeräys dU-Alb
(mg/vrk)Virtsan kemiallinen
seulonta
Normaali < 3,0 < 30 -
Lisääntynyt albuminuria 3–30 30–300 -
Proteinuria > 30 > 300 +
Liuskakokeet antavat positiivisen tuloksen, kun albumiinipitoisuus on 200–300 mg/l.
Kohde-elinvauriot
Vasemman kammion hypertrofia (LVH)
Sydämen vasemman kammion liikakasvu eli hypertrofia (LVH) on yleisin kohonneen verenpa ineen aiheuttama elinmuutos.
Hypertensio ssa sitä esiint yy 2–5-kertaisest i normotensio on verrattuna. Ks. lisätietoa aiheesta .
Kohonneen verenpa ineen lisäksi LVH:n muutettavissa olevia itsenä isiä riskitekijöitä ovat runsas suolan käyttö ja lihavuus [61], [62], [63].
Suolan käytön vähentäminen [B] ja laihduttaminen [C] pienent ävät vasemman kammion massaa [62], [63]. Geneet tinen alttius, diabetes,
uniapnea , munuaisten vajaatoiminta ja tupakointi assosioituvat poikkileikkausasetelmissa suurempaan vasemman kammion massaan
[61].
LVH on itsenä inen sydän- ja verisuonisa irauksien vaaraa lisäävä tekijä. LVH on yhteydessä  kokonaiskuolleisuuden kasvun, eteisvärinän,
sydämen systolisen vajaatoiminna n (HFrEF), diastolisen toiminna n häiriön (HFpEF), sydäninfarktin, pienent yneen koronaarireservin,
aivohalvauksen, sydänäkkikuoleman ja kammioperäisten rytmihäiriöiden riskiin. Ks. Käypä hoito -suositus Sydämen vajaatoiminta
«Sydämen vajaatoiminta».
Eri EKG-kriteerein määritelty LVH suurentaa fataalien ja ei-fataalien sydän- ja verisuonitautitapahtumien riskin 2–5-kertaiseksi.
Riski on erityisen suuri, jos volttikriteerien lisäksi EKG:ssä  on repolarisaatiomuutoksia.
Ks. lisätietoa aiheesta .
LVH:n perusselvitys tehdään EKG:n avulla (ks. lisätietoa aiheesta ), [64], [65], [66], [67], (taulukko 6).
Sydämen ultraäänitutkimuksella todetun LVH:n todennä köisyys voidaan arvioida Cornellin amplitudien, painoindeksin ja systolisen
verenpa ineen avulla [67], «hoi04010c.pdf».
Sydämen kaikututkimus on EKG:tä herkempi LVH:n diagnostiikassa. Se tulee tehdä erityisest i silloin, jos EKG ei vasemman
haarakatkoksen tai muun merkittävän QRS-poikkeaman johdosta sovellu LVH:n arviointiin tai jos kaikututkimuksen tekemiseen on
lisäaiheita, kuten
epäily sydämen systolisest a tai diastolisest a vajaatoiminna sta
epäily merkittävästä läppäviasta
aiemmin tutkimaton eteisvärinä tai muu merkittävä rytmihäiriö. Ks. Käypä hoito -suositus Eteisvärinä «Eteisvärinä».1
14.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 8/29
Taulukko 6. Sydämen vasemman kammion hypertrofian (LVH) diagnostiikka EKG:n avulla
Menetelmä Normaalilöydös tai viitealueTulkinta
EKG
Sokolow–Lyon: SV1 + RV5 (tai RV6) < 35 mm Epäherkkä, spesifinen
Cornellin voltit: SV3 + RaVL miehet: < 28 mm naiset: < 20
mmEpäherkkä, spesifinen
Cornellin tulo miehet: QRS:n kesto (ms) × (RaVL (mm) + SV3 (mm)) < 2 440 mm × ms Epäherkkä, spesifinen
Cornellin tulo naiset: QRS:n kesto (ms) × (RaVL (mm) + SV3 (mm) + 6
(mm))< 2 440 mm × ms Epäherkkä, spesifinen
ST-T-strain ei normaalisti Epäherkkä, spesifinen
 Molemmat (Sokolow–Lyon ja Cornell) yhdistettyinä: herkkyys kohtalainen ja spesifisyys hyvä. EKG-amplitudeissa 1 mm = 0,1 mV
Munuaissairaus
Munuaissairaudet altistavat hypertensio n kehittymiselle, ja toisaalta kohonnut verenpa ine voi johtaa hypertensiiv isen munuaisvaurion
syntyyn. Lievästikin kohonnut verenpa ine nopeuttaa munuaissairauksien etenem istä. Ks. lisätietoa aiheesta .
Lisääntynyt albumiinin eritys ja pienenev ä GFR ilmentävät munuaistoiminna n heikentymistä ja lisäävät verisuonitapahtumien vaaraa
sekä munuaisvaurion etenem istä [68].
Lisääntynyt albuminuria ja pienent ynyt GFR ovat varhaisia merkkejä kohde-elinvauriosta.
Albuminuria (U-Alb/Krea ≥ 3 mg/mmol; albuminuria ≥ 30 mg/vrk) ja munuaistoiminna n heikkenem inen (GFR < 60 ml/min)
lisäävät verisuonitapahtumien vaaraa [69]. Ks. myös lisäaineist o , [70], [71], [72], [73] ja taulukko 5, (ks. Käypä hoito -suosituksen
Diabeteksen munuaistauti taulukko 1 «Diabeteksen munuaistauti»), [73].
Munuaisten kaikututkimusta suositellaan, jos eGFR on < 30 ml/min//1, 73 m tai potilaalla on proteinu ria (makroalbuminuria; U-
Alb/Krea > 30 mg/mmol tai U-Alb > 300 mg/vrk). Ks. myös kohta Aiheita erikoissairaanhoidon konsultaatioon «A9».
Silmät
Vaikea hypertensiiv inen retinopatia (verenvuoto, mikroaneurysmat, kovat eksudaatit, papilla- tai makulaturvotus) ennu staa
suurentunutta aivohalvaus- ja kuoleman riskiä [74], [75], [76].
Silmän pohjatutkimus on syytä tehdä aina, kun diastolinen painetaso on ≥ 120 mmHg.
Luotettavin tutkimustapa on silmänpohjien valokuvaus.
Kohde-elinvaurio suurissa verisuonissa
Kohonneeseen verenpa ineeseen liittyviä verisuonitason vauriota voidaan arvioida mittaamalla [77]
keskeisen verenkierron suonten jäykkyyttä pulssiaallon etenem isno peuden avulla
kaulavaltimon seinä mäpaksuutta (intima-mediapaksuus, IMT) tai ateroskleroottista plakkia kaikukuvauksella
nilkka-olkavarsipainesu hde (Ankle-Brachial Index, ABI) .
Kohonneen verenpa ineen hoitopäätökset voidaan tehdä ilman edellä lueteltuja tutkimuksia.
Eksogeenisen ja sekundaarisen hypertension epäily
Verenpa inepo tilaan ensit apaamisella on syytä kiinnit tää huomiota seuraaviin asioihin:
ravinto ja nautintoaineet :
suola
alkoholi
tupakka ja ei-lääkkeelliset nikotiinit uotteet
lakritsiuutetta sisältävät tuotteet , [78]
huumeet, erityisest i amfetamiini, kokaiini ja muut stimulantit
lääkitykset [79], [80]:
tulehduskipulääkkeet, COX-2-selektiiviset mukaan luettuina (ks. Käypä hoito -suositus Kipu «Kipu»), [81]
estrogeenia  ja progesteronia sisältävät ehkäisyvalmisteet
estrogeenia  tai testosteronia sisältävät hormonikorvausvalmisteet
glukokortikoidit, mineralokortikoidit, anaboliset steroidit
sympatomimeetteja sisältävät nuha-, yskän- ja allergialääkkeet
kalsineu riinin estäjät (syklosporiini ja takrolimuusi)
erytropoietiini
eräät masennu slääkkeet, kuten MAO:n estäjät, trisykliset antidepressa ntit ja selektiiviset serotoniinin ja noradrenaliinin
takaisino ton estäjät (SNRI-lääkkeet)
toisen polven psykoosilääkkeet (esim . klotsapiini,  risper idoni ja ketiapiini)
eräät syöpälääkkeet.
Sekundaari nen hypertensio:1
1
1
1
1
1
24.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 9/29
syitä:
munuaisparenkyymin sairaudet (renaalinen hypertensio )
renovaskulaarinen hypertensio
primaarinen aldosteronism i
muut endokrinologiset syyt:
akromegalia
Cushingin oireyhtymä
feokromosytooma
kilpirauhasen toimintahäiriöt
primaarinen hyperparatyreoosi
muut syyt:
uniapnea
aivokasvaimet
aortan koarktaatio
monogeeniset  hypertensio muodot (mm. Liddlen oireyhtymä)
Sekundaarinen hypertensio  on harvinainen,  mutta noin 1–5 %:ssa tapauksista kohonneen verenpa ineen taustalla on mahdollisest i
parannet tavissa oleva sairaus [82]. Ks. lisäaineist o .
Munuaissairauksiin liittyvä hypertensio  on yleisin sekundaarisen hypertensio n muoto. Käytännössä kaikkiin
munuaisparenkyymin sairauksiin voi liittyä kohonnut verenpa ine.
Munuaisverisuoniperäisen hypertension tavallisim mat syyt ovat ateroskleroottinen munuaisvaltimon ahtauma (noin 90 %
renovaskulaarisest a hypertensio sta) ja fibromuskulaarinen dysplasia (noin 10 %).
Primaari a hyperald osteronismia tulee epäillä, jos potilaalla on hypokalemiataipumus ja huonosti hoitoon reagoiva
hypertensio .
Lakritsiuutetta sisältävien tuotteiden käyttö tulee selvittää ennen jatkotutkimuksia, koska joillakuilla verenpa inepo tilailla
pienet kin määrät lakritsiuutetta voivat aiheuttaa hankalahoitoisen hypertensio n, johon osalla potilaista liittyy
hypokalemiataipumus.
Muut sekundaarista hypertensio ta aiheuttavat sairaudet ovat hyvin harvinaisia, tai kohonnut verenpa ine ei niissä  ole ensisij ainen
kliininen ongelma.
Verenpa inepo tilaan lähettämistä erikoislääk ärin konsultaatioon (ks. seuraava kohta) voidaan harkita, jos anamneesi,  kliiniset
löydökset tai peruslaboratoriokokeet antavat aiheen epäillä sekundaarista hypertensio ta.
Sekundaarista hypertensio ta tulee epäillä, jos
potilaan verenpa inetaso on noussut nopeasti
potilas on < 30-vuotias
potilaan hypertensio  on hoitoresist entti
potilaalla on laaja-alaisia kohde-elinvaurioita (LVH, munuaisvaurio, silmänpohjalöydöksiä).
Aiheita erikoissairaanhoidon konsultaatioon
Potilaalla on hypertensiiv inen kriisi. Ks. kohta Hypertensiiv inen kriisi «A10».
Epäillään sekundaarista hypertensio ta. Ks. kohta Eksogeenisen ja sekundaarisen hypertensio n epäily «A3».
Kyseessä  on raskaudenajan hypertensio .
Kyseessä  on hoitoresist entti hypertensio : verenpa inetavoitetta ei omahoidosta ja vähintään kolmen lääkkeen yhdistelmähoidosta (yksi
lääkkeistä diureetti) huolimatta ole saavutettu.
Potilaalle on vaikea löytää sopivaa lääkitystä.
Laskenna llinen GFR pienenee seurannassa 25 % tai < 30 ml/min, albuminuria lisääntyy (U-Alb/Krea > 30 mg/mmol tai dU-Prot > 500
mg) ACE:n estäjän tai sartaanin käyttämisest ä huolimatta, tai kehittyy erotusdiagnostinen tai merkittävä hoito-ongelma.
Taulukko 7. Suositus elintapojen muutoksista kohonneen verenpaineen ehkäisyssä ja osana hoitoa
Tekijä Tavoite
Natriuminsaanti, mg/vrk < 2 000 (vastaa < 5 g:aa NaCl/vrk)
Kaliuminsaanti, mg/vrk Naiset ≥ 3 100
Miehet ≥ 3 500
Kalsiuminsaanti, mg/vrk ≥ 800
Tyydyttyneet ja trans-rasvahapot, E % < 10
n-3-sarjan monityydyttymättömät
rasvahapot, E%≥ 1
Alkoholin käyttö, g viikossa (annosta
viikossa)Naiset < 100 (< 9)
Miehet < 160 (< 14)
Liikapaino ja lihavuus Liikapainoisilla (painoindeksi 25–29,9 kg/m) ja lihavilla (painoindeksi vähintään 30 kg/m) 5–10 %:n
suuruinen painon väheneminen [60]1
2
2
3 4 5
6 5
2 24.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 10/29
Tekijä Tavoite
Vyötärölihavuus Vyötärön ympärysmitta miehillä < 100 cm ja naisilla < 90 cm
Fyysinen aktiivisuus Vähintään viidesti viikossa vähintään 30 minuuttia kerralla kohtuukuormitteista liikuntaa, esimerkiksi
reipasta kävelyä
TupakointiTupakoinnin lopettaminen [83]
Vastaa 87 mmol:n natriummäärää
Vastaa naisilla 79 mmol:n ja miehillä 90 mmol:n kaliummäärää
Tärkein lähde kovat maito- ja muut eläinrasvat
 Tärkeimmät lähteet rasvaiset maitovalmisteet ja voi, rasvaiset leivonnaiset ja rasvaiset liharuoat
Osuus energiansaannista
Tärkeimmät lähteet kala (eikosapentaeeni- ja dokosaheksaeenihappo) ja rypsiöljy (alfa-linoleenihappo)
Kohonneen verenpaineen ehkäisy ja hoito elintapamuutoksilla
Kohonneen verenpa ineen tärkeimpiä muutettavissa olevia riskitekijöitä ovat suolan (natriumin) liiallinen saanti, runsas alkoholin
käyttö, vähäinen fyysinen aktiivisuus ja ylipaino.
Koko väestöön jo varhaislapsuudesta asti kohdistuvien toimenpit eiden avulla pyritään estämään verenpa ineen iänmukainen nousu.
Verenpa inetta alentavat ja muita sydän- ja verisuonitautien vaaratekijöitä vähentävät elintapamuutokset ovat keskeinen osa kohonneen
verenpa ineen hoitoa [83], [84], [85].
Suomalaisten miesten ja naisten natriuminsa anti on 1970-luvun alusta pienent ynyt kolmannek sen ja kasvisten ja hedelmien käyttö
on kolminkertaistunut [86], [87], [88], [89], [90]. Ravinno n kovat rasvat ovat korvautuneet  osin pehmeillä kasvisper äisillä rasvoilla ja
öljyillä [89], [90].
Ruokavalion edullinen kehitys on kuitenkin 2000-luvulla pysähtynyt. Suolan ja kovien rasvojen saanti on edelleen runsasta [90], [91],
[92], [93]. Ylipainoisuus ja alkoholin käyttö ovat lisääntyneet  tasaisest i 1970-luvulta alkaen [3], [7], [94], [95].
Elintapamuutosten toteuttaminen vaatii pitkäjänteistä ja suunnit elmallista neuvontaa [96]. Ks. lisäaineist o .
Natrium
Suomalaisten miesten keskimääräinen natriuminsa anti on noin 3 700 mg/vrk (suolaa 9,5 g/vrk) ja naisten 2 700 mg/vrk (suolaa
7 g/vrk) [90].
Natriuminsa anti ylittää monink ertaisest i fysiologisen tarpeen (230 mg/vrk) ja turvalliseksi vähimmäissaannik si (575 mg/vrk; vastaava
suolamäärä 1,5 g/vrk) määritetyn tason [97].
Runsas natriuminsa anti lisää iänmukaista verenpa ineen nousua [98], [99] ja suurentaa aivohalvauksen [100], [101] sekä sydän- ja
verisuonitautitapahtumien ja -kuolemien vaaraa. Riski suurenee linea arisest i ilman kynnysarvoa tai J-käyrää vähäisest ä suolan käytöstä
alkaen [102], [103], [104], [105]. Tästä linjasta poikkeavia tuloksia on esitetty väestötutkimuksissa , joissa yksi keskeinen ongelma on liittynyt
yhdestä kertavirtsanäytteestä tehtyihin natriumin ja kreatiniinin mittauksiin ja niist ä kaavan avulla laskettuun suolan käytön arviointiin
[106], [107], [108], [109]. Menet elmä ei kuvaa yksilön lyhyen eikä pitkän aikavälin suolan käyttöä [109].
Natriuminsa annin vähentäminen alentaa verenpa inetta annoksesta riippu valla tavalla [A], [110], [111].
Yli 4 viikkoa kestäneissä  tutkimuksissa  suolansaannin vähentäminen noin 6 grammaa päivässä (vastaa natriummäärää 2 300 mg eli
100 mmol) alentaa verenpa inetta [112].
hypertensiiv isillä potilailla keskimäärin 7/4 mmHg
normotensiiv isillä potilailla keskimäärin 4/2 mmHg.
Lisäksi se saattaa pienent ää sydän- ja verisuonisa irauksien riskiä [62], [108], [113], [114], [115], [116].
Natriuminsa annin rajoittaminen parantaa verenpa inelääkkeistä erityisest i angiotensiinik onvertaasin (ACE) estäjien [B],
angiotensiinir esept orin (ATR) salpaajien [C], beetasalpaajien [B] ja diureettien vaikutusta [B].
Lisäksi se vähentää verenpa inelääkkeiden tarvetta [B] ja voi vähentää vasemman kammion hypertrofiaa [B].
Muut ravintotekijät
Runsaasti kasviksia, hedelmiä ja marj oja sisältävä ruokavalio alentaa kohonnutta verenpa inetta.
Vaikutus tehostuu, jos ruokavalioon lisätään rasvattomia ja vähärasvaisia maitovalmisteita tai vähennet ään natriuminsa antia [B].
Kaliumin vähäinen saanti (< 1 600 mg/vrk) ravinnosta suurentaa aivohalvausvaaraa [117].
Kaliumin- [A], kalsiumin- [A] ja mag nesiuminsaan nin [B] lisäämi nen voivat alentaa verenpa inetta. Suomalaisten
keskimääräinen kaliuminsa anti (naiset 3 700 mg/vrk ja miehet 4 400 mg/vrk), kalsiuminsa anti (naiset 1 070 mg/vrk, miehet 1 300
mg/vrk) ja magnesiu minsa anti (naiset 370 mg/vrk, miehet 450 mg/vrk) ovat kansainvälisest i runsaita ja ylittivät suositustasot 80 %:lla,
kun ravinno nsaannin aliraportoijat on poistettu tarkasteluista [90].
Suomalaisilla kalium-, kalsium- ja magnesiu mlisien vaikutukset verenpa ineeseen voivat siksi olla kansainvälisissä  tutkimuksissa
osoitettuja pienem piä.
Kuidunsaan nin lisäämi nen voi alentaa verenpa inetta [A].
Tyydyttyneen rasvan käytön vähentäminen ja korvaaminen tyydyttämättömillä rasvoilla pienent ää veren kokonaiskolesteroli- ja LDL-
kolesterolipitoisuutta ja parantaa insu liinih erkkyyttä muttei alenna  verenpa inetta [118], [119]. Suomalaiset saavat ravinno staan paljon
tyydyttyneitä rasvoja (suositus < 10 E%), miehet 15,1 E% ja naiset 14,4 E% [90].1 
2 
3 
4
5 
6 4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 11/29
Kalaperäiset n-3-sarjan rasvahapot alentavat suurina annoksina  verenpa inetta [A].
Lakritsin ja salmiakin sisältämä glykyrretiinih appo (glykyrritsiinih apon aktiivinen metaboliitti) voi nostaa verenpa inetta ja aiheuttaa
hypokalemiaa . Glykyrretiinih appo estää kortisolia inaktiiviseksi kortisoniksi muuttavan 11beeta-hydroksisteroididehydrogenaasin
toimintaa. Kortisolin sitoutuminen mineraalikortikoidiresept oriin lisääntyy, ja aldosteronin kaltainen vaikutus kasvaa.
Mineralokortikoidivaikutuksen johdosta natriumin eritys virtsaan vähenee ja kaliumin eritys lisääntyy. Henkilöillä, joilla 11beeta-
hydroksisteroididehydrogenaasi toimii perinnö llisten syiden johdosta vajavaisest i, vaikutus saattaa tulla esille jo satunnaisista ja pienist ä
määristä lakritsiuutetta sisältäviä tuotteita. Henkilöiden, joilla on kohonnut verenpa ine ja taipumus mataliin veren kaliumarvoihin, on
syytä olla käyttämättä lakritsiuutetta sisältäviä valmisteita.
Vapaa-ajan liikunta ja muu fyysinen aktiivisuus
Runsaasti liikkuvien verenpa ine on alhaisem pi kuin vähän liikkuvien, ja heillä esiint yy vähemmän kohonnutta verenpa inetta [120] ja
valtimosairauksia.
Kohtuukuormitteinen kestävyysliikuntaharjoittelu laskee lepoverenpa inetta keskimäärin 8/5 mmHg henkilöillä, joilla on kohonnut
verenpa ine. Liikuntaharjoittelun vaikutus normaalialueella olevaan lepoverenpa ineeseen on puolestaan vähäinen [A] .
Pitkäaikaisrekisteröinnil lä mitattu päiväaikainen verenpa ine hyper- ja normotensiiv isillä pienenee kestävyysharjoittelun jälkeen noin
3/3 mmHg. Yöaikainen verenpa ine ei sen sijaan muutu [B].
Kohtuukuormitteinen lihasvoimaharjoittelu kuntosalilla ilmeisest i alentaa kohonnutta verenpa inetta muutaman mmHg-yksikön verran
erityisest i henkilöillä, joiden verenpa ine on lievästi kohonnut (tai normaalialueella) [B].
Henkilöille, joilla on todettu lievästi tai kohtalaisest i kohonnut verenpa ine, suositellaan kohtuukuormitteista kestävyysliikuntaa 150
minuuttia viikossa (esim . reipa sta kävelyä 30 minuuttia 5 päivänä viikossa). Määrä vastaa terveysliikuntasuosituksen
kestävyysliikuntaosaa [121].
Ks. Käypä hoito -suositus Liikunta «Liikunta (ylläpito lopetettu)», [122].
Lihavuus
Vähäener giaisen ruokavalion avulla saavutettu noin 4 kg:n laihtuminen alentaa liikapainoisten hypertensiiv isten henkilöiden systolista
ja diastolista verenpa inetta noin 4/3 mmHg [B], [123], [124]. Laihduttamisen pitkäaikaisvaikutukset saattavat olla pienem piä [125], [126].
Lihavuusleikkauksen avulla saavutettu 24 kg:n painon lasku ei näytä alentavan verenpa inetta enem män kuin ruokavaliohoito [127].
Laihdutuslääke orlistaatin avulla saavutettu laihtuminen alentaa verenpa inetta vähemmän kuin ruokavalion avulla saavutettu [B], [123],
[124], [128].
Uusien diabeteslääkkeiden (GLP-1-agonistit ja SGLT2:n estäjät) on havaittu laskevan painoa ja alentavan verenpa inetta
pitkäaikaiskäytössä [129], [130], [131], [132].
Ylipainon vähentäminen,  jota voidaan täydentää vähänatriumisella dieetillä, näyttää pienent ävän sydämen vasemman kammion massaa
[C].
Pitkäaikaiseen edulliseen verenpa inetulokseen tarvitaan laihtumisen ohella myös pysyviä ravinno n laadun muutoksia, erityisest i suolan
käytön vähentämistä [133], [134].
Ks. Käypä hoito -suositus Lihavuus (lapset , nuoret ja aikuiset) «Lihavuus (lapset , nuoret ja aikuiset)», [60].
Alkoholin käyttö
Runsas alkoholin käyttö kohottaa verenpa inetta [135], suurentaa aivohalvauksien vaaraa [101], [136] ja saattaa vähentää
verenpa inelääkityksen tehoa [137].
Runsaan alkoholin käytön kohtuullistaminen alentaa kohonnutta verenpa inetta [B].
Alkoholin keskimääräisen viikkokulutuksen tulisi miehillä olla enint ään 14 annosta (160 g alkoholia) ja naisilla 9 annosta (100 g
alkoholia), eikä päiväkulutus saisi olla > 5 annosta (55 g alkoholia).
Ks. myös Käypä hoito -suositus Alkoholiongelmat «Alkoholiongelmat», [138].
Rentoutus
Erilaisten rentoutus- ja biopalauteohjelmien ja akupunktiohoidon pitkäaikaisvaikutuksista verenpa ineen alentajina ei ole selvää näyttöä
[139], [140], [141], [142], [143], [144], [145].
Tupakointi
Tupakointi lisää sympaattisen hermoston aktiivisuutta ja nostaa sydämen syketasoa [146], [147], [148]. Kroonisest i tupakoivilla sydämen
minuuttitilavuus on korkeampi tupakoimattomiin verrattuna [149].
Pienessä  34 potilaan tutkimuksessa  tupakoinnin lopettamisen havaittiin alentavan systolisen verenpa ineen päivätasoa noin 4 mmHg
[150], mutta ennen aamun ensim mäistä tupakkaa mitattua verenpa inetasoa se ei näyttäisi alentavan [146], [150]. Vaikka tupakoinnin
vaikutus verenpa ineeseen on kokonaisuutena aika vähäinen ja lyhytkestoinen,  on tupakoinnin verenkiertoelimistön sairastuvuusriskiä
lisäävä vaikutus erittäin merkittävä [151], [152], [153].
Elintapamuutosten tavoitteet ja toteuttaminen
Kohonneen verenpa ineen ehkäisyä ja hoitoa koskevat elintapaohjeet esitetään taulukossa 7, lautasmalli kuvassa «Lautasmalli» ja
ruokakolmio kuvassa «Ruokakolmio». Ks. Valtion ravitsemusneu vottelukunnan (VRN) ravitsemussuositukset internetsivuilta
http://www. ruokavirasto.fi/vrn/ravitsemussuositukset.4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 12/29
Natriumin keskimääräinen päivittäinen saanti tulee vähentää < 2 000 mg:aan (ruokasuolaa < 5 g) [154], [155].
Tavoitteeseen pyritään
korvaamalla runsassuolaiset elintarvikkeet tuotteilla, joissa on pakkausmerkintä "vähemmän suolaa" tai "suolaa vähennet ty" [156].
Sydänmerkki auttaa valitsemaan tällaisia tuotteita. Ks. http://www. sydanmerkki.fi.
suosimalla vähäsuolaisia (< 1 % suolaa) leipiä , koska runsaan käyttönsä vuoksi leipä  on yksittäisistä elintarvikkeista suurin suolan
lähde
korvaamalla leipä  ja leivänpäälliset aamupalalla suolattomaan puuroon, hedelmiin ja marjoihin
vähentämällä punaisen lihan ja prosesso idun lihan määrää < 500 grammaan viikossa
korvaamalla suolaa sisältäviä elintarvikkeita kasviksilla, hedelmillä ja marjoilla tavoitteena  näiden vähintään 500 g/vrk:n
yhteissa anti
luopumalla suolan käytöstä ruoanvalmistuksessa  ja ruokapöydässä.
Noin viidennes suomalaisista saa ravinno staan suositeltua vähemmän kaliumia [90]. Kaliuminsa antia voidaan kasvattaa nauttimalla
aikaisem paa enem män
täysjyväviljavalmisteita
kasviksia
marjoja
hedelmiä.
Maitovalmisteiden päivittäinen käyttö, 3–4 annosta (1 annos on 2 dl maitotuotetta tai 2–3 viipaletta juustoa), turvaa yleensä  kalsiumin
riittävän saannin.
Kalsiumlisää (enint ään 1 000 mg/pv) suositellaan, jos maitovalmisteiden käyttö on vähäistä.
Rasvan määrä ja laatu saadaan suositusten (taulukko 7) mukaiseksi seuraavasti:
Valitaan rasvattomia tai vain vähän tyydyttynyttä rasvaa sisältäviä elintarvikkeita.
Valitaan Sydänmerkin kriteerit täyttävää, vähintään 60 % rasvaa sisältävää margariinia  ja kasviöljyä.
Kalarasvojen riittävä saanti varmistetaan nauttimalla kahdella viikoittaisella aterialla rasvaista kalaa.
n-3-sarjan monityydyttymättömien rasvojen saantia voidaan lisätä käyttämällä myös rypsiö ljyä ja rypsiö ljypohjaista margariinia .
Kohonnutta verenpa inetta voidaan vähentää kohtuukuormitteisel la kestävyystyyppisel lä liikunnalla, esim erkiksi reippa alla kävelyllä,
jonka kesto on vähintään 30 minuuttia (yhtenä tai useampana jaksona) ja joka toistuu useim pina  päivinä viikossa, mieluiten päivittäin
[157].
Ylipainoisia (painoindeksi 25–29,9 kg/m) ja lihavia (painoindeksi vähintään 30 kg/m) tulee kannustaa laihduttamaan siten, että
tavoitteena  on 5–10 %:n pudotus lähtöpainosta [60], [158].
Alkoholin viikkokulutuksen tulisi olla
miehillä enint ään 160 g (< 14 ravintola-annosta)
naisilla < 100 g (< 9 ravintola-annosta).
Ravintola-annos on esim erkiksi pullo (33 cl) keskiolutta, 12 cl viiniä  tai 4 cl väkeviä alkoholijuomia. Yksi ravintola-annos sisältää 12
grammaa absoluuttista alkoholia.
Kuva 4.2 24.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 13/29
Lautasmalli. Ravitsemussuositusten mukainen ateria kootaan niin sanotun lautasmallin mukaan: 1. Puolet lautasesta täytetään kasviksilla,
esim erkiksi salaateilla, raasteilla tai keitetyillä kasviksilla. Salaattiin lisätään muutama tippa  öljypohjaista salaattikastiketta. 2. Neljännes
lautasesta täytetään perunalla, pastalla tai riisillä. 3. Neljännes lautasesta täytetään vähärasvaisella ja vähäsuolaisella kalalla, kanalla tai
lihalla. Kasvisruokavaliossa liha korvataan pavuilla ja linsseil lä tai muilla kasviproteiiniv almisteilla. 4. Ruokajuomaksi valitaan rasvaton
maito. 5. Lisäksi nautitaan yksi tai kaksi palaa pehmeällä margariinilla voideltua täysjyväleipä ä.
Lähde: Valtion ravitsemusneuvottelukunta, suomalaiset ravitsemussuositukset  https://www. ruokavirasto.fi/vrn/ravitsemussuositukset
Kuva 5.
Ruokakolmio. © Valtion ravitsemusneuvottelukunta
Lähde: Valtion ravitsemusneuvottelukunta, suomalaiset ravitsemussuositukset  https://www. ruokavirasto.fi/vrn/ravitsemussuositukset
Ravitsemusohjeita kohonneen verenpaineen ehkäisyyn ja hoitoon
Vältä suolan ja suolaa sisältävien mausteseosten käyttöä ruoanvalmistuksessa  ja pöytämausteina .
Vältä runsassuolaisia elintarvikkeita. Valitse leivät, liha- ja kalajalosteet, juustot ja valmisruoat vähäsuolaisina  (pakkausmerkintä
"vähemmän suolaa" tai "suolaa vähennet ty" tai Sydänmerkki)
Syö kasviksia, hedelmiä ja marjoja vähintään 500 grammaa/vrk.
Suosi rypsiö ljyjä ja rypsiö ljypohjaisia kasvimargariinej a.
Käytä rasvattomia tai vähärasvaisia maitovalmisteita.
Syö kalaa vähintään kahdesti viikossa.
Laihduta, jos olet ylipainoinen tai lihava.
Käytä alkoholia enint ään kohtuullisest i.
Vältä lakritsiuutetta sisältäviä tuotteita.
Lääkehoidon vaikutukset verenpaineeseen ja siedettävyys
Kohonneen verenpa ineen hoidossa käytettävät ensisij aiset lääkeryhmät ovat (aakkosjärjestyksessä )
angiotensiinik onvertaasient syymin estäjät (ACE:n estäjät)
angiotensiinir esept orin (ATR, tyyppi 1) salpaajat
diureetit
kalsiumkanavan salpaajat.
Beeta-adrener gisten resept orien salpaajia (beetasalpaajat) voidaan käyttää ensisij aislääkkeenä  silloin, kun niille on muukin käyttöaihe.
Kyseiset  lääkkeet alentavat kohonnutta verenpa inetta keskimäärin saman verran [A].
Verenpa ine laskee yhdellä lääkkeellä keskimääräistä annosta käytettäessä  keskimäärin 9/6 mmHg (systolinen/d iastolinen paine)
[159].
Useat tekijät, kuten ikä, elintavat, kohonneen verenpa ineen lähtötaso ja mahdollinen muu samanaikainen verenpa inetta alentava
lääkehoito, voivat vaikuttaa verenpa ineen laskun suuruuteen.
Pieninä  annoksina  kaikkien ensisij aislääkeryhmien valmisteet ovat hyvin siedettyjä [A].4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 14/29
Erityisest i diureettien, beetasalpaajien ja kalsiumkanavan salpaajien haittavaikutukset lisääntyvät annosta suurennet taessa  [159].
Lääkehoidon tehoa ja siedettävyyttä voidaan parantaa käyttämällä usean lääkkeen "pient en" annosten yhdistelmää  [159], [160]. Ks. kohta
Lääkkeiden annokset ja yhdistelmähoito «A4».
Lääkehoidon vaikutukset sydän- ja verisuonitautitapahtumiin
Systolisen verenpa ineen alentaminen 10 mmHg ja diastolisen 5 mmHg lääkkein vähentää 5 vuodessa  aivohalvauksia 30–40 % ja vakavia
sepel valtimotautitapahtumia 16 % [A], iäkkäillä ja keski-ikäisillä suhteellisest i yhtä paljon [161].
Isoloituneen systolisen hypertensio n lääkehoito vähentää 4 vuodessa  sepel valtimotapahtumia keskimäärin 23 % ja aivohalvauksia 30 %
[A].
Keskeistä sydän- ja verisuonitautitapahtumien ja -kuolemien vähentämisessä  on kohonneen verenpa ineen tehokas alentaminen [160].
Useim miten siihen tarvitaan yhdistelmähoitoa [162]. Ks. kappale Lääkkeiden annokset ja yhdistelmähoito «A4».
Hoidot, joiden pohjana on ACE:n estäjä, ATR:n salpaaja, beetasalpaaja, diureetti tai kalsiumkanavan salpaaja, vähentävät sydän- ja
verisuonitautitapahtumia [A], [159], [163], [164], [165], [166], [167].
Mineralokortikoidiresept orin salpaajat [168], alfasalpaaja pratsosiini ja sent raalisest i sympaattista järjestelmää estävät lääkkeet klonidiini
ja moksonidiini alentavat kohonnutta verenpa inetta, mutta niiden vaikutuksista verenpa inepo tilaiden kardiovaskulaaritapahtumiin ei
ole tutkimusnäyttöä, joskin spironolaktonin ennu steellinen hyöty on osoitettu sydämen vajaatoimintapotilailla.
Kohonneen verenpa ineen alentaminen 10/5 mmHg pienent ää sydämen vajaatoiminna n riskiä noin 40 % [169], [170]. Suurempi
verenpa ineen lasku pienent ää riskiä enem män.
Lääkehoidon aiheet
Lääkehoito aloitetaan, jos verenpa ine pysyy elintapahoidoista huolimatta kohonneena  «Vastaanottopainetasoon perustuva hoitokaavio»
ja «Kotipainetasoon perustuva hoitokaavio».
Toistuvissa vastaanottomittauksissa  systolinen verenpa ine ≥ 160 mmHg tai diastolinen paine ≥ 100 mmHg [A] Kohonnut painetaso
varmistetaan kotimittausten tai verenpa ineen pitkäaikaisrekisteröinnin avulla.
Toistuvissa vastaanottomittauksissa  systolinen verenpa ine on 140–159 mmHg tai diastolinen verenpa ine 90–99 mmHg, ja
kotimittausten tai pitkäaikaisrekisteröinnin perusteella verenpa ine on kohonnut [B].
Ks. kotimittausten ja pitkäaikaisrekisteröinnin vastaavat painetasot taulukosta 4.
Sydän- ja verisuonitautien kokonaisvaaraa on lisäksi aina pyrittävä pienent ämään tehokkaan elintapaohjauksen ja tarvittaessa
lääkehoidon (erityisest i statiinit ) avulla.
Sydän- ja verisuonitautien kokonaisvaara voidaan arvioida FINRISKI-laskurilla: https://www. terveyskirjasto.fi/pg t00013.
Kuva 6.
Vastaanottopainetasoon perustuva hoitokaavio4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 15/29
Kuva 7.
Kotipainetasoon perustuva hoitokaavio
Kohonneen verenpaineen hoidon tavoite
Kohonneen verenpa ineen vähimmäishoitotavoite on vastaanottomittausten perusteella < 140/90 mmHg [A].
Hoitotavoite on < 130/80 mmHg, jos tautiriski on suuri (kardiovaskulaarisairaus tai oireettomilla > 10 %:n riski FINRISKI-laskurilla
https://www. terveyskirjasto.fi/pg t00013) ja tiukempi tavoite voidaan haitoitta saavuttaa [171], [B]. Ks. kotimittausten ja
pitkäaikaisrekisteröinnin vastaavat painetasot taulukosta 4.
Korkea ikä ei vaikuta hoitotavoitteisiin,  joskin > 80-vuotiailla käytännön tavoite voi potilaan kokonaistilanteen perusteella olla <
150/90 mmHg g [172], [173].
Verenpa ineen vähimmäishoitotavoite diabeetikoilla on < 140/80 mmHg [C], [C]. Hoitotavoitteeseen < 130/80 mmHg pääseminen voi
pienent ää diabeetikon aivohalvausriskiä [C]. Tiukempaan tavoitteeseen pyritään, jos se voidaan haitoitta saavuttaa.
Hoitotavoite on < 130/80 mmHg kroonista munuaistautia sairastavalla potilaalla (eGFR < 60 ml/min/1, 73 m) ja tapauksissa , joissa
diabeettiseen tai ei-diabeettiseen munuaistautiin liittyy albuminuria (U-Alb > 300 mg/vrk tai U-Alb/Krea > 30 mg/mmol) ja tavoite
voidaan haitoitta saavuttaa [C]. Ks. myös Käypä hoito -suositus Diabeteksen munuaistauti «Diabeteksen munuaistauti», [73].
Lääkkeiden annokset, yhdistelmähoito ja ottoaika
Useim mat potilaat tarvitsevat yhdistelmähoitoa tavoitteen saavuttamiseksi [174].
Kahden verenpa inelääkkeen yhdistelmä alentaa kohonnutta verenpa inetta enem män kuin yhden lääkkeen annoksen
kaksink ertaistaminen [A].
Pienten annosten yhdistelmällä tavoitteet voidaan saavuttaa nopeasti ilman merkittäviä haittavaikutuksia [159].
Useim pia eri ryhmiin kuuluvia verenpa inelääkkeitä voidaan yhdistää «Kohonnutta verenpa inetta alentavan yhdistelmälääkehoidon
valinta».
Jos verenpa ineen lähtötaso on > 160/100 mmHg (kotimittauksissa  > 145/90 mmHg), lääkehoito on syytä aloittaa suoraan yhdistelmällä
«Kohonnutta verenpa inetta alentavan yhdistelmälääkehoidon valinta».24.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 16/29
Suositeltavia kahden lääkkeen yhdistelmiä ovat ACE:n estäjä tai ATR:n salpaaja yhdistettynä kalsiumkanavan salpaajaan tai
diureettiin.
Jos verenpa ineen hallintaan tarvitaan kolme lääkettä, mielekäs yhdistelmä on ACE:n estäjä tai ATR:n salpaaja yhdistettynä
diureettiin ja kalsiumkanavan salpaajaan.
Hoitoresist entissä hypertensio ssa mineralokortikoidiresept orin salpaajan lisääminen lääkehoitoon (spironolaktoni 12,5–25 mg/vrk
usein riittää) voi olla tehokasta [168], [175].
Verenpa inepo tilaiden hoidossa ei tule käyttää RAS-järjestelmää lamaavien lääkkeiden (ACE:n estäjä, ATR:n salpaaja) yhdistelmiä,
koska monoterapiaan verrattuna yhdistelmät lisäävät haittavaikutuksia mutta eivät vähennä  sydän- ja verisuonitautitapahtumia [176],
ks. Vältä viisaasti -suositus .
Syyt huonoon hoitovasteeseen on selvitettävä.
Ks. kohta Syyt kohonneen verenpa ineen huonoon hoitovasteeseen «A5».
Lääkkeet voidaan ottaa yhdessä  tai kahdessa  erässä aamulla ja/tai illalla .
Kuva 8.
Kohonnutta verenpa inetta alentavan yhdistelmälääkehoidon valinta. Ensisij aisest i suositellaan ACE:n estäjän tai ATR:n salpaajan
yhdistämistä kalsiumkanavan salpaajaan tai/ja tiatsididiureettiin. Beetasalpaajia voidaan käyttää yhdistelmä hoidossa silloin, kun se on
muusta syystä (oireinen sepel valtimotauti, rytmihäiriöt, sydämen vajaatoiminta) aiheellinen.  ACE:n estäjän tai ATR:n salpaajan
yhdistäminen beetasalpaajaan ei ole verenpaineen laskun kannalta optimaalinen yhdistelmä (musta katkoviiva), mutta sitäkin yhdistelmää
voidaan käyttää, jos se on muusta syystä aiheellinen (esim . sepel valtimotauti on aihe beetasalpaajan käytölle).
Beetasalpaajien ja diureetin yhdistelmää (keltainen katkoviiva) tulisi välttää ensis ijaisena  lääkityksenä  potilailla, joilla on metabolinen
oireyhtymä tai suurentunut riski sairastua diabetekseen.  Verenpa ineen laskun tehostamiseksi voidaan lisäksi käyttää
dihydropyridiinir akenteisen kalsiumkanavan salpaajan ja diureetin tai kalsiumkanavan salpaaja dihydropyridiinin ja beetasalpaajan
yhdistelmää (musta yhtenäinen viiva). Beetasalpaajien yhdistämistä verapamiiliin tai diltiatseem iin on vältettävä, koska siihen liittyy
bradykardian ja sydämen johtumishäiriön vaara (punainen katkoviiva).
Lääkkeen valinta eri sairausryhmissä
Lääkehoito räätälöidään yksilöllisest i.
Lääkevalintoihin vaikuttavat
kohonneen verenpa ineen vaikeusaste
kohonneeseen verenpa ineeseen liittyvät elinvauriot
muut samanaikaiset riskitekijät, sairaudet ja lääkitykset
lääkehoidon kustannukset.
Esimerkkejä verenpa inelääkkeen valinna sta eri sairaustiloissa ja erityistilanteissa  on taulukossa 8.
Taulukko 8. Esimerkkejä suositeltavista verenpainelääkkeistä eri sairaustiloissa ja erityistilanteissa.
Ei kohde-elinvaurioita
Komplisoitumaton hypertensio ACE:n estäjä, ATR:n salpaaja, kalsiumkanavan salpaaja, diureetti
Kohde-elinvaurio tai sydän- ja verisuonisairaus
LVH ACE:n estäjä, ATR:n salpaaja, kalsiumkanavan salpaaja, diureetti
Mikroalbuminuria tai proteinuria ACE:n estäjä, ATR:n salpaaja4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 17/29
Munuaisvaurio ilman albuminuriaa ACE:n estäjä, ATR:n salpaaja, kalsiumkanavan salpaaja, diureetti (furosemidi, jos eGFR < 30
ml/min/1,73 m)
Sairastettu aivohalvaus ACE:n estäjä, ATR:n salpaaja, kalsiumkanavan salpaaja, diureetti
Sairastettu sydäninfarkti Beetasalpaaja (ensimmäisen vuoden ajan), ACE:n estäjä (ATR:n salpaaja, jos ACE:n estäjä ei sovi)
Oireinen sepelvaltimotauti Beetasalpaaja, kalsiumkanavan salpaaja
Sydämen vajaatoiminta ACE:n estäjä, ATR:n salpaaja, diureetti, beetasalpaaja, mineralokortikoidireseptorin salpaaja
Eteisvärinä
Kohtauksittainen ATR:n salpaaja, ACE:n estäjä, beetasalpaaja
Pysyvä Beetasalpaaja, verapamiili (huom. ei näiden kahden yhteiskäyttöä)
Perifeerinen valtimotauti ACE:n estäjä, ATR:n salpaaja, kalsiumkanavan salpaaja
Erityistilanteet
Diabetes ACE:n estäjä, ATR:n salpaaja, kalsiumkanavan salpaaja, diureetti
Raskaudenaikainen hypertensio Beetasalpaaja, alfa- ja beetasalpaajan yhdistelmä (labetaloli), dihydropyridiinirakenteinen
kalsiumkanavan salpaaja (nifedipiini)
Astma Kalsiumkanavan salpaaja, ATR:n salpaaja, diureetti
Komplisoitumaton hypertensio
Tärkeintä ovat riittävä verenpa ineen lasku ja sydän- ja verisuonitautivaaran pienent äminen,  joihin useim miten tarvitaan
yhdistelmähoitoa. Ks. kohta Lääkkeiden annokset ja yhdistelmähoito «A4».
Ensisij aislääkkeiksi suositellaan ACE:n estäjää, ATR:n salpaajaa, diureettia ja kalsiumkanavan salpaajaa [160].
Beetasalpaajia ei suositella ensisij aislääkkeeksi, koska ne pienent ävät aivohalvausriskiä vähemmän kuin muut ensisij aislääkkeet,
erityisest i iäkkäillä [B]. Beetasalpaajien ja erityisest i niiden ja diureetin yhdistelmää tulisi välttää ensisij aislääkityksenä  potilailla, joilla
on metabolinen oireyhtymä tai suurentunut riski sairastua diabetekseen [A]. Ks. Vältä viisaasti -suositus .
Isoloitunut systolinen hypertensio
Isoloituneen systolisen hypertensio n hoidossa voidaan käyttää [177], [178], [179], [180]
pienia nnoksista diureettia
kalsiumkanavan salpaajaa
ACE:n estäjää tai ATR:n salpaajaa
tai näiden yhdistelmiä.
Dyslipidemiat
Dyslipidemia vaikuttaa oleellisest i valtimosairauksien kokonaisriskiin, joten sen hoito on hypertensio ssa tärkeää [181].
Dyslipidemia ei vaikuta verenpa inelääkkeiden valintaan.
Verenpa inelääkkeiden lipidivaikutukset ovat vähäisiä, ja niiden kliininen merkitys on epäselvä [B].
Ks. Käypä hoito -suositus Dyslipidemiat «Dyslipidemiat», [181].
Diabetes
ACE:n estäjään, ATR:n salpaajaan, diureettiin, beetasalpaajaan ja kalsiumkanavan salpaajaan pohjautuva verenpa ineen lääkehoito
parantaa ennu stetta [A].
Diabeetikon verenpa ineen lääkehoito tulisi yleensä  aloittaa kahden lääkeaineen yhdistelmällä, johon kuuluvat ACE:n estäjä (tai ATR:n
salpaaja) sekä kalsiumkanavan salpaaja tai diureetti.
Beetasalpaajaa ei yleensä  käytetä ensim mäisenä  verenpa inelääkkeenä , ellei sille ole muuta aihetta (esim . sepel valtimotauti)
Metabolisessa  oireyhtymässä kohonnutta verenpa inetta hoidetaan kuten diabeteksessa .
Ainakin tyypin 2 diabeetikon verenpa ineen hoitotulokset saattavat parantua käyttämällä hyperglykemian hoitoon SGLT2:n estäjiä tai
inkretiinim imeettejä, jotka laskevat verenpainetta [182], [183].
Ks. Käypä hoito -suositus Tyypin 2 diabetes «Tyypin 2 diabetes», [184].
Vasemman kammion hypertrofia (LVH)
Kohonneen verenpa ineen hoito estää LVH:n kehittymistä ja saattaa johtaa jo syntyneen LVH:n vähenem iseen (regressio on) [185].
Tehokkaampi verenpa ineen alentaminen  johtaa todennä köisem min LVH:n estymiseen ja regressio on kuin vähemmän tehokas
alentaminen.
Samansuuruista verenpa ineen laskua kohden ACE:n estäjät, ATR:n salpaajat ja kalsiumkanavan salpaajat ovat tehokkaampia
vähentämään LVH:ta kuin beetasalpaajat. Tiatsididiureettien teho on suurempi kuin beetasalpaajien mutta pienem pi kuin kolmen ensin
mainitun [185], [A].
Nykynäytön perusteella ACE:n estäjiä, ATR:n salpaajia ja kalsiumkanavan salpaajia on pidettävä ensisij aisina  valintoina LVH:n
hoidossa, tarvittaessa  diureetilla täydennettynä, ellei suolarajoitus toteudu riittävän hyvin [A], [186].
Sepelvaltimotauti
Lääkitys ACE:n estäjällä tulisi aloittaa kaikille sepel valtimotautia sairastaville, joilla on hypertensio  [A].24.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 18/29
ATR:n salpaaja voi korvata ACE:n estäjän niillä sepel valtimotautipotilailla, joille ACE:n estäjä ei sovi [A].
Beetasalpaajat parantavat ennu stetta, ja niitä tulee käyttää kohonneen verenpa ineen hoitoon sepel valtimotautipotilailla, joilla on
sydämen vajaatoiminta tai heikentynyt vasemman kammion systolinen toiminta (ejektiofraktio < 40 %) [187]
Beetasalpaajat ovat tehokkaita sydänlihasiskemian ja siitä aiheutuvien oireiden hoidossa
Pitkäkestoisest a beetasalpaajahoidosta ei kuitenkaan ole osoitettu ennu stehyötyä, kun sepel valtimotautikohtauksesta on kulunut yli
vuosi ja vasemman kammion toiminta on normaali [188].
Sepel valtimotautipotilailla verenpa ineen  hoitotavoitteeseen pääsemiseksi voidaan ACE:n estäjän ja mahdollisen beetasalpaajan ohella
käyttää kalsiumkanavan salpaajia ja diureetteja.
Beetasalpaajan oheen sopii dihydropyridiinit yyppinen kalsiumkanavan salpaaja.
Jos beetasalpaaja ei sovi, sen sijaan voidaan harkita diltiatseem in tai verapamiilin käyttöä, muttei kuitenkaan silloin, jos vasemman
kammion systolinen toiminta on heikentynyt.
Sydämen vajaatoiminta
Kalsiumkanavan salpaajat ovat mahdollisest i vähemmän tehokkaita sydämen vajaatoiminna n estossa kuin ACE:n estäjät, ATR:n
salpaajat, diureetit ja beetasalpaajat [10], [170]. Ero kuitenkin häviää, kun sallitaan kalsiumkanavan salpaajien yhteiskäyttö muiden
verenpa inelääkkeiden kanssa  [189].
Sydämen vajaatoiminna ssa, jossa vasemman kammion supistusvoima on säilynyt (diastolinen vajaatoiminta), kohonnutta verenpa inetta
voidaan hoitaa kaikilla verenpa inelääkkeillä, mutta diureetit saattavat lisäksi helpottaa vajaatoiminna n oireita [190].
Systolisessa  vajaatoiminna ssa ACE:n estäjät, ATR:n salpaajat, tietyt beetasalpaajat ja mineralokortikoidiresept orin salpaajat parantavat
ennu stetta, joten niiden käyttö on aiheellista verenpa ineest a riippu matta. Diureetteja taas käytetään natriumin ja nest een kertymisest ä
johtuvien oireiden lievittämiseen.  Sydänvaikutteiset  kalsiumkanavan salpaajat (verapamiili ja diltiatseem i) ovat vasta-aiheisia  [190], [191].
Rytmi- ja johtumishäiriöt
Aivoembolian ehkäisem iseksi eteisvärinän aktiivinen etsiminen on aiheellista verenpa inepo tilailta, etenkin > 60-vuotiailta ja niiltä, joilla
esiint yy vasemman kammion hypertrofia tai sydänsairaus.
Eteisvärinään liittyvän tromboembolian riskin arviossa hypertensio  antaa yhden CHADSVASc-pisteen,  joten eteisvärinää sairastavat
verenpa inepo tilaat ovat usein ja > 65-vuotiaat verenpa inepo tilaat poikkeuksetta antikoagulaatiohoidon tarpeessa .
Antikoagulaatiohoidon aikana hyvä verenpa ineen hallinta on erityisen tärkeää aivoverenvuodon riskin pienent ämiseksi, koska
kohonnut systolinen verenpa ine (> 160 mmHg) suurentaa vuotoriskiä.
Eteisvärinässä beetasalpaaja, sykettä hidastava kalsiumkanavan salpaaja tai digoksiini on usein tarpeen osana lääkitystä.
ACE:n estäjät ja ATR:n salpaajat saattavat estää eteisvärinän ilmaantumista verenpa inepo tilailla tehokkaammin kuin muut
verenpa inelääkkeet [192], mutta oleellista on verenpa ineen hyvä hallinta.
Lisälyöntien ja muiden hyvänlaatuisten rytmihäiriöiden aiheuttamia oireita voidaan verenpa inepo tilailla lievittää beetasalpaajilla samoin
kuin muilla potilailla.
Beetasalpaajat ja sykettä hidastavat kalsiumkanavan salpaajat sekä digoksiini ovat vasta-aiheisia  hitaissa rytmihäiriöissä (sairas sinu s -
oireyhtymä ja 2.–3. asteen eteis-kammiokatkos), ellei potilaalle ole asennet tu tahdistinta.
Perifeerinen raajojen valtimosairaus
Kohonnutta verenpa inetta alentava hoito vähentää sydän- ja verisuonitautitapahtumien vaaraa perifeeristä raajojen valtimosairautta
sairastavilla [193], [194].
ACE:n estäjiä, ATR:n salpaajia, kalsiumkanavan salpaajia, diureetteja ja beetasalpaajia voidaan käyttää verenpa ineen alentamiseen [193].
Beetasalpaajat eivät ole vasta-aiheisia  perifeeristä raajojen valtimosairautta sairastavilla [193], [194], ja niiden käyttö saattaa olla aiheellista
samanaikaisen sepel valtimotaudin, sydämen vajaatoiminna n tai eteisvärinän yhteydessä  [193].
Aivoverenkierron sairaudet
Kohonneen verenpa ineen lääkehoito vähentää aivohalvauksen sairastaneid en hypertensio potilaiden sairastumista uuteen
aivohalvaukseen [195].
Optimaalista lääkehoitoa ei ole määritelty, ja potilaan muut sairaudet ja riskitekijät on otettava huomioon [195].
Ennustenäyttöä on ACE:n estäjän ja diureetin yhdistelmästä sekä ATR:n salpaajaan pohjautuvasta hoidosta [B], [196], [197].
Ks. lisäaineist o eri verenpa inelääkkeiden käyttöön liittyvistä erityiskysymyksistä .
Ks. Käypä hoito -suositus Aivoinfarkti ja TIA «Aivoinfarkti ja TIA», [198].
PROGRESS-tutkimuksessa  selvitettiin aivoverenkiertohäiriöpotilailla myös verenpa ineen lääkehoidon vaikutuksia kognitioon ja
muistisairauden kehittymiseen.  Ks. kohta Muistisairaudet ja niiden ehkäisy «A11».
Muistisairaudet ja niiden ehkäisy
Keski-iän kohonnut verenpa ine on selkeästi myöhemmän iän kognitiivisen heikentymisen ja muistisairauden ennu stetekijä, mutta
kognitiivisen heikentymisen yhteys vanhuusiässä mitattuun verenpa ineeseen on epäselvä [199].
Epidemiologisissa  tutkimuksissa  vanhuusiässä mitattu korkeampi verenpa ine on jopa näyttänyt liittyvän pienem pään
muistisairausriskiin. Kyse voi kuitenkin olla käänteisest ä kausaliteetista, koska kehittyvään muistisairauteen liittyy verenpa ineen laskua
[199].2 24.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 19/29
Kohonneen verenpa ineen alentamisest a lääkkein voi olla hyötyä kognitiivisten toimintojen ja myös muistisairauden ehkäisyn kannalta
[B].
Muistisairailla verenpa inepo tilailla noudatetaan yleisiä  iäkkäiden ja hauraiden potilaiden hoitoperiaatteita, siten että kliininen tila ja
toimintakyky huomioidaan [173].
Iäkkäät potilaat (> 75–80-vuotiaat)
Yli 75–80-vuotiaat ovat heterogeeninen joukko täysin toimintakykyisistä monisa iraisiin,  hauraisiin ja dementoituneisiin laitospotilaisiin,
mikä täytyy ottaa huomioon kohonneen verenpa ineen merkitystä ja hoidon aloitusta arvioitaessa  [173], [200].
Ennen vanhuusikää aloitettua hyvin sopivaa verenpa ineh oitoa ei pidä muuttaa pelkän ikääntymisen perusteella
Hyvä verenpa ineen seuranta on hyödyllistä vanhoillakin.
Matala v erenpaine voi iäkkäillä paradoksaalisest i olla huonon ennu steen merkki [201], [202], [203], [204] .
Tämä ennu steyhteys voi johtua käänteisestä kausaliteetista ja liittyä heikentyneeseen kognitioon ja kehittyvään muistisairauteen,
gerastenia an (hauraus-raihnausoireyhtymä), autonomiseen neuropatiaan tai muihin verenpa inetta alentaviin taustasairauksiin,
kuten sydämen pumppaustoiminna n heikentymiseen [199], [205], [206].
On mahdollista, että matala verenpa ine on vanhoilla ja haurailla itsessä än haitallista, mikä edellyttää varovaisuutta heidän
verenpa ineensa  hoidossa [173], [207].
Elintapamuutoksista on näissä ikäryhmissä verenpa ineen kannalta vain rajallista hyötyä, koska tilan syynä on usein suurten suonten
jäykistyminen hemodynaamisine seurauksineen.
Yleistilaan suhteutettua fyysistä aktiivisuutta voidaan suositella.
Mahdollisilla ravinto-ohjeilla ei saa heikentää vanhan potilaan yleis- tai ravitsemustilaa eikä edistää sarkopenia n kehittymistä.
Laihdutus tulee > 75-vuotiailla kyseeseen  vain poikkeustapauksissa  [208]. Ks. Käypä hoito -suositus Lihavuus (lapset , nuoret ja
aikuiset) «Lihavuus (lapset , nuoret ja aikuiset)».
Ortostaattinen hypotensio  ja toisaalta valkotakki- ja pseu dohypertensio  on pidettävä mielessä  hoitoa harkittaessa . Ks. kohta Kohonneen
verenpa ineen luokittelu «A1».
Kolmen minuutin ortostaattinen koe on aina tehtävä ennen lääkityksen aloitusta ja lääkemuutosten jälkeen.  Ks. kohta
Terveydenhuollossa tehtävät mittaukset «A12».
Iäkkäiden hoidossa on huomioitava myös muiden kuin verenpa inelääkkeiden (esim . prostatahyperplasian hoidossa käytettävät
alfaresept orin salpaajat, Parkinso nin taudissa käytettävät lääkkeet) verenpa inetta alentavat vaikutukset.
Suhteellisen hyväkuntoisilla > 75–80-vuotiailla kohonneen verenpa ineen alentaminen lääkityksellä vähentää
kardiovaskulaaritapahtumia ja sydämen vajaatoimintaa ja pienent ää kuolemanvaaraa [A].
HYVE T- ja SPRINT-tutkimuksissa  verenpa ineen alentamisen hyöty ei riippu nut potilaan fyysistä tilaa kuvaavasta
gerastenia indeksistä, joskaan tutkimuksissa ei ollut mukana hauraimpia vanhoja potilaita.
Verenpa ineen hoidon vaikutukset kognitioon ja muistisairauksiin ovat erityisen tärkeitä iäkkäillä. Ks. kohta Muistisairaudet ja niiden
ehkäisy «A11».
Iäkkäillä potilailla verenpa inelääke valitaan yleisten periaatteiden mukaan, mutta annokset on säädettävä yksilöllisest i ja hauraimmilla
potilailla yli kolmen lääkkeen käyttöön on oltava erityiset perusteet. Iäkkään vaihtelevan verenpa ineen tasaamisessa  lääkkeiden
jakamisest a aamu- ja ilta-annoksiin voi olla hyötyä.
Iäkkään potilaan arviointia, hoitoa ja hoitotavoitteita eri tilanteissa  on koottu taulukkoon 9.
Korkea ikä ei sellaisena an vaikuta hoitotavoitteisiin,  mutta etenkin > 80-vuotiailla tavoite täytyy yksilöllistää ja säätää toimintakyvyn
ja mahdollisen gerastenia n mukaan [173].
Toimintakykyisillä tai korkeintaan kohtalaisest i haurailla tavoitteet voivat olla samat kuin nuoremmilla, kun taas hauraimmilla
tavoitearvo voi olla korkeampi. Gerastenian ja toimintakyvyn arviointi ovat tärkeitä.
Diastolisen paineen suositeltavasta alarajasta iäkkäillä ei ole yksimielisyyttä [209], [210].
Matala diastolinen paine (< 60 mmHg) ei ole este yleisten periaatteiden mukaiselle, verenpa ineen hoidolle, mutta hoidon
tehokkuutta ja haittoja on arvioitava yksilöllisest i potilaan oireita seuraten.
Liian matala diastolinen paine voi olla haitallinen aivojen pient en suonten toiminna n kannalta [211].
Iäkkään vaihtelevan verenpa ineen tasaamisessa  lääkkeiden jakamisest a aamu- ja ilta-annoksiin voi olla hyötyä.
Taulukko 9. Iäkkään potilaan hoitokaavio toimintakyvyn mukaan (mukailtu lähteestä [173])
Potilaan itsenäinen toimintakyky ja
jokapäiväisistä toiminnoista
selviäminenLääkehoito Verenpainetavoitteet
Säilyneet hyvin, lievä tai kohtalainen
gerastenia mahdollinenEi eroa < 75-vuotiaiden hoidosta Ei eroa < 75-vuotiaiden hoitotavoitteisiin
Toimintakyky heikentynyt, mutta potilas
selviää jokapäiväisistä toimistaLääkevalinnassa ei eroa < 75-vuotiaiden hoidosta Kattava geriatrinen arvio harkittava hyötyjen ja
riskien arvioon. Systolisen verenpaineen tavoite
usein < 150 mmHg. < 130 mmHg:n systolinen
verenpaine voi aiheuttaa haittoja.
Toimintakyky ja jokapäiväisistä toimista
selviytyminen heikentyneetLääkevalinnassa ei eroa < 75-vuotiaiden hoidosta, mutta
aloitus tarkoin harkittava, edettävä varovasti ja vältettävä
yli 3 lääkkeen käyttöä. Harkittava myös olemassa olevanKattava geriatrinen arvio hyötyjen ja riskien
arvioon. Systolisen verenpaineen tavoite usein <
150 mmHg. < 130 mmHg:n systolinen verenpaine4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 20/29
Potilaan itsenäinen toimintakyky ja
jokapäiväisistä toiminnoista
selviäminenLääkehoito Verenpainetavoitteet
hoidon keventämistä tai lopetusta. Pseudohypertensio on
huomioitava.voi aiheuttaa haittoja. Muistettava muut
verenpaineeseen vaikuttavat sairaudet ja
lääkkeet. Usein verenpaineen vaihtelu aiheuttaa
ongelmia.
Munuaistaudit
Yhdistelmälääkitys, johon kuuluvat ACE:n estäjä (tai ATR:n salpaaja) ja kalsiumkanavan salpaaja tai diureetti, on suositeltava hoidon
aloitukseen.
ACE:n estäjiä ja ATR:n salpaajia suositellaan käytettäväksi albuminuriaa aiheuttavien munuaissairauksien yhteydessä , koska niiden on
osoitettu tehokkaimmin hidastavan munuaissairauden etenem istä [212]. Ks. lisäaineist o .
Tiatsididiureetit voivat menet tää kohonnutta verenpa inetta alentavan tehonsa, kun eGFR on < 30–45 ml/min/1, 73 m, jolloin
diureetiksi valitaan loop-diureetti (furosemidi).
Hyperkalemiavaaran vuoksi kaliumia säästäviä diureetteja on käytettävä harkitusti potilailla, joilla on keskivaikea munuaisten
vajaatoiminta (eGFR 30–59 ml/min/1, 73 m), ja yleensä  vältettävä potilailla, joilla on vaikea-asteinen munuaisten vajaatoiminta (eGFR
< 30 ml/min/1, 73 m).
Munuaisten vajaatoiminna ssa ja renovaskulaarisessa  hypertensio ssa ACE:n estäjien ja ATR:n salpaajien käyttö edellyttää seerumin
kreatiniini-  ja kaliumpitoisuuksien seurantaa.
ACE:n estäjien ja ATR:n salpaajien yhteiskäyttö voi tulla kysymykseen vain poikkeustapauksissa  ja erikoislääkärin valvonnassa.
Renovaskulaarisessa  hypertensio ssa arvioidaan pallolaajennu ksen tai leikkaushoidon tarve ja mahdollisuudet [213].
Pallolaajennu sta tai leikkaushoitoa voidaan harkita, jos potilaalla on etenev ä munuaisvaurio (pienenev ä GFR) tai hoitoresist entti
hypertensio .
Ks. Käypä hoito -suositus Diabeteksen munuaistauti «Diabeteksen munuaistauti», [73].
Astma ja keuhkoahtaumatauti
Diureetit, kalsiumkanavan salpaajat ja ATR:n salpaajat soveltuvat astmaa tai keuhkoahtaumatautia sairastavien kohonneen
verenpa ineen hoitoon [214].
Diureetit, varsink in yhdessä  beeta-resept oriagonistien ja glukokortikoidien kanssa  saattavat aiheuttaa hypokalemiaa. Vaikeassa
keuhkoahtaumataudissa ne saattavat myös pahentaa hiilidioksidiretentiota ja huonontaa limaneritystä. Jos vaste on kalsiumkanavan
salpaajan ja ATR:n salpaajan yhdistelmällä huono, kaliumia säästäviä diureetteja voidaan harkita.
ACE:n estäjien käyttöä hankaloittaa se, että ne saattavat aiheuttaa kuivaa yskää, mitä voi olla vaikea erottaa astman aiheuttamista
oireista.
Beetasalpaajat saattavat heikentää keuhkofunktiota ja heikentää laajentavien keuhkolääkkeiden vaikutusta, mutta ahtauttavassa
keuhkosairaudessa  beetasalpaajien on osoitettu säilyttävän edullisen sydän- ja verisuonitautivaikutuksensa .
Jos potilas sietää, voidaan painavissa indikaatioissa, kuten eteisvärinässä, sydäninfarktin jälkeen ja sydämen systolisessa
vajaatoiminna ssa, käyttää beeta-selektiivistä salpaajaa [215].
Raskausajan kohonnut verenpaine
Kohonnut verenpa ine raskauden aikana voi olla [216]
raskaudesta riippu maton (ollut jo ennen raskautta tai ilmaantunut ennen 20. raskausviikkoa)
raskauden indusoima gestationaalinen hypertensio , joka kehittyy 20. raskausviikolla tai sen jälkeen ja korjaantuu 42 päivässä
synnytyksen jälkeen
pre-eklampsia: gestationaalinen hypertensio , johon liittyy merkittävä proteinu ria (Alb/Krea-suhde > 30 mg/mmol tai U-Alb > 300
mg/vrk)
raskaudesta riippu mattoman ja gestationaalisen hypertensio n ja siihen liittyvän albuminurian yhdistelmä.
Cochrane-katsausten mukaan raskauden ajan kohonneen verenpa ineen (SVP 140–169 mmHg tai DVP 90–109 mmHg) hoito vähentää
lumehoitoon verrattuna vaikean hypertensio n ilmaantumista noin 50 % mutta ei ehkäise pre-eklampsiaa, ennena ikaisia synnytyksiä eikä
gestaatioikään nähden pienipa inoisuutta [217], [218].
Näyttöön perustuvaa tietoa hoidon aloitustasosta ja tavoitetasosta ei ole [209], [216]. Euroopan kardiologisen seuran (ESC) suositusten
mukaan verenpa inelääkitys aloitetaan, jos systolinen painetaso on ≥ 150 mmHg tai diastolinen painetaso ≥ 95 mmHg. Hoito voidaan
aloittaa jo painetasolla > 140/90 mmHg, jos potilaalla on gestationaalinen hypertensio , proteinu riaa, muita kohde-elinvaurioita tai
raskausajan hypertensio on liittyviä oireita, kuten päänsärkyä, näköhäiriöitä ja turvotuksia.
Hoidolla tavoiteltava painetaso on < 140/90 mmHg. Tiukempi hoitotavoite < 130/80 mmHg voi vähentää vaikean hypertensio n
ilmaantumista, mutta se ei vähennä  kohonneeseen verenpa ineeseen liittyviä päätetapahtumia äidillä, sikiöllä eikä vastasyntyneel lä [218],
[219]. Verenpa ineen alentamisen vaikutuksia sikiön kasvuun selvittäneen meta-analyysin mukaan suurempi lääkehoidolla saavutettu
verenpa ineen lasku lisäsi pienipa inoisuutta syntymäviikkoon nähden [220]. Jo 10 mmHg:n keskiverenpa ineen ero lume- ja
lääkehoitoryhmien välillä selitti 145 grammaa pienem pää syntymäpainoa [220]. Sikiön kannalta on varottava liiallista verenpa ineen
alentamista [220], ja lääkitystä on usein kevennet tävä keskiraskaudessa , jolloin verenpa ine fysiologisista syistä laskee.
Lääkehoitona voidaan käyttää beetasalpaajia, alfa- ja beetasalpaajan yhdistelmää (labetaloli) ja verisuonia laajentavia pitkävaikutteisia
kalsiumkanavan salpaajia.2
2
2
2
14.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 21/29
Pelkän beetasalpaajan käyttö on aiheellista vain, jos potilas on takykardinen (syketaajuus > 90/min) eikä takykardiaa saada muulla
lääkityksellä hallintaan. Beetasalpaajat saattavat lisätä small for date -vaaraa [221].
Diureetit ovat suhteellisest i vasta-aiheisia , koska ne pienent ävät kiertävää veritilavuutta ja voivat heikentää istukan toimintaa [216].
Näyttö kalsiumkanavan salpaajien hyödyistä perustuu lähinnä  nifedipiinil lä tehtyihin tutkimuksiin.
ACE:n estäjät ja ATR:n salpaajat ovat vasta-aiheisia  [222].
Hypertensiivinen kriisi
Hypertensiivisellä k riisillä tarkoitetaan verenpa ineen huomattavaa nousua, jossa systolinen paine on > 200 mmHg tai diastolinen
paine > 130 mmHg.
Kriisi jaetaan vaikeusasteensa  mukaan
hypertensiiv iseen hätätilanteeseen
kiireellistä hoitoa vaativaan tilaan.
Hypertensiivinen hätätilanne:
Keskeisiä  kohde-elinlöydöksiä ja -oireita ovat
sydänisk emia
sydämen vajaatoiminta
aivo-oireet
munuaisten nopeasti pahenev a vajaatoiminta
verenvuodot silmän verkkokalvoissa
aortan dissek oituminen.
Hoidon tavoitteena  on alentaa verenpa inetta turvalliselle tasolle (diastolinen paine yleensä  100–110 mmHg) kohde-elinten
verenkiertoa vaarantamatta. Potilaat kuuluvat päivystystapauksina  erikoissairaanhoitoon ja vaativat siellä useim miten
valvontatasoista hoitoa [223].
Lukinkalvonalaisen vuodon, aivoverenvuodon ja aivoinfarktin yhteydessä  ilmaantuvan hypertensio n hoito on harkittava
tapauskohtaisest i. Ks. Käypä hoito -suositus Aivoinfarkti ja TIA, lisäaineist o . Erotusdiagnoosia tehtäessä  on tärkeää sulkea pois
hypertensiiv inen enkefalopatia, jossa hypertensio n tehokas hoito on aiheellinen.
Hoidossa tarvitaan useim miten suoneen annet tavaa lääkitystä.
Tehostetussa hoidossa käytettävissä ovat
labetaloli
nikardipiini
natriumnitroprussidi
glyseryylinitraatti
klonidiini
diureetti, jos potilaalla on sydämen vajaatoiminta.
Ks. lisäaineist o .
Avohoidossa hypertensiiv isen kriisin hoitoon voidaan käyttää keskipitkä- tai pitkävaikutteista kalsiumkanavan salpaajaa. Lääkettä ei saa
pureskella .
Kiireellistä hoitoa vaativassa t ilass a potilaat ovat yleensä  oireettomia ja vaikeat kohde-elinlöydökset puuttuvat.
Tähän mennessä  ei ole tehty tutkimuksia, jotka osoittaisivat, että verenpa ineen välittömästä voimakkaasta laskusta olisi hyötyä. Ei
myöskään ole tutkimusnäyttöä siitä, että jokin lääkeryhmä olisi toista parempi sairastavuuden tai kuolleisuuden vähentäjänä [224].
Verenpa inelääkitys aloitetaan Käypä hoito -suosituksen yleisten periaatteiden mukaisest i. Hoitovaste tarkistetaan 1–3 vuorokauden
kuluessa  [225].
Antitromboottinen lääkehoito
Verihiutale-estäjä on aiheellinen verenpa inepo tilaille, joilla on todettu valtimosairaus (sepel valtimotauti, muu kuin eteisvärinään liittyvä
iskeem inen aivoverenkierron häiriö tai perifeerinen valtimotauti) [226]. Sepel valtimotaudissa [187] ja perifeerisessä  valtimotaudissa [227]
käytetään asetyylisalisyylihappoa (ASA) 100 mg/vrk tai klopidogreelia 75 mg/vrk ja edellä mainituissa aivoverenkierron häiriöissä
yleensä  ASA:n ja dipyridamolin yhdistelmää tai klopidogreelia [198].
Ilman kliinisest i todettua valtimosairautta (primaarisessa  ehkäisyssä) verihiutale-eston iskeem isiä tautitapahtumia ehkäisevä vaikutus
on vähäinen,  2000-luvulla tehdyissä tutkimuksissa  jopa kyseena lainen.  Kallonsisä isten (NNH=1 000) ja muiden vakavien verenvuotojen
(NNH=250) lisääntyminen kumoaa mahdollisen nettohyödyn lähes kokonaan tai johtaa jopa nettohaittaan [226], [228]. Ks. Vältä viisaasti -
suositus .
Verenpa inepo tilaat eivät tässä suhteessa  eroa muista primaarisen ehkäisyn piirissä olevista potilaista [226].
Eteisvärinäpotilailla antikoagulaatiohoito (suora antikoagulantti tai varfariini)  on aiheellinen CHADSVASc-riskinarvion mukaan. Ks.
Käypä hoito -suositus Eteisvärinä «Eteisvärinä», [192].
Antitromboottista hoitoa käyttävien potilaiden osalta on erityisen tärkeää, että verenpa ine on suositusten mukaisest i hallinna ssa.
Renaalinen denervaatio2 24.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 22/29
Tutkimustulokset renaalisen dener vaation verenpa inetta alentavasta vaikutuksesta vaikeahoitoisen hypertensio n hoidossa eivät nykyisin
puolla sen käyttöä potilashoidossa [229], [230], [231]. Ennustenäyttö ja tieto hoidon pitkäaikaisvaikutuksesta verenpa ineeseen puuttuvat.
Syyt kohonneen verenpaineen huonoon hoitovasteeseen
Hoitotavoitteen saavuttamisen esteenä  voivat olla lääkäristä, potilaasta tai hoitojärjestelmästä johtuvat seikat taulukko 10, [232].
Taulukko 10. Syitä ja ratkaisumahdollisuuksia kohonneen verenpaineen huonoon hoitovasteeseen
Syy Ratkaisumahdollisuus
Lääkäri tai hoitaja
Kohonneen verenpaineen tunnistamatta jääminen
Riittämätön elintapaohjaus
Lääkehoidon liian myöhäinen aloittaminen
Lääkehoidon riittämätön tehostaminen
Lääkeaineinteraktiot
Vuorovaikutuksen puutteet
Sekundaarinen hypertensioVerenpaineen mittaus, kotimittaustulosten tulkinta
Elintapojen kartoitus, motivoiva haastattelu
Hoitosuositusten noudattaminen
Hoitosuositusten mukainen lääkeyhdistelmien käyttö
Lääkityksen kokonaisarviointi
Hoidosta päättäminen yhdessä potilaan kanssa, ymmärrettävät ja
havainnolliset hoito-ohjeet
Ks. eksogeenisen tai sekundaarisen hypertension epäily «A3»
Potilas
Riittämätön elintapahoito (lihavuus, liikunnan puute, suolan käyttö,
lakritsiuutetta sisältävät tuotteet, alkoholi, tupakka)
Verenpaineen kotimittaus riittämätöntä tai väärin tehtyä
Lääkkeiden haittavaikutukset
Verenpainetta kohottavat lääkkeet
Epäselvät hoitotavoitteet
Lääkehoidon toteutumatta jääminenPotilaan ohjaus ravitsemusterapeutin tai terveydenhuollon
ammattilaisen antamaan elintapaneuvontaan
Kotimittausten ohjeistus ja seuranta
Mahdollisten lääkehaittojen kartoitus ja hoito
Lääkityksen kokonaisarviointi
Suullinen ja kirjallinen potilasneuvonta
Hoitosuunnitelma
Lääkityksen säännöllisen käytön tiedustelu, hinnaltaan edullisten
lääkkeiden käyttö
Mahdollisimman yksinkertainen lääkehoito
Kerran päivässä annosteltava lääkitys (jos mahdollista), lääkkeenoton
yhdistäminen päivärutiineihin, lääkeannostelijan käyttö
Hoitojärjestelmä
Hoitoon pääsyn vaikeus
Hoidon jatkuvuuden toteutumatta jääminen
Hoidon seurannan vaikeusRiittävä lääkärien ja hoitajien määrä, hoitotiimit
Pitkäaikaiset potilas-lääkäri- tai potilas-hoitajasuhteet
Sähköisesti tai puhelimitse tapahtuva seuranta
Sekundaarisest a hypertensio sta ks. edellä oma kappaleensa .
Ks. lisätietoa: [233], [234].
Lääkityksen vähentäminen ja lopettaminen
Lääkityksen asteittaista vähentämistä ja jopa lopettamista voidaan harkita, jos verenpa ine on lievässä komplisoitumattomassa
hypertensio ssa pysynyt toteutuneid en elintapamuutosten ja lääkehoidon vaikutuksesta optimaalisena  (< 120/80 mmHg) ainakin yhden
vuoden ajan.
Jos lääkitystä vähennet ään tai se lopetetaan, verenpa inetta on sen jälkeen ehdottomasti seurattava huolellisest i, koska se usein kohoaa
uudelleen [235].
Verenpa inelääkityksen hyötyjä ja haittoja ja niiden vaikutusta elämänlaatuun on tarkoin harkittava potilailla, joilla on useita sairauksia
tai geriatrisia oireyhtymiä, muistisairauden loppuvaihe tai jatkuva avun tarve jokapäiväisissä  toimissa [173].
Nämä potilaat ovat usein > 85-vuotiaita, ja kattavasta geriatrisest a arviosta on hyötyä päätöksent eossa.
Verenpa inelääkityksen lopettamisen kokonaisvaikutuksista ja turvallisuudesta ei ole käytettävissä satunnaistettuja tutkimuksia.
Seuranta
Verenpa inelääkkeen aloituksen tai muutoksen jälkeen suositellaan 1–2 kuukauden välein tehtäviä yhteydenottoja, kunnes verenpa ineen
hoitotasapaino on saavutettu.
Kun verenpa ine on tavoitetasolla, seurantakäyntien tiheys suunnit ellaan potilaskohtaisest i lääkityksen, kohde-elinvaurioiden ja muiden
sairauksien mukaan [236]. Osasta yhteydenotoista voi vastata sairaanhoitaja tai terveydenhoitaja, jos työnjaosta on niin sovittu [237],
taulukko 11. Myös puhelinkontakteja ja sähköistä asiointia voidaan hyödyntää hoitotavoitteessa  olevien potilaiden seurannassa.
Kohonneen verenpa ineen kohde-elinvaurioiden ja muiden valtimotautien riskitekijöiden kartoitus on suositeltavaa tehdä ainakin
kahden vuoden välein.
Mekaaninen resept ien uusiminen ilman tilannea rviota ei ole hyväksyttävä käytäntö.
Hoitotavoitteen ulkopuolella olevat ohjataan vastaanotolle ja syyt huonoon hoitovasteeseen selvitetään.
Taulukko 11. Verenpainepotilaan arviokäynnin sisältö
Jokaisella seurantakäynnillä arvioitava:
verenpainetaso, kotimittausarvojen tulkinta4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 23/29
sydämen toiminta, sykkeen tunnustelu
elintavat (paino, elintarvikevalinnat ja suolan käyttö, alkoholin käyttö, tupakointi, liikunta)
lääkehoidon toteutuminen
hoitotavoitteen toteutuminen
Yksilöllisen harkinnan mukaan 1–2 vuoden välein arvioitava:
kohde-elinvauriot: U-Alb/Krea, eGFR, EKG
valtimotaudin muut riskitekijät: lipidit, verensokeri
primaaripreventiossa valtimotaudin kokonaisriski FINRISKI-laskurilla https://www.terveyskirjasto.fi/pgt00013
verenpainelääkitykseen liittyvät laboratoriokokeet (P-K, P-Na, P-Krea, eGFR)
Suomalaisen Lääkäriseuran Duodecimin ja Suomen Verenpaineyhdistys ry:n asettama työryhmä
Kohonnut verenpa ine -suosituksen historiatiedot
Puheenjohtaja:
Antti Jula, LKT, tutkimusprofesso ri, sisätautien erikoislääkäri; Terveyden ja hyvinvoinnin laitos
Jäsenet:
Ilkka Kantola, LKT, dosent ti, professo ri, sisätautien erikoislääkäri, toimialuejohtaja; Tyksin medisiininen toimialue
Päivi Korhonen,  LT, professo ri, yleislääketieteen ja sisätautien erikoislääkäri; Turun yliopiston kliininen laitos, yleislääketiede
Seppo  Lehto, LT, dosent ti, sisätautien ja kardiologian erikoislääkäri, sisätautien ylilääkäri ja medisiinisen hoidon tulosalueen johtaja;
LSHP/Lapin keskussairaala
Eero Mervaala, LT, professo ri; Helsing in yliopiston lääketieteellinen tiedekunta, farmakologia, Käypä hoito -toimittaja
Kaj Metsärinne,  LKT, dosent ti, sisätautien ja nefrologian erikoislääkäri, nefrologian ylilääkäri ja vastuualuejohtaja; Tyksin medisiininen
toimialue
Teem u Niiranen,  LT, dosent ti, sisätautien ja terveydenhuollon erikoislääkäri, erikoistutkija; Turun yliopisto
Ilkka Pörsti, LT, professo ri, sisätautien ja nefrologian erikoislääkäri; Tampereen yliopisto ja Taysin sisätautien vastuualue
Timo Strandberg, LKT, professo ri; Helsing in yliopisto, HUS, Sisätaudit ja kuntoutus, Oulun yliopisto, Elinikäisen terveyden tutkimuksen
keskus
Mikko Syvänne,  LT, dosent ti, professo ri, kardiologian, sisätautien ja yleislääketieteen erikoislääkäri
Ilkka Tikkanen,  LKT, professo ri, sisätautien ja nefrologian erikoislääkäri, osastonylilääkäri; HYKS Vatsakeskus, nefrologia ja
Lääketieteellinen tutkimuslaitos Minerva, Biomedicum 2, Helsink i
Asiantuntijat:
Risto Kaaja, LKT, professo ri, sisätautien erikoislääkäri; Turun yliopisto
Tuula Tikkanen,  LKT, dosent ti, sisätautien ja yleislääketieteen erikoislääkäri, va ylilääkäri, Helsing in sisätautien poliklinikka
Sidonnaisuudet
Sidonnaisuusilmoitukset on kerätty 10.9.2020 julkaistun suosituksen laatimisen yhteydessä .
Antti Jula: Sivutoimet: Vastaanotto, Mehiläinen Turku, Pihlajalinna  Parainen.  Ohjaushankkeet: Suomen Sydänliitto, Ravitsemuksen
asiantuntijaryhmän puheenj ohtaja.
Ilkka Kantola: Sivutoimet: Vastaanotto, Terveystalo Pulssi Turku. Tutkimusrahoitus: Amicus, Bayer, Boehringer-Ingelheim, Idorsia,
MSD,Sanofi-Genz yme, Takeda. Luento-, koulutus- ja asiantuntijapalkkiot: Amicus, Sanofi-Genz yme, Takeda. Korvaukset koulutus- ja
kongressik uluista: Amicus, Sanofi-Genz yme, Takeda. Luottamustoimet: Suomen verenpa iney hdistys hallitus.
Päivi Korhonen:Sivutoimet: Varsina is-Suomen sairaanhoitopiiri, ylilääkäri; Keski-Satakunnan terveydenhuollon kuntayhtymä,
erikoislääkäri. Luento-, koulutus- ja asiantuntijapalkkiot: Orion, MSD. Luottamustoimet: Duodecim , Suomen Lääketieteen Säätiö,
Satakunnan Sydänpiir i, Suomen Verenpa iney hdistys.
Seppo Lehto: Luento-, koulutus- ja asiantuntijapalkkiot: Amgen, Sanofi, Novo, Pfizer, Bayer. Korvaukset koulutus- ja kongressik uluista:
Amgen. Luottamustoimet: SKS preventiojaoksen jäsen, ESC asiantuntijana. Ohjaushankkeet: Pohjois-Savon Sote (PoSoTe).
Eero Mervaala: Sivutoimet: Käypä hoito -toimittaja; Lääketieteellinen asiantuntija (farmakologia), Synlab-laboratoriot. Luottamustoimet:
jäsen, Suomen Verenpa iney hdistyksen hallitus; jäsen, Lääketietoverkosto, FIMEA.
Kaj Metsäri nne: Sivutoimet: Vastaanotto, Terveystalo Pulssi. Tutkimusrahoitus: Bayer Oy, Novo Nordisk Oy. Luento-, koulutus- ja
asiantuntijapalkkiot: Astellas Oy, Baxter Oy, Bayer Oy, Boehringer Ingelheim Oy, Vifor Pharma Oy. Korvaukset koulutus- ja
kongressik uluista: Novo Nordisk Oy. Luottamustoimet: Diabetes Käypä hoito neuvottelukunta.
Teemu Niiranen:Sivutoimet: THL, asiantuntijalääkäri; Rauman kaupunki, erikoislääkäri; Helsing in yliopisto/FIMM, koordinaattori.
Tutkimusrahoitus: Apurahat: Suomen akatemia, Emil Aaltosen säätiö, Paavo Nurmen säätiö, Suomen lääketieteen säätiö, Valtion
tutkimusrahoitus. Luottamustoimet: Suomen Verenpa iney hdistys, varapuheenj ohtaja.
Ilkka Pörsti: Luento-, koulutus- ja asiantuntijapalkkiot: AstraZeneca . Korvaukset koulutus- ja kongressik uluista: AstraZeneca .
Luottamustoimet: Suomen Verenpa iney hdistyksen hallituksen jäsen, puheenj ohtaja 2017-2019; Tampereen tuberkuloosisäätiön hallituksen4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 24/29
jäsen; Pirkanmaan kulttuurirahaston Pirkanmaan sydäntutkimusrahaston asiantuntija; Pirkanmaan sairaanhoitopiiri, Valtion
tutkimusrahatoimikunnan jäsen.
Timo Strandberg: Sivutoimet: Hus, ylilääkäri. Tutkimusrahoitus: Amgen, MSD, NovoNordisk, Sanofi. Luento-, koulutus- ja
asiantuntijapalkkiot: Amgen, Boehringer, MSD, NovoNordisk, Orion, Sanofi, Servier. Korvaukset koulutus- ja kongressik uluista:
NovoNordisk. Luottamustoimet: EUGMS, Suomen verenpa iney hdistyksen hallituksen varajäsen.
Mikko Syvänne: Sivutoimet: Vastaanotto, Suomen Terveystalo, Myyrmäki; vastaanotto, Eiran Lääkäriasema; Coronaria asiantuntija
(verenpa ineen vuorokausirekisteröintien lausunnot). Luento-, koulutus- ja asiantuntijapalkkiot: Orion, Novo Nordisk, Pfizer, Medaffcon.
Korvaukset koulutus- ja kongressik uluista: Novo Nordisk.
Ilkka Tikkanen: Luento-, koulutus- ja asiantuntijapalkkiot: AstraZeneca  Oy, Boehringer Ingelheim Finland Ky, MSD Finland Oy,
Mundipharma Oy, Servier Finland Oy. Muut sidonnaisuudet: Lausuntopalkkio, Coronaria Oy.
Kirjallisuusviite
Kohonnut verenpa ine. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecimin ja Suomen Verenpa iney hdistys ry:n asettama
työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2020 (viitattu pp.kk.vvvv). Saatavilla internetissä: www. kaypahoito.fi
Tarkemmat viittausohjeet: http://www. kaypahoito.fi/web /kh/viittaaminen
Vastuun rajaus
Käypä hoito -suositukset ja Vältä viisaasti -suositukset ovat asiantuntijoiden laatimia yhteenv etoja yksittäisten sairauksien diagnostiikan ja
hoidon vaikuttavuudesta. Suositukset toimivat lääkärin tai muun terveydenhuollon ammattilaisen päätöksent eon tukena hoitopäätöksiä
tehtäessä . Ne eivät korvaa lääkärin tai muun terveydenhuollon ammattilaisen omaa arviota yksittäisen potilaan parhaasta mahdollisest a
diagnostiikasta, hoidosta ja kuntoutuksesta hoitopäätöksiä tehtäessä .
Tiedonhakukäytäntö
Systemaattinen kirjallisuushaku on hoitosuosituksen perusta. Lue lisää artikkelista khk00007
Kirjallisuutta
1. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessm ent of 84 behavioural, environmental and occupational, and metabolic risks or clusters of
risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet  2018;392:1923-1994 «PMID: 30496105»
2. Mueller NT, Noya-Alarcon O, Contreras M ym. Association of Age With Blood Pressu re Across the Lifespa n in Isolated Yanomami and Yekwana Villages. JAMA Cardiol 2018;3:12 47-1249
«PMID: 30427998»
3. Borodulin K, Levälahti E, Saarikoski L ym. Kansallinen FINRISKI 2012 -terveystutkimus - Osa 2: Tutkimuksen taulukkoliite. Terveyden ja hyvinvoinnin laitos, Raportti 2013/2 2.
http://u rn.fi/URN:ISBN:978-952-302-054-2
4. Koskinen S, Lundqvist A, Ristiluoma N. Terveys, toimintakyky ja hyvinvointi Suomessa  2011. Terveyden ja hyvinvoinnin laitos. Raportti 2012/68. http://u rn.fi/URN:ISBN:978-952-245-
769-1
5. Laatikainen T, Jula A, Kastarinen M, Salomaa V, Borodulin K, Harlad K, Peltonen M, Jousilahti P, Vartiainen E. Verenpa inetasot ja hoitotasapaino FINRISKI-tutkimusalueilla 1982-
2012. Suom Lääkäril 2013;2 4:1803-9
6. Vartiainen E, Laatikainen T, Peltonen M ym. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010;39:504-18 «PMID: 19959603»
7. Koponen P, Borodulin K, Lundqvist A, Sääksjärvi K, Koskinen S (toim). Terveys, toimintakyky ja hyvinvointi Suomessa . FinTerveys 2017 -tutkimus. Terveyden ja hyvinvoinnin laitos
(THL),
8. Lewington S, Clarke R, Qizilbash N ym. Age-specif ic relevance of usual blood pressu re to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospect ive
studies. Lancet  2002;360:1903-13 «PMID: 12493255»
9. Dzeshka MS, Shantsila A, Shantsila E ym. Atrial Fibrillation and Hypertensio n. Hypertensio n 2017;70:854-861 «PMID: 28893897»
10. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent  hypertensio n trials. J Hypertens 2008;26:1477-86 «PMID: 18551026»
11. Franco OH, Peeters A, Bonneu x L ym. Blood pressu re in adulthood and life expect ancy with cardiovascular disease in men and women: life course analysis. Hypertensio n 2005;46:280-6
«PMID: 15983235»
12. Kiiskinen U, Vartiainen E, Puska P ym. Long-term cost and life-expect ancy conseq uences of hypertensio n. J Hypertens 1998;16:1103-12 «PMID: 9794712»
13. Berry JD, Dyer A, Cai X ym. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321-9 «PMID: 22276822»
14. Jousilahti P, Laatikainen T, Peltonen M ym. Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland
over 40 years: population based observational study. BMJ 2016;352:i721 «PMID: 26932978»
15. Stergiou GS, Alpert B, Mieke S ym. A universal standard for the validation of blood pressu re measuring devices: Association for the Advancem ent of Medical Instrumentation/European
Society of Hypertensio n/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. J Hypertens 2018;36:472-478 «PMID: 29384983»
16. Williams B, Mancia  G, Spiering W ym. 2018 ESC/ESH Guidelines for the management of arterial hypertensio n. Eur Heart J 2018;39:3021-3104 «PMID: 30165516»
17. Lane D, Beevers M, Barnes N ym. Inter-arm differences in blood pressu re: when are they clinica lly significant? J Hypertens 2002;20:1089-95 «PMID: 12023677»
18. Kimura A, Hashimoto J, Watabe D ym. Patient characteristics and factors associated with inter-arm difference of blood pressu re measurements in a gener al population in Ohasama,
Japan. J Hypertens 2004;22:2277-83 «PMID: 15614021»
19. Johansso n JK, Puukka PJ, Jula AM. Interarm blood pressure difference and target organ damage in the gener al population. J Hypertens 2014;32:260-6 «PMID: 24284500»
20. McAlister FA, Straus SE. Evidence based treatment of hypertensio n. Measurement of blood pressu re: an evidence based review. BMJ 2001;32 2:908-11 «PMID: 1130 2909»
21. Jula A, Puukka P, Karanko H. Multiple clinic and home blood pressu re measurements versus ambulatory blood pressu re monitoring. Hypertensio n 1999;34:261-6 «PMID: 10454451»
22. Kantola I, Vesalainen R, Kangassalo K ym. Bell or diaphragm in the measurement of blood pressu re? J Hypertens 2005;23:499-503 «PMID: 15716689»
23. Kallistratos MS, Poulimenos LE, Manolis AJ. Atrial fibrillation and arterial hypertensio n. Pharmacol Res 2018;128:322-326 «PMID: 29055746»
24. COMMISSION REGULATION (EU) No 847/2012
25. Kumpusalo E, Teho A, Laitila R ym. Janus faces of the white coat effect: blood pressu re not only rises,  it may also fall. J Hum Hypertens 2002;16:725-8 «PMID: 12420197»
26. Fagard RH, Celis H, Thijs L ym. Daytime and nighttime blood pressu re as predictors of death and cause-specif ic cardiovascular events in hypertensio n. Hypertensio n 2008;51:55-61
«PMID: 18039980»
27. Angelousi A, Girerd N, Benet os A ym. Association between orthostatic hypotensio n and cardiovascular risk, cerebrovascular risk, cognitive decline and falls as well as overall mortality: a
systematic review and meta-analysis. J Hypertens 2014;32:1562-71; discussion 1571 «PMID: 24879490»
28. Kantola I, Jula A, Niiranen T. Ortostaattisen hypotensio n tutkiminen ja hoito. Suom Lääkäril 2018;74:1811-3
29. Niiranen TJ, Mäki J, Puukka P ym. Office, home, and ambulatory blood pressu res as predictors of cardiovascular risk. Hypertensio n 2014;64:281-6 «PMID: 24842916»
30. Bliziotis IA, Destounis A, Stergiou GS. Home versus ambulatory and office blood pressu re in predicting target organ damage in hypertensio n: a systematic review and meta-analysis. J
Hypertens 2012;30:1289-99 «PMID: 22499289»
31. Niiranen TJ, Hänninen MR, Johansso n J ym. Home-measured blood pressu re is a stronger predictor of cardiovascular risk than office blood pressu re: the Finn- Home study.
Hypertensio n 2010;55:134 6-51 «PMID: 20385970»
32. Ward AM, Takahashi O, Stevens R ym. Home measurement of blood pressu re and cardiovascular disease: systematic review and meta-analysis of prospect ive studies. J Hypertens
2012;30:449-56 «PMID: 22241136 »
33. Johansso n JK, Niiranen TJ, Puukka PJ ym. Factors affecting the difference between morning  and evening  home blood pressu re: the Finn- Home study. Blood Press 2011;20:27-36
«PMID: 20849356»
34. Niiranen TJ, Johansso n JK, Reunanen A ym. Optimal schedule for home blood pressu re measurement based on prognostic data: the Finn- Home Study. Hypertensio n 2011;57:1081-6
«PMID: 21482956»
35. Mancia  G, Parati G. Ambulatory blood pressu re monitoring and organ damage. Hypertensio n 2000;36:894-900 «PMID: 11082163»
36. Kikuya M, Hansen TW, Thijs L ym. Diagnostic thresholds for ambulatory blood pressu re monitoring based on 10-year cardiovascular risk. Circulation 2007;115:2145-52 «PMID:
17420350»
37. Banegas JR, Ruilope LM, de la Sierra A ym. Relationship between Clinic and Ambulatory Blood-Pressu re Measurements and Mortality. N Engl J Med 2018;378:1509-1520 «PMID:
29669232»
38. Sega R, Facchetti R, Bombelli M ym. Prognostic value of ambulatory and home blood pressu res compared with office blood pressu re in the gener al population: follow-up results from the
Pressio ni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005;111:17 77-83 «PMID: 15809377»4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 25/29
39. Hansen TW, Li Y, Boggia J ym. Predictive role of the nighttime blood pressu re. Hypertensio n 2011;57:3-10 «PMID: 21079049»
40. Niiranen TJ, Asayama K, Thijs L ym. Outcome-driven thresholds for home blood pressu re measurement: international database of home blood pressu re in relation to cardiovascular
outcome. Hypertensio n 2013;6 1:27-34 «PMID: 23129700»
41. Niiranen TJ, Jula AM, Kantola IM ym. Prevalence and determinants of isolated clinic hypertensio n in the Finnish  population: the Finn- HOME study. J Hypertens 2006;24:463-70
«PMID: 16467649»
42. Ugajin T, Hozawa A, Ohkubo T ym. White-coat hypertensio n as a risk factor for the development of home hypertensio n: the Ohasama study. Arch Intern Med 2005;165:1541-6 «PMID:
16009871»
43. Sivén SS, Niiranen TJ, Kantola IM ym. White-coat and masked hypertensio n as risk factors for progressio n to sustained  hypertensio n: the Finn- Home study. J Hypertens 2016;34:54-60
«PMID: 26630213»
44. Ohkubo T, Kikuya M, Metoki H ym. Prognosis of "masked" hypertensio n and "white-coat" hypertensio n detected by 24-h ambulatory blood pressu re monitoring 10-year follow-up from
the Ohasama study. J Am Coll Cardiol 2005;46:508-15 «PMID: 16053966»
45. Stergiou GS, Asayama K, Thijs L ym. Prognosis of white-coat and masked hypertensio n: International Database of HOme blood pressu re in relation to Cardiovascular Outcome.
Hypertensio n 2014;63:675-82 «PMID: 24420553»
46. Verdecch ia P, Reboldi GP, Angeli F ym. Short- and long-term incid ence of stroke in white-coat hypertensio n. Hypertensio n 2005;45:203-8 «PMID: 15596572»
47. Niiranen TJ, Jula AM, Kantola IM ym. Comparison of agreem ent between clinic and home-measured blood pressu re in the Finnish  population: the Finn- HOME Study. J Hypertens
2006;24:1549-55 «PMID: 16877957»
48. Mancia  G, Facchetti R, Bombelli M ym. Long-term risk of mortality associated with selective and combined  elevation in office, home, and ambulatory blood pressu re. Hypertensio n
2006;47:846-53 «PMID: 16567588»
49. Hansen TW, Jeppesen J, Rasmussen S ym. Ambulatory blood pressu re monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 2006;19:243-50 «PMID:
16500508»
50. Wang GL, Li Y, Staessen JA ym. Anthropometric and lifestyle factors associated with white-coat, masked and sustained  hypertensio n in a Chinese population. J Hypertens 2007;25:2398-
405 «PMID: 17984660»
51. Björklund K, Lind L, Zethelius B ym. Isolated ambulatory hypertensio n predicts cardiovascular morbidity in elderly men. Circulation 2003;10 7:1297-302 «PMID: 12628951»
52. Hänninen MR, Niiranen TJ, Puukka PJ ym. Metabolic risk factors and masked hypertensio n in the gener al population: the Finn- Home study. J Hum Hypertens 2014;28:421-6 «PMID:
24384630»
53. Hänninen MR, Niiranen TJ, Puukka PJ ym. Determinants of masked hypertensio n in the gener al population: the Finn- Home study. J Hypertens 2011;29:1880-8 «PMID: 21841499»
54. Sega R, Trocino  G, Lanzarotti A ym. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertensio n: Data from the gener al population (Pressio ne
Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2001;104:138 5-92 «PMID: 11560854»
55. Hänninen MR, Niiranen TJ, Puukka PJ ym. Comparison of home and ambulatory blood pressu re measurement in the diagnosis of masked hypertensio n. J Hypertens 2010;28:709-14
«PMID: 20061982»
56. Hänninen MR, Niiranen TJ, Puukka PJ ym. Target organ damage and masked hypertensio n in the gener al population: the Finn- Home study. J Hypertens 2013;31:1136 -43 «PMID:
23466942»
57. Bobrie G, Chatellier G, Genes N ym. Cardiovascular prognosis of "masked hypertensio n" detected by blood pressu re self-measurement in elderly treated hypertensiv e patients. JAMA
2004;291:134 2-9 «PMID: 15026401»
58. Hänninen MR, Niiranen TJ, Puukka PJ ym. Prognostic significance of masked and white-coat hypertensio n in the gener al population: the Finn- Home Study. J Hypertens 2012;30:705-12
«PMID: 22278146»
59. Tikkanen T, Lindgren L, Tikkanen I ym. Pseudohypertensio  - harvinainen vai yleinen verenpa ineen hoidon pulmatilanne? Duodecim  1995;111:8 58-62
60. Lihavuus (aikuiset). Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Lihavuustutkijat ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim ,
2013 (viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
61. Stewart MH, Lavie CJ, Shah S ym. Prognostic Implications of Left Ventricular Hypertrophy. Prog Cardiovasc Dis 2018;61:446-455 «PMID: 30408469»
62. He FJ, Burnier M, Macgregor GA. Nutrition in cardiovascular disease: salt in hypertensio n and heart failure. Eur Heart J 2011;32 :3073-80 «PMID: 21705359»
63. MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensiv e patients. N Engl J
Med 1986;314 :334 -9 «PMID: 2935737»
64. SOKOLOW M, LYON TP. The ventricular complex in left ventricular hypertrophy as obtained  by unipo lar precordial and limb leads. Am Heart J 1949;37:161-86 «PMID: 18107386»
65. Molloy TJ, Okin PM, Devereux RB ym. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 1992;20:1180-6
«PMID: 1401620»
66. Schillaci G, Verdecch ia P, Borgioni C ym. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol 1994;74:714-9 «PMID: 7942532»
67. Varis JP, Puukka PJ, Karanko HM ym. Risk assessm ent of echocardiographic left ventricular hypertrophy with electrocardiography, body mass index and blood pressu re. Blood Press
2014;23:39 -46 «PMID: 23772751»
68. Gerstein HC, Mann JF, Yi Q ym. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6 «PMID:
11466120»
69. Anavekar NS, McMurray JJ, Velazquez EJ ym. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-95 «PMID:
15385655»
70. Gall MA, Borch-Johnsen K, Hougaard P ym. Albuminuria and poor glycem ic control predict mortality in NIDDM. Diabetes 1995;44:130 3-9 «PMID: 7589828»
71. Pontremoli R, Sofia A, Ravera M ym. Prevalence and clinical correlates of microalbuminuria in essent ial hypertensio n: the MAGIC Study. Microalbuminuria: A Genoa Investigation on
Complications. Hypertensio n 1997;30:1135 -43 «PMID: 9369267»
72. Rodicio JL, Campo C, Ruilope LM. Microalbuminuria in essent ial hypertensio n. Kidney Int Suppl 1998;68:S51-4 «PMID: 9839284»
73. Diabeettinen nefropatia. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Nefrologiyhdistyksen asettama työryhmä. Helsink i: Suomalainen Lääkäriseura
Duodecim , 2007 (viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
74. Breslin DJ, Gifford RW Jr, Fairbairn JF 2nd ym. Prognostic importance of ophthalmoscopic findings in essent ial hypertensio n. JAMA 1966;195:335 -8 «PMID: 5951889»
75. FRANT R, GROEN J. Prognosis of vascular hypertensio n; a 9 year follow-up study of 418 cases. Arch Intern Med (Chic) 1950;85:727-50 «PMID: 15414008»
76. Ong YT, Wong TY, Klein R ym. Hypertensiv e retinopathy and risk of stroke. Hypertensio n 2013;6 2:706-11 «PMID: 23940194»
77. Williams B, Mancia  G, Spiering W ym. 2018 ESC/ESH Guidelines for the management of arterial hypertensio n: The Task Force for the management of arterial hypertensio n of the
European Society of Cardiology and the European Society of Hypertensio n: The Task Force for the management of arterial hypertensio n of the European Society of Cardiology and the
European Society of Hypertensio n. J Hypertens 2018;36:1953-2041 «PMID: 30234752»
78. Tikkanen T. Lääkkeiden ja nautintoaineid en aiheuttama hypertensio . Käyt Lääk 1998;41:88–94
79. Grossman E, Messer li FH. Drug-induced hypertensio n: an unappreciated cause of seco ndary hypertensio n. Am J Med 2012;125:14-22 «PMID: 22195528»
80. Rossi GP, Seccia  TM, Maniero C ym. Drug-related hypertensio n and resist ance to antihypertensiv e treatment: a call for action. J Hypertens 2011;29:2295-309 «PMID: 22002334»
81. Kipu. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in, Suomen Anest esiologiyhdistyksen ja Suomen Yleislääketieteen yhdistyksen asettama työryhmä. Helsink i:
Suomalainen Lääkäriseura Duodecim , 2015 (viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
82. Tikkanen I, Tikkanen T. Sekundaariset hypertensio t. Kirjassa: Kardiologia, 3. uudistettu painos. Airaksinen J, Aalto-Setälä K, Hartikainen J ym. (Toim.), Kustannus Oy Duodecim  2016,
1296 s.
83. Tupakka- ja nikotiinir iippu vuuden ehkäisy ja hoito. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Yleislääketieteen yhdistyksen asettama työryhmä.
Helsink i: Suomalainen Lääkäriseura Duodecim , 2018 (viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
84. Williams B, Mancia  G, Spiering W ym. 2018 ESC/ESH Guidelines for the management of arterial hypertensio n. Eur Heart J 2018;39:3021-3104 «PMID: 30165516»
85. Whelton PK, Carey RM, Aronow WS ym. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management
of High Blood Pressu re in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinica l Practice Guidelines.  Hypertensio n 2018;71:e13- e115
«PMID: 2913335 6»
86. Kastarinen M, Laatikainen T, Salomaa V ym. Trends in lifestyle factors affecting blood pressu re in hypertensiv e and normotensiv e Finns during 1982-2002. J Hypertens 2007;25:299-
305 «PMID: 17211236»
87. Laatikainen T, Pietinen P, Valsta L ym. Sodium in the Finnish  diet: 20-year trends in urinary sodium excretion among the adult population. Eur J Clin Nutr 2006;60:965-70 «PMID:
16482074»
88. Reiniv uo H, Valsta LM, Laatikainen T ym. Sodium in the Finnish  diet: II trends in dietary sodium intake and comparison between intake and 24-h excretion of sodium. Eur J Clin Nutr
2006;60:1160-7 «PMID: 16639417»
89. Puska P, Vartiainen E, Laatikainen T, Jousilahti P, Paavola M (toim.). The North Karelia Project: From North Karelia to national action. Terveyden ja hyvinvoinnin laitos. Helsink i
University Printing House, Helsink i 2009. 309 s. www.thl.fi/documents/18 9940/261635/Teem a%202009%201.pdf
90. Valsta L, Kaartienen N, Tapanainen H, Männist ö S (toim.) Nutrition in Finland - The Ntional FinDiet2017 Survey. THL Raportti 12/2018
91. Paturi M, Tapanainen H, Reiniv uo H, Pietinen P (toim.) Finravinto 2007 -tutkimus. The National FINDIET 2007 Survey. Kansanterveyslaitoksen julkaisuja
B23/2008.https://w ww.julkari.fi/handle/10 024/109891
92. Helldán A, Raulio S, Kosola M ym. Finravinto 2012 -tutkimus. The National FINDIET 2012 Survey. THL Raportti 16/2013. http://u rn.fi/URN:ISBN:978-952-245-951-0
http://u rn.fi/URN:ISBN:978-952-245-951-0
93. Ovaskainen ML, Tapanainen H, Raulio S ym. Finnr avinto-tutkimus: Kovan rasvan käyttö kasvoi selvästi vuosina  2007-2012. Suom Lääkär 2014; 69:1067-72
94. Paturi M, Tapanainen H, Reiniv uo H, Pietinen P (toim.) Finravinto 2007 -tutkimus. The National FINDIET 2007 Survey. Kansanterveyslaitoksen julkaisuja B23/2008
95. Mäkelä P, Mustonen H, Tigerstedt C (toim). Suomi juo. Suomalaisten alkoholinkäyttö ja sen muutokset 1968-2008. THL. Yliopistopaino 2010. Helsink i.
https://w ww.julkari.fi/handle/10 024/80301
96. Kastarinen MJ, Puska PM, Korhonen MH ym. Non-pharmacological treatment of hypertensio n in primary health care: a 2-year open randomized controlled trial of lifestyle intervention
against hypertensio n in eastern Finland. J Hypertens 2002;20:2505-12 «PMID: 12473876»
97. Commissio n of the European Communities. Reports of the Scient ific Committee for Food (Thirty-first series). Nutrient and ener gy intakes for the European Community. Luxembourg,
1993 https://ec. europa.eu/food/sites/food/files/sa fety/docs/sci- com_scf_out89.pdf
98. Intersalt: an international study of electrolyte excretion and blood pressu re. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Resea rch Group. BMJ
1988;297:319 -28 «PMID: 3416162»
99. Elliott P, Stamler J, Nichols R ym. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressu re within and across populations. Intersalt Cooperative Resea rch
Group. BMJ 1996;312 :1249-53 «PMID: 8634612»
100. Perry IJ, Beevers DG. Salt intake and stroke: a possible direct effect. J Hum Hypertens 1992;6:23-5 «PMID: 1583626»4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 26/29
101. Yamori Y, Nara Y, Mizushima S ym. Nutritional factors for stroke and major cardiovascular diseases: international epid emiological comparison of dietary prevention. Health Rep
1994;6:22-7 «PMID: 7919085»
102. Alderman MH, Cohen H, Madhavan S. Dietary sodium intake and mortality: the National Health and Nutrition Examination Survey (NHANES I). Lancet  1998;351:781-5 «PMID:
9519949»
103. Tuomilehto J, Jousilahti P, Rastenyte D ym. Urinary sodium excretion and cardiovascular mortality in Finland: a prospect ive study. Lancet  2001;35 7:848-51 «PMID: 11265954»
104. He J, Ogden LG, Vupputuri S ym. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 1999;282:2027-34 «PMID: 10591385»
105. Strazzullo P, D'Elia L, Kandala NB ym. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospect ive studies. BMJ 2009;339 :b4567 «PMID: 19934192»
106. Mente A, O'Donnel l M, Rangarajan S ym. Urinary sodium excretion, blood pressu re, cardiovascular disease, and mortality: a community-level prospect ive epid emiological cohort study.
Lancet  2018;392:496-506 «PMID: 30129465»
107. Cobb LK, Anderson CA, Elliott P ym. Methodological issues in cohort studies that relate sodium intake to cardiovascular disease outcomes: a science advisory from the American Heart
Association. Circulation 2014;129:1173-86 «PMID: 24515991»
108. Cappuccio FP, Beer M, Strazzullo P ym. Population dietary salt reduction and the risk of cardiovascular disease. A scient ific statement from the European Salt Action Network. Nutr
Metab Cardiovasc Dis 2018;29:107-114 «PMID: 30583888»
109. Campbell NRC, He FJ, Tan M ym. The International Consortium for Quality Resea rch on Dietary Sodium/Salt (TRUE) position statement on the use of 24-hour, spot, and short duration
(<24 hours) timed urine collections to assess dietary sodium intake. J Clin Hypertens (Greenwich ) 2019;21:700-709 «PMID: 31087778»
110. He FJ, MacGregor GA. Effect of longer-term salt reduction on blood pressu re (Cochrane Review). In: The Cochrane Library, Issue 4, 2008. Chichester, UK: John Wiley & Sons, Ltd.
111. He FJ, MacGregor GA. Importance of salt in determining blood pressu re in children: meta-analysis of controlled trials. Hypertensio n 2006;48:861-9 «PMID: 17000923»
112. He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressu re. Cochrane Database Syst Rev 2004;:CD 004937 «PMID: 15266549»
113. Cook NR, Cutler JA, Obarzanek E ym. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertensio n prevention
(TOHP). BMJ 2007;334 :885-8 «PMID: 17449506»
114. Bibbins-Domingo K, Chertow GM, Coxson PG ym. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010;362:590-9 «PMID: 20089957»
115. He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet  2011;37 8:380-2 «PMID: 21803192»
116. Cook NR, Cutler JA, Obarzanek E ym. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertensio n prevention
(TOHP). BMJ 2007;334 :885-8 «PMID: 17449506»
117. Khaw KT, Barrett-Connor E. Dietary potassium and stroke-associated mortality. A 12-year prospect ive population study. N Engl J Med 1987;316 :235-40 «PMID: 3796701»
118. Aro A, Pietinen P, Valsta LM ym. Lack of effect on blood pressu re by low fat diets with different fatty acid compositions. J Hum Hypertens 1998;12:383-9 «PMID: 9705040»
119. Jula A, Marniem i J, Huupponen R ym. Effects of diet and simvastatin on serum lipids, insu lin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA
2002;287:598-605 «PMID: 11829698»
120. Huai P, Xun H, Reilly KH ym. Physical activity and risk of hypertensio n: a meta-analysis of prospect ive cohort studies. Hypertensio n 2013;6 2:1021-6 «PMID: 24082054»
121. U.S. Department of Health and Human Services.  2008 Physical Activity Guidelines for Americans. Be Active, Healthy, and Happy! ODPHP Publication No. U0036, October 2008.
www.health.gov/paguidelines/pd f/paguide.pdf http://w ww.health.gov/paguidelines/pd f/paguide.pdf(63 s.)
122. Liikunta. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Käypä hoito -johtoryhmän asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2016 (viitattu
25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
123. Neter JE, Stam BE, Kok FJ ym. Influence of weight reduction on blood pressu re: a meta-analysis of randomized controlled trials. Hypertensio n 2003;42:878-84 «PMID: 12975389»
124. Horvath K, Jeitler K, Siering U ym. Long-term effects of weight-reducing  interventions in hypertensiv e patients: systematic review and meta-analysis. Arch Intern Med 2008;168:571-80
«PMID: 18362248»
125. Aucott L, Rothnie H, McIntyre L ym. Long-term weight loss from lifestyle intervention benef its blood pressu re?: a systematic review. Hypertensio n 2009;54:756-62 «PMID: 19704106»
126. Siebenhofer A, Jeitler K, Berghold A ym. Long-term effects of weight-reducing  diets in hypertensiv e patients. Cochrane Database Syst Rev 2011;:CD 008274 «PMID: 21901719»
127. Gloy VL, Briel M, Bhatt DL ym. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013;34 7:f5934
«PMID: 24149519»
128. Siebenhofer A, Horvath K, Jeitler K ym. Long-term effects of weight-reducing  drugs in hypertensiv e patients. Cochrane Database Syst Rev 2009;:CD 007654 «PMID: 19588440»
129. Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs 2019;79:219-230 «PMID: 30701480»
130. Zelniker TA, Wiviott SD, Raz I ym. SGLT2 inhibitors for primary and seco ndary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-
analysis of cardiovascular outcome trials. Lancet  2019;393:31- 39 «PMID: 30424892»
131. Sun F, Wu S, Guo S ym. Impact of GLP-1 recept or agonists on blood pressu re, heart rate and hypertensio n among patients with type 2 diabetes: A systematic review and network meta-
analysis. Diabetes Res Clin Pract 2015;110:26-37 «PMID: 26358202»
132. Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressu re. Diabetologia 2018;61:2098-2107 «PMID: 30132034»
133. Fagerberg B, Andersson OK, Isaksson B ym. Blood pressure control during weight reduction in obese hypertensiv e men: sepa rate effects of sodium and ener gy restriction. Br Med J (Clin
Res Ed) 1984;288:11-4 «PMID: 6418295»
134. Bao DQ, Mori TA, Burke V ym. Effects of dietary fish and weight reduction on ambulatory blood pressu re in overweight hypertensiv es. Hypertensio n 1998;32:710-7 «PMID: 9774368»
135. Marmot MG, Elliott P, Shipley MJ ym. Alcohol and blood pressu re: the INTERSALT study. BMJ 1994;308:1263-7 «PMID: 7802765»
136. Gill JS, Shipley MJ, Tsementzis SA ym. Alcohol consumption--a risk factor for hemorrhagic and non-hemorrhagic stroke. Am J Med 1991;90:489-97 «PMID: 2012089»
137. Puddey IB, Parker M, Beilin LJ ym. Effects of alcohol and caloric restrictions on blood pressu re and serum lipids in overweight men. Hypertensio n 1992;20:533-41 «PMID: 1356922»
138. Alkoholiongelmat. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Päihdelääketieteen yhdistyksen asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim ,
2018 (viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
139. Spence JD, Barnett PA, Linden W ym. Lifestyle modifications to prevent and control hypertensio n. 7. Recommendations on stress management. Canadian Hypertensio n Society,
Canadian Coalition for High Blood Pressu re Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ
1999;160:S46-50 «PMID: 103338 53»
140. Nakao M, Yano E, Nomura S ym. Blood pressu re-lowering effects of biofeedback treatment in hypertensio n: a meta-analysis of randomized controlled trials. Hypertens Res 2003;26:37-
46 «PMID: 12661911»
141. Canter PH, Ernst E. Insufficient  evidence to conclude whether or not Transcend ental Meditation decreases blood pressu re: results of a systematic review of randomized clinica l trials. J
Hypertens 2004;22:2049-54 «PMID: 15480084»
142. Dickinso n H, Campbell F, Beyer F ym. Relaxation therapies for the management of primary hypertensio n in adults: a Cochrane review. J Hum Hypertens 2008;22:809-20 «PMID:
18548088»
143. Lee MS, Pittler MH, Guo R ym. Qigong for hypertensio n: a systematic review of randomized clinica l trials. J Hypertens 2007;25:1525-32 «PMID: 17620944»
144. Yeh GY, Wang C, Wayne PM ym. The effect of tai chi exercise on blood pressu re: a systematic review. Prev Cardiol 2008;11:8 2-9 «PMID: 18401235»
145. Lee H, Kim SY, Park J ym. Acupuncture for lowering blood pressu re: systematic review and meta-analysis. Am J Hypertens 2009;22:122-8 «PMID: 19008863»
146. Minami J, Ishimitsu T, Matsuoka H. Effects of smoking cessa tion on blood pressu re and heart rate variability in habitual smokers. Hypertensio n 1999;33:5 86-90 «PMID: 993117 0»
147. Groppel li A, Giorgi DM, Omboni S ym. Persistent blood pressu re increase induced by heavy smoking. J Hypertens 1992;10:495-9 «PMID: 1317 911»
148. Linneb erg A, Jacobsen RK, Skaaby T ym. Effect of Smoking on Blood Pressu re and Resting Heart Rate: A Mendelian Randomization Meta-Analysis in the CARTA Consortium. Circ
Cardiovasc Genet  2015;8:832-41 «PMID: 26538566»
149. Choudhary MK, Eräranta A, Tikkakoski AJ ym. Effect of present  versus previous smoking on non-invasive haemodynamics. Sci Rep 2018;8:136 43 «PMID: 30206258»
150. Oncken CA, White WB, Cooney JL ym. Impact of smoking cessa tion on ambulatory blood pressu re and heart rate in postmenopausal women. Am J Hypertens 2001;14:942-9 «PMID:
11587162»
151. Ursoniu S, Mikhailidis DP, Serban MC ym. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials.
Pharmacol Res 2017;122:105-117 «PMID: 28602797»
152. Booth JN 3rd, Colantonio LD, Howard G ym. Healthy lifestyle factors and incid ent heart disease and mortality in candidates for primary prevention with statin therapy. Int J Cardiol
2016;207:196-202 «PMID: 26803243»
153. Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol 2014;11:2 76-89 «PMID: 24663092»
154. WHO. Guideline: Sodium intake for adults and children. Genev a, World Health Organization (WHO), 2012
155. Terveyttä ruoasta. Suomalaiset ravitsemussuositukset 2014. Valtion ravitsemusneu vottelukunta 2014. Tampere 2014. ISBN 978-952-453-800-8 (painettu), ISBN 978-952-453-801-5
(verkkojulkaisu)
156. Evira (Elintarviketurvallisuusvirasto). Pakkausmerkintäopas. Eviran ohje 17005/3, 2008.http://ww w.evira.fi/po rtal/fi/tietoa+evirasta/julkaisut/
157. Pesca tello LS, Franklin BA, Fagard R ym. American College of Sports Medicine position stand. Exercise and hypertensio n. Med Sci Sports Exerc 2004;36:533-53 «PMID: 15076798»
158. Clinica l Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res 1998;6 Suppl
2:51S-209S «PMID: 9813653»
159. Law MR, Wald NJ, Morris JK ym. Value of low dose combination treatment with blood pressu re lowering drugs: analysis of 354 randomised trials. BMJ 2003;32 6:1427 «PMID:
12829555»
160. Turnbull F, Blood Pressu re Lowering Treatment Trialists' Collaboration.. Effects of different blood-pressu re-lowering regimens on major cardiovascular events: results of prospect ively-
designed overviews of randomised trials. Lancet  2003;362:1527-35 «PMID: 14615107»
161. MacMahon S, Rodgers A. The effects of blood pressu re reduction in older patients: an overview of five randomized controlled trials in elderly hypertensiv es. Clin Exp Hypertens
1993;15 :967-78 «PMID: 8268901»
162. Hansso n L, Zanchetti A, Carruthers SG ym. Effects of intensiv e blood-pressu re lowering and low-dose aspirin in patients with hypertensio n: principa l results of the Hypertensio n Optimal
Treatment (HOT) randomised trial. HOT Study Group. Lancet  1998;351:1755-62 «PMID: 9635947»
163. Psaty BM, Smith NL, Siscovick DS ym. Health outcomes associated with antihypertensiv e therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-
45 «PMID: 9042847»
164. Psaty BM, Lumley T, Furberg CD ym. Health outcomes associated with various antihypertensiv e therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-44
«PMID: 12759325»
165. Blood Pressu re Lowering Treatment Trialists' Collaboration., Turnbull F, Neal B ym. Effects of different regimens to lower blood pressu re on major cardiovascular events in older and
younger adults: meta-analysis of randomised trials. BMJ 2008;336 :1121-3 «PMID: 18480116»
166. Turnbull F, Woodward M, Neal B ym. Do men and women respo nd differently to blood pressu re-lowering treatment? Results of prospect ively designed overviews of randomized trials.
Eur Heart J 2008;29:2669-80 «PMID: 18852183»
167. Turnbull F, Neal B, Algert C ym. Effects of different blood pressu re-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of
prospect ively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-9 «PMID: 15983291»4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 27/29
168. Calhoun DA. Use of aldosterone antagonists in resist ant hypertensio n. Prog Cardiovasc Dis 2006;48:387-96 «PMID: 16714158»
169. Moser M, Hebert PR. Prevention of disease progressio n, left ventricular hypertrophy and congestive heart failure in hypertensio n treatment trials. J Am Coll Cardiol 1996;27:1214-8
«PMID: 8609345»
170. Law MR, Morris JK, Wald NJ. Use of blood pressu re lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expect ations
from prospect ive epid emiological studies. BMJ 2009;338 :b1665 «PMID: 19454737»
171. SPRINT Resea rch Group., Wright JT Jr, Williamson JD ym. A Randomized Trial of Intensiv e versus Standard Blood-Pressu re Control. N Engl J Med 2015;373:2103-16 «PMID:
26551272»
172. Beckett NS, Peters R, Fletcher AE ym. Treatment of hypertensio n in patients 80 years of age or older. N Engl J Med 2008;358:1887-98 «PMID: 18378519»
173. Benet os A, Petrovic M, Strandberg T. Hypertensio n Management in Older and Frail Older Patients. Circ Res 2019;124:1045-1060 «PMID: 30920928»
174. Ahola TL, Johansso n JK, Jula AM. Komplisoitumattoman hypertensio n lääkehoito ei vastaa hoitosuosituksia. SLL 2016;71:219-
175. Chapman N, Dobson J, Wilson S ym. Effect of spironolactone on blood pressu re in subjects with resist ant hypertensio n. Hypertensio n 2007;49:839-45 «PMID: 17309946»
176. ONTARGET Investigators., Yusuf S, Teo KK ym. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59 «PMID: 18378520»
177. Prevention of stroke by antihypertensiv e drug treatment in older persons with isolated systolic hypertensio n. Final results of the Systolic Hypertensio n in the Elderly Program (SHEP).
SHEP Cooperative Resea rch Group. JAMA 1991;265:3255-64 «PMID: 2046107»
178. Staessen JA, Fagard R, Thijs L ym. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertensio n. The Systolic Hypertensio n
in Europe (Syst-Eur) Trial Investigators. Lancet  1997;350:757-64 «PMID: 9297994»
179. Kjeldsen SE, Dahlöf B, Devereux RB ym. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertensio n and left ventricular hypertrophy: a
Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-8 «PMID: 12243636»
180. Hansso n L, Lindholm LH, Ekbom T ym. Randomised trial of old and new antihypertensiv e drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old
Patients with Hypertensio n-2 study. Lancet  1999;354:1751-6 «PMID: 10577635»
181. Dyslipidemiat. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Sisätautilääkärien Yhdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura
Duodecim , 2017 (viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
182. Zinman B, Wanner  C, Lachin JM ym. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117-28 «PMID: 26378978»
183. Neal B, Perkovic V, Mahaffey KW ym. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-657 «PMID: 28605608»
184. Tyypin 2 diabetes. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in, Suomen Sisätautilääkärien yhdistyksen ja Diabetesliiton Lääkärineu voston asettama työryhmä.
Helsink i: Suomalainen Lääkäriseura Duodecim , 2018 (viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
185. Salvetti M, Paini A, Bertacchini F ym. Changes in left ventricular geometry during antihypertensiv e treatment. Pharmacol Res 2018;134 :193-199 «PMID: 29959031»
186. Dahlöf B, Gosse P, Guéret P ym. Perindopril/ind apamide combination more effective than enalapril in reducing  blood pressu re and left ventricular mass: the PICXEL study. J Hypertens
2005;23:2063-70 «PMID: 16208150»
187. Sepel valtimotautikohtaus: epästabiili angina pect oris ja sydäninfarkti ilman ST-nousuja. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Kardiologisen Seuran
asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2014 (viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
188. Stabiili sepel valtimotauti. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Kardiologisen Seuran asettama työryhmä. Helsink i: Suomalainen Lääkäriseura
Duodecim , 2015 (viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
189. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressu re-lowering treatment. 6. Prevention of heart failure and new- onset  heart failure--meta-analyses of randomized trials. J
Hypertens 2016;34:373-84; discussion 384 «PMID: 26780184»
190. Sydämen vajaatoiminta. Käypä hoito -suositus. Suomalaisen Lääkäriseura Duodecim in ja Suomen Kardiologisen Seuran asettama työryhmä. Helsink i: Suomalainen Lääkäriseura
Duodecim , 2017 (viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
191. Ettehad D, Emdin CA, Kiran A ym. Blood pressu re lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet  2016;387:957-967 «PMID:
26724178»
192. Eteisvärinä. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Kardiologisen Seuran asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2017
(viitattu 25.9.2019). Saatavilla internetissä: www.kaypahoito.fi
193. Aboyans V, Ricco JB, Bartelink MEL ym. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular
Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesent eric, renal, upper  and lower extremity arteriesE ndorsed by: the European Stroke
Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular
Surgery (ESVS). Eur Heart J 2018;39:763-816 «PMID: 28886620»
194. Diehm N, Schmidli J, Setacci C ym. Chapter III: Management of cardiovascular risk factors and medical therapy. Eur J Vasc Endovasc Surg 2011;42 Suppl 2:S33-42 «PMID: 22172471»
195. Furie KL, Kasner  SE, Adams RJ ym. Guidelines for the prevention of stroke in patients with stroke or transient  ischemic attack: a guideline for healthcare professio nals from the american
heart association/american stroke association. Stroke 2011;42:227-76 «PMID: 20966421»
196. PROGRESS Collaborative Group.. Randomised trial of a perindopril-based blood-pressu re-lowering regimen among 6,105 individuals with previous stroke or transient  ischaemic attack.
Lancet  2001;35 8:1033-41 «PMID: 11589932»
197. Schrader J, Lüders S, Kulschewski A ym. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principa l results of a prospect ive
randomized controlled study (MOSES). Stroke 2005;36:1218-26 «PMID: 15879332»
198. Aivoinfarkti ja TIA. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Neurologinen yhdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura
Duodecim , 2020 (viitattu 8.6.2020). Saatavilla internetissä: www.kaypahoito.fi
199. Iadecola C, Gottesman RF. Neurovascular and Cognitive Dysfunction in Hypertensio n. Circ Res 2019;124:1025-1044 «PMID: 30920929»
200. Antikainen R, Strandberg T, Tuomilehto J. Yli 80-vuotiaiden kohonneen verenpa ineen lääkehoito kannattaa. Suom Lääkäril 2009;64:909-13
201. Hakala SM, Tilvis RS, Strandberg TE. Blood pressu re and mortality in an older population. A 5-year follow-up of the Helsink i Ageing  Study. Eur Heart J 1997;18:1019-23 «PMID:
9183596»
202. Rastas S, Pirttilä T, Viramo P ym. Association between blood pressu re and survival over 9 years in a gener al population aged 85 and older. J Am Geriatr Soc 2006;54:912-8 «PMID:
16776785»
203. Boshuizen HC, Izaks GJ, van Buuren S ym. Blood pressu re and mortality in elderly people aged 85 and older: community based study. BMJ 1998;316 :1780-4 «PMID: 9624064»
204. van Bemmel T, Gussek loo J, Westendorp RG ym. In a population-based prospect ive study, no association between high blood pressu re and mortality after age 85 years. J Hypertens
2006;24:287-92 «PMID: 16508574»
205. Qiu C, Winblad B, Fratiglioni L. The age-depend ent relation of blood pressu re to cognitive function and dementia. Lancet  Neurol 2005;4:487-99 «PMID: 16033691»
206. van Bemmel T, Holman ER, Gussek loo J ym. Low blood pressu re in the very old, a conseq uence of imminent  heart failure: the Leiden 85-plus Study. J Hum Hypertens 2009;23:27-32
«PMID: 18650839»
207. Gottesman RF. Should Hypertensio n Be Treated in Late Life to Preserve Cognitive Function? Con Side of the Argument. Hypertensio n 2018;71:787-792 «PMID: 29643178»
208. Lihavuus (lapset , nuoret ja aikuiset). Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in, Suomen Lihavuustutkijat ry:n ja Suomen Lastenlääkäriyhdistys ry:n asettama
työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim, 2020 (viitattu pp.kk.vvvv). Saatavilla internetissä: www.kaypahoito.fi
209. Somes GW, Pahor M, Shorr RI ym. The role of diastolic blood pressu re when treating isolated systolic hypertensio n. Arch Intern Med 1999;159:2004-9 «PMID: 10510985»
210. Wang JG, Staessen JA, Franklin SS ym. Systolic and diastolic blood pressu re lowering as determinants of cardiovascular outcome. Hypertensio n 2005;45:907-13 «PMID: 15837826»
211. Blanco PJ, Müller LO, Spence JD. Blood pressu re gradients in cerebral arteries: a clue to pathogenesis of cerebral small vessel  disease. Stroke Vasc Neurol 2017;2:108-117 «PMID:
28989801»
212. Hilgers KF, Mann JF. ACE inhibitors versus AT(1) recep tor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002;13:110 0-8 «PMID: 11912272»
213. Chobanian AV, Bakris GL, Black HR ym. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressu re: the JNC 7
report. JAMA 2003;289:2560-72 «PMID: 12748199»
214. Farsang C, Kiss I, Tykarski A, Narkiewicz K. Treatment of hypertensio n in patients with chronic obstuctive pulmonary disease (COPD). ESH nes letter 2016; 17:nr.62
215. Löfdahl CG. Antihypertensiv e drugs and airway function, with specia l reference to calcium channel  blockade. J Cardiovasc Pharmacol 1989;14 Suppl 10:S40-51; discussion S59-62
«PMID: 2483571»
216. Regitz-Zagrosek V, Roos-Hessel ink JW, Bauersachs J ym. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:316 5-3241 «PMID:
30165544»
217. Abalos E, Duley L, Steyn DW ym. Antihypertensiv e drug therapy for mild to moderate hypertensio n during pregnancy. Cochrane Database Syst Rev 2018;10:CD002252 «PMID:
30277556»
218. Nabhan AF, Elsedawy MM. Tight control of mild-moderate pre-existing or non-proteinu ric gestational hypertension. Cochrane Database Syst Rev 2011;:CD 006907 «PMID: 21735406»
219. Magee LA, von Dadelszen P, Rey E ym. Less-tight versus tight control of hypertensio n in pregnancy. N Engl J Med 2015;372:407-17 «PMID: 25629739»
220. von Dadelszen P, Ornstein MP, Bull SB ym. Fall in mean arterial pressu re and fetal growth restriction in pregnancy hypertensio n: a meta-analysis. Lancet  2000;355:87-92 «PMID:
10675164»
221. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertensio n during pregnancy. Cochrane Database Syst Rev 2003;:CD 002863 «PMID: 12917933»
222. Mastrobattista JM. Angiotensin converting enzyme inhibitors in pregnancy. Semin Perinatol 1997;21:124-34 «PMID: 9201818»
223. Papadopoulos DP, Mourouzis I, Thomopoulos C ym. Hypertensio n crisis. Blood Press 2010;19:328-36 «PMID: 20504242»
224. Perez MI, Musini VM. Pharmacological interventions for hypertensiv e emergencies.  Cochrane Database Syst Rev 2008;:CD 003653 «PMID: 18254026»
225. Varon J. Treatment of acute severe hypertensio n: current and new er agents. Drugs 2008;68:283-97 «PMID: 18257607»
226. Antithrombotic Trialists' (ATT) Collaboration., Baigent C, Blackwell L ym. Aspirin in the primary and seco ndary prevention of vascular disease: collaborative meta-analysis of individual
participa nt data from randomised trials. Lancet  2009;373:18 49-60 «PMID: 19482214»
227. Alaraajojen tukkiva valtimotauti. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Verisuonikirurgisen Yhdistyksen asettama työryhmä. Helsink i: Suomalainen
Lääkäriseura Duodecim , 2010 (viitattu 25.9.2019) Saatavilla internetissä: www.kaypahoito.fi
228. Mahmoud AN, Gad MM, Elgendy AY ym. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized
controlled trials. Eur Heart J 2019;40:607-617 «PMID: 30561620»
229. Metsärinne K, Mäkikallio T, Booth N, Majamaa H, Isojärvi J, Roine RP. Munuaisvaltimon sympaattinen dener vaatio hoitoresist entin hypertensio n hoidossa. Suom Lääkäril
2013;6 8:1967-72
230. Persu A, Jin Y, Baelen M ym. Eligibility for renal dener vation: experience at 11 European expert cent ers. Hypertensio n 2014;63:1319 -25 «PMID: 24664290»
231. Mahfoud F, Lüscher TF, Andersson B ym. Expert consen sus document from the European Society of Cardiology on catheter-based renal dener vation. Eur Heart J 2013;34 :2149-57
«PMID: 23620497»
232. Carey RM, Muntner P, Bosworth HB ym. Prevention and Control of Hypertensio n: JACC Health Promotion Series. J Am Coll Cardiol 2018;72:1278-1293 «PMID: 30190007»4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 28/29
233. Calhoun DA, Jones D, Textor S ym. Resist ant hypertension: diagnosis, evaluation, and treatment. A scient ific statement from the American Heart Association Professio nal Education
Committee of the Council for High Blood Pressu re Resea rch. Hypertensio n 2008;51:1403-19 «PMID: 18391085»
234. Sarafidis PA, Bakris GL. Resist ant hypertensio n: an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749-57 «PMID: 19022154»
235. Nelson M, Reid C, Krum H ym. A systematic review of predictors of maintenance of normotensio n after withdrawal of antihypertensiv e drugs. Am J Hypertens 2001;14:98-105 «PMID:
11243314 »
236. Birtwhistle RV, Godwin MS, Delva MD ym. Randomised equivalence trial comparing three month and six month follow up of patients with hypertensio n by family practitioners. BMJ
2004;328:204 «PMID: 14726370»
237. Clark CE, Smith LF, Taylor RS ym. Nurse led interventions to improve control of blood pressu re in people with hypertensio n: systematic review and meta-analysis. BMJ 2010;341:c39 95
«PMID: 20732968»
Artikkelin tunnus: hoi04010 (004.010)
© 2025 Suomalainen Lääkäriseura Duodecim
Aiheeseen liittyviä suosituksia
Aivoinfarkti ja TIA
Julkaistu: Helmikuu 2024
Potilaalle
Tiivistelmä
Alkoholiongelmat
Julkaistu: Elokuu 2018
Potilaalle
Tiivistelmä
PDF
Diabeettinen retinopatia
Julkaistu: Kesäkuu 2024
Potilaalle
Tiivistelmä
Diabeteksen munuaistauti
Julkaistu: Lokakuu 2024
Potilaalle
Tiivistelmä
Dyslipidemiat
Julkaistu: Joulukuu 2022
Potilaalle
Tiivistelmä
Eteisvärinä
Julkaistu: Helmikuu 2025
Potilaalle
Tiivistelmä
Lihavuus (lapset, nuoret ja aikuiset)
Julkaistu: Maaliskuu 2024
Potilaalle
Tiivistelmä
Lihavuus (lapset, nuoret ja aikuiset)
Julkaistu: Maaliskuu 2024
Potilaalle
Tiivistelmä
Liikunta (ylläpito lopetettu)
Julkaistu: Tammikuu 2016
PDF
Tyypin 2 diabetes
Julkaistu: Maaliskuu 2024
Potilaalle
Tiivistelmä4.3.2025 klo 17.13 Kohonnut verenpaine
https://www.kaypahoito.fi/hoi04010 29/29
Kolesterolilääkkeet - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Lääkehoito (https://sydan.fi/elamaa-sairauden-kanssa/laakehoito/)/Kolesterolilääkkeet
Kolesterolilääkkeet
(https://sydan.fi/fakta/kolesterolilaakkeet/)
Kolesterolilääkkeillä (lipidilääkkeet) hoidetaan rasva-aineenvaihdunnan
häiriöitä.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 28.9.2017
Päivitetty 7.3.2025
 
Lue seuraavaksi Taideterapia eheyttää ja tasapainottaa arkea sydänsairauden kanssa (https://sydan.fi/artikkeli/taideterapia-
eheyttaa-ja-tasapainottaa-arkea-sydansairauden-kanssa/)
Valtimosairauksien riskin pienentäminen tai jo syntyneen taudin pahenemisen
estäminen vaatii usein häiriintyneen rasva-aineenvaihdunnan hoitoa. Tätä
arvioidaan veren rasva- eli lipidiarvojen perusteella. Käytännössä se tarkoittaa
kokonaiskolesterolin (fS-kol), HDL-kolesterolin (fS-kol-HDL), LDL-kolesterolin (fS-
kol-LDL) ja triglyseridin (fS-trigly tai TG) mittaamista.
Rasva-arvot on yksi valtimosairauksien kokonaisriskin osatekijä yhdessä iän,
sukupuolen, perimän, tupakoinnin, verenpaineen ja sokeriaineenvaihdunnan
kanssa. Terveillä kokonaisriskiä arvioidaan FINRISKI-laskurilla. Sydäntapahtuman
riski on aina erittäin suuri niillä, joilla on jo todettu sepelvaltimo-, aivovaltimo-
tai ääreisvaltimosairaus. Heillä ei enää käytetä riskilaskureita.
Rasva-aineenvaihdunnan parantamisessa elintavat ovat aina mukana. Terveillä
ihmisillä, jos valtimosairauksien riski on pieni tai kohtalainen eivätkä rasva-arvot
ole vahvasti poikkeavat, ruokavalio, liikunta ja muut elintavat ovat riittävä hoito.
Mitä suurempi sairastumisen riski, ja etenkin jos valtimosairaus on jo todettu,
sitä todennäköisemmin tarvitaan lääkehoitoa.
Statiinit
Statiinit ovat tärkein kolesterolilääkkeiden ryhmä. Ne estävät soluja
valmistamasta kolesterolia (kolesterolisynteesiä), jolloin solut ottavat enemmän
kolesterolia pois verenkierrosta. Tällöin erityisesti haitallisen LDL-kolesterolin
määrä veressä laskee. Tavoitearvo määräytyy sairastumisen riskin mukaan.
Statiinit pienentävät vakavan valtimosairaustapahtuman (sydäninfarkti tai
aivoverenkiertosairaus) riskiä ensimmäisen käyttövuoden jälkeen vuosittain
neljänneksellä (25 %) lääkettä käyttämättömiin verrattuna, kun LDL-
kolesteroliarvo laskee 1 mmol/l:n. Tehokkaampi statiinihoito pienentää näitä
riskejä enemmän.
Statiinit aiheuttavat pienelle osalle käyttäjistä lihaskipuja ja mahdollisesti
lihasheikkoutta. Tyypillistä on isojen lihasryhmien (hartiat, selkä, reidet) kipu,
joka alkaa pian lääkkeen käyttöönoton jälkeen. Lihaskivut ovat muutenkin
tavallisia, joten kaikki statiinihoidon aikana ilmenevät vaivat eivät johdu
lääkityksestä. Jos kohtalainenkin epäily syy-yhteydestä on, statiinivalmistetta
voidaan vaihtaa tai annosta pienentää. Useimmiten sopiva hoito on
löydettävissä, mutta pieni osa ihmisistä ei voi käyttää statiineja.
Harvoissa tapauksissa statiinihoito vaurioittaa lihassoluja, jolloin vereen vuotaa
kreatiinikinaasi-entsyymiä. Sitä voidaan mitata verikokeella (S-CK).Lue seuraavaksi Taideterapia eheyttää ja tasapainottaa arkea sydänsairauden kanssa (https://sydan.fi/artikkeli/taideterapia-
eheyttaa-ja-tasapainottaa-arkea-sydansairauden-kanssa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Statiinien haittavaikutuksia voidaan vähentää
Haittojen välttämiseksi on kartettava yhteiskäyttöä sellaisten lääkkeiden kanssa,
jotka hidastavat joidenkin statiinien (erityisesti simvastatiinin) poistumista
elimistöstä. Tavallisimmin tällaisia yhteiskäytössä huomioitavia lääkeaineita ovat
makrolidiantibiootit (klaritromysiini ja erytromysiini) ja eräät sienilääkkeet.
Terbinafiini on statiinienkin kanssa käytettynä turvallinen sienilääke.
Greippi hidastaa statiinien poistumista elimistöstä, joten kaikkia greippiä
sisältäviä tuotteita tulee välttää.
Osalla ihmisistä statiinien poistuminen on hidastunut geneettisistä syistä, jolloin
lääkepitoisuudet saattavat nousta muita herkemmin haitallisen korkeiksi.
Ongelmatapauksissa tällaista farmakogeneettistä mekanismia voidaan tutkia
tekemällä geenitesti, jolla tutkitaan -polymorfismia. Testiä ei
kuitenkaan tehdä systemaattisesti hoitoa aloitettaessa. Geenimutaation
kantajat voivat käyttää statiinia, mutta tavallista huomattavasti pienemmillä
annoksilla.
Ihmisillä, joilla on diabeteksen esiaste (lievä glukoosiaiheenvaihdunnan häiriö),
statiinit voivat jouduttaa tilan etenemistä diabetekseksi. Kaikki käyttäjät
huomioon ottaen diabeteksen riski lisääntyy 9 % eli noin joka 250:s käyttäjä saa
diabetesdiagnoosin. Vakavat valtimotautitapahtumat (sydäninfarktit,
aivoinfarktit ja niistä johtuvat kuolemat) kuitenkin vähenevät, joten
kokonaisvaikutus on suotuisa. Statiinit ovat erityisen hyödyllisiä diabeetikoille,
koska heidän valtimotautiriskinsä on suuri.
Elintapahoidon jatkaminen statiinilääkityksen aikana on oleellisen tärkeää.
Erityisen tärkeää se on diabeteksen esiasteita sairastavilla, koska heillä jo
muutaman kilon painonpudotus yhdistettynä liikuntaan ja laadullisesti
terveelliseen ravintoon pienentää merkittävästi diabeteksen riskiä.
Elintapahoitoon voi kuulua myös kasvistanoli- tai -sterolituotteiden (muun
muassa näitä sisältävät levitteet) käyttö, mikä tehostaa statiinien vaikutusta.
Yksittäistapausten tai satunnaistamattomien aineistojen perusteella statiineihin
on yhdistetty joukko muita haittoja, muun muassa muistihäiriöt, kaihi ja
haimatulehdus. Tarkemmissa tutkimuksissa näitä epäilyjä ei ole voitu yleistää.
Vakuuttavasti on osoitettu, etteivät statiinit aiheuta syöpää.
Muita lipidilääkkeitä ovat fibraatit, etsetimibi, resiinit ja PCSK9-estäjät. Niiden
käyttö on statiineihin verrattuna vähäistä.SLCO1B1Lue seuraavaksi Taideterapia eheyttää ja tasapainottaa arkea sydänsairauden kanssa (https://sydan.fi/artikkeli/taideterapia-
eheyttaa-ja-tasapainottaa-arkea-sydansairauden-kanssa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Fibraatit
Fibraatit pienentävät triglyseridiarvoa ja suurentavat hieman HDL-
kolesteroliarvoa. Niitä voidaan harkinnan mukaan käyttää, jos statiinit eivät sovi.
Etsetimibi
Etsetimibi estää kolesterolin imeytymistä suolesta. Se ei yksinään ole kovin
tehokas kolesterolilääke, mutta tuo pientä lisähyötyä statiinihoitoon liitettynä.
Jos LDL-kolesteroli ei ole laskenut statiinihoidolla riittävän alas, liitetään sen
rinnalle usein etsetimibi hoitoa tehostamaan. Lääkkeestä on vain yksi
annosvahvuus, 10 mg, ja se otetaan kerran päivässä. Markkinoilla on myös
yhdistelmäpillereitä, joissa on statiinia ja etsetimibiä samassa pillerissä.
Resiinit
Resiinit eli sappihappojen sitojat (kolestyramiini, kolestipoli ja kolesevelaami)
pienentävät LDL-kolesteroliarvoa, mutta eivät yhtä tehokkaasti kuin statiinit.
Vatsavaivat ja vaatimaton teho rajoittavat resiinien käyttökelpoisuutta, ja
käyttö onkin nykyisin hyvin vähäistä.
PCSK9-estäjät
Nämä lääkkeet estävät LDL-reseptorien hajoamista maksasolun pinnalla, jolloin
toimivia reseptoreja jää sieppaamaan LDL-kolesterolia pois verenkierrosta.
Muista lipidilääkkeistä poiketen nämä lääkkeet otetaan pistoksena ihon alle
kerran tai kahdesti kuukaudessa. Lääkkeillä on erityiskorvattavuus periytyvää
vaikeaa rasva-aineenvaihdunnan häiriötä sairastavien potilaiden (FH-tauti)
hoidossa, sekä rajoitetusti peruskorvauus sepelvaltimotautia tai muuta
valtimotautia sairastavilla, jos statiini- ja etsetimibihoidosta huolimatta LDL-
kolesteroli on edelleen yli 2,0 mmol/l. Tällä hetkellä saatavilla on kaksi
valmistetta, evolokumabi ja alirokumabi.
Inklisiraani
Tämän lääkkeen vaikutukset välittyvät myös PCSK9-proteiinin kautta, mutta eri
mekanismilla kuin edellä mainitut PCSK9-estäjät. Inklisiraani toimii maksasolun
sisällä, jossa se estää kyseisen proteiinin muodostumista. Lopputulema on sama,
eli LDL-kolesterolia verenkierrosta sieppaavia reseptoreita säilyy maksasolun
pinnalla toimintakykyisenä. Terveydenhuollon ammattilainen antaa lääkkeenLue seuraavaksi Taideterapia eheyttää ja tasapainottaa arkea sydänsairauden kanssa (https://sydan.fi/artikkeli/taideterapia-
eheyttaa-ja-tasapainottaa-arkea-sydansairauden-kanssa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
pistoksena. Ensimmäisen annoksen jälkeen toinen annos annetaan vasta kolmen
kuukauden kuluttua, ja jatkossa vain puolen vuoden välein. Lääkkeellä on
rajoitettu peruskorvattavuus.
Ikosapenttietyyli
Ikosapenttietyyliä käytetään statiinihoidon lisänä valtimotautipotilailla tai
diabeetikoilla, joilla on lisäksi muita valtimotaudin riskitekijöitä, ja joilla on
triglyseridipitoisuus ≥  1,7 mmol/l. Kyseessä on omega-3-rasvahapon,
eikosapentaeenihapon (EPA) stabiili etyyliesteri. Vaikutusmekanismia
sydäntapahtumien vähenemiseen ei täysin tunneta.
Useimmilla lipidilääkkeillä on alempi erityiskorvaus sepelvaltimotaudissa ja FH-
taudissa. Poikkeukset mainitaan taulukossa.
Lääkeaine Valmistenimet Huomauksia
Statiinit
AtorvastatiiniAtorbir
Lipistad
Lipitor
Orbeos
AtorvastatinAtorvastatin-nimellä
rinnakkaisvalmiste neljältä
lääkeyritykseltä
FluvastatiiniLescol
FluvastatinFluvastatin-nimellä
rinnakkaisvalmiste kolmelta
lääkeyritykseltä
LovastatiiniLovastatin
LovabetaLovastatin-nimellä rinnakkaisvalmiste
Pravastatiini PravastatinPravastatin-nimellä
rinnakkaisvalmiste kahdelta
lääkeyritykseltä
RosuvastatiiniCrestor
RosuvastatinRosuvastatin-nimellä
rinnakkaisvalmiste seitsemältä
lääkeyritykseltä
SimvastatiiniLipcut
Zocor
SimvastatinSimvastatin-nimellä
rinnakkaisvalmiste neljältä
lääkeyritykseltä
Fibraatit
Betsafibraatti Bezalip Ei sv-korvausta
FenofibraattiFenofibrate Biogaran (ei sv-
korvausta, erityislupavalmiste)
Lipanthyl
Gemfibrotsiili Gevilon Ei sv-korvausta, erityislupavalmisteLue seuraavaksi Taideterapia eheyttää ja tasapainottaa arkea sydänsairauden kanssa (https://sydan.fi/artikkeli/taideterapia-
eheyttaa-ja-tasapainottaa-arkea-sydansairauden-kanssa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Muut lipidilääkkeet
EtsetimibiEzetrol
EtsetimibeRinnakkaisvalmiste seitsemältä
lääkeyritykseltä
Rosuvastatiini +
etsetimibiRosuvastatin/etsetimibe Kaksi annosvahvuutta
KolestyramiiniQuestran
CholestyraminUseita rinnakkaisvalmisteita, mutta
kaikilla ei korvattavuutta ja osa
erityislupavalmisteita
KolestipoliColestipol
ColestidUseita rinnakkaisvalmisteita, mutta
kaikilla ei korvattavuutta ja osa
erityislupavalmisteita
Evolokumabi Repatha Annostellaan pistoksina
Alirokumabi Praluent Annostellaan pistoksina
Inklisiraani LeqvioAnnostellaan pistoksina,
ammattilaisten toimesta
Ikosapenttietyyli VazkepaRajoitetusti erityiskorvattava
sepelvaltimotautia sairastavilla
potilailla.
 
TILAA KOLESTEROLI KOHDALLEEN -LEHTINEN SYDÄNKAUPASTA
Jäsenenä tuet sydänyhteisön edunvalvontaa
LIITY MUKAAN (HTTPS://SYDAN.FI/LIITY-JASENEKSI)Lue seuraavaksi Taideterapia eheyttää ja tasapainottaa arkea sydänsairauden kanssa (https://sydan.fi/artikkeli/taideterapia-
eheyttaa-ja-tasapainottaa-arkea-sydansairauden-kanssa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Kotihoito-ohje sepelvaltimoiden varjoainekuvauksen tai pallolaajennuksen jälkeen - Potilasohjeet - intra.pirha.fi.pdf
Päivitetty 28.3.2024
Tays Sydänsairaala / kardiologia
Potilasohje: 15.00.38
Kotihoito-ohje sepelvaltimoiden varjoainekuvauksen tai
pallolaajennuksen jälkeen
Yleistä
Sinulle on tehty sepelvaltimoiden varjoainekuvaus tai pallolaajennus, jonka vuoksi ranne- tai reisivaltimoon on pistetty
reikä. Vaikka vuoto pistoskohdassa on saatu osastolla loppumaan, vaatii pistoskohdan parantuminen vielä aikaa ja
omaseurantaa.
Jälkihoito
Kolmioliinaa voit pitää toimenpidepäivänä käden tukena.
Poista ranteen sidos toimenpidettä seuraavana päivänä. Tämän jälkeen sidosta et enää tarvitse.
Mikäli sinulla on diabetes ja käytössä metformiinia sisältävä lääke, pidä se tauolla kaksi vuorokautta
varjoainekuvauksen jälkeen.
Tarvittaessa voit ottaa kotona särkylääkkeen, mikäli pistospaikalla tuntuu särkyä.
Autolla ajoa ei suositella seuraavan vuorokauden aikana.
Vältä kahden päivän ajan
raskaiden esineiden nostelua
saunomista. Suihkussa voit käydä normaalisti seuraavana päivänä.
kovempaa rasitusta tai kuntourheilua.
Muuta huomioitavaa
Jos pistoskohta kipeytyy voimakkaasti, alkaa vuotaa tai turpoaa, hakeudu ensisijaisesti lähimpään
terveyskeskuspäivystykseen. Mikäli pistoskohta alkaa vuotaa tai turpoaa äkillisesti, pistoskohdan painaminen jämäkästi
on hyvä ensihoito.26.2.2025 klo 22.04 Kotihoito-ohje sepelvaltimoiden varjoainekuvauksen tai pallolaajennuksen jälkeen - Potilasohjeet - intra.pirha.fi
https://potilasohjeet.pirha.fi/w/kotihoito-ohje-sepelvaltimoiden-varjoainekuvauksen-tai-pallolaajennuksen-jalkeen 1/1
Krooninen sepelvaltimo-oireyhtymä.pdf
Krooninen sepelvaltimo-oir eyhtymä
Käypä hoito -suositus | Julkaistu: 28.06.2022 | Tila:
Aihepiiri(t): Kardiologia , Kuntoutus , Työterveyshuolto , Yleislääketiede
Suomalaisen Lääkäriseuran Duodecimin ja Suomen Kardiologisen Seuran asettama työryhmä
Miten viitata Käypä hoito -suositukseen?  «K1»
Keskeinen sanoma
Krooninen sepel valtimo-oireyhtymä on sairaus, jossa sepel valtimoihin kehittyy ateroskleroosia.
Sairaus voidaan todeta oireiden perusteella.
Oireeton ateroskleroosi voidaan todeta kuvantamistutkimuksissa .
Diagnostiikka perustuu anamneesiin ja sepel valtimoiden ateroskleroosin tai iskemian osoitukseen.
Hoidon perusta on riskitekijöiden minim ointi ja optimaalinen ennu stetta parantava lääkehoito, joiden toteutuminen tulee varmistaa kattavan sydänvalmennu ksen
avulla.
Oireita lievittävää lääkehoitoa käytetään tarvittaessa .
Potilasta voidaan lisäksi hoitaa kajoavilla toimenpit eillä, jos hänellä on todettu suuren vaaran merkkejä tai oireet vaikuttavat merkittävästi hänen työkykyynsä tai
elämänlaatuunsa.
Potilaalle tulee laatia yksilöllinen ja tavoitteellinen hoito- ja kuntoutussuunnit elma.
Hyvinvointialueilla tulee olla suunnit elmallinen palveluketju kroonista sepel valtimo-oireyhtymää sairastaville potilaille.
Ks. video Päivityksiä kroonisen sepel valtimo-oireyhtymän Käypä hoito -suositukseen .
Tiivistelmä ja potilasversio
Suosituksen tiivistelmä «Krooninen sepel valtimo-oireyhtymä»
Suosituksen yleiskielinen potilasversio suomeksi «Krooninen sepel valtimo-oireyhtymä (sepelvaltimotauti)» ja ruotsiksi «Kronisk t kranskärlssyndrom
(kranskärlssjukdom)»
Tavoitteet26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 1/31
Suosituksen tavoitteena  on
ohjata ja yhtenäistää diagnostiikkaa tilanteissa , joissa oireiden aiheuttajaksi epäillään kroonista sepel valtimo-oireyhtymää
yhtenäistää kroonista sepel valtimo-oireyhtymää sairastavien hoitoa
parantaa hoidon vaikuttavuutta
kohdentaa terveydenhuollon voimavaroja oikein
parantaa potilaiden elämänlaatua sekä työ- ja toimintakykyä.
Kohderyhmä
Suositus on tarkoitettu kaikille
kroonista sepel valtimo-oireyhtymää hoitaville lääkäreille ja muulle henkilökunnalle
hoidon järjestelyistä vastaaville
potilasjärjestöille
apteekeille.
Määritelmät
Suosituksessa  käsitellään kroonista sepe lvaltimo-oireyhtymää eli sydämen valtimoiden sairautta, jossa suonen seinä miin kehittyy ateroskleroosia.
Oireetonta kuvantamisessa  todettua tautia kutsutaan sepel valtimoiden ateroskleroosiksi.
Sepel valtimoiden ateroskleroosi voi olla pitkään oireeton.
Kroonisest a sepel valtimotaudista puhutaan, kun potilas on oireinen,  aiemmin revaskularisoitu tai sairastanut aiemman sepel valtimotautikohtauksen.
Kroonisen sepel valtimo-oireyhtymän oireena  voi olla rintakipu, hengenahdistus tai jokin muu epätyypillinenk in oire.
Oireen esiint yessä  pitkään samanlaisena  samoissa tilanteissa  käytetään termiä vakaa sepel valtimoperäinen rintakipu (aiemmin stabiili sepel valtimotauti).
Oire voi pahentua tai helpottua ajan kuluessa .
Jos potilaan oirekuva ja rasituksen sieto vaihtelee merkittävästi tai muuttuu huonommaksi, voi kyseessä  olla sepel valtimotautikohtaus (ks. Käypä hoito -suositus
Sepel valtimotautikohtaus «Sepel valtimotautikohtaus», [1]).
Revaskularisaation ja sepel valtimotautikohtauksen jälkeen potilasta hoidetaan samoin periaattein kuin oireisessa  kroonisessa  sepel valtimotaudissa, vaikka hän olisi
oireeton.
Suosituksessa  käsitellään myös sydänlihaksen pient en suonten toiminna llisia häiriöitä.
Esiintyvyys
Oikeus kroonisen sepel valtimotaudin ja siihen liittyvän rasva-aineenv aihdunnan häiriön erityiskorvattaviin lääkkeisiin (koodi 206) oli Suomessa  vuonna 2020
kaikkiaan 183 190 henkilöllä [2].
Miehiä heistä oli 117 452 (64 %).
KELAn tilaston mukaan 31.12.2018 alle 65-vuotiaita oli 31 184 (18 %) ja tästä ryhmästä noin 50 % oli 60–64-vuotiaita (KELA-lääkekorvaustilastot [3]).26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 2/31
Iskeem isen sydänsairauden (diagnoosit I20–25 ja 412–414) vuoksi Suomessa  oli 31.12.2019 työkyvyttömyyseläkkeellä noin 1 400 henkilöä (0,7 % kaikista
työkyvyttömyyseläkkeiden syistä).
Naisten osuus oli 23 %.
Tilastokeskuksen mukaan ikävakioitu sepelvaltimotautikuolleisuus on vähentynyt voimakkaasti viimeisten vuosikymmenten aikana, mutta sepel valtimotauti on
edelleen merkittävä kuolinsyy. Vuonna 2020 sepel valtimotauti aiheutti miehillä lähes joka viidennen ja naisilla joka kahdeksannen kuoleman. Sepel valtimotautiin
kuolleita oli yhteensä  8 600 https://www. stat.fi/til/ksyyt/2020/ksyyt_2020_2021-12-10_kat_002_fi.html.
WHO:n tilaston mukaan sydänsairaudet olivat maailman yleisin kuolinsyy vuonna 2019 https://www. who.int/data/gho/data/themes/m ortality-and-global-health-
estimates, [4].
Iskeem iset sydänsairaudet ovat merkittävä työkyvyttömyyseläkkeen syy, ks. kuva «Suomessa  asuvat työ- ja kansaneläkejärjestelmästä työkyvyttömyyseläkkeelle
2003–2021 siirtyneet  (diagnoosit I20-25)».26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 3/31
Kuva 1.
Suomessa  asuvat työ- ja kansaneläkejärjestelmästä työkyvyttömyyseläkkeelle 2003–2021 siirtyneet  (diagnoosit I20-25)
Lähde: Eläketurvakeskus, suunnitteluosasto, tilastosuunnittelija Joonas Hautamäki
Riskitekijät26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 4/31
Valtimotaudin tärkeät riskitekijät, joihin ei voida vaikuttaa, ovat
ikä
kroonisen sepel valtimo-oireyhtymän esiintyvyys nousee iän myötä
sukupuoli
miehillä oireyhtymä alkaa keskimäärin nuorempana kuin naisilla
naisilla oireyhtymä ilmenee tyypillisem min myöhemmällä iällä
varhainen menopaussi saattaa aikaistaa ilmaantumista naisilla.
Perintötekijät ovat merkittäviä sepel valtimotaudin riskitekijöitä.
Sukurasitus (ensim mäisen asteen sukulainen,  alle 55-vuotias mies tai alle 65-vuotias nainen,  on sairastanut sepel valtimotautikohtauksen tai hänelle on tehty
revaskularisaatio) [5], [6].
Sepel valtimotaudin kehittyminen tapahtuu monien geenien vaikutuksesta, ja useamman riskigeenin samanaikainen esiint yminen (ns. polygeeninen riskisumma)
varhaistaa taudin ilmaantumista [7], [8].
Valtimotaudin tärkeät riskitekijät, joihin voidaan vaikuttaa, ovat
tupakointi (ks. Käypä hoito -suositus Tupakka- ja nikotiinir iippu vuuden ehkäisy ja hoito «Tupakka- ja nikotiinir iippu vuuden ehkäisy ja hoito», [9])
THL:n tilastojen mukaan suomalaisen aikuisväestön tupakointi on pääsääntöisest i vähentynyt viimeisen kymmenen vuoden aikana, mutta kehitys näyttää
pysähtyneen vuonna 2018
dyslipidemia (ks. Käypä hoito -suositus Dyslipidemiat «Dyslipidemiat», [10])
suurentunut LDL-kolesterolipitoisuus on merkittävin yksittäinen riskitekijä
diabetes (ks. Käypä hoito -suositus Tyypin 2 Diabetes «Tyypin 2 diabetes», [11])
kroonisen sepel valtimo-oireyhtymän osana diabetes esiint yy noin 25–35 %:lla potilaista
pre-diabetes lisää sepel valtimo-oireyhtymän ilmaantumista
hypertensio  (ks. Käypä hoito -suositus Kohonnut verenpa ine «Kohonnut verenpa ine» , [12])
vähäinen liikunta, runsas istuminen
keskivartalolihavuus (ks. Käypä hoito -suositus Lihavuus (lapset , nuoret ja aikuiset) «Lihavuus (lapset , nuoret ja aikuiset)», [13]).
Muita tunnet tuja vaaratekijöitä ovat
todettu muiden valtimoiden ateroskleroosi [14], [15], [16], [17], (ks. Käypä hoito -suositus Alaraajojen tukkiva valtimotauti «Alaraajojen tukkiva valtimotauti», [18]),
erektiohäiriö saattaa olla laajan ateroskleroosin oire
munuaisten vajaatoiminta [19], [20], [21], [22]
inflammaatiot, kuten matala-asteinen tulehdus
hampaiden kiinnit yskudossairaudet
reumasairaudet [23], [24], [25]26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 5/31
reumasairauksiin ilmeisest i liittyy suurentunut sydän- ja verisuonitautien riski [B]
lisääntynyt sairastavuus liittynee inflammaatioon
ei-alkoholiperäinen rasvamaksatauti (NAFLD) [26], [27], (ks. Käypä hoito -suositukset Lihavuus (lapset , nuoret ja aikuiset) «Lihavuus (lapset , nuoret ja aikuiset)») [6]
ja Ei-alkoholiperäinen rasvamaksatauti (NAFLD) «Ei-alkoholiperäinen rasvamaksatauti (NAFLD)», [28]),
uniapnea  [29]
psyykkinen kuormitus, ks. Käypä hoito -suositus Depressio  «Depressio » ja , [30]
matala sosioekonominen asema.
Riskitekijöihin vaikuttaminen kattavan sydänvalmennuksen avulla
Sydänvalmennu ksella tarkoitetaan kroonisen sepel valtimo-oireyhtymän yhteydessä  suunnit elmallista potilaslähtöistä palveluketjua, jonka tavoitteena  on auttaa
valmennet tavaa tiedostamaan sepel valtimotaudin luonne kroonisena  pitkäaikaissairautena ja ymmärtämään ehkäisevien hoitotoimenpit eiden merkitys
valtimotapahtumien estossa myös oireyhtymän oireettomassa vaiheessa .
Ateroskleroottisissa  valtimosairauksissa  raja primaari- ja sekundaariprevention välillä on liukuva. Oireettoman potilaan riski valtimotapahtumaan voi olla yhtä suuri
tai suurempikin kuin jo sairastuneel la potilaalla.
Valtimotaudin riskitekijöihin tulee puuttua kattavan sydänvalmennu ksen avulla aina, kun potilaalla epäillään ateroskleroottista valtimotautia joko
riskitekijäkasauman (FINRISKI «FINRISKI-laskuri», SCORE) tai oireiden perusteella.
Kaikki kroonista sepel valtimo-oireyhtymää sairastavat kuuluvat riskitekijöiden hallinna n osalta erityisen suuren riskin ryhmään oireyhtymän toteamistavasta
riippu matta (ks. Käypä hoito -suositus Dyslipidemiat «Dyslipidemiat», [10]).
Ennusteeseen vaikuttava sydänvalmennu s edellyttää todettujen riskitekijöiden hoitamista moniammatillisest i ja kokonaisvaltaisest i elämäntapaohjauksella,
liikunnallisella sydänkuntoutuksella, lääkehoidon optimoinnil la ja tarvittaessa  revaskularisaatiolla.
Kattavalla sydänvalmennu ksella voidaan ilmeisest i vähentää kokonais- ja kardiovaskulaarikuolleisuutta sekä vähentää sydän- ja aivoinfarktien ilmaantumista
tavanomaiseen hoitoon verrattuna potilailla, joilla on todettu krooninen sepel valtimo-oireyhtymä [B].
Elintapojen muuttaminen on suositeltavaa iästä riippu matta.
Potilaalla tulee olla aktiivinen rooli sydänvalmennu ksessa . Moniammatillisen valmennu ksen valmentajina voivat toimia terveydenhuollon ammattilaiset, kuten
lääkärit, sydänhoitajat ja sydänsairauksien hoitoon perehtyneet  fysioterapeutit sekä lääkehoidon erityiskysymyksissä  terveydenhuollon yksiköissä työskentelevät
farmaseutit ja apteekkien sydänyhteyshenkilöt (farmaseutti tai proviisori).
Eurooppalaisilla sepel valtimotautipotilailla tehdyt selvitykset, joissa on mukana myös suomalaisia potilaita, osoittavat, että kroonista sepel valtimo-oireyhtymää
sairastavilla riskitekijöiden vähentäminen toteutuu edelleen puutteellisest i (EUROASPIRE) [31], [32], [33].
Hoitotulosten parantamiseksi suunnit elmallinen sydänvalmennu s tulisi todennä köisest i tarjota kaikille potilaille, joilla todetaan krooninen sepel valtimo-oireyhtymä.
Liikunnallinen sydänkuntoutus on tärkeä osa sydänvalmennu sta [34], ja käytännön ohjeita sen toteuttamisest a on suosituksessa  Sepel valtimotautipotilaan
liikunnallinen kuntoutus: Hyvä fysioterapiakäytäntö «Sepel valtimotautipotilaan liikunnallinen kuntoutus», [35] ja lisätietoaineist ossa .
Ks. lisätietoa Sydänvalmennu ksen sisältö .26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 6/31
Taulukko 1. Kattavan sydänvalmennuksen tavoitteet
Kattavan sydänvalmennuksen tavoitteina on saavuttaa:
LDL-kolesterolipitoisuus < 1,4 mmol/l (ks. Käypä hoito -suositus Dyslipidemiat «Dyslipidemiat», [10])
yksilöllisesti voidaan pyrkiä < 1,0 mmol/l:n pitoisuuteen erityisesti, jos potilaalla on ollut toistuvia valtimotautitapahtumia
verenpaine < 130/80 mmHg (ks. Käypä hoito -suositus Kohonnut verenpaine «Kohonnut verenpaine», [12])
normoglykemia (verensokerin paastoarvo < 5,5 mmol/l, glukoosirasituskokeen kahden tunnin arvo < 7,8 mmol/l ja HbA-pitoisuus < 42 mmol/mol; diabeetikoilla HbA-pitoisuus < 53
mmol/mol) (ks. Käypä hoito -suositus Tyypin 2 Diabetes «Tyypin 2 diabetes», [11])
täydellinen tupakoimattomuus (ks. Käypä hoito -suositus Tupakka- ja nikotiiniriippuvuuden ehkäisy ja hoito «Tupakka- ja nikotiiniriippuvuuden ehkäisy ja hoito», [9])
tupakoinnin lisäksi tulisi pidättäytyä myös muista nikotiinivalmisteista, kuten sähkötupakasta ja nuuskasta (AHA/ESC Joint opinion) [36]
säännöllinen terveysvaikutteinen liikuntaharrastus [34], [35], [37]
säännöllisen, monipuolisen ja riittävän tehokkaan liikunnan sekä liikunnallisen sydänkuntoutuksen avulla voidaan vaikuttaa kroonista sepelvaltimo-oireyhtymää sairastavan
ennusteeseen, elämänlaatuun, riskitekijöiden hallintaan ja fyysiseen suorituskykyyn [A]
ks. lisätietoa Sepelvaltimo-oireyhtymä ja liikunta .
Seulonta
Sepel valtimotaudin diagnostisia tutkimuksia ei suositella taudin seulontaan oireettomassa väestössä.
Diagnostiset tutkimukset ja sepel valtimokalkin kuvantaminen tarkentavat arviota valtimotautitapahtuman riskistä, mutta oireettomilla potilailla niihin perustuva
interventio ei ole vähentänyt riskiä verrattuna kliinisiin riskitekijöihin perustuvaan interventioon [38], [39].
Ahtauttavan sepelvaltimotaudin diagnostiikka
Sepel valtimotaudin diagnostiikkaan vaikuttavat kliiniseen arvioon perustuva oireiden laatu, ahtauttavan sepel valtimotaudin kliininen enna kkotodennä köisyys,
diagnostisten tutkimusten saatavuus ja liitännäissairaudet.
Huomioidaan potilaan yksilölliset lähtökohdat.
Oireet
Sepel valtimotaudin tyypillinen oire on rintalastan takana tuntuva rasituksessa  ilmenev ä kipu, joka helpottaa levossa tai nitraateilla.
Kaikilla potilailla ei ole rintakipua, vaan oireena  voi olla myös rintakehällä tuntuva epämukavuus, paine, hengenahdistus, närästys, pahoinvointi tai merkittävä
suorituskyvyn lasku.
Oireet voidaan jakaa tyypilliseen ja epätyypilliseen rintakipuun sekä muuhun kipuun (taulukko 2).
Kivun luonne vaikuttaa myös ahtauttavan sepel valtimotaudin kliiniseen enna kkotodennä köisyyteen.
Oireiden vaikeusaste arvioidaan Canadian Cardiovascular Societyn (CCS ) luokituksen mukaisest i oireiden ilmaantumisen herkkyyden mukaan neljään luokkaan
(taulukko 3), [40].1C 1C26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 7/31
Taulukko 2. Rintakivun kliininen luokittelu
Rintakivun tyyppi Luokittelu
Tyypillinen Oireessa on kaikki kolme tyypillistä piirrettä:
rintakehän alla tuntuu kipua tai epämukavuutta, joka kestää alle 10 minuuttia
oire ilmenee fyysisessä ponnistelussa tai voimakkaassa tunnetilassa
oire helpottaa minuuttien sisällä levossa tai nitraateilla.
Epätyypillinen Oireessa on kaksi tyypillistä piirrettä.
Muu kipu Oireessa on vain yksi tai ei yhtään tyypillistä piirrettä.
Taulukko 3. Rintakivun luokittelu Canadian Cardiovascular Societyn (CCS) mukaan [40]
CCS-luokka Rintakivun esiintyminen Rasitustaso
I Tavallinen fyysinen rasitus ei aiheuta rintakipua.
Rintakipua esiintyy raskaassa, nopeasti alkaneessa tai pitkittyneessä ponnistelussa.120 W tai yli
II Rintakipu aiheuttaa vähäisen rajoitteen tavalliseen toimintaan.
Rintakipua esiintyy vauhdikkaan kävelyn tai portaiden nousemisen aikana, liikkuessa aterian jälkeen, kylmässä, tuulessa, voimakkaassa
tunnetilassa tai ensimmäisinä heräämisen jälkeisinä tunteina. Normaalivauhtisessa kävelyssä rintakipu tulee yli kahden korttelivälin (yli 200
m) jälkeen tai kahden tai useamman kerrosvälin nousun jälkeen.80–120 W
III Rintakipu aiheuttaa merkittävän rajoitteen tavalliseen toimintaan.
Tavallisissa oloissa rintakipu tulee normaalivauhtisessa kävelyssä 1–2 korttelivälin (alle 200 m) matkalla tai yhden kerrosvälin nousussa.20–80 W
IV Fyysinen rasitus ilman kipua ei ole mahdollista.
Rintakipu voi tulla jo levossa.Alle 20 W
Perustutkimukset
Kliinisen tutkimuksen tulos on yleensä  normaali, mutta se voi paljastaa rintakivun vaihtoehtoisen syyn. Lisäksi voidaan todeta liitännäissairauksien,  kuten perifeerisen
valtimotaudin, sydämen vajaatoiminna n tai toiminna llisen mitraalivuodon, löydöksiä.
Sepel valtimotautia epäiltäessä  rekisteröidään kaikilta lepo-EKG.
Rekisteröinnin tulos on usein normaali.
EKG:ssä  voi kuitenkin näkyä sepel valtimotautiin viittaavina löydöksinä  Q-aaltoja, ST-segmentin laskuja, T-inversioita tai haarakatkos.
EKG:st ä on apua myös diagnostisen testin valinna ssa.
Sepel valtimotautia epäiltäessä  suositellaan määrittämään verenpa ine sekä tutkimaan veren lipidiarvot, paastoglukoosi, HbA-pitoisuus, perusverenkuva,
kreatiniinipit oisuus ja harkinna n mukaan ALAT. Tutkittavalta tiedustellaan myös mahdollinen sepel valtimotaudin sukurasite.
Thoraxin röntgenkuvaus tehdään, jos se on erotusdiagnostiikassa tarpeel lista.
Kliinisen ennakkotodennäköisyyden arviointi1c26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 8/31
Kliinisel lä enna kkotodennä köisyydellä tarkoitetaan sitä, mikä on ahtauttavan sepelvaltimotaudin todennä köisyys kliinist en tietojen perusteella, kun huomioidaan
taudin yleisyys väestötasolla.
Ahtauttava sepel valtimotauti löytyy nykyisin aiempaa harvemmin potilailta, joita tutkitaan kliinisen epäilyn vuoksi. Tuoreissa  tutkimuksissa  ahtauttavan
sepel valtimotaudin kliininen enna kkotodennä köisyys on vain noin kolmannes verrattuna aiempiin tutkimuksiin [41], [42], [43].
Yleisin tutkimuksen aihe on epätyypillinen rintakipu.
Oireisen henkilön kliinist ä enna kkotodennäköisyyttä voidaan arvioida iän, sukupuolen, riskitekijöiden lukumäärän ja rintakivun tyypin avulla yli 40 000
eurooppalaisen potilaan aineist oon perustuvan tiedon pohjalta [41].
Hengenahdistukseen liittyvä kliininen ennakkotodennä köisyys on samankaltainen kuin epätyypillisessä  rintakivussa [42].
Lepo-EKG:ssä  näkyvät sepel valtimotautiin viittaavat löydökset, sydämen ultraäänitutkimuksessa  näkyvät sepel valtimotaudille tyypilliset vasemman kammion
supistumishäiriöt ja rintakehän alueen TT-kuvauksessa  näkyvä sepel valtimokalkki ovat merkkejä suurentuneest a sepel valtimotaudin todennä köisyydestä.
Oireettoman henkilön FINRISKI-laskuri «FINRISKI-laskuri» kertoo todennä köisyyden sairastua sydäninfarktiin tai sepel valtimotautiin seuraavan 10 vuoden aikana
iän, sukupuolen ja yleisim pien riskitekijöiden (tupakointi, suuri kolesterolipitoisuus, verenpa ine, diabetes ja sukurasite) perusteella.
SCORE-laskurilla «SCORE2 ja SCORE2-OP» voidaan arvioida, millainen on henkilön valtimotautikuoleman vaara 10 vuoden kuluessa  [44].
Uusimpana on käytössä SCORE2 [45].
Oireettoman henkilön riskilaskurit soveltuvat hyvin potilaan motivointiin riskitekijöiden hoidossa.
Kliinisen enna kkotodennä köisyyden arviointi auttaa käyttämään oikein sepel valtimotaudin diagnostisia tutkimuksia, koska tutkimustuloksen luotettavuus riippu u
ahtauttavan sepel valtimotaudin kliinises tä enna kkotodennä köisyydestä Bayesin teoreem an mukaisest i [37]
Ahtauttavan sepel valtimotaudin kliinisen  enna kkotodennä köisyyden arviointi potilaan oireiden sekä sydän- ja verisuonitautien riskitekijöiden määrän perusteella
(ks. kuva «Ahtauttavan sepel valtimotaudin kliinise n enna kkotodennä köisyyden arviointi iän, sukupuolen, oireiden ja riskitekijöiden lukumäärän perusteella») [41].26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 9/31
Kuva 2.
Ahtauttavan sepel valtimotaudin kliinine n enna kkotodennä köisyys iän, sukupuolen, oireiden ja riskitekijöiden lukumäärän perusteella esitettynä prosent uaalisena  osuutena
potilaista. Sininen väri kuvaa erittäin pientä kliinist ä enna kkotodennä köisyyttä, vihreä pient ä kliinist ä enna kkotodennä köisyyttä ja keltainen suurentunutta kliinist ä
enna kkotodennä köisyyttä. Arvot ovat arvioita 35-, 45-, 55-, 65- ja 75-vuotiaista potilaista ja pyöristetty lähimpään kokonaislukuun.
Lähde: Winther S, Schmidt SE, Mayrhofer T ym. Incorporating Coronary Calcification Into Pre-Test Assessment of the Likelihood of Coronary Artery Disease. J Am Coll Cardiol 2020;76:2421-32
Jatkotutkimukset
Erittäin pienen kliinisen enna kkotodennä köisyyden (≤ 5 %) potilailla on todennä köistä, että oireet johtuvat muusta syystä kuin sepel valtimotaudista.
Kun kliininen enna kkotodennä köisyys on erittäin pieni,  ahtauttava sepel valtimotauti löytyy vain hyvin harvoin ja riski sydäntapahtumalle on pieni (vuotuinen riski <
1 %) [41], [42], [43], [46].
Tässä potilasryhmässä väärän positiivisen tuloksen mahdollisuus on suuri, kun käytetään kajoamatonta diagnostista tutkimusmenet elmää, eikä jatkotutkimuksia
yleensä  tulisi tehdä.
Oireisel la potilaalla voidaan harkita sepel valtimotaudin sulkemista pois ensisij aisest i sepel valtimoiden TT-kuvauksella.
Sepel valtimotaudin riskitekijöiden selvittäminen ja neuvonta ovat kuitenkin tarpeen.26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 10/31
Mikäli ahtauttava sepel valtimotauti ei ole suljettavissa pois kliinisen enna kkotodennä köisyyden perusteella (kliininen enna kkotodennä köisyys > 5 %), diagnostiset
tutkimukset auttavat selvittämään, onko oireiden taustalla sepel valtimotauti.
Kun kliininen enna kkotodennä köisyys on pieni (> 5 – ≤ 15 %), löytyy ennu steen kannalta merkittävä sepel valtimotauti vain harvoin ja diagnostisia tutkimuksia tulee
käyttää harkiten. Sydäntapahtuman riski on pieni (vuotuinen riski < 1 %) [46], [47].
Kun kliininen enna kkotodennä köisyys on suurentunut (> 15 %), diagnostisten tutkimusten hyöty on suurin.
Kajoamattomia tutkimuksia voidaan käyttää myös riskin arvioimiseen ja ohjaamaan hoitopäätöksiä.
Jos sepel valtimotauti on todennä köinen tyypillisen oirekuvan perusteella, voidaan diagnoosi tehdä kliinisin perustein, mikäli diagnostisten tutkimusten tulokset eivät
vaikuttaisi potilaan hoitoon esim erkiksi, jos revaskularisaatio ei tule kyseeseen liitännäissairauden vuoksi.
Ennustetta parantava lääkitys ja tarvittaessa oirelääkitys voidaan aloittaa kliinisen arvion perusteella jo ennen diagnostisten tutkimusten tekemistä.
Diagnostisen tutkimuksen valinna n perusteita esitetään kuvassa «Diagnostisen tutkimuksen valinna n perusteet».
Ahtauttavassa sepel valtimotautiepä ilyssä diagnostisen tutkimuksen tarkemman valinna n tulisi perustua kroonisen sepel valtimo-oireyhtymän diagnostiikkaan, hoitoon
hyvin perehtyneen lääkärin arvioon ja alueelliseen hoitoketjuun tutkimusten saatavuus huomioiden.
Sepel valtimotauti voidaan todeta kajoamattomasti sepel valtimoiden TT-tutkimuksella. Tutkimuksessa  näkyy ahtaumien lisäksi ahtauttamaton sepel valtimoiden
ateroskleroosi. Runsas sepel valtimoiden ateroskleroosi on merkki erityisen suuresta valtimotautiriskistä ahtauman asteesta riippu matta, mikä tulee huomioida
riskitekijöiden hoidon tavoitteissa  (ks. Käypä hoito -suositus Dyslipidemiat «Dyslipidemiat», [10]). Ennen revaskularisaatiota keskivaikean ahtauman (50–90 %)
hemodynaaminen merkittävyys tulee yleensä  selvittää joko palautuvaa iskemiaa osoittavalla kajoamattomalla tutkimuksella tai sepel valtimon sisäisellä
painem ittauksella.
Sepel valtimoiden TT-tutkimus sopii erityisest i ahtauttavan sepel valtimotaudin sulkemiseen pois, kun kliininen enna kkotodennä köisyys on edellä kuvatun mukaisesti
pieni tai suurentunut ja hyvä kuvanlaatu todennä köinen.
Rasituksen aiheuttama sydänlihasiskemia voidaan selvittää kajoamattomasti kliinisessä  rasituskokeessa  EKG-muutosten, rasitusultraäänikuvauksessa  näkyvän
liikehäiriön tai sydänlihasper fuusion kuvauksessa  näkyvän perfuusiopuutoksen perusteella. Lievät sepel valtimotautimuutokset, jotka eivät aiheuta hemodynaamisest i
merkittävää ahtaumaa, eivät näy näissä tutkimuksissa , joten valtimotaudin riskitekijöiden selvittäminen ja neuvonta ovat tarpeen kaikille.
Sydänlihasiskemian osoitus rasitustestillä sopii ahtauttavan sepel valtimotaudin toteamiseen,  kun kliininen enna kkotodennä köisyys on suurentunut tai
sepel valtimotauti on todettu.
Rasitus-EKG-tutkimuksessa  tulee ottaa huomioon väärän negatiivisen löydöksen mahdollisuus erityisest i, jos oireet ovat tyypilliset. Tällöin lisätutkimukset saattavat
olla aiheellisia. Ennusteen kannalta merkittävä tauti on kuitenkin epätodennä köinen,  jos rasitus-EKG:n löydös on normaali ja virhelähteet huomioidaan.
Sepel valtimoiden kajoava varjoainek uvaus mahdollistaa tarkan anatomisen kuvantamisen ja ahtauman hemodynaamisen merkittävyyden varmentamisen
painev aijeritutkimuksella.
Sepel valtimoiden kajoava varjoainek uvaus sopii sepel valtimotaudin toteamiseen ja revaskularisaatiotarpeen arvioimiseen erityisest i, kun potilaalla on tyypillinen
elämää rajoittava oireisto, aiemmin todettu sepel valtimotauti oireilee lääkehoidosta huolimatta tai havaitaan suuren vaaran löydöksiä, kuten tyypillinen rintakipu
yhdessä  heikentyneen vasemman kammion systolisen toiminna n kanssa .
Jos sepel valtimotautia sairastavan potilaan vasemman kammion toiminta on heikentynyt huomattavasti ja oireet ovat pääasiallisest i vajaatoiminna sta johtuvia, on
elossa olevan ja infarktoituneen sydänlihaksen erottaminen toisistaan (viabiliteetin kuvantaminen)  usein tarpeen revaskularisaatiohoitoa harkittaessa .26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 11/31
Kuva 3.
Diagnostisen tutkimuksen valinna n perusteet.
Sepelvaltimoiden TT-tutkimus
Sepel valtimoiden TT-tutkimus mahdollistaa sepel valtimoiden anatomian tarkan kuvantamisen kajoamattomasti laskimoon annet tavan varjoaineen avulla.26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 12/31
Tutkimuksen herkkyys ja negatiivinen ennustearvo ovat erinomaiset (> 95 %) [48].
Sepel valtimoiden TT-tutkimus soveltuu ahtauttavan sepel valtimotaudin sulkemiseen pois valikoiduilla rintakipupotilailla, joillakliininen enna kkotodennä köisyys on
pieni tai suurentunut [A].
Tutkimusta voidaan harkita ensisij aisena  diagnostisena  testinä, jos on tarpeen sulkea pois ahtauttava sepel valtimotauti oireiden aiheuttajana potilailla, joilla on erittäin
pieni kliininen enna kkotodennä köisyys.
Sepel valtimoiden TT-tutkimuksesta ei ole hyötyä oireettomilla potilailla seulontatarkoituksessa  [49].
Sepel valtimoiden TT-tutkimuksen tulkinta vaatii osaamista. Kokemus vähentää erityisest i väärien positiivisten löydösten määrää [50].
Sepel valtimoiden TT-tutkimuksen löydökset voivat johtaa tarpeet tomiin lisätutkimuksiin potilailla, joilla on aiemmin todettu sepel valtimotauti, runsaasti
sepel valtimokalkkia tai kuvanlaatu on huono.
Ahtaumien lisäksi sepel valtimoiden TT-tutkimuksessa  näkyy myös ahtauttamaton sepel valtimoiden ateroskleroosi, joka ei selitä potilaan oireita. Ennen
revaskularisaatiota keskivaikean ahtauman (50–90 %) hemodynaaminen merkittävyys (iskemia) tulee yleensä  selvittää joko palautuvaa iskemiaa osoittavalla
kajoamattomalla tutkimuksella tai sepel valtimon sisäisellä painem ittauksella.
Runsas sepel valtimokalkki vaikeuttaa ahtaumien toteamista ja voi aiheuttaa vääriä positiivisia löydöksiä. 66 %:lla yli 65-vuotiasta miehistä ja 47 %:lla yli 65-
vuotiasta naisista on sepel valtimokalkkia. Tässä ikäryhmässä sepel valtimoiden TT:n löydösten kliininen merkitys on vähäisem pi kuin nuoremmilla
https://www. mesa-nhlbi.org/Calcium/input.aspx, [51].
Hyvä kuvanlaatu on luotettavan tutkimuksen edellytys.
Tutkimusta ei suositella potilaille, joilla on nopea tai epäsäännöllinen syke (runsaat lisälyönnit  tai eteisvärinä).
Myös huomattava ylipaino huonontaa kuvanlaatua.
Sepel valtimoiden TT-tutkimuksella ei toistaiseksi voida luotettavasti osoittaa sepel valtimostenttien sisäisiä ahtaumia. Ohitussiir teet näkyvät tutkimuksessa  hyvin,
mutta ahtaumien luotettava toteaminen ei onnist u siirteiden saumakohdissa eikä vastaanottavissa, usein hyvin kalkkisissa  suonissa .
Sepel valtimoiden TT-tutkimus altistaa potilaan ioniso ivalle säteilylle, minkä vuoksi on syytä välttää tarpeet tomia tutkimuksia ja käyttää nykyaikaista kuvaustekniikkaa,
jolla kuvaus on mahdollista tehdä kohtuullisella [52], 1–4 mSv:n säteilyaltistuksella [53].
Sepel valtimoiden TT-tutkimuksessa  todettu normaali sepel valtimoanatomia ennu staa pient ä kuoleman- ja valtimotautitapahtuman vaaraa. Suuren vaaran merkkejä sen
sijaan ovat ahtauttava kolmen suonen sepel valtimotauti, päärunkoahtauma ja ahtauma vasemman eteen laskevan haaran alkuosassa. Suuren vaaran löydökset voivat
olla aiheena  sepel valtimoiden kajoavaan varjoainek uvaukseen,  mikäli revaskularisaatiota harkitaan ennu steen parantamiseksi [54], [55].
Kaikille potilaille, joilla todetaan ahtauttava sepel valtimotauti, tulee aloittaa ennu stetta parantava hoito ja tarvittaessa  oireita lievittävä lääkehoito [56].
Runsas sepel valtimoiden ateroskleroosi on merkki erityisen suuresta valtimotautiriskistä ahtauman asteesta riippu matta, mikä tulee huomioida riskitekijöiden
hoidon tavoitteissa  (ks. Käypä hoito -suositus Dyslipidemiat «Dyslipidemiat», [10]). Toisin kuin kolesterolia alentavalla lääkehoidolla, ASA-lääkityksellä ei näytä
olevan ennu stevaikutusta potilailla, joilla todetaan sepel valtimoiden ateroskleroosi, mutta ei ahtauttavaa tautia [57], [58], [59].
Sepel valtimokalkki (CAC-score eli Agatston score) näkyy sepel valtimoiden TT-kuvauksessa  ilman varjoainetta.
Sepel valtimokalkki on merkki ateroskleroosista, mutta pelkän kalkkikuvauksen perusteella ei ole mahdollista todeta tai sulkea pois ahtauttavaa tautia. Kalkkikuvaus
tarkentaa ahtauttavan sepel valtimotaudin todennä köisyyden arviointia kliiniseen arvioon verrattuna [41]. Ainoana menet elmänä se ei kuitenkaan sovellu ahtauttavan
sepel valtimotaudin toteamiseen,  eikä sen käyttö valtimotaudin riskin arviossa ole vakiintunut Suomessa .26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 13/31
Sepel valtimoiden TT-tutkimuksen käyttöaiheet kroonisen sepel valtimotaudin diagnostiikassa:
Tutkimus soveltuu ahtauttavan sepel valtimotaudin sulkemiseen pois valikoiduilla oireisilla potilailla, joilla kliininen enna kkotodennä köisyys on edellä kuvatun
mukaisest i pieni tai suurentunut [A].
Tutkimusta voidaan harkita ahtauttavan sepel valtimotaudin sulkemiseen pois oireisilla potilailla, joilla on erittäin pieni kliininen enna kkotodennä köisyys.
Tutkimusta ei suositella käytettäväksi sepel valtimoahtaumien toteamiseen potilailla, joilla sepel valtimotauti on todettu aiemmin tai diagnostinen kuvanlaatu on
epätodennä köinen epäsäännöllisen sykkeen tai runsaan sepel valtimokalkin vuoksi.
Kliininen rasituskoe
Kliininen rasituskoe eli rasitus-EKG on edelleen käyttökelpoinen diagnostinen testi, kun epäillään ahtauttavaa sepel valtimotautia [37]. Syynä ovat testin helppous ja hyvä
saatavuus.
Tarjoaa tärkeää tietoa ennu steesta.
Rasitus-EKG tarjoaa iskemian arvion lisäksi tärkeää informaatiota:
oireiden yhteydestä rasitukseen
potilaan suorituskyvystä
verenpa ineen rasitusvasteesta
sykkeen käyttäytymisest ä
mahdollisista rytmihäiriöistä.
Rasituskokeen osuvuutta ahtauttavan sepelvaltimotaudin toteamisessa  on selvitetty lukuisissa  tutkimuksissa , joissa sen keskimääräinen herkkyys (sensit iivisyys) on
ollut 68 % ja spesif isyys 77 % [60]. Herkkyys on huonompi, noin 40–50 %, jos lähteenä  käytetään vain sellaisia tutkimuksia, joissa niin sanottu valikoitumisharha
(referral bias) on huomioitu virhelähteenä  [61].
valikoitumisharha tarkoittaa virhettä, joka syntyy siitä, että tutkittavan todennä köisyys päätyä diagnostiseen koronaariangiografiaan on suurempi positiivisen kuin
negatiivisen testituloksen jälkeen.
Positiivisena  tuloksena  pidetään vähintään 1 mm:n tasomaista tai alasviettävää ST-välin laskua 0,06–0,08 s J-pisteen jälkeen rasituksen provosoimana [62].
Diagnostisessa  tutkimuksessa  tulisi pyrkiä maksimaaliseen,  oirerajoitteiseen suoritukseen ilman anti-iskeem istä lääkevaikutusta. Beetasalpaajalääkitys tauotetaan, ellei
sen käytölle ole muuta välttämätöntä syytä.
Rasituskokeen väärän negatiivisen tuloksen mahdollisuus on syytä ottaa huomioon erityisest i silloin, jos kokeen aikana ilmenee tyypillinen oire, maksimaalista
kuormitustasoa ei ole saavutettu (vähintään 85 % laskenna llisest a maksimisykkeestä) tai potilaalla on käytössä anti-iskeem isiä lääkkeitä.
Muutamat poikkeavuudet lepo-EKG:ssä  estävät luotettavan iskemian toteamisen,  esim erkiksi LVH, LBBB, tahdistettu rytmi, WPW ja huomattavat > 1 mm:n ST-
muutokset levossa esim erkiksi digoksiini lääkityksen vuoksi [63].
Väärän positiivisen tuloksen mahdollisuus on suuri, kun ahtauttavan sepel valtimotaudin kliininen enna kkotodennä köisyys on erittäin pieni tai pieni,  eikä kliinisen
rasituskokeen käyttöä tällöin yleensä  suositella [64], ks. Vältä viisaasti -suositus .
Väärän negatiivisen tuloksen mahdollisuus on huomioitava erityisest i silloin, jos potilaan oirekuva on tyypillinen ja ahtauttavan sepel valtimotaudin kliininen
enna kkotodennä köisyys on suurentunut.
Naisilla väärät positiiviset löydökset ovat yleisem piä kuin miehillä.26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 14/31
Rasituskokeessa  tärkeäksi todettuja sepe lvaltimotaudin huonoa ennu stetta kuvaavia tekijöitä ovat [65]
heikko suorituskyky (alle 5 MET-yksikköä)
voimakkaat ja laaja-alaiset iskeem iset EKG-muutokset (ST-nousu tai ST-lasku)
tyypillinen rintakipuoire pienel lä kuormalla tai sykkeellä
vaimea systolisen verenpa ineen nousu tai erityisest i verenpa ineen lasku
kammiotakykardia ja -värinä.
Rasitus-EKG:n käyttöaiheet kroonisessa  sepel valtimo-oireyhtymässä:
Rasitus-EKG soveltuu ahtauttavan sepel valtimotaudin toteamiseen oireisilla potilailla, joilla kliininen enna kkotodennä köisyys on suurentunut eivätkä poikkeavuudet
lepo-EKG:ssä  estä iskemian toteamista.
Tutkimus soveltuu myös ennu steen arvioimiseen ja ohjaamaan hoidon valintaa potilailla, joilla on todettu sepel valtimotauti.
Jos potilaalla on todettu sepel valtimotauti, lääkitystä ei tauoteta.
Tutkimus soveltuu suoritus- ja työkyvyn arviointiin potilailla, joilla on todettu sepel valtimotauti.
Toistuvia tutkimuksia ei suositella, ellei potilaan oireissa  tai kliinisessä  tilassa tapahdu muutoksia.
Sydänlihaksen perfuusion isotooppikuvaus ja PET-kuvaus
Sydänlihaksen perfuusion isotooppik uvaus tehdään teknetiumleimatulla radioaktiivisella lääkeaineel la, joka kertyy sydänlihakseen verenkierron mukaisest i.
Tavallisim mat lääkeaineet  ovat 99mTc-tetrofosmiini ja -MIBI. Ahtauttava sepel valtimotauti aiheuttaa paikallisen pienenem än rasituksen aikana annet un merkkiaineen
sydänlihasjakaumassa [66].
Sydänlihaksen perfuusion PET-kuvaus tehdään radioaktiivisella lääkeaineel la, jonka jakauma sydänlihaksessa  kuvastaa verenvirtauksen määrää. Ahtauttava
sepel valtimotauti aiheuttaa paikallisest i alentuneen sydänlihaksen verenvirtauksen. Tällä hetkellä sydänlihaksen verenvirtauksen PET-kuvaukseen soveltuvien
radiolääkkeiden lyhyt puoliintumisaika rajoittaa tutkimuksen käytön sairaaloihin, joissa on niiden tuotantoon sopiva syklotroni tai gener aattori [67].
Isotooppi-  ja PET-kuvauksen herkkyys ahtauttavan sepel valtimotaudin diagnostiikassa on parempi kuin rasitus-EKG:n (87–90 %), mutta sen spesif isyys merkittävän
stenoosin suhteen on hieman pienem pi kuin rasitusultraäänikuvauksen (70–85 %) [48].
Isotooppi-  ja PET-kuvaus voidaan tehdä lääkerasituksena , jos tutkittavan fyysinen rasittaminen ei ole mahdollista tai jos potilaalla on eteisvärinä, vasen haarakatkos tai
tahdistettu rytmi. Lääkerasitus tehdään yleensä  vasodilatoivalla lääkkeellä, kuten adenosiinil la tai regadenosonilla.
Isotooppitutkimuksella voidaan todeta myös infarktialueet ja mitata sekä vasemman kammion tilavuus että ejektiofraktio.
PET-tutkimuksella voidaan erottaa elossa oleva sydänlihas infarktin arvesta (viabiliteetin tutkiminen)  tutkimalla sydänlihaksen glukoosiaineenv aihduntaa
fluorileimatulla fluorodeoksiglukoosilla (FDG).
Maksimaalisen dynaamisen tai lääkerasituksen jälkeen sydäntapahtuman riski on < 1 %, jos sydänlihaksen perfuusion tulos on normaali. Kohtalainen tai laaja (> 10 %
vasemman kammion massasta) sydänlihaksen perfuusiopuutos on suuren vaaran löydös [68], [69], [70].
Rasitusultraäänikuvaus
Ahtauttava sepel valtimotauti voidaan rasitusultraäänikuvauksessa  todeta iskemian aiheuttaman palautuvan seinä mäliikehäiriön perusteella.
Rasitusultraäänikuvauksen herkkyys on erikoistuneissa  keskuksissa  sepel valtimotaudin diagnostiikassa hyvä (85 %), samoin spesif isyys (82 %) [48], [71].26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 15/31
Rasitusultraäänikuvaus voidaan tehdä lääkerasituksena , jos fyysinen rasitus ei ole mahdollinen.  Tällöin menet etään fyysisen rasituksen informaatio oireista,
verenpa ine- ja sykevasteesta sekä suorituskyvystä. Lääkerasitus tehdään yleensä  dobutamiinilla, joka suurentaa sykettä, sydänlihaksen supistusvireyttä ja
hapenk ulutusta.
Nykyisillä ultraäänilaitteilla ja tarvittaessa  ultraäänivarjoaineel la tutkimus on diagnostinen suurimmalla osalla potilaista, mutta se vaatii tekijältään osaamista.
Ultraäänikuvauksella saadaan myös tietoa mahdollisista infarktialueista, sydänlihaksen viabiliteetista sekä sydämen rakenteesta ja toiminna sta (ks. teksti jäljempänä).
Jos maksimaalisen rasituksen aikana ei todeta iskemiaa, potilaan sydäntapahtuman riski seuraavan vuoden aikana on < 1 %. Laaja-alainen iskemia on suuren vaaran
löydös [69], [70].
Rasitusultraäänikuvauksen ja isotooppitutkimuksen käyttöaiheet kroonisen sepelvaltimotaudin diagnostiikassa
Sydänlihaksen perfuusio- tai rasitusultraäänitutkimukset soveltuvat ahtauttavan sepel valtimotaudin toteamiseen oireisilla potilailla, joilla kliininen
enna kkotodennä köisyys on suurentunut.
Iskemiadiagnostiikka on mahdollista myös, jos rasitustesti ei onnist u tai iskemian toteaminen ei ole EKG:n perusteella mahdollista.
Kuvantaminen soveltuu sydänlihasiskemian toteamiseen ja ohjaamaan hoidon valintaa potilailla, joilla on todettu sepel valtimotauti.
Sepelvaltimoiden kajoava varjoainekuvaus
Sepel valtimoiden kajoava varjoainek uvaus mahdollistaa sepel valtimoiden erittäin tarkan anatomisen kuvantamisen sekä ahtauman hemodynaamisen merkityksen
varmentamisen painev aijeritutkimuksen avulla.
Sepel valtimoiden kajoava varjoainek uvaus on tarpeen ao. tilanteissa :
kajoamattomissa tutkimuksissa  todetaan suuren vaaran löydöksiä ja viitteet sepel valtimotaudista
kajoamattomat tutkimukset eivät ole mahdollisia tai eivät sovellu potilaalle
revaskularisaatiotarpeen arvioimiseksi.
Sepel valtimoiden kajoava varjoainek uvaus ilman edeltäviä kajoamattomia testejä voi olla aiheellinen seuraavissa tilanteissa :
potilaalla on sepel valtimotaudille tyypillinen,  elämää rajoittava rintakipu
tyypillinen rintakipuoire ilmaantuu kevyessä  rasituksessa  tai levossa (CCS  3–4), tai se on kehittynyt hyvin nopeasti (ns. crescendo angina pectoris)
potilaalla on elämää rajoittavia oireita optimaalisest a lääkehoidosta huolimatta
sepel valtimotauti on todettu aiemmin
tyypilliseen rintakipuun liittyy heikentynyt vasemman kammion systolinen toiminta
ahtauttavan sepel valtimotaudin osoittamiseksi tai sulkemiseksi pois, jos sepel valtimotaudin diagnoosi jää kajoamattomien tutkimusten jälkeen epävarmaksi.
Sydämen rakenteen ja toiminnan kuvantaminen
Sydämen ultraäänikuvauksella arvioidaan sydämen toimintaa ja mahdollisia rakenteellisia vikoja.
Ultraäänikuvaus tulee tehdä epäiltäessä  kroonista sepel valtimo-oireyhtymää, jos
potilaan oireet ja löydökset viittaavat sydämen vajaatoimintaan, läppävikaan (sivuääni), sairastettuun sydäninfarktiin (Q-aallot) tai johonkin muuhun
rakenteelliseen sydänvikaan [72]
suunnit ellaan kajoavaa hoitoa.26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 16/31
Ultraäänikuvaus tulee tehdä aina, kun ahtauttava sepel valtimotauti on todettu, erityisest i vasemman kammion systolisen toiminna n arvioimiseksi.
Krooninen sepel valtimo-oireyhtymä ei yleensä  aiheuta poikkeavia ultraäänikuvauslöydöksiä, mutta iskemian tai sairastetun infarktin aiheuttamia paikallisia
seinä mäliikehäiriöitä voidaan havaita. Ne lisäävät sepel valtimotaudin todennä köisyyttä.
Ultraäänikuvauksella voidaan havaita sairauksia ja tautitiloja, jotka voivat aiheuttaa sepel valtimotautia muistuttavia oireita, kuten läppäviat, sydämen vajaatoiminta ja
hypertrofinen kardiomyopatia.
Ultraäänikuvauksella voidaan todeta sairastetun sydäninfarktin tai kroonisen sydänlihasiskemian aiheuttama vasemman kammion systolinen toimintahäiriö
(ejektiofraktio < 40 %), joka ennu staa kuolemanvaaraa ja tulevia sydäntapahtumia [73], [74].
Sydämen magneet tikuvauksella on mahdollista tutkia vasemman kammion systolista toimintaa ja mahdollisia rakenteellisia vikoja sekä todeta infarktiarvet niin
sanotulla jälkitehostumatekniikalla. Lääkerasituksen aikana voidaan tunnist aa myös sydänlihasiskemia ja perfuusiohäiriöt, mutta magneet tikuvaus ei ole toistaiseksi
vakiintunut laajaan kliiniseen käyttöön sepel valtimotaudin diagnostiikassa.
Mikrovaskulaaritauti
Mikrovaskulaaritaudissa sydänlihaksen verenvirtausreservi on pienent ynyt pient en valtimoiden ja hiussuonten (mikrosirkulaatio) toimintahäiriön vuoksi [75].
Mikrovaskulaaritauti voi esiint yä samanaikaisest i ahtauttavan sepel valtimotaudin kanssa , mutta se voi myös olla itsenä inen sepel valtimotaudille tyypillisen rintakivun
aiheuttaja.
Arviot mikrovaskulaaritaudin yleisyydestä vaihtelevat. Suomalaisessa  aineist ossa mikrovaskulaaritauti todettiin PET-kuvauksessa  4 %:lla kroonisen
sepel valtimotautioireyhtymän epäilyn vuoksi tutkituista potilaista [76]. Ahtauttava sepel valtimotauti löytyi puolestaan 34 %:lta potilasta. Ilman ateroskleroosia
mikrovaskulaaritauti on harvinainen.
Valtimotaudin lisäksi mikrovaskulaaritauti voi olla seurausta eri syistä johtuvista sydänlihassairauksista, ja se on yleinen sydämen vajaatoiminna ssa.
Mikrovaskulaaritaudin diagnoosi perustuu alentuneen sepel valtimoiden virtausreservin, lisääntyneen sepel valtimoiden virtausvastuksen tai pient en sepel valtimoiden
säätelyhäiriön osoittamiseen,  kun epik ardiaalisuonten ahtauma on suljettu pois [37], [75].
Kajoamattomista, kliinisest i käytetyistä sepel valtimotaudin diagnostisista tutkimuksista mikrovaskulaaritauti voidaan todeta vain sydänlihasper fuusion PET-kuvauksen
avulla (kun ahtauttava sepel valtimotauti poikkeavan verenvirtausreservin syynä on suljettu pois).
Kajoavia tutkimuksia voidaan tarvittaessa  harkita yksilöllisen arvion perusteella.
Riskitekijöiden hoidon tärkeys korostuu, mikäli oireiden perusteella epäillään mikrovaskulaaritautia tai mikrovaskulaaritauti on todettu.
Anti-iskeem isten oirelääkkeiden hyöty on epävarma.
Kroonisen sepelvaltimo-oireyhtymän lääkehoito
Kroonisen sepel valtimo-oireyhtymän lääkehoidon tavoitteena  on
parantaa taudin ennu stetta ehkäisem ällä sydänper äisiä kuolemia ja sydäninfarkteja
lievittää oireita ja parantaa elämänlaatua.
Jos potilaalla on todettu ateroskleroosi tai krooninen sepel valtimo-oireyhtymä, suositellaan statiinilääkitystä.
Oireettomassa ateroskleroosissa  ASA-lääkityksestä ei ole todettu ennu stehyötyä [59], [77], [78], [79].26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 17/31
Jokaisen oireisen,  kroonista sepel valtimo-oireyhtymää sairastavan potilaan lääkitykseen kuuluvat ennu stetta parantavat asetyylisalisyylihappo (ASA) tai muut sairaudet
huomioiden ADP-resept orin salpaaja (klopidogreeli) tai antikoagulaatiohoito.
Oireisille potilaille tulee aloittaa ainakin yksi oireita lievittävä lääke lyhytvaikutteisen nitraatin lisäksi. Ensisij aisia ovat beetasalpaaja ja/tai kalsiumkanavan salpaaja [80].
Jos oireita vielä on, lisätään lääkitykseen  pitkävaikutteinen nitraatti. Lääkkeiden valinna ssa on huomioitava muut sairaudet, lääkitykset ja mahdolliset
haittavaikutukset. Lääkehoidon vaste tulee tarkistaa seurannassa.
Ennustetta parantava lääkehoito
Dyslipidemioiden hoito
Jos potilaalla on todettu ateroskleroosi tai krooninen sepel valtimo-oireyhtymä, suositellaan statiinia .
Statiinit  parantavat sepel valtimotautipotilaan ennu stetta.
Statiini aloitetaan kaikille LDL-kolesterolipitoisuudesta riippu matta riittävän tehokkaalla valmisteella ja annoksella.
Hoitotavoitteen saavuttamiseksi tai haittavaikutusten vähentämiseksi statiiniin voidaan yhdistää etsetimibi tai PCSK9:n estäjä.
Tehokkaan statiinia nnoksen ja etsetimibin yhdistelmällä LDL-kolesterolipitoisuutta voidaan pienent ää yli 50 %.
Statiinin ja etsetimibin yhteiskäyttöä selvittäneid en satunnaistettujen tutkimusten meta-analyysissa  yhdistelmähoito pienensi statiinim onoterapiaa enem män
kokonais- (27 % vs. 17 %) ja LDL-kolesterolipitoisuutta (39 % vs. 24 %) [81].
Etsetimibi yksinä än pienent ää kokonaiskolesterolipitoisuutta keskimäärin 13 % ja LDL-kolesterolipitoisuutta 19 % [82].
Etsetimibimonoterapian vaikutusta päätetapahtumiin ei ole tutkittu.
Hoitoa PCSK9:n estäjällä voidaan harkita, jos potilaalla on sairastettu sydäninfarkti ja LDL-kolesterolitavoitteesta jäädään selvästi suurimmasta siedetystä
statiinia nnoksesta ja etsetimibistä huolimatta.
PCSK9:n estäjillä on hyvä näyttö LDL-kolesterolitason laskusta.
Alirokumabi ja evolokumabi ovat monoklonaalisia vasta-aineit a, jotka annostellaan ihonalaisest i 2–4 viikon välein. LDL-kolesterolitaso laskee noin 60 %.
Evolokumabi yhdistettynä statiinih oitoon vähensi suuren vaaran sepel valtimotautipotilailla (81 %:lla aiempi sydäninfarkti) kardiovaskulaaritapahtumia 15 % (NNT =
50) 2 vuoden seurannassa [83].
Alirokumabi yhdistettynä statiinih oitoon vähensi sepel valtimotautikohtauspotilailla kardiovaskulaaritapahtumia 15 % (NNT = 63) ja kokonaiskuolleisuutta 15 %
(NNT = 167) noin 3 vuoden seurannassa [84].
Inklisiraani estää PCSK9-synteesiä . Se annostellaan ihonalaisest i hoidon alussa, 3 kuukauden kuluttua ja sen jälkeen 6 kuukauden välein. LDL-kolesterolitaso laskee
noin 50 % [85].
Tutkimusnäyttö inklisiraanin ennu stevaikutuksesta puuttuu toistaiseksi.
Ennen PCSK9:n estäjän käytön aloittamista tulee arvioida riskitekijöiden hoidon toteutuminen kokonaisuutena ja tarvittaessa  korjata merkittävimpiä ongelmia.
Lääkehoitoon sitoutuminen tulee varmistaa.
Potilaan kokonaisennu ste tulee ottaa huomioon.
Antitromboottiset lääkkeet
Oireettomassa ateroskleroosissa  ASA-lääkityksestä ei ole todettu ennu stehyötyä [59], [77], [78], [79].26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 18/31
Jokaisen oireisen,  kroonista sepel valtimo-oireyhtymää sairastavan potilaan lääkitykseen kuuluvat ennu stetta parantava asetyylisalisyylihappo (ASA) tai muut sairaudet
huomioiden ADP-resept orin salpaaja (klopidogreeli) tai antikoagulaatiohoito.
ASA-annos on yleensä  100 mg/vrk.
Klopidogreeli on todettu ASAn kanssa  vähintään yhdenveroiseksi [86], ja sitä käytetään ASAlle allergisille.
Muilla valtimotautipotilailla (krooninen sepel valtimo-oireyhtymä ja aivoverenkiertohäiriö tai perifeerinen valtimotauti tai diabetes), ASAn tilalla voi harkita pysyvää
klopidogreelilääkitystä.
ASAn ja toisen antitrombootin yhteiskäyttöä voidaan harkita kardiologin ohjeistamana.
Pienia nnoksisen rivaroksabaanin (2,5 mg x 2) tai tikagrelorin (60 mg x 2) yhteiskäyttöä sekundaaripreventiossa
on hyödyllistä harkita hyvin suuren iskemiavaaran potilaille
voidaan harkita suuren iskemiavaaran potilaille, joilla ei ole merkittävää vuotoriskiä [87], [88], [89].
Sepel valtimon pallolaajennu ksen tai stenttauksen jälkeen ASAn ja klopidogreelin yhdistelmää käytetään määräaika, yleensä  1–12 kuukautta. Tämän lääkeyhdistelmän
keston määrittää sepel valtimotoimenpit een tehnyt lääkäri huomioiden tromboosiriskin ja toisaalta vuotoriskin [80], [88], [90].
Mikäli suunnit ellun hoidon toteuttamisessa tulee ongelmia, on syytä konsultoida kardiologia.
Sepel valtimoiden ohitusleikkauksen (CABG) jälkeen yleensä  ASA (tai klopidogreeli ASA-allergisille) on riittävä.
Jos eteisvärinää sairastavalle tehdään pallolaajennu s, suositellaan käytettäväksi suoraa antikoagulanttia, johon liitetään klopidogreeli määräajaksi [91].
ASAn (tai ADP-resept orin salpaajan) pitkäaikaiskäyttö on haitallista antikoagulanttia käyttävillä kroonista sepel valtimo-oireyhtymää sairastavilla, koska se lisää heillä
verenvuotoja ilman lisähyötyä [92].
Angiotensiinik onvertaasin (ACE) estäjät
ACE:n estäjät parantavat ennu stetta kroonista sepel valtimotautia sairastavilla, joilla on vasemman kammion systolinen toimintahäiriö (ejektiofraktio ≤ 40 %) [93], [94].
Jos vasemman kammion toiminta on normaali, ACE:n estäjät parantavat ennu stetta potilailla, joilla sydäntapahtuman riski on suuri.
ACE:n estäjä tulisi aloittaa kaikille kroonista sepel valtimotautia sairastaville potilaille, joilla on hypertensio  tai diabetes.
Pienen riskin potilailla ennu stehyödystä ei ole varmaa tutkimusnäyttöä, joten ACE:n estäjähoidon hyödyt ja haitat tulee miettiä tapauskohtaisest i.
Jos potilas ei siedä ACE:n estäjää, voidaan käyttää angiotensiini II -resept orin salpaajia [95], [96], vaikka tutkimusnäyttö niiden hyödystä kroonisessa
sepel valtimotaudissa on vähäinen vasemman kammion toiminna n ollessa  normaali.
Diabeteslääkkeet
Ennustetta parantavaa SGLT2:n estäjää tai GLP1-resept oriagonistia suositellaan käyttämään ensil injan lääkehoitona sepel valtimotautipotilaille [97], joilla diagnosoidaan
tyypin 2 diabetes.
SGLT2:n estäjistä empagliflotsiini ja kanagliflotsiini vähentävät sydän- ja verisuonitautitapahtumia siten, että empagliflotsiini vähentää kardiovaskulaari- ja
kokonaiskuolleisuutta ja kanagliflotsiini sydäninfarkteja tyypin 2 diabetesta sairastavilla valtimotautipotilailla [A] .
SGLT2:n estäjät vähentävät sydämen vajaatoiminna sta johtuvan sairaalahoidon tarvetta [98], [99].
GLP1-resept oriagonistit (dulaglutidi, liraglutidi ja semaglutidi) vähentävät sydän- ja verisuonitapahtumia diabetesta sairastavilla sepel valtimotautipotilailla [A].
Metformiinia  jo käyttävälle diabeetikolle näitä lääkkeitä suositellaan toisen linjan lääkehoitona.26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 19/31
Oireita lievittävä lääkehoito
Beetasalpaajat
Beetasalpaajat vähentävät iskemiaa, lievittävät tehokkaasti oireita [80], [100] ja ovat ensisij ainen valinta anti-iskeem iseksi lääkkeeksi.
Beetasalpaajilla ei ilmeisest i ole ennu stetta parantavaa vaikutusta kroonista sepel valtimo-oireyhtymää sairastavilla, joiden vasemman kammion funktio on normaali [B].
Merkittävässä vasemman kammion toimintahäiriössä (ejektiofraktio ≤ 40 %) beetasalpaajien ennu stehyödystä on hyvä tutkimusnäyttö [101].
Sairastetun sydäninfarktin jälkeen beetasalpaajien pitkäaikaiskäyttöä tulee harkita ennu stetta parantavan hyödyn vuoksi [102].
Pitkäkestoisest a beetasalpaajahoidosta ei ole osoitettu ennu stehyötyä, kun sepel valtimotautikohtauksesta on kulunut yli 1 vuosi, vasemman kammion toiminta on
normaali ja kyseessä  on pienen riskin potilas [C].
Sykettä hidastavat kalsiumsalpaajat
Verapamiilia tai diltiatseem ia voidaan käyttää iskemiaa lievittävinä lääkkeinä , jos beetasalpaajat eivät sovi, mutta niiden ennu stetta parantavasta vaikutuksesta ei ole
näyttöä.
Sykettä hidastavia kalsiumsalpaajia ei bradykardia- ja AV-johtumishäiriövaaran vuoksi tule yhdistää beetasalpaajahoitoon.
Sykettä hidastavia kalsiumsalpaajia ei tule käyttää, jos vasemman kammion systolinen toiminta on heikentynyt.
Dihydropyridiinit
Dihydropyridiinir yhmän kalsiumsalpaajaa voidaan käyttää sepel valtimotautipotilaan verenpa ineen hoidossa tai anti-iskeem isenä  lääkkeenä  etenkin beetasalpaajaan
yhdistettynä [103].
Laajempaa näyttöä ennu stehyödyistä ei ole.
Lyhytvaikutteiset  nitraatit
Kielenalustablettina (glyseryylinitraatti) tai -suihkeena  (isosorbididinitraatti) annosteltava lyhytvaikutteinen nitraatti määrätään kaikille sepel valtimotautipotilaille
käytettäväksi tarvittaessa .
Lyhytvaikutteisia  nitraattivalmisteita käytetään lievittämään rintakipua tai ehkäisevästi ennen rasitusta.
Pitkävaikutteiset  nitraatit
Nitraatteja voidaan harkita lievittämään rasitusrintakipuoiretta, jos beetasalpaajasta ja/tai kalsiumkanavan salpaajasta ja lyhytvaikutteisest a nitraatista huolimatta
potilaalla on edelleen oireita.
Nitraattitoleranssin välttämiseksi suositellaan lääkkeen annostelua siten, että vuorokauteen tulee vähintään 10 tunnin jakso ilman nitraattivaikutusta.
Revaskularisaatiotarpeen arviointi ja hoidon valinta kroonista sepelvaltimo-oireyhtymää sairastavalla
Jos potilas oireilee optimaalisest a lääkehoidosta huolimatta tai kajoamattomissa tutkimuksissa  (rasitus-EKG, perfuusiotutkimus, sepel valtimoiden TT) todetaan
ennu stetta huonontavia löydöksiä, potilas tulee kuvantaa sepel valtimoiden kajoavalla varjoainek uvauksella.
Ennen toimenpid että potilaalle tulee kertoa toimenpit een riskit, mahdollisten löydösten merkitys sekä hoitovaihtoehdot.
Revaskularisaatio pyritään toteuttamaan oikea-aikaisest i varjoainek uvauksen löydösten perusteella tarvittaessa  lisämittauksia hyödyntäen. Oireiden lisäksi
revaskularisaatiota puoltavat kajoamattomissa tutkimuksissa  todetut huonoon ennu steeseen viittaavat löydökset.26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 20/31
Jos potilas on optimaalisella lääkehoidolla oireeton tai vähäoireinen,  revaskularisaatiohoidolla ei saavuteta ennu steellista merkitystä eikä oirehyötyä [56], [104], [105], [106].
Kajoavia tutkimuksia ja hoitoa puoltavat oireet, jotka haittaavat jokapäiväistä elämää asianmukaisest a lääkehoidosta huolimatta. Revaskularisaatio ei paranna
potilaan ennu stetta, mutta sillä saadaan lisähyötyä oireiden hoidossa [A].
Revaskularisaatiota tulee harkita, jos todetaan matala ejektiofraktio. Laaja iskemia-alue puoltaa revaskularisaatiota hoitomuotona.
Varjoainek uvauksessa  nähtävien ahtaumien merkityksen arvioinnin perusteena  tulee yleensä  olla iskemianäyttö joko kajoamattomien tutkimusten tai kajoavan
painev aijeritutkimuksen perusteella.
Varjoainek uvauksen yhteydessä  on mahdollista tehdä merkittävien ahtaumien pallolaajennu s ja stentin asennu s.
Potilaan sydänsairauden (esim . mahdollisen läppävian) laajuuden tulee olla kattavasti selvitetty ennen revaskularisaatiohoidon valintaa.
Revaskularisaatiohoidon valintaan (PCI vs. CABG, Coronary Artery Bypass Grafting, sepel valtimo-ohitusleikkaus) vaikuttavat useat eri tekijät:
sepel valtimotaudin vaikeusaste ja sepel valtimoiden anatomia
leikkausriski (EUROSCORE II, STS)
liitännäissairaudet
ikä.
Jos sepel valtimoahtaumien anatomia on ennu steellisest i merkittävä, on syytä neuvotella sydänkirurgin kanssa  ennen hoitopäätöksen tekemistä.
Tarvittaessa  taudin vaikeusasteen arvioinnissa  voidaan käyttää SYNTAX scorea (ks. http://sy ntaxscore.org/calculator/start.htm ja laskuri
http://sy ntaxscore.org/calculator/syntaxscore/frameset.htm) [61], [107].
Päärunkoahtauman hoitomuodon valintaan vaikuttaa sepel valtimotaudin vaikeusaste ja ahtauman anatomia. SYNTAX scoren ollessa  matala ≤ 22 ovat sekä PCI että
ohitusleikkaus sopivia hoitovaihtoehtoja. Taudin vaikeusasteen kasvaessa  (SYNTAX score > 22) on ohitusleikkaus parempi hoitovaihtoehto.
Revaskularisaatiohoidon valinna ssa tulee huomioida mahdolliset sydämen läppien sairaudet (ahtauma tai vuoto), vasemman kammion funktio ja aortan tilanne sekä
mahdolliset liitännäissairaudet, kuten diabetes, keuhkosairaudet, aiemmat aivoverenkiertohäiriöt sekä merkittävät munuaissairaudet.
Diabeetikoilla kolmen suonen taudin hoidoksi suositellaan yleensä  ohitusleikkausta. Monisu onitautia sairastavilla diabeetikoilla ohitusleikkaus vähentää
kuolleisuutta ja uusintatoimenpit eiden tarvetta verrattuna lääkestenteillä tehtäviin sepel valtimotoimenpit eisiin [A].
Revaskularisaatiomenet elmää arvioitaessa  huomioidaan myös revaskularisaation kattavuus.
Jos kardiologille ja sydänkirurgille jää epävarmuutta potilaan parhaasta hoitovaihtoehdosta, erityisen ongelmallisten potilaiden asiat käsitellään kokouksessa , jossa
kokonaisvaltaiseen arvioon tarvittavien erikoisalojen lääkärit (toimenpid ekardiologit, sydänkirurgit, kliiniset  kardiologit, sydänanest esiologit) suunnit televat potilaalle
parhaan hoitovaihtoehdon konsultoiden tarvittaessa  muita erikoisaloja.
Hoitopäätös tehdään yhdessä  potilaan kanssa  keskustellen.
PCI
Painev aijerimittaus auttaa tarvittaessa  tunnist amaan hemodynaamisest i merkittävän ahtauman [108]. Rajapintaisen ahtauman arviointi painev aijerilla kohdentanee
PCI-toimenpit eet paremmin.
PCI-toimenpit eissä  käytetään yleensä  moderneja lääkestenttejä.
Perustelluissa tapauksissa  (lisääntynyt vuotoriski tai pieni restenoosiriski) lääkepallon käyttö lääkestentin sijaan voi olla aiheellista, mutta vertailevat tutkimukset
lääkeainest entteihin puuttuvat.26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 21/31
Sepelvaltimo-ohitusleikkaus
Sepel valtimoiden ohitusleikkaukseen päädyttäessä :
LITA-LAD-ohitetta on pyrittävä käyttämään aina, kun se on mahdollista.
Nuorille potilaille suositellaan molempien ITA-ohitteiden käyttöä.
Värttinävaltimoa kannattaa käyttää muiden kriittisten stenoosien hoidossa [109].
Siirteinä  pyritään suosimaan valtimosiirteitä.
Sepel valtimoiden ohitusleikkaus voidaan toteuttaa joko sydän-keuhkokoneen avulla tai lyövän sydämen tekniikalla (OPCAB). Jälkimmäisest ä on etua, jos aortta on
kalkkeutunut.
Veren hyytymiseen vaikuttavien lääkitysten tauotuksesta päätetään potilaskohtaisest i ja paikallisest i.
ASA-lääkitystä jatketaan yleensä  leikkaukseen saakka.
Työ- ja toimintakyvyn arviointi
Työkyvyn arvioinnissa  tarvitaan erikoissairaanhoidon spesif istä osaamista lisätutkimuksineen ja työterveyshuollon tuntemusta työolosuhteista.
Anamnest inen haastattelu on hyvin oleellinen.  Suoriutuminen tasamaakävelystä, ylämäessä  tai portaissa noususta ja päivittäisistä toiminno ista kuvaa toimintakykyä.
Suoriutumista arvioidaan CCS -luokituksella, ks. taulukko 3.
Perustutkimus on kliininen,  työjohteinen  ja oirerajoitteinen kliininen rasituskoe, jota täydennet ään tarvittavin tutkimuksin. Vaihtoehtoisest i voidaan käyttää
kävelymattotestiä tai yläraajaergometriaa.
6 minuutin kävelytesti on käyttökelpoinen erityisest i voinnin arvioimisen ja liikunnallisen kuntoutuksen suunnit telun osana sekä potilaan rohkaisem isessa
liikkumiseen.
Työkyvyn arvioimiseksi kliinisessä  rasituskokeessa  kokonaissuorituskyky ilmoitetaan tavallisim min 3–4 viimeisen rasitusminuutin työn keskiarvona (W), joka
suhteutetaan iän ja koon mukaiseen viitearvoon.
Metabolisten ekvivalenttien (MET) käyttö selkeyttää työn ja aineenv aihdunnallisen kuormittavuuden välistä vertailua. Työtehtävistä ja ammateista on valmiina MET-
tasoina kuvattuja kuormittavuustuloksia (ks. lisätietoa ).
Työssä käyviltä on tärkeää selvittää arjessa pärjäämisen lisäksi selviytymistä tyypillisistä työtehtävistä.
Psyykkinen tilanne ja henkinen stressi voivat heikentää sopeutumista kuormittaviin tilanteisiin.
Sepel valtimotautipotilaiden työ- ja toimintakykyyn vaikuttavat merkittävästi sairauden komplikaatiot, kuten rytmihäiriöalttius tai sydämen vajaatoiminta.
Ammatilliset vaatimukset on otettava huomioon erityisest i fyysisest i raskaissa tai fyysistä reagointia vaativissa tehtävissä.
Ammattikuljettajat ovat erityisryhmä.
TRAFICOM päivittää kansallisia ohjeita ajoterveydestä. Lääkärillä on ilmoitusvelvollisuus muista kuin tilapäisistä yli 6 kuukautta jatkuvista ajoterveysrajoituksista
koskien kaikkia hoitotilanteita https://www. traficom.fi/fi/liikenne/t ieliikenne/t erveydenhuollon-ammattilaisille.
Ks. TRAFICOM Ajoterveyden arviointiohjeet terveydenhuollon ammattilaisille https://www. traficom.fi/fi/saadokset/ajoterveyden-arviointiohjeet-
terveydenhuollon-ammattilaisille. Ryhmän 1 ajoterveysvaatimukset eivät täyty, jos henkilöllä on rintakipuja levossa, vähäisessä  rasituksessa  tai henkisen paineen
alaisena  (CCS -luokka 4), (ks. Käypä hoito -suositus Sairauspoissaolon tarpeen arviointi «Sairauspoissaolon tarpeen arviointi», [110]).
Ryhmän 2 ajoterveysvaatimukset eivät täyty, jos henkilöllä on sydänoireita tasamaakävelyssä tai henkisen paineen alaisena  (CCS -luokat 3–4).26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 22/31
CCS -luokka 2 vain kardiologin arvion perusteella.
Työhön paluu ja ammatillinen kuntoutus
Työterveyshuollossa seurataan ja tuetaan potilaan työkykyä.
Työtä on joskus mahdollista muokata voinnin huonontuessa  yhteistyössä työnantajan kanssa . Tästä huolimatta sairauspoissaolo on joskus tarpeen.
Jos sairausloma pitkittyy yli 90 päivän, potilaalla on velvollisuus toimittaa Kelaan työterveyshuollossa laadittava selvitys työhön paluun mahdollisuuksista. Muuten
sairauspäivärahan maksaminen Kelasta päättyy.
Osasairauspäivärahalla voidaan tukea työhön palaamista määräaikaisella 40–60-prosent tisella työajalla.
Työeläkevakuuttaja tai Kela voi tukea entiseen tai uuteen työhön paluuta ammatillisena  kuntoutuksena  työkokeilulla.
Uudelleenk oulutus tai elinkeino tuki ammatillisena  kuntoutuksena  voi myös olla mahdollista, ellei paluu entiseen työhön onnist u.
Työhön paluuta tukevat interventiot saattavat hyödyttää työhön paluuta 6 kuukauteen saakka, mutta ei sen jälkeen [111]. Kansainvälisessä  katsauksessa  oli mukana myös
psykologisia interventioita, mutta toisaalta työhön ei tutkimuksissa  ollut tehty muutoksia.
Työhön paluuta tukeviin toimiin tulee kiinnit tää huomiota.
Suomalaisessa  tutkimuksessa  [112] todettiin, että jopa 27 % alle 50-vuotiaista jää työkyvyttömyyseläkkeelle vuoden kuluttua sairastumisest a.
Preventioon on hyvä kiinnit tää huomiota.
Huono sosioekonominen asema yhdistettynä sydänsairauteen aiheuttaa riskin ohjautua työelämän ulkopuolelle sairastumisen jälkeen [113].
Seuranta Seuranta
Kroonisen sepel valtimo-oireyhtymän hoidon ja seurannan tavoitteena  on vähentää oireyhtymään liittyvää kokonaiskuolleisuutta, sairaalahoidon tarvetta ja iskeem isiä
valtimotapahtumia koko valtimopuuston alueella (ks. Käypä hoito -suositukset Sepel valtimotautikohtaus «Sepel valtimotautikohtaus», [1], Aivoinfarkti ja TIA
«Aivoinfarkti ja TIA», [114], Alaraajojen tukkiva valtimotauti «Alaraajojen tukkiva valtimotauti», [115]) sekä ylläpitää ja parantaa potilaan suorituskykyä ja elämänlaatua.
Diagnoosin jälkeen kroonisen sepel valtimo-oireyhtymän hoito ja säännöllinen seuranta jatkuvat loppuelämän ajan myös sairauden oireettomassa vaiheessa .
Seurannan avulla pyritään varmistamaan ennu steeseen vaikuttavan lääkehoidon, omahoidon ja asetettujen hoidon tavoitteiden toteutuminen sekä toteamaan
mahdolliset hoidon haittavaikutukset.
Hoidon jatkuvuudesta on huolehdittava erikoissairaanhoidon ja perusterveydenhuollon yhteistyönä.
Potilaalle tulee kirjata yksilöllinen hoito- ja seurantasuunnit elma sydänvalmennu ksen toteuttamista varten.
Seurantakäynneil lä arvioidaan potilaan oireet (CCS - ja NYHA-luokka) ja verenpa ineen kotimittausten tulokset sekä määritellään lipidiarvot, HbA ja lääkitykseen
liittyvät turvakokeet. Samalla tulee selvittää myös potilaan ruokailu-, liikunta- ja tupakointitottumukset ja arvioida psyykkistä ja sosiaalista hyvinvointia ja voimavaroja
(esim erkiksi mahdollista masennu sta, ahdistusta ja kuolemanpel koa).
Akuutin sepel valtimokohtauksen sekä elektiivisen revaskularisaation jälkeen sydämen ultraäänitutkimus tulee kontrolloida, jos on todettu merkittävä vasemman
kammion systolisen toiminna n häiriö.
Seurannassa sydämen ultraäänitutkimusta tulee harkita potilailla, joilla kliinisin perustein epäillään sydämen vajaatoimintaa, todetaan suurentunut BNP-pitoisuus tai
selvästi poikkeava EKG-löydös viittaa sydämen vajaatoimintaan (ks. Käypä hoito -suositus Sydämen vajaatoiminta «Sydämen vajaatoiminta», [116])1C26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 23/31
Maksimaalisella rasituskokeella voidaan arvioida jäännösiskemian esiint ymistä revaskularisaation jälkeen tai oireiden uusiessa . Rasituskokeesta saatua tietoa voidaan
käyttää apuna potilaan toimintakyvyn arvioinnissa  ja liikunnallisen kuntoutuksen ohjauksessa . Koe tehdään optimoidun lääkehoidon aikana ilman lääketauotuksia.
Seurannan yhteydessä  on tärkeää kiinnit tää huomiota myös oireyhtymään yleises ti liittyvien liitännäissairauksien,  kuten sydämen vajaatoiminna n, rytmihäiriöiden,
diabeteksen, ylipainon, uniapnea n ja depressio n esiint ymiseen (Ks. Käypä hoito -suositukset Sydämen vajaatoiminta «Sydämen vajaatoiminta», [116], Eteisvärinä
«Eteisvärinä», [117], Tyypin 2 diabetes «Tyypin 2 diabetes», [11], Lihavuus (lapset , nuoret ja aikuiset) «Lihavuus (lapset , nuoret ja aikuiset)», [13], Uniapnea
(obstruktiivinen uniapnea  aikuisilla) «Uniapnea  (obstruktiivinen uniapnea  aikuisilla)», [118] ja Depressio  «Depressio », [30]).
Seurantatiheyteen ja seurantatutkimusten laajuuteen vaikuttavat potilaan yksilöllinen arvio ja oireyhtymään liittyvät liitännäissairaudet.
Kroonisen sepel valtimo-oireyhtymän diagnoosin, elektiivisen sepel valtimotoimenpit een ja akuutin sepel valtimokohtauksen jälkeen suositellaan seurantakäyntien
järjestämistä tiheämmin ensim mäisen vuoden aikana tai hoito-ongelmissa ja tämän jälkeen vähintään vuosittain.
Potilaalla tulee olla tieto, kuinka päästä oireiden uusiutuessa  tai vaikeutuessa  viiveettä hoidon arvioon joko yleislääkärin tai kardiologin vastaanotolle.
Mikäli oire uusii revaskularisaation jälkeen vuoden kuluessa , tulee kardiologia konsultoida herkästi.
Seuranta ja riskitekijöihin vaikuttaminen kattavan sydänvalmennu ksen avulla edellyttää terveydenhuollon ammattilaisten moniammatillista yhteistyötä ja alueellisest i
rakennet tavia kroonisen sepel valtimo-oireyhtymän suunnit elmallisia palvelu- ja hoitoketjuja, joissa hoito voidaan toteuttaa potilaan yksilöllisen tarpeen mukaisesti.
Erikoissairaanhoidon ja perusterveydenhuollon vastaanottokäynteihin perustuvaa hoitoketjua voidaan täydentää ja osin korvata digitaalisilla hoitopoluilla.
Digitaaliset hoitopolut soveltuvat erityisen hyvin potilasohjaukseen ja omahoidon tukemiseen.  (ks. Terveyskylä https://www. terveyskyla.fi/)
Liikunnallinen sydänkuntoutus on oleellinen osa sydänvalmennu sta ja kroonista sepel valtimo-oireyhtymää sairastavien omahoitoa, koska sillä voidaan vaikuttaa
sairautta pahentaviin riskitekijöihin [34], [35], [37], [119], [120]. Liikunnan ja liikunnallisen sydänkuntoutuksen merkitystä on kuvattu lisätietoaineist ossa Sepel valtimo-
oireyhtymä ja liikunta .
Vuosittaista influenssa rokotusta suositellaan kroonista sepel valtimo-oireyhtymää sairastaville.
Influenssa rokote voidaan antaa ilman varoaikaa sairastetun sepel valtimotautikohtauksen jälkeen.
Pneumokokkirokotusta suositellaan kaikille kroonista sepel valtimo-oireyhtymää sairastaville https://t hl.fi/fi/web /infektiotaudit-ja-rokotukset/rokotteet-a-
o/pneu mokokkirokotteet/riskiryhmien-pneumokokkirokotukset
Seurannassa on tärkeää motivoida ja sitouttaa potilas pitkäaikaisen sairauden hoitoon. Ks. kohta Riskitekijöihin vaikuttaminen kattavan sydänvalmennu ksen avulla
«A1».
Psykososiaalinen tuki tulee huomioida osana kroonista sepel valtimo-oireyhtymää sairastavan seurantaa.
Psykososiaalisista interventioista on jonkin verran näyttöä sydänper äisen kuolleisuuden vähentämisest ä ja psyykkisten oireiden lieventymisest ä [121].
Psykososiaaliset riskitekijät tulee seurannassa ottaa huomioon ja pyrkiä vaikuttamaan niihin .
Seksuaaliterveyden tukeminen tulee huomioida osana kroonista sepel valtimo-oireyhtymää sairastavan seurantaa.
Sepel valtimotautipotilaan riskitekijöiden tehokkaalla hoidolla voidaan vaikuttaa myönteisest i seksuaaliterveyteen [122], [123], [124].
Sepel valtimotautipotilaat odottavat lääkärin tai hoitajan ottavan puheeksi seksuaaliterveyteen liittyvät asiat vastaanottokäynneil lä [122], [125].
Ks. lisätietoa Sepel valtimotautipotilaan seksuaaliterveys .
Arviointikriteerit26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 24/31
Alueellisten hoitoketjujen laatua ja vaikuttavuutta tulee arvioida ja parantaa sepel valtimotaudin kansallisest a laaturekisteristä saatavan tiedon avulla.
Laadun ja vaikuttavuuden seuranta tulee sisällyttää kaikkiin sydänvalmennu sohjelmiin, ja niitä tulee jatkuvasti kehittää saadun tiedon perusteella.
Alueelliseen hoidon ja seurannan toteutumisen arvioon voidaan käyttää sähköisistä potilaskertomusjärjestelmistä, esim erkiksi Duodecim in päätöksent uki, EBMEDS -
palvelusta, saatavaa tietoa.
Arviointikriteereitä ovat
oikea-aikainen hoito
jatkotutkimusten oikea kohdentuminen
optimaalisen hoitomuodon valinta.
Suomalaisen Lääkäriseuran Duodecimin ja Suomen Kardiologisen Seuran asettama työryhmä
Krooninen sepel valtimo-oireyhtymä -suosituksen historiatiedot
Puheenjohtaja:
Pekka Porela, dosent ti, sisätautien ja kardiologian erikoislääkäri; TYKS, Sydänkeskus, Turku
Kokoava kirjoittaja:
Heidi Mahrberg, fysioterapeutti; Tays Sydänsairaala Oy, Suomen Sydänfysioterapeutit ry
Työryhmän  jäsenet:
Oili Junttila, LL, yleislääketieteen erikoislääkäri; Limingan terveyskeskus, kliininen opettaja; OY
Erkki Ilveskoski, LT, dosent ti, sisätautien ja kardiologian erikoislääkäri, ylilääkäri; TAYS, Sydänsairaala
Kari Kaikkonen,  LT, kardiologian erikoislääkäri; OYS Sydän-osaamiskeskus, Oulu
Tomi Kaukonen,  LL, kardiologian erikoislääkäri; Tampereen Sydänsairaala
Johanna Keränen,  sairaanhoitaja; PPSHP, OYS Sydän-osaamiskeskus
Jari Laukkanen,  professo ri, kardiologian erikoislääkäri; Keski-Suomen sairaanhoitopiiri ja Itä-Suomen yliopisto
Tuula Meina nder, LL, BSc, sisätautien ja kardiologian erikoislääkäri, terveydenhuoltoon erikoistuva lääkäri, aluehallintoylilääkäri; Etelä-Suomen aluehallintovirasto,
(Käypä hoito -toimittaja)
Eliisa Mäenpä ä, LT, työterveyshuollon erikoislääkäri; Suomen Terveystalo
Pertti Pasanen,  LL, yleislääketieteen erikoislääkäri, apulaisylilääkäri; Kainuun sote-kuntayhtymä, Suomussalmen terveysasema
Helena Rajala, LT, dosent ti, sisätautien ja kardiologian erikoislääkäri; HUS Sydän- ja keuhkokeskus, kardiologian linja
Antti Saraste, professo ri, kardiologian erikoislääkäri; TYKS, Sydänkeskus, Turku
Antti Valtola, LT, dosent ti, ylilääkäri, sydän- ja rintaelinkirurgian erikoislääkäri; KYS Sydänkeskus
Aija Vatanen,  kardiologian erikoislääkäri; KYS Sydänkeskus26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 25/31
Sidonnaisuudet
Sidonnaisuusilmoitukset on kerätty 28.6.2022 julkaistun suosituksen laatimisen yhteydessä
Erkki Ilveskoski: Koulutus-, konsultointi ja asiantuntijatoimintaa: Bayer, Astra Zeneca . Korvaukset kongressi-  ja seminaari kuluista: Cardirad Oy, Abbott Oy.
Oili Junttila: Tutkimusrahoitus: Boehringer Ingelheim. Luottamustoimet terveydenhuollon alalla: GPF ry, hallituksen jäsen; lääkäriliiton Oulun paikallisosaston
hallituksen jäsen.
Kari Kaikkonen: Sivutoimet: kardiologi; Oulun Sydänkeskus. Koulutus-, konsultointi ja asiantuntijatoimintaa: Amgen, AstraZeneca , Bayer, Boehringer-Ingelheim,
Roche diagnostics, Sanofi Oy, Vifor Pharma. Korvaukset kongressi-  ja seminaari kuluista: Amgen, Bayer, Boehringer-Ingelheim. Luottamustoimet terveydenhuollon alalla:
Suomen Kardiologinen Seura; hallituksen jäsen. Muut sidonnaisuudet: Osakeomistus, Ab Hur Oy.
Tomi Kaukonen: Sivutoimet: Invasiivikardiologi; Helsing in Sydänsairaala. Koulutus-, konsultointi ja asiantuntijatoimintaa: Cardirad Oy. Muut sidonnaisuudet: Angio-
One Oy, omistaja.
Johanna Keränen: Koulutus-, konsultointi ja asiantuntijatoimintaa: Sydänliitto, TULPPA-verkkovalmennu s hankkeessa  asiantuntijana, Boehringer Ingelheim, Amgen,
Pfizer, Novartis. Luottamustoimet terveydenhuollon alalla: Suomen kardiologiset hoitajat, hallitus. Ohjaushankkeet: PoPSote hanke, Asiakkaan ja ammattilaisen
digipalvelut osahanke.
Jari Laukkanen: Luottamustoimet terveydenhuollon alalla: Sydäntutkimussäätiö.
Heidi Mahrberg: Sivutoimet: Toiminim i Heidi Mahrberg; yksityisvastaanotto, Tays Sydänsairaalalla. Koulutus-, konsultointi ja asiantuntijatoimintaa: Suomen
Sydänliitto ry, Karpatiat ry, Sydän-Suomen alue ry (ent. Hämeenm aan Sydänpiir i), Uudenm aan Sydänpiir i, Sydänlapset  ja -nuoret. Luottamustoimet terveydenhuollon
alalla: Suomen Sydänfysioterapeutit ry puheenj ohtaja 2011–2019 ja hallitustyöskentely 2019–; Käypä hoidon sepel valtimoneuvottelukunnan jäsen; Käypä hoito -suositus
Sepel valtimotautikohtaus jäsen.
Tuula M einander: Sivutoimet: Tampereen yliopisto, oikeuslääketiede, väitöskirjatutkija. Luento-, koulutus- ja asiantuntijapalkkiot: Suomen Lääkäriliitto; Suomalainen
Lääkäriseura Duodecim ; Suomen Kardiologinen Seura; Bayer Oy; Boehringer Ingelheim; Terve Media Oy. Korvaukset seminaari- ja kongressik uluista: Bayer Oy, Amgen
AB. Luottamustoimet: Käypä hoito, Sepelvaltimotauti-neuvottelukunta, sihteeri ja jäsen; Käypä hoito, Diabetes-neuvottelukunta, sihteeri ja jäsen; Suomen Kardiologinen
Seura, Sydänääni-lehden toimittaja ja nettitoimittaja; European Society of Cardiology, eurooppalaisen kardiologikoulutuksen opetussuunnit elman päivitystoimikunnan
nuorten kardiologien edustaja; Pohjoismaisen työryhmän jäsen, Guidelines International Network; Tays Sydänsairaala 2018–, luottamusvaltuutettu.
Eliisa M äenpää: Sivutoimet: Suomen Lääkäriliiton Luottamuslääkäri; Valviran pysyvä asiantuntija. Koulutus-, konsultointi ja asiantuntijatoimintaa: Asiantuntijaluentoja
työterveyshuollon alalta; Suomen Lääkäriliitto, Duodecim , Roche, Almamedia. Luottamustoimet terveydenhuollon alalla: Suomen Lääkäriliitto, Luottamuslääkäri,
Luottamuslääkäritoimikunnan puheenj ohtaja, Prosessio  Jaos, Tampereen Terveyspoliittinen valiokunta.
Pertti Pasan en: Ohjaushankkeet: Kansallisen sepel valtimotaudin laaturekisterin yhteistyöryhmän jäsen; Kainuun hyvinvointialueen väliaikaisen valmistelutoimielimen
jäsen.
Pekka Porela: Koulutus-, konsultointi ja asiantuntijatoimintaa: Bayer. Luottamustoimet terveydenhuollon alalla: Suomen Liikennel ääketieteen Yhdistys ry, hallituksen
jäsen.
Helena Rajala: Koulutus-, konsultointi ja asiantuntijatoimintaa: Abbott. Korvaukset kongressi-  ja seminaari kuluista: Abbott, Sanofi.
Antti Sarast e: Tutkimusrahoitus: Astra Zeneca  (työpaikan tutkimussopimus), Precordior (työpaikan tutkimussopimus). Koulutus-, konsultointi ja asiantuntijatoimintaa:
Abbott, Amgen, Astra Zeneca , Bayer, Boehringer Ingelheim, Pfizer. Luottamustoimet terveydenhuollon alalla: Sydäntutkimussäätiö, tieteellinen valiokunta.26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 26/31
Antti Valtola: Sivutoimet: Konsultti, Satucon Oy. Korvaukset kongressi-  ja seminaari kuluista: Abbott Finland Oy, Edwards Lifesciences Nordic Oy, Grex Medical Oy,
Johnson & Johnson Finland Oy. Luottamustoimet terveydenhuollon alalla: Suomen Thoraxkirurgiyhdistys: hallituksen jäsen, Suomen Kardiologinen Seura: hallituksen
jäsen. Muut sidonnaisuudet: Satucon Oy.
Aija Vatanen: Muut sidonnaisuudet: Omistaa 75 kpl Orionin osakkeita.
Kirjallisuusviite
Krooninen sepel valtimo-oireyhtymä. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Kardiologisen Seuran asettama työryhmä. Helsink i:
Suomalainen Lääkäriseura Duodecim , 2022 (viitattu pp.kk.vvvv). Saatavilla internetissä: www. kaypahoito.fi
Tarkemmat viittausohjeet: http://www. kaypahoito.fi/web /kh/viittaaminen
Vastuun rajaus
Käypä hoito -suositukset ja Vältä viisaasti -suositukset ovat asiantuntijoiden laatimia yhteenv etoja yksittäisten sairauksien diagnostiikan ja hoidon vaikuttavuudesta.
Suositukset toimivat lääkärin tai muun terveydenhuollon ammattilaisen päätöksenteon tukena hoitopäätöksiä tehtäessä . Ne eivät korvaa lääkärin tai muun
terveydenhuollon ammattilaisen omaa arviota yksittäisen potilaan parhaasta mahdollisest a diagnostiikasta, hoidosta ja kuntoutuksesta hoitopäätöksiä tehtäessä .
Tiedonhakukäytäntö
Systemaattinen kirjallisuushaku on hoitosuosituksen perusta. Lue lisää artikkelista khk00007
Kirjallisuutta
1. Sepel valtimotautikohtaus. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Kardiologisen Seuran asettama työryhmä Helsink i: Suomalainen Lääkäriseura Duodecim , 2022 (viitattu 8.6.2022). Saatavilla
internetissä: www.kaypahoito.fi
2. Julkari. Suomen lääketilasto 2020. Lääkealan turvallisuus- ja kehittämiskeskus, Fimea, Kansaneläkelaitos
3. KELA-lääkekorvaustilastot, https://w ww.kela.fi/terveys-ja-laakkeet_laakkeet https://w ww.kela.fi/terveys-ja-laakkeet_laakkeet
4. lähde: WHO, https://w ww.who.int/data/gho/data/themes/m ortality-and-global-health-estimates https://w ww.who.int/data/gho/data/themes/m ortality-and-global-health-estimates
5. Nasir K, Budoff MJ, Wong ND ym. Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2007;116:619-26 «PMID: 17646582»
6. Lieb W, Song RJ, Vasan RS ym. Premature Parental Cardiovascular Disease and Subclinica l Disease Burden in the Offspring. J Am Heart Assoc 2020;9:e015406 «PMID: 32896212»
7. Mars N, Koskela JT, Ripatti P ym. Polygenic and clinica l risk scores and their impact on age at onset  and prediction of cardiometabolic diseases and common cancer s. Nat Med 2020;26:549-557 «PMID: 32273609»
8. Christiansen MK, Winther S, Nissen L, ym. Polygenic Risk Score-enhanced  Risk Stratification of Coronary Artery Disease in Patients with Stable Chest Pain. Circulation: Genomic and Precisio n Medicine.  In Press.
9. Tupakka- ja nikotiinir iippu vuuden ehkäisy ja hoito. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Yleislääketieteen yhdistyksen asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim ,
2018 (viitattu 26.4.2021). Saatavilla internetissä: www.kaypahoito.fi
10. Dyslipidemiat. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Sisätautilääkärien Yhdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2021 (viitattu 26.4.2021). Saatavilla
internetissä: www.kaypahoito.fi
11. Tyypin 2 diabetes. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in, Suomen Sisätautilääkärien yhdistyksen ja Diabetesliiton Lääkärineu voston asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim,
2020 (viitattu 26.4.2021). Saatavilla internetissä: www.kaypahoito.fi
12. Kohonnut verenpa ine. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Verenpa iney hdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2020 (viitattu 26.4.2021). Saatavilla
internetissä: www.kaypahoito.fi
13. Lihavuus (lapset , nuoret ja aikuiset). Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in, Suomen Lihavuustutkijat ry:n ja Suomen Lastenlääkäriyhdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura
Duodecim , 2020 (viitattu 26.4.2021). Saatavilla internetissä: www.kaypahoito.fi
14. Nallegowda M, Lee E, Brandstater M ym. Amputation and cardiac comorbidity: analysis of severity of cardiac risk. PM R 2012;4:657-66 «PMID: 22698850»
15. Marsico F, Giugliano G, Ruggiero D ym. Prevalence and severity of asymptomatic coronary and carotid artery disease in patients with abdominal aortic aneurysm. Angiology 2015;66:360-4 «PMID: 24965380»
16. Chun KC, Teng KY, Chavez LA ym. Risk factors associated with the diagnosis of abdominal aortic aneurysm in patients screened  at a regional Veterans Affairs health care system. Ann Vasc Surg 2014;28:87-92 «PMID: 24189004»
17. Takigawa M, Yokoyama N, Yoshimuta T ym. Prevalence and prognosis of asymptomatic coronary artery disease in patients with abdominal aortic aneurysm and minor or no perioperative risks. Circ J 2009;73:12 03-9 «PMID:
19443955»
18. Alaraajojen tukkiva valtimotauti. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Verisuonikirurgisen Yhdistyksen asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2021 (viitattu
26.4.2021). Saatavilla internetissä: www.kaypahoito.fi26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 27/31
19. Kalra PR, García-Moll X, Zamorano J ym. Impact of chronic kidney disease on use of evidence- based therapy in stable coronary artery disease: a prospect ive analysis of 22,272 patients. PLoS One 2014;9:e10 2335 «PMID:
25051258»
20. Matsushita K, Sang Y, Ballew SH ym. Subclinica l atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol 2015;26:439-47 «PMID: 25145930»
21. Di Angelantonio E, Danesh  J, Eiriksdottir G ym. Renal function and risk of coronary heart disease in gener al populations: new prospect ive study and systematic review. PLoS Med 2007;4:e270 «PMID: 17803353»
22. Manjunath G, Tighiouart H, Ibrahim H ym. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47-55 «PMID: 12570944»
23. Yiu KH, Mok MY, Wang S ym. Prognostic role of coronary calcification in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol 2012;30:345-50 «PMID: 22409930»
24. Romero-Díaz J, Vargas-Vóracková F, Kimura-Hayama E ym. Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology (Oxford) 2012;51:110 -9 «PMID: 22039268»
25. Ungprasert P, Charoenpo ng P, Ratanasrimetha P ym. Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol 2014;33:10 99-104 «PMID: 24859783»
26. Kim D, Choi SY, Park EH ym. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012;56:605-13 «PMID: 22271511»
27. Chen CH, Nien CK, Yang CC ym. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 2010;55:1752-60 «PMID: 19688595»
28. Ei-alkoholiperäinen rasvamaksatauti (NAFLD). Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Yleislääketieteen yhdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2020
(viitattu 26.4.2021). Saatavilla internetissä: www.kaypahoito.fi
29. Strausz S, Havulinna  AS, Tuomi T, ym. Obstructive sleep apnoea and the risk for coronary heart disease and type 2 diabetes: a longitudinal population-based study in Finland. BMJ Open 2018;8(10):e022752 «PMID: 30327404»
30. Depressio . Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Psykiatriyhdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2021 (viitattu 26.4.2021). Saatavilla internetissä:
www.kaypahoito.fi
31. Kotseva K, De Backer G, De Bacquer D ym. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.
Eur J Prev Cardiol 2019;26:824-835 «PMID: 30739508»
32. De Backer G, Jankowski P, Kotseva K ym. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019;285:135 -146 «PMID:
31054483»
33. Ferrannini G, De Bacquer D, De Backer G ym. Screening  for Glucose Perturbations and Risk Factor Management in Dysglycem ic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement:
A Report From ESC EORP EUROASPIRE V. Diabetes Care 2020;43:726-733 «PMID: 32079627»
34. Dibben G, Faulkner J, Oldridge N ym. Exercise- based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2021;11:CD 001800 «PMID: 34741536»
35. Sepel valtimotautipotilaan liikunnallinen kuntoutus. Hyvä fysioterapiakäytäntö. Suomen Fysioterapeutit ry:n asettama työryhmä. Suomen Fysioterapeutit – Finlands Fysioterapeuter ry 2016. Saatavilla internetissä:
www.suomenfysioterapeutit.fi
36. Willett J, Achenbach S, Pinto FJ ym. The Tobacco Endgame: Eradicating a Worsening  Epidemic A Joint Opinio n From the American Heart Association, World Heart Federation, American College of Cardiology, and the European
Society of Cardiology. J Am Coll Cardiol 2021;78:77-81 «PMID: 34052093»
37. Knuuti J, Wijns W, Saraste A ym. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-477 «PMID: 31504439»
38. Clerc OF, Fuchs TA, Stehli J ym. Non-invasive screening  for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging
2018;19:838-846 «PMID: 29452348»
39. Rozanski A, Muhlestein JB, Berman DS. Primary Prevention of CVD: The Role of Imaging Trials. JACC Cardiovasc Imaging 2017;10:304-317 «PMID: 28279378»
40. Campeau L, Corbara F, Crochet D ym. Left main coronary artery stenosis: the influence of aortocoronary bypass surgery on survival. Circulation 1978;57:1111- 5 «PMID: 305831»
41. Winther S, Schmidt SE, Mayrhofer T ym. Incorporating Coronary Calcification Into Pre-Test Assessm ent of the Likelihood of Coronary Artery Disease. J Am Coll Cardiol 2020;76:2421-2432 «PMID: 33213720»
42. Juarez-Orozco LE, Saraste A, Capodanno D ym. Impact of a decreasing  pre-test probability on the performance of diagnostic tests for coronary artery disease. Eur Heart J Cardiovasc Imaging 2019;20:1198-1207 «PMID:
30982851»
43. Winther S, Schmidt SE, Rasmussen LD ym. Validation of the European Society of Cardiology pre-test probability model for obstructive coronary artery disease. Eur Heart J 2021;42:1401-1411 «PMID: 3318 0904»
44. Piepo li MF, Hoes AW, Agewall S ym. 2016 European Guidelines on cardiovascular disease prevention in clinica l practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular
Disease Prevention in Clinica l Practice (constituted by represent atives of 10 societies and by invited experts)Developed with the specia l contribution of the European Association for Cardiovascular Prevention & Rehabilitation
(EACPR). Eur Heart J 2016;37:2315-2381 «PMID: 27222591»
45. Visser en FLJ, Mach F, Smulders YM ym. 2021 ESC Guidelines on cardiovascular disease prevention in clinica l practice. Eur Heart J 2021;42:3227-3337  «PMID: 34458905»
46. Foldyna B, Udelson JE, Karady J, ym. Pretest probability for patients with suspect ed obstructive coronary artery disease: re-evaluating Diamond-Forrester for the contemporary era and clinica l implications: insig hts from the
PROMISE trial. Eur Heart J Cardiovasc Imaging 2018;20:574-581
47. Reeh J, Therming CB, Heitmann M ym. Prediction of obstructive coronary artery disease and prognosis in patients with suspect ed stable angina. Eur Heart J 2018;40:1426-1435
48. Knuuti J, Ballo H, Juarez-Orozco LE ym. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability.
Eur Heart J 2018;39:332 2-3330  «PMID: 29850808»
49. Muhlestein JB, Lappé DL, Lima JA ym. Effect of screeni ng for coronary artery disease using  CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinica l trial. JAMA
2014;312 :2234-43 «PMID: 25402757»
50. Lu MT, Meyersohn NM, Mayrhofer T ym. Central Core Laboratory versus Site Interpretation of Coronary CT Angiography: Agreem ent and Association with Cardiovascular Events in the PROMISE Trial. Radiology 2018;287:87-95
«PMID: 29178815»
51. Lowenst ern A, Alexander KP, Hill CL ym. Age-Related Differences in the Noninv asive Evaluation for Possible Coronary Artery Disease: Insig hts From the Prospect ive Multicent er Imaging Study for Evaluation of Chest Pain
(PROMISE) Trial. JAMA Cardiol 2020;5:193-201 «PMID: 31738382»
52. Gimelli A, Achenbach S, Buechel RR ym. Strategies for radiation dose reduction in nuclear cardiology and cardiac computed tomography imaging: a report from the European Association of Cardiovascular Imaging (EACVI), the
Cardiovascular Committee of European Association of Nuclear Medicine (EANM), and the European Society of Cardiovascular Radiology (ESCR). Eur Heart J 2018;39:286-296 «PMID: 29059384»
53. Menke J, Unterberg-Buchwald C, Staab W ym. Head-to-head comparison of prospect ively triggered vs retrospect ively gated coronary computed tomography angiography: Meta-analysis of diagnostic accuracy, image quality, and
radiation dose. Am Heart J 2013;16 5:154-63.e3 «PMID: 23351817»
54. Chow BJ, Small G, Yam Y ym. Incremental prognostic value of cardiac computed tomography in coronary artery disease using  CONFIRM: COroNary computed tomography angiography evaluation for clinica l outcomes: an
InteRnational Multicent er registry. Circ Cardiovasc Imaging 2011;4:463-72 «PMID: 21730027»
55. Hulten EA, Carbonaro S, Petrillo SP ym. Prognostic value of cardiac computed tomography angiography: a systematic review and meta-analysis. J Am Coll Cardiol 2011;57:1237-47 «PMID: 21145688»
56. Maron DJ, Hochman JS, Reynolds HR ym. Initial Invasive or Conser vative Strategy for Stable Coronary Disease. N Engl J Med 2020;382:139 5-1407 «PMID: 32227755»
57. SCOT-HEART Investigators., Newby DE, Adamson PD ym. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med 2018;379:924-933 «PMID: 30145934»26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 28/31
58. Sharma A, Coles A, Sekaran NK ym. Stress Testing Versus CT Angiography in Patients With Diabetes and Suspect ed Coronary Artery Disease. J Am Coll Cardiol 2019;73:893-902 «PMID: 30819356»
59. Chow BJ, Small G, Yam Y ym. Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: results from the CONFIRM (COronary CT Angiography EvaluatioN
For Clinica l Outcomes: An InteRnational Multicent er registry) registry. Arterioscler Thromb Vasc Biol 2015;35:981-9 «PMID: 25676000»
60. Gibbons RJ, Abrams J, Chatterjee K ym. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003;10 7:149-58 «PMID: 12515758»
61. Task Force Members., Montalesco t G, Sechtem U ym. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of
Cardiology. Eur Heart J 2013;34 :2949-3003 «PMID: 23996286»
62. Sovijärvi A, Kettunen R. Kliininen rasituskoe. Kirjassa: Kardiologia. Heikkilä J, Kupari M, Airaksinen J ym. (toim.). Helsink i: Kustannus Oy Duodecim  2008:216-34
63. Laukkanen J, Nieminen T, Savonen K, Kervinen K, Poutanen T, Raatikainen P. Kliinisen rasituskokeen käyttö sydänsairauksissa . Suomen kardiologisen seuran suositus; Suom lääkäril 2016;9:633-644
64. Meina nder T, Saraste a, Porela P. Kliininen rasituskoe ahtauttavan sepel valtimotaudin toteamisessa  pienen enna kkotodennä köisyyden potilailla. Duodecim  2019;135 :2104
65. Kettunen R, Laukkanen J. Rasituskoe sepel valtimotaudin diagnostiikassa ja ennu steen arvioinnissa . Suom Lääkäril 2011;66:627-33
66. Hesse B, Tägil K, Cuocolo A ym. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging 2005;32:855-97 «PMID: 15909197»
67. Sciagrà R, Lubberink M, Hyafil F ym. EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging. Eur J Nucl Med Mol Imaging 2021;48:1040-1069 «PMID: 33135 093»
68. Hachamovitch R, Rozanski A, Shaw LJ ym. Impact of ischaemia and scar on the therapeutic benef it derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion
scint igraphy. Eur Heart J 2011;32 :1012-24 «PMID: 21258084»
69. Smulders MW, Jaarsma C, Nelemans PJ ym. Comparison of the prognostic value of negative non-invasive cardiac investigations in patients with suspect ed or known coronary artery disease-a meta-analysis. Eur Heart J Cardiovasc
Imaging 2017;18:980-987 «PMID: 28329376»
70. Shaw LJ, Berman DS, Picard MH ym. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging 2014;7:593-604 «PMID: 24925328»
71. Sicari R, Nihoyannopoulos P, Evangelista A ym. Stress echocardiography expert consensu s statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr 2008;9:415-37 «PMID:
18579481»
72. American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association ym. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011
Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American
Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine,  Society of Cardiovascular Computed
Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicia ns. J Am Coll Cardiol 2011;57:1126-66
73. Daly CA, De Stavola B, Sendon JL ym. Predicting prognosis in stable angina--results from the Euro heart survey of stable angina: prospect ive observational study. BMJ 2006;332 :262-7 «PMID: 16415069»
74. Emond M, Mock MB, Davis KB ym. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-57 «PMID: 7994804»
75. Del Buono MG, Montone RA, Camilli M ym. Coronary Microvascular Dysfunction Across the Spect rum of Cardiovascular Diseases: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;78:135 2-1371 «PMID: 34556322»
76. Stenst röm I, Maaniitty T, Uusitalo V ym. Frequency  and angiographic characteristics of coronary microvascular dysfunction in stable angina: a hybrid imaging study. Eur Heart J Cardiovasc Imaging 2017;18:1206-1213 «PMID:
28950300»
77. McNeil JJ, Nelson MR, Woods RL ym. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med 2018;379:1519-1528 «PMID: 30221595»
78. ASCEND Study Collaborative Group., Bowman L, Mafham M ym. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018;379:1529-1539 «PMID: 30146931»
79. Gaziano JM, Brotons C, Coppolecch ia R ym. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet
2018;392:1036-1046 «PMID: 30158069»
80. Giacoppo D, Matsuda Y, Fovino LN ym. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with seco nd-gener ation drug-
eluting stents: a systematic review and meta-analysis of randomized clinica l trials. Eur Heart J 2021;42:308-319 «PMID: 33284979»
81. Morrone D, Weintraub WS, Toth PP ym. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment respo nse: a pooled analysis of over 21,000 subjects from 27
clinica l trials. Atherosclerosis 2012;223:251-61 «PMID: 22410123»
82. Pandor A, Ara RM, Tumur I ym. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009;265:568-80 «PMID: 19141093»
83. Sabatine MS, Giugliano RP, Keech  AC ym. Evolocumab and Clinica l Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:1713-1722 «PMID: 28304224»
84. Schwartz GG, Steg PG, Szarek M ym. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018;379:2097-2107 «PMID: 30403574»
85. Wright RS, Ray KK, Raal FJ ym. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol 2021;77:1182-1193 «PMID: 33663735»
86. CAPRIE Steering Committee.. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet  1996;348:132 9-39 «PMID: 8918275»
87. Bhatt DL, Fox KA, Hacke W ym. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17 «PMID: 16531616»
88. Mauri L, Kereiakes DJ, Yeh RW ym. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-66 «PMID: 25399658»
89. Bonaca MP, Bhatt DL, Cohen M ym. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800 «PMID: 25773268»
90. Cassese S, Byrne RA, Tada T ym. Clinica l impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 2012;33:30 78-87
«PMID: 23091199»
91. Lopes RD, Hong H, Harskamp RE ym. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled
Trials. JAMA Cardiol 2019;4:747-755 «PMID: 31215979»
92. European Heart Rhythm Association., European Association for Cardio-Thoracic Surgery., Camm AJ ym. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the
European Society of Cardiology (ESC). Eur Heart J 2010;31:2 369-429 «PMID: 20802247»
93. Lopes RD, Hong H, Harskamp RE ym. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled
Trials. JAMA Cardiol 2019;4:747-755 «PMID: 31215979»
94. McMurray JJ, Adamopoulos S, Anker SD ym. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the
European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:17 87-847 «PMID: 22611136 »
95. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group.. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL
randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet  2002;360:752-60 «PMID: 12241832»
96. Pfeffer MA, McMurray JJ, Velazquez EJ ym. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;34 9:1893-906 «PMID: 14610160»26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 29/31
97. Cosent o F, Grant P, Aboyans V ym. , ESC Scient ific Document Group, 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-
diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), European Heart Journal 2020;2:255-323
98. Zelniker TA, Wiviott SD, Raz I ym. SGLT2 inhibitors for primary and seco ndary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet
2019;393:31- 39 «PMID: 30424892»
99. Cosent ino F, Cannon CP, Cherney DZI ym. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV
Trial. Circulation 2020;142:2205-2215 «PMID: 33026243»
100. Heidenreich  PA, McDonald KM, Hastie T ym. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281:1927-36 «PMID: 10349897»
101. Thompson PL. Should ß-blockers still be routine after myocardial infarction? Curr Opin Cardiol 2013;2 8:399-404 «PMID: 23703252»
102. Collet JP, Thiele H, Barbato E ym. 2020 ESC Guidelines for the management of acute coronary syndromes in patients present ing without persistent ST-segment elevation. Rev Esp Cardiol (Engl Ed) 2021;74:544 «PMID:
34020768»
103. Husted SE, Ohman EM. Pharmacological and emerging therapies in the treat-ment of chronic angina.Lancet 2015;386:691701
104. Laukkanen JA, Kunutsor SK. Revascularization versus medical therapy for the treatment of stable coronary artery disease: A meta-analysis of contemporary randomized controlled trials. Int J Cardiol 2021;32 4:13-21 «PMID:
33068645»
105. Navarese EP, Lansky AJ, Kereiakes DJ ym. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. Eur Heart J
2021;42:4638-4651 «PMID: 34002203»
106. Chaitman BR, Alexander KP, Cyr DD ym. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incid ence,  Prognosis, and Treatment Comparisons. Circulation 2021;143:790-804 «PMID: 33267610»
107. Neumann FJ, Sousa-Uva M, Ahlsson A ym. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165 «PMID: 30165437»
108. Tonino  PA, De Bruyne B, Pijls NH ym. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213-24 «PMID: 19144937»
109. Authors/Task Force members., Windecker S, Kolh P ym. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the
European Association for Cardio-Thoracic Surgery (EACTS)Developed with the specia l contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-619 «PMID:
25173339 »
110. Sairauspoissaolon tarpeen arviointi. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in Verkostovaliokunnan asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2019 (viitattu pp.kk.vvvv). Saatavilla
internetissä: www.kaypahoito.fi
111. Hegewald J, Wegewitz UE, Euler U ym. Interventions to support return to work for people with coronary heart disease. Cochrane Database Syst Rev 2019;3:CD 010748 «PMID: 30869157»
112. Lautamäki A, Gunn JM, Airaksinen KEJ ym. Permanent  work disability in patients =50 years old after percutaneous coronary intervention and coronary artery bypass grafting (the CRAGS study). Eur Heart J Qual Care Clin
Outcomes 2017;3:10 1-106 «PMID: 28927176»
113. Virtanen M, Lallukka T, Ervasti J ym. The joint contribution of cardiovascular disease and socioeconomic status to disability retirement: A register linkage study. Int J Cardiol 2017;230:222-227 «PMID: 28063665»
114. Aivoinfarkti ja TIA. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Neurologinen yhdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2020 (viitattu pp.kk.vvvv). Saatavilla
internetissä: www.kaypahoito.fi
115. Alaraajojen tukkiva valtimotauti. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Verisuonikirurgisen Yhdistyksen asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2021 (viitattu
pp.kk.vvvv). Saatavilla internetissä: www.kaypahoito.fi
116. Sydämen vajaatoiminta. Käypä hoito -suositus. Suomalaisen Lääkäriseura Duodecim in ja Suomen Kardiologisen Seuran asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2017 (viitattu pp.kk.vvvv). Saatavilla
internetissä: www.kaypahoito.fi
117. Eteisvärinä. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Kardiologisen Seuran asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2021 (viitattu pp.kk.vvvv). Saatavilla internetissä:
www.kaypahoito.fi
118. Uniapnea  (obstruktiivinen uniapnea  aikuisilla). Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in, Suomen Keuhkolääkäriyhdistyksen ja Suomen Unitutkimusseu ra ry:n asettama työryhmä. Helsink i: Suomalainen
Lääkäriseura Duodecim , 2021 (viitattu pp.kk.vvvv). Saatavilla internetissä: www.kaypahoito.fi
119. Ambrosetti M, Abreu A, Corrà U ym. Secondary prevention through comprehensiv e cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and
Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2020;: «PMID: 33611446»
120. Pelliccia  A, Sharma S, Gati S ym. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42:17-96 «PMID: 32860412»
121. Richards SH, Anderson L, Jenk inso n CE ym. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2017;4:CD002902 «PMID: 28452408»
122. Rusieck i L, Zdrojowy R, Gebala J ym. Sexual health in Polish elderly men with coronary artery disease: importance, expect ations, and reality. Asian J Androl 2020;22:526-531 «PMID: 31929194»
123. Dursun M, Cimen S, Sulukaya M ym. The predictive value of red cell distribution width on erectile dysfunction. Andrologia 2019;51:e1337 4 «PMID: 3134 7716»
124. Kalka D, Gebala J, Rusieck i L ym. Relation of Postexercise Reduction of Arterial Blood Pressu re and Erectile Dysfunction in Patients with Coronary Heart Disease. Am J Cardiol 2018;122:229-234 «PMID: 29751956»
125. Ghanbari Afra L, Taghadosi M, Gilasi HR. Relationship Between Ischemic Heart Disease and Sexual Satisfaction. Glob J Health Sci 2015;8:263-9 «PMID: 26234982»
Artikkelin tunnus: hoi50102 (050.102)
© 2025 Suomalainen Lääkäriseura Duodecim
Aiheeseen liittyviä suosituksia
Alaraajojen tukkiva valtimotauti
Julkaistu: Helmikuu 2021
Potilaalle
Tiivistelmä
Depressio26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 30/31
Julkaistu: Toukokuu 2024
Potilaalle
Tiivistelmä
Dyslipidemiat
Julkaistu: Joulukuu 2022
Potilaalle
Tiivistelmä
Ei-alkoholiperäinen rasvamaksatauti (NAFLD)
Julkaistu: Tammikuu 2020
Potilaalle
Tiivistelmä
Kohonnut verenpaine
Julkaistu: Syyskuu 2020
Potilaalle
Tiivistelmä
Lihavuus (lapset, nuoret ja aikuiset)
Julkaistu: Maaliskuu 2024
Potilaalle
Tiivistelmä
Lihavuus (lapset, nuoret ja aikuiset)
Julkaistu: Maaliskuu 2024
Potilaalle
Tiivistelmä
Sairauspoissaolon tarpeen arviointi
Julkaistu: Elokuu 2019
Potilaalle
Tiivistelmä
Sepelvaltimotautikohtaus
Julkaistu: Maaliskuu 2022
Potilaalle
Tiivistelmä
Sydämen vajaatoiminta
Julkaistu: Joulukuu 2023
Potilaalle
Tiivistelmä
Tupakka- ja nikotiiniriippuvuuden ehkäisy ja hoito
Julkaistu: Marraskuu 2024
Potilaalle
Tiivistelmä
Tyypin 2 diabetes
Julkaistu: Maaliskuu 2024
Potilaalle
Tiivistelmä26.2.2025 klo 21.55 Krooninen sepelvaltimo-oireyhtymä
https://www.kaypahoito.fi/hoi50102 31/31
Kuntoutusohjaus - Hoito- ja palveluketjut - pirha.fi.pdf
Kuntoutusohjaus
Kuntoutusohjauksen t avoitteena on ohjauksen ja neuv onnan
keinoin
tukea sepel valtimot autia sairast avan omahoit oa ja sy dänt erveellist en elint apojen t oteuttamist a
tukea sopeutumist a sairastumisen aiheutt amassa muuttuneessa elämäntilant eessa
tukea työ- ja t oimint akykyä sekä ar jessa p ärjäämist ä
Sydänsairaalassa kunt outussuunnitt elijoiden ant ama
kunt outusohjaus pit ää sisällään
sydänsairastuneen ja läheist en tuk emisen, ohjauksen ja neuv onnan 
yksilöllisen kunt outus- ja p alvelutarpeen ar vioinnin
kunt outuksen suunnitt elun ja kunt outumissuunnit elman laatimisen
kunt outus- ja muiden p alveluiden tiedott amisen sekä p alveluiden piir iin hak eutumisen a vust amisen
kunt outuspr osessin seurannan ja ar vioinnin
Sepel valtimot autia sairast avalle ja läheisille on er ilaisia kunt outusmahdollisuuksia, joiden t arve, mielekkyys sekä oik ea-
aikaisuus ar vioidaan y hdessä potilaan kanssa ja ohjat aan sopiv an kunt outusp alvelun piir iin. K untoutusohjaust a on
mahdollisuus saada lähi- t ai et ävastaanott opalveluna. K untoutusohjaus on potilaalle maksut onta, lähet että ei t arvita.
H y ö d y l l i si ä  l i nk k e j ä :  
K unt outusohjaus: tuk e a ja kunt outuskursseja  (Sydänsairaala)
K unt outusohjaus  (Terveysky lä)
Milloin kunt outusohjaust a?
A m m a t t i l a i se l l e
Tarvitseek o sepel valtimot autipotilas: 
kunt outust arpeen ar viointia ja suunnitt elua sekä apua sy dänkunt outukseen/sy dänkurssille hak eutumiseen?
tukea sairauden kanssa elämiseen?
lisätiet oa ja ohjaust a: sepel valtimot audist a, kunt outuksest a, palveluist a, tukit oimist a, uusissa ja
epäsel vissä tilant eissa?
yhteyshenkilö ä, joka tuk ee kunt outumisjär jestelmässä t oimimist a?
P o t i l a a l l e
kun t arvitset y ksilöllist ä lisätiet oa ja ohjaust a sairaudest a, kunt outuksest a, palveluist a, tukit oimist a, uusissa ja
epäsel vissä tilant eissa
kun haluat sel vittää millaisia p alveluja ja k einoja on omahoit osi tueksi ja/t ai toimint a- ja t yökykysi p arant amiseksi
kun t arvitset y hteyshenkilö ä kunt outumisjär jestelmässä t oimimiseen4.3.2025 klo 17.15 Kuntoutusohjaus - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/kuntoutusohjaus 2/4
Sydänkunt outuskurssit
Tarjolla on er ilaisia tuki- ja kunt outusp alveluja r iippuen potilaan tilant eest a, voima varoista ja t avoitteista.
Sydänkunt outuskurssit o vat potilaalle ja läheiselle maksutt omia.
T a m pe r e e n S y dä nsa i r a a l a n  j a  S y d ä n l i i t o n  so p e u t u m i sv a l m e n n u sk u r ssi
Pirkanmaalaisille äsk ettäin sepel valtimot autiin sairastuneille.
Viikonloppukurssilla saa sy dänt erveyteen, sairaut een ja omaan hoit oon liitt yvää tiet oa sekä tuk ea ammattilaisil ta ja
toisilta samankal taista kokeneil ta.
Voi osallistua y ksin t ai läheisen kanssa.
Kurssille hak eutuminen Sy dänsairaalan kunt outussuunnitt elijoiden kautt a.
K unt outuskurssit  (Sydänsairaala)
S y dä nl i i t o n k u r ssi t
Tavoitteena on tuk ea sairastuneen v almiuksia t äysip ainoiseen elämään muuttuneessa  elämäntilant eessa sekä
löytää h yvin vointia ja jaksamist a tuk evia k einoja.
Kurssit perustuv at vertaisuut een ja t arjoavat mahdollisuuden t avata toisia samankal taisessa elämäntilant eessa
olevia.
Kursseja jär jestetään ymp äri Suome a ja niihin v oi hak eutua asuinp aikast a riippumatt a.
Kurssille v oi tulla jok o yksin ja monille m yös läheisen kanssa. 
Sy dänliit on kurssit 
T u l pp a - r y h m ä k u nt o u t u s
Perust erveydenhuollon t oimint aa, joka on t arkoitettu kaik en ikäisille sepel valtimot autiin sairastuneille.
Kuntoutusr yhmä k okoontuu k erran viik ossa kymmenen k ertaa, jonka jälk een jär jestetään seurant atapaamiset puolen
vuoden ja vuoden kuluttua
Terveydenhuollon ammattihenkilöt, sairaanhoit aja ja fysiot erapeutti, ohjaa vat ryhmiä t erveyskeskuksissa
Ryhmässä saa ohjaust a omahoit oon, er ityisesti ra vitsemukseen ja liikunnan har rastamiseen, tuk ea ohjaajil ta
sekä sy dänsairauden it se k okeneel ta vertaisohjaajal ta
Tulpp a-kunt outuksella on m yös digit aalinen v aihtoeht o, joka on osana T erveysky län Omapolku –v erkkopalvelua.
Tulpp a-verkkovalmennus ei ole vielä kä ytössä Pir han alueella.
T ulpp a-kunt outus (Sydänliitt o)
K e l a n a i k u i st e n sy dä nk u n t o u t u sk u r ssi t
Kela jär jestää kunt outus- ja sopeutumisv almennuskursseja sy dänsairautt a sairast aville, t yöelämässä t ai työelämän
ulkopuolille ole ville
Kuntoutus t oteutuu r yhmäkunt outuksena, jossa huomioidaan kunt outujan y ksilöllinen kunt outust arve- ja t avoite.
Kurssi sisäl tää ryhmäk eskust elujen ja pienr yhmät yöskentelyn lisäksi monipuolist a toimint aa sekä
kunt outusasiantuntijoiden kanssa t apahtuvia y ksilöllisiä t apaamisia.
Aikuist en sy dänkunt outuskurssi k oostuu 3 x 5 vr k jaksoist a noin vuoden aikana. K ursseja jär jestetään
kunt outuslait oksissa er ipuolilla Suome a
Kuntoutust a voi hak ea Kelan lomakk eella KU132. Lisäksi t arvitaan lääkär in laatima B-lausunt o kunt outust a varten.
Työelämässä ole vat (16- 67v) v oivat hak ea kunt outuksen ajal ta kunt outusrahaa K elast a.
Sy dänkunt outuskurssi aikuiselle  (Kela)
Edellinen
Fysiot erapeutin ohjausSeur aa v a
Psykososiaalinen tuki
Päivit etty 26 .11.202 44.3.2025 klo 17.15 Kuntoutusohjaus - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/kuntoutusohjaus 3/4
Lihasvoimaharjoittelu-ja-sepelvaltimotauti-Sydänsairaala.pdf
 Potilasohje  
 SKOY PO0075  1 (2) 
  19.11.2018   
 
 
TAYS Sydän sairaala  Oy  www.s ydan sairaala .fi 
 
 
 
Lihasvoimaharjoittelu on kestävyysliikunnan ohella tärkeä osa sepelvaltimotaudin hoitoa. Lihasvoimaha r-
joittelulla voit parantaa valtimoiden sisäkalvon toimintaa , vaikuttaa positiivisesti kehonkoostumukseen,  
sokeriaineenvaihdun taan, veren kolesteroliarvoihin ja  perusaineenvaihduntaan . Lihasvoimaharjoittelu on 
turvallista.  
 
 tavoitteena 2–3 kertaa viikossa  
 tärkeintä suorituskyvyn ylläpitämisen tai parantamisen kannalta on harjoittaa isoja lihasryhmiä  
 pidä harjoitteet dynaamisina – vältä staattista lihasjännitystä vaativia liikkeitä  
 tee eri kehon osia kuormittavia harjoituksia vuorotellen  
 
Alku- ja loppuverryttely  
Alkulämmittelyssä sydämen syke ja verenpaine kohoavat vähitellen, hengitys tehostuu ja sydän valmi s-
tautuu tulevaan rasitukseen. Tee 5 –15min alkulämmittely esim. kävelymatolla tai kuntopyörällä ennen 
lihasvoimaharjoittelua . 
 
Lopeta harjoittelu rauhallisesti jäähdytellen ja t ee palauttavat venytykset. Tällöin sydämen syke ja vere n-
paine palautuvat vähitellen ja hengitys rauhoittuu.  
 
Lihasvoimaharjoittelu  
Lihasvoimaharjoittelua aloiteltaessa ensimmäisten viikkojen aikana tavoitteena on harjoitteluun totuttelu. 
Aloittelijalle s opiva harjoituskerta määrä on 1 –2 kertaa viikossa. Harjoitusvastus on sopiva kun jaksat 
tehdä 15–20 toistoa. Tee toistoja yksi sarja. Pidä sarjojen välissä 1 –2 min tauko. Aloittelijalle sopiva ras i-
tustaso on hyvin kevyt  – kevyt (Borg 10, asteikolla 6 –20) Voit opetella arvioimaan liikkumisen rasittavuu t-
ta oheisen taulukon avulla.   
 
Jos olet aiemmin tehnyt säännöllistä lihasvoimaharjoittelua tai edistyessäsi (4 –6 viikon  harjoittelun jä l-
keen), rasitustasoa voi nostaa kevyelle – hieman rasittavalle tasolle (Borg  12). Tee kaksi sarjaa.  
 
Lihasvoimaharjoittelun tulee olla asteittain kehittyvää. Säännöllisen harjoittelun aloittamisen jälkeen su o-
situstasolle eteneminen vie kuusi kuukautta. Lisää vastusta ja harjo ittelukertoja. Tavoitteena on 2 –3 har-
joituskertaa viikos sa ja rasitustasoa voi nostaa korkeintaan rasittavalle tasolle (Borg 14–16).  
 
Turvallisen ja tehokkaan harjoittelun pohjana on omien rasitustuntemusten ja oireiden tunnistaminen.  
 
 
 
1–3 sarjaa jokaista harjoitusta  
10–15 toistoa sarjassa  
8–10 harjoitetta kerralla  
harjoitteiden välissä 1 –2 min lepotauko  
 
 Lihasvoimaharjoittelu ja sepelvaltimotauti   
 Potilasohje  
 SKOY PO0075  2 (2) 
  19.11.2018   
 
 
TAYS Sydän sairaala  Oy  www.s ydan sairaala .fi 
 
 
 
 

Lihavuus on sydän- ja verisuonisairauksien riskitekijä - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Oletko kiinnostunut toimimaan vapaaehtoisena? Lue lisää Sydänliiton vapaaehtoistoiminnasta.
(https://sydan.fi/tule-mukaan/tule-vapaaehtoiseksi/)
Etusivu (https://sydan.fi/)/Terveys & Hyvinvointi (https://sydan.fi/terveys-hyvinvointi/)/
Lihavuus on sydän- ja verisuonisairauksien riskitekijä
Lihavuus on sydän- ja verisuonisairauksien
riskitekijä (https://sydan.fi/fakta/lihavuus-
on-sydan-ja-verisuonisairauksien-riskitekija/)
Lihavuudella tarkoitetaan ylimääräisen rasvakudoksen kertymistä kehon eri
osiin. Terveyden kannalta haitallista on vyötärölihavuus: vatsaonteloon
kertynyt liikarasva lisää sydän- ja verisuonisairauksien riskiä.
Kuva: Anna Kara
Tuija Pusa, Asiantuntija, ravitsemus ja elintapamuutoksen tuki
Julkaistu 22.8.2018
Päivitetty 6.3.2023
 
Lue seuraavaksi Vinkkejä painonhallintaan (https://sydan.fi/fakta/vinkkeja-painonhallintaan/)
Lihavuus vaikuttaa useimmilla ennen pitkää epäedullisesti verenpaineeseen,
rasva-aineenvaihduntaan, veren hyytymistekijöihin ja elimistön
tulehdusreaktioihin. Liikunnalla ja terveellisellä ruokavaliolla voidaan vaikuttaa
ehkäisevästi eri riskitekijöihin. Laihduttaminen vähentää sairastumisriskiä, mutta
usein jo pelkällä elintapojen muutoksilla ilman laihtumista on myönteisiä
vaikutuksia.
Lihavuuden astetta mitataan terveydenhuollossa painoindeksillä ja
vyötärönympäryksellä. Painoindeksi ja vyötärönympärys ovat usein riittäviä
toisiaan täydentäviä mittareita. Terveydenhuollossa on käytössä tarkempia
mittausmenetelmiä, joilla voidaan arvioida liikarasvan määrää ja sijaintia.
Painoindeksi ja vyötärönympärys
Painoindeksin voi helposti määrittää laskurin
(https://sydan.fi/fakta/painoindeksi/) avulla. Testin tulosta voi verrata oheiseen
taulukkoon. Taulukon arvot on tarkoitettu työikäisiä aikuisia koskeviksi.
Esimerkiksi painoindeksi 28 tarkoittaa, että henkilö on ylipainoinen.
Painoindeksin määritelmät aikuisille (Lihavuus (lapset, nuoret ja aikuiset). Käypä
hoito -suositus. Duodecim, 2021 (https://www.kaypahoito.fi/hoi50124))
Painoindeksi (BMI, kg/m) Painon luokitus
18,5-24,9 normaali paino
25-29,9 liikapaino (=ylipaino)
30-34,9 lihavuus
35-39,9 vaikea lihavuus
40 tai yli sairaalloinen lihavuus
Painoindeksi soveltuu valtaosalle ihmisistä painon määrittämiseen. Poikkeuksen
muodostaa hyvin lihaksikkaiden ihmisten painon määritys, sillä painoindeksiä
laskettaessa ei tehdä eroa lihas- tai rasvakudoksen välillä. Tällöin saadaan
virheellinen tulos, jonka mukaan henkilö on ylipainoinen, vaikka kyse olisikin
lihaksikkuudesta.
Vyötärönympärysmitta
Vyötärönympäryksen (https://sydan.fi/fakta/painoindeksi/) mittaaminen on
tehokas rasvakudoksen sijainnin selvittäjä. Vatsaonteloon kertyvällä rasvalla on
todettu selvä yhteys lisääntyneeseen sydän- ja verisuonitautien vaaraan sekä
tyypin 2 diabetekseen.2Lue seuraavaksi Vinkkejä painonhallintaan (https://sydan.fi/fakta/vinkkeja-painonhallintaan/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Vatsaonteloon kertyvä rasva on aineenvaihdunnallisesti aktiivisempaa kuin
lantiolle ja reisiin kertyvä rasva. Se on siten vaarallisempaa terveydelle, mutta
myös helpommin laihdutettavissa. Mittanauha on hyvä väline rasvakudoksen
sijainnin selvittämisessä ja sairastumisriskin arvioinnissa.
On hyvä kuitenkin muistaa, että suurentunut vyötärönympärys on yksi monista
vaaratekijöistä. Sairastumisvaaraa arvioidessaan lääkäri ottaa huomioon myös
muut vaaratekijät, joita ovat kohonnut verenpaine, suurentuneet veren rasva-
arvot ja häiriytynyt sokeriaineenvaihdunta.
Miten vyötärönympärys mitataan?
Vyötärönympärys mitataan 1 – 2 cm navan yläpuolelta paljaalta iholta.
Mittanauhan tulee olla vaakasuorassa eli yhtä korkealla edestä, takaa ja sivuilta.
Mitattaessa painon tulee olla tasan molemmilla jaloilla. Ensin hengitetään sisään
ja sitten ulos ja mittanauhan lukema katsotaan uloshengityksen lopuksi.
Mittanauha ei saa mitattaessa kiristää eikä olla liian löysällä.
Vyötärön ympärysmitta ja lihavuuteen liittyvät terveyshaitat (Lihavuus (lapset,
nuoret ja aikuiset). Käypä hoito -suositus. Duodecim, 2021
(https://www.kaypahoito.fi/hoi50124))
Vyötärön
ympärysmitta
(cm)TavoitearvoLievä
terveyshaittaHuomattava terveyshaitta
Miehet < 94 94-101 > 102
Naiset < 80 80-87 > 88
Ei lihavuuteen
liittyvää
sairastumisvaaraaVältä painon
nousua tai
pudota painoaPainoa tulisi pudottaa. Hae
terveydenhuollon
ammattilaisen apua painon
alentamiseen
Ylipainosta tasapainoon
Kevyen olon ja terveyden kannalta sopivan painon saavuttaminen ei onnistu
hetkessä, eikä sen tarvitsekaan. Hitaasti elämäntapojen muutoksella saavutettu
laihdutustulos on yleensä pysyvämpi kuin kertarysäyksellä saavutettu. Omien
ruokailu- ja liikuntatottumusten muuttaminen vaatii voimavaroja, mutta on
mielenkiintoista ja innostavaa: on hienoa huomata, kuinka pienillä päätöksillä olo
paranee ja samalla paino mahdollisesti laskee.Lue seuraavaksi Vinkkejä painonhallintaan (https://sydan.fi/fakta/vinkkeja-painonhallintaan/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Lihavuus lisää veren ” pahan ”  eli LDL-kolesterolin pitoisuutta ja samalla vähentää
”hyvän ”  eli HDL-kolesterolin määrää. Lihavuuden vaikutus on yksilöllinen, mutta
ylipainon laihduttaminen korjaa sekä LDL-kolesterolin että HDL-kolesterolin
määrää veressä. Samat elämäntapamuutokset sopivat painonhallintaan ja
kolesterolin (https://sydan.fi/fakta/kolesteroli-kohdalleen/) alentamiseen.
Maltillinen laihdutus
Hitaassa painonpudotuksessa on se etu, että pääpaino ei ole kilojen tarkkailussa.
Alusta alkaen tähdätään pysyvään ruokavalio- ja liikuntatottumusten
muutokseen. Samalla ruokavalio pysyy monipuolisena ja säilytetään kallisarvoista
lihasmassaa. Ruokatottumusten muutos vaati harjoitteluaikansa. Kaikkea ei voi
muuttaa kerralla. Anna aikaa itsellesi.
Dieettien heikkoutena on usein yksipuolisuus. Dieettien laihduttava vaikutus
perustuu yksinomaan niiden vähäiseen energiasisältöön. Tällaisia dieettejä ei voi
– eikä jaksa –  noudattaa terveyttään vaarantamatta paria viikkoa kauempaa.
Myös laihdutuksen aikana ruoasta tulisi saada riittävästi vitamiineja ja
kivennäisaineita. Dieetit eivät myöskään ohjaa pysyviin ruokatottumusten
muutoksiin. Ne eroavat paljon tavallisesta ruoasta eivätkä sovi pysyväksi
ravinnoksi. Useimmiten dieetin jälkeen palataan entisiin ruokailutottumuksiin.
Pettymys on suuri painon noustessa uudelleen.
Uuteen hoikempaan olemukseen tottuminenkin vie aikansa. Elimistön, mutta
myös silmien tulisi ehtiä totuttautua rauhassa.
Diabetes ja ylipaino
Jatkuvasti yleistyvä ylipainon kertyminen keskivartaloon vatsan alueelle on
seurantatutkimuksissa osoittautunut merkittäväksi tyypin 2 diabeteksen,
sydäninfarktien ja aivohalvausten vaaratekijäksi.
Näkyvin vaaran merkki on suurentunut vyötärönympärys, minkä seurauksena
verenpaine kohoaa ja voidaan havaita häiriöitä sekä sokeri- että rasva-
aineenvaihdunnassa.
Sekä sepelvaltimotaudin että tyypin 2 diabeteksen kehittymisen taustalla ovat
elintavat, mutta myös geneettiset tekijät, jotka altistavat toiset muita
herkemmin huonojen elintapojen epäedullisille vaikutuksille. Elintavat
vaikuttavat tunnettujen riskitekijöiden välityksellä. Tärkeä ehkäistävissä oleva
välivaihe on vyötärölihavuus ja siihen kytköksissä oleva metabolinen oireyhtymä
(MBO).Lue seuraavaksi Vinkkejä painonhallintaan (https://sydan.fi/fakta/vinkkeja-painonhallintaan/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Liikunnan hyödyt sydämelle ja verenkierrolle - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Sairastuneen liikunta (https://sydan.fi/elamaa-sairauden-kanssa/sairastuneen-liikunta/)/
Liikunnan hyödyt sydämelle ja verenkierrolle
Liikunna n hyödyt sydämelle ja verenkierrolle
Jos sinulla on korkea verenpaine, kolesteroliarvot koholla, ylipainoa, stressiä
tai verensokeri koholla, liikunnasta voi olla apua näihin kaikkiin.
Kuva: Sydänmerkki
Annukka Alapappila ja Paula Mannonen
Julkaistu 31.8.2018
Päivitetty 5.8.2019
 
Lue seuraavaksi Kestävyys, voima ja liikehallinta ovat kunnon kolme aluetta –  tärkeitä myös sydänsairaalle
(https://sydan.fi/fakta/kestavyys-voima-ja-liikehallinta/)

Tulosten saavuttaminen edellyttää, että liikkuminen on säännöllistä ja että se
nostaa jonkin verran sydämen sykettä.
Säännöllinen ja kohtuullisen ripeä liikunta
alentaa verenpainetta (https://sydan.fi/fact/kohonnut-verenpaine/)
lisää valtimoita suojaavan HDL-kolesterolin ja vähentää ahtaumia lisäävien
LDL-kolesterolin ja triglyseridien pitoisuutta
(https://sydan.fi/fact/kolesteroli-ja-triglyseridiarvot/) veressä
parantaa sokeritasapainoa lisäämällä elimistön insuliiniherkkyyttä ja
laskemalla verensokeria
parantaa elimistön kykyä käyttää rasvaa energialähteenä
laskee sykettä ja kasvattaa sydänlihaksen voimaa ja kestävyyttä
rentouttaa, parantaa mielialaa ja helpottaa masennuksen oireita. Nämä
vaikutukset edellyttävät, että etsii sellaiset liikkumisen tavat, joista pitää.
vähentää stressihormoneiden tuotantoa ja parantaa unen laatua
kiinteyttää ja auttaa pitämään painon kurissa.
parantaa elimistön hapensaantia ja sydämen verenkiertoa
pitää kunnossa lihaksia, tasapainoa ja toimintakykyä
vilkastaa aineenvaihduntaa ja ehkäisee ummetusta
Hyvät vaikutukset eivät rajoitu sydämen ja verisuonten tilan paranemiseen,
vaan liikunta ehkäisee myös syöpää, kakkostyypin diabetesta ja monia muita
kroonisia sairauksia.
 
Lue myös Vinkkejä stressin ja kielteisten tunteiden hallintaan
(https://sydan.fi/fact/vinkkeja-stressin-ja-kielteisten-tunteiden-hallintaan/)ja
Riittävästi unta ja lepoa (https://sydan.fi/fact/riittavasti-unta-ja-lepoa/)Lue seuraavaksi Kestävyys, voima ja liikehallinta ovat kunnon kolme aluetta –  tärkeitä myös sydänsairaalle
(https://sydan.fi/fakta/kestavyys-voima-ja-liikehallinta/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Liikunta sydäninfarktin jälkeen - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Oletko kiinnostunut toimimaan vapaaehtoisena? Lue lisää Sydänliiton vapaaehtoistoiminnasta.
(https://sydan.fi/tule-mukaan/tule-vapaaehtoiseksi/)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Sairastuneen liikunta (https://sydan.fi/elamaa-sairauden-kanssa/sairastuneen-liikunta/)/Liikunta sydäninfarktin jälkeen
Liikunta sydäninfarktin jälkeen
(https://sydan.fi/fakta/liikunta-
sydaninfarktin-jalkeen/)
Liikunta on olennainen osa kuntoutumista. Säännöllisellä liikunnalla on
hyvä mahdollisuus vaikuttaa sepelvaltimotautiin. Sydänlihaksen on
kuitenkin annettava toipua infarktista, ja siksi tulee muistaa muutamaLuet tällä hetkellä Liikunta sydäninfarktin jälkeen Lue seuraavaksi Liikunta ja synnynnäiset sydänviat
(https://sydan.fi/fakta/liikunta-ja-synnynnaiset-sydanviat/)

seikka liikunnasta toipumisen aikana. Valtimopistoskohta paranee parissa
viikossa eikä se sen jälkeen enää rajoita liikuntaa.
Annukka Alapappila, Liikunta-asiantuntija
Julkaistu 30.8.2018
Päivitetty 7.2.2023Jaa sivu 
Ensimmäiset viikot kotonaLuet tällä hetkellä Liikunta sydäninfarktin jälkeen Lue seuraavaksi Liikunta ja synnynnäiset sydänviat
(https://sydan.fi/fakta/liikunta-ja-synnynnaiset-sydanviat/)

Arki kotona on hyvä aloittaa kevyillä kotitöillä ja kevyesti liikkuen. Kävelylle voi
lähteä heti. Aluksi riittää 10 – 15 minuutin kävely useamman kerran päivässä.
Kannattaa muistaa, että oireet, kuten rintakipu ja hengenahdistus, eivät kuulu
liikuntaan. Liikunnan aikana ja sen jälkeen tulee olla hyvä olo. Vähitellen liikunnan
pitäisi tuntua selvästi helpommalta kuin kotiutuessa sairaalasta.
Lisää liikuntaa asteittain
Päivittäistä liikuntaa on hyvä lisätä sitä mukaan, kun toipuminen edistyy ja kunto
kohenee. Liikunnan avulla oppii tuntemaan oman voinnin ja saa tietoa toipumisen
edistymisestä. Kun liikunta tuntuu helpolta ja kevyeltä eikä oireita ilmene,
liikuntakertojen määrää voi lisätä, sitten pidentää aikaa ja lopuksi lisätä vauhtia.
Kävely tai pyöräily tai muuten liikkuminen hieman rasittavasti ja liikkumisen
monipuolistaminen esimerkiksi liikkumalla vaihtelevassa maastossa on sallittua.
Kunnon kasvaessa onkin hyvä pidentää liikunnan kestoa vähitellen 30-60
minuuttiin päivässä.
Tämä teksti sisältää yleisiä ohjeita liikuntaan sydäninfarktin jälkeen toipumisen
ajaksi. Jos lääkäri tai fysioterapeutti on antanut erityisiä ohjeita, niitä tulee
noudattaa.
Toipuminen kestää infarktin laajuudesta riippuen 2 – 8 viikkoa. Kun toipuminen
sydäninfarktista alkaa olla takana ja liikkuminen sujuu mukavasti, kannattaa
tutusta Sepelvaltimotautia sairastavan liikunta –  ohjeistukseen
(https://sydan.fi/fakta/sepelvaltimotautia-sairastavan-liikunta/).Luet tällä hetkellä Liikunta sydäninfarktin jälkeen Lue seuraavaksi Liikunta ja synnynnäiset sydänviat
(https://sydan.fi/fakta/liikunta-ja-synnynnaiset-sydanviat/)
Liikuntaohje-sydäninfarktin-jälkeen-Sydänsairaala.pdf
 Potilasohje  
 SKOY PO0074  1 (2) 
  11.12.2018   
 
 
TAYS Sydänsairaala  Oy  www.sydansairaala .fi 
 
 
 
Kotiutumisen jälkeen  
Toipilasvaihe sydäninfarktin  jälkeen kestää noin kuukauden.  Liikunta edistää toipumista sydäni n-
farktista, joten jatka itsenäistä  liikuntaa saamiesi ohjeiden mukaan. Säännöllinen liikunta on jat-
kossa osa sepelvaltimotaudin oma hoitoa.  
 
 
 Aluksi liikunnan tul ee olla rasittavuudeltaan  kevyttä , jotta sydän saa aikaa toipua.  Voit 
opetella arvioimaan liikkumisen rasittavuutta oheisen taulukon avulla.  
 Suositeltavin liikuntamuoto on kävely. Kävelyä on helppo tauottaa sekä säädellä tunt e-
mustesi mukaan.  
 Liiku toipilasvaiheessa mieluummin useita kertoja päivässä kuin pitkään samalla kerralla.  
Aluksi riittää 10 –15 min kävely us eamman kerran päivässä.  
 Sovita  päivittäinen kävely omaan toimintakykyysi ja arkeesi.  
 Aloita kävelylenkit rauhallisesti tai tee edeltävästi kevyitä verryttelyliikkeitä. Alkulämmitt e-
lyssä sydän valmistautu u tulevaan kuormitukseen  ja liikunta tuntuu miellyttävämmältä.  
 Päätä liikunta jäähdytellen tai tekemällä kevyitä venyttelyliikkeitä.  
 Ensimmäisinä viikkoina syke saa nousta n. 20–30 lyöntiä leposykkeestä. Mittaa leposyke 
seisten ennen liikkeelle lähtöä.  
 
 Kevyitä k otitöitä voit tehdä heti sairaalasta kotiutumisen jälkeen.  
 Vältä ensimmäisinä viikkoina raskaita , sydäntä kuormittavia töitä. Tällaisia ovat mm. pa i-
navat nostot,  kantaminen sekä pitkään kädet koholla työskentely.  
 
Toipumisen edetessä (n.  2 viikos ta eteenpäin)  
 Lisää rasittavuutta vähitellen matkaa pidentämällä ja kävelemällä vaihtelevassa maasto s-
sa. Voit lisätä myös vauhtia.  
 Liikunta saa tuntua hieman rasittavalta ja myöhemmin rasittavaltakin.  
 Hengitys on hyvä liikunnan rasittavuuden  mittari. Liikkuessa saa hengästyä, mutta heng i-
tys ei saa muuttua puuskuttavaksi tai ahdistavaksi.  
 Tavoitteena on palata liikuntaharrastuksiin tai aloittaa säännöllinen kuntoliikunta. Ras-
kaampiin koti - ja piha töihin voit palata vähitellen toipumisen edetes sä.  
 
 Liikuntaohje sydäninfarktin jälkeen  
 Potilasohje  
 SKOY PO0074  2 (2) 
  11.12.2018   
 
 
TAYS Sydänsairaala  Oy  www.sydansairaala .fi 
 
Liiku turvallisesti  
 Pidä noin tunnin tauko ruokailun tai sydänlääkkeiden oton jälkeen .  
 Vältä rintatuntemuksia aiheuttavaa fyysistä kuormitusta.  
 Pidä nitrovalmiste mukana. Jos tunnet rasituksen yhteydessä rintakipua tai hengenahdi s-
tusta, hi dasta  vauhtia tai  pysähdy ja ota nitrovalmistetta. Mikäli oire ei mene ohitse  5 mi-
nuutissa, soita 112.  
 Keven nä liikuntaa kovalla tuulella, pakkasella ja  helte ellä. 
 Vältä rasitusta  jos olet sairas,  huonovointinen  tai henkisesti kuormittunut.  
 
 
 
 
 
 
 
 
 
 
  

Lääkeyliherkkyys - Terveyskirjasto.pdf
Lue artikkeli:
Terveyskirjasto.fi
Lääkeyliherkkyys
Lääkärikirja Duodecim
7.10.2024
Ihotautien ja allergologian erikoislääkäri Maria Lönnrot
Keskeistä
Lääkeyliherkkyys ilmenee
useimmiten ihottumana.
Yleisimmät aiheuttajat ovat
mikrobilääkkeet,
tulehduskipulääkkeet,
epilepsialääkkeet ja
syöpätautilääkkeet.
Infektiot voivat aiheuttaa
samanlaista ihottumaa kuin
lääkkeet.
Lievät lääkkeen aiheuttamiksi
epäillyt reaktiot eivät vaadi
välitöntä lääkärin arviota tai
jatkotutkimuksia.
Lääkeyliherkkyyden
mekanismi ja oireet
Lääkeyliherkkyyden syntymekanismi voi olla
joko immunologinen (allerginen) tai ei-
immunologinen (ei-allerginen). Allergiset
lääkeyliherkkyysreaktiot toistuvat aina jos
potilas saa lääkettä, jolle on allergisoitunut.
Ei-allergiset reaktiot eivät välttämättä aina
toistu. Periaatteessa mikä tahansa lääke voi
aiheuttaa yliherkkyysreaktion, mutta
tavallisimmin sitä aiheuttavat
mikrobilääkkeet, tulehduskipulääkkeet,
epilepsialääkkeet ja syöpälääkkeet. Lääkkeentunnettuun vaikutusmekanismiin liittyvät
haittavaikutukset eivät ole yliherkkyyttä:
esimerkiksi antibioottihoito voi
antibakteerisen vaikutuksensa myötä
sekoittaa suoliston bakteeritasapainoa. Tästä
aiheutuvat suolisto-oireet eivät ole
lääkeyliherkkyyttä.
Lääkeyliherkkyyden oirekuvaan kuuluu
lähes aina jonkinlainen ihottuma, ja
vaikeammissa reaktioissa on mukana myös
yleisoireita, kuten kuumetta, nivelkipuja tai
yleistä sairauden tunnetta. Samanlainen
ihottuma voi syntyä lääkkeen tai jonkin
muun tekijän aiheuttamana. Esimerkiksi
infektion ja sen hoitoon käytetyn
antibioottikuurin aikana ilmaantuva
ihottuma voi olla yhtä hyvin infektion kuin
antibiootin laukaisema. Vain harvoin,
esimerkiksi verenkuvamuutoksina
esiintyvissä lääkereaktioissa, iho ei
välttämättä oireile mitenkään.
Lääkeyliherkkyys voi ilmentyä varsin
monentyyppisenä ihottumana (mm.
eksanteema, ekseema, nokkosihottuma,
monimuotoinen punavihoittuma, purppura,
punahukka, punajäkälä, erilaiset iho-
oireyhtymät), joista vain muutama kuvataan
tarkemmin tässä artikkelissa. Sama lääke
voi aiheuttaa eri ihmisille erilaisen
ihottuman.
Yleisin lääkeyliherkkyyden oire on
rokkoihottuma (eksanteema), jossa laajat
ihoalueet ovat punakirjavan, kutiavan
ihottuman peitossa (kuva 1). Ihottuma alkaa
päivien tai vasta muutaman viikon kuluttua
lääkkeen aloituksesta. Ihottuman
parantuminen on hidasta: lääkkeen
lopettamisen jälkeen ihottuman
parantumiseen menee vähintään muutama
päivä, joskus useampi viikko.
Kuva 1. Eksanteema.  Lääkeainea llergia
sisäisest i nautitulle lääkkeelle ilmenee iholla
usein eksanteem ana. Ihoreaktion ulkonäöstä
ei voi päätellä aiheuttavaa lääkettä. Kuva: R.
Suhonen.
Toiseksi yleisin lääkeyliherkkyyden oire on
nokkosihottuma . Nokkosihottuman
liitännäisoireena voi esiintyä ihon tai
limakalvojen voimakasta paikallista
turvotusta eli angioedeemaa . Jos
nokkosihottuman aiheuttaja on lääkeaine,
on kyseessä niin sanottu välitön
yliherkkyysreaktio, jolloin iho-oire alkaa
yleensä jo tunnin kuluessa lääkehoidon
aloituksesta. Reaktion taustalla on usein
IgE-vasta-ainevälitteinen allergia
lääkeaineelle. Voimakkaaseen IgE-
välitteiseen lääkeallergiaan liittyy
anafylaktisen reaktion  riski. Lääkkeet voivat
aiheuttaa nokkosihottumaa ja angioedeemaa
myös ilman IgE-välitteistä allergiaa. Näitä
ei-allergisia yliherkkyysreaktioita voivat
aiheuttaa muun muassatulehduskipulääkkeet, opioidikipulääkkeet
(esim. kodeiini) ja röntgenvarjoaineet.
Jos angioedeema esiintyy ilman
nokkosihottumaa, tulee huomioida
verenpainelääkkeisiin liittyvän
yliherkkyyden mahdollisuus: pienellä osalla
potilaista ACE-estäjät (lääkeaineen nimessä
pääte -priili) ja angiotensiinireseptorin
salpaajat (pääte -sartaani) laukaisevat
angioedeemaa, joka ilmenee satunnaisesti,
joskus vain muutaman kerran vuodessa.
Turvotusoire alkaa tyypillisesti muutaman
viikon kuluttua lääkkeen aloituksen jälkeen,
mutta se saattaa alkaa vasta kuukausien tai
jopa vuosien viiveellä. Angioedeema on
tavallisinta pään alueella, jossa esimerkiksi
huuli, poski tai silmäluomi turpoaa
voimakkaasti 1–3 vuorokauden ajaksi.
Turvotus paikantuu harvoin
hengenvaarallisesti nielun alueelle, mutta
tämän mahdollisuuden vuoksi
angioedeemaa laukaiseva lääke tulee
lopettaa. Jos tarvitaan korvaavaa lääkettä,
se valitaan muista verenpainelääkeryhmistä.
Lääkeihottumassa on joskus myös
rakkuloita. Monimuotoinen punavihoittuma
(erythema multiforme)  oirehtii 1–2 cm:n
läpimittaisina läiskinä, joissa erottuu pari
sisäkkäistä punakkaa rinkulaa kuin
maalitaulussa. Läiskän keskustaan voi
kehittyä kudosnestettä sisältävä rakkula.
Toistopunoittuma (erythema fixum) tekee
iholle tai limakalvolle äkäisen punakan
ihottumaläiskän, joka sekin saattaa
rakkuloida (kuva 2). Läiskiä on tavallisesti
aluksi vain yksi, ja läiskä toistuu
aiheuttajalääkettä käytettäessä aina
tismalleen samassa ihokohdassa. Ajan
myötä lääkkeen käytön jatkuessa läiskien
määrä lisääntyy ja oirekuva voimistuu.
Parantuneesta toistopunoittumasta jää
herkästi ihoon rusehtava pigmenttiläiskä,
joka haalistuu ja häviää kuukausien
kuluessa.
Kuva 2. Erythema fixum. Toistopunoitus,
erythema fixum (fixed drug eruption), on
sisäisen lääkkeen aiheuttama
erikoislaatuinen allerginen reaktio.
Särkylääkkeet ja antibiootit ovat
tavallisim pia syitä noin 5–6 tunnissa
lääkkeen nauttimisest a aina samalle
kohdalle syntyvään reaktioon, joka jättää
sammuttuaan pitkäkestoisen
pigmenttijäljen. Laikkuja voi olla yksi tai
useampi.
On olemassa myös harvinaisempia ja
vakavampia lääkkeiden laukaisemia
reaktioita. Näistä esimerkiksi Stevens–
Johnsonin oireyhtymään ja harvinaiseen
TEN-lääkereaktioon (toksinen
epidermaalinen nekrolyysi) liittyy äkäisen
punakoita ihottumaläiskiä, ihon ja
limakalvojen rakkulointia, ihon pinnallista
kuoriutumista ja yleisoireita. Nämä vaikeat
lääkereaktiot vaativat sairaalahoitoa, TEN
jopa tehohoitoa ihon laaja-alaisen
kuoriutumisen vuoksi. Muita esimerkkejä
vaikeista, mutta melko harvinaisista
lääkkeiden aiheuttamista iho-oireyhtymistä
ovat AGEP (akuutti generalisoitunut
eksantematoottinen pustuloosi) ja DRESS(drug reaction with eosinophilia and
systemic symptoms).
Lääkeyliherkkyyden hoito
Lievät ihottumaoireet eivät vaadi
hakeutumista lääkärin vastaanotolle
ihottumaa näyttämään, vaikka aiheuttajaksi
epäiltäisiin lääkettä. Näissä tilanteissa voi
tiedustella kiireettömästi toimintaohjeita
lääkettä määränneeltä taholta tai omalta
terveysasemalta. Ihottumasta kannattaa
ottaa valokuvia, joita voi näyttää lääkärille,
kun ihottuman syytä ja lääkehoidon jatkoa
jatkossa pohditaan.
Jos kuitenkin oirekuva on voimakas
(esim. voimakkaasti punoittava ihottuma
laaja-alaisesti iholla tai runsaasti
rakkuloita/ihorikkeymiä) tai jos siihen
liittyy kuumetta ja yleistä sairauden
tunnetta, on lääkärin arvio tarpeen
pikaisemmin. Anafylaktisen reaktion
vaatima välitön ensihoito on kuvattu
erikseen. Muiden vaikeiden lääkereaktioiden
kohdalla lääkärin arvio on hyvä tehdä
oirekuvan voimakkuudesta riippuen 1–3
vuorokauden kuluessa.
Jos lääkeihottuma on lievä, sen hoidoksi
riittää epäillyn lääkkeen käytön
lopettaminen. Voimakkaammin oirehtiva
ihottuma voi edellyttää hoidoksi
kortisonivoidetta tai sisäistä kortisonihoitoa
tablettikuurin muodossa. Nokkosihottuman
ensisijainen hoito on kuitenkin aina
antihistamiini. Sitä voi ostaa apteekista
ilman reseptiä, joten lievässä nokkosrokossa
voi kokeilla antihistamiinia omatoimisesti.
Lääkäri antaa ohjeistuksen lääkkeen
jatkokäytöstä. Lääkkeen ja ihottumareaktion
välinen syy-seuraussuhde on usein
epävarma. Jos ihoreaktio on ollut lievä ja
lääkkeen rooli sen aiheuttajana on
epävarma, voi hoitava lääkäri antaa luvan
kokeilla samaa lääkettä jatkossa, jos tarvetta
kyseiselle lääkkeelle ilmenee.
Voimakkaammissa ihoreaktioissa, tai jos
lääke vaikuttaa ilmiselvältä ihoreaktion
aiheuttajalta, epäilty lääke merkitään
potilaan niin sanottuihin riskitietoihin
sairauskertomukseen. Kyseistä lääkettä ei
käytetä jatkossa uudelleen, vaan valitaan
sen tilalle korvaava lääke. Jos käyttökieltoon
merkitty lääke olisi potilaan terveydentilan
kannalta tärkeä, voidaan epäiltyä
lääkeyliherkkyyttä tutkia
allergiatutkimuksiin erikoistuneessa
yksikössä. Tutkimuksiin saatetaan päätyä
myös, jos potilaalle on kertynyt kieltolistalle
monia lääkkeitä siten, että korvaavan
lääkkeen valinta on vaikeutunut.
Lääkeyliherkkyyden
tutkiminenLievät reaktiot, joita epäilään
lääkeyliherkkyydeksi, eivät edellytä
tutkimuksia.
Epäiltyä lääkeyliherkkyyttä voidaan tutkia
ihokokeilla, joita ovat ihopistokoe ,
ihonsisäinen koe ja epikutaanitesti .
Muutamien lääkkeiden kohdalla voidaan
määrittää verestä IgE-vasta-aineita.
Positiivinen testireaktio edellä mainituissa
testeissä viittaa lääkeallergiaan.
Varmin keino osoittaa lääkkeen ja epäillyn
lääkereaktion yhteys on lääkealtistus, jossa
potilaalle annetaan valvotuissa oloissa
tutkittavaa lääkettä alkaen hyvin pienestä
annoksesta. Lääkealtistus kestää
vuorokaudesta useampaan päivään riippuen
siitä, epäilläänkö nopeasti vai hitaasti
ilmaantuvaa allergiaoiretta. Altistustestiä ei
tehdä, jos epäillään lääkkeen aiheuttavan
voimakkaan, terveyttä uhkaavan reaktion.
Kirjallisuutta
1. Liippo  J. Lääkeyliherkkyys. Lääkärin tietokannat / Lääkärin käsikirja [online; vaatii
käyttäjätunnuksen] . Kustannus Oy Duodecim . Päivitetty 15.3.2021.
2. Lammintausta K, Alanko K. Lääkeaineiden aiheuttamat ihoreaktiot. Duodecim
2011;12 7(5):448–56. [https://www.duodecimlehti.fi/duo99380]
Aiemmat kirjoittajat: Ihotautien erikoislääkäri Matti Hannuksela
Artikkelin tunnus: dlk00450 (032.051)
© 2025 Kustannus Oy Duodecim
Lääkärin tutkimus ja EKG - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/
Lääkärin tutkimus ja EKG
Lääkärin tutkimus ja EKG
(https://sydan.fi/fakta/laakarin-tutkimus-ja-
ekg/)
Sydänsairautta epäiltäessä sydänäänten kuuntelu stetoskoopilla
(auskultaatio) ja sydämen sähköisen toiminnan tutkiminen EKG:llä ovat
perusselvityksiä.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 26.1.2024
Lue seuraavaksi Sydämen ultraäänitutkimus (https://sydan.fi/fakta/sydamen-ultraaanitutkimus/)
 
Lääkärin tutkimus ( ) pitää sisällään yleistä havainnointia tutkittavan
ruumiinrakenteesta ja yleistilasta. Pituus ja paino on hyvä kirjata, ja useimmat
potilastietojärjestelmät laskevat luvuista automaattisesti myös painoindeksin
(BMI).
Sydämen kuuntelu stetoskoopilla
Sydänäänet voi kuulla stetoskoopilla rintakehän päältä. Sydänäänet syntyvät
sydämen läppien avautuessa ja sulkeutuessa. Läpät ovat eräänlaisia venttiilejä,
jotka estävät veren virtaamisen väärään suuntaan. Jos läppä alkaa vuotaa (esim.
mitraalivuoto (https://sydan.fi/fakta/hiippalapan-vuoto/)) tai ahtautuu (esim.
aorttaläpän ahtauma (https://sydan.fi/fakta/aorttalapan-ahtauma/)), syntyy
ns. sivuääni. Kokenut kuuntelija pystyy määrittämään jo pelkän sivuäänen
perusteella, mistä läppäviasta voisi olla kysymys, ja kuinka vaikea-asteinen
läppävika todennäköisesti on.
Sydämen kuuntelu paljastaa siis erityisesti sydämen läppävian
(https://sydan.fi/fakta/lappaviat/). Kuuntelun aikana tehdään havaintoja
sydämen tahdista (hidas, nopea, epätasainen), mutta stetoskoopilla ei voi tehdä
rytmihäiriön diagnoosia. Kuuntelu ei kerro mitään sydämen sepelvaltimoista,
mutta stetoskoopilla voi kuulla muiden valtimoiden (kaulavaltimoiden tai
nivusvaltimoiden) ahtauman.
Keuhkojen kuuntelussa voi löytyä hengenahdistukselle keuhkoperäinen selitys.
Vaikea sydämen vajaatoiminta voi aiheuttaa verentungosta keuhkoissa, minkä
lääkäri kuulee stetoskoopilla hengitysäänten rahinoista.
EKG eli elektrokardiogrammi
EKG:stä käytetään usein myös nimitystä sydänfilmi. Tutkittava makaa
tutkimuspöydällä rintakehä, ranteet ja nilkat paljaana. Joskus voidaan joutua
ajamaan osa rintakarvoista pois, jotta tutkimuselektrodit saadaan kiinnitettyä
riittävän tiiviisti iholle. Elektrodit kiinnitetään kumpaankin ranteeseen ja toiseen
nilkkaan, sekä kuuteen kohtaan rintakehällä. Näistä saadaan aikaiseksi ns. 12-
kanavainen EKG, jossa eri kanavilta saadaan tietoa sydämen eri alueiden
toiminnasta. Sydämen toiminnasta nauhoitetaan yleensä muutaman sekunnin
kestoinen näyte. Jos epäillään rytmihäiriötä, nauhoitusta voidaan tarvittaessa
pidentää.statusLue seuraavaksi Sydämen ultraäänitutkimus (https://sydan.fi/fakta/sydamen-ultraaanitutkimus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
EKG:ssa näkyy omina heilahduksinaan eteisten supistuminen (P-aalto),
kammioiden supistuminen (QRS-kompleksi) ja kammioiden palautuminen
sähköiseen lepotilaan (T-aalto).
Akuutin rintatuntemuksen, kuten rintakivun, aikana nauhoitettu EKG voi
paljastaa meneillään olevan sydäninfarktin
(https://sydan.fi/fakta/sydaninfarkti/). EKG:n perusteella kardiologi pystyy jo
päättelemään, mikä sydämen sepelvaltimoista on akuutti ongelma, sillä
sydämen hapenpuute synnyttää muutoksia tiettyihin EKG:n kanaviin. EKG on siis
sydäninfarktin perustutkimus, ja nauhoitus tehdään siksi
ambulanssihenkilökunnan toimesta jo paikan päällä hälytyskohteessa.
Jos sydäninfarkti ei ole juuri nyt meneillään, EKG voi olla normaali, eikä yksistään
paljasta sepelvaltimotautia. Siksi päivystyspoliklinikalla tutkitaan
sydäninfarktiepäilyissä aina myös verikoe, ns. troponiinitesti
(https://sydan.fi/fakta/verikoetutkimukset-sydansairauksien-diagnostiikassa-
ja-seurannassa/).
EKG on rytmihäiriöiden (https://sydan.fi/fakta/sydamen-rytmihairiot/)
perustutkimus. Oireiden perusteella lääkäri voi epäillä tiettyjä rytmihäiriöitä,
mutta diagnoosin varmistamiseksi häiriöstä tarvitaan aina EKG-varmennus.
Rytmihäiriön pitää kuitenkin osua nauhoitushetkeen. Ohittunut rytmihäiriö ei
jätä jälkiä, joista rytmihäiriödiagnoosin voisi varmuudella asettaa. Koska monet
rytmihäiriöt esiintyvät vain ajoittain, vaikka muutaman sekunnin kestoisina
kerran viikossa, eivät ne useinkaan osu nauhoitushetkeen, ja rytmihäiriön
metsästämiseksi tarvitaan muitakin tutkimuksia.
(https://sydan.fi/fakta/rytmihairion-tutkiminen/)
Vaikka kohtaus ei osuisi 12-kanavaisen EKG:n nauhoitushetkeen, antaa EKG
paljon hyödyllistä tietoa sydämen toiminnasta. Siitä nähdään mahdolliset sähkön
johtumisen ongelmat, sekä viitteet sydänlihaksen paksuuntumisesta tai
sydänlokeroiden laajentumisesta. Sairastetun sydäninfarktin arpi voi näkyä.
Sydämen vajaatoiminnassa EKG ei juuri koskaan ole normaali.
EKG:n tulkinnasta
Rekisteröintilaitteet mittaavat automaattisesti useita eri arvoja EKG:stä.
Automaattimittaukset ovat luotettavia mittaamaan erimerkiksi sykkeen
nopeutta ja sydämen sähköisen toiminnan eri vaiheiden kestoa (ns.
aikaintervalleja).Lue seuraavaksi Sydämen ultraäänitutkimus (https://sydan.fi/fakta/sydamen-ultraaanitutkimus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Laite ehdottaa myös mahdollisia diagnooseja. Nämä eivät ole täysin luotettavia,
joten potilaan ei pidä säikähtää koneen tekemää diagnoosiehdotusta.
Laitteet on viritetty tarkoituksella yliherkiksi esimerkiksi sydämen
hapenpuutteen arvioinnissa. Toisaalta automaatti ei ole aukoton rytmihäiriöiden
tunnistamisessa. Myös sähköisen palautumisajan, ns. QT-ajan mittaamisessa laite
on heikko, joten tämä vaatii aina lääkärin tekemän mittauksen. EKG:n tulkinta
on siis aina lääkärin tehtävä. Lääkäri voi käyttää apuvälineenä erityistä EKG-
viivainta.
Normaaliarvoja (pienet poikkeamat ovat tavallisia):
Leposyke: 60-100/min.
PQ- eli PR-väli: alle 200 millisekuntia (ms) eli alle 0,2 sekuntia (s)
QRS-kompleksin kesto: alle 120 ms eli alle 0,12 s
QT/QTc (automaatti antaa ehdotuksen, mutta lääkärin varmistettava omalla
mittauksella): QT-aika (https://sydan.fi/fakta/mika-pitka-qt-oireyhtyma-on/)
vaihtelee sykkeen mukaan, siksi ilmoitetaan QTc-aika, joka on sykekorjattu.
Miehillä alle 440 ms, naisilla alle 460 ms.Lue seuraavaksi Sydämen ultraäänitutkimus (https://sydan.fi/fakta/sydamen-ultraaanitutkimus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Masennus ja sepelvaltimotauti - Ammattilaispalvelu.pdf
Työskenteletkö sydänterveyden tai siihen liittyvien teemojen parissa? Tilaa Sydänliiton ammattilaisille suunnattu uutiskirje.
(https://sydan.fi/tilaa-ammattilaisten-uutiskirje)
Löydä tilaisuutesi sopiva kokemustoimija Sydänliiton kokemustoimijahausta.
(https://sydan.fi/kokemustoimijahaku/?personDiagnoses=&personAge=&personCity=&personLanguages=&query=)
Etusivu (https://sydan.fi/ammattilaispalvelu/)/Masennus ja sepelvaltimotauti
Masennus  ja sepelvaltimotauti
(https://sydan.fi/ammattilaispalvelu/artikkeli/masennus-
ja-sepelvaltimotauti/)
Masennus on yleistä sepelvaltimotautia sairastavilla. Sairastuneita kohtaavalla
ammattilaisella on keskeinen rooli tunnistaa, tukea ja ohjata hoidon pariin.
Sara Sutela, Sara Sutela
Julkaistu 8.2.2023
 
Masennuksen ja sepelvaltimotaudin tiedetään olevan yhteydessä kahdella eri tapaa.
Masentuneilla on suurempi riski sairastua sydän- ja verenkiertoelinten sairauksiin kuin ei
masentuneilla. Sydäninfarktin ja sepelvaltimotautidiagnoosin saaneet myös sairastuvat
masennukseen herkästi toipumisvaiheen aikana.Lue seuraavaksi Lääkehoidon ohjauksen muistilista (https://sydan.fi/ammattilaispalvelu/artikkeli/laakehoidon-ohjauksen-muistilista/)
Masennus lisää riskiä sairastua sepelvaltimotautiin
Masennuksesta kärsivillä voi olla pitkäaikaisia haasteita huolehtia terveydestään. Tupakointi,
alkoholinkäyttö, lihavuus, diabetes ja vähäinen liikunta ovat yleisempiä masentuneiden
keskuudessa. Elintavat selittävät siis osan masentuneiden suuremmasta riskistä sairastua,
mutta ei kuitenkaan kaikkea. Tutkimusten perusteella masennus on myös itsenäinen riskitekijä.
Arvellaan, että masennus saattaa vaikuttaa hormonaalisten tekijöiden sekä aivojen
välittäjäaineiden muutosten kautta. Masennus todennäköisesti myös lisää elimistön hiljaista
tulehdusta, mikä kiihdyttää ateroskleroosia.
Sydäninfarkti altistaa masennukselle
Sairastumisen jälkeinen masennus sen sijaan kehittyy useimmiten reaktiona elämäntilanteen
muutokseen. Sairastuminen on järkyttävä ja stressiä aiheuttava tapahtuma, joka voi laittaa
tulevaisuuden suunnitelmia uuteen uskoon. Suru, ahdistus, syyllisyys ja pelko voivat olla läsnä.
Lisäksi sairastunut voi kokea neuvottomuutta ja avuttomuutta uuden edessä.
Masennus sairastumisen jälkeen on hyvin yleistä. Arviolta joka toisella on ahdistuneisuutta ja
joka neljännellä sairastuneella on masennusoireilua sydäninfarktin jälkeen. Masennuksen ja
ahdistuneisuuden tunnistaminen ja hoito on tärkeää, koska se vaikuttaa haitallisesti
sydänsairauden hoitoon. Voimavarojen ollessa vähäiset, omahoito, kuten lääkehoito ja
riskitekijöiden seuranta on heikompaa. Elintapamuutosten tekeminen ja terveellisten
elintapojen noudattaminen voi olla mahdotonta. Tämä lisää riskiä uusintainfarktiin ja
sairaalahoitoon. Varhaisessa vaiheessa tunnistettu masennus parantaa myös sydänsairauden
ennustetta.
Masennus voi puhjeta kenelle tahansa, mutta tietyt taustatekijät lisäävät todennäköisyyttä.
Masennus on todennäköisempää sydänsairastuneilla, jotka ovat aikaisemmin sairastaneet
masennusta ja kokevat yleisen terveydentilansa huonoksi. Muita masennuksen riskiä lisääviä
tekijöitä ovat taloudelliset huolet, matala koulutustaso, tupakointi ja yksinäisyys. Työikäisillä
masennus on yleisempää kuin vanhemmilla ikäluokilla.
Kysy, havainnoi, kuuntele ja tue
Henkilökohtaisesta tilanteesta keskustelu ja masennuksesta puhuminen voi auttaa asiakasta
selvittämään ajatuksiaan ja normalisoimaan tilannetta. Varmista, että tila on rauhallinen ja
tilanne kiireetön.
Mielialan ja masennuksen puheeksi ottaminen saattaa jo helpottaa asiakkaan oloa,
varsinkin jos asiasta keskusteleminen on läheisten kanssa hankalaa.
Kartoittavia kysymyksiä:
Miten olet jaksanut viime aikoina?
Minkälainen mieliala sinulla on ollut?
Miten toipuminen on lähtenyt käyntiin?
Miten arki sujuu sydänsairauden toteamisen jälkeen?
Tarvittaessa testaa masennusta kartoittavalla testillä, kuten BDI-21
(https://www.mielenterveystalo.fi/fi/oirekyselyt/pitka-masennuskysely-bdi-21) tai DEPS
(https://www.kaypahoito.fi/pgr00041).Lue seuraavaksi Lääkehoidon ohjauksen muistilista (https://sydan.fi/ammattilaispalvelu/artikkeli/laakehoidon-ohjauksen-muistilista/)
Ota asiakkaan viesti matalasta mielialasta huomioon. Terveydenhuollon henkilökunnan
välinpitämättömyys on erittäin haitallista silloin, kun asiakas tuo itselleen hankalan aiheen
esille.
Kirjaa, raportoi ja ohjaa asiakas eteenpäin saamaan apua tilanteeseensa.
Onko teidän työpaikassanne selkeä ohjeistus, siitä miten ja mihin ohjataan asiakkaat, joilla
on mielialan kanssa ongelmia? Jos ei, voisiko sellaisen tehdä?
Onko yksikössänne tarvetta kirjallisella ohjausmateriaalille mielialaan ja masennukseen
liittyvistä asioista?
Tunnetko ilmaiset masennuksen ja ahdistuksen hoitoon suunnitellut omahoito-ohjelmat
(https://www.mielenterveystalo.fi/fi/omahoito)?
 
 
Vaccarino ym. 2020. Depression and coronary heart disease: 2018 position paper of the ESC
working group on coronary pathophysiology and microcirculation, European Heart Journal,
Volume 41, Issue 17, 1.
Murphy ym. 2020. Anxiety and depression after a cardiac event: prevalence and
predictors.  , .
Sepelvaltimotautikohtaus. 2022. Käypä Hoito -suositus.Frontiers in psychology10Lue seuraavaksi Lääkehoidon ohjauksen muistilista (https://sydan.fi/ammattilaispalvelu/artikkeli/laakehoidon-ohjauksen-muistilista/)
Mikä on antikoagulantti ja miten sitä käytetään_ - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Lääkehoito (https://sydan.fi/elamaa-sairauden-kanssa/laakehoito/)/
Mikä on antikoagulantti ja miten sitä käytetään?
Mikä on antikoagulantti ja miten sitä
käytetään? (https://sydan.fi/fakta/mika-on-
antikoagulantti-ja-miten-sita-kaytetaan/)
Lääkkeitä, jotka vaikuttavat veren hyytymiseen estämällä veritulpan
syntymistä, kutsutaan antikoagulanteiksi. Niitä on nimitetty suomenkielessä
”verenohennuslääkkeiksi ” , mutta ilmaisu ei ole oikea, sillä ne eivät ohenna tai
laimenna verta, vaan hidastavat sen hyytymistä. Hoito on yleistä, yli 200 000
suomalaista käyttää antikoagulanttia.
Kuva: Johannes Romppanen
Lue seuraavaksi Hyytymän esto antikoagulanteilla (https://sydan.fi/fakta/hyytyman-esto-antikoagulanteilla/)
Anna-Mari Hekkala, ylilääkäri
Julkaistu 13.11.2018
Päivitetty 29.10.2020
 
Tavallisin tarve antikoagulanttihoidolle on eteisvärinä. Tähän rytmihäiriöön
liittyy riski verihyytymän syntymiseen eteislokeron sopukkaan, mikä liikkeelle
lähtiessään voi aiheuttaa valtimon veritulpan, pahimmassa tapauksessa
aivoinfarktin. Muita syitä hoitaa lääkityksellä veren hyytymisen esto ovat
esimerkiksi sydämen tekoläppä, keuhkoveritulppa, laskimotukos tai vaikea
sydämen vajaatoiminta.
Antikoagulanttihoidon lääkkeet
Hoito voidaan toteuttaa tällä hetkellä viidellä eri tablettilääkkeellä. Vanhin ja
tunnetuin niistä on varfariini (Marevan®). Marevan vaikuttaa veren
hyytymisessä kaikkiin K-vitamiinista riippuviin tekijöihin, tästä syystä ravinnon K-
vitamiini saattaa vaikuttaa lääkehoidon tasapainoon. Annostelu on yksilöllistä, ja
se määritetään verestä mitattavan INR-arvon perusteella. Annosten
milligrammamääriä ei siis voi vertailla tuttavan kanssa.
Uudempia lääkkeitä kutsutaan suoriksi antikoagulanteiksi, Ne ovat saaneet
nimensä siitä, että ne vaikuttavat suoraan yhteen kohtaan veren
hyytymisjärjestelmässä. Loppuvaikutus on kuitenkin kaikilla sama. Suoria
antikoagulantteja ovat dabigatraani (Pradaxa®), rivaroksabaani (Xarelto®),
apiksabaani (Eliquis®) ja edoksabaani (Lixiana®). Näiden lääkkeiden annostelu
on vakio, eli sitä ei säädellä verikokeen perusteella. Myöskään ravinnon K-
vitamiini ei vaikuta niiden tehoon. Suorat antikoagulantit ovat lyhytvaikutteisia,
sen vuoksi on tärkeätä ottaa lääkkeet säännöllisesti. Potilaat, joilla on sydämessä
mekaaninen tekoläppä, eivät voi käyttää suoria antikoagulantteja.
Marevan-tabletit ovat edullisia, päivän annos maksaa tavallisesti vain muutamia
senttejä. Suorat antikoagulantit ovat toistaiseksi selvästi Marevania kalliimpia.
Lääkkeisiin on kuitenkin mahdollista saada erityiskorvattavuus lääkärin B-
lausunnolla. Korvauksen jälkeen lääkkeen päiväkustannus on noin yksi euro, ja
lääkitys kerryttää myös vuosittaista lääkekattoa.Lue seuraavaksi Hyytymän esto antikoagulanteilla (https://sydan.fi/fakta/hyytyman-esto-antikoagulanteilla/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Ongelmallisia tilanteita
Koska lääkityksen tarkoitus on hidastaa veren hyytymistä, kaikki antikoagulantit
voivat altistaa potilaan verenvuodolle. Vuodot ovat yleensä lieviä, kuten
nenäverenvuoto tai lisääntynyt mustelmataipumus. Haavaa voi joutua
painamaan pidempään, jotta verenvuoto tyrehtyy. Jos vuoto ei lopu, tai toistuu
usein, pitää potilaan ottaa yhteyttä terveyskeskukseen tai päivystykseen.
Lääkäri tarkistaa oikean annostuksen. Annostusta, varsinkaan suorien
antikoagulanttien, ei pidä koskaan säätää itse kysymättä apua ammattilaiselta.
Jotta lääkevirheitä, kuten unohtamisia tai yliannostuksia, ei tapahtuisi, lääkkeet
kannattaa jakaa annosjakelijaan eli dosettiin. Tarvittaessa voi laittaa puhelimen
hälytyksen muistuttamaan lääkkeen ottamisajasta.
Lääkityksestä pitää aina mainita apteekissa ostettaessa tavallisia
reseptivapaitakin valmisteita. Esimerkiksi monet tulehduskipulääkkeet kuten
ibuprofeiini (Burana®) eivät sovi antikoagulantin käyttäjälle. Kuumeen ja kivun
hoitoon onkin turvallisinta käyttää parasetamolia (Panadol®, Paratabs®).
Moniin toimenpiteisiin liittyy lisääntynyt vuotovaara, joten lääkityksestä pitää
ehdottomasti kertoa jo ennakolta lääkärille, esimerkiksi hammaslääkärille. Pienet
toimenpiteet voidaan yleensä tehdä ilman lääketaukoa, mutta lääkitys voidaan
myös joutua hetkeksi keskeyttämään ennen suunniteltua toimenpidettä.
Antikoagulaatiohoidon seuranta
Hoito edellyttää säännöllistä seurantaa. Lääkityksen aloituksen jälkeen
suositellaan ensimmäistä kontrollia jo kuukauden päähän. Käynnillä arvioidaan,
onko hoito onnistunut toivotulla tavalla ja onko ilmaantunut haittavaikutuksia
sekä mitataan tarvittaessa ainakin verenkuva ja munuaisten toimintakoe.
Kontrollikäynti tulisi tehdä vähintään vuosittain. Iäkkäiden ja hauraiden
potilaiden tilanne tarkistetaan useammin, joskus jopa kolmen kuukauden välein.
Lisäksi Marevania käyttävät potilaat käyvät yleensä kerran kuukaudessa INR-
mittauksessa.
Jotta lääkitys olisi tehokas ja myös turvallinen, on tärkeätä huolehtia lääkkeen
oikeasta ja säännöllisestä annostelusta.
Sydänkaupasta (https://www.sydankauppa.fi/epages/sydankauppa.sf/fi_FI/?
ObjectPath=/Shops/2015052803/Products/2255) voi tilata jokaiselle
antikoagulantin käyttäjälle soveltuvan SOS-kortin, joka kannattaa pitääLue seuraavaksi Hyytymän esto antikoagulanteilla (https://sydan.fi/fakta/hyytyman-esto-antikoagulanteilla/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
lompakossa mukana myös matkoilla. Lue seuraavaksi Hyytymän esto antikoagulanteilla (https://sydan.fi/fakta/hyytyman-esto-antikoagulanteilla/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Miten sepelvaltimoiden pallolaajennus tehdään_.pdf
Mi ten se pel val ti moi den pal lo laa jen nus
teh dään?
Pallolaajennus muistuttaa sepelvaltimoiden varjoainetutkimusta. Toimenpide
tehdään paikallispuudutuksessa joko rannevaltimon tai reisivaltimon kautta.
Lääkäri ohjaa ohuen katetrin sepelvaltimon suulle. Toimenpiteen kulkua seurataan
röntgenläpivalaisun avulla. Aluksi ahtautuneeseen suoneen viedään  ohut lanka, jota pitkin
voidaan  kuljettaa toimenpiteessä tarvittavia välineitä suonen sisällä.
Katetrin päässä oleva lieriön muotoinen pallo laajennetaan ahtauman kohdalla. Usein
toimenpiteen yhteydessä asetetaan laajennettuun kohtaan stentti eli tukiverkko. Stentin
tarkoituksena on estää laajennetun suonen uudelleen ahtautuminen.
Muutaman kuukauden aikana toimenpiteen
jälkeen verisuonen sisäkalvo kasvaa
suojaamaan stenttiä. Tämän
paranemisprosessin aikana käytetään
tehokasta veren hyytymistä estävää
lääkitystä.
Toimenpiteen kesto vaihtelee ahtaumien
määrästä ja ominaisuuksista riippuen
puolesta tunnista kahteen tuntiin.
Pallolaajennuksen jälkeen potilasta
seurataan vuodelevossa 2-6 tunnin ajan.
Kotiutus voi olla yksinkertaisimmissa
tapauksissa jo samana päivänä.
Sydän infarktin yhteydessä tehdyn
pallolaajennuksen jälkeen hoitoaika on
pidempi, yleensä muutamia päiviä.
Toimenpiteen jälkeen on vältettävä pistoskohdan rasittamista noin viikon ajan. Stentti ei näy
lentokentän turvatarkastuksessa eikä siitä tarvitse erikseen mainita.
Tarkistettu 3.11.2020

Miten sepelvaltimoiden pallolaajennus tehdään_Terveyskylä.pdf
Mi ten se pel val ti moi den pal lo laa jen nus
teh dään?
Pallolaajennus muistuttaa sepelvaltimoiden varjoainetutkimusta. Toimenpide
tehdään paikallispuudutuksessa joko rannevaltimon tai reisivaltimon kautta.
Lääkäri ohjaa ohuen katetrin sepelvaltimon suulle. Toimenpiteen kulkua seurataan
röntgenläpivalaisun avulla. Aluksi ahtautuneeseen suoneen viedään  ohut lanka, jota pitkin
voidaan  kuljettaa toimenpiteessä tarvittavia välineitä suonen sisällä.
Katetrin päässä oleva lieriön muotoinen pallo laajennetaan ahtauman kohdalla. Usein
toimenpiteen yhteydessä asetetaan laajennettuun kohtaan stentti eli tukiverkko. Stentin
tarkoituksena on estää laajennetun suonen uudelleen ahtautuminen.
Muutaman kuukauden aikana toimenpiteen
jälkeen verisuonen sisäkalvo kasvaa
suojaamaan stenttiä. Tämän
paranemisprosessin aikana käytetään
tehokasta veren hyytymistä estävää
lääkitystä.
Toimenpiteen kesto vaihtelee ahtaumien
määrästä ja ominaisuuksista riippuen
puolesta tunnista kahteen tuntiin.
Pallolaajennuksen jälkeen potilasta
seurataan vuodelevossa 2-6 tunnin ajan.
Kotiutus voi olla yksinkertaisimmissa
tapauksissa jo samana päivänä.
Sydän infarktin yhteydessä tehdyn
pallolaajennuksen jälkeen hoitoaika on
pidempi, yleensä muutamia päiviä.
Toimenpiteen jälkeen on vältettävä pistoskohdan rasittamista noin viikon ajan. Stentti ei näy
lentokentän turvatarkastuksessa eikä siitä tarvitse erikseen mainita.
Tarkistettu 3.11.2020
Miksi Terveyskylä? – Katso video
Nikotiini pois elämästä - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Terveys & Hyvinvointi (https://sydan.fi/terveys-hyvinvointi/)/
Tupakka ja nuuska (https://sydan.fi/terveys-hyvinvointi/tupakkatuotteet-ja-alkoholi/)/
Nikotiini pois elämästä
Nikotiini pois elämästä
Tupakkatuotteiden sisältämä nikotiini on monin tavoin terveydelle
haitallista.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 29.11.2018
Päivitetty 7.2.2023
 
Yleensä ihmiset tietävät, että tupakka on haitallista keuhkoille. Se altistaa paitsi
keuhkosyövälle, myös keuhkoahtaumataudille.Lue seuraavaksi Miehistä otettiin jälleen mittaa Karjala-turnauksessa (https://sydan.fi/uutinen/%e2%80%8bmiehista-
mittaa-karjala-turnauksessa/)
Harvemmin tulee ajatelleeksi, että tupakka on erittäin vaarallista sydän- ja
verenkiertoelimistölle (https://sydan.fi/fact/tupakka-ja-sydan-ja-
verisuoniterveys/). Tupakka sisältää useita verisuonille haitallisia ainesosia, joista
nikotiini on yksi tärkeimmistä. Siksi kaikenlaiset nikotiinia sisältävät tuotteet,
esimerkiksi nuuska, ovat sydämelle vaarallisia.
Parasta olisi, jos ei koskaan aloittaisi tupakointia tai nikotiinin käyttöä. Nuorena
haittoja ei kuitenkaan tule ajatelleeksi, tai niitä ei pidä tärkeänä koska sairaudet
ilmenevät yleensä vasta vuosien käytön jälkeen.
Nikotiini aiheuttaa riippuvuutta aivojen nikotiinireseptoreiden kautta. Osa
ihmisistä kykenee lopettaman nikotiinin käytön helposti, mutta toisilla
nikotiinireseptoreiden rakenne on sellainen, että lopettaminen on
huomattavasti vaikeampaa. Mutta ei mahdotonta. Nykyisin nikotiiniriippuvuus
ja sen biologinen tausta ymmärretään aiempaa paremmin, ja
terveydenhuollosta voi saada monenlaista tukea (https://sydan.fi/fact/tukea-
tupakoinnin-lopettamiseen/) tupakoinnin ja nikotiinituotteiden käytön
lopettamiseen.
Ihmisen elimistö ei tarvitse nikotiinia. Tupakalla ei ole mitään terveyttä edistäviä
vaikutuksia, mutta haittoja sitäkin enemmän. Lopettaminen kannattaa
(https://sydan.fi/fact/tupakoinnin-lopettaminen-ei-ole-koskaan-myohaista/)
aina!
Faktoja nikotiinituotteiden lopettamisen hyödyistä:
veren hyytymisen ja valtimoiden tukkeutumisen vaara pienenee
kohonnut verenpaine laskee
elimistön hapensaanti paranee
sydämen rytmihäiriötaipumus vähenee
hengitys ei haise ja suu on raikas!
 Lue seuraavaksi Miehistä otettiin jälleen mittaa Karjala-turnauksessa (https://sydan.fi/uutinen/%e2%80%8bmiehista-
mittaa-karjala-turnauksessa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Nitraatit - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Lääkehoito (https://sydan.fi/elamaa-sairauden-kanssa/laakehoito/)/Nitraatit
Nitraatit (https://sydan.fi/fakta/nitraatit/)
Nitraatteja eli nitroja käytetään sepelvaltimotaudin kohtausoireiden hoitoon
ja ehkäisyyn.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 22.6.2022
 
Lue seuraavaksi Ivabradiini (https://sydan.fi/fakta/ivabradiini/)
Nitraatit jaetaan lyhyt- ja pitkävaikutteisiin. Nämä lääkkeet laajentavat
verisuonia, jolloin sepelvaltimoiden verenvirtaus lisääntyy, ja muiden suonten
laajentuessa sydämen työ kevenee.
Lyhytvaikutteiset nitrot
Lyhytvaikutteisia nitroja (pikanitroja) käytetään sepelvaltimotaudin
(https://sydan.fi/sydantietoa/sydansairaudet/sepelvaltimotauti/) oireiden
hoitoon. Puhutaan myös kohtausnitrosta. Liukeneva tabletti (resoribletti)
pannaan kielen alle sulamaan tai suihkemuotoista valmistetta suihkutetaan
kielen päälle. Nitrosid® on pureskeltuna lyhytvaikutteinen. Vaikutus alkaa
tyypillisesti parissa minuutissa. Jos rintakivun helpottumiseen menee selvästi
pidempi aika, kyse ei todennäköisesti ole nitron vaikutuksesta.
Pikanitroa voi ottaa myös ennakoivasti esimerkiksi liikkeelle lähtiessä tai ennen
portaiden tai ylämäen nousua. Vaikutus kestää parikymmentä minuuttia.
Nitrojen käyttömäärälle ei ole ylärajaa. Jos kohtauslääkettä kuitenkin tarvitsee
runsaasti, esimerkiksi useita kertoja päivässä, pitää pohtia sairauden
lisäselvityksiä, lähinnä pallolaajennuksen tai ohitusleikkauksen mahdollisuutta
ajatellen. Äkillisesti lisääntynyt tarve tai nitron aiemmasta kokemuksesta
poikkeava tehottomuus voi johtua sepelvaltimotaudin pahenemisesta tai
vakavasta kohtauksesta, jolloin on soitettava hätänumeroon 112.
Pitkävaikutteiset nitrot
Pitkävaikutteisia nitroja on nieltävinä tabletteina ja laastareina. Ne ovat
hyödyksi silloin, kun pikanitrojen tarve on säännöllistä kuten päivittäistä. Niillä ei
ole vaikutusta sepelvaltimotaudin kulkuun (ennustevaikutusta), joten niitä ei ole
tarpeen käyttää varmuuden vuoksi, ainoastaan oireiden lievittämiseksi.
Pitkävaikutteisia nitroja voidaan käyttää myös vaikeaoireisessa sydämen
vajaatoiminnassa, erityisesti kun se johtuu sepelvaltimotaudista.
Nitraattien teho säilyy parhaiten, kun niiden vaikutuksessa on päivittäinen
tauko. Siksi rasitusrintakivuissa pitkävaikutteisten nitrojen vaikutus on paras
kohdentaa aktiiviseen päiväaikaan ottamalla lääke aamulla ja tarvittaessa
iltapäivällä.
Pitkävaikutteisesta nitraatista voi olla apua myös vasospastisessa anginassa eli
valtimoiden spasmitaipumuksessa.Lue seuraavaksi Ivabradiini (https://sydan.fi/fakta/ivabradiini/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Nitrojen haittavaikutukset
Tavallisin haittavaikutus on päänsärky. Taipumus siihen saattaa mennä ohi
käyttöä jatkettaessa, mutta joskus se muodostuu esteeksi nitrojen käytölle.
Nitraattien verisuonia laajentava vaikutus voi joskus laskea verenpainetta liikaa,
erityisesti saunomisen tai alkoholin käytön yhteydessä. Verenpaineen lasku voi
johtaa pyörtymiseen. Tällöin apuun tulleiden ei pidä nostaa pyörtynyttä
pystyyn, vaan antaa hänen olla makuulla ja nostaa jalat kohoasentoon.
Nitron haittoja, ennen kaikkea huimausta ja pyörtymistä, voi ehkäistä ottamalla
lääke istuallaan tai makuulla. Nitroa ei pidä ottaa mihin vaivaan hyvänsä, ei
esimerkiksi pistäviin tai muihin ei-sydänperäisiin rintakipuihin eikä varsinkaan
rytmihäiriötuntemuksiin, joiden yhteydessä verenpaine saattaa jo valmiiksi olla
matala. Samasta syystä nitroa ei tule ottaa huimauksen hoitoon.
 
Lääkeaine Valmistenimet Huomauksia
Lyhytvaikutteiset
Glyseryylitrinitraatti eli
nitroglyseriiniNitro 0,5 mg
resoriblettiAlempi erityiskorvaus kroonisessa
sydämen vajaatoiminnassa ja
kroonisessa sepelvaltimotaudissa
(Nitro)
IsosorbididinitraattiDinit sumute
suuonteloon
Nitrosid 5-10 mg (ei
retard-muoto)
pureskeltunaAlempi erityiskorvaus kroonisessa
sydämen vajaatoiminnassa ja
kroonisessa sepelvaltimotaudissa
Pitkävaikutteiset tabletit
IsosorbididinitraattiNitrosid ja Nitrosid
retard nieltynäAlempi erityiskorvaus kroonisessa
sydämen vajaatoiminnassa ja
kroonisessa sepelvaltimotaudissa
IsosorbidimononitraattiImdur
Isangina
Ismox
Ormox
Isosorbide
mononitrate
VitabalansAlempi erityiskorvaus kroonisessa
sydämen vajaatoiminnassa ja
kroonisessa sepelvaltimotaudissa
Pitkävaikutteiset laastarit
Glyseryylitrinitraatti eli
nitroglyseriiniDeponit
Nitro
Transiderm-NitroAlempi erityiskorvaus kroonisessa
sydämen vajaatoiminnassa ja
kroonisessa sepelvaltimotaudissaLue seuraavaksi Ivabradiini (https://sydan.fi/fakta/ivabradiini/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
OmaSydän-etähoitopalvelu - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p alveluk etjut  /Sepel valtimot autipotilaan hoit oketju  /
Sepel valtimot audin jatk ohoit o ja seurant a  / OmaSy dän-et ähoit op al v elu
 Sepel v al timot autipotilaan hoit ok et ju
Sepel valtimot audin diagnostiikka
Sepel valtimot audin hoit o
Sepel valtimot autik ohtaus
Sydänvalmennus
Sepel valtimot audin jatk ohoit o ja seurant a
Seurant a sepel valtimot autidiagnoosin jälk een
OmaSy dän-et ähoit op al v elu
Sepel valtimot autipotilaan ajot erveys
Sepel valtimot autipotilaan t yökyvyn ar viointi
Sepel valtimot audin lausunnot



OmaSy dän-et ähoit opalvelu
OmaSy dän mobiiliso vellus – Sepel valtimot autipotilaan et ähoit opalvelu 12kk
Ensisijainen ja useimmilla potilailla aino a seurant amenet elmä sepel valtimot autidiagnoosin jälk een
Potilaiden r ekrytointi OmaSy dän et ähoit opalveluun sepel valtimoiden v arjoainekuv auksen y hteydessä
Sepel valtimot autik ohtaus
Stabiili sepel valtimot auti
Määr itetään v altimosairauden r iskit ekijät ja y ksilölliset hoit otavoitteetKuuntele4.3.2025 klo 17.25 OmaSydän-etähoitopalvelu - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotaudin-jatkohoito-ja-seuranta/omasydan-etahoitopalvelu 1/2
Verenpaine, diabet es, k olest eroli, tup akointi, liikunt a, ruoka valio ja p ainonhallint a
Etäkontr ollit 3kk, (6kk) ja 12kk OmaSy dän et ähoit opalvelun kautt a
Laborat oriokokeet (PVK, LDL, Alat, Na, K, kr ea, diabeetik oilta Hb A1c. Lääkär in har kinnan mukaan
muut laborat oriokokeet)
Kontr ollikysel y ja elämänlaatukysel y 15D OmaSy dän mobiiliso velluksen kautt a
Potilaan p ääsy digit aaliseen t aust amat eriaaliin omahoidon tuk emiseksi ja tiedon lisäämiseksi
Sydänsairaalan digihoit aja t ekee k ontr ollin y hteydessä y hteenvedon r iskit ekijöiden hoidost a ja
tarvittaessa k onsul toi kar diologia sekundaar iprevention t ehost amisest a (Kol, RR) ja sepel valtimot audin oir eista.
Tavoitteena v altimosairauden r iskit ekijöiden k okonaisv altainen t ehokas hoit o
Sepel v al timot autipotilaan et ähoit op al v elu (Sydänsairaala)
Edellinen
Seurant a sepel valtimot autidiagnoosin jälk eenSeur aa v a
Sepel valtimot autipotilaan ajot erveys
Päivit etty 20 .11.202 4
Ev äst eet
Saa vut et t a vuusselost e
Tiet osuoja
© Pir kanmaan h yvin v ointialueT akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.
T ämän sivun lö y dät osoitt eella pir ha.fi/hoit ok et jut4.3.2025 klo 17.25 OmaSydän-etähoitopalvelu - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotaudin-jatkohoito-ja-seuranta/omasydan-etahoitopalvelu 2/2
Pallolaajennus avaa suonen tukoksen - Sydänliitto.pdf
Pallolaajennus avaa suonen tukoksen  
Anna -Mari Hekkala , ylilääkäri  
Julkaistu 10.2.2023  
Pallolaajennus avaa sepelvaltimossa olevan tukoksen ja päästää veren virtaamaan sydänlihakseen.  
Sepelvaltimotauti on mahdollista saada pysymään aisoissa lääkityksen, hyvien elintapojen ja niin sanottujen 
kajoavien hoitomuotojen ansiosta. Kajoavalla hoidolla tarkoitetaan pitkälle kehittyneiden ahtaumien hoitoa 
pallolaajennuksella tai ohitusleikkauksel la. 
Elintapa - ja lääkehoito kuuluvat asiaan aina. Pallolaajennusta tai ohitusleikkausta tarvitaan usein 
sydäninfarktitilanteessa, tai jos sairaus aiheuttaa elämää haittaavia oireita.  
Pallolaajennus on sepelvaltimotaudin yleisin kajoava hoitomuoto. Nykyisin yli 90% kajoavasta hoidosta 
tehdään pallolaajennuksella, ja vain alle 10% ohitusleikkauksella.  
Pallolaajennuksen tekee kardiologi paikallispuudutuksessa tavallisimmin rannevaltimon, joskus 
nivusvaltimon kautta. Toimenpide alkaa aina varjoainekuvauksella, jossa nähdään ahtaimmat ja 
pallolaajennukselle otolliset kohteet. Pistokohdan kautta valtimoon o hjataan pallokatetri, jonka kulkua 
seurataan röntgenlaitteella. Sepelvaltimon ahtauman kohdalla pallo laajennetaan paineen avulla, jolloin se 
puristaa tukkeuman suonen seinämää vasten ja avaa suonen. Yleensä samalla ahtaumakohtaan asennetaan 
metallinen tuk iverkko eli stentti, joka pitää suonen paremmin auki. Stentit estävät valtimon ahtautumista 
heti uudelleen.  
Pallolaajennus avaa tukkeutuneen suonen  
Valtaosa pallolaajennuksista tehdään sepelvaltimotautikohtauksen yhteydessä. Jos äkillisesti tukkeutunut 
suoni päästään avaamaan nopeasti, toimenpide estää sydänlihasta tuhoutumasta.  
Pallolaajennuksella voidaan yleensä hoitaa kerrallaan 1 –3 suonta, ja se voidaan tarvittaessa tehdä 
uudelleen. Myös aiemmin ohitusleikattua potilasta voidaan hoitaa myöhemmin pallolaajennuksella.  
Vakaaoireisessa sepelvaltimotaudissa pallolaajennus on lähinnä oireiden hoitoa. Siksi jokaista todettua 
ahtaumaa ei ole tarpeen hoitaa. Ahtauman vaikutuksia veren virtaukseen suonen sisällä voidaan tutkia 
painevaijeritutkimuksella, jolla saadaan käsitys ah tauman vaikeusasteesta. Jos virtaus nähdään riittäväksi, 
pallolaajennusta ei tarvita.  
Yksi pallolaajennuksen ongelma on valtimon ahtautuminen uudelleen. Tätä kutsutaan restenoosiksi tai 
arpiahtaumaksi. Arpiahtauma kehittyy muutamalle prosentille hoidetuista potilaista. Riski on suurempi, jos 
hoidettavia suonia on useita, hoidetut ahtaumat o vat pitkiä tai hoidetut suonet pieniä. Uusi ahtauma 
ilmenee tavallisimmin kuuden tai viimeistään kahdentoista kuukauden sisällä pallolaajennuksesta. Silloin 
tutut rintakipuoireet palaavat. Lääkäri tekee uuden varjoainekuvauksen ja arvioi, pitääkö pallolaaj ennus 
uusia.  
Toinen, äkillisempi ja vakavampi ongelma on stenttitromboosi. Siinä suoni tukkeutuu stentin kohdalta 
nopeasti syntyneen verihyytymän vuoksi. Onneksi stenttitromboosi on kuitenkin harvinainen. Sitä torjutaan 
ennalta käyttämällä  verihiutaleiden takertumista estäviä lääkkeitä , yleensä asetyylisalisyylihapon estäjää ja 
ADP -salpaajaa. Stentin asennuksen jälkeen tällaista kahden lääkkeen yhdistelmää käytetään yleensä 
muutamia kuukausia, tai vuoden ajan. Toimenpiteen tehnyt kardiologi määrittää hoidon pituuden. 
Lääkitystä ei missä än tapauksessa saa keskeyttää omin päin, vaikka siihen liittyisi esimerkiksi lisääntynyttä 
mustelmataipumusta. Vakavampien verenvuotojen sattuessa on heti otettava yhteyttä lääkäriin tai 
soitettava hätänumeroon.  
Pallolaajennuksen jälkeen  
Jos pallolaajennus on tehty sydäninfarktin yhteydessä, potilas jää tavallisesti sairaalahoitoon 1 –7 
vuorokaudeksi. Joissain ennalta suunnitelluissa eli elektiivisissä tapauksissa kotiutus jo toimenpidepäivänä 
saattaa tulla kyseeseen.  
Valtimoon tehty pisto paranee noin viikossa. Vuotovaaran vuoksi potilaan on vältettävä kovaa fyysistä 
kuormitusta, saunomista ja yli viiden kilon taakkojen nostamista muutaman päivän ajan – erityisesti silloin, 
kun toimenpide on tehty nivusvaltimon kautta.  
Autolla ei saa ajaa ensimmäisenä vuorokautena pallolaajennuksen jälkeen. Sydäninfarktipotilaan varoajat 
ovat pidempiä ja niistä hän saa sairaalasta yksilölliset ohjeet.  
Valtaosa pallolaajennuksista onnistuu hyvin ja johtaa toivottuun tulokseen. Joskus tukosta ei kuitenkaan 
saada avattua tai toimenpiteen yhteydessä syntyy jokin haitta eli komplikaatio. Sepelvaltimo saattaa 
esimerkiksi olla niin vaikeasti kalkkeutunut, ette i pallolaajennus sujukaan ennakkoon toivotulla 
tavalla.  Näissä tilanteissa saatetaan joutua tekemään ohitusleikkaus. Hätäleikkauksen riski on kuitenkin 
hyvin pieni.  
https://sydan.fi/fakta/pallolaajennus -avaa -suonen -tukoksen/#  
 
Psykososiaalinen tuki - Hoito- ja palveluketjut - pirha.fi.pdf
Psy k ososiaalinen tuki
Psyy kkinen kuor mitus on y ksi sepel v al timot audin r iskit ekijä. Elimist össämme v ap autuu adr enaliinia, joka saa ihakset
jännitt ymään, v er enp aineen k oho amaan ja sy dämen pumpp aamaan t ehokkaammin v er t a.
Sy dänsairaus tulee useimmit en y llätt äen. H yv ä mieliala ja psyy kkinen v ointi perustuv at ennak oinnin ja hallinnan
tunt eeseen.
Sairastuminen v oi m y ös it sessään herätt ää tur v att omuutt a, pelk oja, vihaa t ai syy llisyy tt ä. Sairastumisen herätt ämät
pelot ja huolet o v at mielelle luonnollinen t ap a r e agoida muuttuneeseen elämäntilant eeseen. Sairastumisen
aiheutt amat elämänmuut okset v oiv at al tist aa psyy kkiselle kr iisille.
Sy dänsairaus v aikutt aa moneen elämän osa-alueeseen esimer kiksi omat har rastukset ja t y ö, läheiset ihmissuht eet,
oma minäkuv a. Sairastuneest a v oi tuntua, ett ä positiivisia ja tuttuja asioit a on negatiivisiin ja uusiin v er rattuna liian
v ähän.
Puhuminen on usein p aras lääk e pelk ojenkin kanssa p är jäämisen. Läheiset ja v er t aistukihenkilöt v oiv at autt aa
sairastunutt a kuunt elemalla, m y öt äelämällä ja tuk emalla. T ar vitt aessa v oi ohjat a käsitt elemään pelk oja psy k ologin
v ast aanot olle.
Psy k ologin v ast aanot olla pelk oja v oidaan lähest y ä k eskust ellen sekä mielikuv a-, r ent outus- ja al tistushar joitust en
a vulla. Samalla tunnist et aan hait allisia usk omuksia, joit a pelk oihin v oi liitt y ä.
Psyy kkinen kuor mitus sepel v al timot audin r iskit ekijänä   (Kä yp ä hoit o -suosituksen lisätiet o aineist o )
Sy dänpotilaan henkinen tuk eminen hoit ot y össä  (Opinnä y t et y ö T AMK, pdf) 
Sy dänsair aus ja mieliala   (T er v e ysky lä)
Psy k ososiaalisen tuen esimer kkik einoja
Musiikki
Käsit y öt
Y st ä v ät 
Puhuminen
R ent outuminen
Liikunt ahar rastus
V er t aistuki
P er he
Luont o
Tiet o sairaudest a
Tiet o jatkuvuudest a
Huolihetki
T er v e y denhuollon ammattilaiset
Mielen h yvin v oinnin omahoit o-ohjelma   (Mielent er v e yst alo )
Psy k ososiaalisen tuen ja p al v eluiden per iaat e
sepel v al timot autipotilaalla
Psy k ososiaalinen tuki ja p al v elut  (Kä yp ä hoit o )4.3.2025 klo 17.16 Psykososiaalinen tuki - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/psykososiaalinen-tuki 2/4
P sy k i a t r i a n e r i k o i st a so
Yleissairaalapsy kiatr ian poliklinikka (PPSY)
P otilaille, jotka kärsiv ät t er v e y dentilansa t ai muiden sairauksien aiheutt amist a mielent er v e y den häir iöist ä t ai joiden
sairauden t ai oir eilun syyn sel vitt äminen v aatii lisätutkimuksia. Esimer kiksi kun potilaalla on sairauskr iisi, kipuoir e y ht ymä
t ai elimellisoir einen häir iö. Eikä perust er v e y denhuollon p al v elut ole r iitt ä viä.
Yleissairaalapsy kiatr in poliklinikan potilaaksi p ääseminen v aatii aina lääkär in t ek emän lähett een.
Jos potilas on osast ohoidossa, soitt o psy kiatr iselle sairaanhoit ajalle.
Muissa t ap auksissa: lääkär i t ek ee lähett een ja PPSY :n poliklinikka käsitt elee nämä ja on y ht e y dessä potilaaseen. 
Pir kanmaan alueen psy kiatr inen hoit o
M i e l e nt e r v e y st y ö n pe r u st a so
Sairaanhoit ajan / lääkär in v ast aanott o omassa t y öt er v e y dessä t ai t er v e ysk eskuksessa
Mielent er v e ys- ja p äihdep al v elut
A m m a t t i a u t t a j a t
Sepel v al timot audin hoidost a v ast aa v a henkilökunt a
E i  a m m a t t i k o u l u t e t u t  a u t t a j a t :  V a p a a e h t o i so r g a n i sa a t i o t
Sy dänliit on v er t aistukit oimint a:  V er t aistuki  (Sy dänliitt o )
Sy dänliit on ammattilaisp al v elu on t ar k oit ettu  sy dänt er v e y den p ar issa t y ösk ent ele ville ammattilaisille oman t y ön
tueksi. Lö y dät p al v elust a vinkk ejä ja ohjeit a asiakkaan ohjaamiseen mm. monipuolisen v er t aistuen 
p ar iin:  ammat tilaisp al v elu  (Sy dänliitt o )
S o si a a l i ne n v e r k o st o :  pe r h e ,  y st ä v ä t ,  t y ö t o v e r i t
T ap ahtuneen käsitt el y , puhuminen
O m a  a pu :  t i e do n h a nk i n t a  sa i r a u d e st a ,  i t se h o i t o
Sopeutuminen sairauden kanssa elämiseen
Edellinen
K unt outusohjausSeur aa v a
Sairaanhoit ajan ohjaus
Päivit ett y 2. 12.202 4
T akaisin y lös4.3.2025 klo 17.16 Psykososiaalinen tuki - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/psykososiaalinen-tuki 3/4
Psyykkinen kuormitus sepelvaltimotaudin riskitekijänä.pdf
Lisätietoa aiheesta
Käypä hoito -työryhmä Krooninen sepelvaltimo-oireyhtymä
28.6.2022
Stressaavat elämäntapahtumat (kuten puolison kuolema, työpaikan menettäminen, sairastuminen tai
avioero viimeisen vuoden aikana) ovat yhteydessä 12 % suurempaan riskiin sairastua
sepelvaltimotautiin. Kuormittavista ihmissuhteista kärsivillä %-osuus oli 9 % suurempi, kuin
osallistujilla, joilla ei ollut stressiä «Wang C, Lê-Scherban F , Taylor J ym. Associations o...» 1.
Tutkimuksessa oli tutkittu keskimäärin 63-vuotiaita naisia 15 vuoden ajan.
Työstressi lisää suhteellista sepelvaltimotautitapahtuman uusiutumisriskiä 65 % «Li J, Zhang M,
Loerbroks A ym. Work stress and the...» 2.
Masennus heikentää kuntoutusinterventioiden toteutumista «Edwards BL, Sydeman SJ. Depression Is
Associated W...»3.
Sydänpotilaat, joilla on myös masennusta, voivat hyötyä sekä psyykkisestä tuesta että
sydänkuntoutuksesta «Rutledge T, Redwine LS, Linke SE ym. A meta-analys...» 4.
Työntekijöillä, jotka kokevat työssään epäsuhtaa ponnistelujensa ja siitä saatujen palkkioiden välillä,
on lisääntynyt riski sepelvaltimosairaudelle «Dragano N, Siegrist J, Nyber g ST  ym. Ef fort-Reward...» 5.
Tämä on itsenäinen riskitekijä verrattuna kokemukseen työpaineista.
Työn stressitekijät, kuten työpaineet ja pitkät työpäivät korreloivat kohtalaisesti kohonneseen riskiin
sepelvaltimo-oireytymään ja siihen liittyvään infarktiin «Kivimäki M, Kawachi I. Work Stress as a
Risk Facto...» 6.
Kohonnut riski oli altistuneilla henkilöillä 10–40 % verrattuna henkilöihin, jotka eivät kokeneet
stressiä.
Erot miesten ja naisten, eri ikäisten ja erilaisen sosiekonomisen aseman välillä olivat pieniä.
Lisäksi havaittiin yhteys stressin ja tyypin II diabeteksen välillä.
Työpaineineille ja niiden vaihtelulle altistuminen korreloi 7–21 % korkeampaan
sepelvaltimotautiriskiin verrattuna henkilöihin, jotka eivät altistuneet työpaineille. Miesten ja naisten
välillä ei havaittu eroa tässä suhteessa «Rugulies R, Framke E, Sørensen JK ym. Persistent a...» 7.
Matala sosioekonominen asema.
Kirjallisuutta
1. Wang C, Lê-Scherban F , Taylor J ym. Associations of Job Strain, Stressful Life Events, and Social
Strain With Coronary Heart Disease in the Women's Health Initiative Observational Study . J Am Heart
Assoc 2021;10:e017780 «PMID: 33618543» PubMed
2. Li J, Zhang M, Loerbroks A ym. Work stress and the risk of recurrent coronary heart disease events: A
systematic review and meta-analysis. Int J Occup Med Environ Health 2015;28:8-19 «PMID:
26159942» PubMed
3. Edwards BL, Sydeman SJ. Depression Is Associated With Reduced Outpatient Cardiac Rehabilitation
Completion Rates: A SYSTEMA TIC LITERA TURE REVIEW  AND MET A-ANAL YSIS. J
Cardiopulm Rehabil Prev 2019;39:365-372 «PMID: 30913045» PubMed
4. Rutledge T, Redwine LS, Linke SE ym. A meta-analysis of mental health treatments and cardiac
rehabilitation for improving clinical outcomes and depression among patients with coronary heart
disease. Psychosom Med 2013;75:335-49 «PMID: 23630306» PubMed
5. Dragano N, Siegrist J, Nyber g ST  ym. Ef fort-Reward Imbalance at Work and Incident Coronary Heart
Disease: A Multicohort Study of 90,164 Individuals. Epidemiology 2017;28:619-626 «PMID:
28570388» PubMed
6. Kivimäki M, Kawachi I. Work Stress as a Risk Factor for Cardiovascular Disease. Curr Cardiol Rep
2015;17:630 «PMID: 26238744» PubMed
7. Rugulies R, Framke E, Sørensen JK ym. Persistent and changing job strain and risk of coronary heart
disease. A population-based cohort study of 1.6 million employees in Denmark. Scand J Work Environ4.3.2025 klo 17.16 Psyykkinen kuormitus sepelvaltimotaudin riskitekijänä
https://www.kaypahoito.fi/nix03096 1/2
Health 2020;46:498-507 «PMID: 32202306» PubMed
Artikkelin tunnus: nix03096  (050.102)
© 2024 Suomalainen Lääkäriseura Duodecim4.3.2025 klo 17.16 Psyykkinen kuormitus sepelvaltimotaudin riskitekijänä
https://www.kaypahoito.fi/nix03096 2/2
Rasituskoe - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/Rasituskoe
Rasituskoe
(https://sydan.fi/fakta/rasituskoe/)
Rasituskokeella selvitetään tavallisimmin rasituksen aikana ilmaantuvan
oireen syytä.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 16.1.2024
 
Lue seuraavaksi Älykello, eteisvärinä ja tahdistin (https://sydan.fi/kysymys/alykello-eteisvarina-ja-tahdistin/)
Rasitus voidaan suorittaa polkupyöräergometrilla eli kuntopyörällä, tai
kävelymatolla. Suomessa käytetään tavallisemmin kuntopyörää. Kokeen
suoritusta valvoo aina kaksi ammattilaista, laitteistoa hoitava sairaanhoitaja sekä
tulosten tulkinnasta vastaava lääkäri.
Kokeen suorittaminen
Kokeen aluksi kiinnitetään elektrodit kuten tavallisessa lepo-EKG-
rekisteröinnissä, paitsi raajaelektrodit kiinnitetään vartalolle. Muutoin jalkojen ja
käsivarsien liike polkemisen aikana häiritsisi liikaa. Samalla lääkäri haastattelee, ja
kuuntelee sydänäänet stetoskoopilla. Olkavarteen kiinnitetään
verenpainemansetti. Koska rintakehällä on elektrodeja, polkeminen suoritetaan
rintakehä paljaana. Naiset voivat tarvittaessa käyttää elektrodien päällä
pehmeitä rintaliivejä.
Koe aloitetaan kevyellä rasituksella, jota vähitellen lisätään. Rasitus lopetetaan,
kun tutkittava ei jaksa enää jatkaa. Lääkäri voi määrätä kokeen lopetettavaksi,
kun syketaso osoittaa riittävää rasitusta, sydänfilmiin ilmaantuu tiettyjä
muutoksia, tai verenpaine nousee liikaa. Yläverenpaine (systolinen paine) nousee
aina rasituksen aikana, alaverenpaine (diastolinen) ei juurikaan. Itse
polkemisvaihe kestää noin 8-12 minuuttia. Kuormitusohjelma valitaan
tapauskohtaisesti: heikompikuntoiselle kevyempi, kovakuntoiselle haastavampi.
Kun rasitusvaihe on ohi, koe jatkuu vielä palautumisvaiheen seurannalla, jolloin
tutkittava makaa rentoutuen tutkimuspöydällä.
Kokeen aikana -lähtötilanteessa, rasituksessa ja palautuessa- seurataan
jatkuvasti sydämen toimintaa sydänsähkökäyrästä. Lisäksi mitataan
verenpainetta muutaman minuutin välein. Saavutettu suorituskyky kiinnostaa.
Kokeen päätyttyä lääkäri yleensä kertoo tutkimuksen tuloksista.
Kokeen aiheet
Rasituskoetta käytetään rasituksen aikana ilmaantuvan oireen selvittämiseen.
Tällainen oire voi olla rintakipu, rytmihäiriö, hengenahdistus tai huimaus.
Tavallisin syy rasituskokeelle on sepelvaltimotaudin
(https://sydan.fi/sydantietoa/sydansairaudet/sepelvaltimotauti/) tutkiminen.
Kyse voi olla diagnoosin tekemisestä, tai suorituskyvyn arvioimisesta
toimenpidehoidon jälkeen.Lue seuraavaksi Älykello, eteisvärinä ja tahdistin (https://sydan.fi/kysymys/alykello-eteisvarina-ja-tahdistin/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Koetta voidaan käyttää myös rytmihäiriöiden (https://sydan.fi/fakta/sydamen-
rytmihairiot/) selvittämiseen, tai hoidon tehon arvioimiseen. Joskus kokeella
tutkitaan rytmihäiriöille altistavia mekanismeja, kuten pitkä QT-oireyhtymässä
(https://sydan.fi/fakta/pitka-qt-oireyhtyma/). Myös vaikea-asteista läppävikaa
sairastavan potilaan suorituskyvyn mittaamiseen rasituskoe soveltuu.
Rasituskoetta voidaan tarvita myös työkyvyn arvioinnissa, tyypillisimmillään
potilailla, jotka tekevät raskasta fyysistä työtä tai toimivat ammattikuljettajina.
Joskus saattaa herätä ajatus, pitäisikö rasituskoe tehdä varmuuden vuoksi,
vaikkapa suvussa esiintyvän sepelvaltimotaudin vuoksi. Nyrkkisääntönä voidaan
pitää, että oireettomia henkilöitä ei kannata tutkia, sillä rasituskokeen tulosten
tulkintaa peilataan niin voimakkaasti oireisuuteen. Poikkeuksen muodostavat
erityisammateissa (esim. lentäjät, sukeltajat, palomiehet) toimivat, joilla
rasituskoe voi olla osa terveystarkastusta.
Ideaalitilanteessa tutkimukseen johtanut oire ilmaantuu kokeen aikana.
Rasituskokeen rajoitteet
Rasituskoe ei onnistu, jos tutkittava ei pysty polkemaan kuntopyörää
vakiovauhdilla (noin 60 kierrosta minuutissa). Esimerkiksi polvivaivat voivat silloin
estää riittävän suorituksen onnistumisen.
Samoin jotkin yleissairaudet, kuten vaikea keuhkoahtaumatauti, saattavat estää
rasituskokeen tekemisen maksimaalisena suorituksena. Silloin keuhkojen
toiminta pysäyttää suorituksen ennen kuin sydäntä on ehditty kuormittaa
riittävästi. Iäkkäillä heikentynyt reisien lihaskunto voi aiheuttaa saman
lopputuloksen.
Kun etsitään merkkejä sydämen hapenpuutteesta (iskemiasta) eräät sydämen
sähkönkulkuun liittyvät tilanteet voivat estää kokeen käyttämisen tähän
tarkoitukseen. Esimerkiksi jos tutkittavalla on EKG:ssä vasen haarakatkos (LBBB)
tai tahdistinrytmi, iskemiaa ei pysty arvioimaan.
Rasituskokeen löydösten tulkinta vaatii lääkäriltä kokemusta. Kokeessa ei
välttämättä tule ilmi mitään, vaikka tutkittavalla olisi sepelvaltimotauti. Tällöin
puhutaan väärästä negatiivisesta tuloksesta. Tulos voi olla myös väärä
positiivinen, eli EKG:n perusteella voidaan epäillä sairautta, vaikka
jatkotutkimuksissa se ei varmistuisi. Tulosten tulkinnassa huomioidaan siksi ainaLue seuraavaksi Älykello, eteisvärinä ja tahdistin (https://sydan.fi/kysymys/alykello-eteisvarina-ja-tahdistin/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
kokonaisuus, eli henkilön sydänsairauden vaaratekijät ja hänen oireensa.
Yhdistämällä taustat ja tulokset löydetään varmimmin oikeat negatiiviset (ei
epäilyä sairaudesta) ja positiiviset (vahva epäily sairaudesta) tapaukset.
Spiroergometria
Spiroergometriatutkimus tehdään kuten rasituskoe, mutta lisäksi mitataan
hengityskaasuja. Siten pystytään määrittämään keuhkotuuletusta,
hapenkulutusta ja hiilidioksidituottoa. Näin saadaan selville maksimaalinen
hapenottokyky.
Tutkimusta käytetään erityisesti tutkittaessa rasitushengenahdistusoiretta, kun
on epäselvää, onko syynä sydän- vai keuhkoperäinen syy. Sitä käytetään myös
sydämen vajaatoimintapotilailla osana sydänsiirtoarviota. Käytännössä
spiroergometriatutkimusta tarvitaan suhteellisen harvoin.Lue seuraavaksi Älykello, eteisvärinä ja tahdistin (https://sydan.fi/kysymys/alykello-eteisvarina-ja-tahdistin/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Revaskularisaatio - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p al v eluk et jut  / Sepel v al timot autipotilaan hoit ok et ju  / Sepel v al timot audin hoit o  /
R e v askular isaatio
 Sepel v al timot autipotilaan hoit ok et ju
Sepel v al timot audin diagnostiikka
Sepel v al timot audin hoit o
Sepel v al timot audin hoidon kulmakiv et
Sepel v al timot audin r iskit ekijät
Sepel v al timot audin ennust ett a p arant a v a lääk ehoit o
Sepel v al timot audin oir eit a lie vitt ä v ä lääk ehoit o
R e v askular isaatio
Yleist ä ohitusleikkauksest a
Sepel v al timot autik oht aus
Sy dän v almennus
Sepel v al timot audin jatk ohoit o ja seurant a



R e v askular isaatio
Sepel v al timoiden v ar jo ainekuv aust a suosit ellaan , jos potilas on oir einen h yv äst ä lääk ehoidost a huolimatt a t ai
kajo amatt omissa tutkimuksissa on viitt eit ä huonost a sepel v al timot audin ennust eest a.
R e v askular isaatiolla on t audin ennust et t a p ar ant a v a v aikutus Kuuntele4.3.2025 klo 17.21 Revaskularisaatio - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/hoito/revaskularisaatio 1/3
Lähes aina sepel v al timot autik oht auksen y ht e y dessä. 
St abiilisti oir eile v assa t audissa, jos potilaalla on:
Mer kitt ä v ä v asemman p äärungon aht auma, 
LAD:n t yv en aht auma t ai
K olmen suonen t auti y hdist ett ynä v asemman kammion v ajaat oimint aan (EF<35%).
Hoit o v aiht oeht oja o v at  p allolaajennus (PCI)  t ai ohitusleikkaus (C ABG) . Hoit omuot o p äät et ään y ksilöllisesti
diagnostisen sepel v al timoiden v ar jo ainekuv auksen jälk een
Yksink er t aiset aht aumat hoidet aan y leensä heti diagnostisen kuv auksen jälk een p allolaajennuksella
V aik e ampien aht aumien PCI-hoit o a v ar t en so vit aan y leensä uusi aika lähiviik oille
Ohitusleikkaus t ehdään oir eiden v aik eusast eest a r iippuen 1-8 viik on sisään diagnostisest a kuv auksest a
Hankalimmat hoit op äät ökset t ehdään y ht eist y önä sy dänkirur gien ja kar diologien k esk en (He ar t T e am -käsitt el y)
Hoit omuodon v alint aan v aikutt a v at 
Sepel v al timo aht aumien määrä 
Aht aumien sijainti (y hden v ai use amman suonen alueella, suonen t yviosissa, p äärungossa, haaraumak ohdissa), 
Aht aumien laatu (kalkkisuus)
Saat a villa ole v a ohit esuonimat er iaali (aiemmin t ehd y t suoik ohjut oimenpit eet, v ammat)
P otilaat muut sairaudet ( esim. muistisairaus, alk oholismi, k euhk osairaudet, munuaist en v ajaat oimint a, maksan
v ajaat oimint a, ASO-t auti)
Muut leikkausr iskiä nost a v at t ekijät ( esim. obesit eetti, jatkuv a tup ak ointi, aiemmat sy dänleikkaukset, ihon kunt o )
P otilaan ikä, edel t ä v ä t oimint aky ky , potilaan oma t oiv e hoit omuodost a
Ohitusleikkaust a puol t a v at t ekijät
Diabet es ja t odettu k olmen suonen t auti p ar emman pitkäaikaisennust een vuoksi 
Laaja-alainen t auti ja kalkkiset ja/t ai suont en haaraumak ohdissa sijait se v at aht aumat
Laaja-alainen sepel v al timot auti ja alentunut ejektiofraktio
Hoit o a v aativ a läpp ä vika t ai r int a-aor t an aneur ysma
T a ys Sy dänsairaalassa t ehdään vuositt ain noin 1500 sepel v al timoiden r e v askular isaatiot oimenpidett ä, joist a 84% on
PCI-t oimenpit eit ä ja 16% ohitusleikkauksia (v . 2022).
 
Edellinen
Sepel v al timot audin oir eit a lie vitt ä v ä lääk ehoit oSeur aa v a
Yleist ä ohitusleikkauksest a
Päivit ett y 28 . 11.202 4
T akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.4.3.2025 klo 17.21 Revaskularisaatio - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/hoito/revaskularisaatio 2/3
Riittävästi unta ja lepoa - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Terveys & Hyvinvointi (https://sydan.fi/terveys-hyvinvointi/)/
Uni ja stressi (https://sydan.fi/terveys-hyvinvointi/stressi/)/Riittävästi unta ja lepoa
Riittävästi unta ja lepoa
Riittävän levon ja palautumisen turvaamiseksi sepelvaltimotautia sairastavan
kannattaa kiinnittää erityistä huomiota riittävään uneen ja säännölliseen
unirytmiin.
Kuva: Anna Kara
Paula Mannonen
Julkaistu 22.5.2015
Päivitetty 14.8.2019
 
Lue seuraavaksi Vinkkejä stressin ja kielteisten tunteiden hallintaan (https://sydan.fi/fakta/vinkkeja-stressin-ja-kielteisten-
tunteiden-hallintaan/)
Uni ja lepo ovat välttämätöntä vastapainoa päivän rasituksille. Nukkuessa
elimistö rakentaa ja korjaa soluja ja täyttää niiden energiavarastoja. Ja vaikka
ihmisen tietoinen minä on unessa, aivot käsittelevät ja järjestelevät päivän
tapahtumia ja tunteita.  Näillä öisillä toiminnoilla on suuri merkitys niin
ruumiilliselle ja henkiselle hyvinvoinnille kuin muistamiselle ja oppimiselle.
Sydänongelmien jälkeen väsymys on tavallista voimakkaampaa ja levon tarve
suurempi, mutta nukkuminen ei silti tahdo aina onnistua.  Etenkin toipumisen
alussa esiintyy usein nukahtamisvaikeuksia ja painajaisia ja uni on katkonaista tai
levotonta. Ne johtuvat sairauden aiheuttamasta fyysisestä ja psyykkisestä
stressitilasta ja siitä, että elimistö ei ole vielä tottunut sydänlääkkeisiin
(https://sydan.fi/fact/sydan-ja-verisuonisairauksien-laakkeet/).
Riittävän levon ja palautumisen turvaamiseksi sepelvaltimotautia sairastavan
kannattaa kiinnittää erityistä huomiota riittävään uneen ja säännölliseen
unirytmiin. Unen tarve on yksilöllinen, mutta keskimäärin yöunien tulisi kestää 7-
8 tuntia. Alkuvaiheessa on lisäksi hyvä levätä päivällä tunti tai pari.
Ohjeita univaikeuksien hoitamiseen:
yritä rauhoittaa ympäristösi ennen nukkumaanmenoa. Voit myös tehdä
jotain rentouttavaa: kevyt iltapala, lämmin kylpy, sauna tai
rentoutusharjoitus saattaa auttaa nukahtamaan.
mene vuoteeseen vasta väsyneenä. Jos piristyt uudelleen, nouse ylös ja tee
jotain muuta, kunnes tunnet olosi taas väsyneeksi.
koeta nousta ja mennä nukkumaan aina suurin piirtein samaan aikaan, myös
viikonloppuna. Sisäinen kello voi mennä sekaisin, jos torkut vapaapäivänä
vuoteessa monta tuntia normaalin heräämisajan jälkeen. Vaikka nukkumaan
meno siirtyisi, yritä silti pitää kiinni heräämisajasta.
ota mahdolliset iltalääkkeet aina samaan aikaan pari tuntia ennen
nukkumaanmenoa
aamu on hyvä aloittaa kirkkaassa valossa, mutta illalla sitä on parempi
välttää
televisio ja tietokone on parempi sijoittaa muualle kuin makuuhuoneeseen
tartu stressaaviin asioihin ja töihin hyvissä ajoin ennen nukkumaanmenoa
vältä kahvia, kaakaota ja energiajuomia illalla
kevyt iltapala voi helpottaa nukahtamista, mutta raskas ateria valvottaa
alkoholi heikentää unen laatua (https://sydan.fi/fact/alkoholia-enintaan-
kohtuullisesti/). Muistathan, että alkoholi ei sovi yhteen kaikkien lääkkeiden
kanssa.Lue seuraavaksi Vinkkejä stressin ja kielteisten tunteiden hallintaan (https://sydan.fi/fakta/vinkkeja-stressin-ja-kielteisten-
tunteiden-hallintaan/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
säännöllinen liikunta (https://sydan.fi/fact/liikunnan-vaikutuksia-sydamen-
terveyteen/) parantaa yöunta. Kuormittavaa liikuntaa ei kuitenkaan tulisi
harrastaa noin kolmeen tuntiin ennen nukkumaanmenoa. Kevyt iltakävely
voi silti rentouttaa.
terveellinen ruokavalio on hyväksi yöunelle
pimeä, viileä ja meluton makuuhuone sekä sopiva patja, tyyny ja peitto
auttavat nukahtamaan. Jos kärsit ulkopuolelta tulevista äänistä, kokeile
korvatulppia.  Liikaa valoa voi taas vähentää silmäsuojuksilla, joita käytetään
usein muun muassa pitkillä lennoilla.
jos univaikeudet jatkuvat, keskustele asiasta lääkärin kanssa.
Lue myös Liikunta hyvän unen edistäjänä (https://sydan.fi/fact/unijaliikunta/) ja
Hyvän unen ruokavinkit (https://sydan.fi/fact/hyvan-unen-ruokavinkit/).Lue seuraavaksi Vinkkejä stressin ja kielteisten tunteiden hallintaan (https://sydan.fi/fakta/vinkkeja-stressin-ja-kielteisten-
tunteiden-hallintaan/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Rintakipu - Sydänsairaala.pdf
Etusivu (https://www.sydansairaala.fi)➝Tietoa (https://www.sydansairaala.fi/tietoa/)➝Rintakipu
Rinta kipu
Rintakipu voi olla paitsi sydänperäistä myös lihaksista, tukirangasta, ruokatorvesta,
vatsasta tai keuhkoista johtuvaa. Sepelvaltimotauti on tavallisin rintakipua aiheuttava
sydänsairaus.
Mistä sydän pe räisen rinta kivun tunnistaa?
Rintakivun vaivatessa on tärkeää tunnistaa, millaisesta rintakivusta on kyse.
Sepelvaltimotaudissa sydänlihakselle happea vievän valtimon ahtautuminen aiheuttaa
sydänlihaksen hapenpuutteen. Se aistitaan tyypillisesti rasituksen aikaisena rintakipuna.
Sydänperäinen rintakipu vaikeutuu tyypillisesti rasituksessa, ja lepo puolestaan helpottaa
oireita.
Sydänperäinen rintakipu tuntuu rintakehän keskiosassa tai kauttaaltaan koko rintakehällä.
Kipukohtaa ei pysty osoittamaan sormella, toisin kuin lihas- ja tukirankaperäisessä
rintakivussa.
Sydänperäinen rintakipu voi myös säteillä selkään, kaulaan ja olkavarsiin. Kipu voi olla
luonteeltaan puristavan ja ahdistavan tuntuista.Aihee seen liit tyvää
Sepelvaltimotauti ➝
(https://www.sydansairaala.fi/tietoa/sepelvaltimotauti/)
Sydäninfarkti ➝
(https://www.sydansairaala.fi/tietoa/sydansairaudet-
sydaninfarkti/)
Sepelvaltimotaudin hoito ➝
(https://www.sydansairaala.fi/potilaana/sepelvaltimotaudin-
hoito/)
Hoitoon Sydänsairaalaan 
(https://www.sydansairaala.fi/hoitoon-
sydansairaalaan/)
Hoitopaikan valinta 
(https://www.sydansairaala.fi/hoitoon-
sydansairaalaan/hoitopaikan-valinnanvapaus/)
Jaa sivu:
(http://www.facebook.com/sharer/sharer.php?
u=https://www.sydansairaala.fi/tietoa/rintakipu/)
(http://twitter.com/share?
url=https://www.sydansairaala.fi/tietoa/rintakipu/&text=Rintakipu)
(http://www.linkedin.com/shareArticle?
url=https://www.sydansairaala.fi/tietoa/rintakipu/&title=Rintakipu&summary=&sourc➝
➝(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Sydäninfarktissa oire voi alkaa myös levossa, jolloin rintakipu saattaa herättää
esimerkiksi yöllä. Sydäninfarktissa puristava rintakipu on tyyppioire. Johtavana oireena
voi olla myös hengenahdistus, yleistilan heikkeneminen, närästys tai ylävatsakipu.(mailto:?
subject=Rintakipu&body=https://www.sydansairaala.fi/tietoa/rintakipu/)
Rinta kipu – milloin hoitoon?
Rasitukseen liittyvän rintakivun aiheuttaja täytyy aina selvittää. Jos oire helpottuu muutaman minuutin kuluttua rasituksen lopettamisen jälkeen eikä
rintakipua ilmaannu levossa, voidaan tutkimukset tehdä lähiviikkojen aikana. Silloin tutkimuksiin voi hakeutua joko omalääkärin tai sydänlääkärin kautta.
Jos rintakipu alkaa levossa ja oirekuva sopii sydäninfarktiin, täytyy hoitoon hakeutua välittömästi soittamalla yleiseen hätänumeroon 112.
Tehokas alkuhoito aloitetaan heti potilaan luona, kun sairaankuljetus saapuu paikalle. Ensihoitajat ottavat potilaalta sydänfilmin (EKG). Tarvittaessa
Pirkanmaan alueella ensihoitajat ottavat yhteyden Tays Sydänsairaalan päivystävään sydänlääkäriin. Alkuhoidon jälkeen potilas kuljetetaan Tays
Sydänsairaalan hoidettavaksi. Sydäninfarktin hoito on tukkeutuneen sepelvaltimon välitön avaaminen pallolaajennuksella.
Rintakivun syy on aina tärkeä selvittää.
Sydän pe räiset äkil liset oireet
Voimakkaan, äkillisen tai rasituksen yhteydessä tulevan
rintakivun syynä voi olla sepelvaltimotukos eli sydäninfarkti.
Katso video ▶
(https://player.vimeo.com/video/558422857?
texttrack=fi&rel=0&showinfo=0)
(https://player.vimeo.com/video/558422857?
texttrack=fi&rel=0&showinfo=0)
(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Riskitekijöiden hoidon tavoitteet - Hoito- ja palveluketjut - pirha.fi.pdf
Riskit ekijöiden hoidon t a v oitt eet
Huom. y ksilöllisesti ikä ja muut mahdolliset t ekijät huomioiden hoit a v a lääkär i v oi määr itt ää m y ös y leisist ä t a v oitt eist a
poikk e a v at t a v oitt eet
LDL -k olest er olipit oisuus < 1,4mmol/l
y ksilöllisesti v oidaan p yr kiä < 1, 0 mmol/l:n pit oisuut een er it yisesti, jos potilaalla on ollut t oistuvia
v al timot autit ap ahtumia
Dyslipidemiat   (Kä yp ä hoit o -suositus)
Lepo v er enp aine < 130/80mmHg
Yli 65 vuotiailla <140/80mmHg
K ohonnut v er enp aine  (Kä yp ä hoit o -suositus)
Nor maali sok er iaineen v aihdunt a
V er ensok er in p aast o ar v o < 5 , 5 mmol/l, gluk oosirasitusk ok een ar v o < 7 , 8mmol/l ja Hb A 1C - pit oisuus < 42mmol/mol;
diabeetik oilla Hb A 1C - pit oisuus < 53mmol/mol
T yypin 2 diabet es  (Kä yp ä hoit o -suositus)
T ä y dellinen tup ak oimatt omuus
tup ak oinnin lisäksi tulisi pidätt ä y t y ä m y ös muist a nik otiiniv almist eist a, kut en sähk ötup akast a ja nuuskast a
T up akka- ja nik otiinir iippuvuuden ehkäisy ja hoit o  (Kä yp ä hoit o -suositus)
Säännöllinen t er v e ysv aikutt einen liikunt ahar rastus
Liikunnan ja liikunnallisen sy dänkunt outuksen v aikut t a vuus osana kr oonist a sepel v al timo-oir e y ht ymää sair ast a v an
hoit o a  (Kä yp ä hoit o )
Sepel v al timot autipotilaan liikunnallinen kunt outus  (T er v e yspor tti)
Kr ooninen sepel v al timo-oir e y ht ymä ja liikunt a  (Kä yp ä hoit o )
K eskiv ar t aloliha vuuden hallint a
Vy öt är ön ymp är ysmitt aa ( cm) kä y t et ään kuv aamaan k eskiv ar t alolle k er t yv ää liikarasv aa.
Mer kitt ä v ä vy öt är öliha vuuden raja-ar v ona on naisilla 88cm ja miehillä 102cm
Last en,  nuor t en ja aikuist en liha vuus  (Kä yp ä hoit o -suositus)
P ainoindeksi ja vy öt är ön ymp är ys  (Kä yp ä hoit o )
Edellinen
Sy dän v almennus ja sen osa-alueetSeur aa v a
F ysiot erapeutin ohjaus4.3.2025 klo 17.09 Riskitekijöiden hoidon tavoitteet - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/riskitekijoiden-hoidon-tavoitteet 2/3
Ruoka sydämen hoitajana - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Ruoka & Ravitsemus (https://sydan.fi/ruoka-ravitsemus/)/
Ruoka sydämen hoitajana
Ruoka sydämen hoitajana
Sydämen kannalta keskeiset valinnat liittyvät rasvan määrään ja laatuun.
Kuva: Jarno Hämäläinen
Tuija Pusa
Julkaistu 21.5.2015
Päivitetty 5.8.2019
 
Omakuntoutusohjelmaan (https://sydan.fi/fact/omatoimisen-kuntoutuksen-
opas/) kuuluu oman ruokavalion pohdinta. Sydämen kannalta keskeiset valinnat
liittyvätLue seuraavaksi Sydänpotilaan ravitsemus (https://sydan.fi/kysymys/sydanpotilaan-ravitsemus/)
rasvan määrään ja laatuun. Rasvoja pitäisi kaiken kaikkiaan syödä vain
kohtuudella ja niiden tulisi olla enimmäkseen pehmeitä kasvirasvoja.
Rasvojen saanti liittyy myös ravinnon proteiinien eli valkuaisaineiden
valintaan. Kala, kasvivalkuainen ja vaalea liha ovat punaista lihaa parempia
vaihtoehtoja, ja maitotuotteista kannattaa valita rasvaton versio. Runsas
rasvan saanti ja eläinrasvojen käyttö nostavat veren kolesterolipitoisuutta.
suolaan. Suomalaiset saavat ravinnostaan edelleen moninkertaisesti suolaa
tarpeeseen nähden. Runsas suolankäyttö nostaa verenpainetta.
hiilihydraatteihin. Jotkut hiilihydraatit –  muun muassa sokerit ja valkoinen
vilja –  imeytyvät ruuansulatuskanavasta nopeasti vereen. Samalla ne
nostavat verensokerin korkealle, mikä altistaa monille terveysongelmille,
etenkin jos ruoka sisältää nopeiden hiilihydraattien ohella runsaasti rasvaa.
Sydämen kannalta on tärkeää syödä hitaasti imeytyviä hiilihydraatteja kuten
kasviksia, täysjyväviljaa ja hedelmiä.
Imeytymisnopeuteen vaikuttaa erityisesti ruuan sisältämä kuitu: mitä enemmän
kuitua, sen tasaisempana verensokeri pysyy.  Kuitu auttaa myös poistamaan
kolesterolia elimistöstä. Jos ateria sisältää nopeita hiilihydraatteja, kuitu
hidastaa niidenkin imeytymistä.
suojaravintoainesiin eli vitamiineihin ja hivenaineisiin, jotka parantavat
elimistön vastustuskykyä ja estävät tulehdustiloja. Hyviä lähteitä ovat
kasvikset, marjat ja hedelmät.
syötävän määrään ja kaloripitoisuuteen. Elimistö varastoi kaikki
kuluttamatta jääneet ravintoaineet rasvana.
ruuan valmistukseen. Hyvistä aineksista valmistuu sydänystävällisin ateria
keittämällä, höyrystämällä ja uunissa kypsentämällä.  Paistamiseen sopivat
parhaiten rypsiöljy tai pullomargariini.
Omia ruokatottumuksiaan muuttaessa on hyvä tutkia tarkkaan elintarvikkeiden
pakkausmerkintöjä.
Lyhyt ravinto-oppi
Ruoka antaa elimistölle välttämättömiä rakennusaineita ja energiaa. Makro- tai
energiaravintoaineita ovat rasvat, proteiini (valkuaisaine) ja hiilihydraatit.
Neljännen ryhmän muodostavat mikroravinteet eli vitamiinit ja kivennäis- ja
hivenaineet. Ihminen tarvitsee näitä kaikkia.
Rasva (https://sydan.fi/fact/rasvan-laatu-ratkaisee/) toimii elimistössä
pitkäaikaisen energian lähteenä, mutta myös solukalvojen ja hormonien raaka-
aineena. Lisäksi sitä tarvitaan muun muassa rasvaliukoisten vitamiinien jaLue seuraavaksi Sydänpotilaan ravitsemus (https://sydan.fi/kysymys/sydanpotilaan-ravitsemus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
hermoston toiminnassa. Osan tarvitsemistaan rasvahapoista elimistö valmistaa
itse, mutta ns. välttämättömät rasvahapot (omega-3 ja omega-6) saadaan
ravinnosta.
Kolesterolin kannalta hyviä omega-rasvoja on paljon muun muassa kalassa,
rypsi- ja oliiviöljyssä sekä pähkinöissä ja siemenissä. Vähärasvaisen lihan tai kanan
rasvakoostumus on myös suhteellisen hyvä. Haitallisia ovat teollisesti kovettujen
kasvirasvojen sisältämät transrasvat, joita on monissa paistorasvoissa (ja
uppopaistetuissa tuotteissa) sekä pitkään säilyvissä elintarvikkeissa. Myös
runsasrasvainen liha ja lihavalmisteet sisältävät huonoa LDL-kolesterolia lisäävää
eläinrasvaa.
Proteiini (https://sydan.fi/fact/proteiinia-sopivasti/)on ensisijaisesti elimistön
rakennusainetta. Muun muassa lihakset, monet elimistön vasta-aineet,
hermoston välittäjä-aineet ja entsyymit ovat enimmäkseen proteiinia.  Sitä
saadaan erityisesti lihasta, kalasta, kananmunista, maitotuotteista ja
palkokasveista, pähkinöistä ja täysjyväviljasta.
Hiilihydraatit ovat elimistön tärkein nopean energian lähde. Ne muodostuvat
erilaisista sokereista ja niitä saadaan eniten viljasta ja viljatuotteista sekä
perunasta. Myös kasviksissa, juureksissa ja hedelmissä sekä sokeria tai
tärkkelystä sisältävissä makeisissa, maidossa, marjoissa, hedelmissä, hunajassa,
mehuissa, virvoitusjuomissa ja vastaavissa tuotteissa on hiilihydraatteja.
Suositeltavia ovat hitaasti imeytyvät hiilihydraatit, jotka sisältävät yleensä paljon
kuitua: kasvikset, hedelmät ja marjat. Valkoinen (kuorittu) vilja ja siitä tehdyt
valmisteet ja leivonnaiset on syytä jättää vähälle, samoin sokeriset karkit ja
makeat juomat. Perunaakin kannattaa syödä vain kohtuudella ja mieluiten
keitettynä.
Suojaravintoaineet eli vitamiinit ja hiven- ja kivennäisaineet ovat myös
välttämättömiä. Ne suojaavat elimistöä monilta haitallisilta muutoksilta solujen
härskiintymisestä tulehduksiin ja osallistuvat nestetasapainon säilyttämiseen ja
monien muiden elimistön toimintojen hoitamiseen. Suojaravintoaineita saadaan
erityisesti kasviksista, marjoista ja hedelmistä, mutta myös kalasta, maidosta ja
lihasta.
Terveellisen ruokavalion perusteet
Ravintosuositusten mukaan ihmisen tulisi saada päivittäisestä energiastaan 25-
35 % rasvoina (tästä kaksi kolmannesta tyydyttämätöntä rasvaa), 50-60 %
hiilihydraatteina (runsaskuituisia ja paljon suojaravinteita sisältäviä aineksia) ja
10-20 % valkuaisaineena.Lue seuraavaksi Sydänpotilaan ravitsemus (https://sydan.fi/kysymys/sydanpotilaan-ravitsemus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Jos et halua perehtyä tarkemmin ruokien ravintoainekoostumukseen, selviät
pitkälle pelkästään syömällä sopivan määrän, suhteellisen säännöllisesti ja
kokoamalla aterian lautasmallin (https://sydan.fi/fact/lautasmalli/) mukaan.
Sydänmerkki (https://www.sydanmerkki.fi/sydanmerkki) auttaa valitsemaan
ruokakaupassa.
Tietoa ja ideoita sydämen kannalta hyvään ruokavalioon löydät seuraavista
linkeistä:
kasvisten marjojen ja hedelmien käyttö (https://sydan.fi/fact/kasvikset-
ovat-yksi-terveellisen-ruokavalion-kulmakivista/)
kuidun tarve (https://sydan.fi/fact/kuitu-monipuolisen-ruuan-osana/)
vähemmän suolaa (https://sydan.fi/fact/suolaa-vain-kohtuudella/)
rasvan määrä ja laatu kohdalleen (https://sydan.fi/fact/rasvan-laatu-
ratkaisee/)
sydänystävällinen ruuanvalmistus ja leipominen
(https://sydan.fi/fact/sydanystavallinen-ruoanvalmistus/)
säännöllisen ateriarytmin (https://sydan.fi/fact/ateriarytmi-lisaa-
hyvinvointia/) merkitysLue seuraavaksi Sydänpotilaan ravitsemus (https://sydan.fi/kysymys/sydanpotilaan-ravitsemus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sairaanhoitajan ohjaus - Hoito- ja palveluketjut - pirha.fi.pdf
Sairaanhoit ajan ohjaus
Sairaanhoit ajan ant aman ohjauksen t avoitteena on potilaan sit outtaminen omahoit oon ja r iskit ekijöiden hallint aan.
Ohjauksen a vulla potilast a motiv oidaan ott amaan v astuut a omast a terveydest ään ja t ekemään sit ä tuk evia v alint oja.
Ohjauksessa kunnioit etaan potilaan it semääräämisoik eutta ja se t apahtuu potilaan ehdoilla. Laadukkaalla ohjauksella
pyritään v ahvistamaan potilaan k otona sel viytymist ä ja v ähent ämään heidän y hteydenott oja hoit ojaksojen jälk een. 
Potilaalle annett avan lisätiedon ja ohjauksen a vulla p yritään m yös  lie vittämään pelk oja ja jännitt yneisyy ttä ennen
toimenpit eitä / leikkauksia. Sairaanhoit aja huomioi ohjauksessaan sen, onk o potilas sairast anut sy däninf arktin.
P otilaan ohjaus ja motiv ointi
Moniammatillinen y ht eist y ö osana potilaan ohjauspr osessia
Potilasohje: Op as sepel v al timot autia sair ast a v alle (Terveyspor tti, pdf)
Sairaanhoit ajan ohjauksen sisäl tö
Tutkimus- ja hoit otoimenpit eiden ohjaus ja niihin liitt yvät seurant a- ja hoit o-ohjeet
Perustiet oa sepel valtimot audist a: riskit ekijät, synt y, oireet, tiet o sairauden kr oonisuudest a 
  Kr ooninen sepel v al timo-oir e y ht ymä (Käypa hoit o -suositus)
  Sepel v al timot autik oht aus (Käypä-hoit o –suositus)
  Tiet o a sepel v al timot audist a (Sydänsairaala) 
Sepel v al timot auti (Sydänliitt o)
Lääk ehoit oon sit outtaminen
Lääkk eet ja niiden v aikutus, lääkk eiden ott o
Lääk ehoidon mer kitys sairauden hoidossa – v ain ot ettu lääk e autt aa!
Elämänt ap aohjaust a annet aan y ksilöllisesti potilaan r iskit ekijöiden mukaan 
Sydänystävällinen ruoka valio
Painonhallinnan tuki
Päiht eettömyys, tup akointi ja alk oholi
Suun hoit o
Seksuaalisuuden huomiointi
Verenpaineen hoit o
Tietoa mielialan mer kityksest ä toipumiselle, psy kososiaalinen tuki
Sosiaalitur va
Hoit oon hak eutuminen
Jatk ohoit oon linkitt yvät asiat
 Sepel v al timot autipotilaan ohjaus  Ohitusleikkauspotilaan ohjaus
Lääk ehoit oon sit outtaminen
Sepel valtimot autipotilaan lääk ehoidon t avoitteena on p arant aa taudin ennust etta ehkäisemällä sy dänperäisiä kuolemia
ja sy däninf arkteja, sekä lie vittää oir eita ja p arant aa elämänlaatua. Lääk ehoit oon sit outuminen on y ksi jatk ohoidon
onnistumisen edell ytys ja omahoidon kulmakivi. Lääkk eet tulee kä yttää säännöllisesti lääkär in ant amien ohjeiden
mukaan. Säännöllisen lääk ehoidon t oteuttamist a voi helpott aa kä yttämällä apuna dosettia eli lääk eannost elijaa.4.3.2025 klo 17.17 Sairaanhoitajan ohjaus - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/sairaanhoitajan-ohjaus 2/4
L ä ä k e h o i t o o n si t o u t u m i se n  k e i n o j a :
Neuv onta, potilasopetus ja motiv ointi
Parempi annost elu ja kä yttötapa
Seurannan jär jestäminen
Potilas-lääkär isuhde
H y ö d y l l i si ä  l i nk k e j ä :
Mit en aut t aa potilast a sit outumaan lääk ehoit oonsa?  (Duodecim)
Hoit oon sit outuminen ja st atiinihoit o (Käypä hoit o)
Verenpaineen hoit o
Kohonneen v erenpaineen hoit aminen on t ärkeää, sillä sairastuvuus ja kuolleisuus sy dän- ja
verisuonit auteihin lisäänt yvät verenpaineen nousun m yötä. Kohonneen v erenpaineen hoidossa kä ytetään
elämänt apahoit oa ja t arvittaessa t ämän r innalla lääk ehoit oa. Verenpaine t avoitteena on < 130/80mmHg (Yli 65
vuotiailla <140/80mmHg)
V e r e np a i ne e n se u r a nt a
Mittaus olka varresta verenpainemitt arilla
Ennen mitt aust a 5min lepo a, rauhallinen ymp äristö
Mittaukset k otona aamuisin ennen lääkk een ott oa, sekä il taisin. Mitt ausar vot on h yvä laitt aa y lös.
V e r e np a i ne e n h o i t o  e l i n t a v o i l l a
Suolan kä ytön v ähent äminen, suositus enint ään 5g p äivässä
Alkoholin kä ytön v ähent äminen, tup akoinnin lopett aminen
Fyysisen aktiivisuuden lisääminen, y lipainon pudott aminen
Terveellinen ruoka valio
Stressin v älttäminen
Salmiakin ja lakr itsin v älttäminen
H y ö d y l l i si ä  l i nk k e j ä :
K ohonnut v er enp aine (Käypä hoit o -suositus)
K ohonnut v er enp aine (Duodecim, T erveyskir jasto)
Verenpaineeseen v aikutt avat elint avat (T erveysky lä)
Kohonnut v erenpaine (Sy dänsairaala)
Edellinen
Psykososiaalinen tukiSeur aa v a
Elämänt apaohjaus
Päivit etty 13.12.202 44.3.2025 klo 17.17 Sairaanhoitajan ohjaus - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/sairaanhoitajan-ohjaus 3/4
Selpelvaltimotauti-ja-liikunta-Sydänsairaala.pdf
 Potilasohje  
 SKOY PO0073  1 (2) 
  11.12.2018   
 
 
TAYS Sydänsairaala Oy  www.sydan sairaala .fi 
 
 
 
Sydän, kuten muutkin lihakset, tarvitsee harjoitusta pysyäkseen kunnossa. Tämän 
vuoksi liikunnan tulee olla luonnollinen osa sepelvaltimotautia sairastavan henkilön 
elämää. On tärkeää, että löydät itsellesi mieluisan ja kunnollesi sopivan liikuntamu o-
don. 
 
Säännöllinen liikunta johtaa terveyshyötyihin ja hidastaa sepelvaltimotaudin etenemi s-
tä. Säännöllisellä liikunnalla pystyt vaikuttamaan useisiin sepelvaltimotaudin riskiteki-
jöihin. Liikunta:  
 parantaa sydämen pumppaustehoa  
 parantaa valtimoiden sisäkalvon toimintaa  ja valtimonseinämän tulehdusrea k-
tiota 
 parantaa kolesterolitasapainoa , mikä hidastaa valtimoiden ahtautumista   
 lisää elimistön insuli iniherkkyyttä ja parantaa veren sokeritasapainoa  
 alentaa verenpainetta  
 auttaa painonhallinnassa  
 
Lisäksi liikunta kohentaa mielialaa ja vähentää stressiä. Liikunnan avulla suorituskyky 
paranee ja ark iaskareet sujuvat helpommin.  
Liiku säännöllisesti ja monipuolisesti  
Fyysinen aktiivisuus eli arki - ja hyötyliikunta  
 mielellään päivittäin, vähintään 3 –4 kertaa vi ikossa  
 30–60 minuuttia kerrallaan  
 huomioi kevyt aloitus, vältä pitkäkestoista, raskasta, kohoasennossa tapahtuvaa työske n-
telyä yläraajoilla ja tauota työskentelyä tarvittaessa  
 esim. työ - ja kauppamatkat kävellen tai pyörällä, porraskävely, koti - ja piha -askareet  
Kestävyysliikunta  
 suositeltavin liikuntamuoto  
 mielellään päivittäin , vähintään 3 kertaa viikossa  
 minimikestoltaan 20 min, mieluiten 60 min kerta , vähintään 2,5 tuntia viikossa   
 voit helposti säädellä tehoa tuntemustesi mukaan  
 esim. kävely, pyöräily, hiihto, uinti  
 
 
käännä  Sepelvaltimotauti  ja liikunta  
 Potilasohje  
 SKOY PO0073  2 (2) 
  11.12.2018   
 
 
TAYS Sydänsairaala Oy  www.sydan sairaala .fi 
 
Lihasvoimaharjoittelu  
 2–3 kertaa viikossa  
 alku- ja loppuverryttely on tärkeää  
 esim. kuntosaliharjoittelu, kotivoimistelu  
 10–15 toistoa, kohtuulli sesti kuormittavalla teholla, 1 –3 sarjaa. 8 –10 liikettä, jotka kuormi t-
tavat suurimpia lihasryhmiä   
 pyydä fysioterapeutiltasi tarvittaessa erillinen ohje lihasvoimaharjoittelun turvallisesta t o-
teuttamisesta   
Liiku tehokkaasti  ja turvallisesti  
 voit hengästyä ja hikoilla, vältä kuitenkin rintakipua ja hengenahdistusta  
 voit arvioida rasittavuutta esim. sykkeen avulla, tärkeintä on kuitenkin seurata omia 
tuntem uksia  esim. rasitustuntemusasteikon avulla.  
 liikunta saa tuntua hieman rasittavalta tai rasittavalta, jos se on oireetonta ja palaudut siitä 
hyvin .  
 jokainen liikuntakerta sisältää 5 –15 min alku - ja loppuverryttelyn . 
 asianmukainen alku - ja loppuverryttely on erityisen tärkeää, jos liikuntaharjoittelu toteut e-
taan varhain aamulla tai kylmässä.  
 lisää liikunnan määrää ja kuormittavuutta vähitellen , jopa 10 min liikunnan lisääminen tuo 
terveyshyötyjä  
 
 pidä n. 1 tunnin tauko lääkkeen oton tai aterian jälkeen enne n kuntoliikuntaa  
 keven nä liikuntaa kovassa  tuulessa,  pakkasessa ja helteessä  
 vältä rasitusta, jos olet sairas, huonovointinen tai leposykkeesi on paljon normaalia kork e-
ampi  
 
 
 

Sepelvaltimoiden ja sydämen tietokonetomografia - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/
Sepelvaltimoiden ja sydämen tietokonetomografia
Sepelvaltimoiden ja sydämen
tietokonetomografia
(https://sydan.fi/fakta/sepelvaltimoiden-ja-
sydamen-tietokonetomografia/)
Tietokonetomografiaa (lyhenne TT) käytetään sepelvaltimoiden kalkin ja
kaventumien selvittämiseen. Sitä käytetään myös eräiden sydämen
rakenteiden tutkimiseen.
Anna-Mari Hekkala, ylilääkäri
Lue seuraavaksi Diabetes ja sydän –  vahva pari (https://sydan.fi/artikkeli/diabetes-ja-sydan-vahva-pari/)
Julkaistu 22.1.2024
Päivitetty 4.2.2025
 
Tutkittavalle laitetaan käden pinnalliseen laskimoon kanyyli, jonka kautta
annetaan tutkimuksessa tarvittavaa jodipitoista varjoainetta. Tarvittaessa
annetaan lisäksi sydämen sykettä hidastavaa beetasalpaajaa, sekä
nitrosuihketta, jonka tarkoitus on laajentaa sydämen pieniä verisuonia.
Tutkittava makaa rauhallisesti kuvauspöydällä, ja hoitaja pyytää ajoin
pidättämään hengitystä. Kuvausvaihe itse laitteella kestää vain muutamia
minuutteja.
Sepelvaltimoiden tietokonekuvaus
Tärkein tietokonetomografian käyttöaihe on sepelvaltimoiden kuvantaminen.
Se on käyttökelpoinen erityisesti tilanteissa, joissa tutkittavalla on
sydänperäiseksi epäiltäviä oireita, mutta sepelvaltimotaudin
ennakkotodennäköisyys on pieni tai korkeintaan kohtalainen. Henkilöllä ei
esimerkiksi ole juurikaan tyypillisiä valtimotaudin riskitekijöitä. Kuvauksella
voidaan hyvin poissulkea sepelvaltimotaudin
(https://sydan.fi/sydantietoa/sydansairaudet/sepelvaltimotauti/) mahdollisuus
oireiden aiheuttajana.
Lausunnossa kerrotaan valtimoiden kokonaiskalkkikertymä, ns. calcium score.
Jos luku on 0-100, sepelvaltimokohtauksen
(https://sydan.fi/fakta/sydaninfarkti/) riski on pieni. Pistemäärä 100-400
merkitsee kohtalaista riskiä, ja yli 400 suurta riskiä. Runsaat kalkkeumat
saattavat näyttää kuvauksessa todellista suuremmilta, ja aiheuttaa siksi
ylitulkintaa. Tämän vuoksi kuvausta ei ole hyödyllistä tehdä, jos
valtimokovettumatauti on jo tiedossa.
Kuvausta ei tehdä oireettomille ihmisille puhtaasta mielenkiinnosta esimerkiksi
sepelvaltimotaudin sukurasitteen tai yleisen terveystarkastuksen vuoksi.
Kuvausta ei käytetä myöskään valtimotaudin seurantaan.
Milloin sepelvaltimoiden tietokonekuvaus voi olla ongelmallinen
Sydämen liike aiheuttaa pieniä haasteita kuvauksen onnistumiselle. Sykettä
rauhoitetaan tarvittaessa kuvauksen yhteydessä annettavalla lääkkeellä.
Optimaalinen tilanne olisi, jos syke olisi alle 65/min. EteisvärinärytmiLue seuraavaksi Diabetes ja sydän –  vahva pari (https://sydan.fi/artikkeli/diabetes-ja-sydan-vahva-pari/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
(https://sydan.fi/fakta/eteisvarina/) tai runsaat lisälyönnit saattavat estää
kuvien riittävän analysoinnin.
Myös vaikea lihavuus heikentää kuvanlaatua, koska röntgenkuvien kohina
kasvaa. Sädeannos on myös suurempi.
Koska kuvauksessa annetaan jodipitoista varjoainetta, vaikea jodiallergia on este
kuvaukset tekemiselle. Varjoaine poistuu elimistöstä munuaisten kautta, joten
myös vaikea munuaisten vajaatoiminta on yleensä este.
Sepelvaltimoiden runsaat kalkkeumat vaikeuttavat huomattavasti valtimoiden
analyysia. Siksi tämä tutkimusmuoto soveltuu sepelvaltimotaudin tutkimiseen
huonosti potilailla, joilla on jo tiedossa vaikea valtimoiden kovettumistauti, tai
runsaiden valtimotaudin riskitekijöiden ja iän vuoksi sellainen on jo ennakkoon
arvioituna todennäköinen. Näissä tilanteissa sepelvaltimoita tutkitaan muilla
menetelmillä.
Sydämen tietokonekuvaus
Sydämen tietokonekuvauksella tarkoitetaan sydämen rakenteiden kuvaamista.
Kuvausta käytetään arvioitaessa aorttaläpän
(https://sydan.fi/fakta/aorttalapan-ahtauma/) rakennetta ja kalkkeutumisen
määrää ennen läppätoimenpidettä (ns. TAVI-toimenpide). Samalla pystytään
kuvaamaan sydämestä lähtevä aorttasuoni.
Kuvausta voidaan tarvita, jos ultraäänitutkimuksella
(https://sydan.fi/fakta/sydamen-ultraaanitutkimus/) ei saada riittävää käsitystä
joistain sydämen rakennepoikkeavuuksista, sydämen sisäisistä verihyytymistä tai
sydänläpän tulehduksesta. TT-kuvaus on erittäin hyvä tutkittaessa sydänpussin
sairauksia.Lue seuraavaksi Diabetes ja sydän –  vahva pari (https://sydan.fi/artikkeli/diabetes-ja-sydan-vahva-pari/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sepelvaltimoiden pallolaajennuksen riskit ja hoitotulokset-Terveyskylä.pdf
Se pel val ti moi den pal lo laa jen nuk sen ris -
kit ja hoi to tu lok set
Pallolaajennuksen hoitotulokset ovat hyviä. Alle viidelle %:lle potilaista
toimenpide joudutaan uusimaan stentin uudelleen ahtautumisen vuoksi. Näissä
tapauksissa suoni la ajennetaan uudelleen.
Tarvittaessa voidaan  tehdä myös ohitusleikkaus, jos uusi pallolaajennus ei ole mahdollinen.
Suonen uudelleen ahtautumista voidaan  vähentää käyttämällä lääkeaineella päällystettyjä
stenttejä tai käsittelemällä suonta lääkeainetta vapauttavalla pallolla.
Pallolaajennukseen liittyy samanlaisia punktioreitteihin kohdistuvia komplikaatioita kuin
varjoainekuvauksessa. Toimenpiteen aikana käytetään veren hyytymistä estäviä lääkkeitä, jotka
lisäävät jonkin verran vuotoriskiä.
Suonen repeytyminen pallolaajennuksen yhteydessä on harvinaista ja on yleensä hoidettavissa
päällystetyllä stentillä tai leikkauksella. Stenttitromboosi eli metalliverkon tukkeutuminen
verihyytymän seurauksena on vakava komplikaatio, joka liittyy tavallisimmin veren hyytymistä
estävän lääkityksen lopettamiseen tai keskeyttämiseen liian varhain. Stenttitromboosin riski on
alle yksi %:a ensimmäisen vuoden aikana toimenpiteen jälkeen. Jos rintakipuoireet palaavat tai
pahentuvat toimenpiteen jälkeen, on syytä ottaa yhteys hoitavaan lääkäriin. Kiireellisissä
tapauksissa tulee soittaa välittömästi hätänumeroon 112.
Tarkistettu 3.11.2020
Miksi Terveyskylä? – Katso video
Sepelvaltimoiden tietokonetomografia.pdf
Se pel val ti moi den tie to ko ne to mo gra fia
Nykyaikaiset nopeat tietokonetomografialaitteet (TT) mahdollistavat liikkuvan
sydämen tarkkojen yksityiskohtien kuvaamisen.
Tutkimuksen tarkoitus
Tutkimuksessa selviää, onko sepelvaltimoissa valtimoiden kovettumatautia eli ateroskleroosia ja
jos on, kuinka laaja-alaisia muutoksia nähdään .
Tutkimuksella voidaan  suurella varmuudella poissulkea sepelvaltimotauti. Sen sijaan TT:n
perusteella on hyvin vaikeaa arvioida, onko sepelvaltimo ahtautunut merkittävästi vai onko
kyseessä vain lievä seinämän sairaus. Ahtautuma-asteen arvioimiseksi voidaan tehdä
lisätutkimuksia.
Vaikka kyseessä on säteilytutkimus, sepelvaltimoiden TT-kuvauksen sädeannos on pieni.
Tutkimuksen kulku
Kuvaus tapahtuu TT-laitteen kuvauspöydällä maaten. Kuvausta varten asennetaan laskimoon
kanyyli, josta annetaan tarvittaessa sydäm en sykettä rauhoittavaa lääkettä (tavallisimmin
beetasalpaajaa) sekä kuvauksessa tarvittavaa jodivarjoainetta.

Tarkimmat kuvat sepelvaltimoista saadaan, kun sydäm en syke on alle 65/min. Ennen tutkimusta
potilas saa nitrosuihkeen, joka laajentaa sepelvaltimoita. Tämä tehdään , jotta pienimmätkin
suonet erottuisivat kuvissa hyvin.
Jodivarjoaine voi aiheuttaa lämmöntunnetta vartalolla, joka menee nopeasti ohitse. Ennen
kuvausta on tärkeää tietää, mikäli joskus aikaisemmin varjoaineesta on tullut yliherkkyysoireita,
kuten ihottumaa tai limakalvojen turvotusta.
Itse kuvaus kestää vain muutamia minuutteja, jonka jälkeen vointia seurataan röntgenosaston
tiloissa puoli tuntia.
Aiheeseen liittyvää
Tarkistettu 11.7.2023Tietokonetomografia- eli TT-tutkimus (Tutkimukseen tulijan talo)
Sepelvaltimoiden varjoainekuvaus - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/
Sepelvaltimoiden varjoainekuvaus
Sepelvaltimoiden varjoainekuvaus
(https://sydan.fi/fakta/sepelvaltimoiden-
varjoainekuvaus/)
Sepelvaltimoiden varjoainekuvauksella eli angiografialla selvitetään
sepelvaltimoiden kulku ja verenvirtaus niiden sisällä. Kuvaus paljastaa
mahdolliset ahtautuneet kohdat.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 25.1.2024
Päivitetty 1.8.2024
 
Lue seuraavaksi Elektrofysiologinen tutkimus (https://sydan.fi/fakta/elektrofysiologinen-tutkimus/)
Tutkittava makaa liikkumatta kapealla tutkimuspöydällä, ja kuvauksen tekevä
kardiologi seisoo tutkittavan oikealla puolella. Potilas on hereillä, ja voi
keskustella henkilökunnan kanssa tutkimuksen aikana.
Kuvaus tehdään yleensä oikean ranteen värttinävaltimon kautta, mutta
tarvittaessa voidaan reittinä käyttää myös oikeaa nivusvaltimoa. Lääkäri
puuduttaa ihon pistokohdan, ja punktoi sitten suuremmalla neulalla itse
valtimosuonen. Pistokohdasta ujutetaan valtimoa pitkin taipuisa katetri
sydämen ja aortan yhtymäkohtaan asti, sillä sieltä sepelvaltimot saavat alkunsa.
Katetrin kautta ruiskutetaan jodipitoista varjoainetta suoraan sepelvaltimoon.
Kardiologi liikuttaa potilaan ympärillä röntgenputkea, ja ottaa valtimopuustosta
kuvia useasta eri suunnasta. Yleensä hän kertoo potilaalle jo heti tutkimuksen
päätyttyä, mitä kuvauksessa löytyi.
Jos kuvaus tehdään akuutissa sydäninfarktin
(https://sydan.fi/fakta/sydaninfarkti/) tilanteessa, kuvauksessa löytynyt
merkittävä ahtauma voidaan avata pallolaajennuksella samassa istunnossa.
Joskus näin voidaan tehdä myös elektiivisessä, eli suunnitellussa tapauksessa.
Usein suunniteltu pallolaajennus tehdään kuitenkin myöhemmin, uudessa
toimenpiteessä.
Jos kyseessä on pelkkä suunniteltu kuvaus, tutkittava pääsee kotiin jo saman
päivän aikana.
Milloin varjoainekuvaus tehdään?
Varjoainekuvaus tehdään yleensä aina sydäninfarktitapauksissa. Tietyt
sydäninfarktitilanteet kuvataan niin pian kuin mahdollista, vaikka yöllä, sillä
verisuonten tilanne pitää saada selville nopeasti, ja tukkeutunut suoni avataan
samalla. Suuri osa sydäninfarktitapauksista kuvataan kiireellisesti, noin 1-2
päivän kuluessa sairaalaan saapumisesta.
Varjoainekuvaus voidaan tehdä suunnitellusti eli elektiivisesti, jos potilaalla on
lääkehoidosta huolimatta haittaava rasitusoire. Samoin jos muussa
tutkimuksessa, kuten sepelvaltimoiden tietokonekuvauksessa
(https://sydan.fi/fakta/sepelvaltimoiden-ja-sydamen-tietokonetomografia/) on
löytynyt vaikeasti ahtautunut kohta, tai potilaalla on paljon oireita eivätkä muut
tutkimusmenetelmät sovellu, angiografia on tarpeen. Lähtökohtana näissä
tilanteissa on tutkia sepelvaltimon pallolaajennuksen mahdollisuutta. Joskus
hoidoksi suositellaan ohitusleikkausta.Lue seuraavaksi Elektrofysiologinen tutkimus (https://sydan.fi/fakta/elektrofysiologinen-tutkimus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Varjoainekuvaus voidaan tehdä myös tutkittaessa sydämen vajaatoiminnan
syitä, tai selvitettäessä sepelvaltimoiden tilannetta ennen läppätoimenpidettä.
Miten löydöksiä tulkitaan?
Tutkimuksessa kuvataan kahden valtimon, oikean ja vasemman sepelvaltimon
kulku. Valtimot saavat alkunsa aortan tyveltä, heti aorttaläpän yläpuolelta.
Vasemmasta sepelvaltimosta erkaantuu pian kaksi päähaaraa, etulaskeva ja
kiertävä sepelvaltimo. Näistä ja oikeasta päähaarasta lähtee useita pieniä
sivuhaaroja.
Sepelvaltimoiden anatomia ei ole kaikilla samanlainen, vaan variaatioita on
paljon. Joillain oikea sepelvaltimo on suurin, ja ruokkii myös sydämen vasenta
puolta. Tästä käytetään nimitystä oikean sepelvaltimon dominanssi.
Kuvauksen lausuntoon kirjataan valtimoiden ja niiden sivuhaarojen nimet
kirjainlyhentein. Lyhenne on peräisin valtimon englanninkielisestä nimestä. Usein
lyhenteen perään merkitään myös pienellä kirjaimella lisämerkintä ” a ” , ” b ”  tai ” c ” ,
jolla ilmaistaan tarkemmin, mistä valtimonkohdasta on kysymys. Näin toimitaan,
kun kyseisestä kohdasta löytyy kaventuma.
Ahtauman aste ilmaistaan prosenttiluvulla valtimon sisäpinnasta. Merkintä
”50%”  tarkoittaa, että puolet valtimon sisäosasta on ahtautunut ateroskleroosin
eli valtimotaudin seurauksena. Merkintä ” 100% ”  tarkoittaa, että suoni on
kokonaan tukossa. Lievät löydökset, esim. 20% tai 30% ovat varsin tavallisia,
erityisesti ikääntyessä, ja jos tutkittavalla on valtimotaudin riskitekijöitä.
Päähaarojen lyhenteet:
LCALeft coronary artery; vasen sepelvaltimo; käytetään myös lyhennettä LM (left
main)
LAD Left ascending descending; vasemman sepelvaltimon eteen laskeva haara
LCX Left circumflex; vasemman sepelvaltimon kiertävä haara.
RCA Right coronary artery; oikea sepelvaltimo
 
Vaikka kuvauksessa löytyisi ahtautuneita kohtia, se ei tarkoita automaattisesti
pallolaajennustarvetta. Jos löydös on rajapintainen, eli suonen kaventuma on
vaikka 50-70%, ahtauman merkitystä tutkitaan usein lisäksiLue seuraavaksi Elektrofysiologinen tutkimus (https://sydan.fi/fakta/elektrofysiologinen-tutkimus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
painevaijeritutkimuksella. Tutkimuksessa lasketaan ns. virtausreservi (fractional
flow reserve, lyhenne FFR), joka auttaa kardiologia määrittämään kaventuman
vaikeusastetta.
Varjoainekuvauksen riskit
Koska varjoainekuvauksessa viedään tutkimusvälineitä kehon sisälle,
tutkimukseen liittyy tiettyjä riskejä. Myös potilaaseen liittyvät seikat, kuten ikä,
yleistila ja muut sairaudet vaikuttavat komplikaatioriskiin.
Pelkän kuvauksen komplikaatiot ovat kuitenkin harvinaisia. Vakavia
komplikaatioita on alle 1%:lla potilaista, ja kuolleisuus on alle 0,1%.
Tavallisin haitta on punktiokohtaan syntyvä verenpurkauma. Joskus
pistoskohtaan saattaa muodostua verisuonen pullistuma (ns.
pseudoaneurysma), jota voidaan joutua jälkikäteen hoitamaan.
Varjoaine voi aiheuttaa allergisen reaktion. Nykyisin reaktioita on noin 1 %:lla
tutkittavista. Jos tiedossa on jo etukäteen varjoaineallergia, annetaan ennen
toimenpidettä esilääkityksenä antihistamiinin lisäksi kortikosteroidia.
Varjoaine voi vaurioittaa munuaisia, jos munuaisten toiminta on jo valmiiksi
muusta syystä heikentynyt. Korkea ikä lisää riskiä. Munuaisongelmia ehkäistään
huolehtimalla riittävästä nesteytyksestä, ja käyttämällä varjoainetta
mahdollisimman vähän.Lue seuraavaksi Elektrofysiologinen tutkimus (https://sydan.fi/fakta/elektrofysiologinen-tutkimus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sepelvaltimoiden varjoainekuvaus eli koronaariangiografia.pdf
Se pel val ti moi den var joai ne ku vaus eli
ko ro naa rian gio gra fia
Sepelvaltimoiden varjoainekuvauksella tutkitaan sepelvaltimoiden , sydämen
vasemman kammion ja läppien kuntoa ja toimintaa.
Sepelvaltimotaudin diagnoosi voidaan  usein tehdä potilaan oireiden, lääkärin kliinisen
tutkimuksen ja rasituskokeen eli rasitus-EKG:n perusteella. Sepelvaltimoiden varjoainekuvaus
on aiheellinen, jos potilaan arvellaan hyötyvän sepelvaltimon/sepelvaltimoiden
pallolaajennuksesta tai ohitusleikkauksesta. Ennen toimenpiteitä tarvitaan mahdollisimman
tarkka tieto sepelvaltimoiden tilasta. Koronaariangiografia näyttää sepelvaltimoiden mahdolliset
ahtaumat.
Kun sepelvaltimotaudin oireisto on vakaa, varjoainekuvaus tehdään  esimerkiksi muutaman
kuukauden kuluessa lähetteen saapumisesta toimenpideyksikköön. Jos kyseessä on äkillisesti
ilmaantunut tai äkillisesti pahentunut ja epävakaa oireisto, kuvaus tehdään kiireellisesti.
Sepelvaltimoiden varjoainekuvaus voidaan tehdä polikliinisesti jolloin kotiudutaan samana
päivänä. Toisinaan sairaalassa täytyy olla par i päivää vuodeosastolla esimerkiksi munuaisten
vajaatoimintaa sairastavat tarvitsevat nesteytystä varjoaineen poistumiseksi elimistöstä.
Toimenpiteen kulku

Toimenpide tehdään  paikallispuudutuksessa rannevaltimosta tai nivusvaltimosta.
Sepelvaltimoon asetetun katetrin avulla ruiskutetaan jodipitoista varjoainetta, jonka
kulku sepelvaltimoissa kuvataan röntgensäteiden avulla. Kuvauksia tehdää n useista
suunnista ja molemmista sepelvaltimoista erikseen.
Tarvittaessa varjoainetutkimusta täydennetään sepelvaltimon sisäisellä
painemittauksella tai ultraäänikuvauksella. Varjoainetutkimuksen tuloksien
perusteella hoitopäätös tehdään  potilaan kanssa eri vaihtoehdoista keskustellen.
Yliherkkyys jodille
Ennen tutkimusta annetaan esilääkitys, joka ehkäisee mahdollista yliherkkyysreaktiota
jodia sisältävälle varjoaineelle.
Jos potilas on aiemmin saanut vakavia yliherkkyysoireita jodia sisältävästä
varjoaineesta, sepelvaltimoiden varjoainekuvaus voidaan  potilaan ja lääkärin yhteisen
harkinnan mukaan tehdä. Silloin käytetään vahvaa, allergisia reaktioita ehkäisevää
lääkitystä.
Sepelvaltimoiden varjoainekuvauksen riskit
Sepelvaltimoiden varjoainekuvaus ei ole täysin vaaraton toimenpide. Valtimon
pistospaikan kipu, mustelma tai turvotus ovat melko tavallisia, mutta yleensä viattomia
seuraamuksia. Joskus pistospaikan vuoto voi pitkittää sairaalahoitoa ja
poikkeustapauksissa valtimoon voi syntyä repeämä, joka joudutaan ompelemaan
leikkaussalissa vuodon tyrehdyttämiseksi. Henkeä uhkaavat valtimoverenvuodot
lantion alueelle tai vatsakalvon takaiseen tilaan ovat erittäin harvinaisia.
Sepelvaltimoiden varjoainekuvauksen aikana voi tullarytmihäiriö, jota hoidetaan joko
lääkkeillä tai sähköisellä rytminsiirrolla. Jännitys ja valtimon pistoon liittyvä kipu voivat
laukaista kiertäjähermon toimintaa kiihdyttävän heijasteen, joka johtaa verenpaineen
laskuun ja sykkeen hidas tumiseen. Silloin tulee heikottava, huono olo ja pahoinvointia.
Oireet korjautuvat nopeasti nesteensiirrolla ja kiertäjähermoa salpaavalla lääkkeellä.
Hyvin sairaissa ja pinnaltaan hauraissa sepelvaltimoissa katetrin kärki voi saada aikaan
paikallisia vaurioita. Sisäpinnaltaan rosoisesta ateroskleroottisesta aortasta voi irrota
kalkkisiruja, kolesterolimassaa tai paikallista hyytymää, josta voi olla seurauksena
aivoverenkierron häiriö, jopa aivoinfarkti. Kuolema varjoainekuvauksessa on
äärimmäisen harvinainen komplikaatio, joka liittyy lähinnä kaikista vaikeimmin
sairaiden potilaiden tutkimuksiin.
Tutkimuksessa käytettävä varjoaine voi pahentaa jo olemassa olevaa munuaisten
vajaatoimintaa. Hyvä nestehoito ennen ja jälkeen varjoainekuvauksen vähentää
munuaisvaurion vaaraa. Sepelvaltimokuvauksen vakavimpien komplikaatioiden
(vakava verenvuoto, aivoinfarkti, kuolema, vakava munuaisvaurio) yhteenlaskettu riski
on noin 0,5 – 1 %.
Aiheeseen liittyvää
Tarkistettu 16.7.2020Mitä tapahtuu sepelvaltimoiden varjoainekuvauksessa?  (video, youtube.com)
Sepelvaltimoiden varjoainekuvaus ja pallolaajennus - Potilasohjeet - intra.pirha.fi.pdf
Päivitetty 4.11.2024
Tays Sydänsairaala / kardiologia
Potilasohje 15.00.14
Sepelvaltimoiden varjoainekuvaus  ja pallolaajennus
Sepelvaltimot ovat sydämen pinnalla kulkevia verisuonia, jotka huolehtivat sydänlihaksen verenkierrosta. Lääkäri on
arvioinut, että osana oireittesi selvittelyä tai hoitoasi sinulle tulee tehdä sepelvaltimoiden varjoainekuvaus ja/tai
pallolaajennustoimenpide.
Toimenpide tehdään paikallispuudutuksessa ranne- (> 90% toimenpiteistä) tai nivusvaltimon (< 10%) kautta.
Ensisijainen toimenpidereitti on oikea rannevaltimo. Toisinaan toimenpidereittiä joudutaan vaihtamaan toimenpiteen
aikana, jos ensisijainen reitti ei olekaan käyttökelpoinen esimerkiksi suonen pienen koon vuoksi. Yleensä tämä selviää
vasta toimenpiteen aloituksen jälkeen.
Toimenpiteen aikana ruiskutetaan varjoainetta suoraan sepelvaltimoon katetrin kautta ja samanaikaisesti
röntgenlaitteella kuvataan varjoaineen täyttämät sepelvaltimot. Saat lääkäriltä tiedon toimenpiteen löydöksistä
välittömästi toimenpiteen jälkeen. Pallolaajennuksessa laajennetaan sepelvaltimossa todettu ahtauma, joka haittaa
verenkiertoa sydänlihakseen aiheuttaen oireita. Laajennuksen jälkeen ahtaumakohtaan voidaan asettaa metallinen
tukiverkko eli stentti tukemaan laajennettua kohtaa.
Varjoainekuvaukseen liittyvät komplikaatiot ovat harvinaisia, mutta pistokohtaan/kohtiin jää yleensä mustelmaa joksikin
aikaa. Hyvin harvinaisia toimenpiteeseen liittyviä haittatapahtumia ovat allerginen reaktio, aivoverenkiertohäiriö ja
kuvauskatetrista johtuva sepelvaltimon vaurioituminen.
Sepelvaltimoiden pallolaajennuksen mahdollisia, mutta harvinaisia komplikaatioita ovat verisuonivaurio, sepelvaltimon
hyytymä tai repeytymä sekä verenvuoto sydänpussiin. 
Voit tutustua toimenpiteen kulkuun katsomalla animaatiovideon verkkosivuiltamme:
sydansairaala.fi/potilaana/varjoainekuvaus_ja_pallolaajennus.
Muihin palveluihimme voit tutustua osoitteessa http://www.sydansairaala.fi/potilaana
Toimenpiteeseen valmistautuminen
Voit syödä ja juoda ja ottaa kaikki lääkkeesi normaalisti toimenpideaamuna.
Mikäli sinulla on käytössä varfariini (Marevan®), tulisi INR-arvon olla toimenpidepäivänä alle 3.0.
Ota mukaan lääkelista ja käytössäsi olevat lääkkeet kahden päivän ajaksi
Jätä korut ja kellot kotiin.
Suosittelemme laittamaan väljät ja helposti puettavat olovaatteet päälle. Ylävartalon alueen vaatetuksessa ei saa
olla metallia (esim. metallinapit, vetoketjut, rintaliivien hakaset tai kaarituet)
Autolla ajaminen on kielletty vuorokauden ajan toimenpiteestä.
Saapumisaikasi ei ole sama kuin toimenpiteen ajankohta, vaan alkamisajankohta tarkentuu päivän aikana. Varaudu
odottamaan.
Mikäli olet yliherkkä jodille, epäilet olevasi raskaana tai sairastut ennen toimenpiteeseen tuloa, ota yhteyttä arkena
Sydänsairaalaan takaisinsoittopalveluun, puhelin 050 408 7311.
Jatkohoito
Tutkimuksen jälkeen olet seurannassa muutaman tunnin ajan. Sepelvaltimoiden varjoainekuvaus / pallolaajennus
tehdään yleensä polikliinisesti, jolloin pääset kotiin samana päivänä. Varaudu kuitenkin myös jäämään yhdeksi yöksi
sairaalaan, jos vointisi sitä edellyttää. Kirjalliset kotihoito-ohjeet, lääkelistan ja sairauslomatodistuksen saat kotiin
lähtiessäsi.26.2.2025 klo 22.03 Sepelvaltimoiden varjoainekuvaus ja pallolaajennus - Potilasohjeet - intra.pirha.fi
https://potilasohjeet.pirha.fi/w/sepelvaltimoiden-varjoainekuvaus-ja-pallolaajennus 1/2
Kotiuduttuasi vältä raskaita ruumiillisia ponnistuksia, saunomista tai pitkiä kävelymatkoja kahden vuorokauden ajan. Jos
pistospaikassa ilmenee jotakin erityistä kotiuduttuasi, ota yhteys lähimpään terveyskeskuspäivystykseen.26.2.2025 klo 22.03 Sepelvaltimoiden varjoainekuvaus ja pallolaajennus - Potilasohjeet - intra.pirha.fi
https://potilasohjeet.pirha.fi/w/sepelvaltimoiden-varjoainekuvaus-ja-pallolaajennus 2/2
Sepelvaltimokohtauksen riskinarvio - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p al v eluk et jut  / Sepel v al timot autipotilaan hoit ok et ju  / Sepel v al timot autik oht aus  /
Sepel v al timok oht auksen r iskinar vio
 Sepel v al timot autipotilaan hoit ok et ju
Sepel v al timot audin diagnostiikka
Sepel v al timot audin hoit o
Sepel v al timot autik oht aus
Sepel v al timot autik oht aus
Sepel v al timok oht auksen r iskinar vio
Sepel v al timok oht auksen ensihoit o (NS TEMI/U AP)
Sepel v al timok oht auksen ensihoit o (S TEMI)
V ar jo ainekuv aus ja r eper fuusiohoit o
Jatk ohoit o osast olla t ai sy dän v al v onnassa
Sepel v al timot audin lääk ehoit o
Sy dän v almennus
Sepel v al timot audin jatk ohoit o ja seurant a



Riskinar vioKuuntele4.3.2025 klo 17.23 Sepelvaltimokohtauksen riskinarvio - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotautikohtaus/riskinarvio 1/3
L y h y en aika v älin v aaraa kuv aa v at t ekijät
S u u r i  v a a r a
I n v a si i v i ne n a r v i o  t a r pe e n e l l e i  v a st a - a i h e t t a  t a i  se l k e ä ä  se k u n d a a r i st a  sy y t ä  i sk e m i a l l e :
T oistuv a t ai pitkitt yv ä r int akipu
Uusiutuv a isk emia
Suur entunut tr oponiinipit oisuus
Isk emiaan viitt aa v at muut okset EK G:ssä
Hemod ynaaminen ep ä v akaus (tihe ä sy k e, mat ala v er enp aine )
Mer kitt ä v ä r y tmihäir iö (t oistuv a kammiot aky kar dia, kammio v är inä t ai A V -katk os
M u u t  l y h y e n a i k a v ä l i n su u r t a  v a a r a a  k u v a a v a t  t e k i j ä t :
Iäkäs potilas
Pitkäaikaissairaus ( diabet es, mer kitt ä v ä munuaist en v ajaat oimint a, sy dämen v ajaat oimint a, aiempi tiedossa ole v a
sepel v al timot auti)
Pitkä viiv e oir eiden alust a hoit oon hak eutumiseen
P i e ni  v a a r a
Rint akipu, joka ei uusiudu seurannassa
Ei t oistuv aa isk emiaa
Pieni tr oponiinipit oisuus
Ei isk emiaan viitt aa via EK G-muut oksia
Hemod ynaamisesti v akaa potilas
Ei mer kitt ä viä r y tmihäir iöit ä
Nuor i potilas
Ei pitkäaikaissairauksia
Nope a hoit oon hak eutuminen
Sepel v al timot autik oht auksen Kä yp ä hoit o -suositukseen 
Sy dänper äiseksi ep äil t ä v än r int akivun diagnostiikka   (Kä yp ä hoit o, pdf)
Riskinar vio ja hoit opolku Pir ha
S TEMI-potilaan ensisijainen hoit o on pr imaar i PCI
K onsul t oidaan PCI-p äivyst äjää (p. 050- 3005594)
P otilas kuljet et aan suoraan T A YS Sy dänsairaalaan
NS TEMI- ja U AP -potilaalle aloit et aan lääkit ys ja potilas ar vioidaan er ik oissairaanhoidon p äivyst y ksessä
Suur en v aaran potilaat ot et aan hoit oon T A YS Sy dänsairaalaan
Pienen v aaran potilaat v oidaan tutkia m y ös a v ot er v e y denhuollossa ja t ar vitt aessa jatk otutkimukset t ehdä
elektiivisesti jok o a v ot er v e y denhuollossa t ai er ik oissairaanhoidossa
Iäkäs, monisairas ja heik on t oimint akyvyn omaa v a potilas v oidaan tutkia ja hoit aa m y ös perust er v e y denhuollossa
Edellinen
Sepel v al timot autik oht ausSeur aa v a
Sepel v al timok oht auksen ensihoit o (NS TEMI/U AP)
Päivit ett y 28 . 11.202 44.3.2025 klo 17.23 Sepelvaltimokohtauksen riskinarvio - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotautikohtaus/riskinarvio 2/3
Sepelvaltimokohtauspotilaan_hoito_pikaohje.pdf
 
OHJE SEPELVALTIMOTAUTIKOHTAUKSEN HOIDOSTA  
 
 KAIKILLE ASA 250 mg p.o . , tarvittaessa nitraatti, beetasalpaaja, kipulääkitys, sedaatio ja happilisä, jos 
spO2 < 90% sekä hemodynamiikan arvio ja hoito kliinisen tilanteen mukaan.  
1. Sydäninfarkti ilman ST -nousua (NSTEMI) ja epästabiili angina pectoris   
• Potilas kuljetetaan ensisijaisesti paikalliseen sairaalaan. Suuren vaaran potilaat pyritään ohjaamaan 
sepelvaltimoiden varjoainekuvaukseen 24 tunnin kuluessa rintakivun alusta.  
• PCI-päivystäjän konsultaatio  on aiheen, jos potilaalla on henkeä uhkaava rytmi häiriö, hän on 
kardiogeenisessa sokissa tai kipuilee hyvästä lääkehoidosta huolimatta ja EKG:ssa todetaan 
kivunaikainen iskemia.  
• Potilaalle  aloitetaan ASA  250 mg  ja enoksapariini  1 mg/kg sc x 2. Enoksapariinia  ei aloiteta, jos 
käytössä on  suora antikoagul antti tai varfariini ja INR on yli 2. Iäkkäillä ja munuaisten 
vajaatoiminnassa enoksapariinin annosta pienennetään. Muu antitromboottinen lääkitys sovitaan 
myöhemmin.  
• Varfariinilääkitystä tai suor aa antikoagulanttia ei pääsääntöisesti tauoteta  
• Potilas ote taan hoitoon sydänvalvontaan (SYVA) tai sydänosastolle (OSA2) . Jatkuva rytmin seuranta 
on ehdoton . Ennen varjoainekuvausta annetaan Deslox  (desloratadiini)  5mg / Histec  (setiritsiini)  10 
mg p.o..  Jos hoitolinja on konservatiivinen, se voidaan joskus toteuttaa myös muissa yksiköissä.  
2. ST -nousuinfarkti (STEMI)   
• Kun EKG:ssa  todetaan ST -nousuinfarkti, toimitetaan EKG TAYS Sydänsairaalan kardiologille 
paikallisesti sovitun käytännön mukaan joko sähköpostilla (mm. Medtronic, Zoll, Philips) tai 
laittamalla EKG välittömästi Fimlabiin (mm. TAYS Acuta, VALS, VAS)  
• EKG:n lähettämise n jälkeen otetaan yhteys TAYS Sydänsairaalan PCI-päivystäjään p. 050 300 5594. 
Jos puhelimeen ei saada yhteyttä eli puhelin ei hälytä, hätätilanteissa varanumero on 050 402 4241 
(päivystävä sairaanhoitaja). Varanumeroon ei tule soittaa tilanteissa, joissa kardiologin puhelin on 
varattuna tai puhelin hälyttää ilman että puheluun vastataan.  
 
1. JOS HOITO ON VÄLITÖN PALLOLAAJENNUS  annetaan potilaalle ASA 250 mg,  enoksapariini  40 mg 
i.v. ja Brilique 180 mg p.o.  ja Deslox  (desloratadiini)  5mg / Histec  (setiritsiini)  10 mg p .o.. Näiden 
toimenpiteiden jälkeen siirto välittömästi TAYS Sydänsairaalan Kardiologiseen yksikköön, 
Elämänaukio 1 krs. 2 
2. JOS HOITO ON TROMBOLYYSI  se toteutetaan tavanomaiseen tapaan erillisen ohjeen mukaisesti. 
Liuotushoidon aloittami sen jälkeen potilas siirretään välittömästi päivystys ACUTAan. PCI -
päivystäjää konsultoidaan kontrolli EKG:sta 60 minuuttia liuotuksen jälkeen.   
3. Iäkkäällä ja monisairaalla potilaalla hoito voi olla myös konservatiivinen, jolloin se toteutetaan 
tilanteen mukaan joko perusterveydenhuollossa tai erikoissairaanhoidon yksikössä . 
Kaikki muut kardiologiset konsultaatiot virka - ja päivystysaikana:  
aluesairaaloista ja terveyskeskuksista p. 311 64410,  
PSHP:n ambulansseista p. 311 74112 (TAYS Ensihoitokeskus).  
Ayl Essi Ryödi    Oyl Jyri Koivumäki  
TAYS Sydänsairaala   TAYS Sydänsairaala  27.4.2023  
Sepelvaltimotaudin ehkäisy - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/
Sepelvaltimotaudin ehkäisy
Sepelvaltimotaudin ehkäisy
(https://sydan.fi/fakta/sepelvaltimotaudin-
ehkaisy/)
Sepelvaltimotaudissa on kyse sydämen omien valtimoiden, sepelvaltimoiden
sairastumisesta. Valtimot voivat sairastua samalla tavoin muuallakin
elimistössä. Siksi täsmälleen samoilla ennaltaehkäisevillä toimilla hoidetaan
paitsi sydämen, myös muiden elinten, kuten aivojen verenkiertoa.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 9.2.2023
Päivitetty 18.12.2023
Lue seuraavaksi Sepelvaltimotaudin kehittyminen (https://sydan.fi/fakta/sepelvaltimotaudin-kehittyminen/)
 
Valtimotaudin aiheuttaa yleensä valtimoiden kovettuminen eli ateroskleroosi.
Ateroskleroosin (https://sydan.fi/fact/sepelvaltimotaudin-kehittyminen/)
käynnistää kolesterolin kertyminen valtimosuonen seinämään.
Tapahtumaketjuun vaikuttavat monet tekijät, jotka osaltaan kiihdyttävät
suonen sisäpintaan syntyneen pesäkkeen kasvua.
Geenit ja ikääntyminen
Geenit eli perimätekijät ovat yksi selitys sille, miksi toisilla valtimotauti kehittyy
nuorempana ja hyvistäkin elintavoista huolimatta. Sepelvaltimotaudin taustalla
ei ole yhtä tai kahta geenimutaatiota eli -virhettä, vaan tuhansia erilaisia pieniä
tekijöitä. Siksi periytyvyyden testaaminen yksittäisellä ihmisellä on ollut vaikeaa.
Nykyaikaisella tekniikalla pystytään kuitenkin tutkimaan miljoonia eri
geenivirheitä suhteellisen edullisesti, ja laskemaan henkilökohtainen riskiluku
sairaudelle. Testi on vasta tutkimuskäytössä, eli se ei kuulu tavanomaisten
tutkimusten piiriin.
Yksi merkittävä periytyvä valtimotaudin vaaratekijä, vaikea-asteinen rasva-
aineenvaihdunnan häiriö eli FH-tauti (https://sydan.fi/fact/familiaalinen-
hyperkolesterolemia-fh/), on jo tutkittavissa geenitestillä suhteellisen helposti.
Kyseisessä sairaudessa yksi geenivirhe riittää aiheuttamaan taudin. Siksi myös
sukulaisten, kuten lasten tutkiminen onnistuu verikokeella.
Valtimotautien, oli kyse sitten sepelvaltimotaudista tai aivoverenkierron
häiriöistä, vaara lisääntyy ikääntyessä. Eletyt vuodet ja niiden kautta lisääntyvä
sairauksien riski on toinen asia, jonka kulkuun emme luonnollisesti voi itse
vaikuttaa.
Monet valtimotaudin vaaratekijät liittyvät
elintapoihin
Ihminen voi itse vaikuttaa omaan riskiinsä sairastua. Omilla valinnoilla on siis
suuri merkitys, ja jokainen voi edistää omaa terveyttään.
Tupakointi (https://sydan.fi/sydantietoa/terveys-hyvinvointi/tupakoinnin-
lopettaminen/) ja nikotiinituotteet ovat haitallisia verisuonille. Käytön
lopettaminen on siis suuresti suositeltavaa. Nikotiini aiheuttaa riippuvuuttaLue seuraavaksi Sepelvaltimotaudin kehittyminen (https://sydan.fi/fakta/sepelvaltimotaudin-kehittyminen/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
aivojen nikotiinireseptorien kautta. Toisilla vaikutus on voimakkaampi ja
lopettaminen voi siksi olla hyvin vaikeaa. Onneksi markkinoilla on lääkkeitä,
joiden avulla lopettaminen onnistuu helpommin.
Ravinnolla (https://sydan.fi/fact/terveellinen-ruoka-on-sydanystavallista-
ruokaa/) on myös paljon väliä. Ruuan rasvoilla on merkitystä, erityisesti sillä
paljonko sisään laittaa ns. kovia rasvoja pehmeiden kustannuksella.
Nyrkkisääntönä voidaan pitää, että kovien rasvojen osuus kannattaisi pitää
mahdollisimman pienenä. Ruuan kuitu vaikuttaa rasvojen imeytymiseen
suolistosta. Toisilla imeytyminen on tehokasta, jolloin ravinnosta saatava puhdas
kolesteroli nostaa vereen päätyvää kolesterolia helpommin.
Verenpaine (https://sydan.fi/fact/verenpaine/) rasittaa putkistoa eli verisuonia.
Niinpä toiveissa olisi, että verenpaine säilyisi ihanteellisella tasolla. Perimällä on
vaikutusta siihen, että toisilla verenpaine nousee herkemmin. Monilla elintapa-
asioilla voi kuitenkin myös vaikuttaa paineeseensa ja näistä tärkeimmät ovat
suolan saanti ravinnosta, ylipaino ja liikunta.
Liikunta (https://sydan.fi/fact/liikunnasta-elintapa/) on ylipäätänsä tärkeä osa
valtimoiden hoitoa. Tai voisi ajatella toisinpäinkin: liikkumattomuus on
haitallista. Liiku siis aina kun se on mahdollista. Sydän rakastaa liikuntaa.
Ylipainoon (https://sydan.fi/fact/lihavuus-on-sydan-ja-verisuonisairauksien-
riskitekija/), erityisesti vatsan seutuun kertyvään rasvavarastoon, liittyy paljon
terveyshaittoja. Diabetes (https://sydan.fi/fakta/diabetes-ja-sydan/) on
itsenäinen valtimosairauksien vaaratekijä, mutta vyötärölihavuuden tiedetään
olevan valtimoille ja sydämelle haitallista muutenkin. Normaalipaino on siis
tärkeä tavoiteltava asia. Jos on jo ylipainoa, pikkuhiljaa tapahtuva, pysyviin
tuloksiin johtava painon pudotus olisi hieno juttu.
Huomioi myös nämä
Monissa tutkimuksissa on havaittu, että pitkäaikainen stressi lisää riskiä sairastua
valtimosairauksiin. Kyse voi olla vuosia jatkuvista paineista työpaikalla,
esimerkiksi työpaikkakiusaamisesta tai liiallisesta työmäärästä. Myös
yksityiselämässä, esimerkiksi parisuhteessa jatkuva tyytymättömyys lisää vaaraa.
Hampaiston tulehdukset, parodontiitit (https://sydan.fi/fact/parodontiitti-ja-
sydanterveys/), saattavat ylläpitää tulehdusta koko kehossa. Siksi hampaiden
huolenpito kuuluu asiaan.Lue seuraavaksi Sepelvaltimotaudin kehittyminen (https://sydan.fi/fakta/sepelvaltimotaudin-kehittyminen/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Naiset sairastuvat (https://sydan.fi/fact/sepelvaltimotaudin-riskitekijat-
naisella/) valtimotauteihin keskimäärin noin kymmenen vuotta miehiä
myöhemmin. Naisten sairastumisriski kasvaa vaihdevuosi-iän jälkeen, kun veren
rasva-arvot muuttuvat epäsuotuisemmiksi ja monille kertyy liikakiloja, jotka
omalta osaltaan vaikuttavat esimerkiksi verenpaineeseen ja veren sokeriarvoihin.
Monesti naisen elämäntilanne saattaa samalla olla sellainen, että perheestä
huolehtiminen vie aikaa ja voimia oman terveyden edistämisen kustannuksella.
Keski-iässä nainen joutuu terästäytymään oman valtimoterveyttä edistävien
elintapojen (https://sydan.fi/fact/arkiliikunta-hyvaksi-naisen-sydamelle/)
suhteen.
Uni-apnea (https://www.hengitysliitto.fi/fi/hengityssairaudet/uniapnea) lisää
vaaraa sairastua sydän- ja verenkiertoelinten sairauksiin. Toisaalta merkittävin
uniapnean taustasyy on ylipaino, joten painonhallinnalla voi ehkäistä myös
uniapnean kehittymistä.
Viimeisimmät tutkimushavainnot ovat näyttäneet, että myös ilmansaasteet
osallistuvat valtimoiden sairastumiseen. Taustalla on monia mekanismeja, joita
ilmansaasteiden pienhiukkaset aiheuttavat. Kaikki eivät voi muuttaa
maaseudulle katupölyä ja muita saasteita pakoon. Silloin meidän olisi yhdessä
keksittävä keinoja, miten haitallisia pienhiukkasia syntyisi hengitysilmaamme
mahdollisimman vähän.Lue seuraavaksi Sepelvaltimotaudin kehittyminen (https://sydan.fi/fakta/sepelvaltimotaudin-kehittyminen/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sepelvaltimotaudin ennustetta parantava lääkehoito - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p al v eluk et jut  / Sepel v al timot autipotilaan hoit ok et ju  / Sepel v al timot audin hoit o  /
Sepel v al timot audin ennust et t a p ar ant a v a lääk ehoit o
 Sepel v al timot autipotilaan hoit ok et ju
Sepel v al timot audin diagnostiikka
Sepel v al timot audin hoit o
Sepel v al timot audin hoidon kulmakiv et
Sepel v al timot audin r iskit ekijät
Sepel v al timot audin ennust et t a p ar ant a v a lääk ehoit o
Sepel v al timot audin oir eit a lie vitt ä v ä lääk ehoit o
R e v askular isaatio
Yleist ä ohitusleikkauksest a
Sepel v al timot autik oht aus
Sy dän v almennus
Sepel v al timot audin jatk ohoit o ja seurant a



Ennust ett a p arant a v a lääk ehoit o
Antitr omboottinen lääk ehoit o
A set yy lisalisyyshappo (A S A) 100mg x1 tulee olla kä y t össä kaikilla   sepel v al timot autia sair ast a villa  potilailla
Ei nä y tt ö ä lääkk een h y öd yst ä ilman v ar maa diagnoosia suur en r iskin potilaillakaan
Antik o agulaatiohoit o (v ar f ar iini, DO A C) on t a v allisesti y ksinään r iitt ä v ä st abiilin t audin hoidossa (y li 1 vuosi  sairast etust a sy däninf ar ktist a)
A S A -aller gisilla  kä y t et ään klopidogr eelia annoksella 7 5mgx1
Sair ast etun sy däninf ar ktin jälk een  kä y t et ään ASAn r innalla ADP -salp aajaa 12kk ajan pienent ämään uuden sy däninf ar ktin ja sy dänkuolleisuuden
r iskiä
ASA 100mg x1 + klopidogr eeli 7 5mg x1 T AI
ASA 100mg x1 + tikagr elor i 90mg x2 T AI
ASA 100mg x1 + prasugr eeli 10mg x1 
Elektiivisesti t ehd yn PCI-t oimenpit een jälk een  kaksoisantitr omboottisen hoidon k est o suunnit ellaan y ksilöllisesti
Hoit o aika on t a v allisesti 6-12kk 
 ADP -salp aaja v oidaan y leensä t auott aa 3kk kuluttua t oimenpit eest ä, jos se on t ar peellist a esimer kiksi suur en vuot or iskin kirur gisen
t oimenpit een vuoksi
ASAn tulee jatkua ilman t auk o a
ADP -salp aaja tulisi aloitt aa uudelleen heti kun mahdollist a ja jatkaa alkuperäisen hoit o ajan loppuun
T auotuksest a suosit ellaan aina k onsul t oimaan kar diologiaKuuntele4.3.2025 klo 17.20 Sepelvaltimotaudin ennustetta parantava lääkehoito - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/hoito/ennustetta-parantava-laakehoito 1/3
Akuutissa vuot otilant eessa t auot et aan ADP -salp aaja, mutt a jatk et aan ASA 100mgx1. Kar diologin k onsul t aatiot a hoidon jatk ost a suosit ellaan.
Nenä v er en vuodon, hematur ian, must elmat aipumuksen yms. y ht e y dessä on p yr itt ä v ä ensisijaisesti v aikutt amaan vuodon v älilliseen aiheutt ajaan
( esim. vir t satieinf ektio t ai kuiv at limakal v ot) ja v ast a t oissijaisesti muutt amaan lääk ehoit o a
Suur en t ai k oht alaisen isk eemisen r iskin potilailla v oidaan kä y tt ää pitkäaikaist a antitr omboottist a lääk ehoit o a
P otilaan vuot or iski tulee ar v oida t ar kkaan ennen hoidon aloitust a (aiemmat vuodot, anemia, sairast etut aiv ot ap ahtumat, munuaist en
v ajaat oimint a)
Lääk e v aiht oeht oina o v at ASA 100mg x1 + Tikagr elor i 60mg x2, ASA 100mg x1 ja Klopidogr eeli 7 5mg x1 t ai ASA 100mg x1 ja Riv ar oksab aani
2, 5mg x2
Hoit o suosit ellaan aloit ett a v aksi y ht eist y össä er ik oissairaanhoidon kanssa
H yper k olest er olemian hoit o
St atiinihoit o p ar ant aa sepel v al timot autipotilaiden ennust et t a ja on sit en aiheellinen kaikille LDL -ar v ost a r iippumatt a.
T a v oitt eena kaikilla sepel v al timot autipotilailla on  LDL < 1.4 ja 50% v ähenn ys perust asost a
Jos potilaalla on t oistuv a sy däninf ar kt eja r iskit ekijöiden h yv äst ä hoidost a huolimatt a, t a v oit e on LDL < 1. 0
Ensijainen lääk ehoit o v aiht oeht o on st atiini suur immalla siedet y llä annoksella 
A t or v ast atiini 40-80mg t ai r osuv ast atiini 20-40mg o v at t a v allisimmat kä y t et y t lääkk eet ja annostukset
Jos st atiinihoit o ei ole y ksinään r iit t ä v ä,  lisät ään r innalle et setimibi 10mgx1
Monot erapiaa ei suosit ella huonon t ehon vuoksi. St atiineja huonosti siet ä ville potilaillekin kannatt aa yr itt ää saada lääkit y kseen edes pieni annos
st atiinia ( esim. R osuv ast atiini 5mg 3- 7 k er t aa viik ossa)
Jos potilaalle tulee st atiinist a hait t a v aikutuksia , suosit ellaan k ok eilemaan ns. siedät yshoit o a
St atiinilääkit ys aloit et aan y hdellä t abletilla viik ossa ja annost a nost et aan 2-4 viik on v älein aina y hdellä t abletilla viik ossa suur imp aan siedett yyn
annokseen saakka
PCSK9-salp aajan aloitus on aiheen, jos maksimaalisest a  si edet yst ä st atiinin ja et setimibin annoksest a huolimatt a LDL > 2. 6 . 
Suositus noudatt aa K elan k or v att a vuuskr it eer ejä. T odellisuudessa potilaat v oisiv at h y öt y ä lääkk eest ä, jos LDL on y li 1.4 , mutt a lääkk een kallis
hint a on est eenä
K or v att a vuus v aatii hoit a v an lääkär in laatiman B-lausunnon, jossa kuv at aan sepel v al timot audin kulku ( er it yisesti sairast etut sy däninf ar ktit),
k ok eillut st atiinit annostuksineen ja niiden haitt a v aikutukset sekä LDL -ar v ot. B-lausunt oon tulee liitt ää kar diologin t ai sisät autilääkär in suositus
lääkk een aloituksest a
A CEn est äjät
Kä y t et ään ensisijaisena lääkk eenä sepel v al timot autipotilailla v er enp aineen hoidossa
Parant a v at ennust ett a potilailla, joilla on L VEF 40% t ai alle, v aikka v er enp aine olisi alle t a v oit et ason
Molemmissa potilasr y hmissä p yr it ään suur imp aan siedett yyn annokseen
T oissijaisena lääkk eenä kä y t et ään A T2-salp aajia ( esim. A CEn-est äjän aiheutt aman yskän vuoksi)
Beet asalp aajat
Kä y t et ään v ähint ään y hden vuoden ajan sy däninf ar ktist a r y tmihäir iöiden est oon ja kuolleisuutt a v ähent ämään
St abiilissa v aiheessa p arant a v at ennust ett a potilailla, joilla on L VEF 40% t ai alle
Muil t a lääkit ys v oidaan lopett aa vuoden kuluttua inf ar ktist a er it yisesti, jos tulee haitt a v aikutuksia ( esim. huono sy kk eennousu rasituksessa,
impot enssi)
Oir eisen potilaan hoit ossa ensisijaisia lääkk eit ä 
Diabet eslääkk eet
SGL T - 2 ja GLP1-analogeja suosit ellaan potilaille, joilla on t yypin 2 diabet es ja sepel v al timot auti
Emp agliflot siini ja kanagliflot siini v ähent ä v ät sy dän- ja v er isuonit autit ap ahtumia. Emp agliflot siini v ähent ää kar dio v askulaar i- ja k ok onaiskuolleisuutt a
ja kanagliflot siini v ähent ää sy däninf ar kt eja t yypin 2 diabet est a sairast a villa v al timot autipotilailla.
Dap agliflot siini v ähent ää suur essa v al timot autir iskissä ole vien t yypin 2 diabeetikk ojen sy dämen v ajaat oimint ajaksoja
GLP1-r esept or iagonistit ( dulaglutidi, liraglutidi ja semaglutidi) v ähent ä v ät sy dän- ja v er isuonit ap ahtumia diabet est a sairast a villa v al timot autipotilailla
 
Edellinen
Sepel v al timot audin r iskit ekijätSeur aa v a
Sepel v al timot audin oir eit a lie vitt ä v ä lääk ehoit o
Päivit ett y 28 . 11.202 4 Kuuntele
 Sanakirja
Käännös4.3.2025 klo 17.20 Sepelvaltimotaudin ennustetta parantava lääkehoito - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/hoito/ennustetta-parantava-laakehoito 2/3
Ev äst eet
Saa vut et t a vuusselost e
Tiet osuoja
© Pir kanmaan h yvin v ointialueT akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.
T ämän sivun lö y dät osoitt eella pir ha.fi/hoit ok et jut4.3.2025 klo 17.20 Sepelvaltimotaudin ennustetta parantava lääkehoito - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/hoito/ennustetta-parantava-laakehoito 3/3
Sepelvaltimotaudin hoito - Sydänsairaala.pdf
Etusivu (https://www.sydansairaala.fi)➝Potilaana (https://www.sydansairaala.fi/potilaana/)➝Sepelvaltimotaudin hoito
Sepel val ti mo taudin hoito
Sepelvaltimotaudissa sydänlihakseen verta tuovat sepelvaltimot ovat ahtautuneet
rasvakalkkeumien takia, mikä johtaa sydänlihaksen hapenpuutteeseen ja kipuoireeseen.
Sepelvaltimotauti voi aiheuttaa rintakipua etenkin rasituksessa tai jo levossakin. Äkillinen
suonen tukkeutuminen saattaa aiheuttaa sydäninfarktin. Muita oireita voivat olla
väsyminen, hengenahdistus, rytmihäiriöt ja sydämen vajaatoiminta.
Toisinaan pelkkä sepelvaltimotaudin lääkehoito ei ole riitä. Sepelvaltimoiden
varjoainekuvaus tarvitaan aina ennen kajoavia eli elimistön sisälle ulottuvia toimenpiteitä.Aihee seen liit tyvää
Sepelvaltimotauti ➝
(https://www.sydansairaala.fi/tietoa/sepelvaltimotauti/)
Sepelvaltimotaudin hoidon vaikuttavuus ➝
(https://www.sydansairaala.fi/hoitoon-
sydansairaalaan/hoidon-vaikuttavuus/)
Sydämen toiminnan arviointi ja seuranta ➝
(https://www.sydansairaala.fi/potilaana/sydamen-
perustutkimukset/)
Rintakipu ➝
(https://www.sydansairaala.fi/tietoa/rintakipu/)
Hoitopaikan valinta 
(https://www.sydansairaala.fi/hoitoon-
sydansairaalaan/hoitopaikan-valinnanvapaus/)
Hoitoon pääsyn ajat 
(https://www.sydansairaala.fi/hoitoon-
sydansairaalaan/hoitoon-paasyn-ajat/)➝
➝(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Usein ensivaiheen hoitona ja lievemmissä tautimuodoissa päästään hyvään
hoitotulokseen sepelvaltimon pallolaajennuksella ja stenttauksella. Taudin vaikeammissa
muodoissa voidaan tehdä sepelvaltimoiden ohitusleikkaus.
Miten sepel val ti mo tautia tutki taan?
Potilaalle tehdään ensimmäiseksi kliininen rasituskoe, jolla pyritään selvittämään
rintakivun syytä. Siinä tutkittava potilas polkee kuntopyörää, ja lääkäri tarkkailee
samanaikaisesti polkijan verenpainetta ja sydänfilmimuutoksia. Jos rasitus aiheuttaa
hapenpuutteen sydänlihakseen, se kyetään havaitsemaan sydänfilmin avulla. Näin lääkäri
voi arvioida, onko kyse sepelvaltimotaudista ja aloittaa tarvittaessa lääkehoidon. Kliinisen
rasituskokeen perusteella kyetään myös arvioimaan, onko lääkehoito riittävä vai
tarvitaanko vielä tarkempia tutkimuksia, kuten sepelvaltimoiden varjoainekuvausta.
Sepelvaltimotaudin lääkehoito koostuu sairauden ennusteeseen vaikuttavasta hoidosta,
joita ovat aspiriini ja kolesterolia alentava statiini. Lisäksi voidaan käyttää beetasalpaajia.
Niitä käytetään oireiden lievitykseen. Jos potilas on sairastanut sydäninfarktin tai hänellä
on sydämen vajaatoiminta, beetasalpaajilla on myös sairauden ennustetta parantava
vaikutus. Lisäksi voidaan käyttää ns. ACE-estäjiä tai AT-salpaajia erityisesti, jos mukana
on sydämen vajaatoimintaa. Myös nitraatti kuuluu sepelvaltimotautipotilaan oireita
helpottavaan lääkitykseen.
Mikäli rintakipu häiritsee arkielämässä selviytymistä hyvästä lääkehoidosta huolimatta,
voidaan sepelvaltimoiden varjoainekuvauksen jälkeen harkita muita hoitomuotoja. Niitä
ovat sepelvaltimoahtauman pallolaajennus tai ohitusleikkaus.
Oikean hoitomuodon valinta perustuu kansainvälisiin hoitosuosituksiin ja kokemukseen.
Hoitomuodon valintaan vaikuttavat varjoainekuvauslöydöksen lisäksi potilaan mahdolliset
taustasairaudet (tavallisimpia ovat diabetes, munuaisten vajaatoiminta ja
keuhkosairaudet), mahdolliset sydämen liitännäissairaudet, ikä ja potilaan oma
hoitotahto.Jaa sivu:
(http://www.facebook.com/sharer/sharer.php?
u=https://www.sydansairaala.fi/potilaana/sepelvaltimotaudin-
hoito/) (http://twitter.com/share?
url=https://www.sydansairaala.fi/potilaana/sepelvaltimotaudin-
hoito/&text=Sepelvaltimotaudin hoito)
(http://www.linkedin.com/shareArticle?
url=https://www.sydansairaala.fi/potilaana/sepelvaltimotaudin-
hoito/&title=Sepelvaltimotaudin
hoito&summary=&source=https://www.sydansairaala.fi/potilaana/s
hoito/) (mailto:?subject=Sepelvaltimotaudin
hoito&body=https://www.sydansairaala.fi/potilaana/sepelvaltimota
hoito/)
Mikä on sepel val ti moiden varjoai ne ku vaus?
Sepelvaltimoiden varjoainekuvauksella saadaan selvyys siitä, onko kyseessä
sepelvaltimotauti vai ei. Sepelvaltimotaudin diagnoosi voidaan tehdä, jos sepelvaltimoissa
nähdään merkittäviä kaventumia.
Varjoainekuvauksessa kuvataan sydämen pinnalla kulkevat ja sydänlihakselle verta vievät
sepelvaltimot. Sepelvaltimoita on kaksi eli oikea ja vasen sepelvaltimo. Lisäksi
molemmissa sepelvaltimoissa on useita haaroja, jotka kaikki saadaan kuvattua
varjoainekuvauksen yhteydessä.
Sepelvaltimoiden varjoainekuvaus on syytä tehdä, jos rintakipu on vaikea tai oire
huonontaa elämänlaatua asianmukaisesta lääkehoidosta huolimatta. Varjoainekuvaus on
tarpeen myös tiettyjen kliinisessä rasituskokeessa paljastuvien löydösten vuoksi, jotka
ennakoivat vaikeaa sepelvaltimotautia. Jos rintakivun syy on jäänyt avoimeksi kliinisen
rasituskokeen ja muiden tutkimusten jälkeen, on perusteltua tehdä diagnostinen
sepelvaltimoiden varjoainekuvaus.
Miten sepel val ti moiden varjoai ne ku vaus tehdään?
Sepelvaltimoiden varjoainekuvaus tehdään paikallispuudutuksessa, jolloin tutkittava on
koko ajan hereillä. Sydänlääkäri voi tehdä tutkimuksen joko ranne- tai reisivaltimon kautta.
Sepelvaltimoiden suuaukolle laitetun katetrin kautta ruiskutetaan varjoainetta ja
samanaikaisesti läpivalaisulaitteella kuvataan varjoaineen täyttämät sepelvaltimot.
Useimmat tutkimukset voidaan tehdä polikliinisesti, jolloin potilas tulee Sydänsairaalaan
aamulla ja pääsee kotiin saman päivän aikana varjoainekuvauksen jälkeen. Toisinaan
potilas on varjoainekuvauksen jälkeen yhden yön sairaalassa, jos käytössä on esimerkiksi
verenohennuslääke tai potilaalla on vaikea munuaisten vajaatoiminta.
Mitä ovat pallo laa jennus ja stent taus?
Sepelvaltimotauti syntyy, kun sydänlihakselle happea vievä sepelvaltimo ahtautuu.
Kyseinen ahtauma voidaan hoitaa pallolaajennuksella ja metalliverkkoputken eli stentin
laittamisella (= stenttaus). Ensin ahtautunut sepelvaltimo laajennetaan pallokatetrin
avulla. Toimenpidettä kutsutaan pallolaajennukseksi. Sen jälkeen ahtauman kohdalle
viedään stentti, jonka tarkoituksena on varmistaa suonen auki pysyminen.
Nykyisin suurin osa stenteistä on päällystetty lääkeaineella, jolloin puhutaan
lääkestenteistä. Niissä oleva lääke estää tehokkaasti hoidetun kohdan uudelleen
ahtautumista toimenpiteen jälkeen. Sydänlääkäri arvioi yksilöllisesti, milloin on
hyödyllisintä laittaa tavallinen stentti ja milloin lääkestentti.
Milloin poti laalle tehdään pallo laa jennus?
Pallolaajennus tehdään sepelvaltimoiden varjoainekuvauksessa nähtyihin merkittäviin
ahtaumiin. Potilaan oirekuvaus on keskeisessä asemassa, kun harkitaan ahtaumien
hoitoa pallolaajennuksella ja stenttauksella.
Epäselvissä tilanteissa ahtauman kliinisen merkityksen arvioinnissa voidaan käyttää
apuna kliinisen rasituskokeen löydöstä ja sepelvaltimoiden varjoainekuvauksen
yhteydessä tehtyjä lisätutkimuksia. Niitä ovat sepelvaltimon sisäinen ultraäänitutkimus
(IVUS) ja valokerroskuvaus (OCT). Niiden avulla saadaan tarkka kuva ahtauman
vaikeusasteesta. Myös ahtauman merkitystä sydänlihaksen verenkierrolle voidaan tutkia
varjoainekuvauksen yhteydessä (FFR-tutkimus).
Näiden pohjalta arvioidaan yksilöllisesti paras hoitomuoto, joka voi olla optimaalinen
lääkehoito, pallolaajennus ja stenttaus tai ohitusleikkaus.
Miten pallo laa jennus etenee käytän nössä?
Pallolaajennus ja stenttaus tehdään paikallispuudutuksessa, jolloin hoidettava on koko
ajan hereillä. Sydänlääkäri voi tehdä toimenpiteen joko ranne- tai reisivaltimon kautta.
Sepelvaltimoiden suuaukolle laitetun katetrin kautta viedään ohut vaijeri ahtaumakohdan
ohi. Sen jälkeen kyseisen vaijerin avulla tehdään ensin pallolaajennus ja sen jälkeen
stenttaus.
Useimmat pallolaajennukset ja stenttaukset tehdään polikliinisesti, jolloin potilas tulee
Sydänsairaalaan aamulla ja pääsee kotiin saman päivän aikana toimenpiteen jälkeen.
Toisinaan potilas on toimenpiteen jälkeen yhden yön sairaalassa, jos käytössä on
esimerkiksi verenohennuslääke tai potilaalla on vaikea munuaisten vajaatoiminta.
Nykyisin suurin osa pallolaajennuksista tehdään sepelvaltimoiden varjoainekuvauksen
yhteydessä, jolloin erillistä käyntiä pallolaajennuksen vuoksi tarvita.
Mitä sepel val ti moiden ohitus leik kauk sessa tapahtuu?
Leikkaushoitoa edeltää aina kardiologin ja sydänkirurgin ammatillinen hoitoneuvottelu.
Esilääkitylle potilaalle tehdään leikkaussalissa esivalmisteluja ja potilas nukutetaan.
Ohitusleikkaus tehdään pysäytettynä olevaan sydämeen tavallisimmin rintalastan
pitkittäisestä avauksesta, jolloin leikkausalue säilyy verettömänä ja liikkumattomana.
Sydämen pysäytystä varten käytetään sydänkeuhkokonetta, jossa elimistöstä palaava
veri hapetetaan ja palautetaan sitten takaisin verenkiertoon. Näin korvataan sydämen ja
keuhkojen toiminta keskimäärin reilun tunnin ajaksi.
Verisuonisiirre ommellaan ohuella verisuonilangalla ahtauman alajuoksulle
sepelvaltimoon tehtyyn muutaman millimetrin mittaiseen avaukseen. Tukosta tai
ahtaumaa ei pääsääntöisesti poisteta. Siirteinä käytetään rintakehän avauksen
yhteydessä esille saatavia rinnanseinän sisävaltimoita, käsivarren värttinävaltimoa tai
alaraajojen laskimoita.
Ohitusleikkaus voidaan tehdä tarvittaessa myös sydäntä pysäyttämättä, ilman
sydänkeuhkokonetta. Tällöin potilaan oma sydän huolehtii normaalisti verenkierrosta
koko leikkauksen ajan. Sydämen pinnalla kulkevat sepelvaltimot saadaan halutusta
kohtaa vakautettua erityisellä tukivarrella niin, että siirteen ompelu mahdollistuu. Lyövän
sydämen leikkauksessa aorttaverisuoneen ei tarvitse välttämättä kajota, mikä pienentää
aivoverenkierron häiriön riskiä, jos potilaalla on kalkkinen nouseva aorttaverisuoni tai
kalkkiset aivoverisuonet ja mahdollinen aiempi aivoverenkierron tukos. Lyövän sydämen
tekniikkaan voidaan päätyä myös keuhkosairauden tai munuaisten vajaatoiminnan takia.
Miten hoito jatkuu ohitus leik kauksen jälkeen?
Leikkauksen jälkihoito Sydänsairaalassa kestää keskimäärin 4–6 vuorokautta ja edelleen
jatkohoitosairaalassa saman verran. Rintalasta luutuu 6–8 viikossa ja mahdollinen
sairausloma on 2–3 kuukauden mittainen. Leikkauksen tavoitteena on usein
elämänlaadun ja suorituskyvyn paraneminen, toisinaan myös vakavan tautikohtauksen
ehkäisy.
Jatkossa hyvän pitkäaikaistuloksen saavuttamiseksi on tärkeää hoitaa
sepelvaltimotautiin johtaneita riskitekijöitä, sillä korkea verenpaine, korkea kolesteroli ja
diabetes vaikuttavat myös siirrännäissuonten aukipysyvyyteen. Sepelvaltimotaudin
säännöllinen seuranta on tarpeen.
Sepel val ti moiden varjoai ne ku vaus ja
pallo laa jennus
Varjoainekuvauksen perusteella arvioidaan, hyötyykö potilas
sepelvaltimoiden toimenpiteestä, kuten pallolaajennuksesta tai
ohitusleikkauksesta.
Katso video ▶
(https://player.vimeo.com/video/503380968?
texttrack=fi&rel=0&showinfo=0)
(https://player.vimeo.com/video/503380968?
texttrack=fi&rel=0&showinfo=0)

Sepelvaltimotaudin hoito.pdf
Se pel val ti mo tau din hoito
Sepelvaltimotaudin hoidon perusta on hyvä riskitekijöiden hoito, terveet
elämäntavat ja lääkehoito.
Tehokas kohonneen verenpaineen hoito, veren kolesterolipitoisuutta alentava lääkehoito ja hyvä
diabeteksen lääkehoito yhdessä terveellisten elämäntapojen kanssa hidastavat
sepelvaltimotaudin etenemistä ja lisäävät potilaan elinvuosia. Veren hyytymistaipumusta
ehkäistään pienellä annoksella asetyylisalisyylihappoa.
Jos rintakipu rajoittaa elämää, on aiheellista hakeutua lääkärin vastaanotolle. Tarvittaessa
tehdään  sepelvaltimoiden varjoainekuvaus, jonka perusteella päät etään jatkohoito.
Pallolaajennusta tai ohitusleikkausta tarvitaan, jos oireet ovat lääkehoidosta huolimatta
hankalia. Näitä kajoavia toimenpiteitä tarvitaan myös vähäoireisilla potilailla, jos kriittisiä
ahtaumia todetaan sepelvaltimoiden tyviosissa.
Hoitomuodon valinta perustuu ahtaumien sijaintiin, lukumäärään ja vaikeusasteeseen. Myös
liitännäissairaudet vaikuttavat, päädytäänkö ohitusleikkaukseen vai pallolaajennukseen.
Ennustetta parantavaa lääkitystä ja terveellisiä elämäntapoja tarvitaan aina myös
toimenpiteiden jälkeen.
Jos toimenpidehoitojen jälkeen esiintyy rintakipuoireita, niitä helpotetaan nopeasti vaikuttavilla
nitrovalmisteilla. Valmisteita on olemassa tabletteina ja suihkeena. Näitä potilas voi itse

annostella tarpeen mukaan. Vakaassa sepelvaltimotaudissa nitrovalmiste poistaa rintakivun
yleensä nopeasti.
Terveyskylän Kuntoutumistalosta ja Painonhallintatalosta löydät lisää tietoa ja neuvoja
terveellisistä elämäntavoista. Kuntoutumistalosta löydät myös Liikunta sydäninfarktista
kuntoutumisen tukena-oppaan.
TÄRKEÄÄ
Jos nitrovalmisteen käyttö tai oireet lisääntyvät, on hakeuduttava lääkärin vastaanotolle.
Aiheeseen liittyvää
Tarkistettu 3.7.2020Omahoito
Sepelvaltimoiden varjoainekuvaus eli koronaariangiografia
Sepelvaltimoiden pallolaajennus
Sepelvaltimoiden ohitusleikkaus
Tietoa ja tukea (Kuntoutumistalo)
Liikunta sydän infarktista kuntoutumisen tukena (Kuntoutumistalo)
Painonhallinta    talo  (Painonhallinta    talo )
Dyslipidemiat eli veren poikkeavat rasva-arvot (kaypahoito.fi)
Askeleita omatoimiseen kuntoutumiseen (s ydan.fi)
Sepelvaltimotaudin lausunnot - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p alveluk etjut  /Sepel valtimot autipotilaan hoit oketju  /
Sepel valtimot audin jatk ohoit o ja seurant a  / Sepel v al timot audin lausunnot
 Sepel v al timot autipotilaan hoit ok et ju
Sepel valtimot audin diagnostiikka
Sepel valtimot audin hoit o
Sepel valtimot autik ohtaus
Sydänvalmennus
Sepel valtimot audin jatk ohoit o ja seurant a
Seurant a sepel valtimot autidiagnoosin jälk een
OmaSy dän-et ähoit opalvelu
Sepel valtimot autipotilaan ajot erveys
Sepel valtimot autipotilaan t yökyvyn ar viointi
Sepel v al timot audin lausunnot



Sepel valtimot audin lausunnot
B-lausunt o sepel valtimot autilääkk eiden er ityiskorvattavuudest a
Diagnoosik oodit: I20–I22, I2 4.0, I25
Kroonisen sepel valtimot audin osoitt avan lausunnon edell ytetään perustuv an er ikoissairaanhoidon sisät autien t ai
kardiologian y ksikössä suor itettuun tutkimukseen. T apauksissa, joissa kr oonisen sepel valtimot audin oir eet ja
löydökset o vat kiist attomat ja selk eät, v oidaan h yväksy ä myös muun, potilast a pitkäaikaisesti hoit avan lääkär inKuuntele4.3.2025 klo 17.09 Sepelvaltimotaudin lausunnot - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotaudin-jatkohoito-ja-seuranta/sepelvaltimotaudin-lausunnot 1/2
tutkimukseen perustuv a lausunt o, jos er ikoissairaanhoidon tutkimukseen ei ole hoidollist a tarvetta eikä sellaist a ole
vaikeudett a saat avissa.
Oikeus er ityiskorvattavaan lääk ehoit oon v oidaan m yöntää
seuraa vin perust ein:
Potilaan sel vä angina pect oris -oir e on kliinisen tutkimuksen perust eella tulkitt avissa kr ooniseksi, ja se
reagoi lääk ehoidolle. Jos lepo-ek g ei anna r iittävää osoitust a sepel valtimot audin olemassaolost a (esim.
infarktiar pi), diagnoosi tulee v arment aa esimer kiksi kliinisellä rasitusk okeella.
Potilas on sairast anut sy däninf arktin t ai hänelle on t ehty sepel valtimo-ohitusleikkaus t ai pallolaajennus
Potilaalla on r intakipuoir een lisäksi asianmukaisessa kuv antamistutkimuksessa (kut en
esimer kiksi v arjoainetutkimuksessa, rasitusul traäänikuv auksessa, sy dänlihaksen per fuusion gammakuv auksessa
tai sepel valtimoiden TT -tutkimuksessa) osoit ettu mer kittävä aht auma sepel valtimoissa.
Huom! Sepel valtimoiden TT -tutkimuksessa t odettu seinämäkalkk euma ilman mer kittävää aht aumaa ei oik euta
KELA:n kr iteerien mukaan sepel valtimot autilääkit yksen er ityiskorvattavuut een
206 Kr ooninen sepel v al timot auti ja kr ooniseen sepel v al timot autiin liit t yv ä r asv a-aineen v aihdunnan häir iö (KELA)
Edellinen
Sepel valtimot autipotilaan t yökyvyn ar viointi
Päivit etty 13.12.202 4
Ev äst eet
Saa vut et t a vuusselost e
Tiet osuoja
© Pir kanmaan h yvin v ointialueT akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.
T ämän sivun lö y dät osoitt eella pir ha.fi/hoit ok et jut4.3.2025 klo 17.09 Sepelvaltimotaudin lausunnot - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotaudin-jatkohoito-ja-seuranta/sepelvaltimotaudin-lausunnot 2/2
Sepelvaltimotaudin lääkehoito - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/
Sepelvaltimotaudin lääkehoito
Sepelvaltimotaudin lääkehoito
(https://sydan.fi/fakta/sepelvaltimotaudin-
laakehoito/)
Lääkehoitoa tarvitaan sepelvaltimotaudissa aina, sairauden kaikissa vaiheissa.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 10.2.2023
Päivitetty 7.3.2025
 
Lue seuraavaksi Ohitusleikkaus kiertää sepelvaltimon ahtauman (https://sydan.fi/fakta/ohitusleikkaus-kiertaa-
sepelvaltimon-ahtauman/)
Sepelvaltimotaudin lääkehoito voidaan jakaa kahteen ryhmään. Yhteen ryhmään
kuuluvat lääkkeet, joilla pysäytetään itse ateroskleroosi
(https://sydan.fi/fakta/sepelvaltimotaudin-kehittyminen/) eli sairauden
eteneminen, ja ehkäistään siten sydäninfarkteja. Toisaalta moni potilas tarvitsee
lääkkeitä, joilla helpotetaan sepelvaltimotaudin oireita.
Monesti sepelvaltimotautipotilaalla on muitakin sydänsairauksia, kuten
esimerkiksi sairastetun sydäninfarktin vuoksi kehittynyt sydämen vajaatoiminta,
tai rytmihäiriötaipumus kuten eteisvärinä (https://sydan.fi/fakta/eteisvarina/).
Tässä kirjoituksessa käsitellään pääasiassa sepelvaltimotaudin lääkkeitä. Muiden
sairauksien hoitoon käytettävät lääkkeet saattavat vaikuttaa yksilöllisesti myös
sepelvaltimotaudin lääkevalintoihin.
Sepelvaltimotaudin lääkkeet ovat pääasiassa alemman erityiskorvattavuuden
piirissä (numero 206). Korvattavuuden hakemista varten tarvitaan lääkärin
laatima B-lausunto.
Ennusteeseen vaikuttava lääkitys
Tähän ryhmään kuuluvilla lääkkeillä on todettu olevan merkittävää hidastavaa
vaikutusta sepelvaltimotaudin etenemiseen. Niiden tiedetään vähentävän
sepelvaltimotautipotilaan kuolleisuutta ja uusia sydäninfarkteja, siksi puhutaan
ennusteeseen vaikuttavasta lääkehoidosta. Säännöllinen lääkitys on tärkeä. Älä
koskaan lopeta tai vähennä lääkitystä neuvottelematta asiasta lääkärin kanssa.
Sepelvaltimotautipotilas tarvitsee veren hyytymistä ehkäisevän lääkityksen
(https://sydan.fi/fakta/verihiutaleita-estavat-laakkeet-valtimotautien-
hoidossa/). Lääkkeellä ehkäistään verihyytymän syntymistä sairaan verisuonen
sisälle. Tavallisesti käytetään asetyylisalisyylihappoa (lyhenne ASA). Allergiset
potilaat voivat käyttää vaihtoehtoisesti klopidogreeli-nimistä lääkeainetta.
Pallolaajennuksen ja sydäninfarktin jälkeen tarvitaan määräaika, tavallisesti
korkeintaan vuoden ajan, kaksi hyytymistä estävää lääkettä, mutta
pitkäaikaiskäytössä yksi yleensä riittää.
Kaikille sepelvaltimotautipotilaille aloitetaan statiinilääkitys laskemaan
kolesterolia (https://sydan.fi/fact/kolesterolilaakkeet/). LDL-kolesterolin
tavoitetaso on alle 1,4 mmol/l. Käytännössä ateroskleroosin suhteen olisi
parasta, että LDL-taso olisi mahdollisimman matala. Jos kolesteroli ei laskeLue seuraavaksi Ohitusleikkaus kiertää sepelvaltimon ahtauman (https://sydan.fi/fakta/ohitusleikkaus-kiertaa-
sepelvaltimon-ahtauman/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
riittävästi statiinihoidosta huolimatta, voidaan rinnalle lisätä kolesterolin
imeytymistä estävä etsetimibi-valmiste. Jos tälläkään hoidolla ei saada riittäviä
hoitotuloksia, voidaan harkita uudempia lääkkeitä, PCSK9-estäjiä.
Useimmilla sepelvaltimotautipotilailla on kohonnut verenpaine. Verenpaine pitää
hoitaa tehokkaasti, siten että paine on kotona lepotilassa pääasiassa alle 130/85
mmHg. Verenpaineen hoitona kannattaa käyttää ACE-estäjää
(https://sydan.fi/fact/acen-estajat/). Jos lääke aiheuttaa yskää, vaihtoehtona
on ATR-salpaajien (https://sydan.fi/fakta/atrn-salpaajat/) ryhmään kuuluva
valmiste. Näitä lääkkeitä käytetään myös aina, jos potilas on ehtinyt sairastaa
sydäninfarktin, joka vaikuttaa sydämen supistumiseen.
Diabeteksen hoitotasapaino pitäisi olla mahdollisimman hyvä. Kaikki
diabeteslääkkeet sopivat sepelvaltimotautipotilaalle, mutta kahden
lääkeryhmän on todettu olevan erityisen hyödyllisiä. Näistä
glukoosinkuljettajaproteiini 2:n estäjät (ns. SGLT2-estäjät) ovat
tablettimuotoisia. Tavallisia valmisteita ovat esimerkiksi empagliflotsiini
(Jardiance®) ja dapagliflotsiini (Forxiga®). Toinen hyödyllinen lääkeryhmä on
nimeltään GLP-analogit. Nämä ovat pistoksina otettavia lääkkeitä, jotka
auttavat myös painonhallinnassa. Lääkenimiä ovat esimerkiksi semaglutidi
(Ozempic®) ja liraglutidi (Saxenda®, Victoza®).
Oireita lievittävä lääkitys
Oireita helpottavat lääkkeet auttavat tavalla tai toisella sairaan sydämen työtä,
mutta eivät vaikuta itse ateroskleroosiin.
Näistä tunnetuimpia lienevät ” nitrot ” , joita käytetään tarvittaessa
oirekohtaukseen, mutta myös säännöllisesti. Nitrot eli nitraatit
(https://sydan.fi/fact/nitraatit/) laajentavat verisuonia.
Yleensä sydäninfarktin jälkeen jokaiselle potilaalle aloitetaan
beetasalpaajalääkitys (https://sydan.fi/fact/beetasalpaajat/). Lääke rauhoittaa
sykettä ja estää pulssin nousua rasituksessa. Se ehkäisee myös rytmihäiriöiltä.
Jos ei ole muita syitä käyttää lääkettä, kuten esimerkiksi sydämen
vajaatoimintaa tai rytmihäiriötaipumusta, lääkityksen keskeyttämistä voidaan
harkita vuosi sydäninfarktin jälkeen. Lääkäri päättää jatkosta tapauskohtaisesti.
Jos ongelmana on sepelvaltimoiden supistelu- eli spasmitaipumus
(https://sydan.fi/question/sepelvaltimon-spasmi/), kalsiumestäjälääkkeet
(https://sydan.fi/fact/kalsiuminestajat/) voivat tuoda avun.Lue seuraavaksi Ohitusleikkaus kiertää sepelvaltimon ahtauman (https://sydan.fi/fakta/ohitusleikkaus-kiertaa-
sepelvaltimon-ahtauman/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Kipulääkkeet ja erektiolääkkeet
Omatoimiseen kivun ja kuumeen hoitoon (https://sydan.fi/fakta/ohjeita-
sydanpotilaille-kipulaakkeiden-kaytosta/) soveltuvat parhaiten parasetamoli -
valmisteet. Varsinaisia tulehduskipulääkkeitä (esim. ibuprofeeni, ketoprofeeni,
indometasiini) ei saisi käyttää säännöllisesti ja pitkäaikaisesti ilman lääkärin
ohjetta.
Erektiohäiriöt ovat varsin tavallisia sepelvaltimotautipotilailla. Tavallisia
erektiohäiriöiden hoitoon käytettäviä lääkkeitä kuten esim. sildenafiilia tai
tadalafiilia voi yleensä käyttää turvallisesti, kunhan vain ei käytä samanaikaisesti
nitraattivalmisteita. Näiden yhtäaikainen käyttö on kiellettyä hankalien
haittavaikutusten vuoksi.
Seuranta
Sepelvaltimotautipotilaan tulisi käydä kontrollikäynneillä terveyskeskuksessa tai
työterveyslääkärillä noin kerran vuodessa. Käyntien yhteydessä tarkastetaan
lääkityksen sopivuus ja riittävyys, sekä arvioidaan oireisuus, elintapahoidon
toteutuminen ja muu elämänlaatu. Pelkkä reseptien uusinta ei ole seurantaa.Lue seuraavaksi Ohitusleikkaus kiertää sepelvaltimon ahtauman (https://sydan.fi/fakta/ohitusleikkaus-kiertaa-
sepelvaltimon-ahtauman/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sepelvaltimotaudin oireet - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/
Sepelvaltimotaudin oireet
Sepelvaltimotaudin oireet
(https://sydan.fi/fakta/sepelvaltimotaudin-
oireet/)
Tyypillinen sepelvaltimotaudin oire on rintakipu, mutta oire voi olla
toisenlainenkin. Sepelvaltimotaudin kohtaus, sydäninfarkti, on
hengenvaarallinen ja hoidolla on kiire. Siksi jokaisen on hyvä tuntea
sairaudesta ilmoittelevat oireet.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 9.2.2023
Päivitetty 7.3.2025
Lue seuraavaksi Sydäninfarkti (https://sydan.fi/fakta/sydaninfarkti/)
 
Sydänperäisestä rintakehän oireesta käytetään usein termiä 
Tämä tarkoittaa suomeksi rinnassa tuntuvaa ahdistusta. Englannin kielinen termi
kuvaa sydänperäistä oiretta vieläkin paremmin.
Sepelvaltimotaudin oire on tyypillisimmillään kipua, mutta oire voi olla myös
hengenahdistuksen eli hapen loppumisen tunnetta, tai kiristävää ja painavaa
tuntemusta. Yhteistä näille kaikille on tuntemuksen laaja-alaisuus, eli oire tuntuu
epämääräisesti laajalla alueella rintakehällä. Oire saattaa säteillä kaulalle,
hampaisiin, yläraajoihin, selkään lapojen väliin tai ylävatsalle. Joskus oireilu on
pelkästään tätä säteilykipua. Närästys, joka ilmaantuu vain rasituksessa, voi olla
sydänoire.
Sepelvaltimotaudin oire johtuu sydämen hapenpuutteesta. Siksi oire ilmaantuu
yleensä rasitustilanteessa, ja lepo eli rasituksen lopettaminen helpottaa eli vie
oireen pois. Tyypillisimmillään oire ilmenee siis esimerkiksi ripeästi kävellessä tai
portaita noustessa. Myös pakkasilma, vastatuuli tai kantamukset voivat
edesauttaa oireen tuloa. Henkinen stressi voi laukaista tuntemuksen.
Rinnan alueella tuntuva kipu ei ole onneksi läheskään aina sydämestä peräisin.
Tavallinen kivun lähde on rintakehän seinämä, kuten lihaksisto. Silloin kipu on
yleensä pitkään keskeytyksettä jatkuvaa (useita tunteja tai vuorokausia), usein
luonteeltaan ” jäytävää ” , ja helpottuu venyttelyllä tai kipulääkkeellä. Lihasten
painelu saattaa lisätä kivun tunnetta. Samoin jos kipu tuntuu pistävänä pienellä
alueella, ja sisään hengittäminen pahentaa tunnetta, on kyse yleensä jostain
muusta kuin sydänoireesta. Rintakehän alueella on sydämen, lihasten ja luiden
lisäksi paljon muutakin, kuten ruokatorvi ja keuhkot.
Milloin pitää epäillä sepelvaltimotautia?
Jos oire sisältää edellä kuvailtuja tyypillisiä osia, joita ovat tuntemuksen laaja-
alaisuus, pahentuminen rasituksessa ja helpottuminen levossa, pitää epäillä
sepelvaltimotautia. Tällaista oireistoa kutsutaan  oireistoksi. Jos
henkilöllä on vielä sepelvaltimotaudin vaaratekijöitä, esimerkiksi kohonnut
kolesteroli tai tupakointihistoria, sepelvaltimotaudin epäily on vahva ja asiaa
pitää selvittää.
Erityisesti vähän liikkuvilla vanhuksilla oireet voivat kuitenkin olla hyvinkin
epämääräisiä, eikä sepelvaltimotautia voida todeta tai poissulkea pelkästään
oirekuvauksen perusteella.angina pectoris.
chest discomfort, 
tyypilliseksiLue seuraavaksi Sydäninfarkti (https://sydan.fi/fakta/sydaninfarkti/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Milloin pitää soittaa hätänumeroon 112?
Kun ahtautunut sepelvaltimo on vaarassa tukkeutua kokonaan, on kyse
 (https://sydan.fi/fakta/sydaninfarkti/). Toisinaan sydäninfarkti
ilmaantuu ilman selviä etukäteisoireita, mutta yleensä varoittavia
ennusmerkkejä esiintyy. Joskus edeltävät oireet vaikeutuvat nopeasti
muutamien päivien kuluessa. Silloin voi olla kyse uhkaavasta sydäninfarktista, ja
tilanne vaatii hoitoa nopeasti kuten varsinainen sydäninfarktikin.
Sydäninfarktissa rintatuntemus on voimakas ja jatkuu levosta huolimatta.
Rintakehän oireen lisäksi saattaa esiintyä pahoinvointia, kylmänhikisyyttä ja
yleistä huonovointisuutta.
Sydäninfarkti hoidetaan aina sairaalassa. Päivystykseen ei lähdetä omalla autolla,
vaan soitetaan  hätänumeroon 112. Ambulanssi nauhoittaa
sydänfilmin eli EKG:n, jolloin jo paikan päällä selviää, kuinka kiireellisestä
tapauksesta on kyse.sydäninfarktista
viivyttelemättäLue seuraavaksi Sydäninfarkti (https://sydan.fi/fakta/sydaninfarkti/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sepelvaltimotaudin oireet.pdf
Se pel val ti mo tau din oi reet
Sepelvaltimotaudin tavallisin oire on rasituksessa ilmaantuva puristava kipu tai
ahdistava tunne rintakehällä. Oireena voi olla myös hengenahdistusta, närästystä,
väsymystä ja pahoinvointia.
Vakaassa sepelvaltimotaudissa oire voi ilmaantua rasituksessa tai voimakkaan tunnereaktion
yhteydessä. Tavallisin oire on rasituksessa ilmaantuva puristava kipu, ahdistava tunne
rintakehällä, kaulalla, hartiaseudulla, lapaluiden välissä tai käsissä. Kipu yleensä pysäyttää
liikkumisen.
Oireena voi olla myös hengenahdistusta, närästystä sekä yleistä väsymyksen-ja
pahoinvoinnintunnetta. Diabeetikoilla ei välttämättä esiinny selkeitä kipuoireita.
Epävakaassa sepelvaltimotaudissa oireita tulee jo pienessä rasituksessa ja jopa levossa.
Kohtausten voimakkuus ja tiheys vaihtelee potilaskohtaisesti.
Pahimmassa tapauksessa sepelvaltimon seinämään kertynyt ahtauma voi revetä, jolloin
repeämän kohdalle syntyvä hyytymä tukkii sepelvaltimon. Näin syntyy sydäninfarkti eli
sydän veritulppa. Kyseessä on aina uhkaava tilanne, joka vaatii välitöntä hoitoa.

RINTAKIPUKOHTAUS
Aiheeseen liittyvää
Tarkistettu 3.7.2020Jos nitrovalmistetta ei ole käytössä ja oireiden kesto 5 minuuttia: SOITA 112!
Jos nitrovalmiste käytössä: ota nitrovalmistetta 3 kertaa 5 minuutin välein. Jos oireet
eivät 15 minuutissa helpota, SOITA 112!
Käypä hoito-ohje potilaalle: Sepelvaltimotautikohtaus (kaypahoito.fi)
Sepelvaltimotaudin oireita lievittävä lääkehoito - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p al v eluk et jut  / Sepel v al timot autipotilaan hoit ok et ju  / Sepel v al timot audin hoit o  /
Sepel v al timot audin oir eit a lie vit t ä v ä lääk ehoit o
 Sepel v al timot autipotilaan hoit ok et ju
Sepel v al timot audin diagnostiikka
Sepel v al timot audin hoit o
Sepel v al timot audin hoidon kulmakiv et
Sepel v al timot audin r iskit ekijät
Sepel v al timot audin ennust ett a p arant a v a lääk ehoit o
Sepel v al timot audin oir eit a lie vit t ä v ä lääk ehoit o
R e v askular isaatio
Yleist ä ohitusleikkauksest a
Sepel v al timot autik oht aus
Sy dän v almennus
Sepel v al timot audin jatk ohoit o ja seurant a



Oir eit a lie vitt ä v ä lääk ehoit o
Beet asalp aajat
Hidast a v at sy kk een nousua rasituksessa ja v ähent ä v ät sy dänlihaksen hapent ar v ett aKuuntele4.3.2025 klo 17.20 Sepelvaltimotaudin oireita lievittävä lääkehoito - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/hoito/oireita-lievittava-laakehoito 1/3
T är k e ä r int akipuoir ett a helpott a v a lääkit ys sepel v al timot audissa. Annostuksessa p yr itt ä v ä suur imp aan t eho a v aan
annokseen. Huom! Liian iso annos v oi aiheutt aa huono a sy k enousua rasituksessa ja sit ä kautt a
hengenahdistusoir ett a 
Haitt a v aikutus kannatt aa huomioida er it yisesti, jos iäkkäälle ihmiselle k ehit yy hengenahdistusoir e ja kä y t össä on
beet asalp aaja
Sy k ett ä hidast a v at kalsiumsalp aajat v erap amiili ja dil tiat seemi
V oidaan kä y tt ää oir eiden hoidossa beet asalp aajien tilalla t ai k ombinoituna beet asalp aajaan er it yisesti nope assa
et eisv är inässä
Eiv ät so v ellu kä y t ett ä v äksi, jos EF < 40%
Pitkä v aikutt eiset nitraatit
Annost elu 1- 2 k er t aa p äiv ää p äiv ässä
V oiv at aiheutt aa or t ost atismia
Kä y tt ö ei est ä l y h y t v aikutt eisen nitraatin kä y tt ö ä k oht ausoir eisiin
L y h y t v aikutt eiset nitraatit
P otilas h y öt yy lääkit y ksest ä, jos hänellä on t oisinaan t oistuvia r int akipuk oht auksia
Edellinen
Sepel v al timot audin ennust ett a p arant a v a lääk ehoit oSeur aa v a
R e v askular isaatio
Päivit ett y 27 . 11.202 4
T akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.
T ämän sivun lö y dät osoitt eella pir ha.fi/hoit ok et jut4.3.2025 klo 17.20 Sepelvaltimotaudin oireita lievittävä lääkehoito - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/hoito/oireita-lievittava-laakehoito 2/3
Ev äst eet
Saa vut et t a vuusselost e
Tiet osuoja
© Pir kanmaan h yvin v ointialue4.3.2025 klo 17.20 Sepelvaltimotaudin oireita lievittävä lääkehoito - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/hoito/oireita-lievittava-laakehoito 3/3
Sepelvaltimotaudin rintakivun sijainti - Terveyskirjasto.pdf
Lue artikkeli:
Terveyskirjasto.fiSepelvaltimotaudin rintakivun sijainti
Lääkärikirja Duodecim -kuvat
30.3.2009
Kuva 1. Sepelvaltimotaudin rintakivun
sijainti. Vasemmalla : puristavan
rintakivun alue keskellä rintalastaa ja sen
ympärillä; joskus kipu voi tuntua ylävatsalla.
Keskellä: Kipu voi säteillä keskelle selkää
lapojen väliin. Oikealla : Kivun säteily
leukaperiin, hartioihin, olkavarsiin ja
vatsaan. Lisää tietoa rintakivusta: ks.
Rintakipu; sepel valtimotaudista: ks.
Sepel valtimotauti.
Artikkelin tunnus: ldk00395
© 2024 Kustannus Oy Duodecim4.3.2025 klo 17.33 Sepelvaltimotaudin rintakivun sijainti - Terveyskirjasto
https://www.terveyskirjasto.fi/ldk00395 1/1
Sepelvaltimotaudin riskitekijät - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p al v eluk et jut  / Sepel v al timot autipotilaan hoit ok et ju  / Sepel v al timot audin hoit o  /
Sepel v al timot audin r iskit ekijät
 Sepel v al timot autipotilaan hoit ok et ju
Sepel v al timot audin diagnostiikka
Sepel v al timot audin hoit o
Sepel v al timot audin hoidon kulmakiv et
Sepel v al timot audin r iskit ekijät
Sepel v al timot audin ennust ett a p arant a v a lääk ehoit o
Sepel v al timot audin oir eit a lie vitt ä v ä lääk ehoit o
R e v askular isaatio
Yleist ä ohitusleikkauksest a
Sepel v al timot autik oht aus
Sy dän v almennus
Sepel v al timot audin jatk ohoit o ja seurant a



Sepel v al timot audin r iskit ekijät
Pysyv ät
Ikä
MiessukupuoliKuuntele4.3.2025 klo 17.20 Sepelvaltimotaudin riskitekijät - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/hoito/sepelvaltimotaudin-riskitekijat 1/2
P er int öt ekijät (Mer kitt ä v ä, jos alle 55-vuotiaalla miehellä t ai alle 65-vuotiaalla naisella on t odettu sepel v al timot auti)
Muokatt a v at
T up ak ointi
Dyslipidemia
Diabet es
H yper t ensio
V ähäinen liikunt a
K eskiv ar t aloliha vuus
V al timot audin k ehit t ymiselle  v oiv at al tist aa lisäksi t odettu muiden v al timoiden at er oskler oosi, munuaist en
v ajaat oimint a, inflammaatiot (mat ala-ast einen tulehdus), r eumasairaudet, uniapne a, psyy kkinen kuor mitus ja mat ala
sosioek onominen asema
 
Edellinen
Sepel v al timot audin hoidon kulmakiv etSeur aa v a
Sepel v al timot audin ennust ett a p arant a v a lääk ehoit o
Päivit ett y 18 . 11.202 4
Ev äst eet
Saa vut et t a vuusselost e
Tiet osuoja
© Pir kanmaan h yvin v ointialueT akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.
T ämän sivun lö y dät osoitt eella pir ha.fi/hoit ok et jut4.3.2025 klo 17.20 Sepelvaltimotaudin riskitekijät - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/hoito/sepelvaltimotaudin-riskitekijat 2/2
Sepelvaltimotaudin tutkimukset - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/
Sepelvaltimotaudin tutkimukset
Sepelvaltimotaudin tutkimukset
(https://sydan.fi/fakta/sepelvaltimotaudin-
tutkimuk set/)
Sepelvaltimotaudin tutkiminen perustuu potilaan oireistoon. Oireiden ja
taustatekijöiden eli ateroskleroosiin viittaavien riskitekijöiden perusteella
herää epäilys, jonka jälkeen tehdään tarvittavat jatkoselvitykset.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 2.2.2023
Päivitetty 7.3.2025
 
Lue seuraavaksi Ablaatioasiaa flutterista ja flimmeristä (https://sydan.fi/kysymys/ablaatioasiaa-flutterista-ja-flimmerista/)
 
Tutkiminen alkaa siis aina lääkärin haastattelulla (esitiedot eli ).
Haastattelussa selvitetään mahdollisimman tarkoin oireen laatu, sekä sitä
pahentavat ja helpottavat tekijät. Lisäksi selvitetään mahdolliset
sepelvaltimotaudin vaaratekijät (https://sydan.fi/fact/sepelvaltimotaudin-
ehkaisy/). Esitietojen perusteella lääkäri muodostaa käsityksensä, voisiko
taustalla olla sepelvaltimotauti vai pitäisikö tutkimukset kohdistaa johonkin
muuhun.
Lääkärin kliinisessä tutkimuksessa ( ) kuunnellaan stetoskoopilla
sydänläppien äänet sekä kaula- ja nivusvaltimot. Rintakehän tunnustelulla
etsitään mahdollisia kivun lähteitä lihaksistosta ja luiden rustoliitoksista.
Verenpaine mitataan.
Sydänfilmi ja verikokeet
Meneillään oleva sydäninfarkti näkyy sydänfilmissä eli EKG:ssä
(https://sydan.fi/fakta/laakarin-tutkimus-ja-ekg/). Jos kyseessä ei kuitenkaan
ole tällainen akuutti tilanne, sepelvaltimotautia ei yleensä näe lepotilassa
otetusta sydänfilmistä tai verikokeista. Sydänfilmi on siitä huolimatta tärkeä
perustutkimus, sillä se kertoo paljon sydämen tilanteesta, esimerkiksi muiden
sydänsairauksien mahdollisuudesta tai vanhoista infarkteista.
Päivystystilanteessa, epäiltäessä sydäninfarktia, verinäytteestä voidaan
määrittää ns. sydänlihaksen merkkiaineita. Kyse on troponiini-nimisestä
merkkiaineesta (lyhenne TnI tai TnT tutkimuslaboratoriosta riippuen). Troponiini
nousee sydänlihaksen hapenpuutteessa, mutta myös monissa muissa tilanteissa
kuten esimerkiksi nopean rytmihäiriön, sydänlihastulehduksen,
keuhkoveritulpan, vaikean tulehduksen jne. yhteydessä. Lääkäri tulkitsee
tuloksen merkityksen muiden tietojen kuten potilaan oireiston ja EKG:n
perusteella.
Verikokeilla tutkitaan aina sepelvaltimotaudin vaaratekijöitä (rasva- ja
sokeriarvot). Toistaiseksi ei ole rutiinikäytössä sellaisia geenitestejä, joita
suositeltaisiin sepelvaltimotaudin vaaran arviointiin.
Rasituskoe
Rasituskoke (https://sydan.fi/fakta/rasituskoe/)en ideana on selvittää,
ilmeneekö sydänfilmissä sydämen hapenpuutteeseen viittaavia ilmiöitä sydämen
kuormittuessa.anamneesi
statusLue seuraavaksi Ablaatioasiaa flutterista ja flimmeristä (https://sydan.fi/kysymys/ablaatioasiaa-flutterista-ja-flimmerista/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Rasituskoe voidaan tehdä, jos tutkittavalla on sepelvaltimotautiin viittaavia
oireita, ja jos sepelvaltimotauti voisi olla riskitekijöiden perusteella mahdollinen.
Rasituskokeessa nähdään myös mahdolliset rytmihäiriöt, jotka saattaisivat olla
oireiden syynä. Lisäksi selviää tutkittavan fyysinen kunto.
Rasituskokeen aikana voidaan samanaikaisesti tutkia sydäntä ultraäänellä (ns.
rasitus-ECHO-tutkimus), mutta Suomessa näitä tutkimuksia tehdään vain
harvoissa paikoissa.
Rasituskokeeseen liittyy tiettyjä tulkinnallisia haasteita. Tämä tarkoittaa sitä,
että koe ei välttämättä ole täysin sairauden toteava tai poissulkeva.
Tulkinnallisten ongelmien vuoksi rasituskokeen asema sepelvaltimotaudin
perustutkimuksena on viime vuosina vähentynyt.
Varjoainekuvaus
Varjoainekuvaus eli angiografia (https://sydan.fi/fakta/sepelvaltimoiden-
varjoainekuvaus/) kertoo tarkasti, onko sepelvaltimoissa merkittäviä
ahtaumakohtia, ja missä kohdin ahtaumat sijaitsevat.
Varjoainekuvaus tehdään aina sydäninfarktin yhteydessä, ellei ole selviä
perusteita pidättäytyä kuvauksesta. Sellainen peruste voi olla esimerkiksi vaikeat
perussairaudet tai hyvin korkea ikä.
Tietokonetomografia
Viime vuosina on sepelvaltimoiden tietokonekuvaus (tietokonetomografia eli TT-
kuvaus (https://sydan.fi/fakta/sepelvaltimoiden-ja-sydamen-
tietokonetomografia/)) tuonut uuden, hyvän mahdollisuuden selvittää
sepelvaltimoiden tilannetta.
Tutkimuksessa nähdään, onko valtimoissa ateroskleroosia eli
rasvoittumapesäkkeitä ja kalkkia. Sepelvaltimotaudin mahdollisuus oireiden
taustalla voidaan siis varsin luotettavasti selvittää.
Tietokonekuvaukseen voidaan yhdistää tarvittaessa PET-tutkimus
(positroniemissiotomografia). Näin sepelvaltimoiden tilanteesta saadaan vielä
parempi käsitys kuin pelkällä tietokonekuvauksella. PET-kuvantamisen
laajempaa käyttöä rajoittaa toistaiseksi vielä laitteiden saatavuus.Lue seuraavaksi Ablaatioasiaa flutterista ja flimmeristä (https://sydan.fi/kysymys/ablaatioasiaa-flutterista-ja-flimmerista/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sydänperfuusion gammakuvaus
Tästä tutkimuksesta käytetään myös yleisnimeä ”isotooppiperfuusio
(https://sydan.fi/fakta/sydamen-isotooppitutkimus-ja-pet-kuvaus/)” tai vain
”isotooppikuvaus ” . Tutkimus tehdään kuten tavallinen rasituskoe, mutta sen
lisäksi rasituksen loppupuolella annetaan käden laskimoon merkkiainetta
(tallium- tai teknetiumisotooppi). Sydäntä kuvataan erityisellä kameralla, joka
näyttää, onko sydämessä alueita jonne merkkiaine ei pääse etenemään.
Puutosalue viittaa verisuonen ahtautumiseen.
Kuvaus voidaan tehdä, vaikka kuntopyörän polkeminen ei onnistuisi. Silloin
pyörän tilalla ” rasitustestinä ”  käytetään lääkeainetta. Joskus perfuusiokuvausta
käytetään varjoainekuvauksen tai tietokonekuvauksen jälkeen, kun halutaan
tutkia löydettyjen ahtaumien merkitystä sydämen toiminnalle.
Sepelvaltimotaudin seulonnasta
Seulonnalla tarkoitetaan oireettomien, lähtökohtaisesti terveiden ihmisten
tutkimista jonkin sairauden suhteen. Monia saattaa mietityttää, pitäisikö omat
sepelvaltimot kuvata jollain menetelmällä, jotta voisi tietää, onko valtimotauti jo
kehittynyt. Voisiko välttyä sydäninfarktilta, jos pallolaajennus tehtäisiin ajoissa
”ennakoivasti ” ?
Valtimotauti kehittyy hitaasti vuosien kuluessa, eikä kaikkia kehittyviä lieviä
seinämämuutoksia voi nähdä käytössä olevilla röntgentutkimuksilla. Rasituskoe
on liian epäherkkä oireettomien tutkimiseen, eli kokeen tulos saattaa olla
normaali, vaikka valtimoissa olisi sairautta. Sydäninfarkti voi syntyä myös
sellaiseen valtimon kohtaan, jossa ei vielä ole näkyvää ahtaumaa.
Vaikka kuvaus tehtäisiin, eikä juuri nyt todettaisi muutoksia, se ei tarkoita,
etteikö valtimotauti voisi kehittyä lähivuosina. Kuvaus pitäisi siten toistaa useita
kertoja elämän aikana.
Näistä syistä systemaattista  valtimotaudin seulontaa
röntgentutkimuksilla tai rasituskokeella ei tehdä. Sen sijaan valtimotaudin
riskitekijöitä, kuten kolesterolia ja verenpainetta, kannattaa seuloa jo
varhaisessa keski-iässä. Puuttumalla riskitekijöihin riittävän aikaisin voidaan myös
valtimotaudin kehittymistä merkittävästi hidastaa.
LUE LISÄÄ SYDÄN- JA VERISUONISAIRAUKSIEN TUTKIMUKSISTA
(HTTPS://SYDAN.FI/FACT/SYDAN-JA-VERISUONITAUTIEN-TUTKIMUKSET/)oireettomien ihmistenLue seuraavaksi Ablaatioasiaa flutterista ja flimmeristä (https://sydan.fi/kysymys/ablaatioasiaa-flutterista-ja-flimmerista/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sepelvaltimotauti - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla vinkeillä
täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/Sepelvaltimotauti
Sepelvaltimotauti
(https://sydan.fi/fakta/sepelvaltimotauti/)
Kun sydämen omat valtimot, sepelvaltimot, sairastuvat on kyseessä
sepelvaltimotauti
Anna-Mari Hekkala, ylilääkäri
Julkaistu 9.2.2023
Päivitetty 7.3.2025
 
Lue seuraavaksi Sepelvaltimotaudin oireet (https://sydan.fi/fakta/sepelvaltimotaudin-oireet/)
Sepelvaltimot ovat sydämen pinnalla kulkevia valtimoita, jotka vievät happea ja
ravinteita sydänlihakselle itselleen. Happea ei siis kulkeudu sydämelle sen sisällä
kiertävästä verestä, vaan veren kuljettamiseen tarvitaan omat verisuonet.
Sepelvaltimotaudin kehittyminen
Sepelvaltimotaudissa sydämen valtimoiden sisäkerrokseen alkaa kehittyä
rasvapesäkkeitä, jotka ajan myötä aiheuttavat valtimon ahtautumisen. Kyse on
ateroskleroosista eli valtimoiden kovettumistaudista.
LUE LISÄÄ SEPELVALTIMOTAUDIN KEHITTYMISESTÄ
(HTTPS://SYDAN.FI/FACT/SEPELVALTIMOTAUDIN-KEHITTYMINEN/)
Kun valtimosta on ahtautunut yli puolet, veren virtaus alkaa vaikeutua ja sydän
alkaa kärsiä hapen puutteesta kuormittavissa tilanteissa, kuten rasituksessa.
Sisäpinnan ahtaumakohta voi myös tukkeutua äkillisesti, jolloin seurauksena on
akuutti kohtaus, sydäninfarkti (https://sydan.fi/fact/sydaninfarkti/). Sydämen
hapenpuute saa aikaan sepelvaltimotaudin oireet.
LUE LISÄÄ SEPELVALTIMOTAUDIN OIREISTA
(HTTPS://SYDAN.FI/FACT/SEPELVALTIMOTAUDIN-OIREET/)
 
Sepelvaltimotaudin tutkimukset
Akuutti sydäninfarkti on yleensä todettavissa kohtauksen aikana otetusta
sydänfilmistä eli EKG:stä.  Vahvistusta voidaan hakea vielä tutkimalla verikokeella
sydänlihaksesta vereen vapautuvia merkkiaineita. Usein sepelvaltimotauti ei
onneksi kuitenkaan etene infarktiin asti, vaan oireet ovat ohimeneviä ja ajoittain
esiintyviä. Silloin lepotilassa otettu EKG ei paljasta sepelvaltimotautia, vaan
tarvitaan muitakin tutkimuksia.
LUE LISÄÄ SEPELVALTIMOTAUDIN TUTKIMUKSISTA
(HTTPS://SYDAN.FI/FACT/SEPELVALTIMOTAUDIN-TUTKIMUKSET/)
 
Sepelvaltimotauti on krooninen sairaus
Kun sepelvaltimotauti on todettu tavalla tai toisella, sitä hoidetaan lopun elämää
toteuttamalla sydänterveellisiä elintapoja
(https://sydan.fi/fact/sepelvaltimotaudin-elintapahoito/) ja käyttämällä sairauttaLue seuraavaksi Sepelvaltimotaudin oireet (https://sydan.fi/fakta/sepelvaltimotaudin-oireet/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
hidastavaa lääkitystä (https://sydan.fi/fact/sepelvaltimotaudin-laakehoito/). Jos
valtimoiden ahtautumat ovat kehittyneet merkittäviksi, siten että verenvirtaus on
huomattavasti vaikeutunutta, ahtautunut kohta voidaan avata pallolaajennuksella.
Näin tehdään myös, jos verisuoni on tukkeutunut äkillisesti eli potilaalla on
sydäninfarkti. Joskus tarvitaan sepelvaltimoiden ohitusleikkausta. Toimenpiteet
(https://sydan.fi/fact/sepelvaltimotaudin-toimenpidehoito/) eivät pysäytä
ateroskleroosin etenemistä, vaan lääkitys ja hyvät elintavat kuuluvat kaikille.
Sepelvaltimotauti on pysyvä eli krooninen sairaus.
Valtimoiden ahtautumiseen vaikuttavat monet tekijät, kuten perimä, diabetes,
kohonnut verenpaine, tupakointi ja muut nikotiinituotteet, kohonnut kolesteroli,
stressi, jopa ilmansaasteet. Omilla elintavoilla on suuri merkitys sairauden
ennaltaehkäisyssä ja hoidossa. Vaikka sepelvaltimotautia ei voi parantaa pois, sen
etenemistä on mahdollista hidastaa ja jopa pysäyttää.
LUE LISÄÄ SEPELVALTIMOTAUDIN EHKÄISYSTÄ
(HTTPS://SYDAN.FI/FACT/SEPELVALTIMOTAUDIN-EHKAISY/)
 
Sepelvaltimotaudin sanastoa
Sepelvaltimot= sydämen omia valtimoita, joita on yleensä kolme päähaaraa (LAD,
LCX ja RCA). Nämä jakaantuvan pienempiin haaroihin eli osiin. Ruotsiksi nimi on
 ja englanniksi .
LM= (   vasen päärunko. Lyhyt valtimorunko, josta sydämen
vasemmalle puolelle verta vievät kaksi päähaaraa (LAD ja LCX) saavat alkunsa.
LAD= (   vasemman sepelvaltimon eteen laskeva
haara.
LCX= (   vasemman sepelvaltimon kiertävä haara.
RCA= (   oikea sepelvaltimo.
Sepelvaltimotauti= Sydämen omat valtimot sairastuvat, jolloin osa sydänlihasta ei
saa riittävää verenkiertoa. Syynä on yleensä ateroskleroosi eli valtimoiden
kovettuminen. Englannin kielellä nimi on , tästä johdettuna
suomen kielessä käytetään joskus nimitystä ” koronaaritauti ” .kransartär coronary artery
engl.Left Main)
engl.Left Anterior Descending)
eng.Left Circumflex)
engl.Right Coronary Artery)
coronary artery diseaseLue seuraavaksi Sepelvaltimotaudin oireet (https://sydan.fi/fakta/sepelvaltimotaudin-oireet/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sydäninfarkti = (sepelvaltimotautikohtaus tai ” sydänkohtaus ” ) Sepelvaltimotaudin
ilmenemismuoto, jossa yksi kohta sepelvaltimoista menee äkillisesti tukkoon, tai on
uhkaavasti tukkeutumassa.
PCI= (   pallolaajennus) Toimenpide, jossa
kardiologi avaa ahtaan verisuonen viemällä verisuonireittiä pitkin välineet
sepelvaltimosuoneen.
Stentti= Verkkoputki, jonka kardiologi asettaa ahtaumakohtaan. Verkkoputkella
halutaan tukea sairastuneen suonen seinämää, jottei se ahtautuisi tästä kohdin
uudelleen.
CABG= (   ohitusleikkaus) Sydänkirurgin
suorittama leikkaus, jossa ahtautuneiden sepelvaltimoiden väylät ohitetaan toisilla
verisuonilla.
Ahtaumaprosentti= Sepelvaltimon ahtauma ilmoitetaan prosenttilukuna.
Esimerkiksi 90%:n ahtaumassa suonen sisäpinta-alasta on siinä kohden vain 10%
avoimena.
Preventio= ennaltaehkäisy
Primaaripreventio= Toimet, joilla ehkäistään ettei terve henkilö sairastuisi.
Sekundaaripreventio= Toimet, joilla ehkäistään jo sairastuneen potilaan sairauden
etenemistä.
 
 
Haluatko lukea sepelvaltimotautiin liittyvistä asioista
vielä laajemmin?
             
LUE LISÄÄ SEPELVALTIMOTAUTI -SIVULTA
(HTTPS://SYDAN.FI/SYDANTIETOA/SYDANSAIRAUDET/SEPELVALTIMOTAUTI/)engl.Percutaneus Coronary Intervention, 
engl.Coronary Artery Bypass Grafting, Lue seuraavaksi Sepelvaltimotaudin oireet (https://sydan.fi/fakta/sepelvaltimotaudin-oireet/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sepelvaltimotauti - Sydänsairaala.pdf
Etusivu (https://www.sydansairaala.fi)➝Tietoa (https://www.sydansairaala.fi/tietoa/)➝Sepelvaltimotauti
Sepel val ti mo tauti
Sydänlihas tarvitsee jatkuvasti verta ja happea. Sepelvaltimotaudissa sydänlihakseen
verta tuovat sepelvaltimot ovat ahtautuneet rasvakalkkeumien takia, mikä johtaa
sydänlihaksen hapenpuutteeseen ja kipuoireeseen.
Sepelvaltimotauti on tavallisin rintakipua aiheuttava sydänsairaus. Sepelvaltimotauti voi
aiheuttaa rintakipua etenkin rasituksessa tai jo levossakin. Äkillinen suonen
tukkeutuminen saattaa aiheuttaa sydäninfarktin. Muita oireita voivat olla väsyminen,
hengenahdistus, rytmihäiriöt ja sydämen vajaatoiminta.
Sydänperäinen rintakipu vaikeutuu tyypillisesti rasituksessa ja lepo puolestaan helpottaa
oireita.
Lue lisää sepelvaltimotaudin hoidosta
(https://www.sydansairaala.fi/potilaana/sepelvaltimotaudin-hoito/)Aihee seen liit tyvää
Rintakipu ➝
(https://www.sydansairaala.fi/tietoa/rintakipu/)
Sepelvaltimotaudin hoito ➝
(https://www.sydansairaala.fi/potilaana/sepelvaltimotaudin-
hoito/)
Sydämen toiminnan arviointi ja seuranta ➝
(https://www.sydansairaala.fi/potilaana/sydamen-
perustutkimukset/)
Sepelvaltimotaudin omahoito ➝
(https://www.sydansairaala.fi/tietoa/omahoito/)
Sepelvaltimotautipotilaan hoitoketju Pirkanmaan
hyvinvointialueella ➝
(https://www.terveysportti.fi/apps/dtk/ltk/article/shp01058?
db=282&toc=6378)
Hoitopaikan valinta 
(https://www.sydansairaala.fi/hoitoon-
sydansairaalaan/hoitopaikan-valinnanvapaus/)
Sepelvaltimotautiklinikka 
(https://www.sydansairaala.fi/sepelvaltimotautiklinikka/)
Jaa sivu:➝
➝(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Sepel val ti mo taudin ylei simmät riski te kijät
Riskitekijät kartoitetaan aina lääkärin vastaanotolla. Tärkeimpiä riskitekijöitä
sepelvaltimotaudille ovat tupakointi, diabetes, verenpainetauti, kohonnut kolesteroli ja
sukuhistoria.
Sukuhistorialla tarkoitetaan, että ensimmäisen asteen sukulaisella (vanhemmat tai
sisarukset) on ollut sydäninfarkti, tai on tehty pallolaajennus tai ohitusleikkaus alle 55
vuoden iässä (miehet) tai alle 65 vuoden iässä (naiset).
Sepel val ti mo tautia sairas tavan seuranta
Riippumatta sepelvaltimotaudin hoitomuodosta (lääkehoito, pallolaajennus tai
ohitusleikkaus), tärkeintä on säännöllinen seuranta sydänsairauksiin perehtyneen lääkärin
vastaanotolla. Jokaisella seurantakäynnillä tarkastetaan lääkehoidon riittävyys ja
asianmukaisuus.
Oireiden uusiutuessa tai vaikeutuessa lääkäri arvioi sepelvaltimoiden varjoainekuvauksen
tarpeen.(http://www.facebook.com/sharer/sharer.php?
u=https://www.sydansairaala.fi/tietoa/sepelvaltimotauti/)
(http://twitter.com/share?
url=https://www.sydansairaala.fi/tietoa/sepelvaltimotauti/&text=Sepelvaltimotauti)
(http://www.linkedin.com/shareArticle?
url=https://www.sydansairaala.fi/tietoa/sepelvaltimotauti/&title=Sepelvaltimotauti&s
(mailto:?
subject=Sepelvaltimotauti&body=https://www.sydansairaala.fi/tietoa/sepelvaltimota
Milloin on syytä hakeutua lääkä riin?
Rasitukseen liittyvän rintakivun aiheuttaja täytyy aina selvittää. Jos oire helpottuu muutaman minuutin kuluttua rasituksen lopettamisen jälkeen eikä
rintakipua ilmaannu levossa, voidaan tutkimukset tehdä lähiviikkojen aikana. Silloin tutkimuksiin voi hakeutua joko omalääkärin (terveysasema,
työterveyshuolto) tai sydänlääkärin kautta.(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Sydän pe räiset äkil liset oireet
Voimakkaan, äkillisen tai rasituksen yhteydessä tulevan
rintakivun syynä voi olla sepelvaltimotukos eli sydäninfarkti.
Katso video ▶
(https://player.vimeo.com/video/558422857?
texttrack=fi&rel=0&showinfo=0)
(https://www.sydansairaala.fi/)
Usein kysyttyä
(http://www.sydansairaala.fi/tietoa/usein-
kysyttya/)
Anna palautetta
(https://www.sydansairaala.fi/anna-
palautetta/)Palve lu neu vonta
Tampere 03 311 64145
Arkisin klo 7.30–15
info@sydansairaala.fi
Jos haluat perua ajan tai sinulla on
kysyttävää hoitoosi liittyen, ota yhteyttä
puhelimitse sinua hoitavaan yksikköön.Yksityisvastaanottojen
ajanvaraus ja tiedustelut
Tampere p. 050 573 6875
ma–to klo 11–18, pe klo 11–15
Jyväskylä p. 041 731 3712
ma–pe klo 10–14
Huom. Matkapuhelinnumeroihin ei voi
lähettää tekstiviestejä.
Varaa aika
(https://sydansairaala.mbooking.fi/ajanvaraus)Sydänsairaala sosiaalisessa
mediassa
Facebook
(https://www.facebook.com/sydansairaala)
Instagram
(https://www.instagram.com/sydansairaala/)LinkedIn
(https://fi.linkedin.com/company/sydansairaala)YouTube
(https://www.youtube.com/channel/UCl2MGYGAqj88jYNOe
(https://www.sydansairaala.fi/ajankohtaista/sydansairaala-
on-yksi-maailman-parhaista-
sydansairaaloista-myos-2024/)
(https://player.vimeo.com/video/558422857?
texttrack=fi&rel=0&showinfo=0)
(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Sepelvaltimotauti - Terveyskirjasto.pdf
Lue artikkeli:
Terveyskirjasto.fi
Sepelvaltimotauti
Lääkärikirja Duodecim
1.11.2023
Kardiologian erikoislääkäri Raimo Kettunen
Keskeistä
Rasituksessa ilmaantuva ja
levossa helpottava rintakipu on
sepelvaltimotaudin tyypillinen
ensi oire.
Äkillisesti alkaneen puristavan
rintakivun syynä voi olla
välitöntä sairaalahoitoa vaativa
sepelvaltimotautikohtaus.
Sepelvaltimotautia voidaan
hoitaa tehokkaasti terveellisillä
elintavoilla, lääkkeillä,
pallolaajennuksella ja
ohitusleikkauksella.
Sepelvaltimotautia ei voida
parantaa, mutta sen etenemistä
voidaan merkittävästi hidastaa
lääkehoidolla ja terveellisillä
elintavoilla.
Sepelvaltimotautia voidaan
tehokkaasti ehkäistä ajoissa
korjatuilla elintavoilla
(tupakoimattomuus, liikunta ja
terveellinen ruokavalio) ja
tarvittaessa verenpaine-,
kolesteroli- ja diabeteslääkkeillä.
YleistäSepelvaltimotauti ("koronaaritauti") johtuu
sydänlihasvaltimoiden seinämien
kovettumisesta ja ahtautumisesta (kuva 1).
Sepelvaltimot lähtevät aortan tyvestä ja
sijaitsevat sydämen pinnalla (kuva 2).
Sepelvaltimoita on kaksi, vasen ja oikea.
Vasen sepelvaltimo haarautuu kahdeksi
suureksi haaraksi. Niinpä vaikea-asteisinta
sepelvaltimotautia kutsutaan kolmen suonen
taudiksi ja lievintä yhden suonen taudiksi.
Sepelvaltimotauti on syöpien ohella
Suomen tärkein kansantauti. Se kuuluu
sydän- ja verisuonisairauksiin, jotka
kuormittavat eniten terveydenhuoltoa.
Päinvastoin kuin usein kuvitellaan, naisia
kuolee sepelvaltimotautiin yhtä paljon kuin
miehiä.
Sepelvaltimotaudin syyt
Sepelvaltimotauti johtuu valtimotaudista ,
joka pitkälle edetessään ahtauttaa
sepelvaltimoita. Yksikin ahtauma (kuva 1)
voi aiheuttaa verenkierron häiriintymisen ja
hapenpuutteen osassa sydänlihasta (kuva 2).4.3.2025 klo 17.31 Sepelvaltimotauti - Terveyskirjasto
https://www.terveyskirjasto.fi/dlk00077/sepelvaltimotauti 1/6
Kuva 1. Valtimon ahtauman
kehittyminen. Valtimotaudissa
kolesterolia ja tulehdussoluja kertyy hitaasti
valtimon seinä män sisäkalvon alle.
Kertymää nimitetään plakiksi. Plakin pinta
on haurasta kudosta, johon voi syntyä
repeä miä. Kohdalle muodostuu
verihyytymä, joka äkisti kaventaa suonta tai
tukkii sen kokonaan.
Kuva 2. Sepelvaltimot. Sepel valtimot
haarautuvat aortan tyvestä. Niiden
tehtävänä on kuljettaa happea  ja ravintoa
sydänlihakselle. Sepel valtimossa oleva
ahtauma heikentää verenvirtausta, jonka
seurauksena  rasituksen yhteydessä
sydänlihas kärsii hapen puutteesta. Tämä
tuntuu rintakipuna, jota kutsutaan nimellä
angina pect oris. Lisää tietoa, ks. artikkeli
Sepel valtimotauti.
Iän mukana sekä naisten että miesten
sairastumisriski suurenee, mutta
sepelvaltimotautia aiheuttavista
hoidettavissa olevista riskitekijöistä
tärkeimmät ovat tupakointi , kohonnut veren
kolesteroli , kohonnut verenpaine  ja
diabetes . Valtimotaudin kehittymisestä
enemmän: ks. Valtimotauti (ateroskleroosi) .Sepelvaltimotaudin oireet
Sepelvaltimotaudin tavallisin oire on
rintakipu, joka tyypillisesti:
alkaa ruumiillisessa rasituksessa
(reippaasti liikkuessa tai muussa
lihastyössä), mutta voi ilmetä myös
ruokailun jälkeen ja henkisessä
rasituksessa
tuntuu keskellä rintaa puristavana tai
muutoin epämiellyttävänä tuntemuksena
voi säteillä olka- ja käsivarsiin,
leukaperiin, selkään lapojen väliin tai
ylävatsalle (kuva 3)
helpottuu levossa ja nitrolääkkeellä
muutamassa minuutissa
toistuu samanlaisena.
Tällaista rintakipua kutsutaan nimellä
angina pectoris . Kivulle on tyypillistä, että
se ilmaantuu fyysisessä tai henkisessä
rasituksessa toistuvasti ja samanlaisena,
mutta helpottuu nopeasti levossa.
Lievimmillään angina pectoris-kipu voi
tuntua vain rasituksen alussa, mutta
helpottua rasitusta jatkettaessa.
Kuva 3. Sepelvaltimotaudin rintakivun
sijainti. Vasemmalla : puristavan
rintakivun alue keskellä rintalastaa ja sen
ympärillä; joskus kipu voi tuntua ylävatsalla.
Keskellä: Kipu voi säteillä keskelle selkää
lapojen väliin. Oikealla : Kivun säteily
leukaperiin, hartioihin, olkavarsiin ja
vatsaan. Lisää tietoa rintakivusta: ks.
Rintakipu; sepel valtimotaudista: ks.
Sepel valtimotauti.4.3.2025 klo 17.31 Sepelvaltimotauti - Terveyskirjasto
https://www.terveyskirjasto.fi/dlk00077/sepelvaltimotauti 2/6
Aina sepelvaltimotautikipu ei ole näin
tyypillistä. Joskus kipu voi olla luonteeltaan
polttavaa tai tuntua ylävatsan puolella.
Joskus oireena voi olla ainoastaan
rasituksessa tuntuva ohimenevä
hengenahdistus. Etenkin naisilla ja
vanhuksilla sepelvaltimotauti voi joskus
ilmetä ilman rintakipuja, ja oireina on
pelkästään rinnan epämiellyttävää
ahdistusta, uupumista, huonovointisuutta
tai pahoinvointia rasitukseen liittyen.
Aina sepelvaltimotauti ei "varoittele
etukäteen" angina pectoris -oireella. Sen
ensimmäinen ilmenemismuoto voi olla
sydäninfarkti . Oireena on tällöin voimakas,
levossakin tuntuva puristava rintakipu, joka
ei mene aina nitrolääkkeelläkään ohitse
muutamassa minuutissa.
Rinnan alueella tuntuvat kiputuntemukset
ovat yleisiä ja johtuvat usein muista syistä
kuin sepelvaltimotaudista, varsinkin nuorilla
ja keski-ikäisillä. Seuraavat piirteet
viittaavat siihen, että kyseessä ei ole
sepelvaltimotauti:
Kipu on aika lievää ja ilmenee levossa.
Liikkuminen on mahdollista kivusta
huolimatta.
Kipu jatkuu pitkään tunti- tai
päiväkaupalla.
Kipu liittyy hengitykseen.
Kipu on luonteeltaan terävää ja esiintyy
pienellä alueella jossain rintakehällä.
Sepelvaltimotaudin
toteaminen
Tavanomaisessa lääkärin tutkimuksessa ei
rasitusrintakipuna eli angina pectoriksena
ilmenevää sepelvaltimotautia sairastavalta
potilaalta yleensä löydy mitään poikkeavaa.
Myös sydämen sähkökäyrä eli EKG  on usein
normaali.Jos oireet viittaavat sepelvaltimotautiin,
tehdään usein ensimmäisenä tutkimuksena
rasituskoe, jossa potilas polkee kuntopyörää
asteittain lisääntyvällä vastuksella, ja
samalla seurataan sydämen sähkökäyrää.
Kokeen aikana ilmenevä rintakipu ja
sydänlihaksen hapenpuutteeseen sopivat
EKG-muutokset viittaavat
sepelvaltimotautiin. Sen perusteella voidaan
usein tehdä diagnoosi ja aloittaa lääkehoito.
Jos lääkehoito ei riitä pitämään oireita
poissa tai jos oireet ja rasituskokeessa
todetut EKG-muutokset ja muut havainnot
viittaavat vaikea-asteiseen
sepelvaltimotautiin, tutkimuksia jatketaan.
Vaihtoehtoja ovat sydänlihaksen
verenkierron (perfuusion)
isotooppitutkimus, sepelvaltimoiden
tietokonekerroskuvaus tai varjoainekuvaus.
Sepelvaltimotaudin hoito
Sepelvaltimotautiin sairastunut tarvitsee
ehdottomasti jatkuvaa lääkehoitoa, mutta
tupakoinnin lopettaminen , liikunta  ja
terveellinen ravinto  ovat yhtä tärkeitä
Lääkehoito
Kaikille sepelvaltimotautia sairastaville
aloitetaan pieniannoksinen
asetyylisalisyylihappolääke
("sydänaspiriini"), joka ehkäisee
valtimoveritulpan eli tukoksen
muodostumista sepelvaltimoon. Se onkin
sepelvaltimotautipotilaan tärkein lääke. Jos
se ei haittavaikutustensa takia sovi, tilalla
voidaan käyttää yhtä tehokasta
klopidogreelia. Ennestään muista syistä
verenohennuslääkkeitä  käyttävät
sepelvaltimotautipotilaat eivät kuitenkaan
aina tarvitse muuta tukosta estävää lääkettä.
Nopeasti vaikuttavat nitrovalmisteet
(tabletti tai suihke) on tarkoitettu potilaiden4.3.2025 klo 17.31 Sepelvaltimotauti - Terveyskirjasto
https://www.terveyskirjasto.fi/dlk00077/sepelvaltimotauti 3/6
itsensä annosteltavaksi tarpeen mukaan.
Niillä saadaan rintakipu väistymään
nopeasti.
Nitroa voi käyttää aina, kun rintakipu
tuntuu kiusalliselta eikä täysin häviä
levähtämällä. Sitä kannattaa käyttää myös
ennen sellaista ruumiillista rasitusta, jonka
tietää aiheuttavan rintakipua. Tällöin kivulta
vältytään ja samalla suorituskyky ja
elämänlaatu paranevat. Nitro on varsin
turvallinen lääke, mutta voi varsinkin
hoidon alussa aiheuttaa päänsärkyä ja
joskus ohimenevää verenpaineen laskua,
huimausta tai pyörrytystä.
Itse annosteltavia "pikanitroja" on kahta
laatua. Suussa sulava nitrotabletti
(resoribletti) asetetaan kielen alle. Se alkaa
tehota jo parissa minuutissa. Jos kipu ei
hellitä, otetaan uusi tabletti 2–3 minuutin
kuluttua edellisestä. Näin voidaan jatkaa
aina 4–5 tablettiin asti. Lääkkeen vaikutus
kestää 20–30 minuuttia.
Nitrosuihke suunnataan suuonteloon
kielen päälle. Sen vaikutus alkaa yhtä
nopeasti kuin tavallisilla nitrotableteilla.
Tarvittaessa voidaan ottaa useita suihkeita
minuutin parin välein. Suihkenitron
vaikutus kestää muutaman tunnin.
Muita sepelvaltimotaudin oireita estäviä
lääkkeitä ovat beetasalpaajat,
pitkävaikutteiset nitrot eli nitraatit ja
kalsiuminestäjät. Beetasalpaajalääke estää
oireiden syntymistä estämällä sykkeen
nousua ja laskemalla verenpainetta ja siten
vähentämällä sydämen kuormitusta.
Sepelvaltimotaudin hoitoon kuuluvat
myös valtimotaudin etenemistä ehkäisevät
lääkkeet. Kaikille sepelvaltimotautiin
sairastuneille aloitetaan kolesterolilääke
veren kolesteroliarvosta riippumatta. Veren
kolesterolin tavoitearvot ovat
sepelvaltimotautipotilailla tiukemmat kuin
terveillä. Pahan kolesterolin eli LDL-kolesterolin  tavoitearvona pidetään 1,4
millimoolia litrassa. Tämän saavuttamiseksi
tarvitaan käytännössä lähes aina
kolesterolilääkkeitä, joista yleisimmät ovat
niin sanottuja statiineja (ks. Kolesteroli ).
Statiinien ja muiden kolesterolilääkkeiden
haittavaikutukset ovat paljon
harvinaisempia kuin yleensä luullaan. Myös
kohonneen verenpaineen  ja diabeteksen
tehokas hoito kuuluu asiaan.
Toimenpidehoito
Jos oireet eivät pysy lääkityksellä poissa tai
jos taudin laatu muutoin vaatii, hoitona on
sepelvaltimon pallolaajennus tai
ohitusleikkaus. Hoitomuodon valinta
riippuu siitä, millaisia ahtaumia todetaan,
millaisia toimenpiteitä potilaan muu
terveydentila sallii ja mihin hoitoon potilas
itse on suostuvainen.
Pallolaajennuksessa sepelvaltimoon
viedään ranne- tai reisivaltimon kautta ohut
letku (katetri), jonka päässä olevaa
pallukkaa laajentamalla suonen ahtauma
avataan (kuva 4). Samalla suonen sisälle
asetetaan usein metalliverkkoputki (stentti),
jonka avulla ahtautuman uusiutumisvaara
vähenee.4.3.2025 klo 17.31 Sepelvaltimotauti - Terveyskirjasto
https://www.terveyskirjasto.fi/dlk00077/sepelvaltimotauti 4/6
Kuva 4. Sepelvaltimon pallo laajennus.
Ohjainkatetrin läpi uitetaan ahtautuneeseen
sepel valtimoon ohjainkara, joka toimii
”raiteena ” pallolaajennu skatetrille.
Pallolaajennu skatetri ohjataan ahtauman
kohdalle ja laajennet aan, jolloin ahtauma
puristuu seinä mää vasten ja sepel valtimo
jää aiempaa laajemmaksi. Samalla tavalla
uitetaan paikalle verkkoputki, joka
laajennet tuna jää suonen seinä män
myötäiseksi.
Ohitusleikkauksessa ahtaumien ohitse
johdetaan muualta (alaraajoista,
kyynärvarresta tai rintaontelon sisältä)
otetut verisuonisiirrännäiset, jolloin
sydänlihaksen verenkierto normaalistuu
(kuva 5).
Kuva 5. Ohitusleikkaus. Rintakehän
sisäseinä män valtimo (LITA) on irroteltu
rintakehän seinä stä ja liitetty vasempaan
etulaskevaan sepel valtimoon (LAD)
ahtaumakohdan alapuolelle. Muina siirteinä
on käytetty säärestä otettuja laskimoita.
Tässä yksi laskimosiirre johtaa verta
aortasta oikeaan sepel valtimoon (RCA) ja
toinen laskimosiirre vasempaan kiertävään
sepel valtimoon (LCX).
Sepelvaltimotaudin ja sen
eten emisen ehkäisy
Sepelvaltimotaudin syntyä voidaan
tehokkaimmin ehkäistä hyvillä elintavoilla
eli tupakoimattomuudella, liikunnalla ja
terveellisellä ruokavaliolla. Kohonnut
verenpaine ja kohonnut veren
kolesteroliarvo edellyttävät myös usein
lääkitystä (ks. Valtimotauti (ateroskleroosi) ).
Myös diabeteksen ehkäisy ja hoito
liikunnalla, painonhallinnalla ja
terveellisellä ruokavaliolla ehkäisee samalla
sepel- ja muun valtimotaudin syntyä.
Vaikuttamalla näihin jo nuorella iällä
voidaan sepelvaltimotaudin vaaraa
huomattavasti pienentää.
Sepelvaltimotauti ja muut valtimotaudit
johtuvat yleensä useiden vaaratekijöiden
yhteisvaikutuksesta. Siten päätökseen ryhtyä
ehkäiseviin toimenpiteisiin, varsinkin
lääkehoitoihin, vaikuttaa arvio
kokonaisvaarasta sairastua valtimotauteihin.
Viimeistään keski-iän alkaessa kannattaa4.3.2025 klo 17.31 Sepelvaltimotauti - Terveyskirjasto
https://www.terveyskirjasto.fi/dlk00077/sepelvaltimotauti 5/6
tehdä valtimotaudin ja diabeteksen
riskiarvio terveydenhoitajan tai lääkärin
kanssa ja suunnitella tarvittavat
elintapamuutokset.
Sepelvaltimotautia tulee ehkäistä erityisen
pontevasti sellaisilla potilailla, joilla on jo
todettu muu valtimotauti  (aivovaltimoissa
tai alaraajavaltimoissa) tai joilla on diabetes
tai munuaisten vajaatoiminta.
Kun sepelvaltimotauti on todettu,
tarvitaan elintapamuutosten lisäksi aina
myös lääkkeitä. Taudin etenemisen
pysäyttäminen ei ole muutoin mahdollista.
Sepelvaltimotautia sairastavan ei kannatavälttää liikuntaa. Säännöllisellä
kuntoliikunnalla voidaan vähentää
kohtausten uusiutumista ja tautiin liittyviä
oireita. Ks. Sepelvaltimotauti – liikuntaohje .
Lisää tietoa sepelvaltimotaudista
Sydänliitto: Sepelvaltimotauti
[https://sydan.fi/fakta/sepelvaltimotauti]
Terveyskylä: Tietoa sepelvaltimotaudista
[https://www.terveyskyla.fi/sydansairaudet/tietoa/sepel
valtimotauti/tietoa-sepelvaltimotaudista]
Krooninen sepelvaltimo-oireyhtymä:
Käypä hoito -suosituksen Krooninen
sepelvaltimotauti potilasversio, 2023
Kirjallisuutta
1. Sepel valtimotauti ja sydäninfarkti. Kirjassa: Mäkijärvi M, Aro A, Laukkanen J, ym. toim.
Sydänsairaudet. Helsink i: Kustannus Oy Duodecim  2014.
2. Krooninen sepel valtimo-oireyhtymä 2022. Käypä hoito -suositus.
[https://www.kaypahoito.fi/hoi50102] Suomalaisen Lääkäriseuran Duodecim in ja Suomen
Kardiologisen Seuran asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim .
Saatavilla internetissä: www. käypähoito.fi
3. Porela P. Krooninen sepel valtimo-oireyhtymä (sepel valtimotauti). Lääkärin käsikirja [online;
vaatii käyttäjätunnuksen] . Kustannus Oy Duodecim . Päivitetty 15.09.2022.
4. Dyslipidemiat. Käypä hoito -suositus. [https://www.kaypahoito.fi/hoi50025] Suomalaisen
Lääkäriseuran Duodecim in ja Suomen Sisätautilääkärien Yhdistys ry:n asettama työryhmä.
Helsink i: Suomalainen Lääkäriseura Duodecim , 2022. Saatavilla internetissä:
www. käypähoito.fi
Aiemmat kirjoittajat: Sisätautien erikoislääkäri Pertti Mustajoki
Artikkelin tunnus: dlk00077 (002.008)
© 2025 Kustannus Oy Duodecim4.3.2025 klo 17.31 Sepelvaltimotauti - Terveyskirjasto
https://www.terveyskirjasto.fi/dlk00077/sepelvaltimotauti 6/6
Sepelvaltimotautia sairastavan liikunta - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Oletko kiinnostunut toimimaan vapaaehtoisena? Lue lisää Sydänliiton vapaaehtoistoiminnasta.
(https://sydan.fi/tule-mukaan/tule-vapaaehtoiseksi/)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Sairastuneen liikunta (https://sydan.fi/elamaa-sairauden-kanssa/sairastuneen-liikunta/)/Sepelvaltimotautia sairastavan liikunta
Sepelvaltimotautia sairastavan liikunta
(https://sydan.fi/fakta/sepelvaltimotautia-
sairastavan-liikunta/)
Lääkehoidon ohella säännöllinen liikunta, sydänystävällinen ruoka,
painonhallinta, mielen hyvinvointi, riittävä uni ja tupakoimattomuus ovat
sepelvaltimotaudin hoidon kulmakiviä. Liikunnalla on hyvä mahdollisuus
vaikuttaa sepelvaltimotautiin.Luet tällä hetkellä Sepelvaltimotautia sairastavan liikunta Lue seuraavaksi Voimisteluohjelma sydänleikkauksen jälkeen
(https://sydan.fi/fakta/voimisteluohjelma-sydanleikkauksen-
jalkeen/)

Annukka Alapappila, Liikunta-asiantuntija
Julkaistu 30.8.2018
Päivitetty 8.8.2024Jaa sivu 
Säännöllisen liikunnan avulla voi vaikuttaa sepelvaltimotautia pahentaviin
riskitekijöihin ja jopa hidastaa sairauden etenemistä. Liikunnan aloittaminen
kannattaa aina.
Säännöllinen liikuntaLuet tällä hetkellä Sepelvaltimotautia sairastavan liikunta Lue seuraavaksi Voimisteluohjelma sydänleikkauksen jälkeen
(https://sydan.fi/fakta/voimisteluohjelma-sydanleikkauksen-
jalkeen/)

parantaa sydämen pumppaustehoa ja rasituksen sietokykyä
kehittää sydän- ja verenkiertoelimistön kuntoa
parantaa valtimoiden sisäkalvon toimintaa ja uudissuonten muodostumista
lisää hyvää veren HDL-kolesterolipitoisuutta ja vähentää pahaa LDL-kolesterolipitoisuutta,
mikä hidastaa valtimoiden ahtautumista
vähentää veren triglyseridipitoisuutta
alentaa lepoverenpainetta
auttaa painonhallinnassa
lisää elimistön insuliiniherkkyyttä ja parantaa veren sokeritasapainoa
kehittää lihasvoimaa
virkistää
→ parantaa elämänlaatua ja arjessa jaksamista sekä sairauden ennustetta
Liikunnallinen elämäntapa
Liikunnassa tärkeää on säännöllisyys ja liikunnan tulisikin olla päivittäinen osa
arkea. Jos kunto on päässyt heikentymään tai liikunta on vähäistä, niin kannattaa
aloittaa maltillisesti ja edetä pienin askelin vähitellen liikuntaa lisäten. Päivittäisen
liikunnan voi koota useasta lyhyestä liikuntajaksosta. Kunnon kohentuessa tulee
ensin lisätä liikunnan kestoa 30-60 minuuttiin päivässä ja sitten vasta tehoa. Sopiva
teho vastaa reipasta kävelyä ja hengästyminen on vain hyväksi.Luet tällä hetkellä Sepelvaltimotautia sairastavan liikunta Lue seuraavaksi Voimisteluohjelma sydänleikkauksen jälkeen
(https://sydan.fi/fakta/voimisteluohjelma-sydanleikkauksen-
jalkeen/)

Päivittäinen liikunta voi koostua arkisesta liikkumisesta, kuten esimerkiksi
työmatkapyöräilystä, puutarhatöistä ja hieman hengästyttävästä
kestävyysliikunnasta. Kaikki arkiliikunnan hetket kannattaakin hyödyntää. Jos
kunto on hyvä ja liikkuminen oireetonta, voi liikkua rasittavalla tasolla. Kovempaa
tehoa voi kokeilla ainakin aluksi ns. intervallityyppisesti, jolloin liikunta on välillä
reippaampaa ja välillä rauhallisempaa
Kestävyysliikuntamuodoiksi sopivat esimerkiksi kävely, golf, luonnossa liikkuminen,
kuntopyöräily, hiihto, uinti, sauvakävely, hölkkä, tanssi, soutu ja erilaiset pallopelit.
Kannattaa suosia liikuntamuotoja, joista itse pitää. Kohentunut kestävyyskunto
keventää arkea ja liikkuminen sujuu entistä paremmin ja pidempään.
Lihasvoimasta tulee huolehtia vähintään kaksi kertaa viikossa. Kotona, kuntosalilla
tai luonnossa voi vahvistaa lihaksia monipuolisesti. Lihasvoimaharjoittelussa
kannattaa keskittyä isojen, toimintakyvyn kannalta tärkeiden, lihasryhmien
harjoittamiseen. Alaraajojen isot lihakset ovat liikkumiskyvyn kannalta tärkeitä.
Hyvä lihasvoima helpottaa monista arjen askareista selviytymistä ja sen merkitys
korostuu ikääntyessä.
Liiku rohkeasti kehoasi kuunnellen
Omat tuntemukset ovat tärkeitä sopivan liikunnan tehon arvioinnissa. Liikkuessa
saa ja on hyväkin hengästyä. Liikunta on teholtaan sopivaa, kun se on oireetonta,
ei uuvuta ja olo on jälkeenpäin virkistynyt. On tärkeää, että oppii tunnistamaan
hengästymisen ja hengenahdistuksen eron. Hengästyminen kuuluu liikuntaan ja onLuet tällä hetkellä Sepelvaltimotautia sairastavan liikunta Lue seuraavaksi Voimisteluohjelma sydänleikkauksen jälkeen
(https://sydan.fi/fakta/voimisteluohjelma-sydanleikkauksen-
jalkeen/)

sitä voimakkaampaa mitä rasittavampaa liikunta on. Hengenahdistus tuntuu
ahdistavalta eikä helpota levossa. Omaa kehoa kuunnellen oppii liikkumaan
turvallisesti ja samalla tehokkaasti.
Normaalista poikkeava väsymys tai uupumus saattaa olla merkki liian suuresta
rasituksesta. Liikunnasta palautuminen kestää yleensä yhtä kauan kuin itse
liikunta. Osa sydänlääkkeistä, mm. beetasalpaajat, hidastavat sykkeen nousua
liikunnan aikana. Siksi liikunnan rauhallinen aloittaminen tai riittävän pitkä
alkuverryttely (5-15 min.) ja liikunnan päättäminen jäähdytellen tekevät
liikunnasta miellyttävämpää.
Lääkkeet mahdollistavat liikunnan harrastamisen lievittämällä oireita tehostaen
sydänlihaksen hapensaantia ja parantamalla rasituksen sietoa. Rasituksessa
ilmenevä rintakipu, hengenahdistus, ylävatsakipu ja huono olo ovat tyypillisiä
sepelvaltimotaudin oireita. Jos oireet ilmenevät esimerkiksi ylämäkeä kävellessä,
kevennä vauhtia, levähdä ja ota tarvittaessa pikanitro oireisiin. Jos oireet eivät
helpota nopeasti levosta ja pikanitrosta huolimatta, hakeudu hoitoon.
Millainen liikunta sinua miellyttää?
Sepelvaltimotauti ei koskaan estä kaikkea liikuntaa. Suunnittele ja varaa itsellesi
aikaa säännölliseen liikuntaan. Mieti, miten liikunta voisi olla pysyvä osa arkeasi.
Pysähdy miettimään omaa liikuntahistoriaasi ja omia tottumuksiasi. Voit käyttää
apuna liikuntasuunnitelmaa ja -päiväkirjaa. Liikkumiseen löytyy monenlaisia
vaihtoehtoja. Voit pohtia, nauttisitko liikunnasta seurassa vai yksin. InnostuisitkoLuet tällä hetkellä Sepelvaltimotautia sairastavan liikunta Lue seuraavaksi Voimisteluohjelma sydänleikkauksen jälkeen
(https://sydan.fi/fakta/voimisteluohjelma-sydanleikkauksen-
jalkeen/)

luonnossa liikkumisesta? Tulisiko liikunnasta helpommin pysyvä tapa, jos sopisit
yhteiset ajat vaikkapa kävelylenkeille ystävän tai läheisen kanssa? Tavoitteena on,
että löydät itsellesi sopivat ajankohdat ja mieluisat tavat liikkua. Liikunnan tuomat
mukavat kokemukset auttavat liikkumaan säännöllisesti.
Jos liikunta tuntuu pelottavalta tai ahdistavalta, sinun kannattaa keskustella
fysioterapeutin, terveydenhoitajan tai vertaistukihenkilön kanssa. Voit myös
hakeutua ohjattuun liikuntaryhmään tai liikunnalliseen kuntoutukseen. Pyydä sitä
varten lähete hoitavalta lääkäriltäsi.
Liikkujan muistilista
Lähde liikkeelle lämmitellen (5-15 min) ja päätä liikunta jäähdytellen.
Tehosta liikuntaa omien tuntemuksiesi mukaan.
Liikunnan aikana saat ja on hyväkin hengästyä.
Muista, että liikunnan aikana ja sen jälkeen tulee olla hyvä olo.
Kysy lääkäriltä lääkkeittesi mahdollisesta vaikutuksesta liikuntaan.
Kevennä liikuntaa, jos sääolosuhteet ovat erityisen vaativat.
Pidä nitrovalmiste mukana. Jos oire yllättää, ota nitrovalmistetta ja levähdä. Jatka
rauhallisemmin, kun oire on hellittänyt.
Voimakkaiden oireiden ilmaantuessa hakeudu hoitoon.
Saavutat terveyshyötyjä liikkumalla säännöllisesti.Luet tällä hetkellä Sepelvaltimotautia sairastavan liikunta Lue seuraavaksi Voimisteluohjelma sydänleikkauksen jälkeen
(https://sydan.fi/fakta/voimisteluohjelma-sydanleikkauksen-
jalkeen/)

Tukea liikuntaan
Liikuntaa on tarjolla monenlaista tukea. Tarvittaessa yksilöllistä liikuntaohjausta saa
muun muassa terveyskeskuksen fysioterapeutilta, sydänhoitajalta,
työterveyshuollosta, paikallisesta sydänyhdistyksestä tai -piiristä tai kunnan
erityisryhmien liikunnanohjaajalta.
Tietoa, taitoa ja tukea sairauteen liittyen sekä käytännön vinkkejä liikkumiseen ja
sairauden hoitamiseen löytyy sydan.fi-sivuilta (https://sydan.fi/) ja
Kuntoutumistalo.fi-sivuilta
(https://www.terveyskyla.fi/kuntoutumistalo/kuntoutujalle/syd%C3%A4nsairaudet).
Sydänliiton kursseilla (https://sydan.fi/apua-ja-tukea/kurssikalenteri/?
eventDistricts=&eventDates=&eventSicknessGroup=&eventTargetGroup=&query=)
pääsee tapaamaan toisia samassa elämäntilanteessa olevia ja jakamaan
kokemuksia myös liikkumisesta yhdessä toimien ja oppien. Tulppa-kuntoutuksesta
saa lisätietoa omasta terveyskeskuksesta. Vertaistukihenkilön
(https://sydan.fi/apua-ja-tukea/vertaistukihaku/?
personDiagnoses=&personAge=&personCity=&personLanguages=&query=) kanssa
voi jutella luottamuksella liikkumisesta, tunteista ja kokemuksistasi. Tule mukaan -
sivuilta (https://sydan.fi/tule-mukaan/?
eventDates=&eventDistricts=&eventSpecies=&eventCities=&query=) löytyy tietoa
Sydänliiton toiminnasta, joihin voi osallistua. Samoilta sivuilta löytyyLuet tällä hetkellä Sepelvaltimotautia sairastavan liikunta Lue seuraavaksi Voimisteluohjelma sydänleikkauksen jälkeen
(https://sydan.fi/fakta/voimisteluohjelma-sydanleikkauksen-
jalkeen/)

verkkoluentotarjonta ja tapahtumakalenteri sekä voi halutessa liittyä jäseneksi
sydänyhdistykseen. Olet lämpimästi tervetullut mukaan sydänyhdistyksen
liikuntatoimintaan.
Tämä teksti sisältää yleisiä ohjeita sepelvaltimotautia sairastavan liikuntaan. Jos
lääkäri tai fysioterapeutti on antanut erityisiä ohjeita, niitä tulee noudattaa.Luet tällä hetkellä Sepelvaltimotautia sairastavan liikunta Lue seuraavaksi Voimisteluohjelma sydänleikkauksen jälkeen
(https://sydan.fi/fakta/voimisteluohjelma-sydanleikkauksen-
jalkeen/)

Sepelvaltimotautikohtaus (sydäninfarkti, ”sydänkohtaus”) - Terveyskirjasto.pdf
Lue artikkeli:
Terveyskirjasto.fi
Sepelvaltimotautikohtaus
(sydäninfarkti, ”sydänkohtaus”)
Käyvän hoidon potilasversiot
21.12.2022
Kirsi Tarnanen ja Jorma Komulainen
Käypä hoito -suositus
Sepelvaltimotautikohtaus
Potilasversio tulostettavassa muodossa
(PDF)
Patientinformation på svenska
Kranskärlssyndrom, akut (akut koronart
syndorm, hjärtinfarkt, "hjärtattack")
Sepelvaltimot ovat sydämen pinnalla
kulkevia, sydänlihassoluille verta
vieviä suonia. Sepelvaltimotaudissa
nämä valtimot ahtautuvat ja
kovettuvat, eikä veri pääse
virtaamaan riittävällä nopeudella.
Sepelvaltimotautikohtauksessa
valtimoon muodostuu paikallisen
suonirepeämän aiheuttamana
verihyytymä, joka voi pysäyttää sen
alueen verenkierron tai heikentää
sitä. Sepelvaltimotautikohtauksen
tyyppioireita ovat rintakipu tai
puristuksen tunne rinnalla.
Mikä on
sepelvaltimotautikohtaus?
Sepelvaltimon äkillisestä tukkeutumisesta
johtuvia oireita nimitetään
sepelvaltimotautikohtauksiksi.
Kohtaukset luokitellaan 3 ryhmään:epästabiili angina pectoris (Unstable
Angina Pectoris, UAP); ahtauma tukkii
suonen vain osittain tai liukenee
nopeasti, eikä sydänlihassolutuhoa ehdi
syntyä
sydäninfarkti ilman ST-nousuja,
NSTEMI; sydäninfarkti, jossa suoni ei
ole kokonaan tukossa, mutta
sydänlihasmerkkiaine (troponiini) on
koholla ja EKG:ssa voi olla muutoksia
ST-nousuinfarkti, STEMI; sydäninfarkti,
jossa suoni on kokonaan tukossa ja
sydänlihassoluja alkaa tuhoutua.
ST-nousuinfarktissa välitön pallolaajennus
on ensiarvioisen tärkeää. Muut
kohtaustyypit hoidetaan yksilöllisen vaaran
arvion mukaisella kiireellisyydellä.
Milloin soitetaan
hätänumeroon 112?
Sepelvaltimotautikohtauksen tyyppioireita
ovat rintakipu tai puristava tunne rinnan
alueella. Kipu voi säteillä käsiin, selkään,
niskaan, leukaperiin tai ylävatsaan.
Oireiden kirjo saattaa olla naisilla
laajempi kuin miehillä.
Ikääntyneillä oireet voivat olla
epätyypillisiä: hengenahdistusta, hikoilua,
pahoinvointia, sekavuutta tai tajunnan
menetys.4.3.2025 klo 17.32 Sepelvaltimotautikohtaus (sydäninfarkti, ”sydänkohtaus”) - Terveyskirjasto
https://www.terveyskirjasto.fi/khp00135/sepelvaltimotautikohtaus-sydaninfarkti-sydankohtaus 1/5
Hätänumeroon 112 tulee soittaa, jos
oireena on äkillinen kova rintakipu tai
hengenahdistus, joka ei helpota
muutamassa minuutissa.
Ennen ambulanssin saapumista
suositellaan lepoasentoa. Jos
hätäkeskuksesta niin neuvotaan, potilaalle
voidaan antaa pureskeltavaksi 250–500 mg
asetyylisalisyylihappoa (ASA, aspiriini), ellei
hän ole sille allerginen.
Potilas, jolla on jo käytössään ”nitro”, voi
tarvittaessa ottaa sitä alkuannoksen jälkeen
2 lisäannosta 5 minuutin välein, jos hän
pystyy istumaan.
Hätäkeskus hälyttää paikalle
ensihoitoyksikön. Odotathan, että apu
saapuu paikalle, etkä jätä potilasta yksin.
Diagnoosi ja tutkimukset
Sepelvaltimotautikohtauksen diagnoosi
perustuu potilaan aiempien sairauksien ja
riskitekijöiden kartoitukseen (anamneesi),
oireisiin (kliininen taudinkuva),
sydänfilmiin eli EKG-tutkimukseen ja
troponiini-entsyymin määritykseen (verikoe,
jolla määritetään, onko viitettä
sydänlihassolujen vauriosta).
Tarvittaessa näitä tutkimuksia
täydennetään sydämen ultraääni- eli
kaikututkimuksella ja muilla
kuvantamistutkimuksilla.
Ensi- ja akuuttivaiheen
hoito
Hoitotulos on sitä parempi, mitä
nopeammin potilaalle päästään antamaan
hoitoa.
Ensihoitoyksikkö aloittaa ensihoidon  jo
sairaalaan kuljetuksen aikana. Ensihoitoa
jatketaan päivystyspoliklinikalla.ST-nousuinfarktin ensisijaisena hoitona
on välitön pallolaajennus. Ensihoitoyksikkö
voi kuljettaa potilaan lääkärin konsultaation
perusteella suoraan sairaalan
toimenpidelaboratorioon pallolaajennusta
varten.
Toissijainen ST-nousuinfarktin
hoitomuoto on lääkkeellinen liuotushoito,
jollei sille ole vasta-aiheita, kuten
merkittävä verenvuotovaara tai äskettäinen
aivoinfarkti. Liuotushoitoa voidaan antaa 12
tuntiin asti oireiden alusta. Liuotushoidon
tehoa arvioidaan sydänfilmin (EKG) ja
potilaan oireiden avulla.
Muut kuin ST-nousuinfarktipotilaat
kuljetetaan ensin sairaalan tai
terveyskeskuksen ensiapuun alkuarviota
varten.
Useimmille
sepelvaltimotautikohtauspotilaille tehdään
sairaalassa sepelvaltimoiden
varjoainekuvaus, koronaariangiografia.
Tutkimusten ja diagnoosin varmistumisen
jälkeen hoitomuodoksi valitaan yksilöllisesti
joko lääkehoito ja pallolaajennus tai
ohitusleikkaus tai pelkkä lääkehoito.
Akuuttivaiheen jälkeen jatkohoito
sairaalassa  (sydänvalvonta,
valvontatasoinen hoito, EKG-monitorointi ja
sydämen varjoainekuvaus NSTEMI- ja UAP-
potilaiden osalta) määräytyy ensihoidossa
tai ensiavussa tehdyn vaaran arvion
perusteella.
Sydäninfarktin sairastaneen potilaan
vuodelepo sairaalassa pyritään
minimoimaan. Liikunnallinen kuntoutus
aloitetaan sairaalassa niin pian kuin
mahdollista. Tavoitteena on ehkäistä
mahdollisia komplikaatioita ja edistää
toipumista ja kuntoutumista.
Elintapamuutosten ohjaus aloitetaan jo
sairaalassa. Kotiuttamisaikataulu on
yksilöllinen.4.3.2025 klo 17.32 Sepelvaltimotautikohtaus (sydäninfarkti, ”sydänkohtaus”) - Terveyskirjasto
https://www.terveyskirjasto.fi/khp00135/sepelvaltimotautikohtaus-sydaninfarkti-sydankohtaus 2/5
Antitromboottinen
lääkehoito
Valtimotukoksia hoitava ja ehkäisevä
(antitromboottinen) lääkitys aloitetaan
mahdollisimman pian: ST-
nousuinfarktipotilaille yleensä välittömästi
ja muille potilaille sairaalahoidon aikana.
Jatkossakin lääkehoitoon kuuluvat
verenhyytymistä estävä lääkitys,
kolesterolilääkitys ja tarvittaessa
beetasalpaaja ja verenpainelääkitys.
Jotta jatkohoito ja potilaan toipuminen
onnistuisivat mahdollisimman hyvin,
tarvitaan siihen potilaan sitoutumista niin
lääke- kuin omahoitoonsa.
Riskitekijät
Tietyt riskitekijät altistavat verta
kuljettavien valtimoiden ahtautumiselle
(ateroskleroosi) ja tukkeutumiselle. Nämä
tekijät suurentavat
sepelvaltimotautikohtaukseen sairastumisen
riskiä, etenkin jos samalla henkilöllä on
useita eri riskitekijöitä:
ikä
sukuhistoria: sepelvaltimotauti
lähisukulaisella (mies alle 55 tai nainen
alle 65 vuotta)
miessukupuoli
tupakointi (aktiivinen tai passiivinen)
suuri LDL-kolesterolipitoisuus
diabetes
kohonnut verenpaine
vähäinen liikunta ja runsas istuminen
krooninen munuaisten vajaatoiminta
krooniset tulehdukselliset sairaudet,
erityisesti reumasairaudet
muu todettu ateroskleroottinen
valtimotauti.
Omahoito ja sen tavoitteetOmahoidon ohjaus aloitetaan
moniammatillisena yhteistyönä
sairaalajakson alussa, ja sitä jatketaan koko
sairaalahoitojakson ajan ja sen jälkeen.
Omahoidon ohjauksessa kartoitetaan
potilaan kyky ja halu hallita riskitekijöitä
(verenpaine, LDL-kolesterolin pitoisuus,
normaali sokeriaineenvaihdunta,
painonhallinta, sydänystävällinen
ruokavalio, säännöllinen liikunta, riittävä
uni ja lepo, stressinhallinta sekä
tupakoimattomuus). Samalla potilasta
kannustetaan pysyviin elintapojen
muutoksiin.
Kuntoutus ja omahoito
Sydänkuntoutuksella tarkoitetaan
suunnitelmallista ja moniammatillisesti
toteutettavaa kuntoutusohjelmaa, joka on
laadittu sepelvaltimotautikohtaukseen
sairastuneen toipumisen edistämiseksi.
Sydänkuntoutus on osa
sepelvaltimotautikohtauksen saaneen
potilaan hoitoa.
Kuntoutuksella pyritään mahdollisimman
hyvään niin fyysiseen, psyykkiseen kuin
sosiaaliseenkin toimintakykyyn.
Kuntoutuksessa saa myös tärkeää
vertaistukea.
Liikunnallinen kuntoutus (säännöllinen
hyöty- ja kestävyysliikunta sekä
lihaskuntoharjoittelu) on keskeistä
toipilasvaiheen jatkuessa (2–16 viikon
aikana kotiutumisesta) ja sen jälkeenkin.
Toipilasajan alussa (2–4 viikkoa) fyysinen
rasitus ohjataan tekemään aluksi kevyellä
rasituksella, minkä jälkeen rasitusta lisätään
maltillisesti yksilölliset tekijät huomioiden.
Liikunnallisen kuntoutuksen
toteuttamiseen löytyy käytännön ohjeita
Suomen fysioterapeuttien julkaisemasta
suosituksesta Sepelvaltimotautipotilaan4.3.2025 klo 17.32 Sepelvaltimotautikohtaus (sydäninfarkti, ”sydänkohtaus”) - Terveyskirjasto
https://www.terveyskirjasto.fi/khp00135/sepelvaltimotautikohtaus-sydaninfarkti-sydankohtaus 3/5
liikunnallinen kuntoutus: Hyvä
fysioterapiakäytäntö
[https://www.suomenfysioterapeutit.fi/fysioterapia/a
mmatin-
kehittaminen/fysioterapiasuositukset/sepelvaltimotautip
otilaan-liikunnallinen-kuntoutus/] (2. päivitys
julkaistu vuonna 2022).
Seuranta
Sydänsairauksiin perehtyneen
sairaanhoitajan tai sydänfysioterapeutin
seurantaa suositellaan 2–4 viikon kuluttua
kotiutumisesta, jotta voidaan arvioida
potilaan suorituskyky ja lisäohjauksen tarve.
Jos potilaan seurantaa jatketaan
perusterveydenhuollossa, ensimmäinen
varsinainen seurantakäynti pyritään
järjestämään 1–2 kuukauden kuluttua.
Seurantaa varten tehdään kirjallinen
hoitosuunnitelma, josta käyvät ilmi
jatkoseurantapaikka, tarvittavat tutkimukset
ja riskitekijöiden tavoitetasot.
Seurantakäynneillä kiinnitetään huomiota
potilaan vointiin ja arvioidaan lääkehoidon
toteutumista.
Lisäksi pyritään havaitsemaan potilaan
mahdollinen masennus (depressio on yleistä
sydäntapahtuman sairastaneilla) ja
arvioidaan potilaan suoritus-, työ- ja
ajokykyä sekä tarvetta kuntoutukseen.
Pysyvä jatkoseuranta toteutetaan
yksilöllisesti.
Hyvä tietää
Sepelvaltimotautipotilaan ensisijainen
kipulääke muuhun kuin sydänkipuun on
parasetamoli. Tulehduskipulääkkeet lisäävät
infarktin sairastaneilla uusintainfarktin ja
kuoleman vaaraa.
Sairauspoissaolon pituus
sepelvaltimotautikohtauksen yhteydessäriippuu vaurion koosta ja työn
kuormittavuudesta.
Ajokykyyn ja autolla-ajokiellon pituuteen
otetaan kantaa siinä vaiheessa, kun potilas
kotiutuu sairaalasta.
Työikäisistä sepelvaltimotautikohtauksen
sairastaneista suurin osa palaa takaisin
työelämään.
Sepelvaltimotautipotilaalle suositellaan
vuosittaista kausi-influenssarokotusta ja yli
65-vuotiaalle myös pneumokokkirokotusta.
Sepelvaltimotautikohtauks
et lukujen valossa
Aiempina vuosikymmeninä tyypillinen
sepelvaltimotautikohtauksen saanut potilas
oli 40–60-vuotias mies. Sittemmin
esiintymishuippu on siirtynyt vanhempiin
ikäryhmiin, ja samalla naisten osuus
sairastuneista on kasvanut.
Nykyään sepelvaltimotautikohtaukseen
sairastuneista runsas puolet on yli 75-
vuotiaita ja yli 60 % on naisia.
Sairaaloissamme hoidetaan nykyisin
vuosittain noin 22 000
sepelvaltimotautikohtausta.
Iskeeminen (hapen puutteesta johtuva)
sydänsairaus aiheuttaa lähes 17 % kaikista
suomalaisten kuolemista vuosittain. 15–64-
vuotiaiden ikäryhmässä se on toiseksi
yleisin kuolinsyy syöpäsairauksien jälkeen.
Sepelvaltimotautikohtauksen
uusiutumisriski riippuu riskitekijöiden
määrästä ja omahoidon toteutumisesta.
Sydäntapahtuman jälkeen sen uusiutumisen
riski on suurentunut.
Suomalaisen tutkimuksen mukaan 24 %
sai uusintatapahtuman (kuolema,
sepelvaltimotautikohtaus tai aivotapahtuma)
ensimmäisen vuoden kuluessa
sepelvaltimotautikohtaukseen
sairastumisesta.4.3.2025 klo 17.32 Sepelvaltimotautikohtaus (sydäninfarkti, ”sydänkohtaus”) - Terveyskirjasto
https://www.terveyskirjasto.fi/khp00135/sepelvaltimotautikohtaus-sydaninfarkti-sydankohtaus 4/5
Lisätietoa aiheesta
Suomen Sydänliitto ry – Finlands
Hjärtförbund rf on terveysjärjestö
[https://sydan.fi/sydanliitto/], jonka tavoitteena
on edistää sydänterveyttä, lisätä ihmisten
voimavaroja ja hyvinvointia sekä tukea
kaikkia, joita sydänsairaus koskettaa.
Sivustolta löytyy tietoa niin
sydäninfarktista
[https://sydan.fi/fakta/sydaninfarkti/?
gclid=EAIaIQobChMIguOEl9HH9gIVCtd3Ch38ygNqE
AAYASAAEgIlyfD_BwE], sydänterveydestä ja
hyvinvoinnista [http://www.sydan.fi/] kuin
vertaistuestakin [https://sydan.fi/apua-ja-
tukea/vertaistuki/].
Sydänliiton sivustoilta löytyy myös
sydänaiheista sanastoa yleiskielellä:
https://sydan.fi/fakta/sanasto/
[https://sydan.fi/fakta/sanasto/]
Potilasversiossa mainitut organisaatiot
antavat lisätietoa aiheeseen liittyen.
Suomalaisen Lääkäriseuran Duodecimin
Käypä hoito -toimitus ei vastaa muiden
organisaatioiden antaman tiedon laadusta
tai luotettavuudesta.
Tekijät
Potilasversion tekstin on Lääkäriseura
Duodecimin Käypä hoito -suosituksen
Sepelvaltimotautikohtaus  pohjaltakirjoittanut potilaiden osallisuutta tukeva
toimittaja Kirsi Tarnanen .
Tekstiä ovat kommentoineet Käypä hoito
-työryhmän puheenjohtaja, sisätautien ja
kardiologian erikoislääkäri, osastonlääkäri
Ilkka Tierala  HYKS Meilahden sairaalan
sydäntutkimusosastolta, työryhmän kokoava
kirjoittaja, sisätautien ja kardiologian
erikoislääkäri, apulaisylilääkäri Essi Ryödi
TAYS Sydänsairaalasta ja Sydänliitto .
Tekstin on tarkistanut ja hyväksynyt
Käypä hoito -päätoimittaja, dosentti,
lastentautien ja lastenendokrinologian
erikoislääkäri Jorma Komulainen
Suomalaisesta Lääkäriseurasta
Duodecimista.
Vastuun rajaus
Käypä hoito -suositukset ja Vältä viisaasti -
suositukset ovat asiantuntijoiden laatimia
yhteenvetoja yksittäisten sairauksien
diagnostiikan ja hoidon vaikuttavuudesta.
Suositukset toimivat lääkärin tai muun
terveydenhuollon ammattilaisen
päätöksenteon tukena hoitopäätöksiä
tehtäessä. Ne eivät korvaa lääkärin tai muun
terveydenhuollon ammattilaisen omaa
arviota yksittäisen potilaan parhaasta
mahdollisesta diagnostiikasta, hoidosta ja
kuntoutuksesta hoitopäätöksiä tehtäessä.
Artikkelin tunnus: khp00135 (050.130)
© 2024 Suomalainen Lääkäriseura Duodecim4.3.2025 klo 17.32 Sepelvaltimotautikohtaus (sydäninfarkti, ”sydänkohtaus”) - Terveyskirjasto
https://www.terveyskirjasto.fi/khp00135/sepelvaltimotautikohtaus-sydaninfarkti-sydankohtaus 5/5
Sepelvaltimotautikohtaus.pdf
Sepelvaltimotautikohtaus
Käypä hoito -suositus | Julkaistu: 23.03.2022 | Tila:
Aihepiiri(t): Akuuttilääketiede , Kardiologia , Kuntoutus , Radiologia , Sisätaudit , Työterveyshuolto , Yleislääketiede
Suomalaisen Lääkäriseuran Duodecimin ja Suomen Kardiologisen Seuran asettama työryhmä
 
Miten viitata Käypä hoito -suositukseen?  «K1»
Suositus sisältää seuraavat aiemmat Käypä hoito -suositukset:
Sydäninfarktin diagnostiikka
Sepel valtimotautikohtaus: epästabiili angina pect oris ja sydäninfarkti ilman ST-nousuja
ST-nousuinfarkti.
Keskeinen sanoma
Sepel valtimoiden äkillisest ä ahtautumisest a tai tukkeutumisest a johtuvia oirekuvia nimitetään sepel valtimotautikohtauksiksi. Niihin luetaan
epästabiili angina pect oris (UAP)
sydäninfarkti ilman ST-nousuja (NSTEMI)
ST-nousuinfarkti (STEMI).
Sydäninfarktin diagnoosi perustuu anamneesiin,  kliiniseen taudinkuvaan, EKG-löydöksiin ja troponiinim ääritykseen.
Työdiagnoosia täydennet ään sydämen ultraäänitutkimuksella ja tarvittaessa  muilla kuvantamistutkimuksilla.
Puristava rintatuntemus on sepel valtimotautikohtauksen tyyppio ire. Potilaan iän tai muiden sairauksien vaikutuksesta johtavana oireena  voi olla esim erkiksi
myös hengenahdistus, yleistilan heikkeneminen,  närästys tai ylävatsakipu.
Kaikissa akuutteja potilaita hoitavissa terveydenhuollon toimipist eissä  ja ambulansseissa  tulee olla mahdollisuus välittömään 15–16-kytkentäisen EKG:n
rekisteröintiin ja analysointiin. EKG tulee olla välittömästi siirrettävissä sähköisest i hoitopäätöksen tekevän lääkärin nähtäväksi.
Koko maassa tulee olla selkeät alueelliset ensih oidon, perusterveydenhuollon, päivystyksen ja kardiologian vastuuhenkilöiden kesken sovitut hoito-ohjeet.
Sepel valtimotautikohtausta epäiltäessä  ja hoidettaessa  potilaalle tehdään yksilöllinen vaaran arvio ja hoitolinja valitaan sen mukaan.
STEMI-potilaat ovat aina erityisen suuren vaaran potilaita, ja välitön lääke- ja toimenpid ehoito on heidän ennu steensa  kannalta elintärkeää.
Antitromboottinen lääkitys annet aan paikallisten hoito-ohjeiden mukaisest i.
NSTEMI:ssä tai UAP:ssä suurimman vaaran potilaat pyritään kuvaamaan vuorokauden sisällä.
Antitromboottinen lääkitys annet aan paikallisten hoito-ohjeiden mukaisest i.
Lääkityksen laajuus, erityisest i ADP-resept orin salpaajan käyttö, riippu u diagnoosista, potilaan vaaran arvioinnist a, sepel valtimoiden
varjoainek uvaukseen pääsyn nopeudesta ja potilaan yksilöllisest ä verenvuotovaarasta.
Päätös ADP-resept orin salpaajan aloituksesta tehdään yleensä  vasta sepel valtimoiden varjoainek uvauksen löydösten perusteella.
Jos näyttää todennä köiseltä, ettei sepel valtimoiden varjoainek uvausta ole mahdollista järjestää suurimman vaaran potilaille vuorokauden sisällä, ADP-
resept orin salpaajan aloitusta tulee NSTEMI-potilaille harkita jo ennen toimenpid että.
Antitromboottisessa  lääkityksessä  on monta mahdollista yhdistelmää. Lääkkeiden käytöstä tulee olla alueelliset ohjeet.
Sepel valtimotautikohtauksen sairastaneen potilaan mobilisointi ja liikunnallinen kuntoutus tulee aloittaa jo varhaisessa  vaiheessa  sairaalassa.
Potilaan tulee saada riskitekijöihin, elämäntapoihin ja lääkitykseen liittyvää ohjeistusta ja neuvontaa.
Potilaille tulee laatia yksilöllinen ja tavoitteellinen hoito- ja kuntoutussuunnit elma.
Suosituksessa  on linkkejä Duodecim in EKG-tietokannan kuviin Terveysportissa. Tietokanta on maksullinen ja vaatii erilliset käyttöoikeudet.
Tiivistelmä ja potilasversio
Suosituksen tiivistelmä «Sepel valtimotautikohtaus»
Suosituksen yleiskielinen potilasversio suomeksi «Sepel valtimotautikohtaus (sydäninfarkti, ”sydänkohtaus”)» ja ruotsiksi «Kranskärlssyndrom, akut (akut
koronart syndrom, hjärtinfarkt, "hjärtattack")»
Tavoitteet
Suosituksen tavoitteena  on
auttaa havaitsemaan mahdollisim man varhain, kattavasti ja täsmällisest i tapaukset, joissa potilaan akuuttien oireiden aiheuttajana on
sepel valtimotautikohtaus
tehostaa ja yhdenm ukaistaa sepel valtimotautikohtaukseen sairastuneen diagnostiikkaa, vaaran arviointia ja hoitoa sekä vähentää uusintatapahtumia ja
kuolleisuutta.
Kohderyhmät
Suositus on tarkoitettu perusterveydenhuollossa, työterveyshuollossa, ensih oidossa ja sairaaloissa sydänpotilaita hoitaville lääkäreille ja muille
terveydenhuollon ammattilaisille, hätäkeskuspäivystäjille, hoidon järjestelyistä vastaaville tahoille, potilasjärjestöille, farmaseuteille ja proviisoreille, tutkijoille
ja kuolinsyitä kirjaaville lääkäreille.
Määritelmät
Suosituksessa  käytettävät lyhenteet löytyvät lisätietoaineist osta .
Sepel valtimoiden äkillisest ä ahtautumisest a tai tukkeutumisest a johtuvia ja siitä aiheutuvan sydänlihaksen iskemian aiheuttamia oirekuvia nimitetään
sepel valtimotautikohtauksiksi (acute coronary syndromes) [1]. Niihin luetaan26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 1/41
epästabiili angina pect oris (UAP)
sydäninfarkti ilman ST-nousuja (NSTEMI)
ST-nousuinfarkti (STEMI).
Jos ahtauma tai hyytymä tukkii suonen vain osittain tai liukenee nopeasti, solutuhoa ei välttämättä kehity. Tällöin kyseessä  on epästabiili angina pect oris
(UAP).
Jos sepel valtimotukos johtaa sydänlihassolujen tuhoutumiseen,  kyseessä  on sydäninfarkti (NSTEMI tai STEMI).
Sydäninfarktin diagnoosi edellyttää, että troponiinipit oisuus ylittää viitealueen ylärajan (99. persent iilin, jonka alapuolelle jää 99 % terveistä), peräkkäisissä
näytteissä  todetaan troponiinipit oisuuden muutos (suurenem inen tai pienenem inen)  ja että jokin seuraavista ehdoista täyttyy [2]:
Potilaalla on sydänlihaksen iskemiaan sopivat oireet.
Potilaalla on sydänlihaksen iskemiaan sopivat EKG-muutokset.
Kuvantamisessa  todetaan uusi sydänlihasvaurio.
Sydäninfarktit luokitellaan etiologisest i viiteen eri tyyppiin,  ks. :
tyyppi 1: sepel valtimon seinä män ateroomaplakin repeä mä tai eroosio ja siihen liittyvä trombin muodostuminen ja spasmi [3], [4]
tyyppi 2: sydänlihaksen äkillisest i lisääntyneen hapenk ulutuksen tai vähentyneen  hapensa annin aiheuttama sydänlihasvaurio (aiheuttajana esim . nopea
rytmihäiriö, anem ia, keuhkopöhö, keuhkokuume tai sepsis)
tyyppi 3: enna lta diagnosoimattoman sydäninfarktin aiheuttama äkkikuolema
tyypit 4 ja 5: sepel valtimoiden PCI-toimenpiteeseen (tyyppi 4) tai ohitusleikkaukseen (tyyppi 5) liittyvä sydänlihasvaurio
sepel valtimon dissek aatio ja takotsubo omana ryhmänään.
Ks. lisätietoa aiheesta .
Aiemmin sairastettu sydäninfarkti voidaan todeta kuvantamistutkimuksella, EKG:llä tai patologis-anatomisin löydöksin.
Esiintyvyys
Aiempina  vuosikymmeninä  tyypillinen sydäninfarktipotilas oli 40–60-vuotias mies. Sittemmin esiint ymishuippu  on siirtynyt vanhempiin ikäryhmiin, ja
samalla naisten osuus sairastuneist a on kasvanut. Nykyään sepel valtimotautikohtaukseen sairastuneist a runsas puolet on yli 75-vuotiaita ja yli 60 % on naisia
[5].
Sairaaloissamme hoidetaan nykyisin vuosittain noin 22 000 sepel valtimotautikohtausta (sisältää sekä ensim mäiset että uusintakohtaukset).
Kokonaisuutena kohtauksien määrä on ollut hiljalleen laskussa vuosien aikana «Sepel valtimotautikohtaukset Suomessa /100 000 henkilöä, ikäryhmä 35–
84-vuotiaat».
Merkittävää muutosta ei ole kuitenkaan tapahtunut ensim mäisen vakavan kohtauksen ilmaantuvuudessa  nuoremmissa ikäluokissa, etenkään naisilla [6].
Iskeem inen sydänsairaus aiheuttaa lähes 17 % kaikista suomalaisten kuolemista vuosittain. 15–64-vuotiaiden ikäryhmässä se on toiseksi yleisin kuolinsyy
syöpäsairauksien jälkeen [7].
Sairastetun sydäninfarktin jälkeen sairaalaan elossa saapuneilla 35–74-vuotiailla miehillä sydäninfarktin ikävakioitu kuolleisuus ensim mäisen vuoden aikana
on ollut viime vuosina  11–19 % ja naisilla 9–18 %.
Sepel valtimotautikohtauksen 28 vuorokauden ikävakioitu kohtaustappavuus 35–84-vuotiaiden ikäryhmässä oli vuonna 2016 miehillä 42 % ja naisilla 32 %
(ICD-10 koodit I20–I25).
Kaksi kolmesta sepel valtimotautikohtaukseen kuolleesta meneh tyy jo kotonaan, matkalla sairaalaan tai ensia vussa «Suomessa  vuosina  2008–2017
sepel valtimotautikohtaukseen kuolleet».
Sairaalasta kotiutumisen jälkeen (29–365) vuorokautta sepel valtimotautikohtauksesta) kuolleisuus on vähäistä suhteessa  alkuvaiheen kuolleisuuteen
«Suomessa  vuosina  2008–2017 sepel valtimotautikohtaukseen kuolleet».
Ruotsalaisen SWEDEHEART-laaturekisterin vuosiraportin 2019 mukaan sairaalaan elävänä saapuneid en alle 80-vuotiaiden potilaiden kuolleisuus
sydäninfarktiin vuosina  2017–2018 oli 30 vuorokauden kuluttua sairastumisest a 3,6 % ja 1 vuoden kuluttua 7,8 % [8].
STEMI-potilaiden kuolleisuus oli alkuvaiheessa  (< 30 vuorokautta sairastumisest a) selkeästi suurempi kuin NSTEMI-potilaiden, mutta 1 vuoden kuluttua
sairastumisest a kuolleisuus molemmissa ryhmissä oli lähes samaa tasoa [8].
RIKS-HIA-rekisterin mukaan sydäninfarktiin sairastuneid en kuolleisuus vuoden kuluttua tapahtumasta oli vuosina  2003–2009 yli 2-kertainen UAP-
potilaisiin nähden [9].
Kuva 1.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 2/41
Sepel valtimotautikohtaukset Suomessa /100 000 henkilöä, ikäryhmä 35–84-vuotiaat. Sepel valtimotautikohtauksien vuosittaisessa  määrässä* voidaan nähdä
laskua vuosien kuluessa
*Ikävakioitu Euroopan standardiväestöön (ESP)
Lähde: THL, Sydän- ja verisuonitautirekisteri
© Suomalainen Lääkäriseura Duodecim
Kuva 2.
Vuosina  2008–2017 Suomessa  sepel valtimotautikohtaukseen kuolleiden 35–74-vuotiaiden lukumäärät luokiteltuna ennen sairaalahoitoa (kotona, ambulanssissa
tai ensia vussa ennen sisäänkirjausta) kuolleisiin,  sairaalassa tai pian kotiutumisen jälkeen (≤ 28 päivää) kuolleisiin ja ensim mäisen vuoden aikana kohtauksesta
(29–365 päivää) kuolleisiin,  miehet/naiset.
Lähde: THL, Sydän- ja verisuonitautirekisteri
© Suomalainen Lääkäriseura Duodecim
Ennuste ja sen arviointi
Potilaiden pitkän ajan ennu ste vaihtelee taudinkuvan, aiempien riskitekijöiden määrän, sosioekonomisen aseman, annet un hoidon sekä omahoitoon ja
kuntoutukseen sitoutumisen mukaan.
Lyhyen aikavälin ennu stetta kuvastavat erityisest i troponiinipit oisuus ja EKG.
Suurentuneen troponiinipit oisuuden yhteydessä  kuoleman vaara on 3–8-kertainen niihin potilaisiin nähden, joilla troponiinipit oisuus ei suurene [10], [11],
[12].
EKG:ssä  todettava ST-lasku alkuvaiheess a tai seurannan aikana huonontaa lyhyen ja pitkän aikavälin ennu stetta [10], [13], [14], [15].
Erilaisia pisteytysjärjestelmiä voidaan käyttää sekä lyhyen että pitkän ajan vaaran arvioimiseksi. Ks. lisätietoa aiheesta .
Vaikka uusintatapahtumien vaara olisi lyhyellä aikavälillä pieni,  pitkän aikavälin ennu ste voi kuitenkin olla huono ja se tulee arvioida erikseen .
Tulovaiheessa  todettava matala verenpa ine (systolinen alle 100 mmHg), suuri syketaajuus (yli 100 lyöntiä minuutissa), munuaisten vajaatoiminta, heikentynyt
vasemman kammion pumppauskyky, aiemmin sairastetut infarktit, tupakointi, korkea ikä ja diabetes assosioituvat kaikki huonompaan
pitkäaikaisennu steeseen [16], [17], [18].
Naissukupuoli on suuremman sairaalakuolleisuuden riskitekijä. Sukupuoliero selittyy todennä köisest i sairastuneid en naisten korkeammalla iällä,
liitännäissairauksilla ja kohtauksen joskus epätyypillisillä kliinisil lä piirteillä [19], [20]. Naisten pitkäaikaisennu ste on kuitenkin miehiä parempi [21], [22].
Gerastenia  heikentää ennu stetta merkittävästi iästä riippu matta [23].
Verikokeista erityisest i suurentuneet  (pro-)BNP-, troponiini-  ja kreatiniinia rvot ennustavat pitkäaikaisseu rannassa lisääntynyttä kuolleisuutta (ks.
lisätietoaineist o ).
Rytmihäiriön aiheuttamaa äkkikuolemaa parhaiten ennu stavat tekijät ovat vasemman kammion heikentynyt pumppauskyky, kliininen sydämen vajaatoiminta
ja kammiotakykardia [24].
Jos vasemman kammion toiminta todetaan heikentyneek si sairaalassa sydäninfarktin jälkeen,  tilanne arvioidaan uudelleen sydämen ultraäänitutkimuksella
kardiologin vastaanotolla, vakaassa tilanteessa  aikaisint aan 6 viikon kuluttua kotiutumisest a.
Sydäninfarktin sairastamisen jälkeen uusintatapahtuman riski on suurentunut pitkäaikaisest i. Ennuste on rekisteriselvitysten perusteella samansuuntainen
Suomessa  [25] ja Ruotsissa  [25].26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 3/41
Suomalaisen rekisteritutkimuksen mukaan 24 % sydäninfarktipotilaista sai uusintatapahtuman (kuolema, sydäninfarkti tai aivotapahtuma) ensim mäisen
vuoden kuluessa  sydäninfarktiin sairastumisest a.
Kolmen vuoden seurannassa uusintatapahtuman sai 37 % tutkituista.
2000-luvulla sairastuneid en pitkäaikaisennu ste oli parempi kuin 1990-luvulla sairastuneid en [25].
Ruotsalaisessa  aineist ossa uusintatapahtuman (kuolema, sydäninfarkti tai aivotapahtuma) ensim mäisen vuoden aikana sai 18 % potilaista. Kahden
vuoden seurannassa uusintatapahtuman sai 30 % tutkituista [26].
Patofysiologia
Ateroskleroosin kehittymiselle ja valtimotromboosille altistavat riskitekijät suurentavat sydäninfarktiin sairastumisen riskiä. Riskitekijöiden kasaantuminen
suurentaa riskiä entisest ään.
Itsenä isiä riskitekijöitä ovat
ikä
sukuhistoria: sepel valtimotauti alle 55-vuotiaalla miespu olisella tai alle 65-vuotiaalla naispu olisella ensim mäisen asteen sukulaisella
miessu kupuoli
tupakointi (aktiivinen tai passiiv inen)
suuri LDL-kolesterolipitoisuus
diabetes
kohonnut verenpa ine
vähäinen liikunta ja runsas istuminen
krooninen munuaisten vajaatoiminta
krooniset  tulehdukselliset sairaudet, erityisest i reumasairaudet, ks. näytönastekatsaus [B] / Käypä hoito -suositus Krooninen sepel valtimo-oireyhtymä.
Riskitekijät lisäävät sepel valtimotaudin todennä köisyyttä. Mitä useampia riskitekijöitä potilaalla on, sitä todennä köisem min oireet johtuvat
sepel valtimotaudista.
Sepel valtimotautikohtauksen todennä köisyyttä lisää myös tiedossa oleva muu ateroskleroottinen valtimotauti.
Osalla potilaista ei ole tiedossa edellä lueteltuja klassisia  riskitekijöitä. Sepel valtimotautikohtauksen mahdollisuus on aina syytä pitää mielessä , kun
aikuispo tilaalla esiint yy rintakipua.
Työdiagnoosi ja vaaran arvio
Työdiagnoosin tekeminen alkaa jo potilaan tilannet ta vakautettaessa . Sen perusteella
tunnist etaan sepel valtimotautikohtaus
määrätään välitön hoito
päätetään hoitopaikasta.
Työdiagnoosit sepel valtimotautikohtausta epäiltäessä  ovat
STEMI
NSTEMI tai UAP
muu sydänper äinen rintakipu
muu rintakehän alueen kipu.
Oireiden, kliinisen tutkimuksen, EKG-löydöksen, troponiinim ääritysten, sydämen ultraäänitutkimuksen ja hoidonaikaisen seurannan perusteella kyetään
arvioimaan potilaan vaara lyhyellä aikavälillä (taulukko 1).
Tekijät, jotka sepel valtimotautikohtauksen yhteydessä  ennu stavat suurta vaaraa lyhyellä aikavälillä, luetellaan taulukossa 1, [16], [18].
Yksittäiset vaaraa lisäävät tekijät suhteutetaan kokonaisuuteen,  ja hoitopäätösten tulee pohjautua hoidosta saatavaksi arvioituun hyötyyn suhteessa  hoidon
aiheuttamaan haittaan.
Hyvin iäkkäillä monisa irailla potilailla hoidon tärkein tavoite on oireiden helpottaminen.
Suuren vaaran potilaille ei yleensä  tarvita sydämen ultraäänitutkimuksen ja varjoainek uvauksen lisäksi muita tutkimuksia.
Pienen vaaran potilaiden diagnostiikassa ja pidemmän aikavälin vaaraa arvioitaessa käytetään harkinna n mukaan kroonisen sepel valtimotaudin
kajoamattomia diagnostisia tutkimuksia, joita ovat koronaari-TT ja perfuusiotutkimus [27].
Ks. suositeltu tutkimusprotokolla «Sydänper äiseksi epäiltävän rintakivun diagnostiikka».
Taulukko 1. Lyhyen aikavälin vaaraa kuvaavat tekijät sepelvaltimotautikohtauspotilailla
Suuri vaara Pieni vaara
Toistuva tai pitkittyvä rintakipu Rintakipu, joka ei uusiudu seurannassa
Uusiutuva iskemia Ei toistuvaa iskemiaa
Suurentunut troponiinipitoisuus Pieni troponiinipitoisuus
Iskemiaan viittaavat muutokset EKG:ssä Ei iskemiaan viittaavia EKG-muutoksia
Hemodynaaminen epävakaus (tiheä syke, matala verenpaine) Hemodynaamisesti vakaa potilas
Merkittävä rytmihäiriö (toistuva kammiotakykardia, kammiovärinä tai AV-katkos) Ei merkittäviä rytmihäiriöitä
Iäkäs potilas Nuori potilas
Pitkäaikaissairaus (diabetes, merkittävä munuaisten vajaatoiminta, sydämen vajaatoiminta, aiempi
tiedossa oleva sepelvaltimotauti)Ei pitkäaikaissairauksia
Pitkä viive oireiden alusta hoitoon hakeutumiseen Nopea hoitoon hakeutuminen26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 4/41
Kuva 3.
Sydänper äiseksi epäiltävän rintakivun diagnostiikka.
Kaavion PDF-versio «hoi50130b.pdf»
© Suomalainen Lääkäriseura Duodecim
Diagnostiikka
Oireet
Sepel valtimotautikohtauksen kliininen kuva on laaja, ja se ulottuu oireettomasta tapahtumasta äkkikuolemaan.
Yleisin ilmentymä on puristava, rintalastan takainen,  painava ja ahdistava rintakipu tai -tuntemus.
Kipu voi säteillä yläraajoihin, selkään, nisk aan, leukaperiin tai ylävatsaan.
Hengittäminen tai asenno n muutos eivät yleensä  vaikuta kipuun.
Sydäninfarktia voi edeltää lisääntyvä, aiempaa herkemmin esiint yvä vakaa oireilu (ns. crescend o angina) tai epästabiili oire.
Sepel valtimotautikohtaukselle tyypillinen  rintatuntemus kestää yleensä  vähintään muutamia minuutteja.
Muita oireita voivat olla muun muassa hengenahdistus, hikoilu, pyörrytyksen tai heikotuksen tunne ja närästys.
Hengenahdistus, raskas olo, hikisyys ja pahoinvointi, äkillinen yleistilan heikkenem inen ja sekavuus voivat olla sydäninfarktin ainoita oireita erityisest i
vanhuksilla ja diabeetikoilla.
Sepel valtimotautikohtauksen oireistossa on vain vähän eroa miesten ja naisten välillä [28], [29], [30], [31].
Vaikka tyypillinen rintakipu on molemmilla sukupuolilla tavallisin yksittäinen sepelvaltimotautikohtauksen ilmentymä, oireiden kirjo on naisilla laajempi
kuin miehillä.
Oireet ja kyky tunnist aa ja kuvata oireita voivat vaihdella myös iän ja pitkäaikaissairauksien mukaan.
Oireet, jotka lisäävät tai vähentävät sepel valtimotautikohtauksen todennä köisyyttä, luetellaan taulukossa 2, [32], [33].
Taulukko 2. Sepelvaltimotautikohtauksen todennäköisyyteen vaikuttavia oireita
Vaikutus todennäköisyyteen Oire
Lisäävä Kivun säteily yläraajoihin tai leukaan
Kivun pahentuminen liikkuessa
Hikoilu
Pahoinvointi tai oksentelu
Pahempi kuin aiempi rintakipu
Painon tunne
Mukailtu Kardiologia-oppikirjan (2016) artikkelin Sepelvaltimotautikohtauksen diagnoosi taulukosta 4 [33]26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 5/41
Vaikutus todennäköisyyteen Oire
Vähentävä Sisäänhengityksessä paheneva kipu
Paikallinen kipu
Pistävä kipu
Palpoitavissa oleva kipu
Liikkuminen ei pahenna
Mukailtu Kardiologia-oppikirjan (2016) artikkelin Sepelvaltimotautikohtauksen diagnoosi taulukosta 4 [33]
Kliiniset löydökset
Sepel valtimotautikohtaukselle ei ole spes ifisiä kliinisiä  löydöksiä.
Kliinisel lä tutkimuksella arvioidaan potilaan hemodynaamista tilaa.
Sympatikotonian ja kivun aiheuttama lievä takykardia ja hypertonia ovat mahdollisia sepel valtimotautikohtauksen kliinisiä  löydöksiä.
Alaseinä infarkti voi aiheuttaa hypotoniaa ja bradykardiaa tai täydellisen eteis-kammiokatkoksen vagaalisen heijasteen tai johtoratajärjestelmän iskemian
kautta.
Sydäninfarktin komplikaationa saattaa kehittyä hiippa läppävuoto joko paikallisen iskemian tai nystylihaksen repeä män myötä. Tällöin systolinen sivuääni ei
välttämättä kuulu mutta potilaan hemodynaaminen tila huononee nopeasti.
Hankausääni voi kuulua sydänpussin ärsytyksen yhteydessä  (Dresslerin oireyhtymä). Se esiint yy tyypillisest i muutamia päiviä vanhan infarktin yhteydessä .
Hemodynaamisen romahduksen voi aiheuttaa vapaan seinä män tai kammioväliseinä män repeä mä. Jälkimmäinen aiheuttaa voimakkaan pansystolisen
sivuäänen [34].
Laaja iskemia, sydänlihasvaurio tai mekaaninen komplikaatio voi johtaa sydämen vaikeaan vajaatoimintaan tai kardiogeeniseen sokkiin. Tähän viittaavat suuri
syke- ja hengitystaajuus, hengenahdistus, keuhkojen kosteat rakkularahinat, raajojen viileys, matala verenpa ine, sekavuus ja levottomuus. (Ks. kohta
Kardiogeeninen sokki «A1»)
EKG
EKG on avainasemassa sepel valtimotautikohtauksen
diagnoosin teossa
vaaran arviossa
hoitomuodon valinna ssa [35].
EKG:n rekisteröinti
Sepel valtimotautikohtausta epäiltäessä  EKG tulee rekisteröidä 10 minuutin sisällä. Lääkärin on tulkittava se välittömästi ja annet tava hoitopäätökset viiveettä.
EKG on avainasemassa sepel valtimotautikohtauksen diagnostiikassa, hoidon kiireellisyyden arvioinnissa  ja hoitopaikan valinna ssa.
STEMI:ssä diagnoosi ja hoidon onnist uminen perustuvat välittömään EKG:hen ja sen tulkintaan.
Ensih oidolla ja avoterveydenhuollon toimipist eillä on oltava mahdollisuus toimittaa sähköisest i EKG välittömästi hoitopäätöksen tekevän lääkärin
nähtäväksi.
Jos alkuvaiheen EKG ei ole diagnostinen,  rekisteröinti tulee uusia herkästi
oireen jatkuessa  tai vaikeutuessa
oireen uusiutuessa .
Vanhoja EKG-tallenteita kannattaa etsiä vertailua varten.
EKG:n digitaalinen arkistointi tulee saattaa valtakunnallisest i mahdollisim man kattavaksi.
Sepel valtimotautikohtausta epäiltäessä  tulee aina rekisteröidä 15–16 kytkentää (EKG-12 + VR + V–V).
Oikeanpuoleinen rintakytkentä VR tulee rekisteröidä oikean kammion infarktin tunnist amiseksi.
Selän puolelta kytkennä t V–V tulee rekisteröidä erityisest i sivuseinä infarktin tunnist amiseksi (EKG:ssä  yleensä  ST-laskua kytkennö issä V–V) [A].
EKG rekisteröidään
diagnoosivaiheessa
tarvittaessa  hoitovasteen arvioimiseksi
tarvittaessa  oireen uusiessa
revaskularisaation jälkeen vaurion laajuuden arvioinnissa
kotiutusvaiheessa .
Iskemian ilmentyminen EKG:ssä
Sepel valtimotautikohtauksessa  kivun aikana rekisteröity EKG on harvoin normaali [36].
Sydänlihasiskemia näkyy EKG:ssä  ST-nousuna, ST-laskuna tai T-aaltomuutoksina . Ks. taulukko 3.
STEMI:ssä ST-nousun määrä mitataan J-pisteestä. Ks. kuva «J-piste EKG:ssä », taulukko 3.
J-piste on normaalisti kohonnut miehillä useammin kuin naisilla.
Miehillä J-piste laskee ikääntymisen myötä.
Keskenään rinna kkaisia kytkentöjä ovat muun muassa
etuseinä kytkennä t V–V, alaseinä kytkennä t II, III ja aVF sekä sivuseinä kytkennä t I ja aVL sekä lisäkytkennät V–V.
Rintakivun aikana aiemmin negatiivinen T-aalto voi iskemian merkkinä muuttua positiiviseksi (pseu donormalisaatio) [37].
NSTEMI:ssä patofysiologia on erilainen,  ja se voi vaihdella tapauksittain. EKG:n antama anatominen tieto on rajallisem paa kuin STEMI:ssä.
Taulukko 3. Akuutin sydänlihasiskemian EKG-ilmentymät, kun EKG ei osoita LVH:ta eikä LBBB:tä
Akuutin sydänlihasiskemian EKG-ilmentymä Löydös
ST-nousu Uusi ST-nousu ≥ 1 mm J-pisteestä mitattuna kahdessa anatomisesti rinnakkaisessa kytkennässä
Poikkeukset:
Kytkennöissä V-V ST-nousun raja:
≥ 2 mm ≥ 40-vuotiailla miehillä
LBBB = Vasen haarakatkos (left bundle branch block)
LVH = Vasemman kammion hypertrofia (left ventricular hypertrophy)4 7 9
4
7 9 1 4
1 6 7 9
2 326.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 6/41
Akuutin sydänlihasiskemian EKG-ilmentymä Löydös
≥ 2,5 mm < 40-vuotiailla miehillä tai
≥ 1,5 mm naisilla iästä riippumatta
Kytkennöissä VR, V–V ST-nousun raja:
0,5 mm
ST-lasku ja T-aaltomuutokset Uusi horisontaalinen tai alaspäin viettävä vähintään 0,5 mm:n ST-lasku tai yli 1 mm:n T-aallon inversio kahdessa
anatomisesti rinnakkaisessa kytkennässä
LBBB = Vasen haarakatkos (left bundle branch block)
LVH = Vasemman kammion hypertrofia (left ventricular hypertrophy)
Kuva 4.
J-piste EKG:ssä . J-pisteeksi nimitetään kohtaa, jossa QRS-kompleksi loppuu ja ST-segmentti alkaa (nuoli). ST-nousu mitataan J-pisteen heilahduksena  (mm)
käyttäen PQ- tai TP-segmenttiä isoelektrisenä  tasona (vaakaviiva).
Kuva: Markku Eskola
EKG STEMI:ssä
Sepel valtimon tukkeutuessa  T-aalto muuttuu nopeasti korkeaksi ja symmetriseksi.
Ellei suoni aukea, valtaosassa tapauksista kehittyy ST-tason nousu tai sivuseinä infarktissa ST-tason lasku kytkentöihin V–V. Ks. taulukko 3.
STEMI:ssä voidaan erotella toisistaan preinfarktioireyhtymä ja kehittymässä oleva sydäninfarkti (evolving myocardial infarction), joiden tunnist aminen voi
auttaa sekä reper fuusiohoidon valinna ssa että hoidon kiireellisyyden arvioinnissa  [38], [39], [B]. Ks. kuvat «Preinfarktisyndrooma», «Kehittyvä infarkti ja
positiivinen T-aalto» ja «Kehittyvä infarkti ja negatiivinen T-aalto» ja lisätietoaineist o .
Kun infarktin aiheuttanut suoni on avautunut, T-aalto kääntyy kokonaan negatiiviseksi ja ST-segmentti palautuu yleensä  normaaliksi, mikä heijastaa
sydänlihassolujen verenkierron palautumista.
ST-segmentti voi jäädä koholle, vaikka infarktin aiheuttanut suoni on avautunut, jos mikroverenkierto on hidastunut perifeerisen trombikylvön tai
kudosödeem an takia.
Katso EKG-esim erkit lisätietoaineist osta . Huom.! EKG-tietokanta on maksullinen  ja vaatii käyttöoikeudet.
EKG:n tulkintaa vaikeuttavia muutoksia kuvataan lisätietoaineist ossa .
STEMI:ssä tukossa oleva suoni voidaan määrittää maksimaalisen ST-nousun (iskemian ydinalue) perusteella [40]. Ks. kuvat ja «Morfologisen EKG-
tulkinna n periaatteita», [41]. EKG:n anatominen tulkinta edellyttää ST-segmentin nousun esiint ymistä .
STEMI:ssä iskemian vahvuutta voidaan arvioida infarktin akuuttivaiheessa  rekisteröidystä EKG:st ä. Tämä iskemia-aste jaetaan iskemian vahvuuden mukaan
kolmeen luokkaan , [41].
Uusi tai oletettavasti uusi LBBB antanee vain vähän lisäarvoa reper fuusiohoidon tarpeen arvioinnissa  [B].4 7 9
1 426.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 7/41
Kuva 5.
Preinfarktisyndrooma. Alaseinä kytkennö issä II ja III esiint yy preinfarktioireyhtymän merkkinä ST-nousu ja positiivinen T-aalto ilman patologista Q-aaltoa.
Kuva: Markku Eskola
Kuva 6.
Kehittyvä infarkti ja positiivinen T-aalto
EKG-löydös kuvaa kehittyvää infarktia (evolving myocardial infarction) ilman merkkiä suonen avautumisest a. Etuseinä kytkennö issä V–V todetaan patologinen
Q-aalto, ST-nousu ja positiivinen T-aalto. Tässä yhteydessä  positiivinen T-aalto viittaa tukossa olevaan infarktisuoneen.
Kuva: Markku Eskola
Kuva 7.
Kehittyvä infarkti ja negatiivinen T-aalto. EKG-löydös kuvaa kehittyvää infarktia (evolving myocardial infarction), jossa negatiivinen T-aalto heijastaa kudostason
verenkierron palautumista. ST-segmentti on edelleen kohonnut.
Kuva: Markku Eskola1 326.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 8/41
Kuva 8.
Morfologisen EKG-tulkinna n periaatteita
Kuvassa nähdään kahden eri potilaan akuutin ST-nousuinfarktin EKG-muutokset. Molemmat edustavat tilannet ta jossa iskeem inen alue, ja samalla uhkaava
sydänlihasvaurio, on suhteellinen iso. Kuvan keskellä esitetään sepel valtimoanatomia sekä sepel valtimotautikohtaukselle tyypilliset patofysiologiset muutokset:
plakin repeä mä ja suonen sisäinen hyytymä. Vasemmanpuoleisessa  esim erkissä nähdään ST-välin nousua kytkennö issä II, III ja aVF alaseinä infarktin merkkinä.
Kytkentöjen I ja aVL sekä V–V ST-välin laskut ovat ns. resipr okaalisia muutoksia. On tärkeä huomata kytkentöjen V ja V ST-välin nousut merkkinä ison
dominantin sepel valtimon tukoksesta, ja näin ollen kertoo kohonneest a lyhyen aikavälin riskistä. On tärkeä huomata että kytkentöjen II, III ja aVF J-piste on yli
50 % R-aallon korkeudesta merkkinä III asteen iskemiasta. Oikealla näkyy esim erkki etuseinä infarktista, jossa kytkennö issä I ja aVL on nähtävissä ST-välin
nousua. Tämä on merkki vasemman eteen laskevan sepel valtimohaaran (LAD) alkuosan tukoksesta.
Lähde: Nikus K, Eskola M, Porela P, Airaksinen J. EKG:n iskemia-aste uhkaavan ST-nousuinfarktin yksilöllisessä vaaran arvioinnissa. Suomen Lääkärilehti 2008;63:1509-14
Julkaistaan Suomen Lääkärilehden luvalla.
EKG UAP:ssa ja NSTEMI:ssä
EKG antaa tietoa sepel valtimotaudin vaikeusasteesta, mutta anatominen tieto on rajallista, jos EKG:st ä puuttuu vauriovirtalöydös.
Sepel valtimotautikohtauspotilaista 10–15 %:lla EKG on normaali [42].
Sepel valtimotautikohtauksessa  kivun aikana rekisteröity EKG on kuitenkin vain harvoin normaali [36].
Pienik in (0,5 mm:n) ST-välin lasku potilaalla, joka kärsii pahentuneest a tai uudesta rintakivusta, viittaa vahvasti iskeem iseen etiologiaan ja lisää
uusintatapahtumien vaaraa [43].
Globaali-iskemian tunnusomainen EKG-löydös auttaa tunnist amaan hyvin kiireellistä hoitoa vaativat tapaukset isosta joukosta potilaita, joilla epäillään tai on
todettu sepel valtimotautikohtaus.
Vähintään 6 kytkennä n ST-lasku, varsink in jos maksimaalinen muutos kytkennö issä V–Vyhdistyy kyseist en kytkentöjen negatiiviseen T-aaltoon sekä
kytkennä n aVR ST-nousuun, on merkki vaikeasta kolmen suonen taudista tai päärunkotaudista ja suurentuneest a päätetapahtumien riskistä [A], [40], [42],
[44]. Kyseisest ä EKG-löydöksestä käytetään termiä globaali-iskemia.
Rintakytkentöjen ST-lasku ja positiivinen  T-aalto viittaavat LAD:n tiukkaan ahtaumaan [45]. Ks. myös kuva «Paikallinen subendokardiaalinen iskemia
EKG:ssä », [40].
T-aallon negatiivisuus kytkennö issä V/V–V/Vyhdistettynä kyseist en kytkentöjen isoelektriseen tai minim aalisest i kohonneeseen ST-segmenttiin viittaa
etuseinä n iskemian jälkitilaan. Jos taudinkuva sopii sepel valtimotautikohtaukseen, kyseessä  on useim miten LAD:n merkittävä kaventuma tai LAD-tukos
yhdistyneenä  hyvään kollateraalisuonitukseen yleensä  oikeasta sepel valtimosta [42].1 3 5 6
4 6 
1 2 3 4 26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 9/41
Kuva 9.
Paikallinen subendokardiaalinen iskemia EKG:ssä . Paikallinen subendokardiaalinen iskemia kytkennö issä V–V, joissa todetaan ST-segmentin lasku ja
positiivinen T-aalto (kytkennä t V–V vasemmalla ja V–V oikealla puolella).
Lähde: Nikus K, Eskola M. EKG sepelvaltimotautikohtauksen vaaran arvioinnissa. Suomen Lääkärilehti 2004;59:2365-72
Julkaistaan Suomen Lääkärilehden luvalla.
Iskemian tulkinta haarakatkosten yhteydessä
Oikeassa haarakatkoksessa  (RBBB) esiin tyy usein ST-T-muutoksia, mikä vaikeuttaa iskemian tulkintaa. ST-nousu tai Q-aalto viittaa kuitenkin vahvasti
iskemiaan tai infarktiin.
Uusi tai oletettavasti uusi LBBB antanee vain vähän lisähyötyä, kun arvioidaan reper fuusiohoidon tarvetta [B].
Vasen haarakatkos (LBBB) yhdistettynä sydäninfarktin kliiniseen kuvaan viittaa STEMI:iin, erityisest i jos todetaan
QRS-kompleksin kanssa  samansuuntainen (konkordantti) 1 mm suurempi ST-nousu [B], (kuva «Vasen haarakatkos, jossa on konkordantti 1 mm:ä
suurempi ST-nousu kytkennä ssä V5 ja konkordantti 1 mm:ä suurempi ST-lasku kytkennö issä III ja aVF») tai
QRS-kompleksin kanssa  konkordantti 1 mm suurempi ST-lasku kytkennö issä V, V tai V [B], (kuva «Vasen haarakatkos, jossa etuseinä kytkennö issä V2–
V4 konkordantti ST-segmentin lasku»).
Iskemian tulkinta LBBB:ssä ja kammiotahdistinrytmin aikana on vaikeaa, minkä vuoksi arvio kiireellisen revaskularisaation tarpeest a tulee tehdä pääosin
oireiden ja hemodynaamisten parametrien perusteella.
Pelkän ST-nousun korkeuden spesif isyys on erittäin huono.
Vertailu aiempiin EKG-tallenteisiin on erityisen tärkeää.
Kuva 10.2 5
1 3 4 6
1 2 326.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 10/41
Kuvassa nähdään vasen haarakatkos, jossa on konkordantti 1 mm:ä suurempi ST-nousu kytkennä ssä V5 ja konkordantti 1 mm:ä suurempi ST-lasku kytkennö issä
III ja aVF. Myös kytkennä n V3 ST-nousua (6 mm) voidaan pitää viitteellisenä  akuutille ST-nousuinfarktille.
© HYKS/HUS Kardiologian klinikka
Kuva 11.
Kuvassa nähdään vasen haarakatkos, jossa etuseinä kytkennö issä V2–V4 on konkordantti (QRS-kompleksin kanssa  samansuuntainen)  ST-segmentin lasku, joka
on suuruudeltaan yli 1 mm.
Kuva: Markku Eskola
EKG aiemmin sairastetussa sydäninfarktissa
EKG:ssa  nähtävä Q-aalto tai QS-kompleksi on usein merkki sairastetusta infarktista (ks. taulukko 4), jos QRS-kompleksin tulkintaa häiritseviä tekijöitä ei ole.
Ks. taulukko 5.
Patologinen Q-aalto voi kehittyä ST-segmentin nousun jälkeen [46], [47], [48]. Q-aallon kehittyminen voi viedä 2–3 vuorokautta [49].
Muita Q-aallon taustalla olevia syitä ja oireettoman potilaan Q-aallon nimeämistä sairastetuksi infarktiksi kuvataan tarkemmin lisätietoaineist ossa .
Taulukko 4. Sairastettuun sydäninfarktiin viittaavat patologisen Q-aallon kriteerit
Patologisen Q-aallon
kriteeritMikä tahansa ≥ 20 ms:n pituinen Q-aalto kytkennöissä V–V tai QS-kompleksi kytkennöissä V ja V
≥ 30 ms:n pituinen ja ≥ 1 mm:n syvyinen Q-aalto tai QS-kompleksi kahdessa rinnakkaisessa kytkennässä I, II, aVL, aVF tai V–V; rinnakkaiset
kytkennät: I, aVL; V–V; II, aVF
R-aalto > 40 ms ja R/S > 1 kytkennöissä V–V yhdistyneenä positiiviseen T-aaltoon
EKG erotusdiagnostiikassa
EKG:n tulkinna ssa on erityisest i huomioitava muut ST-muutoksia aiheuttavat vakavat tilat, kuten aortan dissek aatio, keuhkoveritulppa ja äkillisest i
kohonnutta kallonsisä istä painetta aiheuttavat sairaudet. Ks. taulukko 5.
Takotsubo-oireyhtymälle ei ole käyttökelpoisia EKG-kriteereitä [50].
Takotsubo-oireyhtymä voi aiheuttaa esim erkiksi etuseinä n STEMI:n kaltaisen EKG-muutoksen.
Taulukko 5. EKG:n tulkintaan liittyviä tiloja, jotka aiheuttavat erotusdiagnostisia ongelmia. Ks. myös Terveysportin EKG-tietokannan artikkelit (Huom. tietokannan käyttö on
maksullista ja vaatii käyttöoikeudet) «ST-väli infarktin erotusdiagnoosissa», «T-aalto infarktin erotusdiagnoosissa», «Myoperikardiitin EKG-kriteerit», «Myokardiitti vai
sydäninfarkti?» sekä kuvat «Infarktin erotusdiagnostiikka: varhainen repolarisaatio» ja «Infarktin erotusdiagnostiikka: hypertrofinen kardiomyopatia».
ST-nousu Varhainen repolarisaatio
Perimyokardiitti
Hypertrofinen kardiomyopatia
Brugadan oireyhtymä
Keuhkoembolia
Vasemman kammion hypertrofia
Hyperkalemia
Hyperkalsemia
Takotsubo
Aortan dissekaatio (ja siihen mahdollisesti liittyvä sepelvaltimon tukkeuma tai dissekaatio)
ST-nousu ei ole spesifinen sydäninfarktille, ja T-aalto muuttuu herkästi muissakin tiloissa kuin iskemiassa, joten niiden spesifisyys on heikoin kaikista taulukon EKG-
parametreista. Poikkeava Q-aalto voi esiintyä sydäninfarktin lisäksi muissa tiloissa, jotka johtavat sydänlihaskuolioon. Myös poikkeavuus sydänlihasmassan paikantumisessa tai
sydämen sähköisessä aktivaatiossa voi johtaa Q-aaltojen syntymiseen.
Mukailtu Kardiologia-oppikirjan (2016) taulukosta 24.30b [51]2 3 2 3
4 6
4 6
1 226.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 11/41
ST-lasku Sympatikotonia
Hyperventilaatio
Mikrovaskulaarisen verenkierron häiriö
Vasemman kammion hypertrofia
Digitalis
Tiheälyöntisyyskohtauksen jälkitila
Hiippaläpän prolapsi
Takotsubo
T-aaltomuutos Normaalin variantti
Hyperventilaatio
Kohonnut kallonsisäinen paine
Elektrolyyttihäiriö
Akuutti keuhkoverenkierron vastuksen nousu (esim. keuhkoembolia)
Takotsubo
Myokardiitti tai perimyokardiitti
Repolarisaation muisti-ilmiö
Q-aalto Vasemman kammion hypertrofia (kytkentä V)
Hypertrofinen kardiomyopatia
Oikean kammion paine- ja tilavuuskuormitus
Ilmarinta
Duchennen lihasdystrofia
Sydämen poikkeava asento (kytkennät II, III ja aVF)
Aiemmin sairastettu myokardiitti
Vasemman etuhaarakkeen katkos (oikeanpuoleiset rintakytkennät)
Pre-eksitaatio
ST-nousu ei ole spesifinen sydäninfarktille, ja T-aalto muuttuu herkästi muissakin tiloissa kuin iskemiassa, joten niiden spesifisyys on heikoin kaikista taulukon EKG-
parametreista. Poikkeava Q-aalto voi esiintyä sydäninfarktin lisäksi muissa tiloissa, jotka johtavat sydänlihaskuolioon. Myös poikkeavuus sydänlihasmassan paikantumisessa tai
sydämen sähköisessä aktivaatiossa voi johtaa Q-aaltojen syntymiseen.
Mukailtu Kardiologia-oppikirjan (2016) taulukosta 24.30b [51]
Troponiinit
Troponiinit  ovat sydänlihassolujen rakennepr oteiinej a, joita voi vapautua verenkiertoon minkä tahansa sydänlihasvaurion yhteydessä . Ks. taulukko 6.
Troponiinien pitoisuusmääritysten avulla täydennet ään sepel valtimotautikohtauksen diagnostiikkaa ja vaaran arviota [11].
Sydäninfarktin diagnoosi voidaan tehdä, kun sepel valtimotautikohtaukseen sopivan taudinkuvan yhteydessä  todetaan kahdessa  peräkkäisessä  näytteessä
herkän troponiinin pitoisuuden suurenem inen tai pienenem inen ja vähintään toinen arvoista ylittää 99. persent iilin mukaisen päätöksent eon raja-arvon [A].
Herkillä troponiinim ääritysmenet elmillä pystytään havaitsemaan enem män suuren vaaran tapauksia ja siten tarkentamaan potilaiden vaaran arviointia [52],
[53].
Samalla kuitenkin todetaan myös muita kuin sepel valtimotautikohtauksen aiheuttamia troponiinipit oisuuden nousuja aiempaa useammin. Ks. taulukko 6.
Herkillä troponiinit esteillä (hs-TnI tai hs-TnT) voidaan kehittyvä sydäninfarkti todeta aiempaa nopeammin [54], [55], [56].
Troponiinipit oisuus on suositeltavaa tutkia tulonäytteestä ja 1–3 tunnin kuluttua ensim mäisest ä näytteestä.
75 %:lla NSTEMI-potilaista troponiinipit oisuus on koholla tai muuttunut merkittävästi jo 1 tunnin kuluessa  tulonäytteestä [54]. 99 %:lla niist ä potilaista,
joilla troponiini on negatiivinen 1 tunnin kuluttua tulonäytteestä otetussa näytteessä, se myös jää negatiiviseksi [54]
1 tunnin protokollalla kotiutus on nopeampaa ja yhtä turvallista kuin vanhalla 3 tunnin ohjeella [57].
1 ja 2 tunnin protokollat ja niihin hyväksyttyjä määritysmenet elmiä käsitellään lisätietoaineist ossa .
Mittaamattoman pieni herkkä troponiinipit oisuus yhdessä  normaalin EKG:n kanssa riittää sydäninfarktin sulkemiseen pois, kun oireesta on kulunut
vähintään 2 tuntia ja potilas on oireeton [A], [58].
Tutkimukset uusitaan kliinisen tarpeen mukaan eli silloin, jos uusia oireita ilmaantuu tai epäily sydäninfarktista on vahva.
Suurentunut troponiinipit oisuus osoittaa, että potilaalla on sydänlihasvaurio. Muut kuin iskeem isen sydänlihasvaurion syyt tulee kuitenkin ottaa huomioon.
Ks. taulukko 6.
Huomattavasti (yli 5-kertaisest i) suurentuneen troponiinipit oisuuden aiheuttajana on useim miten sydäninfarkti, kun taas lievästi suurentuneen
troponiinipit oisuuden taustalla on varsin usein jokin muu äkillinen tai krooninen sairaus [59], [60], [61].
Hs-TnT-pitoisuus voi olla suurentunut 7–14 ja hs-TnI-pitoisuus 4–7 vuorokautta kohtauksen alusta.
Hs-TnT-nousu voi olla kaksihuippu inen [62].
Vaikeaa kroonista sepel valtimotautia tai munuaisten vajaatoimintaa sairastavalla herkän troponiinin pitoisuus voi olla suurentunut, mikä voi viitata pitkän
aikavälin huonompaan ennu steeseen [63], [64], [65], [66].
Akuutin sydäninfarktin diagnoosiin vaaditaan troponiinipit oisuuden muutos kahden näytteen välillä – muuttumaton suurentunut troponiinipit oisuus on
todennä köisest i krooninen löydös.
Huomattavalla osalla terveistä on mitattavissa suurentuneita herkän troponiinin pitoisuuksia voimakkaan fyysisen rasituksen jälkeen,  mikä on tärkeää
huomioida erotusdiagnostiikassa [67].
Troponiinin määrityksen tulos tulisi saada tarvittaessa  1 tunnin kuluessa  näytteeno tosta. Ellei siihen kyetä, tulee harkita vieritestien (ns. pikatestit, point of
care -testit) käyttöönottoa.
Vier itestien antama tulos on pienil lä troponiinipit oisuuksilla epäluotettavampi kuin automatisoitujen, herkkien troponiinit estien, koska vieritestien
huonomman herkkyyden vuoksi niiden toistettavuus on huonompi. Eri menet elmien erilaiset ominaisuudet ja päätösrajat tulisi ottaa huomioon alueellisest i
hoitoketjun päätöksent eossa yhtenäisen diagnostiikan turvaamiseksi.
STEMI:ssä laboratoriotuloksia ei tule odottaa tai ottaa ennen hoitopäätöstä.126.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 12/41
Kun hoitona on primaari PCI, verikokeet otetaan sepel valtimoiden varjoainek uvauksen yhteydessä  tai vasta sen jälkeen.
Taulukko 6. Troponiinipitoisuuden suureneminen ilman merkittävää ateroskleroottista sepelvaltimotautia [2]
Sydänlihasruhje tai muu sydänlihakseen kohdistuva trauma, esimerkiksi leikkaus, ablaatiohoito, tahdistimen asennus tai kardioversio
Sepelvaltimon spasmi
Embolinen sydäninfarkti
Sepelvaltimon dissekaatio
Sydämen akuutti tai krooninen kongestiivinen vajaatoiminta
Aortan dissekaatio
Aorttaläpän sairaus
Hypertrofinen kardiomyopatia
Voimakkaasti koholla oleva verenpaine
Taky- tai bradyarytmiat tai johtumishäiriöt
Takotsubo
Rabdomyolyysi
Keuhkoembolia, vakava pulmonaalihypertensio
Munuaisten vajaatoiminta
Akuutti neurologinen sairaus, kuten aivohalvaus tai lukinkalvonalainen verenvuoto
Systeemisairaudet, esimerkiksi amyloidoosi, hemokromatoosi, sarkoidoosi ja skleroderma
Krooniset inflammatoriset sydänlihassairaudet (sydänsarkoidoosi ja jättisolumyokardiitti)
Akuutti sydänlihastulehdus ja endo- tai perikardiittimuutosten ulottuminen sydänlihakseen
Lääkkeiden toksisuus ja myrkyt
Kriittisesti sairaat potilaat, etenkin hengitysvajauksen tai sepsiksen yhteydessä
Palovammat, etenkin sellaiset, joiden laajuus on yli 30 % kehon pinta-alasta
Fyysinen rasitus [67]
Kajoamaton kuvantaminen sepelvaltimotautikohtauksen diagnostiikassa
Kuvantamistutkimusten käyttö sepel valtimotautikohtauksen diagnostiikassa perustuu sepel valtimoahtauman, sydänlihaksen toimintahäiriön, solukuoleman
tai vaurioalueen sidekudoksen (arven) toteamiseen.
Sydämen ultraäänitutkimus on kajoamattomista kuvantamistutkimuksista tärkein, ja sen tulee olla helposti saatavilla. Vasemman kammion heikentynyt
systolinen toiminta on tärkeä ennu stetekijä ja ohjaa lääkehoitoa [68], [69].
Tutkimus tulee tehdä jo ennen sepel valtimoiden varjoainek uvausta, viimeistään toimenpid epöydällä [70].
Ultraäänitutkimuksen tekeminen ei saa viivästyttää revaskularisaatiota.
Sydämen ultraäänitutkimus tulee tehdä sairaalahoidon aikana kaikille sydäninfarktipotilaille osana kokonaisarviota.
Ultraäänitutkimuksella nähdään mahdollinen iskemian aiheuttama seinä män liikehäiriö, mutta sen puuttuminen ei sulje pois kehittyvää sydäninfarktia.
Aiemmin sairastettu infarkti saattaa näkyä liikehäiriönä tai seinä män ohentumisena .
Ultraäänitutkimus voi auttaa erottamaan tautitilat, jotka aiheuttavat sydäninfarktia muistuttavan taudinkuvan tai erotusdiagnostisia vaikeuksia tuottavia
EKG-muutoksia (aortan dissek aatio, sydänpussitulehdus, takotsubo-oireyhtymä, sydäntamponaatio, keuhkoembolia, läppävika, sydämen vajaatoiminta ja
kardiomyopatia).
Vasemman kammion varjoainek uvausta ei suositella tehtäväksi rutiinino maisest i, mutta se saattaa antaa erotusdiagnostisest i tärkeää tietoa esim erkiksi
takotsubossa (tyypillisest i laaja dyskinesia kammion kärjessä ).
Sydämen magneet tikuvausta voidaan harkita erotusdiagnostisena  tutkimuksena  tulehduksellista sydänsairautta epäiltäessä .
Sepel valtimoiden tietokonetomografia (sepel valtimoiden TT) mahdollistaa sepel valtimoahtaumien toteamisen.  Se soveltuu erityisest i kroonisen
sepel valtimotaudin sulkemiseen pois potilailla, joilla taudin todennä köisyys on pieni tai keskisuuri [27].
Sepel valtimoiden varjoainetehosteinen TT soveltuu todennä köisest i akuutin sepel valtimotautikohtauksen sulkemiseen pois sellaisilla valikoiduilla potilailla,
joilla ei todeta suuren vaaran merkkejä (EKG-muutos ja troponiinipit oisuuden suurenem inen)  ja sepel valtimotaudin todennä köisyys on pieni tai keskisuuri [B].
TT-kuvauksessa  todettu sepel valtimoahtauma ei välttämättä ole potilaan oireiden takana. Erityisest i potilailla, joilla on aiemmin todettu sepel valtimotauti tai
sen todennä köisyys on suuri, tulee harkita muita erotusdiagnostisia tutkimuksia.
Sepel valtimoiden TT ei ole vakiintunut kliiniseen käyttöön sepel valtimotautikohtauksen yhteydessä , eikä sen käyttö vähennä  sydäntapahtumien esiint yvyyttä
lyhyellä aikavälillä [B], [71].
Sepel valtimoiden TT:n käyttö edellyttää hyvää asiantuntemusta ja potilaiden huolellista valikointia. Tutkimusta ei suositella potilaille, joilla on nopea ja
epäsäännöllinen syke, koska tällöin kuvanlaatu ei todennä köisest i ole diagnostinen.
Laajalla monileiketietokonetomografialla (Triple Rule-Out) voidaan tarvittaessa  diagnosoida tai sulkea pois keuhkoembolia ja aortan dissek aatio rintakivun
aiheuttajana.
Sydänlihasiskemian osoitukseen perustuvia sepel valtimotaudin diagnostisia tutkimuksia (kliininen kuormituskoe, rasitusultraääni, rasitusmagneet tikuvaus,
sydänlihasper fuusion isotooppitutkimus SPECT- tai PET-kameralla) voidaan käyttää ahtauttavan sepel valtimotaudin sulkemiseen pois, kajoavan hoidon
tarpeen arviointiin ja kohteen osoittamiseen sellaisilla potilailla, joilla ei todeta suuren vaaran merkkejä (EKG-muutos ja troponiinipä ästö), tai täydentämään
kajoavaa varjoainek uvausta (esim . kajoavan hoidon tarpeen arviointi monisu onitaudissa). Iskemian kuvantamistutkimuksilla voidaan havaita myös elävä
sydänlihas, jonka toiminta voi parantua revaskularisaation jälkeen (viabiliteetti) [27].
Erotusdiagnostiikka
Rintakivun ja EKG-muutosten diagnostiikassa tulisi huomioida etenkin ne erotusdiagnostiset vaihtoehdot, jotka ovat välittömästi henkeä uhkaavat. Ks.
taulukko 7.
Suurentuneen troponiinipit oisuuden syy tulee selvittää [61]. Muut kuin iskeem isen sydänlihasvaurion syyt tulee ottaa huomioon. Ks. taulukko 6.
Tautitiloja, joissa todetaan sydäninfarkti ilman tukkeuttavaa sepel valtimotautia, kutsutaan kirjallisuudessa  termillä "MINOCA" eli Myocardial Infarction with
Non-Obstructive Coronary Arteries [61], [72].
Kyseessä  on työdiagnoosi, joka ohjaa jatkotutkimuksia.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 13/41
Taulukko 7. Sepelvaltimotautikohtauksen erotusdiagnostisia vaihtoehtoja
Erotusdiagnoosi
Henkeä uhkaavat Aortan dissekaatio
Keuhkoembolia
Paineilmarinta
Sydämen tamponaatio
Kordaruptuura
Ulkusperforaatio
Ruokatorven repeämä
Ei henkeä uhkaavat Sydänpussi- ja sydänlihastulehdus
Ilmarinta
Keuhkon tai keuhkopussin tulehdus
Kostokondraalikipu
Mondorin oireyhtymä
Ruokatorvitulehdus
Ruokatorven kouristus
Ulkus
Toiminnalliset kivut
Alkava vyöruusu
Hyperventilaatio-oireyhtymä
Masennus
Mukailtu Kardiologia-oppikirjan (2016) taulukosta 24.20 [73]
Lopullinen diagnoosi
Lopullinen diagnoosi tehdään myöhemmin, kun kaikkien diagnostisten tutkimusten tulokset ovat käytettävissä. Ks. lisätietoaineist o «hoi50130a.pdf».
Sepel valtimotautikohtauksen lopulliset diagnoosit (ICD10):
STEMI (I21.0x–I21.3x)
NSTEMI (I21.4x)
Jos alkuvaiheen ST-nousu korjaantuu ilman reper fuusiohoitoa, diagnoosi on NSTEMI.
UAP (I20.0x). Ks. kuva «Sepel valtimotautikohtauksen luokittelun vuokaavio».
Jos potilaalla todetaan EKG:ssä  uusi tai oletettavasti uusi vasen haarakatkos, päädiagnoosiksi tulee STEMI vain, jos varjoainek uvauksessa  todetaan
STEMI:hin sopiva sepel valtimotukos.
Muussa tapauksessa  troponiinipä ästön yhteydessä  tilanne luokitellaan NSTEMI:ksi. Ks. kuva «Sepel valtimotautikohtauksen luokittelun vuokaavio».
Vasemman haarakatkoksen sivudiagnoosia (I44.7) tulisi käyttää.
Takotsubon diagnoosi perustuu kliiniseen kuvaan ja kuvantamislöydökseen (sydämen ultraäänitutkimus, sepel valtimoiden varjoainek uvaus ja tarvittaessa
vasemman kammion varjoainek uvaus).
Takotsubo-oireyhtymälle ei ole ICD-10-luokituksessa  omaa diagnoosikoodia. Työryhmä suosittelee käytettäväksi ICD-10 koodia I21.90, koska
taudinkuva ja diagnostiikka on akuutin sydäntapahtuman tyyppinen.
Kyseessä  on akuutti sairaus, joten termiä kardiomyopatia ei tule käyttää.
Työryhmä suosittelee, että ICD-10-diagnoosiryhmää I22 käytettäisiin vain lähipäivien (ad 28 vuorokautta) aikana tapahtuviin sydäninfarktin uusiutumisiin.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 14/41
Kuva 12.
Sepel valtimotautikohtauksen luokittelun vuokaavio
Sepel valtimotautikohtauksen työdiagnoosina  on oirekuvan ja EKG:n perusteella joko ST-nousuinfarkti (STEMI) tai sydäninfarkti ilman ST-nousua (NSTEMI) /
epästabiili angina pect oris (UAP). Lopullinen diagnoosi määräytyy edellisten lisäksi sydänlihasmerkkiainem äärityksen tuloksen perusteella. Kehittyvässä ST-
nousuinfarktissa ei pidä jäädä odottamaan merkkiainev astausta. Takotsubon diagnoosinu mero on I21.90.
© Suomalainen Lääkäriseura Duodecim
Sepelvaltimotautikohtauksen alkuvaiheen hoito
Sepel valtimotautikohtauksen hoidon tärkeimmät tavoitteet ovat
oireiden ja sydänlihasiskemian helpottaminen
haitallisten sydäntapahtumien (kuolema, sydäninfarkti, uusiutuva iskemia) estäminen.
Samalla on huolehdittava siitä, ettei hoidolla aiheuteta potilaalle uusia haittoja, kuten munuaisten toiminna n häiriöitä tai verenvuoto-ongelmia.
Sepel valtimotautikohtauksen hoidosta tulee olla laadittuna alueellinen hoitoketju.
Sepelvaltimotautikohtauksen hoitoketju
Hätäkeskus
Sepel valtimotautikohtaukseen sairastuneid en hoitoon hakeutuminen ja ensih oidon aloitus voidaan tehokkaimmin ja turvallisim min järjestää ensih oitopalvelun
kautta.
Ensih oitopalvelu aktivoidaan soittamalla yleiseen hätänumeroon 112.
Hätänumeroon tulisi soittaa heti, jos potilas saa uutena oireena  äkillisen voimakkaan rintakivun tai hengenahdistuksen tai hän menet tää tajuntansa.
Jos potilaalla on jo diagnosoitu sepel valtimotauti, hätänumeroon tulisi soittaa, elleivät lepoon asettuminen ja itsehoitona otettu lyhytvaikutteinen nitraatti
(kielenalusresoribletti tai sumute) vie kipua pois muutamassa minuutissa tai jos kipuun liittyy tajunnan menet ys, pahoinvointi, oksent elu, kylmänhikisyys
tai selvä yleisvoinnin huononem inen.
Ensia putoimenpit eiksi voidaan ohjeistaa ehdoton lepo, 250–500 mg asetyylisalisyylihappoa (ASAa) pureskeltuna (ellei potilaalla ole yliherkkyyttä
valmisteelle) sekä oma lyhytvaikutteinen  nitraatti, jos potilas jaksaa istua.
Sepel valtimotaudin diagnoosin tekemisen yhteydessä  potilaille tulisi antaa selkeät ohjeet lyhytvaikutteisen nitraatin käytöstä (alkuannos ja tarvittaessa  2
lisäannosta 5 minuutin välein).
Potilasta, jolla epäillään sydäninfarktia, ei pitäisi jättää yksin, ja hätäkeskukseen tulisi soittaa uudestaan, jos potilas menee puhumattomaksi tai hänen
vointinsa  heikkenee muuten.
Hätäkeskus tekee protokollansa mukaisen riskinarvion ja hälyttää sen perusteella paikalle sopivan ensih oitoyksikön.
Ks. lisätietoa hätäkeskuksen ohjeistuksista .
Sepel valtimotautikohtauksen ensih oito
Ensih oidossa tehdään työdiagnoosi ja samalla vaaran arvio esitietojen, kliinisen tutkimuksen ja EKG:n perusteella, ja näiden perusteella valitaan hoitolinja
«Sepel valtimotautikohtaus – hoitopolku».
Sepel valtimotautikohtauksen ensih oito tulee aloittaa heti ensim mäisen terveydenhuoltokontaktin (ensih oitoyksikkö, päivystys, lääkäriasema tms.) yhteydessä
samalla, kun tehdään diagnostiikkaa sydänper äiseksi sopivan oireen etiologiasta.
Hoitohenkilökunnan tulee aloittaa ensih oito jo ennen lääkärin tekemää diagnoosia.
Ensih oidon tavoitteena  on sydämen hapenkulutuksen vähentäminen,  hapent arjonnan lisääminen ja hoitostrategian mukaisen veren hyytymiseen vaikuttavan
lääkityksen aloittaminen.  Ks. taulukko 8 ja taulukot 12, 11, 13, joissa esitetään antitromboottinen hoitostrategia STEMI- ja NSTEMI-tilanteissa .26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 15/41
Nopea oikeaan diagnoosiin pääsy on tärkeää, koska hoitotulos on sitä parempi, mitä nopeammin potilaalle päästään antamaan sydänlihasiskemiaa vähentävää
hoitoa [73], [75].
STEMI:n diagnosointi oireiden ja EKG:n perusteella jo sairaalan ulkopuolella lyhentää merkittävästi reper fuusiohoidon viivettä ja parantaa potilaan
ennu stetta [76], [77].
Ensih oitajalla tulee olla alueellisest i hyväksytty ohjeisto, joka sallii epäillyn sepel valtimotautikohtauksen ensih oidon aloituksen välittömästi [78].
Ensih oitopalvelulla ja jokaisessa  terveydenhuollon toimipist eessä  tulee olla
valmiudet rekisteröidä 15–16-kytkentäinen EKG (= 12-kytkentäinen EKG + VR ja V–V) ja lähettää se vuorokaudenajasta riippu matta sähköisest i
konsultoivan lääkärin tulkittavaksi sekä mahdollisuus konsultoida suoraan reper fuusiohoidosta päättävää lääkäriä, jos EKG:n perusteella epäillään
STEMI:ä.
valmius välittömään kammiovärinän defibrillaatioon ja kammiotakykardian synkronoituun rytminsiir toon.
Hoidon ja kuljetuksen aikana EKG:tä tulee monitoroida jatkuvasti. Uusimmat monitoimimonitorit tulostavat automaattisest i uuden EKG:n,  jos EKG-johtimet
pidetään kiinnit ettyinä ja ST-tasoissa tapahtuu muutoksia. Tätä ominaisuutta kannattaa hyödyntää, jos potilaan oireet jatkuvat tai uusiutuvat.
Ensih oidon tehtävä on tapauskohtaisest i valita alueellisen hoitoonohjausohjeen mukaisest i potilaan hoitopaikka. Epäselvissä tapauksissa  hoitopaikasta
konsultoidaan alueellisessa  hoitoketjussa nimettyä konsultoivaa lääkäriä.
Jos potilaan tila ei vaadi välitöntä kuljetusta (ensih oito on tarkasti arvioinut potilaan tilan ja oireiston, todennä köisyys ja EKG puhuvat vahvasti
sepel valtimotautikohtausta vastaan tai kyseessä  on ohimenny t oireenm ukaisest i hoidettava tilanne) , tallennet tu sähköinen EKG tulisi pystyä tallentamaan
potilaan sairauskertomukseen.
Taulukko 8. Yleinen ensihoito sepelvaltimotautikohtauksessa
Välittömät hoitotoimenpiteet Potilas asetetaan lepoon hyvään asentoon ja hänelle aloitetaan jatkuva peruselintoimintojen valvonta (vakavan
verenkiertokomplikaation ja rytmihäiriöiden mahdollisuus).
Potilaan seurantaan kuuluvat kivun kirjaaminen (esim. NRS tai VAS 0–10), verenpaineen mittaus, syketaajuuden ja
happikyllästeisyyden jatkuva seuranta sekä EKG-monitorointi defibrillaattorilla rytmihäiriöiden ja ST-tason muutosten
havaitsemiseksi.
15–16-kytkentäinen EKG tulee rekisteröidä 10 minuutin sisällä potilaan kohtaamisesta tai saapumisesta vastaanotolle ja arvioida
välittömästi.
Jos potilaan oireen epäillään olevan sydänperäinen, avataan perifeerinen suoniyhteys.
Varaudutaan mahdolliseen elvytystilanteeseen.
Happi Sepelvaltimotautikohtauksessa rutiininomaista happihoitoa ei suositella potilaille, joiden veren happikyllästeisyys SpO ≥ 90 % (Vältä
viisaasti suositus ). Hapenanto voi jopa suurentaa sydäninfarktin kokoa [79], [80], [81].
Lisähapen käyttöä suositellaan, jos potilaalla on mitattu hypoksemia (SpO < 90 %), sokki tai selkeä hengitysvajaus.
Jos lisähappea annetaan, tavoitteena on SpO 94–98 % ja vaikeassa COPD:ssä 88–92 %.
Nitraatti Nitraatilla hillitään rintakipua ja akuuttia iskemiaa, mutta sen ennustetta parantavasta vaikutuksesta ei ole näyttöä.
Rintakipuiselle potilaalle annetaan 2 annosta nopeavaikutteista nitraattia, kunhan systolinen verenpaine on vähintään 100 mmHg.
Lisäannoksia voidaan antaa 5 minuutin välein verenpainetta seuraten.
Jos rintakipu jatkuu muusta hoidosta huolimatta tai potilaalla on hypertensio tai vasemman kammion vajaatoiminta (keuhkopöhö),
aloitetaan nitraatti-infuusio, jota säädetään vasteen mukaan tavoitteena potilaskohtainen normotensio.
Nitraatteihin tulee suhtautua kriittisesti, jos potilaalla on oikean kammion infarkti, vaikea aorttastenoosi tai tuore elvytyksen jälkitila.
Hypotensiovaaran takia nitraatteja tulee välttää, jos potilas on nauttinut avanafiilia, sildenafiilia tai vardenafiilia 24 tunnin sisällä tai
tadalafiilia 48 tunnin sisällä.
Asetyylisalisyylihappo (ASA) ASA on sepelvaltimotautikohtauksen peruslääke, ja sen hyöty on hyvin osoitettu.
Annos on 250–500 mg pureskellen, ellei potilaalla ole todettua yliherkkyyttä. Jos epäillään, ettei potilas pysty ottamaan lääkettä suun
kautta, sitä annostellaan korkeintaan 250 mg suonensisäisesti.
ASA kannattaa yleensä antaa, vaikka se olisi potilaan kotilääkkeenä.
Opiaatti Hyvä kivunhoito vähentää sympatikotoniaa ja vasokonstriktiota ja näiden myötä sydämen työmäärää.
Rutiininomaista opiaattien antoa tulee välttää. Opiaatit hidastavat mahalaukun tyhjenemistä, aiheuttavat pahoinvointia ja heikentävät
suun kautta otettavien antitromboottisten ja muiden lääkkeiden tehoa [82], [83], [84], [85], [86].
Kovaan kipuun morfiinin (oksikodonin) aloitusannos on 4 mg i.v. ja jatkossa 2–4 mg i.v. toistetusti 5 minuutin välein.
Nykyinen tutkimusnäyttö ei ole pystynyt osoittamaan, että jokin opiaattiryhmän lääke olisi toista turvallisempi [87].
Tulehduskipulääkkeitä ei tule käyttää kivun hoitoon.
Beetasalpaus Rutiininomainen varhainen suonensisäinen beetasalpaus ei ilmeisesti paranna ennustetta PCI-hoidetuilla STEMI-potilailla [B]. Meta-
analyyseissä [88], [89], [90] hoito hemodynaamisesti stabiileilla potilailla todettiin turvalliseksi. Lisäksi se vähensi kammioarytmioita ja
näytti parantavan infarktin jälkeistä vasemman kammion toimintaa, mutta ennustevaikutusta ei kyetty osoittamaan.
Sepelvaltimotautikohtauksessa tai sen epäilyssä varhainen beetasalpaus vaikuttaa hyödylliseltä potilaille, joilla ei ole sille vasta-aiheita
[B]. Cochrane-katsauksen [91] mukaan varhainen beetasalpaus epäillyssä tai todetussa sydäninfarktissa todennäköisesti vähentää
lyhyen aikavälin (< 3 kk) uusintainfarkteja sekä pitkän aikavälin (> 3 kk) kokonaiskuolleisuutta ja kardiovaskulaarista kuolleisuutta
verrokkiryhmään nähden. Beetasalpaus vähentää katekoliamiinien vaikutusta ja sydämen hapenkulutusta harventamalla sykettä,
laskemalla verenpainetta ja pienentämällä sydämen kontraktiliteettia [92], [93].
Varhainen beetasalpaus suurentanee kardiogeenisen sokin riskiä infarktipotilailla (STEMI/NSTEMI), joilla on epävakaa
hemodynamiikka [B]. Hoitoon tulee suhtautua kriittisesti, ellei vasemman kammion funktiosta ole tietoa [94], [95].
Jos potilas on takykardinen tai hypertensiivinen eikä hänellä ole akuuttia vajaatoimintaa, sokkia eikä johtumishäiriöitä, ensihoidon
yhteydessä voidaan ensihoitolääkärin ohjeen mukaan antaa lyhytvaikutteista beetasalpaajaa suonensisäisesti, esimerkiksi metoprololia
2,5–5 mg i.v. annoksina.
Bentsodiatsepiini Ahdistuneisuuden hoito bentsodiatsepiinilla voi vähentää hapen kulutusta sekä opiaattien määrää.
Annostelu: diatsepaami 2,5 mg i.v./loratsepaami 1 mg i.v. tarvittaessa toistetusti
Pahoinvointilääke Paras teho (opiaattipahoinvointi mukaan luettuna) on serotoniiniantagonisteilla (esim. ondansetroni 4 mg i.v.) ja droperidolilla
(DHBP 1,25 mg i.v.).
EKG:stä tulee tarkistaa QT-aika ennen annostelua.4 7 9
2
2
226.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 16/41
Kuva 13.
Sepel valtimotautikohtaus – hoitopolku
Kaavion PDF-versio «hoi50130c.pdf»
© Suomalainen Lääkäriseura Duodecim
Ensih oito päivystyspoliklinikalla
Aktiivihoidon piirissä oleva potilas, jolla epäillään sepel valtimotautikohtausta, kuuluu yhteispä ivystyksessä  erikoissairaanhoitoon.
Alkuvaiheen hoidosta ks. taulukko 8.
Aloitetaan valitun hoitomuodon mukainen veren hyytymiseen vaikuttava lääkitys. Ks. kohta Antitromboottinen lääkitys «A2».
STEMI-epäilyssä päätös reper fuusiohoitomuodon (primaari PCI vai liuotushoito) valinna sta on kiireellinen.  Ks. kohta Reper fuusiohoitomuodon valinta
STEMI:ssä «A#»
Päätös tehdään alueellisen hoitoketjun ja tarvittaessa  tilannek ohtaisest i toimenpid ekardiologin konsultaation perusteella.
Samanaikaisest i kartoitetaan mahdolliset vasta-aiheet liuotushoidolle ja muulle antitromboottiselle lääkitykselle. Ks. taulukko 9.
Ensih oito esitetään taulukoissa 8 ja 10.
Yleinen ensih oito ja valitun lääkehoidon mukainen ensih oito tapahtuvat samanaikaisest i.
Alkuvaiheen hoito perusterveydenhuollossa
Alkuvaiheen hoidosta ks. taulukko 8.
STEMI-epäilyssä on oltava suoraan yhteydessä  hoitopäätöksen tekevään lääkäriin (yleensä  päivystävä toimenpid ekardiologi) alueellisen hoitoketjun
mukaisest i.
Jos aktiivihoidon piirissä olevalla potilaalla epäillään sepel valtimotautikohtausta, hänet tulee siirtää sairaalahoitoon.
Reperfuusiohoitomuodon valinta STEMI:ssä
Jos EKG:ssä  todetaan STEMI:iin sopiva löydös, on mahdollisim man nopea reper fuusiohoito aiheellinen
Potilaan ilmoittamaan oireiden kestoon pohjautuvaa reper fuusiohoidon valintaa käsittelevät tutkimukset antavat ristiriitaisia tuloksia [A].
EKG:llä arvioitu iskemian kesto on ilmeisest i potilaan ilmoittamaa oireiden kestoa parempi kriteeri valittaessa  reper fuusiohoitoa [B].
Primaari PCI
STEMI-potilaan ensisij ainen hoito on primaari PCI (välitön pallolaajennu s).
Primaari PCI -hoitoon menev ä STEMI-potilas kuljetetaan suoraan toimenpid esaliin.
Antikoagulanttia käyttävillä potilailla primaari PCI on aina ensisij ainen.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 17/41
Jos potilaalla epäillään taudinkuvan perusteella akuuttia STEMI:ä mutta hänellä on EKG:ssa  haarakatkos tai tahdistettu rytmi, tulisi ensisij aisest i pyrkiä
välittömään sepel valtimoiden varjoainek uvaukseen.
Primaari PCI vähentää STEMI-potilaiden kuolleisuutta ja uusintainfarkteja sairaalassa toteutettuun liuotushoitoon nähden [A].
Primaari PCI saattaa vähentää kuolleisuutta, uusintainfarkteja ja uuden sydäninfarktin aiheuttamia sairaalahoitojaksoja verrattuna tapahtumapaikalla
annet tuun liuotushoitoon [C].
Primaari PCI tulisi voida tehdä alle 120 minuutin kuluessa  ensim mäisest ä hoitokontaktista. Muussa tapauksessa  tulee harkita liuotushoidon antamista.
Uhkaavassa etuseinä infarktissa tulee harkita liuotushoidon antamista, ellei PCI:tä ole mahdollista tehdä 90 minuutin kuluessa  ensim mäisest ä kontaktista.
Hyvin organiso idussa järjestelmässä eivät päivystysaikana tehtävien toimenpit eiden hoitotulokset ole huonompia kuin päiväsaikaan [96].
Liuotushoito
Lääkkeellinen liuotus on toissijainen hoitomuoto, jos primaari PCI ei ole järjestettävissä riittävän nopeasti.
Liuotushoito tulisi aloittaa 10 minuutin kuluessa  STEMI-diagnoosista [97].
Kohteessa  annet tu liuotushoito vähentää kuolleisuutta sairaalassa annet tuun liuotushoitoon verrattuna [A].
Liuotushoito voidaan antaa 12 tuntiin asti oireiden alusta, jos primaari PCI:tä ei saada järjestettyä, mutta liuotushoito menet tää tehoaan selvästi 3 tunnin
jälkeen oireiden alusta [68], [98].
Yli 12 tunnin päästä kivun alkamisest a hoitoon tulevat STEMI-potilaat eivät hyödy liuotushoidosta, vaan se voi päinvastoin olla heille haitallista verenvuotojen
lisääntymisen vuoksi [98], [99], [100].
Liuotushoito toteutetaan tenek teplaasilla tai reteplaasilla. Ks. annostelu taulukosta 10 ja vasta-aiheet taulukosta 9.
Liuotushoidon jälkeen potilas tulee kuljettaa suoraan yksikköön, jossa on valmius välittömään invasiiviseen tutkimukseen.
Liuotushoidon teho arvioidaan EKG:n ja oireiden avulla. Pelaste- eli rescu e-PCI on aiheellinen,  jos vaikuttaa, ettei liuotushoito ole tehonnut.
Seuranta-EKG tulee rekisteröidä viimeistään 60 minuutin kohdalla liuotushoidon alkamisest a.
Tarvittaessa  rekisteröinti voidaan tehdä jo aiemmin, jotta pelaste-PCI voidaan järjestää viipymättä.
Rintakivun häviäminen ei luotettavasti kuvaa hoidon tehoa [101].
ST-nousun korjaantumisella arvioidaan liuotushoidon tehoa, vaikkei se ole täysin luotettava mittari.
Ellei ST-nousu kytkennä ssä, jossa alun perin oli suurin muutos, ole 60 minuutin kuluttua liuotushoidon aloittamisest a laskenut yli 50 %, infarktin
aiheuttanut suoni on todennä köisest i edelleen tukossa tai ainakin kudostason hiussuonien virtaus on huono [102].
Uudesta liuotushoidosta ei ole hyötyä, vaan tällöin tulee mahdollisim man nopeasti suorittaa sepel valtimoiden varjoainek uvaus ja pallolaajennu s
(pelaste-PCI).
Liuotushoidon yhteydessä  annet tava muu antitromboottinen hoito esitetään taulukossa 11.
Liuotushoidossa potilaalle annet aan sekä verihiutale-estäjiä (kaikille ASA ja ADP-resept orin salpaaja klopidogreeli) että antikoagulanttia (joko
enoksapariini tai fondaparinuuksi) ja fibrinolyytti eli liuotuslääke.
Jos potilas on jo saanut prasugreeli- tai tikagrelorilatauksen, liuotushoitoa ei tule antaa kuin vitaali-indikaatiolla (elvytys tai kardiogeeninen sokki).
Erityisest i iäkkäillä ja verenvuotovaaran potilailla ensisij ainen hoitomuoto on välitön PCI.
Jos liuotushoitoon päädytään, yli 75-vuotiaille tulee harkita puolikasta tenek teplaasiannosta kallonsisä isen verenvuodon riskin vähentämiseksi [97].
Tehonneen liuotushoidon jälkeen suoritetaan 2–24 tunnin kuluessa  sepel valtimoiden varjoainek uvaus [68].
Taulukko 9. Liuotushoidon vasta-aiheet
Ehdottomat vasta-aiheet Todettu verenvuototaipumus (hyytymishäiriö, trombosytopenia ym.)
Merkittävä trauma, pään vamma tai suuri leikkaus 3 edellisen viikon aikana tai neurokirurginen leikkaus edellisen
kuukauden aikana
Aiempi aivoverenvuoto ajankohdasta riippumatta
Aivoinfarkti tai hoidettu SAV 6 edellisen kuukauden aikana
Aivokasvain, AV-malformaatio, hoitamaton aivoverisuonen aneurysma
Ruoansulatuskanavan verenvuoto edellisen kuukauden aikana
Perusteltu epäily aortan dissekaatiosta
Tuoreet punktiot, joita ei voida komprimoida (esim. maksabiopsia tai lannepisto)
Suhteelliset vasta-aiheet
(varovaisuutta ja harkintaa noudatettava)TIA edellisten 6 kuukauden aikana
Verenpaine edelleen yli 180/110 mmHg asianmukaisen lääkityksen jälkeen
Antikoagulanttilääkitys hoitoannoksin (esim. apiksabaani, dabigatraani, edoksabaani, rivaroksabaani, varfariini)
Prasugreeli- tai tikagrelorihoito, erityisesti juuri latausannoksen saaneella
Aktiivinen maha- tai pohjukaissuolen haavauma
Pitkälle edennyt maksasairaus (maksakirroosi, portahypertensio)
Raskaus tai synnytys edeltävän viikon aikana
Infektiivinen endokardiitti
Aktiivinen syöpäsairaus
Taulukko 10. Liuotushoidon toteutus
Reteplaasi Tenekteplaasi
Reteplaasia annostellaan 10 yksikköä x 2 siten, että bolusten väli on 30
minuuttia.Tenekteplaasia annostellaan painon mukaan yhtenä boluksena seuraavasti. Yli 75-vuotiaille
suositellaan 50 %:n annosta [97].
paino (kg) annos (mg)
< 60 30
60–69 35
70–79 40
80–89 4526.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 18/41
Reteplaasi Tenekteplaasi
≥ 90 50
Akuuttivaihe sairaalassa
Sepel valtimotautikohtauspotilaiden jatkohoitopaikka määräytyy ensih oidossa tai ensia vussa tehtävän vaaran arvion perusteella.
STEMI-potilaat kuljetetaan suoraan toimenpid esaliin ja toimenpit een jälkeen sydänvalvontaan.
Valvontatasoinen hoito on tarpeen potilailla, joilla on jatkuva tai laaja-alainen iskemia tai epävakaa hemodynamiikka.
Jatkuvaa EKG:n monitorointia tarvitaan STEMI-potilaalla vähintään 48 tunnin ajan ja NSTEMI-potilaalla ainakin varjoainek uvaukseen asti.
Invasiivinen verenpa ineen monitorointi on tarpeen vain, jos potilas on hemodynaamisest i epävakaa tai happeu tuminen on heikentynyt.
Keuhkovaltimokatetrin asettamista harkitaan yksilökohtaisest i kardiogeenisessa  sokissa. Sen rutiinino maista käyttöä ei suositella [103].
Kardiogeeninen sokki
Kardiogeeninen sokki on sydämen vajaatoiminna n ääritilanne,  jossa sydämen minuuttitilavuuden pienent yminen aiheuttaa kudosper fuusion merkittävän
heikkenem isen.
Potilas voi olla takykardinen,  hypotensiiv inen ja sekava. Hengitystaajuus on suurentunut, periferia on viileä ja voidaan todeta hypoksia.
Esiint yvyys sydäninfarktin yhteydessä  on 5–10 % [104].
Alkuvaiheessa  kuolleisuus on 40–50 % [105].
Valtaosalla potilaista on monen suonen sepel valtimotauti tai vasemman päärungon akuutti ahtauma.
PCI lienee ensisij ainen revaskularisaatiomuoto, jos sillä saadaan nopeasti riittävän laaja-alainen revaskularisaatio.
Vaikeassa monisu onitaudissa välitön ohitusleikkaus voi olla tarpeen [106].
Muita syitä voivat olla suuri sydänlihasvaurio, iskemian aiheuttama laaja-alainen sydänlihaksen herpaantuminen tai rakennek omplikaatio, kuten
nystylihaksen, kammioväliseinä män tai kammion vapaan seinä män repeä mä.
Jos syynä on rakennek omplikaatio, nopea diagnoosi ja operatiivinen hoito ovat välttämättömiä.
Hemodynamiikka optimoidaan lääkkein ja tarvittaessa  mekaanisia  tukihoitoja käyttäen.
Levosimendaanin hyödystä ennu steeseen kardiogeenisen sokin hoidossa ei ole näyttöä, mutta se vaikuttaa parantavan hemodynamiikkaa [107].
Mekaanisten tukihoitojen hyödystä kardiogeenisen sokin hoidosta ei ole kattavaa tutkimusnäyttöä, mutta käyttöä voidaan harkita erityistilanteissa , kuten
PCI:n aikana [104].
Aortan vastapulsaattorin käyttö ei vähentänyt kuolleisuutta sydäninfarktista johtuvassa kardiogeenisessa  sokissa [108].
Impella (= väliaikaiseen hoitoon tarkoitettu, pien ikokoinen sydämen apupumppu) vähentää vasemman kammion jälkikuormaa ja lisää
minuuttivirtausta. Sen käytöstä kardiogeenisen sokin hoidossa ei ole vielä näyttöä.
VA-ECMO:sta (= ExtraCorporeal Membrane Oxygenation, kehonulkoinen hapetus) ei ole vielä satunnaistettua tutkimusnäyttöä kardiogeenisen sokin
hoidossa, mutta tutkimuksia aiheesta on meneil lään. Maailmanlaajuisen ECMO-hoidon rekisterin viimeisim män raportin mukaan kaikista
kardiogeenisist a sokkipotilaista, jotka päätyivät ECMO-hoitoon, kotiutui 42 % [109].
Antitromboottinen lääkehoito
Koska erilaisia antitromboottisten lääkkeiden mahdollisia yhdistelmiä on useampia, lääkkeiden käytöstä tulee olla alueelliset ohjeet.
Lääkitys tulee räätälöidä potilaskohtaisesti erityisest i vanhuksilla, munuaisten vajaatoimintaa sairastavilla sekä potilailla, joilla on suurentunut verenvuoto- tai
tromboosiriski.
STEMI-potilaille, joille valitaan hoitomuodoksi primaari PCI, tehokas antitromboottinen hoito aloitetaan välittömästi lääkärin tehtyä diagnoosin ja
hoitopäätöksen EKG:n perusteella ensik ontaktin yhteydessä .
NSTEMI:ssä tai UAP:ssa antitromboottisen lääkityksen laajuus, erityisest i ADP-resept orin salpaajan käyttö, riippu u diagnoosista, potilaan vaaran arvioinnist a,
sepel valtimoiden varjoainek uvaukseen pääsyn nopeudesta ja potilaan yksilöllisest ä verenvuotovaarasta.
Päätös ADP-resept orin salpaajan aloituksesta tehdään pääsääntöisest i vasta sepe lvaltimoiden varjoainek uvauksen löydösten perusteella.
Mikäli näyttää todennä köiseltä, että sepe lvaltimoiden varjoainek uvausta ei ole mahdollista järjestää suurimman vaaran potilaille vuorokauden sisällä, tulee
ADP-resept orin salpaajan aloitusta harkita jo ennen toimenpid että NSTEMI-potilaille.
Antitromboottisen lääkityksen annostus eri tilanteissa  esitetään taulukoissa 12, 11, 13.
Potilailla, jotka ovat suuressa  uuden sepe lvaltimotautikohtauksen vaarassa, tulee harkita pitkäkestoista antitromboottista yhdistelmähoitoa. Ks. kappale
Pitkäkestoinen antitromboottinen lääkitys «A4» ja taulukko 18.
Asetyylisalisyylihappo (ASA)
Asetyylisalisyylihapon (ASAn) käyttö aloitetaan heti aina, kun epäillään sepel valtimotautikohtausta, eikä potilaan ole osoitettu olevan sille yliherkkä [A].
Latausannos on 250–500 mg suun kautta tai 250 mg suonensisä isest i. Annos on sama myös antikoagulaatiohoitoa käyttäville.
ASAa pitkäaikaisest i käyttäville potilaille kannattanee antaa latausannos sepel valtimotautikohtauksen yhteydessä .
ASAlle allergisille potilaille aloitetaan pelkkä ADP-resept orin salpaaja, mieluiten prasugreeli tai tikagrelori mahdollisen klopidogreeliresist enssin vuoksi.
Klopidogreelin käyttöä ainoana hoitona ei suositella [110].
Akuuttivaiheen antikoagulaatiohoito
Antikoagulaatiolääkitys liitetään ASA-lääkitykseen kaikilla potilailla, joiden työdiagnoosina  on sepel valtimotautikohtaus.
Primaari PCI:llä hoidetuilla STEMI-potilailla enoksapariini lienee yhtä turvallinen ja vähintään yhtä tehokas estämään päätetapahtumia kuin fraktioimaton
hepariini [B].
Fondaparinuuksia ei suositella STEMI:n yhteydessä  [111].
NSTEMI-potilailla pienim olekyylisten hepariinien ryhmässä enoksapariinist a on hyvä tutkimusnäyttö [112], [113], [114], [115].
Daltepariinilla ja tintsapariinilla tutkimusnäyttöä on vähemmän tässä tilanteessa .
NSTEMI- ja UAP-potilailla voidaan pien imolekyylisen hepariinin sijasta vaihtoehtoisest i käyttää myös fondaparinuuksia [116], [B].
Alkuperäisen enoksapariinin biosimilaareilla ei ole julkaistu merkittäviä tutkimuksia sepel valtimotautikohtauksen yhteydessä , mutta käytännössä ei ole
havaittu niiden olevan alkuperäistä tehottomampia.
Enoksapariinin voi yleensä  lopettaa PCI-hoitoon, ellei sen jatkamiseen ole muuta syytä.
STEMI:ssä ensim mäinen annos enoksapariinia  tai fraktioimatonta hepariinia  annetaan suonensisä isest i heti diagnoosin asettamisen jälkeen.  Ks. taulukko 11.
Alkuannos paikallisen hoito-ohjeistuksen mukaisest i ja lisäannos PCI:n yhteydessä  toimenpid elääkärin ohjeistuksen mukaisest i.®26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 19/41
Jos NSTEMI-potilaan tiedetään olevan verenvuotovaarassa ennen lääkityksen aloittamista, on syytä odottaa, kunnes laboratoriokokeiden vastaukset on saatu.
Jos NSTEMI- tai UAP-potilaalla on käytössä oraalinen antikoagulantti, parenteraalista antikoagulanttia ei annet a ennen varjoainek uvausta.
Jos varfariinia  käyttävällä potilaalla INR on alle 2, harkitaan parenteraalisen antikoagulantin aloitusta.
Peroraalista antikoagulanttia jatketaan tauotta [117], [118], [119], [120].
PCI:n yhteydessä  antikoagulanttia käyttäville potilaille on annet tava joko enoksapariinia  tai hepariinia  suonensisä isest i [121].
Lisäannos enoksapariinia  PCI:n yhteydessä on yleensä  0,3–0,5 mg/kg i.v.
Bivalirudiinin (suora lyhytvaikutteinen infusoitava trombiininest äjä) rutiinino maista aloittamista ei voida suositella, koska satunnaistetun tutkimuksen ja
laajan meta-analyysin perusteella se ei ole hepariinia  parempi antikoagulantti sepel valtimotautikohtauspotilaalle [122], [123].
Bivalirudiinia  voidaan harkita suuren verenvuotovaaran potilaille, kun antikoagulaatiohoidon vaikutus halutaan minim oida pallolaajennu ksen jälkeen.
Suorien antikoagulanttien annostukset PCI:n jälkeen kuvataan taulukossa 13.
Taulukko 11. Antitromboottisen lääkityksen vaihtoehdot STEMI:ssä
Lääke STEMI, primaari PCI STEMI, liuotushoito
Ei AK-hoitoa AK-hoito < 75-vuotias ≥ 75-vuotias AK-hoito
ASA 250–500 mg p.o. (tai 250 mg i.v.), jos ei allergiaa
Antikoagulantti
Enoksapariini Yleensä enintään 0,6
mg/kg i.v.Yleensä enintään 0,5
mg/kg i.v. vasta
toimenpidesalissaBolus 30 mg i.v.
ja 15 min kuluttua
liuotushoidosta
1 mg/kg s.c.
Tarvittaessa lisäannos
toimenpidesalissaEnsisijaisesti primaari PCI
Ei bolusta ennen
liuotushoitoa. 15 minuutin
kuluttua liuotushoidosta
0,75 mg/kg s.c.
Tarvittaessa lisäannos
toimenpidesalissaEnsisijaisesti primaari PCI
Fraktioimaton hepariini (UFH) 70–100 IU/kg i.v. 70–100 IU/kg i.v. vasta
toimenpidesalissaEi Ei Ei
Fondaparinuuksi* Ei Ei 2,5 mg i.v.* Ei Ensisijaisesti primaari PCI
ADP-reseptorin salpaaja
Klopidogreeli 600 mg p.o. 600 mg p.o. 300 mg p.o. 75 mg p.o. [B] Ensisijaisesti primaari PCI
Prasugreeli 60 mg p.o. 60 mg p.o. Ei Ei Ensisijaisesti primaari PCI
Tikagrelori 180 mg p.o. 180 mg p.o. Ei Ei Ensisijaisesti primaari PCI
Fibrinolyytti eli liuotuslääke Ei Ei Ohjeen mukaan 50 %, jos tenekteplaasi** Ensisijaisesti primaari PCI
Antitromboottinen lääkitys STEMI:ssä. Liuotushoito toteutetaan tenekteplaasilla tai reteplaasilla, ja sitä tulee harkita, jos primaari PCI:tä ei pystytä järjestämään alle 2 tunnin
kuluessa (tai alle 1,5 tunnissa etuseinäinfarktissa).
** Yli 75-vuotiailla tulee harkita puolikasta tenekteplaasiannosta, joka vähentää selvästi kallonsisäisen verenvuodon riskiä.
Jos potilas on jo saanut prasugreeli- tai tikagrelorilatauksen, liuotushoitoa ei tulisi antaa kuin vitaali-indikaatiolla (elvytys tai kardiogeeninen sokki).
Antikoagulanttia käyttäville potilaille suositellaan primaari PCI:tä STEMI-tilanteessa.
Sepelvaltimoiden varjoainekuvauksen tai PCI:n yhteydessä annetaan lisäantikoagulaatio i.v. (esim. UFH) kaikille antikoagulantteja käyttäville potilaille. Enoksapariinin tilalla
voidaan harkita fraktioimatonta hepariinia annoksella 70–100 IU/kg i.v.
Fondaparinuuksia ei suositella primaari PCI:n yhteydessä.
*Fondaparinuuksi aloitetaan annoksella 2,5 mg x 1 s.c. 24 tunnin kuluttua liuotushoidosta ja sitä jatketaan sairaalassaolon ajan.
p.o. = suun kautta
i.v. = suonensisäisesti
s.c. = ihonalaisesti
Taulukko 12. Antitromboottisen lääkityksen vaihtoehdot NSTEMI:ssä
Lääke Aloitusannos Jatkohoito
≤ 75-vuotias > 75-vuotias tai eGFR  < 30 AK-hoito
ASA 250–500 mg p.o. (tai 250 mg i.v.), jos ei allergiaa 100 mg x 1 p.o.
Antikoagulantti
Enoksapariini 1 mg/kg s.c. 0,75 mg/kg s.c. Ei, jos INR hoitotasolla tai ei tiedossa
tai suora antikoagulantti käytössä0,75–1 mg/kg x 2 s.c.,
yleensä voidaan lopettaa PCI:n
jälkeen
Fraktioimaton hepariini (UFH) 70–100 IU/kg i.v. 70–100 IU/kg i.v. Ei -
Fondaparinuuksi* 2,5 mg s.c. 2,5 mg s.c. Ei, jos INR hoitotasolla tai ei tiedossa
tai suora antikoagulantti käytössä2,5 mg x 1 s.c.
ADP-reseptorin salpaaja**
Klopidogreeli 600 mg p.o. 600 mg p.o. Vain harkinnanvaraisesti 75 mg x 1 p.o.
Prasugreeli 60 mg p.o. 60 mg p.o. Ei 10 mg x 1 p.o.
(5 mg x 1 p.o., jos > 75-vuotias
tai < 60 kg)
Tikagrelori 180 mg p.o. 180 mg p.o. Vain harkinnanvaraisesti 90 mg x 2 p.o.
* PCI:n yhteydessä on annettava 70–100 IU/kg fraktioimatonta hepariinia, kun käytetään fondaparinuuksia.
** ADP-reseptorin salpaajaa ei yleensä suositella aloitettavaksi ennen varjoainekuvausta. Aloitusta voidaan harkita, jos sepelvaltimoiden varjoainekuvaus ei onnistu 24 tunnin
aikana.
Enoksapariini ja fondaparinuuksi voidaan yleensä lopettaa PCI:n jälkeen, jos lääkitykselle ei ole muuta indikaatiota.
p.o. = suun kautta
i.v. = suonensisäisesti
s.c. = ihonalaisesti
Taulukko 13. Antikoagulanttien annokset sepelvaltimotoimenpiteen jälkeen. Ks. tarvittaessa tarkemmin valmisteyhteenvedoista.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 20/41
Lääke
(viite)Normaali
annos
PCI:n jälkeenRedusoitu
annos
PCI:n jälkeenTilanteet, jolloin käytetään redusoitua annosta,
ja muut huomiot
Apiksabaani
[119]5 mg x 2 2,5 mg x 2 eGFR 15–29 tai kaksi kolmesta seuraavasta:
ikä ≥ 80 vuotta
paino ≤ 60 kg
Krea ≥133
Dabigatraani
[118]150 mg x 2 110 mg x 2 ikä ≥ 80 vuotta tai verapamiili käytössä, lisäksi
harkinnan mukaan, jos
ikä 75–80-vuotta,
eGFR 30–50
Edoksabaani
[120]60 mg x 1 30 mg x 1 eGFR 15–50 tai
paino < 60 kg tai P-glykoproteiinin (P-gp:n) estäjä
(siklosporiini, dronedaroni, erytromysiini,
ketokonatsoli) käytössä
Rivaroksabaani
[117]20 mg x 1 15 mg x 1 eGFR 15–49*
Varfariini INR aiemman tavoitteen mukaan
(yleensä 2–3)INR aiemman tavoitteen mukaan
(yleensä 2–3)Mekaaninen tekoläppä, mitraalistenoosi, vasemman
kammion trombi, hyytymishäiriö tai muu erityinen syy
ADP-resept orin salpaajat
Ryhmän lääkkeissä  vaihtoehtoina ovat suun kautta annosteltavat klopidogreeli, prasugreeli ja tikagrelori ja suonensisä isest i annosteltava kangrelori.
ADP-resept orin salpaajien keskinäiset erot ovat melko vähäiset. Tärkeintä on, että potilas käyttää jotain näistä suunnit ellun ajan.
Merkittävimmät erot ovat vaikutuksen alkamisen nopeudessa  (prasugreeli ja tikagrelori noin ½–2 tuntia vs. klopidogreeli noin 3–6 tuntia annoksen mukaan).
Prasugreeli ja tikagrelori estävät klopidogreelia tehokkaammin sydäninfarkteja ja stenttitrombooseja mutta aiheuttavat enem män verenvuotoja etenkin
iäkkäillä ja verenvuotovaarassa olevilla potilailla [124], [125], [126].
Prasugreelia ja tikagreloria on verrattu keskenään 2 satunnaistetussa tutkimuksessa , mutta niissä  saadut tulokset ovat keskenään ristiriitaiset, eikä ole vielä
varmaa näyttöä, että toinen olisi toista parempi [127], [128], [129], [130], [131].
ADP-resept orin salpaaja aloitetaan STEMI-potilaalle välittömästi, kun hoitomuodoksi on valittu primaari PCI.
STEMI:ssä on syytä käyttää ensisij aisest i joko prasugreelia tai tikagreloria.
NSTEMI-potilaalle ADP-resept orin salpaaja aloitetaan ennen varjoainek uvausta vain, jos varjoainek uvausta ei ole mahdollista järjestää 24 tunnin kuluessa
sairaalaan tulosta [129].
Ennen varjoainek uvausta annet un ADP-resept orin salpaajan on todettu lisäävän verenvuotovaaraa vähentämättä iskeem isiä tapahtumia [129], [132], [133].
Jos varjoainek uvaus ei ole mahdollinen 24 tunnin kuluessa , ADP-resept orin salpaajan aloittamista tulee kuitenkin harkita, jos verenvuotovaara
arvioidaan pienek si ja sepel valtimotautikohtaus on todennä köinen.
Erityisest i antikoagulaatiolääkitystä käyttävät potilaat tulee pyrkiä kuvaamaan 24 tunnin kuluessa . Tällöin antikoagulantin lisänä käytetään vain ASAa,
kunnes sepel valtimoiden anatomia on tiedossa.
Globaalissa iskemiassa ei suositella ADP-resept orin salpaajan lataamista ennen varjoainek uvausta.
Epäselvissä tapauksissa  on syytä konsultoida paikallisen hoitoketjun mukaisest i kardiologia.
ADP-resept orin salpaajalääkityksen kesto on yleensä  12 kuukautta.
Suuren verenvuotovaaran potilailla hoidon kesto suunnit ellaan yksilöllisest i ja kestoa lyhennet ään (ks. kohta Verenvuotovaara «A5»).
Stentin asettamisen jälkeen antitromboottista lääkitystä ei saa yleensä  tauottaa kokonaan ensim mäisen 1–3 kuukauden aikana muutoin kuin henkeä
uhkaavan verenvuodon takia.
Ensim mäisen kuukauden aikana kaksoisverihiutale-estäjähoidon (ADP-resept orin salpaaja + ASA) tauotus suurentaa stenttitromboosin riskin jopa
monikymmenkertaiseksi [134].
Toimenpid ekardiologia on syytä konsultoida tauotuksesta ja lääkityksen uudelleen jatkamisest a
Uudenaikaisia lääkestenttejä käytettäessä  ensim mäisen kuukauden jälkeen jatkaminen yhdellä verihiutale-estäjällä näyttää turvalliselta [135], [136].
Jos ADP-resept orin salpaaja joudutaan vaihtamaan toiseen valmisteeseen kesken hoidon, annet aan uuden lääkkeen latausannos.
Lääkevaihdon toteutuksesta ja aikataulusta on olemassa hyvä kansainvälinen katsaus [137].
Klopidogreeli
Klopidogreelin latausannos on 600 mg suun kautta [B].
Klopidogreelia jatketaan annoksella 75 mg kerran päivässä.
Klopidogreelia voidaan käyttää sepel valtimotautikohtauksen hoitoon, jos potilaan verenvuotovaara arvioidaan suurentuneek si, kuten antikoagulanttia
käyttävillä tai iäkkäillä potilailla.
Antikoagulanttia käyttävillä potilailla klopidogreelista on enem män tutkimustietoa kuin tikagrelorista [117], [118], [119], [120], [138].
Suuressa  rekisteritutkimuksessa  klopidogreelin käyttö yli 80-vuotiailla sepel valtimotautikohtauspotilailla liittyi vähäisem pään verenvuotovaaraan ja
kuolleisuuteen verrattuna tikagreloriin [139].
Satunnaistetussa tutkimuksessa  klopidogreeli vähensi merkittäviä verenvuotokomplikaatioita yli 70-vuotiailla 29 % vuoden aikana verrattuna tikagreloriin
tai prasugreeliin NSTEMI-potilailla (95 % potilaista oli tikagrelorihoidolla) ilman iskeem isten tapahtumien riskin kasvua [126].
Klopidogreelin aktivoituminen elimistössä voi olla puutteellista potilailla, joilla on CYP 2C19-geenin tietty variantti, mutta siitä huolimatta rutiinino mainen
trombosyyttifunktion mittaaminen tai CYP 2C19-geeniv ariantin määritys ei ole aiheellista [140].
Prasu greeli
Prasugreelin latausannos on 60 mg suun kautta.
Prasugreelia jatketaan annoksella 10 mg kerran päivässä.
Yli 75-vuotiailla ja alle 60 kg painavilla ylläpitoannos on 5 mg kerran päivässä.
Jos potilaalla on käytössä antikoagulaatiohoito, prasugreelia ei suositella.
Jos potilas on sairastanut aivoverenvuodon tai iskeem isen aivoverenkiertohäiriön, prasugreeli on vasta-aiheinen [124].
Välittömällä pallolaajennu ksella hoidetuilla STEMI-potilailla prasugreeli latausannoksella 60 mg lienee yhtä tehokas kuin klopidogreeli latausannoksella 300
mg [B].26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 21/41
UAP- ja NSTEMI-tilanteessa  prasugreeli aloitetaan vasta varjoainek uvauksen yhteydessä  juuri ennen PCI:tä [124], [129].
Prasugreelin aloitus ennen varjoainek uvausta puolitetulla latausannoksella (30 mg) ei vähentänyt iskeem isiä tapahtumia mutta lisäsi verenvuotoja [132].
Konser vatiivisest i hoidetuilla potilailla tehdyssä tutkimuksessa  prasugreeli ei ollut klopidogreelia tehokkaampi ja se lisäsi potilaiden verenvuotovaaraa [141].
Tikagrelori
Tikagrelorin latausannos on 180 mg suun kautta.
Tikagreloria jatketaan annoksella 90 mg kaksi kertaa päivässä.
Tikagrelori lienee yhtä tehokas kuin klopidogreeli päätetapahtumien estossa välittömällä pallolaajennu ksella hoidetuilla ST-nousuinfarktipotilailla [B].
Tikagrelorilla verenvuotovaara on hieman suurempi kuin klopidogreelilla [125].
Sepel valtimotautikohtauspotilaalla voidaan harkita 3 kuukauden jälkeen jatkaa turvallisest i pelkällä tikagrelorilla 12 kuukauteen saakka ilman ASAa [142], [143].
Merkittävät verenvuodot vähentyivät 1 vuoden kohdalla 44 % (NNT = 32).
Iskeem isissä  tapahtumissa ei ollut ryhmien välillä merkitsevää eroa [142].
Kangrelori
Kangrelori on infusoitava reversiibeli ADP-resept orin salpaaja, jota voidaan käyttää PCI:n yhteydessä  ja 4 tuntia sen jälkeen.
Suuressa  meta-analyysissa  kangrelori vähensi klopidogreeliin verrattuna yhdistelmäpäätetapahtumia (kuolema, sydäninfarkti, uusi revaskularisaatio tai
stenttitrombi, NNT = 111) PCI:n yhteydessä kroonista sepel valtimotautia tai sepel valtimotautikohtausta sairastavilla [144].
Kangrelori-infuusiota tulee harkita PCI:n yhteydessä , ellei potilas ole saanut luotettavasti ADP-resept orin salpaajaa suun kautta (esim . elvytetyt tai
oksent elevat potilaat).
Tikagrelorin latausannos voidaan antaa kangrelori-infuusion aikana heti, kun se on mahdollista. Klopidogreeli tai prasugreeli suositellaan annet tavaksi vasta
infuusion lopettamisen yhteydessä  lääkkeiden ristireaktion vuoksi.
Infusoitavat adjuvanttilääkkeet
Rutiinino maisest i käytetystä glykoproteiini IIb/IIIa:n estäjästä ei ole hyötyä verrattuna lääkkeen selektiiviseen aloitukseen sepel valtimoiden
varjoainek uvauksen yhteydessä  [145], [146].
Lääkityksen rutiinino mainen aloitus lisää merkittävästi verenvuotovaaraa.
Kliinisessä  käytössä on kaksi suonensisä isest i annosteltavaa tämän ryhmän lääkettä. Ks. lisätietoa aiheesta .
Käytännön työssä lääkkeen aloitusta voidaan harkita sepel valtimoiden varjoainek uvauksen yhteydessä , jos sepel valtimossa havaitaan hyytymää ja
verenvuotovaaran ei arvioida ylittävän mahdollista hyötyä. Erityistä varovaisuutta tulee verenvuotovaaran takia noudattaa elvytetyillä, iäkkäillä,
antikoagulaatiohoitoa käyttävillä potilailla ja tapauksissa , joissa toimenpid ereittinä on nivusvaltimo.
Glykoproteiini IIb/IIIa:n estäjiä ei ole tutkittu satunnaistetuissa tutkimuksissa  yhdessä  prasugreelin tai tikagrelorin kanssa  käytettynä.
Kangrelorin osalta ks. edellinen kappale.
Invasiivin en arvio ja revaskularisaatio
Sepel valtimoiden varjoainek uvauksella varmistetaan sepel valtimotaudin diagnoosi ja vaikeusaste sekä arvioidaan revaskularisaation tarve.
Sepel valtimoiden varjoainek uvauksella voidaan yleensä  todeta kohtauksen aiheuttanut suonimuutos ("culprit-leesio ") tarvittaessa  suonensisä isiä
kuvantamistekniikoita käyttäen.
Epäillyn sepel valtimotautikohtauksen vuoksi sairaalaan otetuista potilaista 8–19 %:lla ei todeta varjoainek uvauksessa  merkittäviä sepel valtimoahtaumia [10],
[147].
Erityisen suuren vaaran ja suuren vaaran sepel valtimotautikohtauspotilaiden varhainen varjoainek uvaus ja revaskularisaatio yhdistettynä riittävään
antitromboottiseen hoitoon vähentävät vakavia sydäntapahtumia (kuolema, sydäninfarkti) konser vatiiviseen hoitoon verrattuna [148] [149], [150], [151].
STEMI-potilaille välitön lääke- ja toimenpidehoito on ennu steen kannalta elintärkeää.
NSTEMI-potilailla sepel valtimoiden varjoainek uvaukseen tulee pyrkiä sairaalahoidon aikana mahdollisim man pikaisest i [A]:
Erityisen suuren vaaran potilailla tutkimus on syytä tehdä 2 tunnin kuluessa  [A].
Suuren vaaran potilailla tutkimus on syytä tehdä 24 tunnin kuluessa  [A].
Jos potilas on oireeton ja vakaa, tutkimus voidaan tehdä myöhemminkin, mutta viimeistään alle 72 tunnissa  [A]. Tällöin tulee harkita ADP-resept orin
salpaajan aloitusta jo odotusajaksi.
Pienen vaaran UAP-potilaiden lyhyen aikavälin ennu ste on hyvä, eikä siihen voida vaikuttaa välittömällä varjoainek uvauksella [A].
Sepel valtimotautikohtauksen saaneid en vaara meneh tyä tai kokea sydänper äinen haittatapahtuma on suurin ensim mäisten päivien aikana kohtauksen jälkeen.
Varjoainek uvauksen kiireellisyydestä ks. taulukko 14.
Revaskularisaatiohoidon (PCI, ohitusleikkaus) tavoitteena  on
parantaa potilaan ennu stetta
estää iskemian aiheuttamia komplikaatioita
lievittää rintakipuoireita
parantaa suorituskykyä.
Satunnaistettuja tutkimuksia, joissa olisi verrattu ohitusleikkausta ja PCI:tä sepel valtimotautikohtaukseen sairastuneilla potilailla, ei ole tehty.
Käytännön työssä revaskularisaatiomenetelmä valitaan sepel valtimotautikohtauksen saaneilla samoilla periaatteilla kuin kroonisen vakaaoireisen
sepel valtimotaudin yhteydessä  [152].
Hoitokäytäntöihin ja revaskularisaatiomenet elmän valintaan vaikuttavat
sepel valtimotaudin vaikeusaste ja sepel valtimoiden anatomia (esim . SYNTAX score)
toimenpit eeseen liittyvät tekniset  näkökohdat
liitännäissairaudet
PCI:hin jälkeen tarvittaviin antitromboottisiin lääkkeisiin liittyvä verenvuotovaara
hoitomyöntyvyys
potilaan mielipide hoitovaihtoehdoista hänelle annet un informaation jälkeen.
Hoitopäätös tehdään tarvittaessa  kardiologin ja sydänkirurgin yhteistyönä.
Tapauskohtaisest i neuvotellaan muiden erikoisalojen edustajien kanssa  (Heart Team). Tämän toteuttamiseksi tulee olla mahdollisuus siirtää
varjoainek uvauksen kuvatiedostot viiveettä Heart Teamin nähtäväksi.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 22/41
Taulukko 14. Varjoainekuvauksen kiireellisyys.
Välitön Erittäin kiireellinen
(< 2 tuntia)Kiireellinen, ensimmäisen
vuorokauden aikana
(< 24 tuntia)Kiireellinen, samalla hoitojaksolla
(< 72 tuntia)
EKG ST-nousu tai sellainen oire ja
EKG-muutos, jonka taustalta
sepelvaltimon tukosta ei voida
sulkea poisGlobaali-iskemia ST-lasku, T-inversio Normaali
Hemodynamiikka ja
ultraäänilöydösKardiogeeninen sokki Epävakaa, akuutti iskeeminen
sydämen vajaatoimintaVakaa, mutta ultraäänellä
todetaan iskeeminen liikehäiriöVakaa, ei poikkeavaa
kuvantamislöydöstä
Rytmihäiriöt Elvytetty kammiovärinästä ja
STEMI:ä ei voida sulkea poisLääkitykselle reagoimaton
kammiotakykardiaToistuva kammiotakykardia Elvytetty kammiovärinästä, NSTEMI ja
neurologisesti toipumassa,
ohittunut kammiotakykardia
Oire ja kliininen kuva Jatkuvaa oireilua, eikä STEMI:ä
voida sulkea pois,
pelaste-PCIJatkuvaa oireilua tai iskeemiset
ST-muutokset kivun aikanaToistuvaa oireilua tai suuri
troponiinipäästö
Onnistuneen liuotushoidon
jälkeenOire väistyy seurannassa, mutta
sepelvaltimotautikohtaus on
todennäköinen tai varjoainekuvaus on
aiheellinen erotusdiagnostiikassa
PCI:n suorittaminen ja revaskularisaation laajuus
Sepel valtimotautikohtauspotilaiden invasiivisissa  toimenpit eissä  värttinävaltimon käyttö toimenpid ereittinä vähentää verenvuoto- ja muita
vaskulaarikomplikaatioita sekä kuolleisuutta verrattuna reisiv altimon kautta tehtävään tutkimukseen ja on siten turvallisem pi [A].
PCI:ssä tulee suosia uuden sukupolven lääkestenttien asent amista [153].
Vaihtoehtoisest i voidaan käyttää titaanioksidistenttiä, joka TIDES-ACS-tutkimuksessa  osoittautui yhtä tehokkaaksi kuin lääkestentti [154].
Erityisest i suuren vuotovaaran potilailla tai pienissä  haaroissa voidaan käyttää lääkepalloa [155], [156].
Lääkepallon käytöstä STEMI:n hoidossa ei ole toistaiseksi tehty satunnaistettua kontrolloitua tutkimusta.
STEMI:ssä ennen PCI:tä tehty rutiinino mainen manuaalinen trombi-imu ei vähennä  kuolleisuutta verrattuna perinteiseen PCI:hin [A]. Sitä voidaan harkita, jos
suonessa  on runsas trombikuorma.
Ks. PCI:n toteutuksesta tarkemmin lisätietoaineist osta .
STEMI:n yhteydessä  todetussa monisu onitaudissa tulee primaaritoimenpit eessä  hoitaa infarktin aiheuttanut ahtauma ja muut merkittävät ahtaumat joko
primaaritoimenpit een yhteydessä  tai viimeistään lähiviikkoina [A].
Sokkipotilailla hoidetaan ensisij aisest i vain culprit-ahtauma primaaritoimenpit eessä  [157].
Tiukat ahtaumat (yli 90 %) merkittävissä suonihaaroissa voidaan hoitaa ilman erillistä iskemian osoitusta [152].
Lievempien ahtaumien (50–90 %) aiheuttama sydänlihasiskemia voidaan arvioida joko varjoainek uvauksen yhteydessä  tehtävällä intrakoronaarisella
virtausreservimittauksella (painev aijerimittaus) tai kajoamattomalla iskemian osoituksella.
Sepel valtimotautikohtauksessa  monisu onitautia sairastavilla potilailla painev aijerimittaus ennen lääkestenteillä toteutettavaa revaskularisaatiota on
turvallista [A].
Painev aijerimittaus voi muuttaa hoitolinjaa jopa kolmasosalla potilaista ja
merkittävien ahtaumien hoito vähentää suunnit telemattomia toimenpit eitä ja hoitojaksoja [158] [159], [160], [161], [162].
Monikeskustutkimuksessa  vuoden kohdalla ei ollut eroa ensisij aisessa  päätetapahtumassa (kokonaiskuolleisuus, sydäninfarkti tai
uusintarevaskularisaatio) angiografiaohjatusti tehdyssä ryhmässä verrattuna painev aijerimittausohjattuun ryhmään (4,2 % vs. 5,5 %, p = 0,31) [163].
Tuoreessa  tutkimuksessa  STEMI-tilanteessa  tehdyllä painev aijeritutkimuksella non-culprit suonissa  ei kuitenkaan todettu hyötyä verrattuna pelkkään
angiografiseen arvioon vuoden seurannan aikana [163].
Jos sepel valtimotaudin hoito edellyttää pikaista ohitusleikkausta, voi pelkkä infarktin aiheuttaneen suonen virtauksen palauttaminen tai parantaminen
pallolaajennu ksella ilman stenttiä olla riittävä ensiv aiheen toimenpid e [164].
Myöhään hoitoon hakeutuneen STEMI-potilaan hoito
Oireiden pitkä kesto (yli 12 tuntia) ei ole este PCI-hoidolle.
12–48 tuntia oireiden alusta infarktisuoni tulisi hoitaa vain oireiden jatkuessa  [165]. Tapauskohtaisest i voidaan harkita infarktisuonen avaamista esim erkiksi
erittäin kriittisessä  anatomisessa  kohdassa tai hemodynaamisista syistä.
Yli 48 tunnin jälkeen infarktisuonen hoitoa ei suositella ilman iskemiaosoitusta [166].
Sydänkirurgian rooli sepelvaltimotautikohtauksen hoidossa
Osalla STEMI-potilaista ei PCI:llä voida saavuttaa riittävää revaskularisaatiota.
Välitöntä ohitusleikkausta tulee harkita, jos PCI ei ole teknisest i mahdollinen tai sen yritys epäonnist uu ja sydäninfarkti on johtamassa laaja-alaiseen
sydänlihasvaurioon.
NSTEMI-potilaista 5–10 %:lla ohitusleikkauksen katsotaan johtavan parempaan pitkäaikaisennu steeseen [167].
Stabiloituneessa  sepel valtimotautikohtauksessa  ohituskirurgian tarve ja mahdollisuudet tulee arvioida kuten kroonisessa  sepel valtimotaudissa [61].
Heart Team -käsittely on suositeltavaa.
Erityisest i monisu onitautia sairastavilla diabeetikoilla ohitusleikkauksen katsotaan antavan paremman pitkäaikaisennu steen pallolaajennu kseen verrattuna
[168], [169], [170].
Jos ohitusleikkaus arvioidaan suositeltavaksi hoitomuodoksi stabiloituneen STEMI:n tai NSTEMI:n jälkeen,  leikkaus pyritään tekemään samalla
sairaalahoitojaksolla (0–7 vrk).
Herkästi oireileville ja hemodynaamisest i epästabiileille potilaille ohitusleikkaus on pyrittävä tekemään päivystysluontoisest i.
Tarvittaessa  leikkausta viivästetään lääkityksestä johtuvan verenvuotovaaran minimoimiseksi.
ADP-resept orin salpaaja lopetetaan enne n leikkausta. Tikagrelorin vaikutus häviää yleensä  kolmessa , klopidogreelin viidessä  ja prasugreelin seitsemässä
vuorokaudessa . ASAa, pienim olekyylistä hepariinia  ja tarvittaessa  glykoproteiini IIb/IIIa:n estäjiä tai kangrerolia voidaan jatkaa operaatioon saakka.
Sepel valtimotautikohtauspotilailla myös ohitusleikkauksen jälkeen ADP-resept orin salpaajan ja ASAn yhdistelmähoidolla on saatu näyttöä paremmasta tehosta
pelkkään ASAan verrattuna. Ohitusleikkauksen jälkeen tulisi harkita ASAn ja jonkin ADP-resept orin salpaajan yhdistelmää 12 kuukauden ajan [171], [172], [173]
verenvuotovaara ja muu tarvittava lääkitys huomioiden.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 23/41
Antikoagulaatiohoitoa käyttäville potilaille aloitetaan vain ASA 100 mg kerran vuorokaudessa  antikoagulaatiohoidon lisäksi, ei ADP-resept orin salpaajaa.
ASA lopetetaan vakaassa tilanteessa  12 kuukauden kuluttua leikkauksesta.
Sepelvaltimotautikohtaus ja elvytys
Elvytetyn potilaan invasiivinen arvio
Potilailla, jotka saavat sydänpysähdyksen sydänlihaksen äkillisen iskemian vuoksi, on alkurytminä yleensä  kammiovärinä.
Muut alkurytmit (asystole ja pulssiton rytmi, PEA) voivat liittyä subakuutin sydäninfarktin komplikaatioihin (kardiogeeninen sokki, nystylihaksen repeä mä,
tamponaatio).
Jos kammiovärinä saadaan hoidettua nopeasti ja potilaan tajunta palaa, noudatetaan normaaleja sepel valtimotautikohtauksen hoitolinjoja.
Ellei tajunta palaa, tilanne arvioidaan tapauskohtaisest i:
STEMI:ssä primaari PCI on suositeltavampi kuin liuotushoito elvytyksen jälkitilaan liittyvän verenvuotoriskin vuoksi.
Jos EKG:ssa  ei todeta ST-nousuja ja potilaan hemodynamiikka on vakaa, välitön varjoainek uvaus ei ole välttämätön vaan se voidaan tehdä myöhemmin
potilaan neurologisen ennu steen selvittyä [174], [175]. Ks. taulukko 14.
Pitkittyvässä kammiovärinäkierteessä  voidaan turvautua ECMO-avusteiseen elvytykseen,  jos se on saatavilla ja potilas täyttää hoidon kriteerit (ks. alla).
Muussa tapauksessa  voidaan harkita elvytyksen aikaista liuotushoitoa.
ECMO-avusteinen elvytys (eCPR) sepelvaltimotautikohtauksessa
ECMO-avusteisel la elvytyksellä tarkoitetaan ECMO:n (extracorporeal membrane oxygenation, kehonulkoinen hapetus) asennu sta potilaalle elvytyksen aikana.
ECMO-avusteista elvytystä voidaan harkita hengen pelastavana hoitoyrityksenä  valikoiduilla potilailla, joilla epäillään hoidettavissa olevaa (esim . STEMI)
sydänpysähdyksen etiologiaa [176], [177], [178], [179], [180].
Yleensä  potilas kuljetetaan painantalaitteella elvyttäen sairaalaan, jossa ECMO asennet aan. ECMO tukee potilaan verenkiertoa ja happeu tumista ja toimii
siltahoitona sydänpysähdyksen aiheuttaneen sairauden hoitotoimenpit eelle (esim . PCI).
eCPR-hoidosta on yksi pieni satunnaistettu tutkimus tilanteessa , jossa sairaalan ulkopuolella todettiin defibrillaatioille resist entti kammiovärinä.
Verrokkiryhmän potilaista ei kukaan selvinny t hengissä, kun taas eCPR-ryhmästä 43 % potilaista oli elossa 6 kuukauden kuluttua [181].
Tehokkaan ja viiveettömän eCPR:n edellytyksenä  on, että hoitopolku on enna lta sovittu [182].
Työryhmän suosittelemat hoitokriteerit ja toimintamalli on luotu "expert opinio n"- periaatteella [183], [184], [185], [186], [187].
ECMO:n hoitokriteerit:
Elottomuus on nähty tai kuultu.
Lähtörytmi on defibrilloitava.
hoitoresist entti tai toistuva kammiovärinä tai kammiotakykardia
vain erityistä harkintaa käyttäen PEA:ssa (ei asystolessa ).
Potilas on alle 70-vuotias.
Tiedossa ei ole merkittäviä perussairauksia tai toimintakykyä heikentäviä tekijöitä.
Aika ilman mitään elvytystä on kestänyt korkeintaan 5 minuuttia (no-flow time).
Tehokas paineluelvytys on varmistettu kuljetuksen aikana paineluelvytyslaitteen ja intubaation avulla.
Tehokkaan elvytyksen merkkinä pulsaatio on tunnet tavissa tai nähtävissä painek äyrässä tai potilaalla on todettavissa elonmerkkejä (kakominen,  ääntely,
oma hengitys).
ETCO2 > 1,3 kPa.
Parhaat tulokset saavutetaan, jos ECMO-hoito päästään aloittamaan tunnin sisällä (low flow time).
Selviytyminen on mahdollista pidemmälläkin viiveellä, jos elvytys on tehokasta ja potilaalla on välillä tunnet tavissa syke tai todetaan muita elonmerkkejä
(kakominen,  ääntely, oma hengitys).
Toiminta ECMO:ssa:
Ensih oito tekee arvion potilaan sopivuudesta hoitoon ja on suoraan yhteydessä  ECMO:n asent amisest a päättävään lääkäriin.
Erityistä huomiota tulee kiinnit tää potilaan toimintakyvyn arvioon.
Potilas tuodaan suoraan toimenpid esaliin.
Moniammatillisen hoitotiimi (kardiologi, ensih oitolääkäri, sydänkirurgi, sydänanest esialääkäri) tekee lopullisen päätöksen ECMO:n asennu ksesta, kun
potilas saapuu.
Huonoon ennu steeseen ja hoidon hyödyttömyyteen sairaalaan tullessa  viittaavat
laktaattipitoisuus > 18 mmol/l
pH < 6,8
PaO < 6,7 kPa.
Rytmihäiriöt sepelvaltimotautikohtauspotilaalla
Takykardiat
Kammi ovärinä
Kammiovärinä voi olla STEMI:n ensio ire.
Aikainen kammiovärinä (alle 48 tuntia kohtauksen alusta) voi merkitä lisääntynyttä sairaalakuolleisuuden vaaraa, mutta pitkäaikaiskuolleisuuteen sillä ei
ole vaikutusta [188].
Myöhäinen (yli 48 tuntia kohtauksen alusta) kammiovärinä lisää sekä sairaalahoidon aikaista että myöhempää kuolleisuutta [189].
Kammiovärinä hoidetaan välittömällä defibrilloinnil la.
Beetasalpaajaa, amiodaronia tai lidokaiinia  voidaan antaa suonensisä isest i infuusiona estämään toistuvan kammiovärinän uusiutumista.
Usein kannattaa aloittaa 24 tunnin amiodaroni-infuusio.
Kammiovärinä syntyy useim miten kriittisen iskemian seurauksena , minkä vuoksi kammiovärinän uusiutuessa  tulee pyrkiä nopeaan revaskularisaatioon.
Elektrolyyttihäiriöt, etenkin hypomagnesem ia ja hypokalemia, tulee korjata kammioperäisten rytmihäiriöiden estämiseksi.
Yhdenmuotoinen kammi otakykardia
Pitkäkestoinen yhdenm uotoinen kammiotakykardia (kesto yli 30 sekuntia tai romahduttaa hemodynamiikan alle 30 sekunnissa ) lisää sairaalahoidon
aikaista ja myöhempää kuolleisuutta riippu matta siitä, missä vaiheessa  hoitoa se ilmaantuu [188], [189].226.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 24/41
Hoito sähköisellä synkronoidulla kardioversiolla on toteutettava kiireellisest i.
Takykardian uusiutuessa  ensisij ainen lääkehoito on suonensisä inen amiodaroni.
Lidokaiini saattaa olla tehokas lisälääke, jos takykardia on iskemian aiheuttama. Beetasalpaajaa tai sotalolia voidaan käyttää, joskin akuutissa sydämen
vajaatoiminna ssa ja bradykardiassa niitä pitää välttää. Sotalolia ei tule käyttää myöskään silloin, jos QT-aika on pidentynyt. Ks. taulukko 15.
Jatkuvasti toistuvissa takykardioissa voidaan harkita lääkehoidon tukena ylitahdistushoitoa.
Pitkäkestoinen yhdenm uotoinen kammiotakykardia voi käynnist yä iskemian seurauksena , mutta sen aiheuttajana on aiempi sydänlihaksen arpimuutos.
Pelkkä iskemian hoito (revaskularisaatio) ei poista pitkäkestoisen kammiotakykardian uusiutumisen riskiä. Hoito on kohdistettava spesif isest i
rytmihäiriöön; lääkityksen aloittamisen lisäksi on useim miten asennet tava rytmihäiriötahdistin.
Lyhytkestoinen kammi otakykardia (k esto alle  30 sekuntia):
Infarktin akuuttivaiheessa  ei yksinä än merkitse huonoa ennu stetta.
Hoidoksi riittää rytminseu ranta. Beetasalpausta kannattaa harkita.
Nopeutunut kammi orytmi (accelerated idioventricular rhythm, AIVR; alle 120/min)
voi esiint yä reper fuusiorytmihäiriönä, mutta se ei ole merkki onnist uneest a reper fuusiosta (kuva «Nopeutunut kammiorytmi eli AIVR»)
assosioituu suureen sydänlihasvaurioon ja viivästyneeseen kudostason perfuusion palautumiseen [190].
Polymorfinen kammi otakykardia
Tila voi enteillä kammiovärinää.
Polymorfinen kammiotakykardia on usein kriittisen iskemian tai vaikean vasemman kammion dysfunktion merkki.
Hoitona on pikainen revaskularisaatio.
Lääkehoitoina tulevat kysymykseen beetasalpaaja ja amiodaroni, joista amiodaroni on suositeltavampi, jos on hemodynaamisia haasteita.
Hypokalemia ja hypomagnesem ia tulee korjata.
Kammi olisäly önnit
ovat yleisiä  eivätkä vaadi spesif istä hoitoa.
Sinustakykardia
voi johtua hyperdynaamisest a hemodynamiikasta, kivusta, hypovolemiasta tai sydämen vajaatoiminna sta
voidaan hoitaa beetasalpaajalla tarvittaessa. Ennen hoidon aloitusta on varmistettava, ettei syynä ole hypovolemia tai vaikea sydämen vajaatoiminta.
Eteisvärinä:
Sekä uusi että aiempi eteisvärinä ilmentävät sairaalahoidon jälkeistä lisääntynyttä kuoleman vaaraa [191].
Tromboembolisten komplikaatioiden riski on suurentunut.
Kammiovasteeltaan tiheä eteisvärinä voi vaikeuttaa iskemiaa.
Sykkeen seurannan toteuttamiseksi voidaan käyttää suoneen annet tavaa beetasalpaajaa, verapamiilia tai amiodaronia.
Verapamiilia ei tule käyttää, jos EF on alentunut.
IC-ryhmän lääkkeitä ei tule käyttää sinu srytmin palauttamiseksi.
Jos eteisvärinään liittyy hemodynaamisia ongelmia tai jos se vaikeuttaa iskemian hoitoa, sinu srytmi palautetaan sähköisellä kardioversiolla.
Ks. tarkemmin lisätietoaineist osta .
Taulukko 15. Suonensisäisten rytmilääkkeiden annostelu akuutissa sydäninfarktissa
Valmiste Annostelu Huomattava
Beetasalpaajat:
Metoprololi 2,5–5 mg 2 min:n boluksena, 1–3 annosta Ei, jos bradykardia, hypotensio, vasospastinen angina tai akuutti
vajaatoiminta
Esmololi 0,5–1 mg/kg 1 minuutissa
jatkoinfuusio 0,06–0,2 mg/kg/minHyvin lyhytvaikutteinen
Lidokaiini 0,5–1,0 mg/kg boluksena tai
hoitoresistentissä tilanteessa infuusiona: 2–4 mg/min
Amiodaroni 150–300 mg 10 minuutissa, 150 mg:n lisäannoksia tarvittaessa 6–8 24
tunnissa
jatkuva infuusio 900–1 800 mg/vrkVoidaan käyttää myös akuutin sydämen vajaatoiminnan
yhteydessä
Digoksiini 0,25–0,5 mg boluksena, voidaan uusia 2 tunnin välein 3 kertaa Eteisvärinän kammiovasteen hidastamiseen (myös sydämen
vajaatoiminnassa)
Atropiini 0,5–1,0 mg nopeana boluksena, yhteensä ad 2,0 mg Vagaalisen heijasteen kumoamiseen
Isoprenaliini Infuusiona 0,05–2,0 μg/kg/min Annos titrataan sykevasteen mukaan.
AV-katkoksen tilapäishoitona (väliaikaista) tahdistinta
suunniteltaessa26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 25/41
Kuva 14.
Nopeutunut kammi orytmi eli AIVR on yleinen infarktipotilaan rytmihäiriö. Se saattaa liittyä suonen aukenem iseen,  mutta voi esiint yä muutenkin. AIVR voi
esiint yä pätkinä normaalin rytmin keskellä, mutta se saattaa olla vallitseva rytmi tuntienk in ajan. Tärkeintä on, ettei sitä sekoita potilaan normaaliin rytmiin.
Siihen saattaa liittyä AV-dissosiaatio, jolloin P-aallot kulkevat omassa rytmissään, tai joskus retrogradinen johtuminen kammioista eteisiin kuten tässä
esim erkissä. Tällöin P-aallot tulevat ST-segmentin päälle. Koska kyseessä  on kammioperäinen rytmi, on QRS-morfologia erilainen kuin potilaalla muuten, eikä
AIVR:n aikaisest a QRS:stä voi tehdä mitään arviota infarktin koosta Q-aalloilla tai iskemiasta ST-segmentillä.
AIVR ei tavallisest i vaikuta merkittävästi hemodynaamiseen tilanteeseen eikä vaadi yleensä  spesif istä hoitoa.
© HYKS/HUS Kardiologian klinikka
Bradykardiat
Sinusbradykardia:
Tila esiint yy alaseinä infarktissa reaktiivisena vagaalisen tonuksen lisääntymisen mekanism illa.
Yleensä  sinu sbradykardia menee ohi muutamien tuntien kuluessa  eikä vaadi hoitoa.
Tahdistimen tarve määritetään yleisten periaatteiden perusteella.
Eteis-kammi okatkos:
Proksimaalisest a katkoksesta puhutaan, kun katkos paikantuu eteis-kammiosolmukkeen tasolle (ennen Hisin kimpun lähtökohtaa):
yleensä  alaseinä infarktissa
Mobitz 1 -katkos
menee yleensä  itsestään ohi eikä sinä nsä merkitse huonoa ennu stetta
pysyvää tahdistinta ei yleensä  tarvita.
Distaalisessa  katkoksessa  infarktivaurio katkaisee johtumisjärjestelmän eteis-kammiosolmukkeen distaalipuolelta Hisin kimpusta eteenpä in:
etuseinä ninfarktissa, kun sept aalihaarojen verenkierto pysähtyy
Mobitz 2 -tyypin toisen tai kolmannen asteen (totaaliblokki) katkos
asystolen ja kammiovärinän riski suuri
katkos jää useim miten pysyväksi ja vaatii pysyvän tahdistimen asennu ksen
hemodynaamiikkaa uhkaavissa tilanteissa joudutaan käyttämään myös tilapäistä tahdistusta tai isoprenaliini- infuusiota rytmin ylläpitämiseksi, kun
odotetaan pysyvän tahdistimen asennu sta
merkitsee heikentynyttä pitkäaikaisennu stetta, ei niink ään itsenä isenä  tekijänä vaan sydämen vajaatoiminna n ja kammiorytmihäiriöiden ilmaantumisen
vuoksi.
Bi- ja trifask ikulaari katkos:
Akuutin etuseinä infarktin yhteydessä  bi- ja trifaskikulaarikatkos osoittavat laajaa lihasvauriota.
Tila voi edetä toisen tai kolmannen asteen katkokseksi, joskin katkos voi myös pysähtyä tälle tasolle.
Jos ilmenee hetkenkin häiriö eteis-kammiosolmukkeen tasolla, pysyvän tahdistimen asennu s on tarpeen.
Ks. tarkemmin lisätietoaineist osta .
Sydäninfarktin komplikaatiot
Mekaaniset komplikaatiot
Jos sepel valtimotautikohtauspotilaan hemodynaaminen tila muuttuu äkillisest i tai ilmaantuu uusi sivuääni, on syytä epäillä rakennek omplikaatiota. Tällöin
välitön sydämen ultraäänitutkimus on aiheellinen.
Tyypillisiä komplikaatioita ovat
akuutti nystylihaksen repeä mä ja siitä aiheutuva hiippa läppävuoto
kammioväliseinä n repeä mä
vapaan seinä n repeä mä ja sydäntamponaatio.
Hoitona on useim miten välitön tai kiireellinen kirurgia.
Varjoainek uvaus pyritään tekemään ennen leikkausta, ellei sitä ole jo tehty.
Mekaanisten komplikaatioiden kirurgista hoitoa käsitellään tarkemmin lisätietoaineist ossa .
Kammionsisäinen trombi
Ison infarktin komplikaationa voi olla kammionsisä inen trombi, jolloin tulisi harkita antikoagulaatiohoitoa ja seurata hoidon tehoa ultraääni- tai
tietokonekuvauksella [68]. Suorien antikoagulanttien tehosta on vain vähäistä tutkimusnäyttöä [192], [193].26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 26/41
Profylaktista antikoagulaatiohoitoa ison etuseinä infarktinkaan jälkeen ei lisääntyneen verenvuotovaaran takia tule aloittaa sinu srytmissä olevalle
sydäninfarktipotilaalle [194].
Perikardiitti
Sydäninfarktin aiheuttama iso sydänlihasvaurio voi joskus aiheuttaa akuutin perikardiitin.
Yleensä  tyypilliset oireet ja kliiniset  löydökset helpottavat diagnoosin tekoa.
Ks. EKG-esim erkki (EKG-tietokanta, kuva Myoperikardiittipotilaan EKG-kulku «Myoperikardiittipotilaan EKG-kulku», Huom.! EKG-tietokanta on
maksullinen ja vaatii käyttäjäoikeudet).
Sydämen kaikututkimus on aiheellinen perikardiumeffuusion toteamiseksi.
Stenttitromboosi
Stenttitromboosia esiint yy kuukauden kuluessa  sepel valtimotoimenpit eestä 0,5–1,2 %:lla, 1 vuoden kuluessa  0,8–1,6 %:lla ja 4–5 vuoden seurannassa noin 4–
5 %:lla potilaista [195], [196] [197], [198].
Jos kaksoisverihiutale-estolääkitys joudutaan kokonaan keskeyttämään ennena ikaisest i lääkeainest entin asent amisen jälkeen,  stenttitromboosin vaara kasvaa
ensim mäisen kuukauden aikana monikymmenkertaiseksi [210]. Ajan kuluessa  riski pienenee.
Lääkeainest entin jälkeen kaksoisverihiutale-estolääkitystä ei pidä kokonaan tauottaa ensim mäisen 3 kuukauden aikana kuin henkeä uhkaavassa
verenvuototilanteessa .
Uudenaikaisia lääkestenttejä käytettäessä  ensim mäisen kuukauden jälkeen jatkaminen yhdellä verihiutale-estäjällä näyttää turvalliselta [135], [136].
Toimenpid ekardiologia on syytä konsultoida, jos ennena ikaista tauottamista suunnit ellaan. Stenttitromboosi aiheuttaa useim miten STEMI:n, jonka ennu ste
on huonompi kuin aiemmin hoitamattoman suonen STEMI:ssä [199], [200]. Kuuden kuukauden kuolleisuus on 17–25 %.
Stenttitromboosin hoito PCI:llä on suositeltavaa.
Rutiinim aisest a uuden stentin asettamisest a ei ole hyötyä [201].
Tapausselostuksien perusteella liuotushoidosta voi olla hyötyä, jos PCI:tä ei ole saatavilla.
Stenttitromboosi voi johtua useasta eri syystä:
huono lääkemyöntyvyys tai ennena ikainen kaksoisverihiutale-estolääkityksen tauottaminen
alilaajentunut stentti tai toimenpit eessä  tullut suonen seinä män dissek aatio
Sepel valtimon sisäisellä ultraäänitutkimuksella (IVUS) tai valokerroskuvauksella (OCT) havaitaan mekaaniset  stenttitromboosille altistaneet  syyt, kuten
alilaajentunut stentti. Näitä tutkimuksia tulisi harkita stenttitromboosin invasiivisen hoidon yhteydessä  [202], [203].
huono lääkevaste klopidogreelille [110].
Heikentynyt klopidogreelivaste ennu staa suurentunutta kardiovaskulaarikuoleman, sydäninfarktin ja stenttitromboosin vaaraa
sepel valtimotoimenpit een jälkeen [A].
Jos mekaanista syytä stenttitromboosille ei kyetä osoittamaan, tulee harkita lääkkeen vaihtoa prasugreeliin tai tikagreloriin.
Huono hoitomyöntyvyys on yleisin selitys huonolle klopidogreelivasteelle [204].
Verenvuotovaara
Verenvuotokomplikaatioiden välttäminen on yhtä tärkeää kuin iskeem isten komplikaatioiden ehkäisy.
Vakavat verenvuotokomplikaatiot huonontavat sepel valtimotautikohtauksen ennu stetta yhtä paljon kuin iskeem iset komplikaatiot.
Verenvuotokomplikaatio lisää kuolleisuuden jopa 7-kertaiseksi muutoin ongelmattoman PCI:n jälkeen [205], [206], [207].
Verenvuotokomplikaatioihin liittyvä huono ennu ste selittyy osittain potilaiden muilla sairauksilla tai vaaratekijöillä, mutta hemodynaamisia ongelmia
aiheuttavan verenvuodon lisäksi elimistön verenvuotoa hillitsevillä reaktioilla, verensiir roilla, antitromboottisten lääkkeiden käytön lopettamisella ja
hemostaattisilla lääkkeillä on merkitystä.
Antitromboottisten lääkkeiden tauotuksesta tulee neuvotella toimenpid ekardiologin kanssa  myös verenvuodon yhteydessä .
Liian herkkää lääkkeiden tauotusta tulee välttää.
Jopa 40 %:lla PCI:llä hoidetuista sepel valtimotautikohtauspotilaista on ainakin 1 verenvuotovaaraa lisäävä tekijä [208].
Vakavia verenvuotoja ilmenee määritelmän ja potilasryhmän mukaan 2–12 %:lla PCI:llä hoidetuista potilaista [208].
Antikoagulaatiohoitoa käyttävistä potilaista jopa 11–44 %:lla todetaan verenvuotoja 1 vuoden kohdalla muiden verenvuotoriskiä suurentavien lääkitysten
(ADP-resept orin salpaaja, ASA) kestosta riippu vasti [117], [118], [119], [120], [138].
Verenvuotovaara arvioidaan potilaan esitietojen, kliinisen tutkimuksen, kreatiniinipu hdistuman (eGFR), verenkuvan, maksan toimintakokeiden,
hemoglobiinin ja potilaan käyttämän muun lääkityksen perusteella.
Tärkein verenvuotovaaraa lisäävä tekijä on antikoagulanttihoito [117], [118], [119], [120], [138], [156].
Muut verenvuotovaaraa listaavat tekijät on listattu taulukkoon 16.
Lisäksi verenvuotovaaran on kuvattu suurentuneen hätätoimenpit eissä , komplisoituneissa  toimenpit eissä , nivusreitin suuria valtimosisäänviejiä
käytettäessä , kardiogeenisen sokin, automaattisen elvytyslaitteen ja vastapulsaattorin käytön yhteydessä , GP IIb/IIIa:n estäjiä käytettäessä  ja perifeerisessä
valtimotaudissa.
Antikoagulantin ja verihiutale-estäjien yhdistelmä lisää merkittävästi verenvuotovaaraa.
Yleensä  sairaalavaiheen jälkeen käytetään ainoastaan ADP-resept orin salpaajaa yhdessä  antikoagulantin kanssa  ilman ASAa 12 kuukauden ajan [117], [118],
[119], [120], [138].
ADP-resept orin salpaajista klopidogreeli on ensisij ainen tässä tilanteessa . Uudempia ADP-resept orin salpaajia voidaan harkita vain, jos iskeem inen vaara
arvioidaan erityisen suureksi. Prasugreelia tai tikagreloria käytettäessä  ASAn käyttö lopetetaan sairaalasta kotiin päästessä .
Tutkimusnäyttö suorien antikoagulanttien ja uusimpien ADP-resept orin salpaajien yhteiskäytöstä on toistaiseksi erittäin vähäistä [117], [118], [119], [120].
Sairaalavaiheen jälkeen ASAa käytetään klopidogreelin rinna lla ensim mäisen kuukauden ajan erityisest i, jos iskeem inen tai stenttitromboosin riski on
erityisen suuri ja verenvuotoriski pieni.
12 kuukauden kuluttua sepel valtimotautikohtauksesta käytetään ainoastaan antikoagulanttia, paitsi jos potilaalla on erityisen suuri uusintatapahtumien
riski, jolloin lääkitykseen voidaan lisätä ASA.
Antikoagulanttia käyttävillä potilailla tulisi välttää glykoproteiini IIb/IIIa:n estäjien käyttöä [209].
Suuren verenvuotovaaran potilaalla voidaan myös käyttää 3 kuukauden kaksoisverihiutale-estäjähoidon jälkeen pelkästään tikagreloria 12 kuukauteen asti,
mikä näyttää vähentävän verenvuotokomplikaatioita [142], [143] lisäämättä iskeem isiä tapahtumia, kuten stenttitromboosin vaaraa.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 27/41
Suuren verenvuotovaaran potilailla, joille oli asetettu nykyaikainen sepel valtimon lääkestentti, voitiin ADP-resept orin salpaaja turvallisest i tauottaa 1
kuukauden kohdalla pallolaajennu shoidosta ilman, että iskeem isen yhdistelmäpäätetapahtuman (kuolema, aivohalvaus tai sydäninfarkti) riski kasvoi
merkittävästi vuoden seurannassa. Tauottaminen vähensi kliinisest i merkittäviä verenvuotoja 31 % [135].
Akuutin verenvuotokomplikaation yhteydessä  tulee yksilöllisest i arvioida hyytymiseen vaikuttavan lääkityksen tauottaminen ja jatkaminen.
Kaksoisverihiutale-estäjälääkityksen tauottamiseen liittyy suuri stenttitromboosin vaara erityisest i ensim mäisen kuukauden aikana [210].
Vakavissa verenvuodoissa pyritään aktiivisest i etsimään ja hoitamaan vuodon syy ja palauttamaan antitromboottinen hoito heti, kun se on turvallista.
Henkeä uhkaavassa verenvuodossa voidaan antaa verihiutaleita, mutta tikagrelorin osalta niiden teho näyttää heikommalta [211].
Tikagrelorin voinee ainakin osittain kumota jääplasmalla [212].
Verenvuotovaaraa voidaan vähentää
suunnit telemalla yksilöllinen antitromboottinen hoito (erityisest i iäkkäille ja lievääkin munuaisten vajaatoimintaa poteville) [213], [214]
suosimalla värttinävaltimoreittiä [215], ks. [A]
käyttämällä PCI:n tekniikkana lääkepallokäsittelyä stentin asennu ksen sijaan [155].
välttämällä verensiir toja, jos hemoglobiinia rvo on yli 80 g/l [213]
Punasolusiirtojen tarve arvioidaan aina yksilöllisin perustein. Punasolusiirto anem ian yhteydessä  saattaa paradoksaalisest i heikentää kudosten
hapensa antia ja potilaan ennu stetta, joten oireettomalla potilaalla tulee rutiinino maista verensiir toa välttää [219], [220].
Ruoansulatuskanavan verenvuotojen ehkäisyssä PPI-lääkitys tulee aloittaa kaikille verenvuotovaarassa oleville potilaille ja rutiinino maisest i antikoagulattia
käyttäville potilaille, joilla on antitromboottinen lääkitys [213] [216], [217], [218].
Taulukko 16. Verenvuotovaaraa pallolaajennushoidon jälkeen lisääviä tekijöitä (ARC-riskipisteytys). Suuren verenvuotovaaran potilaiksi määritellään potilaat, joilla on joko 1
pääkriteeri tai 2 sivukriteeriä [130].
Pääkriteerit (1 riittää) Antikoagulaatiohoito
Vaikea munuaisten vajaatoiminta (eGFR < 30 ml/min)
Anemia (hemoglobiini < 110 g/l)
Aiempi spontaani punasolujen siirtoon johtanut verenvuoto 6 kk:n kuluessa
Trombosytopenia (< 100 x 10)
Perinnöllinen vuodolle altistava sairaus
Maksakirroosi, johon liittyy portahypertensio
Aktiivinen syöpäsairaus*
Aiempi spontaani kallonsisäinen vuoto
Aiempi traumaattinen kallonsisäinen vuoto (< 12kk)
Kallonsisäinen AV-malformaatio
Tuore kohtalainen tai vaikea iskeeminen aivohalvaus (< 6 kk)
Kiireellinen tuleva leikkaus (< 1 kk), jota ei voida siirtää
Tuore suuri leikkaus tai trauma (< 1 kk)
Sivukriteerit (2 vaaditaan) Ikä ≥ 75 v
Kohtalainen munuaisten vajaatoiminta (eGFR 30–59)
Lievä anemia (110–129 g/l miehillä tai 110–119 g/l naisilla)
Aiempi spontaani sairaalahoitoa tai punasolujen siirtoa vaatinut verenvuoto (6–12 kk
aiemmin) (joka ei täytä pääkriteeriä)
Pitkäaikainen NSAID tai kortikosteroidien käyttö
Iskeeminen aivohalvaus, (joka ei täytä pääkriteeriä)
* Aktiivinen syöpäsairaus tarkoittaa 12 kuukautta ennen pallolaajennushoitoa tehtyä diagnoosia tai meneillään olevia syöpähoitoja (kirurgia, sädehoito tai solunsalpaajahoito).
Jatkohoito
Jatkohoidon onnist umisen edellytyksenä  on potilaan sitoutuminen sekä näyttöön perustuvaan lääkehoitoonsa että omahoitonsa toteuttamiseen [61], [221], [222].
Sepel valtimotaudin riskitekijöiden hoito ja potilaan ohjaaminen,  sitouttaminen ja osallistaminen omahoitoon aloitetaan moniammatillisena  yhteistyönä
sairaalajakson alussa ja sitä jatketaan koko sairaalahoitojakson ajan ja sen jälkeen.
Mobilisointi
Vuodelepo pyritään minim oimaan komplikaatioiden ehkäisem iseksi ja kuntoutumisen ja toipumisen edistämiseksi [61].
Liikunnallinen kuntoutus aloitetaan jo varhaisessa  vaiheessa  sairaalassa, kun hemodynamiikka on vakaa. Sairaalavaiheessa  potilasopetus ja kuntouttavat
toimenpit eet korostuvat [221].
Potilasta hoitava lääkäri määrittää mobilisoinnin turvallisen aloitusajankohdan.
Harjoittelu toteutetaan akuuttivaiheessa  oirekynnyksen alapuolella.
Toipilasajan alussa (2–4 viikkoa) fyysinen rasitus ohjataan toteuttamaan kevyellä rasituksella, minkä jälkeen rasitusta lisätään maltillisen nousujohteisest i
yksilölliset tekijät huomioiden.
Säännöllinen hyöty- ja kestävyysliikunta sekä lihaskuntoharjoittelu ovat keskeistä toipilasvaiheen jatkuessa  (2–16 viikon aikana kotiutumisest a) ja sen
jälkeenk in [221]. Ks. myös kohta Vähäinen liikunta «A6».
Potilaiden, joilla on merkittävä vasemman kammion vaurio, tulisi olla vuodelevossa ainakin 12 tuntia sydäninfarktin jälkeen.
24–48 tunnin vuodelepo on tarpeen,  jos potilaalla on oireita tai merkittäviä rytmihäiriöitä tai hänelle on kehittynyt merkittävä sydänlihasvaurio.
Kotiuttamisaikataulu on yksilöllinen:
Komplisoitumattoman sydäninfarktin jälkeen nopea kotiutus (1–3 vrk) on valikoiden turvallista [A].
Kotiuttamista voidaan harkita, jos potilas on mobilisoitunut, toimenpid ekomplikaatioita, merkittäviä rytmihäiriöitä tai sydämen vajaatoimintaa ei ole ja
potilas on saanut hyvän ohjauksen kotihoitoon.
UAP-potilaan kotiuttamista voidaan harkita jo toimenpid epäivänä.926.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 28/41
Vajaatoimintapotilaat ja monisu onitautia sairastavat tarvitsevat pidemmän hoitojakson.
Potilaan ohjeistus kotiutuessa ja seuranta
Koska kohtauksen uusiutumisen todennä köisyys on suurin kotiutusta seuraavina viikkoina, potilaalle on annet tava selkeät menet telyohjeet mahdollisen
sepel valtimotautikohtaukseen viittaavien oireiden uusiutumisen varalta.
Suuren infarktin sairastaneita tai vaikeaa sepel valtimotautia sairastavia tulee seurata erikoissairaanhoidossa, jossa
arvioidaan lisärevaskularisaation tarve
optimoidaan lääkitys
arvioidaan rytmihäiriötahdistimen tarve.
Jos potilas siirtyy avoterveydenhuollon seurantaan, ensim mäinen seurantakäynti pyritään järjestämään 1–2 kuukauden kuluttua.
Kun potilas siirtyy erikoissairaanhoidosta avoterveydenhuollon seurantaan, hänen kanssa an on suositeltavaa tehdä kirjallinen hoitosuunnit elma, josta
ilmenev ät jatkoseurannan paikka, tarvittavat jatkotutkimukset ja riskitekijöiden tavoitetasot.
Pysyvä jatkoseuranta toteutetaan yksilöllisest i, vähintään 6–12 kuukauden välein.
Seurantakäynneil lä tulee kiinnit tää huomiota potilaan vointiin, arvioida lääkehoidon toteutuminen ja pyrkiä suurentamaan lääkeannokset tavoitemääriinsä .
Mahdolliset mielenterveyden ongelmat, kuten masennu s, ahdistus ja kuolemanpel ko, pyritään havaitsemaan ja arvioidaan suoritus-, työ- ja ajokykyä sekä
kuntoutustarvetta.
Sydänsairauksiin perehtyneen fysioterapeutin tai sairaanhoitajan suorittamaa seurantaa suositellaan 2–4 viikon kohdalla kotiutumisest a suorituskyvyn
arvioimiseksi ja lisäohjauksen mahdollistamiseksi.
Käynnin yhteydessä
arvioidaan toipumista ja sydämen suorituskykyä sekä kokonaisvaltaista toimintakykyä
annet aan potilaalle lisää tietoa siitä, kuinka hän voi itse vaikuttaa sepel valtimotaudin riskitekijöihin ja toteuttaa omahoitoaan
ohjataan perustellen nousujohteiseen liikunnan lisäämiseen kohti sepel valtimotautia sairastavan liikuntasuositusta (Ks. Sepel valtimotautipotilaan
liikunnallinen kuntoutus -fysioterapiasuositus «Sepel valtimotautipotilaan liikunnallinen kuntoutus», [221])
järjestetään tarvittaessa  jatko-ohjaus tai seuranta-aika erikoissairaanhoitoon, perusterveydenhoitoon tai kolmannel le sektorille (käytännöissä alueellisia
eroja)
tehdään yksilöllisen hoitosuunnit elma, joka sisältää tavoitteen asettamisen yhdessä potilaan kanssa
konsultoidaan tarvittaessa  kuntoutussuunnit telijaa tai -ohjaajaa kuntoutustarpeen arvioimiseksi (voi toteutua myös muun terveydenhuollon ammattilaisen
konsultaationa; käytännöissä alueellisia eroja).
Kuntoutustarve tulee arvioida jokaisen kontaktin yhteydessä , ja potilaalle tulee tarjota paikallisest i valittuja kuntoutusohjelmia sekä esim erkiksi Kelan tukemaa
kuntoutusta ja kolmannen sektorin palveluita. Ks. kohta Sydänkuntoutus «A7».
Tehtyjen toimenpit eiden vaikutus potilaan vointiin sekä mahdolliset sepel valtimotaudin etenem iseen viittaavat oireet tulee selvittää.
Seurannan alkuvaiheessa  on tärkeää varmistaa potilaan ymmärrys taudin hoidosta ja ennu steesta. Alkuvaiheessa  korostuu myös omahoidon tukeminen.  Kyky
ja halu hallita riskitekijöitä kartoitetaan ja potilasta kannustetaan pysyvään elintapojen muutokseen.
Sepel valtimotautipotilaiden riskitekijöiden hoitoon koulutettujen sairaanhoitajien toteuttamalla hoidolla on suotuisa vaikutus potilaiden riskitekijöihin [A].
Sepel valtimotautipotilaalle suositellaan vuosittaista kausi-influenssa rokotusta ja yli 65-vuotiaalle myös pneu mokokkirokotetta [223], [224]. Ks. lisätietoa aiheesta
.
Omaisille annet aan toimintaohjeet siitä, kuinka menet ellä äkillisen rintakivun tai tajuttomuuden yhteydessä , ja heitä kehotetaan osallistumaan
elvytyskoulutukseen.
Kotiuttamisvaiheessa  laaditaan tarvittavat lausunnot lääkkeiden korvattavuudesta.
Sepelvaltimotaudin riskitekijöiden hoito
Riskitekijöiden hoidon tavoitteet on koottu taulukkoon 17.
Sepel valtimotaudin sekundaaripreventiolla eli riskitekijöiden tehokkaalla hoidolla pyritään estämään uusintatapahtumia, vähentämään potilaan oireita,
pienent ämään sydämen vajaatoiminna n kehittymisen riskiä tai sen vaikeutumista ja parantamaan potilaan ennu stetta.
Koska sepel valtimotaudin synty on monisyinen,  riskitekijöiden hoidon on oltava kokonaisvaltaista ja myös psykososiaalisiin tekijöihin on kiinnit ettävä
huomiota.
Taulukko 17. Sepelvaltimotaudin riskitekijöiden hoidon tavoitteet
Riskitekijän hoidon tavoitteet Käypä hoito -suositus tai muu viite
Verenpaine alle 130/80 mmHgKohonnut verenpaine «Kohonnut verenpaine», [225]
LDL-kolesterolipitoisuus alle 1,4 mmol/lDyslipidemiat «Dyslipidemiat», [226], [227]
Normaali sokeriaineenvaihduntaTyypin 2 diabetes «Tyypin 2 diabetes», [228]
BMI alle 25 kg/mLihavuus (lapset, nuoret ja aikuiset) «Lihavuus (lapset, nuoret ja aikuiset)», [229]
Hyötyliikuntaa päivittäin
Kestävyysliikuntaa vähintään 3–5 päivänä viikossa 30–60 minuuttia
Lihaskuntoharjoittelua 2 kertaa viikossa[221], [222]
Tupakoimattomuus Tupakka- ja nikotiiniriippuvuuden ehkäisy ja hoito «Tupakka- ja nikotiiniriippuvuuden ehkäisy ja
hoito», [230]
Verenpa ine
Kohonneen verenpa ineen hoidossa on pyrittävä hyvään hoitotasapainoon.
Hoidon tavoitetaso on 120–130/70–80 mmHg vastaanotolla mitattuna.
Yli 65-vuotiaille ja erityisest i gerastenia potilaille hoitotavoite määritellään yksilöllisest i.
Ks. Käypä hoito -suositus Kohonnut verenpaine «Kohonnut verenpa ine» , [225], [231], [27].
Dyslipidemiat
Sepel valtimotautikohtauksen sairastaneilla tavoite on mahdollisim man pieni LDL-kolesterolipitoisuus, jota tavoitellaan sekä elämäntavoilla (ruokavalio ja
liikunta) että lääkehoidolla.226.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 29/41
Sepel valtimotautikohtauksen sairastaneille suositellaan alle 1,4 mmol/l:n pitoisuutta ja 2 vuoden sisällä uusiutuneen sepel valtimotautikohtauksen
sairastaneille alle 1,0 mmol/l:n pitoisuutta [227].
Maksimaalinen statiinih oito parantaa sepel valtimotautikohtauspotilaiden ennu stetta ja on siten aiheellinen kaikille LDL-arvoista riippu matta.
Dyslipidemioiden tehokas lääkkeetön ja lääkkeellinen hoito suuriannoksisel la statiinilla (esim . rosuvastatiini ≥ 20 mg/vrk tai atorvastatiini ≥ 40 mg/vrk) ja
tarvittaessa  herkästi myös etsetimibillä tulee aloittaa jo sairaalavaiheessa .
Sepel valtimopotilailla ja erityisest i sepel valtimotautikohtauksen yhteydessä  suuresta statiinia nnoksesta (atorvastatiini 80 mg/vrk) on saatu kliinist ä lisähyötyä
tavanomaiseen statiinia nnokseen verrattuna.
Akuuttia sepel valtimotapahtumaa seuraavien viikkojen päätetapahtumien vähentämiseksi suuriannoksinen statiinih oito (rosuvastatiini 20–40 mg tai
atorvastatiini 40–80 mg) on aiheellista aloittaa sairaalassa viiveettä ja jo ennen sepel valtimotoimenpid että [232], [233], [234].
LDL-kolesterolipitoisuus pyritään saamaan mahdollisim man pienek si. Ks. Käypä hoito suositus Dyslipidemiat «Dyslipidemiat», [226], [227].
Jos LDL-kolesterolipitoisuus on lähtötilanteessa  erityisen suuri (≥ 3,5 mmol/l), suositellaan aloittamaan maksimaalisen siedetyn statiinih oidon lisäksi
etsetimibi 10 mg kerran vuorokaudessa  jo alkuvaiheessa  hoitotavoitteeseen pääsemiseksi.
Etsetimibin on osoitettu pienent ävän kolesterolipitoisuutta ja vähentävän kardiovaskulaaritapahtumia sepel valtimotautikohtauksen jälkeen,  jos LDL-
kolesterolin tavoitepitoisuuteen ei ole päästy pelkällä statiinih oidolla [235].
PCSK9:n estäjillä on hyvä näyttö LDL-kolesterolipitoisuuden pienenem isest ä. Ne vähentävät päätetapahtumia sepel valtimotautikohtauksen sairastaneilla
potilailla, erityisest i jos LDL-kolesterolipitoisuus ei statiinilla ja etsetimibillä pienene alle 2,6 mmol/l:iin.
Lääkkeet annostellaan ihonalaisest i 2–4 viikon välein. LDL-kolesterolipitoisuus pienenee noin 60 %.
Evolokumabi vähensi suuren vaaran sepel valtimotautipotilailla (81 %:lla aiempi sydäninfarkti) kardiovaskulaaritapahtumia 15 % (NNT = 50) 2 vuoden
seurannassa [236].
Alirokumabi vähensi sepel valtimotautikohtauspotilailla kardiovaskulaaritapahtumia 15 % (NNT 63) ja kokonaiskuolleisuutta 15 % (NNT = 167) noin 3
vuoden seurannassa [237].
PCSK9:n estäjillä hoitoa rajoittaa kustannus-hyötysuhde. Ruotsissa  SWEDEHEART-rekisterin perusteella yhden uusintainfarktin eston arvioidaan maksavan
846 000 €, kun käytetään ESC:n suosituksen ohjeita [238].
Ennen PCSK9:n estäjän käytön aloittamista tulee arvioida riskitekijöiden hoidon toteutuminen kokonaisuutena ja tarvittaessa  korjata merkittävimpiä
ongelmia.
Lääkemyöntyvyys tulee varmistaa.
Potilaan kokonaisennu ste tulee ottaa huomioon.
Hoitoa PCSK9:n estäjällä voidaan harkita, jos potilaalla on sairastettu sydäninfarkti ja suurimmasta siedetystä statiinia nnoksesta ja etsetimibistä huolimatta
LDL-pitoisuustavoitteista jäädään selvästi.
Sokeriaineenv aihdunnan häiriöt ja diabetes
Noin kolmasosalla sepel valtimotautikohtaukseen sairastuneist a on ennest ään diabetes, ja lopuista noin 60 %:lla voidaan todeta sokeriaineenv aihdunnan häiriö
[239].
Sokeriaineenv aihdunnan häiriötä tulee sepel valtimotautikohtaukseen sairastuneilla seuloa aktiivisest i [61].
Oireettomilla diagnoosi perustuu joko plasman glukoosipit oisuuden suurentuneeseen paastoarvoon (vähintään 7 mmol/l), 2 tunnin arvoon
glukoosirasituskokeessa  (yli 11 mmol/l) tai HbA:n mittaukseen (≥ 48 mmol/mol, ≥ 6,5 %). Diabeteksen diagnostisten kriteerien osalta viitataan Käypä
hoito suositukseen Tyypin 2 diabetes «Tyypin 2 diabetes» [228].
Sepel valtimotautikohtauksen akuutissa vaiheessa  veren suurta sokeripitoisuutta tulee herkästi hoitaa insu liini- infuusiolla.
Veren sokeripitoisuuden tavoitetasoa ei tutkimusten perusteella voida yksisel itteisest i määritellä, mutta liian tiukasta glukoosin seurannasta voi olla haittaa
[240].
Diabeteksen hoidossa pyritään hyvään tasapainoon: HbA-pitoisuuden osalta tavoitteena  on päästä lääkehoidon aikana alle 53 mmol/mol:n pitoisuuteen (alle
7,0 %), mutta yksilöllisest i voidaan sopia suurempikin tavoitearvo. Ks. Käypä hoito -suositus Tyypin 2 diabetes «Tyypin 2 diabetes», [228].
SGLT2:n estäjät ja GLP-1-resept oriagonistit ovat suositeltavia lääkkeitä tyypin 2 diabeetikoilla, joilla on valtimotauti tai ovat suuressa  riskissä valtimotaudille.
SGLT2:n estäjistä empagliflotsiini ja kanagliflotsiini vähentävät sydän- ja verisuonitautitapahtumia siten, että empagliflotsiini vähentää kardiovaskulaari- ja
kokonaiskuolleisuutta ja kanagliflotsiini vähentää sydäninfarkteja tyypin 2 diabetesta sairastavilla valtimotautipotilailla [A].
Dapagliflotsiini vähentää suuressa  valtimotautiriskissä olevien tyypin 2 diabeetikkojen sydämen vajaatoimintajaksoja [241].
GLP1-resept oriagonistit (dulaglutidi, liraglutidi ja semaglutidi) vähentävät sydän- ja verisuonitapahtumia diabetesta sairastavilla valtimotautipotilailla [A].
Kardiologin tulee ottaa kantaa diabeteksen optimaaliseen hoitoon jo sairaalahoitojakson aikana.
Ylipaino
Ylipaino on myös sepel valtimotaudin itsenäinen riskitekijä.
Normaali painoindeksi (BMI) on 18,5–24,9 kg/m.
Ylipainoisilla (BMI 25–29,9 kg/m) ja lihavilla (BMI yli 30 kg/m) tavoitteena  on vähentää painoa pysyvästi 5–10 %. Ks. Käypä hoito -suositus Lihavuus
(lapset , nuoret ja aikuiset) «Lihavuus (lapset , nuoret ja aikuiset)», [229].
Sydänterveellinen ruokavalio ja liikunta ovat tärkeä osa ylipainon hoitoa.
Ravitsemusasiantuntijoiden ja liikkumisen ammattilaisten hyödyntäminen voi edistää tavoitteiden saavuttamista.
Vähäinen liikunta
Liikkumattomuus on terveydelle haitallista .
Vähäinen fyysinen aktiivisuus ja huono fyysinen kunto, erityisest i kardiorespir atorinen kunto, suurentavat ennena ikaisen kuoleman riskiä.
Runsas istuminen on terveydelle haitallista.
Oikein toteutetulla liikunnalla on vähän terveyshaittoja.
Liikunta on vaikuttavaa, turvallista ja tärkeä osa potilaan onnist unutta omahoitoa [61], [221].
Sekundaariprevention toteutumiseksi potilaat tulee ohjata liikkumaan säännöllisest i [61], [221], [222].
Potilaalle suositellaan päivittäistä hyötyliikuntaa
Arkiliikkumisen lisääminen ja istumisen vähentäminen ovat merkityksellisiä muokatessa  arkea aktiivisem maksi [221].
Kestävyysliikuntaa suositellaan vähintään 3–5 päivänä viikossa 30–60 minuuttia kerrallaan kohtuullisella kuormalla.
Lihaskuntoharjoittelua suositellaan 2 kertaa viikossa [222], koska se parantaa toimintakykyä, fyysistä kuntoa ja lihasten voimaa ja massaa.1c
1c
2
2 226.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 30/41
Myös epäsäännöllisen liikunnan lisääminen on edullista, erityisest i muutoin vähän liikkuvilla [61].
Tupakointi
Tupakoinnin lopettaminen on ensia rvoisen tärkeää [242], [243]. Ks. lisätietoa aiheesta ja Käypä hoito -suositus Tupakka- ja nikotiinir iippu vuuden ehkäisy ja hoito
«Tupakka- ja nikotiinir iippu vuuden ehkäisy ja hoito», [230].
Tupakoinnin lopettaminen vähentää uusintainfarktien vaaraa [A].
Tupakoinnin lopettamisella potilas voi eniten vaikuttaa omaan sydän- ja verisuonisa irauksien ennu steeseensa .
Parhaan mahdollisen tehon saavuttamiseksi sairaalahoidon aikana aloitetaan tupakoinnin lopettamiseen tähtäävä intensiiv inen potilasohjaus, joka jatkuu
tukevana yhteydenpit ona vähintään kuukauden ajan kotiutumisen jälkeen.  Tarvittaessa  hoitoon liitetään nikotiinik orvaushoito [244].
Nikotiinik orvaushoito voidaan aloittaa heti, kun hemodynamiikka on vakaa.
Tupakoimattomuuteen kannustetaan jokaisella seurantakäynnillä.
Lääkehoidoista varenik liini on tehokas ja turvallinen sepel valtimotautikohtauksen jälkeen sairaalassa aloitettuna [245]. Bupropioni lisää
tupakoimattomuuden todennä köisyyttä, mutta sen teho on varenik liinia  heikompi [245], [246], [247].
Masennus sydäninfarktin jälkeen
Masennu s ja ahdistuneisu us ovat yleisiä  sydäninfarktin sairastaneilla.
Masennu ksesta kärsivillä hoitoon sitoutuminen on tavallista heikompaa ja riskitekijöiden hoito toteutuu huonommin. Sydäninfarktin jälkeen esiint yvä
masennu s onkin yhteydessä  lisääntynees een kuolleisuuteen ja suurentuneeseen uusien tapahtumien riskiin [248], [249], [250].
Masennu kseen liittyviä oireita suositellaan arvioimaan seurantakäyntien yhteydessä . Masennu ksen seulonnan vaikutuksista elämänlaatuun, masennu ksen
esiint yvyyteen tai haittatapahtumien vähentymiseen ei ole kuitenkaan näyttöä [251].
Sydäninfarktin jälkeen esiint yvän masennu ksen seulonnassa eniten tutkittu on BDI-II-kysely (Beck Depressio n Inventory-II). Useiden kyselyiden herkkyys ja
tarkkuus ovat kuitenkin hyväksyttävällä tasolla [252].
Essitalopraami vähentää masennu soireita eikä se lisää sydämeen liittyviä riskejä sydäninfarktin jälkeen.  Myös sitalopraamista, sertraliinist a, fluoksetiinist a ja
mirtatsapiinist a on osoitettu olevan hyötyä sepel valtimotautipotilaiden masennu ksen hoidossa [253], [254], [255].
Trisykliset masennu slääkkeet ovat haittavaikutusprofiilinsa  takia ongelmallisia sydänpotilailla. Ks. Käypä hoito -suositus Depressio  «Depressio », [256].
Kognitiivis-behavioraalinen terapia yhdistettynä lääkehoitoon on todennä köisest i tehokkaampaa kuin pelkkä lääkehoito [252].
Seksielämä sepelvaltimotautikohtauksen jälkeen
Sydänpotilaat murehtivat usein seksielämän jatkamisen turvallisuudesta, ja heillä saattaa olla myös seksuaalihäiriöitä [257].
Äkkikuoleman tai sydäntapahtuman riski on kuitenkin melko pieni.
Seksi suurentaa akuutin sydäninfarktin riskiä lyhytaikaisest i hieman, mutta se on sydäninfarktin syynä alle 1 % tapahtumista ja äkkikuoleman syynä vain 1–
1,7 % tapauksista [258].
Seksi vastaa tyypillisest i 3–5 MET:n kuormaa eli 2 kerrosvälin nousua [258]. Yleensä , kun 2 kerrosvälin nousu toteutuu oireettomasti, yhdyntä on turvallista.
Mahdolliset seksuaalihäiriöiden taustasyyt tulee pyrkiä selvittämään.
Taustasyynä voi olla esim erkiksi valtimotauti, psykososiaalinen ongelma tai lääkitys.
Seurantakäynneil lä potilailta tulisi tiedustella myös mahdollisista seksuaalihäiriöistä ja heille tulisi tarjota neuvontaa tai hoitoa.
PDE5:n estäjät ovat yleensä  turvallisia kroonista sepel valtimotautia sairastaville, mutta niiden käyttöä tulee välttää, jos potilaalla on käytössään myös
nitraattilääkitys, sillä yhteiskäytöstä voi seurata merkittävä verenpa inetason lasku [258].
Erektiohäiriöissä on hyvä muistaa myös paikallishoidon mahdollisuus.
Lääkehoidon jatkaminen
Antitromboottinen lääkitys
ASAn käyttöä jatketaan pääsääntöisest i pysyvästi annoksella 100 mg/vrk, ellei sille ole vasta-aiheita (verenvuotovaara, antikoagulaatiohoito tai allergia) [A].
ASAn siedätyshoitoa voidaan harkita erityistilanteissa .
Enoksapariini-  tai fondaparinuuksilääkitys voidaan useim miten lopettaa PCI:n jälkeen.
Riskipotilailla jatketaan tarvittaessa  laskimotukosprofylaksiaa. Ks. Käypä hoito suositus Laskimotukos ja keuhkoembolia «Syvä laskimotukos ja
keuhkoembolia», [259].
Suurempaa annosta jatketaan erityistapauksissa  harkinna n mukaan.
Jos varjoainek uvauksen jälkeen päädytään ohitusleikkaukseen,  pienim olekyylisen hepariinin käyttöä jatketaan leikkaukseen asti.
Ison transm uraalisen etuseinä vaurion yhteydessä  lienee hoitoannoksen antaminen sairaalahoidon ajan hyödyllistä.
ADP-resept orin salpaajalääkityksen (klopidogreeli, prasugreeli tai tikagrelori) kesto sepel valtimotautikohtauksen jälkeen on yleensä  12 kuukautta.
Jos ASA on vasta-aiheinen,  käytetään klopidogreelia pysyvästi.
Jos ensim mäisenä  vuotena on käytetty prasugreelia tai tikagreloria, vaihdetaan pysyväksi lääkitykseksi klopidogreeli.
Suuren verenvuotovaaran potilailla on harkittava ASAn tai ADP-resept orin salpaajan käytön lyhentämistä. Jos ASAn käyttö lopetetaan varhain, se tulee aloittaa
uudelleen ADP-resept orin salpaajan loppuessa , paitsi jos antikoagulantin tarve jää pysyväksi.
Vaihtoehtona 12 kuukauden kaksoisverihiutale-estolle etenkin suuren vuotovaaran potilaalla on ASAn tauottaminen 3 kuukauden kohdalla ja
tikagrelorimonoterapian jatkaminen 12 kuukauteen asti [142], [143].
Hoito ei suurentanut iskeem isten tapahtumien, kuten stenttitromboosin, riskiä, mutta se vähensi merkittävän verenvuodon vaaraa 44 % [142].
Antikoagulanttia käyttävien potilaiden antitromboottinen hoito suunnit ellaan yksilöllisest i niin,  että otetaan huomioon sekä tukos- että vuotovaara [152], [260],
[261], [262].
Suoria antikoagulantteja tulee käyttää varfariinin sijasta PCI:n jälkeen potilailla, joilla on eteisvärinä, laskimotukos tai keuhkoveritulppa [117], [118], [119], [120].
Taulukossa 13 kuvataan käytettävät suorien antikoagulanttien annokset sepel valtimotoimenpit een jälkeen.
ASA ja ADP-resept orin salpaaja suurentavat verenvuotoriskiä, minkä vuoksi kolmoishoitoa ei yleensä  tule jatkaa kotiutumisen jälkeen tai sen pituus on
minim oitava.
ASA voidaan lopettaa lääkityksestä lähipäivinä tai viimeistään 1 kuukauden kohdalla klopidogreelia käytettäessä  [117], [118], [119], [120], [263].
Suuren verenvuotovaaran potilailla pyritään käyttämään uudenaikaisia lääkestenttejä [264], [265] tai lääkepallohoitoa [155], jolloin ADP-resept orin
salpaajalääkitystä jatketaan yksilöllisen arvion mukaan, yleensä  3–12 kuukautta, minkä jälkeen jatketaan yleensä  pelkkää antikoagulanttia.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 31/41
Varfariinia  käytetään suorien antikoagulanttien sijasta ASAn ja ADP-resept orin salpaajan lisäksi, jos potilaalla on mitraalistenoosi, mekaaninen tekoläppä [266]
tai vasemman kammion trombi [192].
Prasugreelin ja tikagrelorin yhteiskäytöstä suorien antikoagulanttien tai varfariinin kanssa  on niukasti tutkimusnäyttöä.
Protonipu mpun estäjälääkitystä tulee harkita antikoagulantin ja ASAn tai ADP-resept orin salpaajan yhteiskäytön ajaksi [217]].
Pitkäkestoinen antitromboottinen lääkitys
Toista antitromboottista lääkettä ASAn lisäksi sekundaaripreventiossa (yli vuoden jälkeen sepel valtimotautikohtauksesta) pitäisi harkita potilaille, joilla on
suuri tai kohtalainen iskeem isten tapahtumien riski mutta ei suurta verenvuotovaaraa. Ks. taulukko 18.
Pitkäaikaista antitromboottista lääkitystä ei tule aloittaa potilaille, joilla on suuri verenvuotovaara, kuten merkittävä verenvuoto ensim mäisen hoitovuoden
aikana tai antikoagulaatiohoito. Ks. kohta Verenvuotovaara «A5».
Hoito suunnit ellaan yksilöllisest i ja voidaan toteuttaa klopidogreelilla (75 mg kerran päivässä), tikagrelorilla (60 mg kaksi kertaa päivässä) tai pienia nnoksisel la
rivaroksabaanilla (2,5 mg kaksi kertaa päivässä) [267], [268], [269].
Pitkäkestoinen ASAan yhdistetty klopidogreelihoito, jonka potilasvalinna ssa käytettiin iskeem isen riskin arviossa DAPT-laskuria, vähensi vakaaoireisessa
sepel valtimotaudissa iskeem isiä tapahtumia 48 % 18 kuukauden seurannassa suuren vaaran potilailla (DAPT riskipist eet ≥ 2). Merkittävät verenvuodot
lisääntyivät 1,3-kertaisest i [267].
Pitkäkestoinen pienia nnoksinen rivaroksabaanihoito ASAan yhdistettynä vähensi vakaaoireisessa  valtimotaudissa yhdistelmäpäätetapahtumaa 24 %
keskimäärin 23 kuukauden seurannassa suuren vaaran potilailla (kardiovaskulaarikuolema, aivohalvaus ja sydäninfarkti). Merkittävät verenvuodot
lisääntyivät 1,7-kertaisest i [268].
Pitkäkestoinen tikagrelorihoito ASAan yhdistettynä vähensi vakaaoireisessa  sepel valtimotaudissa yhdistelmäpäätetapahtumaa 15 % kolmen vuoden
seurannassa suuren vaaran potilailla (kardiovaskulaarikuolema, aivohalvaus ja sydäninfarkti). Merkittävät verenvuodot lisääntyivät 2,2-kertaisest i [269].
Pitkäaikainen antitromboottisen hoidon aloittaminen tulee kirjata potilaan riskitietoihin ja ohje menet telystä verenvuototilanteessa  tai verenvuotoriskin
kasvaessa  (yleensä  hoidon lopettaminen)  sairauskertomukseen.  Hoidon jatko tulee arvioida säännöllisest i vähintään vuosittain, ja potilaiden verenkuvaa sekä
munuaisten toimintaa mittaavia verikokeita tulee seurata.
Taulukko 18. Potilasryhmiä ja -piirteitä, joiden osalta tulee harkita pitkäaikaisen antitromboottisen hoidon aloittamista (yli vuoden kuluttua sepelvaltimotautikohtauksesta, ei
suurentunutta verenvuotovaaraa). Potilaan verenvuotovaara (ks. kohta Verenvuotovaara «A5») tulee arvioida ennen hoidon aloittamista ja arvioida hoidon aikana vähintään
vuosittain säännöllisesti.
Suuri iskeeminen riski Kohtalainen iskeeminen riski
Diffuusi tai monen suonen sepelvaltimotauti ja vähintään 1 seuraavista:
lääkehoitoa vaativa diabetes
uusiva sydäninfarkti
alaraajojen valtimokovettumatauti
munuaisten vajaatoimintaAinakin 1 seuraavista:
diffuusi tai monen suonen sepelvaltimotauti
lääkehoitoa vaativa diabetes
uusiva sydäninfarkti
alaraajojen valtimokovettumatauti
sydämen vajaatoiminta
munuaisten vajaatoiminta
Verenpa ineen hoito
Jos verenpa ine on kohonnut, ACE:n estäjä tai ATR:n salpaaja, beetasalpaaja, diureetti ja kalsiumkanavan salpaaja -pohjaiset hoidot vähentävät sydän- ja
verisuonitautitapahtumia [A].
Verenpa inelääkkeen laskiessa  verenpa inetta 10/5 mmHg sepel valtimotautiriski vähenee keskimäärin 22 % [270].
ACE:n estäjä, ATR:n salpaaja ja sakubitriili-valsartaani
ACE:n estäjä tulisi aloittaa kaikille sepel valtimotautipotilaille, joilla on hypertensio  (ks. Käypä hoito -suositus Kohonnut verenpa ine «Kohonnut verenpa ine» ,
[225]), ejektiofraktio alle 40 %, diabetes tai krooninen munuaisten vajaatoiminta, ellei potilaalla ole vasta-aiheita (kuten vaikea-asteinen munuaisten
vajaatoiminta tai hyperkalemia) [61].
ACE:n estäjä tulisi aloittaa 24 tunnin kuluessa  STEMI:stä, ellei ole vasta-aiheita [271].
ATR:n salpaaja voi korvata ACE:n estäjän niillä sepel valtimotautipotilailla, joille ACE:n estäjä ei sovi (ks. Käypä hoito -suositus Kohonnut verenpa ine
«Kohonnut verenpa ine» , [225]).
Jos potilaalla on oireinen krooninen sydämen vajaatoiminta ja ejektiofraktio on alle 35 %, voidaan harkita ACE:n estäjä- tai ATR:n salpaajalääkityksen
vaihtamista sakubitriilin ja valsartaanin yhdistelmään [272].
Sakubitriili-valsartaanin kanssa  ei tule käyttää muita ACE:n estäjiä tai ATR:n salpaajia 36 tunnin varoajalla.
Paradise-MI-tutkimuksessa  sakubitriili-valsartaani ei vähentänyt tilastollisest i merkitsevästi primaaripäätetapahtumia (kardiovaskulaarikuolema,
ensim mäinen sydämen vajaatoiminna sta johtuva sairaalahoito tai sydämen vajaatoiminta) ramipriiliin verrattuna akuutin sydäninfarktin sairastaneilla [263].
Primaaripäätetapahtumien lukumäärä oli kuitenkin sakubitriili-valsartaaniryhmässä pienem pi, ja kun tarkasteltiin kaikkia kardiovaskulaarikuolemia ja
sydämen vajaatoimintatapahtumia (ei vain ensim mäistä vajaatoimintatapahtumaa), sakubitriili-valsartaani osoittautui tehokkaammaksi.
Beetasalpaajat
Beetasalpaajat ovat tehokkaita sydänlihasiskemian ja siitä aiheutuvien oireiden hoidossa.
Beetasalpaajien annos pyritään säätämään siten, että leposyke on 55–60/min [61].
Vasospastisessa  angiinassa beetasalpaajia suositellaan välttämään, sillä ne saattavat pahentaa oireita [27].
Jos beetasalpaajaa tarvitaan, kannattaa valita nebivololi [273].
Kalsiumsalpaajat ja nitraatit ovat suositeltavampia [61].
Beetasalpaajalääkityksen yhdistämisest ä muuhun verenpa inelääkitykseen ks. Käypä hoito -suositus Kohonnut verenpa ine «Kohonnut verenpa ine» , [225].
Sairastetun sydäninfarktin jälkeen beetasalpaajien pitkäaikaiskäyttöä tulee harkita ennu stetta parantavan hyödyn vuoksi [61].
Beetasalpaajien on todettu vähentävän kuolleisuutta sekä uusia sydän- ja verisuonitautitapahtumia sydäninfarktin sairastaneilla sydämen
vajaatoimintapotilailla [274], [275], [276], [277], [278], [279], [280].
Beetasalpaajahoitoa suositellaan jatkettavaksi pysyvästi niillä sepel valtimotautipotilailla, joilla on infarktiarpi, sydämen vajaatoiminta tai oireeton
vasemman kammion toimintahäiriö [276].
Pitkäkestoisest a beetasalpaajahoidosta ei ole osoitettu ennu stehyötyä, kun sepel valtimotautikohtauksesta on kulunut yli 1 vuosi, vasemman kammion
toiminta on normaali ja kyseessä  on pien en riskin potilas [C].26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 32/41
Sepel valtimotautipotilailla, jotka eivät ole sairastaneet  sydäninfarktia ja joilla ei ole sydämen vajaatoimintaa, beetasalpaajan suojavaikutuksen suhteen näyttö
on puutteellista [61].
Kalsiumkanavan salpaajat
Kalsiumkanavan salpaajien ei ole osoitettu vaikuttavan sepel valtimotaudin ennu steeseen,  eikä niiden aloittaminen ole yleensä  aiheellista.
Jos potilas ei siedä beetasalpaajaa, voitaneen vaihtoehtoisest i käyttää sykettä hidastavia kalsiumkanavan salpaajia (verapamiili ja diltiatseem i)
rintakipuoireiden helpottamiseen,  kunhan potilaalla ei ole vasemman kammion toimintahäiriötä tai merkittävää johtumishäiriötä [B].
Dihydropyridiinir yhmän kalsiumkanavan salpaajia voidaan käyttää kohonneen verenpa ineen hoitoon tai rintakipujen helpottamiseen beetasalpaajien
lisänä.
Amlodipiinia  voidaan käyttää turvallisesti hypertensio n hoitoon [281].
Kalsiumkanavan salpaajalääkityksen yhdistämisest ä muuhun verenpa inelääkitykseen ks. Käypä hoito -suositus Kohonnut verenpa ine «Kohonnut verenpa ine» ,
[225].
Nitraatit
Pitkävaikutteista nitraattilääkitystä ei tarvita, jos potilaalla ei esiinny  akuutin vaiheen jälkeen haittaavaa angina pect oris -oiretta.
Rintakivun, hypertensio n ja vajaatoiminnan oireenm ukaisessa  hoidossa ne voivat usein olla aiheellisia. Erityisest i jos revaskularisaatio jää epätäydelliseksi,
nitraattihoito saattaa lieventää oirekuvaa.
Potilaille on annet tava lääkemääräys lyhytvaikutteisest a nitraattivalmisteesta mahdollisest i uusiutuvan rintakipukohtauksen ensih oitolääkkeeksi. Potilasta
suositellaan pitämään tätä lääkettä aina mukanaan.
Jos potilas on käyttänyt PDE5:n estäjiä 24 tunnin (avanafiili, sildenafiili, vardenafiili) tai 48 tunnin (tadalafiili) sisällä, yhteiskäytöstä nitraatin kanssa  voi
seurata merkittävä verenpa inetason lasku.
Spironolaktoni ja eplerenoni
Spironolaktonia voidaan harkita aloitettavaksi, jos ejektiofraktio on alle 35 %, vaikka sen käytöstä sydäninfarktin jälkeen on ristiriitainen näyttö.
Sepel valtimotautikohtauksessa  aldosteronin haitallista vaikutusta pyrittiin ehkäisem ään ALBATROSS-tutkimuksessa  (n = 1 603), mutta hoidolla ei todettu
ennu stevaikutusta pelkkään standardihoitoon verrattuna [282].
Muutoin spironolaktoni- tai eplener onihoitoa sepel valtimotautikohtauksessa  koskevat julkaisut ovat anekdotaalisia.
Kipulääkitys
Tulehduskipulääkkeet ja koksibit lisäävät uusintainfarktin ja kuoleman vaaraa infarktin sairastaneilla, joten niitä tulee mahdollisuuksien mukaan välttää [283].
Ensisij ainen kipulääke on parasetamoli.
Erityisryhmät
Monisairaat potilaat ja gerastenia
Ikä on sepel valtimotaudin tärkein riskitekijä.
Yli kolmasosa sepel valtimotautikohtauspotilaista on yli 75-vuotiaita [284], ja heistä kaksi kolmannest a on monisa iraita vanhuksia [285].
Sepel valtimotautikohtauksen hoidosta tehtyjen laajojen tutkimusten potilaista kuitenkin vain noin 10 % on ollut yli 75-vuotiaita [284].
Heilläkin esiint yy merkitsevästi vähemmän liitännäissairauksia kuin muilla samanikäisillä [284].
Päätelmät ikääntyneid en sepel valtimotautikohtauksen hoidosta perustuvat kontrolloitujen satunnaistutkimusten jälkikäteisiin (post hoc)
alaryhmäanalyyseihin. Hoitotutkimusten tulokset eivät siten ole suoraan sovellettavissa ikääntyneisiin.  Koska satunnaistettuja tutkimuksia tuskin enää
tehdään tässä tarkoituksessa , päätelmiä hoidon vaikuttavuudesta voitaisiin saada ainoastaan laajan kansallisen toimenpid erekisterin avulla [286].
Iäkkäiden potilaiden sepel valtimotautikohtauksen erityispiir teitä
Sepel valtimotautikohtauksen oireet ovat ikääntyneillä usein lieviä ja epätyypillisiä.
Pääoireina  ovat usein hengenahdistus (49 %) [287], hikoilu (26 %), pahoinvointi (24 %) ja pyörtyminen (19 %), joskus ainoastaan sekavuus [288].
EKG:st ä puuttuvat usein ST-muutokset (43 %) [288].
Vajaatoiminta liittyy taudinkuvaan jopa yli 40 %:lla [288].
Ikääntyneillä sepel valtimotautikohtausta pitää epäillä huomattavasti herkemmin kuin nuoremmilla.
Anem ia ja kilpirauhasen toimintahäiriöt voivat olla sepel valtimotautikohtauksen laukaisevia tekijöitä [288].
Hoitomuodon valinta iäkkäillä potilailla
Invasiivisella hoidolla voidaan vaikuttaa ikääntyneid en suuren vaaran potilaiden elinajanodotteeseen,  uusintakohtauksiin,  sairaalahoidon tarpeeseen ja
elämänlaatuun yhtä paljon kuin nuorempien, jos potilaalla ei ole toimintakykyä merkittävästi haittaavaa muistihäiriötä, aivo-, munuais- tai keuhkosairautta tai
elinajanodotetta lyhentävää syöpä- tai yleissa irautta [289], [290].
Sepel valtimotautikohtaukseen sairastuneita yli 75-vuotiaita suuren vaaran potilaita on hoidettava invasiivisilla menet elmillä samoin perustein kuin alle 75-
vuotiaita [B], ellei heillä ole merkittäviä toimenpit eiden komplikaatiovaaraa lisääviä sairauksia [284].
Itsenä isen toimintakykynsä menet täneillä potilailla keskitytään oireiden hoitoon. Kajoavaan hoitoon turvaudutaan vain, jos oireita ei muutoin saada hallintaan.
Verenvuotokomplikaatiot heikentävät muutoin hyviä hoitotuloksia [289]. Jos ikääntynyt, suuren verenvuotovaaran potilas on toipunut
sepel valtimotautikohtauksesta oireettomaksi ja iskemiamuutokset ovat hävinneet  EKG:st a eikä vasemman kammion toimintakyvyssä ole muutosta,
pallolaajennu shoidosta ja sen myötä aloitetusta antitromboottisest a lääkityksestä voi olla enem män haittaa kuin hyötyä [291].
Sepel valtimotaudin laajuuden ja akuutin ahtauman selvittäminen varjoainek uvauksella voi auttaa kokonaisvaltaisen hoidon suunnit telussa
Iäkkäiden verenvuotovaarassa olevien potilaiden PCI-hoidossa voidaan harkita lääkepallon käyttöä [155].
Monisa iraiden ikääntyneid en yksilöllisissä hoitopäätöksissä  joudutaan usein pidättäytymään kokonaan invasiivisista tutkimuksista ja hoidoista.
Hoitopäätökset tehdään yhteistyössä potilaan ja tarvittaessa  hänen omaistensa  kanssa .
Hoidon toteuttaminen
Antitromboottisen lääkehoidon aiheuttamat verenvuotokomplikaatiot ovat ikääntyneillä merkittävä ongelma.
Antitromboottisen hoidon kesto tulee suunnit ella yksilöllisest i siten, että huomioidaan vuoto- ja iskemiavaara.
Mahansuojalääkkeitä on ruoansulatuskanavan verenvuotojen estämiseksi käytettävä herkästi [217], [218].
Monilääkitys lisää lääkeinteraktioiden vaaraa.
Munuaisten vajaatoiminta altistaa lääkeinteraktioille.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 33/41
Munuaisten toimintakyky on syytä arvioida ainakin laskenna llisen kreatiniinipu hdistuman avulla ennen invasiivisest a hoidosta päättämisest ä [214], [284],
[293]. Ks. GFR-laskuri: «GF R-laskuri».
Munuaisten vajaatoiminta
Munuaisten vajaatoimintaa potevat on suljettu pois useim mista sepel valtimotautikohtausten hoitoa koskevista tutkimuksista [292]. Noin kolmasosalla
sepel valtimotautikohtauspotilaista on kuitenkin munuaisten toimintahäiriö [293], minkä vuoksi sepel valtimotautikohtauksen invasiivisen hoidon
hyödyllisyydestä varsink aan munuaisten vaikeaa vajaatoimintaa potevilla ei olla varmoja [284].
Munuaisten krooninen vajaatoiminta suurentaa kuitenkin erittäin selvästi sydän- ja verisuonitauti- sekä kokonaiskuolleisuutta [284], [293].
Myös diabetekseen liittymätön munuaisten lieväkin toimintahäiriö on yhteydessä  sepel valtimotaudin eri ilmenem ismuotoihin.
Toisaalta munuaisten vajaatoiminta lisää myös antikoagulaatiohoitoon ja invasiiviseen hoitoon liittyvää verenvuotovaaraa.
Vaara korreloi munuaisten vajaatoiminna n vaikeusasteeseen.
Troponiinipit oisuudet saattavat suurentua munuaisten vajaatoiminna ssa ilman sydänlihasvauriotakin varsink in dialyysipo tilailla ja aiheuttaa tulkintavirheen
vaaran arvioinnissa .
Toisaalta suurentunut troponiinipit oisuus ilman sydäninfarktia kuvaa huonompaa pitkäaikaisennu stetta erityisest i munuaisten vajaatoiminna ssa.
Ks. lisätietoa akuutin munuaisvaurion diagnostiikasta, hoidosta ja ehkäisystä Käypä hoito -suosituksesta Munuaisvaurio (akuutti) «Munuaisvaurio (akuutti)»,
[294].
Hoidon toteuttaminen
Kreatiniinipu hdistuman arviointi kuuluu kaikkien iäkkäiden ja pienik okoisten potilaiden sekä munuaisten vajaatoimintaa potevien
sepel valtimotautikohtauksen hoidon suunnit teluun [284], [293].
Jos kreatiniinipu hdistuma on alle 60 ml/min, verenvuotovaara suurenee merkitsevästi [295]. Tällöin on harkittava annosten pienent ämistä yksilöllisest i
siten, että huomioidaan tromboosivaara.
Jos kreatiniinipu hdistuma on alle 30 ml/min, pienim olekyylisen hepariinin,  fondaparinuksin, glykoproteiini IIb/IIIa:n estäjien ja muiden munuaisten
kautta poistuvien lääkkeiden annoksia on muutettava [213].
Munuaisten toimintahäiriön varhainen toteaminen mahdollistaa optimaalisen nest eytyksen ennen toimenpid ehoitoja.
Fondaparinuuksi saattaa aiheuttaa vähemmän verenvuotokomplikaatioita munuaisten vajaatoimintaa potevilla kuin hepariiniv almisteet [116], [284].
Antikoagulaatiohoito edellyttää erityistä varovaisuutta, jos mitattu tai arvioitu kreatiniinipu hdistuma on alle 30 ml/min [284].
Sepel valtimotautikohtauspotilaista jopa 13 %:lle kehittyy munuaisten toimintahäiriö [296], jonka syy on todennä köisest i monitekijäinen.
Rutiinino mainen nest eytys ennen varjoainek uvausta tai sen jälkeen normovoleem isella potilaalla ei pienennä  munuaisvaurion riskiä, mutta se altistaa
dekompensa atiolle [218].
Suuren vaaran potilaille (taulukko 19) suositellaan nest eytystä 0,9-prosent tisella NaCl:llä tai Ringer-tyyppisil lä liuoksilla: 1 ml/kg/h 3–4 tunnin ajan ennen
ja 4–6 tuntia jälkeen varjoaineen annon, tai 1,4-prosent tisella Na-bikarbonaatilla 3 ml/kg/h 1 tunnin ajan ennen varjoaineen antoa.
Hypovolemia tulee kuitenkin korjata nest eytyksellä ennen varjoainek uvausta (Ringer, NaCl tai 1,4-prosent tinen bikarbonaatti).
Taulukko 19. Erityisen suuri akuutin munuaisvaurion riski
eGFR < 45 ml/min/173 m
Toistuvat varjoaineannokset 48–72 tunnin sisällä
Vaikea sepsis
Kohonnut intra-abdominaalipaine
Vaikea rabdomyolyysi, palovamma tai tuumorilyysioireyhtymä
Sytostaattihoidot, joihin liittyy suuri akuutin munuaisvaurion riski
Sepelvaltimotautikohtauspotilaan ajoterveyden ja työkyvyn arviointi
Työkyky
Työikäisistä sepel valtimotautikohtauspotilaista suurin osa palaa takaisin työelämään.
Potilaalle tulee kertoa alustava ennu ste hänen työkyvystään niin pian kuin mahdollista.
Sairauspoissaolon pituus riippu u vaurion koosta ja työn kuormittavuudesta.
Pienen ja komplisoitumattoman infarktin jälkeen riittää 2 viikon sairauspoissaolo [298], [299].
Fyysisest i raskas työ tai vuorotyö voi vaatia helpotettuja työjärjestelyjä.
Sairauspoissaolo voi olla tarpeen monen suonen tautia sairastaville ennen revaskularisaation täydentämistä.
Rasituskoe tai spiroergometria voi auttaa jäljellä olevan työkyvyn arvioinnissa .
Liikenneajoneuvon kuljettaminen sepelvaltimotautikohtauksen jälkeen
Ajokykyyn ja autolla-ajokiellon pituuteen on otettava kantaa potilaan kotiutuessa  sairaalasta.
UAP:
ryhmät 1 ja 2: 1 viikko.
NSTEMI tai STEMI [221], [222]:
ryhmä 1: ajokieltoa on vähintään 1 viikko.
ryhmä 2: ajokieltoa on vähintään 6 viikkoa
Sydämen vajaatoiminta, jäännösiskemia ja kammioperäiset rytmihäiriöt voivat pitkittää ajokieltoa.
Jos seurantakäynnillä EF < 35 %, ryhmän 2 ajoterveysvaatimukset eivät täyty.
Ammattiautoilun jatkamisen edellytys on, ettei potilaalla ole rintakipuja tai muita iskemiaan viittaavia oireita (CCS  > 2) ja ettei hänelle kehity kliinist ä
sydämen vajaatoimintaa tai hemodynamiikkaan haitallisest i vaikuttavia kammioperäisiä rytmihäiriöitä. Potilaan suorituskyky saa olla korkeintaan
lievästi heikentynyt.
Rasituskokeella voidaan tarvittaessa  arvioida suorituskykyä, rytmihäiriöiden esiin tyvyyttä ja iskemiaa.
Ammattikuljettajien tulee käydä vuosittain lääkärintarkastuksessa . Heidän terveydentilansa pitää täyttää edellä mainitut yleisper iaatteet.226.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 34/41
Ks. lisätietoja ja vaatimusten päivitykset: Traficom.fi (ks. viimeisin päivitys Ajoterveyden arviointiohjeet terveydenhuollon ammattilaisille:
https://www. traficom.fi/fi/saadokset/ajoterveyden-arviointiohjeet-terveydenhuollon-ammattilaisille).
Sydänkuntoutus
Sydänkuntoutuksella tarkoitetaan suunnitelmallista ja moniammatillisest i toteutettavaa kuntoutusohjelmaa, joka on laadittu sepel valtimotautikohtaukseen
sairastuneen toipumisen edistämiseksi. Kuntoutuksella pyritään mahdollisim man hyvään fyysiseen,  psyykkiseen ja sosiaaliseen toimintakykyyn [222], [302], [303].
Liikunnallisen kuntoutuksen lisäksi kuntoutuksella tarkoitetaan potilaan tietojen lisäämistä sydänsairaudestaan, sen hoidosta ja hoidon tavoitteista sekä
vertaistuen tarjoamista. Sydänkuntoutuksen korvaavaksi termiksi on tämän vuoksi esitetty kattavampaa termiä "sydänvalmennu s" [304].
Sepel valtimotautipotilaiden liikuntapainotteisen kuntoutuksen on osoitettu pienent ävän kokonais- ja sydänkuolleisuutta ja vaikuttavan edullisest i sydän- ja
verisuonisa irauksien vaaratekijöihin [A], [221].
Suomalaisista sydänpotilaista vain pieni osa saa systemaattista kuntoutusta.
Sekundaariprevention tavoitteiden on todettu toteutuvan Euroopan laajuisest i huonosti. Euroaspire V -tutkimuksen tulosten mukaan verenpa ine oli
hoitotavoitteessa  42 %:lla potilaista ja LDL-kolesterolipitoisuus vain 29 %:lla potilaista puolen vuoden kuluttua indeksitapahtumasta. Tupakoitsijoista jopa 55
% jatkoi tupakointia sydäntapahtuman jälkeen [305].
Jokaiselle sepel valtimotautikohtauksen sairastaneel le tulee tehdä yhteistyössä hänen kanssa an yksilöllinen hoito- ja kuntoutussuunnit elma joko jo sairaalassa
tai pian kotiutumisen jälkeen.
Hoito- ja kuntoutussuunnit elman päätavoitteena  tulee olla potilaan ohjaus ja sitouttaminen omahoitoon ja riskitekijöiden hallintaan.
Sairastuneid en kyky ottaa aktiivinen rooli omahoidossaan on tärkeää sairastuvuuteen ja kuolleisuuteen liittyvien riskien pienent ämisessä .
Omahoidon kulmakivet ovat
lääkehoito ja siitä huolehtiminen
tupakoimattomuus
verenpa ineen lääkkeellinen ja lääkkeetön hoito
lipidiprofiili ja painonhallinta
sydänterveellinen ruokavalio
säännöllinen liikunta
riittävä lepo ja uni
stressinh allinta.
Ensisij aisest i suositellaan sydänpotilaille suunnattua avokuntoutusta, poikkeustapauksissa  laitoskuntoutusta.
Lääkärin ja muun hoitoon ja seurantaan osallistuvan henkilöstön tulee arvioida kuntoutuksen tarve ja toteutuneen kuntoutuksen onnist uminen jokaisen
seurantakäynnin yhteydessä .
Työryhmä suosittelee erilaisten valmennu sohjelmien kehittämistä ja käyttöönottoa osana digitaalisia hoitopolkuja.
Potilaalle voidaan tarvittaessa  tehdä kliininen kuormituskoe rasituksen aikaisen sydänlihasiskemian ja rytmihäiriöiden selvittämiseksi tukemaan liikunnallisen
kuntoutuksen suunnit telua ja rohkaisem aan potilasta liikkumaan [306].
Kliininen kuormituskoe toteutetaan lääkärin valvonnassa.
Kliinisessä  työssä myös 6 minuutin kävelytesti on käyttökelpoinen erityisest i osana voinnin arviointia, liikunnallisen kuntoutuksen suunnit telua sekä
potilaan rohkaisem isessa  liikkumaan.
Liikuntaohjauksessa  tulee ottaa huomioon ja arvioida potilaan yksilöllinen vointi, suorituskyky, motivaatiotaso, liikuntahistoria, tuen tarve, yleiset  ja
yksilölliset tavoitteet sekä
ohjauksen oikea-aikaisuus
progressiiv inen liikunnan lisääminen mahdollisuuksien mukaan
ohjeiden päivitys tarvittaessa  tai tilanteen muuttuessa
sydäntapahtuman laajuus ja mahdollinen sydämen vajaatoiminta huomioitava
nitraattivalmisteen käytön ohjaus.
Kestävyysliikunnan ja lihasvoimaharjoittelun ehdottomista vasta-aiheista ks. .
Liikunnallisen kuntoutuksen toteuttamisest a on käytännön ohjeita suosituksessa  Sepel valtimotautipotilaan liikunnallinen kuntoutus: Hyvä
fysioterapiakäytäntö [221].
Kuntoutuksen alueellinen organiso inti osana sydänpotilaan hoitoketjua kuuluu sairaanhoitopiirille.
Käytännön toteutuksesta huolehtivat perusterveydenhuolto ja muun muassa Sydänliitto https://sy dan.fi/apua-ja-tukea/kuntoutus2?
eventDistricts=&eventDates=&eventSicknessGr oup=&eventTargetGroup=&query=.
Alueellinen sepelvaltimotautikohtauspotilaan hoidon ohjaus
Kansalaisten tietoutta sepel valtimotaudista ja hätänumeroon sekä toissijaisest i päivystysapu-neuvontanumeroon soittamisen tärkeydestä tulee lisätä.
Jokaisessa  terveydenhuollon toimipist eessä  tulee olla kirjalliset, ajantasaiset toimintaohjeet rintakipuisen potilaan hoidosta.
Sairaanhoitopiirin ensih oidon vastuulääkäri vastaa yhdessä  alueen perusterveydenhuollon ja erikoissairaanhoidon päivystyksestä vastaavien lääkäreiden ja
vastuualueen kardiologien kanssa
hoitoketjun suunnit telusta
ohjauksesta
ajantasaisest a, kirjallisest a hoito-ohjeesta, joka sisältää palveluiden alueellisen saatavuuden.
Alueellisen hoidon tarkka suunnit telu ja etukäteispä ätökset siitä, missä ja miten tietynlaiset potilaat hoidetaan, ovat hoitoketjun kulmakiviä, joita
sairaanhoitopiirien tai erityisvastuualueiden rajat eivät saa häiritä.
On pyrittävä huolehtimaan siitä, että koko maan riittävän hyvin kattava kardiologisten päivystyspist eiden verkko saadaan pidetyksi yllä.
Sepel valtimotautikohtauksen hoidon viiveettömin ja tehokkain aloitus toteutuu ensih oidossa.
Toimenpit eiden keskittäminen ja pidentyneet  kuljetusmatkat tulee huomioida ensih oidon resursseissa .
Toimiva hoitoketju edellyttää alueellisest i hyvää suunnit teluyhteistyötä ensih oidon, perusterveydenhuollon ja erikoissairaanhoidon kesken.
Myös ensih oitoryhmän sisäinen työnjako tulee olla määritelty.
Diagnostiikan ja hoidon aloituksen viiveitä tulee seurata myös alueellisest i.
Jos potilas on hakeutunut perusterveydenhuollon tai työterveyshuollon yksikköön (julkinen tai yksityinen) , hänet tulee arvioida välittömästi ja hänelle tulee
aloittaa akuuttihoito ennen siirtokuljetusta.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 35/41
Alueen ensih oitopalveluun tulee kuulua hoitotason ensih oitoyksikkö tai -yksiköitä, joiden lääkevalikoimassa ovat ASA, nitraattisuihke ja -infuusio, opiaatti,
beetasalpaaja, pienim olekylaarinen hepariini sekä PCI- ja liuotushoitojen yhteydessä  käytettävät lääkkeet tai alueellisten ohjeiden mukaisest i hyytymiseen
vaikuttavat lääkkeet, bentsodiatsepiini ja pahoinvointilääke.
STEMI:n hoitomuodot ovat primaari PCI ja liuotushoito tapahtumapaikalla.
Kumpi tahansa hoitomuoto viiveettä toteutettuna on parempi kuin hoidotta jättäminen.
Välitön PCI on STEMI:n paras hoito, jos se on saatavissa riittävän nopeasti riittävän suuren volyymin keskuksessa . Pitkien etäisyyksien vuoksi tämä ei
kuitenkaan ole mahdollista kaikkialla Suomessa .
Osassa maata käytetään pitkien etäisyyksien vuoksi ensisij aisest i tapahtumapaikalla annet tavaa liuotushoitoa. Tällöin potilaat tulee kuitenkin liuotushoidon
aloittamisen jälkeen toimittaa suoraan sellaiseen sairaalaan, jossa on mahdollisuus päivystysluonteiseen välittömään varjoainek uvaukseen ja PCI-hoitoon,
jos liuotushoito vaikuttaa jääneen tehottomaksi.
Hoitolinjasta riippu matta potilas kuljetetaan lähimpään riittävän suuren volyymin sairaalaan, jossa varjoainek uvaus ja mahdollinen PCI voidaan tehdä
ympäri vuorokauden.
Ensih oidon ilmoitus suoraan vastaanottavaan toimenpid eyksikköön nopeuttaa hoitoon pääsyä ja parantaa tuloksia [307].
PCI-hoitoon tuleva STEMI-potilas tulee tuoda suoraan toimenpid esaliin.
Hyvin toimiva hoitoketju ja hoito-ohjeiden mukainen toiminta parantaa sepel valtimotautikohtauspotilaan hoidon tuloksia [308].
Suomalaisen Lääkäriseuran Duodecimin ja Suomen Kardiologisen Seuran asettama työryhmä
Sepel valtimotautikohtaus-suosituksen historiatiedot
Puheenjohtaja:
Ilkka Tierala, LL, sisätautien ja kardiologian erikoislääkäri, osastonlääkäri; HYKS Meilahden sairaala, Sydäntutkimusosasto
Kokoava kirjoittaja:
Essi Ryödi, LT, sisätautien ja kardiologian erikoislääkäri, apulaisylilääkäri; TAYS Sydänsairaala
Jäsenet:
Markku Eskola, LT, kardiologian dosent ti, sisätautien ja kardiologian erikoislääkäri, sairaalajohtaja, ylilääkäri; TAYS Sydänsairaala
Pertti Jääskeläinen,  LT, dosent ti, sisätautien ja kardiologian erikoislääkäri, apulaisylilääkäri; KYS Sydänkeskus
Johanna Keränen,  sairaanhoitaja; OYS
Heidi Lehtola, LT, kardiologian erikoislääkäri; OYS, kardiologian osasto
Heidi Mahrberg, fysioterapeutti, palveluvastaava; Tays Sydänsairaala
Tuula Meina nder, LL, BSc, sisätautien ja kardiologian erikoislääkäri, terveydenhuoltoon erikoistuva lääkäri, osastonylilääkäri; Hämeenl inna n ja Riihimäen
Sydänsairaala, Käypä hoito -toimittaja
Ari Palomäki, akuuttilääketieteen professori, sisätautiopin dosent ti, sisätautien ja akuuttilääketieteen erikoislääkäri, tulosalueylilääkäri, ylilääkäri; Tampereen
yliopisto ja Kanta-Hämeen keskussairaala, konser vatiivinen tulosalue ja päivystysklinikka
Mikko Parry, LT, sisätautien ja kardiologian erikoislääkäri; HYKS Sydän- ja keuhkokeskus, kardiologia
Pertti Pasanen,  LL, yleislääketieteen erikoislääkäri, apulaisylilääkäri; Kainuun sote-kuntayhtymä, Suomussalmen terveysasema
Pekka Porela, LT, dosent ti, kardiologian erikoislääkäri, osastonylilääkäri; TYKS Sydänkeskus
Jyrki Puolakka, LL, anest esiologian erikoislääkäri, osastonlääkäri; HUS Akuutti, Ensih oito, Helsink i
Tuomas Rissanen,  LT, dosent ti, kardiologian erikoislääkäri, ylilääkäri; Pohjois-Karjalan keskussairaala, Siun Sote, Sydänkeskus
Antti Saraste, apulaisprofesso ri, kardiologian erikoislääkäri; TYKS Sydänkeskus ja Turun yliopisto
Antti Valtola, LT, kirurgian, sydän- ja rintaelinkirurgian erikoislääkäri, ylilääkäri; KYS Sydänkeskus, Sydän- ja rintaelinkirurgia
Asiantuntijat:
Anna-Mari Hekkala, LT, sisätautien ja kardiologian erikoislääkäri, ylilääkäri, Suomen Sydänliitto ry
Jani Mononen,  LL, akuuttilääketieteen erikoislääkäri, osastonylilääkäri, HUS Akuutti, Meilahden yhteispä ivystys
Kjell Nikus, LT, professo ri (emeritus), sisätautien ja kardiologian erikoislääkäri
Arto Pietilä, FM, tilastotieteilijä, THL, Helsink i
Veik ko Salomaa, LKT, sisätautien erikoislääkäri, tutkimusprofesso ri (emeritus), THL, Helsink i
Marjut Varpula, LT, sisätautien ja kardiologian erikoislääkäri, HUS Sydän- ja keuhkokeskus
Sidonnaisuudet
Sidonnaisuusilmoitukset on kerätty 23.3.2022 julkaistun suosituksen laatimisen yhteydessä
Markku Eskola: Luento-, koulutus- ja asiantuntijapalkkiot: Amgen AB, Novo Nordisk, Edwards Lifesciences; Ohjaushankkeet: THL:n kansallinen
sepel valtimotaudin laaturekisteri.
Pertti Jääsk eläinen: Sivutoimet: Konsultti, Satucon Oy; muutaman viikon tutkijajaksoja FinHCM-projektissa, KYS Medisiininen keskus ja Itä-Suomen
yliopisto; Tutkimusrahoitus: Novartis Oy:n PARADISE-MI-tutkimus; Actelion Oy:n EXPOSURE-tutkimus; Luento-, koulutus- ja asiantuntijapalkkiot: Actelion,
AstraZeneca , Bayer, BMS, BMS-Pfizer-allianssi,  Boehringer Ingelheim, Cardiome, MSD, Novartis; Korvaukset seminaari- ja kongressik uluista: Actelion, Bayer,
Boston Medical, Edwards Lifesciences,  Hexacath, MSD, Terumo; Luottamustoimet: Suomen Kardiologisen Seuran hallitus, sihteeri 2016–2018; Muut
sidonnaisuudet: Satucon Oy, asiantuntijalääkäri, aiempi osakeomistus (viimeisten 3 vuoden aikana), Orion Oy.
Johanna Keränen: Luento-, koulutus- ja asiantuntijapalkkiot: Sydänliitto, Digi-Tulppa-hankkeessa  asiantuntijana, Boehringer Ingelheim, Amgen;
Luottamustoimet: Suomen kardiologiset hoitajat, hallitus.
Heidi Lehtola: Sivutoimet: Oulun Sydänkeskus, kardiologian erikoislääkäri; Korvaukset seminaari- ja kongressik uluista: Boston Scient ific, Edwards
Lifesciences,  Medtronic; Luottamustoimet: SKS, Sydänääni-lehden päätoimittaja.
Heidi Mahrberg: Sivutoimet: Toiminim i Heidi Mahrberg, yksityisvastaanotto Tays Sydänsairaalalla; Luento- koulutus- ja asiantuntijapalkkiot: Suomen
Sydänliitto, Karpatiat ry, Hämeenm aan Sydänpiir i (nyk. Sydän-Suomen alue ry), Uudenm aan Sydänpiir i, Sydännuoret ja -aikuiset. Luottamustoimet: Käypä hoito,
Sepel valtimotauti-neuvottelukunnan jäsen; Suomen Sydänfysioterapeutit ry, hallituksen puheenj ohtaja 2011–2019, hallituksen jäsen 2019–.26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 36/41
Tuula M einander: Sivutoimet: Tampereen yliopisto, oikeuslääketiede, väitöskirjatutkija; Luento-, koulutus- ja asiantuntijapalkkiot: Suomen Lääkäriliitto,
Suomalainen Lääkäriseura Duodecim , Suomen Kardiologinen Seura, Bayer Oy, Boehringer Ingelheim, Terve Media Oy; Korvaukset seminaari- ja
kongressik uluista: Bayer Oy, Amgen AB; Luottamustoimet: Käyvän hoidon Sepel valtimotautineu vottelukunnan sihteeri ja jäsen, Käyvän hoidon Diabetes-
neuvottelukunnan sihteeri ja jäsen; Suomen Kardiologinen Seura, Sydänääni-lehden toimittaja ja nettitoimittaja, European Society of Cardiology, eurooppalaisen
kardiologikoulutuksen opetussuunnit elman päivitystoimikunnan nuorten kardiologien edustaja, Pohjoismaisen työryhmän jäsen, Guidelines International
Network, Tays Sydänsairaala 2018–, luottamusvaltuutettu.
Ari Palomäk i: Sivutoimet: Tampereen yliopisto, Lääketieteen ja terveysteknologian tiedekunta, akuuttilääketieteen professo ri; Tutkimusrahoitus: Bayer Nordic
Suomi Oy, Zenico r Medical Systems AB; Luento-, koulutus- ja asiantuntijapalkkiot: Bayer Nordic Suomi Oy, Oy Bristol-Myers Squibb (Finland) Ab, Pfizer Finland
Oy, Sanofi Oy; Luottamustoimet: Suomen Akuuttilääketieteen Yhdistys ry:n puheenj ohtaja, European Society for Emergency  Medicine Councilin jäsen, European
Society for Emergency  Medicine Resea rch Committeen jäsen, UEMS (European Specia list Association), Section and Board of Emergency  Medicinen jäsen;
Ohjaushankkeet: Lukuisat kehityshankkeet Kanta-Hämeen maakunnan/sa iraanhoitopiirin alueella ja puitteissa , Tähtisairaala-yhteistyö (Kanta-Häme, Pirkanmaa
ja Etelä-Pohjanmaa); Muut sidonnaisuudet: Hämeen Kanta Oy:n (ei th-alan toimintaa) hallituksen puheenj ohtaja; Suomen lääketieteellinen informaatiopalvelu
Oy:n (oma pieny ritys muutaman ystävän kanssa , th-alan luentoja ym.) hallituksen puheenj ohtaja; PAL Finland Oy:n (tuotekehitys, maahantuonti ja tukkumyynti
(mm. sairaalatarvikkeiden – hengityssuojaimet ym. – maahantuontia) hallituksen jäsen.
Mikko Parry : Luento-, koulutus- ja asiantuntijapalkkiot: Boehringer Ingelheim, Bayer; Luottamustoimet: Suomen kardiologisen seuran akuuttijaoksen
puheenj ohtaja; Ohjaushankkeet: Apotti Oy, Apotti-asiantuntija.
Pertti Pasan en: Ei aiheeseen liittyviä sidonnaisuuksia.
Pekka Porela: Korvaukset seminaari- ja kongressik uluista: Bayer.
Jyrki Puolakka: Ei aiheeseen liittyviä sidonnaisuuksia.
Tuomas R issan en: Tutkimusrahoitus: Boston Scient ific, B. Braun; Luento-, koulutus- ja asiantuntijapalkkiot: Boston Scient ific, B. Braun, Abbott, Bayer, BMS,
MSD, AstraZeneca , Amgen, Boehringer Ingelheim; Korvaukset seminaari- ja kongressik uluista: Boston Scient ific, B. Braun, Abbott, Medtronic, Cardirad;
Luottamustoimet: Suomen Kardiologinen Seura, Sydänliitto; Muut sidonnaisuudet: Heart2Save, Amgen.
Essi Ryödi: Sivutoimet: Sydänlääkäri Essi Ryödi Oy, erikoislääkäri, toimitusjohtaja (kardiologin yksityisvastaanotto, luenno inti, opetus- ja asiantuntijatehtävät);
Tutkimusrahoitus: Duodecim  Oy:n kannustusapuraha väitöskirjatyöhön; Luento-, koulutus- ja asiantuntijapalkkiot: NovoNordisk, BMS-Pfizer-allianssi,  Bayer,
Zora Biosciences,  Suomen Kardiologinen Seura, MSD; Korvaukset seminaari- ja kongressik uluista: Boston Scient ific, Abbot; Luottamustoimet: Suomen
Kardiologisen Seuran hallituksen varasihteeri 2016–2018; Suomen Kardiologisen Seuran hallituksen puheenj ohtaja 2018–2020 ja edellinen puheenj ohtaja 2020–
2022.
Antti Sarast e: Sivutoimet: TYKS Sydänkeskus, Turun yliopistollinen keskussairaala, ylilääkäri; Tutkimusrahoitus: Astra Zeneca ; Luento-, koulutus- ja
asiantuntijapalkkiot: Astra Zeneca , Novartis, Bayer, Abbott, Amgen; Korvaukset seminaari- ja kongressik uluista: Bayer, Abbott, Boehringer Ingelheim;
Luottamustoimet: Sydäntutkimussäätiö, Suomen Kardiologinen Seura, European Society of Cardiology.
Ilkka Tierala : Ei aiheeseen liittyviä sidonnaisuuksia.
Antti Valtola: Sivutoimet: Satucon Oy:n konsultti; Luento-, koulutus- ja asiantuntijapalkkiot: Oy Eli Lilly Finland Ab; Korvaukset seminaari- ja
kongressik uluista: Abbott Finland Oy, Edwards Lifesciences Nordic Oy, Grex Medical Oy, Johnson & Johnson Finland Oy; Luottamustoimet: Suomen
Thoraxkirurgiyhdistyksen hallituksen jäsen; Suomen Kardiologisen Seuran hallituksen jäsen; Muut sidonnaisuudet: Satucon Oy.
Kirjallisuusviite
Sepel valtimotautikohtaus. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Kardiologisen Seuranasettama työryhmä. Helsink i:
Suomalainen Lääkäriseura Duodecim , 2022 (viitattu pp.kk.vvvv). Saatavilla internetissä: www. kaypahoito.fi
Tarkemmat viittausohjeet: http://www. kaypahoito.fi/web /kh/viittaaminen
Vastuun rajaus
Käypä hoito -suositukset ja Vältä viisaasti -suositukset ovat asiantuntijoiden laatimia yhteenv etoja yksittäisten sairauksien diagnostiikan ja hoidon
vaikuttavuudesta. Suositukset toimivat lääkärin tai muun terveydenhuollon ammattilaisen päätöksent eon tukena hoitopäätöksiä tehtäessä . Ne eivät korvaa
lääkärin tai muun terveydenhuollon ammattilaisen omaa arviota yksittäisen potilaan parhaasta mahdollisest a diagnostiikasta, hoidosta ja kuntoutuksesta
hoitopäätöksiä tehtäessä .
Tiedonhakukäytäntö
Systemaattinen kirjallisuushaku on hoitosuosituksen perusta. Lue lisää artikkelista khk00007
Kirjallisuutta
1. Sepel valtimotautikohtaus: epästabiili angina pect oris ja sydäninfarkti ilman ST-nousuja – vaaran arviointi ja hoito. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Kardiologisen Seuran
asettama työryhmä. Duodecim  2003;119 :430-41
2. Thygesen K, Alpert JS, Jaffe AS ym. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2 551-67 «PMID: 22922414»
3. Fuster V, Badimon L, Badimon JJ ym. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326:242-50 «PMID: 1727977»
4. Fuster V, Badimon L, Badimon JJ ym. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310 -8 «PMID: 1728735»
5. Koukkunen H, Salomaa V, Lehto S ym. Coronary events in persons aged 75 years or older in Finland from 1995 to 2002: the FINAMI study. Am J Geriatr Cardiol 2008;17:78-86 «PMID: 18326953»
6. Salomaa V. Worrisome trends in the incid ence of coronary artery disease events among young individuals. Eur J Prev Cardiol 2020;27:1175-1177 «PMID: 31941364»
7. Tilastokeskus. Kuolemansyyt. http://t ilastokeskus.fi/til/ksyyt/
8. SWEDEHEART Annual Report 2019. Sivut 73 ja 78–9. https://ww w.ucr.uu.se/swed eheart/dokument-sh/arsrapporter-sh/1-swed eheart-annual-report-2019/
9. Dudas K, Björck L, Jernberg T ym. Differences between acute myocardial infarction and unstable angina: a longitudinal cohort study reporting findings from the Register of Information and Knowledge about Swedish
Heart Intensiv e Care Admissio ns (RIKS-HIA). BMJ Open 2013;3: «PMID: 23288269»
10. Vikman S, Airaksinen K, Peuhkurinen K ym. Sepel valtimokohtauksen hoito Suomessa . Duodecim  2005;121:753-9
11. Heidenreich  PA, Alloggiamento T, Melsop K ym. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38 :478-85 «PMID: 11499741»
12. Morrow DA, Cannon CP, Rifai N ym. Ability of minor elevations of troponins I and T to predict benef it from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction:
results from a randomized trial. JAMA 2001;286:2405-12 «PMID: 11712935»
13. Savonitto S, Ardissino  D, Granger CB ym. Prognostic value of the admissio n electrocardiogram in acute coronary syndromes. JAMA 1999;281:707-13 «PMID: 10052440»
14. Diderholm E, Andrén B, Frostfeldt G ym. ST depressio n in ECG at entry indicates severe coronary lesions and large benef its of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG
substudy. The Fast Revascularisation during InStability in Coronary artery disease. Eur Heart J 2002;23:41-9 «PMID: 11741361»
15. Jernberg T, Lindahl B, Wallentin L. ST-segment monitoring with continuous 12-lead ECG improves early risk stratification in patients with chest pain and ECG nondiagnostic of acute myocardial infarction. J Am Coll
Cardiol 1999;34:1413-9 «PMID: 10551686»
16. Morrow DA, Antman EM, Charlesworth A ym. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinica l score for risk assessm ent at present ation: An intravenous nPA for treatment of
infarcting myocardium early II trial substudy. Circulation 2000;102:2031-7 «PMID: 11044416»
17. Lansky AJ, Goto K, Cristea E ym. Clinica l and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage
strategY (ACUITY) trial. Circ Cardiovasc Interv 2010;3:30 8-16 «PMID: 20647564»
18. Eagle KA, Lim MJ, Dabbous OH ym. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-33
«PMID: 15187054»
19. Liakos M, Parikh PB. Gender Disparities in Present ation, Management, and Outcomes of Acute Myocardial Infarction. Curr Cardiol Rep 2018;20:64 «PMID: 29909444»
20. Kanic V, Vollrath M, Tapajner A ym. Sex-Related 30-Day and Long-Term Mortality in Acute Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention. J Womens Health (Larchmt) 2017;26:374-
379 «PMID: 28355097»
21. Peters SAE, Colantonio LD, Dai Y ym. Trends in Recurrent Coronary Heart Disease After Myocardial Infarction Among US Women and Men Between 2008 and 2017. Circulation 2021;143:650-660 «PMID: 32951451»
22. Walli-Attaei M, Joseph  P, Roseng ren A ym. Variations between women and men in risk factors, treatments, cardiovascular disease incid ence,  and death in 27 high-inco me, middle-inco me, and low-inco me countries
(PURE): a prospect ive cohort study. Lancet  2020;396:97-109 «PMID: 32445693»
23. Dou Q, Wang W, Wang H ym. Prognostic value of frailty in elderly patients with acute coronary syndrome: a systematic review and meta-analysis. BMC Geriatr 2019;19:222 «PMID: 31416442»26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 37/41
24. Ponikowski P, Voors AA, Anker SD ym. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the
European Society of Cardiology (ESC)Developed with the specia l contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200 «PMID: 27206819»
25. Piironen M, Ukkola O, Huikuri H ym. Trends in long-term prognosis after acute coronary syndrome. Eur J Prev Cardiol 2017;24:274-280 «PMID: 27856805»
26. Jernberg T, Hasvold P, Henriksson M ym. Cardiovascular risk in post-myocardial infarction patients: nationwid e real world data demonstrate the importance of a long-term perspect ive. Eur Heart J 2015;36:1163-70
«PMID: 25586123»
27. Knuuti J, Wijns W, Saraste A ym. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-477 «PMID: 31504439»
28. Rubini Gimenez  M, Reiter M, Twerenbold R ym. Sex-specif ic chest pain characteristics in the early diagnosis of acute myocardial infarction. JAMA Intern Med 2014;174:241-9 «PMID: 24275751»
29. Devon HA, Rosenf eld A, Steffen AD ym. Sensit ivity, spec ificity, and sex differences in symptoms reported on the 13-item acute coronary syndrome checklist. J Am Heart Assoc 2014;3:e0 00586 «PMID: 24695650»
30. van der Meer MG, Backus BE, van der Graaf Y ym. The diagnostic value of clinica l symptoms in women and men present ing with chest pain at the emergency  department, a prospect ive cohort study. PLoS One
2015;10:e0116431 «PMID: 25590466»
31. Brush JE Jr, Krumholz HM, Greene EJ ym. Sex Differences in Symptom Phenotypes Among Patients With Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes 2020;13:e0 05948 «PMID: 32063049»
32. Swap CJ, Nagurney JT. Value and limitations of chest pain history in the evaluation of patients with suspect ed acute coronary syndromes. JAMA 2005;294:2623-9 «PMID: 16304077»
33. Kardiologia. Airaksinen J, Aalto-Setälä K, Hartikainen H ym. (toim.). 3. uudistettu painos. Kustannus Oy Duodecim  2016. s. 444
34. Kardiologia. Airaksinen J, Aalto-Setälä K, Hartikainen H ym. (toim.). 3. uudistettu painos. Kustannus Oy Duodecim  2016. ss. 442-55
35. Savonitto S, Fusco R, Granger CB ym. Clinica l, electrocardiographic, and biochemical data for immediate risk stratification in acute coronary syndromes. Ann Noninv asive Electrocardiol 2001;6:64-77 «PMID:
11174865»
36. Saitoh M, Matsuo K, Nomoto S ym. Prognostic significance of electrocardiographic change during anginal attack in patients with unstable angina. Intern Med 2000;39:369-74 «PMID: 10830175»
37. Noble RJ, Rothbaum DA, Knoebel SB ym. Normalization of abnormal T waves in ischemia. Arch Intern Med 1976;136 :391-5 «PMID: 1267547»
38. Eskola MJ, Holmvang L, Nikus KC ym. The electrocardiographic window of opportunity to treat vs. the different evolving stages of ST-elevation myocardial infarction: correlation with therapeutic approach, coronary
anatomy, and outcome in the DANAMI-2 trial. Eur Heart J 2007;28:2985-91 «PMID: 17932102»
39. Leivo J, Anttonen E, Jolly SS ym. The high-risk ECG pattern of ST-elevation myocardial infarction: A substudy of the randomized trial of primary PCI with or without routine manual thrombectomy (TOTAL trial). Int J
Cardiol 2020;319 :40-45 «PMID: 32470531»
40. Nikus KC, Eskola MJ. EKG sepel valtimokohtauksen vaaran arvioinnissa . Suom Lääkäril 2004;59:2365-72
41. Nikus KC, Eskola MJ, Porela P, Airaksinen J. EKG:n iskemia-aste uhkaavan ST-nousuinfarktin yksilöllisessä  vaaran arvioinnissa . Suom Lääkäril 2008;63:15 09-14
42. Nikus K, Pahlm O, Wagner G ym. Electrocardiographic classification of acute coronary syndromes: a review by a committee of the International Society for Holter and Non-Invasive Electrocardiology. J Electrocardiol
2010;43:91-103 «PMID: 19913800»
43. Cannon CP, McCabe CH, Stone PH ym. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study.
Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol 1997;30:133- 40 «PMID: 9207634»
44. Nikus KC, Eskola MJ, Sclarovsky S. Electrocardiographic present ations of left main or severe triple vessel  disease in acute coronary syndromes--an overview. J Electrocardiol 2006;39:S68-72 «PMID: 16934826»
45. Nikus KC, Eskola MJ, Virtanen VK ym. ST-depressio n with negative T waves in leads V4-V5--a marker of severe coronary artery disease in non-ST elevation acute coronary syndrome: a prospect ive study of Angina at
rest, with troponin, clinica l, electrocardiographic, and angiographic correlation. Ann Noninv asive Electrocardiol 2004;9:207-14 «PMID: 15245335»
46. Edwards WD, Tajik AJ, Seward JB. Standardized nomenclature and anatomic basis for regional tomographic analysis of the heart. Mayo Clin Proc 1981;56:479-97 «PMID: 7266059»
47. Parkinso n J, Bedford DE. Successiv e changes in the electrocardiogram after cardiac infarction (coronary thrombosis). Heart 1928;14:195-239
48. HELLERSTEIN HK, KATZ LN. The electrical effects of injury at various myocardial locations. Am Heart J 1948;36:184-220 «PMID: 18873258»
49. Sclarovsky S (toim.) Electrocardiography of acute myocardial ischemic syndromes. Martin Dunitz, London 1999
50. Johnson NP, Chavez JF, Mosley WJ 2nd ym. Performance of electrocardiographic criteria to differentiate Takotsubo cardiomyopathy from acute anterior ST elevation myocardial infarction. Int J Cardiol 2013;16 4:345-
8 «PMID: 21802749»
51. Kardiologia. Airaksinen J, Aalto-Setälä K, Hartikainen H ym. (toim.). 3. uudistettu painos. Kustannus Oy Duodecim  2016. s. 447
52. Mills NL, Churchhouse AM, Lee KK ym. Implementation of a sensit ive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspect ed acute coronary syndrome. JAMA 2011;30 5:1210-
6 «PMID: 21427373»
53. Hochholzer W, Reich lin T, Twerenbold R ym. Incremental value of high-sensit ivity cardiac troponin T for risk prediction in patients with suspect ed acute myocardial infarction. Clin Chem 2011;57:1318 -26 «PMID:
21771945»
54. Twerenbold R, Neumann JT, Sörensen NA ym. Prospect ive Validation of the 0/1-h Algorithm for Early Diagnosis of Myocardial Infarction. J Am Coll Cardiol 2018;72:620-632 «PMID: 30071991»
55. Keller T, Zeller T, Peetz D ym. Sensit ive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868-77 «PMID: 19710485»
56. Reich lin T, Hochholzer W, Bassetti S ym. Early diagnosis of myocardial infarction with sensit ive cardiac troponin assays. N Engl J Med 2009;361:858-67 «PMID: 19710484»
57. Chew DP, Lambrakis K, Blyth A ym. A Randomized Trial of a 1-Hour Troponin T Protocol in Suspect ed Acute Coronary Syndromes: The Rapid Assessm ent of Possible Acute Coronary Syndrome in the Emergency
Department With High-Sensit ivity Troponin T Study (RAPID-TnT). Circulation 2019;140:1543-1556 «PMID: 31478763»
58. Bandstein N, Ljung R, Johansso n M ym. Undetectable high-sensit ivity cardiac troponin T level in the emergency  department and risk of myocardial infarction. J Am Coll Cardiol 2014;63:2569-2578 «PMID:
24694529»
59. Twerenbold R, Jaffe A, Reich lin T ym. High-sensit ive troponin T measurements: what do we gain and what are the challenges? Eur Heart J 2012;33:5 79-86 «PMID: 22267244»
60. Reich lin T, Schindler C, Drexler B ym. One-hour rule-out and rule-in of acute myocardial infarction using  high-sensit ivity cardiac troponin T. Arch Intern Med 2012;172:1211-8 «PMID: 22892889»
61. Collet JP, Thiele H, Barbato E ym. 2020 ESC Guidelines for the management of acute coronary syndromes in patients present ing without persistent ST-segment elevation. Eur Heart J 2021;42:1289-1367 «PMID:
32860058»
62. Laugaudin G, Kuster N, Petiton A ym. Kinetics of high-sensitivity cardiac troponin T and I differ in patients with ST-segment elevation myocardial infarction treated by primary coronary intervention. Eur Heart J Acute
Cardiovasc Care 2016;5:354-63 «PMID: 25943557»
63. Vavik V, Pedersen EKR, Svingen GFT ym. Usefulness of Higher Levels of Cardiac Troponin T in Patients With Stable Angina Pectoris to Predict Risk of Acute Myocardial Infarction. Am J Cardiol 2018;122:1142-1147
«PMID: 30146101»
64. Januzzi JL Jr, Suchindran S, Hoffmann U ym. Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain. J Am Coll Cardiol 2019;73:251-260 «PMID: 30678753»
65. Apple FS, Murakami MM, Pearce LA ym. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002;106:2941-5 «PMID: 12460876»
66. de Lemos JA, Drazner MH, Omland T ym. Association of troponin T detected with a highly sensit ive assay and cardiac structure and mortality risk in the gener al population. JAMA 2010;304:2503-12 «PMID:
21139 111»
67. Paana T, Jaakkola S, Bamberg K ym. Cardiac troponin elevations in marathon runner s. Role of coronary atherosclerosis and skeletal muscle injury. The MaraCat Study. Int J Cardiol 2019;295:25-28 «PMID: 31420104»
68. Ibanez B, James S, Agewall S ym. 2017 ESC Guidelines for the management of acute myocardial infarction in patients present ing with ST-segment elevation: The Task Force for the management of acute myocardial
infarction in patients present ing with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-177 «PMID: 28886621»
69. St John Sutton M, Pfeffer MA, Plapper t T ym. Quantitative two-dimensio nal echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective
effects of captopril. Circulation 1994;89:68-75 «PMID: 8281697»
70. Neskovic AN, Hagendorff A, Lancel lotti P ym. Emergency echocardiography: the European Association of Cardiovascular Imaging recommendations. Eur Heart J Cardiovasc Imaging 2013;14 :1-11 «PMID: 23239795»
71. Foy AJ, Liu G, Davidson WR Jr ym. Comparative effectiveness of diagnostic testing strategies in emergency  department patients with chest pain: an analysis of downstream testing, interventions, and outcomes. JAMA
Intern Med 2015;175:428-36 «PMID: 25622287»
72. Kunadian V, Chieffo A, Camici PG ym. An EAPCI Expert Consensu s Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary
Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 2020;41:35 04-3520 «PMID: 32626906»
73. Kardiologia. Airaksinen J, Aalto-Setälä K, Hartikainen H ym. (toim.). 3. uudistettu painos. Kustannus Oy Duodecim  2016. s. 443
74. Boden WE, Eagle K, Granger CB. Reper fusion strategies in acute ST-segment elevation myocardial infarction: a comprehensiv e review of contemporary management options. J Am Coll Cardiol 2007;50:917-29 «PMID:
17765117»
75. Chan AW, Kornder J, Elliott H ym. Improved survival associated with pre-hospital triage strategy in a large regional ST-segment elevation myocardial infarction program. JACC Cardiovasc Interv 2012;5:1239-46
«PMID: 23257372»
76. Ducas RA, Labos C, Allen D ym. Association of Pre-hospital ECG Administ ration With Clinica l Outcomes in ST-Segment Myocardial Infarction: A Systematic Review and Meta-analysis. Can J Cardiol 2016;32:1531-1541
«PMID: 27707525»
77. Nam J, Caners K, Bowen JM ym. Systematic review and meta-analysis of the benef its of out-of-hospital 12-lead ECG and advance notification in ST-segment elevation myocardial infarction patients. Ann Emerg Med
2014;64:176-86, 186.e1-9 «PMID: 24368054»
78. Cantor WJ, Hoogeveen P, Robert A ym. Prehospital diagnosis and triage of ST-elevation myocardial infarction by paramedics without advanced  care training . Am Heart J 2012;164:201-6 «PMID: 22877805»
79. Hofmann R, James SK, Jernberg T ym. Oxygen Therapy in Suspect ed Acute Myocardial Infarction. N Engl J Med 2017;377:1240-1249 «PMID: 28844200»
80. Sepeh rvand N, James SK, Stub D ym. Effects of supplemental oxygen therapy in patients with suspect ed acute myocardial infarction: a meta-analysis of randomised clinica l trials. Heart 2018;104:1691-1698 «PMID:
29599378»
81. Cabello JB, Burls A, Emparanza JI ym. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev 2016;12:CD007160 «PMID: 27991651»
82. Kubica J, Adamski P, Ostrowska M ym. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur
Heart J 2016;37:245-52 «PMID: 26491112 »
83. Bellandi B, Zocchi C, Xanthopoulou I ym. Morphine use and myocardial reper fusion in patients with acute myocardial infarction treated with primary PCI. Int J Cardiol 2016;221:567-71 «PMID: 27420579»
84. Ibrahim K, Goli RR, Shah R ym. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: Design, rationale, and sample
characteristics of the PACIFY randomized trial. Contemp Clin Trials 2018;64:8-12 «PMID: 29170073»
85. Hobl EL, Stimpfl T, Ebner J ym. Morphine decreases clopidogrel concent rations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014;63:630-635 «PMID: 24315907»
86. Silvain J, Storey RF, Cayla G ym. P2Y12 recept or inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb
Haemost 2016;116:369-78 «PMID: 27196998»
87. McEvoy JW, Ibrahim K, Kickler TS ym. Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized
Clinica l Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). Circulation 2018;137:307-309 «PMID: 29046319»
88. Elgendy IY, Elgendy AY, Mahmoud AN ym. Intravenous ß-blockers for patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials. Int J Cardiol 2016;223:891-897 «PMID:
27584567»
89. Sterling LH, Filion KB, Atallah R ym. Intravenous beta-blockers in ST-segment elevation myocardial infarction: A systematic review and meta-analysis. Int J Cardiol 2017;228:295-302 «PMID: 27866018»
90. Hoedemaker NP, Roolvink V, de Winter RJ ym. Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled
meta-analysis of randomized clinica l trials. Eur Heart J Acute Cardiovasc Care 2020;9:469-477 «PMID: 30759994»
91. Safi S, Sethi NJ, Nielsen EE ym. Beta-blockers for suspect ed or diagnosed acute myocardial infarction. Cochrane Database Syst Rev 2019;12:CD012484 «PMID: 31845756»
92. Chatterjee S, Chaudhuri D, Vedanthan R ym. Early intravenous beta-blockers in patients with acute coronary syndrome--a meta-analysis of randomized trials. Int J Cardiol 2013;16 8:915-21 «PMID: 23168009»
93. Bangalore S, Makani H, Radford M ym. Clinica l outcomes with ß-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014;127:939-53 «PMID: 24927909»
94. Chen ZM, Pan HC, Chen YP ym. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet  2005;366:1622-32 «PMID: 16271643»
95. Kontos MC, Diercks DB, Ho PM ym. Treatment and outcomes in patients with myocardial infarction treated with acute ß-blocker therapy: results from the American College of Cardiology's NCDR(®). Am Heart J
2011;16 1:864-70 «PMID: 21570515»
96. Casella G, Ottani F, Ortolani P ym. Off-hour primary percutaneous coronary angioplasty does not affect outcome of patients with ST-Segment elevation acute myocardial infarction treated within a regional network for
reper fusion: The REAL (Registro Regionale Angioplastiche dell'Emilia-Romagna) registry. JACC Cardiovasc Interv 2011;4:270-8 «PMID: 21435603»
97. Armstrong PW, Gershlick AH, Goldstein P ym. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013;36 8:1379-87 «PMID: 23473396»
98. Indications for fibrinolytic therapy in suspect ed acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic
Therapy Trialists' (FTT) Collaborative Group. Lancet  1994;343:311- 22 «PMID: 7905143»
99. Randomised trial of late thrombolysis in patients with suspect ed acute myocardial infarction. EMERAS (Estudio Multicént rico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group. Lancet
1993;34 2:767-72 «PMID: 8103875»
100. Newby LK, Rutsch WR, Califf RM ym. Time from symptom onset  to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996;27:1646-55 «PMID: 8636549»
101. Califf RM, O'Neil W, Stack RS ym. Failure of simple clinica l measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med 1988;108:658-62 «PMID: 3128953»
102. Van de Werf F, Bax J, Betriu A ym. Management of acute myocardial infarction in patients present ing with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute
Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-45 «PMID: 19004841»
103. Binanay C, Califf RM, Hasselblad V ym. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005;294:1625-33 «PMID: 16204662»
104. Combes A, Price S, Slutsky AS ym. Temporary circulatory support for cardiogenic shock. Lancet  2020;396:199-212 «PMID: 32682486»
105. Thiele H, Ohman EM, de Waha-Thiele S ym. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J 2019;40:2671-2683 «PMID: 31274157»26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 38/41
106. Mehta RH, Lopes RD, Ballotta A ym. Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel  coronary artery disease? Am Heart J 2010;159:141-7 «PMID:
20102880»
107. Fang M, Cao H, Wang Z. Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis. Med Intensiv a (Engl Ed) 2018;42:409-415 «PMID: 29126662»
108. Thiele H, Zeymer U, Neumann FJ ym. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012;367:1287-96 «PMID: 22920912»
109. Thiagarajan RR, Barbaro RP, Rycus PT ym. Extracorporeal Life Support Organization Registry International Report 2016. ASAIO J 2017;63:60-67 «PMID: 27984321»
110. Claassens DMF, Vos GJA, Bergmeijer TO ym. A Genotype-Guided Strategy for Oral P2Y Inhibitors in Primary PCI. N Engl J Med 2019;381:1621-1631 «PMID: 31479209»
111. Yusuf S, Mehta SR, Chrolavicius S ym. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-30
«PMID: 16537725»
112. Cohen M, Demers C, Gurfinkel EP ym. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave
Coronary Events Study Group. N Engl J Med 1997;337 :447-52 «PMID: 9250846»
113. Antman EM. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicent er trial. Rationale, study
design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. Am Heart J 1998;135:S353-60 «PMID: 9628449»
114. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet  1996;347:561-8 «PMID: 8596317»
115. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospect ive randomised multicent re study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease.
Investigators. Lancet  1999;354:701-7 «PMID: 10475180»
116. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators., Yusuf S, Mehta SR ym. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-76
«PMID: 16537663»
117. Gibson CM, Mehran R, Bode C ym. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016;375:2423-2434 «PMID: 27959713»
118. Cannon CP, Bhatt DL, Oldgren J ym. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017;377:1513-1524 «PMID: 28844193»
119. Lopes RD, Heizer G, Aronson R ym. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med 2019;380:1509-1524 «PMID: 30883055»
120. Vranckx P, Valgimigli M, Eckardt L ym. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successf ul coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a
randomised, open- label, phase 3b trial. Lancet  2019;394:1335 -1343 «PMID: 31492505»
121. Ferguson JJ, Califf RM, Antman EM ym. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy:
primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54 «PMID: 15238590»
122. Erlinge D, Omerovic E, Fröbert O ym. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med 2017;377:1132 -1142 «PMID: 28844201»
123. Zhang S, Gao W, Li H ym. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Int J Cardiol 2016;209:87-95
«PMID: 26882192»
124. Wiviott SD, Braunwald E, McCabe CH ym. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15 «PMID: 17982182»
125. Wallentin L, Becker RC, Budaj A ym. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57 «PMID: 19717846»
126. Gimbel M, Qaderdan K, Willemsen L ym. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open- label, non-
inferiority trial. Lancet  2020;395:1374-1381 «PMID: 32334703»
127. Motovska Z, Hlinomaz O, Miklik R ym. Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicent er Randomized PRAGUE-18
Study. Circulation 2016;134 :1603-1612 «PMID: 27576777»
128. Motovska Z, Hlinomaz O, Kala P ym. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor. J Am Coll Cardiol 2018;71:371-381 «PMID:
29154813»
129. Schüpke S, Neumann FJ, Menich elli M ym. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med 2019;381:1524-1534 «PMID: 31475799»
130. Urban P, Mehran R, Colleran R ym. Defining  High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation 2019;140:240-261 «PMID: 31116 032»
131. Navarese EP, Khan SU, Kolodziejczak M ym. Comparative Efficacy and Safety of Oral P2Y Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. Circulation
2020;142:150-160 «PMID: 32468837»
132. Montalesco t G, Bolognese L, Dudek D ym. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013;36 9:999-1010 «PMID: 23991622»
133. Labos C, Dasgupta K, Nedjar H ym. Risk of bleeding associated with combined  use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011;18 3:18 35-43
«PMID: 21948719»
134. Kobayashi Y, Lønborg J, Jong A ym. Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS. J Am Coll Cardiol 2018;72:132 1-1329 «PMID: 3021332 2»
135. Valgimigli M, Frigoli E, Heg D ym. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med 2021;38 5:1643-1655 «PMID: 34449185»
136. Windecker S, Latib A, Kedhi E ym. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. N Engl J Med 2020;382:1208-1218 «PMID: 32050061»
137. Angiolillo DJ, Rollini F, Storey RF ym. International Expert Consensu s on Switching Platelet P2Y Recept or-Inhibiting Therapies.  Circulation 2017;136 :1955-1975 «PMID: 29084738»
138. Dewilde WJ, Oirbans T, Verheugt FW ym. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open- label, randomised,
controlled trial. Lancet  2013;38 1:110 7-15 «PMID: 23415013»
139. Szummer K, Montez-Rath ME, Alfredsson J ym. Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome: Insig hts From the SWEDEHEART Registry. Circulation
2020;142:1700-1708 «PMID: 32867508»
140. Doll JA, Neely ML, Roe MT ym. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. J Am Coll Cardiol 2016;67:936-947 «PMID: 26916483»
141. Roe MT, Armstrong PW, Fox KA ym. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367:1297-309 «PMID: 22920930»
142. Mehran R, Baber U, Sharma SK ym. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med 2019;381:2032-2042 «PMID: 31556978»
143. Kim BK, Hong SJ, Cho YH ym. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinica l
Trial. JAMA 2020;323:2407-2416 «PMID: 32543684»
144. Steg PG, Bhatt DL, Hamm CW ym. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet  2013;38 2:1981-92 «PMID: 24011551»
145. De Luca G, Navarese EP, Cassetti E ym. Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol 2011;10 7:198-
203 «PMID: 21211597»
146. Sciahbasi A, Biondi-Zoccai G, Romagnoli E ym. Routine upstream versus selective downstream administ ration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-
analysis of randomized trials. Int J Cardiol 2012;155:243-8 «PMID: 21035214»
147. Anderson HV, Cannon CP, Stone PH ym. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinica l trial. A randomized comparison of tissue-type plasminogen activator versus placebo and
early invasive versus early conser vative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50 «PMID: 7594098»
148. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospect ive randomised multicent re study. FRagmin and Fast Revascularisation during InStability in Coronary artery
disease Investigators. Lancet  1999;354:708-15 «PMID: 10475181»
149. Cannon CP, Weintraub WS, Demopoulos LA ym. Comparison of early invasive and conser vative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl
J Med 2001;34 4:1879-87 «PMID: 11419424»
150. Fox KA, Poole-Wilson P, Clayton TC ym. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet  2005;366:914-20
«PMID: 16154018»
151. Lagerqvist B, Husted S, Kontny F ym. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet
2006;368:998-1004 «PMID: 16980115»
152. Neumann FJ, Sousa-Uva M, Ahlsson A ym. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165 «PMID: 30165437»
153. Palmerini T, Bened etto U, Biondi-Zoccai G ym. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensiv e Network Meta-Analysis. J Am Coll Cardiol 2015;65:2496-507 «PMID:
26065988»
154. Tonino  PAL, Pijls NHJ, Collet C ym. Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in Acute Coronary Syndrome: The Randomized TIDES-ACS Trial. JACC Cardiovasc Interv 2020;13:16 97-1705
«PMID: 32703593»
155. Rissanen TT, Uskela S, Eränen J ym. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a sing le-blind, randomised, non-inferiority trial. Lancet
2019;394:230-239 «PMID: 31204115»
156. Jeger RV, Farah A, Ohlow MA ym. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open- label randomised non-inferiority trial. Lancet  2018;392:849-856 «PMID: 30170854»
157. Thiele H, Akin I, Sandri M ym. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med 2017;377:2419-2432 «PMID: 29083953»
158. Gershlick AH, Khan JN, Kelly DJ ym. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel  disease: the
CvLPRIT trial. J Am Coll Cardiol 2015;65:963-72 «PMID: 25766941»
159. Wald DS, Morris JK, Wald NJ ym. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013;36 9:1115 -23 «PMID: 23991625»
160. Smits PC, Abdel-Wahab M, Neumann FJ ym. Fractional Flow Reserve-Guided Multivessel  Angioplasty in Myocardial Infarction. N Engl J Med 2017;376:1234-1244 «PMID: 28317428»
161. Mehta SR, Wood DA, Storey RF ym. Complete Revascularization with Multivessel  PCI for Myocardial Infarction. N Engl J Med 2019;381:1411-1421 «PMID: 31475795»
162. Engstrøm T, Kelbæk H, Helqvist S ym. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel  disease (DANAMI-3—
PRIMULTI): an open- label, randomised controlled trial. Lancet  2015;386:665-71 «PMID: 26347918»
163. Puymirat E, Cayla G, Simon T ym. Multivessel  PCI Guided by FFR or Angiography for Myocardial Infarction. N Engl J Med 2021;38 5:297-308 «PMID: 33999545»
164. Widimsky P, Holmes DR Jr. How to treat patients with ST-elevation acute myocardial infarction and multi-vessel  disease? Eur Heart J 2011;32 :396-403 «PMID: 21118 854»
165. Ndrepepa  G, Kastrati A, Mehilli J ym. Mechanica l reper fusion and long-term mortality in patients with acute myocardial infarction present ing 12 to 48 hours from onset  of symptoms. JAMA 2009;301:487-8 «PMID:
19190313»
166. Hochman JS, Lamas GA, Buller CE ym. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006;355:2395-407 «PMID: 17105759»
167. Chang M, Lee CW, Ahn JM ym. Comparison of Outcome of Coronary Artery Bypass Grafting Versus Drug-Eluting Stent Implantation for Non-ST-Elevation Acute Coronary Syndrome. Am J Cardiol 2017;120:380-386
«PMID: 28595861»
168. Farkouh ME, Domanski M, Sleeper  LA ym. Strategies for multivessel  revascularization in patients with diabetes. N Engl J Med 2012;367:2375-84 «PMID: 23121323»
169. Verma S, Farkouh ME, Yanagawa B ym. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet
Diabetes Endocrinol 2013;1:317 -28 «PMID: 24622417»
170. Ramanathan K, Abel JG, Park JE ym. Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes. J Am Coll Cardiol 2017;70:2995-3006 «PMID: 29241487»
171. Cardoso R, Knijnik L, Whelton SP ym. Dual versus sing le antiplatelet therapy after coronary artery bypass graft surgery: An updated meta-analysis. Int J Cardiol 2018;269:80-88 «PMID: 30072154»
172. Gupta S, Belley-Cote EP, Agahi P ym. Antiplatelet Therapy and Coronary Artery Bypass Grafting: Analysis of Current Evidence With a Focus on Acute Coronary Syndrome. Can J Cardiol 2019;35:1030-1038 «PMID:
3137 6904»
173. Solo K, Lavi S, Kabali C ym. Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. BMJ 2019;367:l5476 «PMID: 31601578»
174. Lemkes JS, Janssens GN, van der Hoeven NW ym. Coronary Angiography after Cardiac Arrest without ST-Segment Elevation. N Engl J Med 2019;380:139 7-1407 «PMID: 30883057»
175. Desch  S, Freund A, Akin I ym. Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation. N Engl J Med 2021;38 5:2544-2553 «PMID: 34459570»
176. Ouweneel  DM, Schotborgh JV, Limpens J ym. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensiv e Care Med 2016;42:1922-1934 «PMID:
27647331»
177. Beyea MM, Tillmann BW, Iansavichene AE ym. Neurologic outcomes after extracorporeal membrane oxygenation assist ed CPR for resuscitation of out-of-hospital cardiac arrest patients: A systematic review.
Resuscitation 2018;130 :146-158 «PMID: 30017957»
178. Holmberg MJ, Geri G, Wiberg S ym. Extracorporeal cardiopulmonary resuscitation for cardiac arrest: A systematic review. Resuscitation 2018;131:9 1-100 «PMID: 30063963»
179. Twohig CJ, Singer B, Grier G ym. A systematic literature review and meta-analysis of the effectiveness of extracorporeal-CPR versus conventional-CPR for adult patients in cardiac arrest. J Intensiv e Care Soc
2019;20:347-357 «PMID: 31695740»
180. Bartos JA, Grunau B, Carlson C ym. Improved Survival With Extracorporeal Cardiopulmonary Resuscitation Despite Progressiv e Metabolic Derangement Associated With Prolonged Resuscitation. Circulation
2020;141:877-886 «PMID: 31896278»
181. Yannopoulos D, Bartos J, Raveend ran G ym. Advanced  reper fusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, sing le cent re, open- label,
randomised controlled trial. Lancet  2020;396:1807-1816 «PMID: 3319 7396»
182. Grunau B, Carrier S, Bashir J ym. A comprehensiv e regional clinica l and educational ECPR protocol decreases time to ECMO in patients with refractory out-of-hospital cardiac arrest. CJEM 2017;19:424-433 «PMID:
28810931»
183. Debaty G, Babaz V, Durand M ym. Prognostic factors for extracorporeal cardiopulmonary resuscitation recipient s following out-of-hospital refractory cardiac arrest. A systematic review and meta-analysis.
Resuscitation 2017;112:1-10 «PMID: 28007504»
184. D'Arrigo S, Cacciola S, Dennis M ym. Predictors of favourable outcome after in-hospital cardiac arrest treated with extracorporeal cardiopulmonary resuscitation: A systematic review and meta-analysis. Resuscitation
2017;121:62-70 «PMID: 29020604»12
12
1226.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 39/41
185. Wang J, Ma Q, Zhang H ym. Predictors of survival and neurologic outcome for adults with extracorporeal cardiopulmonary resuscitation: A systemic review and meta-analysis. Medicine (Baltimore) 2018;97:e132 57
«PMID: 30508912»
186. Michels G, Wengenm ayer T, Hagl C ym. Recommendations for extracorporeal cardiopulmonary resuscitation (eCPR): consensu s statement of DGIIN, DGK, DGTHG, DGfK, DGNI, DGAI, DIVI and GRC. Clin Res
Cardiol 2019;108:455-464 «PMID: 30361819»
187. Grunau B, Kime N, Leroux B ym. Association of Intra-arrest Transpo rt vs Continued On-Scene Resuscitation With Survival to Hospital Discharge Among Patients With Out-of-Hospital Cardiac Arrest. JAMA
2020;324:1058-1067 «PMID: 32930759»
188. Newby KH, Thompson T, Stebbins A ym. Sustained  ventricular arrhythmias in patients receiv ing thrombolytic therapy: incid ence and outcomes. The GUSTO Investigators. Circulation 1998;98:2567-73 «PMID:
9843464»
189. Henkel DM, Witt BJ, Gersh BJ ym. Ventricular arrhythmias after acute myocardial infarction: a 20-year community study. Am Heart J 2006;151:806-12 «PMID: 16569539»
190. Terkelsen CJ, Sørensen JT, Kaltoft AK ym. Prevalence and significance of accelerated idioventricular rhythm in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary
intervention. Am J Cardiol 2009;104:1641-6 «PMID: 19962468»
191. Jabre P, Roger VL, Murad MH ym. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation 2011;12 3:15 87-93 «PMID: 21464054»
192. Robinso n AA, Trankle CR, Eubanks G ym. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. JAMA Cardiol 2020;5:685-692 «PMID: 32320043»
193. Alcalai R, Butnaru A, Moravsky G ym. Apixaban versus Warfarin in Patients with Left Ventricular Thrombus, A Prospect ive Multicent er Randomized Clinica l Trial. Eur Heart J Cardiovasc Pharmacother 2021;: «PMID:
34279598»
194. Le May MR, Acharya S, Wells GA ym. Prophylactic warfarin therapy after primary percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2015;8:155-162
«PMID: 25616920»
195. Doyle B, Rihal CS, O'Sullivan CJ ym. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007;116:2391-8 «PMID: 17984377»
196. Wenaweser P, Daemen J, Zwahlen M ym. Incid ence and correlates of drug-eluting stent thrombosis in routine clinica l practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008;52:1134 -
40 «PMID: 18804739»
197. Laarman GJ, Suttorp MJ, Dirksen MT ym. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-13 «PMID: 16971717»
198. Vink MA, Dirksen MT, Suttorp MJ ym. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a
follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv 2011;4:24-9 «PMID: 21251625»
199. Iakovou I, Schmidt T, Bonizzoni E ym. Incid ence,  predictors, and outcome of thrombosis after successf ul implantation of drug-eluting stents. JAMA 2005;293:2126-30 «PMID: 15870416»
200. Chechi T, Vecch io S, Vittori G ym. ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 2008;51:2396-402 «PMID: 18565395»
201. Burzotta F, Parma A, Pristipino  C ym. Angiographic and clinica l outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study. Eur Heart J 2008;29:3011-
21 «PMID: 18987096»
202. Alfonso F. The "vulnerable" stent why so dreadful? J Am Coll Cardiol 2008;51:2403-6; PMID: 18565396
203. Holmes DR Jr, Kereiakes DJ, Garg S ym. Stent thrombosis. J Am Coll Cardiol 2010;56:135 7-65 «PMID: 20946992»
204. Puurunen M, Mustonen P. [Clopidogrel resist ance- -assessm ent of drug respo nse and clinica l significance] . Duodecim  2010;126:1021-8 «PMID: 20593625»
205. Ndrepepa  G, Berger PB, Mehilli J ym. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component  of a quadruple end point. J Am Coll
Cardiol 2008;51:690-7 «PMID: 18279731»
206. Mehran R, Pocock SJ, Stone GW ym. Associations of major bleeding and myocardial infarction with the incid ence and timing of mortality in patients present ing with non-ST-elevation acute coronary syndromes: a risk
model from the ACUITY trial. Eur Heart J 2009;30:1457-66 «PMID: 19351691»
207. Palmerini T, Bacchi Reggiani L, Della Riva D ym. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. J Am Coll Cardiol 2017;69:2011-2022 «PMID: 28427576»
208. Ueki Y, Bär S, Losdat S ym. Validation of the Academic Resea rch Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary
bleeding risk scores. EuroIntervention 2020;16:371-379 «PMID: 32065586»
209. Lahtela H, Karjalainen PP, Niemelä M ym. Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment? Thromb Haemost 2009;102:1227-33 «PMID:
19967155»
210. Génér eux P, Rutledge DR, Palmerini T ym. Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insig hts From the Xience V Coronary Stent System Trials. Circ Cardiovasc
Interv 2015;8: «PMID: 25940520»
211. Schoener  L, Jellinghaus S, Richter B ym. Reversal of the platelet inhibitory effect of the P2Y inhibitors clopidogrel, prasugrel, and ticagrelor in vitro: a new  approach to an old issue. Clin Res Cardiol 2017;106:868-
874 «PMID: 28653184»
212. Hobl EL, Derhaschnig U, Firbas C ym. Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor. Eur J Clin Invest 2013;4 3:12 58-61 «PMID: 24112116»
213. Steg PG, Huber K, Andreotti F ym. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur
Heart J 2011;32 :1854-64 «PMID: 21715717»
214. Alexander KP, Chen AY, Roe MT ym. Excess dosing  of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:310 8-16 «PMID: 16380591»
215. Lee MS, Wolfe M, Stone GW. Transradial versus transfemoral percutaneous coronary intervention in acute coronary syndromes: re-evaluation of the current body of evidence.  JACC Cardiovasc Interv 2013;6 :1149-52
«PMID: 24262614»
216. Bhatt DL, Cryer BL, Contant CF ym. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:19 09-17 «PMID: 20925534»
217. Agewall S, Cattaneo M, Collet JP ym. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013;34 :1708-13, 1713a-1713b «PMID:
23425521»
218. Chan FK, Ching JY, Hung LC ym. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-44 «PMID: 15659723»
219. Stamler JS, Jia L, Eu JP ym. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 1997;276:2034-7 «PMID: 9197264»
220. Rao SV, Eikelboom JA, Granger CB ym. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1193-204 «PMID: 17456480»
221. Sepel valtimotautipotilaan liikunnallinen kuntoutus (online). Hyvä fysioterapiakäytäntö -suositus. Suomen Fysioterapeuttien asettama työryhmä. Helsink i: Suomen Fysioterapeutit ry, 2011 (päivitetty 23.5.2016).
Saatavilla Internetissä: www.suomenfysioterapeutit.fi
222. Ambrosetti M, Abreu A, Corrà U ym. Secondary prevention through comprehensiv e cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention
and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2020;:204748732091337 9 «PMID: 32223332 »
223. Ciszewski A. Cardioprotective effect of influenza and pneumococcal vaccina tion in patients with cardiovascular diseases. Vaccine 2018;36:202-206 «PMID: 29221893»
224. Feldman C, Normark S, Henriques-Normark B ym. Pathogenesis and prevention of risk of cardiovascular events in patients with pneu mococcal community-acquired pneu monia. J Intern Med 2019;285:635-652
«PMID: 30584680»
225. Kohonnut verenpa ine. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Verenpa iney hdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2020 (viitattu
14.06.2021). Saatavilla internetissä: www.kaypahoito.fi
226. Dyslipidemiat. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Sisätautilääkärien Yhdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2017 (viitattu
14.06.2021). Saatavilla internetissä: www.kaypahoito.fi
227. Mach F, Baigent C, Catapano AL ym. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111- 188 «PMID: 31504418»
228. Tyypin 2 diabetes. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in, Suomen sisätautilääkäreiden yhdistyksen ja Diabetesliiton lääkärineu voston asettama työryhmä. Helsink i: Suomalainen Lääkäriseura
Duodecim , 2018 (viitattu 10.11.2019). Saatavilla Internetissä: www.kaypahoito.fi
229. Lihavuus (lapset , nuoret ja aikuiset). Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in, Suomen Lihavuustutkijat ry:n ja Suomen Lastenlääkäriyhdistys ry:n asettama työryhmä. Helsink i: Suomalainen
Lääkäriseura Duodecim , 2020 (viitattu 14.06.2021). Saatavilla internetissä: www.kaypahoito.fi
230. Tupakka- ja nikotiinir iippu vuuden ehkäisy ja hoito. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Yleislääketieteen yhdistyksen asettama työryhmä. Helsink i: Suomalainen Lääkäriseura
Duodecim , 2018 (viitattu 10.11.2019). Saatavilla internetissä: www.kaypahoito.fi
231. Piepo li MF, Hoes AW, Agewall S ym. 2016 European Guidelines on cardiovascular disease prevention in clinica l practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on
Cardiovascular Disease Prevention in Clinica l Practice (constituted by represent atives of 10 societies and by invited experts)Developed with the specia l contribution of the European Association for Cardiovascular
Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381 «PMID: 27222591»
232. Ma M, Bu L, Shi L ym. Effect of loading dose of atorvastatin therapy prior to percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of six randomized controlled trials. Drug Des
Devel Ther 2019;13:12 33-1240 «PMID: 3135 4240»
233. Pan Y, Tan Y, Li B ym. Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials. Lipids Health Dis 2015;14:97
«PMID: 26306625»
234. Liakopoulos OJ, Kuhn EW, Slottosch I ym. Statin Therapy in Patients Undergoing Coronary Artery Bypass Grafting for Acute Coronary Syndrome. Thorac Cardiovasc Surg 2018;66:434-441 «PMID: 28427094»
235. Cannon CP, Blazing MA, Giugliano RP ym. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387-97 «PMID: 26039521»
236. Sabatine MS, Giugliano RP, Keech  AC ym. Evolocumab and Clinica l Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:1713-1722 «PMID: 28304224»
237. Schwartz GG, Steg PG, Szarek M ym. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018;379:2097-2107 «PMID: 30403574»
238. Allahyari A, Jernberg T, Hagström E ym. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent  myocardial infarction: a simulation study. Eur Heart J 2020;41:39 00-
3909 «PMID: 32072178»
239. Bartnik M, Rydén L, Ferrari R ym. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25:1880-
90 «PMID: 15522466»
240. de Mulder M, Umans VA, Cornel JH ym. Intensiv e glucose regulation in hyperglycem ic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2
(BIOMArCS-2) glucose trial. JAMA Intern Med 2013;17 3:18 96-904 «PMID: 24018647»
241. Wiviott SD, Raz I, Bonaca MP ym. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380:347-357 «PMID: 30415602»
242. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessa tion in patients with coronary heart disease: a systematic review. JAMA 2003;290:86-97 «PMID: 12837716»
243. Chow CK, Jolly S, Rao-Melacini P ym. Association of diet, exercise,  and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010;121:750-8 «PMID: 20124123»
244. Rigotti NA, Clair C, Munafò MR ym. Interventions for smoking cessa tion in hospitalised patients. Cochrane Database Syst Rev 2012;:CD 001837 «PMID: 22592676»
245. Windle SB, Dehghani P, Roy N ym. Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicl ine in patients admitted to hospital. CMAJ 2018;190:E347-E354
«PMID: 29581161»
246. Suissa K, Larivière J, Eisenb erg MJ ym. Efficacy and Safety of Smoking Cessa tion Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc
Qual Outcomes 2017;10: «PMID: 28093398»
247. Grandi SM, Shimony A, Eisenb erg MJ. Bupropion for smoking cessa tion in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Can J Cardiol
2013;2 9:1704-11 «PMID: 24267809»
248. Gehi A, Haas D, Pipkin S ym. Depressio n and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 2005;165:2508-13 «PMID: 16314548»
249. Zuidersma M, Ormel J, Conradi HJ ym. An increase in depressiv e symptoms after myocardial infarction predicts new cardiac events irrespect ive of depressiv e symptoms before myocardial infarction. Psychol Med
2012;42:683-93 «PMID: 22571951»
250. Lichtman JH, Froelicher ES, Blumenthal JA ym. Depressio n as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scient ific statement from the
American Heart Association. Circulation 2014;129:135 0-69 «PMID: 24566200»
251. Kronish  IM, Moise N, Cheung YK ym. Effect of Depression Screening  After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinica l Trial. JAMA Intern Med 2020;180:45-53 «PMID:
31633746»
252. Nieuwsma JA, Williams JW Jr, Namdari N ym. Diagnostic Accuracy of Screening  Tests and Treatment for Post-Acute Coronary Syndrome Depressio n: A Systematic Review. Ann Intern Med 2017;167:725-735 «PMID:
29132152»
253. Kim JM, Bae KY, Stewart R ym. Escitalopram treatment for depressiv e disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. J Clin Psychiatry 2015;76:62-8 «PMID: 25375836»
254. Hanash JA, Hansen BH, Hansen JF ym. Cardiovascular safety of one-year escit alopram therapy in clinica lly nondepressed  patients with acute coronary syndrome: results from the DEpressio n in patients with Coronary
ARtery Disease (DECARD) trial. J Cardiovasc Pharmacol 2012;60:397-405 «PMID: 22820898»
255. Thombs BD, de Jonge P, Coyne JC ym. Depressio n screening  and patient outcomes in cardiovascular care: a systematic review. JAMA 2008;300:2161-71 «PMID: 19001627»
256. Depressio . Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Psykiatriyhdistys ry:n asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2020 (viitattu 14.06.2021). Saatavilla
internetissä: www.kaypahoito.fi
257. Steink e EE, Jaarsma T, Barnason SA ym. Sexual counselling for individuals with cardiovascular disease and their partners: a consensu s document from the American Heart Association and the ESC Council on
Cardiovascular Nursing  and Allied Professio ns (CCNAP). Eur Heart J 2013;34 :3217-35 «PMID: 23900695»
258. Levine GN, Steink e EE, Bakaeen FG ym. Sexual activity and cardiovascular disease: a scient ific statement from the American Heart Association. Circulation 2012;125:1058-72 «PMID: 22267844»
259. Laskimotukos ja keuhkoembolia. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Kardiologisen Seuran asettama työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2016 (viitattu
14.06.2021). Saatavilla internetissä: www.kaypahoito.fi1226.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 40/41
260. Lip GY, Huber K, Andreotti F ym. Antithrombotic management of atrial fibrillation patients present ing with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensu s Document
of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions
(EAPCI). Eur Heart J 2010;31:1311- 8 «PMID: 20447945»
261. Rubboli A, Halperin JL, Airaksinen KE ym. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensu s document with focus on atrial fibrillation.
Ann Med 2008;40:428-36 «PMID: 18608125»
262. Karjalainen PP, Porela P, Ylitalo A ym. Safety and efficacy of combined  antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007;28:726-32 «PMID: 17267456»
263. Collet JP, Thiele H, Barbato E ym. 2020 ESC Guidelines for the management of acute coronary syndromes in patients present ing without persistent ST-segment elevation. Eur Heart J 2021;42:1289-1367 «PMID:
32860058»
264. Urban P, Meredith IT, Abizaid A ym. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med 2015;373:2038-47 «PMID: 26466021»
265. Varenne O, Cook S, Sideris G ym. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised sing le-blind trial. Lancet  2018;391:41-50 «PMID: 29102362»
266. Steffel J, Verhamme P, Potpara TS ym. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J
2018;39:1330 -1393 «PMID: 29562325»
267. Yeh RW, Secem sky EA, Kereiakes DJ ym. Development and Validation of a Prediction Rule for Benef it and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA
2016;315 :1735-49 «PMID: 27022822»
268. Eikelboom JW, Connolly SJ, Bosch J ym. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017;377:1319 -1330  «PMID: 28844192»
269. Bonaca MP, Bhatt DL, Cohen M ym. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800 «PMID: 25773268»
270. Law MR, Morris JK, Wald NJ. Use of blood pressu re lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expect ations from prospect ive epid emiological
studies. BMJ 2009;338 :b1665 «PMID: 19454737»
271. ISIS-4: a randomised factorial trial assessing  early oral captopril, oral mononitrate, and intravenous magnesiu m sulphate in 58,050 patients with suspect ed acute myocardial infarction. ISIS-4 (Fourth International
Study of Infarct Survival) Collaborative Group. Lancet  1995;345:669-85 «PMID: 7661937»
272. McMurray JJ, Packer M, Desai AS ym. Angiotensin- nepr ilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004 «PMID: 25176015»
273. Kook H, Hong SJ, Yang KS ym. Comparison of nebivolol versus diltiazem in improving coronary artery spasm and quality of life in patients with hypertensio n and vasospastic angina: A prospect ive, randomized,
double-blind pilot study. PLoS One 2020;15:e0239039 «PMID: 32915892»
274. Andersson C, Shilane D, Go AS ym. ß-blocker therapy and cardiac events among patients with newl y diagnosed coronary heart disease. J Am Coll Cardiol 2014;64:247-52 «PMID: 25034059»
275. Bangalore S, Bhatt DL, Steg PG ym. ß-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014;7:872-81
«PMID: 25271049»
276. Freem antle N, Cleland J, Young P ym. beta Blockade after myocardial infarction: systematic review and meta regressio n analysis. BMJ 1999;318 :1730-7 «PMID: 10381708»
277. Hwang D, Lee JM, Kim HK ym. Prognostic Impact of ß-Blocker Dose After Acute Myocardial Infarction. Circ J 2019;83:410-417 «PMID: 30464110»
278. Leizorovicz A, Lechat P, Cucherat M ym. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency  Bisoprolol
Study. Am Heart J 2002;143:30 1-7 «PMID: 11835035»
279. Packer M, Bristow MR, Cohn JN ym. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334 :134 9-55 «PMID:
8614419»
280. Poole-Wilson PA, Swedberg K, Cleland JG ym. Comparison of carvedilol and metoprolol on clinica l outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):
randomised controlled trial. Lancet  2003;36 2:7-13 «PMID: 12853193»
281. Pitt B, Byington RP, Furberg CD ym. Effect of amlodipine on the progressio n of atherosclerosis and the occurrence of clinica l events. PREVENT Investigators. Circulation 2000;102:1503-10 «PMID: 11004140»
282. Beygui F, Cayla G, Roule V ym. Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinica l Trial. J Am Coll Cardiol 2016;67:1917-27 «PMID: 27102506»
283. Schjerning  Olsen AM, Fosbøl EL, Lindhardsen J ym. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial
infarction: a nationwide cohort study. Circulation 2011;123:2226-35 «PMID: 21555710»
284. Hamm CW, Bassand JP, Agewall S ym. ESC Guidelines for the management of acute coronary syndromes in patients present ing without persistent ST-segment elevation: The Task Force for the management of acute
coronary syndromes (ACS) in patients present ing without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32 :2999-3054 «PMID: 21873419»
285. Ekerstad N, Löfmark R, Carlsson P. Elderly people with multi-morbidity and acute coronary syndrome: doctors' views on decisio n-making. Scand J Public Health 2010;38:325-31 «PMID: 19948651»
286. Brieger D, Aliprandi-Costa B. Developments in procedural and disease registries: a focus on coronary artery disease. Curr Opin Cardiol 2013;2 8:405-10 «PMID: 23703251»
287. Roberts R, Fromm RE. Management of acute coronary syndromes based on risk stratification by biochemical markers: an idea whose time has come. Circulation 1998;98:1831-3 «PMID: 9799199»
288. Brieger D, Eagle KA, Goodman SG ym. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insig hts from the Global Registry of Acute Coronary Events. Chest
2004;126:461-9 «PMID: 15302732»
289. Bach RG, Cannon CP, Weintraub WS ym. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004;141:186-95
«PMID: 15289215»
290. Tegn N, Abdelnoor M, Aaberge L ym. Invasive versus conser vative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pect oris (After Eighty study): an open- label
randomised controlled trial. Lancet  2016;387:1057-1065 «PMID: 26794722»
291. Savonitto S, Cavallini C, Petronio AS ym. Early aggressiv e versus initially conser vative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. JACC
Cardiovasc Interv 2012;5:906-16 «PMID: 22995877»
292. Coca SG, Krumholz HM, Garg AX ym. Underrepresent ation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006;296:1377-84 «PMID: 16985230»
293. Goldenberg I, Subirana I, Boyko V ym. Relation between renal function and outcomes in patients with non-ST-segment elevation acute coronary syndrome: real-world data from the European Public Health Outcome
Resea rch and Indicators Collection Project. Arch Intern Med 2010;170:888-95 «PMID: 20498417»
294. Munuaisvaurio (akuutti). Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in, Suomen Anest esiologiyhdistyksen, Tehohoitolääketieteen alajaoksen ja Suomen Nefrologiyhdistyksen asettama työryhmä.
Helsink i: Suomalainen Lääkäriseura Duodecim , 2020 (viitattu 14.06.2021). Saatavilla internetissä: www.kaypahoito.fi
295. Subherwal S, Bach RG, Chen AY ym. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse
outcomes with Early implementation of the ACC/AHA Guidelines)  Bleeding Score. Circulation 2009;119:1873-82 «PMID: 19332461»
296. Marenzi G, Cabiati A, Bertoli SV ym. Incid ence and relevance of acute kidney injury in patients hospitalized with acute coronary syndromes. Am J Cardiol 2013;111:8 16-22 «PMID: 23273525»
297. Nijssen EC, Rennenb erg RJ, Nelemans PJ ym. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced neph ropathy (AMACING): a
prospect ive, randomised, phase 3, controlled, open- label, non-inferiority trial. Lancet  2017;389:1312 -1322 «PMID: 28233565»
298. Kovoor P, Lee AK, Carrozzi F ym. Return to full normal activities including work at two weeks after acute myocardial infarction. Am J Cardiol 2006;97:952-8 «PMID: 16563893»
299. Isaaz K, Coudrot M, Sabry MH ym. Return to work after acute ST-segment elevation myocardial infarction in the modern era of reper fusion by direct percutaneous coronary intervention. Arch Cardiovasc Dis
2010;103:310 -6 «PMID: 20619241»
300. Report of the Expert Group on Driving and Cardiovascular Disease. Brussels, October 2013. New Standards for Driving and Cardiovascular Diseases.
https://ec. europa.eu/transpo rt/road_safety/sites/roadsafety/files/pd f/behavior/driving_and_cardiovascular_disease_final.pdf
301. TRAFICOM. Ajoterveyden arviointiohjeet terveydenhuollon ammattilaisille. https://w ww.traficom.fi/sit es/d efault/files/m edia/file/Ajoterveysohje_v1.2.pdf
302. Taylor RS, Brown A, Ebrahim S ym. Exercise- based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004;116:682-92 «PMID:
15121495»
303. Rantala M, Virtanen V. Kannattaako sydänpotilaan kuntoutus? Duodecim  2008;124:254-60
304. Hekkala AM, Kaikkonen K. Sydänkuntoutuksesta sydänvalmennu kseen - vanhaa hoitoa uudella tavalla. Duodecim  2020;136 :237-9
305. Kotseva K, Wood D, De Bacquer D ym. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev
Cardiol 2016;23:636-48 «PMID: 25687109»
306. Laukkanen J, Nieminen T, Savolainen K ym. Kliinisen rasituskokeen käyttö sydänsairauksissa . Suomen Kardiologisen Seuran työryhmän suositus (9/2016). Suom Lääkäril 2016;71:633-40
307. Young DR, Murinso n M, Wilson C ym. Paramedics as decisio n makers on the activation of the catheterization laboratory in the presence of acute ST-elevation myocardial infarction. J Electrocardiol 2011;44:18-22
«PMID: 20832811»
308. Jernberg T, Johanson P, Held C ym. Association between adoption of evidence- based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011;30 5:1677-84 «PMID: 21521849»
Artikkelin tunnus: hoi50130 (050.130)
© 2025 Suomalainen Lääkäriseura Duodecim
Aiheeseen liittyviä suosituksia
Krooninen sepelvaltimo-oireyhtymä
Julkaistu: Kesäkuu 2022
Potilaalle
Tiivistelmä26.2.2025 klo 21.59 Sepelvaltimotautikohtaus
https://www.kaypahoito.fi/hoi50130 41/41
Sepelvaltimotautipotilaan ajoterveys - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p al v eluk et jut  / Sepel v al timot autipotilaan hoit ok et ju  /
Sepel v al timot audin jatk ohoit o ja seurant a  / Sepel v al timot autipotilaan ajot er v e ys
 Sepel v al timot autipotilaan hoit ok et ju
Sepel v al timot audin diagnostiikka
Sepel v al timot audin hoit o
Sepel v al timot autik oht aus
Sy dän v almennus
Sepel v al timot audin jatk ohoit o ja seurant a
Seurant a sepel v al timot autidiagnoosin jälk een
OmaSy dän-et ähoit op al v elu
Sepel v al timot autipotilaan ajot er v e ys
Sepel v al timot autipotilaan t y ökyvyn ar viointi
Sepel v al timot audin lausunnot



Ajot er v e ys
Ajot er v e ysohje  (T raficom, pdf)
Kr ooninen sepel v al timo-oir e y ht ymä
Ajot er v e ysv aatimust en t ä y tt ymist ä seurat aan säännöllisin lääkär int ar kastuksin. P erust er v e y denhuollon lääkär i v oi
t ehdä seurant at ar kastukset. Seurant a v äli on y ksilöllinen.Kuuntele4.3.2025 klo 17.08 Sepelvaltimotautipotilaan ajoterveys - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotaudin-jatkohoito-ja-seuranta/ajoterveys 1/3
Ajolup a v oidaan m y önt ää/e v ät ä seuraa vin edell y t y ksin:
Ry hmän 1 ajot er v e ysv aatimukset eiv ät t ä y t y , jos henkilöllä on r int akipua t ai hengenahdistust a le v ossa,
pese y t y essä, puk eutuessa t ai muussa v ähäisessä rasituksessa t ai henkisen p aineen alaisena (CCS luokka 4).
Ry hmän 2 ajot er v e ysv aatimukset eiv ät t ä y t y , jos henkilöllä on sy dänoir eit a (r int akipua t ai hengenahdistust a)
t a v allisessa t asamaakä v el yssä t ai sit ä v ähäisemmässä rasituksessa (le v ossa, pese y t y essä, pukiessa) t ai
henkisen p aineen alaisena (CCS luokka 3-4). CCS-luokka 2 v ain kar diologin ar vion perust eella.
Ajot er v e ysv aatimukset t ä y tt yv ät, jos suor itusky ky on nor maali t ai enint ään lie v ästi alentunut (CCS 1- 2) ja kliinisessä
rasitusk ok eessa t odet aan nor maali t ai enint ään lie v ästi alentunut suor itusky ky eikä t odet a sy dämen hapenpuutt eelle
diagnostisia muut oksia eikä sen aiheutt amia v aka via r y tmihäir iöit ä t ai v er enkier r on muut oksia.
Sepel v al timot autik oht aus
Ajoky kyyn ja aut olla-ajokiellon pituut een on ot ett a v a kant aa potilaan k otiutuessa sairaalast a
U AP
r y hmät 1 ja 2 ajokiel t o 1 viikk o
NS TEMI ja S TEMI
Ry hmä 1: ajokiel t o v ähint ään 1 viikk o
Ry hmä 2: ajokiel t o v ähint ään 6 viikk o a
Sepel v al timok oht aus  (Kä yp ä hoit o -suositus)
Ohitusleikkauksen jälk een ajokiel t o, kunnes potilas on t oipunut
leikkauksest a ja leikkaushaa v a on p arantunut, kuit enkin:
Ry hmä 1
v ähint ään 4 viikk o a
Ry hmä 2 ja ammattikuljett ajat
t y öt er v e yslääkär in k ontr olliin asti, v ähint ään 6 viikk o a
Oir eisilla t ar vitt aessa rasitusk oe
Ohitusleikkauksen jälk een sairausloman pituus on 2- 3 kk.
Ammattikuljett ajat tulee ott aa er it yisr y hmänä t y öt er v e yslääkär in k ontr ollissa huomioon. Haast eellisissa t ap auksissa
heit ä on mahdollist a ohjat a Ajopolien k onsul t aatioon ( Helsinki, T ur ku, K uopio ) .
Edellinen
OmaSy dän-et ähoit op al v eluSeur aa v a
Sepel v al timot autipotilaan t y ökyvyn ar viointi
Päivit ett y 20 . 11.202 44.3.2025 klo 17.08 Sepelvaltimotautipotilaan ajoterveys - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotaudin-jatkohoito-ja-seuranta/ajoterveys 2/3
Ev äst eet
Saa vut et t a vuusselost e
Tiet osuoja
© Pir kanmaan h yvin v ointialueT akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.
T ämän sivun lö y dät osoitt eella pir ha.fi/hoit ok et jut4.3.2025 klo 17.08 Sepelvaltimotautipotilaan ajoterveys - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotaudin-jatkohoito-ja-seuranta/ajoterveys 3/3
Sepelvaltimotautipotilaan fysioterapia - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p al v eluk et jut  / Sepel v al timot autipotilaan hoit ok et ju  / Sepel v al timot autipotilaan fysiot er apia
 Sepel v al timot autipotilaan hoit ok et ju
Sepel v al timot autipotilaan fysiot er apia
Sepel v al timot audin diagnostiikka
Sepel v al timot audin hoit o
Sepel v al timot autik oht aus
Sy dän v almennus
Sepel v al timot audin jatk ohoit o ja seurant a




Sepel v al timot autipotilaan fysiot erapia
Sepe v al timot autipotilaan fysiot erapia sairaalassa
Esitiedot,  haast at t elu
F ysiot er apeut tinen tut kiminen ja ar viointi:  
Hengit yst oiminnot; neur ologinen st atus; liikkumisky ky; vir e ystila; omat oimisuus; kivut; sy k e v ast e
F ysiot er apeut tinen kunt outus / fysiot er apeut tinen ohjaus ja neuv ont a:
v ar hainen mobilisaatio (aloitus lääkär in luv alla); hengit y ksen t ehost aminen; v er enkier r on vilkastutt aminen
nousujoht einen liikkumisen lisääminen: k e vy t rasitust aso noin viik on ajan (Bor g 11/20) -> k ohti
sepel v al timot autipotilaan liikunt asuositust a
raskaiden ponnist elujen ja raskaiden t aakk ojen nost ojen sekä pist osk ohdan v oimakkaan v en y t y ksen v äl tt äminen
v al timopist osk ohdan p arantumisen aikana (noin 2 p äiv ää)
lämmitt el y , jäähd y tt el y; v auhdin säät ö; t auotus; hengäst ymisen ja hengenahdistuksen er ott aminen
omat oimisuuden tuk eminen
apuv äline ar vio ja kä y t ön ohjaus
por rashar joitt elu ennen k otiutumist a t ar vitt aessa
k otiohjeet: liikunnan nousujoht einen lisääminen, oir eiden tunnist aminen ja hoit oon hak eutuminen
F ysiot er apiasuunnit elman laatiminen:
suunnit elma jatk ofysiot erapiast a
sisäl t ää t a v oitt een asett amisen y hdessä potilaan kanssaKuuntele
CHAT4.3.2025 klo 17.10 Sepelvaltimotautipotilaan fysioterapia - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotautipotilaan-fysioterapia 1/2
Sepel v al timot autipotilaan fysiot erapia k otiutumisen jälk een
poliklinikalla
Esitiedot,  haast at t elu
F ysiot er apeut tinen tut kiminen ja ar viointi / fysiot er apeut tinen kunt outus:
v ointi, mahdolliset oir eet, kipu; t oipumisen et eneminen, liikkumisen lisä ys ar jessa, ar jen t oimint ojen sujuvuus,
mahdolliset haast eet t ai est eet liikunnan lisäämiselle
mieliala, liikkumismotiv aatio, k oettu kunt ot aso
6 min kä v el y t esti, hengit y ksen sujuvuus, limaisuus
hengit ysfunktiomitt aukset, r y hti, y läraajojen ja -v ar t alon liikkuvuus, lihasv oimat
F ysiot er apeut tinen ohjaus ja neuv ont a:
suor ituskyvyn ar vioinnin / t oipumisen mukaisen / sairausk oht ainen ohjaus k ohti liikunnallist a elämänt ap aa
motiv ointi, kannust aminen, y ksilöllisyys
F ysiot er apiasuunnit elman laatiminen:
jatk ofysiot erapiasuunnit elma
sisäl t ää t a v oitt een asett amisen, t ar vitt aessa y ksilöllinen har joitusohjelma
P otilasohje:  Op as sepel v al timot autia sair ast a v alle  (T er v e yspor tti, pdf)
P otilaan ohjaus ja motiv ointi
Päivit ett y 28 . 11.202 4
Ev äst eet
Saa vut et t a vuusselost e
Tiet osuoja
© Pir kanmaan h yvin v ointialueT akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.
T ämän sivun lö y dät osoitt eella pir ha.fi/hoit ok et jut4.3.2025 klo 17.10 Sepelvaltimotautipotilaan fysioterapia - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotautipotilaan-fysioterapia 2/2
Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim.pdf
Sepelvaltimotautipotilaan liikunnallinen kuntoutus
Hyvä fysioterapiakäytäntö
Suomen Fysioterapeutit - Finlands Fysioterapeuter ry:n asettama työryhmä
Arto Hautala, Annukka Alapappila, Hanna Häkkinen,  Renja Karhunen,  Juho Korpi, Jari Laukkanen,  Leena  Meinil ä ja Kai Savonen
18.11.2022
Lukijalle
Suomen Fysioterapeutit Ry käynnist i Hyvä fysioterapiakäytäntö -hankkeen vuonna 2004. Tavoitteena  on tuottaa näyttöön perustuvia, suomalaiseen
terveydenhuoltoon soveltuvia fysioterapiasuosituksia sekä toimia tiiviissä  yhteistyössä eri verkostojen kanssa  kuntoutuksen ja fysioterapian näkyvyyden
lisäämiseksi (Käypä hoito, Kela, THL). Tavoitteena  on fysioterapian vaikuttavuuden ja tehokkuuden paranem inen edistämällä tieteelliseen näyttöön
perustuvaa fysioterapiakäytäntöä ja näyttöön perustuvan tiedon käyttöönottoa sekä yhtenäistää valtakunnallista fysioterapiakäytäntöä. Hyvä
fysioterapiakäytäntö on toimintatapa, jossa yhdistyvät näyttöön perustuvat työkäytännöt, organisa ation toiminna n ja fysioterapeuttien osaamisen
kehittäminen.
Sepel valtimotautipotilaan liikunnallinen kuntoutus -fysioterapiasuosituksen toinen määräaikaispäivitys perustuu järjestelmällisest i koottuun
tutkimustietoon, jonka näytön aste ja luotettavuus on arvioitu taulukon «Näytön asteen luokitus fysioterapiassa ...»1 mukaan. Samoja näytön asteen tasoja
käytetään kuvaamaan tilannet ta, jossa tutkimukset osoittavat tutkitun menet elmän vaikuttavuuden tai tilannet ta, jossa tutkimukset osoittavat, että kyseinen
menet elmä ei ole vaikuttava. Tekstissä olevien suosituslauseiden lopussa on näytön astetta kuvaava kirjain (A–D). Näytönastekatsaukset löytyvät erillisenä
liitteenä .
Taulukko 1. Näytön asteen luokitus fysioterapiassa «Honkanen M, Jousimaa J, Komulainen J, Kunnamo I, S...»1
Koodi Näytön aste Selitys
A Vahva tutkimusnäyttöOn epätodennäköistä, että uudet tutkimukset muuttaisivat arviota vaikutuksen suunnasta tai suuruudesta.
Tutkimuksissa on käytetty tutkittavan aiheen suhteen parasta tutkimusasetelmaa.
Vähintään kaksi tasokasta tutkimusta (esim. RCT-asetelma), joiden tulokset ovat samansuuntaiset.
Lopputulosmuuttujalla on arvioitu suoraan potilaalle tärkeää kliinistä hyötyä tai haittaa.
Tulosten alfa- ja beetavirheet (väärät positiiviset ja väärät negatiiviset tulokset) sekä 95 %:n luottamusvälit ovat pieniä.
Tutkitut väestöt vastaavat hoitosuosituksen kohdeväestöä tai ovat siihen sovellettavissa.
B Kohtalainen tutkimusnäyttö Uudet tutkimukset saattavat vaikuttaa arvioon vaikutuksen suuruudesta ja suunnasta.
Tutkimuksissa on käytetty tutkittavan aiheen suhteen parasta saavutettavaa tutkimusasetelmaa.
Tasokkaita tutkimuksia on vain yksi tai
Tasokkaita tutkimuksia on useita, mutta tuloksissa on vähäistä ristiriitaa tai4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 1/23
Koodi Näytön aste Selitys
Useita kelvollisia tutkimuksia, joiden tuloksissa ei ole systemaattista virhettä ja tulokset ovat samansuuntaiset.
Lopputulosmuuttujalla on arvioitu suoraan potilaalle tärkeää kliinistä hyötyä tai haittaa.
Tutkitut väestöt vastaavat hoitosuosituksen kohdeväestöä tai ovat siihen sovellettavissa.
C Heikko tutkimusnäyttöUudet tutkimukset todennäköisesti vaikuttavat arvioon vaikutuksen suuruudesta ja mahdollisesti sen suunnasta.
Tasokkaita, tutkittavan aiheen suhteen parasta tutkimusasetelmaa käyttäviä tutkimuksia on useita, mutta tuloksissa on
merkittävää ristiriitaa tai
Kelvollisia kontrolloituja tutkimuksia, joiden tulokset voidaan yleistää kohdeväestöön, on ainakin yksi.
Vertailtavien ryhmien tulee olla samanaikaisia, historiallinen vertailuryhmä tai vertaaminen kirjallisuudesta poimittuihin
arvoihin ei riitä.
Lopputulosmuuttujalla ei ole arvioitu suoraan potilaalle tärkeää kliinistä hyötyä tai haittaa.
Tutkitut väestöt eivät täysin vastaa hoitosuosituksen kohdeväestöä tai ole siihen sovellettavissa.
D Hyvin heikko tutkimusnäyttöMikä tahansa arvio vaikutuksen suunnasta ja suuruudesta on epävarma.
Kliinisiä tutkimuksia ei ole olemassa tai ne ovat menetelmällisesti heikkoja.
Arvio perustuu pääosin kliiniseen kokemukseen ja osaamiseen.
Työryhmä voi tehdä D-asteen kannanoton, kun on kysymys diagnostiikan tai hoidon kannalta tärkeästä päätöskohdasta.
Suosituslauseeseen liittyy silloin näytönastekatsaus, jossa perustellaan työryhmän kannanotto.
Tekstissä on viitattu myös yksittäisten tutkimusten tuloksiin sekä muihin kirjallisuuslähteisiin,  jotka on merkitty tekstiin viitenumeroin. Viiteluettelo on
suositustekstin lopussa. Järjestelmällinen kirjallisuushaku on tehty vuoden 2015 elokuusta vuoden 2021 marraskuun alkuun julkaistuista tutkimuksista
PEDro-, PubMed- ja Cochrane-tietokannoista. Haku on tehty Suomalaisen Lääkäriseuran Duodecim in Hoitosuositustyöryhmien käsikirjan
«https://www. terveysportti.fi/dtk/khk/avaa?p_artikkeli=khk00007»1 mukaan «Komulainen J, Honkanen M, Malmivaara A, Sipilä R (...»2. Hakustrategia
on saatavissa työryhmältä. Koko suositus ja siihen liittyvät näytönastekatsaukset sekä sähköiset tausta-aineist ot on saatavilla osoitteesta
www. suomenfysioterapeutit.fi «https://www. suomenfysioterapeutit.fi/fysioterapia/ammatin-
kehittaminen/f ysioterapiasuositukset/sepelvaltimotautipotilaan-liikunnallinen- kuntoutus/»2.
Lyhenteet
Taulukko 2. Lyhenteet
ACE Angiotensiinikonvertaasi
AT2 Tyypin kaksi angiotensiinireseptori
BNP B-tyypin natriureettinen peptidi4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 2/23
CABG Sepelvaltimon (-valtimoiden) ohitusleikkaus
CCSSydän- ja verisuonisairauksien vaikeusasteen arviointiin kehitetty luokitus (Canadian Cardiovascular Society), jossa kartoitetaan tutkittavan oireet suhteessa
tyypillisiin arkipäivän toimintoihin ja ponnistuksiin.
HDL High Density Lipoprotein eli ns. "hyvä kolesteroli", joka kuljettaa kolesterolia pois elimistöstä.
LDL Low Density Lipoprotein eli ns. "huono kolesteroli", joka kuljettaa kolesterolia verestä kudoksiin päin.
NTproBNP B-tyypin natriureettisen peptidin esiaste.
NSTEMISepelvaltimotautikohtaus eli sydäninfarkti ilman ST-nousuja, jolloin elektrokardiografiarekisteröinnissä (EKG) ei havaita ST-nousua, mutta siinä voi esiintyä
ST-vajoamaa tai EKG voi pysyä normaalina.
NYHASydän- ja verisuonisairauksien vaikeusasteen arviointiin kehitetty luokitus (New York Heart Association), jossa kartoitetaan tutkittavan oireet suhteessa
tyypillisiin arkipäivän toimintoihin ja ponnistuksiin.
MET Kuvaa fyysisen aktiivisuuden aiheuttamaa lisääntynyttä energiankulutusta verrattuna lepotasoon. 1 MET vastaa hapenkulutusta 3,5 ml/kg/min.
PCI Sepelvaltimon (-valtimoiden) pallolaajennus
RM Maksimitoistojen määrä, esimerkiksi 1 RM = yhden toiston maksimikuorma.
RPE Koettu fyysinen kuormittuneisuus asteikolla 6–20
STSydämen sähköisen toimintasyklin repolarisaatiovaihetta kuvaava kohta EKG:ssä. ST-segmentin tason muutoksia käytetään esimerkiksi sydäninfarktin
yhteydessä sydänlihaksen hapenpuutetta arvioitaessa
STEMISepelvaltimotautikohtaus eli ST-nousu-sydäninfarkti, ST-segmentin nousu perusviivasta merkitsee yleensä vaikeaa, koko sydänlihaksen paksuuden
käsittävää hapenpuutetta
Tavoitteet ja rajaukset
Suosituksessa  tarkastellaan liikunnan tutkittuja vaikutuksia sepel valtimotautiin sekä sepel valtimotautipotilaan liikunnallisen sydänkuntoutuksen
menet elmiä ja vaikuttavuutta sekä lyhyesti esitellään sydänkuntoutuksen muita avaintekijöitä.
Sepel valtimotautipotilaan kuntoutus on monialaista terveydenhuollon eri osaajien suunnit telemaa ja ohjaamaa tavoitteellista toimintaa.
Suosituksessa  käsitellään sepel valtimotautipotilaan liikunnallista kuntoutusta sillä oletuksella, että sairauden kliininen kuva sallii sen.
Suositus ei arvioi liikunnallisessa  kuntoutuksessa  käytettävien tutkimus- ja arviointimenet elmien toistettavuutta ja pätevyyttä.
Suosituksessa  ei arvioida erikseen pallolaajennu kseen,  ohitusleikkaukseen,  läppäleikkauksiin,  sydämensiir toon, rytmihäiriöihin, vajaatoimintaan,
tulehduksellisiin sydänsairauksiin tai diabetekseen liittyviä erityispiir teitä.
Liikunnan merkitys sepel valtimotaudin ehkäisyssä ja riskitekijöiden hoidossa on kuvattu Liikunnan Käypä hoito -suosituksessa
«https://www. kaypahoito.fi/hoi50075»3.
Liikuntaan liittyvät määritelmät esitetään Liikunnan Käypä hoito -suosituksessa  «https://www. kaypahoito.fi/hoi50075»3.4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 3/23
Kohderyhmät
Suosituksen kohderyhmänä ovat sepel valtimotautipotilaiden hoitoon ja kuntoutukseen osallistuvat
fysioterapeutit
lääkärit
kuntoutussuunnit telijat – ja ohjaajat
terveydenhuollon ja liikunnan ammattilaiset sekä opisk elijat
kouluttajat, kuten terveys- ja sosiaalialan oppilaitosten opettajat
sekä kaikki ne henkilöt, jotka tarvitsevat tietoa tehdessä än sepel valtimotautipotilaan kuntoutusta koskevia suunnit elmia ja päätöksiä.
Suosituksen keskeinen viesti
Liikuntaa sisältävä sydänkuntoutus vähentää kliinisest i merkittävästi sepel valtimotaudista johtuvia sydäntapahtumia verrattuna tavanomaiseen
sepel valtimotautipotilaan jatkohoitoon.
Säännölliseen liikuntaan perustuva sydänkuntoutus on kustannusvaikuttava toimintamalli verrattuna tavanomaiseen jatkohoitoon.
Säännöllinen kestävyysliikunta, lihasvoimaharjoittelu ja riittävä arkiaktiivisuus ovat potilaan iästä ja sukupuolesta riippu matta keskeinen osa
sepel valtimotautipotilaan kuntoutumista läpi elämän.
Sepel valtimotautipotilaan liikunnallinen kuntoutus alkaa jo sairaalassa yksilölliset tekijät huomioiden.
Liikunnallisen sydänkuntoutuksen tavoitteena  on, että potilas oppii ja rohkaistuu liikkumaan säännöllisest i, riittävän kuormittavasti ja turvallisest i.
Sepel valtimotautipotilaan kuntoutuskäytännön sekä yksilöllisen tavoitteen tulee olla kirjattu ja yhdessä  potilaan hoitoon ja kuntoutukseen osallistuvien
kanssa  sovittu.
Hoitava lääkäri ja fysioterapeutti ovat keskeisessä  asemassa potilaan ohjaamisess a kuntoutukseen ja kuntoutussuunnit elma tulisi tehdä jo sairaalassa.
Kuntoutussuunnit elmasta tulee käydä ilmi, miten, missä ja milloin kuntoutus toteutuu.
Liikunnallinen sydänkuntoutus parantaa sepel valtimotautipotilaiden elämänlaatua verrattuna tavanomaiseen hoitoon.
Sepel valtimotaudin lääkehoito ei vaikuta olenna isest i liikunnallisen kuntoutuksen toteuttamiseen.
Sepelvaltimotauti ja liikunta
Sepelvaltimotaudin diagnosointi ja hoito
Sepel valtimotauti on krooninen sairaus, jossa sydämen omat valtimot ahtautuvat «Krooninen sepel valtimo-oireyhtymä. Käypä hoito -su...»3.
Sepel valtimotautikohtaukseksi nimitetään sepel valtimoiden äkillisest ä ahtautumisest a tai tukkeutumisest a johtuvia oirekuvia.
Sepel valtimotautikohtauksen ilmenem ismuotoja ovat epästabiili angina pect oris (UAP), sydäninfarkti ilman ST-nousuja (NSTEMI) ja ST-nousuinfarkti
(STEMI) «Komulainen J, Honkanen M, Malmivaara A, Sipilä R (...»2.4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 4/23
Sepel valtimotautipotilaan sairaalahoidon syitä ovat akuutti sydäntapahtuma tai suunnit eltu sydäntoimenpid e (ohitusleikkaus tai pallolaajennu s).
Sepel valtimotaudin riskitekijät, diagnosointi, kliininen tutkiminen ja lääketieteellinen hoito on kuvattu Käypä hoito -suosituksissa
«https://www. kaypahoito.fi»4:
Sepel valtimotautikohtaus «https://www. kaypahoito.fi/hoi50130»5
Krooninen sepel valtimo-oireyhtymä «https://www. kaypahoito.fi/hoi50102»6
Liikuntakelpoisuuden arviointi ja liikuntaan liittyvät riskit
Liikunnan turvallisuutta tarkasteltaessa  sepel valtimotautipotilaat jaetaan kolmeen ryhmään «Krooninen sepel valtimo-oireyhtymä. Käypä hoito -su...»3 ja
ne on esitelty taulukossa «Sepel valtimotautipotilaiden luokittelu liikunnan turvallisuuden perusteella ...»3.
Taulukko 3. Sepelvaltimotautipotilaiden luokittelu liikunnan turvallisuuden perusteella
Ryhmä Suorituskyky Löydökset ja oireet Liikunta
A. Stabiili sepelvaltimotautiNYHA 1–2
CCS 1–2
tai yli 6 METNormaali verenpainevaste rasituksessa.
Ei sydämen vajaatoimintaa.
Ei rintakipua levossa.
Ei vakavia rytmihäiriöitä.Kohtuukuormitteinen liikunta ei aiheuta vaaraa.
Rasittavassa liikunnassa vaara on hieman suurentunut.
B. Vaikeampi sepelvaltimotautiNYHA 3-4
CCS 3-4
tai alle 6 METVoimakkaat ST-muutokset,
rintakipu, vakavat rytmihäiriöt
tai systolisen verenpaineen lasku rasituksessaLiikuntaan liittyy kohtalainen tai suuri
sydänkomplikaatioiden vaara kuormituksessa.
C. Epästabiili kompensoitumaton
sepelvaltimotautiVerenkiertoelimistöä kuormittavaa liikuntaa ei suositella.
Vaikka suurin osa sepel valtimotautipotilaista kuuluukin A-ryhmään «Vu ori I, Kesäniem i A. Sepel valtimotauti ja sydämen...»4, sepel valtimotautipotilailla
on kuitenkin joitakin kestävyysliikuntaa ja lihasvoimaharjoittelua estäviä syitä «Balady G, Gardner A. Exercise prescription for pat...»5:
epästabiili sepel valtimotauti
riittämättömässä hoitotasapainossa oleva sydämen vajaatoiminta
hoidosta huolimatta ilmenev ät eteis- tai kammioperäiset rytmihäiriöt
vaikea-asteinen aorttaläpän ahtauma (läpän pinta-ala < 1,0 cm2)
oireita aiheuttava sydänlihas- tai sydänpussitulehdus
riittämättömässä hoitotasapainossa oleva verenpa inetauti (systolinen lepoverenpa ine > 180 mmHg ja/tai diastolinen lepoverenpa ine > 110 mmHg)
akuutti yleisoireita aiheuttava sairaus tai kuume
oireita aiheuttava verenpa ineen lasku (> 20 mmHg makuulta seiso maan noustessa )4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 5/23
sinu sper äinen tiheälyöntisyys levossa (> 120 lyöntiä minuutissa)
III asteen eteis-kammiokatkos ilman tahdistinhoitoa
äskettäin sairastettu veritulppa
akuutti laskimontukkotulehdus
riittämättömässä hoitotasapainossa oleva diabetes
tuki- ja liikuntaelinsa irauksista aiheutuvat rajoitteet
aineenv aihduntahäiriöt, kuten kilpirauhastulehdus, hypo- tai hyperkalemia
hypovolemia.
Liikunnan vaikutukset sepelvaltimotautia sairastavalle
Sepel valtimotautipotilaiden säännölliseen liikuntaan perustuva sydänkuntoutus
Ei vähennä  kokonais- «Säännölliseen liikuntaan perustuva sepelvaltimotautipotilaan kuntoutus ei vähennä  kuolleisuutta enem män kuin tavanomainen
hoito.»A tai sydän- ja verisuonitaudeista johtuvaa kuolleisuutta verrattuna tavanomaiseen hoitoon «Säännölliseen liikuntaan perustuva
sepel valtimotautipotilaan kuntoutus ei vähennä  sydän- ja verisuonitaudeista johtuvaa kuolleisuutta enem män kuin tavanomainen hoito.»A.
Vähentää uusien,  mistä tahansa syystä aiheutuvien, sairaalahoitojen tarvetta verrattuna tavanomaiseen hoitoon «Säännölliseen liikuntaan perustuva
sepel valtimotautipotilaan kuntoutus vähentää uusien,  mistä tahansa syystä aiheutuvien sairaalahoitojen tarvetta enem män kuin tavanomainen hoito.
Vähentynyt tarve johtuu nimenomaan liikunnasta, vaikka kuntoutus sisältäisi muitakin komponent teja.»A.
Vähentynyt tarve johtuu nimenomaan liikunnasta, vaikka kuntoutus sisältäisi muitakin komponent teja. Tarpeen vähenem inen ei ole yhteydessä
liikuntapainotteisen kuntoutuksen toteuttamispaikkaan tai -tapaan, eikä myöskään liikunnan määrään «Säännölliseen liikuntaan perustuva
sepel valtimotautipotilaan kuntoutus vähentää uusien,  mistä tahansa syystä aiheutuvien sairaalahoitojen tarvetta enem män kuin tavanomainen hoito.
Vähentynyt tarve johtuu nimenomaan liikunnasta, vaikka kuntoutus sisältäisi muitakin komponent teja.»A.
Vähentää uusien,  sydän- ja verisuonitaudeista aiheutuvien, sairaalahoitojen tarvetta verrattuna tavanomaiseen hoitoon tai kuntoutukseen,  joka ei sisällä
liikuntaa «Säännölliseen liikuntaan perustuva sepelvaltimotautipotilaan kuntoutus vähentää uusien,  sydän- ja verisuonitaudeista aiheutuvien
sairaalahoitojen tarvetta enem män kuin tavanomainen hoito tai kuntoutus, joka ei sisällä liikuntaa.»A.
Vähentää sydäninfarktien vaaraa verrattuna tavanomaiseen hoitoon «Säännölliseen liikuntaan perustuva sepelvaltimotautipotilaan kuntoutus vähentää
sydäninfarktin vaaraa enem män kuin tavanomainen hoito. Vaaran pienenem inen johtuu nimenomaan liikunnasta, vaikka kuntoutus sisältäisi muitakin
komponent teja.»A.
Vaaran pienenem inen johtuu nimenomaan liikunnasta, vaikka kuntoutus sisältäisi muitakin komponent teja «Säännölliseen liikuntaan perustuva
sepel valtimotautipotilaan kuntoutus vähentää sydäninfarktin vaaraa enem män kuin tavanomainen hoito. Vaaran pienenem inen johtuu nimenomaan
liikunnasta, vaikka kuntoutus sisältäisi muitakin komponent teja.»A. Laitoksessa  tapahtuva kuntoutus on vaikuttavampaa «Säännölliseen liikuntaan
perustuva sepel valtimotautipotilaan kuntoutus vähentää sydäninfarktin vaaraa enem män kuin tavanomainen hoito. Vaaran pienenem inen johtuu
nimenomaan liikunnasta, vaikka kuntoutus sisältäisi muitakin komponent teja.»A kuin kotona tapahtuva; vaikuttavuus ei kuitenkaan ole yhteydessä
liikunnan määrään «Säännölliseen liikuntaan perustuva sepelvaltimotautipotilaan kuntoutus vähentää sydäninfarktin vaaraa enem män kuin4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 6/23
tavanomainen hoito. Vaaran pienenem inen johtuu nimenomaan liikunnasta, vaikka kuntoutus sisältäisi muitakin komponent teja.»A. Vaaran
vähenem inen havaitaan sekä fataaleissa  että ei-fataaleissa  infarkteissa  «Säännölliseen liikuntaan perustuva sepelvaltimotautipotilaan kuntoutus
vähentää sekä fataalin että ei-fataalin sydäninfarktin vaaraa enem män kuin tavanomainen hoito.»A.
Ei vähennä  revaskularisaation (pallolaajennus tai ohitusleikkaus) tarvetta verrattuna tavanomaiseen hoitoon «Säännölliseen liikuntaan perustuva
sepel valtimotautipotilaan kuntoutus ei vähennä  revaskularisaatiotoimenpit eitä enem män kuin tavanomainen hoito.»A.
Pallolaajennu ksen jälkeen ei ilmeisest i vähennä  revaskularisaation tarvetta, mutta ilmeisest i vähentää toimenpit een jälkeisten sydän- ja
verisuonitapahtumien vaaraa verrattuna tavanomaiseen hoitoon «Säännölliseen liikuntaan perustuva sepelvaltimotautipotilaan kuntoutus
pallolaajennu ksen jälkeen ilmeisest i vähentää toimenpit een jälkeisten sydän- ja verisuonitapahtumien vaaraa, mutta ei myöhemmän ohitusleikkauksen
tarvetta verrattuna tavanomaiseen hoitoon.»B.
Pallolaajennu ksen jälkeen ilmeisest i nopeuttaa vasemman kammion pumppaustehon palautumista, mutta ei pienennä  vasemman kammion kokoa tai
paranna kävelynopeutta verrattuna tavanomaiseen hoitoon «Säännölliseen liikuntaan perustuva sepelvaltimotautipotilaan kuntoutus pallolaajennu ksen
jälkeen ilmeisest i nopeuttaa vasemman kammion pumppaustehon palautumista, mutta ei pienennä  vasemman kammion kokoa tai paranna
kävelynopeutta verrattuna tavanomaiseen hoitoon.»B.
Lisää ilmeisest i koettua ener gisyyttä tai vähentää väsymystä verrattuna tavanomaiseen hoitoon «Säännölliseen liikuntaan perustuva
sepel valtimotautipotilaan kuntoutus ilmeisest i lisää koettua ener gisyyttä tai vähentää väsymystä enem män kuin tavanomainen hoito.»B.
Ilmeisest i parantaa elämänlaatua verrattuna tavanomaiseen hoitoon «Dibben G, Faulkner J, Oldridge N ym. Exercise- base...»6.
Lisäksi liikuntapainotteinen sydänkuntoutus ilmeisest i vähentää sydämen vajaatoimintapotilaan sairaalahoitoon joutumisen riskiä
«Liikuntapainotteinen sydänkuntoutus vähentää sydämen vajaatoimintapotilaan sairaalahoitoon joutumisen riskiä.»B.
Lisäksi sepel valtimotautipotilailla, joilla on todettu sydämen systolinen vajaatoiminta:
Ilmeisest i pienent ää plasman BNP- ja NTproBNP-pitoisuutta verrattuna tavanomaiseen hoitoon «Säännölliseen liikuntaan perustuva
sepel valtimotautipotilaan kuntoutus ilmeisest i pienent ää plasman BNP- ja NTproBNP-pitoisuutta enem män kuin tavanomainen hoito.»B.
Ilmeisest i lisää maksimaalisessa  kuormituskokeessa  saavutettua sykettä, systolista verenpa inetta ja sydämen minuuttitilavuutta verrattuna
tavanomaiseen hoitoon «Säännölliseen liikuntaan perustuva sepelvaltimotautipotilaan kuntoutus ilmeisesti lisää maksimaalisessa  testissä saavutettua
sykettä, systolista verenpa inetta ja sydämen minuuttitilavuutta enem män kuin tavanomainen hoito.»B.
Ilmeisest i parantaa maksimaalisessa  kuormituskokeessa  saavutettua työtehoa, aerobista kynnystä ja 6 minuutin kävelytestitulosta verrattuna
tavanomaiseen hoitoon «Säännölliseen liikuntaan perustuva sepelvaltimotautipotilaan kuntoutus ilmeisesti parantaa maksimaalisessa  testissä
saavutettua työkuormaa ja aerobista kynnystä sekä 6 minuutin kävelytestitulosta enem män kuin tavanomainen hoito.»B.
Sepel valtimotautipotilaiden säännölliseen kestävyysliikuntaan perustuva sydänkuntoutus
Parantaa maksimaalista hapeno ttokykyä enem män kuin tavanomainen hoito «Säännölliseen kestävyysliikuntaan perustuva sepel valtimotautipotilaan
kuntoutus parantaa maksimaalista hapenottokykyä enem män kuin tavanomainen hoito. Kestävyysliikuntaan perustuvan kuntoutuksen vaikuttavuus ei ole
yhteydessä  kuntoutusjakson toteuttamistapaan.»A.
Vaikuttavuus ei ole yhteydessä  kuntoutusjakson toteuttamistapaan «Säännölliseen kestävyysliikuntaan perustuva sepel valtimotautipotilaan kuntoutus
parantaa maksimaalista hapeno ttokykyä enem män kuin tavanomainen hoito. Kestävyysliikuntaan perustuvan kuntoutuksen vaikuttavuus ei ole4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 7/23
yhteydessä  kuntoutusjakson toteuttamistapaan.»A. Vaikuttavuus on ilmeisest i suurempi aloitettaessa  kestävyysliikunta viimeistään kolmen kuukauden
kuluessa  sydäntapahtumasta «Säännölliseen kestävyysliikuntaan perustuvan sepel valtimotautipotilaan kuntoutuksen vaikuttavuus maksimaaliseen
hapeno ttokykyyn on ilmeisest i suurempi aloitettaessa  kestävyysliikunta viimeistään kolmen kuukauden kuluessa  sydäntapahtumasta.»B.
Maksimaalisen hapeno ttokyvyn paranem inen on suorassa yhteydessä  kestävyysliikunnan aiheuttamaan ener giankulutukseen
«Sepel valtimotautipotilaan kestävyysharjoitteluun perustuvassa liikunnallisessa  kuntoutuksessa  havaittu maksimaalisen hapeno ttokyvyn paranem inen
on suorassa yhteydessä  kestävyysliikunnan aiheuttamaan ener giankulutukseen.  Kuntoutusjakson aikaisen kestävyysliikunnan ener giankulutuksen
huomioimisen jälkeen yksittäisten harjoituskertojen tiheydellä, kestolla tai intensit eetillä, kuten myöskään kuntoutusjakson kestolla ei ole yhteyttä
maksimaalisen hapeno ttokyvyn paranem iseen. »A. Kuntoutusjakson aikaisen kestävyysliikunnan ener giankulutuksen huomioimisen jälkeen
yksittäisten harjoituskertojen tiheydellä, kestolla tai intensit eetillä, kuten myöskään kuntoutusjakson kestolla ei ole yhteyttä maksimaalisen
hapeno ttokyvyn paranem iseen «Sepel valtimotautipotilaan kestävyysharjoitteluun perustuvassa liikunnallisessa  kuntoutuksessa  havaittu
maksimaalisen hapeno ttokyvyn paranem inen on suorassa yhteydessä  kestävyysliikunnan aiheuttamaan ener giankulutukseen.  Kuntoutusjakson
aikaisen kestävyysliikunnan ener giankulutuksen huomioimisen jälkeen yksittäisten harjoituskertojen tiheydellä, kestolla tai intensit eetillä, kuten
myöskään kuntoutusjakson kestolla ei ole yhteyttä maksimaalisen hapeno ttokyvyn paranem iseen. »A.
Polkupyöräergometrillä suoritettu harjoittelu ilmeisest i parantaa maksimaalista hapeno ttokykyä enem män kuin juoksumatolla suoritettu harjoittelu
«Polkupyöräergometrillä suoritettu kestävyysharjoitteluun perustuva sydänkuntoutus parantaa maksimaalista hapeno ttokykyä enem män kuin
vastaava juoksumatolla suoritettu harjoittelu sepel valtimotautipotilailla.»A.
Laskee systolista, mutta ei diastolista lepoverenpa inetta verrattuna tavanomaiseen hoitoon «Säännölliseen kestävyysliikuntaan perustuva
sepel valtimotautipotilaan kuntoutus laskee systolista, mutta ei diastolista lepoverenpa inetta verrattuna tavanomaiseen hoitoon. Vaikuttavuus systoliseen
lepoverenpa ineeseen ei ole yhteydessä  kuntoutusjakson toteuttamistapaan.»A.
Vaikuttavuus systoliseen lepoverenpa ineeseen ei ole yhteydessä  kuntoutusjakson toteuttamistapaan «Säännölliseen kestävyysliikuntaan perustuva
sepel valtimotautipotilaan kuntoutus laskee systolista, mutta ei diastolista lepoverenpa inetta verrattuna tavanomaiseen hoitoon. Vaikuttavuus
systoliseen lepoverenpa ineeseen ei ole yhteydessä  kuntoutusjakson toteuttamistapaan.»A.
Vähentää seerumin/pl asman LDL-kolesterolipitoisuutta ja lisää HDL-kolesterolipitoisuutta, mutta ei vaikuta triglyseridi- tai
kokonaiskolesterolipitoisuuteen verrattuna tavanomaiseen hoitoon «Säännölliseen kestävyysliikuntaan perustuva sydänkuntoutus vähentää
seerumin/pl asman LDL-kolesterolipitoisuutta ja lisää HDL-kolesterolipitoisuutta, mutta ei vaikuta triglyseridi- tai kokonaiskolesterolipitoisuuteen
verrattuna tavanomaiseen hoitoon.»A.
Vähentää plasman C-reaktiivisen proteiinin «Säännölliseen kestävyysliikuntaan perustuva sepel valtimotautipotilaan kuntoutus vähentää plasman herkän
C-reaktiivisen proteiinin pitoisuutta enem män kuin tavanomainen hoito.»A ja fibrinogeenin pitoisuutta verrattuna tavanomaiseen hoitoon «Säännölliseen
kestävyysliikuntaan perustuva sepel valtimotautipotilaan kuntoutus vähentää plasman fibrinogeenipit oisuutta enem män kuin tavanomainen hoito.»A.
Ilmeisest i parantaa autonomisen hermoston toimintaa sykevaihtelulla mitattuna verrattuna tavanomaiseen hoitoon «Liikuntaharjoittelu yhdessä
optimoidun lääkityksen kanssa  ilmeisest i lisää sydämen sykevaihtelua.»B.
Parantaa valtimoiden sisäkalvon toimintaa (endoteelifunktiota) verrattuna tavanomaiseen hoitoon «Kestävyysliikuntaan perustuva
sepel valtimotautipotilaan kuntoutus parantaa valtimoiden sisäkalvon toimintaa (endoteelifunktiota) enem män kuin tavanomainen hoito.»A.4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 8/23
Parantaa vasemman kammion pumppaustehoa verrattuna tavanomaiseen hoitoon «Säännölliseen kestävyysliikuntaan perustuva sydänkuntoutus
parantaa vasemman kammion pumppaustehoa verrattuna tavanomaiseen hoitoon.»A.
Sepel valtimotautipotilailla, joilla on todettu sydämen systolinen vajaatoiminta
Ilmeisest i parantaa maksimaalista hapenottokykyä sekä vasemman kammion pumppaustehoa enem män kuin tavanomainen hoito «Säännölliseen
kestävyysliikuntaan perustuva sepel valtimotautipotilaan kuntoutus ilmeisest i parantaa maksimaalista hapeno ttokykyä sekä vasemman kammion
pumppaustehoa enem män kuin tavanomainen hoito.»B.
Ilmeisest i pienent ää plasman NTproBNP-pitoisuutta enem män kuin tavanomainen hoito «Säännölliseen kestävyysliikuntaan perustuva
sepel valtimotautipotilaan kuntoutus ilmeisest i pienent ää plasman NTproBNP-pitoisuutta enem män kuin tavanomainen hoito.»B.
Yli kuusi kuukautta jatkuessa an ilmeises ti pienent ää vasemman kammion tilavuutta enem män kuin tavanomainen hoito «Yli kuusi kuukautta jatkuva,
kestävyysharjoitteluun perustuva sepel valtimotautipotilaan kuntoutus ilmeisest i pienent ää vasemman kammion loppusystolista sekä -diastolista
tilavuutta enem män kuin tavanomainen hoito.»B.
Intervallityyppinen korkeaintensit eettinen kestävyysharjoittelu
Lisää maksimisykettä ja parantaa maksimaalista hapeno ttokykyä, mutta ei aerobista kynnystä enem män kuin yhtäjaksoinen matalaintensit eettisem pi
kestävyysharjoittelu «Intervallityyppinen korkeaintensit eettinen kestävyysharjoittelu lisää maksimisykettä ja parantaa maksimaalista hapeno ttokykyä,
mutta ei aerobista kynnystä enem män kuin yhtäjaksoinen matalaintensit eettisem pi kestävyysharjoittelu sepel valtimotautipotilailla.»A.
Laskee systolista lepoverenpa inetta vähemmän kuin yhtäjaksoinen matalaintensit eettinen kestävyysharjoittelu «Intervallityyppinen
korkeaintensit eettinen kestävyysharjoittelu laskee systolista, mutta ei diastolista lepoverenpa inetta vähemmän kuin yhtäjaksoinen
matalaintensit eettisem pi kestävyysharjoittelu sepel valtimotautipotilailla.»A.
Ei vaikuta seerumin/pl asman LDL-, HDL-, triglyseridi- tai glukoosipit oisuuteen,  eikä kehonpainoon, suotuisammin kuin yhtäjaksoinen
matalaintensit eettinen kestävyysharjoittelu «Intervallityyppinen korkeaintensit eettinen kestävyysharjoittelu ei vaikuta seerumin/pl asman LDL-, HDL-,
triglyseridi- tai glukoosipit oisuuteen eikä kehonpainoon enem män kuin yhtäjaksoinen matalaintensit eettisem pi kestävyysharjoittelu
sepel valtimotautipotilailla.»A.
Ei laske leposykettä, eikä paranna vasemman kammion pumppaustehoa tai valtimoiden endoteelifunktiota enem män kuin yhtäjaksoinen
matalaintensit eettinen kestävyysharjoittelu «Intervallityyppinen korkeaintensit eettinen kestävyysharjoittelu ei vaikuta leposykkeeseen,  vasemman
kammion pumppaustehoon tai valtimoiden endoteelifunktioon enem män kuin yhtäjaksoinen matalaintensit eettisem pi kestävyysharjoittelu
sepel valtimotautipotilailla.»A.
Sepel valtimotautipotilaiden säännölliseen lihasvoimaharjoitteluun perustuva sydänkuntoutus
Ilmeisest i parantaa ylä- sekä alavartalon maksimivoimaa verrattuna tavanomaiseen hoitoon «Säännölliseen lihasvoimaharjoitteluun perustuva
sepel valtimotautipotilaan kuntoutus ilmeisest i parantaa ylä- sekä alavartalon maksimivoimaa verrattuna tavanomaiseen hoitoon.»B.
Yhdistetty kestävyysliikunta ja lihasvoimaharjoittelu
Parantaa maksimaalisessa  testissä saavutettua työtehoa, mutta ei maksimaalista hapeno ttokykyä enem män kuin kestävyysharjoitteluun perustuva
kuntoutus «Yhdistettyyn kestävyysliikuntaan ja voimaharjoitteluun perustuva sepel valtimotautipotilaan kuntoutus parantaa maksimaalisessa  testissä4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 9/23
saavutettua työtehoa, mutta ei maksimaalista hapeno ttokykyä yhtä paljon kuin kestävyysharjoitteluun perustuva kuntoutus.»A.
Parantaa ylä- «Yhdistettyyn kestävyysliikuntaan ja voimaharjoitteluun perustuva sepel valtimotautipotilaan kuntoutus parantaa ylä- sekä alavartalon
maksimivoimaa enem män kuin kestävyysharjoitteluun perustuva kuntoutus.»A ja alavartalon «Yhdistettyyn kestävyysliikuntaan ja voimaharjoitteluun
perustuva sepel valtimotautipotilaan kuntoutus parantaa ylä- sekä alavartalon maksimivoimaa enem män kuin kestävyysharjoitteluun perustuva
kuntoutus.»A maksimaalista lihasvoimaa enem män kuin kestävyysharjoitteluun perustuva kuntoutus.
Lisää rasvatonta kehonpainoa ja vähentää kehon rasvakudoksen määrää enem män kuin kestävyysharjoitteluun perustuva kuntoutus «Yhdistettyyn
kestävyysliikuntaan ja voimaharjoitteluun perustuva sepel valtimotautipotilaan kuntoutus lisää rasvatonta kehonpainoa ja vähentää rasvaprosent tia sekä
kehon rasvamäärää enem män kuin pelkkään kestävyysliikuntaan perustuva kuntoutus.»A.
Ilmeisest i parantaa maksimaalista hapenottokykyä enem män kuin tavanomainen  hoito «Yhdistettyyn kestävyysliikuntaan ja voimaharjoitteluun perustuva
sepel valtimotautipotilaan kuntoutus ilmeisest i parantaa maksimaalista hapeno ttokykyä enem män kuin tavanomainen hoito.»B.
Ilmeisest i parantaa koko vartalon maksimivoimaa enem män kuin tavanomainen hoito «Yhdistettyyn kestävyysliikuntaan ja voimaharjoitteluun perustuva
sepel valtimotautipotilaan kuntoutus ilmeisest i parantaa koko vartalon maksimivoimaa enem män kuin tavanomainen hoito.»B.
Sepelvaltimotaudin hoidossa käytettävät lääkkeet ja liikunta
Yksilöllisest i ja sairauden vaikeusasteen mukaisest i toteutetun lääkehoidon aikana sepel valtimotautipotilas voi liikkua suositusten mukaisest i «Kettunen
R. Lääkehoidon merkitys sydänsairauksissa ...»7.
Sepel valtimotautipotilaiden tavallisim pia lääkkeitä ovat kolesterolia alentavat lääkkeet, veren hyytymisjärjestelmään vaikuttavat lääkkeet,
nitraattivalmisteet ja kohonnutta verenpa inetta alentavat lääkkeet.
Hyytymisjärjestelmään vaikuttavien lääkkeiden tauoton käyttö on tärkeää etenkin akuutin sydäntapahtuman ja sydämeen kohdistuneid en toimenpit eiden
jälkeen (pallolaajennu s ja verkkoputken asennu s).
Liikunnallisen kuntoutuksen toteutuksessa  huomioitavia keskeisiä  lääkkeitä ovat nitraatit ja beetasalpaajat.
Nitraatteja käytetään rintakipuoireiden estoon ja niiden hoitoon.
käytetään liikunnallisen kuntoutuksen aikana lääkärin ohjeiden mukaisest i.
voidaan käyttää myös liikuntasuoritusta edeltävästi tai liikunnan aikana, jos rintakipuoireisto edellyttää nitraatin käyttöä.
vakaassa sepel valtimotaudissa lyhytvaikutteisen nitraatin käyttö on suositeltavaa, jos rintakipuoireita ilmenee herkästi erityisest i rasituksen alussa tai
sen aikana.
potilaat tulee ohjata oikein toteutettuun nitraattivalmisteiden käyttöön.
Beetasalpaajia käytetään sepel valtimotaudin ja sydäninfarktin jälkitilan hoitoon sekä monien rytmihäiriöiden hoidossa.
eivät vaikuta oleellisest i liikuntakelpoisuuteen,  vaikka ne laskevat liikunnan aikaista syketasoa. Tämä lääkevaikutus tulee kuitenkin huomioida, mikäli
liikunnan rasittavuutta ohjataan sykkeen seurannan avulla.
syketasoa alentava vaikutus riippu u olenna isest i beetasalpaajan annoksesta. Lääkeannos optimoidaan yksilöllisest i oirekuva huomioiden, jotta syketaso
olisi sopiva, sekä levossa että rasituksessa .
lisäksi saattaa aiheuttaa väsymyksen tunnetta erityisest i liikuntasuorituksen aikana ja nykyisin suositaan mahdollisim man selektiivisiä beetasalpaajia.4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 10/23
joissakin erityistapauksissa  syketasoa ja oireita voidaan arvioida tarkemmin lääkehoidon aikana tehdyn rasituskokeen avulla.
Statiinit  ovat yleisest i käytettyjä kolesterolia alentavia lääkkeitä sepel valtimotautipotilailla.
Keskeisin käyttöä rajoittava haittavaikutus on lihaskipu. Haittoja lisäävät lääkeaineint eraktiot, ikä, pieni kehon paino, suuri statiinia nnos sekä
perinnö lliset tekijät.
Statiinit  saattavat myös voimistaa liikunnan yhteydessä  lihaskipuja ja kreatiinik inaasipit oisuuden (CK) nousua «Parker BA, Thompson PD. Effect of
statins on skele...»8.
Lihasoireiden syyt tulee selvittää, jotta liikuntaa ja lääkehoitoa voidaan jatkaa turvallisest i.
Lisätietoa statiinien mahdollisista sivuvaikutuksista löytyy dyslipidemioiden Käypä hoito -suosituksesta «https://www. kaypahoito.fi/hoi50025»7.
Statiinien ohella kolesterolin alentamiseen voidaan käyttää myös etsetimibia ja PCKS9-estäjiä.
Lisäksi ACE:n estäjiä, AT2-resept orin salpaajia, diureetteja, kalsium- ja beetasalpaajia käytetään kohonneen verenpa ineen alentamiseen,  mutta ne eivät
vaikuta oleellisest i liikkumiseen.
Ikä ja liikunnallinen sydänkuntoutus
Ikääntyneet  (yli 75-vuotiaat) sydänpotilaat hyötyvät liikunnallisest a sydänkuntoutuksesta samalla tavoin kuin heitä nuoremmat potilaat, vaikka heillä on
usein vaikeampi sepel valtimotauti ja muita sairauksia «Khadanga S, Savage PD, Ades PA. Resistance Trainin. ..»9, «Marchionni N, Fattirolli F, Fumagalli S
ym. Improv...»10, «Piepo li MF, Corrà U, Benzer W ym. Secondary preven...»11, «Williams MA, Fleg JL, Ades PA ym. Secondary preven...»12.
Iäkkäiden sydänpotilaiden harjoitteluun ei näytä sisältyvän merkittävää sydänkomplikaatioiden riskiä «Menez es AR, Lavie CJ, Forman DE ym. Cardiac
rehabi...»13.
Ikääntyneillä aerobinen kapasiteetti, lihasvoima ja -kestävyys lisääntyvät liikuntaharjoittelulla suhteellisest i enem män kuin nuoremmilla potilailla
«Menez es AR, Lavie CJ, Forman DE ym. Cardiac rehabi...»13.
Sukupuolten väliset erityispiirteet
Sepel valtimotaudin esiint yvyydessä  ei ole sukupuolieroja, mutta se ilmenee naisilla tyypillisest i miehiä myöhemmällä iällä «Niemelä M, Kervinen K,
Romppanen H, Vikman S. Nais...»14.
Sepel valtimotaudin riskitekijät ovat samat sukupuolesta riippu matta.
Naisilla riskitekijöiden hallinta on miehiä heikompaa «Vynckier P, Kotseva K, Gevaert S ym. Gender differ...»15 ja erityisest i fyysinen aktiivisuus oli
vähäisem pää naisilla kuin miehillä «Vynckier P, Ferrannini G, Kotseva K ym. Gend er dif...»16.
Sekä miehillä että naisilla rintakipu on yleisin sepel valtimotaudin oire «Niemelä M, Kervinen K, Romppanen H, Vikman S. Nais...»14.
Naisten oireet poikkeavat osittain miesten oireista ja ovat epätyypillisem piä.
Sepel valtimotautikohtauksessa  naisilla oireet voivat jäädä useammin tunnist amatta.
Noin 40 %:lla naisista ei esiinny  rintakipua sydänkohtauksen yhteydessä .
Naisilla sepel valtimotautikohtaus ilmenee useammin epävakaana rintakipuna ja sydäninfarktina ilman ST-nousua «Niemelä M, Kervinen K, Romppanen
H, Vikman S. Nais...»14.4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 11/23
Liikunnallinen sydänkuntoutus ja sen järjestäminen
Sydänpotilaan kuntoutus on suunnit elmallista, tavoitteellista ja monialaista terveydenhuollon ammattilaisten ohjaamaa toimintaa «Dibben G, Faulkner J,
Oldridge N ym. Exercise- base...»6.
Sydänkuntoutuksen tavoitteena  on sydänpotilaan toimintakyvyn, itsenä isen selviytymisen,  elämänlaadun ja hyvinvoinnin säilyminen tai parantuminen
sekä työikäisillä työkyvyn säilyminen,  lisääntyminen tai sen palautuminen.
Sydänkuntoutuksen avaintekijöitä ovat potilaan tilan arviointi, fyysisen aktiivisuuden ohjaus, liikuntaharjoittelu, ravinto-ohjaus, painonhallinta,
lipidiprofiilin optimointi, kohonneen verenpa ineen hoito, tupakoinnin lopettaminen ja psyykkisest ä sekä sosiaalisest a hyvinvoinnist a huolehtiminen
«Piepo li MF, Corrà U, Benzer W ym. Secondary preven...»11, «Chow CK, Jolly S, Rao-Melacini P ym. Association o...»17.
Avaintekijöihin vaikuttamalla sydänpotilaan vointi kohentuu, oireet vähenev ät, sydäntapahtumien riski vähenee ja sitoutuminen lääkehoitoon lisääntyy.
Terveelliset elintavat kohentavat myös elämänlaatua ja parantavat sairauden ennu stetta «Piepo li MF, Corrà U, Benzer W ym. Secondary preven...»11,
«Balady GJ, Williams MA, Ades PA ym. Core component ...»18.
Kuntoutuksen järjestäminen ja kustannusvaikuttavuus
Säännölliseen liikuntaan perustuva sydänkuntoutus on kustannusvaikuttava terveydenhuollon resurssien käytön toimintamalli verrattuna tavanomaiseen
sydänpotilaan jatkohoitoon «Säännölliseen liikuntaan perustuva sydänkuntoutus on kustannusvaikuttava terveydenhuollon resurssien käytön
toimintamalli verrattuna tavanomaiseen  sydänpotilaan jatkohoitoon.»A.
Kotona toteutettu sydänpotilaiden etäkuntoutus lisää fyysistä toimintakykyä ja aktiivisuutta sekä vähentää depressio ta verrattuna sydänpotilaiden
tavanomaiseen jatkohoitoon «Kotona toteutettu sydänpotilaiden etäkuntoutus lisää fyysistä toimintakykyä, fyysistä aktiivisuutta ja vähentää depressio ta
verrattuna sydänpotilaiden tavanomaiseen jatkohoitoon.»A.
Kotona toteutettu sydänpotilaiden etäkuntoutus verrattuna suositusten mukaiseen sydänkuntoutukseen lisää fyysistä toimintakykyä ja aktiivisuutta,
elämänlaatua, lääkehoidon toteutumista, tupakoinnin lopettamista ja fysiologisissa  riskitekijöissä tapahtuvia suotuisia muutoksia yhtä paljon. Myös
depressio n oireet ja sairaalaan joutuminen sydänsyistä vähenee samalla tavalla molemmissa ryhmissä «Kotona toteutettu sydänpotilaiden
etäkuntoutus verrattuna suositusten mukaiseen sydänkuntoutukseen lisää fyysistä toimintakykyä, fyysistä aktiivisuutta, elämänlaatua, lääkehoidon
toteutumista, tupakoinnin lopettamista ja fysiologisissa  riskitekijöissä tapahtuvia suotuisia muutoksia yhtä paljon. Myös depressio n oireet ja sairaalaan
joutuminen sydänsyistä vähenee samalla tavalla molemmissa ryhmissä.»A.
Potilasohjaus, joka sisältää motivoivaa kommunikointia kirjeitse, puhelimitse tai henkilökohtaisin tapaamisin,  ilmeisest i parantaa sydänkuntoutukseen
osallistumista ja säännölliseen liikuntaan sitoutumista «Potilasohjaus, joka sisältää motivoivaa kommunikointia kirjeitse, puhelimitse tai henkilökohtaisin
tapaamisin ilmeisest i parantaa sydänkuntoutukseen osallistumista ja säännölliseen liikuntaan sitoutumista.»B.
Avo- ja laitoskuntoutus ilmeisest i parantavat yhtä tehokkaasti terveyteen liittyvää elämänlaatua ja sepel valtimotaudin riskitekijöitä sydäntapahtuman tai
revaskularisaation jälkeen sekä sydämen vajaatoiminta potilailla. Eroja ei havaittu myöskään kuolleisuudessa  tai sydäntapahtumissa «Avo- ja
laitoskuntoutus parantavat yhtä tehokkaasti terveyteen liittyvää elämänlaatua ja sepel valtimotaudin riskitekijöitä sydäntapahtuman tai revaskularisaation
(ohitusleikkaus tai pallolaajennu s) jälkeen sydämen vajaatoimintapotilailla. Eroja ei havaittu myöskään kuolleisuudessa  tai sydäntapahtumissa.»B.4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 12/23
Suomessa  ei ole erityistä lainsä ädäntöä sepel valtimotautia sairastavien kuntoutuksen järjestämisest ä. Säännölliseen liikuntaan perustuva sydänkuntoutus
on lääkinnä llistä kuntoutusta, jonka järjestämisest ä vastaa hyvinvointialue. Lääkinnä llisen kuntoutuksen tarve, tavoitteet ja sisältö on määriteltävä
kirjallisessa  yksilöllisessä  kuntoutussuunnitelmassa. Hyvinvointialue vastaa lisäksi kuntoutuspalvelun ohjauksesta ja seurannasta sekä nimeää potilaalle
tarvittaessa  kuntoutuksen yhdyshenkilön «Terveydenhuoltolaki (1326/2010). 29 §. Lääkinnä lli...»19. Lääkinnä llisen kuntoutuksen ohella
Kansaneläkelaitos järjestää harkinna nvaraisena  kuntoutuksena  sydänsairautta sairastavan kuntoutus- ja sopeutumisvalmennu skursseja «Laki
Kansaneläkelaitoksen kuntoutusetuuksista ja k...»20. Kuntoutussuunnit elman laatiminen ja kuntoutukseen ohjaaminen ovat keskeisim mät toimenpit eet
sydänkuntoutuksen toteutumiseksi. Vastuu kuntoutussuunnit elman tekemisest ä on hoitavalla lääkärillä ja se tulee tehdä mahdollisim man varhain, jotta
kuntoutuksella voidaan vaikuttaa kuntoutuvan henkilön tilanteeseen mahdollisim man tehokkaasti «Valtiontalouden Tarkastusvirasto. Lääkinnä llinen
k...»21.
Euroaspire (IV) raportin mukaan 51 % sepelvaltimotautipotilaista tarjottiin Euroopassa jonkinlaista sydänkuntoutusta ja 81 % heistä osallistui ainakin
puoleen tarjotuista kuntoutuskäynneist ä «Kotseva K, Wood D, De Bacquer D ym. Determinants o...»22.
Raportissa ei ole maakohtaista erittelyä eikä Suomessa  ole saatavilla valtakunnallisest i kattavaa tietoa sydänkuntoutukseen osallistumisest a.
Kuntoutuksen toteutumatta jääminen voi johtua siitä, että sydänkuntoutujille ei aina tehdä kuntoutussuunnit elmaa, tai suunnit elman taso ei ole sellainen
kuin lainsä ädäntö edellyttää. Kuntoutussuunnit elman merkitystä ei aina täysin ymmärretä lääkäreiden keskuudessa . Kuntoutussuunnit elmalla on arvoa
paitsi kuntoutuksen käynnist äjänä, myös kuntoutujan kuntoutukseen sitouttajana. Toisena  syynä kuntoutuksen toteutumatta jäämiseen voi olla se, että
hoitoketju usein katkeaa potilaan liikkuessa  perusterveydenhuollon ja erikoissairaanhoidon välillä «Valtiontalouden Tarkastusvirasto. Lääkinnä llinen
k...»21.
Liikunnallisen sydänkuntoutuksen sisältö
Sepel valtimotautipotilaiden kuntoutuminen on yksilöllistä ja siihen vaikuttavat tehdyn toimenpit een lisäksi esim erkiksi potilaan ikä, sairaushistoria sekä
aikaisem pi fyysinen aktiivisuus.
Tarkkaa aikataulua liikunnallisen kuntoutuksen etenem iselle on vaikea määritellä ja siksi tässä suosituksessa  annet ut aikamääreet ovat suuntaa antavia
«Dibben G, Faulkner J, Oldridge N ym. Exercise- base...»6.
Tässä suosituksessa  liikunnallinen sydänkuntoutus on jaettu sairaalassa tapahtuvaan kuntoutukseen,  kotiutumisen jälkeiseen kuntoutukseen sekä
loppuelämän kestävään omaehtoiseen kuntoutumiseen,  ks. kuva 1.
Vink kejä ja työkaluja liikunnallisen kuntoutuksen toteuttamisen tueksi löytyy lisätietoaineist osta «Käytännön työkaluja liikunnalliseen
sydänkuntoutukseen»1.4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 13/23
Kuva 1. Sepel valtimotautipotilaan liikunnallisen kuntoutuksen etenem inen.  Mukailtu lähteestä Simon M ym. 2018 «Simon M, Korn K, Cho L ym. Cardiac
rehabilitation:...»23.
Fyysisen suorituskyvyn arviointi
Sepel valtimotautipotilaan fyysisen toimintakyvyn arviointia voidaan käyttää apuna sairauden diagnostiikassa, nykytilan ja muutosten seurannassa sekä
kuntoutuksen vaikutusten arvioinnissa . Suorituskyvyssä tapahtuvat muutokset voivat toimia myös potilaan tavoitteina  ja motivoida liikkumaan.
Sepel valtimotautipotilaan fyysisen suorituskyvyn arvioinnissa  voidaan edetä taulukossa «Sepel valtimotautipotilaan fyysisen suorituskyvyn arviointi...»4
esitetyllä tavalla.
Taulukko 4. Sepelvaltimotautipotilaan fyysisen suorituskyvyn arviointi
EsitiedotSepelvaltimotaudin nykytila sekä toteutunut hoito
Muut sairaudet
Lääkitys sekä mahdolliset liikkumisrajoitukset
Arvio tämänhetkisestä fyysisestä aktiivisuudesta, liikuntatottumuksista sekä työn kuormittavuudesta
Arvio kokonaistilanteen vaikutuksesta liikuntaan
Ensisijaiset testitKestävyyskunto
Kliininen rasituskoe
6 minuutin kävelytesti
Yksilöllisen tarpeen ja tavoitteiden mukaiset
testitTuki ja liikuntaelimistön kunto
Lihasvoima- ja kestävyys
Rintakehän ja hartiaseudun liikkuvuus *
Motorinen kunto4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 14/23
Tasapaino
Reaktiokyky
Koordinaatio
Hengitysfunktioiden tarkempi testaus
Sisäänhengityslihasten voima*, **
Keuhkojen tilavuus*
* Pääsääntöisesti ohitusleikatuille potilaille.
** Myös mikäli potilaan terveydentila ei salli muuta kestävyyskunnon testausta.
Fyysisen toimintakyvyn testaamiseksi ja lähtökunnon arvioimiseksi suositellaan ensisij aisest i kestävyyskunnon arviointia joko kliinisen rasituskokeen tai
kuuden minuutin kävelytestin avulla «Balady GJ, Williams MA, Ades PA ym. Core component ...»24, «Task Force on Myocardial Revascularization of the
...»25, «Achttien RJ, Vromen T, Staal JB ym. Development of...»26, «Fletcher GF, Ades PA, Kligfield P ym. Exercise sta...»27, «Laukkanen J, Nieminen T,
Savonen K ym. Kliinisen r...»28, «Savonen K, Laukkanen J, Peltonen J. Suorituskyky j...»29.
Oirerajoitteinen rasituskoe voidaan toteuttaa turvallisest i 7–14 vuorokauden kuluttua akuutin sydäninfarktin (STEMI) pallolaajennu shoidosta (PCI) tai
24 tunnin kuluttua toimenpit eestä, mikäli pallolaajennu s on tehty suunnit ellusti «Task Force on Myocardial Revascularization of the ...»25.
Ohitusleikatuille potilaille ei ole määritelty tarkkoja aikakriteerejä fyysisen toimintakyvyn arvioimiseksi, joten testaamisen aikataulutus perustuu
kliiniseen päätöksent ekoon.
Muu fyysisen toimintakyvyn testaaminen etenee yksilöllisen tarpeen ja tavoitteiden mukaisest i.
Lisäksi toimintakyvyn testaamisen yhteydessä  voidaan valvotusti selvittää, millaista fyysistä kuormitusta potilas sietää ja millaisella teholla liikkuminen on
turvallista.
Potilaan sitoutuminen liikunnalliseen sydänkuntoutukseen ilmeisest i lisääntyy, mikäli toimintakyvyn arviointia tehdään vähintään kuuden kuukauden
välein «Task Force on Myocardial Revascularization of the ...»25.
Suunniteltua ohitusleikkausta edeltävä liikunnallinen kuntoutus
Suunnit eltua ohitusleikkausta edeltävän liikunnallisen kuntoutuksen tulisi sisältää sisäänhengityslihasten voimaa lisääviä harjoituksia sekä aerobista
harjoittelua «Hulzebos EH, Smit Y, Helders PP ym. Preoperative p...»30, «Steinm etz C, Bjarnason-Wehrens B, Baumgarten H ym....»31.
Suunnit eltuun sydänleikkaukseen tulevilla potilailla leikkausta edeltävä harjoittelujakso vähentää postoperatiivisia atelektaaseja sekä keuhkokuumetta ja
lyhentää sairaalajakson pituutta «Suunnit eltuun sydänleikkaukseen tulevilla potilailla leikkausta edeltävä harjoittelujakso vähentää postoperatiivisia
atelektaaseja sekä keuhkokuumetta ja lyhentää sairaalajakson pituutta.»A.
Sairaalassa tapahtuva kuntoutus
Sairaalassa kuntoutus on ensisij aisest i potilaan aktivoimista liikkeelle (mobilisointi).
Potilaalle kerrotaan, kuinka hän voi lisätä omaa aktiivisuuttaan vuodeosastolla sekä annet aan lisätietoa päivittäisen aktiivisuuden vaikutuksista
toipumisessa .4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 15/23
Akuutin sydäntapahtuman jälkeen kuntoutuksen ja elintapaohjauksen voi yleensä  aloittaa pallolaajennu sta seuraavana päivänä, mikäli sydänlihaksen
vaurio on pieni eikä toimenpit eestä ole aiheutunut komplikaatioita «Cortes OL, Villar JC, Devereaux PJ ym. Early mobil...»32.
Vuodelepo on tarpeen,  mikäli potilaalla on oireita, merkittäviä rytmihäiriöitä tai hänelle on kehittynyt merkittävä sydänlihasvaurio «Piepo li MF, Corrà
U, Benzer W ym. Secondary preven...»11.
Suuren tai komplisoituneen sydänlihasvaurion jälkeen kuntoutus aloitetaan, kun potilaan kliininen tila on vakaa ja rasitusta lisätään maltillisest i oireet
huomioiden «Piepo li MF, Corrà U, Benzer W ym. Secondary preven...»11.
Ohitusleikkauksen jälkeen varhainen mobilisointi on turvallista «Doiron KA, Hoffmann TC, Beller EM. Early intervent...»33, «van der Peijl ID, Vliet
Vlieland TP, Versteegh MI ...»34, «Ennis S, Lobley G, Worrall S ym. Effectiveness and...»35 ja kerran päivässä toteutettu fysioterapia on ilmeisest i yhtä
tehokasta toipumisen ja omatoimisuuden palautumisen kannalta kuin useammin päivässä toteutettu fysioterapia «van der Peijl ID, Vliet Vlieland TP,
Versteegh MI ...»34.
Sairaalassa tapahtuva ohjattu liikkuminen voi nopeuttaa potilaan suorituskyvyn palautumista «Stein R, Maia CP, Silveira AD ym. Inspir atory musc...»36,
«Aida N, Shibuya M, Yoshino K ym. Respiratory muscl...»37, «Hirschhorn AD, Richards D, Mungovan SF ym. Supervi...»38, «Zanini M, Nery RM, de
Lima JB ym. Effects of Diffe...»39.
Ohitusleikattujen potilaiden kuntoutuksen tulisi sisältää sairaalassa myös hengitystä tehostavia harjoituksia (puhallusharjoitukset, sisäänhengityksen
syventäminen)  «Zanini M, Nery RM, de Lima JB ym. Effects of Diffe...»39, «Westerdahl E, Lindmark B, Eriksson T ym. Deep- brea...»40.
Sisäänhengityksen syventämiseen tähtäävät hengitysharjoitukset voivat nopeuttaa atelektaasien aukeamista ohitusleikkauksen jälkeen.  Hengityksen
syventämistekniikoilla ei ole eroa atelektaasien aukeamisen kannalta «Westerdahl E, Lindmark B, Eriksson T ym. Deep- brea...»40, «Westerdahl E,
Lindmark B, Almgren SO ym. Chest phy...»41 .
Hengityslihasten aktivointi ja rintakehän lihasten venyttely saattavat nopeuttaa fyysisen suorituskyvyn palautumista ohitusleikkauksen jälkeen «Stein
R, Maia CP, Silveira AD ym. Inspir atory musc...»36, «Aida N, Shibuya M, Yoshino K ym. Respiratory muscl...»37.
Ohitusleikatuilla rintakehää tukeva liivi saattaa vähentää sydänleikkauksen jälkeistä rintalastan instabiliteettia ja syviä sternuminfektioita «Rintakehää
tukeva liivi saattaa vähentää sternotomian jälkeistä rintalastan instabiliteettia ja syviä sternuminfektioita.»C.
Rintakehää tukevan liivin käyttöä suositellaan erityisest i potilaille, joilla rintalastaan kohdistuu voimakasta rasitusta (pitkittynyt yskä, ylipaino
(erityisest i, jos painoindeksi on 35 tai yli), suurten rintojen aiheuttama venytys, yläraajoja kuormittavat liikkeet tai vatsalihasten käyttö makuulta
istumaan noustessa ) «Go rlitzer M, Wagner F, Pfeiffer S ym. Prevention o...»42.
Kotiutumisen jälkeen tapahtuva liikunnallinen kuntoutus
Kotiutumisen jälkeen liikunnallisella sydänkuntoutuksella tuetaan pysyvää liikunnallista elämäntapaa «Vu ori I, Kesäniem i A. Sepel valtimotauti ja
sydämen...»4, «Hämäläinen H. Sydänpotilaan kuntoutus. Kirjassa: H...»44.
Potilaan tulee saada perusteellinen liikuntaohjaus sekä mahdollisuus osallistua ohjattuun liikuntaan muutamia kertoja (mieluiten 6–10 kertaa) sairaalasta
kotiutumisen jälkeen «Vu ori I, Kesäniem i A. Sepel valtimotauti ja sydämen...»4, «Hämäläinen H. Sydänpotilaan kuntoutus. Kirjassa: H...»44.
Liikunnallinen kuntoutus voidaan toteuttaa joko yksilö- tai ryhmäkuntoutuksena  yksilöllisen tarpeen ja paikallisen käytännön mukaisest i «Hämäläinen H,
Röberg M. Kokonaisvaltainen katse sy...»47.4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 16/23
Tavoitteena  on, että potilas oppii ja rohkaistuu liikkumaan säännöllisest i, riittävän kuormittavasti ja turvallisest i. Lisäksi ohjauksessa  keskitytään sopivan
liikuntaohjelman laatimiseen.
Potilaalla on oltava mahdollisuus osallistua liikunnalliseen kuntoukseen tarpeen vaatiessa  myös myöhemmin omaehtoisen kuntoutumisen aikana «Vu ori
I, Kesäniem i A. Sepel valtimotauti ja sydämen...»4, «Hämäläinen H. Sydänpotilaan kuntoutus. Kirjassa: H...»44.
Potilaan motivaation ylläpitämiseksi kuntoutushenkilöstön tulee tukea liikuntaohjelman toteutumista ja seurata kuntoutuksen edistymistä olenna isena
osana potilaan kokonaisvaltaista hoitoa.
Sairaalasta kotiutuessa  koulutettu hoitohenkilökunta laatii yhdessä  potilaan kanssa jatkokuntoutussuunnit elman ja yksilölliset tavoitteet sekä antaa
selkeät ja kirjalliset kotiharjoitteluohjeet «Franklin B...»43, «Hämäläinen H. Sydänpotilaan kuntoutus. Kirjassa: H...»44, «Squires R. Acute coronary
syndromes: unstable angi...»45.
Ohjauksessa  tulee käydä läpi liikunnallisen kuntoutuksen toteuttamistavat, aikataulutus sekä potilaan omatoimisen harjoittelun turvallinen
suoritustapa sekä teho «Hämäläinen H. Sydänpotilaan kuntoutus. Kirjassa: H...»44, «Balady GJ, Ades PA, Bittner VA ym. Referral, enrol...»46.
Ohjeet käydään potilaan kanssa  läpi ja varmistetaan, että potilas ymmärtää ne. Ohjeiden antajan tulee myös varmistaa, että potilaan kuntoutus jatkuu
suunnit ellusti «Go rlitzer M, Wagner F, Pfeiffer S ym. Prevention o...»42, «Hämäläinen H. Sydänpotilaan kuntoutus. Kirjassa: H...»44.
Ohjeiden antaja voi olla lääkäri, hoitaja tai fysioterapeutti paikallisen käytännön mukaisest i.
Sepelvaltimotautipotilaan liikkumisen suositus
Sepel valtimotautipotilaan liikkumisen suositus rakentuu aina yksilöllisest i huomioiden potilaan fyysinen kunto, sairaushistoria, kliininen nykytila sekä
henkilökohtaiset tavoitteet liikunnalle «Achttien RJ, Vromen T, Staal JB ym. Development of...»26, «Hansen D, Stevens A, Eijnde BO ym. Endurance
exerc...»48, «Ambrosetti M, Abreu A, Corrà U ym. Secondary preve...»49.
Sepel valtimotautipotilaan fyysistä aktiivisuutta lisätään progressiiv isest i kohti tässä suosituksessa  esitettyä tavoitemäärää.
Kestävyysharjoittelun ohjelmoinnist a löytyy esim erkkejä lisätietoaineist osta «Sepel valtimotautipotilaan kestävyysharjoittelu»2.
Lihasvoimaharjoittelun ohjelmoinnist a löytyy esim erkkejä lisätietoaineist osta «Sepel valtimotautipotilaan lihasvoimaharjoittelu»3.
Sepel valtimotautipotilaille suositellaan yleisest i säännöllistä ja monipu olista liikuntaa seuraavasti «Dibben G, Faulkner J, Oldridge N ym. Exercise-
base...»6, «Piepo li MF, Corrà U, Benzer W ym. Secondary preven...»11, «Balady GJ, Williams MA, Ades PA ym. Core component ...»24, «Fletcher GF, Ades
PA, Kligfield P ym. Exercise sta...»27, «Pelliccia  A, Sharma S, Gati S ym. 2020 ESC Guideli...»50, «Jia  S, Liu Y, Yuan J. Evidence in Guidelines for T...»51,
«European Association of Cardiovascular Prevention ...»52:
1. Hyöty- ja arkiaktiivisuus
mielellään päivittäin, vähintään 3–4 kertaa viikossa
vähintään 30 min (mielellään 60 min) / kerta
vähintään kohtuullisest i kuormittavaa fyysistä aktiivisuutta, kuten reipa sta kävelyä, puutarhatöitä tai kotitöitä
2. Kestävyysliikunta
mielellään päivittäin, vähintään 3 kertaa viikossa4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 17/23
vähintään 2,5 tuntia viikossa, mielellään 3–4 tuntia
vähintään 20 min (mielellään 60 min) / kerta
kuntoutuksen alussa kevyesti tai kohtuullisest i kuormittava teho (RPE 12–14, tai 50 % maksimaalisest a suoritus- tai hapeno ttokyvystä).
Kuntoutuksen edetessä  kuormitusta nostetaan asteittain (RPE >15 tai 80 % maksimaalisest a suoritus- tai hapeno ttokyvystä. (Taulukko
«Kestävyysliikunnan kuormittavuuden arviointi...»5).
3. Lihasvoimaharjoittelu
2–3 päivänä viikossa
8–10 suurimpia lihasryhmiä kuormittavaa liikettä, 10–15 toistoa/liike ja 1–3 sarjaa
kohtuullisest i kuormittavalla teholla (RPE 10–16 tai (20) 40–60 % yhden toiston maksimista (1 RM))
Sepel valtimotautipotilaiden liikunnassa on lisäksi huomioitava:
alku- ja loppuverryttely (5–15 min)
sääolosuhteiden vaikutus liikunnan kuormittavuuteen
Erityisest i pakkanen ja helle lisäävät liikunnan kuormittavuutta.
mahdolliset muutokset kliinisessä  tilassa (oireet, lääkitykset).
Taulukko 5. Kestävyysliikunnan kuormittavuuden arviointi
Matala–kohtalainen intensiteetti Kohtalainen–korkea intensiteetti
Kliininen rasituskoe
Maksimisyke (HRmax) 67–75 % HRmax 75–85 % HRmax
Sykereservi (HRRmax)* 40–60 % HRRmax 60–70 % HRRmax
Kuormamaksimi (wattmax) 40–60 % wattmax 60–80 % wattmax
Maksimaalinen hapenottokyky (VO2max ) 40–60 % VO2max 60–80 % VO2max
Muut tavat arvioida kuormitusta
Borgin asteikko 6–20 (RPE) 12–14 RPE >15 RPE
Hengästyminen Sallii puheen Estää puheen
*Liikuntaharjoittelun sykealueen voi laskea esimerkiksi sykereservin avulla, jolloin 40–70 % sykereservistä = (maksimisyke – leposyke) * (0,4 → 0,7) + leposyke
Suomen Fysioterapeutit ry:n asettama työryhmä
Sepel valtimotautipotilaan liikunnallinen kuntoutus -suosituksen historiatiedot «Sepel valtimotautipotilaan liikunnallinen kuntoutus»44.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 18/23
Arto Hautala, FT, THM, ft, dosentti, puheenjohtaja
Fysioterapian ja kuntoutuksen apulaisprofesso ri, Jyväskylän Yliopisto
Annukka Alapappila, ft, TtM
Liikunta-asiantuntija, Suomen Sydänliitto ry
Hanna Häkkinen, ft YAMK, koord inaattori
Kehittämisasiantuntija, Suomen Fysioterapeutit ry
Renja Karhunen, ft, TtK, kokoava kirjoittaja
Fysioterapeutti, Kuopion yliopistollinen sairaala
Juho Korpi, ft, TtM, koord inaattori
Kehittämisasiantuntija, Suomen Fysioterapeutit ry
Jari Laukkanen, LT, dosentti
Professo ri, kardiologian erikoislääkäri, Itä-Suomen yliopisto ja Keski-Suomen sairaanhoitopiiri
Leena Meinilä, ft
Fysioterapeutti, Suomen Sydänfysioterapeutit ry
Kai Savonen, LT, LitM, TtM, dosentti
Liikuntalääketieteen ja terveydenhuollon erikoislääkäri, Kuopion liikuntalääketieteen tutkimuslaitos
Sidonnaisuudet
Sidonnaisuusilmoitukset on kerätty 18.11.2022 julkaistun suosituksen laatimisen yhteydessä :
Arto Hautala: Ei sidonnaisuuksia
Annukka Alapappila: Ei sidonnaisuuksia
Renja Karhunen: Ei sidonnaisuuksia
Jari Laukkanen: Luottamustoimet terveydenhuollon alalla: Sydäntutkimussäätiö
Leena Meinilä: Ei sidonnaisuuksia
Kai Savonen: Korvaukset kongressi-  ja seminaari kuluista: Novo Nordisk
Vastuun rajaus4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 19/23
Sepel valtimotautipotilaan liikunnallinen kuntoutus -suositus on asiantuntijoiden laatima yhteenv eto liikunnallisen kuntoutuksen menet elmistä ja
vaikuttavuudesta. Se ei korvaa lääkärin tai muun terveydenhuollon ammattilaisen omaa arviota yksittäisen potilaan parhaasta mahdollisest a diagnostiikasta,
hoidosta ja kuntoutuksesta hoitopäätöksiä tehtäessä .
Kirjallisuutta
1. Honkanen M, Jousimaa J, Komulainen J, Kunnamo I, Sipilä R (toim.). Duodecim in hoitosuositustyöryhmien käsikirja. 2016, osa I päivitetty 2.12.2019,
osa III lisätty 12.2.2021
2. Komulainen J, Honkanen M, Malmivaara A, Sipilä R (toim.). Hoitosuositustyöryhmien käsikirja. Suomalainen Lääkäriseura Duodecim , 2012
3. Krooninen sepel valtimo-oireyhtymä. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecim in ja Suomen Kardiologisen Seuran asettama
työryhmä. Helsink i: Suomalainen Lääkäriseura Duodecim , 2022
4. Vuori I, Kesäniem i A. Sepel valtimotauti ja sydämen vajaatoiminta. Kirjassa Taimela S, Kujala U, Vuori I (toim.). Liikuntalääketiede (4. p.). Duodecim .
2010, ss. 348–369
5. Balady G, Gardner A. Exercise prescription for patients with cardiovascular and cerebrovascular disease. Kirjassa: Pesca tello LS, Arena R, Riebe D,
Thompson PD (toim.) ACSM's guidelines for exercise testing and prescription. Philadelphia: Lippinco tt, Williams & Wilkins, 2014, ss. 236-259
6. Dibben G, Faulkner J, Oldridge N ym. Exercise- based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2021;11:CD 001800
«PMID: 34741536»PubMed
7. Kettunen R. Lääkehoidon merkitys sydänsairauksissa . Kirjassa Mäkijärvi M, Kivelä A, Kettunen R ym. (Toim.). Sydänsairaudet. Duodecim  2008, ss.
192–199
8. Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise,  myopathy, and muscle outcomes. Exerc Sport Sci Rev 2012;40:188-94 «PMID:
23000957»PubMed
9. Khadanga S, Savage PD, Ades PA. Resist ance Training  for Older Adults in Cardiac Rehabilitation. Clin Geriatr Med 2019;35:459-468 «PMID:
31543178»PubMed
10. Marchionni N, Fattirolli F, Fumagalli S ym. Improved exercise tolerance and quality of life with cardiac rehabilitation of older patients after myocardial
infarction: results of a randomized, controlled trial. Circulation 2003;10 7:2201-6 «PMID: 12707240»PubMed
11. Piepo li MF, Corrà U, Benzer W ym. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the
Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010;17:1-17
«PMID: 19952757»PubMed
12. Williams MA, Fleg JL, Ades PA ym. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): an
American Heart Association scient ific statement from the Council on Clinica l Cardiology Subcommittee on Exercise,  Cardiac Rehabilitation, and
Prevention. Circulation 2002;105:1735-43 «PMID: 11940556»PubMed
13. Menez es AR, Lavie CJ, Forman DE ym. Cardiac rehabilitation in the elderly. Prog Cardiovasc Dis 2014;57:152-9 «PMID: 25216614»PubMed
14. Niemelä M, Kervinen K, Romppanen H, Vikman S. Naisten sepel valtimotauti. Duodecim  2009;125:739-464.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 20/23
15. Vynckier P, Kotseva K, Gevaert S ym. Gender differences in cardiovascular risk factor awareness: Results from the ESC EORP EUROASPIRE V Registry.
Int J Cardiol 2022;352:152-157 «PMID: 35122913»PubMed
16. Vynckier P, Ferrannini G, Kotseva K ym. Gend er differences in lifestyle management among coronary patients and the association with education and
age: results from the ESC EORP EUROASPIRE V registry. Eur J Cardiovasc Nurs 2022;21:717-723 «PMID: 35134902»PubMed
17. Chow CK, Jolly S, Rao-Melacini P ym. Association of diet, exercise,  and smoking modification with risk of early cardiovascular events after acute
coronary syndromes. Circulation 2010;121:750-8 «PMID: 20124123»PubMed
18. Balady GJ, Williams MA, Ades PA ym. Core component s of cardiac rehabilitation/seco ndary prevention programs: 2007 update: a scient ific statement
from the American Heart Association Exercise,  Cardiac Rehabilitation, and Prevention Committee, the Council on Clinica l Cardiology; the Councils on
Cardiovascular Nursing , Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of
Cardiovascular and Pulmonary Rehabilitation. J Cardiopulm Rehabil Prev 2007;27:121-9 «PMID: 17558191»PubMed
19. Terveydenhuoltolaki (1326/2010). 29 §. Lääkinnä llinen kuntoutus. Finlex.
20. Laki Kansaneläkelaitoksen kuntoutusetuuksista ja kuntoutusrahaetuuksista (566/2005). 12 §. Harkinna nvarainen kuntoutus. Finlex.
21. Valtiontalouden Tarkastusvirasto. Lääkinnällinen kuntoutus. Valtiontalouden tarkastusviraston tuloksellisuustarkastuskertomukset 193/2009, ss. 52,
70–72.
22. Kotseva K, Wood D, De Bacquer D ym. Determinants of participa tion and risk factor control according to attendance in cardiac rehabilitation
programmes in coronary patients in Europe: EUROASPIRE IV survey. Eur J Prev Cardiol 2018;25:1242-1251 «PMID: 29873511»PubMed
23. Simon M, Korn K, Cho L ym. Cardiac rehabilitation: A class 1 recommendation. Cleve Clin J Med 2018;85:551-558 «PMID: 30004380»PubMed
24. Balady GJ, Williams MA, Ades PA ym. Core component s of cardiac rehabilitation/seco ndary prevention programs: 2007 update: a scient ific statement
from the American Heart Association Exercise,  Cardiac Rehabilitation, and Prevention Committee, the Council on Clinica l Cardiology; the Councils on
Cardiovascular Nursing , Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of
Cardiovascular and Pulmonary Rehabilitation. Circulation 2007;115:2675-82 «PMID: 17513578»PubMed
25. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery
(EACTS)., European Association for Percutaneous Cardiovascular Interventions (EAPCI)., Wijns W ym. Guidelines on myocardial revascularization. Eur
Heart J 2010;31:2 501-55 «PMID: 20802248»PubMed
26. Achttien RJ, Vromen T, Staal JB ym. Development of evidence- based clinica l algorithms for prescription of exercise- based cardiac rehabilitation. Neth
Heart J 2015;23:563-75 «PMID: 26481496»PubMed
27. Fletcher GF, Ades PA, Kligfield P ym. Exercise standards for testing and training : a scient ific statement from the American Heart Association.
Circulation 2013;12 8:873-934 «PMID: 23877260»PubMed
28. Laukkanen J, Nieminen T, Savonen K ym. Kliinisen rasituskokeen käyttö sydänsairauksissa : Suomen Kardiologisen Seuran työryhmän suositus. Suom
Lääkäril 2016;71:633-40
29. Savonen K, Laukkanen J, Peltonen J. Suorituskyky ja kardiorespir atorinen kunto: kuormitusfysiologiasta kliiniseen päätöksent ekoon. Duodecim
2015;131:16 93-9 «PMID: 26591646»PubMed4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 21/23
30. Hulzebos EH, Smit Y, Helders PP ym. Preoperative physical therapy for elective cardiac surgery patients. Cochrane Database Syst Rev 2012;11:CD 010118
«PMID: 23152283»PubMed
31. Steinm etz C, Bjarnason-Wehrens B, Baumgarten H ym. Prehabilitation in patients awaiting elective coronary artery bypass graft surgery - effects on
functional capacity and quality of life: a randomized controlled trial. Clin Rehabil 2020;34:1256-1267 «PMID: 32546065»PubMed
32. Cortes OL, Villar JC, Devereaux PJ ym. Early mobilisation for patients following  acute myocardiac infarction: a systematic review and meta-analysis of
experimental studies. Int J Nurs Stud 2009;46:1496-504 «PMID: 19411076»PubMed
33. Doiron KA, Hoffmann TC, Beller EM. Early intervention (mobilization or active exercise)  for critically ill adults in the intensiv e care unit. Cochrane
Database Syst Rev 2018;3:CD 010754 «PMID: 29582429»PubMed
34. van der Peijl ID, Vliet Vlieland TP, Versteegh MI ym. Exercise therapy after coronary artery bypass graft surgery: a randomized comparison of a high and
low frequency  exercise therapy program. Ann Thorac Surg 2004;77:1535-41 «PMID: 15111138 »PubMed
35. Ennis S, Lobley G, Worrall S ym. Effectiveness and Safety of Early Initiation of Poststernotomy Cardiac Rehabilitation Exercise Training : The SCAR
Randomized Clinica l Trial. JAMA Cardiol 2022;7:817-824 «PMID: 35731506»PubMed
36. Stein R, Maia CP, Silveira AD ym. Inspir atory muscle strength as a determinant of functional capacity early after coronary artery bypass graft surgery.
Arch Phys Med Rehabil 2009;90:1685-91 «PMID: 19801057»PubMed
37. Aida N, Shibuya M, Yoshino K ym. Respiratory muscle stretch gymnastics in patients with post coronary artery bypass grafting pain: impact on
respir atory muscle function, activity, mood and exercise capacity. J Med Dent Sci 2002;49:157-70 «PMID: 12641387»PubMed
38. Hirschhorn AD, Richards D, Mungovan SF ym. Supervised moderate intensit y exercise improves distance walked at hospital discharge following
coronary artery bypass graft surgery--a randomised controlled trial. Heart Lung Circ 2008;17:129-38 «PMID: 18060837»PubMed
39. Zanini M, Nery RM, de Lima JB ym. Effects of Different Rehabilitation Protocols in Inpatient Cardiac Rehabilitation After Coronary Artery Bypass Graft
Surgery: A RANDOMIZED CLINICAL TRIAL. J Cardiopulm Rehabil Prev 2019;39:E19-E25 «PMID: 3134 3586»PubMed
40. Westerdahl E, Lindmark B, Eriksson T ym. Deep- breathing exercises reduce atelectasis and improve pulmonary function after coronary artery bypass
surgery. Chest 2005;128:3482-8 «PMID: 16304303»PubMed
41. Westerdahl E, Lindmark B, Almgren SO ym. Chest physiotherapy after coronary artery bypass graft surgery--a comparison of three different deep
breathing techniques. J Rehabil Med 2001;33:7 9-84 «PMID: 11474953»PubMed
42. Gorlitzer M, Wagner F, Pfeiffer S ym. Prevention of sternal wound complications after sternotomy: results of a large prospect ive randomized multicent re
trial. Interact Cardiovasc Thorac Surg 2013;17 :515-22 «PMID: 23760221»PubMed
43. Franklin B (toim.). ACSM's guidelines for exercise testing and prescription. Philadelphia: Lippinco tt, Williams & Wilkins, 2000
44. Hämäläinen H. Sydänpotilaan kuntoutus. Kirjassa: Heikkilä J (toim.). Kardiologia. Helsink i: Duodecim , 2000:1149-56
45. Squires R. Acute coronary syndromes: unstable angina pect oris and acute myocardial infarction. Kirjassa: Ehrman J. Clinica l exercise physiology.
Champaign: Human Kinetics 2013:2 15-37
46. Balady GJ, Ades PA, Bittner VA ym. Referral, enrollment, and delivery of cardiac rehabilitation/seco ndary prevention programs at clinica l cent ers and
beyond: a presidential advisory from the American Heart Association. Circulation 2011;12 4:2951-60 «PMID: 22082676»PubMed4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 22/23
47. Hämäläinen H, Röberg M. Kokonaisvaltainen katse sydänkuntoutukseen.  Kela, Sosiaali- ja terveysturvan tutkimuksia 2006
48. Hansen D, Stevens A, Eijnde BO ym. Endurance exercise intensit y determination in the rehabilitation of coronary artery disease patients: a critical re-
appraisal of current evidence.  Sports Med 2012;42:11-30 «PMID: 22145810»PubMed
49. Ambrosetti M, Abreu A, Corrà U ym. Secondary prevention through comprehensiv e cardiovascular rehabilitation: From knowledge to implementation.
2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J
Prev Cardiol 2020;: «PMID: 33611446»PubMed
50. Pelliccia  A, Sharma S, Gati S ym. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J
2021;42:17-96 «PMID: 32860412»PubMed
51. Jia S, Liu Y, Yuan J. Evidence in Guidelines for Treatment of Coronary Artery Disease. Adv Exp Med Biol 2020;1177:37-73 «PMID: 32246443»PubMed
52. European Association of Cardiovascular Prevention and Rehabilitation Committee for Science Guidelines. , EACPR., Corrà U ym. Secondary prevention
through cardiac rehabilitation: physical activity counselling and exercise training : key component s of the position paper from the Cardiac Rehabilitation
Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur Heart J 2010;31:19 67-74 «PMID: 20643803»PubMed
Artikkelin tunnus: sfs00002
© 2024 Suomen Fysioterapeutit – Finlands Fysioterapeuter ry4.3.2025 klo 17.54 Sepelvaltimotautipotilaan liikunnallinen kuntoutus - Duodecim
https://www.terveysportti.fi/dtk/sfs/avaa?p_artikkeli=sfs00002 23/23
Sepelvaltimotautipotilaan sosiaaliturva - Hoito- ja palveluketjut - pirha.fi.pdf
Sosiaalitur v a
Sairastuminen v oi v aikutt aa ar k een monella er i t a v alla esimer kiksi t aloudellisen p är jäämisen ja t y ö- ja t oimint akyvyn
muuttumisen m y öt ä. Sosiaalitur v a k oostuu er ilaisist a p al v eluist a ja rahallisist a etuuksist a, joiden t ar k oituksena on
tur v at a r iitt ä v ä t oimeentulo ja huolenpit o kaikissa elämäntilant eissa. Sairast aminen ja kunt outuminen o v at esimer kk ejä
t ällaisist a elämän v aiheist a.
Pal v eluja ja etuuksia on aina it se haett a v a. Oik eus niiden saamiseen synt yy , kun y ksilöllinen t ar v e ja lakien ja säädöst en
v aatimat edell y t y kset t ä y tt yv ät. Sy dänpotilaallakin y ksilöllinen sairaustilanne ja elämäntilanne v aikutt a v at etuuden
m y önt ämiseen. 
T er v e y denhuollossa t y ösk ent elee sosiaalit y önt ekijöit ä, joiden kanssa v oi k eskust ella ja saada ohjaust a mm.
sosiaalitur v aan ja sosiaalip al v eluihin liitt y en. Sosiaalit y önt ekijän p al v elut o v at maksutt omia eikä lähet ett ä t ar vit a.
Sosiaalit y önt ekijään v oi ott aa y ht e y tt ä asiakas t ai omainen it se t ai t oinen ammattilainen. Yht e ystiedot lö y t yv ät suoraan
hoit o y ksik öist ä ja t er v e y denhuollon y ksik öiden int er net -sivuil t a. 
T oimeentulon tur v aa
K ela t ar jo aa er i elämäntilant eisiin etuuksia t oimeentulon tur v aamiseksi. 
K ela tur v aa t y ökyvy tt öm yy dest ä aiheutuv aa ansionmenet yst ä maksamalla sairausp äiv ärahaa t ai
osasairausp äiv ärahaa t y öst ä poissaolon ajal t a.  
Sair ausp äiv är aha  (K ela)
Osasair ausp äiv är aha  (K ela)
Hoidon, tutkimuksen ja kunt outuksen t akia t eht yjä matk oja k or v at aan K elan matkak or v auksest a, samoin
y öp ymiskuluja, mikäli y öp yminen on ollut t ar peen hoit oon ehtimiseksi. Sy dänlääkk eet kuuluv at K elan
lääk ek or v auksen piir iin. K unt outuksen aikana t oimeentulona v oi olla K elan kunt outusraha. K elan v ammaistukia
m y önnet ään tiet yin kr it eer ein, jos sairaudet aiheutt a v at pitkäk est oisesti t oimint akyvyn laskua. Lisäksi K ela huolehtii
t y ökyvy tt öm yy den pitkitt y essä kansaneläkk een maksamisest a. 
Mat kak or v aukset  (K ela)
Y öp ymiskulut   (K ela)
Lääk ek or v aukset  (K ela)
K unt outusr aha  (K ela)
V ammaistuki   (K ela)
Kansaneläk e  (K ela)
Jos sairastuminen uhkaa lähivuosina joht aa t y öikäisellä henkilöllä t y ökyvy tt öm yy t een t ai sairastuminen heik ent ää
t y ö- ja ansioky ky ä, ammatillisen kunt outuksen k einoin v oidaan p arant aa t y öllist ymisen, t y öhön p aluun ja t y össä
jatkamisen edell y t y ksiä. Ammatillist a kunt outust a jär jest ä v ät K elan lisäksi t y öeläk elait okset,  t ap atur ma- ja
liik enne v akuutuslait okset  ja TE-p al v elut. 
Ammatillinen kunt outus  (S TM)
Eläkk eet er i elämäntilant eissa  (T y öeläk e )
K unt outuksen k or v aust oiminnan ohjeet   (Liik enne v akuutusk eskus)
 
T y öeläk e y htiöt huolehtiv at t y öelämässä t oimivien ja v akiintuneesti t y öelämässä olleiden ammatillisest a
kunt outuksest a sekä t y ökyvy tt öm yyseläkk eist ä. T y ökyvy tt öm yyseläk ett ä m y önnet ään t oist aiseksi v oimassa ole v ana
t y ökyvy tt öm yyseläkk eenä ja osat y ökyvy tt öm yyseläkk eenä. K unt outustuki ja osakunt outustuki o v at määräaikaisesti
m y önnett yjä t y ökyvy tt öm yyseläkk eit ä. 4.3.2025 klo 17.18 Sepelvaltimotautipotilaan sosiaaliturva - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/sepelvaltimotautipotilaan-sosiaaliturva 2/4
K otiin annett a v aa tuk e a ja p al v elua
Sosiaalihuol t olain mukaan sosiaalip al v eluja on jär jest ett ä v ä tueksi jokap äiv äisest ä elämäst ä sel viy t ymiseen.
Esimer kiksi asumisen tuen, t aloudellisen tuen, kr iisitilant eiden tuen ja er ilaisist a syist ä johtuv an t oimint akyvyn tuen
t ar peet o v at tilant eit a, joit a sosiaalihuol t olain mukaiset sosiaalip al v elut k osk e v at. Sosiaalip al v eluja jär jest ä v ät
h yvin v ointialueet. Sosiaalip al v eluja haet aan sil t ä h yvin v ointialueel t a, jonka alueella henkilöllä on k otikunt a. 
Sosiaalip al v elut  (S TM)
Pal v elujen t ar v e ar vioidaan t ek emällä p al v elut ar peen ar viointi. 
K otiin annett a v a k otip al v elu tuk ee ja autt aa, kun asiakas t ar vit see sairauden t ai alentuneen t oimint akyvyn vuoksi
apua k otiin sel viy t y äkseen ar kip äiv än askar eist a ja henkilök oht aisist a t oiminnoist a. K otip al v elun tukip al v eluja o v at
esimer kiksi at er iap al v elu, siiv ousp al v elu, v aat ehuol t o ja kaupp a- ja muut asioimisp al v elut. K otip al v elun lisäksi k ot ona
sel viy t ymist ä tuet aan k otisairaanhoidon a vulla.  Sosiaalihuol t olakiin perustuv a k otip al v elu ja t er v e y denhuol t olakiin
perustuv a k otisairaanhoit o muodost a v at y hdessä käsitt een k otihoit o.   
K otip al v elu  (S TM)
K otisair aanhoit o  (S TM)
Omaishoit o t ar k oitt aa sairaan, v ammaisen t ai v anhuksen hoit amist a omaisen t ai muun läheisen a vulla. Omaishoidon
tuki muodostuu hoidett a v alle annett a vist a p al v eluist a sekä hoit ajalle annett a v ast a hoit op alkkiost a, v ap aast a ja
omaishoit o a tuk e vist a p al v eluist a. 
Omaishoit o  (S TM)
Lapsiper he v oi hak e a sosiaalihuol t olain mukaist a per het y öt ä tueksi ja a vuksi kuor mitt a v assa elämäntilant eessa
esimer kiksi v anhemman sairast aessa. Sosiaalihuol t olain mukainen per het y ö on sosiaalip al v elua, joka ei v aadi
last ensuojelun asiakkuutt a. 
P er het y ö  (THL)
Sosiaalihuol t olain mukaist a har kinnan v araist a kuljetusp al v elua v oi hak e a pienituloinen ikäihminen, jolla on v aik euksia
kä y tt ää julkisia kulkuv älineit ä. Pal v elun m y önt ämiseen v aikutt aa t aloudellisen tilant een lisäksi hakijan ikä sekä
liikkumis- ja t oimint aky ky . 
Ikäänt yneiden kuljetusp al v elut
Mikäli sosiaalihuol t olain mukaiset p al v elut eiv ät so vi, t ai ne eiv ät ole r iitt ä viä, sosiaalip al v eluja t ar jot aan
er it yislainsäädännön perust eella. V ammaisp al v elulain mukaan jär jest ett ä viä p al v eluit a o v at mm. henkilök oht ainen
apu, asunnonmuut ost y öt ja asunt oon kiint e ästi asennetut laitt eet ja v älineet. V ammaisp al v elulain mukainen
v aik e a v ammaisen kuljetusp al v elu saatt ajap al v eluineen mahdollist aa opisk elua, t y össäkä yntiä sekä asiointi-
ja vir kist ysmatk oja henkilölle, joka t ar vit see t aksia t er v e y dentilansa t ai v ammansa t akia.  
V ammaisp al v elut ja tukit oimet  (S TM)
H y öd y llisiä linkk ejä:
Eläk etur v ak eskus
Jär jest öjen sosiaalitur v aop as
K ela
Pir ha sosiaalip al v elut
Pir ha p al v eluneuv ont a
T er v e ysk y lä
T y öeläk e
Edellinen
Elämänt ap aohjausSeur aa v a
Sepel v al timot autipotilaan ohjaus ja motiv ointi
Päivit ett y 25 . 11.202 44.3.2025 klo 17.18 Sepelvaltimotautipotilaan sosiaaliturva - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydanvalmennus/sepelvaltimotautipotilaan-sosiaaliturva 3/4
Sepelvaltimotautipotilaan työkyvyn arviointi - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p alveluk etjut  /Sepel valtimot autipotilaan hoit oketju  /
Sepel valtimot audin jatk ohoit o ja seurant a  / Sepel v al timot autipotilaan t y ök yvyn ar viointi
 Sepel v al timot autipotilaan hoit ok et ju
Sepel valtimot audin diagnostiikka
Sepel valtimot audin hoit o
Sepel valtimot autik ohtaus
Sydänvalmennus
Sepel valtimot audin jatk ohoit o ja seurant a
Seurant a sepel valtimot autidiagnoosin jälk een
OmaSy dän-et ähoit opalvelu
Sepel valtimot autipotilaan ajot erveys
Sepel v al timot autipotilaan t y ök yvyn ar viointi
Sepel valtimot audin lausunnot



Sepel valtimot autipotilaan t yökyvyn
arviointi
Työkyvyn ar vioinnissa t arvitaan er ikoissairaanhoidon spesifist ä osaamist a lisätutkimuksineen ja t yöterveyshuollon
tuntemust a työolosuht eista.
Anamnestinen haast attelu on h yvin oleellinen. Suor iutuminen t asamaakä velystä, ylämäessä t ai por taissa nousust a ja
päivitt äisist ä toiminnoist a kuv aa toimint akykyä.Kuuntele
CHAT4.3.2025 klo 17.08 Sepelvaltimotautipotilaan työkyvyn arviointi - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotaudin-jatkohoito-ja-seuranta/sepelvaltimotautipotilaan-tyokyvyn-arviointi 1/3
Suor iutumist a arvioidaan CCS-luokituksella, ks. t aulukk o 3 Rint akivun luokit t elu Canadian Car dio v ascular
Societ yn (CCS) mukaan  (Käypä hoit o -suositus). 
Perustutkimus on kliininen, t yöjoht einen ja oir erajoitt einen kliininen rasitusk oe, jot a täydennet ään t arvittavin
tutkimuksin. V aihtoeht oisesti v oidaan kä yttää kä velymatt otestiä t ai yläraajaer gometr iaa.
6 minuutin kä velytesti on kä yttökelpoinen er ityisesti v oinnin ar vioimisen ja liikunnallisen kunt outuksen
suunnitt elun osana sekä potilaan r ohkaisemisessa liikkumiseen.
Työkyvyn ar vioimiseksi kliinisessä rasitusk okeessa k okonaissuor itusky ky ilmoit etaan t avallisimmin 3–4 viimeisen
rasitusminuutin t yön k eskiar vona (W), joka suht eutetaan iän ja k oon mukaiseen viit earvoon.
Metabolist en ekviv alenttien (MET) kä yttö selk eyttää työn ja aineen vaihdunnallisen kuor mittavuuden v älist ä vertailua.
Työtehtävistä ja ammat eista on v almiina MET -tasoina kuv attuja kuor mittavuustuloksia. Ks.  lisätiet o a (Käypä
hoito)
Työssä kä yviltä on t ärkeää sel vittää ar jessa p ärjäämisen lisäksi sel viytymist ä tyypillisist ä työtehtävistä.
Psyy kkinen tilanne ja henkinen str essi v oivat heik entää sopeutumist a kuor mittaviin tilant eisiin.
Sepel valtimot autipotilaiden t yö- ja t oimint akykyyn v aikutt avat mer kittävästi sairauden k omplikaatiot, kut en
rytmihäir iöalttius t ai sy dämen v ajaat oimint a
Työterveyshuollossa seurat aan ja tuet aan potilaan t yökykyä
Työtä on joskus mahdollist a muokat a voinnin huonontuessa y hteistyössä t yönant ajan kanssa. T ästä huolimatt a
sairauspoissaolo on joskus t arpeen.
Jos sairausloma pitkitt yy y li 90 p äivän, potilaalla on v elvollisuus t oimitt aa K elaan t yöterveyshuollossa laaditt ava
selvitys työhön p aluun mahdollisuuksist a. Muut en sairausp äivärahan maksaminen K elast a päättyy.
Osasairausp äivärahalla v oidaan tuk ea työhön p alaamist a määräaikaisella 40–60-pr osenttisella t yöajalla.
Työeläk evakuutt aja t ai Kela v oi tuk ea entiseen t ai uut een t yöhön p aluut a ammatillisena kunt outuksena t yökokeilulla.
Uudelleenk oulutus t ai elink einotuki ammatillisena kunt outuksena v oi m yös olla mahdollist a, ellei p aluu
entiseen t yöhön onnistu.
Työhön p aluut a tuk evat int erventiot saatt avat hyödyttää työhön p aluut a 6 kuukaut een saakka, mutt a ei sen jälk een
110. Kansain välisessä kat sauksessa oli mukana m yös psy kologisia int erventioit a, mutt a toisaal ta työhön
ei tutkimuksissa ollut t ehty muut oksia.
Työhön p aluut a tuk eviin t oimiin tulee kiinnitt ää huomiot a.
Suomalaisessa tutkimuksessa 111 todettiin, ett ä jop a 27 % alle 50-vuotiaist a jää
työkyvy ttömyyseläkk eelle vuoden kuluttua sairastumisest a.
Preventioon on h yvä kiinnitt ää huomiot a.
Huono sosioek onominen asema y hdist ettynä sy dänsairaut een aiheutt aa
Sy dänpotilaan t oimint ak yvyn tut kiminen  (Käypä hoit o)
Edellinen
Sepel valtimot autipotilaan ajot erveysSeur aa v a
Sepel valtimot audin lausunnot
Päivit etty 13.12.202 44.3.2025 klo 17.08 Sepelvaltimotautipotilaan työkyvyn arviointi - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotaudin-jatkohoito-ja-seuranta/sepelvaltimotautipotilaan-tyokyvyn-arviointi 2/3
Ev äst eet
Saa vut et t a vuusselost e
Tiet osuoja
© Pir kanmaan h yvin v ointialueT akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.
T ämän sivun lö y dät osoitt eella pir ha.fi/hoit ok et jut4.3.2025 klo 17.08 Sepelvaltimotautipotilaan työkyvyn arviointi - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotaudin-jatkohoito-ja-seuranta/sepelvaltimotautipotilaan-tyokyvyn-arviointi 3/3
Sepelvaltimotautipotilaan_hoitoketju.pdf
Sepelvaltimotautipotilaan hoitoketju
Asiakas Minulla on oireita, hakeudun
tutkimuksiin Saan hoitoa ja tukea,  
osallistun hoitooni Minulla on kohtausoireita,
otan yhteyttä ensihoitoon Sitoudun omahoitoon ja 
elintapojeni muutokseen Jatkan elämääni uusien 
elintapojen ja jatkohoidon 
kanssa
Ammattilainen Diagnostiikka HoitoSepelvaltimotauti -
kohtausSydänvalmennus Jatkohoito ja seuranta
Tutkimus ja
hoitoOireet
Erotusdiagnostiikka
Ennakkotodennäköisyyden 
arviointi
Diagnostisen tutkimuksen 
valinta
Perusterveydenhuollossa 
tehtävät tutkimukset, PTH rooli
Hoidon porrastusHoidon kulmakivet
Riskitekijät
Ennustetta parantava 
lääkehoito
Oireita lievittävä lääkehoito
Revaskularisaatio
Yleistä ohitusleikkauksestaSepelvaltimotautikohtaus
Riskinarvio
Sepelvaltimokohtauksen 
ensihoito (NSTEMI/UAP)
Sepelvaltimokohtauksen 
ensihoito (STEMI)
Varjoainekuvaus ja 
reperfuusiohoito
Jatkohoito osastolla tai 
sydänvalvonnassa
LääkehoitoSydänvalmennus ja sen osa -
alueet​
Riskitekijöiden hoidon 
tavoitteetSeuranta 
sepelvaltimotautidiagnoosin 
jälkeen
OmaSydän etähoitopalvelu
Riskitekijöiden hoidon 
tavoitteet
Ajoterveys
Työkyvyn arviointi
Lausunnot
Sydänvalmennus
OhjausHyödynnä ohjausmateriaalia asiakkuuspolkujen mukaisesti
Tietoa sepelvaltimotaudista ja 
sen hoidosta
Krooninen sepelvaltimo -
oireyhtymä -Käypä hoito -
suositusSepelvaltimotautikohtaus –
Käypä hoito –suositus
Hoito ja ohjanta vuodeosastolla 
Sepelvaltimotauti ja 
sydäninfarktipotilaan ohjausFysioterapeutin ohjaus
Kuntoutusohjaus​
Psykososiaalinen tuki​
Sairaanhoitajan ohjaus​
Seksuaalineuvonta
Sosiaaliturva​
Vertaistuki​
Potilaan ohjaus ja motivointiVertaistuki
Kuntoutusohjaus
Liikunnallinen 
sydänkuntoutus
TiedonkulkuLäheteohjeet Läheteohjeet
Seuranta sepelvaltimotauti -
diagnoosin jälkeen
Oireet
Tarkka anamneesi on diagnostiikan kulmakivi. Sen 
perusteella  tehdään rintakivun kliininen luokittelu, jota 
tarvitaan sepelvaltimotaudin ennakkotodennäköisyyden 
arvioinnissa.
Rintakivun 
tyyppiLuokittelu
Tyypillinen Oireessa on kaikki kolme tyypillistä 
piirrettä:
•Rintakehän alla tuntuu kipua tai 
epämukavuutta, joka kestää alle 10 
minuuttia
•Oire ilmenee fyysisessä ponnistelussa tai 
voimakkaassa tunnetilassa
•Oire helpottaa minuuttien sisällä levolla 
tai nitraateilla
Epätyypillinen Oireessa on kaksi tyypillistä piirrettä
Muu kipu Oireessa on vain yksi tai ei yhtään 
tyypillistä piirrettäCCS (Canadian Cardiovascular Society )-luokitus kuvaa rintakipuoireen 
esiintymistä suhteessa rasitustasoon. Luokitus on tärkeä hoitomuodon 
valintaa ja hoidon kiireellisyyttä arvioitaessa. Luokituksen lisäksi potilaan muut 
potilaan toimintakykyä rajoittavat tekijät on tärkeä kuvata. 
CCS -
luokkaRintakivun esiintyminen Rasitus -
taso
I Tavallinen fyysinen rasitus ei aiheuta rintakipua. Rintakipua esiintyy 
raskaassa, nopeasti alkaneessa tai pitkittyneessä ponnistelussa.120 W tai 
yli
II Rintakipu aiheuttaa vähäisen rajoitteen tavalliseen toimintaan. 
Rintakipua esiintyy vauhdikkaan kävelyn tai portaiden nousemisen 
aikana, liikkuessa aterian jälkeen, kylmässä, tuulessa, 
voimakkaassa tunnetilassa tai ensimmäisinä heräämisen jälkeisinä 
tunteina. Normaalivauhtisessa kävelyssä rintakipu tulee yli kahden 
korttelivälin (yli 200 m) jälkeen tai kahden tai useamman kerrosvälin 
nousun jälkeen.80-120 W
III Rintakipu aiheuttaa merkittävän rajoitteen tavalliseen toimintaan. 
Tavallisissa oloissa rintakipu tulee normaalivauhtisessa kävelyssä 
1-2 korttelivälin (alle 200 m) matkalla tai yhden kerrosvälin 
nousussa.20-80 W
IV Fyysinen rasitus ilman kipua ei ole mahdollista. Rintakipu voi tulla jo 
levossa.Alle 20 W
Potilaan oireen ollessa epätyypillinen, ei rintakivun luokittelu aina onnistu. Tällöin 
diagnostisen tutkimuksen tarve arvioidaan muiden käytettävissä olevien tietojen pohjalta.
Alkuun
Kroonisen rintakipuoireen muita syitä
•Ei-sydänperäiset syyt
•Tuki-ja liikuntaelinsairaudet
•Kylkivälilihaksen kiputila
•Tietzen oireyhtymä
•Kaula -tai rintarangan 
säteilykipu
•Olkapään kipu
•Refluksitauti
•Alkava vyöruusu
•Fibromyalgia
•Toiminnalliset kivutSydänperäiset syyt
•Vasemman kammion 
seinämähypertrofia
•Aorttastenoosi
•Hypertrofinen kardiomyopatia
•Nopeat rytmihäiriöt, runsas 
lisälyöntisyys
•Sydämen mikroverenkierron 
häiriö tai sepelvaltimon spasmi
•Mitraaliprolapsi
Alkuun
Alkuun
Ennakkotodennäköisyyden arviointi
•auttaa käyttämään oikein sepelvaltimotaudin diagnostisia 
tutkimuksia
•kliinisen ennakkotodennäköisyyden arviointi tehdään potilaan
•iän
•sukupuolen
•rintakivun luokittelun ja
•sydän -ja verisuonitautien riskitekijöiden (sukurasite, tupakointi, 
dyslipidemia , diabetes, verenpainetauti) määrän perusteella
Tämän taulukon mukaan potilaat luokitellaan
•<5 % erittäin pienen
•5-15 % pienen ja
•>15 % suurentuneen
ennakkotodennäköisyyden potilaisiinRintakivun 
tyyppiLuokittelu
Tyypillinen Oireessa on kaikki kolme tyypillistä 
piirrettä:
•Rintakehän alla tuntuu kipua tai 
epämukavuutta, joka kestää alle 10 
minuuttia
•Oire ilmenee fyysisessä ponnistelussa 
tai voimakkaassa tunnetilassa
•Oire helpottaa minuuttien sisällä 
levolla tai nitraateilla
Epätyypillinen Oireessa on kaksi tyypillistä piirrettä
Muu kipu Oireessa on vain yksi tai ei yhtään 
tyypillistä piirrettä

Diagnostisen tutkimuksen valinta
•Tutkimusmenetelmän valinta 
perustuu kliiniseen 
ennakkotodennäköisyyteen
•erittäin pieni <5 %: 
sepelvaltimotautia ei yleensä tarvitse 
poissulkea vaan oire johtuu jostakin 
muusta
•Pieni 5 -15 %: ennusteen kannalta 
merkittävä sepelvaltimotauti löytyy 
vain harvoin ja diagnostisia 
tutkimuksia tulee käyttää harkiten
•Suurentunut > 15 %: diagnostisten 
tutkimusten hyöty on suurin ja ne 
ovat yleensä tarpeen
•Tutkimusmenetelmän valinta on 
kuvattu oheisessa Käypä Hoidon 
kuvassa
•Valinta vaatii yleensä kardiologin 
kannanoton
•Kaikille potilasryhmille tulee tehdä 
riskitekijöiden kartoitus ja antaa 
elämäntapaohjanta
Alkuun
Alkuun
Perusterveydenhuollossa tehtävät tutkimukset ,PTH:n rooli
•Anamneesi, riskitekijöiden kartoitus
•Status: sydämen ja keuhkojen auskultaatio, 
valtimostatus, sydämen vajaatoiminnan 
löydökset (kaulalaskimopaine, turvotukset, 
maksa)
•Verenpaine
•BMI (paino ja pituus), vyötärönympärys
•Laboratoriokokeet:
•PVK, K, Na, krea, fP-gluk, HbA1c, lipidit, 
alat, ( troponiini T vain akuutin tai epästabiilin 
oireen yhteydessä)
•proBNP , jos epäillään sydämen vajaatoimintaa
•Thx-rtgotetaan herkästi lisätutkimuksena
→Arvio kliinisestä 
ennakkotodennäköisyydestä•EKG
•Otetaan kaikilta potilailta
•On yleensä normaali
•Kiinnitä huomiota etenkin
•Q-aallot
•ST-välin muutokset, T -inversiot
•Haarakatkokset
•Rytmi
•Kliininen rasituskoe valikoiduille potilaille
•Sepelvaltimotaudin ennakkotodennäköisyyden ollessa 
suurentunut (> 15 %) aloitetaan sepelvaltimotaudin 
lääkehoito jo ennen diagnostisia tutkimuksia
•ASA 100 mg x 1
•Statiini
•Nitrosuihke
•Yksi anti -iskeeminen lääke
•Beetasalpaaja ( bisoprololi , metoprololi ) tai jos se ei sovellu, 
pitkävaikutteinen nitraatti

Kliinisen rasituskokeen käyttö
•Sydänlihasiskemian osoitus rasitustestillä sopii ahtauttavan 
sepelvaltimotaudin toteamiseen, kun kliininen 
ennakkotodennäköisyys on suurentunut (>15 %)
•Muistettava väärän negatiivisen mahdollisuus eli 
tässä ryhmässä kliininen rasituskoe ei 
poissulje sepelvaltimotautia
•Keskimääräinen herkkyys (sensitiivisyys) 68 % 
jaspesifisyys 77 %
•Helppo ja hyvin saatavilla
•Tarjoaa tärkeää tietoa ennusteesta (katso Käypä Hoito)
•Voidaan käyttää ohjaamaan hoidon valintaa
•Kokeen suorittaminen luotettavasti vaatii osaamista
•Muistettava tauottaa anti -iskeemiset lääkkeet (etenkin 
beetasalpaaja) 2-3 vrk ennen tutkimusta!
•Tulos vaikuttaa kliiniseen ennakkotodennäköisyyteen
•Normaali tulos laskee
•Iskemiaosoitus nostaa•Kliinistä rasituskoetta voidaan käyttää 
avoterveyden huollossa ensimmäisenä 
diagnostisena testinä vain valikoidusti
•Tuomaan lisäselvyyttä tilanteessa, jossa 
anamneesin perusteella oirekuva jää epäselväksi
•Ennakkotodennäköisyyden tulee olla suurentunut 
(>15 %)
•Lieväoireiselle (CCS1 -2) potilaalle
•Iskemian arvion lisäksi koe antaa tärkeää 
informaatiota
•oireiden yhteydestä rasitukseen
•potilaan suorituskyvystä
•verenpaineen rasitusvasteesta
•sykkeen käyttäytymisestä
•mahdollisista rytmihäiriöistä
Alkuun
Diagnostiikka
•Perusterveydenhuolto
•Perustutkimukset (linkki ko. Dia)
•Erittäin pienen (<5 %) 
ennakkotodennäköisyyden potilaiden 
muun rintakivun syyn selvittely
•Kliininen rasituskoe valikoiduille 
potilaille (linkki edelliseen diaan)
•Hyvin iäkkäillä ja monisairailla kliininen 
diagnoosinteko ja lääkehoito
•ESH
•Diagnostisen tutkimuksen valinta ja 
tutkimuksen tekeminenHoito
•Perusterveydenhuolto
•Pienen (6 -15 %) ja suurentuneen >15 % ennakkotodennäköisyyden 
potilaiden ohjaaminen erikoissairaanhoitoon
•Riskitekijöiden kartoitus ja hoito
•Lääkehoidon aloitus sepelvaltimotautiepäilyssä (kts. Dia 4)
•Lääkehoidon toteutus tautidiagnoosin varmistuttua
•Jos perusterveydenhuollossa todetaan rasituskokeessa 
sepelvaltimotautiin sopiva löydös ilman korkean riskin löydöksiä, 
voidaan potilaalle aloittaa ennustetta parantava ja anti -iskeeminen
lääkitys
•Jos potilas on optimaalisella lääkehoidolla seurannassa oireeton, ei 
esh:n konsultaatiota tarvita
•Jos potilaalla jää oireita tai diagnoosi jää epävarmaksi, on potilas 
ohjattavaa esh:n arvioon
•Muistettava ennustetta parantavan lääkehoidon ja 
sydänkuntoutuksen tärkeys!
•ESH
•Sepelvaltimotautidiagnoosin tekeminen valitun tutkimuksen pohjalta 
sekä kajoavan hoidon tarpeen arviointi ja toteuttaminenHoidon porrastus​
Alkuun
Läheteohjeet
•Lähettämisen syy
•Sydän -ja verisuonisairauksien riskitekijät
•Aiemmat ja nykyiset sairaudet
•Riskiammatti (esim. ammattiautoilija, lentäjä, 
veturinkuljettaja jne.)
•Nykyoireet
•selkeä oirekuvaus
•rintakivun luokittelu, CCS -luokka
•arvio ennakkotodennäköisyydestä
•Työ-ja toimintakyky
•Suorituskyky
•Tehdyt tutkimukset tuloksineen
•Status: BMI, vyötärönympärys
•Lab
•EKG•Mahdollinen rasituskoe tulosteineen
•Lääkitys ja mahdolliset allergiat (esim. jodi)
•Mahdolliset toimenpiteet ja niiden vaikutus 
oireeseen
•Esim. lääkehoidon vaikutus
•Mahdolliset muut tutkimusten tekemiseen tai 
potilaan hoitoon vaikuttavat tiedot
•Selkeä kysymyksen asettelu, tarve 
erikoissairaanhoidon tutkimuksiin tai hoitoon
Alkuun
Sepelvaltimotaudin hoidon kulmakivet
Hoidon tavoitteena on taudin etenemisen hidastaminen , ennusteen parantaminen , potilaan
oireettomuus sekä potilaan sitouttaminen omahoitoonsa
•Jokaisella potilaalla tulee olla yksilöllinen ja tavoitteellinen hoito -ja kuntoutussuunnitelma
•Kaikki hoitoon osallistuvat ammattilaiset kirjaavat tavoitteet omalta osaltaan sairauskertomukseen
•Riskitekijöiden hoitoon onpuututtava aktiivisesti javarmistettava tavoitearvojen saavuttamin
ensekä potilaan sitoutuminen omahoitoon . Kts Sydänvalmennus
•Jokaisella potilaalla tulee olla käytössä ennusteeseen vaikuttava lääkehoito
•Liikunnalliseen elämäntapaan kannustetaan ja pyritään löytämään keinot painonhallintaan
•Oireinen potilas tulee ohjata kardiologille arvioon revaskularisaation tarpeesta
Alkuun
Riskitekijät
Pysyvät Muokattavat
Ikä Tupakointi
Miessukupuoli Dyslipidemia
Perintötekijät
Merkittävä, jos alle 55 -vuotilaalla 
miehellä tai alle 65 -vuotiaalla naisella 
on todettu sepelvaltimotautiDiabetes
Hypertensio
Vähäinen liikunta
Keskivartalolihavuus
Valtimotaudin kehittymiselle voivat altistaa lisäksi todettu muiden valtimoi -
denateroskleroosi ,munuaisten vajaatoiminta ,inflammaatiot (matala -
asteinen tulehdus ),reumasairaudet ,uniapnea ,psyykkinen kuormitus ja
matala sosioekonominen asemaAlkuun
Ennustetta parantava lääkehoito 1/5
Antitromboottinen lääkehoito
•Asetyylisalisyyshappo (ASA) 100mg x1 tulee olla käytössä kaikil ylisepelvaltimotautia
sairastavilla potilailla
•Ei näyttöä lääkkeen hyödystä ilman varmaa diagnoosia suuren riskin potilaillakaan
•Antikoagulaatiohoito (varfariini , DOAC) on tavallisesti yksinään riittävä stabiilin taudin hoidossa (yli
1vuosi sairastetusta sydäninfarktista )
•ASA-allergisilla käytetään klopidogreelia annoksella 75mgx1
•Sairastetun sydäninfarktin jälkeen käytetään ASAn rinnalla ADP-salpaajaa 12kk ajan
pienentämään uuden sydäninfarktin ja sydänkuolleisuuden riskiä
•ASA 100mg x1 + klopidogreeli 75mg x1 TAI
•ASA 100mg x1 + tikagrelori 90mg x2 TAI
•ASA 100mg x1 + prasugreeli 10mg x1
Alkuun
Ennustetta parantava lääkehoito 2/5
Antitromboottinen lääkehoito jatkuu ..
•Elektiivisesti tehdyn PCI-toimenpiteen jälkeen kaksoisantitromboottisen hoidon kesto suunnitellaan yksilöllisesti
•Hoitoaika on tavallisesti 6-12kk
•ADP-salpaaja voidaan yleensä tauottaa 3kk kuluttua toimenpiteestä , josse on tarpeellista esimerkiksi suuren vuotoriskin kirurgisen
toimenpiteen vuoksi .
•ASAn tulee jatkua ilman taukoa
•ADP-salpaaja tulisi aloittaa uudelleen hetikunmahdollista ja jatkaa alkuperäisen hoitoajan loppuun
•Tauotuksesta suositellaan aina konsultoimaan kardiologia
•Akuutissa vuototilanteessa tauotetaan ADP-salpaaja , mutta jatketaan ASA 100mgx1. Kardiologin konsultaatiota hoidon jatkosta
suositellaan .
•Nenäverenvuodon , hematurian ,mustelmataipumuksen yms.yhteydessä on pyrittävä ensisijaisesti vaikuttamaan
vuodon välilliseen aiheuttajaan (esim . virtsatieinfektio taikuivat limakalvot ) ja vasta toissijaisesti muuttamaan lääkehoitoa
•Suuren tai kohtalaisen iskeemisen riskin potilailla voidaan käyttää pitkäaikaista antitromboottista lääkehoitoa
•Potilaan vuotoriski tulee arvoida tarkkaan ennen hoidon aloitusta (aiemmat vuodot , anemia, sairastetut aivotapahtumat , munuaisten
vajaatoiminta )
•Lääkevaihtoehtoina ovat ASA 100mg x1 + Tikagrelori 60mg x2, ASA 100mg x1 ja Klopidogreeli 75mg x1 tai ASA 100mg x1 ja 
Rivaroksabaani 2,5mg x2
•Hoito suositellaan aloitettavaksi yhteistyössä erikoissairaanhoidon kanssa
Alkuun
Ennustetta parantava lääkehoito 3/5
Hyperkolesterolemian hoito
•Statiinihoito parantaa sepelvaltimotautipotilaiden ennustetta ja on siten aiheellinen kaikille LDL-arvosta riippumatta .
•Tavoitteena kaikilla sepelvaltimotautipotilailla onLDL < 1.4 ja 50% vähennys perustasosta
•Jos potilaalla on toistuva sydäninfarkteja riskitekijöiden hyvästä hoidosta huolimatta , tavoite onLDL < 1.0
•Ensijainen lääkehoitovaihtoehto on statiini suurimmalla siedetyllä annoksella
•Atorvastatiini 40-80mg tai rosuvastatiini 20-40mg ovat tavallisimmat käytetyt lääkkeet ja annostukset
•Jos statiinihoito eiole yksinään riittävä , lisätään rinnalle etsetimibi 10mgx1
•Monoterapiaa eisuositella huonon tehon vuoksi . Statiineja huonosti sietäville potilaillekin kannattaa yrittää saada lääkitykseen edes pieni
annos statiinia (esim . Rosuvastatiini 5mg 3 -7kertaa viikossa )
•Jos potilaalle tulee statiinista haittavaikutuksia ,suositellaan kokeilemaan ns. siedätyshoitoa .
•Statiinilääkitys aloitetaan yhdellä tabletilla viikossa ja annosta nostetaan 2-4 viikon välein aina yhdellä tabletilla viikossa suurimpaan
siedettyyn annokseen saakka
•PCSK9 -salpaajan aloitus on aiheen , josmaksimaalisesta siedetystä statiinin ja etsetimibin annoksesta huolimatta LDL > 2.6.
•Suositus noudattaa Kelan korvattavuuskriteerejä . Todellisuudessa potilaat voisivat hyötyä lääkkeestä , josLDL on yli1.4, mutta lääkkeen
kallis hinta on esteenä
•Korvattavuus vaatii hoitavan lääkärin laatiman B-lausunnon , jossa kuvataan sepelvaltimotaudin kulku (erityisesti sairastetut
sydäninfarktit ), kokeillut statiinit annostuksineen ja niiden haittavaikutukset sekä LDL-arvot . B-lausuntoon tulee liittää kardiologin tai 
sisätautilääkärin suositus lääkkeen aloituksestaAlkuun
Ennustetta parantava lääkehoito 4/5
•ACEn estäjät
•Käytetään ensisijaisena lääkkeenä sepelvaltimotautipotilailla verenpaineen hoidossa
•Parantavat ennustetta potilailla ,joilla on LVEF 40% tai alle, vaikka verenpaine olisialletavoitetason Molemmissa
potilasryhmissä pyritään suurimpaan siedettyyn annokseen
•Toissijaisena lääkkeenä käytetään AT2-salpaajia ( esim . ACEn -estäjän aiheuttaman yskän vuoksi )
•Beetasalpaajat
•Käytetään vähintään yhden vuoden ajan sydäninfarktista rytmihäiriöiden estoon ja kuolleisuutta vähentämään
•Stabiilissa vaiheessa parantavat ennustetta potilailla ,joilla on LVEF 40 % tai alle
•Muilta lääkitys voidaan lopettaa vuoden kuluttua infarktista erityisesti , jostulee haittavaikutuksia (esim . huono
sykkeennousu rasituksessa , impotenssi )
•Oireisen potilaan hoitossa ensisijaisia lääkkeitä
Alkuun
Ennustetta parantava lääkehoito 5/5
•Diabeteslääkkeet
•SGLT -2 ja GLP1 -analogeja suositellaan potilaille ,joilla ontyypin 2 diabetes ja sepelvaltimotauti
•Empagliflotsiini ja kanagliflotsiini vähentävät sydän -ja verisuonitautitapahtumia . Empagliflotsiini vähentää
kardiovaskulaari -ja kokonaiskuolleisuutta ja kanagliflotsiini vähentää sydäninfarkteja tyypin 2 diabetesta
sairastavilla valtimotautipotilailla .
•Dapagliflotsiini vähentää suuressa valtimotautiriskissä olevien tyypin 2 diabeetikkojen sydämen
vajaatoimintajaksoja
•GLP1 -reseptoriagonistit ( dulaglutidi , liraglutidi ja semaglutidi ) vähentävät sydän -ja verisuonitapahtumia
diabetesta sairastavilla valtimotautipotilailla
Alkuun
Oireita lievittävä lääkehoito
•Beetasalpaajat
•Hidastavat sykkeen nousua rasituksessa ja vähentävät sydänlihaksen hapentarvetta
•Tärkeä rintakipuoiretta helpottava lääkitys sepelvaltimotaudissa . Annostuksessa pyrittävä suurimpaan tehoavaan
annokseen . Huom! Liian iso annos voiaiheuttaa huonoa sykenousua rasituksessa ja sitäkautta
hengenahdistusoiretta
•Haittavaikutus kannattaa huomioida erityisesti , josiäkkäälle ihmiselle kehityy hengenahdistusoire ja käytössä on 
beetasalpaaja
•Sykettä hidastavat kalsiumsalpaajat verapamiili ja diltiatseemi
•Voidaan käyttää oireiden hoidossa beetasalpaajien tilalla tai kombinoituna beetasalpaajaan erityisesti nopeassa
eteisvärinässä
•Eivät sovellu käytettäväksi , josEF < 40%
•Pitkävaikutteiset nitraatit
•Annostelu 1-2 kertaa päivää päivässä
•Voivat aiheuttaa ortostatismia
•Käyttö eiestä lyhytvaikutteisen nitraatin käyttöä kohtausoireisiin
•Lyhytvaikuttteiset nitraatit
•Potilas hyötyy lääkityksestä , joshänellä on toisinaan toistuvia rintakipukohtauksia
Alkuun
Revaskularisaatio 1/2
•Sepelvaltimoiden varjoiainekuvausta suositellaan , jospotilas on oireinen hyvästä lääkehoidosta
huolimatta tai kajoamattomissa tutkimuksissa onviitteitä huonosta sepelvaltimotaudin ennusteesta
•Revaskularisaatiolla on taudin ennustetta parantava vaikutus
•Lähes aina sepelvaltimotautikohtauksen yhteydessä .
•Stabiilisti oireilevassa taudissa , jospotilaalla on:
•Merkittävä vasemman päärungon ahtauma ,
•LAD:n tyven ahtauma tai
•Kolmen suonen tauti yhdistettynä vasemman kammion vajaatoimintaan (EF<35%).
•Hoitovaihtoehtoja ovat pallolaajennus (PCI) tai ohitusleikkaus (CABG). Hoitomuoto
päätetään yksilöllisesti diagnostisen sepelvaltimoiden varjoainekuvauksen jälkeen
•Yksinkertaiset ahtaumat hoidetaan yleensä hetidiagnostisen kuvauksen jälkeen pallolaajennuksella
•Vaikeampien ahtaumien PCI-hoitoa varten sovitaan yleensä uusi aika lähiviikoille
•Ohitusleikkaus tehdään oireiden vaikeusasteesta riippuen 1-8 viikon sisään diagnostisesta kuvauksesta
•Hankalimmat hoitopäätökset tehdään yhteistyönä sydänkirurgien ja kardiologien kesken (Heart Team -käsittely )
Alkuun
Revaskularisaatio 2/2
•Hoitomuodon valintaan vaikuttavat
•Sepelvaltimoahtaumien määrä
•Ahtaumien sijainti (yhden vaiuseamman suonen alueella , suonen tyviosissa , päärungossa , haaraumakohdissa ),
•Ahtaumien laatu (kalkkisuus )
•Saatavilla oleva ohitesuonimateriaali (aiemmin tehdyt suoikohjutoimenpiteet , vammat )
•Potilaat muut sairaudet (esim .muistisairaus , alkoholismi , keuhkosairaudet , munuaisten vajaatoiminta , maksan vajaatoiminta , ASO -
tauti)
•Muut leikkausriskiä nostavat tekijät (esim . obesiteetti , jatkuva tupakointi , aiemmat sydänleikkaukset , ihon kunto )
•Potilaan ikä, edeltävä toimintakyky , potilaan oma toive hoitomuodosta
•Ohitusleikkausta puoltavat tekijät :
•Diabetes ja todettu kolmen suonen tauti paremman pitkäaikaisennusteen vuoksi
•Laaja -alainen tauti ja kalkkiset ja/tai suonten haaraumakohdissa sijaitsevat ahtaumat
•Laaja -alainen sepelvaltimotauti ja alentunut ejektiofraktio
•Hoitoa vaativa läppävika tai rinta-aortan aneurysma
•Tays Sydänsairaalassa tehdään vuosittain noin 1500 sepelvaltimoiden revaskularisaatiotoimenpidettä ,joista 84% on PCI -
toimenpiteitä ja 16 % ohitusleikkauksia (v. 2022).
Alkuun
AlkuunYleistä ohitusleikkauksesta
•Leikkaussuunnitelma tehdään yksilöllisesti. LITA -LAD ohite on ennusteellisesti hyödyllinen ja sitä pyritään käyttämään mikäli 
mahdollista. Valtimosiirteitä suositaan etenkin nuorilla potilailla vasemman puolen ohitteiksi .​
•Leikkaus tehdään sydänkeuhko -konetta apuna käyttäen. Lyövän sydämen ohitekirurgiaa tehdään, mikäli nouseva aortta on vaikeasti 
kalkkeutunut. Leikkaus kestää tavallisesti 3 -5 tuntia.​
•Leikkauksen jälkeen​
•Potilas on tehohoidossa leikkauksen jälkeen noin vuorokauden. 5 -6 vuorokauden päästä leikkauksesta potilaat siirtyvät TAYS 
Sydänsairaalasta jatkohoitoon ja kotiutuminen tapahtuu noin 10 vuorokauden päästä leikkauksesta.​
•Leikkauksen jälkeisen sairausloman kesto on 2 -3 kk riippuen potilaan työtehtävien fyysisestä kuormittavuudesta. ​
•Autolla ajo on kielletty, kunnes potilas on toipunut leikkauksesta ja leikkaushaava on parantunut
•Ryhmä 1: vähintään 4 viikkoa
•Ryhmä 2 ja ammattikuljettajat: työterveyslääkärin kontrolliin asti, vähintään 6 viikkoa. Oireisilla tarvittaessa rasituskoe
•Rintalastan luutuminen kestää 6 -8 viikkoa. Eniten rintalastaliitosta kuormittaa yskiminen. Suosittelemme nostorajoituksia 5 kg 
ensimmäisen kuukauden ajan ja 10 kg toisen kuukauden ajan.​
•Kontrollit leikkauksen jälkeen​
•1kkkuluttua leikkauksesta suositellaan kontrollia avoterveydenhuollossa :
•pvk, crp, na, k, krea, lipidit, fP-gluk, inr[jos marevan käytössä], ekg, thx-rtg
•Varmistetaan, että kunto on koheneva, haavat ovat parantuneet ja toipuminen etenee ilman ongelmia. ​
•3kk kuluttua leikkauksesta kardiologin vastaanotto ja sydämen ultraäänitutkimus, jos vasemman kammion funktio on selvästi 
alentunut (EF < 35 -40%): Lääkityksen optimointi ja jatkohoidon ja seurannan suunnittelu
•6 kk kohdalla leikkauksesta avoterveydenhuollossa: Sekundaaripreventiivinen näkökulma , kuntoutussuunnitelma .
•Jatkossa vuosittain.

Sepelvaltimotautikohtaus
•Tarkemmat alueelliset ohjeet: Sepelvaltimokohtauspotilaan hoito japikaohje
•Sepelvaltimotautikohtaus jaotellaan kolmeen eri taudinkuvaan
•Epästabiili angina pectoris (UAP)
•Sydäninfarkti ilman ST -tason nousuja (NSTEMI)
•ST-nousuinfarkti (STEMI)
•Vaaranarvio ja hoitopäätökset perustuvat anamneesiin, kliiniseen taudinkuvaan, EKG -
löydökseen ja troponiinimääritykseen
•Epäiltäessä potilaalla sepelvaltimotautikohtausta 15 -16-kytkentäinen EKG tulee ottaa 
ja arvioida aina 10 minuutin kuluessa niin ambulanssissa kuin terveydenhuollon 
toimipisteessä. Teveydenhuollon yksikössä tulee tarkastaa myös troponiiniarvo ellei 
kyseessä ole ST -nousuinfarkti
•Riskiarvio perustuu potilaan oireisiin, status löydöksiin, EKG -muutoksiin 
jatroponiiniarvoon
Alkuun
Riskinarvio
Lyhyen aikavälin vaaraa kuvaavat tekijät
Sepelvaltimotautikohtaus: Käypä 
hoito –suositus www.käypähoito.fiInvasiivinen arvio 
tarpeen ellei vasta -
aihetta tai selkeää 
sekundaarista syytä
iskemialle
Alkuun
Riskinarvio ja hoitopolku Pirha
•STEMI -potilaan ensisijainen hoito on 
primaari PCI 
•Konsultoidaan PCI -päivystäjää (p. 
050-3005594)
•potilas kuljetetaan suoraan TAYS 
Sydänsairaalaan
•NSTEMI -ja UAP -potilaalle aloitetaan 
lääkitys ja potilas arvioidaan 
erikoissairaanhoidon päivystyksessä 
•Suuren vaaran potilaat otetaan 
hoitoon TAYS Sydänsairaalaan
•Pienen vaaran potilaat voidaan tutkia 
myös avoterveydenhuollossa ja 
tarvittaessa jatkotutkimukset tehdä 
elektiivisesti joko avoterveydenhuollossa 
tai erikoissairaanhoidossa 
•Iäkäs, monisairas ja heikon 
toimintakyvyn omaava potilas voidaan 
tutkia ja hoitaa myös 
perusterveydenhuollossa
Sepelvaltimotautikohtaus: Käypä hoito –
suositus www.käypähoito.fi
Alkuun
Sepelvaltimokohtauksen ensihoito (NSTEMI/UAP)
Potilaan tutkiminen, riskinarvio (EKG) ja ensihoito toteutetaan yhtä aikaa
Lääkkeetön hoito
•Potilas asetetaan lepoon ja aloitetaan 
jatkuva peruselintoimintojen valvonta
•Korkean riskin potilaille avataan perifeerinen 
suoniyhteys
•Lisähappi, jos SpO2 < 90%
•Kuljetus / siirto erikoissairaanhoidon 
päivystykseenLääkehoito
•Nitraatti, jos verenpaine > 100mmHg
•ASA 250mg kaikille ellei allergiaa
•Korkean riskin potilaille enoksapariini
1mg/kg s.c. paitsi, jos käytössä 
antikoagulaatiohoito
•Kipuun tarvittaessa opiaatti
•Hypertensiivisille / takykardisille
beetasalpaaja i.v. mikäli lääkäri katsoo 
tämän tarpeelliseksi
Alkuun
Sepelvaltimokohtauksen ensihoito (STEMI)
Potilaan tutkiminen, riskinarvio (EKG) ja ensihoito toteutetaan yhtä aikaa
Lääkkeetön hoito
•Potilas asetetaan lepoon ja aloitetaan 
jatkuva peruselintoimintojen valvonta
•Potilaalle avataan perifeerinen suoniyhteys
•Lisähappi, jos SpO2 < 90%
•Konsultoidaan PCI -päivystäjää (050 -
3005594) ja kuljetus suoraan TAYS 
SydänsairaalaLääkehoito
•Nitraatti, jos verenpaine > 100mmHg
•ASA 250mg kaikille ellei allergiaa
•Kipuun tarvittaessa opiaatti
•Hypertensiivisille / takykardisille
beetasalpaaja i.v. mikäli lääkäri katsoo 
tämän tarpeelliseksi
•PCI-päivystäjän konsultaation perusteella 
tikagrelori (Brilique ®) 180 mg p.o. ja 
enoksapariini 40mg i.v.
Alkuun
Varjoainekuvaus ja reperfuusiohoito
STEMI
•Ensisijainen hoito on primaari PCI, jos se 
voidaan tehdä alle 120 minuutin kuluessa 
ensimmäisestä kontaktista
•Mikäli tämä aikaraja ylittyy harkitaan 
liuotushoitoa
•Päätöksen hoitomuodosta tekee PCI -
päivystäjä ennen ADP -reseptorin salpaajan 
antamista (liuotushoidetuille klopidogreeli )NSTEMI
•Varjoainekuvaus tulee tehdä <24 tunnissa
•Tarvittaessa < 2 tunnissa, jos globaali -
iskemia, epävakaa hemodynamiikka , 
jatkuva oireilu tai toistuva 
kammiotakykardia, jos alkuhoidolla 
tilanne ei korjaannu
•Reperfuusiomuoto (PCI/CABG) valitaan 
löydöksen ja potilaan muun 
kokonaistilanteen perusteella
Alkuun
Jatkohoito osastolla tai sydänvalvonnassa
•Vuodelepo pyritään minimoimaan
•Jatkuva rytminseuranta kliinisen tilanteen mukaan, STEMI potilailla aina vähintään 
24h
•Potilaan riskitekijät kartoitetaan ja tehdään sydämen ultraäänitutkimus
•Aloitetaan hoitosuosituksen mukainen ( Sepelvaltimotautikohtaus : Käypä hoito –
suositus, 2022) lääkitys sepelvaltimotautiin ja tarvittaessa sydämen vajaatoimintaan 
(Sydämen vajaatoiminta : Käypä hoito suositus, 2017)
Alkuun
Lääkehoito
•ASA 100mg päivässä kaikille, joilla ei ole antikoagulaatihoitoa ,pysyvästi
•ADP-reseptorin salpaaja pääsääntöisesti vuoden ajan
•Antikoagulaatiohoidetuilla ja ASA -allergisilla lääkitys määrätään yksilöllisesti
•Antikoagulaatio ensisijaisesti suorilla antikoagulanteilla
•Jatketaan normaalilla annoksella ellei vuotovaaraa katsota suureksi, jolloin käytetään redusoitua 
annosta
•ASA yleensä vain sairaalahoidon ajan, ADP -salpaajana klopidogreeli vuoden ajan
•Suuriannoksinen statiini (esim. rosuvastatiini ≥ 20mg/vrk tai atorvastatiini ≥ 40mg/vrk)
•Tarvittaessa kombinoidaan etsetimibi
•ACE:n estäjä tai ATR:n salpaaja potilaille, joilla EF < 40%, verenpainetauti tai krooninen 
munuaisten vajaatoiminta
•Beetasalpaaja kaikille vuoden ajan ellei vasta -aihetta
•Pysyvästi, jos infarktiarpi, vasemman kammion toimintahäiriö tai sydämen vajaatoiminta
•Tyypin 2 diabeetikoilla tulee olla käytössä SGL2:n estäjä ja/tai GLP1 -reseptoriagonisti
Alkuun
Sepelvaltimotautikohtaus
Hoito ja ohjanta vuodeosastolla
•Sepelvaltimotaudin riskitekijöiden hoito sekä potilaan ohjaaminen, sitouttaminen ja 
osallistaminen omahoitoon aloitetaan moniammatillisena yhteistyönä sairaalajakson 
alussa ja sitä jatketaan koko sairaalahoitojakson ajan ja sen jälkeen.
•Sairaanhoitaja antaa potilaille yksilöllistä hoitoa ja ohjausta
•Sepelvaltimotautikohtauspotilaan hoito vuodeosastolla
•Sepelvaltimotautipotilaan ohjaus sairaalassa 
Alkuun
Sepelvaltimotautikohtauspotilaan hoito vuodeosastolla
•NEWS -pisteitä seurataan säännöllisesti 2x/vuorokaudessa tai useammin potilaan voinnin mukaan.
•Rytminseurantaa toteutetaan tarvittaessa lääkärin ohjeiden mukaan (rytmihäiriöiden mahdollisuuksien vuoksi)
•Verensokeria seurataan niiltä, joilla on
•Tiedossa oleva diabetes (hoitotasapainoa arvioiden yksilöllisesti)
•Uusi sepelvaltimotauti , erillisen ohjeen mukaan
•Punktiokohtien seuraaminen, mahdollisten punktiokohtien komplikaatioiden vuoksi 
•Perifeerisen suoniyhteyden tarpeellisuuden arvioiminen / suoniyhteyden ylläpitäminen.
•Voinnin seuraaminen ja tarvittaessa voinnin muutoksien hoitaminen, mm. kivun huomioiminen ja tarvittaessa 
lääkärin konsultoiminen voinnin muutoksista
•Mobilisointi kun lääkäri on määrittänyt tälle turvallisen aloitusajankohdan, fysioterapeutti tapaa potilaan .
•Lääkehoidosta huolehtiminen
•Ohjaus
•Jatkokontrollien ohjaaminen / huolehtiminen
Sydäninfarktipotilaan jatkohoito vuodeosastolla: Hoitotyön tietokanta -Duodecim (terveysportti.fi)
Alkuun
Sepelvaltimotautipotilaan ohjaus sairaalassa
Hoidon onnistumisen kannalta on tärkeää, että potilas sitoutuu omahoitoonsa. Hoitajan 
antamalla tuella on tässä merkitystä. Läheisten ja omaisten tuki auttaa sitouttamaan 
potilasta, siksi omaisten mukaan ottamista suositellaan. Potilaan ohjaus aloitetaan heti 
potilaan tullessa sairaalaan ja ennen potilaan kotiutumista tulee hänen tietää :
•miksi onollut hoidossa jamitä hoitojakson aikana ontehty
•sairaudestaan jasenhoidon keskeisistä piirteistä
•mikä onlääkitys jamiten setoteutetaan, pikanitron käytön ohjeistaminen, korvattavuus
•mitkä ovat toipilasvaiheen kotihoito -ohjeet
•missä jamilloin jatkokontrollit toteutetaan
•miten toimia, jostilanne kotona vaikeutuu, milloin hakeutua hoitoon jaminne
Moniammatillinen yhteistyö osana potilaan ohjausprosessiaPotilaan ohjaus ja motivointiPotilasohje
"opas sepelvaltimotautia 
sairastavalle "
Alkuun
Seuranta sepelvaltimotautidiagnoosin jälkeen
Seurantakäynnit
•OmaSydän etähoitopalvelu onensisijainen ja useimmilla
potilailla ainoa seurantamenetelmä
•Etäkontrollit 3kk ja 12kk, minkä jälkeen kontrollit siirtyvät
perusterveydenhuoltoon
•OmaSydämen lisäksi perusterveydenhuollon lääkärikontrollit
•Diabeteetikot
•Muu komplisoitunut tilanne
•OmaSydämen lisäksi erikoissairaanhoidon (sydänpoliklinikka ) 
kontrollit sepelvaltimotautikohtauksen jälkeen
•Alentunut vasemman kammion supistuvuus EF alle 40%
•Jäännösahtaumien toimenpidehoidon tarpeen harkinta
•Sydämen UÄ-seurannan tarve muun sydänsairauden
vuoksi
•Työkykyarvio , jostarvitaan kardiologin arviota
•Jos potilas eiole OmaSydän etähoitopalvelussa , 
kontrollit perusterveydenhuollon lääkärillä
•1-3kk ensidiagnoosin jälkeen
•Jatkossa seurantakäynnit perusterveydenhuollossa
•12kk välein , joshoitotasapaino hyvä
•3-6kk välein , joshoitoa tehostettavaPerusterveydenhuollon seurantakäynnillä huomioitavat asiat
•Valtimosairauden riskitekijöiden hoito
•Verenpaine
•Kolesteroli
•Diabetes
•Munuaisfunktio
•Tupakointi
•Painonhallinta
•Liikunta
•Oireet
•Työkyky
•Mieliala
•Ajoterveys
•Seksuaaliterveys
•Määrättyjen lääkitysten käyttö jareseptien uusinta
Alkuun
Sydänvalmennus
Sepelvaltimotaudin hoidon perusta on riskitekijöiden minimointi ja 
optimaalinen ennustetta parantava lääkehoito, joiden toteutuminen 
tulee varmistaa kattavan sydänvalmennuksen avulla.
Sydänvalmennuksella tarkoitetaan suunnitelmallista potilaslähtöistä 
palveluketjua, jonka tavoitteena on auttaa valmennettavaa 
tiedostamaan sepelvaltimotaudin luonne kroonisena 
pitkäaikaissairautena ja ymmärtämään ehkäisevien 
hoitotoimenpiteiden merkitys valtimotapahtumien estossa myös 
oireyhtymän oireettomassa vaiheessa.
Sydänvalmennuksen sisältö (kaypahoito.fi)
Lisätietoa:
Käypä hoito –suositus Krooninen sepelvaltimo -oireyhtymäAmmattilaisten keinoja tukea 
sairastunutta omahoidossa, 
kuntoutumisessa sekä 
riskitekijöihin vaikuttamisessa
Fysioterapeutin ohjaus
Kuntoutusohjaus
Psykososiaalinen tuki
Sairaanhoitajan ohjaus
Seksuaalineuvonta
Sosiaaliturva
Vertaistuki
Potilaan ohjaus ja motivointiRiskitekijöiden kartoitus Riskitekijöiden hoidon tavoitteetAlkuun
Riskitekijöiden hoidon yleiset tavoitteet
Huom. yksilöllisesti ikä ja muut mahdolliset tekijät huomioiden hoitava lääkäri voi määrittää myös yleisistä tavoitteista poi kkeavat tavoitteetLinkkejä
LDL-kolesterolipitoisuus < 1,4mmol/l
-yksilöllisesti voidaan pyrkiä < 1,0 mmol /l:n pitoisuuteen erityisesti, jos potilaalla on ollut toistuvia 
valtimotautitapahtumia
Lisätietoa: Dyslipidemiat (kaypahoito.fi)Ruoka & Ravitsemus (sydan.fi)
Painonhallintapolku | Painonhallintatalo (terveyskylä.fi)
Liikunta sepelvaltimotaudin hoidossa(terveyskyla.fi)
Lepoverenpaine < 130/80mmHg
-Yli 65 vuotiailla <140/80mmHg
Lisätietoa: Kohonnut verenpaine (kaypahoito.fi)sydän.fi/sydantietoa/terveys -hyvinvointi/verenpaine
Painonhallintapolku | Painonhallintatalo (terveyskyla.fi)
Ruoka & Ravitsemus (sydan.fi)
sydan.fi/apua -ja-tukea/painonhallinta
sydan.fi//terveys -hyvinvointi/liikuntavinkit/
sydän.fi/testi/testaa -suolan -saantisi
Normaali sokeriaineenvaihdunta
-Verensokerin paastoarvo < 5,5 mmol /l, glukoosirasituskokeen arvo < 7,8mmol/l ja HbA 1C -pitoisuus < 
42mmol/mol; diabeetikoilla HbA 1C -pitoisuus < 53mmol/mol
Lisätietoa: Tyypin 2 diabetes (kaypahoito.fi)Painonhallintapolku | Painonhallintatalo (terveyskylä.fi)
Ruoka & Ravitsemus (sydan.fi)
sydan.fi//terveys -hyvinvointi/liikuntavinkit/
Täydellinen tupakoimattomuus
-tupakoinnin lisäksi tulisi pidättäytyä myös muista nikotiinivalmisteista, kuten sähkötupakasta ja nuuskasta
Lisätietoa: Tupakka -ja nikotiiniriippuvuuden ehkäisy ja hoito (kaypahoito.fi)hengitysliitto.fi/elamanlaatu -ja-hyvinvointi/savuttomuus/
Käypä hoito, tupakka -ja nikotiiniriippuvuuden ehkäisy ja hoito
Terveyskirjasto, tupakoinnin lopettaminen
Terveyskirjasto, tupakka ja sairaudet
Terveyskylä, sydänsairaus ja tupakka
Sydänsairaala, tupakointi ja alkoholi
Säännöllinen terveysvaikutteinen liikuntaharrastus
Lisätietoa:
Liikunnan ja liikunnallisen sydänkuntoutuksen vaikuttavuus osana kroonista sepelvaltimo -oireyhtymää sairastavan hoitoa 
(kaypahoito.fi)
Sepelvaltimotautipotilaan liikunnallinen kuntoutus -Duodecim (terveysportti.fi)
Krooninen sepelvaltimo -oireyhtymä ja liikunta (kaypahoito.fi)sydän.fi/elamaa -sairauden -kanssa/sairastuneen -liikunta
Liikunta sepelvaltimotaudin hoidossa (terveyskylä .fi)
Liikkumisen aloittaminen | Kuntoutumistalo (terveyskyla.fi)
sydan.fi//terveys -hyvinvointi/liikuntavinkit/
sydän.fi/testaa -liikuntatottumuksesi
Sepelvaltimotautia sairastavan liikunta / Sydänsairaala
Keskivartalolihavuuden hallinta
-Vyötärön ympärysmittaa (cm) käytetään kuvaamaan keskivartalolle kertyvää liikarasvaa. Merkittävä 
vyötärölihavuuden raja -arvona on naisilla 88cm ja miehillä 102cm
Lisätietoa: Lihavuus (lapset, nuoret ja aikuiset) (kaypahoito.fi), Painoindeksi ja vyötärön ympärys (kaypahoito.fi)sydan.fi/apua -ja-tukea/painonhallinta
Painonhallintapolku | Painonhallintatalo (terveyskylä.fi)
Painonhallinta ja ravitsemus / Sydänsairaala
Taulukko mukaellen : Krooninen sepelvaltimo -oireyhtymä (kaypahoito.fi) Riskitekijöiden kartoitusAlkuun
Fysioterapeutin ohjaus
Fysioterapian 
tavoitteet sairaalassa
Fysioterapian 
tavoitteet 
kotiutumisen jälkeen
Kohti liikunnallista 
elämäntapaaHyödyllisiä linkkejä:
Sepelvaltimotautipotilaan liikunnallinen kuntoutus (Duodecim -terveysportti.fi)
Krooninen sepelvaltimo -oireyhtymä ja liikunta (Käypä hoito -
suosituksen lisätietoaineisto )
Video: Liikuntavinkkejä sepelvaltimotautia sairastavalle / SydänsairaalaSydän, kuten muutkin lihakset, tarvitsee harjoitusta pysyäkseen
kunnossa .Tämän vuoksi liikunnan tulee olla luonnollinen osa
sepelvaltimotautia sairastavan elämää .On tärkeää, että
sairastunut löytää jamotivoituu itselleen mieluisiin jakunnolleen
sopiviin liikkumisen muotoihin .
Säännöllinen jamonipuolinen liikunta ovat iästä jasukupuolesta
riippumatta keskeinen osa sepelvaltimotautia sairastavan
omahoitoa -läpi elämän .Liikunnan tulee olla riittävän
kuormittavaa jaturvallista .
Alkuun
FYSIOTERAPIAN TAVOITTEET SAIRAALAVAIHEEN FYSIOTERAPIASSA
Fysioterapeutti Potilas
•saakäsityksen potilaan suorituskyvystä 
jakokonaisvaltaisesta toimintakyvystä
•tunnistaa potilaan yksilölliset tarpeet
•ohjaa potilasta voimavaralähtöisesti kohti omatoimisuutta
•varmistaa, että potilas saa tarvitsemansa tiedon ja tuen 
liikkumisen aloittamiseen ja mahdollisten toipilasajan 
rajoitteiden huomioimiseen
•varmistaa potilaan jatkofysioterapian
•huomioi potilaan läheiset•oppii toimimaan ja liikkumaan turvallisesti 
jatilanteeseensa sopivalla rasitustasolla
•rohkaistuu liikkumaan turvallisesti tasamaalla ja tarvittaessa 
myös portaissa ennen kotiutumista
•tunnistaa itselleen sopivan rasitustason ja 
osaa annostella kuormitusta oikein
•osaa arvioida oireisuuttaan ja tietää, kuinka toimia oireiden 
ilmaantuessa
•osaa noudattaa mahdollisia sairauden ja 
toipilasajan aiheuttamia rajoituksia
•saa tarvitsemaansa tietoa sairaudesta ja sen omahoidosta
•motivoituu edistämään kuntoutumistaan nousujohteisesti
•tietää, mihin olla yhteydessä liikkumiseen liittyvissä 
kysymyksissä
Ohitusleikkauspotilaan fysioterapiaSepelvaltimotautipotilaan fysioterapia
Sydäninfarktipotilaan fysioterapiaPotilaan ohjaus ja motivointi
Alkuun
FYSIOTERAPIAN TAVOITTEET SAIRAALAVAIHEEN JÄLKEISESSÄ FYSIOTERAPIASSA
Fysioterapeutti Potilas
Poliklinikalla
•saakäsityksen potilaan toipumisesta, suorituskyvystä 
jakokonaisvaltaisesta toimintakyvystä
•tunnistaa potilaan yksilölliset tarpeet ja motivoi 
potilasta kohti liikunnallista elämäntapaa
•varmistaa, että potilaalla on riittävästi tietoa ja taitoa 
motivoituakseen toteuttaa säännöllistä ja monipuolista 
liikuntaa
•varmistaa, että potilas tietää mistä saa tukea 
tarvittaessa liikkumiseen liittyvissä asioissa
•varmistaa potilaan jatkofysioterapian tarvittaessa
•huomioi potilaan läheiset•oppii toimimaan ja liikkumaan turvallisesti 
jatilanteeseensa sopivalla ja riittävän tehokkaalla 
rasitustasolla
•tunnistaa itselleen sopivan rasitustason ja 
osaa annostella ja tarvittaessa vaihdella kuormitusta 
oikein
•osaa arvioida oireisuuttaan ja tietää, kuinka toimia 
oireiden ilmaantuessa
•saa tarvitsemaansa lisätietoa sairaudesta ja sen 
omahoidosta
•motivoituu edistämään kuntoutumistaan 
nousujohteisesti itsenäisen harjoittelun avulla tai 
ohjatusti
•tietää kuinka voi hoitaa itseään liikunnan keinoin ja 
sitoutuu liikunnalliseen elämäntapaan
•osaa olla tarvittaessa yhteydessä liikkumiseen 
liittyvissä kysymyksissä
Ohitusleikkauspotilaan fysioterapiaSydäninfarktipotilaan fysioterapiaSepelvaltimotautipotilaan fysioterapiaPotilaan ohjaus ja motivointi
Alkuun
Liikunnan avulla voi vaikuttaa useisiin sepelvaltimotaudinriskitekijöihin, 
hidastaa sepelvaltimotaudin etenemistä ja saavuttaa muun muassa
seuraavia terveyshyötyjä:
•hengitys -ja verenkiertoelimistön toiminta tehostuu
•vasemman kammion pumppausteho paranee
•valtimoiden sisäkalvon toiminta (endoteelifunktio) tehostuu ja 
valtimonseinämän tulehdusreaktio vähenee
•kolesteroli -ja sokeritasapaino paranee
•verenpaine (yläpaine) alenee
•painonhallinta paranee
•lihasvoimat kohenevat
•sympaattisen hermoston yliaktiivisuus rauhoittuu
•uudissuonien muodostuminen tehostuu
Lisäksi liikunta saattaa kohentaa mielialaa ja vähentää stressiä. Liikunnan 
avulla suorituskyky paranee ja arkiaskareet sujuvat helpommin.Kohti liikunnallista elämäntapaa
Sepelvaltimotautia 
sairastavan liikuntasuositusSopivan rasitustason 
tunnistaminenTurvallinen liikkuminenHyödyllisiä linkkejä:
Ammattilaiselle :
Sepelvaltimotautipotilaan liikunnallinen kuntoutus
(Duodecim -terveysportti.fi)
Sepelvaltimotautikohtaus (kaypahoito.fi)
Krooninen sepelvaltimo -oireyhtymä ja liikunta
Liikunnan ja liikunnallisen sydänkuntoutuksen
vaikuttavuus osana kroonista sepelvaltimo -
oireyhtymää sairastavan hoitoa (näytönastekatsaus )
Liikunta , sepelvaltimotautipotilaan liikunnallisen
kuntoutus ja sydänvalmennus
Potilaalle:
Sepelvaltimotaudin omahoito/sydansairaala.fi
Liikunta sepelvaltimotaudin hoidossa/Terveyskylä
Liikuntavinkit/sydan.fi
Alkuun
Sepelvaltimotautipotilaan fysioterapia
SEPELVALTIMOPOTILAAN 
FYSIOTERAPIA SAIRAALASSASEPELVALTIMOTAUTIPOTILAAN 
FYSIOTERAPIA KOTIUTUMISEN 
JÄLKEEN
POLIKLINIKALLA
Alkuun
Potilasohje
"opas sepelvaltimotautia 
sairastavalle"Sepelvaltimotautipotilaan fysioterapia sairaalassa
Esitiedot ,haastattelu
Fysioterapeuttinen tutkiminen jaarviointi :
•hengitystoiminnot ;neurologinen status; liikkumiskyky ;vireystila ;omatoimisuus ;kivut;sykevaste
Fysioterapeuttinen kuntoutus / fysioterapeuttinen ohjaus ja neuvonta :
•varhainen mobilisaatio (aloitus lääkärin luvalla );hengityksen tehostaminen ;verenkierron vilkastuttaminen
•nousujohteinen liikkumisen lisääminen :kevyt rasitustaso noin viikon ajan (Borg 11/20) 
kohti sepelvaltimotautipotilaan liikuntasuositusta
•raskaiden ponnistelujen ja raskaiden taakkojen nostojen sekä pistoskohdan voimakkaan venytyksen välttäminen 
valtimopistoskohdan parantumisen aikana (noin 2 päivää)
•lämmittely, jäähdyttely; vauhdin säätö; tauotus; hengästymisen ja hengenahdistuksen erottaminen
•omatoimisuuden tukeminen
•apuvälinearvio jakäytön ohjaus
•porrasharjoittelu ennen kotiutumista tarvittaessa
•kotiohjeet :liikunnan nousujohteinen lisääminen ,oireiden tunnistaminen jahoitoon hakeutuminen
Fysioterapiasuunnitelman laatiminen
•suunnitelma jatkofysioterapiasta
•sisältää tavoitteen asettamisen yhdessä potilaan kanssaPotilaan ohjaus ja 
motivointiAlkuun
Sepelvaltimotautipotilaan fysioterapia kotiutumisen jälkeen 
poliklinikalla (ohjauspoliklinikka )
Esitiedot, haastattelu
Fysioterapeuttinen tutkiminen ja arviointi /fysioterapeuttinen kuntoutus :
•vointi, mahdolliset oireet, kipu; toipumisen eteneminen, liikkumisen lisäys arjessa , a rjen toimintojen 
sujuvuus, m ahdolliset haasteet tai esteet liikunnan lisäämiselle
•mieliala, liikkumismotivaatio, koettu kuntotaso
•6 min kävelytesti, hengityksen sujuvuus, limaisuus,
•(hengitysfunktiomittaukset, ryhti, yläraajojen ja -vartalon liikkuvuus, lihasvoimat
Fysioterapeuttinen ohjaus ja neuvonta:
•suorituskyvyn arvioinnin / toipumisen mukaisen / sairauskohtainen ohjaus kohti liikunnallista elämäntapaa
•motivointi, kannustaminen, yksilöllisyys
Fysioterapiasuunnitelman laatiminen:
• jatkofysioterapiasuunnitelma
• sisältää tavoitteen asettamisen. Tarvittaessa yksilöllinen harjoitusohjelma.Potilasohje
"opas sepelvaltimotautia 
sairastavalle”
Potilaan ohjaus ja 
motivointiAlkuun
Sydäninfarktipotilaan fysioterapia
SYDÄNINFARKTIPOTILAAN FYSIOTERAPIA 
SAIRAALASSASYDÄNINFARKTIPOTILAAN FYSIOTERAPIA 
KOTIUTUMISEN JÄLKEEN
POLIKLINIKALLA
Alkuun
Sydäninfarktipotilaan fysioterapia sairaalassa
Esitiedot ,haastattelu
Fysioterapeuttinen tutkiminen jaarviointi :
•hengitystoiminnot ;neurologinen status; liikkumiskyky ;vireystila ;omatoimisuus ;kivut;sykevaste
Fysioterapeuttinen kuntoutus / fysioterapeuttien ohjaus ja neuvonta :
•varhainen mobilisaatio (aloitus lääkärin luvalla ),omatoimisuuden tukeminen
•hengityksen tehostaminen ;verenkierron vilkastuttaminen
•nousujohteinen liikkumisen lisääminen :rasitustaso noin 2viikkoa kevyt (Borg 11/20); ja 1kksaakka kevyt -hieman rasittava (Borg 11 -13/20)
•raskaiden ponnistelujen ja raskaiden taakkojen nostojen sekä pistoskohdan voimakkaan venytyksen välttäminen valtimopistoskohdan 
parantumisen aikana (noin 2 päivää)
•kohti sepelvaltimotautipotilaan liikuntasuositusta noin 1kk -->
•lämmittely, jäähdyttely, vauhdin säätö, tauotus
•hengästymisen ja hengenahdistuksen erottaminen
•apuvälinearvio jakäytön ohjaus
•porrasharjoittelu ennen kotiutumista tarvittaessa
•kotiohjeet :liikunnan nousujohteinen lisääminen ,oireiden tunnistaminen jahoitoon hakeutuminen
Fysioterapiasuunnitelman laatiminen :
•Jatkofysioterapiasuunnitelma,sisältää tavoitteen asettamisen yhdessä potilaan kanssaPotilasohje
"opas sepelvaltimotautia 
sairastavalle”
Potilaan ohjaus ja 
motivointiAlkuun
Sydäninfarktipotilaan fysioterapia kotiutumisen jälkeen 
poliklinikalla (ohjauspoliklinikka )
Esitiedot, haastattelu
Fysioterapeuttinen tutkiminen jaarviointi /fysioterapeuttinen kuntoutus :
•Vointi, mahdolliset oireet, kipu; toipumisen eteneminen, liikkumisen lisäys arjessa , a rjen toimintojen sujuvuus, 
mahdolliset haasteet tai esteet liikunnan lisäämiselle
•mieliala, liikkumismotivaatio, koettu kuntotaso
•6 min kävelytesti, hengityksen sujuvuus, limaisuus,
•hengitysfunktiomittaukset, ryhti, yläraajojen ja -vartalon liikkuvuus, lihasvoimat
Fysioterapeuttinen ohjaus ja neuvonta:
•suorituskyvyn arvioinnin / toipumisen mukaisen / sairauskohtainen ohjaus kohti liikunnallista elämäntapaa
•motivointi, kannustaminen, yksilöllisyys
Fysioterapiasuunnitelman laatiminen:
• jatkofysioterapiasuunnitelma
• sisältää tavoitteen asettamisen. Tarvittaessa yksilöllinen harjoitusohjelma.Liikunnallinen elämäntapa
Potilasohje
"opas sepelvaltimotautia 
sairastavalle”
Potilaan ohjaus ja motivointiAlkuun
Ohitusleikkauspotilaan fysioterapia
OHITUSLEIKKAUSPOTILAAN 
FYSIOTERAPIA 
PREOPERATIIVISESTIOHITUSLEIKATUN 
FYSIOTERAPIA 
POSTOPERATIIVISESTI
KOTIUTUMISEN JÄLKEEN
POLIKLINIKALLAOHITUSLEIKATUN
FYSIOTERAPIA 
POSTOPERATIVISESTI 
SAIRAALASSA
Alkuun
Ohitusleikkauspotilaan preoperatiivinen fysioterapia
Esitiedot , haastattelu
Fysioterapeuttinen tutkiminen jaarviointi :
•perusliikkuminen
•rasitusksensieto ,oireisuus
•ryhti jaolkanivelliikkuvuudet ,puristusvoimat
•hengitys jahengistyfunktiot ,limaisuus
•Mediastiniittiriskipisteet
•motivaatio ,kuntoutusmyönteisyys
Fysioterapeuttinen ohjaus ja neuvonta :
•postoperatiivisen kuntoutumisen eteneminen
•hengityksen tehostaminen
•verenkierron vilkastuttaminen
•rintalastan kuormitustekijät
•nousujohteinen liikkumisen lisääminen
•kuinka liikkua ennen leikkausta ,tarvittaessa yksilöllinen harjoitusohjelma
Fysioterapiasuunnitelman laatiminen :
•sisältää tavoitteen asettamisen yhdessä potilaan kanssaLinkki prevideoon :
https://www.youtube.com/watch?v=u
GX3tpx2uUo
QR-koodi videoon :
Potilasohje
"opas sydänleikkaukseen
tulevalle"
Potilaan ohjaus ja 
motivointiAlkuun
Ohitusleikatun postoperatiivinen fysioterapia sairaalassa
(Esitiedot ,haastattelu ,mikäli eipreoperatiivista kontaktia )
Fysioterapeuttinen tutkiminen jaarviointi :
•hengitystoiminnot ;neurologinen status; liikkumiskyky ;vireystila ;omatoimisuus ;kivut;sykevaste
•Mediastiniittiriskipisteet /Posthoraxtuen tarve
Fysioterapeuttinen kuntoutus / fysioterapeuutinen ohjaus ja neuvonta :
•varhainen mobilisaatio --> liikkumisen asteittainen lisääminen
•hengityksen tehostaminen ;verenkierron vilkastuttaminen
•rintalastan kuormitustekijät :1. kk max 5kg, 2.kk 5 -10kg, kylkitekniikka , rintakehän tukeminen yskiessä , raskaiden taakkojen kantamisen ja 
riuhtovien liikkeiden välttäminen
•nousujohteinen liikkumisen lisääminen : sairavaiheen rasitustaso kevyt (Borg 11/20); kotiutuessa –
2kkhieman rasittava (Borg 13/20), porrasharjoittelu ennen kotiutumista
•omatoimisuuden tukeminen
•apuvälinearvio tarvittaessa , käytön ohjaus
•toipilas -ajan ohjeet :kotivoimiteluliikkeet ,rintalastan kuormitustekijät ,liikunnan lisääminen
Fysioterapiasuunnitelman laatiminen :
• Jatkofysioterapiasuunnitelma , joka sisältää tavoitteen asettamisen yhdessä potilaan kanssaPotilasohje
"opas sepelvaltimoiden 
ohitusleikkauksesta toipuvalle"
Potilaan ohjaus ja 
motivointiAlkuun
Ohitusleikatun postoperatiivinen fysioterapia kotiutumisen 
jälkeen poliklinikalla (noin 2kk leikkauksesta)
(Esitiedot, haastattelu)
Fysioterapeuttinen tutkiminen ja arviointi:
•vointi, mahdolliset oireet, kipu
•toipumisen eteneminen, liikkumisen lisäys arjessa , a rjen toimintojen sujuvuus, m ahdolliset haasteet 
tai esteet liikunnan lisäämiselle
•mieliala, liikkumismotivaatio, koettu kuntotaso
•6 min kävelytesti, hengityksen sujuvuus, limaisuus, hengitysfunktiomittaukset
•ryhti, yläraajojen ja -vartalon liikkuvuus, lihasvoimat
Fysioterapeuttinen ohjaus ja neuvonta:
•suorituskyvyn arvioinnin / toipumisen mukaisen / sairauskohtainen ohjaus kohti liikunnallista 
elämäntapaa
•motivointi, kannustaminen, yksilöllisyys
•laaditaan tarvittaessa yksilöllinen harjoitusohjelma.
Fysioterapiasuunnitelman laatiminen:
•jatkofysioterapiasuunnitelma, sisältää tavoitteen asettamisenPotilasohje
"opas sepelvaltimotautia 
sairastavalle"
Potilaan ohjaus ja 
motivointiAlkuun
Sepelvaltimotautipotilaan liikuntasuositus
RPE= koettu 
kuormittavuus ns. Borg 
asteikolla 6 -20 arvioitunaHyötyliikunta ja arkiaktiivisuus esimerkiksi
•Mielellään päivittäin, vähintään 3 -4 kertaa viikossa
•Vähintään 30 min., mielellään 60 min. / kerta
•Vähintään kohtuullisesti kuormittavaa fyysistä aktiivisuuttaPuutarhanhoito
Kotityöt
Porraskävely
Kestävyysliikunta esimerkiksi
•Mielellään päivittäin, vähintään 3 kertaa viikossa
•Vähintään 2,5 tuntia /vko, mielellään 3 -4 tuntia / vko
•Kuntoutuksen alussa kevyesti tai kohtuullisesti kuormittava 
teho (RPE 12 -14, tai 50% maksimaalisesta suoritus -ja 
hapenottokyvystä) --> Kuntoutuksen edetessä kuormitusta 
nostetaan asteittain (RPE >15 tai 80% maksimaalisesta 
suoritus -jahapenottokyvystä)Kävely
Pyöräily
Hiihto
Uinti
Lihasvoimaharjoittelu esimerkiksi
•2 –3 päivänä viikossa
•8-10 suurimpia lihasryhmiä kuormittavaa liikettä, 10 -15 
toistoa/liike, 1 -3 sarjaa
•Kohtuullisesti kuormittavalla teholla (RPE 10 -16 tai (20) 
40-60 % yhden toiston maksimista (1RM))Kuntosaliharjoittelu
Kotivoimistelu
Luonto -kuntosali
Turvallinen 
liikkuminenSopivan rasitustason 
tunnistaminen
Alkuun
Sopivan rasitustason tunnistaminen
Ohjaa sepelvaltimotautipotilasta
tunnistamaan sopiva rasitustaso ja 
kuuntelemaan tuntemuksiaan ,kuten
hengästymistä ,lihasväsymystä jayleistävointia
harjoittelun aikana jajälkeen .
Rasituksesta tulee palautua hyvin . 
Rasitustuntemuksien arvioinnin apuna voi
käyttää oheista asteikkoa , ns. Borgin asteikko / RPE -
asteikko 6-20.
•Liikuntaan kuuluu hengästyminen -ei
hengenahdistus .
•Liikuntaan kuuluu hikoilu –eituskanhiki .
Turvallinen liikkuminen
Alkuun
Turvallinen liikkuminen
Kannusta sepelvaltimotautipotilasta liikkumaan riittävän tehokkaasti , 
mutta turvallisesti
•asianmukainen alku-ja loppuverryttely (5 –15 minuuttia )
•liikunnan määrää ja kuormittavuutta lisätään nousujohteisesti
•hengästyminen ja hikoilu on ok, kuitenkin oireita , kuten rintakipua ja hengenahdistusta tulee välttää
•palautumiseen tulee kiinnittää huomiota
•pitkäkestoinen ja raskas liikunta sekä yläraajojen pitkäkestoinen staattinen kohoasento eivät sovikaikille
•merkityksellisen voinnin vaihtelun tunnistaminen , reilusti liikkuva usein havaitsee voinnin muutoksen
paremmin
•sääolosuhteiden vaikutus liikunnan rasittavuuteen tulee huomioida (kova tuuli, pakkanen ja helle )
•rasitusta tulee välttää , joson sairas , huonovointinen tai oireinen
•nitrovalmiste tulee pitää mukana liikkuessakin , rasituksen yhteydessä ilmaantuvan oireilun, kuten rintakivun 
taihengenahdistuksen yllättäessä potilaan tulee pysähtyä ja toimia hoitoon hakeutuminen -ohjeen 
mukaisesti.
Sopivan rasitustason tunnistaminen
Alkuun
Kuntoutusohjaus
Kuntoutusohjauksen tavoitteena on ohjauksen ja neuvonnan keinoin
➢tukea sepelvaltimotautia sairastavan omahoitoa ja sydänterveellisten elintapojen toteuttamista
➢tukea sopeutumista sairastumisen aiheuttamassa muuttuneessa elämäntilanteessa
➢tukea työ -ja toimintakykyä sekä arjessa pärjäämistä
Sydänsairaalassa kuntoutussuunnittelijoiden antama kuntoutusohjaus pitää sisällään
➢sydänsairastuneen ja läheisten tukemisen, ohjauksen ja neuvonnan​
➢yksilöllisen kuntoutus -ja palvelutarpeen arvioinnin
➢kuntoutuksen suunnittelun ja kuntoutumissuunnitelman laatimisen
➢kuntoutus -jamuiden palveluiden tiedottamisen sekä palveluiden piiriin hakeutumisen avustamisen
➢kuntoutusprosessin seurannan ja arvioinnin
•Sepelvaltimotautia sairastavalle ja läheisille on erilaisia kuntoutusmahdollisuuksia, joiden tarve, mielekkyys sekä oikea -
aikaisuus arvioidaan yhdessä potilaan kanssa ja ohjataan sopivan kuntoutuspalvelun piiriin.
•Kuntoutusohjausta on mahdollisuus saada lähi-tai etävastaanottopalveluna. Kuntoutusohjaus on potilaalle maksutonta, 
lähetettä ei tarvita.
Hyödyllisiä linkkejä:
www.sydansairaala.fi/tietoa/kuntoutusohjaus
www.terveyskyla.fi/kuntoutumistalo/ammattilaiset/kuntoutumisen -tukeminen/kuntoutusohjaus
Milloin kuntoutusohjausta? Sydänkuntoutuskurssit
Alkuun
Milloin kuntoutusohjausta?
Ammattilaiselle
Tarvitseeko sepelvaltimotautipotilas: 
•kuntoutustarpeen arviointia ja suunnittelua sekä apua sydänkuntoutukseen/sydänkurssille hakeutumiseen?
•tukea sairauden kanssa elämiseen?
•lisätietoa ja ohjausta: sepelvaltimotaudista, kuntoutuksesta, palveluista, tukitoimista, uusissa ja epäselvissä 
tilanteissa?
•yhteyshenkilöä, joka tukee kuntoutumisjärjestelmässä toimimista?
Potilaalle
•kun tarvitset yksilöllistä lisätietoa ja ohjausta sairaudesta, kuntoutuksesta, palveluista, tukitoimista, uusissa 
ja epäselvissä tilanteissa
•kun haluat selvittää millaisia palveluja ja keinoja on omahoitosi tueksi ja/tai toiminta -ja työkykysi 
parantamiseksi
•kun tarvitset yhteyshenkilöä kuntoutumisjärjestelmässä toimimiseenAlkuun
Sydänkuntoutuskurssit 1/2
Tarjolla on erilaisia tuki -ja kuntoutuspalveluja riippuen potilaan tilanteesta, voimavaroista ja 
tavoitteista. Sydänkuntoutuskurssit ovat potilaalle ja läheiselle maksuttomia.
Tampereen Sydänsairaalan ja Sydänliiton sopeutumisvalmennuskurssi
•Pirkanmaalaisille äskettäin sepelvaltimotautiin sairastuneille.
•Viikonloppukurssilla saa sydänterveyteen, sairauteen ja omaan hoitoon liittyvää tietoa sekä tukea 
ammattilaisilta ja toisilta samankaltaista kokeneilta.
•Voi osallistua yksin tai läheisen kanssa.
•Kurssille hakeutuminen Sydänsairaalan kuntoutussuunnittelijoiden kautta.
Sydänliiton kurssit
•Tavoitteena on tukea sairastuneen valmiuksia täysipainoiseen elämään muuttuneessa 
elämäntilanteessa sekä löytää hyvinvointia ja jaksamista tukevia keinoja.
•Kurssit perustuvat vertaisuuteen ja tarjoavat mahdollisuuden tavata toisia samankaltaisessa 
elämäntilanteessa olevia.
•Kursseja järjestetään ympäri Suomea ja niihin voi hakeutua asuinpaikasta riippumatta.
•Kurssille voi tulla joko yksin ja monille myös läheisen kanssa. 
Alkuun
Sydänkuntoutuskurssit 2/2
Tulppa -ryhmäkuntoutus
•Perusterveydenhuollon toimintaa, joka on tarkoitettu kaiken ikäisille sepelvaltimotautiin sairastuneille.
•Kuntoutusryhmä kokoontuu kerran viikossa kymmenen kertaa, jonka jälkeen järjestetään seurantatapaamiset puolen vuoden ja 
vuoden kuluttua
•Terveydenhuollon ammattihenkilöt, sairaanhoitaja ja fysioterapeutti, ohjaavat ryhmiä terveyskeskuksissa
•Ryhmässä saa ohjausta omahoitoon, erityisesti ravitsemukseen ja liikunnan harrastamiseen, tukea ohjaajilta sekä 
sydänsairauden itse kokeneelta vertaisohjaajalta
•Tulppa -kuntoutuksella on myös digitaalinen vaihtoehto, joka on osana Terveyskylän Omapolku –verkkopalvelua. Tulppa -
verkkovalmennus ei ole vielä käytössä Pirhan alueella.
Kelan aikuisten sydänkuntoutuskurssit
•Kela järjestää kuntoutus -ja sopeutumisvalmennuskursseja sydänsairautta sairastaville, työelämässä tai työelämän ulkopuolille 
oleville
•Kuntoutus toteutuu ryhmäkuntoutuksena, jossa huomioidaan kuntoutujan yksilöllinen kuntoutustarve -ja tavoite. Kurssi sisältää 
ryhmäkeskustelujen ja pienryhmätyöskentelyn lisäksi monipuolista toimintaa sekä kuntoutusasiantuntijoiden kanssa tapahtuvia 
yksilöllisiä tapaamisia.
•Aikuisten sydänkuntoutuskurssi koostuu 3 x 5 vrk jaksoista noin vuoden aikana. Kursseja järjestetään kuntoutuslaitoksissa eri
puolilla Suomea
•Kuntoutusta voi hakea Kelan lomakkeella KU132. Lisäksi tarvitaan lääkärin laatima B -lausunto kuntoutusta varten.
•Työelämässä olevat (16 -67v) voivat hakea kuntoutuksen ajalta kuntoutusrahaa Kelasta
Alkuun
Vertaistuki
Sairastuminen pysäyttää, se tuo mukanaan uusien asioiden opettelua 
ja uuteen tilanteeseen sopeutumista niinsairastuneelle kuin 
läheisille. Sydänliitto on sairastuneen ja läheisten tukena tarjoten 
sepelvaltimotautiin sairastuneelle tarkoitettuja kursseja, vertaistukea, 
apua ja tukea luotettavasti.
Vertaistuki perustuu kokemusten jakamiseen. Sydänliitolla on 
koulutettuja vertaistukihenkilöitä, jotka ovat itsesairastuneet 
sydänsairauteen tai ovat sairastuneen läheisiä. He haluavat toimia 
kuuntelijoina, keskustelijoina ja rohkaisijoina toisille sairastuneille 
jaläheisille. Vertaistukitoiminta on aina ehdottoman luottamuksellista.
Vertaistukea löytyy myös Sydänliiton paikallisten sydänyhdistysten 
toiminnan kautta. Sydänyhdistykset järjestävät 
monenlaisia tapahtumia ja tapaamisia, joista on mahdollisuus löytää 
vertaisia, joilla on taustalla samankaltainen kokemus.Tietoa , tukea ja toimintaa sydänsairastuneille ja 
läheisille
•https://sydan.fi/sydantietoa
•https://sydan.fi/apua -ja-tukea/
•https://sydan.fi/vertaistuki/
•https://sydan.fi/tule -mukaan/
Sydänliiton ammattilaispalvelu on tarkoitettu 
sydänterveyden parissa työskenteleville
ammattilaisille oman työn tueksi. 
Löydät palvelusta vinkkejä jaohjeita asiakkaan 
ohjaamiseen mm. monipuolisen vertaistuen 
pariin https://sydan.fi/ammattilaispalvelu
Psykososiaalinen tukiAlkuun
Sosiaaliturva
Sairastuminen voivaikuttaa arkeen monella eritavalla esimerkiksi
taloudellisen pärjäämisen jatyö-jatoimintakyvyn muuttumisen myötä .
Sosiaaliturva koostuu erilaisista palveluista jarahallisista etuuksista ,joiden
tarkoituksena onturvata riittävä toimeentulo jahuolenpito kaikissa
elämäntilanteissa .Sairastaminen jakuntoutuminen ovat esimerkkejä tällaisista
elämänvaiheista .
Palveluja jaetuuksia onaina itsehaettava .Oikeus niiden saamiseen syntyy ,kun
yksilöllinen tarve jalakien jasäädösten vaatimat edellytykset täyttyvät .
Sydänpotilaallakin yksilöllinen sairaustilanne jaelämäntilanne vaikuttavat etuuden
myöntämiseen .
Terveydenhuollossa työskentelee sosiaalityöntekijöitä ,joiden kanssa voi
keskustella jasaada ohjausta mm. sosiaaliturvaan jasosiaalipalveluihin liittyen .
Sosiaalityöntekijän palvelut ovat maksuttomia eikä lähetettä tarvita .
Sosiaalityöntekijään voiottaa yhteyttä asiakas taiomainen itsetaitoinen
ammattilainen .Yhteystiedot löytyvät suoraan hoitoyksiköistä jaterveydenhuollon
yksiköiden internet -sivuilta .Hyödyllisiä linkkejä :
•Eläketurvakeskus
•Järjestöjen sosiaaliturvaopas
•Kela
•Pirha sosiaalipalvelut
•Pirha terveyssosiaalityö /sosiaalityö
•Pirkanmaan kotitori
•Terveyskylä
•Työeläke.fi
Toimeentulon turvaa Kotiin annettavaa tukea ja palvelua
Alkuun
Toimeentulon turvaa
•Kela tarjoaa eri elämäntilanteisiin etuuksia toimeentulon turvaamiseksi.
•Kela turvaa työkyvyttömyydestä aiheutuvaa ansionmenetystä maksamalla sairauspäivärahaa tai 
osasairauspäivärahaa työstä poissaolon ajalta.
•Hoidon, tutkimuksen ja kuntoutuksen takia tehtyjä matkoja korvataan Kelan matkakorvauksesta , samoin 
yöpymiskuluja ,mikäli yöpyminen on ollut tarpeen hoitoon ehtimiseksi. Sydänlääkkeet kuuluvat Kelan 
lääkekorvauksen piiriin. Kuntoutuksen aikana toimeentulona voi olla Kelan kuntoutusraha .Kelan 
vammaistukia myönnetään tietyin kriteerein, jos sairaudet aiheuttavat pitkäkestoisesti toimintakyvyn 
laskua. Lisäksi Kela huolehtii työkyvyttömyyden pitkittyessä Kansaneläkkeen maksamisesta.
•Jos sairastuminen uhkaa lähivuosina johtaa työikäisellä henkilöllä työkyvyttömyyteen tai sairastuminen 
heikentää työ -ja ansiokykyä, ammatillisen kuntoutuksen keinoin voidaan parantaa työllistymisen, työhön 
paluun ja työssä jatkamisen edellytyksiä. Ammatillista kuntoutusta järjestävät Kelan lisäksi 
työeläkelaitokset ,tapaturma -ja liikennevakuutuslaitokset ja TE-palvelut .
•Työeläkeyhtiöt huolehtivat työelämässä toimivien ja vakiintuneesti työelämässä olleiden ammatillisesta 
kuntoutuksesta sekä työkyvyttömyyseläkkeistä . Työkyvyttömyyseläkettä myönnetään toistaiseksi 
voimassa olevana työkyvyttömyyseläkkeenä ja osatyökyvyttömyyseläkkeenä. Kuntoutustuki ja 
osakuntoutustuki ovat määräaikaisesti myönnettyjä työkyvyttömyyseläkkeitä.
Alkuun
Alkuun
Kotiin annettavaa tukea ja palvelua
•Sosiaalihuoltolain mukaan sosiaalipalveluja on järjestettävä tueksi jokapäiväisestä elämästä selviytymiseen. Esimerkiksi 
asumisen tuen, taloudellisen tuen, kriisitilanteiden tuen ja erilaisista syistä johtuvan toimintakyvyn tuen tarpeet ovat tilante ita, joita 
sosiaalihuoltolain mukaiset sosiaalipalvelut koskevat. Sosiaalipalveluja järjestävät hyvinvointialueet. Sosiaalipalveluja haetaa n 
siltä hyvinvointialueelta, jonka alueella henkilöllä on kotikunta.
•Palvelujen tarve arvioidaan tekemällä palvelutarpeen arviointi.
•Kotiin annettava kotipalvelu tukee ja auttaa, kun asiakas tarvitsee sairauden tai alentuneen toimintakyvyn vuoksi apua kotiin 
selviytyäkseen arkipäivän askareista ja henkilökohtaisista toiminnoista. Kotipalvelun tukipalveluja ovat esimerkiksi ateriapalve lu, 
siivouspalvelu, vaatehuolto ja kauppa -ja muut asioimispalvelut. Kotipalvelun lisäksi kotona selviytymistä tuetaan 
kotisairaanhoidon avulla .Sosiaalihuoltolakiin perustuva kotipalvelu ja terveydenhuoltolakiin perustuva kotisairaanhoito 
muodostavat yhdessä käsitteen kotihoito.
•Omaishoito tarkoittaa sairaan, vammaisen tai vanhuksen hoitamista omaisen tai muun läheisen avulla. Omaishoidon tuki 
muodostuu hoidettavalle annettavista palveluista sekä hoitajalle annettavasta hoitopalkkiosta, vapaasta ja omaishoitoa tukevista
palveluista.
•Lapsiperhe voi hakea sosiaalihuoltolain mukaista perhetyötä tueksi ja avuksi kuormittavassa elämäntilanteessa 
esimerkiksi vanhemman sairastaessa. Sosiaalihuoltolain mukainen perhetyö on sosiaalipalvelua, joka ei vaadi lastensuojelun 
asiakkuutta.
•Sosiaalihuoltolain mukaista harkinnanvaraista kuljetuspalvelua voi hakea pienituloinen ikäihminen, jolla on vaikeuksia käyttää 
julkisia kulkuvälineitä. Palvelun myöntämiseen vaikuttaa taloudellisen tilanteen lisäksi hakijan ikä sekä liikkumis -ja toiminta kyky.
•Mikäli sosiaalihuoltolain mukaiset palvelut eivät sovi, tai ne eivät ole riittäviä, sosiaalipalveluja tarjotaan erityislainsäädä nnön 
perusteella. Vammaispalvelulain mukaan järjestettäviä palveluita ovat mm. henkilökohtainen apu, asunnonmuutostyöt ja 
asuntoon kiinteästi asennetut laitteet ja välineet. Vammaispalvelulain mukainen vaikeavammaisen kuljetuspalvelu
saattajapalveluineen mahdollistaa opiskelua, työssäkäyntiä sekä asiointi -javirkistysmatkoja henkilölle, joka 
tarvitsee taksia terveydentilansa tai vammansa takia.
Sairaanhoitajan ohjaus
Sairaanhoitajan antaman ohjauksen tavoitteena on 
potilaan sitouttaminen omahoitoon ja riskitekijöiden 
hallintaan.
Ohjauksen avulla potilasta motivoidaan ottamaan 
vastuuta omasta terveydestään ja tekemään sitä 
tukevia valintoja. Ohjauksessa kunnioitetaan potilaan 
itsemääräämisoikeutta ja se tapahtuu potilaan ehdoilla.
Laadukkaalla ohjauksella pyritään vahvistamaan 
potilaan kotona selviytymistä ja vähentämään heidän 
yhteydenottoja hoitojaksojen jälkeen.
Potilaalle annettavan lisätiedon ja ohjauksen avulla 
pyritään myös lievittämään pelkoja ja jännittyneisyyttä 
ennen toimenpiteitä / leikkauksia.
Sairaanhoitaja huomioi ohjauksessaan sen, onko 
potilas sairastanut sydäninfarktin.
Sairaanhoitajan ohjauksen sisältöPotilaan ohjaus ja motivointiSepelvaltimotautipotilaan 
ohjaus sairaalassa
Sepelvaltimotautipotilaan 
ohjaus kotiutuessa
Sepelvaltimotautipotilaan 
ohjaus poliklinikallaOhitusleikkauspotilaan 
ohjaus sairaalassa
Ohitusleikkauspotilaan 
ohjaus postoperatiivisesti 
poliklinikalla
Ohitusleikkauspotilaan 
ohjaus 
perusterveydenhuollossa
Alkuun
Sairaanhoitajan ohjauksen sisältö
•Tutkimus -ja hoitotoimenpiteiden ohjaus ja niihin liittyvät seuranta -ja hoito -ohjeet
•Perustietoa sepelvaltimotaudista: riskitekijät, synty, oireet, tieto sairauden kroonisuudesta 
•Krooninen sepelvaltimo -oireyhtymä ( käypa hoito -suositus)
•Sepelvaltimotautikohtaus (käypä -hoito –suositus)
•Tietoa sepelvaltimotaudista / Sydänsairaala
•sydan.fi/ sydantietoa /sydansairaudet /sepelvaltimotauti /
•Lääkehoitoon sitouttaminen
•Lääkkeet ja niiden vaikutus, lääkkeiden otto
•Lääkehoidon merkitys sairauden hoidossa –vain otettu lääke auttaa!
•Elämäntapaohjausta annetaan yksilöllisesti potilaan riskitekijöiden mukaan
•Sydänystävällinen ruokavalio
•Painonhallinnan tuki
•Päihteettömyys , tupakointi ja alkoholi
•Suun hoito
•Seksuaalisuuden huomiointi
-Verenpaineen hoito
-Tietoa mielialan merkityksestä toipumiselle, psykososiaalinen tuki
-Sosiaaliturva
-Hoitoon hakeutuminen
-Jatkohoitoon linkittyvät asiat
Alkuun
Sepelvaltimotautipotilaan ohjaus
Sepelvaltimotautipotilaan ohjausprosessi on kokonaisuus, joka aloitetaan heti 
diagnoosin saatua. Kotiutettaessa sairaalasta potilasohjauksessa kiinnitetään 
huomiota siihen, mitä tietoa potilas tarvitsee selviytyäkseen arjesta kotona. 
Ohjauspoliklinikalla syvennytään tarkemmin riskitekijöiden hallintaan ja niihin 
kysymyksiin ja aiheisiin, jotka potilasta ovat askarruttaneet kotona.
Ohjaus sairaalassa Ohjaus kotiutuessa Ohjaus poliklinikallaAlkuun
Sepelvaltimotautipotilaan ohjaus sairaalassa
Hoidon onnistumisen kannalta on tärkeää, että potilas sitoutuu omahoitoonsa. Hoitajan 
antamalla tuella on tässä merkitystä. Läheisten ja omaisten tuki auttaa sitouttamaan 
potilasta, siksi omaisten mukaan ottamista suositellaan. Potilaan ohjaus aloitetaan heti 
potilaan tullessa sairaalaan ja ennen potilaan kotiutumista tulee hänen tietää :
•miksi onollut hoidossa jamitä hoitojakson aikana ontehty
•sairaudestaan jasenhoidon keskeisistä piirteistä
•mikä onlääkitys jamiten setoteutetaan, pikanitron käytön ohjeistaminen, korvattavuus
•mitkä ovat toipilasvaiheen kotihoito -ohjeet
•missä jamilloin jatkokontrollit toteutetaan
•miten toimia, jostilanne kotona vaikeutuu, milloin hakeutua hoitoon jaminne
Moniammatillinen yhteistyö osana potilaan ohjausprosessiaPotilaan ohjaus ja motivointiPotilasohje
"opas sepelvaltimotautia 
sairastavalle"
Alkuun
Moniammatillinen yhteistyö osana potilaan ohjausprosessia
Omahoitaja välittää tiedon potilaasta moniammatillisen yhteistyön jäsenille yksilöllisesti potilaan 
tarpeen mukaan. 
•Fysioterapeutti
•uudet sepelvaltimotautipotilaat, sydäninfarktin sairastaneet, lääkärin arvion mukaan muut
•aloitus lääkärin määräyksestä
•Farmaseutti
•Uusia lääkkeitä aloitettu
•Hoitajan arvion mukaan
•Sosiaalityöntekijä
•Sosiaaliturvan asiat, asumisen ongelmat, päihdekuntoutus, lastensuojelu, sosiaalipalvelut, perhetilanteen / 
sosiaalisten suhteiden pulmat
•Hoitajan arvion mukaan
•Diabetes -hoitaja
•Uusi diabetes tai haasteet diabeteksen hoidossa
•Hoitajan arvion mukaan
•Sihteeri
•Kotiutuessa yhteys sihteeriin, joka hoitaa potilaan jatkokontrollien varaukset ja kutsujen lähettämiset.
•Kuntoutussuunnittelija
•Kotiutuessa hoitajan arvion mukaan ohjataan potilas kuntoutussuunnittelijalle
Alkuun
Sepelvaltimotautipotilaan ohjaus kotiutuessa
Kotiutukseen valmistautuminen aloitetaan hyvissä ajoin ja potilasohjaus heti diagnoosin selkiytyessä.
Kotiutus toteutetaan yhteistyössä potilaan, lääkärin, sairaanhoitajan, fysioterapeutin ja sihteerin 
kanssa
Potilaan kotiutuessa hoitaja huolehtii, että:
•Potilas on saanut riittävästi yksilöllistä ohjausta
•Jo olemassa olevaan kotihoitoon on ilmoitettu kotiutumisajankohdasta tai kotiin saatavia palveluita 
on järjestetty potilaalle sairaalasta käsin
•Potilas saa ajantasaisen hoitotyön yhteenvedon, jossa lukee selkokielellä potilaan hoitojakson 
tapahtumat ja jatkohoito, sekä omahoito -ohjeet.
•Potilaalla on Sydänsairaalan kansio, joka sisältää:
•Hoitotyön yhteenvedon
•Jatkotutkimusohjeet ja laboratoriolähetteet (mikäli tulevat paperisina mukaan)
•Reseptit ja lääkekortti
•Sairauslomatodistus
•Laboratorioyhteenveto hoitojakson ajalta
Kotiutushoitajan työnkuva
Potilasohje
"opas sepelvaltimotautia 
sairastavalle" Moniammatillinen yhteistyö osana 
potilaan ohjausprosessiaPotilaan ohjaus ja motivointiAlkuun
Kotiutushoitaja
•Toimii potilaan hoitoon osallistuvien tukena ja apuna tarvelähtöisesti, sekä tekee yhteistyötä Sydänsairaalan ulkopuolisten 
potilaan hoitoon osallistuvien tahojen kanssa (kotiutustiimit, kotisairaanhoito, alueelliset sydänhoitajat ja terveysasemat).
•Kartoittaa päivän kotiutuvat kardiologiset potilaat ja sopii omahoitajien kanssa työnjaon potilaiden kotiuttamisen suhteen.
•Kotiutushoitajan pääpaino on sellaisten potilaiden ohjaamisessa ja kotiuttamisessa, jotka saavat hoitojaksolla 
diagnoosinsa uutena ja joilla on siten paljon omaksuttavaa omahoitoonsa ja hoitopolkuunsa liittyen.
•Selvittää potilaan kotona selviytymistä ja avun tarvetta potilaan ja tarvittaessa omaisten kanssa keskustelemalla. 
Järjestää tarvittaessa kotiutustiimin/kotisairaanhoidon aloituksen tai on yhteydessä jo olemassa olevaan 
kotisairaanhoitoon. Ohjaa tarvittaessa hyvinvointialueen palveluihin.
•Täyttää yhdessä muiden kanssa kotiutussuunnitelmaa ja siirtää sen potilaalle selkeässä muodossa potilaskertomukseen 
Hoitotyön yhteenvetoon.
•Ohjauskeskustelu, Hoitotyön yhteenvedon päivittäminen sekä erityisesti jatkohoitosuunnitelman läpikäyminen 
kotiuttamiensa potilaiden kanssa. Huolehtii, että kaikki tarvittavat asiat tulee huomioiduksi ja kotiutuminen on sujuvaa ja 
turvallista.
•Tarkistuspuhelut kotiutuville sovitusti tarpeen mukaan.
•Osallistuu tarvittaviin koulutuksiin, ylläpitää osaamistaan kotiuttamiseen ja potilaiden ohjaamiseen liittyen.
•Perehdyttää uudet työntekijät yksikön kotiutuskäytäntöihin yksikön muiden hoitajien kanssa.
•Osastolle tulevien ulkoisten puheluiden hoitaminen takaisinsoittopalveluna ja näiden kirjaaminen ja laskuttaminen.
•Potilaan kotiutusprosessin ja oman työn kehittäminen muiden kotiutushoitajien, palvelupäällikön, 
palveluvastaavan, osaston lääkärin ja toimintopäällikön kanssa.Alkuun
Sepelvaltimotautipotilaan ohjaus poliklinikalla 1/2
Ohjauspoliklinikan tavoitteena on tarjota sydänpotilaille henkilökohtaista tukea elinikäisen, parantumattoman sairauden kanssa
elämiseen. Poliklinikalla syvennetään potilaan saamaa tietoa sairaudesta, riskitekijöiden hallinnasta ja vastataan potilasta 
mahdollisesti askarruttaneisiin kysymyksiin.
Ohjauspoliklinikka on sairaanhoitajan, sekä fysioterapeutin yhteisvastaanotto, joka toteutuu Sydänsairaalan eri yksiköissä. E m. 
ammattilaisten ajat voivat toteutua myös erillisinä aikoina yksiköstä riippuen.
Diagnoosin saamisen jälkeen vastaanottokäynti ajoittuu noin 2 –3 viikon päähän potilaan kotiutumisesta.
Ohjauspoliklinikkatoimintaa on Elämänaukiolla ja Valkeakosken Sydänsairaalassa.
Läheinen on tervetullut vastaanotolle.
Kriteerit ohjauspoliklinikalle tuleville potilaille:
•Uusi sepelvaltimotauti tai nähdään tarve ohjaukselle
•Tarkoitettu työikäisille ja hyvän toimintakyvyn omaaville eläkeläisille (alle 80 -vuotias)
•Pääsääntöisesti sairaalasta suoraan kotiutuva alueen potilas
Huomioitavaa:
•Nokialaiset ohjataan Nokian terveyskeskuksen sydänhoitajan ja fysioterapeutin yhteisvastaanotolle
•Valkeakosken sairaalan vastuualueella (sis. Valkeakosken lisäksi Akaa, Lempäälä, Kangasala, Pälkäne, Urjala ja Vesilahti) 
asuville, uuden sepelvaltimotautidiagnoosin saaneille varataan aika Valkeakosken ohjauspoliklinikalle. Tieto 
tästä kirjataan Uranuksen määräyskenttään ja lääkärin epikriisiin.Sepelvaltimotautipotilaan 
ohjauksen tavoitteet poliklinikalla
Sepelvaltimotautipotilaan 
ohjauksen sisältö poliklinikalla
Fysioterapia ohjauspoliklinikallaAlkuun
Sepelvaltimotautipotilaan ohjaus poliklinikalla 2/2
Esitiedot:
-Nykysairaus, aikaisempi sydäntausta, muut vaikuttavat sairaudet
-Tutkimukset, toimenpiteet, tulokset
-Perhe, asuminen, työ
-Toimintakyky, apuvälineet, ulkopuolinen avuntarve
Nykytilan kartoitus:
-Fyysinen, ja psyykkinen vointi, toimintakyky, arjessa pärjääminen
-Esitietolomake, mitä asioita potilas on nostanut esille
-Sydänohjauksen tarve, selvitetään potilaan oma käsitys 
sairaudestaan
-Toteutunut kotiseuranta (verenpaine, pulssi, verensokeri)
-Elämäntapamuutoksiin halukkuus (ravitsemus, painon hallinta, 
tupakka)
-Lääkehoidon sujuminen, ymmärrys tärkeydestä, 
erityiskorvattavuus
-Vastaanotolla mitataan verenpaine ja pulssi
Ohjaus /ohjauksen sisältöJatkosuunnitelma:
•Sisältää tavoitteen asettamisen
•Aiemmin sovitut kontrolliajat ja -kokeet 
(avoterveydenhuolto/ erikoissairaanhoito)
•Sydänohjauksen ja seurannan jatkuminen 
avoterveydenhuollossa
•Tarvittaessa konsultoidaan 
moniammatillista tiimiä: lääkäri, 
diabeteshoitaja, ravitsemusterapeutti, 
psykiatrinen sairaanhoitaja, 
seksuaalineuvoja, 
fysioterapeutti, kuntoutusohjaaja
•Vastaanottokäynnistä kirjoitettava teksti 
tulee omakantaan luettavaksi. 
Pyydettäessä lähetetään postitse 
kotiin. Jatkohoitopaikkaan lähetetään 
sähköinen hoitopalaute.
Alkuun
Sepelvaltimotautipotilaan ohjauksen tavoitteet poliklinikalla
Tavoitteena on, että potilas:
1. tietää, mitä sepelvaltimotauti tarkoittaa ja ymmärtää sen merkityksen
2. ymmärtää tehdyt tutkimukset, toimenpiteet ja tulokset
3. ymmärtää lääkehoidon merkityksen ja osaa toteutuksen
4. osaa oireiden ilmaantuessa toimia ja tarvittaessa hakeutua hoitoon
5. tietää riskitekijänsä ja tunnistaa elämäntapamuutostarpeensa sekä niiden merkityksen 
sairauteen
6. motivoituu ja sitoutuu sepelvaltimotaudin omahoitoon
7. saa tarvitsemaansa tukea sairauteensa liittyen
8. tietää ja ymmärtää jatkohoitosuunnitelmansa
9. läheinen saa tietoa ja ohjausta potilaan sairaudesta, jotta voi tukea häntä 
kuntoutumisessa ja huolehtia myös omasta jaksamisestaan
Alkuun
Sepelvaltimotautipotilaan poliklinikkaohjauksen sisältöä
-Sairaalan loppulausunnon selventäminen: (toimenpiteet, tutkimukset, löydökset)
-Sepelvaltimotauti sairautena, sen synty, oireet, hoito ja riskitekijöiden merkitys sairauden hallinnassa 
Krooninen sepelvaltimo -oireyhtymä ( käypa hoito -suositus); Sepelvaltimotautikohtaus (käypä -hoito –
suositus); Tietoa sepelvaltimotaudista (Sydänsairaala) ;riskitekijät ;
sydan.fi/ sydantietoa /sydansairaudet /sepelvaltimotauti /
-Elämäntapaohjaus, muutoksessa tukeminen ja motivointi omahoitoon ( sydänystävällinen ravitsemus , 
painon hallinta , tupakointi , alkoholin käyttö , seksuaalisuus , suunterveys )
-Lääkeohjaus: merkitys, keskeisimmät sivuvaikutukset, ajantasainen lääkelista, lääkedosetti, 
erityskorvattavuus, pikanitron käyttö
-Omaseurannan ohjaus: verenpaineet, pulssi, paino ja verensokeri tarvittaessa
-Kerrataan potilaan tavoitearvot : rasva -arvot, verenpaine, verensokeri, paino/BMI/vyötärön ympärys, liikunta
-Sydän kuntoutuksen markkinointi ja ohjaus kuntoutusohjaajalle
-Sosiaalihoitajan tarve ja ohjaus sosiaalihoitajalle tarvittaessa
-Ohjataan Nitron käyttö ja hoitoon hakeutuminen sydänoireiden lisääntyessä tai akuutissa tilanteessa
Potilaan ohjaus ja motivointi
Alkuun
Ohitusleikkauspotilaan ohjaus
Ohitusleikkauspotilaan ohjausprosessi on kokonaisuus, joka aloitetaan 
heti sepelvaltimotautidiagnoosin saatua. Itse ohitusleikkaukseen liittyvä 
ohjaus jakautuu pre-ja postoperatiiviseen ohjaukseen. Leikkauksesta 
toipumisen jälkeen tavoitteet ovat samat kuin muillakin sepelvaltimotautia 
sairastavilla.
Ohjaus sairaalassaOhjaus postoperatiivisesti 
poliklinikalla
Ohitusleikkauspotilaan ohjauksen tavoitteet
Ohitusleikkauspotilaan 
ohjaus 
perusterveydenhuollossaAlkuun
Ohitusleikkauspotilaan ohjauksen tavoitteet
Potilas:
•Tietää, miten ohitusleikkaus voi vaikuttaa fyysisesti ja psyykkisesti
•Tietää, mitä hänelle tapahtuu sairaalajakson aikana (leikkaus, tehohoito, osastohoito, 
jatkohoito)
•Ymmärtää leikkauksesta toipumiseen kuluvan aikaa
•Tietää, milloin pitää hakeutua hoitoon kotiuduttua leikkauksesta
•Tietää, mitkä ovat hänen riskitekijänsä sepelvaltimotaudissa ja sitoutuu tarvittaviin 
elämäntapamuutoksiin
•Tietää, mitä lääkkeitä syö ja miksi
Alkuun
Ohitusleikkauspotilaan ohjaus sairaalassa
Potilas valmistellaan ennen leikkausta osastolla ja leikkaus kestää n. 5 -6h toimenpiteestä 
riippuen. Leikkauksen jälkeen potilaat ovat vähintään 1 vuorokauden teho -osastolla hoidossa, 
josta siirtyvät osastolle jatkohoitoon.
Hoito sairaalassa sydänleikkauksen jälkeen kestää yleensä 8 -12 vuorokautta. Teho -osasto hoidon 
jälkeen hoito jatkuu vielä muutaman vuorokauden ajan Sydänsairaalassa, josta yleensä siirrytään 
vielä jatkohoitoon oman kunnan sairaalaan 4 -6. leikkauksen jälkeisenä päivänä.
Kotiutusvaiheessa kirurgi, kardiologi, sairaanhoitaja ja fysioterapeutti keskustelevat potilaan 
kanssa lääkitykseen, toipumiseen, liikkumiseen , kuntoutumiseen, elämäntapoihin , kotiutukseen ja 
jatkohoitoon liittyvistä asioista. Toimeentuloon, sosiaaliturvaan, perheeseen, sekä jaksamiseen 
liittyvissä asioissa on mahdollisuus keskustella sosiaalityöntekijän kanssa.
Hyödyllisiä linkkejä:
Terveyskylä, hoito sairaalassa sydänleikkauksen jälkeen
Terveyskylä, toipilasaika sydänleikkauksen jälkeen
Ohitusleikkauspotilaan ohjauksen sisältö 
sairaalassa
Alkuun
Ohitusleikkauspotilaan ohjauksen sisältö sairaalassa
Ohjaus preoperatiivisesti :
•Taustatiedot: mm. aikaisemmat sairaudet ja toimenpiteet, 
kotilääkitys, näkö, kuulo, ruokavalio, allergiat, liikuntakyky, 
mahdolliset apuvälineet, vatsantoiminta, lähiomainen
•Leikkaukseen ja hoitopolkuun liittyvä ohjaus: muun 
muassa leikkausvalmistelut vuodeosastolla, vuorokauden 
kestävä tehohoitojakso leikkauksen jälkeen sekä 
mahdollinen valvontajakson voinnin sitä vaatiessa
•Leikkauksen jälkeinen toipuminen ja sen eteneminen 
vuodeosastolla: muun muassa verenpaineen, lämmön ja 
verensokerin seuranta, uni, ruokahalu ja mobilisointi
•Tyypillisimmät mahdolliset muutokset voinnissa 
leikkauksen jälkeen ja niiden hoito: esimerkiksi 
rytmihäiriöt, pahoinvointi, mielialan vaihtelut
•Potilaan lääkitykset ja siinä tapahtuvat mahdolliset 
muutokset sairaalajakson aikana
•Läheisten osallistuminen hoitoon ja kuntoutukseenOhjaus postoperatiivisesti:
•Leikkaushaavan kotihoito -ohje
•Haavakipu: potilaan hoitajalle antaman 
haavakipuinformaation merkitys, kipulääkkeen vaikutus
•Lääkehoito : muutokset sairaalajakson aikana ja ohjaus 
uusista lääkkeistä
•Ravinto ja nesteet: merkitys toipumisen kannalta
•Mobilisointi: varhaisen liikkumisen merkitys, eteneminen
•Elämäntapaohjaus : sepelvaltimotaudin eteneminen ja 
siihen vaikuttaminen omilla elintavoilla
•Läheisten huomioiminen ja ohjaus
Potilasohje
"opas 
sydänleikkaukseen 
tulevalle"Potilasohje
"opas sepelvaltimoiden 
ohitusleikkauksesta 
toipuvalle"Potilasohje
"opas 
sepelvaltimotautia 
sairastavalle"
Alkuun
Leikkaushaavan kotihoito -ohje
Haavan puhtaus
•Haava tulee pitää puhtaana ja välttää haava -alueen turhaa 
koskettelua tulehtumisvaaran vuoksi. Haavataitos tulee vaihtaa, 
mikäli sidokset kostuvat läpi verestä tai kudosnesteestä. Pese 
kädet huolellisesti ennen ja jälkeen haavasidoksen poistamista 
tai uuden asettamista.
•Voit käydä suihkussa ja varovasti kastella haavan, kun 
leikkauksesta on kulunut yksi vuorokausi. Haavasidos poistetaan 
ennen suihkuun menoa. Suihkun jälkeen haava -alue kuivataan 
kevyesti painelemalla puhtaalla pyyhkeellä. Haavan voi peittää 
puhtaalla sidoksella, mikäli se erittää kudosnestettä. Siisti haava 
saa olla ilman sidosta.
Ompeleet
•Haavalla voi olla sulavat ompeleet, joita ei poisteta. Tällöin 
saunaan ja uimaan voi mennä 12 vuorokauden kuluttua 
leikkauksesta
•Mikäli haavalla on poistettavat ompeleet. Ompeleiden poisto 
päivämäärä määritellään teille erikseen. Varatkaa itse aika 
ompeleiden poistoon etukäteen. Suihkuun, saunaan ja uimaan 
saa mennä vasta vuorokausi ompeleiden poistamisen jälkeen.Liikunta
•Voit liikkua normaalisti kivun sallimissa rajoissa, annettujen 
ohjeiden mukaisesti. Haava -alueen venytystä, hiertymistä ja 
rasitusta, sekä hikoilua aiheuttavaa liikuntaa tulee välttää kahden 
viikon ajan leikkauksesta
Kipu
•Haava -alueella voi olla kipua muutaman viikon ajan 
toimenpiteestä. Kipulääkettä saa apteekista ilman reseptiä tai 
lääkärin määräämällä reseptillä. Annettuja annosohjeita ei tule 
ylittää.
Turvotus
•Haava -alueella voi olla kipua muutaman viikon ajan 
toimenpiteestä. Kipulääkettä saa apteekista ilman reseptiä tai 
lääkärin määräämällä reseptillä. Annettuja annosohjeita ei tule 
ylittää.
Tulehdus
•Haava voi joskus tulehtua. Tulehduksen oireita ovat haavan 
lisääntyvä kipu, punoitus, kuumotus, erittäminen ja lämmön 
nousut.
Alkuun
Ohitusleikkauspotilaan ohjaus poliklinikalla postoperatiivisesti
Ohjaus ja informaatio
•loppulausunnon läpikäyminen, mitä tapahtunut ja mitä tehty
•Sepelvaltimotaudin/sydäninfarktin synty, oireet, hoito ja riskitekijät
•lääkehoito ; merkitys ja toteutus, B -lausunto (onhan saanut)
•elämäntapaohjaus
•verenpaineen hoito
•psykososiaalinen tuki
•hoitoon hakeutuminen
•kirjalliset ohjeet
Ohitusleikkauspotilaan jatkohoito ja kontrollitOhitusleikkauspotilaan check -lista sairaanhoitajan 
vastaanotolla ( postop .)
Alkuun
Ohitusleikkauspotilaan jatkohoito ja kontrollit
Potilas on tietoinen missä ja milloin
•Sairaalan poliklinikalla
•Terveyskeskuksessa
•Työterveyshuollossa
•Digihoitopolku
•Arvio 2kk leikkauksesta fysioterapiakontrolliin menosta, ajan ohjelmointi tarvittaessa
•Tarvittaessa esim. seksuaalineuvoja, ravitsemusterapeutti, psykiatrinen sairaanhoitaja
•Kotikunnan tarjoamat palvelut, sydänhoitaja/ dehko -hoitaja, fysioterapeutti, Tulppa -ryhmät, 
liikuntatoimi
Sydänsairaalan kuntoutussuunnittelija
-Sopeutumisvalmennuskurssit, Kelan kuntoutus yms.
Sydänpiirien ja –yhdistysten toiminta
Alkuun
Ohitusleikkauspotilaan check -lista sairaanhoitajan
vastaanotolla (postop .)
1.Vointi, mieliala ja yleinen jaksaminen, 
miten on toipuminen sujunut?
2.Oireet:
•Paino / turvotukset
•Kipu (VAS -asteikko)
•Yskä/limaisuus, PEP -puhallukset, 
yskimistekniikka, post -THX-liivi
•Huimaus
•Rytmihäiriöt, uusi tahdistin?
•Verenpaine ja syke
•Tuki-ja liikuntaelinten vaivat, niska -
hartiaseudun jumit?
•Muut oireet
3.Haavat
•paraneminen, tulehduksen merkit
•ompeleiden/hakasten poisto, koska?
•haavanhoito, ihon rasvaus
•onnistuuko haavanhoito kotona?
•tuntopuutokset/ihoherkistymät4.Lääkitys​
•Kipulääkitys​
•Sydänlääkkeet, Marevan 
(ruokavaliorajoitukset)​
•Lääkkeiden mahdolliset haitta -ja 
sivuvaikutukset​
•Dosetin käyttö​
•Lääkekorvaus
5.Liikunta ja lepo​
•Liikuntarajoitusten kertaus
•Liikunnan merkityksen korostaminen 
toipumiselle
•Nukkuminen, väsymys, mahdolliset unihäiriöt​
•Stressi
6. Ravitsemus
•Ruokahalu, mahdolliset ongelmat
•vatsantoiminta, virtsaus
•sydänystävällisen ruokavalion pääpiirteet
•Painonhallinta7.Tupakka ja alkoholi
8.Muut asiat
•Seksuaalisuus (turvalliset asennot)
•Matkustaminen, autolla ajaminen
9. Jatkohoito, kuntoutuminen, omahoito
•Jatkokontrollit, missä ja milloin
•Hoitoon hakeutuminen, jos oireita
•Sairasloma
•Sosiaaliturva, sosiaalityöntekijän konsultointi 
tarvittaessa
•Vertaistuki/sydänkuntoutus, 
kuntoutusohjaajan konsultointi tarvittaessa
•Omaan hoitoon sitoutuminen
•B-todistus, mikäli siihen oikeus
Alkuun
Lääkehoitoon sitouttaminen
Sepelvaltimotautipotilaan lääkehoidon tavoitteena on parantaa taudin ennustetta ehkäisemällä sydänperäisiä 
kuolemia ja sydäninfarkteja, sekä lievittää oireita ja parantaa elämänlaatua. Lääkehoitoon sitoutuminen on 
yksi jatkohoidon onnistumisen edellytys ja omahoidon kulmakivi.
Lääkkeet tulee käyttää säännöllisesti lääkärin antamien ohjeiden mukaan. Säännöllisen lääkehoidon 
toteuttamista voi helpottaa käyttämällä apuna dosettia eli lääkeannostelijaa.
Lääkehoitoon sitoutumisen keinoja:
•Neuvonta, potilasopetus ja motivointi
•Parempi annostelu ja käyttötapa
•Seurannan järjestäminen
•Potilas -lääkärisuhde
Hyödyllisiä linkkejä:
Duodecim -miten auttaa potilasta sitoutumaan lääkehoitoonsa?
Duodecim -hoitoon sitoutuminen ja statiinihoito
Alkuun
Verenpaineen hoito
Kohonneen verenpaineen hoitaminen on tärkeää, sillä sairastuvuus ja kuolleisuus sydän -ja verisuonitauteihin 
lisääntyvät verenpaineen nousun myötä. Kohonneen verenpaineen hoidossa käytetään elämäntapahoitoa ja 
tarvittaessa tämän rinnalla lääkehoitoa. Verenpaine tavoitteena on < 130/80mmHg (Yli 65 vuotiailla 
<140/80mmHg)
•Verenpaineen seuranta
•Mittaus olkavarresta verenpainemittarilla
•Ennen mittausta 5min lepoa, rauhallinen ympäristö
•Mittaukset kotona aamuisin ennen lääkkeen ottoa, sekä iltaisin. Mittausarvot on hyvä laittaa ylös.
•Verenpaineen hoito elintavoilla
•Suolan käytön vähentäminen, suositus enintään 5g päivässä
•Alkoholin käytön vähentäminen, tupakoinnin lopettaminen
•Fyysisen aktiivisuuden lisääminen, ylipainon pudottaminen
•Terveellinen ruokavalio
•Stressin välttäminen
•Salmiakin ja lakritsin välttäminenHyödyllisiä linkkejä:​
Kohonnut verenpaine (käypä hoito –suositus)
Kohonnut verenpaine (Duodecim, Terveyskirjasto)
Terveyskyla .fi/sydansairaudet /tietoa/verenpaine
sydan.fi/ammattilaispalvelu/artikkeli/verenpaineeseen
-vaikuttavat -elintavat/
Kohonnut verenpaine, sydänsairaala
Alkuun
Psykososiaalinen tuki
•Psyykkinen kuormitus on yksi sepelvaltimotaudin riskitekijä. Elimistössämme vapautuu 
adrenaliinia, joka saa lihakset jännittymään, verenpaineen kohoamaan ja sydämen 
pumppaamaan tehokkaammin verta.
•Sydänsairaus tulee useimmiten yllättäen. Hyvä mieliala ja psyykkinen vointi perustuvat 
ennakoinnin ja hallinnan tunteeseen.
•Sairastuminen voi myös itsessään herättää turvattomuutta, pelkoja, vihaa tai syyllisyyttä. 
Sairastumisen herättämät pelot ja huolet ovat mielelle luonnollinen tapa reagoida muuttuneeseen 
elämäntilanteeseen. Sairastumisen aiheuttamat elämänmuutokset voivat altistaa psyykkiselle 
kriisille.
•Sydänsairaus vaikuttaa moneen elämän osa -alueeseen esimerkiksi omat harrastukset ja työ, 
läheiset ihmissuhteet, oma minäkuva. Sairastuneesta voi tuntua, että positiivisia ja tuttuja asioita 
on negatiivisiin ja uusiin verrattuna liian vähän.
•Puhuminen on usein paras lääke pelkojenkin kanssa pärjäämisen. Läheiset ja vertaistukihenkilöt 
voivat auttaa sairastunutta kuuntelemalla, myötäelämällä ja tukemalla. Tarvittaessa voi ohjata 
käsittelemään pelkoja psykologin vastaanotolle
•Psykologin vastaanotolla pelkoja voidaan lähestyä keskustellen sekä mielikuva -, rentoutus -ja 
altistusharjoitusten avulla. Samalla tunnistetaan haitallisia uskomuksia, joita pelkoihin voi liittyä.Psykososiaalisen tuen 
esimerkkikeinoja
Psykososiaalisen tuen 
ja palveluiden periaate 
sepelvaltimotauti -
potilaalla
Vertaistuki Hyödyllisiä linkkejä:
Psyykkinen kuormitus sepelvaltimotaudin riskitekijänä -Käypä hoito suosituksen lisätietoaineisto
Sydänpotilaan henkinen tukeminen hoitotyössä, opinnäytetyö
Terveyskylä, sydänsairaus ja mieliala
Alkuun
Psykososiaalisen tuen esimerkkikeinoja
•Musiikki
•Käsityöt
•Ystävät
•Puhuminen
•Rentoutuminen
•Liikuntaharrastus
•Vertaistuki
•Perhe
•Luonto
•Tieto sairaudesta
•Tieto jatkuvuudesta
•Huolihetki
•Terveydenhuollon ammattilaiset
Hyödyllisiä linkkejä:
Mielen hyvinvoinnin omahoito -ohjelma, mielenterveystaloAlkuun
Psykososiaalisen tuen ja palveluiden periaate 
sepelvaltimotautipotilaalla
•Yleissairaalapsykiatrian poliklinikkaPsykiatrian 
erikoistaso
•Sairaanhoitajan / lääkärin vastaanotto omassa työterveydessä 
tai terveyskeskuksessa Mielenterveys -ja päihdetyön 
vastaanottopalvelut -pirha.fiMielenterveystyön 
perustaso
•Sepelvaltimotaudin hoidosta vastaava henkilökunta Ammattiauttajat
•Sydänliiton vertaistukitoimintaEi ammattikoulutetut auttajat: 
Vapaaehtoisorganisaatiot
•Tapahtuneen käsittely, puhuminen Sosiaalinen verkosto: perhe, ystävät, työtoverit
•Sopeutuminen sairauden kanssa 
elämiseenOma apu: tiedon hankinta sairaudesta, itsehoito
Kuvio mukaellen :Psykososiaalinen tuki ja palvelut (kaypahoito.fi)
Alkuun
Psykiatrian erikoistaso: Yleissairaalapsykiatrian poliklinikka 
(PPSY)
•Potilaille, jotka kärsivät terveydentilansa tai muiden sairauksien aiheuttamista mielenterveyden 
häiriöistä tai joiden sairauden tai oireilun syyn selvittäminen vaatii lisätutkimuksia. Esimerkiksi 
kun potilaalla on sairauskriisi, kipuoireyhtymä tai elimellisoireinen häiriö. Eikä 
perusterveydenhuollon palvelut ole riittäviä.
Pirkanmaan alueen psykiatrinen hoito
•Yleissairaalapsykiatrin poliklinikan potilaaksi pääseminen vaatii aina lääkärin tekemän 
lähetteen.
•Jos potilas on osastohoidossa, soitto psykiatriselle sairaanhoitajalle.
•Muissa tapauksissa: lääkäri tekee lähetteen ja PPSY:n poliklinikka käsittelee nämä ja on 
yhteydessä potilaaseen.
Alkuun
Elämäntapaohjaus
Sydänystävällinen ravitsemus
Painonhallinnan tuki
SuunterveysPäihteettömyyden tuki / tupakointi
Päihteettömyyden tuki / alkoholi
Seksuaalineuvonta
Alkuun
Sydänystävällinen ravitsemus
Sydänystävällinen ruokavalio edistää kuntoutumista, parantaa lääkehoidon vastetta sekä hidastaa ja saattaa 
jopa ehkäistä taudin etenemistä. Se myös vaikuttaa positiivisesti sepelvaltimotaudin taustalla oleviin veren 
rasva -aineenvaihdunnan häiriöön, kohonneeseen verenpaineeseen ja sokeriaineenvaihdunnan 
poikkeavuuksiin. Sydänystävällinen ruokavalio on oleellinen osa sepelvaltimotaudin omahoitoa myös 
pallolaajennuksen tai ohitusleikkauksen jälkeen.
Sydänystävällinen ruokavalio koostuu kaikille suositeltavasta ja monipuolisesta 
ruoasta. Ruokakolmion avulla voi hahmottaa, mistä sydänystävällinen ja monipuolinen ruokavalio koostuu. 
Hyvä pohja sydänystävälliseen ruokavalioon muodostuu kasviksista, hedelmistä ja marjoista sekä 
kokojyvävilja -valmisteista. Kolmion huipulla olevia ruokia tulisi syödä harvoin ja harkiten, ne sisältävät 
runsaasti sydänterveyden kannalta epäedullisia kovia rasvoja, suolaa ja sokeria.
Ravitsemusterapian palvelut Pirkanmaalla: Ravitsemusterapian palvelut -pirha.fi
Sydänmerkki Suolankäyttö
Hyödyllisiä linkkejä:
Sydän ja ruoka -suositus -Ammattilaispalvelu (sydan.fi)
Sepelvaltimotauti ja ruoka
Sydänsairaus ja ruokavalio | Sydänsairauksien talo | Terveyskylä.fi (terveyskyla.fi)Kolesteroli ja ruoka
Ravinnon merkitys leikkauksesta toipuessaAlkuun
Ravinnon merkitys ennen leikkausta ja leikkauksesta toipuessa
Vajaaravitsemustila lisää leikkauskomplikaatioiden riskiä ja hidastaa toipumista. Mikäli ravitsemustilasi on heikentynyt ja/ taisinulla on 
haasteita riittävän ravitsemuksen toteuttamisessa ennen leikkausta, asiasta tulee keskustella hoitohenkilökunnan 
kanssa. Ravinnontarve kasvaa suuren leikkauksen jälkeen. Leikkauksesta toipuva tarvitsee riittävästi energiaa ja muita ravintoa ineita, 
jotta leikkaushaavat ja muut kudokset paranevat.
Leikkauksen jälkeen sairaalaympäristö, vuodelepo, mahdollinen huonovointisuus jakipu voivat aiheuttaa ruokahaluttomuutta ja
ummetusta .Osastohoidossa onuseita erimahdollisuuksia tehostaa ravinnonsaantia jahoitaa ummetusta .Ota rohkeasti asia esiin
hoitohenkilökunnan kanssa .
Ennen leikkausta jakotiutumisen jälkeen ontärkeää huolehtia, että ruokavalio tukee hyvää ravitsemustilaa ennen leikkausta ja
kuntoutumista senjälkeen .Riittävän ravinnonsaannin kannalta onsuositeltavaa :
•Syödä säännöllisesti jausein (2–3tunnin välein), 4–6kertaa päivässä
•Pitää iltapalan jaaamupalan välienintään 10–11tunnin mittaisena
•Syödä jokaisella aterialla javälipalalla jotakin proteiinia sisältävää .Kiinnitä erityisesti huomiota aamu -jailtapalan sekä välipalojen
proteiininlähteisiin
•Hyviä proteiinin lähteitä ovat maitotuotteet (maito, piimä, jogurtti, viili, rahka, maitopohjaiset jälkiruoat, pirtelöt, jäätelö, erilaiset juustot),
soijatuotteet (juoma, soijapohjaiset vaihtoehdot jogurtille, rahkalle javanukkaille, tofu), kananmuna, liha, kala, broileri, kasviproteiinivalmisteet,
pähkinät .
Mikäli ruokahalusi onheikentynyt jaruokamäärät jäävät vähäisiksi, energiansaantia voitehostaa rasvankäyttöä lisäämällä, sillä rasva
lisää tehokkaasti ruokien energiatiheyttä :
•Leipien päälle reilu kerros kasvirasvalevitettä, jossa onrasvaa vähintään 60%
•Öljyä kasvisten joukkoon, öljypohjaista salaatinkastiketta salaattiin, juoksevaa margariinia keittoihin japuuroihin
•Kasvirasvavalmisteita (kasvirasvapohjaiset kermat) ruoanvalmistuksessa
•Siementen, pähkinöiden, mantelijauheen, maapähkinävoin, avokadon ja majoneesin hyödyntäminen.
•Apteekista ostettavien täydennysravintovalmisteiden käyttö on suositeltavaa, jos ruokahalu on huono ja/tai paino 
laskee tahattomasti.Alkuun
Painonhallinnan tuki
•Sydänterveyteen on mahdollista vaikuttaa tekemällä hyviä valintoja ja syömällä sopivia määriä 
kulutukseen nähden. Jo maltillinenkin painonpudotus auttaa ylipainoista vaikuttamaan useisiin 
riskitekijöihin ja tekee liikkumista helpommaksi.
•Ylipaino on yksi sepelvaltimotaudin riskitekijä. 
•Tavoitteena on BMI alle 25kg/m2. Ylipainoisilla, sekä lihavilla painon pudottaminen pysyvästi 5 -
10%. 
•Ylipainon hoitona tärkeässä osassa on sydänterveellinen ruokavalio ja liikunta. 
•Tavoitteiden saavuttamisen apuna voivat olla ravitsemusasiantuntijat, sekä liikkumisen 
ammattilaiset. 
Hyödyllisiä linkkejä:
•Käypä hoito -suositus, lihavuus
•Terveyskylä, painonhallintatalo
•Sydänliitto, sydän ja ruoka -suositus
Alkuun
Suunterveys
•Hampaiden kiinnityskudosten tulehdus, parodontiitti on riskitekijä sepelvaltimoita 
ahtauttavan ateroomaplakin muodostumiselle, verisuonten tukkeutumiselle ja 
läppätulehduksille.
•Suun ja hampaiden säännöllinen hoito ehkäisee suun tulehduksia. Suun ja 
hampaiden tarkastuksessa on hyvä käydä säännöllisesti vähintään kerran vuodessa. 
Huolehdi hyvästä suuhygieniasta: harjaa hampaat 2x/vrk, puhdista hammasvälit 
päivittäin ja harjaa kieli tarvittaessa.
•Huomioi, että osa sepelvaltimotautilääkityksistä voi aiheuttaa myös suuvaikutuksia.
Hyödyllisiä linkkejä:
Terveyskirjasto, suun hoito sydän -ja verisuonisairauksissa
Terveyskirjasto, lääkkeiden vaikutukset suun terveyteen
Terveyskirjasto, Parodontiitin yhteys sydän -ja verisuonisairauksiin
Alkuun
Päihteettömyyden tuki / tupakointi
Tupakointi on yksi tärkeimmistä sepelvaltimotaudin hoidettavista riskitekijöistä ja sen vuoksi 
tupakoinnin lopettaminen on erittäin tärkeää sydänpotilaalle.
Sepelvaltimotaudin riski puolittuu vuodessa ja parinkymmenen vuoden tupakoimattomuus 
pienentää riskin lähes samalle tasolle kuin niillä, jotka eivät ole koskaan tupakoineet.
•Jokaisen sepelvaltimotautia sairastavan tupakoijan tulee saada riittävä vieroitushoito. Vieroitus 
tulee käynnistää sairaalahoidon aikana ja vieroituksen tuen tulee jatkua sairaalasta 
kotiutumisen jälkeen.
•Nikotiinivieroitukseen käytetyt tuotteet ovat turvallisia sepelvaltimotautia sairastavilla.
Pirkanmaan tupakasta ja nikotiinista vieroituksen toimintamalli
Tupakasta vieroituksen neuvontakortti
Hyödyllisiä linkkejä:
•Käypä hoito, tupakka -ja nikotiiniriippuvuuden 
ehkäisy ja hoito
•Terveyskirjasto, tupakoinnin lopettaminen
•Terveyskirjasto, tupakoinnin tärkeimmät 
tunnetut terveyshaitat•THL, tupakka
•Terveyskylä, sydänsairaus ja tupakka
•Sydänsairaala, tupakointi ja alkoholi
Alkuun
Alkuun
Alkuun
Päihteettömyyden tuki / alkoholi
Alkoholin käyttöön sydänsairauksien 
yhteydessä liittyy riskejä, jotka saattavat 
pahentaa sydänoireita. Jos alkoholia 
käyttää, määrän tulee pysyä kohtuurajoissa.
Alkoholin vaikutukset 
sepelvaltimotautipotilaalla:
•Nostaa verenpainetta ja vähentää 
verenpainelääkityksen vaikutusta
•Vähentää sydämen supistumisvoimaa ja voi 
aiheuttaa sydämen vajaatoimintaa
•Lisää sydämen rytmihäiriöitä
•Hämärtää muistia, jolloin lääkkeiden ottaminen 
voi jäädä väliin tai niitä voidaan ottaa liian 
usein
•Voi voimistaa tai heikentää lääkkeiden 
imeytymistä•Altistaa tapaturmille ja jos on käytössä veren 
hyytymiseen vaikuttavia lääkkeitä, kehon 
sisäisten verenvuorojen riski lisääntyy
•Krapulassa rytmihäiriön kääntäminen takaisin 
normaaliin sinusrytmiin on hankalampaa
•Alkoholissa on lisäksi runsaasti kaloreita, 
lähes yhtä paljon kuin rasvassa. Runsas 
käyttö lihottaa ja vaikuttaa veren 
sokeritasapainoon
Hyödyllisiä linkkejä:
•Terveyskirjasto, alkoholi ja terveys
•Terveyskylä, Sydänsairaus ja alkoholi
•Sydänsairaala, tupakointi ja alkoholi
•THL, alkoholi
Alkuun
Seksuaalineuvonta
Seksuaalisuus onosaihmisyyttä jasilläonerilaisia merkityksiä jailmenemismuotoja erielämäntilanteissa .
Sairastumisen kohdatessa elimistö saattaa vaatia aikaa toipuakseen .
Seksielämä aktivoituu yleensä luonnostaan ,kunvointi helpottuu ja toipuminen etenee sekä yleinen fyysinen
suorituskyky paranee . Fyysisenä rasituksena yhdyntää voiollaturvallista kokeilla ,kunkahden porrasvälin
kulkeminen onnistuu .
Mahdollinen seksuaalinen haluttomuus onsairastumisen yhteydessä mahdollista .Kunnon kohentuessa tilanne
yleensä normalisoituu ,mutta josseksuaalisuuteen liittyy haasteita ,niinhaeapua esim .seksuaaliterapeutin
vastaanotolta (seksuaalineuvonta@sydansairaala.fi ).Erektiolääkkeiden käytöstä ohjaa potilas keskustemaan
lääkärin kanssa .
Mikäli ontehty ohitusleikkaus :
Rintakehän kuormitusta tulee välttää kahden kuukauden ajan leikkauksesta ,jolloin jotkin yhdyntäasennot
saattavat ollaliiankuormittavia .Leikkauksen jälkeen elimistö vaatii aikaa toipuakseen ,mutta intiimi läheisyys
jakosketus on sallittua .
Hyödyllinen linkki :
Sepelvaltimotautipotilaan seksuaaliterveys -Käypä hoito -suosituksen lisätietoaineisto
Alkuun
Hoitoon hakeutuminen
Sepelvaltimotaudin tavallisin oire on rasituksessa ilmaantuva puristava kipu tai 
ahdistava tunne rintakehällä. Lisäksi oireina voi olla myös hengenahdistusta, 
närästystä, väsymystä ja pahoinvointia.
Milloin hakeutua hoitoon:
•Jos Nitro valmisteen käyttö tai oireet lisääntyvät, on hakeuduttava lääkärin 
vastaanotolle.
•Jos oireena on äkillinen kova rintakipu tai hengenahdistus, joka ei helpota 
muutamassa minuutissa, tulee soittaa 112.
•Jos oireena on äkillinen kova rintakipu, johon olette ottaneet Nitro -suihketta 1 -3 
suihkausta, eikä kipu helpota 5 minuutissa, tulee soittaa 112.
Sydänperäiset äkilliset oireet video: Sydänperäiset äkilliset oireet (vimeo.com)
Nitron käyttö ja hoitoon hakeutuminen
Alkuun
Nitron käyttö ja hoitoon hakeutuminen
Nitro -valmisteet kuuluvat sepelvaltimotaudin aiheuttaman rintakivun peruslääkkeisiin. Nitraatit laajentavat verisuonia, keventäv ät sydämen työtä ja poistavat 
rintakipua. Nitroa käytetään rintakipukohtauksissa ja rintakipua ehkäisevässä tarkoituksessa. Pikanitron (suihke tai kielen a llelaitettava tabletti) vaikutus alkaa 
parissa minuutissa. Nitroja ovat kielen alle laitettavat tabletit ja suihke, joka annostellaan kielen päälle.
Nitro aiheuttaa vain vähän sivuvaikutuksia. Joillakin saattaa esiintyä ohimenevää kasvojen punoitusta, kuumotusta tai vaarato ntapäänsärkyä. Päänsärkytaipumus 
häviää yleensä lääkkeen käytön jatkuessa. Koska nitro laskee verenpainetta, se voi aiheuttaa huimausta ja lääke kannattaakin ottaa makuulla tai istuen. 
Erektiolääkkeiden käyttö yhdessä nitrovalmisteiden kanssa on kielletty.
Rintakivun hoito
•Jos tunnette rintakehällänne puristavaa tai ahdistavaa kipua, käykää makuulle tai istumaan. Ottakaa Nitro -tabletti kielen alle t ai 1-3 -suihketta kielen päälle. Jos 
kipu jatkuu yli viisi minuuttia, soittakaa numeroon 112 (aluehälytyskeskus) ja toimikaa annettujen ohjeiden mukaisesti.
Toistuvien rintakipujen hoito
•Jos rintakivut toistuvat useasti ja menevät ohi aina yhdellä nitrolla, voi nitroja ottaa tarvittaessa useitakin kertoja vuoro kauden aikana. Yleensä tuolloin 
kannattaa käyttää pitkävaikutteista nitraattia. Lisäksi lääkärin tulee arvioida, tarvitaanko kajoavia sepelvaltimotaudin tutk imuksia. Jos päivittäinen nitrojen tarve 
kasvaa selvästi, ottakaa yhteyttä omaan lääkäriinne. Jos esiintyy lepokipua, hakeutukaa päivystyksenä lääkärin vastaanotolle
Rintakipujen ehkäisy
•Voitte välttää rintakipukohtauksen, kun otatte nitron muutamaa minuuttia ennen rasitusta tai kylmään ilmaan menoa. Huomioikaa nitron verenpainetta alentava 
vaikutus ja käykää tarvittaessa istumaan tai makuulle.
Muuta huomioitavaa
•Pitäkää nitroja aina mukana. Säilyttäkää nitroja alkuperäispakkauksessa ja erillään muista lääkkeistä. Jos tabletit murenevat tai niiden teho tuntuu vähenevän, 
vaihtakaa ne uusiin. Tablettien vanhenemisen (pakkausmerkinnän lisäksi) huomaatte siitä, että ne eivät aiheuta kirvelyä kiele nnealla. 
Nitrojen teho voi myös heikentyä, jos joudutte usein aukaisemaan purkin. Uusikaa nitro -resepti hyvissä ajoin, jotta lääke ei pää se 
loppumaan loman tai matkan aikana.
Alkuun
Potilaan ohjaus ja motivointi
Motivoiva haastattelu / keskustelu
- Potilaslähtöinen vuorovaikutusmenetelmä.
- Todettu vaikuttavaksi pyrittäessä tukemaan potilaita 
terveysperusteiseen elintapamuutokseen.
- Teoreettinen perusta on muutosvaihemallissa, kytkeytyy 
myös kognitiiviseen käyttäytymisterapiaan ja sen 
taustateorioihin.
- Lähtökohtana potilaan muutosvaiheen tunnistaminen ja 
vuorovaikutusstrategian sovittaminen siihen.
- Potilasta tuetaan etenemään muutoksessa vaihe vaiheelta.
- Käypä hoito lisätietoaineisto : Motivoiva haastattelu
- Duodecin oppiportti :Motivoiva keskusteluTeach Back
-Sepelvaltimotautiin sairastuneella tulee olla riittävästi tietoa ja 
osaamista oman terveytensä ja sairautensa hoidossa.
-Joillakin sairastuneilla on vaikeuksia ymmärtää ohjausta sekä terveyttä 
ja hoitoa käsittelevää tietoa, mikä voi johtua esim. henkilön heikosta 
terveyteen liittyvästä lukutaidosta ( lowhealth literacy ), ohjaustavasta 
tai sen ajoituksesta.
-”Teach -back ” on menetelmä, jossa terveydenhuollon ammattilainen 
pyytää potilasta ohjauskeskustelun aikana kertomaan hoitoon liittyvät 
keskeiset asiat voidakseen arvioida potilaan ymmärtäneen ne.
-Teach -back -menetelmän avulla ammattilainen voi myös varmistua, 
mitä asioita ohjauskeskustelussa tulisi vielä kerrata.
-Ohjauskeskustelua jatketaan, kunnes potilas/asiakas tuntee 
hallitsevansa oman hoitonsa.
-Hotus suositus: Tech Back pitkäaikaissairaan ohjausmenetelmänä•Ohjausta suunniteltaessa ja toteutettaessa huomioidaan yksilöllisesti potilaan tilanne (esim. onko sairaus uusi vai uusiutunut, kriisin 
vaihe, elämäntilanne) ​.
•Ohjaus on pääsääntöisesti kahdenkeskistä, osastolla usein hoito -/kuntoutustoimiin linkittyvää.
•Ohjauksen apuna voi käyttää muun muassa muovista mallisydäntä ja sepelvaltimoa, pallolaajennuksen yhteydessä sepelvaltimoon 
laitettavaa stenttimallia, sekä erilaisia teknologisia vaihtoehtoja esim. seuraavia ohjausvideoita:
•Sydänsairaalan sepelvaltimoiden varjoainekuvaus ja pallolaajennus video
•Sydänsairaalan sydämen sepelvaltimoiden ohitusleikkaus video
•Ohjauksessa huomioidaan myös läheisten ohjauksen tarve ​.
•Ohjauksen tulee olla rauhoittavaa, psyykkistä selviytymistä tukevaa.
•Ohjaus sisältää sekä suullista että kirjallista ohjausta.Alkuun
Seuranta sepelvaltimotautidiagnoosin jälkeen 1/2
Seurantakäynnit
•OmaSydän etähoitopalvelu onensisijainen ja useimmilla
potilailla ainoa seurantamenetelmä
•Etäkontrollit 3kk ja 12kk, minkä jälkeen kontrollit siirtyvät
perusterveydenhuoltoon
•OmaSydämen lisäksi perusterveydenhuollon lääkäri -ja/tai 
hoitajakontrollit
•Diabeteetikot
•Muu komplisoitunut tilanne
•OmaSydämen lisäksi erikoissairaanhoidon (sydänpoliklinikka ) 
kontrollit sepelvaltimotautikohtauksen jälkeen
•Alentunut vasemman kammion supistuvuus EF alle 40%
•Jäännösahtaumien toimenpidehoidon tarpeen harkinta
•Sydämen UÄ-seurannan tarve muun sydänsairauden vuoksi
•Työkykyarvio , jostarvitaan kardiologin arviota
•Jos potilas eiole OmaSydän etähoitopalvelussa , 
kontrollit perusterveydenhuollon lääkärillä ja/tai hoitajalla
•1-3kk ensidiagnoosin jälkeen
•Jatkossa seurantakäynnit perusterveydenhuollossa
•12kk välein , joshoitotasapaino hyvä
•3-6kk välein , joshoitoa tehostettavaPerusterveydenhuollon seurantakäynnillä huomioitavat asiat
•Valtimosairauden riskitekijöiden hoito
•Verenpaine
•Kolesteroli
•Diabetes
•Munuaisfunktio
•Tupakointi
•Painonhallinta
•Liikunta
•Oireet
•Työkyky
•Mieliala
•Ajoterveys
•Seksuaaliterveys
•Määrättyjen lääkitysten käyttö jareseptien uusinta
Alkuun
Seuranta sepelvaltimotautidiagnoosin jälkeen 2/2
Milloin kardiologin konsultaatio?
•Levossa tai vähäisessä rasituksessa rintakipua
•Kiireellinen lähete, optimoi sepelvaltimotautilääkitys
•Jos lepo -oire, mikä ei poistu nitrolla --> päivystyslähete Acutaan
•Optimoidusta lääkehoidosta huolimatta rasitusrintakipuoireisto
•Ennen lähetteen tekoa optimoi sepelvaltimotautilääkitys ja kontrolloi sen teho
•Tajunnanmenetys tai epäselvä rytmihäiriöoire (EKG ja Holter perusterveydenhuollossa)
•Epäily sydämen vajaatoiminnasta (alentunut suorituskyky, hengenahdistus, turvotukset, 
pro-BNP koholla, thx-kuvassa vajaatoimintamuutokset)
•LDL > 2,6 mmol /l maksimaalisesta statiini -ja etsetimibilääkityksestä huolimatta 
•PCSK9 tai inklisiraanin aloitusharkinta
•Kardiologin suositus lääkkeen aloituksesta, B -lausunto perusterveydenhuollosta
Alkuun
OmaSydän -Sydänsairaalan sepelvaltimotautipotilaan 
etähoitopalvelu
•OmaSydän mobiilisovellus –Sepelvaltimotautipotilaan etähoitopalvelu 12kk
•Ensisijainen ja useimmilla potilailla ainoa seurantamenetelmä sepelvaltimotautidiagnoosin jälkeen
•Potilaiden rekrytointi OmaSydän etähoitopalveluun sepelvaltimoiden varjoainekuvauksen yhteydessä
•Sepelvaltimotautikohtaus
•Stabiili sepelvaltimotauti
•Määritetään valtimosairauden riskitekijät ja yksilölliset hoitotavoitteet
•Verenpaine, diabetes, kolesteroli, tupakointi, liikunta, ruokavalio ja painonhallinta
•Etäkontrollit 3kk, (6kk) ja 12kk OmaSydän etähoitopalvelun kautta
•Laboratoriokokeet (PVK, LDL, Alat, Na, K, krea, diabeetikoilta HbA1c. Lääkärin harkinnan mukaan muut 
laboratoriokokeet)
•Kontrollikysely ja elämänlaatukysely 15D OmaSydän mobiilisovelluksen kautta
•Potilaan pääsy digitaaliseen taustamateriaaliin omahoidon tukemiseksi ja tiedon lisäämiseksi
•Sydänsairaalan digihoitaja tekee kontrollin yhteydessä yhteenvedon riskitekijöiden hoidosta ja tarvittaessa 
konsultoi kardiologia sekundaariprevention tehostamisesta ( Kol, RR) ja sepelvaltimotaudin oireista.
•Tavoitteena valtimosairauden riskitekijöiden kokonaisvaltainen tehokas hoito
•Sepelvaltimotautipotilaan etähoitopalvelu: https://www.sydansairaala.fi/tietoa/digihoitopolku/
Alkuun
Asiakastyy -
tyväisyys -
kysely
etä-
seurannast a.Potilas 
ohjataan 
ottamaan 
hoitopolku -
sovellus 
käyttöön. Sydänsairaalan 
sovelluksen 
käyttöönotto.Sovelluksessa 
tiedot vastausten 
tarkistuspäivästä, 
ohjeet ja kyselyt.Potilaalle annetaan 
tarvittaessa mm. 
tarkempia ohjeita, 
tukea ja 
keskustellaan 
sovelluksen kautta.
Sepelvaltimotaudin etäseuranta: etäkontrolliajankohdat 3 kk, (6 kk) ja 12 kk
Potilaalle 
tehdään  
ajanvaraus 
vastausten 
tarkistukseen 
(3kk 
kontrolli).
Uranus/
Lifecare Sovellus 
muistuttaa 
potilasta labora -
toriokokeista, 
kyselyistä ja 
vastausten 
tarkistuspäivästä
.Vastausten 
tarkistuspäivä 
(3kk). 
Potilaalle 
tehdään 
ajanvaraus 
vastausten 
tarkistukseen 
(6 kk tai mikäli 
kaikki ok 
suoraan 12 kk)Potilaalle 
annetaan 
tarvittaessa 
mm. 
tarkempia 
ohjeita, tukea 
ja 
keskustellaan 
sovelluksen 
kautta. Sovellus 
muistuttaa 
potilasta labora -
toriokokeista, 
kyselyistä ja 
vastausten 
tarkistuspäivästä
.
Potilaan 12 kk 
etähoitopalvelu päättyy.
Hoito jatkuu 
hoitosuunnitel -
manmukaisesti 
perusterveydenhuollossa.Etähoitopalvelu 
päättyyVastausten 
tarkistuspäivä 
(6kk).
Potilaalle 
tehdään 
ajanvaraus 
vastausten 
tarkistukseen 
(12 kk).Sovellukseen liittyvä yleinen prosessi: sepelvaltimotautipotilaan vuoden kestävä etähoitopalvelu
Potilaalle 
annetaan 
tarvittaessa 
mm. 
tarkempia 
ohjeita, tukea 
ja 
keskustellaan 
sovelluksen 
kautta. Vastausten 
tarkistuspäivä
(12kk).Potilaalle 
kerrotaan 
etäseurannan 
päättymisestä 
ja miten hoito 
jatkuu.Sovellus 
muistuttaa 
potilasta labora -
toriokokeista, 
kyselyistä ja 
vastausten 
tarkistuspäivästä
.
Sisältöteema 
Sisältöteema 
Sisältöteema 
Sovellukseen asiasisällöt luodaan teemoittain 
tukemaan potilaan toipumista, sairauden 
hyväksymistä ja elintapamuutoksia jne. Tavoitteena 
tarjota potilaalle tietoa oikeassa muodossa, oikeaan 
aikaan.Sisältöteema Sisältöteema 
Sisältöteema 
Jos potilaalle tulee  6 kuukauden kontrolliaika, 
tällöin teemana kohti ”ylimääräistä” kontrollia voisi 
olla tsemppaaminen parempaan omahoitoonSairaalassa 
sepelvaltimo -
tautidiagnoosin 
saaneet 
otetaan 
etähoitopalvelu
un
(kesto 12 kk).
OmaSydän mobiilisovellus –12 kk etähoitopalvelu sepelvaltimotautidiagnoosin jälkeenAlkuun
Riskitekijöiden hoidon yleiset tavoitteet
Huom. yksilöllisesti ikä ja muut mahdolliset tekijät huomioiden hoitava lääkäri voi määrittää myös yleisistä tavoitteista poi kkeavat tavoitteet
LDL-kolesterolipitoisuus < 1,4mmol/l
-yksilöllisesti voidaan pyrkiä < 1,0 mmol /l:n pitoisuuteen erityisesti, jos potilaalla on ollut toistuvia valtimotautitapahtumia
Lisätietoa: Dyslipidemiat (kaypahoito.fi)
Lepoverenpaine < 130/80mmHg
-Yli 65 vuotiailla <140/80 mmHg
Lisätietoa: Kohonnut verenpaine (kaypahoito.fi)
Normaali sokeriaineenvaihdunta
-Verensokerin paastoarvo < 5,5 mmol /l, glukoosirasituskokeen arvo < 7,8mmol/l ja HbA 1C -pitoisuus < 42mmol/mol; diabeetikoilla HbA 1C -pitoisuus < 
53mmol/mol
Lisätietoa: Tyypin 2 diabetes (kaypahoito.fi)
Täydellinen tupakoimattomuus
-Tupakoinnin lisäksi tulisi pidättäytyä myös muista nikotiinivalmisteista, kuten sähkötupakasta ja nuuskasta
Lisätietoa: Tupakka -ja nikotiiniriippuvuuden ehkäisy ja hoito (kaypahoito.fi)
Säännöllinen terveysvaikutteinen liikuntaharrastus
-Hyötyliikuntaa päivittäin
-Kestävyysliikuntaa vähintään 3 -5 päivänä viikossa 30 -60 min
-Lihaskuntoharjoittelua 2 -3 päivänä viikossa
Lisätietoa :
Liikunnan ja liikunnallisen sydänkuntoutuksen vaikuttavuus osana kroonista sepelvaltimo -oireyhtymää sairastavan hoitoa (kaypahoi to.fi)
Sepelvaltimotautipotilaan liikunnallinen kuntoutus -Duodecim (terveysportti.fi)
Krooninen sepelvaltimo -oireyhtymä ja liikunta (kaypahoito.fi)
Keskivartalolihavuuden hallinta
-Vyötärön ympärysmittaa (cm) käytetään kuvaamaan keskivartalolle kertyvää liikarasvaa. Merkittävä vyötärölihavuuden raja -arvona o n naisilla 88cm ja miehillä 
102cm
Lisätietoa :Lihavuus (lapset, nuoret ja aikuiset) (kaypahoito.fi), Painoindeksi ja vyötärön ympärys (kaypahoito.fi)
Taulukko mukaellen : Krooninen sepelvaltimo -oireyhtymä (kaypahoito.fi) Riskitekijöiden kartoitusAlkuun
Ajoterveys 1/2
•Ajoterveysohje_Traficom_2021.pdf
•Krooninen sepelvaltimo -oireyhtymä
•Ajoterveysvaatimusten täyttymistä seurataan säännöllisin lääkärintarkastuksin . Perusterveydenhuollon lääkäri voitehdä
seurantatarkastukset . Seurantaväli on yksilöllinen .
•Ajolupa voidaan myöntää /evätä seuraavin edellytyksin :
•Ryhmän 1 ajoterveysvaatimukset eivät täyty, joshenkilöllä on rintakipua tai hengenahdistusta levossa , peseytyessä , pukeutuessa tai 
muussa vähäisessä rasituksessa tai henkisen paineen alaisena (CCS luokka 4).
•Ryhmän 2 ajoterveysvaatimukset eivät täyty, joshenkilöllä on sydänoireita (rintakipua tai hengenahdistusta ) tavallisessa tasamaakävelyssä
tai sitävähäisemmässä rasituksessa (levossa , peseytyessä , pukiessa ) tai henkisen paineen alaisena (CCS luokka 3-4). CCS -luokka 2 vain 
kardiologin arvion perusteella .
•Ajoterveysvaatimukset täyttyvät , jossuorituskyky on normaali tai enintään lievästi alentunut (CCS 1-2) ja kliinisessä rasituskokeessa
todetaan normaali tai enintään lievästi alentunut suorituskyky eikä todeta sydämen hapenpuutteelle diagnostisia muutoksia eikä sen
aiheuttamia vakavia rytmihäiriöitä tai verenkierron muutoksia .
•Sepelvaltimotautikohtaus
•Ajokykyyn ja autolla -ajokiellon pituuteen on otettava kantaa potilaan kotiutuessa sairaalasta
•UAP
•ryhmät 1 ja 2 ajokielto 1 viikko
•NSTEMI ja STEMI
•Ryhmä 1: ajokielto vähintään 1 viikko
•Ryhmä 2: ajokielto vähintään 6 viikkoa
•Sepelvaltimotautikohtaus (kaypahoito.fi)
Alkuun
Ajoterveys 2/2
•Ohitusleikkauksen jälkeen ajokielto, kunnes potilas on toipunut leikkauksesta ja leikkaushaava on 
parantunut, kuitenkin:
•Ryhmä 1
•vähintään 4 viikkoa
•Ryhmä 2 ja ammattikuljettajat
•työterveyslääkärin kontrolliin asti, vähintään 6 viikkoa
•Oireisilla tarvittaessa rasituskoe
•Ohitusleikkauksen jälkeen sairausloman pituus on 2 -3 kk.
•Ammattikuljettajat tulee ottaa erityisryhmänä työterveyslääkärin kontrollissa huomioon. Haasteellisissa 
tapauksissa heitä on mahdollista ohjata Ajopolien konsultaatioon ( Helsinki, Turku, Kuopio ) .Alkuun

Työkyvyn arviointi 1/3
•Työkyvyn arvioinnissa tarvitaan erikoissairaanhoidon spesifistä osaamista lisätutkimuksineen ja 
työterveyshuollon tuntemusta työolosuhteista .
•Anamnestinen haastattelu on hyvin oleellinen . Suoriutuminen tasamaakävelystä , ylämäessä tai portaissa
noususta ja päivittäisistä toiminnoista kuvaa toimintakykyä .
•Suoriutumista arvioidaan CCS -luokituksella , ks. taulukko 3.
•Perustutkimus on kliininen , työjohteinen ja oirerajoitteinen kliininen rasituskoe , jota täydennetään
tarvittavin tutkimuksin . Vaihtoehtoisesti voidaan käyttää kävelymattotestiä tai yläraajaergometriaa .
•6 minuutin kävelytesti on käyttökelpoinen erityisesti voinnin arvioimisen ja liikunnallisen kuntoutuksen
suunnittelun osana sekä potilaan rohkaisemisessa liikkumiseen .
•Työkyvyn arvioimiseksi kliinisessä rasituskokeessa kokonaissuorituskyky ilmoitetaan tavallisimmin 3–4 
viimeisen rasitusminuutin työn keskiarvona (W), joka suhteutetaan iänja koon mukaiseen viitearvoon .
•Metabolisten ekvivalenttien (MET) käyttö selkeyttää työn ja aineenvaihdunnallisen kuormittavuuden välistä
vertailua . Työtehtävistä ja ammateista on valmiina MET-tasoina kuvattuja kuormittavuustuloksia (ks. 
lisätietoa 3).
•Työssä käyviltä on tärkeää selvittää arjessa pärjäämisen lisäksi selviytymistä tyypillisistä työtehtävistä .
•Psyykkinen tilanne ja henkinen stressi voivat heikentää sopeutumista kuormittaviin tilanteisiin.
•Sepelvaltimotautipotilaiden työ -ja toimintakykyyn vaikuttavat merkittävästi sairauden komplikaatiot, 
kuten rytmihäiriöalttius tai sydämen vajaatoiminta
Alkuun
Työkyvyn arviointi 2/3
•Työterveyshuollossa seurataan ja tuetaan potilaan työkykyä.
•Työtä on joskus mahdollista muokata voinnin huonontuessa yhteistyössä työnantajan kanssa. Tästä 
huolimatta sairauspoissaolo on joskus tarpeen.
•Jos sairausloma pitkittyy yli 90 päivän, potilaalla on velvollisuus toimittaa Kelaan työterveyshuollossa 
laadittava selvitys työhön paluun mahdollisuuksista. Muuten sairauspäivärahan maksaminen Kelasta päättyy.
•Osasairauspäivärahalla voidaan tukea työhön palaamista määräaikaisella 40 –60-prosenttisella työajalla.
•Työeläkevakuuttaja tai Kela voi tukea entiseen tai uuteen työhön paluuta ammatillisena kuntoutuksena 
työkokeilulla.
•Uudelleenkoulutus tai elinkeinotuki ammatillisena kuntoutuksena voi myös olla mahdollista, ellei paluu entiseen 
työhön onnistu.
•Työhön paluuta tukevat interventiot saattavat hyödyttää työhön paluuta 6 kuukauteen saakka, mutta ei sen 
jälkeen 110. Kansainvälisessä katsauksessa oli mukana myös psykologisia interventioita, mutta toisaalta työhön ei 
tutkimuksissa ollut tehty muutoksia.
•Työhön paluuta tukeviin toimiin tulee kiinnittää huomiota.
•Suomalaisessa tutkimuksessa 111todettiin, että jopa 27 % alle 50 -vuotiaista jää työkyvyttömyyseläkkeelle 
vuoden kuluttua sairastumisesta.
•Preventioon on hyvä kiinnittää huomiota.
•Huono sosioekonominen asema yhdistettynä sydänsairauteen aiheuttaa
Alkuun
Työkyvyn arviointi 3/3
Alkuun
B-lausunto sepelvaltimotautilääkkeiden erityiskorvattavuudesta
•Diagnoosikoodit: I20 –I22, I24.0, I25
•Kroonisen sepelvaltimotaudin osoittavan lausunnon edellytetään perustuvan erikoissairaanhoidon 
sisätautien tai kardiologian yksikössä suoritettuun tutkimukseen. Tapauksissa, joissa kroonisen 
sepelvaltimotaudin oireet ja löydökset ovat kiistattomat ja selkeät, voidaan hyväksyä myös muun, potilasta 
pitkäaikaisesti hoitavan lääkärin tutkimukseen perustuva lausunto, jos erikoissairaanhoidon tutkimukseen ei 
ole hoidollista tarvetta eikä sellaista ole vaikeudetta saatavissa.
•Oikeus erityiskorvattavaan lääkehoitoon voidaan myöntää seuraavin perustein:
•Potilaan selvä angina pectoris -oire on kliinisen tutkimuksen perusteella tulkittavissa krooniseksi, ja se reagoi 
lääkehoidolle. Jos lepo -ekg ei anna riittävää osoitusta sepelvaltimotaudin olemassaolosta (esim. infarktiarpi), 
diagnoosi tulee varmentaa esimerkiksi kliinisellä rasituskokeella.
•Potilas on sairastanut sydäninfarktin tai hänelle on tehty sepelvaltimo -ohitusleikkaus tai pallolaajennus
•Potilaalla on rintakipuoireen lisäksi asianmukaisessa kuvantamistutkimuksessa (kuten esimerkiksi 
varjoainetutkimuksessa, rasitusultraäänikuvauksessa, sydänlihaksen perfuusion gammakuvauksessa tai 
sepelvaltimoiden TT -tutkimuksessa) osoitettu merkittävä ahtauma sepelvaltimoissa .
•Huom ! Sepelvaltimoiden TT -tutkimuksessa todettu seinämäkalkkeuma ilman merkittävää ahtaumaa ei 
oikeuta KELA:n kriteerien mukaan sepelvaltimotautilääkityksen erityiskorvattavuuteen
•Linkki KELA:n sivuille https://www.kela.fi/laake206
Alkuun
Omasuuntiman asiakkuuspolut
Verkostoasiakkuus
Asiakkaan voimavarat heikot, 
monitahoinen ja haasteellinen hoito.Yhteisöasiakkuus
Asiakkaan voimavarat heikot, 
hoidontoteutus selkeä.
Yhteistyöasiakkuus
Asiakkaan voimavarat hyvät, 
monitahoinen ja haasteellinen hoito.Omatoimiasiakkuus
Asiakkaan voimavarat hyvät, 
hoidontoteutus selkeä.
Lisätietoa:
Tietoa Omasuuntimasta Pirhan verkkosivuilla
Tutustu Omasuuntimaan
Yhteenveto asiakkuuspoluista

Omatoimiasiakkuus
Asiakkuuden kuvaus Potilaalla hyvät voimavarat, selkeä hoidon toteutus
Suunnittelun 
painopiste•Ohjauspoliklinikka
•Sydänvalmennus
•Omahoitoon sitoutuminen
•Omahoitosuunnitelma
•OmaSydän -etäseurantapalvelu
•Kuntoutusohjaus
Hoidon ja palvelujen 
koordinaattori•Potilas itse
•Ammattilainen ohjaa tiedon äärelle, on käytettävissä tarvittaessa
Ajanvaraus•Ohjauspolikäynti ( sh+ft ): osastonsihteeri varaa, ohjauspoliklinikan kriteerit
•OmaSydän –etäseurantapalvelun kautta
Yhteydenpitokeinot•OmaSydän -chat
•Sähköinen hoitokeskustelu ( OmaPirha )
Vastaanotto -
vaihtoehdot•OmaSydän -etäseurantapalvelu
•Ohjauspoliklinikka (mikäli täyttää kriteerit)
•Kuntoutusohjaus
•Työterveyshuollon kontrollit tarvittaessaAlkuun
Yhteistyöasiakkuus
Asiakkuuden kuvaus Potilaalla hyvät voimavarat, hoito monitahoista ja haasteellista
Suunnittelun 
painopiste•Ohjauspoliklinikka
•Sydänvalmennus
•Omahoitoon sitoutuminen
•Omahoitosuunnitelma
•OmaSydän -etäseurantapalvelu
•Kuntoutusohjaus
Hoidon ja palvelujen 
koordinaattori•Kotiutushoitaja
•Moniammatillinen tiimi auttaa valitsemaan ja osallistuu koordinointiin eri sairaudet huomioiden
Ajanvaraus•Ohjauspolikäynti ( sh+ft ): osastonsihteeri varaa, ohjauspoliklinikan kriteerit
•OmaSydän –etäseurantapalvelun kautta
•Mahdolliset muut ajanvaraukset tarvittaessa ammattilaisen tuella
Yhteydenpitokeinot•OmaSydän -chat
•Sähköinen hoitokeskustelu (OmaPirha)
•Ammattilaisen varaamat seurantakäynnit
Vastaanotto -
vaihtoehdot•OmaSydän -etäseurantapalvelu
•Ohjauspoliklinikka (mikäli täyttää kriteerit)
•Pirhan / työterveyshuollon kontrollit, osalle kardiologin vastaanotto tai sisätautipoliklinikka
•KuntoutusohjausAlkuun
Yhteisöasiakkuus
Asiakkuuden kuvausPotilaan voimavarat heikot, hoidon toteutus selkeä
Suunnittelun 
painopiste•Ohjauspoliklinikka
•Sydänvalmennus ,tarvittaessa tehostettuna
•Omahoitoon sitoutuminen
•Kuntoutusohjaus
•Omahoito suunnitelma , hoitoneuvottelu tarvittaessa
Hoidon ja palvelujen 
koordinaattori•Kotiutushoitaja
•Moniammatillinen tiimi opastaa konkreettisesti palveluun (esim. varaa ajan), seuraa ja kannustaa
Ajanvaraus•Ohjauspolikäynti ( sh+ft ): osastonsihteeri varaa, ohjauspoliklinikan kriteerit
•Mahdolliset muut ajanvaraukset ammattilaisen tuella
Yhteydenpitokeinot•Ennakoiva yhteydenpito (esim. puhelimitse)
•Ammattilaisen varaamat seurantakäynnit
Vastaanotto -
vaihtoehdot•Ohjauspoliklinikka (mikäli täyttää kriteerit)
•Pirhan / työterveyshuollon vastaanotot
•Kuntoutusohjaus
•OmaSydän -etäseurantapalvelu soveltuville asiakkailleAlkuun

Verkostoasiakkuus
Potilaan voimavarat heikot, monitahoinen ja haasteellinen hoito
Suunnittelun 
painopiste•Ohjauspoliklinikka
•Moniammatillinen yhteistyö
•Läheisten kanssa yhteistyö
•Tehostettu Sydänvalmennus
•Kuntoutusohjaus
•Omahoitoon sitoutuminen
•Omahoito suunnitelma, hoitoneuvottelu tarvittaessa
Hoidon ja palvelujen 
koordinaattori•Nimetty koordinaattori
•Kotiutushoitaja
•Kotihoito
•Moniammatillinen tiimi räätälöi palvelut, on tukena läheisille ja muille ammattilaisille
Ajanvaraus•Ohjauspolikäynti ( sh+ft ): osastonsihteeri varaa, ohjauspoliklinikan kriteerit
•Muut ajanvaraukset ammattilaisen tuella
Yhteydenpitokeinot•Kutsutaan ammattilaisen varaamille seurantakäynneille
•Ennakoiva yhteydenpito
•Kotihoidon ja omaisten rooli korostunut
Vastaanotto -
vaihtoehdot•Ohjauspoliklinikka (mikäli täyttää kriteerit)
•Pirhan / työterveyshuollon vastaanotot, osalle kardiologin vastaanotto tai sisätautipoliklinikka
•Kuntoutusohjaus
•Vastaanottokäynti läheisen / saattajan saattamana tarvittaessaAlkuun
Tavoite :
•OmaSydän etäseurantapalvelun aktiivinen käyttö
•Työ-ja toimintakyvyn säilyminen
•Potilaan osaamisen hyödyntäminen, vastaanottokäyntien tilalle 
muita paremmin potilaalle sopivia tuki -ja yhteydenpitokeinoja
•Sekundaariprevention varmistaminenTavoite :
•OmaSydän etäseurantapalvelun käyttö
•Työ-ja toimintakyvyn paraneminen
•Tehokkaampi yhteistyö ja tiedonkulku ammattilaisten 
kesken, uusia yhteisiä palveluita
•Sekundaariprevention varmistaminen
Tavoite :
•Toimintakyvyn ja omatoimisuuden tukeminen
•Potilaan osaamisen lisääntyminen, 
voimaantuminen ja motivoituminen
•OmaSydän etäseurantapalvelun käyttöä voi 
harkita
•Sekundaariprevention varmistaminenTavoite :
•Pärjäämisen tukeminen
•Ammattilaisten selkeä koordinaatiovastuun 
määrittäminen ja kantaminen
•Hoidon toteutumisen ja jatkuvuuden turvaaminen
•Sekundaariprevention varmistaminenPotilaalla hyvät voimavarat, selkeä 
hoidon toteutusPotilaalla hyvät voimavarat, hoito 
monitahoista ja haasteellista
Potilaalla hyvät voimavarat, selkeä hoidon toteutus
Potilaan voimavarat heikot, 
monitahoinen ja haasteellinen hoitoPotilaan voimavarat heikot, 
hoidon toteutus selkeääOmahoitoon 
sitouttaminenOmahoitoon 
sitouttaminen
Omahoitoon 
sitouttaminenOmahoitoon 
sitouttaminenTukea ajanvarauksiin
Ennakoivaa yhteydenpitoa
Tehostettu SydänvalmennusTukea ajanvarauksiin tarvittaessa
SydänvalmennusPotilas varaa itse kontrollit / 
OmaSydän etäseurantapalvelu
Sydänvalmennus SydänvalmennusTukea ajanvarauksiin tarvittaessa 
/ OmaSydän etäseurantapalvelu
Ammattilainen ohjaa tiedon 
äärelleAmmattilainen ohjaa tiedon äärelle ja 
auttaa koordinoimaan hoitoa
Ammattilainen opastaa 
konkreettisesti tiedon äärelle ja 
auttaa koordinoimaan hoitoaAmmattilainen räätälöi palvelut 
ja koordinoi hoitoaKotihoidon ja omaisten 
rooli korostunut
Hoitoneuvottelu 
tarvittaessaOmaSuuntimaAlkuun
Ohjauspoliklinikka
kaikille , jotka
täyttävät kriteerit
Sydämen isotooppitutkimus ja PET-kuvaus - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/
Sydämen isotooppitutkimus ja PET-kuvaus
Sydämen isotooppitutkimus ja PET-kuvaus
(https://sydan.fi/fakta/sydamen-
isotooppitutkimus-ja-pet-kuvaus/)
Sydämen isotooppitutkimusta käytetään eräissä erityistilanteissa
sepelvaltimotaudin tutkimisessa. PET-kuvausta käytetään tämän lisäksi
eräiden tulehduksellisten sairauksien, kuten sydänsarkoidoosin ja
tekoläppätulehduksen tutkimisessa.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 25.1.2024
 
Lue seuraavaksi Elektrofysiologinen tutkimus (https://sydan.fi/fakta/elektrofysiologinen-tutkimus/)
 
Sydämen isotooppitutkimus
Tutkimuksesta käytetään myös nimeä sydänlihasperfuusion gammakuvaus tai
SPECT ( ).
Tutkimuksessa annetaan merkkiainetta pinnalliseen laskimoon asetetun kanyylin
kautta. Tarkoituksena on selvittää, miten merkkiaine jakautuu sydämessä
rasituksen aikana. Erityisellä kuvauslaitteistolla otetaan kuvaukset lepo- ja
rasitusvaiheissa.
Rasituskoe on yleensä tavanomainen rasituskoe polkupyöräergometrilla
(https://sydan.fi/fakta/rasituskoe/). Merkkiaine ruiskutetaan laskimoon noin 1-2
minuuttia ennen polkemisvaiheen päättymistä.
Jos polkeminen ei onnistu jostain syystä, esimerkiksi liikuntaelinsairauden vuoksi,
kuvaus voidaan tehdä myös farmakologisena. Silloin käytetään lääkeainetta,
joka lisää sepelvaltimovirtausta moninkertaisesti, ja mahdolliset virtausta
rajoittavat ahtaumat paljastuvat. Tutkimusohjeisiin kuuluu välttää
kofeiinipitoisia juomia vähintään 12 tunnin ajan, varalta jos fyysinen rasituskoe
joudutaan korvaamaan lääkerasituksella.
Milloin tätä tutkimusta tarvitaan?
Isotooppikuvausta käytetään sepelvaltimotaudin
(https://sydan.fi/sydantietoa/sydansairaudet/sepelvaltimotauti/) tutkimisessa,
kun sepelvaltimotauti voisi runsaiden valtimotaudin riskitekijöiden perusteella
olla mahdollinen, mutta muut tutkimusmenetelmät eivät sovellu. Jos esimerkiksi
EKG:ssä on tahdistinrytmi tai vasen haarakatkos (LBBB), sydämen hapenpuutetta
eli iskemiaa ei pysty tavallisessa rasituskokeessa tulkitsemaan. Jos potilaalla on
vaikea munuaisten vajaatoiminta, varjoainetta vaativat tutkimukset kuten
sepelvaltimoiden tietokonekuvaus (https://sydan.fi/fakta/sepelvaltimoiden-ja-
sydamen-tietokonetomografia/) tai angiografia eivät tule ensimmäisenä
kyseeseen.
Isotooppitutkimuksessa nähdään, onko sydänlihaksessa alueita, joiden
verenkierto on vaarassa valtimoahtauman vuoksi. Kuvauksessa nähdään myös
sydänlihaksn arpialueet, eli kohdat, jotka eivät enää toivu, vaikka alueelle
palautettaisiin verenkierto pallolaajennuksella.engl. single photon emission computed tomographyLue seuraavaksi Elektrofysiologinen tutkimus (https://sydan.fi/fakta/elektrofysiologinen-tutkimus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Isotooppikuvausta käytetään siksi usein muiden tutkimusten lisänä, kun
pohditaan vaikkapa angiografiassa löytyneen ahtauman merkitystä sydämen
verenkierrolle.
Sydämen PET-tutkimus
Positroniemissiotomografia eli PET-kuvaus tutkii sydämen verenkiertoa, kuten
isotooppikuvauksin. Sitä käytetään tutkittaessa sepelvaltimokaventumien
merkitystä, tai sydänlihaksen mahdollisia arpialueita.
Menetelmää käytetään myös sydänsarkoidoosiin liittyvän tulehduksen
toteamisessa, sekä sen aktiviteetin seurannassa. Tutkimusta voidaan käyttää
lisäselvityksenä epäiltäessä tahdistimen tai sydämen tekoläpän infektiota.
Tutkimukseen valmistautuminen on samankaltaista kuin sydämen
isotooppikuvauksessa. Rasitus on farmakologinen. Kuvaukseen
valmistautumiseen liittyy kuitenkin vielä muita tärkeitä ohjeita, jotka riippuvat
kysymyksenasettelusta, eli siitä mitä kuvauksella halutaan erityisesti selvittää.
Kun tutkitaan elossa olevan sydänlihaksen tilannetta, tarvitaan glukoosirasitus.
Jos taas tutkitaan tulehdusaktiviteettia, tutkimus tehdään paastossa ja erityisen
vähähiilihydraattisen dieetin jälkeen. Tutkimuspaikka antaa potilaalle tarkat
ohjeet tutkimukseen valmistautumisesta.
Hybridikuvantaminen
Hybridikuvantamisella tarkoitetaan kahden kuvantamismenetelmän
yhdistämistä. Kun yhdistetään PET-kuvaus ja sepelvaltimoiden tietokonekuvaus,
saadaan nopeasti käsitys, miten tietokonekuvauksessa todetut kaventumat
oikeasti vaikuttavat sydämen verenkiertoon. Jos tietokonekuvauksessa todetaan
kaventuma, mutta PET-kuvauksen perusteella alueen verenvirtaus on hyvää,
kaventumaa ei tarvitse hoitaa pallolaajennuksella.Lue seuraavaksi Elektrofysiologinen tutkimus (https://sydan.fi/fakta/elektrofysiologinen-tutkimus/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sydämen rakenne - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Vanha tuttu sepelvaltimotauti - mitä uutta näköpiirissä? Tule verkkoluennolle 29.4.
(https://video.sydan.fi/vanha-tuttu-sepelvaltimotauti)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/
Sydänsairauksien tutkimukset (https://sydan.fi/sydansairaudet/sydansairauksien-tutkimukset/)/
Sydämen rakenne
Sydämen rakenne
Sydän on lihaspumppu, joka muodostuu neljästä lokerosta: kahdesta
eteisestä ja kahdesta kammiosta.
Sydän ja suuret verisuonet. 1 yläonttolaskimo, 2 alaonttolaskimo, 3 oikea eteinen, 4 kolmiliuskaläppä,
5 oikea kammio, 6 keuhkovaltimon läppä, 7 keuhkovaltimo, 8 vasen eteinen, 9 hiippaläppä, 10 vasen
kammio, 11 aorttaläppä, 12 aortta.
Mikko Syvänne ja Anna-Mari Hekkala
Julkaistu 31.8.2018
Päivitetty 1.8.2019
 
Sydänlihas koostuu säikeistä, jotka ovat järjestäytyneet rinnakkain ja peräkkäin.
Säikeiden rytminen lyheneminen ja piteneminen saavat aikaan sydämen
pumppausliikkeen.Lue seuraavaksi Usein kysyttyä kohonneesta verenpaineesta (https://sydan.fi/fakta/usein-kysyttya-kohonneesta-
verenpaineesta/)

Eteiset ja kammiot
Eteiset ottavat vastaan sydämeen tulevan veren ja toimittavat sen kammioihin
eteenpäin pumpattavaksi.
Veri virtaa sydäntä kohden laskimoita pitkin. Kehon yläosista tulevat laskimot
yhtyvät yläonttolaskimoksi, joka laskee oikean eteisen yläosaan. Kehon alaosista
ja sisäelimistä tulevat laskimot laskevat oikean eteisen alaosaan. Oikeasta
eteisestä veri kulkee edelleen oikeaan kammioon, joka pumppaa sen
keuhkovaltimoiden kautta keuhkojen hiussuoniin. Niissä veri luovuttaa
aineenvaihdunnassa kertyneen hiilidioksidin ja täydentää kuluneet
happivarantonsa (pieni verenkierto).
Happeutunut veri kulkee keuhkolaskimoita myöten vasempaan eteiseen ja sieltä
vasempaan kammioon, joka pumppaa veren aortan kautta muualle elimistöön
paitsi keuhkoihin (iso verenkierto),
Eteiset (lat. ja engl. ) ovat ohutseinäisiä, mutta seinämissä on aktiivisesti
supistuvaa lihaskudosta, joka auttaa kammioiden täyttymisessä ja tehostaa
sydämen pumppausvoimaa. Eteiset erottaa toisistaan väliseinä eli septum (engl.
). Sikiökaudella eteisväliseinässä on aukko, jonka kautta veri ohittaa
keuhkot. Syntymän jälkeen keuhkoverenkierron käynnistyttyä aukko sulkeutuu
ja sen kohdalle jää pieni kuoppa nimeltään soikea ikkuna (lat. ).
Noin joka neljännellä aukko sulkeutuu vain toiminnallisesti (eli sen kautta ei
normaalisti virtaa verta) läppärakenteella, jonka vasemman eteisen korkeampi
paine pitää suljettuna.
Kummassakin eteisessä on umpipussimainen uloke, jota kutsutaan
eteiskorvakkeeksi.
Kammiot (lat. , engl. ) tekevät sydämen varsinaisen
pumppaustyön, jonka perusteella määritetään sydämen toimintavaiheet,
systole ja diastole. Oikea kammio on pienempi ja ohutseinäisempi, koska se
pumppaa verta keuhkovaltimoon, jonka normaali paine on korkeintaan 30/15
elohopeamillimetriä (mmHg). Vasen kammio tarvitsee suuremman koon ja
paksumman seinämän pumpatakseen verta eri puolille elimistöä valtimoiden
kautta, joiden paine on 120/80 mmHg. Oikean ja vasemman kammion välissä
olevaa sydänlihaksen osaa kutsutaan kammioväliseinäksi (engl. 
).
Läpät
Läpät ohjaavat veren oikeaan suuntaan.atrium
atrial septum
 foramen ovale
ventriculus ventricle
ventricular
septumLue seuraavaksi Usein kysyttyä kohonneesta verenpaineesta (https://sydan.fi/fakta/usein-kysyttya-kohonneesta-
verenpaineesta/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)

Sydämessä on neljä läppää huolehtimassa veren oikeasta kulkusuunnasta
toiminnan eri vaiheissa:
kolmiliuska- eli trikuspidaaliläppä oikean eteisen ja kammion välissä
keuhkovaltimo- eli pulmonaaliläppä oikean kammion ja keuhkovaltimon
välissä
hiippa- eli mitraaliläppä vasemman eteisen ja kammion välissä
aorttaläppä vasemman kammion ja aortan välissä.
Keuhkovaltimo- ja aorttaläpässä on kolme puolikuun muotoista läppäpurjetta
(niistä käytetään joskus yhteisnimitystä semilunaari- eli puolikuuläpät). Eteis-
kammioläpät ovat rakenteeltaan keskenään samanlaiset, paitsi että oikean
puolen läpässä on kolme ja vasemman puolen läpässä kaksi läppäpurjetta.
Läppäpurjeisiin kiinnittyvät ohuet läppäjänteet (kordat), jotka jännittyvät läpän
sulkeutuessa ja estävät sitä retkahtamasta eteisen puolelle. Läppäjänteet
kiinnittyvät kammion seinämään nysty- eli papillaarilihasten välityksellä.
Läppäpurjeiden tyvet kiinnittyvät sidekudoksiseen renkaaseen (lat. ja engl.
).
Sydänpussi
Sydänpussi ympäröi sydäntä.
Sydänpussi (lat. ja engl. ) on sydäntä ympäröivä sidekudoksinen
kalvo. Se koostuu sisä- ja ulkolehdestä. Lehtien välissä on normaalisti pieni määrä
kudosnestettä voiteluaineena. Sairaustiloissa nesteen määrä voi huomattavasti
lisääntyä.
Sepelvaltimot
Sepelvaltimot kulkevat sydämen ulkopinnalla ja vievät verta sydänlihakselle.
Sepelvaltimot lähtevät aortan tyvestä heti aorttaläpän yläpuolelta. Seuraavassa
esitetään tärkeimpien sepelvaltimohaarojen suomenkieliset nimet ja niiden
yleisesti käytetyt, englanninkieleen perustuvat lyhenteet.
Vasen sepelvaltimo lähtee lyhyellä yhteisellä haaralla (vasen tyvihaara, LM). Sitä
on kutsuttu leskentekijäksi, koska sen ahtautuessa ennuste ilman hoitoa on
huono. Vasemman kammion etupintaa pitkin kulkee eteen laskeva haara (LAD),
joka usein jaetaan a-, b- ja c-osiin tärkeimpien sivuhaarojen kohdilta. LADa on
tämän haaran tyviosana erittäin tärkeä, koska se ruokkii suurta osaa
vasemmasta kammiosta. LAD:n vasemman kammion sivuseinään suuntautuvia
sivuhaaroja kutsutaan diagonaaleiksi (LD tai D), vastakkaiseen suuntaan
kammioiden väliseinää (lat. ja engl. ) ruokkivia haaroja septaalihaaroiksi.annulus
pericardium
septumLue seuraavaksi Usein kysyttyä kohonneesta verenpaineesta (https://sydan.fi/fakta/usein-kysyttya-kohonneesta-
verenpaineesta/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)

Toinen vasemmasta tyvihaarasta lähtevä suoni on kiertävä haara (LCx tai Cx). Se
ja sen tärkeä sivuhaara, LOM tai OM, suonittavat vasemman kammion
sivuseinämää.
Oikea sepelvaltimo (RCA) lähtee aortan vastakkaiselta puolelta. Sen sivuhaaroja
ovat oikean kammion haara (RV) ja RAM-haara, jotka ruokkivat oikeaa
kammiota. RCA kiertyy sydämen alapinnalle, jossa se jakautuu päätehaaroihinsa:
taakse laskeva haara (RPD tai PD) ja taka-sivuhaara (RPL tai PL). Nämä haarat
suonittavat vasemman kammion taka-, ala- ja sivuseinämää. PD-haarasta
lähteen myös septaalihaaroja kammioväliseinän takaosaan.
Normaalien sepelvaltimoiden suonitusalueet vaihtelevat yksilöllisesti. LM ja LAD
ovat aina tärkeitä suonia. Sitä vastoin LCx:n ja RCA:n kokosuhde vaihtelee:
puhutaan jommankumman dominanssista eli vallitsevuudesta. Tämä merkitsee
yksinkertaisesti sitä, että 85 %:lla ihmisistä PD- ja PL-haarat tulevat RCA:sta,
lopuilla 15 %:lla LCx:stä tai sekä RCA:sta että LCx:stä tasapainoisesti.
Pienikokoista RCA:ta kutsutaan joskus hypoplastiseksi, mikä on
normaalivaihteluun kuuluva yksilöllinen ominaisuus, ei poikkeavuus.Lue seuraavaksi Usein kysyttyä kohonneesta verenpaineesta (https://sydan.fi/fakta/usein-kysyttya-kohonneesta-
verenpaineesta/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sydämen rakenne ja toiminta - Sydänsairaala.pdf
Sydämen rakenne ja toiminta
11.12.2018
Sydämen eri osilla on omat tehtävänsä veren kuljettamisessa ja
hapettamisessa
Ihmisen sydän on noin nyrkin kokoinen elin, joka sijaitsee rintalastan ja
kylkiluiden muodostaman panssarin sisällä suojassa ulkoisilta
kolhuilta. Sydämen tehtävä on ylläpitää verenkiertoa pumppaamalla
verta eteenpäin. Sydänlihassolut kykenevät tuottamaan spontaanin
sähköimpulssin ja tähän sähköiseen toimintaan perustuu sydämen
pumppaustoiminta.
Sydämen sähköistä toimintaa voidaan mitata sydänsähkökäyrällä eli
EKG:llä. EKG:ssä todettavat sydämen sähköisen toiminnan muutokset
ovat yksi tärkeimmistä keinoista diagnostisoida erilaisia
sydänsairauksia.
Sydämen neljä lokeroa
Sydämessä on neljä lokeroa: oikea eteinen ja oikea kammio sekä
vasen eteinen ja vasen kammio. Vähähappinen veri valuu laskimoista
sydämen oikeaan eteiseen, josta se pääsee oikeaan kammioon. Oikea
kammio pumppaa vähähappisen veren keuhkoihin, jossa se kulkee
hyvin ohuita hiussuonia pitkin. Hiussuonien ohuiden seinämien kautta
punasoluihin pääsee imeytymään hengityksen kautta keuhkoihin
tullutta happea. Tällä tavalla hapeton laskimoveri muuttuu
hapekkaaksi valtimovereksi.
Valtimoveri kulkeutuu sydämen vasempaan eteiseen
keuhkolaskimoiden kautta. Vasemmasta eteisestä valtimoveri valuu
vasempaan kammioon, joka pumppaa sen eteenpäin ensin aorttaan eliJaa sivu:
(http://www.facebook.com/sharer/sharer.php?
u=https://www.sydansairaala.fi/tietoa/asiantunti
artikkelit/sydamen-rakenne-ja-toiminta/)
(http://twitter.com/share?
url=https://www.sydansairaala.fi/tietoa/asiantun
artikkelit/sydamen-rakenne-ja-
toiminta/&text=Sydämen rakenne ja
toiminta)
(http://www.linkedin.com/shareArticle?
url=https://www.sydansairaala.fi/tietoa/asiantun
artikkelit/sydamen-rakenne-ja-
toiminta/&title=Sydämen rakenne ja
toiminta&summary=Sydämen eri osilla on
omat tehtävänsä veren kuljettamisessa ja
hapettamisessa Ihmisen sydän on noin
nyrkin kokoinen elin, joka sijaitsee
rintalastan ja kylkiluiden muodostaman
panssarin sisällä suojassa ulkoisilta
kolhuilta. Sydämen tehtävä…
&source=https://www.sydansairaala.fi/tietoa/asi
artikkelit/sydamen-rakenne-ja-toiminta/)
(mailto:?subject=Sydämen rakenne
ja
toiminta&body=https://www.sydansairaala.fi/tiet
artikkelit/sydamen-rakenne-ja-toiminta/)(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
elimistön isoimpaan verisuoneen. Aortasta lähtee taas useita
pienempiä valtimoverisuonia, joiden kautta veri kulkee vieden happea
ja ravintoaineita elimistölle.
Sydämen neljä läppää
Veren virtauksen oikean suunnan sydämen pumppaustoiminnan eri
vaiheissa mahdollistavat sydämen eri lokeroiden välillä olevat neljä
erilaista läppärakennetta. Oikean kammion ja eteisen välillä on oikea
eteis-kammioläppä eli trikuspidaaliläppä ja oikean kammion ja
keuhkojen välillä on keuhkovaltimoläppä eli pulmonaaliläppä.
Vasemman puolen eteis-kammioläppä on nimeltään mitraaliläppä
(hiippaläppä) ja vasemman kammion ja aortan välillä oleva läppä on
aorttaläppä.
Sydämen eri läppiin voi kehittyä läppävika, jolloin läppärakenne joko
ahtautuu tai alkaa vuotaa. Ahtautunut läppä vaikeuttaa veren pääsyä
eteenpäin sydämessä. Vuotava läppä taas antaa veren valua takaisin
päin verenkierrossa vähentäen näin eteenpäin kulkevan veren määrää.
Sepel val timot
Sydämen omasta verenkierrosta huolehtivat sepelvaltimot eli
koronaarit. Ne lähtevät aortasta heti aorttaläpän yläpuolelta, kiertävät
sydämen pinnalla ja haarautuvat tiheäksi pienten verisuonten
verkostoksi. Suurimmillaan sepelvaltimoiden läpimitta on 3–5mm.
Läpimitta pienenee asteittain ja siihen vaikuttaa ihmisen ikä, koko ja
mahdollinen valtimotauti.
Tavanomaisesti aortasta lähtee kaksi eri sepelvaltimoa, oikea ja vasen.
Oikean sepelvaltimon (right coronary artery, RCA) tehtävänä on viedä
verta oikealle kammiolle ja eteiselle ja sydämen alaosaan ja sen
verenkierto kattaa noin 30 % sydämestä. Vasen sepelvaltimo suorittaa
70 % sydämen verenkierrosta. Se koostuu yhteisestä päärungosta (left
main artery, LMA), kahdesta pääharasta nimeltään vasen etulaskeva
haara (left anterior descending artery, LAD) ja vasen kiertävä haara
(left circumflex artery, LCX), sekä näiden sivuhaaroista.
Sydämen raken teen ja toiminnan tutki minen
Sydämen rakennetta ja toimintaa voidaan tutkia helpoiten ja
riskittömästi sydämen ultraäänitutkimuksella (ECHO-tutkimus). Muita
tapoja ovat sydämen tietokonekerroskuvaus (CT-kuvaus) ja sydämen
magneettitutkimus (MRI), mutta näitä käytetään vain
erikoistapauksissa osana sydänsairauksien erotusdiagnostiikkaa.
Sepelvaltimoiden kulkua ja mahdollisen sepelvaltimotaudin
aiheuttamia muutoksia voidaan tutkia sepelvaltimoiden
varjoainekuvauksella tai sepelvaltimoiden tietokonekerroskuvauksella
tarvittaessa. Ajoittaisia rytmihäiriöitä tutkitaan helpoiten 24h EKG-
rekisteröinnillä (Holter-tutkimus) ja tarvittaessa tarkemmin sydämen
sähköistä toimintaa kartoittavalla, katetrisaatiolaboratoriossa
tehtävällä elektrofysiologisella tutkimuksella.
Teksti: Essi Ryödi, LT, sisätautien ja kardiologian erikoislääkäri, Tays
Sydänsairaala(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Sydän ja seksi - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Oletko kiinnostunut toimimaan vapaaehtoisena? Lue lisää Sydänliiton vapaaehtoistoiminnasta.
(https://sydan.fi/tule-mukaan/tule-vapaaehtoiseksi/)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Parisuhde (https://sydan.fi/elamaa-sairauden-kanssa/parisuhde/)/Sydän ja seksi
Sydän ja seksi (https://sydan.fi/fakta/sydan-
ja-seksi/)
Seksuaalisuudessa yhdistyvät ihmiselämän eri puolet; keho ja mieli,
ihmissuhteet, kokemukset ja  unelmat. Se muuttaa muotoa iän ja
elämänkokemusten, kuten rakastumisen, eron tai sairauden myötä.Luet tällä hetkellä Sydän ja seksi Lue seuraavaksi Sairastuminen voi tuoda kriisin
parisuhteeseen (https://sydan.fi/artikkeli/sairastuminen-voi-
tuoda-kriisin-parisuhteeseen/)

Päivi Liippola
Julkaistu 22.11.2018
Päivitetty 19.4.2021Jaa sivu 
Seksi liittyy kaikkeen siihen psyykkiseen ja fyysiseen toimintaan, jonka avulla
haetaan seksuaalista mielihyvää. Sydämen sairaus aiheuttaa muutoksia
seksuaalisuuden kokemukseen. Sydänsairauden yhteydessä on tärkeä puhua
seksistä ja sen jatkamisesta.Luet tällä hetkellä Sydän ja seksi Lue seuraavaksi Sairastuminen voi tuoda kriisin
parisuhteeseen (https://sydan.fi/artikkeli/sairastuminen-voi-
tuoda-kriisin-parisuhteeseen/)

Tulipa sydämen sairaus hiipien tai yllättäen, se aiheuttaa muutoksia myös
seksuaalisuuden kokemukseen.
Muutokset omassa kehossa ja sen toiminnassa, tuntemuksissa ja jaksamisessa
voivat tuntua uhkaavilta, parisuhteen ilmapiiri voi olla pelokas ja huolestunut,
tulevaisuus tuntuu karanneen näkymättömiin. Seksi voi tuntua hyvin pelottavalta
ja etäiseltä asialta. Osa sairastuneista toki jatkaa seksielämää sairauden ja sen
hoitojen jälkeen aiempaan tapaan.  Useimpia sydänpotilaita ja heidän
kumppaneitaan seksin sujuminen vähintäänkin huolettaa.
Sairastuminen vaikuttaa seksielämään
Seksitapahtuma on verenkierron, hermoston ja hormonitoiminnan
yhteistoimintaa. Sydänsairaus vaikuttaa  heikentyneen valtimoterveyden ja/tai
verenkiertohäiriöiden kautta monella tavalla sairastuneen seksielämään.
Seksuaalisen aktiivisuuden on huomattu olevan vähäisempää varsinkin, jos
diagnoosin saamisesta on alle neljä vuotta.  Valtaosalla eli 60-90 prosentilla
sepelvaltimotautipotilaista, sydäninfarktin saaneista tai kroonista sydänsairautta
sairastavista on seksuaalihäiriöitä.
Miesten huolena useimmiten on seksuaalisen halukkuuden väheneminen sekä
erektion kehittymisen ja ylläpysymisen vaikeus. Erektio on miehen
seksuaalisuuskokemukselle niin tärkeä, että sen puuttuminen voi lopettaa parinLuet tällä hetkellä Sydän ja seksi Lue seuraavaksi Sairastuminen voi tuoda kriisin
parisuhteeseen (https://sydan.fi/artikkeli/sairastuminen-voi-
tuoda-kriisin-parisuhteeseen/)

seksielämän. Naiset kokevat myös haluttomuuden lisääntymistä sekä  emättimen
kuivuutta ja  yhdyntäkipua. Molemmilla orgasmin saaminen voi vaikeutua itse
sairaudesta tai siihen liittyvistä lääkkeistä johtuen.
Lue lisää erektiohäiriöstä (https://sydan.fi/fakta/erektiohairio-sydanpotilaalla/)
Itse sydänsairauden lisäksi seksielämään vaikuttavat monet muut tekijät, kuten
oheissairaudet, ikä, elämäntapa, mieliala ja ympäristötekijät.  Yleisesti heikentynyt
terveys, uniapnea, diabetes, väsymys ja lääkkeiden sivuvaikutukset kuormittavat
seksuaalitoimintoja. Ikääntyminen voi vaikuttaa seksuaaliseen aktiivisuuteen ja
vaihdevuodet tuovat useimmille ainakin väliaikaisen muutoksen
seksihalukkuuteen. Elintavoista tupakointi, unihäiriöt, alkoholin liikakäyttö tai
liikkumattomuus aiheuttavat seksielämän häiriöitä.
Turvallinen seksi
Sydänsairauden oireet kuten rintakipu, hengitysvaikeudet sekä väsymys voivat
vähentää seksin nautittavuutta. Moni epäilee erektiolääkkeiden turvallisuutta.
Sydäninfarktin jälkeen pitkäkestoinen lihasjännitys voi tuottaa rintakipua ja
kevyempien asentojen löytäminen on tarpeen. Sydänleikkauksen jälkeen taas
kuluu useampi kuukausi, ennen kuin halkaistu rintalasta on luutunut ja kivut
hellittäneet. Hyvä on ottaa käyttöön silloinkin kevyemmät asennot, joissa ei kehoa
tarvitse kannatella käsien varassa eikä rinnan päälle tule painoa. Kumppanilta
tarvitaan sopeutumista ja joustoa sekä luottamusta siihen, että tilanne on
turvallinen.Luet tällä hetkellä Sydän ja seksi Lue seuraavaksi Sairastuminen voi tuoda kriisin
parisuhteeseen (https://sydan.fi/artikkeli/sairastuminen-voi-
tuoda-kriisin-parisuhteeseen/)

Lue lisää sydänpotilaalle sopivista seksiasennoista (https://sydan.fi/fact/usein-
kysyttya-seksista-ja-sydansairaudesta#asennot)
Seksuaalinen kanssakäyminen voi  vähentyä, jos kokee, että sairaus rajoittaa
mahdollisuuksia toteuttaa seksielämää ja seksuaalista ilmaisua. Sairastunut ehkä
myös miettii, mitä kehossa on tapahtunut, miten se nyt reagoi, voiko siihen
luottaa myös seksitilanteessa, aiheutanko vahinkoa? Puoliso tai kumppani käy läpi
samoja pohdintoja. Epävarmuus ja pelko tulevat lähelle kumpaakin.  Joskus
yhdyntävaatimus syntyy tarpeesta todistaa, että kunnossa ollaan.
Sairastuminen on henkisesti kuluttavaa ja se aiheuttaa aina jonkinasteisen kriisin
niin sairastuneelle kuin läheisellekin. Sairauden ja sen tuomien muutosten
hyväksyminen voi viedä aikaa ja tuo ajan tarve on yksilöllinen. Surutyö
menetetystä aiemmasta on kuitenkin käytävä läpi, jotta elämä voi jatkua. Myös
parisuhteen tila voi aiheuttaa huolta. Ahdistuneisuus ja masennus vievät voimia ja
madaltavat seksihaluja.  Huoli ja hätä omasta tai toisen terveydestä ja
hyvinvoinnista kuluttavat  voimavaroja ja vaikuttavat käytökseen. Tästä kaikesta
voi kertyä iso vyyhti, joka ei itsestään aukea. Tarvitaan lohtua, apua, tukea ja
neuvoja.
Lue lisää: Milloin seksi on turvallista? (https://sydan.fi/fakta/seksi-ja-
sydansairaus/)Luet tällä hetkellä Sydän ja seksi Lue seuraavaksi Sairastuminen voi tuoda kriisin
parisuhteeseen (https://sydan.fi/artikkeli/sairastuminen-voi-
tuoda-kriisin-parisuhteeseen/)
Sydäninfarkti - Sydänsairaala.pdf
Etusivu (https://www.sydansairaala.fi)➝Tietoa (https://www.sydansairaala.fi/tietoa/)➝Sydäninfarkti
Sydä nin farkti
Mikä sydä nin farkti on?
Sydäninfarkti on sepelvaltimon tukkeutumisesta johtuva paikallinen sydänlihaskuolio, joka
syntyy, kun osa sydänlihaksesta jää sepelvaltimon tukoksen takia ilman happea ja verta.
Tukkeuman syynä on yleensä valtimon sisäseinämässä olevan kolesterolia sisältävän
pullistuman, eli plakin pinnan repeytyminen. Tällöin paikalle muodostuu verihyytymä, joka
äkisti tukkii suonen. Sydäninfarktia edeltää yleensä sepelvaltimotauti. Happeutumisen
häiriö aiheuttaa oireet, joita nimitetään sepelvaltimokohtauksiksi.
Miten sydä nin farktin tunnistaa?
Sydäninfarktin tyypillinen oire on rintakipu, joka tuntuu yleensä keskellä rintaa laaja-
alaisena tai puristavana. Kipu voi säteillä käsivarsiin, leukaperiin, selkään lapojen väliin tai
ylävatsalle ja se saattaa jatkua yhtä voimakkaana, vaikka potilas asettuu lepoon.Aihee seen liit tyvää
Rintakipu ➝
(https://www.sydansairaala.fi/tietoa/rintakipu/)
Miten pääsen hoitoon Sydänsairaalaan?  ()
Hoitopaikan valinta 
(https://www.sydansairaala.fi/hoitoon-
sydansairaalaan/hoitopaikan-valinnanvapaus/)
Jaa sivu:
(http://www.facebook.com/sharer/sharer.php?
u=https://www.sydansairaala.fi/tietoa/sydansairaudet-
sydaninfarkti/) (http://twitter.com/share?
url=https://www.sydansairaala.fi/tietoa/sydansairaudet-
sydaninfarkti/&text=Sydäninfarkti)
(http://www.linkedin.com/shareArticle?
url=https://www.sydansairaala.fi/tietoa/sydansairaudet-
sydaninfarkti/&title=Sydäninfarkti&summary=&source=https://www.sydansair
sydaninfarkti/) (mailto:?
subject=Sydäninfarkti&body=https://www.sydansairaala.fi/tietoa/sydansairau
sydaninfarkti/)➝
➝(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Potilaalla voi myös esiintyä kylmähikisyyttä, pahoinvointia, hengenahdistusta ja
voimattomuutta.
Kuolion synnyttyä sydämen sähköinen aktiviteetti alkaa horjua, ja voi syntyä rytmihäiriöitä
tai sydämen pumppaushäiriö. Tila vaikuttaa myös ääreisverenkiertoon muualla
elimistössä ja aiheuttaa veren virtauksen häiriöitä.
Miten sydä nin farktia hoide taan?
Sydäninfarktin hoidossa pyritään huolehtimaan elintärkeistä toiminnoista, kuten
hengityksestä, sydämen rytmistä ja verenpaineesta. Vakavat rytmihäiriöt pyritään
estämään ja hoitamaan. Jos sydäninfarktipotilaan hengittäminen on vaikeaa, voidaan
hänelle antaa lisähappea. Rintakipu on sydäninfarktissa ankaraa, ja hyvä kivunhoito on
siksi tärkeää. Verenpainetta ja sykettä pyritään laskemaan lääkkein.
Sydäninfarkti hoidetaan useimmiten joko liuotushoidolla tai pallonlaajennuksella.
Liuotushoitoa annetaan usein jo potilaan kotona tai ambulanssissa. Toimenpiteiden
lisäksi lääkehoitoa jatketaan pitkälle kohtauksen jälkeen.
Sydämen kuormituksen keventäminen tapahtuu huolellisella sykkeen ja verenpaineen
hoidolla, hapetuksesta ja nestetasapainosta huolehtimalla sekä mahdollisten
rytmihäiriöiden estämisellä ja hoitamisella. Kaikki sellainen hoito, joka parantaa sydämen
hapensaantia ja vähentää sydämen hapenkulutusta, pienentää lopullisen sydäninfarktin
voimakkuutta.
Sairastumisen riskiä voi vähentää elämäntavoilla. Infarktipotilaan jatkohoitoon kuuluu
sairauden kanssa elämisen opettelu, tupakoinnin lopettaminen, kolesterolia alentava
ruokavalio, liikuntaohjaus, kuntoutuskurssi ja uusien sepelvaltimokohtauksien ehkäisy.
Infarktipotilaan lääkitys tarkistetaan suositusten mukaiseksi. Sairaalassa annetaan
toimintaohjeet taudin vaikeutumisen varalle.
Milloin on syytä hakeutua lääkä riin?
Jos epäillään sydäninfarktia, nopea tilannearvio ja toiminta ovat tärkeitä, sillä oireiden alettua vaurio etenee nopeasti. Mitä suurempi sepelvaltimon haara
tukkeutuu, sitä suurempi osa sydänlihaksesta on vaarassa vaurioitua. Infarkti todetaan oireiden, sydänfilmin (EKG) ja verikokeiden avulla.(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Sydän pe räiset äkil liset oireet
Voimakkaan, äkillisen tai rasituksen yhteydessä tulevan
rintakivun syynä voi olla sepelvaltimotukos eli sydäninfarkti.
Katso video ▶
(https://player.vimeo.com/video/558422857?
texttrack=fi&rel=0&showinfo=0)
(https://www.sydansairaala.fi/)
Usein kysyttyä
(http://www.sydansairaala.fi/tietoa/usein-
kysyttya/)
Anna palautetta
(https://www.sydansairaala.fi/anna-
palautetta/)Palve lu neu vonta
Tampere 03 311 64145
Arkisin klo 7.30–15
info@sydansairaala.fi
Jos haluat perua ajan tai sinulla on
kysyttävää hoitoosi liittyen, ota yhteyttä
puhelimitse sinua hoitavaan yksikköön.Yksityisvastaanottojen
ajanvaraus ja tiedustelut
Tampere p. 050 573 6875
ma–to klo 11–18, pe klo 11–15
Jyväskylä p. 041 731 3712
ma–pe klo 10–14
Huom. Matkapuhelinnumeroihin ei voi
lähettää tekstiviestejä.Sydänsairaala sosiaalisessa
mediassa
Facebook
(https://www.facebook.com/sydansairaala)
Instagram
(https://www.instagram.com/sydansairaala/)LinkedIn
(https://fi.linkedin.com/company/sydansairaala)YouTube
(https://www.youtube.com/channel/UCl2MGYGAq
(https://player.vimeo.com/video/558422857?
texttrack=fi&rel=0&showinfo=0)
(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Sydäninfarktipotilaan fysioterapia - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p al v eluk et jut  / Sepel v al timot autipotilaan hoit ok et ju  / Sy däninf ar ktipotilaan fysiot er apia
 Sepel v al timot autipotilaan hoit ok et ju
Sy däninf ar ktipotilaan fysiot er apia
Sepel v al timot audin diagnostiikka
Sepel v al timot audin hoit o
Sepel v al timot autik oht aus
Sy dän v almennus
Sepel v al timot audin jatk ohoit o ja seurant a




Sy däninf ar ktipotilaan fysiot erapia
F ysiot erapia sairaalassa
Esitiedot,  haast at t elu
F ysiot er apeut tinen tut kiminen ja ar viointi:
hengit yst oiminnot; neur ologinen st atus; liikkumisky ky; vir e ystila; omat oimisuus; kivut; sy k e v ast e
F ysiot er apeut tinen kunt outus / fysiot er apeut tien ohjaus ja neuv ont a:
v ar hainen mobilisaatio (aloitus lääkär in luv alla), omat oimisuuden tuk eminen
hengit y ksen t ehost aminen; v er enkier r on vilkastutt aminen
nousujoht einen liikkumisen lisääminen: rasitust aso noin 2 viikk o a k e vy t (Bor g 11/20); ja 1kk saakka k e vy t -
hieman rasitt a v a (Bor g 11-13/20)
raskaiden ponnist elujen ja raskaiden t aakk ojen nost ojen sekä pist osk ohdan v oimakkaan v en y t y ksen v äl tt äminen
v al timopist osk ohdan p arantumisen aikana (noin 2 p äiv ää)
k ohti sepel v al timot autipotilaan liikunt asuositust a noin 1kk ->
lämmitt el y , jäähd y tt el y , v auhdin säät ö, t auotus
hengäst ymisen ja hengenahdistuksen er ott aminen
apuv äline ar vio ja kä y t ön ohjaus
por rashar joitt elu ennen k otiutumist a t ar vitt aessa
k otiohjeet: liikunnan nousujoht einen lisääminen, oir eiden tunnist aminen ja hoit oon hak eutuminen
F ysiot er apiasuunnit elman laatiminen:
jatk ofysiot erapiasuunnit elma, sisäl t ää t a v oitt een asett amisen y hdessä potilaan kanssaKuuntele4.3.2025 klo 17.11 Sydäninfarktipotilaan fysioterapia - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydaninfarktipotilaan-fysioterapia 1/2
F ysiot erapia k otiutumisen jälk een poliklinikalla
Esitiedot,  haast at t elu
F ysiot er apeut tinen tut kiminen ja ar viointi / fysiot er apeut tinen kunt outus:
v ointi, mahdolliset oir eet, kipu; t oipumisen et eneminen, liikkumisen lisä ys ar jessa, ar jen t oimint ojen sujuvuus,
mahdolliset haast eet t ai est eet liikunnan lisäämiselle
mieliala, liikkumismotiv aatio, k oettu kunt ot aso
6 min kä v el y t esti, hengit y ksen sujuvuus, limaisuus
hengit ysfunktiomitt aukset, r y hti, y läraajojen ja -v ar t alon liikkuvuus, lihasv oimat
F ysiot er apeut tinen ohjaus ja neuv ont a:
suor ituskyvyn ar vioinnin / t oipumisen mukaisen / sairausk oht ainen ohjaus k ohti liikunnallist a elämänt ap aa
motiv ointi, kannust aminen, y ksilöllisyys
F ysiot er apiasuunnit elman laatiminen:
jatk ofysiot erapiasuunnit elma, sisäl t ää t a v oitt een asett amisen
t ar vitt aessa y ksilöllinen har joitusohjelma
P otilasohje: Op as sepel v al timot autia sair ast a v alle  (T er v e yspor tti, pdf)
P otilaan ohjaus ja motiv ointi
Päivit ett y 2. 12.202 4
Ev äst eet
Saa vut et t a vuusselost e
Tiet osuoja
© Pir kanmaan h yvin v ointialueT akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.
T ämän sivun lö y dät osoitt eella pir ha.fi/hoit ok et jut4.3.2025 klo 17.11 Sydäninfarktipotilaan fysioterapia - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sydaninfarktipotilaan-fysioterapia 2/2
Sydänliitto_pallolaajennus_liikunta.pdf
1Liikunta  
pallolaajennuksen 
jälkeen 

2 3Sinulle on tehty  ahtautuneen sepel ­
valtimon pallolaajennus. Liikkuminen 
on nyt helpompaa kuin ennen pallo ­
laajennusta, koska sydänlihas ei kärsi 
enää hapenpuutteesta. Vain parin 
ensimmäisen viikon aikana sinun tulee 
muistaa muutama erityinen seikka 
liittyen liikuntaan.Innostu  
liikkumisesta
Pallolaajennukseen jälkeen  jo sai ­
raalassa liikkeellä olo tulee aloittaa 
heti, kun saat henkilökunnalta luvan. 
Osastolla liikkuminen on suotavaa. 
Näin toipuminen pallolaajennuksesta 
pääsee käyntiin. Osaston henkilökunta 
antaa sinulle tarvittaessa erityisohjeita 
liikkumiseen.Lähde liikkeelle  
jo sairaalassa
Erityisiä ohjeita 
 
 
 
 
 
 
 
 
 
 
 
KOKEILE,   
ONNISTU JA  
INNOSTU.Kuvat Anna Kara, ellei toisin mainittu
4 5Kotiutumisen jälkeen  liikunta ja arjen 
askareet on hyvä aloittaa maltillisesti. 
Valtimopistoskohdan on annettava 
parantua rauhassa. Siksi sinun tulee 
välttää raskaita ponnisteluja ja koti­
töitä, kuten raskaiden taakkojen 
nostoja ja juoksemista ja pistoskohdan 
voimakasta venyttelyä noin viikon ajan. 
Voit palata tavanomaisiin päivittäisiin 
toimintoihin, kuten arkiaskareisiin  
1–2 vuorokauden kuluttua pallo­
laajennuksesta. Kävelylle voit lähteä 
heti. Ensimmäisten viikkojen aikana Lisää liikuntaa  
kotona
rasitus saa tuntua hieman rasittaval ­
ta eli saat kevyesti hengästyä (RPE 
13–14, katso sivu 9). Jo kahden viikon 
kuluttua voit palata tuttujen liikunta­
harrastuksien pariin. Jos sinulla ei  
ole liikunta harrastusta, kannattaa 
kokeilla rohkeasti eri liikuntamuotoja  
ja löytää itsellesi mieluinen. Sinulle  
on toden näköisesti asennettu pallo ­
laajennuksessa metalliverkko eli stentti 
pitämään valtimon seinämä laajana. 
Tämä verkko ei irtoa liikunnassa.
Kuva Sydänliitto
6 7Lääkehoidon ohella  säännöllinen 
liikunta, sydänystävällinen ruoka, 
painonhallinta, mielen hyvinvointi, 
riittävä uni ja tupakoimattomuus ovat 
sepelvaltimotaudin hoidon kulmakiviä. 
Nyt sinulla on hyvä mahdollisuus vai ­
kuttaa sepelvaltimotautiisi liikkumalla. 
Tiesitkö, että säännöllisen liikunnan 
avulla voit vaikuttaa sepelvaltimotautia 
pahentaviin riskitekijöihin ja jopa hidas ­
taa sairauden etenemistä? Liikunnan 
aloittaminen kannattaa aina.
Säännöllinen liikunta
• parantaa sydämen pumppaustehoa 
ja rasituksen sietokykyä
• kehittää sydän­ ja verenkierto­
elimistön kuntoaLiikunta on olennainen osa  
sepelvaltimotaudin hoitoa
• parantaa valtimoiden sisäkalvon 
toimintaa ja uudissuonten  
muodostumista
• lisää hyvää veren HDL ­kolesteroli­
pitoisuutta ja vähentää pahaa 
LDL­kolesterolipitoisuutta, mikä 
hidastaa valtimoiden ahtautumista
• vähentää veren triglyseridipitoisuutta
• alentaa lepoverenpainetta
• auttaa painonhallinnassa
• lisää elimistön insuliiniherkkyyttä  
ja parantaa veren sokeritasapainoa
• kehittää lihasvoimaa
• virkistää
→ parantaa elämänlaatua ja arjessa  
jaksamista sekä sairauden ennustetta Liikunnassa tärkeää  on säännöllisyys 
ja liikunnan tulisikin olla päivittäinen 
osa arkea. Jos kuntosi on päässyt 
heikentymään tai liikuntasi on vähäistä, 
niin aloita maltillisesti ja etene pienin 
askelin vähitellen liikuntaa lisäten.  
Voit koota päivittäisen liikunnan  
useasta lyhyestä liikuntajaksosta.  
Kunnon kohentuessa lisää ensin  
liikunnan kestoa 30–60 minuuttiin 
päivässä ja sitten vasta tehoa.  
Sopiva teho vastaa reipasta kävelyä  
ja hengästyminen on vain hyväksi. 
Päivittäinen liikunta voi koostua arki ­
sesta liikkumisesta, kuten esimerkiksi 
työmatkapyöräilystä, puutarhatöistä  
ja hieman hengästyttävästä kestävyys ­
liikunnasta (RPE 13–14, katso sivu 5).  
Jos kuntosi on hyvä ja liikkuminen  
oireetonta, voit liikkua rasittavalla  
tasolla (RPE 15–16). Voit kokeilla 
kovempaa tehoa ainakin aluksi ns. 
intervallityyppisesti, jolloin liikut välillä 
reippaammin ja välillä rauhallisemmin.Liikunnallinen  
elämäntapa
Kestävyysliikuntamuodoiksi sopivat 
esimerkiksi kävely, golf, luonnossa 
liikkuminen, kuntopyöräily, hiihto,  
uinti, sauvakävely, hölkkä, tanssi,  
soutu ja erilaiset pallopelit. Suosi 
liikuntamuotoja, joista itse pidät. 
Kohentunut kestävyyskunto keventää 
arkea ja jaksat liikkua entistä paremmin 
ja pidempään. 
Lihasvoimasta tulee huolehtia vähin ­
tään kaksi kertaa viikossa. Kotona, 
kuntosalilla tai luonnossa voit vahvistaa 
lihaksia monipuolisesti. Lihasvoima­
harjoittelussa kannattaa keskittyä  
isojen, toimintakyvyn kannalta  
tärkeiden, lihasryhmien harjoittami ­
seen. Alaraajojen isot lihakset ovat 
liikkumis kyvyn kannalta tärkeitä.  
Hyvä lihas voima helpottaa monista 
arjen askareista selviytymistä ja sen 
merkitys korostuu ikääntyessä.
NÄIN ONNISTUT
• Hyödynnä kaikki arkiliikkumisen hetket.
• Ota tavoitteeksi 30–60 minuuttia  
reipasta liikuntaa päivässä ja lihas­
voimaharjoittelua 2 kertaa viikossa.

8 9Liiku rohkeasti  
kehoasi kuunnellen RPE-asteikko
Omat tuntemukset  ovat tärkeitä 
sopivan liikunnan tehon arvioinnissa. 
Liikkuessa saat ja on hyväkin hengäs ­
tyä. Liikunta on teholtaan sopivaa,  
kun se on oireetonta, ei uuvuta ja olo 
on jälkeenpäin virkistynyt. On tärkeää, 
että tunnistat hengästymisen ja  
hengenahdistuksen eron. Hengästy­
minen kuuluu liikuntaan ja on sitä 
voimakkaampaa mitä rasittavammin 
liikut. Hengenahdistus tuntuu ahdista ­
valta eikä helpota levossa. Omaa kehoa 
kuunnellen opit liikkumaan turvallisesti 
ja samalla tehokkaasti. RPE ­asteikon 
avulla voit arvioida, miten raskaalta 
liikunta sinusta tuntuu. 
Normaalista poikkeava väsymys tai 
uupumus saattaa olla merkki liian suu ­
resta rasituksesta. Liikunnasta palautu ­
minen kestää yleensä yhtä kauan kuin Tämän taulukon  avulla voit arvioida, 
kuinka rasittavalta liikkumisesi tuntuu. 
Asteikon numerot kuvaavat hengäs ­
tymisen ja kokonaiskuormituksen 
tuntemusta.itse liikunta. Osa sydänlääkkeistä, mm. 
beetasalpaajat, hidastavat sykkeen 
nousua liikunnan aikana. Siksi liikunnan 
rauhallinen aloittaminen tai riittävän 
pitkä alkuverryttely (5–15 min.) ja 
liikunnan päättäminen jäähdytellen 
tekevät liikunnasta miellyttävämpää. 
Lääkkeet mahdollistavat liikunnan 
har rastamisen lievittämällä oireita 
tehostaen sydänlihaksen hapen­
saantia ja parantamalla rasituksen 
sietoa. Rasituksessa ilmenevä rintakipu, 
hengenahdistus, ylävatsakipu ja huono 
olo ovat tyypillisiä sepelvaltimotaudin 
oireita. Jos oireet ilmenevät esimerkiksi 
ylämäkeä kävellessä, kevennä vauhtia, 
levähdä ja ota tarvittaessa pikanitro 
oireisiin. Jos oireet eivät helpota  
nopeasti levosta ja pikanitrosta  
huolimatta, hakeudu hoitoon.miten rasittavalta liikkuminen tuntuu?
6
ei juuri hengästymistä7 erittäin kevyt
8
9 hyvin kevyt
10
11 kevyt / sallii laulun
12
vähän hengästymistä 13 hieman rasittava / sallii puheen
14
15 rasittava / puuskututtaa
voimakasta hengästymistä16
17 hyvin rasittava
18
19 erittäin rasittava
20
RPE (Rating of Perceived Exertion) ­asteikko, mukaillen Borg (1982)OTA TÄMÄ 
TAULUKKO  
APUVÄLINEEKSI   
ARKEEN

10 11Sepelvaltimotauti  ei koskaan estä 
kaikkea liikuntaa. Suunnittele ja varaa 
itsellesi aikaa säännölliseen liikuntaan. 
Mieti, miten liikunta voisi olla pysyvä 
osa arkeasi. Pysähdy miettimään omaa 
liikuntahistoriaasi ja omia tottumuksia ­
si. Käytä apuna liikuntasuunnitelmaa 
ja ­päiväkirjaa. Liikkumiseen löytyy 
monenlaisia vaihtoehtoja. Voit pohtia, 
nauttisitko liikunnasta seurassa vai 
yksin. Innostuisitko luonnossa liikkumi ­
sesta? Tulisiko liikunnasta helpommin 
pysyvä tapa, jos sopisit yhteiset ajat 
vaikkapa kävelylenkeille ystävän tai 
läheisen kanssa? Tavoitteena on, että 
löydät itsellesi sopivat ajankohdat 
ja mieluisat tavat liikkua. Liikunnan 
tuomat mukavat kokemukset auttavat 
liikkumaan säännöllisesti. 
Jos liikunta tuntuu pelottavalta tai  
ahdistavalta, sinun kannattaa kes ­
kustella fysioterapeutin, terveyden­
hoitajan, lääkärin tai vertaistuki­
henkilön kanssa. Voit myös hakeutua 
ohjattuun liikunta ryhmään tai liikun ­
nalliseen kuntou tukseen. Pyydä sitä 
varten lähete hoitavalta lääkäriltäsi.Sinulle on tarjolla  monenlaista tukea 
liikkumiseen. Saat tarvittaessa yksi ­
löllistä liikuntaohjausta muun muassa 
terveyskeskuksen fysioterapeutilta, 
sydänhoitajalta, työterveyshuollosta, 
paikallisesta sydänyhdistyksestä tai 
­piiristä tai kunnan erityisryhmien 
liikunnanohjaajalta.
Tietoa, taitoa ja tukea sairauteesi 
liittyen sekä käytännön vinkkejä  
liikkumiseen ja sairautesi hoitamiseen 
löydät sydan.fi­ sivuilta ja Kuntoutumis­
talo.fi­ sivuilta (kuntoutumistalo.fi  
→ Kuntoutujalle → Sydänsairaudet).  
Sydänliiton kursseilla pääset tapaa ­
maan toisia samassa elämäntilanteessa  
olevia ja jakamaan kokemuksia myös 
liikkumisesta yhdessä toimien ja oppien  
(sydan.fi/kurssikalenteri). Voit myös 
kysyä Tulppa­kuntoutuksesta omasta 
terveyskeskuksestasi. Vertaistuki­
henkilön kanssa voit jutella luotta­
muksella liikkumisesta, tunteista ja 
kokemuksistasi (sydan.fi/vertaistuki­
haku). Sydan.fi/tule mukaan ­ sivuilta Millainen liikunta  
sinua miellyttää?Tukea  
liikuntaan
JOS KAIPAAT AMMATTILAISEN TUKEA, OTA YHTEYTTÄ
Nimi  
Puh  
Sähköposti  löydät tietoa Sydänliiton toiminnasta, 
joihin voit osallistua. Näet verkko­
luentotarjonnan ja tapahtuma­
kalenterin sekä voit halutessasi  
liittyä jäseneksi sydänyhdistykseen.  
Olet lämpimästi tervetullut mukaan 
sydänyhdistyksen liikuntatoimintaan.
Mieti, miten liikunta  
voisi olla pysyvä osa arkeasi. 
Pysähdy miettimään  
omaa liikuntahistoriaasi  
ja omia tottumuksiasi.
LIIKKUJAN MUISTILISTA  
• Lähde liikkeelle lämmitellen (5–15 min)  
ja päätä liikunta jäähdytellen.
• Tehosta liikuntaa omien tuntemuksiesi 
mukaan.
• Liikunnan aikana saat ja on hyväkin 
hengästyä.
• Muista, että liikunnan aikana  
ja sen jälkeen tulee olla hyvä olo.
• Kysy lääkäriltä lääkkeittesi mahdollisesta 
vaikutuksesta liikuntaan. 
• Kevennä liikuntaa, jos sääolosuhteet 
ovat erityisen vaativat.
• Pidä nitrovalmiste mukana. Jos oire 
yllättää, ota nitrovalmistetta ja levähdä. 
Jatka rauhallisemmin, kun oire  
on hellittänyt. 
• Voimakkaiden oireiden ilmaantuessa 
hakeudu hoitoon.
• Saavutat terveyshyötyjä liikkumalla 
säännöllisesti.
12 13Kävelty matka  
Viitearvo  Kuuden minuutin  
kävelytesti
Huomiot
 
 
 
 Ohjeita ja  
muistiinpanoja
Henkilökohtaisia ohjeita
 
 
 
 
 
 
 
 
Omat muistiinpanot
 
 
 
 
 
 
 
 

14 15Seuraavat kysymykset  auttavat sinua 
pohtimaan liikuntaasi. Niiden avulla 
voit suunnitella, miten ja milloin lisäät 
liikuntaa. Suunnitelman voit tehdä 
yhdessä terveydenhuollon tai liikunnan 
ammattilaisen kanssa tai itsenäisesti. Liikuntasuunnitelma
Miten liikut nykyisin? 
 
 
 
 
Miten ja milloin haluaisit liikkua?
 
 
 
 
1 esim. puutarhatyö, sauvakävely, siivous, kuntosaliharjoittelu
2 kesto/matka/askeleet
3 ei/kevyt/voimakasLiikuntapäiväkirja
SUUNNITELMA  
AUTTAA SINUA  
ONNISTUMAAN.viikonpäivä liikuntamuoto1määrä2rpe hengästyminen3
maanantai
tiistai
keskiviikko
torstai
perjantai
lauantai
sunnuntai
maanantai
tiistai
keskiviikko
torstai
perjantai
lauantai
sunnuntai
Painettu ympäristöystävällisesti. Opasta ovat olleet kirjoittamassa:sydan.fi Lue sydänterveydestä ja hyvinvoinnista, 
tutustu toimintaamme tai liity jäseneksi
Tämä opas sisältää yleisiä ohjeita 
liikuntaan sepelvaltimon pallo­
laajennuksen jälkeiselle muutamalle 
viikolle ja liikunnallisen elämäntavan 
omaksumiseen. Jos olet saanut  
lääkäriltä tai fysioterapeutilta  
erityisiä ohjeita, noudata niitä. 
2021
Sydänsairaudet ja matkustaminen - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Oletko kiinnostunut toimimaan vapaaehtoisena? Lue lisää Sydänliiton vapaaehtoistoiminnasta.
(https://sydan.fi/tule-mukaan/tule-vapaaehtoiseksi/)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Sairastuneen matkustaminen (https://sydan.fi/elamaa-sairauden-kanssa/sairastuneen-matkustaminen/)/
Sydänsairaudet ja matkustaminen
Sydänsairaudet ja matkustaminen
(https://sydan.fi/fakta/sydansairaudet-ja-
matkustaminen/)
Sydänsairastunut voi matkustaa normaalisti, jos sairaus on vakaassa
vaiheessa.Luet tällä hetkellä Sydänsairaudet ja matkustaminen Lue seuraavaksi Brilique ja kihti
(https://sydan.fi/kysymys/brilique-ja-kihti/)
Kuva: Jarno Hämäläinen
Mari Blek-Vehkaluoto, asiantuntija, elvytys ja
riskitekijät
Julkaistu 12.4.2016
Päivitetty 13.6.2024Jaa
sivu 
Kun sydänsairaus on vakaassa vaiheessa eli sen toteamisesta on jo aikaa ja se ei
aiheuta merkittävä oireita, voi hyvin suunnitella matkustamista. Tuore tai
vaikeaoireinen sydänsairaus asettaa rajoituksia lentomatkustamiselleLuet tällä hetkellä Sydänsairaudet ja matkustaminen Lue seuraavaksi Brilique ja kihti
(https://sydan.fi/kysymys/brilique-ja-kihti/)
(https://sydan.fi/fact/sydansairaudet-ja-lentomatkustaminen/).
Pohdi etukäteen millainen matkakohde ja matkustustapa on sinulle paras
vaihtoehto. Selvitä esimerkiksi matkakohteen aikaero, säätila, korkeuserot ja
etäisyydet. Varaa riittävästi aikaa siirtymiseen ja mieti miten matkatavaroiden
kuljettaminen onnistuu.
Huomioi matka-aika kokonaisuudessaan –  kotoa lentokentälle, turvatarkastus,
koneen lähdön odottaminen, lentomatkustus, mahdolliset välilaskut,
matkakohteen lentokentälle saapuminen tullimuodollisuuksineen,
matkatavaroiden odottaminen ja matka lentokentältä hotellille.
Matkavakuutus kannattaa ehdottomasti ottaa. Selvitä myös etukäteen, mistä
kohdemaassa saat tarvittaessa apua sairauden hoidossa.
Sinulla on oikeus Kelan myöntämään eurooppalaiseen sairaanhoitokorttiin
(https://www.kela.fi/eurooppalainen-sairaanhoitokortti) (European Health
Insurance Card, EHIC), jos sinut on sairausvakuutettu Suomessa tai Suomi vastaa
hoitosi kustannuksista. Kortti on ilmainen.
Matkustajan muistilista
Ota lääkkeet ja lääkemääräykset tai yhteenveto sähköisistä resepteistä käsimatkatavaroihin
mukaan. Varaudu matkan viivästymiseen ottamalla mukaan ainakin muutaman ylimääräisen
päivän lääkkeet. Pidä lääkkeet mielellään alkuperäispakkauksessa, josta käy ilmi lääkkeen
vaikuttava aine.Luet tällä hetkellä Sydänsairaudet ja matkustaminen Lue seuraavaksi Brilique ja kihti
(https://sydan.fi/kysymys/brilique-ja-kihti/)
Ulkomaille matkustettaessa on hyvä olla mukana lyhyt englanninkielinen selostus sairaudesta
ja viimeinen sydänfilmi.
Jos sinulla on tahdistin, pidä mukanasi tahdistinkortti, jonka voit näyttää lentokenttien
turvatarkastuksissa.
Jos käytät antikoagulaatiohoitoa (https://sydan.fi/fact/veren-hyytymista-estavat-laakkeet/)
(suora antikoagulantti tai varfariini), kannattaa pitää mukana SOS-korttia.
(https://www.sydankauppa.fi/epages/sydankauppa.sf/fi_FI/?ObjectID=20713135)
Jos sinulla on varfariinihoito, tarkista ennen matkaa ja heti matkan jälkeen INR-arvo. Ota
mukaan hoitokortti. Selvitä etukäteen, missä voi tarvittaessa matkan aikana tarkistaa INR-
arvon. Huomioi että esimerkiksi muuttunut ruokavalio, vatsatauti ja kuume voivat vaikuttaa
INR-arvoon.
Pitkillä auto- ja lentomatkoilla paikoillaan olo heikentää jalkojen verenkiertoa, lisää jalkojen
turvotusta ja laskimoveritulpan vaaraa. Käytä lento- tai tukisukkia, liikuttele jalkoja ja nouse
ajoittain jaloittelemaan.
SYDÄNSAIRAUDET JA LENTOMATKUSTAMINEN (HTTPS://SYDAN.FI/FAKTA/SYDANSAIRAUDET-JA-
LENTOMATKUSTAMINEN/)
MATKUSTAJAN SOSIAALITURVA JA HOITO ULKOMAILLALuet tällä hetkellä Sydänsairaudet ja matkustaminen Lue seuraavaksi Brilique ja kihti
(https://sydan.fi/kysymys/brilique-ja-kihti/)
Sydänsairauksien tutkimukset - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Sydänsairaudet (https://sydan.fi/sydansairaudet/)/
Sydänsairauksien tutkimukset (https://sydan.fi/sydansairaudet/sydansairauksien-tutkimukset/)/
Sydänsairauksien tutkimukset
Sydänsairauksien tutkimukset
(https://sydan.fi/fakta/sydan-ja-
verisuonitautien-tutkimukset/)
Sydänsairauksien selvittäminen alkaa aina lääkärin haastattelulla, minkä
perusteella valitaan jatkotutkimukset.
Anna-Mari Hekkala, ylilääkäri
Julkaistu 26.1.2024
Päivitetty 1.2.2024
 
Lue seuraavaksi Lääkärin tutkimus ja EKG (https://sydan.fi/fakta/laakarin-tutkimus-ja-ekg/)
 
Oleellinen alku sydänsairauksien tutkimisessa on tutkittavan kokemat oireet.
Oireiden laatu, kesto, altistavat ja helpottavat tekijät kiinnostavat. Haastattelun
perusteella lääkärille pitäisi jo syntyä käsitys, mitä sairautta epäillä, tai ainakin
käsitys, mistä sairauksista tuskin on kysymys.
Lue lisää eri sydänsairauksien oireista:
Sepelvaltimotaudin oireet (https://sydan.fi/fakta/sepelvaltimotaudin-
oireet/)
Rytmihäiriöiden oireet (https://sydan.fi/fakta/sydamen-rytmihairiot/)
Pyörtyminen (https://sydan.fi/fakta/pyortyminen/)
Sydämen vajaatoiminta (https://sydan.fi/fakta/sydamen-vajaatoiminnan-
oireet/)
Sydämen läppävika (https://sydan.fi/fakta/lappaviat/)
Lääkärin on hyödyllistä tietää tutkittavan elintavoista, erityisesti tupakoinnista
ja muidenkin nikotiinituotteiden käytöstä, ruokatottumuksista, alkoholin
käytöstä ja liikunnan harrastamisesta. Nämä tiedot kertovat, millaisia
sydänsairauden riskitekijöitä tutkittavalla on. Elämän stressitilanteet saattavat
selittää oireiden ilmaantumisen juuri nyt.
Monen sydänsairauden taustalla voi olla geneettisiä tekijöitä
(https://sydan.fi/fakta/geenitutkimukset-sydan-ja-verisuonisairauksien-
diagnostiikassa/), joten myös sukuhistorialla on merkitystä. Sydänsairaudet ovat
niin tavallisia, että useimmilla on joku sydänsairauteen sairastunut sukulainen.
Niinpä periytyvyyttä ajatellen ammattilaista kiinnostaa erityisesti ns.
ensimmäisen asteen sukulaisten eli vanhempien ja sisarusten sairaudet, jotka
ovat alkaneet jo ennen vanhuusikää.
Usein henkilön omat mittaustulokset ovat myös hyödyllisiä, erityisesti
verenpainetiedot.
Lue lisää: omat mittaukset (https://sydan.fi/fakta/omat-mittaukset/)
Jatkotutkimukset valitaan haastattelun ja kliinisen tutkimuksen pohjalta
syntyneiden epäilyjen perusteella. EKG kuuluu aina alkuvaiheen tutkimuksiin.
Lue lisää: lääkärin tutkimus ja EKG (https://sydan.fi/fakta/laakarin-tutkimus-ja-
ekg/)Lue seuraavaksi Lääkärin tutkimus ja EKG (https://sydan.fi/fakta/laakarin-tutkimus-ja-ekg/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Lisäksi verikokeella voidaan helposti selvittää sydänsairauksien vaaratekijöitä,
kuten kolesteroliarvot. Päivystyksessä mitataan usein troponiinikoe, joka kertoo
mm. uhkaavasta sydämen hapenpuutteesta.
Lue lisää: verikoetutkimukset sydänsairauksien diagnostiikassa ja seurannassa
(https://sydan.fi/fakta/verikoetutkimukset-sydansairauksien-diagnostiikassa-
ja-seurannassa/)
Näiden alkuselvittelyjen jälkeen valitaan jatkotutkimukset epäillyn sairauden
perusteella. Tutkimusmenetelmiä on paljon, eikä ole yhtä yksittäistä tutkimusta,
joka antaisi vastauksen kaikkiin oireisiin.
Keuhkoröntgen (thorax-rtg) voi olla hyödyllinen, kun tutkitaan
hengenahdistusoiretta. Kuvaan piirtyy sydämen varjo, ja kuvaus saattaa
paljastaa sydämen vajaatoiminnan. Muutoin keuhkoröntgenkuvan hyöty
sydänsairauksien tutkimisessa on varsin vähäinen.
Jos sydämestä kuuluu stetoskoopilla sivuääni, tai EKG:ssa on poikkeavia
löydöksiä, on sydämen ultraäänitutkimus paikallaan.
Lue lisää: sydämen ultraäänitutkimus (https://sydan.fi/fakta/sydamen-
ultraaanitutkimus/)
Rytmihäiriöitä taas tutkitaan usein EKG:n pitkäaikaisrekisteröinnillä eli ns.
Holter-tutkimuksella.
Lue lisää: EKG:n pitkäaikaistutkimus (https://sydan.fi/fakta/ekgn-
pitkaaikaisrekisterointi-holter/)
Jos oire ilmaantuu rasituksessa, rasituskoe voi olla hyödyllinen. Rasituskokeella
on perinteisesti tutkittu sepelvaltimotaudin mahdollisuutta, mutta tähän
tarkoitukseen on nykyisin muitakin hyviä tutkimuksia.
Lue lisää: rasituskoe (https://sydan.fi/fakta/rasituskoe/)
Lue lisää: sepelvaltimoiden ja sydämen tietokonetomografia
(https://sydan.fi/fakta/sepelvaltimoiden-ja-sydamen-tietokonetomografia/)
Lue lisää: sydämen isotooppikuvaus ja PET-tutkimus
(https://sydan.fi/fakta/sydamen-isotooppitutkimus-ja-pet-kuvaus/)
Lue lisää: sepelvaltimoiden varjoainekuvaus
(https://sydan.fi/fakta/sepelvaltimoiden-varjoainekuvaus/)Lue seuraavaksi Lääkärin tutkimus ja EKG (https://sydan.fi/fakta/laakarin-tutkimus-ja-ekg/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sydänlihassairaus selviää usein sydämen ultraäänitutkimuksessa, mutta joskus
lisäselvityksenä voidaan tehdä sydämen magneettikuvaus. Eräissä
sydänlihassairauksissa voidaan joutua ottamaan sydänlihaksesta myös koepala eli
biopsia. Tämä tapahtuu ujuttamalla välineet sydämen oikealle puolelle
laskimoreittiä pitkin.
Lue lisää: sydämen magneetti (https://sydan.fi/fakta/sydamen-
magneettikuvaus/)
Rytmihäiriöitä tutkitaan monin eri tavoin (https://sydan.fi/fakta/rytmihairion-
tutkiminen/), myös invasiivisella eli kajoavalla tutkimuksella.
Elektrofysiologisessa tutkimuksessa rytmihäiriömekanismeja etsitään sydämen
sisältä käsin. Samalla on mahdollisuus tehdä rytmihäiriön parantava
katetriablaatiotoimenpide.
Lue lisää: elektrofysiologinen tutkimus
(https://sydan.fi/fakta/elektrofysiologinen-tutkimus/)
Koska sydämen toimintaan liittyy paljon tärkeitä osatekijöitä, kuten sähköinen
toiminta, sydänlihas, läpät ja sydämen oma verenkierto eli sepelvaltimot,
tarvitaan useanlaisia tutkimustapoja. Monet tutkimuksista täydentävät toisiaan.
On hyvä tietää, että tarkoissa selvityksissä löytyy usein pieniä löydöksiä, joilla ei
ole käytännössä vaikutusta sydämen toimintaan. Siksi lääkärin tekemä tulosten
tulkinta, eli löydösten merkityksen kertominen ymmärrettävästi on tärkeä osa
sydäntutkimuksia.Lue seuraavaksi Lääkärin tutkimus ja EKG (https://sydan.fi/fakta/laakarin-tutkimus-ja-ekg/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Sydäntautien riskien kesyttäminen - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla vinkeillä
täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Kuntoutuminen (https://sydan.fi/elamaa-sairauden-kanssa/kuntoutuminen/)/
Sydäntautien riskien kesyttäminen
Sydäntautien riskien kesyt täminen
Sairastumisen jälkeen elämäntapoihin liittyvät valinnat
vaikuttavat toipumiseen, oireiden kehittymiseen ja taudin
ennusteeseen. 
Kuva: Johannes Romppanen
Paula Mannonen
Julkaistu 20.5.2015
Päivitetty 3.9.2018Jaa sivu 
Luet tällä hetkellä Sydäntautien riskien kesyttäminen Lue seuraavaksi Aloita liikunta kevyesti
sydäntapahtuman jälkeen
(https://sydan.fi/fakta/aloita-liikunta-kevyesti/)
Valtimotauteihin vaikuttavat monet tekijät, joista kaikkiin ei voi
vaikuttaa itse. Monia riskejä voi kuitenkin pienentää. Sairastumisen
jälkeen elämäntapoihin liittyvät valinnat vaikuttavat toipumiseen,
oireiden kehittymiseen ja taudin ennusteeseen.
Perehtyminen sairauden syihin ei ole sama asia kuin syyllisten etsiminen.
Kukaan ei voi sanoa tarkalleen, miksi joku sairastuu ja toinen ei. Ja kun
mennyttä ei voi muuttaa, itsensä tai ympäristön syyttäminen vie vain
turhaan voimia.
Tässä kokonaisuudessa käsitellään niitä sydäntautien riskitekijöitä, joihin
jokainen voi vaikuttaa. Tarjolla on tietoa, mutta myös konkreettisia
esimerkkejä, joita voi halutessaan käyttää oman kuntoutusohjelman
kokoamisessa.
Liikunta on sydäntapahtuman jälkeen syytä aloittaa varovaisesti.
Liikuntatavoitteet on siksi syytä asettaa terveydenhuollosta saamien
ohjeiden mukaan. Sydänlääkkeet taas eivät sovi hyvin yhteen joidenkin
ruoka-aineiden kanssa, joten noudata myös ruuasta saam iasi ohjeita.
Jos olet tupakoitsija, sinulla on käytettävissä omatoimiseen
kuntoutukseen monia muita sepelvaltimotautipotilaita vahvempi keino:
tupakoinnin lopettaminen.  Riippumatta siitä, kuinka kauan olet
polttanut, savuttomuus vähentää sairauden uusimisen ja uusien oireiden
kehittymisen vaaraa merkittävästi. Tupakoinnin jatkaminen puolestaan
kolminkertaistaa uuden sydäntapahtuman riskin.
Omakuntoutusohjelmaan kuuluu myös oman ruokavalion pohdinta.
Terveys ei ole vain fyysinen tila, vaan siihen kuuluvat myös henkinen
tasapaino ja yhteys muihin ihmisiin. Sairastuminen järkyttää tasapainoa
näillä kaikilla ulottuvuuksilla. Siksi toipumisvaiheessa voi ruumiillisten
oireiden ohella esiintyä pelkoa, ahdistusta, eristäytymisen halua,
itkuisuutta, ärtymystä ja muita kielteisiä tunteita ja tiloja. Ne ovat
merkkejä psykologisesta prosessista, jossa ihminen käsittelee terveyden
menettämistä ja sairauden aiheuttamaa uhkaa. Potilaan ohella myös
hänen läheisensä joutuvat käsittelemään tapahtuneen herättämiä
pelkoja.Luet tällä hetkellä Sydäntautien riskien kesyttäminen Lue seuraavaksi Aloita liikunta kevyesti
sydäntapahtuman jälkeen
(https://sydan.fi/fakta/aloita-liikunta-kevyesti/)
Riittävä uni ja lepo ovat välttämätöntä vastapainoa päivän rasituksille.
Nukkuessa elimistö rakentaa ja korjaa soluja ja täyttää niiden
energiavarastoja. Ja vaikka ihmisen tietoinen minä on unessa, aivot
käsittelevät ja järjestelevät päivän tapahtumia ja tunteita.  Näillä öisillä
toiminnoilla on suuri merkitys niin ruumiilliselle ja henkiselle
hyvinvoinnille kuin muistamiselle ja oppimiselle.
Pienestä määrästä alkoholia ei ole sepelvaltimotautia sairastavalle
haittaa, mutta alkoholia ei tulisi nauttia päivittäin, eikä juoda kerralla
enempää kuin 1-2 ravintola-annosta.
Omakuntoutukseen kuuluu myös turvallisuudesta huolehtiminen
kotona. Asiaa kannattaa käydä läpi läheisten kanssa, sillä näin saadaan
parannettua kaikkien turvallisuudentunnetta.Luet tällä hetkellä Sydäntautien riskien kesyttäminen Lue seuraavaksi Aloita liikunta kevyesti
sydäntapahtuman jälkeen
(https://sydan.fi/fakta/aloita-liikunta-kevyesti/)
Tietoa sepelvaltimoiden pallolaajennuksesta.pdf
Tie toa se pel val ti moi den pal lo laa jen nuk -
sesta
Sepelvaltimoiden pallolaajennusta tarvitaan, jos oireet ovat lääkehoidosta
huolimatta hankalia tai todetaan kriittisiä ahtaumia sepelvaltimoiden tyviosissa.
Video on ohjelmamateriaalista 'Elossa 24h', jonka Ylelle on tuottanut ITV Studios Finland.
Sepelvaltimoiden pallolaajennuksen valinta
perustuu ahtaumien sijaintiin, lukumäärään
ja vaikeusasteeseen. Myös
liitännäissairaudet vaikuttavat, päädytäänkö
pallolaajennukseen vai ohitusleikkaukseen.
Ennustetta parantavaa lääkitystä tarvitaan
aina myös toimenpiteiden jälkeen.
Pallolaajennus voidaan  usein tehdä heti
varjoainekuvauksen jatkoksi ”samassa
istunnossa”, mutta toisinaan on tärkeätä
pohtia eri vaihtoehtoja pitempään, jolloin
toimenpiteet tehdään  myöhemmin.
Äkillisissä sepelvaltimotautikohtauksissa ja
sydän infarktissa hoitotoimet ovat lähes aina
välittömiä eli pallolaajennukseen edetään suoraan varjoainekuvauksesta tai järjestetään nopea
ohitusleikkaus sydän kirurgia konsultoiden.
Tarkistettu 3.11.2020VIDEOSepelvaltimoiden pallolaajennus
Miksi Terveyskylä? – Katso video
Tietoa sepelvaltimotaudin lääkehoidosta - Ammattilaispalvelu.pdf
Työskenteletkö sydänterveyden tai siihen liittyvien teemojen parissa? Tilaa Sydänliiton ammattilaisille suunnattu
uutiskirje.
(https://sydan.fi/tilaa-ammattilaisten-uutiskirje)
Löydä tilaisuutesi sopiva kokemustoimija Sydänliiton kokemustoimijahausta.
(https://sydan.fi/kokemustoimijahaku/?personDiagnoses=&personAge=&personCity=&personLanguages=&query=)
Etusivu (https://sydan.fi/ammattilaispalvelu/)/Tietoa sepelvaltimotaudin lääkehoidosta
Tietoa sepelvaltimotaudin lääkehoidosta
(https://sydan.fi/ammattilaispalvelu/artikkeli/tietoa-
sepelvaltimotaudin-laakehoidosta/)
Sepelvaltimotaudin lääkehoidossa tarvitaan ennustetta parantavaa, oireita
lievittävää sekä veren hyytymistä estävää lääkitystä.
Julkaistu 13.2.2023
 
Lääkehoidon epäonnistuminen on harmittavan tavallista, sillä omatoiminen lääkityksen
lopettaminen tai vähentäminen potilaiden toimesta on yleistä. Taustalla on monia syitä,
kuten tiedon puute, haittavaikutusten pelko (erityisesti statiinien), tai sairauden
oireettomuus. Siksi on hyvin tärkeää, että potilas ymmärtäisi lääkityksensä perustelut,
jolloin hoitoon sitoutuminen paranee.Lue seuraavaksi Masennus ja sepelvaltimotauti (https://sydan.fi/ammattilaispalvelu/artikkeli/masennus-ja-sepelvaltimotauti/)
Monesti sepelvaltimotautipotilaalla on muitakin sydänsairauksia, kuten esimerkiksi
sairastetun sydäninfarktin vuoksi kehittynyt sydämen vajaatoiminta, tai
rytmihäiriötaipumus kuten eteisvärinä. Tässä kirjoituksessa käsitellään pääasiassa
sepelvaltimotaudin lääkkeitä. Muiden sairauksien hoitoon käytettävät lääkkeet saattavat
vaikuttaa yksilöllisesti myös sepelvaltimotaudin lääkevalintoihin.
Sepelvaltimotaudin lääkkeet ovat pääasiassa alemman erityiskorvattavuuden piirissä
(numero 206).
Ennusteeseen vaikuttava lääkitys
Tähän ryhmään kuuluvilla lääkkeillä on todettu olevan merkittävää hidastavaa vaikutusta
sepelvaltimotaudin etenemiseen. Niiden tiedetään vähentävän sepelvaltimotautipotilaan
kuolleisuutta ja uusia sydäninfarkteja, siksi puhutaan ennusteeseen vaikuttavasta
lääkehoidosta.
Dyslipidemian hoito
Kaikille sepelvaltimotautipotilaille aloitetaan yleensä statiinilääkitys laskemaan
kolesterolia (https://sydan.fi/fact/kolesterolilaakkeet/). LDL-kolesterolin tavoitetaso on
alle 1,4 mmol/l. Käytännössä ateroskleroosin suhteen olisi parasta, että LDL-taso olisi
mahdollisimman matala. Jos kolesteroli ei laske riittävästi statiinihoidosta huolimatta,
voidaan rinnalle lisätä kolesterolin imeytymistä estävä etsetimibi-valmiste. Jos tälläkään
hoidolla ei saada riittäviä hoitotuloksia, voidaan harkita uudempia lääkkeitä, PCSK9-
estäjiä.
Lääkehoidon lisäksi potilasta tuetaan toteuttamaan sydänpotilaan ravitsemussuosituksia.
Rinnalla voi myös käyttää terveysvaikutteisia elintarvikkeita (kasvistanoli ja -
sterolituotteita).
Verenpaineen hoito
Angiotensiinikonvertaasin estäjä (https://sydan.fi/fakta/acen-estajat/) (ACE-estäjä) on
ensisijainen valinta sepelvaltimotautipotilaan verenpaineen hoitoon. Jos lääke aiheuttaa
haittavaikutuksia, joista tavallisin on kuiva yskä, voidaan tilalle vaihtaa angiotensiini II -
reseptorin salpaaja (https://sydan.fi/fakta/atrn-salpaajat/) (ATR-salpaaja).
Useimmat potilaat tarvitsevat monen verenpainelääkkeen yhdistelmän, jotta paine
saadaan tavoitteisiin. ACE-estäjään tai ATR-salpaajaan voidaan vaivatta yhdistää
tiatsididiureetti tai verisuoniselektiivinen kalsiuminestäjä. Monista lääkkeistä on saatavilla
yhdistelmävalmisteita, joiden käyttö voi monessa tapauksessa parantaa
hoitomyöntyvyyttä.
Diabetes
Kaikki diabeteslääkkeet sopivat sepelvaltimotautipotilaalle, mutta kahden lääkeryhmän
on todettu olevan erityisen hyödyllisiä. Näitä lääkkeitä ovat glukoosinkuljettajaproteiini
2:n estäjät ja GLP-analogit.Lue seuraavaksi Masennus ja sepelvaltimotauti (https://sydan.fi/ammattilaispalvelu/artikkeli/masennus-ja-sepelvaltimotauti/)
Antitromboottiset lääkkeet
Lääkkeellä ehkäistään verihyytymän syntymistä (https://sydan.fi/fakta/verihiutaleita-
estavat-laakkeet-valtimotautien-hoidossa/) sairaan valtimon sisälle. Tavallisesti
käytetään ensisijaisesti asetyylisalisyylihappoa (ASA). Allergiset potilaat voivat käyttää
vaihtoehtoisesti klopidogreeli-valmistetta.
Pallolaajennuksen ja sydäninfarktin jälkeen tarvitaan ns. trombosyyttien kaksoisestoa.
Tämä tarkoittaa sitä, että määräajan käytetään ASAn lisäksi toista lääkettä, tavallisesti
ADP-estäjää (klopidogreeli, tikagrelori tai prasugreeli). Pallolaajennustoimenpiteen
tehnyt kardiologi määrittelee, mikä valmiste valitaan ja kuinka pitkään kaksoisestoa on
tarpeellista käyttää. Näistä ohjeista ei saa poiketa ilman toimenpidekardiologin lupaa.
Kaksoislääkityksen hoidon kesto voi vaihdella kuukaudesta vuoteen, riippuen mm.
potilaan vuotoriskeistä. Jos potilaalla on vaikea sepelvaltimotauti, ja pieni vuotovaara,
voidaan harkita pitkäaikaista kaksoisestoa, jolloin ASAn rinnalla käytetään klopidogreeliä,
pieniannoksista rivaroksabaania tai tikagreloria.
Jos potilaalla on myös eteisvärinä, suositellaan suoraa antikoagulanttia
(https://sydan.fi/fakta/mika-on-antikoagulantti-ja-miten-sita-kaytetaan/).
Akuuttitilanteessa tai pallolaajennuksen jälkeen rinnalle liitetään jokin
trombosyyttiestäjä, mutta pitkäaikaiskäytössä riittää pelkkä antikoagulantti.
Pitkäaikaiseen yhteiskäyttöön liittyy selvästi enemmän vuoto-ongelmia ilman
merkittävää lisähyötyä.
Oireita lievittävä lääkitys
Beetasalpaajat
Yleensä sydäninfarktin jälkeen jokaiselle potilaalle aloitetaan beetasalpaajalääkitys
(https://sydan.fi/fact/beetasalpaajat/). Lääke vähentää tehokkaasti iskemiaa, rauhoittaa
sykettä ja estää pulssin nousua rasituksessa. Se ehkäisee myös rytmihäiriöiltä. Jos ei ole
muita syitä käyttää lääkettä, kuten esimerkiksi sydämen vajaatoimintaa tai
rytmihäiriötaipumusta, lääkityksen keskeyttämistä voidaan harkita vuosi sydäninfarktin
jälkeen.
Kalsiuminestäjät
Jos ongelmana on sepelvaltimoiden supistelu- eli spasmitaipumus
(https://sydan.fi/question/sepelvaltimon-spasmi/), kalsiumestäjälääkkeet
(https://sydan.fi/fact/kalsiuminestajat/) voivat tuoda avun. Helpointa on valita
verisuoniselektiivinen dihydropyridiiniryhmän lääke.
Sydänselektiivisiä verapamiilia tai diltiatseemia voi käyttää anti-iskeemisenä lääkkeenä,
mutta ei yhdessä beetasalpaajan kanssa bradykardiariskin ja AV-johtumisen hidastumisen
vuoksi. Näitä lääkkeitä ei myöskään saa käyttää, jos potilaalla on systolinen
vajaatoiminta.Lue seuraavaksi Masennus ja sepelvaltimotauti (https://sydan.fi/ammattilaispalvelu/artikkeli/masennus-ja-sepelvaltimotauti/)
Nitraatit
Lyhytvaikutteinen nitraattivalmiste (https://sydan.fi/fakta/nitraatit/) määrätään kaikille
sepelvaltimotautipotilaille käytettäväksi tarvittaessa. Vaihtoehtoina on kielenalustabletti
tai suihke suuonteloon. Lääkettä voi käyttää myös ennakoivasti ennen rasitustilannetta.
Pitkävaikutteisia nitraatteja käytetään nykyisin vain tilanteissa, joissa muulla lääkityksellä
ei ole saatu riittävän hyvää oirelievitystä. Saatavilla on tabletteja ja laastarimuotoisia
valmisteita. Annostelussa on muistettava nitraattitoleranssin kehittyminen, eli
vuorokaudessa tulisi olla noin 10 tunnin jakso ilman nitraattivaikutusta.
Muista lääkkeistä
Omatoimiseen kivun ja kuumeen hoitoon soveltuvat parhaiten parasetamoli -valmisteet.
Varsinaisia tulehduskipulääkkeitä (esim. ibuprofeiini, ketoprofeiini, indometasiini) ei saisi
käyttää säännöllisesti ja pitkäaikaisesti ilman lääkärin ohjetta ja erityistä syytä.
Tavallisia erektiohäiriöiden hoitoon käytettäviä lääkkeitä kuten esim. sildenafiilia tai
tadalafiilia voi yleensä käyttää turvallisesti, kunhan vain ei käytä samanaikaisesti
nitraattivalmisteita. Näiden yhtäaikainen käyttö on kiellettyä, sillä seurauksena voi olla
merkittävä verenpaineen lasku ja tajunnanmenetys.
Tupakoimattomuus on tärkeä tavoite sepelvaltimotautia sairastavalla.
Nikotiinikorvaushoitotuotteita ja varenikliinia tai buprobionia voi käyttää vieroitushoidon
tukena.
Vuosittaista influenssarokotusta suositellaan kaikille sepelvaltimotautipotilaille.
Seuranta
Seurannan tavoitteena on varmistaa ennusteeseen vaikuttavan lääkehoidon
toteutuminen ja tavoitteiden saavuttaminen. Lääkehoitoa pitää tarvittaessa tehostaa.
Erityisesti verenpaineen hoito vaatii usein monen lääkkeen yhdistelmää. Potilaan
raportoimiin haittavaikutuksiin pitää reagoida, ja lääkitystä tarvittaessa muuttaa, jotta
hoitomyöntyvyys olisi mahdollisimman hyvä. Pelkkä reseptien uusinta ei ole seurantaa.
Seurantakäynti toteutetaan akuutin sepelvaltimotautikohtauksen jälkeen yleensä noin
yhden kuukauden kuluttua. Pitkäaikaisseurantaa toteutetaan vähintään vuosittain.
Käynnillä tulee tarkastella kotona tehtyjen verenpainemittausten tulokset. Tavoite on
kaikilla potilailla 120-130/<80 mmHg. Yli 80-vuotiailla voidaan erityistapauksissa hyväksyä
systolisen paineen tavoite alle 140 mmHg.
Seurantaverikokeina otetaan:
Lipidit (kokonaiskolesteroli, HDL ja LDL-kolesterolit sekä triglyseridit)
Lipidilääkityksen onnistumisen seuranta. LDL-tavoite on alle 1,4 mmol/l.
Paastoglukoosi ja HbA1cLue seuraavaksi Masennus ja sepelvaltimotauti (https://sydan.fi/ammattilaispalvelu/artikkeli/masennus-ja-sepelvaltimotauti/)
Heikentynyt glukoosinsieto ja diabetes ovat huomattavan tavallisia tässä
potilasjoukossa.
Pieni verenkuva (pvk) ja kreatiniini
Ovat ns. turvakokeita käytetyn lääkityksen vuoksi.
 
 
 Lue seuraavaksi Masennus ja sepelvaltimotauti (https://sydan.fi/ammattilaispalvelu/artikkeli/masennus-ja-sepelvaltimotauti/)
Tietoa sepelvaltimotaudista.pdf
Tie toa se pel val ti mo tau dista
Sepelvaltimotauti johtuu valtimoiden kovettumataudista eli ateroskleroosista,
joka aiheuttaa verenkierron häiriintymisen sepelvaltimossa.
Sepelvaltimot ovat sydän lihaksen pinnalla kulkevia valtimosuonia. Niiden tehtävänä on kuljettaa
sydän lihakselle hapekasta verta ja energiaa. Sepelvaltimotauti johtuu sepelvaltimoiden
kovettumataudista, jossa yksi tai useampi sepelvaltimon kohta ahtautuu ja aiheuttaa
verenkierron häiriintymisen.
Sepelvaltimotaudin syntyyn ja etenemiseen vaikuttavat monet vaaratekijät. Merkittävimpiä
niistä ovat tupakointi, kohonnut veren kolesterolipitoisuus, kohonnut verenpaine ja diabetes.
Sepelvaltimotauti on yleisempää miehillä, iäkkäillä sekä henkilöillä, joilla on suvussa
sepelvaltimotautia. Parhaiten sairastumista voi ehkäistä terveillä elintavoilla ja välttämällä
turhia stressitekijöitä.
Sepelvaltimon seinämään muodostuva ahtauma alkaa kehittyä usein jo nuoruusiässä. Vuosien
kuluessa ahtauma kasvaa. Kun ahtauma on niin suuri että se haittaa verenkiertoa, alkaa
sepelvaltimotauti yleensä oireilla. Jos ahtauma kasvaa ja kehittyy hitaasti, potilas saa vakaan
sepelvaltimotaudin oireet.
Joskus alkava pehmeä plakki repeytyy, jolloin paljastuneeseen suonenseinän kohtaan kertyy
saman tien verihyytymä, joka voi tukkia suonen. Tämä voi johtaa vakavaan rytmihäiriöön ja

sydän pysähdykseen tai epävakaaseen tilanteeseen, joka hoitamattomana johtaa sydäninfarktiin
minuuttien sisällä.
RINTAKIPUKOHTAUS
Tarkistettu 2.7.2020Jos nitrovalmistetta ei ole käytössä ja oireiden kesto 5 minuuttia: SOITA 112!
Jos nitrovalmiste käytössä: ota nitrovalmistetta 3 kertaa 5 minuutin välein. Jos oireet
eivät 15 minuutissa helpota, SOITA 112!
Tietoa sydänsairauksiin liittyvästä kammiotakykardiasta.pdf
Tie toa sy dän sai rauk siin liit ty västä kam -
mio ta ky kar diasta
Kammiotakykardia on yhtäkkiä alkava sydämen tiheälyöntinen rytmihäiriö.
Kammiotakykardia on yhtäkkiä alkava sydäm en tiheälyöntinen rytmihäiriö, joka saa alkunsa
oikeasta tai vasemmasta kammiosta.
Sydän sairauksiin liittyvän kammiotakykardian syynä on tavallisimmin aiemmin sairastettu
sydän infarkti. Muita syitä ovat muun muassa
Rytmihäiriö perustuu useimmiten sydän sairauden aiheuttamaan arpeutumiseen, jota saattaa
olla laajalla alueella sydän lihaksessa. Kammiotakykardiassa syke on nopeampi kuin normaali
syke, mikä aiheuttaa usein sydäm en tykytystä, tajunnanmenetyksen tai jopa
sydäm enpysähdyksen.
Kammiotakykardian lähtökohta voidaan alustavasti paikallistaa rytmihäiriön aikana otetun
EKG:n perusteella.
Kammiotakykardian vaikutukset
Sydän sairauksiin liittyvät kammiotakykardiat ovat usein vaarallisia ja niihin liittyy äkkikuoleman
vaara. Äkkikuoleman estossa tärkein hoitomuoto on rytmihäiriötahdistin.
Katetriablaatiolla tarkoitetaan rytmihäiriötä aiheuttavan sähköhäiriön poistamista sydämen
seinämästä. Ablaatiokatetri viedään  verisuonen kautta sydämen sisälle rytmihäiriötä tuottavaan
kohtaan ja siihen kohdistetaan radiotaajuista sähkövirtaa, joka estää takykardian.
Sydän sairauden aiheuttamassa kammiotakykardiassa hoitokohde on laaja, käsittäen lähes koko
arpialueen.
Tarkistettu 27.12.2022sydän lihassairaus (kardiomyopatia)
tulehdukselliset sydän sairaudet (esimerkiksi sydänsarkoidoosi)
sydän lihastulehdus
läppäsairaudet
kertymäsairaudet
Tupakointi ja alkoholi - Sydänsairaala.pdf
Etusivu (https://www.sydansairaala.fi)➝Tietoa (https://www.sydansairaala.fi/tietoa/)➝Tupakointi ja alkoholi
Tupa kointi ja alko holi
Tupakointi on yksi merkittävimmistä sepelvaltimotaudin riskitekijöistä.
Tupakoinnin lopettaminen on todellinen terveysteko. Tupakoimattomuus
lisää elinvuosia ja parantaa elämänlaatua.
Jos käytät alkoholia, pysyttele kohtuudessa. Vältä humala- ja krapulatiloja.
Liiallinen alkoholinkäyttö lisää rytmihäiriöherkkyyttä ja vaikuttaa haitallisesti
veren rasva-arvoihin. Se nostaa myös verenpainetta, sydämen työmäärää ja
heikentää sydämen supistumiskykyä.
Tupa kointi
Tupakointi on sydänsairauksiin johtavista yksittäisistä riskitekijöistä
haitallisin. Se nopeuttaa verisuonten ahtautumista. Lisäksi se supistaa
sydämen verisuonia ja vaikeuttaa sydämen hapensaantia. Tupakointi lisää
myös veren hyytymistaipumusta. Tupakoinnin lopettamisesta on paljon
hyötyä. Osa hyödyistä näkyy nopeasti. Hyviä vaikutuksia ilmenee myös
pidemmällä aikavälillä. Tupakointi kannattaa siis lopettaa. Sydäninfarktin
sairastaneilla tupakoinnin lopettaminen on tehokkain keino estää uusia
sepelvaltimotautikohtauksia.
Linkki Terveyskylän Keuhkotalon sivuille
(https://www.terveyskyla.fi/keuhkotalo/itsehoito/tupakka)
Nikotiinikorvaustuotteilla voit lieventää vierotusoireita tai kysy lääkäriltä
lopettamisen tueksi siihen tarkoitettua lääkitystä. Voit käyttää tuotteita
turvallisesti ohjeiden mukaan. Kuntoutussuunnittelijalta tai
terveyskeskuksesta saat tarvittaessa tietoa tupakointivieroitusryhmistä ja
muista tukitoimenpiteistä.
Linkki Sydänsairaalan kuntoutusohjauksen sivulle
(https://www.sydansairaala.fi/tietoa/kuntoutusohjaus/)
Ota Terveyskylän Tupakoinnin lopettaminen hyvän hoidon tukena -itsehoito-
ohjelma käyttöösi ja opi toimivia keinoja tupakoinnin lopettamiseen.
Ohjelma kannustaa ja tukee sinua pysyvään savuttomuuteen.Aihee seen liit tyvää
Tupakoinnin lopettaminen hyvän hoidon
tukena -itsehoito-ohjelma (linkki Terveyskylän
sivuille) ➝
(https://www.terveyskyla.fi/kuntoutumistalo/palvel
itsehoito-ohjelmat/tupakoinnin-lopettaminen-
hyvan-hoidon-tukena-itsehoito-ohjelma)
Sydänsairaus ja tupakka (linkki Terveyskylän
sivuille) ➝
(https://www.terveyskyla.fi/sydansairaudet/omaho
ja-tupakka)
Sydänsairaus ja alkoholi (linkki Terveyskylän
sivuille) ➝
(https://www.terveyskyla.fi/sydansairaudet/omaho
ja-alkoholi)
Sepelvaltimotaudin omahoito ➝
(https://www.sydansairaala.fi/tietoa/omahoito/)
Jaa sivu:
(http://www.facebook.com/sharer/sharer.php?
u=https://www.sydansairaala.fi/tietoa/tupakointi-
ja-alkoholi/) (http://twitter.com/share?
url=https://www.sydansairaala.fi/tietoa/tupakointi-
ja-alkoholi/&text=Tupakointi ja alkoholi)
(http://www.linkedin.com/shareArticle?
url=https://www.sydansairaala.fi/tietoa/tupakointi-
ja-alkoholi/&title=Tupakointi ja
alkoholi&summary=&source=https://www.sydansair
ja-alkoholi/) (mailto:?
subject=Tupakointi ja
alkoholi&body=https://www.sydansairaala.fi/tietoa/t
ja-alkoholi/)(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Linkki Terveyskylän itsehoito-ohjelman sivulle
(https://www.terveyskyla.fi/kuntoutumistalo/palvelut/kuntoutumistalon-
itsehoito-ohjelmat/tupakoinnin-lopettaminen-hyvan-hoidon-tukena-
itsehoito-ohjelma)
Tupa koinnin lopet ta misen hyödyt
Tupakoinnin lopettamisen jälkeen
20 minVerenpaine laskee, syketiheys rauhoittuu ja
ääreisverenkierto paranee
24 tuntiaHäkä poistuu elimistöstä
48 tuntiaNikotiini poistuu elimistöstä, maku- ja hajuaisti paranevat
1–2
kuukauttaYskä ja limannousu lievittyvät
2–3
kuukauttaKeuhkotoiminta paranee merkittävästi
1 vuosi Sydäninfarktiriski (sydänkohtausriski) pienenee 50 %
10 vuottaKeuhkosyöpäriski pienenee 50 %
15 vuottaSydänkohtaus- ja aivohalvausriskit laskevat
tupakoimattoman tasolle
Alko holi
Alkoholin vaikutukset sydämeen ja verenkiertoelimistöön riippuvat
oleellisesti käytetystä alkoholimääristä. Kohtuullinen alkoholinkäyttö ei lisää
sydän- ja verisuonitautien vaaraa. Terveydelle haitallinen alkoholimäärä on
kuitenkin verrattain pieni: miehillä noin 1–2 annosta vuorokaudessa ja
naisilla noin 1 annos vuorokaudessa. Runsaaseen alkoholinkäyttöön liittyy
lisääntynyt sydäninfarktin ja sydänperäisen äkkikuoleman riski.
Yksi annos alkoholia on esimerkiksi
pullollinen (0,33 l) keskiolutta, siideriä tai lonkeroa
ravintola-annos (12 cl) mietoa viiniä
ravintola-annos (8 cl) väkevää viiniä
ravintola-annos (4 cl) väkevää alkoholia
Alkoholijuomat sisältävät paljon energiaa. Alkoholin runsas käyttö
vaikeuttaa painonhallintaa muiden haittojen lisäksi.
Painonhallinta ja ravitsemus (linkki)
(https://www.sydansairaala.fi/tietoa/painonhallinta/)(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Sepel val ti mo tau ti po ti laan omahoito
Elämäntapavalinnoilla on suuri merkitys sepelvaltimotaudin hoidossa ja ennaltaehkäisyssä. Sepelvaltimotautia hoidetaan
noudattamalla sydänystävällisiä elintapoja sekä toteuttamalla lääkehoitoa. Valtimoiden ahtautumiseen vaikuttavat monet riskitekijät
kuten perimä, diabetes, kohonnut verenpaine, tupakointi, kohonnut kolesteroli ja stressi. Sepelvaltimotauti ei häviä pois tai sitä ei
voida parantaa, mutta sen etenemistä on mahdollista hidastaa tai eteneminen voidaan jopa pysäyttää.
Siksi itsensä hoitaminen on tärkeää.  Omahoitoon kuuluvat terveellinen ruokavalio, säännöllinen ja monipuolinen liikunta,
tupakoimattomuus, stressin vähentäminen ja positiivinen elämänasenne.
(https://www.sydansairaala.fi/)
Usein kysyttyä
(http://www.sydansairaala.fi/tietoa/usein-
kysyttya/)
Anna
palautetta
(https://www.sydansairaala.fi/anna-
palautetta/)Palve lu neu vonta
Tampere 03 311 64145
Arkisin klo 7.30–15
info@sydansairaala.fi
Jos haluat perua ajan tai sinulla
on kysyttävää hoitoosi liittyen, ota
yhteyttä puhelimitse sinua
hoitavaan yksikköön.Yksityisvastaanottojen
ajanvaraus ja tiedustelut
Tampere p. 050 573 6875
ma–to klo 11–18, pe klo 11–15
Jyväskylä p. 041 731 3712
ma–pe klo 10–14
Huom. Matkapuhelinnumeroihin
ei voi lähettää tekstiviestejä.
Varaa aika
(https://sydansairaala.mbooking.fi/ajanvaraus)Sydänsairaala sosiaalisessa
mediassa
Facebook
(https://www.facebook.com/sydansairaala)
Instagram
(https://www.instagram.com/sydansairLinkedIn
(https://fi.linkedin.com/comYouTube
(https://www.yo
(https://www.sydansairaala.fi/ajanko
on-yksi-maailman-parhaista-
sydansairaaloista-myos-2024/)
(https://www.sydansairaala.fi/amma
Yhteys tiedot
Hämeenlinna
Hämeenlinnan
Sydänsairaala
Parantolankatu 6
13530 Hämeenlinna
P. (Vaihde) 03 6291Jyväskylä
Sydänsairaala Nova
Hoitajantie 3
40620 Jyväskylä
P. (Vaihde) 014 269
1811Riihimäki
Riihimäen
Sydänsairaala
Kontiontie 77
11120 Riihimäki
P. (Vaihde) 03 6291Tampere
Tampereen
Sydänsairaala
Elämänaukio 1
33520 Tampere
P. (Vaihde) 03 311
716Valkeakoski
Valkeakosken
Sydänsairaala
Ulvajankatu 20
37600 Valkeakoski
P. (Vaihde) 03 311
611
© 2017 Sydänsairaala - Saavutettavuus (https://www.sydansairaala.fi/saavutettavuus/) - Tietosuojaseloste (https://www.sydansairaala.fi/rekisteriseloste/) - Anna palautetta
(https://www.sydansairaala.fi/anna-palautetta/)
(https://www.sydansairaala.fi/)
(https://www.sydansairaala.fi/)
Täytyykö rasitusta varoa sydäntapahtuman jälkeen_ - Sydänliitto.pdf
Auta pe lastamaan sydä nisk urien pa ikannuspa lvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Sairastuneen liikunta (https://sydan.fi/elamaa-sairauden-kanssa/sairastuneen-liikunta/)/
Täytyykö rasitusta varoa sydä ntapa htuman jälkeen?
Täytyykö rasitus ta varoa sydänt apaht uman
jälkeen?
Suorituskyvyn yksilöllisyyden vuoksi liikuntatehon tärkein mittari löytyy
omista tuntemuksista. 
Kuva Jarno Hämäläinen
Paula Mannonen
Julkaistu 31.8.2018
Päivitetty 2.8.2019
Lue seuraavaksi Kestävyys, voima ja liikehallinta ovat kunnon kolme aluetta –  tärkeitä myös sydänsairaalle
(https://sydan.fi/fakta/kestavyys-voima-ja-liikehallinta/)
 
Sydäntapahtuman jälkeen on aina syytä aloittaa rauhallisesti ja lisätä liikkumisen
määrää ja rasitusta vähän kerrallaan. Suorituskyky sydäntapahtuman jälkeen
riippuu sairaudesta ja sen vakavuusasteesta. Liikkumisen tehoon vaikuttavat
myös ikä, yleiskunto ja se, kuinka paljon on aikaisemmin harrastanut kuntoilua.
Suorituskyvyn yksilöllisyyden vuoksi liikuntatehon tärkein mittari löytyy omista
tuntemuksista.  Sydäntapahtuman jälkeen on aina syytä aloittaa maltillisesti ja
lisätä liikkumisen määrää ja rasitusta vähän kerrallaan. Toipumisen edetessä ja
kunnon ylläpitovaiheessa voi sitten tehdä kaikkea, mikä ei tunnu pahalta tai
rasita kohtuuttomasti. Sydänlääkkeiden
(https://sydan.fi/fact/sepelvaltimotaudin-laakitys-ja-liikunta/) yhtenä tehtävä
on mahdollistaa liikunta.
Hikoilu, hengästyminen ja sykkeen nousu ovat luonnollisia asioita liikuttaessa,
eikä niitä tarvitse pelätä. Jos olo liikkumisen jälkeen on huono tai väsynyt,
rasitus on ollut liian kova. Omia tuntemuksiaan kuuntelemalla löytää itselleen
sopivan tehon. Ei kannata huolestua, jos jonakin päivänä ei jaksa yhtä paljon kuin
toisena, sillä vireystila vaihtelee monista eri syistä.
Sopivaa liikuntatehoa voidaan terveydenhuollossa arvioida rasituskokeen tai
Kuuden minuutin kävelytestin avulla. Liikunnan tehoa voidaan mitata sekä
sykemittarilla että koetun kuormittavuuden mukaan.
 
Lue myös Liikunnan hyödyt sydämelle ja verenkierrolle
(https://sydan.fi/fact/liikunnan-hyodyt-sydamelle-ja-verenkierrolle/)Lue seuraavaksi Kestävyys, voima ja liikehallinta ovat kunnon kolme aluetta –  tärkeitä myös sydänsairaalle
(https://sydan.fi/fakta/kestavyys-voima-ja-liikehallinta/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
Usein kysytyt kysymykset sepelvaltimotaudista ja lääkityksestä.pdf
Usein ky sy tyt ky sy myk set se pel val ti mo -
tau dista ja lää ki tyk sestä
Sivulle on koottu kysymyksiä lääkityksestä sekä asioista, jotka askarruttavat
sepelvaltimotautiin sairastunutta.
ACE-estäjät
ACE-estäjät, kuten ramipriili, enalapriili ja perindopriili sekä AT-reseptorin salpaajat kuten
losartaani, kandesartaani ja valsartaani alentavat verenpainetta laajentamalla suonia ja
vähentävät sydäm en työmäärää. Tämän ryhmän lääkitys on ennustetta parantava ja aloitetaan
sepelvaltimotautipotilaalla varsinkin, jos potilaalla on kohonnut verenpaine, diabetes tai laaja-
alainen infarkti.
Tämän ryhmän lääkkeet ovat yleensä hyvin siedettyjä. Haittavaikutuksina voi olla huimausta.
ACE-estäjillä on yleisenä haittavaikutuksena kuiva yskä, mitä AT-reseptorin salpaajilla esiintyy
harvemmin.
Avainsanat: ACE-estäjät, ramipriili, enalapriili, perindopriili, AT-reseptorin salpaajat, losartaani,
kandesartaani, valsartaani
ADP-reseptorinsalpaajat
ADP-reseptorinsalpaajiin kuuluvat klopidogreeli (Plavix), prasugreeli (Efient) ja tikagrelori
(Brilique). Jokin näistä lääkkeistä aloitetaan, jos tehdään  pallolaajennus (PCI). Tätä lääkettä
käytetään yleensä 1-12 kuukautta, riippuen pallolaajennustekniikasta. Juuri tehdyn
pallolaajennuksen jälkeen on erityisen tärkeää, että lääkehoitoon ei tule yhtään katkosta, sillä
tuore stenttialue eli laajennettu suonikohta kerää helpommin verihiutaleita ja voi aiheuttaa
hyytymän muodostumisen. Ajan kuluessa suonen sisäpinta paranee ja riski hyytymän
muodostumiseen pienenee.
Veren hyytymiseen vaikuttavien lääkkeiden käytön yhteydessä vuotoajat voivat pidentyä. Myös
vuotoriski maha-suolikanavassa voi lisääntyä. ADP-reseptoreiden käytön aikana ei tulisi
omatoimisesti käyttää tulehduskipulääkkeitä (ibuprofeeni, ketoprofeeni, asetyylisalisyylihappo
kivunhoitoannoksella). Akuuttipotilailla on usein hoidetun ahtauman lisäksi muita
repeämisalttiita ahtaumia, tällöin lääkehoito kohdistuu sekä hoidettuun että muihin ahtaumiin.
Tämän vuoksi akuuttipotilailla ADP-reseptrorisalpaajan käyttöaika on yleensä 12 kuukautta ja
joskus pidempäänkin.
Avainsanat: ADP-reseptorinsalpaajat,klopidogreeli, plavix, prasugreeli, Efient, tikagrelori,
Brilique,
Aikaisemmat kolesteroliarvoni ovat olleet hyvät. Tarvitseeko kolesterolilääkettä
käyttää?
Kolesterolilääkkeillä (statiineilla) on suotuisa vaikutus sepelvaltimotaudin kulkuun riippumatta
kolesteroliarvojen lähtötasosta. Näiden lääkkeiden käytön tavoitteena on vähentää uusien
sepelvaltimoahtaumien syntyä ja toisaalta pysäyttää jo olemassa olevien ahtaumien
vaikeutuminen.;
Sydän infarktin tavallisena syynä on sepelvaltimon seinämän sisäpinnan rikkoontuminen
kolesterolia sisältävän plakin alueella ja tähän kehittyvä verisuonitukos. Kolesterolilääkkeellä
voidaan  vähentää tällaisen seinämävaurion riskiä. Sepelvaltimotautipotilaan kolesterolin
tavoitetaso on alhaisempi kuin yleinen tavoitetaso terveellä henkilöllä.
Avainsanat: Kolesterolilääke, statiinit, kolesteroli, arvot, kolesteroliarvot, sepelvaltimoahtauma
Asetyylisalisyylihappo
Asetyylisalisyylihappo ja ADP-reseptorin salpaajat estävät verihiutaleita takertumasta toisiinsa,
mikä ehkäisee hyytymien syntymistä ja parantaa sepelvaltimopotilaan ennustetta. Hyytymien
estoon käytetään joko yhdistelmähoitoa asetyylisalisyylihappo ja ADP-reseptorin salpaajatai
näistä toista lääkettä erikseen.
ASA eli asetyylisalisyylihappo on ilman reseptiä saatava lääke. ASA:a käytetään lääkärin ohjeen
mukaan, eikä sitä tule lopettaa omatoimisesti. Yleensä ASA on pysyvä lääke. Jos ASA:a ei voida
käyttää allergian vuoksi, tällöin käytetään esim. klopidogreeliä pysyvänä lääkkeenä.
Avainsanat: Asetyylisalisyylihappo, ADP-reseptori, salpaaj at, ASA, Sepelvaltimotaudin
lääkehoito
AT-reseptorin salpaajat
ACE-estäjät, kuten ramipriili, enalapriili ja perindopriili sekä AT-reseptorin salpaajat kuten
losartaani, kandesartaani ja valsartaani alentavat verenpainetta laajentamalla suonia ja
vähentävät sydäm en työmäärää. Tämän ryhmän lääkitys on ennustetta parantava ja aloitetaan
sepelvaltimotautipotilaalla varsinkin, jos potilaalla on kohonnut verenpaine, diabetes tai laaja-
alainen infarkti.
Tämän ryhmän lääkkeet ovat yleensä hyvin siedettyjä. Haittavaikutuksina voi olla huimausta.
ACE-estäjillä on yleisenä haittavaikutuksena kuiva yskä, mitä AT-reseptorin salpaajilla esiintyy
harvemmin.
Avainsanat: ACE-estäjät, ramipriili, enalapriili, perindopriili, AT-reseptorin salpaajat, losartaani,
kandesartaani, valsartaani
Kalsiumestäjät
Kalsiuminestäjät jaotellaan kahteen ryhmään. Verisuonistoon vaikuttavat mm. amlodipiini,
felodipiini ja lerkanidipiini laajentavat verisuonia ja alentavat näin verenpainetta. Niitä käytetään
myös lievittämään rintakipuoiretta. Haittavaikutuksena näillä voi olla kasvojen punoitus,
huimaus, päänsärky ja nilkkojen turvotus.
Niin sanotusti sydäm een vaikuttavilla verapamiililla ja diltiatseemilla on sydämen sykettä
rauhoittava vaikutus. Lisäksi ne alentavat verenpainetta laajentamalla suonia. Nämä ovat
vaihtoehtoisina lääkkeinä esimerkiksi silloin, jos beetasalpaajia ei voida käyttää. Näiden yleinen
haittavaikutus on ummetus, kasvojen punoitus, huimaus, pään särky ja kutina.
Avainsanat: Kalsiuminestäjät, amlodipiini, felodipiini, lerkanidipiini, verapam iililla, diltiatseemilla
Kivunhoito
Omatoimisessa kivunhoidossa suositellaan käytettäväksi parasetamolia.
Tulehduskipulääkkeiden (esimerkiksi ibuprofeiini, ketoprofeeni, asetyylisalisyylihappo
kivunhoitoannoksella) pitkäaikainen käyttö voi vaikuttaa verenpainelääkkeiden tehoon, mutta
satunnaisesti otettuna se ei heikennä verenpainelääkkeiden tehoa.
Tulehduskipulääkkeiden käytöstä on hyvä keskustella hoitavan lääkärin tai apteekin farmaseutin
kanssa. Tulehduskipulääkkeitä ei tulisi käyttää veren hyytymiseen vaikuttavien lääkkeiden
kanssa. Lääkäri voi ohjeistaa tai määrätä reseptillä muitakin kipulääkkeitä.
Avainsanat: kivunhoito, parasetamolia, tulehduskipulääkkeet, ibuprofeiini, ketoprofeeni,
asetyylisalisyylihappo
Kolesterolilääkkeet
Statiini on tärkein sepelvaltimotaudin etenemistä estävä lääkehoito. Sydäinfarktipotilailla
statiinilääkityksen on osoitettu pienentävän sekä uuden sydän infarktin että kuoleman riskiä.
Statiinilääkitys (mm. atorvastatiini, fluvastatiini, pravastatiini, rosuvastatiini, simvastatiini)
aloitetaan, vaikka kolesteroliarvot eivät olisikaan koholla. Statiinit vähentävät kolesterolin
muodostumista ja suojaavat verisuonten seinämiä.
Kolesterolia muodostuu elimistössä eniten ilta-/yöaikaan, joten kolesterolilääke on hyvä ottaa
illalla. Tästä poikkeuksena atorvastatiini ja rosuvastatiini voidaan ottaa mihin
vuorokaudenaikaan tahansa. Haittavaikutuksina voi ilmaantua lihaskipuja.
Etsetimibi estää kolesterolin imeytymistä suolistosta. Etsetimibi yhdistettynä statiiniin alentaa
kolesterolia tehokkaammin. Etsetimibiä käytetään myös, jos statiinit eivät sovi esim.
haittavaikutusten takia potilaalle.
Avainsanat: Statiini, Sydäinfarktipotilailla, Etsetimibi, atorvastatiini, fluvastatiini, pravastatiini,
rosuvastatiini, simvastatiini
Milloin kättä voi käyttää pallolaajennuksen jälkeen?
Tutkimuspäivänä kättä pidetään kantositeessä nukkumaanmenoon asti, ja kädessä olevaa
puristussidettä pidetään seuraavaan aamuun. Sen jälkeen kättä voi käyttää arkiaskareissa.
Ponnistelua, repiviä liikkeitä (esim. raskaiden esineiden nostelu, raskas ruumiillinen työ) ja
liikuntaa (esim. kuntosali, juoksu) tulee välttää viikon ajan.
Avainsanat: Liikunta, pallolaajennus, puristusside, käsi
Milloin voi aloittaa liikunnan?
Tutkimuspäivänä kättä pidetään kantositeessä nukkumaanmenoon asti, ja kädessä olevaa
puristussidettä pidetään seuraavaan aamuun. Sen jälkeen kättä voi käyttää arkiaskareissa.
Ponnistelua, repiviä liikkeitä (esim. raskaiden esineiden nostelu, raskas ruumiillinen työ) ja
liikuntaa (esim. kuntosali, juoksu) tulee välttää viikon ajan.
Avainsanat: Liikunta, pallolaajennus, puristusside, käsi
Minulla on lääkitys sydäninfarktiin/sepelvaltimotautiin ja nyt epämääräistä
huonovointisuutta ja väsymystä. Mitä teen?
Sydän infarktiin tai sepelvaltimotautiin aloitetun lääkehoiton jälkeen, on voinnissa tapahtunut
muutoksia, kuten epämääräistä huonoa oloa ja väsymystä.
Oireet voivat johtua sepelvaltimotaudin hoitoon tarkoitetusta beetasalpaaj alääkityksestä.
Beetasalpaaja voi aiheuttaa jaksamattomuutta, laskea sydämen syketiheyttä ja verenpainetta.
Tällaisessa tilanteessa kannattaa käydä lääkärin vastaanotolla.
Avainsanat: sydän infarkti, sepelvaltimotauti, lääkitys, beettasalpaaja, väsymys, huonovointisuus,
Missä lääkemääräykset uusitaan?
Yleensä sydän infarktin jatkohoito ja sepelvaltimotaudin muu jatkohoito toteutuu
perusterveydenhuollossa (terveyskeskus, työterveyshuolto, yksityinen lääkäriasema), missä
myös lääkemääräykset uusitaan.
Avainsanat: Lääkitys, sydän infarkti, sepelvaltimotauti, reseptit, uusiminen
Mistä saan B-todistuksen?
Teitä sairaalassa hoitanut lääkäri laatii B-todistuksen, joka postitetaan teille ja teidän tulee
toimittaa todistus Kelaan. Toisinaan B-todistus toimitetaan sairaalasta suoraan Kelaan, tällöin
teille kerrotaan asiasta erikseen. Säästäkää kuitit, kun haette apteekista ensimmäisen kerran
sydän lääkkeenne. Voitte hakea korvausta takautuvasti kuitteja vastaan, kun B-todistus on
toimitettu Kelaan.
Saatte lääkekorvausta sen jälkeen, kun alkuomavastuu on täyttynyt. Alkuomavastuu on
kalenterivuosikohtainen. Alkuomavastuu ei koske lapsia ja nuoria. Sitä sovelletaan sen vuoden
alusta, jolloin täyttää 19 vuotta.
Avainsanat: B-todistus, lääkekorvaus, kela, omavastuu
Miten stressi vaikuttaa sydämeen ja verenpaineeseen?
Stressi aiheuttaa elimistön hormonitoiminnan, elimistön vireystilaa säätelevän autonomisen
hermoston ja aineenvaihdunnan muutoksia, jotka ovat sydäm elle ja verenkiertoelimistölle
haitallisia.
Jatkuva psyykkinen stressi voi nostaa verenpainetta. Stressaavassa elämäntilanteessa
elintottumukset voivat muuttua huonommiksi esimerkiksi ruokavalion ja tupakoinnin suhteen.
Toisaalta psyykkinen stressi voi aiheuttaa rintakipuja, jotka eivät johdu sydänsairaudesta.
Avainsanat: Stressi, vireystila, hormonitoiminta, autonominen hermosto
Miten sydänlääkitystä tulisi seurata ja tarkistaa?
Sepelvaltimotauti on pitkäaikaissairaus ja lääkitystä pitää käyttää pysyvästi. Tavallisesti
ensimmäinen seurantakäynti järjestetään 1–3 kuukauden kuluttua sydäninfarkin jälkeen ja
tämän jälkeen vähintään vuosittain, jolloin tarkistetaan vointi, verenpainetaso, keskustellaan
elintottumuksista ja tehdään  peruslaboratoriotutkimukset.
Avainsanat: Sydän lääkitys, sepelvaltimotauti, seuranta, sydän infarkti, verenpaine,
Nopeavaikutteiset nitraatit
Nitraatit laajentavat suonia ja niitä käytetään oiretta lievittävänä lääkkeenä. Nopeasti
vaikuttavat niin sanotut ”pikanitrot” otetaan rintakipukohtauksen ilmaannuttua tai tarvittaessa
ennen rasitusta tai muuta rintakipukohtausta laukaisevaa toimintaa.
Nopeavaikutteinen suihke suihkautetaan kielen päälle samalla pidättäen hengitystä. Annostus
voi olla yksilöllinen. Kipukohtauksen aikana suihkauta 1-3 suihketta. Jos kipu ei hellitä, ota
yhteys lääkäriin/ soita tarvittaessa ambulanssi. Ennen rasitusta tarvittaessa 1-3 suihketta. Pidä
suihkeiden välissä 30 sekunnin tauko.
Nopeasti vaikuttava kielenalustabletti laitetaan kielen alle liukenemaan tai pureskellaan.
Uuden tabletin voi tarvittaessa ottaa viiden minuutin kuluttua.
Yli kolmea tablettia ei tule ottaa 15 minuutin aikana. Jos kipu ei hellitä tässä ajassa, ota yhteys
lääkäriin/ soita tarvittaessa ambulanssi.
Nitraattien, varsinkin lyhytvaikutteisen, haittavaikutuksena voi olla pään särky ja huimaus.
Yhtäaikaisessa nitraattien ja erektiolääkkeiden käytössä on riskejä. Neuvottele mahdollisesta
käytöstä lääkärin kanssa.
Avainsanat: Nitraatit, pikanitrot, kipukohtaus, kielenalustabletti
Pitkävaikutteiset nitraatit
Pitkävaikutteisiin nitraatteihin siirrytään yleensä silloin, jos nopeavaikutteisia nitraatteja
joudutaan käyttämään usein. Lääkäri voi määrätä pitkävaikutteisen nitraatin muistakin syistä.
Pitkävaikutteisten nitraattien käytössä on huomioitavaa nitraattien aiheuttama toleranssi. Tämä
vältetään pitämällä ainakin 12 tunnin nitraatiton jakso vuorokaudessa. Yleisimmin tauko on hyvä
pitää yöaikaan. Kaksi kertaa vuorokaudessa annostelussa annokset on hyvä ottaa aamulla ja
iltapäivällä esim. klo 8 ja klo 16-18.
Nitraattien, varsinkin lyhytvaikutteisen, haittavaikutuksena voi olla pään särky ja huimaus.
Yhtäaikaisessa nitraattien ja erektiolääkkeiden käytössä on riskejä. Neuvottele mahdollisesta
käytöstä lääkärin kanssa.
Avainsanat: Pitkävaikutteiset, nitraatit, nopeavaikutteiset,
Pitääkö ensimmäiset lääkkeet ostaa ilman erityiskorvattavuutta?
Teitä sairaalassa hoitanut lääkäri laatii B-todistuksen, joka postitetaan teille ja teidän tulee
toimittaa todistus Kelaan. Toisinaan B-todistus toimitetaan sairaalasta suoraan Kelaan, tällöin
teille kerrotaan asiasta erikseen. Säästäkää kuitit, kun haette apteekista ensimmäisen kerran
sydän lääkkeenne. Voitte hakea korvausta takautuvasti kuitteja vastaan, kun B-todistus on
toimitettu Kelaan.
Saatte lääkekorvausta sen jälkeen, kun alkuomavastuu on täyttynyt. Alkuomavastuu on
kalenterivuosikohtainen. Alkuomavastuu ei koske lapsia ja nuoria. Sitä sovelletaan sen vuoden
alusta, jolloin täyttää 19 vuotta.
Avainsanat: B-todistus, lääkekorvaus, omavastuu, erityiskorvattavuus, kela
Sairaalasta pääsyn jälkeen verenpainearvoniovat olleet matalat? Pitäisikö olla
huolissaan?
Jotkin verenpaine- ja muut lääkkeet voivat johtaa verenpaineen laskuun. Mikäli teillä ei ole
oireita, kuten huimausta, silmissä sumentumista, ei teidän tarvitse olla huolissanne.
Avainsanat: Matala verenpaine, verenpaine, lääkkeet, silmät sumenee, huimaus
Vaikuttaako sydäninfarktin sairastaminen hammaslääkärissä käyntiin?
Sepelvaltimotautia sairastavan on syytä huolehtia säännöllisestä suun ja hampaiden hoidosta ja
tutkimisesta. Hammaslääkärin tai suuhygienistin tekemässä tarkastuksessa on hyvä käydä
vuosittain. Hoitamattomat tulehdukset suussa voivat pah entaa sepelvaltimotautia. Hampaiden
harjaus ja hammasvälien puhdistus päivittäin ovat tärkeässä osassa suun tulehduksien
ehkäisyssä. Kerro hammaslääkärille terveydentilastasi, sepelvaltimotaudistasi ja lääkityksestäsi.
Veren hyytymistä estävä lääkitys aiheuttaa hammastoimenpiteissä verenvuotoriskin.
Verenvuotoa aiheuttavat toimenpiteet, kuten juurihoito tai hampaan  poisto, on suositeltavaa
ajoittaa tehtäväksi vasta, kun toinen veren hyytymiseen vaikutavista lääkkeistä on suunnitelman
mukaisesti lopetettu.
Avainsanat: sydän infarkti, lääkärikäynti, hammaslääkäri, suuhygienia, sepelvaltimotauti, lääkitys
Voiko sydäninfarkti uusiutua?
Kyllä voi, mutta uusiutumisriskiin voidaan  vaikuttaa. Sepelvaltimotauti on pitkäaikaissairaus,
jota toimenpiteet eivät paranna. Toimenpiteiden tarkoituksena on vähentää oireita ja parantaa
sydän lihaksen verenkiertoa.
Lääkehoito ja sydän ystävälliset elämäntavat ovat keskeisiä sydän infarktin uusiutumisen
ehkäisyssä.
Avainsanat: sydän infarkt, sydän lihaksen verenkierto, uusituminen,
Voinko ajaa autolla sydäninfarktin jälkeen?
Ajokielto ja sen pituus riippuu siitä kuinka vaikea sydän infarkti on ollut. Tavallisimmin ajokielto
kestää joitakin viikkoja. Sydän lihasvaurio infarktiin liittyen voi vielä toipumisvaiheessa aiheuttaa
sydäm en rytmihäiriöitä, jotka voivat merkittävästi vaikuttaa kykyyn kuljettaa ajoneuvoa
turvallisesti.
Hoitava lääkärinne kertoo teille mahdollisesta ajokiellosta ennen sairaalasta kotiutumista.
Ammattiautoilijan paluu työelämään arvioidaan rasituskokeen ja lääkärintarkastuksen
perusteella.
Avainsanat: Ajokielto, sydän infarkti,
Tarkistettu 3.7.2020
Varjoainekuvaus ja reperfuusiohoito - Hoito- ja palveluketjut - pirha.fi.pdf
Hoit o- ja p al v eluk et jut

Hae
V alikk o
Hoit o- ja p al v eluk et jut  / Sepel v al timot autipotilaan hoit ok et ju  / Sepel v al timot autik oht aus  /
V ar jo ainekuv aus ja r eper fuusiohoit o
 Sepel v al timot autipotilaan hoit ok et ju
Sepel v al timot audin diagnostiikka
Sepel v al timot audin hoit o
Sepel v al timot autik oht aus
Sepel v al timot autik oht aus
Sepel v al timok oht auksen r iskinar vio
Sepel v al timok oht auksen ensihoit o (NS TEMI/U AP)
Sepel v al timok oht auksen ensihoit o (S TEMI)
V ar jo ainekuv aus ja r eper fuusiohoit o
Jatk ohoit o osast olla t ai sy dän v al v onnassa
Sepel v al timot audin lääk ehoit o
Sy dän v almennus
Sepel v al timot audin jatk ohoit o ja seurant a



V ar jo ainekuv aus ja r eper fuusiohoit oKuuntele4.3.2025 klo 17.24 Varjoainekuvaus ja reperfuusiohoito - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotautikohtaus/varjoainekuvaus-ja-reperfuusiohoito 1/2
S TEMI
Ensisijainen hoit o on pr imaar i PCI, jos se v oidaan t ehdä alle 120 minuutin kuluessa ensimmäisest ä k ont aktist a
Mikäli t ämä aikaraja y litt yy har kit aan liuotushoit o a
Päät öksen hoit omuodost a t ek ee PCI-p äivyst äjä ennen ADP -r esept or in salp aajan ant amist a (liuotushoidetuille
klopidogr eeli)
NS TEMI
V ar jo ainekuv aus tulee t ehdä <2 4 tunnissa
T ar vitt aessa < 2 tunnissa, jos glob aali-isk emia, ep ä v akaa hemod ynamiikka, jatkuv a oir eilu t ai t oistuv a
kammiot aky kar dia, jos alkuhoidolla tilanne ei k or jaannu
R eper fuusiomuot o (PCI/C ABG) v alit aan lö y döksen ja potilaan muun k ok onaistilant een perust eella
 
Edellinen
Sepel v al timok oht auksen ensihoit o (S TEMI)Seur aa v a
Jatk ohoit o osast olla t ai sy dän v al v onnassa
Päivit ett y 18 . 11.202 4
Ev äst eet
Saa vut et t a vuusselost e
Tiet osuoja
© Pir kanmaan h yvin v ointialueT akaisin y lös
Hoit o- ja p al v eluk et jut y ön k oor dinoinnist a v ast aa Pir kanmaan h yvin v ointialueen hoit ok et jutiimi.
T ämän sivun lö y dät osoitt eella pir ha.fi/hoit ok et jut4.3.2025 klo 17.24 Varjoainekuvaus ja reperfuusiohoito - Hoito- ja palveluketjut - pirha.fi
https://www.pirha.fi/fi/web/hoito-ja-palveluketjut/sepelvaltimotautipotilaan-hoitoketju/sepelvaltimotautikohtaus/varjoainekuvaus-ja-reperfuusiohoito 2/2
Varjoaineyliherkkyys.pdf
Var joai ney li herk kyys
   Yliherkkyysreaktiot ovat nykyisillä varjoaineilla harvinaisia, mutta reaktio voi
pahimmillaan olla hengenvaarallinen.
Varjoaineissa yliherkkyyttä aiheuttavat aineet ovat jodi ja gadolinium. Useimmat reaktiot eivät
ole IgE-välitteistä allergiaa, ja voivat siksi tulla jo ensimmäisellä kuvauskerralla. Ne liittyvät
histamiinin vapautumiseen varjoaineen vaikutuksesta. IgE-välitteinen varsinainen allergia on
harvinainen ja vaatii herkistymisen aikaisemmalla tutkimuskerralla.
Useimmat reaktiot tulevat ensimmäisen tunnin aikana varjoaineen annostelusta, monet jopa
viidessä minuutissa. Harvinaisissa tapauksissa oire tulee vasta päivien kuluttua lievinä iho-
oireina, eivätkä nämä yleensä vaikuta varjoaineiden annosteluun tulevaisuudessa.
Henkilöllä, joka on aiemmin saanut varjoainereaktion, on turvallisinta korvata varjoainetutkimus
muulla menetelmällä. Jos reaktio on ollut lievä, voidaan  tutkimus tehdä suojalääkityksellä.
Vaikeiden reaktioiden jälkeen on varjoaineen käyttöä pyrittävä välttämään. Astma- ja
allergiapotilailla on hieman muita suurempi riski saada reaktio varjoaineista. Sen sijaan
jodipitoisista tuotteista saatu ihoreaktio ei lisää riskiä merkittävästi.
Tarkistettu 16.9.2021

Verenpaineen luokittelu.pdf
Ve ren pai neen luo kit telu
Verenpaine ilmoitetaan kahdella luvulla. Sen mittayksikkö on elohopeamillimetri
eli mmHg.
Verenpaine ilmoitetaan kahdella luvulla. Sen mittayksikkö on elohopeamillimetri eli mmHg.
Systolinen paine eli ”yläpaine” kuvaa verenpainetta sydäm en supistuessa.  Diastolinen paine eli
”alapaine” kuvaa verenpainetta sydäm en lepovaiheen aikana, jolloin sydän lepää ja täyttyy
sydäm een palaavalla verellä. Verenpaine on matalimmillaan lepovaiheen aikana ja
korkeimmillaan supistumisvaiheen aikana.
Verenpaine luokitellaan oheisen taulukon mukaan. Hypertensio tarkoittaa kohonnutta
verenpainetta.
Jaottelu Yläpaine (mmhg) Alapaine (mmhg)
Ihanteellinen <120 ja <80
Normaali 120-129 ja/tai80-84
Tyydyttävä 130-139 ja/tai85-89
 1. asteen  hypertensio 140-159 ja/tai90-99
2. asteen hypertensio 160-179 ja/tai100-109
3. asteen hypertensio >180 ja/tai>110
Tarkistettu 13.7.2020
Verihiutaleita estävät lääkkeet valtimotautien hoidossa - Sydänliitto.pdf
Auta pelastamaan sydäniskurien paikannuspalvelu - liity kuukausilahjoittajaksi! >>
(https://sydan.fi/lahjoita/kuukausilahjoitus/?
utm_source=sydanfi&utm_medium=raita&utm_campaign=ystavanpaivakerays&utm_content=defi)
Kasvisruokaako vaikea tehdä ja se olisi mautonta? Pöh! ⛔ Yllätä itsesi iloisesti maukkailla ja helpoilla
vinkeillä täältä. 😋
(https://sydan.fi/kasvisruokaa/?
utm_source=sydan.fi&utm_medium=raita&utm_campaign=Kasviskampanja_2025)
Etusivu (https://sydan.fi/)/Elämää sairauden kanssa (https://sydan.fi/elamaa-sairauden-kanssa/)/
Lääkehoito (https://sydan.fi/elamaa-sairauden-kanssa/laakehoito/)/
Verihiutaleita estävät lääkkeet valtimotautien hoidossa
Verihiutaleita estävät lääkkeet
valtimotautien hoidossa
(https://sydan.fi/fakta/verihiutaleita-
estavat-laakkeet-valtimotautien-hoidossa/)
Verihiutaleet (trombosyytit) ovat verivirran mukana kulkevia pieniä
solukappaleita. Niiden tehtävä on auttaa elimistöä tyrehdyttämään
verenvuotoja. Ne takertuvat verisuonen vaurioituneeseen kohtaan ja
käynnistävät tapahtumaketjun, jonka lopputuloksena on vuodon pysäyttävä
paikka. Lue seuraavaksi INR-seuranta Marevan-hoidossa (https://sydan.fi/fakta/inr-seuranta-marevan-hoidossa/)
Anna-Mari Hekkala, ylilääkäri
Julkaistu 7.8.2017
Päivitetty 7.3.2025
 
Miksi näitä lääkkeitä tarvitaan?
Ateroskleroosi eli valtimoiden kovettuminen vaurioittaa verisuonen
sisäseinämää, jolloin vaarana on, että verihiutaleet aktivoituvat väärässä
paikassa. Verihiutaleet muodostavat tulpan, joka tukkii elintärkeän verisuonen.
Tavallisimmin kyseessä on sydämelle verta kuljettava sepelvaltimo, tai aivoihin
kulkevat valtimot.
Verihiutaleita estävää lääkitystä tarvitaankin siis sepelvaltimotaudissa ja
potilailla, joilla on ollut aivoverenkierron häiriö. Sepelvaltimon
pallolaajennuksessa valtimon sisälle asetetaan verkkoputki (stentti).
Toimenpidettä seuraavien lähikuukausien aikana riski verkkoputken
tukkeutumiselle on suuri, ja säännöllinen verihiutaleita estävä lääkitys on
erityisen tärkeä.
Lääkkeet
Eniten käytetty verihiutaleiden estäjä on asetyylisalisyylihappo (esim. Aspirin
cardiol®, Disperin®, Primaspan®). Lääkärit käyttävät usein teksteissään
lääkkeestä lyhennettä ” ASA ” . Annostus on yleensä 100 mg kerran päivässä.
Lääkitys on usein pysyvä. Lääke voi aiheuttaa vatsaärsytystä kuten närästystä ja
vatsan polttoa (dyspepsiaa). Jos vatsalaukun limakalvo vaurioituu, seurauksena
voi olla suolistoon tapahtuva hiljainen tihkuvuoto. Pahimmillaan se voi aiheuttaaLue seuraavaksi INR-seuranta Marevan-hoidossa (https://sydan.fi/fakta/inr-seuranta-marevan-hoidossa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
anemian. Mustaksi muuttuvat ulosteet ovat merkki mahdollisesta vuodosta, ja
lääkkeen käyttäjän tulee tällaisessa tapauksessa ottaa yhteyttä
terveyskeskukseen.
Sepelvaltimotautikohtauksen ja pallolaajennuksen jälkeen ASA:n rinnalle
aloitetaan toinen verihiutaleiden estäjä, jonka käyttö on yleensä määräaikaista.
Näitä lääkkeitä on useampi vaihtoehto kuten klopidogreeli (Plavix® tai
geneeriset valmisteet), tikagrelori (Brilique® ja geneeriset valmisteet) ja
prasugreeli (Efient®). Tikagrelori otetaan kaksi kertaa päivässä, klopidogreeli ja
Efient kerran päivässä. Yleisin haittavaikutus on tikagrelori-lääkkeeseen liittyvä
hengenahdistuksen tunne. Kyseessä ei ole keuhkoja tai sydäntä vaurioittava
haitta, ja oire lievittyy yleensä käyttöä jatkettaessa. Lääkitystä ei saa koskaan
lopettaa itsenäisesti, vaan ongelmissa tulee olla yhteydessä lääkkeen
määränneeseen lääkäriin. Klopidogreeliä voidaan käyttää myös yksinään ASA:n
asemasta.
Aivoverenkiertohäiriön jälkeen käytetään usein ASA:n ja dipyridamolin
yhdistelmää (Asasantin®, Orisantin®). Dipyridamolia voidaan käyttää myös
yksistään (Persantin®). Eteisvärinään liittyvää aivoinfarktia ehkäistään kuitenkin
antikoagulanteilla (https://sydan.fi/fact/hyytyman-esto-antikoagulanteilla/).
Ongelmatilanteita
Kun veren hyytymistä heikennetään, vaikutuksen kääntöpuolena on lisääntynyt
vuototaipumus. Yleisin havaittava haitta on mustelmataipumus. Haavan
verenvuodon tyrehtyminen kestää pidempään. Haitat ovat yleensä lieviä. Jos
ilmenee toistuvaa vuoto-ongelmaa, tulee lääkityksestä keskustella lääkärin
kanssa.
Lääkkeiden vaikutus verihiutaleiden toimintaan jatkuu vielä useita päiviä
lääkkeen lopettamisen jälkeen. Pienet toimenpiteet, esimerkiksi hammaslääkärin
vastaanotolla suoritettavat tai paikallisen luomen poisto, eivät yleensä vaadi
lääkityksen keskeyttämistä. Suureen leikkaukseen liittyy suurempi vuotovaara,
jolloin lääkitys voidaan joutua keskeyttämään useita päiviä ennen
toimenpidettä. Keskeytyksestä tulee aina konsultoida hoitavaa lääkäriä.
Esimerkiksi sepelvaltimon pallolaajennuksen jälkeen lääkitystä ei saa lopettaa
ennen kuin hoidettu suoni on riittävästi tervehtynyt, ja kiireettömät leikkaukset
pyritäänkin siirtämään myöhempään, turvalliseen ajankohtaan.Lue seuraavaksi INR-seuranta Marevan-hoidossa (https://sydan.fi/fakta/inr-seuranta-marevan-hoidossa/)(https://sydan.fi/sydantietoa/)(https://sydan.fi/apua-ja-
tukea/)(https://sydan.fi/lahjoita/)(https://sydan.fi/tule-
mukaan/liity-jaseneksi/)
